Drug treatments for COVID-19: living systematic review and network meta-analysis


Supplementary Material

Table of contents	Page
Search strategy	2
Characteristics of included studies	8
Studies included in analysis for each outcome	189
Description of studies excluded at full text stage	197
Discrepancies between preprint and peer-reviewed publications	222
Risk of bias assessments	238
Network plots	299
Complete network meta-analysis results and GRADE	309
Comparative efficacy and safety of baricitinib, ruxolitinib, and tofacitinib:	465
A Bayesian network meta-analysis	
Safety and efficacy of selected drugs for treatment of non-severe covid-19, including nirmatrelvir/ritonavir, molnupiravir, remdesivir, and fluvoxamine	507
Living network meta-analysis protocol and extended methods	527
Detailed risk of bias assessment guidance	541

For additional study characteristics, trial level data and R code, please visit our github:

https://github.com/covid19Inma/covid19_Inma/

For detailed summary of findings tables, please visit our website: https://www.covid19lnma.com/



Search purpose: Systematic search of the COVID-19 literature performed Monday through Friday for the <u>WHO Database</u>. Search strategy as of **05 January 2021**. Searches performed by Tomas Allen, Kavita Kothari, and Martha Knuth.

Use following commands to pull daily new entries:

- Entry_date:([20210101 TO 20210120])
- Entry_date:(20210105)

Duplicates: Duplicates are found in EndNote and Distillr using the Wichor method. Further screening is done by expert reviewers but some duplicates may still be in the database.

Daily Search Strategy:

Database	Daily Search Strategy
Medline (Ovid) 1946-	(coronavir* OR corona virus* OR corona pandemic* OR betacoronavir* OR covid19 OR covid OR nCoV OR novel CoV OR CoV 2 OR CoV2 OR sarscov2 OR sars2 OR 2019nCoV OR wuhan virus*).mp. OR (sars AND cov).mp. OR ((wuhan OR hubei OR huanan) AND (severe acute respiratory OR pneumonia*) AND outbreak*).mp. OR Coronavirus Infections/ OR Coronavirus/ OR betacoronavirus/
CAB Abstracts (Ovid) 1910-	(coronavir* OR corona virus* OR corona pandemic* OR betacoronavir* OR covid19 OR covid OR nCoV OR novel CoV OR CoV 2 OR CoV2 OR sarscov2 OR sars2 OR 2019nCoV OR wuhan virus*).mp. OR (sars AND cov).mp. OR ((wuhan OR hubei OR huanan) AND (severe acute respiratory OR pneumonia*) AND outbreak*).mp. OR exp Betacoronavirus/
Global Health (Ovid) 1910-	(coronavir* OR corona virus* OR corona pandemic* OR betacoronavir* OR covid19 OR covid OR nCoV OR novel CoV OR CoV 2 OR CoV2 OR sarscov2 OR sars2 OR 2019nCoV OR wuhan virus*).mp. OR (sars AND cov).mp. OR ((wuhan OR hubei OR huanan) AND (severe acute respiratory OR pneumonia*) AND outbreak*).mp. OR exp Betacoronavirus/
PsycInfo (Ovid) 1806-	(coronavir* OR corona virus* OR corona pandemic* OR betacoronavir* OR covid19 OR covid OR nCoV OR novel CoV OR CoV 2 OR CoV2 OR sarscov2 OR sars2 OR 2019nCoV OR wuhan virus*).mp. OR (sars AND cov).mp. OR ((wuhan OR hubei OR huanan) AND (severe acute respiratory OR pneumonia*) AND outbreak*).mp. Limits: 2020-
Scopus 1960-	TITLE-ABS-KEY (coronavir* OR "corona virus" OR "corona pandemic" OR betacoronavir* OR covid19 OR covid OR ncov OR "CoV 2" OR cov2 OR sarscov2 OR sars2 OR 2019ncov OR "novel CoV" OR "wuhan virus") OR TITLE-ABS-KEY(sars AND cov) OR (TITLE-ABS-KEY (wuhan OR hubei OR huanan) AND TITLE-ABS-KEY ("severe acute respiratory" OR pneumonia*) AND TITLE-ABS-KEY (outbreak*)) AND (LIMIT-TO (PUBYEAR, 2021) OR LIMIT-TO (PUBYEAR, 2020))
Academic Search Complete (Ebsco)	TI,AB,SU((coronavir* OR "corona virus" OR "corona pandemic" OR betacoronavir* OR covid19 OR covid OR ncov OR "CoV 2" OR cov2 OR sarscov2 OR sars2 OR 2019ncov OR "novel CoV" OR "wuhan virus") OR (sars AND cov) OR ((wuhan OR hubei OR huanan) AND ("severe acute respiratory" OR pneumonia*) AND (outbreak*))

Г	Linda Dangara managarah
	Limits: Dec. 2019-, peer-reviewed
Africa Wide Information (Ebsco)	TI,AB,SU((coronavir* OR "corona virus" OR "corona pandemic" OR betacoronavir* OR covid19 OR covid OR ncov OR "CoV 2" OR cov2 OR sarscov2 OR sars2 OR 2019ncov OR "novel CoV" OR "wuhan virus") OR (sars AND cov) OR ((wuhan OR hubei OR huanan) AND ("severe acute respiratory" OR pneumonia*) AND (outbreak*)))
	Limits: 2019-,
CINAHL (Ebsco)	TI,AB,SU((coronavir* OR "corona virus" OR "corona pandemic" OR betacoronavir* OR covid19 OR covid OR ncov OR "CoV 2" OR cov2 OR sarscov2 OR sars2 OR 2019ncov OR "novel CoV" OR "wuhan virus") OR (sars AND cov) OR ((wuhan OR hubei OR huanan) AND ("severe acute respiratory" OR pneumonia*) AND (outbreak*)) OR ((MH "Coronavirus") OR (MH "Coronavirus Infections"))
	Limits: Dec. 2019-, peer-reviewed
ProQuest Central (Proquest) 1952-	TI,AB,SU((coronavir* OR "corona virus" OR "corona pandemic" OR betacoronavir* OR covid19 OR covid OR ncov OR "CoV 2" OR cov2 OR sarscov2 OR sars2 OR 2019ncov OR "novel CoV" OR "wuhan virus") OR (sars AND cov) OR ((wuhan OR hubei OR huanan) AND ("severe acute respiratory" OR pneumonia*) AND (outbreak*))
	Limits: Dec. 2019-, peer-reviewed
China CDC MMWR	Covid OR cov2 OR coronavirus OR "sars cov" OR ncov
CDC Reports	Covid OR cov2 OR coronavirus OR "sars cov" OR ncov
bioRxiv medRxiv chemRxiv SSRN	Covid OR cov2 OR coronavirus OR "sars cov" OR ncov
(preprints)	
Embase (Ovid)	ncov OR (('coronavirus'/exp OR coronavirus) AND ('wuhan'/exp OR wuhan)) OR 'novel coronavirus' OR (('pneumonia'/exp OR pneumonia) AND wuhan:ti,ab) OR 'covid' OR 2019ncov OR 'sars-cov'/exp OR 'sars-cov' OR covid OR (('coronavirus'/exp OR coronavirus) AND novel) OR (('corona virus':ti,ab) OR 'coronavirus':ti,ab) AND (outbreak:ti,ab) OR epidemic*:ti,ab OR pandemdic*:ti,ab OR quaran*:ti,ab OR lockdown*:ti,ab OR syndemic*:ti,ab)) OR hcov OR 'sars virus'/exp OR 'sars virus' OR 'coronavirus disease 2019'/exp OR 'coronavirus disease 2019' OR 'novel coronavirus pneumonia' OR 'covid 19 virus' OR 'severe acute respiratory syndrome coronavirus 2'/exp OR 'severe acute respiratory syndrome coronavirus 2' OR 'coronavirinae'/exp OR 'coronavirinae' OR 'coronavirus infection'/exp OR 'coronavirus infection' OR 'covid19'/exp OR covid19 OR covid2019 OR 'corona pandemic' OR 'sarscov 2' OR 'sarscov-2' OR 'sars co v 2' OR 'social distancing'/exp OR 'social distancing' OR coivd OR 'flatten the curve' OR 'flattening the curve' OR pandoeconom* OR twindemic* OR 'sars voc'
Global Index Medicus	(nCov OR (coronavirus AND wuhan) OR "novel coronavirus" OR (pneumonia AND wuhan) OR covid OR 2019ncov OR "sars-cov" OR covid OR (coronavirus AND novel) OR (("corona virus" OR coronavirus) AND (ti:outbreak OR ti:epidemic* OR ti:pandemdic* OR ti:quaran* OR ti:syndem* OR hcov OR "sars virus")) OR "coronavirus disease 2019" OR "novel coronavirus pneumonia" OR "COVID 19 virus" OR "severe acute respiratory syndrome coronavirus 2" OR Coronavirinae OR

Web of	"Coronavirus infection" OR covid19 OR covid2019 OR lockdown* OR "social distancing" OR "physical distancing" OR "corona pandemic" OR "sarscov 2" OR "sarscov-2" OR "sars co v 2" OR coivd OR "flatten the curve" OR "flattening the curve" OR "sars voc") TI=coronavirus OR TI=covid OR TI=Covid19 OR TI=ncov OR TI=(SARS NEAR/3 COV) OR
Science	TI="novel coron*virus" OR TI=2019*ncoV OR TI=2019ncov OR TI=(CORON*VIRUS NEAR/3 (OUTBREAK OR pandemic OR 2019 OR new OR novel)) OR TI=coronavirinae OR TI=coronaviridae OR TI=betacoronavirus OR TI=Sars2 OR TI=COV2 OR TI="corona pandemic" OR ((TI=wuhan OR TI=hubei OR TI=huanan) AND (TI="severe acute respiratory" OR TI=pneumonia) AND (TI=outbreak))
PubMed Central	coronavirus[Title] OR "corona virus" [Title] OR "corona pandemic"[Title] OR coronavirinae[Title] OR coronaviridae[Title] OR betacoronavirus[Title] OR covid19[Title] OR covid[Title] OR nCoV[Title] OR "CoV 2"[Title] OR CoV2[Title] OR sars2[Title] OR sarscov2[Title] OR 2019nCoV[Title] OR "novel CoV"[Title] OR "wuhan virus"[Title] OR coronavirus[Abstract] OR "corona virus" [Abstract] OR "corona pandemic"[Abstract] OR coronavirinae[Abstract] OR coronaviridae[Abstract] OR betacoronavirus[Abstract] OR covid19[Abstract] OR covid[Abstract] OR nCoV[Abstract] OR "CoV 2"[Abstract] OR CoV2[Abstract] OR sars2[Abstract] OR sarscov2[Abstract] OR 2019nCoV[Abstract] OR "novel CoV"[Abstract] OR "wuhan virus"[Abstract] OR "COVID-19" [Supplementary Concept] OR "severe acute respiratory syndrome coronavirus 2" [Supplementary Concept] OR ((wuhan[Title] OR hubei[Title] OR huanan[Title]) OR (wuhan[Abstract] OR hubei[Abstract] OR huanan[Abstract]) AND ("severe acute respiratory"[Title] OR pneumonia[Title])) OR (("severe acute respiratory"[Abstract] OR pneumonia[Abstract]) AND (outbreak[Title]) OR outbreak[Abstract])
Science	COVID OR COVID19 OR 2019Ncov OR Ncov OR Coronavirus OR "corona virus" OR (SARS AND
Direct	Cov)
Wiley Online	COVID-19 OR nCov OR 2019ncov OR (pneumonia AND wuhan) OR (sars AND cov) OR COVID OR Covid19 OR "corona virus" OR coronavirus OR COV2 OR SARS2 OR coronavirinae OR coronaviridae OR betacoronavirus OR "corona pandemic" OR ((wuhan OR hubei OR huanan) AND ("severe acute respiratory" OR pneumonia) AND (outbreak))

Weekly, Biweekly or Monthly Searches:

Database	Daily Search Strategy
Eurosurveilla	Hand search
nce	
(weekly)	
American	ncov OR coronavirus OR covid OR 2019ncov OR (SARS AND COV) OR covid19 OR covid2019 OR
Chemical	hcov OR "corona virus"
Society	
(weekly)	
Scielo	TS=nCov OR TS=(coronavirus AND wuhan) OR TS="novel coronavirus" OR TS="nuevo
(Web of	coronavirus" OR TS=((pneumonia OR neumonía) OR AND wuhan) OR TS=covid OR TS=2019ncov
Science)	OR TS="sars-cov" OR TS=(coronavirus AND novel) OR ((TI="corona virus" OR TI=coronavirus)
(weekly)	AND TS=(Wuhan OR outbreak OR epidemic* OR pandemdic* OR quaran* OR lockdown* OR
	Syndemic* OR surto* OR epidemia* OR pandêmica* OU bloqueio* OR brote* OR epidemia* OR
	pandémica* OR cuaranatin*OR encierro*)) OR TS=hcov OR TS="sars virus" OR TS="coronavirus"
	disease 2019" OR TS="Enfermedad por coronavirus 2019" OR TS="novel coronavirus pneumonia"
	OR TS="Nova Pneumonia por Coronavírus" OR TS="severe acute respiratory syndrome coronavirus
	2" OR TS=Coronavirinae OR TS="Coronavirus infection" OR TS="infecções por coronavirus" OR
	TS=covid19 OR TS=covid2019 OR TS="corona pandemic" OR TS="sarscov 2" OR TS="sarscov-2"
	OR TS="sars co v 2" OR TS="social distancing" OR TS= coivd OR TS="flatten the curve" OR TS=
	"flattening the curve" OR TS=pandoeconom* OR TS=twindemic* OR TS="Distanciamento social" OR
	TS=" distancias sociales" OR TS=" isolamento social " OR TS=confinamiento* OR TS=contenção*

AIRITI	(("武漢肺炎" OR "新冠病毒" OR "2019新型冠狀病毒病" OR " 新型冠狀病毒肺炎" OR covid OR
(monthly)	coronavirus OR corona OR hcov OR ncov OR covid2019 OR covid19 OR 2019covid)) = All Fields
JMIR	covid OR Ncov OR hcov OR corona OR coronavirus OR sars OR 2019ncov OR covid19OR covid2019
(monthly)	Exclude PMC articles
Russian	TS=nCov OR TS=(coronavirus AND wuhan) OR TS="novel coronavirus" OR TS=(pneumonia AND
Science	wuhan) OR TS=covid OR TS=2019ncov OR TS="sars-cov" OR TS=(coronavirus AND novel) OR
Index	((TI="corona virus" OR TI=coronavirus) AND (TS=Wuhan OR TS=outbreak OR TS=epidemic* OR
(Web of	TS=pandemdic* OR TS=quaran* OR TS=lockdown* OR TS=Syndemic*)) OR TS=hcov OR TS="sars"
Science)	virus" OR TS="coronavirus disease 2019" OR TS="novel coronavirus pneumonia" OR TS="severe
(monthly)	acute respiratory syndrome coronavirus 2" OR TS=Coronavirinae OR TS="Coronavirus infection"
	OR TS=covid19 OR TS=covid2019 OR TS="corona pandemic" OR TS="sarscov 2" OR TS="sarsc
	2" OR TS="sars co v 2" OR TS="social distancing" OR TS= coivd OR TS="flatten the curve" OR TS= "flattening the curve" OR TS=pandoeconom* OR TS=twindemic*
	nattening the curve OK 15=pandoeconom OK 15=twindering
	TS= коронавирус*
Korean	TS=nCov OR TS=(coronavirus AND wuhan) OR TS="novel coronavirus" OR TS=(pneumonia AND
Science	wuhan) OR TS=covid OR TS=2019ncov OR TS="sars-cov" OR TS=(coronavirus AND novel) OR
Citation	((TI="corona virus" OR TI=coronavirus) AND (TS=Wuhan OR TS=outbreak OR TS=epidemic* OR
Index	TS=pandemdic* OR TS=quaran* OR TS=lockdown* OR TS=Syndemic*)) OR TS=hcov OR TS="sars
(Web of	virus" OR TS="coronavirus disease 2019" OR TS="novel coronavirus pneumonia" OR TS="severe
Science) (monthly)	acute respiratory syndrome coronavirus 2" OR TS=Coronavirinae OR TS="Coronavirus infection" OR TS=covid19 OR TS=covid2019 OR TS="corona pandemic" OR TS="sarscov 2" OR TS="sarscov"
(monthly)	2" OR TS="sars co v 2" OR TS="social distancing" OR TS= coivd OR TS="flatten the curve" OR TS=
	"flattening the curve" OR TS=pandoeconom* OR TS=twindemic*
	TS="코로나" OR TS="코로나2019 " OR TS="코로나19" OR TS=" 코로나바이러스" OR
	TS="코로나바이러스 2019" OR TS="코로나바이러스 19 " OR TS="사스" OR TS=" 전염병"
Oxford	Covid OR Coronavirus OR SARS OR NcoV
Academic	
Group (biweekly)	
Jstage	Covid OR Coronavirus
(biweekly)	Covid OK Corollavirus
Mary Ann	"2019ncov" OR nCov OR (pneumonia AND wuhan) OR "corona virus" OR SARS OR COVID OR
Liebert	CORONAVIRUS
(biweekly)	
Sage	[All "2019ncov"] OR [All ncov] OR [[All pneumonia] AND [All wuhan]] OR [All "corona virus"] OR
Publications	[All sars] OR [All covid] OR [All coronavirus] OR [All sars2] OR [All cov2] OR [All "corona
(biweekly) Taylor and	pandemic"] OR [All coronavirinae] OR [All coronaviridae] OR [All betacoronavirus] [Publication Title: coronavirus] OR [Publication Title: "corona virus"] OR [Publication Title: covid]
Francis	OR [Publication Title: ncov] OR [Publication Title: 2019ncov] OR [Publication Title: pneumonia]
(biweekly)	AND [Publication Title: wuhan]] OR [[Publication Title: sars] AND [Publication Title: cov]] OR
	[Publication Title: coronavirinae] OR [Publication Title: coronaviridae] OR [Publication
	Title: betacoronavirus] OR [Publication Title: sars2] OR [Publication Title: cov2] OR [Publication
	Title: "corona pandemic"]
BioMed	'COVID-19 OR Coronavirus OR "corona virus" OR covid OR nCov OR 2019nCov OR (pneumonia
Central (biweekly)	AND wuhan) OR (SARS AND COV) OR coronavirinae OR coronaviridae OR betacoronavirus OR SARS2 OR COV2 O "corona pandemic"
MDPI	2019ncov OR nCov OR COVID OR coronavirus OR "corona virus" OR (pneumonia AND wuhan) OR
(biweekly)	(SARS AND COV) OR COVID-19 OR Sars-Cov-2 OR Cov2 OR SARS2 OR coronavirinae OR
	coronaviridae OR betacoronavirus OR "corona pandemic"
1	·




Table S1: Characteristics of included trials

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
ARCHITECTS_ NCT04412772, 2021 ARCHITECTS ¹	Meta-analysis NCT04412772	21	United States	61.5	57.1	NR	Inpatient	Severe (100%)	NR	NR	tocilizumab (8 mg/kg (up to 800 mg) single dose) placebo	Mortality Duration of ventilation
Abbasi, 2021 ²	Pre-print IRCT20201003 048904N2	263	Iran	57.2	50.6	Chronic pulmonary disease (6.8%) Cardiovascular disease (19.0%) Diabetes (25.9%) Hypertension (31.2%)	Inpatient	NR	NR	NR	sitagliptin (100mg once daily for 5 days) spironolactone (100mg once daily for 5 days) sitagliptin (100 mg daily for 5 days) spironolactone (100 mg daily for 5 days) standard care	Mortality Mechanical ventilation Duration of hospitalizati on ICU length of stay
Abbass, 2021 ³	Peer-reviewed publication ISRCTN210856 22	120	Egypt	44.7	53.3	Asthma (1.7%) Cardiovascular disease (75.8%) Diabetes (18.3%)	Inpatient	Mild/Mo derate (38.3%) Severe (61.7%)	0	Iv (0.0%)	daclatasvir (60 mg once daily for 10 days) sofosbuvir (400 mg once daily for 10 days) ravidasvir (200 mg once daily for 10 days) sofosbuvir (400 mg once daily for 10 days) standard care	Mortality Mechanical ventilation Viral clearance
Abd- Elsalam_1, 2020 ⁴	Peer-reviewed publication NCT04353336	194	Egypt	40.7	58.8	Chronic heart failure or prolonged qt interval on	Inpatient	NR	NR	NR	hydroxychloroquine (200 mg twice daily for 15 days) standard care	Mortality Mechanical ventilation Duration of hospitalizati

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
						electrocardiog ram (0.0%)						on Time to symptom/cli nical improvemen t Time to to viral clearance
Abd- Elsalam_2, 2020 ⁵	Peer-reviewed publication NCT04447534	191	Egypt	43.6	60.7	Diabetes (13.6%) Hypertension (19.4%)	Inpatient	Mild/Mo derate (70.2%) Severe (29.8%) Severe: Critical (9.9%)	NR	NR	hydroxychloroquine (200 mg twice daily for 6 days) zinc (220 mg twice daily for 15 days) hydroxychloroquine (200 mg twice daily for 6 days)	Mortality Mechanical ventilation Duration of hospitalizati on
Abd- Elsalam_3, 2021 ⁶	Pre-print NCT04403555	164	Egypt	40.9	50	Cardiac problem (0.0%)	NR	NR	NR	NR	ivermectin (12 mg tablets daily for 3 days) standard care	Mortality Mechanical ventilation Duration of hospitalizati on
Abd- Elsalam_4, 2021 ⁷	Peer-reviewed publication NCT04345419	209	Egypt	53.5	59.5	Diabetes (33.0%) Hypertension (34.0%)	Inpatient	NR	NR	NR	remdesivir (100 mg once daily for 10 days) standard care	Mortality Mechanical ventilation Duration of hospitalizati on

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
Abdeen, 2021 ⁸	Peer-reviewed publication	16	Israel	NR	NR	NR	Inpatient	Mild/Mo derate (100.0%)	NR	NR	colchicine (1 mg twice a day on day 1 and 0.5 mg twice a day for 7 ± 4 days thereafter) standard care	NR
Abdeen, 2021 ⁸	Peer-reviewed publication	17	Israel	NR	NR	NR	Inpatient Intensive care (100.0%)	Severe (100%)	NR	NR	tocilizumab (single intravenous infusion of 8 mg/kg up to a total dose of 800 mg over one hour) standard care	NR
Abdelalim, 2021 ⁹	Peer-reviewed publication NCT04484493	108	Egypt	29	46	Diabetes (16.0%) Hypertension (14.0%)	Inpatient (31.0%)	Mild/Mo derate (94.0%) Severe (6.0%)	NR	NR	intranasal corticosteroid spray (100 µg in each nostril once daily for 3 weeks) standard care	NR
Abdulamir, 2021 ¹⁰	Meta-analysis IRCT20111224 008507N3	0	Iran	NR	NR	NR	Inpatient	Severe (100%)	NR	NR	ivermectin (0.2 mg/kg on day 2) standard care	Duration of hospitalizati on Time to symptom/cli nical improvemen t
Abdulamir_2, 2021 ¹¹ 12	Pre-print NCT04753619	150	Iraq	49.3	53.3	Asthma (0.7%) Ischemic heart disease (1.3%) Diabetes (8.0%)	NR	Mild/Mo derate (66.6%)	NR	NR	niclosamaide (4 g/day for 1 day and then 3g/day in 3 divided doses for 7 days) standard care	Mortality Time to symptom/cli nical improvemen t

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
						Hypertension (12.7%)						
Abulmeaty, 2021 ¹³	Peer-reviewed publication NCT04323228, SCTR No. 20092202	52	Saudi Arabia	48.6	63.6	NR	Inpatient	NR	NR	NR	selenium (15 μg) vitamin A (1500 μg) vitamin C (250 μg) vitamin E (90 μg) zinc (7.5 mg) placebo	NR
Ader_1, 2021 DisCoVeRy ¹⁴	Peer-reviewed publication NCT04315948	603	France, Luxembourg	63	71.7	Chronic pulmonary disease (15.1%) Chronic cardiac disease (25.9%) Diabetes (21.9%)	Inpatient Intensive care (43.6%)	Mild/Mo derate (63.8%)	95.4	Unspecified ventilation (95.4%)	lopinavir-ritonavir (400 mg/100 mg every 12 hours for 14 days) interferon beta-1a (subcutaneous) (44 µg on days 1, 3, and 6) lopinavir-ritonavir (400 mg/100 mg every 12 hours for 14 days) hydroxychloroquine (400 mg once daily for 10 days) standard care	Mortality Mechanical ventilation Adverse effects leading to discontinuati on Viral clearance Duration of hospitalizati on Ventilator- free days Time to symptom/cli nical improvemen t

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
Ader_2, 2021 DisCoVeRy ¹⁵	Pre-print NCT04315948	857	Austria, Belgium, France, Luxembourg, Potugal	63.5	69.6	Chronic pulmonary disease (17.6%) Chronic cardiac disease (27.5%) Diabetes (26.1%)	Inpatient Intensive care (43.9%)	Mild/Mo derate (60.6%)	39.2	Nasal canula, face mask (51.1%) High-flow oxygen (17.8%) Niv (3.7%) Iv (17.7%) Ecmo (0.4%)	remdesivir (100 mg once daily for 10 days) standard care	Mortality Mechanical ventilation Duration of hospitalizati on Ventilator- free days Time to symptom/cli nical improvemen t
Ahmadi, 2021 ¹⁶	Peer-reviewed publication IRCT20200408 046990N1	60	Iran	43.1	58.3	Chronic lung disease (0.0%) Heart failure (0.0%)	Outpatient	NR	NR	NR	nanocurcumin (80 mg twice daily for 2 weeks) placebo	Admission to hospital Time to symptom/cli nical improvemen t
Ahmed, 2020 ¹⁷	Peer-reviewed publication	72	Bangladesh	42	46	Ischemic heart disease (0.0%) Heart failure (0.0%) Cardiomyopat hy (0.0%)	Inpatient	Mild/Mo derate (100.0%)	0	Supplemental oxygen, niv, or iv (0.0%)	ivermectin (12 mg once daily for 5 days) doxycycline (12 mg single dose) ivermectin (12 mg once daily for 5 days) placebo	Mechanical ventilation Viral clearance Duration of hospitalizati on Time to to viral clearance

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
Alamdari, 2021 ¹⁸	Peer-reviewed publication IRCT20191228 045924N120, NCT04370288	223	Iran	62.6	54.7	NR	Inpatient	Severe (100%)	NR	NR	methylene blue (methylene blue syrup 1 mg/kg every 8 hours for two days, followed by 1 mg/kg every 12 hours for the next 12 days) standard care (supplemental oxygen, antiviral agents (Remdesivir 200 mg on the first day and 100 mg for 4 days, and IFN-β 44μg/sc, daily for 3 doses), intravenous fluids, antibiotics (Azithromycin 500mg/day, 5 days, Meropenem 1 gr, TDS, 7-10 days, Ceftriaxone 1 gr, BID, 7 days, and Vancomycin 1 gr, BID, 7-10 days), anticoagulants (up to discharge), corticosteroids (Dexamethasone 8 mg/day for 10 days))	Mortality Duration of hospitalizati on
Alavi- Moghaddam, 2021 ¹⁹	Pre-print IRCT20200328 046882N1	57	Iran	57.4	66.7	Pulmonary disease (7.0%) Cardiovascular disease (19.3%)	Inpatient	NR	NR	NR	sofosbuvir (400 mg single dose) interferon beta-1a (subcutaneous) (12 Mu (44 microgram) on day	Mortality Mechanical ventilation Duration of hospitalizati

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
						Diabetes (29.8%) Hypertension (21.1%)					1 and then every other day) lopinavir-ritonavir (200/50 mg twice per day)	on Time to symptom/cli nical improvemen t
Algahtani, 2021 ²⁰	Peer-reviewed publication NCT04860219	54	Egypt	48.6	59.3	Bronchial hyperactivity (0.0%) Pre-existing respiratory diseases (0.0%)	Inpatient	NR	NR	NR	lactoferrin (200 mg once daily) (200 mg once daily for 7 days) lactoferrin (200 mg twice daily) (200 mg twice daily for 7 days) standard care	NR
Alizadeh, 2021 ²¹	Peer-reviewed publication IRCT20200922 048804N1	40	Iran	35.9	54.8	Copd, sleep apnea (0.0%) Heart disease (0.0%) Diabetes (0.0%) Hypertension (0.0%)	Outpatient	NR	NR	NR	melatonin (6 mg daily for 2 weeks) standard care	NR
Altay, 2020 ²²	Pre-print NCT04573153	100	Turkey	35.6	60	Cardiovascular disease (0.0%) Diabetes (5.0%) Hypertension (2.0%)	Outpatient	NR	0	Supplemental oxygen, niv, or iv (0.0%)	L-carnitine tartrate (24 g/day total, given twice daily, for 14 days) N-acetylcysteine () nicotinamide riboside () serine () placebo	Mortality Time to symptom/cli nical improvemen t

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
Aman, 2021 ²³	Peer-reviewed publication EudraCT 2020–001236–10	400	Netherlands	64	68.6	Copd or asthma (18.4%) Pre-existing severe pulmonary disease (0.0%) Cardiovascular disease (21.6%) Heart failure (3.1%) Pre-existing heart failure (0.0%) Diabetes (24.7%) Hypertension (37.7%)	Inpatient	Severe (100%)	NR	Supplemental oxygen (100.0%)	imatinib (400 mg once daily for 10 days) placebo	Mortality Mechanical ventilation Adverse effects leading to discontinuati on Duration of hospitalizati on ICU length of stay Ventilator- free days Duration of ventilation
Amaravadi, 2021 PATCH ²⁴	Pre-print NCT04329923	34	United States	53	26.5	Asthma (11.8%) Diabetes (8.8%) Hypertension (20.6%)	Outpatient	Mild/Mo derate (100.0%)	0	Unspecified ventilation (0.0%)	hydroxychloroquine (200 mg twice daily for 14 days) placebo	Mortality Admission to hospital Viral clearance Time to symptom/cli nical improvemen t

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
Amra, 2021 ²⁵	Pre-print IRCT20170207 032444N3	60	Iran	62.4	54.9	Pulmonary disease (5.9%) Ischemic heart disease (9.8%) Diabetes (37.2%) Hypertension (33.3%)	Inpatient	Severe (100%)	0	Mechanical ventilation (0.0%)	thalidomide (100 mg daily for 14 days) standard care	Mortality Mechanical ventilation
Ananworanich , 2021 ²⁶	Peer-reviewed publication NCT04504032	497	United States	49	39.9	Chronic pulmonary disease, copd, pulmonary hypertension (6.1%) Diabetes (27.7%) Hypertension (51.8%)	Outpatient	Mild/Mo derate (100.0%)	0	Unspecified ventilation (0.0%)	rivaroxaban (10 mg daily for 21 days) placebo	Mortality Mechanical ventilation Admission to hospital Adverse effects leading to discontinuati on Clinically important bleeding
Angus, 2020 REMAP-CAP ²⁷	Peer-reviewed publication NCT02735707	403	Australia, Canada, Ireland, France, Netherlands, New Zealand, United Kingdom, United States	59.9	71.1	Respiratory disease (19.5%) Asthma/copd (16.1%) Severe cardiovascular disease (7.3%) Diabetes (32.1%)	Inpatient Intensive care (100.0%)	Severe (100%)	99.7	High-flow (14.6%) Niv (29.7%) Iv (55.5%) Ecmo (0.8%)	hydrocortisone (fixed-dose) (50 mg four times daily for 7 days) hydrocortisone (shock-dependent) (50 mg four times daily while in shock for up to 28 days) standard care	Mortality Mechanical ventilation Duration of hospitalizati on ICU length of stay

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
Ansarin, 2020 ²⁸	Peer-reviewed publication IRCT20200311 7046797N4	78	Iran	59.8	55.1	Chronic respiratory diseases (0.0%) Diabetes (33.3%) Hypertension (50.0%)	Inpatient	Severe (100%)	NR	NR	bromhexine hydrochloride (8 mg three times daily for 14 days) standard care	Mortality Mechanical ventilation Duration of hospitalizati on
Arabi, 2021 REMAP-CAP ²⁹	Peer-reviewed publication NCT02735707	726	United Kingdom, Canada, Saudi Arabia, Netherlands, United States, Australia, Ireland, France, New Zealand, Germany, Portugal	60.5	70.4	Respiratory disease (24.6%) Severe cardiovascular disease (12.1%) Diabetes (34.5%)	Inpatient Intensive care (100.0%)	Severe (100%)	99.4	None or supplemental oxygen (0.6%) High-flow (26.4%) Niv (40.5%) Iv (32.5%) Ecmo (0.0%)	lopinavir-ritonavir (400 mg-100 mg every 12 hours for a minimum of 5 days up to 14 days or until ICU discharge) hydroxychloroquine (two loading doses of 800 mg 6 hours apart followed 6 hours later by 400 mg twice a day for 6 days) hydroxychloroquine (two loading doses of 800 mg 6 hours apart followed 6 hours later by 400 mg twice a day for 6 days) lopinavir-ritonavir (400 mg-100 mg every 12 hours for a minimum of 5 days up to 14 days or until ICU discharge) standard care	Mortality Mechanical ventilation Duration of hospitalizati on ICU length of stay Ventilator- free days Time to to viral clearance

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
Aref, 2021 ³⁰	Peer-reviewed publication NCT04716569	114	Egypt	45.1	71.9	Copd (1.0%) Bronchial asthma (2.6%) Interstitial pulmonary fibrosis (2.6%) Cerebrovascul ar stroke (3.5%) Diabetes (12.3%) Hypertension (17.5%)	Outpatient	Mild/Mo derate (100.0%)	0	Iv (0.0%)	ivermectin nasal spray (twice daily (70 µg/mL per puff)) standard care	Time to symptom/cli nical improvemen t Time to to viral clearance
Arefin, 2021 ³¹	Peer-reviewed publication NCT04549376	189	Bangladesh	44	84.1	NR	Inpatient	Mild/Mo derate (91.5%) Severe (1.6%)	NR	NR	povidone-iodine nasal irrigation (0.4%) (single application) povidone-iodine nasal irrigation (0.5%) (single application) povidone-iodine nasal irrigation (0.6%) (single application) povidone-iodine nasal spray (0.5%) (single application) povidone-iodine nasal spray (0.6%) (single application) povidone-iodine nasal spray (0.6%) (single application) distilled water nasal irrigation (single application) distilled water nasal	NR

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
											spray (single application)	
Arruda, 2021 ARTAN-C19 ³²	Pre-print NCT04712357	227	Brazil	38	35.4	Asthma (6.3%) Heart disease (3.1%) Diabetes (9.8%) Hypertension (17.0%)	Outpatient	NR	NR	NR	emtricitabine (300 mg and 200 mg once daily for 10 days) tenofovir () tenofovir (300 mg once daily for 10 days) placebo	Admission to hospital
Asadi, 2021 ³³	Peer-reviewed publication IRCT20200324 046850N3	80	Iran	47.3	55.8	Cardiovascular diseases (12.3%) Diabetes (16.4%) Hypertension (9.6%)	Inpatient	NR	NR	NR	naproxen (500 mg twice daily for 5 days) placebo	NR
Axfors_ChiCTR 2000031204, 2020 HYDRA ³⁴	Meta-analysis ChiCTR200003 1204	35	China	18-70	NR	NR	Inpatient	NR	NR	NR	chloroquine (250 mg/day for up to 14 days) placebo	Mortality
Axfors_NCT04 323527, 2020 CloroCOVID ³⁴	Meta-analysis NCT04323527	82	Brazil	≥18	NR	NR	Inpatient	NR	NR	NR	chloroquine (450 mg/day for 5 days) placebo	Mortality

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
Axfors_NCT04 333654, 2020 HYDRA ³⁴	Meta-analysis NCT04333654	8	United States, Belgium, France, Netherlands	18-70	NR	NR	Outpatient	NR	NR	NR	hydroxychloroquine (600 mg/day for 10 days) placebo	Mortality
Axfors_NCT04 335552, 2020 CCAP-1 ³⁴	Meta-analysis NCT04335552	11	United States	≥12	NR	NR	Inpatient	NR	NR	NR	hydroxychloroquine (600 mg/day for 5 days) standard care hydroxychloroquine (600 mg/day for 5 days) azithromycin (250 mg/day for 5 days) azithromycin (75 mg twice daily for 5 days)	Mortality
Axfors_NCT04 338698, 2020 PROTECT ³⁴	Meta-analysis NCT04338698	373	Pakistan	≥18	NR	NR	Inpatient	NR	NR	NR	azithromycin (250 mg/day for 5 days) hydroxychloroquine (200 mg three times daily for 5 days) oseltamivir (75 mg twice daily for 5 days) azithromycin (250 mg/day for 5 day) oseltamivir (75 mg twice daily for 5 days) hydroxychloroquine (200 mg three times daily for 5 days) oseltamivir (75 mg twice daily for 5 days) oseltamivir (75 mg twice daily for 5 days) oseltamivir (75 mg	Mortality

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
											twice daily for 5 days) azithromycin (250 mg/day for 5 days) hydroxychloroquine (200 mg three times daily for 5 days) azithromycin (250 mg/day for 5 days)	
Axfors_NCT04 340544, 2020 COMIHY ³⁴	Meta-analysis NCT04340544	16	Germany	≥18	NR	NR	Outpatient	NR	NR	NR	hydroxychloroquine (600 mg/day for 7 days) placebo	Mortality
Axfors_NCT04 342221, 2020 COV-HCQ ³⁴	Meta-analysis NCT04342221	27	Germany	≥18	NR	NR	Inpatient	NR	NR	NR	hydroxychloroquine (600 mg/day for 7 days) placebo	Mortality
Axfors_NCT04 342650, 2020 CloroCOVID ³⁴	Meta-analysis NCT04342650	152	Brazil	≥18	NR	NR	Outpatient	NR	NR	NR	chloroquine (450 mg/day for 5 days) placebo	Mortality
Axfors_NCT04 345289, 2020 CCAP-1 ³⁴	Meta-analysis NCT04345289	2	Denmark	≥18	NR	NR	Inpatient	NR	NR	NR	hydroxychloroquine (600 mg/day for 7 days) placebo	Mortality
Axfors_NCT04 345692, 2020 OAHU-COVID 19 ³⁴	Meta-analysis NCT04345692	16	United States	18-95	NR	NR	Inpatient	NR	NR	NR	hydroxychloroquine (400 mg/day for 5 days) standard care	Mortality

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
Axfors_NL849 0, 2020 ARCHAIC ³⁴	Meta-analysis NL8490	15	Netherlands	≥18	NR	NR	Inpatient	NR	NR	NR	chloroquine (600 mg/day for 5 days) standard care hydroxychloroquine (600 mg/day for 5 days) standard care	Mortality
Azizi, 2021 ³⁵	Peer-reviewed publication IRCT20190804 044429N4	102	Iran	58.9	34.7	Cardiovascular disease (12.5%) Cerebrovascul ar disease (5.6%) Diabetes (31.9%) Hypertension (18.1%)	Inpatient	NR	NR	NR	pentoxifylline (400 mg three times a day for 10 days) placebo	Mortality Mechanical ventilation Duration of hospitalizati on ICU length of stay
Babalola, 2021 ³⁶	Peer-reviewed publication ISRCTN403029 86	63	Nigeria	44.3	69.3	Diabetes (3.2%) Hypertension (14.5%)	Inpatient	NR	NR	Intranasal oxygen (8.1%) Ventilator (0.0%)	ivermectin (6 mg) (6 mg every 84 hours twice weekly for 2 weeks) ivermectin (12 mg) (12 mg every 84 hours for 2 weeks) lopinavir-ritonavir (daily for 2 weeks)	Mortality Adverse effects leading to discontinuati on Viral clearance Time to to viral clearance
Babalola_2, 2021 ³⁷	Pre-print PACTR202108 891693522	61	Nigeria	40.4	63	Cardiovascular disease (0.0%)	NR	NR	NR	Oxygen use (4.9%)	azithromycin (hydroxycholorquine 200 mg per day for 3	Adverse effects leading to

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
						Hypertension (3.3%)				Ventilator use (3.3%)	days, azithromycin 500 mg per day for three days) hydroxychloroquine () standard care	discontinuati on Viral clearance
Balykova_1, 2020 ³⁸	Peer-reviewed publication NCT04542694	39	Russia	47.3	NR	Chronic heart failure of functional classes iii-iv (0.0%)	Inpatient	Mild/Mo derate (100.0%)	NR	NR	favipiravir (600 mg twice daily for 7 days) standard care	Mortality Time to symptom/cli nical improvemen t Mechanical ventilation Viral clearance
Balykova_2, 2020 ³⁹	Peer-reviewed publication	206	Russia	49.7	48.5	Chronic lung diseases, including asthma and pulmonary sarcoidosis (4.8%) Cardiovascular diseases, including a history of ischemic stroke and heart attack (5.8%) Diabetes (8.7%)	Inpatient	Severe (100%)	NR	Mask or nasal cannula (18.0%)	favipiravir (600 mg twice daily for 14 days) standard care	Mortality Mechanical ventilation Adverse effects leading to discontinuati on Viral clearance Time to symptom/cli nical improvemen t

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
						Hypertension (27.7%)						
Barratt-Due, 2021 NOR- Solidarity ⁴⁰	Peer-reviewed publication NCT04321616	181	Norway	59.8	65.8	Chronic pulmonary disease (5.5%) Chronic cardiac disease (15.5%) Diabetes (17.1%) Hypertension (30.4%)	Inpatient Intensive care (5.5%)	NR	NR	NR	remdesivir (400 mg on day 1, then 200 mg daily up to 9 days) hydroxychloroquine (800 mg twice daily on day 1, then 400 mg twice daily up to 9 days) standard care	Adverse effects leading to discontinuati on
Barrett_P1, 2021 STARS ⁴¹	Peer-reviewed publication NCT04357730	36	United States	60	69.4	Copd (77.8%) Cardiac diseases (88.9%) Diabetes (33.3%) Hypertension (27.8%)	Inpatient	Severe (100%)	NR	Mv (100.0%)	heparin (50 mg tPA IV- bolus, followed by 7 days of heparin 5000 unit bolus (or until extubation)) tPA bolus () standard care	Mortality Clinically important bleeding ICU length of stay Ventilator- free days Duration of ventilation
Barrett_P2, 2021 STARS ⁴¹	Peer-reviewed publication NCT04357730	14	United States	63.5	85.7	Copd (21.4%) Cardiac diseases (7.1%) Diabetes (35.7%)	Inpatient	Severe (100%)	NR	Mv (100.0%)	heparin (50 mg of tPA IV-bolus, followed by tPA drip 2 mg/hr plus heparin 500U/hour over 24 hours, then heparin to maintain	Mortality Clinically important bleeding ICU length of stay

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
						Hypertension (57.1%)					aPTT 60-80s for 7 days) tPA drip () standard care	Ventilator- free days Duration of ventilation
Bauer, 2021 ACEI-COVID ⁴²	Peer-reviewed publication NCT04353596	216	Austria, Germany	72	63.2	Copd (15.7%) Coronary artery disease (21.6%) Heart failure (8.8%) Atrial fibrillation (17.2%) Diabetes (32.8%) Hypertension (97.5%)	Inpatient (92.6%)	NR	2.5	Need of oxygen substitution (42.2%) Oxygen mask therapy (39.2%) Niv (2.5%)	ACEi/ARB (continuation of ACEi/ARB at the dose previously prescribed during routine care) standard care	Mortality Mechanical ventilation Duration of hospitalizati on
Baxter, 2021 ⁴³	Pre-print NCT04559035	79	United States	64	54.4	Asthma (5.7%) Diabetes (11.3%) Hypertension (43.4%)	Outpatient	Mild/Mo derate (100.0%)	NR	Supplemental oxygen (0.0%)	povidone-iodine nasal irrigation (0.5 tsp twice daily for 14 days) sodium bicarbonate nasal irrigation (0.5 tsp twice daily for 14 days)	Admission to hospital

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
Beigel, 2020 ACTT-1 ⁴⁴	Peer-reviewed publication NCT04280705	1062	United States, Denmark, United Kingdom, Greece, Germany, Korea, Mexico, Spain, Japan, Singapore	58.9	64.4	Chronic respiratory disease (7.6%) Chronic oxygen requirement (2.2%) Asthma (11.4%) Coronary artery disease (11.9%) Congestive heart failure (5.6%) T2DM (30.6%) T1DM (0.9%) Hypertension (50.7%)	Inpatient	NR	45	Supplemental oxygen (41.0%) High-flow or niv (18.2%) Iv or ecmo (26.8%)	remdesivir (100 mg/day for 10 days) placebo	Mortality Mechanical ventilation Adverse effects leading to discontinuati on Duration of hospitalizati on Duration of ventilation Time to symptom/cli nical improvemen t
Bhatt, 2021 ⁴⁵	Pre-print CTRI/2020/06/ 025664	44	India	44.3	70.5	Moderate or severe copd, interstitial lung disease, asthma (0.0%) Vascular disorders (9.1%) Diabetes (0.0%) Hypertension (9.1%)	Inpatient	Mild/Mo derate (100.0%)	NR	NR	2-deoxy-D-glucose (split dose (45 mg/kg in the morning, 18 mg/kg in the evening) per day for 28 days or discharge) standard care	Mortality Mechanical ventilation Viral clearance Duration of hospitalizati on Time to symptom/cli nical improvemen t Time to to

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
												viral clearance
Bhatt, 2021 ⁴⁵	Pre-print CTRI/2020/06/ 025664	66	India	45.2	87.7	Moderate or severe copd, interstitial lung disease, asthma (0.0%) Vascular disorders (0.0%) Diabetes (0.0%) Hypertension (0.0%)	Inpatient	Mild/Mo derate (100.0%)	NR	NR	2-deoxy-D-glucose (90 mg) (split dose (45 mg/kg in the morning, 45 mg/kg in the evening) per day for 10 days or discharge) 2-deoxy-D-glucose (126 mg) (split dose (63 mg/kg in the morning, 63 mg/kg in the evening) per day for 10 days or discharge) standard care	Mortality Mechanical ventilation Viral clearance Duration of hospitalizati on Time to symptom/cli nical improvemen t Time to to viral clearance
Bhushan, 2021 ⁴⁶	Peer-reviewed publication CTRI/2020/12/029855	250	India	49.9	70.8	NR	Inpatient	Mild/Mo derate (100.0%)	NR	NR	pegylated interferon alfa-2b (1 µg/kg subcutaneous injection, single dose) standard care	Mortality Mechanical ventilation Viral clearance Duration of hospitalizati on Time to

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
												symptom/cli nical improvemen t
Bikdeli, 2021 INSPIRATION ⁴⁷	Peer-reviewed publication NCT04486508	598	Iran	61.5	57.8	Obstructive airway disease (6.9%) Cardiovascular disease (13.9%) Diabetes (27.6%) Hypertension (44.3%)	Inpatient Intensive care (100.0%)	Severe (100%) Severe: Critical (100.0%)	22.8	Nasal cannula (4.3%) Face mask (10.7%) Reservoir mask (30.6%) High-flow (2.7%) Nippv (31.7%) Iv (20.1%)	enoxaparin (enoxaparin 1 mg/kg daily for 30 days) standard care	Mortality Venous thromboem bolism Clinically important bleeding ICU length of stay Ventilator- free days
Blum, 2021 ⁴⁸	Peer-reviewed publication NCT04348409	50	Brazil	64	30	NR	Inpatient	NR	NR	NR	nitazoxanide (600 mg twice daily for 7 days) placebo	Mortality Mechanical ventilation Adverse effects leading to discontinuati on Duration of hospitalizati on

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
Bosaeed, 2021 FACCT ⁴⁹	Peer-reviewed publication NCT04392973	268	Saudi Arabia	52.6	40.5	Asthma (11.8%) Heart disease (1.6%) History of myocardial infarction (0.0%) An irregular rhythm/ qtc (0.0%) Diabetes (42.1%) Hypertension (40.9%)	Inpatient Intensive care (16.9%)	Severe (100%)	17.7	Supplemental oxygen (74.8%) High-flow, niv (15.3%) Iv, ecmo (2.4%)	favipiravir (1800 mg by mouth twice on day 1 and 800 mg twice daily for 9 days) hydrochloroquine (400 mg twice on day 1 and 200 mg tice daily for 4 days) standard care	Mortality Mechanical ventilation Duration of hospitalizati on Time to symptom/cli nical improvemen t
Brown, 2020 HAHPS ⁵⁰	Peer-reviewed publication NCT04329832	85	United States	55	61.2	Copd (23.5%) Myocardial infarction (10.6%) Congestive heart failure (8.2%) Peripheral vascular disease (3.5%) Cerebrovascul ar disease (8.2%) Diabetes without end- organ damage (25.9%) Diabetes with	Inpatient Intensive care (43.5%)	NR	30.6	Supplemental oxygen (55.3%) High-flow or niv (15.3%) Iv (10.6%) Iv and other organ support (4.7%)	hydroxychloroquine (200 mg twice daily for 5 days) azithromycin (250 mg daily for 5 days)	Mortality Mechanical ventilation Adverse effects leading to discontinuati on Ventilator- free days Time to symptom/cli nical improvemen t

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
						end-organ damage (8.2%)						
Bukhari, 2021 ⁵¹	Pre-print NCT04392713	100	Pakistan	40.5	84.9	Ischemic heart disease (5.8%) Diabetes (11.6%) Hypertension (13.9%)	Inpatient	NR	NR	NR	ivermectin (12 mg single dose) standard care	Viral clearance
Buonfrate, 2021 COVER ⁵²	Pre-print NCT04438850	93	Italy	47.2	58.1	Respiratory condition (6.5%) Cardiovascular disease (23.7%) Diabetes (3.2%)	Outpatient	NR	0	Unspecified ventilation (0.0%)	ivermectin (600 μg/kg) (600 μg/kg single dose for 5 days) ivermectin (1200 μg/kg single dose for 5 days) placebo	Admission to hospital Adverse effects leading to discontinuati on Time to symptom/cli nical improvemen t
Butler, 2021 PRINCIPLE ⁵³	Peer-reviewed publication ISRCTN 86534580	1840	United Kingdom	61.1	44.1	Asthma, copd, or lung disease (37.3%) Angina, heart attack, heart failure, atrial fibrillation,	Outpatient	NR	NR	NR	doxycycline (100 mg once daily for 6 days) standard care	Mortality Mechanical ventilation Duration of hospitalizati on Time to

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
						valve problems (14.2%) Diabetes (18.0%) Hypertension (41.5%)						symptom/cli nical improvemen t
Byakika- Kibwika, 2021 HONEST tria ⁵⁴ l	Pre-print NCT04860284	105	Uganda	32	73.3	Heart disease (0.9%) Diabetes (2.9%) Hypertension (2.9%)	NR	NR	NR	NR	hydroxychloroquine (200 mg twice daily for 5 days) standard care	Adverse effects leading to discontinuati on Viral clearance Time to symptom/cli nical improvemen t Time to to viral clearance
CORIMUNO- SARI- 1_NCT043240 73, 2021 CORIMUNO- SARI-1 ¹⁵⁵	Meta-analysis NCT04324073	144	France	62.3	75	NR	Inpatient	Severe (100%)	NR	NR	sarilumab (400 mg for one to two doses) standard care	Mortality Duration of mechanical ventilation
CORIMUNO- SARI- ICU_NCT0432	Meta-analysis NCT04324073	81	France	61.6	76.5	NR	Inpatient Intensive care (100.0%)	Severe (100%)	NR	NR	sarilumab (400 mg one to two doses) standard care	Mortality

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
4073, 2021 CORIMUNO- SARI-ICU ¹												Duration of mechanical ventilation
CORIMUNO- TOCI- ICU_NCT0433 1808, 2021 ¹ CORIMUNO- TOCI-ICU	Meta-analysis NCT04331808	92	France	64.2	71.7	NR	Inpatient Intensive care (100.0%)	Mild/Mo derate (9.0%)	100	Unspecified ventilation (100.0%)	tocilizumab (8 mg/kg (up to 800 mg) one to two doses) standard care	Mortality Duration of mechanical ventilation
COV- AID_NCT0433 0638, 2021 COV-AID ¹	Meta-analysis NCT04330638	230	Belgium	63.6	77.4	NR	Inpatient	Severe (100%)	NR	NR	tocilizumab (8 mg/kg (up to 800 mg) single dose) siltuximab (11 mg/kg single dose) standard care	Mortality Duration of mechanical ventilation
COVIDOSE2- SSA_NCT0447 9358, 2021 COVIDOSE2- SSA ¹	Meta-analysis NCT04479358	28	United States	65	67.9	NR	Inpatient	Severe (100%)	0	Mechanical ventilation (0.0%)	tocilizumab (40 mg single dose) tocilizumab (120 mg single dose) standard care	Mortality
COVIDSTORM _NCT0457753 4, 2021 COVIDSTORM¹	Meta-analysis NCT04577534	39	Finland	65.7	53.9	NR	Inpatient	Severe (100%)	NR	NR	tocilizumab (8 mg/kg (up to 800 mg) single dose) standard care	Mortality
COVITOZ_NCT 04435717, 2021 COVITOZ-01 ¹	Meta-analysis NCT04435717	26	Spain	57.5	65.4	NR	Inpatient	Severe (100%)	NR	NR	tocilizumab (8 mg/kg (up to 800 mg) single dose) tocilizumab (8 mg/kg up to 800 mg two	Mortality

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
											doses) standard care	
Cadegiani_1, 2021 EAT-DUTA AndroCoV ⁵⁶	Peer-reviewed publication NCT04446429	130	Brazil	42	100	Asthma (0.8%) Copd (0.0%) Myocardial infarction (0.8%) Heart failure (0.8%) Stroke (0.0%) Other cardiac dysfunctions (2.3%) Diabetes (10.8%) Hypertension (25.4%)	Outpatient	Mild/Mo derate (100.0%)	0	Supplemental oxygen, niv, or iv (0.0%)	dutasteride (0.5 mg once daily) placebo	Mortality Mechanical ventilation Admission to hospital Adverse effects leading to discontinuati on Viral clearance Time to symptom/cli nical improvemen t
Cadegiani_2, 2020 ⁵⁷	Pre-print NCT04446429	214	Brazil	NR	100	NR	Outpatient	Mild/Mo derate (100.0%)	NR	NR	proxalutamide (200 mg/day for 15 days) placebo	Mortality Mechanical ventilation Admission to hospital

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
Cadegiani_3, 2021 ⁵⁸	Peer-reviewed publication	236	Brazil	44.9	54.2	Asthma (5.1%) Copd (0.0%) Myocardial infarction (0.8%) Stroke (0.8%) Congestive heart failure (0.8%) T1DM (8.9%) Hypertension (22.5%)	Outpatient	NR	NR	NR	proxalutamide (200 mg/day for 15 days) placebo	Adverse effects leading to discontinuati on Viral clearance Time to symptom/cli nical improvemen t
Cadegiani_4, 2021 ⁵⁹	Pre-print NCT04853134	177	Brazil	44.2	0	Copd (0.6%) Severe cardiovascular disease (0.0%) Diabetes (8.5%) Hypertension (31.1%)	Outpatient	NR	0	Unspecified ventilation (0.0%)	proxalutamide (200 mg daily for 7 days) placebo	Mortality Mechanical ventilation Admission to hospital Adverse effects leading to discontinuati on
Cadegiani_5, 2021 ⁶⁰	Pre-print NCT04728802	645	Brazil	49.5	56.7	Copd (2.5%) Congestive heart failure class iii or iv (0.0%) Diabetes (12.2%) Hypertension (27.1%)	Inpatient	Severe (100%)	66.5	Iv (0.0%) Niv (66.5%) Supplemental oxygen (30.4%)	proxalutamide (300 mg daily for 14 days) placebo	Mortality Mechanical ventilation Duration of hospitalizati on

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
Cao_1, 2020 LOTUS China ⁶¹	Peer-reviewed publication ChiCTR200002 9308.	199	China	58	60.3	Cerebrovascul ar disease (6.5%) Diabetes (11.6%)	Inpatient	Severe (100%)	16.1	Supplemental oxygen (69.8%) High-flow or niv (15.6%) Iv or ecmo (0.5%)	lopinavir-ritonavir (400 mg/100 mg twice daily for 14 days) standard care	Mortality Mechanical ventilation Viral clearance Duration of hospitalizati on ICU length of stay Duration of ventilation Time to symptom/cli nical improvemen t
Cao_2, 2020 ⁶²	Peer-reviewed publication ChiCTR-OPN-2000029580	43	China	63	58.5	Coronary artery heart disease (7.3%) Diabetes (19.5%) Hypertension (39.0%)	Inpatient	Severe (100%)	12.2	Supplemental oxygen (87.8%) High flow or niv (12.2%)	ruxolitinib (5 mg twice daily) placebo	Mortality Mechanical ventilation Duration of hospitalizati on Duration of ventilation Time to symptom/cli nical improvemen t Time to viral clearance

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
Caricchio, 2021 CAN-COVID trial ⁶³	Peer-reviewed publication NCT04362813	454	France, Germany, Hungary, Italy, Russia, Spain, United Kingdom, United States	58	58.8	Chronic obstructive pulmonary disease (7.3%) Asthma (7.7%) Chronic cardiac disease (20.3%) Cerebrovascul ar disease (6.0%) Diabetes (36.1%) Hypertension (55.7%)	Inpatient	Severe (100%)	0	Iv (0.0%)	canakinumab (single dose of canakinumab (450mg for body weight of 40-<60 kg, 600mg for 60-80 kg, and 750 mg for >80 kg) in 250 mL of 5% dextrose infused intravenously over 2 hours) placebo	Mortality Mechanical ventilation Adverse effects leading to discontinuati on Duration of hospitalizati on Duration of ventilation Time to symptom/cli nical improvemen t
Carrouel, 2021 ⁶⁴	Peer-reviewed publication NCT04352959	176	France	43.1	45.5	NR	Inpatient (6.5%)	Mild/Mo derate (100.0%)	0	Unspecified ventilation (0.0%)	R-cyclodextrin (3 daily mouthwashes (morning, noon and evening) for 30 seconds during 7 days) citrox mouthwash () placebo	NR
Castillo, 2020 Pilot Covidiol ⁶⁵	Peer-reviewed publication NCT04366908 (full trial of pilot)	76	Spain	53	59.2	Previous lung disease (7.9%) Cardiovascular disease (4.0%) Diabetes (10.5%)	Inpatient	NR	NR	NR	vitamin D (0.532 mg on day 1, then 0.266 mg on day 3 and 7, and then weekly until discharge or ICU	Mortality Adverse effects leading to discontinuati on

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
						Hypertension (34.2%)					admission) standard care	
Cavalcanti, 2020 ⁶⁶	Peer-reviewed publication NCT04322123	667	Brazil	50.3	58.4	Copd (1.8%) Asthma (6.0%) Heart failure (1.5%) Diabetes (19.1%) Hypertension (38.8%)	Inpatient Intensive care (13.8%)	NR	0	Supplemental oxygen (41.8%) High-flow, niv, or iv (0.0%)	azithromycin (500 mg/day for 7 days) hydroxychloroquine (400 mg twice daily for 7 days) hydroxychloroquine (400 mg twice daily for 7 days) standard care	Mortality Mechanical ventilation Duration of hospitalizati on
Chaccour, 2020 SAINT ⁶⁷	Peer-reviewed publication NCT04390022	24	Spain	26	50	Copd (0.0%) Coronary disease (0.0%) Diabetes (0.0%) Hypertension (0.0%)	Outpatient	Mild/Mo derate (100.0%)	NR	NR	ivermectin (400 μg/kg single dose) placebo	Viral clearance Time to to viral clearance
Chachar, 2020 ⁶⁸	Peer-reviewed publication	50	Pakistan	41.8	62	Chronic lung disease (0.0%) Cardiovascular disease (8.0%) Diabetes (40.0%) Hypertension (26.0%)	Outpatient	Mild/Mo derate (100.0%)	NR	NR	ivermectin (12 mg once, then 12 mg after 12 hours, and 12 mg after 24 hours) standard care	NR
Chahla, 2021 IVER-Leve ⁶⁹	Pre-print NCT04784481	254	Argentina	37.7	47.6	Asthma (1.2%) Diabetes (6.3%)	Outpatient	Mild/Mo derate (100.0%)	NR	NR	ivermectin (6 mg taken four times every 7 days	Mortality Adverse effects

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
						Hypertension (12.6%)					for 4 weeks) standard care	leading to discontinuati on Time to symptom/cli nical improvemen t
Chaudhary, 2021 ⁷⁰	Peer-reviewed publication NCT04603794	0	United States	50.6	59.5	NR	Inpatient	NR	NR	NR	saline mouthwash (30 second oral rinse with 0.9% normal saline) hydrogen peroxide mouthwash (30 second oral rinse with 1% hydrogen peroxide) chlorhexidine gluconate mouthwash (30 second oral rinse with 0.12% chlorhexidine gluconate) povidone-iodine mouthwash (30 second oral rinse with 0.5% povidone iodine)	Adverse effects leading to discontinuati on
Chen_1, 2020 ⁷¹	Pre-print ChiCTR200002 9559	62	China	44.7	46.8	NR	Inpatient	Mild/Mo derate (100.0%)	NR	NR	hydroxychloroquine (200 mg twice daily for 5 days) standard care	Time to symptom/cli nical improvemen t

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
Chen_2, 2020 ⁷²	Pre-print ChiCTR200003 0254	240	China	NR	46.6	Diabetes (11.4%) Hypertension (28.0%)	NR	Mild/Mo derate (88.5%) Severe (11.4%) Severe: Critical (1.3%)	NR	NR	favipiravir (600 mg twice daily for 7 days) umifenovir (200 mg three times daily for 7 to 14 days)	Mortality Time to symptom/cli nical improvemen t
Chen_3, 2020 ⁷³	Peer-reviewed publication NCT04261517	30	China	48.6	70	Severe lung disease (0.0%) Copd (3.3%) Severe heart disease (0.0%) Diabetes (6.7%) Hypertension (26.7%)	Inpatient	Mild/Mo derate (100.0%)	NR	NR	hydroxychloroquine (400 mg once daily for 5 days) standard care	Mortality Adverse effects leading to discontinuati on Viral clearance Time to symptom/cli nical improvemen t Time to to viral clearance
Chen_4, 2020 ⁷⁴	Pre-print ChiCTR200003 0054	48	China	46.9	45.8	Diabetes (18.8%) Hypertension (16.7%)	Inpatient	Mild/Mo derate (100.0%)	NR	Supplemental oxygen (72.9%)	chloroquine (500 mg once daily for 10 days) hydroxychloroquine (200 mg twice daily for 10 days) standard care	Mortality Adverse effects leading to discontinuati on Viral clearance

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
												Duration of hospitalizati on Time to symptom/cli nical improvemen t Time to to viral clearance
Chen_5, 2020 ⁷⁵	Peer-reviewed publication NCT04384380	33	Taiwan	32.9	57.6	Lung disease (0.0%) Cardiac conduction abnormalities at 152 electrocardiog raphic (0.0%)	Inpatient	Mild/Mo derate (100.0%)	NR	Supplemental oxygen (0.0%)	hydroxychloroquine (200 mg twice daily for 7 days) standard care	Mortality Time to to viral clearance
Cheng, 2020 ⁷⁶	Peer-reviewed publication ChiCTR200003 0007	200	China	45	56	Respiratory condition (0.0%) Cardiovascular disease (0.0%) Diabetes (0.0%) Hypertension (0.0%)	Inpatient	NR	27	Supplemental oxygen (60.0%) High-flow nasal cannula or niv (27.0%)	recombinant human granulocyte colony- stimulating factor (5 µg/kg/day for 3 days) standard care	Mortality Mechanical ventilation Viral clearance Duration of hospitalizati on Time to symptom/cli nical

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
												improvemen t
Clemency, 2021 ⁷⁷	Pre-print NCT04377711	400	United States	43.3	44.8	Asthma (6.5%) Cystic fibrosis (0.0%) Idiopathic pulmonary fibrosis (0.0%) Diabetes (7.5%) Hypertension (22.2%)	Outpatient	NR	0	Unspecified ventilation (0.0%)	ciclesonide (320 µg twice daily for 30 days) placebo	Mortality Admission to hospital Adverse effects leading to discontinuati on Time to symptom/cli nical improvemen t
Cohen, 2020 REPLACE COVID trial ⁷⁸	Peer-reviewed publication NCT04338009	152	USA, Canada, Mexico, Sweden, Peru, Bolivia, and Argentina	62	55.3	Chronic pulmonary disease; 11.18 (17.1%) Pre-existing cardiac disease; 11.84 (15.8%) Diabetes (52.0%) Hypertension (100.0%)	Inpatient	Mild/Mo derate (87.5%)	NR	Supplemental oxygen (80.9%)	ACEI/ARB (continuation of ACEI/ARB at the dose previously prescribed during routine care) standard care	Mortality Mechanical ventilation Adverse effects leading to discontinuati on Duration of hospitalizati on

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
Connors, 2021 ACTIV-4B ⁷⁹	Peer-reviewed publication NCT04498273	657	United States	54	40.9	Diabetes (18.3%) Hypertension (35.3%)	Outpatient	NR	NR	NR	aspirin (81 mg once daily for 45 days) apixaban (2.5 TID) (2.5 mg twice daily for 45 days) apixaban (5.0 TID) (5 mg twice daily for 45 days) placebo	Mortality Admission to hospital Venous thromboem bolism Clinically important bleeding
Corral-Gudino, 2020 GLUCOCOVID ⁸	Peer-reviewed publication 2020-001934-37	64	Spain	69.8	60.9	Respiratory condition (7.8%) Heart disease (12.5%) Arrhythmia (0.0%) Diabetes (17.2%) Hypertension (46.9%)	Inpatient	Severe (100%)	0	Mechanical ventilation (0.0%)	methylprednisolone (40 mg twice daily for 3 days, then 20 mg twice daily for 3 days) standard care	Mortality Mechanical ventilation Duration of hospitalizati on
Cremer_1, 2020 Three C Study ⁸¹	Peer-reviewed publication NCT04365153	45	United States	68.8	73.3	Copd (17.8%) Coronary artery disease (22.2%) Atrial fibrillation or flutter (13.3%) Acute myocardial injury (100.0%) Diabetes	Inpatient	NR	46.7	Supplemental oxygen (44.4%) High-flow or niv (24.4%) Iv (22.2%)	canakinumab (600 mg) (600 mg single dose based on weight over 2 hours) canakinumab (300 mg) (300 mg single dose based on weight over 2 hours) placebo	Mortality Time to symptom/cli nical improvemen t

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
						(46.7%) Hypertension (71.1%)						
Cremer_2, 2021 MASH-COVID ⁸²	Peer-reviewed publication NCT04399980, NCT04463004, NCT04492514	40	United States	56.7	65	Chronic obstructive pulmonary disease (7.5%) Coronary artery disease (10.0%) Diabetes (42.5%) Hypertension (55.0%)	Inpatient	Severe (100%)	50	Supplemental oxygen (50.0%) High-flow or niv (50.0%) Iv (0.0%)	mavrilimumab (6mg/kg single intravenous infusion) placebo	Mortality Mechanical ventilation Duration of hospitalizati on Duration of ventilation Time to symptom/cli nical improvemen t
Criner, 2020 ⁸³	Published NCT04252664	584	China	57	61	Asthma (11.0%) Hypertension (39.0%)	Inpatient	Mild/Mo derate (100.0%)	0	Unspecified ventilation (0.0%)	remdesivir (5 days) (200 mg on day 1, then 100 mg daily for 5 days) remdesivir (10 days) (200 mg on day 1, then 100 mg daily for 10 days) standard care	Mortality Adverse effects leading to discontinuati on

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
Crippa, 2021 CANDIDATE ⁸⁴	Peer-reviewed publication NCT04467918	105	Brazil	39.7	34.1	Asthma (3.3%) Diabetes (2.2%) Hypertension (4.4%)	Outpatient	NR	NR	NR	cannabidiol (150 mg twice daily for 14 days) placebo	Mortality Admission to hospital Adverse effects leading to discontinuati on Time to symptom/cli nical improvemen t Time to viral clearance
Cruz, 2020 ATENEA-Co- 300 ⁸⁵	Peer-reviewed publication IG/CIGB300I/C V/2001	20	Cuba	45.4	70	Diabetes (0.0%) Hypertension (25.0%)	Inpatient	Mild/Mo derate (90.0%) Severe (10.0%)	NR	NR	anti-CK2 synthetic peptide (2.5 mg/kg/day for 5 days) standard care	Adverse effects leading to discontinuati on Time to to viral clearance
Darazam_1, 2021 COVIFERON II ⁸⁶	Peer-reviewed publication NCT04521400	168	Iran	59.8	61.9	Copd (1.2%) Asthma (1.8%) Coronary heart disease (14.9%) Ischemic heart disease (18.7%) Congestive	Inpatient	Severe (100%)	NR	NR	interferon beta-1a (high-dose) (subcutaneous) (88 µg/day on days 1, 3 and 6) interferon beta-1a (low-dose) (subcutaneous) (44	Mortality Duration of hospitalizati on Time to symptom/cli nical

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
						heart failure (11.4%) Cerebrovascul ar disease (5.4%) Diabetes (26.8%) Hypertension (37.3%)					μg/day on days 1, 3 and 6)	improvemen t
Darazam_2, 2021 COVIFERON ⁸⁷	Peer-reviewed publication NCT04343768	60	Iran	69	51.7	Coronary heart disease (16.7%) Diabetes (23.3%) Hypertension (33.3%)	Inpatient	Severe (100%)	NR	NR	interferon beta-1a (subcutaneous) (44 µg on days 1, 3 and 6) Interferon beta-1b (subcutaneous) (0·25 mg on days 1, 3 and 6) standard care	Mortality Mechanical ventilation Adverse effects leading to discontinuati on Duration of hospitalizati on Time to symptom/cli nical improvemen t
Darazam_3, 2021 ⁸⁸	Peer-reviewed publication NCT04350684	101	Iran	61.2	56.4	Asthma (5.9%) Coronary heart disease (10.9%) Ischemic heart disease (22.8%)	Inpatient	Severe (100%)	NR	NR	umifenovir (200 mg three times daily for 7 days) standard care	Mortality Mechanical ventilation Adverse effects leading to discontinuati

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
						Diabetes (30.7%) Hypertension (44.5%)						on Duration of hospitalizati on Duration of ventilation Time to symptom/cli nical improvemen t
Darban, 2021 ⁸⁹	Peer-reviewed publication IRCT20151228 025732N52	20	Iran	59	65	NR	Inpatient Intensive care (100.0%)	Severe (100%)	NR	NR	melatonin (6 mg four times daily for 10 days) vitamin C (2 g four times daily for 10 days) zinc sulfate (220 mg and 50 mg four times daily for 10 days) standard care	ICU length of stay
Davoodi, 2020 ⁹⁰	Published IRCT20190727 04434N1	60	Iran	57.7	59.3	Lung disease (1.9%) Diabetes (27.8%)	Outpatient	NR	0	Supplemental oxygen, niv, or iv (0.0%)	febuxostat (80 mg once daily for 5 days) hydroxychloroquine (200 mg twice daily for 5 days)	Mortality Admission to hospital
Davoodi_2, 2021 ⁹¹	Peer-reviewed publication IRCT20190727 044343N2	40	Iran	46	52.5	Lung diseases (7.5%) Cardiovascular disease (0.0%) Diabetes (12.5%)	Inpatient	Severe (100%)	NR	NR	atorvastatin (40 mg once daily for 5 days) placebo	Mechanical ventilation Duration of hospitalizati on

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
						Hypertension (15.0%)						
Davoodian, 2021 ⁹²	Pre-print IRCT20200408 046988N1	96	Iran	56.2	56.8	Heart disease (19.8%) Diabetes (14.8%) Hypertension (18.5%)	Inpatient	NR	NR	Intubated (0.0%)	melatonin (3 mg three times daily for 2 weeks) placebo	NR
Davoudi- Monfared, 2020 ⁹³	Peer-reviewed publication IRCT20100228 003449N28	92	Iran	58.7	54.3	Asthma (1.2%) Copd (1.2%) Ischemic heart disease (28.4%) Diabetes (27.2%) Hypertension (38.3%)	Inpatient	Severe (100%)	29.6	Supplemental oxygen (69.1%) High-flow or niv (4.9%) Iv (24.7%)	interferon beta-1a (subcutaneous) (44 µg/ml three times weekly for 14 days) standard care	Mortality Mechanical ventilation Adverse effects leading to discontinuati on Duration of hospitalizati on ICU length of stay Duration of ventilation Time to symptom/cli nical improvemen t

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
Defteros, 2020 GRECCO-19 ⁹⁴	Published NCT04326790	110	Greece	64	58.1	Copd (4.8%) Coronary artery disease (13.3%) Valvulopathy (4.8%) Atrial fibrillation (10.5%) Diabetes (20.0%) Hypertension (44.8%)	Inpatient	Severe (100%)	2.9	Supplemental oxygen (62.9%) High-flow or niv (2.9%)	colchicine (0.5 mg twice daily for 21 days) standard care	Mortality Mechanical ventilation Adverse effects leading to discontinuati on Duration of hospitalizati on
Delgado- Enciso, 2021 TX-COVID19 ⁹⁵	Peer-reviewed publication RPCEC000003	217	Mexico	43.7	50.3	Asthma (5.2%) Ischemic heart disease (0.0%) Diabetes (16.4%) Hypertension (16.8%)	Outpatient	Mild/Mo derate (88.8000 0000000 001%)	NR	NR	electrolyzed saline (15 ml/day for 7 days, with successive increases up to 30 ml/day if indicated) standard care	Mortality Admission to hospital Adverse effects leading to discontinuati on Time to symptom/cli nical improvemen t
Dequin, 2020 CAPECOVID ⁹⁶	Peer-reviewed publication NCT02517489	149	France	62.2	69.8	Chronic obstructive pulmonary disease (4.0%) Asthma (3.4%) Congestive	Inpatient Intensive care (100.0%)	Severe (100%) Severe: Critical (100.0%)	94	Nonrebreathin g mask with a reservoir bag (6.0%) High-flow (12.8%)	hydrocortisone (200 mg once daily for 7 days, followed by 100 mg once daily for 4 days, and 50 mg once	Mortality Mechanical ventilation

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
						heart failure (4.0%) Cerebrovascul ar disease (1.3%) Diabetes (18.1%)				Niv or iv (81.2%)	daily for 3 days) placebo	
Di Domenico, 2021 ⁹⁷	Peer-reviewed publication RBR-6sx3sz	40	Brazil	NR	37.1	Respiratory condition (8.6%) Cardiovascular disease (8.6%) Diabetes (28.6%) Hypertension (48.6%)	NR	NR	NR	NR	hydrogen peroxide (1% H2O2 for gargling and 0.5% H2O2 for a nasal wash, three times a day for 7 days) placebo	Duration of hospitalizati on Time to symptom/cli nical improvemen t
Di Pierro_1, 2021 ⁹⁸	Peer-reviewed publication NCT04578158	152	Pakistan	NR	57.9	NR	Outpatient	NR	NR	NR	quercetin (200 mg twice daily for 30 days) standard care	Mortality Mechanical ventilation Admission to hospital Duration of hospitalizati on
Di Pierro_2, 2021 ⁹⁹	Peer-reviewed publication NCT04861298	42	Pakistan	49.4	47.6	NR	Outpatient	NR	NR	NR	quercetin (200 mg three times daily for week 1) standard care	Mortality Admission to hospital Adverse effects leading to discontinuati

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
												on Viral clearance
Doaei, 2021 ¹⁰⁰	Peer-reviewed publication IRCT20151226 025699N3	128	Iran	64.5	59.4	Lung diseases (0.0%) Cardiovascular diseases (0.0%)	Inpatient Intensive care (100.0%)	Severe (100%) Severe: Critical (100.0%)	NR	NR	omega 3 (docosahexaenoic acid (200 mg daily for 14 days), eicosapentaenoic acid (400 mg daily for 14 days)) standard care	Mortality
Doi, 2020 ¹⁰¹	Peer-reviewed publication jRCTs0411901 20	89	Japan	50	61.4	NR	Inpatient	NR	NR	Supplemental oxygen (3.4%)	favipiravir (early) (800 mg twice daily for 10 days) favipiravir (late) (800 mg twice daily for 10 days starting on day 6 of enrolment)	Mortality Mechanical ventilation Viral clearance Duration of hospitalizati on Time to symptom/cli nical improvemen t Time to to viral clearance
Dorward, 2021 PRINCIPLE ¹⁰²	Pre-print ISRCTN865345 80	276	United Kingdom	60.5	46.2	Asthma, copd, lung disease (29.6%) Heart	Outpatient	NR	NR	NR	colchicine (500 µg daily for 14 days) standard care	Mortality Mechanical ventilation Duration of

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
						problems (9.2%) Diabetes (12.7%) Hypertension (24.2%)						hospitalizati on Time to symptom/cli nical improvemen t
Duarte, 2021 ¹⁰³	Peer-reviewed publication NCT04355936	162	Argentina	65.3	53.2	Copd (11.4%) Asthma (3.2%) Stroke (7.0%) Diabetes (19.0%) Hypertension (44.9%)	Inpatient	NR	NR	Supplemental oxygen (68.4%)	telmisartan (80 mg twice daily for 14 days) standard care	Mortality Mechanical ventilation Adverse effects leading to discontinuati on Duration of hospitalizati on
Dubée, 2021 HYCOVID ¹⁰⁴	Peer-reviewed publication NCT04325893	250	France, Monaco	77	48.4	Chronic respiratory disease (11.2%) Heart disease (28.8%) Diabetes (17.2%) Hypertension (53.2%)	Inpatient (98.8%)	Mild/Mo derate (100.0%)	NR	Supplemental oxygen (60.4%)	hydroxychloroquine (400 mg twice for first day, 200mg twice daily for 8 days) placebo	Mortality Mechanical ventilation Adverse effects leading to discontinuati on Viral clearance

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
EPIC-HR, 2021 EPIC-HR ¹⁰⁵	Data from authors NCT04960202	0	United States, Argentina, Brazil, Bulgaria, Colombia, Czechia, Hungary, India, Japan, Korea, Malaysia, Mexico, Poland, Puerto Rico, Russia, South Africa, Spain, Taiwan, Thailand, Turkey, Ukraine	44.7	52.4	Chronic lung disease (4.9%) Cardiovascular disease (3.7%) Diabetes (12.8%) Hypertension (32.4%)	Outpatient	NR	NR	Home oxygen (0.0%)	nirmatrelvir /ritonavir (300 mg and 100 mg twice daily for 5 days) placebo	Mortality Admission to hospital Adverse effects leading to discontinuati on
Edalatifard, 2020 ¹⁰⁶	Peer-reviewed publication IRCT20200404 046947N1	68	Iran	58.5	62.9	Respiratory condition (9.7%) Cardiovascular disease (17.7%) Diabetes (35.5%) Hypertension (32.3%)	Inpatient	Severe (100%)	37.1	Nasal cannula (21.0%) Simple mask (11.3%) Reserve mask (29.0%) Niv (37.1%)	methylprednisolone (250 mg/day for 3 days) standard care	Mortality Mechanical ventilation Time to symptom/cli nical improvemen t
Eid, 2021 ¹⁰⁷	Peer-reviewed publication	370	Egypt	NR	43.8	NR	NR	Severe (100%)	NR	NR	cefepime (100 0mg twice daily for 5 days) ceftazidime (1000 mg	Mortality Time to symptom/cli

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
											three times daily for 5 days) standard care	nical improvemen t
El-Bendary, 2021 ¹⁰⁸	Peer-reviewed publication	174	Egypt	53	54.6	Asthma (1.7%) Pulmonary fibrosis (0.6%) Cardiac disease (10.9%) Cvt, pe, or stroke (3.5%) Diabetes (37.4%) Hypertension (21.3%)	Inpatient (79.3%)	NR	2.3	Nasal prong or facial mask (63.8%) Niv (2.3%)	sofosbuvir-daclatasvir (400 mg of sofosbuvir and 60 mg of daclatasvir given once daily for 14 days) standard care	Mortality Mechanical ventilation Viral clearance Duration of hospitalizati on
Elamir, 2021 ¹⁰⁹	Data from authors	50	United States	NR	NR	NR	Inpatient	NR	NR	NR	vitamin D (0.5 mcg daily for 14 days or until hospital discharge) standard care	Mortality Duration of hospitalizati on
Elgohary, 2021 ¹¹⁰	Pre-print NCT04530422	250	Egypt	43.5	0.5	NR	Inpatient	Mild/Mo derate (100.0%)	0	Mechanical ventilation (0.0%)	ledipasvir (once daily for 15 days) sofosbuvir () azithromycin (500mg once then 250mg daily for 6 days) hydroxychloroquine (400mg every 12 hours for one day then 200mg every 12 hours for 9 days) oseltamivir	Mortality Adverse effects leading to discontinuati on Duration of hospitalizati on Time to symptom/cli

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
											(150mg every 12 hours for 10 days)	nical improvemen t Time to to viral clearance
Ely, 2021 COV-BARRIER addendum ¹¹¹	Pre-print NCT04421027	101	Argentina, Brazil, Mexico, United States	58.6	54.5	Chronic respiratory disease (3.0%) Diabetes (35.6%) Hypertension (54.5%)	Inpatient	Severe (100%) Severe: Critical (100.0%)	100	lv or ecmo (100.0%)	baricitinib (4 mg daily for 14 days or until discharge) placebo	Mortality Adverse effects leading to discontinuati on Duration of hospitalizati on ICU length of stay Ventilator- free days Duration of ventilation Time to symptom/cli nical improvemen t
Esquivel- Moynelo, 2020 ESPERANZA ¹¹²	Pre-print RPCEC000003 07	79	Cuba	38	54	Asthma (6.3%) Cardiac diseases (6.3%) Severe arterial hypertension	Inpatient	NR	NR	NR	interferon gamma (subcutaneous) (0.5 MIU twice weekly for 14 days) standard care	Mortality Viral clearance Time to to

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
						(0.0%) Ischemic heart disease (0.0%) Diabetes (4.8%) Hypertension (22.2%)						viral clearance
Esther, 2021 ¹¹³	Pre-print NCT04347538	88	United States	40.7	48.6	Chronic lung disease (12.5%) Heart disease (4.2%) Diabetes (8.3%) Hypertension (19.4%)	Outpatient	NR	0	Unspecified ventilation (0.0%)	hypertonic saline (Twice daily irrigation) surfactant () hypertonic saline (Twice daily irrigation) standard care	NR
Ezer, 2021 CONTAIN ¹¹⁴	Peer-reviewed publication NCT04435795	215	Canada	35	46.3	Asthma, no treatment (4.9%) Ischemic heart disease (0.5%) Diabetes (2.5%) Hypertension (5.9%)	Outpatient	NR	0	Unspecified ventilation (0.0%)	ciclesonide (50 µg twice daily intranasally, or 600 µg twice daily inhaled, for 14 days) placebo	Mortality Admission to hospital
Fakharian, 2021 ¹¹⁵	Peer-reviewed publication IRCT20151227 025726N23	68	Iran	54.6	58.8	Copd (1.5%) Tuberculosis (0.0%) Ischemic heart disease (4.4%) Diabetes	Inpatient	Severe (100%)	100	Unspecified ventilation (100.0%)	adalimumab (40 mg single dose given subcutaneously) standard care	Mortality Mechanical ventilation Duration of hospitalizati on

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
						(27.9%) Hypertension (29.4%)						ICU length of stay
Farahani, 2020 ¹¹⁶	Pre-print IRCT20200406 046963N1	29	Iran	64	65.5	Uncontrolled diabetes mellitus (0.0%)	Inpatient Intensive care (100.0%)	Severe (100%)	NR	NR	methylprednisolone (1000 mg/day for 3 days) prednisolone (1 mg/kg with tapering of dose over 10 days) standard care	Mortality Mechanical ventilation ICU length of stay
Farnoosh, 2021 ¹¹⁷	Peer-reviewed publication NCT04409522	74	Iran	51.8	59.1	Cardiovascular disease (6.8%) Diabetes (22.7%) Hypertension (25.0%)	Inpatient	NR	NR	NR	melatonin (3 mg three times daily for 14 days) standard care	Mortality Adverse effects leading to discontinuati on Duration of hospitalizati on Time to symptom/cli nical improvemen t
Feld, 2020 ¹¹⁸	Peer-reviewed publication NCT04354259	60	Canada	46.7	58.3	Diabetes (5.0%) Hypertension (10.0%)	Outpatient	NR	NR	NR	peginterferon lambda (subcutaneous) (180 µg single injection) placebo	Mortality Admission to hospital Viral clearance Time to to

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
												viral clearance
Fiorentino, 2021 ¹¹⁹	Peer-reviewed publication NCT04637906	101	Italy	61.6	81.2	Chronic pulmonary disease (0.0%) Coronary artery disease (14.4%) Diabetes (10.0%) Hypertension (36.6%)	Inpatient	Severe (100%)	5.5	Hfnc (67.8%) Cpap (7.8%) Niv (5.5%)	L-arginine (1.66 g twice daily) placebo	Mortality Adverse effects leading to discontinuati on Duration of hospitalizati on Time to to viral clearance
Fischer, 2021 ¹²⁰	Pre-print NCT04405570	202	United States	40.1	48.5	NR	Outpatient	NR	NR	NR	molnupiravir (200 mg) (200 mg twice per day for 5 days) molnupiravir (400 mg) (400 mg twice per day for 5 days) molnupiravir (800 mg) (800 mg twice per day for 5 days) placebo	Mortality Admission to hospital Adverse effects leading to discontinuati on Viral clearance Time to to viral clearance

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
Fisher_1, 2021 CATALYST ¹²¹	Pre-print EudraCT2020- 001684-89, ISRCTN405809 03	111	United Kingdom	59.4	64	Chronic obstructive pulmonary disease, asthma, interstitial lung disease (23.4%)	Inpatient Intensive care (40.5%)	NR	51.4	High-flow or cpap (31.5%) Iv (19.8%)	namilumab (150 mg given as a single intravenous dose over 1 hour on day 1) standard care	Mortality Mechanical ventilation Time to symptom/cli nical improvemen t
Fisher_2, 2021 CATALYST ¹²¹	Pre-print EudraCT2020- 001684-89, ISRCTN405809 03	69	United Kingdom	59.9	58	Chronic obstructive pulmonary disease, asthma, interstitial lung disease (26.5%)	Inpatient Intensive care (36.2%)	NR	NR	NR	infliximab (5 mg/kg given as a single intravenous dose over 2 hours on day 1) standard care	Mortality Mechanical ventilation Time to symptom/cli nical improvemen t
Fragoso- Saavedra, 2021 PISCO ¹²²	Pre-print NCT04343963	188	Mexico	52	59.6	Chronic lung disease (4.3%) Heart disease (2.1%) Diabetes (36.2%) Hypertension (35.1%)	Inpatient	Severe (100%)	NR	Supplemental oxygen (100.0%)	pyridostigmine (60 mg daily until prespecified outcomes, discharge or 14 in-hospital days) placebo	Mortality Mechanical ventilation Adverse effects leading to discontinuati on Duration of hospitalizati on Duration of ventilation

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
Fu, 2020 ¹²³	Peer-reviewed publication ChiCTR200003 0262	80	China	35.2	63.8	Diabetes (3.8%) Hypertension (5.0%)	Inpatient	Mild/Mo derate (100.0%)	NR	NR	interferon kappa (nebulised) (2 mg/day for 6 days) trefoil factor 2 (5 mg/day for 6 days) standard care	Mortality Adverse effects leading to discontinuati on Viral clearance Duration of hospitalizati on Time to to viral clearance
Furtado, 2020 COALITION II ¹²⁴	Peer-reviewed publication NCT04321278	447	Brazil	60.2	64	Copd (6.7%) Heart failure (5.6%) Previous stroke (4.0%) Previous mi (4.5%) Diabetes (38.0%) Hypertension (60.9%)	Inpatient	Severe (100%)	50.3	Unspecified ventilation (50.3%)	azithromycin (500 mg daily for 10 days) standard care	Mortality Mechanical ventilation Duration of hospitalizati on Ventilator- free days
Gaitain- Duarte, 2021 ¹²⁵	Pre-print NCT04359095	649	Colombia	55.4	67.6	Chronic respiratory disease (4.4%) Cardiovascular disease (2.7%) Diabetes (12.0%)	Inpatient Intensive care (26.7%)	NR	82.8	Niv (66.0%) High-flow oxygen (9.0%) Iv (7.7%)	colchicine (0.5 mg twice a day for 14 days) rosuvastatin (40 mg once a day for 14 days) colchicine (0.5 mg twice a day for 14	Mortality Mechanical ventilation Adverse effects leading to discontinuati

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
						Hypertension (27.8%)					days) emtricitabine- tenofovir (200 mg/300 mg once a day for 10 days) rosuvastatin (40 mg once a day for 14 days) emtricitabine-tenofovir (200 mg/300 mg once a day for 10 days) standard care	on Duration of hospitalizati on
Galan, 2021 ¹²⁶	Peer-reviewed publication RBR-8h7q82	168	Brazil	53.4	56.5	Previous pulmonary disease (5.4%) Diabetes (26.8%) Hypertension (41.1%)	Inpatient	Severe (100%)	NR	NR	chloroquine (450 mg once daily for 5 days) hydroxychloroquine (400 mg once daily for 5 days) ivermectin (10 mg to 14 mg once daily for 3 days based on weight)	Mortality Mechanical ventilation
Geriak, 2021 ¹²⁷	Peer-reviewed publication NCT04340557	32	United States	57.1	61.3	Cardiovascular disease (3.2%) Diabetes (25.8%) Hypertension (38.7%)	Inpatient	NR	0	Nasal cannula (100.0%) Mechanical ventilation (0.0%)	losartan (12.5 mg twice daily for 10 days) standard care	Mortality Mechanical ventilation Adverse effects leading to discontinuati on Duration of hospitalizati on
Ghaderkhani, 2020 ¹²⁸	Pre-print IR.TUMS.VCR.	56	Iran	44.4	60.4	NR	Inpatient (3.8%)	NR	NR	NR	umifenovir (200 mg every twelve hours for	NR

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
	REC.1399.204, 04.13.2020										10 days) standard care	
Ghandehari, 2021 ¹²⁹	Peer-reviewed publication NCT04365127	42	United States	55.2	100	Diabetes (25.0%) Hypertension (47.5%)	Inpatient	Severe (100%)	7.5	Supplemental oxygen (77.5%) High-flow (7.5%) Mechanical ventilation (0.0%)	progesterone (100 mg twice daily for up to 5 days) standard care	Mortality Mechanical ventilation Adverse effects leading to discontinuati on Duration of hospitalizati on Time to symptom/cli nical improvemen t
Ghanei, 2021 ¹³⁰	Peer-reviewed publication IRCT20200318 046812N2	352	Iran	58.1	51.5	Chronic lung disease, not asthma (4.5%) Chronic heart disease (8.9%) Diabetes (12.2%) Hypertension (24.7%)	Inpatient	Severe (100%)	NR	NR	azithromycin (250 mg once daily for 5 days) naproxen (250 mg twice daily for 5 days) prednisolone (25 mg once daily for 5 days) azithromycin (250 mg once daily for 5 days) naproxen (250 mg twice daily for 5 day) lopinavir-ritonavir (200 mg and 50 mg twice daily for 7 days)	Mortality Mechanical ventilation Duration of hospitalizati on Time to symptom/cli nical improvemen t

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
Ghati, 2021 RESIST ¹³¹	Pre-print CTRI/2020/07/ 026791	900	India	53.1	73.7	Cad (1.1%) Lvd (0.1%) Diabetes (27.7%) Hypertension (28.6%)	Inpatient	NR	2.8	High-flow or niv (2.8%) Iv (0.0%)	atorvastatin (40 mg daily for 10-days or discharge) aspirin (75 mg daily for 10 days or discharge) aspirin (45 mg + 75 mg daily for 10 days or discharge) atorvastatin () standard care	Mortality Mechanical ventilation Adverse effects leading to discontinuati on Duration of hospitalizati on
Goldman, 2020 ¹³²	Peer-reviewed publication NCT04292899	402	United States, Italy, Spain, Gernmany, Hong Kong, Singapore, South Korea, Taiwan	61.5	63.7	Asthma (12.3%) Diabetes (22.7%) Hypertension (49.9%)	Inpatient	Severe (100%)	30.7	Supplemental oxygen (55.4%) Iv (3.3%) High-flow or niv (27.5%)	remdesivir (5 days) (100 mg once daily for 5 days) remdesivir (10 days) (100 mg/day for 10 days)	Mortality Mechanical ventilation Adverse effects leading to discontinuati on Duration of hospitalizati on Time to symptom/cli nical improvemen t

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
Gonzalez Ochoa, 2021 ¹³³	Peer-reviewed publication ISRCTN590486 38	312	Mexico	54.6	47.8	Copd (18.3%) Cardiovascular disease (19.6%) Diabetes (22.8%) Hypertension (34.3%)	Outpatient	NR	0	Supplemental oxygen, niv, or iv (0.0%)	sulodexide (500 RLU twice daily for 3 weeks) placebo	Mortality Mechanical ventilation Admission to hospital Adverse effects leading to discontinuati on Venous thromboem bolism Clinically important bleeding Duration of hospitalizati on
Gonzalez, 2021 ¹³⁴	Pre-print NCT04391127	106	Mexico	53	62.3	Copd (6.6%) Diabetes (34.0%) Hypertension (32.1%)	Inpatient	Mild/Mo derate (100.0%)	0	High oxygen volume (0.0%) Mechanical ventilation (0.0%)	ivermectin (12 mg to 18 mg single dose based on weight) hydroxychloroquine (200 mg twice daily for 5 days) placebo	Mortality Duration of hospitalizati on
Gordon_1, 2021 REMAP-CAP ¹³⁵	Peer-reviewed publication NCT02735707	826	United Kingdom, Netherlands, Austrialia, New Zealand,	61.4	72.6	Respiratory condition (23.9%) Severe cardiovascular disease	Inpatient Intensive care (100.0%)	Severe (100%) Severe: Critical (100.0%)	99.6	High-flow (28.8%) Niv (41.5%) Iv (29.4%)	tocilizumab (8mg/kg, for a maximum of 800 mg, in 24 hours) sarilumab (400 mg	Mortality Mechanical ventilation Duration of hospitalizati on

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
			Ireland, Saudia Arabia			(10.2%) Diabetes (35.4%)					single dose) standard care	ICU length of stay Ventilator- free days
Gordon_2, 2021 REMAP-CAP ¹³⁶	Peer-reviewed publication NCT02735707	953	NR	NR	NR	NR	Inpatient	Severe (100%) Severe: Critical (100.0%)	NR	NR	tocilizumab (8mg/kg, for a maximum of 800 mg, in 24 hours) sarilumab (400 mg single dose)	Mortality
Gottlieb_2, 2021 ¹³⁷ 138	Data from authors NCT04501952, EudraCT Number 2020- 003510-12	584	United States, Spain, Denmark, United Kingdom	50.5	52.1	Chronic lung disease (24.0%) Cardiovascular or cerebrovascul ar disease (7.8%) Diabetes (61.6%) Hypertension (47.7%)	Outpatient	NR	0	Unspecified ventilation (0.0%)	remdesivir (200 mg on day 1 followed by 100 mg on days 2 and 3) placebo	Mortality Admission to hospital Adverse effects leading to discontinuati on
Guimarães, 2021 STOP-COVID ¹³⁹	Peer-reviewed publication NCT04469114	289	Brazil	56	65	Diabetes (23.5%) Hypertension (50.2%)	Inpatient	NR	0	Supplemental oxygen (75.4%) Niv, iv, or ecmo (0.0%)	tofacitinib (10 mg twice daily for up to 14 days or until hospital discharge) placebo	Mortality Mechanical ventilation Adverse effects leading to discontinuati on Duration of hospitalizati

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
												on ICU length of stay Duration of ventilation
Gunst, 2021 CamoCO-19 ¹⁴⁰	Peer-reviewed publication NCT04321096	208	Denmark, Sweden	61	60	Asthma (13.0%) Copd (10.0%) Coronary heart disease (19.0%) Diabetes (17.0%) Hypertension (34.0%)	Inpatient	Mild/Mo derate (33.0%) Severe (67.0%) Severe: Critical (8.0%)	6.6	Supplemental oxygen (59.1%) High-flow or niv (6.6%)	camostat mesilate (200 mg given three times daily for 5 days) placebo	Mortality Mechanical ventilation Adverse effects leading to discontinuati on Duration of hospitalizati on Time to symptom/cli nical improvemen t
Gutiérrez- Castrellón, 2021 ¹⁴¹	Pre-print NCT04517422	300	Mexico	36.5	46.3	Asthma (0.0%) Copd (0.0%) Cystic fibrosis (0.0%) Diabetes (10.3%) Hypertension (19.7%)	Outpatient	NR	NR	NR	Lactiplantibacillus plantarum KABP021 (≥2x109 colony- forming units once daily for 30 days) Lactiplantibacillus plantarum KABP022 () Lactiplantibacillus plantarum KABP023 () Lactiplantibacillus	Mortality Admission to hospital Adverse effects leading to discontinuati on Time to symptom/cli

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
											plantarum KABP033 () placebo	nical improvemen t
Guvenmez, 2020 ¹⁴²	Peer-reviewed publication	24	Turkey	58.8	62.5	NR	Inpatient	NR	0	Mechanical ventilation (0.0%)	lincomycin (600 mg twice daily for 5 days) azithromycin (250 mg/day for 5 days)	Viral clearance
HMO-020- 0224_NCT043 77750, 2021 HMO-020- 0224 ¹	Meta-analysis NCT04377750	54	Israel	63.1	68.5	NR	Inpatient	Severe (100%)	NR	NR	tocilizumab (8 mg/kg (up to 800 mg) single dose) placebo	NR
Hakamifard, 2021 ¹⁴³	Peer-reviewed publication IRCT20180425 039414N3	73	Iran	36.5	63.9	End-stage lung disease (0.0%) Cardiovascular disease (9.7%) Diabetes (25.0%) Hypertension (25.0%)	Inpatient	Severe (100%)	0	Mechanical ventilation, oxygen therapy at home (0.0%)	vitamin C (1 g daily, 400 IU daily for the duration of hospitalization until hospital discharge or intensive care unit admission) vitamin E () standard care	Mortality Duration of hospitalizati on
Hamed, 202 ¹⁴⁴	Peer-reviewed publication	49	United Arab Emirates	48.5	81.6	Diabetes (47.0%) Hypertension (30.0%)	Inpatient	Severe (100%)	NR	NR	methylprednisolone (40 mg twice daily for 7 days) methylprednisolone (40 mg of methylprednisolone twice daily for 7 days) tocilizumab (single 400	Mortality Mechanical ventilation Duration of hospitalizati on ICU length of stay

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
											mg dose of tocilizumab)	Duration of ventilation
Hamidi- Alamdari, 2021 ¹⁸	Peer-reviewed publication NCT04370288	80	Iran	54.5	52.5	Coronary artery bypass graft (2.5%) Ischemic heart disease (2.5%) Diabetes (10.0%) Hypertension (17.5%)	Inpatient	Severe (100%)	NR	NR	methylene blue (1 mg/kg orally every 8 hours for 2 days, 1 mg/kg orally every 12 hours for 12 days) standard care	Mortality Duration of hospitalizati on
Hasan, 2021 ¹⁴⁵	Peer-reviewed publication	168	Iraq	56.3	72.2	Asthma (10.1%) Ischemic heart disease (15.8%) Diabetes (29.8%) Hypertension (53.2%)	Inpatient	Severe (100%)	NR	NR	melatonin (10 mg once daily for 14 days) standard care	Mortality
Hassan, Abdelmaksoud , 2020 ¹⁴⁶	Peer-reviewed publication	105	Egypt	NR	NR	NR	Inpatient	NR	NR	NR	zinc sulfate (220 mg twice daily) standard care	Time to to viral clearance
Hassaniazad, 2021 ¹⁴⁷	Peer-reviewed publication IRCT20200611 047735N1	40	Iran	48.5	55	NR	Inpatient	NR	NR	NR	nano-curcumin (40 mg four times daily for 2 weeks) placebo	NR

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
Hermine, 2020 CORIMUNO- TOCI 1 ¹⁴⁸	Peer-reviewed publication NCT04331808	131	France	64	67.7	Asthma (6.2%) Chronic pulmonary disease, not asthma (4.7%) Chronic cardiac disease (31.2%) Diabetes (33.6%)	Inpatient	Severe (100%)	0	Supplemental oxygen (100.0%) Niv or iv (0.0%)	tocilizumab (8 mg/kg on day 1, and 400 mg on day 3 if oxygen requirement was not decreased by more than 50%) standard care	Mechanical ventilation
Hermine_toci, 2020 CORIMUNO- TOCIDEX ¹⁴⁹	Pre-print NCT04476979	453	French Guiana	63.4	67.8	Asthma (8.4%) Chronic pulmonary disease - not asthma (7.2%) Chronic cardiac disease (15.8%) Diabetes (23.8%) Hypertension (37.1%)	Inpatient	Severe (100%)	0	Supplementar y oxygen (100.0%) High-flow, niv, iv (0.0%)	corticosteroids (10mg/d 5 days and tapering doses up to 10 days (5mg/d for 5 days and 2.5mg/d for 5 days) tocilizumab (8mg/kg intravenously at day 1 with additional doses 400 mg IV recommended if no clinical response) standard care	Mortality Mechanical ventilation
Hernandez- Cardenas, 2021 HYDRA Trial ¹⁵⁰	Pre-print NCT04315896	214	Mexico	49.6	75.2	Cardiovascular disease (0.5%) Diabetes (15.9%) Hypertension (16.8%)	Inpatient	Severe (100%)	80.4	Supplementar y oxygen by nasal prongs (19.6%) High flow oxygen (4.7%) Mechanical	hydroxychloroquine (400 mg daily for 10 days) placebo	Mortality Adverse effects leading to discontinuati on Duration of hospitalizati

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
										ventilation (75.7%)		on Duration of ventilation Time to symptom/cli nical improvemen t
Hinks, 2021 ATOMIC2 ¹⁵¹	Pre-print NCT04381962	295	United Kingdom	45.9	51.5	Asthma (18.0%) Chronic pulmonary disease (4.1%) Myocardial infarction (4.1%) Diabetes (8.5%) Hypertension (17.6%)	Inpatient (0.7%)	Mild/Mo derate (100.0%)	0	Unspecified ventilation (0.0%)	azithromycin (500 mg once daily for 14 days) standard care	Mortality Mechanical ventilation Admission to hospital Duration of hospitalizati on
Holubovska, 2021 ¹⁵²	Pre-print NCT04682873	0	Ukraine	NR	NR	NR	Inpatient	Severe (100%)	0	Supplemental oxygen (20.6%) Iv or niv (0.0%)	enisamium (500 mg four times daily for 7 days) placebo	Time to symptom/cli nical improvemen t
Horby_1, 2020 RECOVERY ¹⁵³	Peer-reviewed publication NCT04381936	6425	United Kingdom	66.2	63.6	Chronic lung disease (20.9%) Tuberculosis (0.4%) Heart disease	Inpatient	NR	76.1	Supplemental oxygen or niv (60.4%) Iv or ecmo (15.7%)	dexamethasone (6 mg once daily for 10 days) standard care	Mortality Mechanical ventilation Duration of hospitalizati on

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
						(27.3%) Diabetes (24.1%)						
Horby_2, 2020 RECOVERY ¹⁵⁴	Peer-reviewed publication NCT04381936	4716	United Kingdom	65.3	62.2	Lung disease (22.2%) Tuberculosis (0.3%) Heart disease (25.7%) Diabetes (27.2%)	Inpatient	NR	76.4	Supplemental oxygen or niv (59.6%) Iv or ecmo (16.8%)	hydroxychloroquine (400 mg twice daily for 10 days) standard care	Mortality Mechanical ventilation Duration of hospitalizati on
Horby_3, 2020 RECOVERY ¹⁵⁵	Peer-reviewed publication NCT04381936	5040	United Kingdom	66.2	61	Chronic lung disease (23.1%) Tuberculosis (0.3%) Heart disease (26.0%) Diabetes (27.5%)	Inpatient	NR	73.8	Supplementar y oxygen or niv (69.7%) Iv (4.0%)	lopinavir-ritonavir (400 mg/100 mg twice daily for 10 days) standard care	Mortality Mechanical ventilation Duration of hospitalizati on
Horby_4, 2021 RECOVERY ¹⁵⁶	Peer-reviewed publication ISRCTN (50189673), NCT04381936	7763	United Kingdom	65.3	62.1	Chronic lung disease (24.9%) Tuberculosis (0.2%) Heart disease (26.3%) Prolonged qtc interval (0.0%)	Inpatient	NR	81.9	Supplemental oxygen or niv (76.0%) Iv (5.8%)	azithromycin (500 mg once daily for 10 days) standard care	Mortality Mechanical ventilation Duration of hospitalizati on

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
						Diabetes (27.5%)						
Horby_5, 2021 RECOVERY ¹⁵⁷	Peer-reviewed publication NCT04381936	4116	United Kingdom	63.6	67.4	Chronic lung disease (23.2%) Tuberculosis (0.2%) Heart disease (22.6%) Diabetes (28.4%)	Inpatient	Severe (100%)	54.6	Supplemental oxygen (45.4%) High-flow or niv (41.0%) Iv (13.7%)	tocilizumab (8 mg/kg, for up to a maximum of 800 mg, once) standard care	Mechanical ventilation Duration of hospitalizati on
Horby_6, 2021 RECOVERY ¹⁵⁸	Pre-print NCT04381936	11340	Indonesia, Nepal, United Kingdom	63.4	69.7	Chronic lung disease (21.3%) Tuberculosis (0.3%) Heart disease (21.3%) Diabetes (25.5%)	Inpatient	NR	31.4	Iv (4.7%) Niv (26.8%) None/supplem entary oxygen (68.6%)	colchicine (1 mg followed by 500 µg 12 hours later and then 500 µg twice daily for 10 days or until discharge) standard care	Mortality Mechanical ventilation Duration of hospitalizati on
Horby_7, 2021 RECOVERY ¹⁵⁹	Pre-print ISRCTN501896 73, NCT04381936	14892	United Kingdom, Indonesia, Nepal	59.2	61.8	Chronic lung disease (19.0%) Tuberculosis (0.3%) Heart disease (10.5%)	Inpatient	NR	33	Niv (28.1%) Iv (4.9%)	aspirin (150 mg once daily until discharge) standard care	Mortality Mechanical ventilation Duration of hospitalizati on

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
						Diabetes (21.8%)						
Hu, 2020 ¹⁶⁰	Peer-reviewed publication ChiCTR200003 0058	10	China	54.9	30	Copd (10.0%) Hypertension (60.0%)	Inpatient	Mild/Mo derate (100.0%)	0	Mechanical ventilation (0.0%)	leflunomide (20 mg once daily for 10 days) standard care	Mortality Viral clearance Time to symptom/cli nical improvemen t Time to viral clearance
Huang_1, 2020 ¹⁶¹	Peer-reviewed publication ChiCTR200002 9542	22	China	44	59.1	Cerebrovascul ar disease (4.5%) Diabetes (9.1%) Hypertension (18.2%)	Inpatient	Mild/Mo derate (63.6%) Severe (36.4%)	NR	NR	chloroquine (500 mg twice daily for 10 days) lopinavir-ritonavir (400 mg/100 mg twice daily for 10 days)	Viral clearance Duration of hospitalizati on Time to symptom/cli nical improvemen t Time to to viral clearance

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
Huang_2, 2020 ¹⁶²	Peer-reviewed publication ChiCTR200002 9387	101	China	42.5	45.5	Severe lung disease (0.0%) Severe heart disease (0.0%)	Inpatient	NR	NR	NR	ribavirin (400-600 mg three times daily for 14 days) lopinavir-ritonavir (400 mg/100 mg twice daily for 14 days) lopinavir-ritonavir (400 mg/100 mg twice daily for 14 days) ribavirin (400-600 mg three times daily for 14 days)	Mortality Adverse effects leading to discontinuati on Viral clearance Duration of hospitalizati on Time to symptom/cli nical improvemen t Time to to viral clearance
Hung, 2020 ¹⁶³	Peer-reviewed publication NCT04276688	127	China	51.3	53.5	Tuberculosis (1.6%) Obstructive sleep apnea (1.6%) Coronary artery disease (7.9%) Cerebrovascul ar disease (1.6%) Diabetes (13.4%)	Inpatient	Mild/Mo derate (100.0%)	NR	NR	interferon beta-1b (subcutaneous) (400 mg twice daily for 14 days) ribavirin (1-3 ml every other day for 14 days) standard care	Mortality Mechanical ventilation Adverse effects leading to discontinuati on Duration of hospitalizati on Time to symptom/cli

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
						Hypertension (28.4%)						nical improvemen t Time to viral clearance
Husain, 2020 ¹⁶⁴	Pre-print	64	NR	NR	NR	NR	Inpatient	NR	NR	NR	doxycycline (100 mg twice daily for 10 days) mometasone nasal spray (100 µg twice daily for 10 days, then 100 µg twice daily for 4 weeks) prednisolone (8 mg twice daily for 5 days) placeboolfactory training ()	Mortality
ImmCoVA_NC T04412291, 2021 ImmCoVA ¹	Meta-analysis NCT04412291	49	Sweden	NR	NR	NR	Inpatient	Severe (100%)	0	Iv (0.0%)	tocilizumab (8 mg/kg single dose, up to a maximum of 800 mg) standard care	Mortality
Ivashchenko, 2020 ¹⁶⁵	Peer-reviewed publication NCT04434248	60	Russia	50.7	50	NR	Inpatient	Mild/Mo derate (100.0%)	NR	Supplemental oxygen (25.0%)	favipiravir (600 mg BID) (600 mg twice daily for 14 days) favipiravir (800 mg BID) (800 mg twice daily for 14 days) standard care	Mortality Mechanical ventilation Adverse effects leading to discontinuati on Viral clearance Time to

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
												symptom/cli nical improvemen t
Ivashkin, 2021 ¹⁶⁶	Peer-reviewed publication NCT04854941	202	Russia	64.5	46	Respiratory condition (9.0%) Cardiovascular disease (65.0%) Diabetes (19.5%)	Inpatient	Severe (100%)	NR	NR	probiotics (Florasan-D containing ~10^9 colony forming units (CFU) of Lacticaseibacillus rhamnosus PDV 1705, ~10^9 CFU of Bifidobacterium bifidum PDV 0903, ~10^9 CFU of Bifidobacterium longum subsp. infantis PDV 1911, and ~10^9 CFU of Bifidobacterium longum subsp. longum PDV 2301, given three times a day for up to 14 days) standard care	Mortality Mechanical ventilation Duration of hospitalizati on
Jagannathan, 2021 ¹⁶⁷	Peer-reviewed publication NCT04331899	120	United States	36	58.3	Asthma (3.3%) Heart disease (3.3%) Diabetes (10.0%) Hypertension (11.7%)	Outpatient	NR	0	Supplemental oxygen, niv, or iv (0.0%)	peginterferon lambda- 1a (180 μg single injection) placebo	Admission to hospital Time to symptom/cli nical improvemen t

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
												Time to viral clearance
Jamaati, 2021 ¹⁶⁸	Peer-reviewed publication IRCT20151227 025726N17	50	Iran	62	72	Pulmonary disease (20.0%) Cardiovascular disease (14.0%) Diabetes (54.0%) Hypertension (50.0%)	Inpatient	Severe (100%)	NR	NR	dexamethasone (20 mg/day from day 1-5, then 10 mg/day from day 6-10) standard care	Mortality Mechanical ventilation Duration of hospitalizati on ICU length of stay
JamaliMoghad amSiahkali, 2021 ¹⁶⁹	Peer-reviewed publication IRCT20200411 047025N1	60	Iran	59.3	50	Copd (10.0%) Ischemic heart disease (18.3%) Diabetes (38.3%) Hypertension (41.7%)	Inpatient	NR	NR	NR	vitamin C (1.5 g every six hours for 5 days) standard care	Mortality Mechanical ventilation Duration of hospitalizati on ICU length of stay
Jeronimo, 2020 Metcovid ¹⁷⁰	Peer-reviewed publication NCT04343729	416	Brazil	55	65.3	Asthma (2.4%) Tuberculosis (2.1%) Copd (0.5%) Heart disease (6.6%) Diabetes (29.1%)	Inpatient Intensive care (35.4%)	NR	81.3	Invasive mechanical ventilation (33.9%) Non-invasive oxygen (47.5%)	methylprednisolone (0.5 mg/kg twice daily for 5 days) placebo	Mortality Mechanical ventilation Viral clearance Duration of hospitalizati on

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
						Hypertension (48.4%)						
Johnston, 2021 The COVID-19 Early Treatment Study ¹⁷¹	Published NCT04354428	231	United States	37	43.3	Pulmonary disease (5.2%) Moderate or severe persistent asthma (0.9%) Chronic obstructive pulmonary disease/emph ysema, (1.7%) Cardiovascular disease (0.0%) T2DM (6.5%) T1DM (0.9%) Hypertension (11.7%)	Outpatient	NR	NR	NR	hydroxychloroquine (200 mg twice daily for 10 days) azithromycin (250 mg once daily for 5 days) hydroxychloroquine (200 mg twice daily for 10 days) placebo	Mortality Admission to hospital Adverse effects leading to discontinuati on Viral clearance Duration of hospitalizati on Time to symptom/cli nical improvemen t Time to to viral clearance
Kalantari, 2021 ¹⁷²	Peer-reviewed publication	62	Iran	57.9	45.2	Copd (4.8%) Asthma (6.5%) Chronic cardiac disease)	Inpatient	Severe (100%)	NR	NR	lopinavir-ritonavir (400 mg twice daily for 10 days) atazanavir (300 mg once a day for 10 days)	Mortality Mechanical ventilation Duration of

							_					79
Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
						(19.4%) Diabetes (32.3%) Hypertension (29.0%)					dolutegravir (100 mg once a day for 10 days) ritonavir (500 mg once a day for 10 days)	hospitalizati on
Kalil, 2020 ACTT-2 ¹⁷³	Peer-reviewed publication NCT04401579	1033	United States, Singapore, South Korea, Mexico, Japan, Spain, United Kingdom, Denmark	55.4	63.1	Asthma (9.4%) Chronic oxygen requirement (1.6%) Chronic respiratory disease (6.7%) Cardiac valvular disease (2.1%) Congestive heart failure (6.0%) Coronary artery disease (9.8%) T2DM (35.8%) T1DM (1.0%) Hypertension (50.5%)	Inpatient	Mild/Mo derate (64.5%)	31.7	Supplemental oxygen (54.6%) High-flow or niv (20.9%) Iv or ecmo (10.8%)	baricitinib (4 mg daily for 14 days) placebo	Mortality Mechanical ventilation Duration of hospitalizati on Duration of ventilation Time to symptom/cli nical improvemen t

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
Kalil_2, 2021 ACTT-3 ¹⁷⁴	Peer-reviewed publication NCT04492475	969	Japan, Mexico, Singapore, South Korea, United States	58.7	58.1	Asthma (12.7%) Chronic respiratory disease (10.9%) Chronic oxygen disease (4.2%) Coronary artery disease (13.2%) Cardiac arrhythmias (9.0%) Cardiac valvular disease (3.1%) Congestive heart failure (7.2%) T2DM (36.7%) T1DM (0.8%) Hypertension (58.3%)	Inpatient	Severe (100%)	7.1	Supplemental oxygen (77.2%) Niv or hfo (7.1%) Iv (0.0%)	interferon beta-1a (44 µg given four times every other day) placebo	Mortality Mechanical ventilation Adverse effects leading to discontinuati on Duration of hospitalizati on Duration of ventilation Time to symptom/cli nical improvemen t
Kasgari, 2020 ¹⁷⁵	Peer-reviewed publication IRCT20200328 046886N1	48	Iran	52.5	37.5	Copd (2.1%) Ischaemic heart disease (22.9%) Diabetes (37.5%)	Inpatient	Mild/Mo derate (100.0%)	NR	NR	ribavirin (600 mg twice daily for 14 days) sofosbuvir-daclatasvir (400 mg/60 mg once daily for 14 days) standard care	Mortality Mechanical ventilation Adverse effects leading to discontinuati on

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	81 Outcomes
						Hypertension (35.4%)						Duration of hospitalizati on ICU length of stay Duration of ventilation
Kasiri, 2021 ¹⁷⁶	Peer-reviewed publication IRCT20190804 044429N6	80	Iran	34.3	50.6	Asthma (1.3%) Diabetes (1.3%) Hypertension (2.6%)	Outpatient	NR	NR	NR	mometasone nasal spray (two puffs of 100 µg twice daily in each nostril for 4 weeks) placeboolfactory training ()	Admission to hospital Adverse effects leading to discontinuati on
Khamis, 2020 ¹⁷⁷	Peer-reviewed publication	89	Oman	55	58.4	Lung disease (5.6%) Heart disease (14.6%) Diabetes (44.9%) Hypertension (53.9%)	Inpatient	Severe (100%)	NR	NR	favipiravir (600 mg twice daily for up to 10 days) inhaled nebulised interferon beta-1a (SNG001) (8 MIU twice daily for 5 days) hydroxychloroquine (200 mg twice daily for 8 days)	Mortality Duration of hospitalizati on
Khavkina, 2021 ¹⁷⁸	Peer-reviewed publication	244	Russia	NR	NR	NR	Inpatient (16.8%)	NR	NR	NR	favipiravir (800 mg twice daily for 10 days) hydroxychloroquine (inpatients) (umifenovir (10 days), intranasal interferon alpha-2b (10 days),	Mortality Time to to viral clearance

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
											hydroxychloroquine (10 days)) intranasal interferon alpha-2b (nebulised) (outpatients) () umifenovir (outpatients) () azithromycinvitamins ()	
Khodashahi, 2020 ¹⁷⁹	Peer-reviewed publication IRCT20200325 046859N2	108	Iran	60.6	55.6	Ischemic heart disease (3.0%) Diabetes (12.0%) Hypertension (13.0%)	Inpatient	Severe (100%)	NR	NR	umifenovir (200 mg four times daily for 7 to 14 days) standard care	Mortality Adverse effects leading to discontinuati on Duration of hospitalizati on
Khoo, 2021 AGILE ¹⁸⁰	Pre-print NCT04746183	18	United Kingdom	56	27.8	NR	Outpatient	NR	NR	NR	molnupiravir (300 mg) (300 mg twice daily for 5 days) molnupiravir (600 mg) (600mg twice daily for 5 days) molnupiravir (800 mg) (800mg twice daily for 5 days) standard care	Mortality Adverse effects leading to discontinuati on

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
Kimura, 2020 ¹⁸¹	Peer-reviewed publication NCT04347538	54	United States	38.2	53.3	Chronic lung disease (15.6%) Heart disease (4.4%) Diabetes (6.7%) Hypertension (24.4%)	Outpatient	NR	NR	NR	irrigation with hypertonic saline (250 ml twice daily) irrigation with hypertonic saline and surfactant (250 ml and 2.5 mg twice daily) standard care	Time to symptom/cli nical improvemen t
Kishoria, 2020 ¹⁸²	Peer-reviewed publication	35	India	38.5	71.9	Congestive heart failure (0.0%) Chest angina or heart arrhythmia (0.0%)	Inpatient	NR	NR	NR	ivermectin (12 mg single dose) standard care	Viral clearance
Klussmann, 2021 CARVIN ¹⁸³	Pre-print DRKS0002452 0	90	Germany	NR	NR	Diabetes (0.0%)	Outpatient	NR	NR	NR	azelastine (0.1%) (one puff per nostril, 3 times a day for 11 days) azelastine (0.02%) (one puff per nostril, 3 times a day for 11 days) placebo (one puff per nostril, 3 times a day for 11 days)	Viral clearance
Kosiborod, 2021 DARE-19 ¹⁸⁴	Peer-reviewed publication NCT04350593	1250	Argentina, Brazil, Canada, India, Mexico, United	61.4	57.4	Copd (4.6%) Atheroscleroti c disease (15.9%) Heart failure (7.2%)	Inpatient	NR	0	Mechanical ventilation (0.0%)	dapagliflozin (10 mg daily for 30 days) placebo	Mortality Mechanical ventilation Adverse effects leading to

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
			Kingdom, United States			Diabetes (50.9%) Hypertension (84.8%)						discontinuati on
Kosmopoulos, 2021 VASCEPA- COVID-19 CardioLink-9 ¹⁸⁵	Peer-reviewed publication NCT04412018	100	Canada	43	45	Cerebrovascul ar disease (2.0%) Coronary artery disease (2.0%) Heart failure (1.0%) Strock/ transcient ischemic attack (0.0%) Unstable angina, (0.0%) Diabetes (9.0%) Hypertension (17.0%)	Outpatient	NR	NR	NR	icosapent ethyl (2g twice daily for 14 days) standard care	Mortality Admission to hospital Adverse effects leading to discontinuati on
Krishnan, 2021 ¹⁸⁶	Data from authors CTRI/2021/06/ 033938	736	India	38.3	62.3	Chronic obstructive pulmonary disease (0.1%) Diabetes mellitus (4.4%) T2DM (1.1%) Hypertension (6.6%)	Outpatient	NR	NR	NR	molnupiravir (800 mg twice daily for 5 days) standard care	Mortality Admission to hospital Adverse effects leading to discontinuati on Viral

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
												clearance Time to symptom/cli nical improvemen t
Krolewiecki, 2021 ¹⁸⁷	Peer-reviewed publication NCT04381884	45	Argentina	40.9	55.6	Chronic lung disease/asthm a (11.1%) Diabetes (15.6%) Hypertension (13.3%)	Inpatient	NR	NR	Supplemental oxygen (6.7%)	ivermectin (0.6 mg/kg/day for 5 days) standard care	Mortality Mechanical ventilation Adverse effects leading to discontinuati on
Kumar_1, 2021 ¹⁸⁸	Peer-reviewed publication CTRI/2020/05/024959	32	India	49.1	86.7	An active tuberculosis (0.0%) Hypertension (20.0%)	Inpatient	Severe (100%) Severe: Critical (100.0%)	30	Niv (30.0%)	itolizumab (0.8 mg/kg in 250 ml weekly as required) standard care	Mortality Mechanical ventilation Adverse effects leading to discontinuati on
Kumar_2, 2021 ¹⁸⁶	Data from authors	1218	India	NR	NR	NR	Outpatient	Mild/Mo derate (100.0%)	NR	NR	molnupiravir (800 mg twice daily for maximum 5 days) standard care	Mortality Admission to hospital Adverse effects leading to discontinuati on Viral

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
												clearance Time to symptom/cli nical improvemen t
Kumari, 2020 ¹⁸⁹	Peer-reviewed publication	150	Pakistan	52.5	56.9	NR	Inpatient	Severe (100%)	0	Mechanical ventilation (0.0%)	vitamin C (50 mg/kg/day) standard care	Mortality Mechanical ventilation Duration of hospitalizati on Time to symptom/cli nical improvemen t
Kyriazopoulou, 2021 SAVE-MORE ¹⁹⁰	Pre-print NCT04680949; EudraCT 2020- 005828-11	606	Greece, Italy	61.8	57.9	Copd (4.0%) Chronic heart failure (3.0%) Coronary heart disease (6.9%) Atrial fibrillation (4.7%) T2DM (15.8%)	Inpatient	Mild/Mo derate (18.4%) Severe (81.7%)	0	Niv or iv (0.0%)	anakinra (100 mg once daily for 7 to 10 days) placebo	Mortality Mechanical ventilation Adverse effects leading to discontinuati on Duration of hospitalizati on ICU length of stay

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
Lakkireddy, 2021 ¹⁹¹	Peer-reviewed publication CTRI/2020/12/030083	130	India	45	74.7	diabetes or hypertension (39.1%)	Inpatient	NR	NR	NR	vitamin D (60000 IUs per day for 8 days (for individuals with BMI 18-25) or 10 days (for individuals with BMI > 25)) standard care	Mortality Adverse effects leading to discontinuati on Duration of hospitalizati on
Lattmann, 2021 ¹⁹²	Pre-print CTRI/2020/10/ 028423	40	India	52.5	65	Asthma (2.5%) Pulmonary embolism (2.5%) Diabetes (17.5%) Hypertension (15.0%)	Inpatient	Mild/Mo derate (100.0%)	15	Supplemental oxygen (85.0%) High-flow or niv (15.0%) Iv (0.0%)	CCK-A agonist and CCK-B antagonist (PNB001) (100 mg orally three times daily for 14 days) standard care	Mortality Mechanical ventilation Adverse effects leading to discontinuati on Duration of hospitalizati on Time to to viral clearance
Lawler, 2021 ATTACC, ACTIV-4a, REMAP-CAP ¹⁹³	Peer-reviewed publication NCT02735707, NCT04505774, NCT04359277, NCT04372589	2245	United Kingdon, United States, Canada, Brazil, Mexico, Nepal, Australia, Netherlands, Spain	58.9	58.7	Chronic respiratory disease (21.8%) Severe cardiovascular disease (10.6%) Diabetes	Inpatient	Severe (100%)	2	Low flow nasal cannula/face mask (66.6%) Hfo (2.4%) Niv (2.0%) Unspecified (16.5%)	therapeutic-dose anticoagulant (therapeutic-dose low molecular weight or unfractionated heparin for the treatment of acute venous thromboembolism for up to 14 days or until	Mortality Venous thromboem bolism Clinically important bleeding

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
						(29.7%) Hypertension (51.9%)					recovery (defined as hospital discharge, or liberation from supplemental oxygen for ≥24 hours)) standard care	
Lemos, 2020 HESACOVID ¹⁹⁴	Peer-reviewed publication REBEC RBR- 949z6v	20	Brazil	56.5	80	Cardiovascular disease (10.0%) Diabetes (35.0%) Hypertension (35.0%)	Inpatient	Severe (100%) Severe: Critical (100.0%)	100	Mechanical ventilation (100.0%)	enoxaparin (1 mg/kg/day to 1 mg/kg twice daily for 14 days based on age and creatinine clearance) standard care	Mortality Venous thromboem bolism Clinically important bleeding Duration of hospitalizati on Ventilator- free days
Lenze, 2020 ¹⁹⁵	Peer-reviewed publication NCT04342663	181	United States	46	28.3	Asthma (17.1%) Severe underlying lung disease, eg, chronic obstructive pulmonary disease or required home oxygen, interstitial lung disease, pulmonary	Outpatient	Mild/Mo derate (100.0%)	0	Supplemental oxygen, niv, or iv (0.0%)	fluvoxamine (100 mg three times daily for 15 days) placebo	Mortality Mechanical ventilation Admission to hospital Adverse effects leading to discontinuati on Duration of hospitalizati on

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
						hypertension (0.0%) Congestive heart failure (0.0%) Diabetes (11.2%) Hypertension (19.7%)						Duration of ventilation
Lescure, 2021 ¹⁹⁶	Peer-reviewed publication NCT04327388; Eudra CT (2020-001162-12), WHO (U1111-1249-6021)	420	Argentina, Brazil, Canada, Chile, France, Germany, Israel, Italy, Japan, Russia, Spain	59	62.7	Copd (4.3%) Asthma (4.1%) Coronary artery disease (5.3%) Diabetes (26.4%) Hypertension (42.5%)	Inpatient Intensive care (35.6%)	Severe (100%) Severe: Critical (38.9%)	19.5	Nasal cannula (42.1%) Face mask (26.7%) Nonrebreather face mask (10.5%) High-flow (6.2%) Niv (1.7%) Iv (11.5%) Other (1.2%)	sarilumab (400 mg) (400 mg single dose) sarilumab (200 mg) (200 mg single dose) placebo	Mortality Mechanical ventilation Duration of hospitalizati on Time to symptom/cli nical improvemen t
Li, 2020 ELACOI ¹⁹⁷	Peer-reviewed publication NCT04252885	86	China	49.4	46.5	Respiratory condition (0.0%) Cardiovascular disease (2.3%) Diabetes (2.3%) Hypertension (10.5%)	Inpatient	Mild/Mo derate (100.0%)	0	Mechanical ventilation (0.0%)	lopinavir-ritonavir (200 mg/50 mg twice daily for 7 to 14 days) umifenovir (200 mg three times daily for 7 to 14 days) standard care	Mortality Adverse effects leading to discontinuati on Viral clearance Time to to

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
												viral clearance
Li_2, 2021 ¹⁹⁸	Peer-reviewed publication ChiCTR200002 9638	96	China	53.5	46.8	Tuberculosis (3.2%) Copd (1.1%) Heart disease (7.5%) Cerebrovascul ar disease (5.3%) Diabetes (9.6%) Hypertension (19.1%)	Inpatient	Mild/Mo derate (87.2%) Severe (12.8%)	25.5	Supplemental oxygen (51.1%) High-flow or niv (25.5%)	recombinant super- combinant interferon (nebulised) (12 MIU twice daily for 28 days) interferon alpha (nebulised) (5 MIU twice daily for 28 days)	Mortality Mechanical ventilation Adverse effects leading to discontinuati on Viral clearance Duration of hospitalizati on Time to symptom/cli nical improvemen t Time to to viral clearance
Li_3, 2020 ¹⁹⁹	Peer-reviewed publication NCT04273763	18	China	52	77.8	Diabetes (11.1%) Hypertension (33.3%)	Inpatient	Mild/Mo derate (100.0%)	0	Mechanical ventilation (0.0%)	bromhexine hydrochloride (32 mg three times daily for 14 days) standard care	Mortality Mechanical ventilation Adverse effects leading to discontinuati

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
												on Time to symptom/cli nical improvemen t Viral clearance Duration of hospitalizati on Time to symptom/cli nical improvemen t
Li_4, 2021 ²⁰⁰	Peer-reviewed publication ChiCTR200002 9898, ChiCTR200002 9899, ChiCTR20000- 31376	23	China	65.7	52.9	Coronary heart disease (5.9%) Diabetes (5.9%) Hypertension (47.1%)	Inpatient	Severe (100%)	100	Supplemental oxygen, niv, or mv (100.0%)	hydroxychloroquine (200 mg twice daily for 5 days) chloroquine (500 mg twice daily for 3 days, then 250 mg twice daily for 2 days)	Viral clearance Duration of hospitalizati on Time to symptom/cli nical improvemen t
Li_4, 2021 ²⁰⁰	Peer-reviewed publication ChiCTR200002 9898, ChiCTR200002 9899,	65	China	60.1	61.9	Coronary heart disease (12.7%) Diabetes (23.8%)	Inpatient	Mild/Mo derate (100.0%)	NR	NR	hydroxychloroquine (200 mg twice daily for 5 days) chloroquine (500 mg twice daily for 3 days,	Viral clearance Duration of hospitalizati on Time to

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
	ChiCTR200003 1376					Hypertension (38.1%)					then 250 mg twice daily for 2 days)	symptom/cli nical improvemen t
Liesenborghs, 2021 DAWn ²⁰¹	Peer-reviewed publication EudraCT 2020-001243-15	65	Belgium	62.5	63.1	Chronic pulmonary disease (3.1%) Heart failure (4.6%) Diabetes (23.1%) Hypertension (41.5%)	Inpatient	Severe (100%)	NR	Supplemental oxygen (64.6%)	itraconazole (capsules (with meal)/oral solution (2 hours before or 1 hour after meal)) standard of care	Mortality Mechanical ventilation Adverse effects leading to discontinuati on Duration of hospitalizati on ICU length of stay Duration of ventilation Time to symptom/cli nical improvemen t
Lomakin, 2021 CORONA ²⁰²	Peer-reviewed publication NCT04397562	206	Russia	58.4	52.9	Cardiac disease (15.5%)	Inpatient	Severe (100%)	1.5	Supplemental oxygen (59.7%) Hfo or niv (1.5%) Iv (0.0%)	levilimab (324 mg, as two 162 mg injections, given once) placebo	Mortality Mechanical ventilation Duration of hospitalizati on

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
Lopes_1, 2021 BRACE CORONA ²⁰³	Peer-reviewed publication NCT04364893	740	Brazil	55.1	59.6	Asthma (3.9%) Coronary heart disease (4.5%) Heart failure (1.4%) Diabetes (31.9%) Hypertension (100.0%)	Inpatient	Mild/Mo derate (100.0%)	0	Mechanical ventilation (0.0%)	standard care ACEi/ARB (continuation of ACEi/ARB at the dose previously prescribed during routine care)	Mortality Mechanical ventilation Duration of hospitalizati on
Lopes_2, 2021 ²⁰⁴	Peer-reviewed publication RBR-8jyhxh (http://www.e nsaiosclinicos. gov.br/rg/RBR -8jyhxh/)	75	Brazil	54.8	45.8	Respiratory condition (12.5%) Cardiovascular disease (45.8%) Diabetes (38.9%)	Inpatient	Severe (100%)	20.8	High-flow (20.8%)	colchicine (0.25 mg to 0.5 mg three times daily for 5 days, then 0.25 mg to 0.5 mg twice daily for 5 days based on weight and glomerular filtration rate) placebo	Mortality Adverse effects leading to discontinuati on Duration of hospitalizati on ICU length of stay
Lopes_3, 2021 ACTION ²⁰⁵	Peer-reviewed publication NCT04394377	615	Brazil	56.6	59.8	Asthma (4.7%) Chronic lung disease (3.1%) Coronary disease (4.5%) Heart failure (2.1%) Vascular disease (0.8%) Valvar heart disease (1.1%)	Inpatient	Mild/Mo derate (93.5%)	7	Supplementar y oxygen (60.0%) Hfo (7.8%) Iv (6.2%) Niv (0.8%)	therapeutic anticoagulation (20 mg rivaroxaban once daily for 30 days in stable patients) standard care	Mortality Mechanical ventilation Venous thromboem bolism Clinically important bleeding Duration of hospitalizati

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
						History of acute myocardial infarction (2.8%) Cardiac arrhythmia (1.1%) Diabetes (24.4%) Hypertension (49.1%)						on Duration of ventilation
Lopez-Medina, 2021 EPIC ²⁰⁶	Peer-reviewed publication NCT04405843	476	Colombia	37	42	Respiratory condition (3.0%) Cardiovascular disease (1.8%) Diabetes (5.5%) Hypertension (13.3%)	Inpatient (1.0%)	Mild/Mo derate (100.0%)	0	Supplemental oxygen (0.5%) High-flow or niv or iv (0.0%)	ivermectin (300 μg/kg/day for 5 days) placebo	Mortality Mechanical ventilation Admission to hospital Adverse effects leading to discontinuati on Time to symptom/cli nical improvemen t
Lou, 2020 ²⁰⁷	Peer-reviewed publication ChiCTR200002 9544	30	China	52.5	72.4	Copd (0.0%) Cardiovascular disease (13.8%) Diabetes	Inpatient	NR	0	Mechanical ventilation (0.0%)	baloxavir marboxil (80 mg once daily for up to 3 doses on days 1, 4, and 7) favipiravir (600 mg	Mortality Mechanical ventilation Viral clearance

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
						(6.9%) Hypertension (20.7%)					three times daily for 14 days) standard care	Time to symptom/cli nical improvemen t Time to to viral clearance
Lyngbakken, 2020 NO COVID- 19 ²⁰⁸	Published NCT04316377	53	Norway	62	66	Copd or asthma (26.4%) Coronary heart disease (9.4%) Diabetes (17.0%) Hypertension (32.1%)	Inpatient	Severe (100%)	NR	Supplemental oxygen (37.7%)	hydroxychloroquine (400 mg twice daily for 7 days) standard care	Mortality Mechanical ventilation Duration of hospitalizati on
MOVe-OUT (MK4482-002), 2021 MOVe-OUT ²⁰⁹	Data from authors NCT04575597	1411	Multicontinent al	43	49	NR	Outpatient	NR	NR	NR	molnupiravir (800 mg twice daily for 5 days) placebo	Mortality Admission to hospital Adverse effects leading to discontinuati on
Maghbooli, 2021 ²¹⁰	Peer-reviewed publication IRCT20200401 046909N1, NCT04386850	106	Iran	49.5	60.4	Chronic disorders lung (10.4%) Cardiac disorder	Inpatient	NR	NR	NR	calcifediol (25 μg once daily) placebo	Mortality Mechanical ventilation Duration of hospitalizati

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities (12.3%) Diabetes (23.6%)	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes on ICU length of stay
						Hypertension (31.1%)						
Mahajan, 2021 ²¹¹	Peer-reviewed publication	82	India	57.7	68.6	Asthma (1.4%) Coronary artery disease (12.8%) Diabetes (60.0%) Hypertension (45.7%)	Inpatient	Severe (100%)	24.3	Supplemental oxygen (75.7%) High-flow or niv (24.3%) Iv (0.0%)	remdesivir (100 mg daily for 5 days) standard care	Mortality Mechanical ventilation Adverse effects leading to discontinuati on Duration of ventilation
Mahmud, 2021 ²¹²	Peer-reviewed publication NCT04523831	400	Bangladesh	39.5	58.8	Asthma (5.2%) Diabetes (13.2%) Hypertension (14.2%)	NR	Mild/Mo derate (100.0%)	0	Supplemental oxygen (0.0%) Niv (0.0%) Iv (0.0%)	doxycycline (100 mg twice daily for 5 days) ivermectin (12 mg once) placebo	Mortality Adverse effects leading to discontinuati on Time to symptom/cli nical improvemen t

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
Majeed, 2021 ²¹³	Peer-reviewed publication CTRI/2020/09/027841	100	India	38.2	71	NR	Inpatient	NR	0	Supplemental oxygen, mechanical ventilation (0.0%)	ImmuActive (once daily for 28 days or until hospital discharge) placebo	Mortality Mechanical ventilation Adverse effects leading to discontinuati on Viral clearance Duration of hospitalizati on Time to to viral clearance
Malonado, 2020 ²¹⁴	Peer-reviewed publication	54	Mexico	57.5	55.4	Diabetes (50.0%) Hypertension (39.5%)	Inpatient	Mild/Mo derate (67.9%)	NR	NR	pentoxifylline (400 mg three times daily until discharge) standard care	Mortality Mechanical ventilation Adverse effects leading to discontinuati on Duration of hospitalizati on
Mansour, 2020 ²¹⁵	Pre-print U1111-1250- 1843	30	Brazil	51.6	53.3	Asthma (3.3%) Ischemic myocardial disease (0.0%) Diabetes	Inpatient	Severe (100%)	NR	NR	icatibant (30 mg three times daily for 4 days) C1 esterase/kallikrein Inhibitor (20 IU/kg on	Mortality Duration of hospitalizati on

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
						(46.7%) Hypertension (50.0%)					day 1 and 4) standard care	ICU length of stay
Marconi, 2021 COV- BARRIER ²¹⁶	Peer-reviewed publication NCT04421027	1525	Argentina, Brazil, Germany, India, Italy, Japan, Korea, Mexico, Russia, Spain, United Kingdom, United States	57.6	63.1	Chronic respiratory disease (4.6%) T1DM (30.0%) Hypertension (47.9%)	Inpatient	Severe (100%)	24.4	Supplemental oxygen (63.4%) High-flow or niv oxygen (24.4%) Iv (0.0%)	baricitinib (4 mg daily for 14 days or until discharge (patients with eGFR≥30 to <60 mL/min/1.73 m² received 2 mg)) placebo	Mortality Mechanical ventilation Adverse effects leading to discontinuati on Duration of hospitalizati on ICU length of stay Ventilator- free days Time to symptom/cli nical improvemen t
Marcos, 2021 BEMICOP ²¹⁷	Peer-reviewed publication NCT04604327	66	Spain	62.6	63.1	Chronic pulmonary disease (16.9%) Cardiopathy (6.2%) Diabetes (7.7%)	Inpatient	NR	NR	Oxygen requirement (58.5%)	therapeutic-dose bemiparin (115 IU/Kg once daily, adjusted to body weight (7,500 IU for patients between 50-70 Kg) prophylactic-dose	Mortality Viral clearance Venous thromboem bolism Clinically

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
						Hypertension (33.9%)					bemiparin (3,500 IU once daily for 10 days)	important bleeding
Maskin, 2021 ²¹⁸	Pre-print NCT04395105	100	Argentina	61.8	70.4	NR	Inpatient Intensive care (100.0%)	Severe (100%) Severe: Critical (100.0%)	100	Mechanical ventilation (100.0%)	dexamethasone (high-dose) (16 mg once daily for 5 days, followed by 8 mg once daily for another 5 days) dexamethasone (low-dose) (6 mg once daily for 10 days)	Mortality Adverse effects leading to discontinuati on Duration of hospitalizati on ICU length of stay Ventilator- free days Duration of ventilation
McCreary, 2021 ²¹⁹	Pre-print NCT04400890	105	United States	56	41	NR	Outpatient	NR	NR	NR	resveratrol (1000 mg four times daily for at least 7 days, up to 15 days) placebo	Mortality Mechanical ventilation Admission to hospital
Mehboob, 2020 ²²⁰	Pre-print NCT04468646	18	Pakistan	53.5	61.1	Respiratory condition (0.0%) Ischemic heart disease (33.3%) Carotid artery bypass	Inpatient	Mild/Mo derate (27.8%) Severe (72.2%) Severe:	NR	NR	aprepitant (80 mg once daily for 3-5 days) standard care	Mortality

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
						grafting (5.6%) Diabetes (38.9%) Hypertension (50.0%)		Critical (38.9%)				
Migled, 2020 ²²¹	Peer-reviewed publication	60	Ecuador	33.3	53.3	Respiratory disease (10.0%) Cardiovascular disease (58.3%)	Outpatient	NR	NR	NR	metisoprinol (children: 50 mg/kg/day divided into 4 daily doses for 4 days then every 8 hours until completing the 14 days) standard care	Mechanical ventilation Admission to hospital Viral clearance
Miller, 2020 CARDEA ²²²	Peer-reviewed publication NCT04345614	30	United States	59.3	46.7	Diabetes (40.0%) Hypertension (46.7%)	Inpatient	Severe (100%) Severe: Critical (13.3%)	13.3	High-flow (13.3%)	Auxora (1.6 mg/kg given in 4 hours for 3 days) standard care	Mortality Mechanical ventilation Time to symptom/cli nical improvemen t Duration of hospitalizati on Time to symptom/cli nical improvemen t

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
Miller, 2021 ²²³	Pre-print	40	United States	54.1	57.5	NR	Inpatient	Mild/Mo derate (12.5%) Severe (87.5%)	32.5	Supplemental oxygen (55.0%) High flow oxygen/niv (32.5%) Invasive ventilation (0.0%)	mupadolimab (1 mg/kg) (1 mg/kg) mupadolimab (2 mg/kg) (2 mg/kg) placebo	Duration of hospitalizati on Time to symptom/cli nical improvemen t Mortality Mechanical ventilation Time to symptom/cli nical improvemen t
Mobarak, 2021 DaclatasvIr and Sofosbuvir for COVid-19 in hospital Emergency Room ²²⁴	Pre-print IRCT20200624 047908N1	1083	Iran	58	54	Asthma (4.8%) Copd (2.1%) Ischemic heart disease (9.1%) Diabetes (27.6%) Hypertension (34.0%)	Inpatient	Mild/Mo derate (100.0%)	NR	NR	sofosbuvir-daclatasvir (400 mg/60mg once daily for 10 days) placebo	Mortality Mechanical ventilation Adverse effects leading to discontinuati on Duration of hospitalizati on

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
Mohan, 2021 RIVET-COV ²²⁵	Pre-print CTRI/2020/06/ 026001	157	India	35.3	88.8	Post tuberculosis sequelae (3.2%) Coronary artery disease (0.8%) Myocardial infarction (0.0%) Prolonged corrected qt interval >450 ms (0.0%) Diabetes (8.8%) Hypertension (11.2%)	Inpatient	Mild/Mo derate (100.0%)	0	Supplemental oxygen (8.0%) Mechanical ventilation (0.0%)	ivermectin (12 mg) (200 μg/kg up to 12 mg single dose) ivermectin (24 mg) (400 μg/kg up to 24 mg as a single dose) placebo	Mortality Mechanical ventilation Viral clearance Time to symptom/cli nical improvemen t
Moni, 2021 ²²⁶	Pre-print ISRCTN168066 63	29	India	59.1	72	Copd (12.0%) Congestive heart failure (24.0%) Coronary artery disease (16.0%) Diabetes (56.0%) Hypertension (44.0%)	Inpatient Intensive care (100.0%)	Mild/Mo derate (100.0%)	0	Iv (0.0%)	nitric oxide (inhaled nitric oxide delivered through a tight fitting face mask and the V60 respiratory assist system in pulses for 30 minutes for three days, every 12 hours. This dose was administered in a crescendodecrescendo fashion as follows:- 10 ppm, 0-5 minutes, 20 ppm, 5-7 minutes, 30 ppm, 7-9 minutes, 50 ppm, 9-11	Mortality Mechanical ventilation Adverse effects leading to discontinuati on Viral clearance Duration of hospitalizati on ICU length of stay

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
											minutes, 80 ppm, 11- 23 minutes, 80 ppm-0 ppm, 23-30 minutes, decreased at 10 ppm/minute) standard care	Duration of ventilation Time to symptom/cli nical improvemen t Time to viral clearance
Monk, 2020 ²²⁷	Peer-reviewed publication 2020-001023- 14 & NCT04385095	101	United Kingdom	57.1	59.2	Chronic lung condition (23.5%) Cardiovascular disease (13.3%) Diabetes (12.2%) Hypertension (29.6%)	Inpatient	Severe (100%)	2	Supplemental oxygen (65.3%) High-flow or niv (2.0%) Iv (0.0%)	inhaled nebulised interferon beta-1a (SNG001) (6 MIU once daily for up to 14 days) placebo	Mortality Adverse effects leading to discontinuati on Duration of hospitalizati on Time to symptom/cli nical improvemen t
Moreira, 2021 ²²⁸	Peer-reviewed publication	39	Brazil	41.1	35.9	Cardiovascular disease (12.8%) Diabetes (10.3%) Hypertension (17.9%)	Outpatient	NR	0	Unspecified ventilation (0.0%)	dexamethasone (6 mg for 3 days) foralumab (50 µg for 10 days) foralumab (50 µg for 10 days) standard care	NR

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
Munch_1, 2021 COVID STEROID ²²⁹	Peer-reviewed publication NCT04348305	30	Denmark	61	80	Chronic pulmonary disease (16.7%) Ischemic heart failure or heart failure (3.3%) Diabetes (13.3%) Hypertension (26.7%)	Inpatient Intensive care (73.3%)	Severe (100%) Severe: Critical (100.0%)	50	Iv (36.7%) Niv or cpap (13.3%) Supplemental oxygen (50.0%)	hydrocortisone (200 mg once daily for 7 days) placebo	Mortality
Munch_2, 2021 COVID STEROID 2 ²³⁰	Pre-print NCT04509973, CTRI2020/10/ 028731	1000	Denmark, India, Sweden, Switzerland	64.5	68.9	Copd (11.5%) Ischemic heart disease or heart failure (13.8%) Diabetes (30.4%)	Inpatient Intensive care (79.6%)	Severe (100%)	46	Iv (2Peer-reviewed publication%) Niv or cpap (25.1%) Open system (54.0%)	dexamethasone (12 mg) (12 mg daily for up to 10 days) dexamethasone (6 mg) (6 mg daily for up to 10 days)	Mortality Mechanical ventilation Ventilator- free days
Murai, 2021 ²³¹	Peer-reviewed publication NCT04449718	240	Brazil	56.2	56.1	Copd (5.1%) Asthma (5.9%) Cardiovascular disease (13.5%) Diabetes (35.4%) Hypertension (52.7%)	Inpatient	Severe (100%)	13.3	Supplementla oxygen (76.2%) Niv (13.3%) Iv (0.0%)	vitamin D3 (200,000 IU/10 ml once) placebo	Mortality Mechanical ventilation Duration of hospitalizati on Duration of ventilation

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
Méndez- Flores, 2021 ²³²	Pre-print NCT04517162	89	Mexico	48.5	41.6	Chronic respiratory disease (2.2%) Asthma (4.5%) Coronary artery disease (0.0%) Congestive heart failure (1.1%) Diabetes (16.9%) Hypertension (20.2%)	Outpatient	NR	NR	NR	polymerized type I collagen (intramuscular dose of polymerized type I collagen (1.5 ml, equivalent to 12.5 mg of collagen) every 12 h for 3 days and then every 24 h for 4 days) placebo	Mortality Mechanical ventilation Admission to hospital Duration of hospitalizati on
Najmeddin, 2021 ²³³	Peer-reviewed publication IRCT20151113 025025N3	66	Iran	66.3	46.9	Copd (1.6%) Severe asthma (0.0%) Congestive heart failure or arrhythmia (0.0%) Ischemic heart disease (25.0%) Diabetes (50.0%) Hypertension (100.0%)	Inpatient	Severe (100%)	12.5	Nasal cannula (1.6%) Simple face mask (25.0%) Face mask with reservoir (57.8%) Niv (4.7%) Iv (7.8%)	ACEi/ARB (continued) ACEi/ARB (changed)	Mortality Mechanical ventilation Adverse effects leading to discontinuati on Duration of hospitalizati on ICU length of stay

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
Niaee, 2020 ²³⁴	Pre-print IRCT20200408 046987N1	180	Iran	56	50	NR	Inpatient	Mild/Mo derate (86.7%)	NR	NR	standard care placebo ivermectin (200 mcg/kg) (200 µg/kg single dose) ivermectin (200 (200 µg/kg on days 1, 3, and 5) 200 () 200 mcg/kg) () ivermectin (400 mcg/kg) (400 µg/kg single dose) ivermectin (400 (400 µg/kg on day 1, and 200 µg/kg on days 1 and 5) 200 () 200 mcg/kg) ()	Mortality Duration of hospitalizati on
Niktale, 2021 Nicovid ²³⁵	Peer-reviewed publication	1512	Iran	48.5	56.2	NR	NR	NR	0	Ventilation (0.0%)	organosulfur (90 mg/kg, 3 times a day for 14 days) placebo (capsule of same appearance)	NR
Nojomi, 202 ²³⁶ 0	Peer-reviewed publication IRCT20180725 040596N2	100	Iran	56.4	60	Asthma (2.0%) Coronary heart disease (9.0%) Diabetes (28.0%) Hypertension (39.0%)	Inpatient	Mild/Mo derate (77.0%)	NR	NR	hydroxychloroquine (1 day) (400 mg/day for 1 day) lopinavir-ritonavir (400 mg twice daily for up to 14 days) hydroxychloroquine (7 to 14 days) (400 mg twice daily for 7 to 14 days) umifenovir (200	Mortality Mechanical ventilation Duration of hospitalizati on Time to symptom/cli nical

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
											mg three times daily for 7 to 14 days)	improvemen t
Nouri-Vaskeh, 2021 ²³⁷	Peer-reviewed publication IRCT20180802 040678N4	82	Iran	63.8	51.2	Copd/asthma (15.0%) Cardiovascular disease (18.8%) Diabetes (23.8%) Hypertension (100.0%)	Inpatient	NR	NR	NR	losartan (25 mg twice daily for 14 days) amlodipine (5 mg/day for at least for 14 days)	Mortality Mechanical ventilation Adverse effects leading to discontinuati on Duration of hospitalizati on ICU length of stay
Nourian, 2020 ²³⁸	Peer-reviewed publication IRCT20100228 003449N29	90	Iran	62.2	NR	Copd (4.9%) Cardiovascular disease (31.7%) Diabetes (45.1%) Hypertension (45.1%)	Inpatient	Mild/Mo derate (100.0%)	NR	NR	sofosbuvir-ledipasvir (400 mg/90 mg daily for 10 days) standard care	Mortality Mechanical ventilation Adverse effects leading to discontinuati on Duration of hospitalizati on ICU length of stay Time to symptom/cli

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
												nical improvemen t
Ogbuagu, 2021 ²³⁹	Data from authors NCT04252664	1005	China	NR	NR	NR	Inpatient	Severe (100%)	NR	NR	remdesivir (100 mg once daily for 5 or 10 days) standard care	NR
Oldenburg, 2021 ACTION ²⁴⁰	Peer-reviewed publication NCT04332107	263	United States	42.7	33.1	Asthma (12.2%) Copd (1.5%) Stroke (0.8%) Diabetes (3.8%) Hypertension (12.2%)	Outpatient	NR	NR	NR	azithromycin (1.2 g given once orally) placebo	Mortality Admission to hospital
Oliynyk, 2021 ²⁴¹	Peer-reviewed publication 0112U001413	126	Ukraine	70.7	60.3	NR	Inpatient Intensive care (100.0%)	Severe (100%)	NR	Intubation (0.0%)	prophylactic-dose enoxaparin (50 anti-Xa IU/kg per day subcutaneously until d- Dimer levels normalize) therapeutic-dose enoxaparin (100 anti- Xa IU/kg twice a day subcutaneously until d- Dimer levels normalize) heparin sodium (80 U/kg/h intravenously,	Mortality Mechanical ventilation Clinically important bleeding

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
											followed by a maintenance dose of 18 U/kg/h until d- Dimer levels normalize)	
Omrani, 2020 Q-PROTECT ²⁴²	Peer-reviewed publication NCT04349592	456	Qatar	41	98.5	NR	Outpatient	Mild/Mo derate (100.0%)	NR	NR	azithromycin (200 mg every 7 hours for 7 days) hydroxychloroquine (250 mg once daily for 5 days) hydroxychloroquine placebo	Mortality Admission to hospital Adverse effects leading to discontinuati on Viral clearance
Onal, 2021 ²⁴³	Pre-print NCT04377789	447	Turkey	NR	56.6	Copd (6.0%) Asthma (13.9%) Tb (2.0%) Cardiac disease (22.6%) Diabetes (28.2%) Hypertension (38.7%)	Inpatient	Severe (100%)	NR	NR	bromelain (100 mg/day in two divided doses) quercetin (1000 mg/day in two divided doses) vitamin C (1000 mg/day in two divided doses) standard care	Mortality
PRINCIPLE Trial Collaborative Group, 2021 PRINCIPLE ²⁴⁴	Peer-reviewed publication ISRCTN865345 80	1979	United Kingdom	60.7	43	Asthma, chronic obstructive pulmonary disease, or	Outpatient	NR	NR	NR	azithromycin (500 mg once daily for three days) standard care	Mortality Mechanical ventilation Admission to hospital

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
						lung disease (35.9%) Angina, heart attack, heart failure, atrial fibrillation, or valve problems (14.5%) Diabetes (18.1%) Hypertension (39.7%)					other trial interventions	Time to symptom/cli nical improvemen t
Padmanabhan , 2020 ²⁴⁵	Pre-print CTRI/2020/05/ 025013	60	India	45.2	60	NR	Inpatient	Mild/Mo derate (100.0%)	NR	NR	Bacille Calmette- Guérin (single dose of 0.1 ml of 2.0 - 8.0 x 106 c.f.u.) placebo	Mortality

•	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
hloroquine, 2020 SOLIDARITY ²⁴⁶	Peer-reviewed publication ISRCTN839711 51, NCT04315948	1854	Albania, Argentina, Austria, Belgium, Brazil, Canada, Colombia, Egypt, Finland, France, Honduras, India, Indonesia, Iran, Ireland, Italy, Kuwait, Lebanon, Lithuania, Luxembourg, Macedonia, Malaysia, Norway, Pakistan, Phillippines, Peru, Saudi Arabia, South Africa, Spain, Switzerland	NR	59.9	Chronic lung disease (6.9%) Asthma (4.7%) Heart disease (20.9%) Diabetes (21.8%)	Inpatient	NR	9	Supplemental oxygen (54.0%) Ventilation (9.0%)	hydroxychloroquine (200 mg twice daily for 10 days) standard care	Mortality Mechanical ventilation Duration of hospitalizati on

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
Pan_interfero n, 2020 SOLIDARITY ²⁴⁶	Peer-reviewed publication ISRCTN839711 51, NCT04315948	4127	Albania, Argentina, Austria, Belgium, Brazil, Canada, Colombia, Egypt, Finland, France, Honduras, India, Indonesia, Iran, Ireland, Italy, Kuwait, Lebanon, Lithuania, Luxembourg, Macedonia, Malaysia, Norway, Pakistan, Phillippines, Peru, Saudi Arabia, South Africa, Spain, Switzerland	NR	63	Chronic lung disease (5.4%) Asthma (4.2%) Heart disease (21.5%) Diabetes (25.0%)	Inpatient	NR	6.6	Supplemental oxygen (69.7%) Ventilation (6.6%)	interferon beta (subcutaneous) (44 µg three times daily for 6 days) standard care	Mortality Mechanical ventilation Duration of hospitalizati on

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
Pan_lopinavir, 2020 SOLIDARITY ²⁴⁶	Peer-reviewed publication ISRCTN839711 51, NCT04315948	2791	Albania, Argentina, Austria, Belgium, Brazil, Canada, Colombia, Egypt, Finland, France, Honduras, India, Indonesia, Iran, Ireland, Italy, Kuwait, Lebanon, Lithuania, Luxembourg, Macedonia, Malaysia, Norway, Pakistan, Phillippines, Peru, Saudi Arabia, South Africa, Spain, Switzerland	NR	59.6	Chronic lung disease (6.6%) Asthma (4.4%) Heart disease (20.9%) Diabetes (24.0%)	Inpatient	NR	8.2	Supplemental oxygen (53.3%) Ventilation (8.2%)	lopinavir-ritonavir (400 mg/100 mg twice daily for 14 days) standard care	Mortality Mechanical ventilation Duration of hospitalizati on

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
Pan_remdesivi r, 2020 SOLIDARITY ²⁴⁶	Peer-reviewed publication ISRCTN839711 51, NCT04315948	5475	Albania, Argentina, Austria, Belgium, Brazil, Canada, Colombia, Egypt, Finland, France, Honduras, India, Indonesia, Iran, Ireland, Italy, Kuwait, Lebanon, Lithuania, Luxembourg, Macedonia, Malaysia, Norway, Pakistan, Phillippines, Peru, Saudi Arabia, South Africa, Spain, Switzerland	NR	62.9	Chronic lung disease (5.4%) Asthma (5.1%) Heart disease (20.9%) Diabetes (25.2%)	Inpatient	NR	8.9	Supplemental oxygen (66.8%) Ventilation (8.9%)	remdesivir (100 mg/day for 10 days) standard care	Mortality Mechanical ventilation Duration of hospitalizati on

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
Pandit, 2021 ⁴⁶	Peer-reviewed publication CTRI/2020/06/026087	40	India	49.2	75	Uncontrolled diabetes mellitus (0.0%) Uncontrolled hypertension (0.0%)	Inpatient	Mild/Mo derate (100.0%)	NR	NR	subcutaneous peginterferon alfa-2b (1 μg/kg single dose) standard care	Mortality Mechanical ventilation Adverse effects leading to discontinuati on Viral clearance Duration of hospitalizati on
Pantos, 2021 Thy-Support ²⁴⁷	Pre-print NCT04348513	5	Greece	65.2	NR	NR	Inpatient Intensive care (100.0%)	Severe (100%) Severe: Critical (100.0%)	NR	NR	triiodothyronine (0.057 g/kg over 1 hour, for a maximum of 30 days) placebo	NR
Parienti, 2021 Attenuate R0 Coronavirus ²⁴⁸	Peer-reviewed publication NCT04685512	60	France	45.2	43.3	Diabetes (3.3%) Hypertension (5.0%)	Outpatient	Mild/Mo derate (100.0%)	0	Unspecified ventilation (0.0%)	emtricitabine (200 mg of emtricitabine given once daily and 245 mg of tenofovir disoproxil fumarate given once daily for 7 days) tenofovir disoproxil fumarate () standard care	Mortality Admission to hospital Adverse effects leading to discontinuati on

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
Pascual-Figal, 2021 COL-COVID ²⁴⁹	Peer-reviewed publication NCT04350320	103	Spain	51	52.4	Copd (1.0%) Obstructive sleep apnea (6.8%) Cardiovascular disease (2.9%) Cerebrovascul ar disease (1.9%) Diabetes (14.6%) Hypertension (27.2%)	Inpatient	NR	0	Niv, iv, ecmo (0.0%)	colchicine (1.5 mg, followed by 0.5 mg every 12 hours during the next 7 days and 0.5 mg every 24 hours for 20 days) standard care	Mortality Mechanical ventilation Adverse effects leading to discontinuati on Duration of hospitalizati on ICU length of stay Time to symptom/cli nical improvemen t
Patel_1, 2021 ²⁵⁰	Peer-reviewed publication ACTRN126200 00454976	33	Australia	62	63.6	Chronic respiratory disease (6.1%) Chronic cardiovascular disease (21.2%) Diabetes (18.2%) Hypertension (48.5%)	Inpatient	Severe (100%)	15.1	Supplemental oxygen (39.4%) High-flow or niv (6.1%) Iv (9.1%)	zinc (0.5 mg/kg/d (elemental zinc concentration 0.24 mg/kg/d) for a maximum of 7 days) standard care	Mortality Mechanical ventilation

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
Patel_2, 2021 OSCAR ²⁵¹	Pre-print NCT04376684	806	Argentina, Belgium, Brazil, Canada, Chile, France, India, Japan, Mexico, Netherlands, Peru, Poland, Russian Federation, South Africa, Spain, United Kingdom, and United States	59.6	71.6	Heart disorder (11.9%) Diabetes (36.7%) Hypertension (49.8%)	Inpatient Intensive care (52.1%)	Severe (100%)	99.2	High-flow or niv (77.2%) Iv (22.1%)	otilimab (90 mg single infusion for one hour) placebo	Mortality Duration of hospitalizati on ICU length of stay Time to symptom/cli nical improvemen t
Pawar, 2021 ²⁵²	Peer-reviewed publication CTRI/2020/05/ 025482	140	India	NR	70.7	NR	Inpatient Intensive care (21.4%)	Mild/Mo derate (78.6%) Severe (21.4%)	NR	ventilator (0.0%)	curcumin (525mg and 2.5mg twice a day for 14 days) piperine () probiotics (probiotics twice daily for 14 days)	Mortality Mechanical ventilation
Perepu, 2021 ²⁵³	Peer-reviewed publication NCT04360824	176	United States	64	56.1	Lung disease (22.5%) Heart disease (31.2%) Diabetes (37.0%) Hypertension (60.1%)	Inpatient Intensive care (61.9%)	Severe (100%)	23.1	Iv (23.1%)	Intermediate-dose enoxaparin (1 mg/kg subcutaneous daily if the BMI was < 30 or 0.5 mg/kg subcutaneous twice daily if the BMI was ≥ 30.) standard care	Mortality Venous thromboem bolism Clinically important bleeding

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
Perlin, 2021 ²⁵⁴	Pre-print NCT04412057	83	United States	58.6	68.7	NR	Inpatient	Severe (100%)	0	Mechanical ventilation (0.0%)	CERC-002 (16 mg/kg up to 1200 mg single dose) placebo	Mortality
Pott-Junior, 2021 IFORS ²⁵⁵	Peer-reviewed publication NCT04431466	32	Brazil	49.4	45.2	NR	Inpatient	Mild/Mo derate (100.0%)	NR	Oxygen supplementati on (20.0%)	ivermectin (100 μg/kg) (100 μg/kg cumulative dose over 7 days) ivermectin (200 μg/kg) (200 μg/kg cumulative dose over 7 days) ivermectin (400 μg/kg) (400 μg/kg cumulative dose over 7 days) standard care	Mechanical ventilation Adverse effects leading to discontinuati on Viral clearance Time to to viral clearance
Prabowo, 2021 ²⁵⁶	Peer-reviewed publication	40	Indonesia	NR	NR	NR	Inpatient	NR	NR	NR	colchicine (0.5 mg twice daily for 7 days) placebo	NR
Purwati, 2021 ²⁵⁷	Peer-reviewed publication	754	Indonesia	37	95.3	NR	Inpatient	Mild/Mo derate (100.0%)	NR	NR	azithromycin (500 mg qd) (500 mg once daily) lopinavir-ritonavir (200/50 mg bid) (200/50 mg twice daily) doxycycline (100 mg bid) (a combination of 200/50 mg lopinavir/ritonavir and 100 mg doxycycline twice a day 100 mg	Adverse effects leading to discontinuati on Viral clearance

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
											twice daily) lopinavirritonavir (200/50 mg bid) (200/50 mg twice daily) azithromycin (500 mg qd) (500 mg once daily) hydroxychloroquine (100 mg bid) (100 mg twice daily) azithromycin (500 mg qd) (500 mg once daily) lopinavirritonavir (400/100 mg bid) (400/100 mg twice daily) doxycycline (100 mg bid) (100 mg twice daily) lopinavirritonavir (400/100 mg bid) (100 mg twice daily) lopinavirritonavir (400/100 mg bid) (400/100 mg twice daily) azithromycin (500 mg once daily)	
Puskarich, 2021 ²⁵⁸	Peer-reviewed publication NCT04311177	117	United States	38.9	50.4	Asthma (10.3%) Copd (0.0%) Chronic bronchitis (0.0%) Obstructive sleep apnea (6.9%)	Outpatient	NR	0	Unspecified ventilation (0.0%)	losartan (25 mg, twice daily for 10 days (for participants with eGFR > 60 mL/min/1.73 m 2) or once daily (for participants with eGFR 30–60 mL/min/1.73 m	Mortality Mechanical ventilation Admission to hospital

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
						Cardiovascular disease (0.0%) Diabetes (6.0%) Hypertension (7.8%)					2)) placebo	
Puskarich_2, 2021 ²⁵⁹	Pre-print NCT04312009	205	United States	55.1	60	Pulmonary hypertension (4.9%) Asthma (13.2%) Copd (11.7%) Chronic bronchitis (3.9%) Obstructive sleep apnea (16.6%) Coronary artery disease (7.8%) Congestive heart failure (4.4%) Diabetes (22.9%) Hypertension (40.5%)	Inpatient Intensive care (12.7%)	Severe (100%)	NR	NR	losartan (50 mg twice daily (100 mg daily total) for 10 days) placebo	Mortality Mechanical ventilation Duration of hospitalizati on Ventilator- free days
REMDACTA_N CT04409262,	Meta-analysis NCT04409262	640	Spain, United States, Brazil, Russia	60.3	63.3	NR	Inpatient	Severe (100%)	NR	NR	tocilizumab (8 mg/kg (up to 800 mg) for one	NR

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
2021 REMDACTA ¹											to two doses) placebo	
RUXCOVID, 2021 RUXCOVID ²⁶⁰	3.0 NCT04362137	432	United States, Argentina, Brazil, Colombia, France, Germany, Mexico, Peru, Russia, Spain, Turkey, United Kingdom	56.6	54.4	NR	Inpatient	Severe (100%)	0	Iv (0.0%)	ruxolitinib (5 mg twice daily for 14 days with possible extension of treatment to 28 days) placebo	Mortality Mechanical ventilation Adverse effects leading to discontinuati on Duration of hospitalizati on Time to symptom/cli nical improvemen t
Raghavan, 2021 ²⁶¹	Peer-reviewed publication CTRI/2021/04/032766	24	India	41.2	70.8	NR	Inpatient	NR	NR	NR	AFO-202 (3 gm per day) N-163 beta glucans (10 gm per day) AFO-202 beta glucan (3 gm per day) standard care	Mortality Mechanical ventilation Duration of hospitalizati on
Rahmani, 2020 ²⁶²	Peer-reviewed publication IRCT20100228 003449N27	80	Iran	60.5	59.1	Asthma (4.5%) Copd (4.5%) Ischemic heart disease (30.3%) Diabetes	Inpatient	Severe (100%)	1.5	Supplemental oxygen (98.5%) High-flow or niv (1.5%)	interferon beta-1b (subcutaneous) (250 µg every other day for 14 days) standard care	Mortality Mechanical ventilation Duration of hospitalizati on

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
						(31.8%) Hypertension (56.1%)						ICU length of stay Time to symptom/cli nical improvemen t
Ramachandra n, 2021 ²⁶³	Pre-print CTRI/2020/09/ 027535	132	India	46.7	74.8	Asthma (0.0%) Diabetes (0.0%)	NR	Mild/Mo derate (69.1000 0000000 001%) Severe (33.3%)	0	Unspecified ventilation (0.0%)	umifenovir (800 mg twice daily for 14 days) placebo	Mortality Viral clearance
Ramakrishnan, 2021 STOIC ²⁶⁴	Peer-reviewed publication NCT04416399	146	United Kingdom	45	42.5	Asthma (15.1%) Cardiovascular disease (8.6%) Diabetes (5.0%)	Outpatient	Mild/Mo derate (100.0%)	0	Supplemental oxygen, niv, or iv (0.0%)	inhaled budesonide (800 µg twice daily until recovered) standard care	Time to symptom/cli nical improvemen t
Ranjbar, 2021 ²⁶⁵	Pre-print IRCT20200204 046369N1	93	Iran	58.7	57	Cardiovascular disease (30.2%) Diabetes (32.6%) Hypertension (45.4%)	Inpatient	NR	NR	NR	methylprednisolone (2 mg/kg infused over 1 hr, which was tapered to half dosage every 5 days) dexamethasone (6 mg/day for 10 days)	Mortality Mechanical ventilation Duration of hospitalizati on
Rashad_1, 2021 ²⁶⁶	Pre-print	305	Egypt	44.4	70.2	NR	Outpatient	Mild/Mo derate (100.0%)	NR	NR	azithromycin (500 mg/day for 7 days) clarithromycin (500	Time to symptom/cli nical improvemen

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
											mg/day for 7 days) standard care	t Time to to viral clearance
Rashad_2, 2021 ²⁶⁷	Peer-reviewed publication CT04519385 (19/08/2020)	149	Egypt	62.5	56.9	Asthma (2.7%) Copd (1.8%) Cardiovascular disease (12.8%) Diabetes (28.4%) Hypertension (47.7%)	Inpatient Intensive care (100.0%)	Severe (100%) Severe: Critical (100.0%)	100	Niv (64.2%) Iv (35.8%)	tocilizumab (4 mg/kg/dose in 100 cc normal saline over one hour repeated after 24 h) dexamethasone (4 mg/kg/day for 3-days followed by 8 mg/day for 10-days)	Mortality
Rashad_3, 2021 ²⁶⁸	Peer-reviewed publication NCT04622891	305	Egypt	44.4	70.2	NR	NR	Mild/Mo derate (100.0%)	0	Unspecified ventilation (0.0%)	azithromycin (500 mg once daily for 7 days) clarithromycin (500 mg twice daily for 7 days) standard care	Mortality Time to symptom/cli nical improvemen t Time to to viral clearance
Rashid, 2021 ²⁶⁹	Peer-reviewed publication NCT04569825	276	Iraq	29.5	28.3	NR	Outpatient	NR	NR	NR	intranasal betamethasone (0.1 mg/mL three times daily until recovery up to 30 days) placebo	NR

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
Rastogi, 2020 SHADE ²⁷⁰	Peer-reviewed publication NCT04459247	40	India	48.5	50	Hypertension (0.0%)	Inpatient	Mild/Mo derate (100.0%)	0	Iv (0.0%)	vitamin D (60000 IU/5 ml/day for 7 days) placebo	Adverse effects leading to discontinuati on Time to to viral clearance
Ravichandran, 2021 ²⁷¹	Pre-print CTRI/2021/05/ 033544	0	India	47	56.2	Severe asthma, (0.0%) Recent heart attack (0.0%) Diabetes (29.0%) Hypertension (19.0%)	Inpatient	NR	NR	NR	indomethacin (75 mg once daily for 5 days for BMI < 30/ 75 mg twice daily for 5 days for BMI >30) paracetamol (650 mg four times daily for 5 days)	Adverse effects leading to discontinuati on Viral clearance Time to symptom/cli nical improvemen t
Ravikirti, 2021 ²⁷²	Peer-reviewed publication CTRI/2020/08/ 027225	115	India	52.5	72.3	Copd (0.9%) Asthma (0.9%) Ischemic heart disease (8.9%) Heart failure (1.8%) Diabetes (35.7%) Hypertension (34.8%)	Inpatient	Mild/Mo derate (100.0%)	NR	NR	ivermectin (12 mg/day for 2 days) placebo	Mortality Mechanical ventilation Viral clearance

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
Reiersen, 2021 STOP-COVID- 2 ²⁷³	Data from authors NCT04668950	547	Canada, United States	48	38	Asthma (13.3%) Lung disease (0.7%) Heart disease (1.5%) Diabetes (9.3%) Hypertension (21.4%)	Outpatient	NR	NR	Supplemental oxygen (0.0%)	fluvoxamine (100 mg twice daily for 15 days) placebo	Admission to hospital
Reis_1, 2020 TOGETHER ²⁷⁴	Data from authors NCT04403100	685	Brazil	53	45	Asthma (8.6%) Copd (2.5%) Cardiovascular disease (3.9%) T2DM (13.1%) T1DM (6.3%) Hypertension (49.3%)	Outpatient	NR	0	Supplemental oxygen, niv, or iv (0.0%)	hydroxychloroquine (400 mg daily for 10 days) lopinavir-ritonavir (400 mg/100 mg twice daily for 10 days) placebo	Mortality Admission to hospital Adverse effects leading to discontinuati on Viral clearance
Reis_2, 2021 TOGETHER ²⁷⁵	Pre-print NCT04727424	1497	Brazil	41.8	7.4	Chronic pulmonary disease (0.6%) Asthma (1.9%) Chronic cardiac disease (1.1%) T1DM (3.1%) T2DM (13.1%) Hypertension (13.0%)	Outpatient	NR	NR	NR	fluvoxamine (100 mg twice daily for 10 days) placebo	Mortality Mechanical ventilation Admission to hospital Viral clearance Duration of hospitalizati on Duration of ventilation

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
												Time to symptom/cli nical improvemen t
Ren, 2020 ²⁷⁶	Peer-reviewed publication ChiCTR200002 9853	20	China	52	60	Copd (0.0%) Cardiovascular disease (5.0%) Diabetes (5.0%) Hypertension (5.0%)	Inpatient	Mild/Mo derate (100.0%)	0	Niv or iv (0.0%)	azvudine (5 mg once daily until discharge) standard care	Mortality Adverse effects leading to discontinuati on Viral clearance Duration of hospitalizati on Time to to viral clearance
Resende, 2021 BISHOP ²⁷⁷	Pre-print RBR-5vpyh4	50	Brazil	54	52	Copd (0.0%) Pneumopathy (10.0%) Cardiopathy (8.0%) Congestive heart failure (0.0%) Diabetes (34.0%)	Inpatient	Severe (100%)	NR	NR	secukinumab (300 mg at day-0 . A second dose of 300 mg could be administered at day 7) standard care	Mortality Mechanical ventilation Duration of hospitalizati on ICU length of stay Ventilator- free days

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
						Hypertension (48.0%)						Duration of ventilation
Rocco, 2020 ²⁷⁸	Peer-reviewed publication RBR-4nr86m, NCT04552483	475	Brazil	37	46.9	Severe respiratory disease, bacterial pneumonia, tuberculosis, severe copd (0.0%) Severe heart disease (0.0%) Severe heart failure (0.0%)	Outpatient	Mild/Mo derate (100.0%)	0	Supplemental oxygen, niv, or iv (0.0%)	nitazoxanide (500 mg three times daily for 5 days) placebo	Mortality Admission to hospital Adverse effects leading to discontinuati on Viral clearance
Rodrigues, 2021 ²⁷⁹	Peer-reviewed publication	84	Brazil	36.5	59.5	NR	Outpatient	NR	NR	NR	azithromycin (250 mg daily for 5 days) hydroxychloroquine (two 200 mg capsules twice daily for 7 days) placebo	Mortality Admission to hospital Viral clearance
Rodriguez- Fortunez, 2021 ²⁸⁰	Published NCT04348383	0	Spain	58.1	80	NR	Inpatient	Severe (100%)	100	Hfo, or niv, oxygen by mask or nasal prongs (80.0%) Ecmo, iv or both (20.0%)	defibrotide (25 mg/ kg/ day 24 hours continuous infusion for 15 days) placebo	NR

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
Roostaei Firozabad, 2021 ²⁸¹	Peer-reviewed publication IRCT20190810 044500N7	52	Iran	36.7	60	Asthma (4.0%) Cardiovascular disease (2.0%) Diabetes (8.0%) Hypertension (6.0%)	Outpatient	NR	NR	NR	levamisole (50 mg three times daily for 3 days) placebo	Mortality Admission to hospital Adverse effects leading to discontinuati on Duration of hospitalizati on
Roozbeh, 2020 ²⁸²	Peer-reviewed publication IRCT20200403 046926N1	60	Iran	43	47.3	Cardiovascular disease (0.0%)	Outpatient	Mild/Mo derate (100.0%)	0	Supplemental oxygen, niv, or iv (0.0%)	sofosbuvir-daclatasvir (400 mg/60 mg for 7 days) standard care	Admission to hospital
Rosas, 2021 COVACTA ²⁸³	Published NCT04320615	452	Canada, Denmark, France, Germany, Italy, Netherlands, Spain, United Kingdom, United States	60.8	69.9	Chronic lung disease (16.2%) Cardiovascular impairment (28.1%) Diabetes (38.1%) Hypertension (62.1%)	Inpatient Intensive care (56.4%)	Severe (100%)	37.7	Unspecified ventilation (37.7%)	tocilizumab (8 mg/kg, maximum 800 mg, up to two times in 24 hours) placebo	Adverse effects leading to discontinuati on Duration of hospitalizati on ICU length of stay Ventilator- free days Time to symptom/cli nical

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
												improvemen t
Rossignol, 2021 ²⁸⁴	Pre-print NCT04486313	935	United States, Puerto Rico	40.3	43.5	NR	Outpatient	Mild/Mo derate (99.6999 9999999	NR	Supplemental oxygen (0.0%)	nitazoxanide (300 mg twice daily for five days) placebo	Mortality Admission to hospital Adverse effects leading to discontinuati on Time to symptom/cli nical improvemen t
Rutgers, 2021 PreToVid ²⁸⁵	Pre-print NL8504	354	Netherlands	66.5	67	NR	Inpatient	Severe (100%)	NR	Supplemental oxygen (96.6%)	tocilizumab (single dose of 8 mg/kg of body weight intravenously or 800mg max, second dose permitted after 8 hours if hypoxia not resolved) standard care	Mechanical ventilation Duration of hospitalizati on ICU length of stay Duration of ventilation

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
Ruzhentsova, 2020 ²⁸⁶	Pre-print NCT04501783	168	Russia	41.8	47	Moderate or severe chronic obstructive pulmonary disease (0.0%) Asthma (0.0%) Severe chronic cardiovascular disorders (0.0%) Diabetes (0.0%)	Inpatient (24.4%)	Mild/Mo derate (100.0%)	NR	Supplemental oxygen (1.8%)	favipiravir (800 mg twice daily for 10 days) standard care	Mechanical ventilation Admission to hospital Adverse effects leading to discontinuati on Viral clearance Time to symptom/cli nical improvemen t Time to to viral clearance
Réa-Neto, 2021 ²⁸⁷	Peer-reviewed publication NCT04420247	142	Brazil	53.8	66.7	Chronic lung disease (8.6%) Diabetes (25.7%) Hypertension (38.1%)	Inpatient Intensive care (84.5%)	Severe (100%)	18.1	Oxygen by mask or nasal prongs (81.0%) Niv (0.0%) Iv (3.8%) Iv and additional organ support (14.3%)	chloroquine/hydroxych loroquine (450 mg of chloroquine once daily for 5 days, or 400 mg of hydroxychloroquine once daily for 5 days) standard care	Mortality Mechanical ventilation Adverse effects leading to discontinuati on Duration of hospitalizati on ICU length of stay

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
												Ventilator- free days
SARCOVID_NC T04357808, 2021 SARCOVID ¹	Meta-analysis NCT04357808	30	Spain	61.7	66.7	NR	Inpatient	Severe (100%)	0	Mechanical ventilation (0.0%)	sarilumab (400 mg single dose) standard care	Mortality
SARICOR_Eudr aCT2020- 001531-27, 2021 SARICOR ¹²⁸⁸	Meta-analysis EudraCT2020- 001531-27	80	Spain	59.4	71.2	NR	Inpatient	Severe (100%)	0	Mechanical ventilation (0.0%)	sarilumab (400 mg single dose) sarilumab (200 mg single dose) standard care	Mortality
SARTRE_Eudra CT2020- 002037-15, 2021 SARTRE ¹²⁸⁹	Meta-analysis EudraCT2020- 002037-15	140	Spain	58.4	72.9	NR	Inpatient	Severe (100%)	0	Mechanical ventilation (0.0%)	sarilumab (200 mg to 400 mg single dose) standard care	Mortality
SILCOR_Eudra CT2020- 001413-20, 2021 SILCOR ¹	Meta-analysis EudraCT2020- 001413-20	158	Spain	62	65.2	NR	Inpatient	Severe (100%)	NR	NR	siltuximab (11 mg/kg single dose) corticosteroids (methylprednisolone then dexamethasone)	Mortality
STORM_NCT0 4345445, 2021 STORM ¹	Meta-analysis NCT04345445	59	Malaysia	53.2	76.3	NR	Inpatient	Mild/Mo derate (100.0%)	0	Mechanical ventilation (0.0%)	tocilizumab (8 mg/kg single dose) dexamethasone (8 mg- 12 OD for 72 hours)	Mortality

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
Sabico, 2021 ²⁹⁰	Peer-reviewed publication SCTR No. 20061006	73	Saudi Arabia	49.7	49.3	Asthma (4.3%) Cardiovascular disease (5.8%) Diabetes (50.7%) Hypertension (55.1%)	NR	NR	0	Unspecified ventilation (0.0%)	vitamin D3 (5000 IU) (5000 IU once daily for 2 weeks) vitamin D3 (1000 IU) (1000 IU once daily for 2 weeks)	Mortality Adverse effects leading to discontinuati on Duration of hospitalizati on Time to symptom/cli nical improvemen t
Sadeghi, 2020 ²⁹¹	Peer-reviewed publication IRCT20200128 046294N2	70	Iran	58	51.5	Chronic pulmonary disease (22.7%) Asthma (3.0%) Heart failure (15.2%) Diabetes (42.4%) Hypertension (34.8%)	Inpatient	Severe (100%)	0	Iv (0.0%)	sofosbuvir-daclatasvir (400 mg/60 mg once daily for 14 days) standard care	Mortality Mechanical ventilation Duration of hospitalizati on Time to symptom/cli nical improvemen t
Salama, 2020 EMPACTA ²⁹²	Peer-reviewed publication NCT04372186	388	United States, Peru, Brazil, Kenya, South Africa, Mexico	55.9	59.1	Copd (4.5%) Asthma (11.4%) Myocardial infarction (1.9%) Atrial	Inpatient Intensive care (15.4%)	Severe (100%)	0	Ventilation (0.0%)	tocilizumab (8 mg/kg, for up to a maximum of 800 mg, in 24 hours) placebo	Mechanical ventilation Adverse effects leading to discontinuati on

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
						fibrillation (3.2%) Diabetes (40.6%) Hypertension (48.3%)						Duration of hospitalizati on Time to symptom/cli nical improvemen t
Salehzadeh, 2020 ²⁹³	Pre-print IRCT20200418 047126N1	100	Iran	56.1	41	Copd (4.0%) Ischemic heart disease (15.0%) Diabetes (11.0%) Hypertension (11.0%)	Inpatient	NR	NR	NR	colchicine (1 mg/day for 6 days) placebo	Mortality Duration of hospitalizati on
Salvarani, 2020 RCT-TCZ- COVID-19 ²⁹⁴	Peer-reviewed publication NCT04346355	126	Italy	60	61.1	Copd (3.2%) Diabetes (15.1%) Hypertension (44.4%)	Inpatient	Severe (100%)	0	Niv or iv (0.0%)	tocilizumab (8mg/kg, for up to a maximum of 800 mg, in 12 hours) standard care	Mortality Mechanical ventilation Duration of hospitalizati on
Samimagham, 2021 ²⁹⁵	Pre-print IRCT20200509 047364N2	20	Iran	46	60	NR	Inpatient	NR	NR	NR	famotidine (160 mg four times daily until discharge up to 14 days) placebo	Mortality Adverse effects leading to discontinuati on Duration of hospitalizati on

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
Santamarina, 2021 ²⁹⁶	Pre-print NCT04489446	40	Chile	55.8	82.5	Asthma (5.0%) Copd (0.0%) Diabetes (20.0%) Hypertension (50.0%)	Inpatient	NR	27.5	Ambient oxygen (32.5%) Hfo (5.0%) Prone position ventilation (27.5%)	sildenafil (25 mg three times daily for seven days) placebo	Mortality Mechanical ventilation Duration of hospitalizati on ICU length of stay Duration of ventilation
Sayad, 2021 ²⁹⁷	Peer-reviewed publication IRCT20130812 014333N145	80	Iran	54.1	55	Pulmonary disorders (10.0%) Cardiovascular disease (17.5%) Diabetes (20.0%) Hypertension (30.0%)	Inpatient	Severe (100%)	NR	NR	sofosbuvir (400 mg once daily for 10 days) velpatasvir (100 mg once daily for 10 days) standard care	Mortality Mechanical ventilation Adverse effects leading to discontinuati on Duration of hospitalizati on Duration of ventilation Time to symptom/cli nical improvemen t
Schwartz_1, 2021 ²⁹⁸	Data from authors NCT04429711	94	Israel	39.5	80.8	NR	Outpatient	NR	0	Niv or iv (0.0%)	ivermectin (150 to 300 μg/kg/day for 3 days) placebo	NR

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
Schwartz_2, 2021 ALBERTA HOPE COVID- 19 ²⁹⁹	Peer-reviewed publication NCT04329611	148	Canada	46.8	44.6	Asthma (13.5%) Diabetes (19.6%) Hypertension (27.7%)	Outpatient	NR	NR	NR	hydroxychloroquine (200 mg twice daily for 5 days) placebo	Mortality Mechanical ventilation Admission to hospital Adverse effects leading to discontinuati on Time to symptom/cli nical improvemen t
Sedighiyan, 2021 ³⁰⁰	Pre-print IRCT20200511 047399N1	39	Iran	66.8	60	Diabetes (100.0%)	Inpatient	NR	NR	NR	omega 3 (670 mg EPA and DHA for two weeks) standard care	NR
Sekhavati, 2020 ³⁰¹	Peer-reviewed publication	111	Iran	57.1	46	Cardiovascular disease (0.0%)	Inpatient	NR	NR	NR	azithromycin (500 mg once daily for 5 days) standard care	Mortality Mechanical ventilation Adverse effects leading to discontinuati on Duration of hospitalizati on

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
												ICU length of stay
Self, 2020 ORCHID ³⁰²	Peer-reviewed publication NCT04332991	479	United States	57	55.7	Asthma (10.2%) Copd (8.1%) Chronic artery disease (8.8%) Cerebrovascul ar disease (7.1%) Congestive heart failure (7.3%) Peripheral vascular disease (4.0%) Prior myocardial infarction (4.4%) Diabetes (34.7%) Hypertension (52.8%)	Inpatient Intensive care (19.0%)	NR	19.2	Face mask (2.1%) Standard nasal cannula (42.4%) High-flow (11.1%) Niv (1.5%) Iv (6.7%) Other (1.7%)	hydroxychloroquine (200 mg twice daily for 5 days) placebo	Mortality Mechanical ventilation Time to symptom/cli nical improvemen t
Sethi, 2021 IMPROVE COVID ³⁰³	Data from authors NCT04367831	94	United States	NR	NR	NR	Inpatient Intensive care (100.0%)	Severe (100%)	NR	NR	prophylactic anticoagulation (If eGFR ≥30 mL/min : BMI < 40 kg/m2: Enoxaparin 40 mg SC	Mortality Venous thromboem bolism Clinically

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
											daily. BMI 40 - 50	important
											kg/m2: Enoxaparin 40	bleeding
											mg SC twice a day. BMI	
											> 50 kg/m2:	
											Enoxaparin 60 mg SC	
											twice a day If eGFR <	
											30 mL/min or acute	
											kidney injury: 50-120	
											kg: Unfractionated	
											heparin 5000 units SC	
											q8h >120 kg:	
											Unfractionated	
											heparin 7500 units SC	
											q8h If CRRT:	
											Unfractionated	
											heparin infusion pre-	
											filter at 500	
											units/hour)	
											intermediate-dose	
											anticoagulation (If	
											eGFR ≥30 mL/min:	
											enoxaparin 1mg/kg SC	
											daily or unfractioned	
											heparin infusion at 10	
											units/kg/hour. If eGFR	
											<30 mL/min or acute	
											kidney injury or CRRT:	
											unfractioned heparin	
											infusion at	
											10units/kg/hr)	

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
Shinkai, 2021 ³⁰⁴	Peer-reviewed publication JapicCTI-205238	156	Japan	45.3	66.7	NR	Inpatient	Mild/Mo derate (100.0%)	0	Unspecified ventilation (0.0%)	favipiravir (800 mg twice daily for 14 days) placebo	Mortality Mechanical ventilation Adverse effects leading to discontinuati on Time to symptom/cli nical improvemen t
Sholzberg, 2021 RAPID ³⁰⁵	Pre-print NCT04362085, NCT04444700	465	Brazil, Canada, ireland, Saudi Arabia, United Arab Emirates, United States of America	60	56.8	Chronic pulmonary disease (13.6%) Coronary artery disease (7.3%) Heart failure (3.2%) Atrial fibrillation (0.4%) Cerebrovascul ar disease (4.1%) Diabetes (34.4%) Hypertension (48.4%)	Inpatient	Mild/Mo derate (100.0%)	0	Niv, iv (0.0%)	therapeutic heparin (administered up to hospital discharge or day 28) standard care	Mortality Mechanical ventilation Venous thromboem bolism Clinically important bleeding Ventilator- free days

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
Shrivastava, 2021 ³⁰⁶	Peer-reviewed publication :CTRI/2020/11 /029388	214	India	NR	NR	NR	Outpatient	NR	NR	NR	Covispray (2–3 sprays in each nostril, 4–5 times per day for 14 days) standard care	Admission to hospital Adverse effects leading to discontinuati on
Siami, 2021 ³⁰⁷	Peer-reviewed publication	120	Iran	NR	NR	Respiratory condition (0.0%)	Inpatient (74.2%)	NR	NR	NR	ammonium chloride (125 mg in 5 ml three times daily for 7 days) placebo	Mortality Mechanical ventilation Duration of hospitalizati on
Sigamani, 2020 ³⁰⁸	Peer-reviewed publication NCT04512027	10	India	28.8	20	Diabetes (0.0%)	Inpatient	Mild/Mo derate (100.0%)	0	Supplemental oxygen, niv, or iv (0.0%)	prolectin-M (40 g/day for 5 days) standard care	Viral clearance
Silva Borba, 2020 CloroCovid- 19 ³⁰⁹	Peer-reviewed publication NCT04323527	81	Brazil	51.1	75.3	Asthma (7.4%) Tuberculosis (3.6%) Cardiovascular disease (9.1%) Diabetes (25.5%) Hypertension (45.5%)	Inpatient Intensive care (45.7%)	Severe (100%)	NR	Supplemental oxygen (88.9%)	chloroquine (600 mg BID) (600 mg twice daily for 10 days) chloroquine (450 mg BID) (450 mg/day for 5 days)	Mortality
Silva, 2021 ³¹⁰	Pre-print NCT04463264	46	Argentina	45.9	72.2	NR	Inpatient (69.4%)	Mild/Mo derate (94.4%)	0	Unspecified ventilation (0.0%)	nitazoxanide (500 mg four times a day for 14 days) placebo	Mortality Adverse effects leading to discontinuati on

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
												Viral clearance
Singh_1, 2021 ³¹¹	Pre-print NCT04402866	25	United Kingdom, Moldova, Ukraine	57.3	68	Diabetes (40.0%) Hypertension (68.0%)	Inpatient	Severe (100%)	NR	Supplemental oxygen (100.0%)	inhaled pan-JAK inhibitor (TD-0903) (1 mg) (1 mg once daily for up to 7 days) inhaled pan-JAK inhibitor (TD-0903) (3 mg) (3 mg once daily for up to 7 days) inhaled pan-JAK inhibitor (TD-0903) (10 mg) (10 mg once daily for up to 7 days) placebo	Mortality Mechanical ventilation Adverse effects leading to discontinuati on Duration of hospitalizati on
Singh_2, 2021 SEV COVID Trial ³¹²	Pre-print CTRI/2020/06/ 025575	40	India	43.3	78.8	Copd (6.1%) Asthma (0.0%) Chronic cardiac disease (6.1%) Diabetes (15.2%) Hypertension (6.1%)	Inpatient	NR	NR	Oxygen supplementati on (15.2%)	hydroxychloroquine (400 mg of hydroxychloroquine once daily, and 600 mg of ribavirin twice daily, for 10 days) rivabirin () standard care	Mortality Mechanical ventilation Duration of hospitalizati on Time to to viral clearance
Singh_3, 2021 SEV COVID Trial ³¹²	Pre-print CTRI/2020/06/ 025575	71	India	53.2	72	Copd (8.8%) Ashtma (2.9%) Chronic cardiac disease (14.7%) Diabetes	Inpatient	Severe (100%)	NR	Oxygen supplementati on (75.0%)	hydroxychloroquine (400 mg of hydroxychloroquine once daily, and 600 mg of ribavirin twice daily, for 10 days) ribavirin () lopinavir-ritonavir (two	Mortality Mechanical ventilation Adverse effects leading to discontinuati

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
						(33.8%) Hypertension (45.6%)					200 mg/50 mg lopinavir-ritonavir tablets twice daily for 10 days) ribavirin () standard care	on Duration of hospitalizati on Time to to viral clearance
Sivapalan, 2021 ProPAC- COVID ³¹³	Peer-reviewed publication NCT04322396	117	Denmark	65.6	55.6	Asthma (22.2%) Copd (8.6%) Bronchiectasis (3.4%) Previous myocardial infarction (5.1%) Heart failure (6.8%) Atrial fibrillation (17.9%) Diabetes (23.9%) Hypertension (38.5%)	Inpatient	Severe (100%)	59	Unspecified ventilation (59.0%)	azithromycin (500 mg once daily on days 1 to 3 then 250 mg once daily for days 4 to 15) hydroxychloroquine (200 mg twice daily on days 1 to 3 then 200 mg twice daily for days 4 to 15) placebo	Mortality Mechanical ventilation Adverse effects leading to discontinuati on Duration of hospitalizati on
Sivapalasinga m_P2, 2021 Sarilumab- COVID-19	Pre-print NCT04315298	457	United States	58.7	72.4	Tuberculosis (0.0%) Diabetes (21.4%) Hypertension (46.4%)	Inpatient	Severe (100%) Severe: Critical (49.5%)	49.5	Low-flow supplemental oxygen (27.6%) High-flow oxygen, niv,	sarilumab (200 mg) (200 mg given intravenously over 1 hour) sarilumab (400 mg) (400 mg given intravenously over 1	Adverse effects leading to discontinuati on

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
										and/or iv (49.5%)	hour) placebo	
Sivapalasinga m_P3_C1, 2021 Sarilumab- COVID-19 ³¹⁴	Pre-print NCT04315298	1365	United States	61.7	64.5	Tuberculosis (0.0%) Diabetes (19.0%) Hypertension (52.7%)	Inpatient	Severe (100%) Severe: Critical (55.0%)	21.8	Low-flow supplemental oxygen (27.0%) Iv (21.8%)	sarilumab (200 mg) (200 mg given intravenously over 1 hour) sarilumab (400 mg) (400 mg given intravenously over 1 hour) placebo	Adverse effects leading to discontinuati on
Sivapalasinga m_P3_C2_Criti cal, 2021 Sarilumab- COVID-19 ³¹⁴	Pre-print NCT04315298	31	United States	48.7	71	Tuberculosis (0.0%) Diabetes (29.0%) Hypertension (41.9%)	Inpatient	Severe (100%) Severe: Critical (100.0%)	100	Iv (100.0%)	sarilumab (800 mg) (800 mg given intravenously over 1 hour) placebo	Mortality Adverse effects leading to discontinuati on
Sivapalasinga m_P3_C3_Criti cal, 2021 Sarilumab- COVID-19 ³¹⁴	Pre-print NCT04315298	8	United States	60.8	62.5	Tuberculosis (0.0%) Diabetes (37.5%) Hypertension (62.5%)	Inpatient	Severe (100%) Severe: Critical (100.0%)	100	Niv or high- flow oxygen (100.0%) Iv (0.0%)	sarilumab (800 mg) (800 mg given intravenously over 1 hour) placebo	Mortality Adverse effects leading to discontinuati on
Skendelas, 2021 ³¹⁵	Peer-reviewed publication NCT04343651	4	United States	63.5	50	Single-lung transplant (100.0%) Severe chronic respiratory disease and requirement	NR	NR	NR	NR	leronlimab (1-2 weekly 700 mg subcutaneous doses) placebo	Mechanical ventilation Adverse effects leading to discontinuati on

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
						for long-term oxygen therapy (0.0%)						
Skipper, 2020 ³¹⁶	Peer-reviewed publication NCT04308668	491	United States, Canada	40	45.8	Asthma (10.4%) Chronic lung disease (0.4%) Cardiovascular disease (1.2%) Diabetes (3.9%) Hypertension (11.0%)	Outpatient	Mild/Mo derate (100.0%)	0	Supplemental oxygen, niv, or iv (0.0%)	hydroxychloroquine (600 mg once daily for 5 days) placebo	Mortality Admission to hospital
Sobngwi, 2021 DOXYCOV ³¹⁷	Pre-print NCT04715295	194	Cameroon	38.5	52.4	Asthma (1.6%) Severe cardiac disease (0.0%) Treated hypertension (1.1%)	Outpatient	Mild/Mo derate (100.0%)	NR	NR	doxycycline (Doxycycline 100mg twice daily for 7 days) azithromycin (500 mg at day 1 and 250 mg from day 2 through 5) hydroxychloroquine (400 mg daily for 5 days)	Admission to hospital Adverse effects leading to discontinuati on Viral clearance
Soin, 2021 COVINTOC ³¹⁸	Published CTRI/2020/05/ 025369	180	India	55	84.9	Copd (2.2%) Respiratory, thoracic, and mediastinal disorders (3.9%) Cardiac disorders (15.1%)	Inpatient	Mild/Mo derate (49.2%)	31.9	Supplemental oxygen (89.9%) Niv (26.8%) Iv (5.0%)	tocilizumab (6 mg/kg, up to a maximum dose of 480 mg, single dose) standard care	Mortality Mechanical ventilation ICU length of stay Ventilator- free days Duration of ventilation

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
						Diabetes (41.3%) Hypertension (39.1%)						Time to symptom/cli nical improvemen t
Solanich, 2021 TACROVID ³¹⁹	Peer-reviewed publication NCT04341038 /EudraCT: 2020-001445-39	55	Spain	63.2	80	Coronary heart disease (7.3%) Diabetes (27.3%) Hypertension (43.6%)	Inpatient	Severe (100%)	29.1	Supplemental oxygen (70.9%) Niv or hfo (29.1%)	methylprednisolone (120 mg of methylprednisolone pulse daily on three consecutive days, 0.05 mg/kg of tacrolimus twice daily until blood trough levels of 8 - 10 ng/mL) tacrolimus () standard care	Mortality Mechanical ventilation Duration of hospitalizati on Duration of ventilation Time to symptom/cli nical improvemen t
Solaymani- Dodaran, 2021 ³²⁰	Peer-reviewed publication IRCT20200318 046812N1	380	Iran	57.6	55	Chronic lung disease (3.5%) Asthma (3.8%) Cardiovascular disease (10.7%) Diabetes (25.7%) Hypertension (34.9%)	Inpatient	Severe (100%)	NR	NR	favipiravir (600 mg three times a day for 7 days) lopinavir-ritonavir (100 mg and 400 mg twice a day for 7 days)	Mortality Mechanical ventilation Duration of hospitalizati on Time to symptom/cli nical improvemen t

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
Song, 2021 ³²¹	Peer-reviewed publication NCT04330586	61	South Korea	46.6	32.8	Chronic airway diseases: asthma and chronic obstructive lung disease (0.0%) Diabetes (14.8%) Hypertension (27.9%)	Inpatient	NR	NR	NR	ciclesonide (320 ug inhalation twice per day for 14 days) standard care	Mortality Adverse effects leading to discontinuati on Viral clearance Duration of hospitalizati on
Song_2, 2021 SAC-COVID ³²²	Pre-print NCT04317040	22	United States	58	63.6	Copd/asthma (9.1%) Heart disease (31.8%) Diabetes (31.8%) Hypertension (50.0%)	Inpatient	Severe (100%)	NR	Supplemental oxygen (100.0%) Mv (0.0%)	CD24Fc antibody (480 mg IV infusion single dose) placebo	Duration of hospitalizati on
Spinner, 2020 ³²³	Peer-reviewed publication NCT04292730	596	France, Germany, Hong Kong, Italy, Netherlands, Korea, Singapore, Spain, Switzerland, Taiwan, United	57	61.1	Asthma (13.9%) Cardiovascular disease (56.3%) Diabetes (39.7%) Hypertension (42.5%)	Inpatient	Mild/Mo derate (100.0%)	0.9	Supplemental oxygen (15.1%) High-flow or niv (0.9%)	remdesivir (10 days) (100 mg once daily for 10 days) remdesivir (5 days) (100 mg once daily for 5 days) standard care	Mortality Mechanical ventilation Adverse effects leading to discontinuati on Duration of hospitalizati on Time to symptom/cli

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
			Kingdom, United States									nical improvemen t
Spyropoulos, 2021 HEP-COVID ³²⁴	conference abstract NCT04401293	257	United States	NR	NR	NR	Inpatient	Severe (100%)	20.6	Nasal cannular (64.4%) Non-rebreather (9.1%) Venti mask (2.4%) Hfnc or niv (15.4%) Invasive mechanical ventilation (5.1%)	full-dose anticoagulant (enoxaparin 1mg/kg subcut bid for creatinine clearance => 30 ml/min or 0.5 mg/kg subcut bid for creatinine clearance 15-29 ml/min) intermediate-dose anticoagulant (unfractionated heparin up to 22,500 IU daily or enoxaparin 30 mg qid or 40 mg bid or dalteparin 5000 units per day)	Mortality Mechanical ventilation Venous thromboem bolism Clinically important bleeding
Sterne_NCT04 244591, 2020 Steroids- SARI ³²⁵	Meta-analysis NCT04244591	47	China	64.5	74.5	NR	Inpatient Intensive care (100.0%)	Severe (100%) Severe: Critical (100.0%)	57.5	Mechanical ventilation (57.5%)	methylprednisolone (40 mg twice daily for 5 days) standard care	Mortality
Sterne_NCT04 325061, 2020 DEXA-COVID 19 ³²⁵	Meta-analysis NCT04325061	19	Spain	60.7	68.4	NR	NR	Severe (100%) Severe:	100	Iv (100.0%)	dexamethasone (20 mg once daily for 5 days, then 10 mg once	Mortality

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
								Critical (100.0%)			daily for 5 days) standard care	
Stone, 2020 BACC ³²⁶	Peer-reviewed publication NCT04356937	243	United States	59.9	58	Copd (9.1%) Asthma (9.1%) Heart failure (9.9%) Myocardial infarction (8.6%) Diabetes (30.9%) Hypertension (48.6%)	Inpatient Intensive care (4.5%)	Severe (100%)	4.5	Supplemental oxygen (79.8%) High-flow or niv (4.1%) Iv (0.4%)	tocilizumab (8mg/kg, for up to a maximum of 800 mg, once) placebo	Mortality Mechanical ventilation Duration of hospitalizati on Duration of ventilation Time to symptom/cli nical improvemen t
Strich, 2021 ³²⁷	Peer-reviewed publication NCT04579393	59	United States	55.6	79.7	Asthma (11.9%) Coronary artery disease (13.6%) Diabetes (37.3%) Hypertension (54.2%)	Inpatient	Mild/Mo derate (39.0%) Severe (61.0%) Severe: Critical (6.8%)	61	Supplementar y oxygen (39.0%) Niv or hfo (54.2%) Iv or ecmo (6.8%)	fostamatinib (150 mg twice daily for 14 days) placebo	Mortality Mechanical ventilation Adverse effects leading to discontinuati on ICU length of stay Time to symptom/cli nical improvemen t

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
Sun, 2020 ³²⁸	Peer-reviewed publication	66	China	49.5	66.7	Cardiovascular disease (1.5%) Diabetes (9.1%) Hypertension (18.2%)	Inpatient	Mild/Mo derate (100.0%)	NR	NR	standard care (150 mg three times daily) diammonium glycyrrhizinate (150 mg three times daily)	Mortality
TOCOVID_Eud raCT2020- 001442-19, 2021 TOCOVID¹	Meta-analysis EudraCT2020- 001442-19	270	Spain	53	63.7	NR	Inpatient Intensive care (100.0%)	Severe (100%)	NR	NR	tocilizumab (162 mg (up to 600 mg) four doses or 400 mg (up to 600 mg) single dose based on patient weight) standard care	Mortality
Taher, 2021 ³²⁹	Peer-reviewed publication IRCT20120215 009014N355	92	Iran	57.5	58.7	Respiratory condition (15.2%) Cardiovascular disease (28.3%) Diabetes (23.9%)	Inpatient	Severe (100%) Severe: Critical (100.0%)	0	Mechanical ventilation (0.0%)	N-acetylcysteine (40 mg/kg/day diluted in 5% dextrose for 3 days as a continuos intravenous infusion) placebo	Mortality Mechanical ventilation Adverse effects leading to discontinuati on Duration of hospitalizati on ICU length of stay Ventilator- free days
Tahmasebi, 2020 ³³⁰	Peer-reviewed publication	80	Iran University of Medical	54.2	60	NR	Inpatient Intensive care (50.0%)	Mild/Mo derate (50.0%)	NR	NR	nanocurcumin (80 mg twice daily for 21 days) placebo	Mortality

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
			Sciences is in Iran)									
Talaschian, 2021 ³³¹	Pre-print IRCT20081027 001411N4	40	Iran	61.7	52.8	Respiratory disorder (8.3%) Cardiovascular disease (44.4%) Diabetes (36.1%) Hypertension (50.0%)	Inpatient	Severe (100%)	8.3	Nasal cannula (50.0%) Simple mask (30.6%) Reservoir mask (11.1%) Niv (8.3%) Iv (0.0%)	tocilizumab (8 mg/kg (if the patient's conditions were not stable, 2 doses by 12 hours were administrated, maximum dose: 800 mg)) standard care	Mortality Mechanical ventilation Adverse effects leading to discontinuati on Time to symptom/cli nical improvemen t
Tang_1, 2020 ³³²	Peer-reviewed publication ChiCTR200002 9868	150	China	46.1	55	Cardiovascular disease (0.0%) Diabetes (14.0%) Hypertension (6.0%)	Inpatient	Mild/Mo derate (99.0%)	NR	NR	hydroxychloroquine (800 mg once daily for 14 to 21 days) standard care	Mortality Adverse effects leading to discontinuati on Viral clearance Time to symptom/cli nical improvemen t Time to to viral clearance

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
Tang_2, 2021 ³³³	Peer-reviewed publication NCT04273321	86	China	56	47.7	Chronic obstructive pulmonary disease (3.5%) Asthma (2.3%) Cardiovascular disease (7.0%) Diabetes (9.3%) Hypertension (36.0%)	Inpatient	Severe (100%)	NR	Nasal cannula (70.9%)	methylprednisolone (1 mg/kg daily for 7 days) standard care	Mortality Mechanical ventilation Viral clearance Duration of hospitalizati on Time to symptom/cli nical improvemen t Time to to viral clearance
Tardif, 2021 COLCORONA ³³	Peer-reviewed publication NCT04322682	4488	Brazil, Canada, Greece, South Africa, Spain, USA	53.5	46.1	Respiratory condition (26.5%) Mi (3.0%) Hf (0.9%) Diabetes (19.9%) Hypertension (36.3%)	Outpatient	NR	NR	NR	colchicine (0.5 mg twice per day for 3 days and then once per day for 27 days thereafter) placebo	Mortality Mechanical ventilation Admission to hospital
Temesgen, 2021 LIVE-AIR ³³⁵	Pre-print NCT04351152	520	Brazil, United States	60.5	64.7	Asthma (10.6%) Interstitial pulmonary fibrosis (0.8%) Copd (7.3%) Congestive	Inpatient	Severe (100%)	40.5	Room air or supplemental oxygen (59.5%) High-flow or	lenzilumab (600 mg, 3 doses, 8 hours apart) placebo	Mortality Time to symptom/cli nical improvemen t

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
						heart failure (11.7%) Coronary artery disease (13.6%) Diabetes (53.4%)				niv (40.5%) Iv (0.0%)		
Thakar, 2020 ³³⁶	Peer-reviewed publication CTRI/2020/04/ 024729	60	India	34.9	78.3	Cardiovascular disease (0.0%)	Outpatient	Mild/Mo derate (100.0%)	0	Supplemental oxygen, niv, or iv (0.0%)	nasal chloroquine drops (0.5 ml six doses daily for 10 days) standard care	Viral clearance
The CORIMUNO- 19 Collaborative group, 2021 CORIMUNO- ANA-1 ³³⁷	Peer-reviewed publication NCT04341584	116	France	66	70.2	Asthma (7.0%) Chronic pulmonary disease (7.9%) Chronic cardiac disease (31.6%) Diabetes (29.8%)	Inpatient	Severe (100%)	0	Supplemental oxygen (100.0%) High-flow or niv or iv (0.0%)	anakinra (200 mg twice daily on days 1 to 3, then 100 mg twice daily on day 4, and 100 mg once on day 5) standard care	Mortality Mechanical ventilation
The REMAP-CAP, ACTIV-4a, and ATTACC Investigators, 2021 REMAP-CAP, ACTIV-4a, ATTACC ³³⁸	Pre-print NCT02735707, NCT04505774, NCT04359277, NCT04372589	1205	Canada, USA, UK, Ireland, Netherlands, Saudi Arabia, Australia, Nepal, Brazil, Mexico	60.9	70	Asthma, chronic obstructive pulmonary disease, bronchiectasis , interstitial lung disease, primary lung cancer,	Inpatient Intensive care (100.0%)	Severe (100%)	98.6	High flow nasal oxygen (33.1%) Niv (38.0%) Iv (27.6%)	therapeutic heparin (according to local protocol for up to 14 days or recovery) standard care	Mortality Venous thromboem bolism Clinically important bleeding

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
						pulmonary						
						hypertension,						
						active						
						tuberculosis,						
						or through the						
						receipt of						
						home oxygen						
						therapy						
						(24.1%)						
						New york heart						
						association						
						class iv						
						symptoms;						
						defined in						
						activ-4a and						
						attacc as a						
						baseline						
						history of						
						heart failure,						
						myocardial						
						infarction,						
						coronary						
						artery disease,						
						peripheral						
						arterial						
						disease, or						
						cerebrovascul						
						ar disease						
						(6.9%)						
						Diabetes						
						(32.7%)						

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
Thomas, 2021 COVID A to Z ³³⁹	Peer-reviewed publication NCT04342728	214	United States	45.2	38.3	Asthma (15.4%) Diabetes (13.6%) Hypertension (32.7%)	Outpatient	NR	NR	NR	ascorbic acid (8000 mg divided in 2 or 3 doses/day for 10 days) zinc gluconate (50 mg/day for 10 days) ascorbic acid (8000 mg divided in 2 or 3 doses/day for 10 days) zinc gluconate (50 mg/day for 10 days) standard care	Mortality Admission to hospital Adverse effects leading to discontinuati on Time to symptom/cli nical improvemen t
Tolouian, 2021 ³⁴⁰	Peer-reviewed publication	111	Iran	52	46	Asthma (6.0%) Copd (7.0%) Cerebrovascul ar accident (2.0%) Coronary heart disease (9.0%) Diabetes (33.0%) Hypertension (39.0%)	Inpatient	NR	NR	NR	bromhexine hydrochloride (8 mg four times a day for 14 days) standard care	Mortality Mechanical ventilation Viral clearance Duration of hospitalizati on ICU length of stay Time to symptom/cli nical improvemen t
Tomazini, 2020 CoDEX ³⁴¹	Peer-reviewed publication NCT04327401	299	Brazil	61.4	62.5	Heart failure (7.7%) Diabetes (42.1%)	Inpatient Intensive care (100.0%)	Severe (100%) Severe:	91	Pressure control ventilation (44.5%)	dexamethasone (20 mg once daily for 5 days, then 10 mg once	Mortality Mechanical ventilation Ventilator-

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
						Hypertension (66.2%)		Critical (100.0%)		Volume control ventilation (46.5%) Other (9.0%)	daily for 5 days) standard care	free days Duration of ventilation
Tornling, 2021 ATTRACT ³⁴²	Pre-print NCT04452435	106	India	52.6	75.5	Copd, idiopathic pulmonary disease (0.0%) Concurrent serious medical condition with special attention to cardiac conditions (0.0%) Diabetes (34.0%) Hypertension (30.2%)	Inpatient	Severe (100%)	0	Supplemental oxygen (57.5%) Mechanical ventilation (0.0%)	angiotensin type 2 receptor agonist C21 (100 mg twice daily for 7 days) placebo	Mortality Mechanical ventilation
Trieu, 2021 ARTI-19 ³⁴³	Pre-print CTRI/2020/09/ 028044	60	India	43.3	63.3	Diabetes (0.0%) Hypertension (0.0%)	Inpatient (46.7%)	Mild/Mo derate (100.0%)	0	Supplemental oxygen, niv, or iv (0.0%)	ARTIVeda (500 mg/day for 5 days) standard care	Mortality Admission to hospital Adverse effects leading to discontinuati on Time to

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
												symptom/cli nical improvemen t
Udwadia, 2020 ³⁴⁴	Peer-reviewed publication CTRI/2020/05/025114	150	India	43.3	73.5	Asthma (0.0%) Chronic obstructive lung disease (0.0%) Prolonged qt defined as qtcf ≥450 msec for men and as qtcf ≥470 msec for women (0.0%) Severely reduced left ventricular function,ejecti on fraction <30% (0.0%)	Inpatient	Mild/Mo derate (100.0%)	0	Niv (0.0%) Iv (0.0%) Ecmo (0.0%)	favipiravir (800 mg twice daily up to 14 days) standard care	Mortality Mechanical ventilation Adverse effects leading to discontinuati on Viral clearance Duration of hospitalizati on Time to symptom/cli nical improvemen t Time to to viral clearance
Ulrich, 2020 TEACH ³⁴⁵	Peer-reviewed publication NCT04369742	128	United states	66.2	59.4	Asthma (15.6%) Copd (7.0%) Non- hypertensive cardiovascular	Inpatient	Severe (100%)	1.6	Nasal cannula (48.4%) High-flow (0.8%) Niv (0.8%) Non-	hydroxychloroquine (200 mg twice daily for 5 days) placebo	Mortality Mechanical ventilation Viral clearance Duration of

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
						disease (25.6%) Diabetes (32.0%) Hypertension (57.8%)				rebreather (14.1%)		hospitalizati on
Vaira, 2020 ³⁴⁶	Peer-reviewed publication	18	Italy	42.1	38.9	NR	Outpatient	NR	NR	NR	corticosteroids (1 mg/kg/day with tapering of dose for 15 days) standard care	NR
Valizadeh, 2020 ³⁴⁷	Peer-reviewed publication	40	Iran	52.4	77.5	Cardiovascular disease (12.5%) Diabetes (7.5%) Hypertension (5.0%)	Inpatient	Severe (100%) Severe: Critical (100.0%)	NR	NR	nanocurcumin (160 mg/day for 14 days) placebo	Mortality
Vallejos, 2021 IVERCOR- COVID19 ³⁴⁸	Peer-reviewed publication NCT04529525	501	Argentina	42.5	52.7	Asthma (7.2%) Copd (2.8%) Previous myocardial infarction (1.8%) Previous coronary angioplasty (0.8%) Previous stroke (1.0%) Heart failure	Outpatient	NR	0	Unspecified ventilation (0.0%)	ivermectin (12 mg daily for 2 days (>48 and <80 kg)) placebo	Mortality Mechanical ventilation Admission to hospital Adverse effects leading to discontinuati on

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
						(0.8%) Diabetes (9.6%) Hypertension (23.8%)						
Veiga, 2021 TOCIBRAS ³⁴⁹	Published NCT04403685	129	Brazil	57.5	68.2	Asthma (3.9%) Copd (3.1%) Heart failure (5.4%) Myocardial infarction (5.4%) Diabetes (32.6%) Hypertension (49.6%)	Inpatient	Severe (100%)	48.1	Supplemental oxygen (51.9%) High-flow or niv (31.8%) Iv (16.3%)	tocilizumab (8 mg/kg, for a maximum of 800 mg, in 24 hours) standard care	Mechanical ventilation Duration of hospitalizati on Ventilator-free days
Vlaar, 2020 PANAMO ³⁵⁰	Peer-reviewed publication NCT04333420	30	Netherlands	60.5	73.3	Copd (0.0%) Severe congestive heart failure nyha-class iii or iv (0.0%) Diabetes (26.7%) Hypertension (30.0%)	Inpatient Intensive care (60.0%)	Severe (100%)	60	Iv (60.0%) Supplemental oxygen (26.7%) Nasal cannula (13.3%)	vilobelimab (800 mg once daily for up to 7 times within 22 days) standard care	Mortality Adverse effects leading to discontinuati on

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
Vyas, 2021 ³⁵¹	Data from authors CTRI/2021/08/ 035424	1220	India	36.5	61.6	Diabetes mellitus (0.3%) T2DM (0.2%) Hypertension (1.1%)	Outpatient	Mild/Mo derate (100.0%)	NR	NR	molnupiravir (800 mg twice a day for 5 days) standard care	Mortality Mechanical ventilation Admission to hospital Adverse effects leading to discontinuati on Viral clearance Time to symptom/cli nical improvemen t
Wanaratna, 2021 ³⁵²	Pre-print	63	Thailand	39.4	40.4	NR	Inpatient	Mild/Mo derate (100.0%)	NR	NR	andrographolide (60 mg three times daily for 5 days) placebo	Adverse effects leading to discontinuati on Viral clearance
Wang_1, 2020 ³⁵³	Peer-reviewed publication NCT04257656	237	China	65	59.3	Cardiovascular disease (7.2%) Diabetes (23.7%) Hypertension (43.2%)	Inpatient	Severe (100%)	16.1	Supplemental oxygen (82.2%) High-flow or niv (15.7%) Iv or ecmo (0.4%)	remdesivir (100 mg once daily for 10 days) placebo	Mortality Mechanical ventilation Adverse effects leading to discontinuati on

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
												Viral clearance Duration of hospitalizati on Duration of ventilation Time to symptom/cli nical improvemen t
Wang_2, 2020 ³⁵⁴	Peer-reviewed publication	20	China	47	45	Acute respiratory distress syndrome (0.0%)	Inpatient	NR	NR	NR	vitamin C (10 g/60 kg twice daily) standard care	NR
Wang_3, 2020 ³⁵⁵	Peer-reviewed publication	60	China	NR	38.3	NR	Inpatient	Mild/Mo derate (100.0%)	NR	NR	lopinavir-ritonavir (2 tablets twice daily) standard care	NR
Wang_4, 2020 ³⁵⁶	Peer-reviewed publication ChiCTR200002 9765	65	China	63	50.8	Diabetes (15.4%) Hypertension (30.8%)	Inpatient	Mild/Mo derate (56.9%)	9.2	Nasal duct (58.5%) Mask (6.2%) High-flow (9.2%)	tocilizumab (400 mg for up to two times in 24 hours) standard care	Duration of hospitalizati on Time to symptom/cli nical improvemen t Time to to

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
												viral clearance
Wang_5, 2020 ³⁵⁷	Peer-reviewed publication ChiCTR 2000030058	50	China	55.8	45.8	Copd (4.2%) Coronary artery disease (2.1%) Diabetes (4.2%) Hypertension (25.0%)	Inpatient	Mild/Mo derate (81.3%) Severe (18.8%) Severe: Critical (4.2%)	NR	NR	leflunomide (50 mg twice daily for 1.5 days, then 20 mg/day for 8 days) standard care	Mortality Adverse effects leading to discontinuati on Viral clearance Duration of hospitalizati on Time to to viral clearance
Wilkinson, 2021 BGBC020, ACCORD-2 ³⁵⁸	Data from authors CTRI/2020/10/ 028602, ISRCTN570856 39	177	United Kingdom, South Africa, India	NR	NR	NR	Inpatient	NR	13.6	Supplemental oxygen (78.5%) Niv (13.6%)	bemcentinib (200 mg once daily for 15 days) standard care	Mortality Time to symptom/cli nical improvemen t
Winchester, 2021 ³⁵⁹	Peer-reviewed publication	80	England	44	36.7	Respiratory condition (1.3%) Cardiovascular disease (0.0%) Diabetes (6.3%)	NR	Mild/Mo derate (100.0%)	NR	NR	nitric oxide nasal spray (5 to 6 times daily at 4 sprays per dose for 9 days) placebo	NR

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
						Hypertension (6.3%)						
Winthrop, 2021 ³⁶⁰	Pre-print NCT04414618	42	United States	56.1	64.3	Any respiratory condition requirin intermittent or continuous ambulatory oxygen prior to hospitalization (0.0%)	Inpatient	Severe (100%)	0	Supplemental oxygen (100.0%) Mechanical ventilation (0.0%)	opaganib (250 mg twice daily for 14 days) placebo	Mortality Mechanical ventilation Adverse effects leading to discontinuati on Duration of hospitalizati on Time to symptom/cli nical improvemen t
Wu, 2020 ³⁶¹	Peer-reviewed publication ChiCTR200003 00001	52	China	58	50	Copd (5.8%) Cardiovascular disease (15.4%) Cerebrovascul ar disease (7.7%) Diabetes (15.4%) Hypertension (28.8%)	Inpatient	NR	NR	NR	triazavirin (250 mg three times daily for 7 days in mildly ill patients) placebo	Mortality Adverse effects leading to discontinuati on Viral clearance Time to symptom/cli nical improvemen

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
												t Time to to viral clearance
Yadegarinia, 2020 ³⁶²	Peer-reviewed publication	34	Iran	64.1	76.5	Diabetes (47.1%) Hypertension (38.2%)	Inpatient	Severe (100%)	NR	NR	umifenovir standard care	Mortality Duration of hospitalizati on
Yadollahzadeh , 2021 ³⁶³	Pre-print IRCT20200328 046885N1	112	Iran	57.6	44.6	Chronic lung disease (3.6%) Cardiovascular disease (15.2%) Diabetes (21.4%) Hypertension (25.0%)	Inpatient	NR	0	Mechanical ventilation (0.0%)	sofosbuvir-daclatasvir (400 mg and 60 mg once a day) lopinavir-ritonavir (400 mg and 100 mg twice daily for 7 days)	Mortality Duration of hospitalizati on
Yaghoubian, 2021 ³⁶⁴	Peer-reviewed publication	0	Iran	52.1	69.7	NR	NR	NR	NR	NR	L-cysteine (90 mg/kg three times a day for two weeks) placebo	NR
Yakoot, 2020 ³⁶⁵	Pre-print DRKS0002220 3	89	Egypt	49	42.7	Asthma (1.1%) Heart disease (9.0%) Diabetes (19.1%) Hypertension (25.8%)	Inpatient	Mild/Mo derate (82.0%) Severe (18.0%)	0	Iv (0.0%)	sofosbuvir-daclatasvir (400 mg/60 mg for 10 days) standard care	Mortality Mechanical ventilation Adverse effects leading to discontinuati on Time to

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
												symptom/cli nical improvemen t
Yethindra, 2020 ³⁶⁶	Peer-reviewed publication	30	Kyrgyzstan	36.5	60	Cardiovascular disease (0.0%)	Inpatient	NR	NR	NR	umifenovir (200 mg three times daily for 1 to 5 days) standard care	Mortality Time to symptom/cli nical improvemen t
Yildiz, 2021 ³⁶⁷	Peer-reviewed publication	150	Turkey	38.3	56	Asthma/copd (6.0%) Cardiac disease (12.7%) Diabetes (7.3%) Hypertension (12.0%)	Inpatient	NR	NR	NR	saline irrigation (10 cc per nose twice daily for one month) triamcinolone acetonide (2 puffs per nose twice daily for one month) saline irrigation (10 cc per nose twice daily for one month) standard care	Time to symptom/cli nical improvemen t
Yogesh, 2021 ³⁶⁸	Peer-reviewed publication CTRI/2020/09/ 027938	100	India	41.2	52	NR	Inpatient	NR	NR	NR	curcumin (Administered as proprietary Curmune tablets daily for 10 day) vitamin C () zinc () standard care	Mortality
Youssef, 2021 ³⁶⁹	Pre-print NCT04311697	203	United States	61	69	NR	Inpatient Intensive care (100.0%)	Severe: Critical (100.0%)	99.5	High-flow (64.8%)	aviptadil (Three twelve-hour infusions over three days of doses of 50, 100, and	Mortality

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
										Niv (16.3%) Iv (18.4%)	150 pmol/kg/hr) placebo	
Yu, 2021 PRINCIPLE ³⁷⁰	Peer-reviewed publication ISRCTN865345 80	2975	United Kingdom	62.8	46.2	Asthma, copd or lung disease (18.3%) Angina, heart attack, heart failure, af, valve problems (15.4%) Diabetes (20.5%) Medication hbp (43.9%)	Outpatient	NR	NR	NR	inhaled budesonide (inhalation of 800 µg twice daily for 14 days) standard care	Mechanical ventilation Time to symptom/cli nical improvemen t
Yuan, 2020 ³⁷¹	Pre-print ChiCTR200002 9431	21	China	61	42.9	NR	Inpatient	Mild/Mo derate (100.0%)	NR	NR	99mTc-methylene diphosphonate (5 ml once daily for 7 days) standard care	NR
Zarehoseinzad , 2021 ³⁷²	Peer-reviewed publication IRCT20200505 047318N1	80	Iran	71.5	100	Chronic obstructive pulmonary disease (12.5%) Cardiac disease (38.8%) Diabetes (25.0%)	Inpatient	Severe (100%)	NR	NR	finasteride (5 mg once daily for 7 days) standard care	Mortality Adverse effects leading to discontinuati on Duration of hospitalizati on ICU length of stay

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
						Hypertension (66.2%)						Duration of ventilation
Zhang_1, 2021 ³⁷³	Peer-reviewed publication NCT04264533	56	China	66.1	64.3	Chronic lung disease (5.4%) End-stage pulmonary disease (0.0%) Coronary heart disease (21.4%) Diabetes (30.4%) Hypertension (44.6%)	Inpatient Intensive care (100.0%)	Severe (100%)	98.2	High-flow (32.1%) Niv (25.0%) Iv (41.1%)	vitamin C (12 g/50 ml given at 12 ml/hour twice daily for 7 days) placebo	Mortality Mechanical ventilation Adverse effects leading to discontinuati on Duration of hospitalizati on ICU length of stay Ventilator- free days Duration of ventilation
Zhang_2, 2020 ³⁷⁴	Peer-reviewed publication	35	China	NR	NR	NR	Inpatient	Severe (100%)	NR	NR	berberine (900 mg/day for 14 days) standard care	Adverse effects leading to discontinuati on

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
Zhang_3, 202 ³⁷⁵	Peer-reviewed publication NCT04295551	130	China	46.3	46.2	Obstructive pneumonia (0.0%) Pulmonary interstitial fibrosis (0.0%) Alveolar proteinosis (0.0%) All allergic alveolitis caused by lung tumors (0.0%) Diabetes (7.7%) Hypertension (16.2%)	Inpatient	NR	NR	NR	xiyanping (10 mg/kg once a day up to 500 mg for 7 to 14 days) standard care	Mortality Adverse effects leading to discontinuati on Time to symptom/cli nical improvemen t Time to to viral clearance
Zhao_1, 2020 ³⁷⁶	Peer-reviewed publication ChiCTR200003 0894, NCT04310228	26	China	73.5	53.9	Tuberculosis (0.0%) Coronary artery disease (23.1%) Diabetes (11.5%) Hypertension (42.3%)	Inpatient	Mild/Mo derate (46.1%) Severe (53.9%) Severe: Critical (3.9%)	3.9	Nasal cannula (65.4%) Niv (3.9%)	favipiravir (600 mg twice daily for 7 days) tocilizumab (4-8 mg/kg in 100 ml for 1 hr) favipiravir (600 mg twice daily for 7 days) tocilizumab (4-8 mg/kg in 100 ml for 1 hr)	Mortality Mechanical ventilation
Zhao_2, 2021 ³⁷⁷	Peer-reviewed publication NCT04333589	55	China	55.7	45.5	Coronary heart disease (7.3%) Diabetes (14.6%)	Outpatient	Mild/Mo derate (98.2%)	NR	NR	favipiravir (600 mg twice daily for 7 days up to 14 days) standard care	Mortality Viral clearance Time to to

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
						Hypertension (30.9%)						viral clearance
Zheng, 2020 ³⁷⁸	Peer-reviewed publication	80	China	50.3	61.2	Cardiovascular disease (0.0%)	Inpatient	NR	NR	NR	sodium tanshinone IIA sulfonate (60 mg once daily for 10 days) standard care	Adverse effects leading to discontinuati on Viral clearance Time to to viral clearance
Zheng, 2020 ³⁷⁹	Peer-reviewed publication ChiCTR200002 9496	89	China	46.7	47.2	Severe lung disease (0.0%) Chronic bronchitis (2.0%) Severe heart disease (0.0%) Coronary heart disease (3.0%) Diabetes (8.1%) Hypertension (6.1%)	Inpatient	Mild/Mo derate (94.4%)	NR	NR	novaferon (20 µg twice daily for 7 to 10 days) lopinavir-ritonavir (50 mg and 200 mg twice daily for 7 to 10 days) novaferon () lopinavir-ritonavir (200 mg/50 mg twice daily for 7 to 10 days)	Adverse effects leading to discontinuati on Viral clearance Time to to viral clearance
Zhong, 2020 ³⁸⁰	Pre-print ChiCTR200002 9851	17	China	63	76.5	Cardiovascular disease (5.9%) Diabetes (23.5%)	Inpatient	Severe (100%) Severe:	94.1	Supplemental oxygen (5.9%) High-flow or	alpha lipoic acid (1200 mg once daily for 7	Mortality Adverse effects leading to

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
						Hypertension (47.1%)		Critical (100.0%)		niv (41.2%) Iv (52.9%)	days) placebo	discontinuati on
Zhou, 2020 ³⁸¹	Peer-reviewed publication	104	China	52.1	57.7	Interstitial pneumonia (0.0%) Severe heart disease (0.0%) Hypertension (0.0%)	Inpatient	Mild/Mo derate (100.0%)	NR	NR	diammonium glycyrrhizinate (150 mg three times daily for 14 days) standard care	Adverse effects leading to discontinuati on
Zhuravel, 2021 ³⁸²	Peer-reviewed publication NCT04623021	104	Russia	58.6	49.5	T2DM (10.7%) Hypertension (62.1%)	Inpatient	Severe (100%)	8.7	Supplemental oxygen (91.3%) Hfnc and/or niv (8.7%) Iv and/or ecmo (0.0%)	nafamostat (4.8 mg/kg/day via 24-hour intravenous infusion for 10 days or until hospital discharge) standard care	Mortality Adverse effects leading to discontinuati on Viral clearance Venous thromboem bolism Duration of hospitalizati on Time to symptom/cli nical improvemen t Time to to viral clearance

Study	Publication status Registration	n	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
de Alencar, 2020 ³⁸³	Peer-reviewed publication U1111-1250-356	140	Brazil	58.5	59.3	Diabetes (37.8%) Hypertension (46.7%)	Inpatient	Severe (100%)	0.7	Supplemental oxygen (68.2%) High-flow or niv (0.7%)	N-acetylcysteine (14 g in the first 4 hours, then 7 g in the next 16 hours) placebo	Mortality Mechanical ventilation Adverse effects leading to discontinuati on Duration of hospitalizati on ICU length of stay

(), empty parentheses indicate that dosing data was not available for that intervention

- 1. The WHO Rapid Evidence Appraisal for COVID-19 Therapies Working Group. Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis. JAMA 2021;326(6):499-518. doi: 10.1001/jama.2021.11330
- 2. Abbasi F, Adatorwovor R, Davarpanah MA, et al. A Randomized Single Blind Controlled Trial of Combination Therapy (Spironolactone and Sitagliptin) in Hospitalized Adult Patients with Covid-19. SSRN Electronic Journal 2021 doi: 10.2139/ssrn.3889411
- 3. Abbass S, Kamal E, Salama M, et al. Efficacy and safety of sofosbuvir plus daclatasvir or ravidasvir in patients with COVID-19: A randomized controlled trial. *J Med Virol* 2021;93(12):6750-59. doi: 10.1002/jmv.27264 [published Online First: 20210824]
- 4. Abd-Elsalam S, Esmail ES, Khalaf M, et al. Hydroxychloroquine in the Treatment of COVID-19: A Multicenter Randomized Controlled Study. Am J Trop Med Hyg 2020;103(4):1635-39. doi: 10.4269/ajtmh.20-0873
- 5. Abd-Elsalam S, Soliman S, Esmail ES, et al. Do Zinc Supplements Enhance the Clinical Efficacy of Hydroxychloroquine?: a Randomized, Multicenter Trial. Biol trace elem res 2020
- 6. Abd-Elsalam S, Noor RA, Badawi R, et al. Clinical study evaluating the efficacy of ivermectin in COVID-19 treatment: A randomized controlled study. *J Med Virol* 2021;93(10):5833-38. doi: 10.1002/jmv.27122 [published Online First: 20210607]
- 7. Abd-Elsalam S, Ahmed OA, Mansour NO, et al. Remdesivir Efficacy in COVID-19 Treatment: A Randomized Controlled Trial. *The American Journal of Tropical Medicine and Hygiene* 2021:tpmd210606. doi: 10.4269/aitmh.21-0606
- 8. Abdeen S, Abu-Fanne R, Bdeir K, et al. Conflicting impacts of tocilizumab and colchicine in COVID-19-associated coagulop. British Journal of Haematology 2021 doi: http://dx.doi.org/10.1111/bjh.17885
- 9. Abdelalim AA, Mohamady AA, Elsayed RA, et al. Corticosteroid nasal spray for recovery of smell sensation in COVID-19 patients: A randomized controlled trial. *Am J Otolaryngol* 2021;42(2):102884. doi: 10.1016/j.amjoto.2020.102884 [published Online First: 20210104]
- 10. Shahbaznejad L, Davoudi A, Eslami G, et al. Effects of Ivermectin in Patients With COVID-19: A Multicenter, Double-blind, Randomized, Controlled Clinical Trial. *Clin Ther* 2021;43(6):1007-19. doi: 10.1016/j.clinthera.2021.04.007 [published Online First: 20210506]

- 11. Abdulamir AS, Gorial FI, Saadi SJ, et al. Effectiveness and Safety of Niclosamaide as Add-on Therapy to the Standard of Care Measures in COVID-19 Management: Randomized controlled clinical trial. medRxiv 2021:2021.06.10.21258709. doi: 10.1101/2021.06.10.21258709
- 12. Abdulamir AS, Gorial FI, Saadi SJ, et al. A randomised controlled trial of effectiveness and safety of Niclosamide as add on therapy to the standard of care measures in COVID-19 management. Ann Med Surg (Lond) 2021;69:102779. doi: 10.1016/j.amsu.2021.102779 [published Online First: 20210904]
- 13. Abulmeaty MMA, Aljuraiban GS, Shaikh SM, et al. The Efficacy of Antioxidant Oral Supplements on the Progression of COVID-19 in Non-Critically III Patients: A Randomized Controlled Trial. Antioxidants (Basel) 2021;10(5) doi: 10.3390/antiox10050804 [published Online First: 20210519]
- 14. Ader F, Peiffer-Smadja N, Poissy J, et al. An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-beta-1a and hydroxychloroquine in hospitalized patients with COVID-19. Clin Microbiol Infect 2021;27(12):1826-37. doi: 10.1016/j.cmi.2021.05.020 [published Online First: 20210526]
- 15. Ader F, Bouscambert-Duchamp M, Hites M, et al. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. *The Lancet Infectious Diseases* doi: 10.1016/S1473-3099(21)00485-0
- 16. Ahmadi R, Salari S, Sharifi MD, et al. Oral nano-curcumin formulation efficacy in the management of mild to moderate outpatient COVID-19: A randomized triple-blind placebo-controlled clinical trial. *Food Sci Nutr* 2021;9(8):4068-75. doi: 10.1002/fsn3.2226 [published Online First: 20210619]
- 17. Ahmed S, Karim MM, Ross AG, et al. A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. *Int J Infect Dis* 2021;103:214-16. doi: 10.1016/j.ijid.2020.11.191 [published Online First: 20201202]
- 18. Hamidi-Alamdari D, Hafizi-Lotfabadi S, Bagheri-Moghaddam A, et al. Methylene Blue for Treatment of Hospitalized Covid-19 Patients: A Randomized, Controlled, Open-Label Clinical Trial, Phase 2. Rev Invest Clin 2021;73(3):190-98. doi: 10.24875/RIC.21000028 [published Online First: 2021/05/22]
- 19. Alavi-moghaddam M, Haghighi M, Sabaghian T, et al. Safety and Efficacy of Sofosbuvir in Hospitalized Adult Patients with SARS-CoV-2: A Preliminary Report. SSRN Electronic Journal 2021 doi: 10.2139/ssrn.3790463
- 20. Algahtani FD, Elabbasy MT, Samak MA, et al. The Prospect of Lactoferrin Use as Adjunctive Agent in Management of SARS-CoV-2 Patients: A Randomized Pilot Study. *Medicina (Kaunas)* 2021;57(8) doi: 10.3390/medicina57080842 [published Online First: 20210819]
- 21. Alizadeh Z, Keyhanian N, Ghaderkhani S, et al. A Pilot Study on Controlling Coronavirus Disease 2019 (COVID-19) Inflammation Using Melatonin Supplement. *Iran J Allergy Asthma Immunol* 2021;20(4):494-99. [published Online First: 20210807]
- 22. Altay O, Arif M, Li X, et al. Combined metabolic cofactor supplementation accelerates recovery in mild-to-moderate COVID-19. medRxiv 2021:2020.10.02.20202614. doi: 10.1101/2020.10.02.20202614
- 23. Aman J, Duijvelaar E, Botros L, et al. Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial. *Lancet Respir Med* 2021;9(9):957-68. doi: 10.1016/S2213-2600(21)00237-X [published Online First: 20210618]
- 24. Amaravadi RK, Giles L, Carberry M, et al. Hydroxychloroquine for SARS-CoV-2 positive patients quarantined at home: The first interim analysis of a remotely conducted randomized clinical trial. *medRxiv* 2021:2021.02.22.21252228. doi: 10.1101/2021.02.22.21252228
- 25. Amra B, Ashrafi F, Soltaninejad F, et al. Thalidomide for the treatment of severe Covid-19: A randomized clinical trial. Research Square 2021 doi: 10.21203/rs.3.rs-379635/v1
- 26. Ananworanich J, Mogg R, Dunne MW, et al. Randomized study of rivaroxaban vs. placebo on disease progression and symptoms resolution in high-risk adults with mild COVID-19. Clin Infect Dis 2021 doi: 10.1093/cid/ciab813 [published Online First: 20210915]
- 27. Angus DC, Derde L, Al-Beidh F, et al. Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial.

 JAMA 2020;324(13):1317-29. doi: 10.1001/jama.2020.17022
- 28. Ansarin K, Tolouian R, Ardalan M, et al. Effect of bromhexine on clinical outcomes and mortality in COVID-19 patients: A randomized clinical trial. *Bioimpacts* 2020;10(4):209-15. doi: 10.34172/bi.2020.27 [published Online First: 20200719]
- 29. Arabi YM, Gordon AC, Derde LPG, et al. Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial. *Intensive Care Med* 2021;47(8):867-86. doi: 10.1007/s00134-021-06448-5 [published Online First: 20210712]
- 30. Aref ZF, Bazeed S, Hassan MH, et al. Clinical, Biochemical and Molecular Evaluations of Ivermectin Mucoadhesive Nanosuspension Nasal Spray in Reducing Upper Respiratory Symptoms of Mild COVID-19.

 Int J Nanomedicine 2021;16:4063-72. doi: 10.2147/IJN.S313093 [published Online First: 20210615]
- 31. Hasan MJ, Rumi S, Banu SS, et al. Virucidal effect of povidone iodine on COVID-19 in the nasopharynx: A structured summary of a study protocol for an open-label randomized clinical trial. *Trials* 2021;22(1):2. doi: 10.1186/s13063-020-04963-2 [published Online First: 20210104]

- 32. Arruda EAG, Pires-Neto RJ, Medeiros MS, et al. Clinical Trial of Efficacy and Toxicity of Disoproxil Tenofovir Fumarate and Emtricitabine for Mild to Moderate SARS-CoV-2 Infections. *medRxiv* 2021:2021.09.28.21264242. doi: 10.1101/2021.09.28.21264242
- 33. Asadi M, Sayar S, Radmanesh E, et al. Efficacy of naproxen in the management of patients hospitalized with COVID-19 infection: A randomized, double-blind, placebo-controlled, clinical trial. *Diabetes Metab*Syndr 2021;15(6):102319. doi: 10.1016/j.dsx.2021.102319 [published Online First: 20211022]
- 34. Axfors C, Schmitt AM, Janiaud P, et al. Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19: an international collaborative meta-analysis of randomized trials. *medRxiv* 2020:2020.09.16.20194571. doi: 10.1101/2020.09.16.20194571
- 35. Azizi H, Rouhani N, Shaki F, et al. Pentoxifylline effects on hospitalized patients with COVID19: A randomized, double-blind clinical trial. *International Immunopharmacology* 2021;101:108227. doi: https://doi.org/10.1016/j.intimp.2021.108227
- 36. Babalola OE, Bode CO, Ajayi AA, et al. Ivermectin shows clinical benefits in mild to moderate COVID19: A randomised controlled double-blind, dose-response study in Lagos. QJM 2021 doi: 10.1093/qjmed/hcab035 [published Online First: 20210218]
- 37. Olufemi Emmanuel B, Ndanusa Y, Ajayi AA, et al. Research Square 2021 doi: 10.21203/rs.3.rs-950352/v1
- 38. Balykova LA, Pavelkina VF, Shmyreva NV, et al. Efficacy and Safety of Some Etiotropic Therapeutic Schemes for Treating Patients with Novel Coronavirus Infection (Covid-19). *Pharmacy & Pharmacology* 2020;8(3):150-59. doi: 10.19163/2307-9266-2020-8-3-150-159
- 39. Balykova LA, Granovskaya MV, Zaslavskaya KY, et al. New possibilities for targeted antiviral therapy for COVID-19. Results of a multi center clinical study of the efficacy and safety of using the drug Areplivir. *Infectious diseases: News, Opinions, Training* 2020;9(3):16-29. doi: 10.33029/2305-3496-2020-9-3-16-29
- 40. Barratt-Due A, Olsen IC, Nezvalova-Henriksen K, et al. Evaluation of the Effects of Remdesivir and Hydroxychloroquine on Viral Clearance in COVID-19: A Randomized Trial. *Ann Intern Med* 2021;174(9):1261-69. doi: 10.7326/M21-0653 [published Online First: 20210713]
- 41. Barrett CD, Moore HB, Moore EE, et al. Study of Alteplase for Respiratory Failure in SARS-CoV-2 COVID-19: A Vanguard Multicenter, Rapidly Adaptive, Pragmatic, Randomized Controlled Trial. Chest 2021 doi: 10.1016/j.chest.2021.09.024 [published Online First: 20210927]
- 42. Bauer A, Schreinlechner M, Sappler N, et al. Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial. *Lancet Respir Med* 2021;9(8):863-72. doi: 10.1016/S2213-2600(21)00214-9 [published Online First: 20210611]
- 43. Baxter AL, Schwartz KR, Johnson RW, et al. Rapid initiation of nasal saline irrigation to reduce severity in high-risk COVID+ outpatients: a randomized clinical trial compared to a national dataset observational arm. *medRxiv* 2021:2021.08.16.21262044. doi: 10.1101/2021.08.16.21262044
- 44. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 Final Report. N Engl J Med 2020;383(19):1813-26. doi: 10.1056/NEJMoa2007764 [published Online First: 20201008]
- 45. Bhatt AN, Shenoy S, Munjal S, et al. 2-Deoxy-D-Glucose as an Adjunct to Standard of Care in the Medical Management of COVID-19: A Proof-of-Concept & Dose-Ranging Randomised Clinical Trial. medRxiv 2021:2021.10.08.21258621. doi: 10.1101/2021.10.08.21258621
- 46. Pandit A, Bhalani N, Bhushan BLS, et al. Efficacy and safety of pegylated interferon alfa-2b in moderate COVID-19: A phase II, randomized, controlled, open-label study. *Int J Infect Dis* 2021;105:516-21. doi: 10.1016/j.ijid.2021.03.015 [published Online First: 20210310]
- 47. Bikdeli B, Talasaz AH, Rashidi F, et al. Intermediate-Dose versus Standard-Dose Prophylactic Anticoagulation in Patients with COVID-19 Admitted to the Intensive Care Unit: 90-Day Results from the INSPIRATION Randomized Trial. *Thromb Haemost* 2021 doi: 10.1055/a-1485-2372 [published Online First: 20210417]
- 48. Blum VF, Cimerman S, Hunter JR, et al. Nitazoxanide superiority to placebo to treat moderate COVID-19 A Pilot prove of concept randomized double-blind clinical trial. *EClinicalMedicine* 2021;37:100981. doi: 10.1016/j.eclinm.2021.100981 [published Online First: 20210627]
- 49. Bosaeed M, Mahmoud E, Alharbi A, et al. Favipiravir and Hydroxychloroquine Combination Therapy in Patients with Moderate to Severe COVID-19 (FACCT Trial): An Open-Label, Multicenter, Randomized, Controlled Trial. *Infect Dis Ther* 2021;10(4):2291-307. doi: 10.1007/s40121-021-00496-6 [published Online First: 20210728]
- 50. Brown SM, Peltan I, Kumar N, et al. Hydroxychloroquine vs. Azithromycin for Hospitalized Patients with COVID-19 (HAHPS): Results of a Randomized, Active Comparator Trial. *Ann Am Thorac Soc* 2020 doi: 10.1513/AnnalsATS.202008-940OC [published Online First: 20201109]
- 51. Shah Bukhari KH, Asghar A, Perveen N, et al. Efficacy of Ivermectin in COVID-19 Patients with Mild to Moderate Disease. medRxiv 2021:2021.02.02.21250840. doi: 10.1101/2021.02.02.21250840
- 52. Buonfrate DaC, Fabio and Martini, Davide and Roncaglioni, Maria Carla and Ojeda Fernandez, Maria Luisa and Alvisi, Maria Francesca and De Simone, Irene and Rulli, Eliana and Nobili, Alessandro and Casalini, Giacomo and Antinori, Spinello and Gobbi, Marco and Campoli, Caterina and Deiana, Michela and Pomari, Elena and Lunardi, Gianluigi and Tessari, Roberto and Bisoffi, Zeno,. High Dose

- Ivermectin for the Early Treatment of COVID-19 (COVER Study): A Randomised, Double-Blind, Multicentre, Phase II, Dose-Finding, Proof of Concept Clinical Trial. . SSRN Electronic Journal 2021 doi: http://dx.doi.org/10.2139/ssrn.3918289 [published Online First: 06 Sep 2021]
- 53. Butler CC, Yu LM, Dorward J, et al. Doxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. *Lancet Respir Med* 2021;9(9):1010-20. doi: 10.1016/s2213-2600(21)00310-6 [published Online First: 20210727]
- 54. Byakika-Kibwika P, Sekaggya-Wiltshire C, Semakula JR, et al. Safety and efficacy of hydroxychloroquine for treatment of non-severe COVID-19 among adults in Uganda: a randomized open label phase II clinical trial. BMC Infect Dis 2021;21(1):1218. doi: 10.1186/s12879-021-06897-9 [published Online First: 20211206]
- 55. Mariette X, Hermine O, Tharaux P-L, et al. Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial. *The Lancet Rheumatology* doi: 10.1016/S2665-9913(21)00315-5
- 56. Cadegiani F, Mccoy J, Wambier C, et al. Early Antiandrogen Therapy With Dutasteride Reduces Viral Shedding, Inflammatory Responses, and Time-to-Remission in Males With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Interventional Trial (EAT-DUTA AndroCoV Trial Biochemical). (February 01, 2021) Cureus 13(2): e13047 doi:107759/cureus13047 2021
- 57. Cadegiani FA, McCoy J, Wambier CG, et al. Proxalutamide (GT0918) Reduces the Rate of Hospitalization and Death in COVID-19 Male Patients: A Randomized Double-Blinded Placebo-Controlled Trial., 29 December 2020, PREPRINT (Version 1). Available at Research Square [https://doiorg/1021203/rs3rs-135303/v1] 2020
- 58. Cadegiani FA, McCoy J, Gustavo Wambier C, et al. Proxalutamide Significantly Accelerates Viral Clearance and Reduces Time to Clinical Remission in Patients with Mild to Moderate COVID-19: Results from a Randomized, Double-Blinded, Placebo-Controlled Trial. *Cureus* 2021;13(2):e13492. doi: 10.7759/cureus.13492 [published Online First: 20210222]
- 59. Cadegiani FA, Zimerman RA, do Nascimento Fonseca D, et al. Proxalutamide (GT0918) Reduces the Rate of Hospitalization in mild-to-moderate COVID-19 Female Patients: A Randomized Double-Blinded Placebo-Controlled Two-Arm Parallel Trial. *medRxiv* 2021:2021.07.06.21260086. doi: 10.1101/2021.07.06.21260086
- 60. Cadegiani FA, do Nascimento Fonseca D, McCoy J, et al. Efficacy of Proxalutamide in Hospitalized COVID-19 Patients: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design Clinical Trial. medRxiv 2021:2021.06.22.21259318. doi: 10.1101/2021.06.22.21259318
- 61. Cao B, Wang Y, Wen D, et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med 2020;382(19):1787-99. doi: 10.1056/NEJMoa2001282 [published Online First: 20200318]
- 62. Cao Y, Wei J, Zou L, et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial. J Allergy Clin Immunol 2020;146(1):137-46 e3. doi: 10.1016/j.jaci.2020.05.019 [published Online First: 20200526]
- 63. Caricchio R, Abbate A, Gordeev I, et al. Effect of Canakinumab vs Placebo on Survival Without Invasive Mechanical Ventilation in Patients Hospitalized With Severe COVID-19: A Randomized Clinical Trial. JAMA 2021;326(3):230-39. doi: 10.1001/jama.2021.9508 [published Online First: 2021/07/21]
- 64. Carrouel F, Valette M, Gadea E, et al. Use of an antiviral mouthwash as a barrier measure in the SARS-CoV-2 transmission in adults with asymptomatic to mild COVID-19: a multicentre, randomized, double-blind controlled trial. Clin Microbiol Infect 2021;27(10):1494-501. doi: 10.1016/j.cmi.2021.05.028 [published Online First: 20210524]
- 65. Castillo ME, Entrenas Costa LM, Vaquero Barrios JMADJF, et al. Effect of Calcifediol Treatment and best Available Therapy versus best Available Therapy on Intensive Care Unit Admission and Mortality Among Patients Hospitalized for COVID-19: A Pilot Randomized Clinical study. *Journal of Steroid Biochemistry and Molecular Biology* 2020
- 66. Cavalcanti AB, Zampieri FG, Rosa RG, et al. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. N Engl J Med 2020;383(21):2041-52. doi: 10.1056/NEJMoa2019014 [published Online First: 20200723]
- 67. Chaccour C, Casellas A, Blanco-Di Matteo A, et al. The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial. EclinicalMedicine 2021;32:100720. doi: 10.1016/j.eclinm.2020.100720 [published Online First: 20210119]
- 68. Zeeshan Khan Chachar A, Ahmad Khan K, Asif M, et al. Effectiveness of Ivermectin in SARS-CoV-2/COVID-19 Patients. International Journal of Sciences 2020;9(09):31-35. doi: 10.18483/ijsci.2378
- 69. Cluster Randomised Trials Ivermectin Repurposing For COVID-19 Treatment Of Outpatients With Mild Disease In Primary Health Care Centers; 2021.
- 70. Chaudhary P, Melkonyan A, Meethil A, et al. Estimating salivary carriage of severe acute respiratory syndrome coronavirus 2 in nonsymptomatic people and efficacy of mouthrinse in reducing viral load: A randomized controlled trial. *J Am Dent Assoc* 2021;152(11):903-08. doi: 10.1016/j.adaj.2021.05.021 [published Online First: 20210611]
- 71. Chen Z, Hu J, Zhang Z, et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. medRxiv 2020:2020.03.22.20040758. doi: 10.1101/2020.03.22.20040758
- 72. Chen C, Zhang Y, Huang J, et al. Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial. *medRxiv* 2020:2020.03.17.20037432. doi: 10.1101/2020.03.17.20037432
- 73. Chen J, Liu D, Liu L, et al. A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19. *Zhejiang Da Xue Xue Bao Yi Xue Ban* 2020;49(2):215-19. doi: 10.3785/j.issn.1008-9292.2020.03.03

- 74. Chen L, Zhang Z-Y, Fu J-G, et al. Efficacy and safety of chloroquine or hydroxychloroquine in moderate type of COVID-19: a prospective open-label randomized controlled study. *medRxiv* 2020:2020.06.19.20136093. doi: 10.1101/2020.06.19.20136093
- 75. Chen CP, Lin YC, Chen TC, et al. A multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate coronavirus disease 2019 (COVID-19). *PLoS One* 2020;15(12):e0242763. doi: 10.1371/journal.pone.0242763 [published Online First: 20201202]
- 76. Cheng LL, Guan WJ, Duan CY, et al. Effect of Recombinant Human Granulocyte Colony-Stimulating Factor for Patients With Coronavirus Disease 2019 (COVID-19) and Lymphopenia: A Randomized Clinical Trial. JAMA Intern Med 2021;181(1):71-78. doi: 10.1001/jamainternmed.2020.5503
- 77. Clemency BM, Varughese R, Gonzalez-Rojas Y, et al. A randomized controlled trial of inhaled ciclesonide for outpatient treatment of symptomatic COVID-19 infections. *medRxiv* 2021:2021.09.07.21261811. doi: 10.1101/2021.09.07.21261811
- 78. Cohen JB, Hanff TC, William P, et al. Continuation versus discontinuation of renin-angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial.

 Lancet Respir Med 2021;9(3):275-84. doi: 10.1016/S2213-2600(20)30558-0 [published Online First: 20210107]
- 79. Connors JM, Brooks MM, Sciurba FC, et al. Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19: The ACTIV-4B Randomized Clinical Trial. Jama 2021;326(17):1703-12. doi: 10.1001/jama.2021.17272
- 80. Corral-Gudino L, Bahamonde A, Arnaiz-Revillas F, et al. Methylprednisolone in adults hospitalized with COVID-19 pneumonia: An open-label randomized trial (GLUCOCOVID). Wien Klin Wochenschr 2021;133(7-8):303-11. doi: 10.1007/s00508-020-01805-8 [published Online First: 20210203]
- 81. Cremer PC, Sheng C, Sahoo D, et al. Canakinumab to Reduce Deterioration of Cardiac and Respiratory Function in Sars-cov2 Associated Myocardial Injury With Heightened Inflammation (canakinumab in Covid-19 Cardiac Injury): Results From the Randomized Three C Study. 2020 AHA LATE-BREAKING SCIENCE ABSTRACTS 2020
- 82. Cremer PC, Abbate A, Hudock K, et al. Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial. *Lancet Rheumatol* 2021;3(6):e410-e18. doi: 10.1016/S2665-9913(21)00070-9 [published Online First: 20210317]
- 83. Criner GJ, Criner GJ, Ahn MY, et al. 561. Safety of Remdesivir vs Standard Care in Patients with Moderate Covid-19. *Open Forum Infectious Diseases* 2020;7(Supplement_1):S345-S46. doi: 10.1093/ofid/ofaa439.755
- 84. Crippa JAS, Pacheco JC, Zuardi AW, et al. Cannabidiol for COVID-19 Patients with Mild to Moderate Symptoms (CANDIDATE Study): A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. *Cannabis Cannabinoid Res* 2021 doi: 10.1089/can.2021.0093 [published Online First: 20211007]
- 85. Cruz LR, Baladron I, Rittoles A, et al. Treatment with an Anti-CK2 Synthetic Peptide Improves Clinical Response in COVID-19 Patients with Pneumonia. A Randomized and Controlled Clinical Trial. ACS Pharmacol Transl Sci 2021;4(1):206-12. doi: 10.1021/acsptsci.0c00175 [published Online First: 20201211]
- 86. Darazam IA, Hatami F, Rabiei MM, et al. An Investigation Into the Beneficial Effects of High-Dose Interferon beta 1-a, Compared to Low-Dose Interferon Beta 1-a (the base therapeutic regimen) in moderate to severe COVID-19, 21 January 2021, PREPRINT (Version 2). Available at Research Square [https://doiorg/1021203/rs3rs-138540/v2] 2021
- 87. Darazam IA, Pourhoseingholi MA, Shokouhi S, et al. Role of Interferon Therapy in Severe COVID-19: The COVIFERON Randomized Controlled Trial, 04 January 2021, PREPRINT (Version 1). Available at Research Square [https://doiorg/1021203/rs3rs-136499/v1] 2021
- 88. Alavi Darazam I, Shokouhi S, Mardani M, et al. Umifenovir in hospitalized moderate to severe COVID-19 patients: A randomized clinical trial. *International Immunopharmacology* 2021;99:107969. doi: https://doi.org/10.1016/j.intimp.2021.107969
- 89. Darban M, Malek F, Memarian M, et al. Efficacy of High Dose Vitamin C, Melatonin and Zinc in Iranian Patients with Acute Respiratory Syndrome due to Coronavirus Infection: A Pilot Randomized Trial.

 Journal of Cellular & Dose Vitamin C, Melatonin and Zinc in Iranian Patients with Acute Respiratory Syndrome due to Coronavirus Infection: A Pilot Randomized Trial.

 Journal of Cellular & Dose Vitamin C, Melatonin and Zinc in Iranian Patients with Acute Respiratory Syndrome due to Coronavirus Infection: A Pilot Randomized Trial.
- 90. Davoodi L, Abedi SM, Salehifar E, et al. Febuxostat therapy in outpatients with suspected COVID-19: A clinical trial. *Int J Clin Pract* 2020;74(11):e13600. doi: 10.1111/ijcp.13600 [published Online First: 20200717]
- 91. Davoodi L, Jafarpour H, Oladi Z, et al. Atorvastatin therapy in COVID-19 adult inpatients: A double-blind, randomized controlled trial. *Int J Cardiol Heart Vasc* 2021;36:100875. doi: 10.1016/j.ijcha.2021.100875 [published Online First: 20210914]
- 92. Davoodian NaS, Farnoosh and Salarbashi, Davoud and Elyasi, Sepideh and Baniasad, Amir and Bejestani, Farhang Soltani. The Effect of Melatonin as an Adjuvant Therapy on COVID-19: A Randomized Clinical Trial. SSRN Electronic Journal 2021 doi: http://dx.doi.org/10.2139/ssrn.3878090 [published Online First: 01 Jul 2021]
- 93. Davoudi-Monfared E, Rahmani H, Khalili H, et al. A Randomized Clinical Trial of the Efficacy and Safety of Interferon beta-1a in Treatment of Severe COVID-19. *Antimicrob Agents Chemother* 2020;64(9):20. doi: 10.1128/AAC.01061-20 [published Online First: 20200820]

- 94. Deftereos SG, Giannopoulos G, Vrachatis DA, et al. Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019: The GRECCO-19 Randomized Clinical Trial. *JAMA Netw Open* 2020;3(6):e2013136. doi: 10.1001/jamanetworkopen.2020.13136 [published Online First: 20200601]
- 95. Delgado-Enciso I, Paz-Garcia J, Barajas-Saucedo CE, et al. Safety and efficacy of a COVID-19 treatment with nebulized and/or intravenous neutral electrolyzed saline combined with usual medical care vs. usual medical care alone: A randomized, open-label, controlled trial. *Exp Ther Med* 2021;22(3):915. doi: 10.3892/etm.2021.10347 [published Online First: 20210629]
- 96. Dequin PF, Heming N, Meziani F, et al. Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support Among Critically Ill Patients With COVID-19: A Randomized Clinical Trial. *JAMA* 2020;324(13):1298-306. doi: 10.1001/jama.2020.16761
- 97. Domênico MBD, Collares K, Santos RBD, et al. Hydrogen peroxide as an auxiliary treatment for COVID-19 in Brazil: a randomized double-blind clinical trial. *Epidemiol Health* 2021;43:e2021051. doi: 10.4178/epih.e2021051 [published Online First: 20210803]
- 98. Di Pierro F, Derosa G, Maffioli P, et al. Possible Therapeutic Effects of Adjuvant Quercetin Supplementation Against Early-Stage COVID-19 Infection: A Prospective, Randomized, Controlled, and Open-Label Study. Int J Gen Med 2021;14:2359-66. doi: 10.2147/IJGM.S318720 [published Online First: 20210608]
- 99. Di Pierro F, Iqtadar S, Khan A, et al. Potential Clinical Benefits of Quercetin in the Early Stage of COVID-19: Results of a Second, Pilot, Randomized, Controlled and Open-Label Clinical Trial. Int J Gen Med 2021;14:2807-16. doi: 10.2147/IJGM.S318949 [published Online First: 20210624]
- 100. Doaei S, Gholami S, Rastgoo S, et al. The effect of omega-3 fatty acid supplementation on clinical and biochemical parameters of critically ill patients with COVID-19: a randomized clinical trial. *J Transl Med* 2021;19(1):128. doi: 10.1186/s12967-021-02795-5 [published Online First: 20210329]
- 101. Doi Y, Hibino M, Hase R, et al. A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19. Antimicrob Agents Chemother 2020;64(12) doi: 10.1128/AAC.01897-20 [published Online First: 20201117]
- 102. PRINCIPLE Trial Collaborative Group, Dorward J, Yu L-M, et al. Colchicine for COVID-19 in adults in the community (PRINCIPLE): a randomised, controlled, adaptive platform trial. *medRxiv* 2021:2021.09.20.21263828. doi: 10.1101/2021.09.20.21263828
- 103. Duarte M, Pelorosso FG, Nicolosi L, et al. Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report (preprint). *medRxiv* 2020:2020.08.04.20167205. doi: 10.1101/2020.08.04.20167205
- 104. Dubee V, Roy PM, Vielle B, et al. Hydroxychloroquine in mild-to-moderate coronavirus disease 2019: a placebo-controlled double blind trial. *Clin Microbiol Infect* 2021;27(8):1124-30. doi: 10.1016/j.cmi.2021.03.005 [published Online First: 20210401]
- 105. World Health Organization. Unpublished data for EPIC-HR (NCT04960202), 2021.
- 106. Edalatifard M, Akhtari M, Salehi M, et al. Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial. Eur Respir J 2020;56(6) doi: 10.1183/13993003.02808-2020 [published Online First: 20201224]
- 107. Eid RA, Elgendy MO, El-Gendy AO, et al. Efficacy of Ceftazidime and Cefepime in the Management of COVID-19 Patients: Single Center Report from Egypt. Antibiotics 2021;10(11):1278.
- 108. El-Bendary M, Abd-Elsalam S, Elbaz T, et al. Efficacy of combined Sofosbuvir and Daclatasvir in the treatment of COVID-19 patients with pneumonia: a multicenter Egyptian study. Expert Rev Anti Infect Ther 2021:1-5. doi: 10.1080/14787210.2021.1950532 [published Online First: 20210715]
- 109. Elamir Y, Amir H, Feliciano N, et al. Abstract #1002919: Endocrine Therapy for COVID19: A Randomized Pilot Study Using Calcitriol. Endocrine Practice 2021;27:S79 S79.
- 110. Elgohary MA-S, Hasan EM, Ibrahim AA, et al. Efficacy of Sofosbuvir plus Ledipasvir in Egyptian patients with COVID-19 compared to standard treatment: Randomized controlled trial. *medRxiv* 2021 doi: 10.1101/2021.05.19.21257429
- 111. Ely EW, Ramanan AV, Kartman CE, et al. Baricitinib plus Standard of Care for Hospitalised Adults with COVID-19 on Invasive Mechanical Ventilation or Extracorporeal Membrane Oxygenation: Results of a Randomised, Placebo-Controlled Trial. medRxiv 2021:2021.10.11.21263897. doi: 10.1101/2021.10.11.21263897
- 112. Idelsis E-MI, J P-E, Y D-R, et al. Effect and safety of combination of interferon alpha-2b and gamma or interferon alpha-2b for negativization of SARS-CoV-2 viral RNA. Preliminary results of a randomized controlled clinical trial. *medRxiv* 2020:2020.07.29.20164251. doi: 10.1101/2020.07.29.20164251
- 113. Esther CR, Kimura KS, Mikami Y, et al. Pharmacokinetic-based failure of a detergent virucidal for SARS-COV-2 nasal infections. Res Sq 2021 doi: 10.21203/rs.3.rs-500168/v1 [published Online First: 20210514]
- 114. Ezer N, Belga S, Daneman N, et al. Inhaled and intranasal ciclesonide for the treatment of covid-19 in adult outpatients: CONTAIN phase II randomised controlled trial. BMJ 2021;375:e068060. doi: 10.1136/bmi-2021-068060

- 115. Fakharian A, Barati S, Mirenayat M, et al. Evaluation of adalimumab effects in managing severe cases of COVID-19: A randomized controlled trial. *Int Immunopharmacol* 2021;99:107961. doi: 10.1016/j.intimp.2021.107961 [published Online First: 20210707]
- 116. Farahani RH MR, Nezami-Asl A et al. . Evaluation of the Efficacy of Methylprednisolone Pulse Therapy in Treatment of Covid-19 Adult Patients with Severe Respiratory Failure: Randomized, Clinical Trial,. 09

 September 2020, PREPRINT (Version 1) available at Research Square [+https://doiorg/1021203/rs3rs-66909/v1+] 2020
- 117. Farnoosh G, Akbariqomi M, Badri T, et al. Efficacy of a Low Dose of Melatonin as an Adjunctive Therapy in Hospitalized Patients with COVID-19: A Randomized, Double-blind Clinical Trial. Arch Med Res 2021 doi: 10.1016/j.arcmed.2021.06.006 [published Online First: 20210623]
- 118. Feld JJ, Kandel C, Biondi MJ, et al. Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial. *Lancet Respir Med* 2021;9(5):498-510. doi: 10.1016/S2213-2600(20)30566-X [published Online First: 20210205]
- 119. Fiorentino G, Coppola A, Izzo R, et al. Effects of adding L-arginine orally to standard therapy in patients with COVID-19: A randomized, double-blind, placebo-controlled, parallel-group trial. Results of the first interim analysis. Eclinical Medicine 2021;40 doi: 10.1016/j.eclinm.2021.101125
- 120. Fischer W, Eron JJ, Holman W, et al. Molnupiravir, an Oral Antiviral Treatment for COVID-19. medRxiv 2021 doi: 10.1101/2021.06.17.21258639 [published Online First: 20210617]
- 121. Fisher BA, Veenith T, Slade D, et al. Namilumab or infliximab compared to standard of care in hospitalised patients with COVID-19 (CATALYST): a phase 2 randomised adaptive trial. *medRxiv* 2021:2021.06.02.21258204. doi: 10.1101/2021.06.02.21258204
- 122. Fragoso-Saavedra S, Núñez I, Audelo-Cruz BM, et al. Pyridostigmine in adults with severe SARS-CoV-2 infection: the PISCO trial. medRxiv 2021:2021.04.28.21255834. doi: 10.1101/2021.04.28.21255834
- 123. Fu W, Liu Y, Liu L, et al. An open-label, randomized trial of the combination of IFN-kappa plus TFF2 with standard care in the treatment of patients with moderate COVID-19. *EClinicalMedicine* 2020;27:100547. doi: 10.1016/j.eclinm.2020.100547 [published Online First: 20200920]
- 124. Furtado RHM, Berwanger O, Fonseca HA, et al. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. *Lancet* 2020;396(10256):959-67. doi: 10.1016/S0140-6736(20)31862-6 [published Online First: 20200905]
- 125. Gaitán-Duarte HG, Álvarez-Moreno C, Rincón-Rodríguez CJ, et al. Effectiveness of Rosuvastatin plus Colchicine, Emtricitabine/Tenofovir and a combination of them in Hospitalized Patients with SARS Covid-19. medRxiv 2021:2021.07.06.21260085. doi: 10.1101/2021.07.06.21260085
- 126. Galan LEB, Santos NMD, Asato MS, et al. Phase 2 randomized study on chloroquine, hydroxychloroquine or ivermectin in hospitalized patients with severe manifestations of SARS-CoV-2 infection. *Pathog Glob Health* 2021;115(4):235-42. doi: 10.1080/20477724.2021.1890887 [published Online First: 20210308]
- 127. Geriak M, Haddad F, Kullar R, et al. Randomized Prospective Open Label Study Shows No Impact on Clinical Outcome of Adding Losartan to Hospitalized COVID-19 Patients with Mild Hypoxemia. Infect Dis Ther 2021;10(3):1323-30. doi: 10.1007/s40121-021-00453-3 [published Online First: 20210511]
- 128. Ghaderkhani S, khaneshan A, Salami A, et al. Efficacy and Safety of Arbidol in Treatment of Patients with COVID-19 Infection: A Randomized Clinical Trial. Research Square 2020 doi: 10.21203/rs.3.rs-91430/v1
- 129. Ghandehari S, Matusov Y, Pepkowitz S, et al. Progesterone in Addition to Standard of Care vs Standard of Care Alone in the Treatment of Men Hospitalized With Moderate to Severe COVID-19: A Randomized, Controlled Pilot Trial. Chest 2021;160(1):74-84. doi: 10.1016/j.chest.2021.02.024 [published Online First: 20210220]
- 130. Ghanei M, Solaymani-Dodaran M, Qazvini A, et al. The efficacy of corticosteroids therapy in patients with moderate to severe SARS-CoV-2 infection: a multicenter, randomized, open-label trial. Respiratory Research 2021;22(1):245. doi: 10.1186/s12931-021-01833-6
- 131. Nirmal G, Siddharthan D, Sushma B, et al. A Randomised Control Trial of Statin and Aspirin as Adjuvant Therapy in Patients with SARS-CoV-2 Infection (RESIST Trial). SSRN 2021 doi: 10.2139/ssrn.3820512
- 132. Goldman JD, Lye DCB, Hui DS, et al. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. N Engl J Med 2020;383(19):1827-37. doi: 10.1056/NEJMoa2015301 [published Online First: 20200527]
- 133. Gonzalez Ochoa A, Raffetto J, Hernandez aG, et al. Sulodexide in the treatment of patients with early stages of COVID-19: a randomised controlled trial, 2020.
- 134. Gonzalez JLB, González Gámez M, Enciso EAM, et al. Efficacy and safety of Ivermectin and Hydroxychloroquine in patients with severe COVID-19. A randomized controlled trial. *medRxiv* 2021:2021.02.18.21252037. doi: 10.1101/2021.02.18.21252037
- 135. Gordon AC, Mouncey PR, Al-Beidh F, et al. Interleukin-6 Receptor Antagonists in Critically III Patients with Covid-19 Preliminary report. *medRxiv* 2021:2021.01.07.21249390. doi: 10.1101/2021.01.07.21249390
- 136. Investigators TR-C, Derde LPG. Effectiveness of Tocilizumab, Sarilumab, and Anakinra for critically ill patients with COVID-19 The REMAP-CAP COVID-19 Immune Modulation Therapy Domain Randomized Clinical Trial. medRxiv 2021:2021.06.18.21259133. doi: 10.1101/2021.06.18.21259133

- 137. Hill JA, Paredes R, Vaca C, et al. LB1. Remdesivir for the Treatment of High-Risk Non-Hospitalized Individuals With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Trial. *Open Forum Infectious Diseases* 2021;8(Supplement_1):S806-S07. doi: 10.1093/ofid/ofab466.1642
- 138. Gottlieb RL, Vaca CE, Paredes R, et al. Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients. New England Journal of Medicine 2021;386(4):305-15. doi: 10.1056/NEJMoa2116846
- 139. Guimaraes PO, Quirk D, Furtado RH, et al. Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia. N Engl J Med 2021;385(5):406-15. doi: 10.1056/NEJMoa2101643 [published Online First: 20210616]
- 140. Gunst JD, Staerke NB, Pahus MH, et al. Efficacy of the TMPRSS2 inhibitor camostat mesilate in patients hospitalized with Covid-19-a double-blind randomized controlled trial. Eclinical Medicine 2021;35:100849. doi: 10.1016/j.eclinm.2021.100849 [published Online First: 20210422]
- 141. Gutiérrez-Castrellón P, Gandara-Martí T, Abreu AT, et al. Efficacy and safety of novel probiotic formulation in adult Covid19 outpatients: a randomized, placebo-controlled clinical trial. *medRxiv* 2021:2021.05.20.21256954. doi: 10.1101/2021.05.20.21256954
- 142. Guvenmez O, Keskin H, Ay B, et al. The comparison of the effectiveness of lincocin(R) and azitro(R) in the treatment of covid-19-associated pneumonia: A prospective study. *J Popul Ther Clin Pharmacol* 2020;27(S Pt 1):e5-e10. doi: 10.15586/jptcp.v27iSP1.684 [published Online First: 20200603]
- 143. Hakamifard A, Id, Soltani R, et al. The effect of vitamin E and vitamin C in patients with COVID-19 pneumonia; a randomized controlled clinical trial. 2021
- 144. Hamed DM, Belhoul KM, Al Maazmi NA, et al. Intravenous methylprednisolone with or without tocilizumab in patients with severe COVID-19 pneumonia requiring oxygen support: A prospective comparison. *J Infect Public Health* 2021;14(8):985-89. doi: 10.1016/j.jiph.2021.06.003 [published Online First: 20210610]
- 145. Hasan ZT, Atrakji D, Mehuaiden DAK. The Effect of Melatonin on Thrombosis, Sepsis and Mortality Rate in COVID-19 Patients. Int J Infect Dis 2021;114:79-84. doi: 10.1016/j.ijid.2021.10.012 [published Online First: 20211012]
- 146. Hassan MH AA, Ghweil AA, et al. . Olfactory disturbances as presenting manifestation among Egyptian patients with COVID-19: Possible role of zinc. Research Square2020; doi:1021203/rs3rs-107577/v1 2020
- 147. Hassaniazad M, Eftekhar E, Inchehsablagh BR, et al. A triple-blind, placebo-controlled, randomized clinical trial to evaluate the effect of curcumin-containing nanomicelles on cellular immune responses subtypes and clinical outcome in COVID-19 patients. *Phytother Res* 2021;35(11):6417-27. doi: 10.1002/ptr.7294 [published Online First: 20210919]
- 148. Hermine O, Mariette X, Tharaux PL, et al. Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial. JAMA Intern Med 2021;181(1):32-40. doi: 10.1001/jamainternmed.2020.6820
- 149. Hermine OaM, Xavier and Tharaux, Pierre Louis and Resche-Rigon, Matthieu and Madjlessi Simon, Tabassome and Porcher, Raphael and Ravaud, Philippe. Tocilizumab Plus Dexamethasone in Patients with Moderate-to-Severe COVID-19 Pneumonia: a Randomized Clinical Trial of the CORIMUNO-19 Study Group. SSRN 2021 doi: http://dx.doi.org/10.2139/ssrn.3909736 [published Online First: 23 Aug 20201]
- 150. Hernandez-Cardenas C, Thirion-Romero I, Rodríguez-Llamazares S, et al. Hydroxychloroquine for the treatment of severe respiratory infection by COVID-19: A randomized controlled trial. *PLOS ONE* 2021;16(9):e0257238. doi: 10.1371/journal.pone.0257238
- 151. Hinks TSC, Cureton L, Knight R, et al. Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial. Lancet Respir Med 2021;9(10):1130-40. doi: 10.1016/S2213-2600(21)00263-0 [published Online First: 20210709]
- 152. Holubovska O, Bojkova D, Elli S, et al. Enisamium is an inhibitor of the SARS-CoV-2 RNA polymerase and shows improvement of recovery in COVID-19 patients in an interim analysis of a clinical trial. medRxiv 2021:2021.01.05.21249237. doi: 10.1101/2021.01.05.21249237 [published Online First: 20210121]
- 153. Group RC, Horby P, Lim WS, et al. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med 2021;384(8):693-704. doi: 10.1056/NEJMoa2021436 [published Online First: 20200717]
- 154. Group RC, Horby PW, Mafham M, et al. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. *medRxiv* 2021:2021.06.15.21258542. doi: 10.1101/2021.06.15.21258542
- 155. Recovery Collaborative Group. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. *Lancet* 2020;396(10259):1345-52. doi: 10.1016/S0140-6736(20)32013-4 [published Online First: 20201005]
- 156. Recovery Collaborative Group. Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. *Lancet* 2021;397(10274):605-12. doi: 10.1016/S0140-6736(21)00149-5 [published Online First: 20210202]
- 157. Group RC. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. *Lancet* 2021;397(10285):1637-45. doi: 10.1016/S0140-6736(21)00676-0 [published Online First: 2021/05/03]

- 158. Horby PW, Campbell M, Spata E, et al. Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. *medRxiv* 2021:2021.05.18.21257267. doi: 10.1101/2021.05.18.21257267
- 159. Abani O, Abbas A, Abbas F, et al. Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet doi: 10.1016/S0140-6736(21)01825-0
- 160. Hu K, Wang M, Zhao Y, et al. A Small-Scale Medication of Leflunomide as a Treatment of COVID-19 in an Open-Label Blank-Controlled Clinical Trial. *Virol Sin* 2020;35(6):725-33. doi: 10.1007/s12250-020-00258-7 [published Online First: 20200721]
- 161. Huang M, Tang T, Pang P, et al. Treating COVID-19 with Chloroquine. J Mol Cell Biol 2020;12(4):322-25. doi: 10.1093/jmcb/mjaa014 [published Online First: 2020/04/03]
- 162. Huang YQ, Tang SQ, Xu XL, et al. No Statistically Apparent Difference in Antiviral Effectiveness Observed Among Ribavirin Plus Interferon-Alpha, Lopinavir/Ritonavir Plus Interferon-Alpha in Patients With Mild to Moderate Coronavirus Disease 2019: Results of a Randomized, Open-Labeled Prospective Study. Front Pharmacol 2020;11(1071):1071. doi: 10.3389/fphar.2020.01071 [published Online First: 20200714]
- 163. Hung IF, Lung KC, Tso EY, et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet 2020;395(10238):1695-704. doi: 10.1016/S0140-6736(20)31042-4 [published Online First: 20200510]
- 164. Husain P, Ahmed S, Husain B. Role of doxycycline, oral steroids, and nasal steroid in treatment of anosmia due to COVID-19 with the new insights into the doxycycline activity., 16 November 2020, PREPRINT (Version 1). 2020 doi: Available at Research Square [https://doi.org/10.21203/rs.3.rs-107710/v1]
- 165. Ivashchenko AA, Dmitriev KA, Vostokova NV, et al. AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical Trial. Clin Infect Dis 2021;73(3):531-34. doi: 10.1093/cid/ciaa1176
- 166. Ivashkin V, Fomin V, Moiseev S, et al. Efficacy of a Probiotic Consisting of Lacticaseibacillus rhamnosus PDV 1705, Bifidobacterium bifidum PDV 0903, Bifidobacterium longum subsp. infantis PDV 1911, and Bifidobacterium longum subsp. longum PDV 2301 in the Treatment of Hospitalized Patients with COVID-19: a Randomized Controlled Trial. *Probiotics Antimicrob Proteins* 2021:1-9. doi: 10.1007/s12602-021-09858-5 [published Online First: 20211013]
- 167. Jagannathan P, Andrews JR, Bonilla H, et al. Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial. *Nat Commun* 2021;12(1):1967. doi: 10.1038/s41467-021-22177-1 [published Online First: 20210330]
- 168. Jamaati H, Hashemian SM, Farzanegan B, et al. No clinical benefit of high dose corticosteroid administration in patients with COVID-19: A preliminary report of a randomized clinical trial. *Eur J Pharmacol* 2021;897:173947. doi: 10.1016/j.ejphar.2021.173947 [published Online First: 20210216]
- 169. JamaliMoghadamSiahkali S, Zarezade B, Koolaji S, et al. Safety and effectiveness of high-dose vitamin C in patients with COVID-19: a randomized open-label clinical trial. *Eur J Med Res* 2021;26(1):20. doi: 10.1186/s40001-021-00490-1 [published Online First: 20210211]
- 170. Jeronimo CMP, Farias MEL, Val FFA, et al. Methylprednisolone as Adjunctive Therapy for Patients Hospitalized With Coronavirus Disease 2019 (COVID-19; Metcovid): A Randomized, Double-blind, Phase IIb, Placebo-controlled Trial. Clin Infect Dis 2021;72(9):e373-e81. doi: 10.1093/cid/ciaa1177
- 171. Johnston C, Brown ER, Stewart J, et al. Hydroxychloroquine with or without azithromycin for treatment of early SARS-CoV-2 infection among high-risk outpatient adults: A randomized clinical trial. EClinicalMedicine 2021;33:100773. doi: 10.1016/j.eclinm.2021.100773 [published Online First: 20210227]
- 172. Kalantari S, Fard SR, Maleki D, et al. Comparing the effectiveness of Atazanavir/Ritonavir/Dolutegravir/Hydroxychloroquine and Lopinavir/Ritonavir/Hydroxychloroquine treatment regimens in COVID-19 patients. *J Med Virol* 2021;93(12):6557-65. doi: 10.1002/jmv.27195 [published Online First: 20210728]
- 173. Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. *N Engl J Med* 2021;384(9):795-807. doi: 10.1056/NEJMoa2031994 [published Online First: 20201211]
- 174. Kalil AC, Mehta AK, Patterson TF, et al. Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial. *The Lancet Respiratory Medicine* 2021;9(12):1365-76. doi: 10.1016/S2213-2600(21)00384-2
- 175. Abbaspour Kasgari H, Moradi S, Shabani AM, et al. Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial. *J Antimicrob Chemother* 2020;75(11):3373-78. doi: 10.1093/jac/dkaa332
- 176. Kasiri H, Rouhani N, Salehifar E, et al. Mometasone furoate nasal spray in the treatment of patients with COVID-19 olfactory dysfunction: A randomized, double blind clinical trial. *Int Immunopharmacol* 2021;98:107871. doi: 10.1016/j.intimp.2021.107871 [published Online First: 20210612]
- 177. Khamis F, Al Naabi H, Al Lawati A, et al. Randomized controlled open label trial on the use of favipiravir combined with inhaled interferon beta-1b in hospitalized patients with moderate to severe COVID-19 pneumonia. Int J Infect Dis 2021;102:538-43. doi: 10.1016/j.ijid.2020.11.008 [published Online First: 20201109]

- 178. Ruzhentsova TA, Chukhlyaev PV, Khavkina DA, et al. Efficacy and safety of favipiravir in a complex therapy of mild to moderate COVID-19. *Infectious diseases: News, Opinions, Training* 2020;9(4):26-38. doi: 10.33029/2305-3496-2020-9-4-26-38
- 179. Khodashahi R, Naderi H, Bojdy A, et al. Comparison the Effect of Arbidol Plus Hydroxychloroquine vs Hydroxychloroquine Alone in Treatment of COVID-19 Disease: A Randomized Clinical Trial. Current Respiratory Medicine Reviews 2021;16(4):252-62. doi: 10.2174/1573398x17666210129125703
- 180. Khoo SH, FitzGerald R, Fletcher T, et al. Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a phase 1, dose-escalating, randomised controlled study. *medRxiv* 2021:2021.05.03.21256309. doi: 10.1101/2021.05.03.21256309
- 181. Kimura KS, Freeman MH, Wessinger BC, et al. Interim analysis of an open-label randomized controlled trial evaluating nasal irrigations in non-hospitalized patients with coronavirus disease 2019. *Int Forum Allergy Rhinol* 2020;10(12):1325-28. doi: 10.1002/alr.22703 [published Online First: 20201020]
- 182. Kishoria N, Mathur SL, Parmar V, et al. IVERMECTIN AS ADJUVANT TO HYDROXYCHOLOROQUINE IN PATIENTS RESISTANT TO STANDARD TREATMENT FOR SARS-CoV-2: RESULTS OF AN OPEN-LABEL RANDOMIZED CLINICAL STUDY. Paripex Indian Journal of Research 2020:1-4. doi: 10.36106/paripex/4801859
- 183. Klussmann J, Lehmann C, Grosheva M, et al. COVID-19: Azelastine nasal spray Reduces Virus-load In Nasal swabs (CARVIN). Early intervention with azelastine nasal sprays reduces viral load in SARS-CoV-2 infected patients. First report on a double-blind placebo-controlled phase II clinical trial. *Research Square* 2021 doi: 10.21203/rs.3.rs-864566/v1
- 184. Kosiborod MN, Esterline R, Furtado RHM, et al. Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Diabetes Endocrinol* 2021;9(9):586-94. doi: 10.1016/S2213-8587(21)00180-7 [published Online First: 20210721]
- 185. Kosmopoulos A, Bhatt DL, Meglis G, et al. A randomized trial of icosapent ethyl in ambulatory patients with COVID-19. *iScience* 2021;24(9):103040. doi: 10.1016/j.isci.2021.103040 [published Online First: 20210826]
- 186. World Health Organization. Unpublished data on Krishnan and Kumar trials on molnupiravir, 2021.
- 187. Krolewiecki A, Lifschitz A, Moragas M, et al. Antiviral effect of high-dose ivermectin in adults with COVID-19: A proof-of-concept randomized trial. *EClinicalMedicine* 2021;37:100959. doi: 10.1016/j.eclinm.2021.100959 [published Online First: 20210618]
- 188. Kumar S, De Souza R, Nadkar M, et al. A two-arm, randomized, controlled, multi-centric, open-label phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-19. Expert Opin Biol Ther 2021;21(5):675-86. doi: 10.1080/14712598.2021.1905794 [published Online First: 20210409]
- 189. Kumari P, Dembra S, Dembra P, et al. The Role of Vitamin C as Adjuvant Therapy in COVID-19. Cureus 2020;12(11):e11779. doi: 10.7759/cureus.11779 [published Online First: 20201130]
- 190. Kyriazopoulou E, Poulakou G, Milionis H, et al. Early Anakinra Treatment for COVID-19 Guided by Urokinase Plasminogen Receptor. medRxiv 2021:2021.05.16.21257283. doi: 10.1101/2021.05.16.21257283
- 191. Lakkireddy M, Gadiga SG, Malathi RD, et al. Impact of daily high dose oral vitamin D therapy on the inflammatory markers in patients with COVID 19 disease. *Sci Rep* 2021;11(1):10641. doi: 10.1038/s41598-021-90189-4 [published Online First: 20210520]
- 192. Lattmann E, Bhalerao P, ShashiBhushan BL, et al. Randomized, Comparative, Clinical Trial to Evaluate Efficacy and Safety of PNB001 in Moderate COVID-19 Patients. *medRxiv* 2021:2021.04.16.21255256. doi: 10.1101/2021.04.16.21255256
- 193. Lawler PR, Goligher EC, Berger JS, et al. Therapeutic Anticoagulation in Non-Critically III Patients with Covid-19. medRxiv 2021:2021.05.13.21256846. doi: 10.1101/2021.05.13.21256846
- 194. Lemos ACB, do Espirito Santo DA, Salvetti MC, et al. Therapeutic versus prophylactic anticoagulation for severe COVID-19: A randomized phase II clinical trial (HESACOVID). *Thromb Res* 2020;196:359-66. doi: 10.1016/j.thromres.2020.09.026 [published Online First: 20200921]
- 195. Lenze EJ, Mattar C, Zorumski CF, et al. Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial. *JAMA* 2020;324(22):2292-300. doi: 10.1001/jama.2020.22760
- 196. Lescure FX, Honda H, Fowler RA, et al. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Respir Med* 2021;9(5):522-32. doi: 10.1016/S2213-2600(21)00099-0 [published Online First: 20210304]
- 197. Li Y, Xie Z, Lin W, et al. Efficacy and Safety of Lopinavir/Ritonavir or Arbidol in Adult Patients with Mild/Moderate COVID-19: An Exploratory Randomized Controlled Trial. *Med (N Y)* 2020;1(1):105-13 e4. doi: 10.1016/j.medj.2020.04.001 [published Online First: 20200519]
- 198. Li C, Luo F, Liu C, et al. Effect of a genetically engineered interferon-alpha versus traditional interferon-alpha in the treatment of moderate-to-severe COVID-19: a randomised clinical trial. *Ann Med* 2021;53(1):391-401. doi: 10.1080/07853890.2021.1890329 [published Online First: 2021/02/24]
- 199. Li T, Sun L, Zhang W, et al. Bromhexine Hydrochloride Tablets for the Treatment of Moderate COVID-19: An Open-Label Randomized Controlled Pilot Study. Clin Transl Sci 2020;13(6):1096-102. doi: 10.1111/cts.12881 [published Online First: 20201010]

- 200. Li Q, Cui C, Xu F, et al. Evaluation of the efficacy and safety of hydroxychloroquine in comparison with chloroquine in moderate and severe patients with COVID-19. Sci China Life Sci 2021;64(4):660-63. doi: 10.1007/s11427-020-1871-4 [published Online First: 20210118]
- 201. Liesenborghs L, Spriet I, Jochmans D, et al. Itraconazole for COVID-19: preclinical studies and a proof-of-concept randomized clinical trial. *EBioMedicine* 2021;66:103288. doi: 10.1016/j.ebiom.2021.103288 [published Online First: 20210319]
- 202. Lomakin NV, Bakirov BA, Protsenko DN, et al. The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study. *Inflamm Res* 2021;70(10-12):1233-46. doi: 10.1007/s00011-021-01507-5 [published Online First: 20210929]
- 203. Lopes RD, Macedo AVS, de Barros ESPGM, et al. Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial. *JAMA* 2021;325(3):254-64. doi: 10.1001/jama.2020.25864 [published Online First: 2021/01/20]
- 204. Lopes MI, Bonjorno LP, Giannini MC, et al. Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebo-controlled clinical trial. RMD Open 2021;7(1):e001455. doi: 10.1136/rmdopen-2020-001455
- 205. Lopes RD, de Barros ESPGM, Furtado RHM, et al. Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial. *Lancet* 2021;397(10291):2253-63. doi: 10.1016/S0140-6736(21)01203-4 [published Online First: 20210604]
- 206. Lopez-Medina E, Lopez P, Hurtado IC, et al. Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19: A Randomized Clinical Trial. *JAMA* 2021;325(14):1426-35. doi: 10.1001/iama.2021.3071
- 207. Lou Y, Liu L, Yao H, et al. Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial. *Eur J Pharm Sci* 2021;157:105631. doi: 10.1016/j.ejps.2020.105631 [published Online First: 20201025]
- 208. Lyngbakken MN, Berdal JE, Eskesen A, et al. A pragmatic randomized controlled trial reports lack of efficacy of hydroxychloroquine on coronavirus disease 2019 viral kinetics. *Nat Commun* 2020;11(1):5284. doi: 10.1038/s41467-020-19056-6 [published Online First: 20201020]
- 209. Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. *N Engl J Med* 2021 doi: 10.1056/NEJMoa2116044 [published Online First: 2021/12/17]
- 210. Maghbooli Z, Sahraian MA, Jamalimoghadamsiahkali S, et al. Treatment With 25-Hydroxyvitamin D(3) (Calcifediol) Is Associated With a Reduction in the Blood Neutrophil-to-Lymphocyte Ratio Marker of Disease Severity in Hospitalized Patients With COVID-19: A Pilot Multicenter, Randomized, Placebo-Controlled, Double-Blinded Clinical Trial. *Endocr Pract* 2021;27(12):1242-51. doi: 10.1016/j.eprac.2021.09.016 [published Online First: 20211013]
- 211. Mahajan L, Singh AP, Gifty. Clinical outcomes of using remdesivir in patients with moderate to severe COVID-19: A prospective randomised study. *Indian J Anaesth* 2021;65(Suppl 1):S41-S46. doi: 10.4103/ija.IJA 149 21 [published Online First: 20210320]
- 212. Mahmud R, Rahman MM, Alam I, et al. Ivermectin in combination with doxycycline for treating COVID-19 symptoms: a randomized trial. *J Int Med Res* 2021;49(5):3000605211013550. doi: 10.1177/03000605211013550 [published Online First: 2021/05/14]
- 213. Majeed M, Nagabhushanam K, Shah K, et al. A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of a Nutritional Supplement (ImmuActive(TM)) for COVID-19 Patients. Evid Based Complement Alternat Med 2021;2021:8447545. doi: 10.1155/2021/8447545 [published Online First: 20211011]
- 214. Maldonado V, Hernandez-Ramirez C, Oliva-Perez EA, et al. Pentoxifylline decreases serum LDH levels and increases lymphocyte count in COVID-19 patients: Results from an external pilot study. *Int Immunopharmacol* 2021;90:107209. doi: 10.1016/j.intimp.2020.107209 [published Online First: 20201126]
- 215. Mansour E, Palma AC, Ulaf RG, et al. Pharmacological inhibition of the kinin-kallikrein system in severe COVID-19 A proof-of-concept study (preprint). *medRxiv* 2020:2020.08.11.20167353. doi: 10.1101/2020.08.11.20167353
- 216. Marconi VC, Ramanan AV, de Bono S, et al. Baricitinib plus Standard of Care for Hospitalized Adults with COVID-19. medRxiv 2021:2021.04.30.21255934. doi: 10.1101/2021.04.30.21255934
- 217. Marcos M, Carmona-Torre F, Vidal Laso R, et al. Therapeutic vs. prophylactic bemiparin in hospitalized patients with non-severe COVID-19 (BEMICOP): an open-label, multicenter, randomized trial. *Thromb Haemost* 2021 doi: 10.1055/a-1667-7534 [published Online First: 20211012]
- 218. Maskin LP, Bonelli I, Olarte GL, et al. High- Versus Low-Dose Dexamethasone for the Treatment of COVID-19-related Acute Respiratory Distress Syndrome: A Multicenter and Randomized Open-label Clinical Trial. medRxiv 2021:2021.09.15.21263597. doi: 10.1101/2021.09.15.21263597
- 219. McCreary MR, Schnell PM, Rhoda DA. Randomized Double-blind Placebo-controlled Proof-of-concept Trial of Resveratrol for Outpatient Treatment of Mild Coronavirus Disease (COVID-19). Res Sq 2021 doi: 10.21203/rs.3.rs-861831/v1 [published Online First: 20210913]

- 220. Mehboob R, Ahmad FJ, Qayyum A, et al. Aprepitant as a combinant with Dexamethasone reduces the inflammation via Neurokinin 1 Receptor Antagonism in severe to critical Covid-19 patients and potentiates respiratory recovery: A novel therapeutic approach (preprint). *medRxiv* 2020:2020.08.01.20166678. doi: 10.1101/2020.08.01.20166678
- 221. Migled B MB, José B, et al. . EXPERIMENTAL STUDY: MANAGEMENT OF METISOPRINOL IN PATIENTS WITH COVID-19. . DOI: 1047460/uctv24i103356 2020
- 222. Miller J, Bruen C, Schnaus M, et al. Auxora versus standard of care for the treatment of severe or critical COVID-19 pneumonia: results from a randomized controlled trial. *Crit Care* 2020;24(1):502. doi: 10.1186/s13054-020-03220-x [published Online First: 20200814]
- 223. Miller RA, Guru P, Bauer P, et al. Clinical Results with a B Cell Activating Anti-CD73 Antibody for the Immunotherapy of COVID-19. medRxiv 2021:2021.09.13.21263406. doi: 10.1101/2021.09.13.21263406
- 224. Mobarak S, Salasi M, Hormati A, et al. Evaluation of the Effect of Sofosbuvir and Daclatasvir in Hospitalised COVID-19 Patients: A Randomized Double-Blind Clinical Trial (DISCOVER). Social Science Research

 Network 2021
- 225. Mohan A, Tiwari P, Suri T, et al. Ivermectin in mild and moderate COVID-19 (RIVET-COV): a randomized, placebo-controlled trial, 02 February 2021, PREPRINT (Version 1). Available at Research Square [https://doiorg/1021203/rs3rs-191648/v1] 2021
- 226. Moni M, Madathil T, Sathyapalan DT, et al. A Feasibility Trial to Evaluate the Composite Efficacy of Inhaled Nitric Oxide in the Treatment of Covid 19 Pneumonia: Impact on Viral Load and Clinical Outcomes. *medRxiv* 2021:2021.04.15.21255300. doi: 10.1101/2021.04.15.21255300
- 227. Monk PD, Marsden RJ, Tear VJ, et al. Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respir Med 2021;9(2):196-206. doi: 10.1016/S2213-2600(20)30511-7 [published Online First: 20201112]
- 228. Moreira TG, Matos KTF, De Paula GS, et al. Nasal Administration of Anti-CD3 Monoclonal Antibody (Foralumab) Reduces Lung Inflammation and Blood Inflammatory Biomarkers in Mild to Moderate COVID-19 Patients: A Pilot Study. Front Immunol 2021;12:709861. doi: 10.3389/fimmu.2021.709861 [published Online First: 20210812]
- 229. Munch MW, Meyhoff TS, Helleberg M, et al. Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia: The COVID STEROID randomised, placebo-controlled trial. *Acta Anaesthesiol Scand* 2021;65(10):1421-30. doi: 10.1111/aas.13941 [published Online First: 20210920]
- 230. Munch MW, Myatra SN, Tirupakuzhi Vijayaraghavan BK, et al. Dexamethasone 12 mg versus 6 mg for patients with COVID-19 and severe hypoxia: an international, randomized, blinded trial. *medRxiv* 2021:2021.07.22.21260755. doi: 10.1101/2021.07.22.21260755
- 231. Murai IH, Fernandes AL, Sales LP, et al. Effect of a Single High Dose of Vitamin D3 on Hospital Length of Stay in Patients With Moderate to Severe COVID-19: A Randomized Clinical Trial. *JAMA* 2021;325(11):1053-60. doi: 10.1001/jama.2020.26848
- 232. Méndez-Flores S, Priego-Ranero Á, Azamar-Llamas D, et al. Effect of polymerized type I collagen in hyperinflammation of adult outpatients with symptomatic COVID-19: a double blind, randomised, placebo-controlled clinical trial. medRxiv 2021:2021.05.12.21257133. doi: 10.1101/2021.05.12.21257133
- 233. Najmeddin F, Solhjoo M, Ashraf H, et al. Effects of Renin-Angiotensin-Aldosterone Inhibitors on Early Outcomes of Hypertensive COVID-19 Patients: A Randomized Triple-Blind Clinical Trial. Am J Hypertens 2021 doi: 10.1093/ajh/hpab111 [published Online First: 20210715]
- 234. MS N, N G, P N, et al. Ivermectin as an adjunct treatment for hospitalized adult COVID-19 patients: A randomized multi-center clinical trial, 24 November 2020, PREPRINT (Version 1). 2020 doi: Available at Research Square [https://doi.org/10.21203/rs.3.rs-109670/v1]
- 235. Niktale H SS, Nosrati A, Ghasemi M, Houshmand M, Mansori I, Niktale R. The therapeutic effect of an organosulfur-derived capsule

(Nicovid) as a supplementary treatment for covid-19 patients. Medical Science, 2021(113):1661-68.

- 236. Nojomi M, Yassin Z, Keyvani H, et al. Effect of Arbidol (Umifenovir) on COVID-19: a randomized controlled trial. BMC Infect Dis 2020;20(1):954. doi: 10.1186/s12879-020-05698-w [published Online First: 20201214]
- 237. Nouri-Vaskeh M, Kalami N, Zand R, et al. Comparison of losartan and amlodipine effects on the outcomes of patient with COVID-19 and primary hypertension: A randomised clinical trial. *Int J Clin Pract* 2021;75(6):e14124. doi: 10.1111/jjcp.14124 [published Online First: 20210313]
- 238. Khalili H, Nourian A, Ahmadinejad Z, et al. Efficacy and safety of sofosbuvir/ ledipasvir in treatment of patients with COVID-19; A randomized clinical trial. *Acta Biomed* 2020;91(4):e2020102. doi: 10.23750/abm.v91i4.10877 [published Online First: 20201110]
- 239. Ogbuagu O, KTT, HFG, et al. Acute Kidney Injury In Patients With Moderate COVID-19 treated With Rdv Versus SoC. Conference on Retroviruses and Opportunistic Infections 2021
- 240. Oldenburg CE, Pinsky BA, Brogdon J, et al. Effect of Oral Azithromycin vs Placebo on COVID-19 Symptoms in Outpatients With SARS-CoV-2 Infection: A Randomized Clinical Trial. *JAMA* 2021;326(6):490-98. doi: 10.1001/jama.2021.11517

- 241. Oliynyk O, Barg W, Slifirczyk A, et al. Comparison of the Effect of Unfractionated Heparin and Enoxaparin Sodium at Different Doses on the Course of COVID-19-Associated Coagulopathy. *Life (Basel)* 2021;11(10) doi: 10.3390/life11101032 [published Online First: 20210930]
- 242. Omrani AS, Pathan SA, Thomas SA, et al. Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19. *EClinicalMedicine* 2020;29-30:100645-45.
- 243. Onal H, Arslan B, Ergun NU, et al. Treatment of COVID-19 Patients with Quercetin: A Prospective, Single Centre, Randomized, Controlled Trial. . *Authorea January 19, 2021* 2021 doi: 10.22541/au.161106492.28349832/v1
- 244. Butler CC, Dorward J, Yu L-M, et al. Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. *The Lancet* 2021;397(10279):1063-74. doi: 10.1016/s0140-6736(21)00461-x
- 245. Padmanabhan U, Mukherjee S, Borse R, et al. Phase II Clinical trial for Evaluation of BCG as potential therapy for COVID-19, 2020.
- 246. Consortium WHOST, Pan H, Peto R, et al. Repurposed Antiviral Drugs for Covid-19 Interim WHO Solidarity Trial Results. N Engl J Med 2021;384(6):497-511. doi: 10.1056/NEJMoa2023184 [published Online First: 20201202]
- 247. Pantos C, Apostolaki V, Kokkinos L, et al. Acute triiodothyronine treatment and red blood cell sedimentation rate (ESR) in critically ill COVID-19 patients: A novel association? Clinical Hemorheology and Microcirculation 2021;79:485-88. doi: 10.3233/CH-211215
- 248. Parienti JJ, Prazuck T, Peyro-Saint-Paul L, et al. Effect of Tenofovir Disoproxil Fumarate and Emtricitabine on nasopharyngeal SARS-CoV-2 viral load burden amongst outpatients with COVID-19: A pilot, randomized, open-label phase 2 trial. Eclinical Medicine 2021;38:100993. doi: 10.1016/j.eclinm.2021.100993 [published Online First: 20210627]
- 249. Pascual-Figal DA, Roura-Piloto AE, Moral-Escudero E, et al. Colchicine in Recently Hospitalized Patients with COVID-19: A Randomized Controlled Trial (COL-COVID). *Int J Gen Med* 2021;14:5517-26. doi: 10.2147/ijgm.S329810 [published Online First: 20210911]
- 250. Patel O, Chinni V, El-Khoury J, et al. A pilot double-blind safety and feasibility randomized controlled trial of high-dose intravenous zinc in hospitalized COVID-19 patients. *J Med Virol* 2021;93(5):3261-67. doi: 10.1002/jmv.26895 [published Online First: 20210309]
- 251. Patel J, Beishuizen A, Ruiz XB, et al. A Randomized Trial of Otilimab in Severe COVID-19 Pneumonia (OSCAR). medRxiv 2021:2021.04.14.21255475. doi: 10.1101/2021.04.14.21255475
- 252. Pawar KS, Mastud RN, Pawar SK, et al. Oral Curcumin With Piperine as Adjuvant Therapy for the Treatment of COVID-19: A Randomized Clinical Trial. *Front Pharmacol* 2021;12:669362. doi: 10.3389/fphar.2021.669362 [published Online First: 20210528]
- 253. Perepu US, Chambers I, Wahab A, et al. Standard prophylactic versus intermediate dose enoxaparin in adults with severe COVID-19: A multi-center, open-label, randomized controlled trial. *J Thromb Haemost* 2021;19(9):2225-34. doi: 10.1111/jth.15450 [published Online First: 20210718]
- 254. Perlin DS, Neil GA, Anderson C, et al. CERC-002, a human anti-LIGHT mAb reduces respiratory failure and death in hospitalized COVID-19 ARDS patients. *medRxiv* 2021:2021.04.03.21254748. doi: 10.1101/2021.04.03.21254748
- 255. Pott-Junior H, Paoliello MMB, Miguel AQC, et al. Use of ivermectin in the treatment of Covid-19: A pilot trial. *Toxicol Rep* 2021;8:505-10. doi: 10.1016/j.toxrep.2021.03.003 [published Online First: 20210309]
- 256. Prabowo NA, Apriningsih H. Colchicine reduces the degree of inflammation in COVID-19 patients. *IOP Conference Series: Earth and Environmental Science* 2021;824(1):012087. doi: 10.1088/1755-1315/824/1/012087
- 257. Purwati, Budiono, Rachman BE, et al. A Randomized, Double-Blind, Multicenter Clinical Study Comparing the Efficacy and Safety of a Drug Combination of Lopinavir/Ritonavir-Azithromycin, Lopinavir/Ritonavir-Doxycycline, and Azithromycin-Hydroxychloroquine for Patients Diagnosed with Mild to Moderate COVID-19 Infections. *Biochem Res Int* 2021;2021:6685921. doi: 10.1155/2021/6685921 [published Online First: 20210209]
- 258. Puskarich MA, Cummins NW, Ingraham NE, et al. A multi-center phase II randomized clinical trial of losartan on symptomatic outpatients with COVID-19. *EClinicalMedicine* 2021;37:100957. doi: 10.1016/j.eclinm.2021.100957 [published Online First: 20210617]
- 259. Puskarich MA, Ingraham NE, Merck LH, et al. Effect of losartan on hospitalized patients with COVID-19-induced lung injury: A randomized clinical trial. *medRxiv* 2021:2021.08.25.21262623. doi: 10.1101/2021.08.25.21262623
- 260. Novartis Pharmaceuticals. Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID): US National Library of Medicine ClinicalTrials.gov; 2021 [Available from: https://clinicaltrials.gov/ct2/show/results/NCT043621372021.

- 261. Raghavan K, Dedeepiya VD, Suryaprakash V, et al. Beneficial Effects of novel Aureobasidium Pullulans strains produced Beta-1,3-1,6 Glucans on Interleukin-6 and D-Dimer levels in COVID-19 patients; results of a randomized multiple-arm pilot clinical study. *medRxiv* 2021:2021.08.09.21261738. doi: 10.1101/2021.08.09.21261738
- 262. Rahmani H, Davoudi-Monfared E, Nourian A, et al. Interferon beta-1b in treatment of severe COVID-19: A randomized clinical trial. *Int Immunopharmacol* 2020;88:106903. doi: 10.1016/i.intimp.2020.106903 [published Online First: 20200824]
- 263. Ramachandran R, Bhosale V, Reddy H, et al. Phase III, Randomized, Double-blind, Placebo controlled trial of Efficacy, Safety and Tolerability of Antiviral drug Umifenovir vs Standard care of therapy in non-severe COVID-19 patients. *Int J Infect Dis* 2021 doi: 10.1016/j.ijid.2021.11.025 [published Online First: 20211118]
- 264. Ramakrishnan S, Nicolau DV, Langford B, et al. Inhaled budesonide in the treatment of early COVID-19 illness: a randomised controlled trial. *medRxiv* 2021:2021.02.04.21251134. doi: 10.1101/2021.02.04.21251134
- 265. Ranjbar K, Shahriarirad R, Erfani A, et al. Methylprednisolone or Dexamethasone, Which One Is the Superior Corticosteroid in the Treatment of Hospitalized COVID-19 Patients: A Triple-Blinded Randomized Controlled Trial, 01 February 2021, PREPRINT (Version 1). Available at Research Square [https://doiorg/1021203/rs3rs-148529/v1] 2021
- 266. Rashad A, Nafady A, Hassan MH, et al. Therapeutic efficacy of macrolides in management of patients with mild COVID-19, 01 February 2021, PREPRINT (Version 1). Available at Research Square [https://doiorg/1021203/rs3rs-181996/v1] 2021
- 267. Rashad A, Mousa S, Nafady-Hego H, et al. Short term survival of critically ill COVID-19 Egyptian patients on assisted ventilation treated by either Dexamethasone or Tocilizumab. *Sci Rep* 2021;11(1):8816. doi: 10.1038/s41598-021-88086-x [published Online First: 20210423]
- 268. Rashad A, Nafady A, Hassan MH, et al. Therapeutic efficacy of macrolides in management of patients with mild COVID-19. Sci Rep 2021;11(1):16361. doi: 10.1038/s41598-021-95900-z [published Online First: 20210811]
- 269. Rashid RA, Zgair A, Al-Ani RM. Effect of nasal corticosteroid in the treatment of anosmia due to COVID-19: A randomised double-blind placebo-controlled study. *Am J Otolaryngol* 2021;42(5):103033. doi: 10.1016/j.amjoto.2021.103033 [published Online First: 20210407]
- 270. Rastogi A, Bhansali A, Khare N, et al. Short term, high-dose vitamin D supplementation for COVID-19 disease: a randomised, placebo-controlled, study (SHADE study). *Postgrad Med J* 2020 doi: 10.1136/postgradmedj-2020-139065 [published Online First: 20201112]
- 271. Ravichandran R, Mohan SK, Sukumaran SK, et al. Indomethacin Use for Mild & Samp; Moderate hospitalised Covid-19 patients: An open label randomized clinical trial. *medRxiv* 2021:2021.07.24.21261007. doi: 10.1101/2021.07.24.21261007
- 272. Ravikirti, Roy R, Pattadar C, et al. Ivermectin as a potential treatment for mild to moderate COVID-19 A double blind randomized placebo-controlled trial. *medRxiv* 2021:2021.01.05.21249310. doi: 10.1101/2021.01.05.21249310
- 273. World Health Organization. Unpublished data on STOP-COVID-2 trial (NCT04668950). 2021
- 274. Reis G, Moreira Silva EAdS, Medeiros Silva DC, et al. Effect of Early Treatment With Hydroxychloroquine or Lopinavir and Ritonavir on Risk of Hospitalization Among Patients With COVID-19. JAMA Network

 Open 2021;4(4)
- 275. Reis G, dos Santos Moreira-Silva EA, Silva DCM, et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. The Lancet Global Health doi: 10.1016/S2214-109X(21)00448-4
- 276. Ren Z, Luo H, Yu Z, et al. A Randomized, Open-label, Controlled Clinical Trial of Azvudine Tablets in the Treatment of Mild and Common COVID-19, A Pilot Study. *Adv Sci (Weinh)* 2020:2001435. doi: 10.1002/advs.202001435 [published Online First: 20200714]
- 277. Resende GG, da Cruz Lage R, Lobê SQ, et al. Blockade of Interleukin Seventeen (IL-17A) with Secukinumab in Hospitalized COVID-19 patients the BISHOP study. *medRxiv* 2021:2021.07.21.21260963. doi: 10.1101/2021.07.21.21260963
- 278. Rocco PRM, Silva PL, Cruz FF, et al. Early use of nitazoxanide in mild COVID-19 disease: randomised, placebo-controlled trial. Eur Respir J 2021;58(1):2003725. doi: 10.1183/13993003.03725-2020 [published Online First: 20210708]
- 279. Rodrigues C, Freitas-Santos RS, Levi JE, et al. Hydroxychloroquine plus azithromycin early treatment of mild COVID-19 in an outpatient setting: a randomized, double-blinded, placebo-controlled clinical trial evaluating viral clearance. Int J Antimicrob Agents 2021;58(5):106428. doi: 10.1016/j.ijantimicag.2021.106428 [published Online First: 20210825]
- 280. Patricia Rodríguez-Fortúnez, Antonio J. Martínez-Mellado RJ-R, Miguel Blanquer-Blanquer PC-R, et al. Defibrotide in the prevention and treatment of acute respiratory distress syndrome in patients with COVID-19. Preliminary safety results. European Journal of Clinical Pharmacology 2021;77(1):20. doi: 10.1007/s00228-021-03164-3

- 281. Roostaei Firozabad A, Meybodi ZA, Mousavinasab SR, et al. Efficacy and safety of Levamisole treatment in clinical presentations of non-hospitalized patients with COVID-19: a double-blind, randomized, controlled trial. *BMC Infect Dis* 2021;21(1):297. doi: 10.1186/s12879-021-05983-2 [published Online First: 20210324]
- 282. Roozbeh F, Saeedi M, Alizadeh-Navaei R, et al. Sofosbuvir and daclatasvir for the treatment of COVID-19 outpatients: a double-blind, randomized controlled trial. *J Antimicrob Chemother* 2021;76(3):753-57. doi: 10.1093/jac/dkaa501 [published Online First: 2020/12/19]
- 283. Rosas IO, Brau N, Waters M, et al. Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia. *N Engl J Med* 2021;384(16):1503-16. doi: 10.1056/NEJMoa2028700 [published Online First: 20210225]
- 284. Rossignol J-F, Matthew CB, Oaks JB, et al. Early treatment with nitazoxanide prevents worsening of mild and moderate COVID-19 and subsequent hospitalization. *medRxiv* 2021:2021.04.19.21255441. doi: 10.1101/2021.04.19.21255441
- 285. Rutgers AaW, Peter E. and van der Holt, Bronno and Postma, Simone and van Vonderen, Marit G.A. and Piersma, Djura P. and Postma, Douwe and van den Berge, Maarten and Jong, Eefje and de Vries, Marten and van der Burg, Leonie and Huugen, Dennis and van der Poel, Marjolein and Kampschreur, Linda M. and Nijland, Marcel and Strijbos, Jaap H. and Tamminga, Menno and Mutsaers, Pim G. N. J. and Schol-Gelok, Suzanne and Dijkstra-Tiekstra, Margriet and Sidorenkov, Grigory and Vincenten, Julien and van Geffen, Wouter H. and Knoester, Marjolein and Kosterink, Jos and Gans, Reinold and Stegeman, Coen and Huls, Gerwin and van Meerten, Tom, . Timely Administration of Tocilizumab Improves Survival of Hospitalized COVID-19 Patients. . *Available at SSRN:*https://ssrncom/abstract=3834311 or http://dxdoiorg/102139/ssrn3834311 2021
- 286. Ruzhentsova T CP, Khavkina D, et al. . Phase 3 Trial of Coronavir (Favipiravir) in Patients with Mild to Moderate COVID-19. . SSRN2020; doi:102139/ssrn3696907 2020
- 287. Rea-Neto A, Bernardelli RS, Camara BMD, et al. An open-label randomized controlled trial evaluating the efficacy of chloroquine/hydroxychloroquine in severe COVID-19 patients. *Sci Rep* 2021;11(1):9023. doi: 10.1038/s41598-021-88509-9 [published Online First: 20210427]
- 288. Merchante N, Cárcel S, Garrido-Gracia JC, et al. Early Use of Sarilumab in Patients Hospitalised with COVID-19 Pneumonia and Features of Systemic Inflammation. *Antimicrob Agents Chemother* 2021:Aac0210721. doi: 10.1128/aac.02107-21 [published Online First: 2021/12/14]
- 289. Sancho-López A, Caballero-Bermejo AF, Ruiz-Antorán B, et al. Efficacy and Safety of Sarilumab in patients with COVID19 Pneumonia: A Randomized, Phase III Clinical Trial (SARTRE Study). Infect Dis Ther 2021;10(4):2735-48. doi: 10.1007/s40121-021-00543-2 [published Online First: 20211017]
- 290. Sabico S, Enani MA, Sheshah E, et al. Effects of a 2-Week 5000 IU versus 1000 IU Vitamin D3 Supplementation on Recovery of Symptoms in Patients with Mild to Moderate Covid-19: A Randomized Clinical Trial. *Nutrients* 2021;13(7) doi: 10.3390/nu13072170 [published Online First: 20210624]
- 291. Sadeghi A, Ali Asgari A, Norouzi A, et al. Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial. *J Antimicrob Chemother* 2020;75(11):3379-85. doi: 10.1093/jac/dkaa334
- 292. Salama C, Han J, Yau L, et al. Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia. N Engl J Med 2021;384(1):20-30. doi: 10.1056/NEJMoa2030340 [published Online First: 20201217]
- 293. Salehzadeh F PF, Ataei S et al. . The Impact of Colchicine on The COVID-19 Patients; A Clinical Trial Study. 21 September 2020, PREPRINT (Version 1) available at Research Square [+https://doiorg/1021203/rs3rs-69374/v1+] 2020
- 294. Salvarani C, Dolci G, Massari M, et al. Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial. JAMA Intern Med 2021;181(1):24-31. doi: 10.1001/jamainternmed.2020.6615
- 295. Samimagham HR, Hassani Azad M, Haddad M, et al. The Efficacy of Famotidine in improvement of outcomes in Hospitalized COVID-19 Patients: A structured summary of a study protocol for a randomised controlled trial. *Trials* 2020;21(1):848. doi: 10.1186/s13063-020-04773-6 [published Online First: 20201013]
- 296. Santamarina M, Beddings I, Lomakin FM, et al. Sildenafil for the Treatment of Patients With COVID-19 and Perfusion Mismatch on Subtraction Computed Tomography Angiography: A Pilot, Placebo-Controlled Randomised Trial: SSRN, 2021.
- 297. Sayad B, Khodarahmi R, Najafi F, et al. Efficacy and safety of sofosbuvir/velpatasvir versus the standard of care in adults hospitalized with COVID-19: a single-centre, randomized controlled trial. *J Antimicrob Chemother* 2021;76(8):2158-67. doi: 10.1093/jac/dkab152 [published Online First: 2021/05/27]
- 298. Schwartz E. Ivermectin vs. Placebo treatment in non-hospitalized patients with COVID-19 A double blind , randomized controlled
- trial. Private correspondence with study author 2021
- 299. Schwartz I, Boesen ME, Cerchiaro G, et al. Assessing the efficacy and safety of hydroxychloroquine as outpatient treatment of COVID-19: a randomized controlled trial. *CMAJ Open* 2021;9(2):E693-E702. doi: 10.9778/cmajo.20210069 [published Online First: 20210618]

- 300. Sedighiyan M, Abdollahi H, Karimi E, et al. Omega-3 polyunsaturated fatty acids supplementation improve clinical symptoms in patients with covid-19: A randomized clinical trial. . *Authorea January 13, 2021*
- 2021 doi: 10.22541/au.161051252.26168891/v1
- 301. Sekhavati E, Jafari F, SeyedAlinaghi S, et al. Safety and effectiveness of azithromycin in patients with COVID-19: An open-label randomised trial. *Int J Antimicrob Agents* 2020;56(4):106143. doi: 10.1016/j.ijantimicag.2020.106143 [published Online First: 20200825]
- 302. Self WH, Semler MW, Leither LM, et al. Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19: A Randomized Clinical Trial. JAMA 2020;324(21):2165-76.
- 303. Sethi S. Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19 (IMPROVE): US National Library of Medicine ClinicalTrials.gov, 2021.
- 304. Shinkai M, Tsushima K, Tanaka S, et al. Efficacy and Safety of Favipiravir in Moderate COVID-19 Pneumonia Patients without Oxygen Therapy: A Randomized, Phase III Clinical Trial. *Infect Dis Ther* 2021;10(4):2489-509. doi: 10.1007/s40121-021-00517-4 [published Online First: 20210827]
- 305. Sholzberg M, Tang GH, Rahhal H, et al. Heparin for Moderately III Patients with Covid-19. medRxiv 2021 doi: 10.1101/2021.07.08.21259351 [published Online First: 20210712]
- 306. Shrivastava R, Vijay M, Maneby N, et al. Clinical Efficacy of an Osmotic, Antiviral and Anti-Inflammatory Polymeric Nasal Film to Treat Covid-19 Early-Phase Respiratory Symptoms. *Open Access Journal of Clinical Trials* 2021;Volume 13:11-20. doi: 10.2147/oajct.S307144
- 307. Siami Z, Aghajanian S, Mansouri S, et al. Effect of Ammonium Chloride in addition to standard of care in outpatients and hospitalized COVID-19 patients: A randomized clinical trial. *Int J Infect Dis* 2021;108:306-08. doi: 10.1016/j.ijid.2021.04.043 [published Online First: 20210418]
- 308. Sigamani A, Shetty S, Madhavi, et al. Galectin antagonist use in mild cases of SARS-CoV-2: pilot feasibility randomised, open label, controlled trial. *J Vaccines Vaccin* 2020;S10 doi: 10.1101/2020.12.03.20238840
- 309. Silva Borba MG, Almeida Val FF, Sampaio VS, et al. Chloroquine diphosphate in two different dosages as adjunctive therapy of hospitalized patients with severe respiratory syndrome in the context of coronavirus (SARS-CoV-2) infection: Preliminary safety results of a randomized, double-blinded, phase IIb clinical trial (CloroCovid-19 Study). medRxiv 2020:2020.04.07.20056424. doi: 10.1101/2020.04.07.20056424
- 310. Silva M, Espejo A, L Pereyra M, et al. Efficacy of Nitazoxanide in reducing the viral load in COVID-19 patients. Randomized, placebo-controlled, single-blinded, parallel group, pilot study. *medRxiv* 2021:2021.03.03.21252509. doi: 10.1101/2021.03.03.21252509
- 311. Singh D, Bogus M, Moskalenko V, et al. A phase 2 multiple ascending dose study of the inhaled pan-JAK inhibitor nezulcitinib (TD-0903) in severe COVID-19. Eur Respir J 2021;58(4) doi: 10.1183/13993003.00673-2021 [published Online First: 20211014]
- 312. Singh BO, Moirangthem B, Panda PK, et al. Safety and efficacy of antiviral therapy alone or in combination in COVID-19 a randomized controlled trial (SEV COVID Trial). *medRxiv* 2021;2021.06.06.21258091. doi: 10.1101/2021.06.06.21258091
- 313. Sivapalan P, Suppli Ulrik C, Sophie Lapperre T, et al. Azithromycin and hydroxychloroquine in hospitalised patients with confirmed COVID-19-a randomised double-blinded placebo-controlled trial. *Eur Respir J* 2021 doi: 10.1183/13993003.00752-2021 [published Online First: 20210603]
- 314. Sivapalasingam S, Lederer DJ, Bhore R, et al. A Randomized Placebo-Controlled Trial of Sarilumab in Hospitalized Patients with Covid-19. *medRxiv* 2021:2021.05.13.21256973. doi: 10.1101/2021.05.13.21256973
- 315. Skendelas JP, Phan D, Caputo V, et al. Novel CCR5 Antagonist for the Treatment of Mild-Moderate COVID-19 Infection after Lung Transplant. *The Journal of Heart and Lung Transplantation* 2021;40(4) doi: 10.1016/j.healun.2021.01.891
- 316. Skipper CP, Pastick KA, Engen NW, et al. Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19: A Randomized Trial. Ann Intern Med 2020;173(8):623-31. doi: 10.7326/M20-4207 [published Online First: 20200716]
- 317. Sobngwi E, Zemsi S, Guewo-Fokeng M, et al. Doxycycline is a safe alternative to Hydroxychloroquine + Azithromycin to prevent clinical worsening and hospitalization in mild COVID-19 patients: An open label randomized clinical trial (DOXYCOV). medRxiv 2021:2021.07.25.21260838. doi: 10.1101/2021.07.25.21260838
- 318. Soin AS, Kumar K, Choudhary NS, et al. Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial. *Lancet Respir Med* 2021;9(5):511-21. doi: 10.1016/S2213-2600(21)00081-3 [published Online First: 20210304]
- 319. Solanich X, Antoli A, Rocamora-Blanch G, et al. Methylprednisolone Pulses Plus Tacrolimus in Addition to Standard of Care vs. Standard of Care Alone in Patients With Severe COVID-19. A Randomized Controlled Trial. Front Med (Lausanne) 2021;8:691712. doi: 10.3389/fmed.2021.691712 [published Online First: 20210614]

- 320. Solaymani-Dodaran M, Ghanei M, Bagheri M, et al. Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia. *Int Immunopharmacol* 2021;95:107522. doi: 10.1016/j.intimp.2021.107522 [published Online First: 20210311]
- 321. Song J-Y, Yoon J-G, Seo Y-B, et al. Ciclesonide Inhaler Treatment for Mild-to-Moderate COVID-19: A Randomized, Open-Label, Phase 2 Trial. J Clin Med 2021;10(16):3545. doi: 10.3390/jcm10163545
- 322. Song N-J, Allen C, Vilgelm AE, et al. IMMUNOLOGICAL INSIGHTS INTO THE THERAPEUTIC ROLES OF CD24Fc AGAINST SEVERE COVID-19. medRxiv: the preprint server for health sciences 2021:2021.08.18.21262258. doi: 10.1101/2021.08.18.21262258
- 323. Spinner CD, Gottlieb RL, Criner GJ, et al. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. *JAMA* 2020;324(11):1048-57. doi: 10.1001/jama.2020.16349
- 324. Spyropoulos AC, Goldin M, Giannis D, et al. Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial. JAMA Intern Med 2021;181(12):1612-20. doi: 10.1001/jamainternmed.2021.6203
- 325. W. H. O. Rapid Evidence Appraisal for COVID-19 Therapies Working Group, Sterne JAC, Murthy S, et al. Association Between Administration of Systemic Corticosteroids and Mortality Among Critically III Patients With COVID-19: A Meta-analysis. *JAMA* 2020;324(13):1330-41. doi: 10.1001/jama.2020.17023
- 326. Stone JH, Frigault MJ, Serling-Boyd NJ, et al. Efficacy of Tocilizumab in Patients Hospitalized with Covid-19. *N Engl J Med* 2020;383(24):2333-44. doi: 10.1056/NEJMoa2028836 [published Online First: 20201021]
- 327. Strich JR, Tian X, Samour M, et al. Fostamatinib for the treatment of hospitalized adults with COVD-19 A randomized trial. Clin Infect Dis 2021 doi: 10.1093/cid/ciab732 [published Online First: 20210901]
- 328. Sun X, Zhang R, Li Y, et al. Clinical value of prophylactic liver protecting drugs in coronavirus disease 2019 (COVID-19). . J Xuzhou Med Univ 2020;40(4):293-96.
- 329. Taher A, Lashgari M, Sedighi L, et al. A pilot study on intravenous N-Acetylcysteine treatment in patients with mild-to-moderate COVID19-associated acute respiratory distress syndrome. *Pharmacol Rep* 2021;73(6):1650-59. doi: 10.1007/s43440-021-00296-2 [published Online First: 20210610]
- 330. Tahmasebi S, El-Esawi MA, Mahmoud ZH, et al. Immunomodulatory effects of nanocurcumin on Th17 cell responses in mild and severe COVID-19 patients. *J Cell Physiol* 2021;236(7):5325-38. doi: 10.1002/jcp.30233 [published Online First: 20201228]
- 331. Mona T, Maryam A, Mahdi M, et al. Research Square 2022 doi: 10.21203/rs.3.rs-463921/v1
- 332. Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. *BMJ* 2020;369:m1849. doi: 10.1136/bmj.m1849 [published Online First: 20200514]
- 333. Tang X, Feng YM, Ni JX, et al. Early Use of Corticosteroid May Prolong SARS-CoV-2 Shedding in Non-Intensive Care Unit Patients with COVID-19 Pneumonia: A Multicenter, Single-Blind, Randomized Control Trial. Respiration 2021;100(2):116-26. doi: 10.1159/000512063 [published Online First: 20210122]
- 334. Tardif JC, Bouabdallaoui N, L'Allier PL, et al. Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial. *Lancet Respir Med* 2021;9(8):924-32. doi: 10.1016/S2213-2600(21)00222-8 [published Online First: 20210527]
- 335. Temesgen Z, Burger CD, Baker J, et al. Lenzilumab Efficacy and Safety in Newly Hospitalized Covid-19 Subjects: Results from the Live-Air Phase 3 Randomized Double-Blind Placebo-Controlled Trial. medRxiv 2021:2021.05.01.21256470. doi: 10.1101/2021.05.01.21256470 [published Online First: 20210505]
- 336. Thakar A, Panda S, Sakthivel P, et al. Chloroquine nasal drops in asymptomatic & mild COVID-19: An exploratory randomized clinical trial. *Indian J Med Res* 2021 doi: 10.4103/ijmr.IJMR_3665_20 [published Online First: 20210121]
- 337. group C-C. Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial. *Lancet Respir Med* 2021;9(3):295-304. doi: 10.1016/S2213-2600(20)30556-7 [published Online First: 20210122]
- 338. Zarychanski R. Therapeutic Anticoagulation in Critically III Patients with Covid-19 Preliminary Report. medRxiv 2021:2021.03.10.21252749. doi: 10.1101/2021.03.10.21252749
- 339. Thomas S, Patel D, Bittel B, et al. Effect of High-Dose Zinc and Ascorbic Acid Supplementation vs Usual Care on Symptom Length and Reduction Among Ambulatory Patients With SARS-CoV-2 Infection: The COVID A to Z Randomized Clinical Trial. JAMA Netw Open 2021;4(2):e210369. doi: 10.1001/jamanetworkopen.2021.0369 [published Online First: 20210201]
- 340. Tolouian R, Mulla ZD, Jamaati H, et al. Effect of bromhexine in hospitalized patients with COVID-19. J Investig Med 2021 doi: 10.1136/jim-2020-001747 [published Online First: 20210315]
- 341. Tomazini BM, Maia IS, Cavalcanti AB, et al. Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial. JAMA 2020;324(13):1307-16. doi: 10.1001/jama.2020.17021
- 342. Tornling G, Batta R, Porter J, et al. The angiotensin type 2 receptor agonist C21 restores respiratory function in COVID19 a double-blind, randomized, placebo-controlled Phase 2 trial. *medRxiv* 2021:2021.01.26.21250511. doi: 10.1101/2021.01.26.21250511


- 343. Trieu V, Saund S, Rahate PV, et al. Targeting TGF-β pathway with COVID-19 Drug Candidate ARTIVeda/PulmoHeal Accelerates Recovery from Mild-Moderate COVID-19. *medRxiv* 2021:2021.01.24.21250418. doi: 10.1101/2021.01.24.21250418
- 344. Udwadia ZF, Singh P, Barkate H, et al. Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial. *Int J Infect Dis* 2021;103:62-71. doi: 10.1016/j.ijid.2020.11.142 [published Online First: 20201116]
- 345. Ulrich RJ, Troxel AB, Carmody E, et al. Treating COVID-19 With Hydroxychloroquine (TEACH): A Multicenter, Double-Blind Randomized Controlled Trial in Hospitalized Patients. *Open Forum Infect Dis* 2020;7(10):ofaa446. doi: 10.1093/ofid/ofaa446 [published Online First: 20200923]
- 346. Vaira LA, Hopkins C, Petrocelli M, et al. Efficacy of corticosteroid therapy in the treatment of long- lasting olfactory disorders in COVID-19 patients. *Rhinology* 2021;59(1):21-25. doi: 10.4193/Rhin20.515 [published Online First: 2020/12/09]
- 347. Valizadeh H, Abdolmohammadi-Vahid S, Danshina S, et al. Nano-curcumin therapy, a promising method in modulating inflammatory cytokines in COVID-19 patients. *Int Immunopharmacol* 2020;89(Pt B):107088. doi: 10.1016/j.intimp.2020.107088 [published Online First: 20201020]
- 348. Vallejos J, Zoni R, Bangher M, et al. Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19) a randomized, double-blind, placebo-controlled trial. *BMC Infect Dis* 2021;21(1):635. doi: 10.1186/s12879-021-06348-5 [published Online First: 20210702]
- 349. Veiga VC, Prats J, Farias DLC, et al. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. *BMJ* 2021;372:n84. doi: 10.1136/bmj.n84 [published Online First: 20210120]
- 350. Vlaar APJ, de Bruin S, Busch M, et al. Anti-C5a Antibody (IFX-1) Treatment of Severe COVID-19: An Exploratory Phase 2 Randomized Controlled Trial. . *Available at SSRN:* https://dxdoiorg/102139/ssrn3658226 2020
- 351. World Health Organization. Unpublished data on Vyas molnupiravir trial (CTRI/2021/08/035424), 2021.
- 352. Wanaratna K, Leethong P, Inchai N, et al. Efficacy and safety of Andrographis paniculata extract in patients with mild COVID-19: A randomized controlled trial. *medRxiv* 2021:2021.07.08.21259912. doi: 10.1101/2021.07.08.21259912
- 353. Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. *Lancet* 2020;395(10236):1569-78. doi: 10.1016/S0140-6736(20)31022-9 [published Online First: 20200429]
- 354. WANG Yali YX, LIU Yongping, ZHANG Jian, FENG Yifan,, SHANG Lei ZK, CHENG Zhijian, HE Xijing. Preliminary clinical effect analysis of the treatment of novel coronavirus pneumonia by internal administration of traditional Chinese medicine plus fumigation and absorption combined with super dose of vitamin C in treating NOVID-19. *Journal of Xi'an Jiaotong University* (Medical Sciences) 2020
- 355. Wang S-Z WH-J, Chen H-M, et al. . Lianhua Qingwen capsule and interferon-α combined with lopinavir /ritonavir for the treatment of 30 COVID-19 patients. B Bengbu Med Coll 2020;45(2):154-55.
- 356. Wang D, Fu B, Peng Z, et al. Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial. Front Med 2021;15(3):486-94. doi: 10.1007/s11684-020-0824-3 [published Online First: 20210309]
- 357. Wang M, Zhao Y, Hu W, et al. Treatment of Coronavirus Disease 2019 Patients With Prolonged Postsymptomatic Viral Shedding With Leflunomide: A Single-center Randomized Controlled Clinical Trial. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 2021;73(11):e4012-e19. doi: 10.1093/cid/ciaa1417
- 358. Bemcentinib, an oral AXL kinase inhibitor, results in lower mortality compared to standard of care (steroids with or without remdesivir) in hospitalised patients with COVID-19. Two randomised phase 2 studies: BGBC020 and ACCORD2. 31st European Congress of Clinical Microbiology and Infectious Diseases; 2021 July 12, 2021; Online.
- 359. Winchester S, John S, Jabbar K, et al. Clinical efficacy of nitric oxide nasal spray (NONS) for the treatment of mild COVID-19 infection. J Infect 2021;83(2):237-79. doi: 10.1016/j.jinf.2021.05.009 [published Online First: 20210513]
- 360. Winthrop KL, Skolnick AW, Rafiq AM, et al. Opaganib in COVID-19 pneumonia: Results of a randomized, placebo-controlled Phase 2a trial. *medRxiv* 2021:2021.08.23.21262464. doi: 10.1101/2021.08.23.21262464
- 361. Wu X, Yu K, Wang Y, et al. Efficacy and Safety of Triazavirin Therapy for Coronavirus Disease 2019: A Pilot Randomized Controlled Trial. *Engineering (Beijing)* 2020;6(10):1185-91. doi: 10.1016/j.eng.2020.08.011 [published Online First: 20200908]
- 362. Yadegarinia D, Tehrani S, Abolghasemi S, et al. Evaluation of the Efficacy of Arbidol in Comparison with the Standard Treatment Regimen of Hospitalized Patients with Covid-19: A Randomized Clinical Trial.

 Archives of Clinical Infectious Diseases 2020;15(5):e106622. doi: 10.5812/archcid.106622
- 363. Yadollahzadeh M, Eskandari M, Roham M, et al. Evaluation of Sovodak (Sofosbuvir/Daclatasvir Treatment Outcome in COVID-19 Patient's Compared with Kaletra (Lopinavir/ritonavir): a Randomized Clinical Trial. Research Square 2021 doi: 10.21203/rs.3.rs-257762/v1

- 364. Yaghoubian H, Niktale H, Yazdi AP, et al. Evaluate the Therapeutic Effect of Allicin (L-cysteine) on Clinical Presentation and Prognosis in Patients with COVID-19. Eur J Transl Myol 2021;31(2) doi: 10.4081/ejtm.2021.9518 [published Online First: 20210618]
- 365. Yakoot M, Eysa B, Gouda E, et al. Efficacy and Safety of Sofosbuvir/Daclatasvir in the Treatment of COVID-19: A Randomized, Controlled Study. SSRN Electronic Journal 2020
- 366. Vityala Y, Tugolbai T, Melis Sholpanbai U, et al. Efficacy of umifenovir in the treatment of mild and moderate COVID-19 patients. *International Journal of Research in Pharmaceutical Sciences* 2020;11(SPL1):506-09. doi: 10.26452/ijrps.v11iSPL1.2839
- 367. Yildiz E, Koca Yildiz S, Kuzu S, et al. Comparison of the Healing Effect of Nasal Saline Irrigation with Triamcinolone Acetonide Versus Nasal Saline Irrigation alone in COVID-19 Related Olfactory Dysfunction:

 A Randomized Controlled Study. *Indian J Otolaryngol Head Neck Surg* 2021:1-6. doi: 10.1007/s12070-021-02749-9 [published Online First: 20210710]
- 368. Yogesh A. Dound MSSSDB. Efficacy and Tolerability of Curmune Formulation in the Management of COVID-19: A Randomised Comparative Clinical Study. The Indian Practitioner 2021;74(3)
- 369. Youssef J, Lee R, Javitt J, et al. Effectiveness of ZYESAMI™ (Aviptadil) in accelerating recovery and shortening hospitalization in critically-ill patients with COVID-19 Respiratory Failure: interim report from a phase 2b/3 multicenter trial: SSRN, 2021.
- 370. Yu LM, Bafadhel M, Dorward J, et al. Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. *Lancet* 2021;398(10303):843-55. doi: 10.1016/s0140-6736(21)01744-x [published Online First: 20210810]
- 371. Yuan X, Yi W, Liu B, et al. Pulmonary radiological change of COVID-19 patients with 99mTc-MDP treatment. medRxiv 2020:2020.04.07.20054767. doi: 10.1101/2020.04.07.20054767
- 372. Zarehoseinzade E, Allami A, Ahmadi M, et al. Finasteride in hospitalized adult males with COVID-19: A risk factor for severity of the disease or an adjunct treatment: A randomized controlled clinical trial.

 Med J Islam Repub Iran 2021;35:30. doi: 10.47176/mjiri.35.30 [published Online First: 20210303]
- 373. Zhang J, Rao X, Li Y, et al. Pilot trial of high-dose vitamin C in critically ill COVID-19 patients. Ann Intensive Care 2021;11(1):5. doi: 10.1186/s13613-020-00792-3 [published Online First: 20210109]
- 374. Zhang BY, Chen M, Chen XC, et al. Berberine reduces circulating inflammatory mediators in patients with severe COVID-19. Br J Surg 2021;108(1):e9-e11. doi: 10.1093/bjs/znaa021
- 375. Zhang XY, Lv L, Zhou YL, et al. Efficacy and safety of Xiyanping injection in the treatment of COVID-19: A multicenter, prospective, open-label and randomized controlled trial. *Phytother Res* 2021;35(8):4401-10. doi: 10.1002/ptr.7141 [published Online First: 20210512]
- 376. Zhao H, Zhu Q, Zhang C, et al. Tocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample size. *Biomed Pharmacother* 2021;133:110825. doi: 10.1016/j.biopha.2020.110825 [published Online First: 20200930]
- 377. Zhao H, Zhang C, Zhu Q, et al. Favipiravir in the treatment of patients with SARS-CoV-2 RNA recurrent positive after discharge: A multicenter, open-label, randomized trial. *Int Immunopharmacol* 2021;97:107702. doi: 10.1016/j.intimp.2021.107702 [published Online First: 20210421]
- 378. Zheng W, G J. Clinical Observation of Tanshinone II A Sulfonate in the Treatment of New Coronary Pneumonia. Digest of the world's latest medical information 2020 2020
- 379. Zheng F, Zhou Y, Zhou Z, et al. SARS-CoV-2 clearance in COVID-19 patients with Novaferon treatment: A randomized, open-label, parallel-group trial. *Int J Infect Dis* 2020;99:84-91. doi: 10.1016/j.ijid.2020.07.053 [published Online First: 20200803]
- 380. Zhong M, Sun A, Xiao T, et al. A Randomized, Single-blind, Group sequential, Active-controlled Study to evaluate the clinical efficacy and safety of α-Lipoic acid for critically ill patients with coronavirus disease 2019 (COVID-19) . *medRxiv* 2020 doi: 10.1101/2020.04.15.20066266
- 381. ZHOU Waimin1 ZF, LI Banglong, TIAN Zhongqiu1. Clinical Value of Diammonium Glycyrrhizinate in Treatment of COVID-19. Chinese Journal of Virology 2020;36(2)
- 382. Zhuravel SV, Khmelnitskiy OK, Burlaka OO, et al. Nafamostat in hospitalized patients with moderate to severe COVID-19 pneumonia: a randomised Phase II clinical trial. *EClinicalMedicine* 2021;41:101169. doi: 10.1016/j.eclinm.2021.101169 [published Online First: 20211027]
- 383. de Alencar JCG, Moreira CL, Muller AD, et al. Double-blind, Randomized, Placebo-controlled Trial With N-acetylcysteine for Treatment of Severe Acute Respiratory Syndrome Caused by Coronavirus Disease 2019 (COVID-19). Clin Infect Dis 2021;72(11):e736-e41. doi: 10.1093/cid/ciaa1443



Mortality (1/3)

ARCHITECTS_NCT04412772_/Beigel		Chahla	Ely
ARCHITECTS_NCT04412772_I Bhushan Chen_2		Chen_2	Ezer
Abbass	Bikdeli	Chen_3	Farnoosh
Abd-Elsalam_1	Blum	Chen_4	Fischer
Abd-Elsalam_3	Bosaeed	Chen_5	Fisher_1
Abd-Elsalam_4	Brown	Cheng	Furtado
Ader_1	Butler	Clemency	Gait?n-Duarte
Ader_2	CORIMUNO-SARI-1_NCT04324073_A	Cohen	Galan
Alamdari	CORIMUNO-SARI-1_NCT04324073_B	Connors	Geriak
Alavi-Moghaddam	CORIMUNO-SARI-ICU_NCT04324073_	_/ Corral-Gudino	Ghanei
Aman	CORIMUNO-SARI-ICU_NCT04324073_	_E Cremer1	Ghati
Amaravadi	CORIMUNO-TOCI-ICU_NCT04331808_	/Cremer_2	Gonzalez
Ananworanich	CORIMUNO-TOCI-ICU_NCT04331808_	_l Criner	Gonzalez Ochoa
Angus	COV-AID_NCT04330638_A	Darazam_2	Gordon_1_A
Arabi	COV-AID_NCT04330638_B	Darazam_3	Gordon_1_B
Axfors_ChiCTR2000031204	COVIDOSE2-SSA_NCT04479358_A	Davoudi-Monfare	e(Gordon_1_C
Axfors_NCT04323527	COVIDOSE2-SSA_NCT04479358_B	Deftereos	Gordon_1_D
Axfors_NCT04333654	COVIDSTORM_NCT04577534_A	Delgado-Enciso	Gottlieb
Axfors_NCT04335552	COVIDSTORM_NCT04577534_B	Dequin	Guimar?es
Axfors_NCT04338698	COVITOZ_NCT04435717_A	Doaei	Gunst
Axfors_NCT04340544	COVITOZ_NCT04435717_B	Dorward	Gutiérrez-Castrell?n
Axfors_NCT04342221	Cadegiani_2	Duarte	HMO-020-0224_NCT04377750
Axfors_NCT04342650	Cadegiani_4	Dubee	HMO-020-0224_NCT04377750_
Axfors_NCT04345289	Cadegiani_5	EPIC-HR	Hamed
Axfors_NCT04345692	Cao_1	Edalatifard	Hamidi-Alamdari
Axfors_NL8490	Cao_2	Eid	Hasan
Babalola	Caricchio	El-Bendary	Hermine_A
Balykova_1	Castillo	Elamir	Hermine_B
Bauer	Cavalcanti	Elgohary	Hermine_toci

Mortality (2/3)

Hernandez-Cardenas	Lakkireddy	Pan_hydroxychloroquine	SARCOVID_NCT04357808_A
Hinks	Lawler	Pan_interferon	SARCOVID_NCT04357808_B
Horby_1	Lemos	Pan_lopinavir	SARICOR_EudraCT2020-001531-27
Horby_2	Lenze	Pan_remdesivir	SARICOR_EudraCT2020-001531-27_
Horby_3	Lescure	Pandit	SARTRE_EudraCT2020-002037-15_A
Horby_4	Li	Parienti	SARTRE_EudraCT2020-002037-15_B
Horby_5_A	Lomakin	Pascual-Figal	Sadeghi
Horby_5_B	Lopes_1	Patel_2	Salama_A
Horby_6	Lopes_2	Perepu	Salama_B
Horby_7	Lopes_3	Puskarich	Salehzadeh
ImmCoVA_NCT04412291_	_ Lopez-Medina	Puskarich_2	Salvarani
ImmCoVA_NCT04412291_	_ Lou	REMDACTA_NCT04409262_	_≀Sayad
Ivashchenko	Lyngbakken	REMDACTA_NCT04409262_	_ISchwartz_2
Ivashkin	MOVe-OUT (MK4482-002)	RUXCOVID	Sekhavati
Jamaati	Maghbooli	Rahmani	Self
JamaliMoghadamSiahkali	Mahajan	Ramachandran	Shinkai
Jeronimo	Mahmud	Rashad_2	Sholzberg
Johnston	Marconi	Rashad_3	Silva
Kalil	Marcos	Ravikirti	Sivapalan
Kalil_2	Mobarak	Reis_1	Sivapalasingam_P2_A
Khodashahi	Mohan	Reis_2	Sivapalasingam_P2_B
Khoo	Munch_1	Rocco	Sivapalasingam_P3_C1_A
Kosiborod	Murai	Rodrigues	Sivapalasingam_P3_C1_B
Kosmopoulos	Niaee	Rosas_A	Sivapalasingam_P3_C2_Critical
Krishnan	Nourian	Rosas_B	Sivapalasingam_P3_C3_Critical
Krolewiecki	Oldenburg	Rossignol	Skipper
Kumar	Oliynyk	Rutgers_A	Soin
Kumari	Omrani	Rutgers_B	Solaymani-Dodaran
Kyriazopoulou	PRINCIPLE Trial Collaborative Grou	ı Réa?Neto	Song

Mortality (3/3)

SpinnerYoussefSpyropoulosZhang_1Sterne_NCT04244591Zhao_2Sterne_NCT04325061ZhuravelStone_Ade Alencar

Stone_B Strich

TOCOVID_EudraCT2020-001442-19

Taher

Talaschian

Tang_1

Tang_2
Tardif

Temesgen

The CORIMUNO-19 Collaborative group

The REMAP-CAP, ACTIV-4a, and ATTACC Investigators

Thomas

Tomazini

Udwadia

Ulrich

Vallejos

Veiga_A

Veiga_B

Vyas

Wang_1

Yadegarinia

Yadollahzadeh

Yakoot

Yethindra

Mechanical ventilation

Abbass	Cremer_2	Horby_3	Oliynyk	Soin
Abd-Elsalam_1	Dabbous_2	Horby_4	PRINCIPLE Trial Collaborative Grou	Solaymani-Dodaran
Abd-Elsalam_3	Darazam_2	Horby_5	Pan_hydroxychloroquine	Spinner
Abd-Elsalam_4	Davoodi_2	Horby_6	Pan_interferon	Spyropoulos
Ader_1	Davoudi-Monfare	Horby_7	Pan_lopinavir	Stone
Ader_2	Deftereos	Ivashchenko	Pan_remdesivir	Strich
Ahmed	Dequin	Jamaati	Pandit	Taher
Alavi-Moghaddam	Dorward	JamaliMoghadamSiahka	Pascual-Figal	Talaschian
Aman	Duarte	Jeronimo	Pott-Junior	Tang_2
Ananworanich	Dubee	Kalil	Puskarich	Tardif
Angus	Edalatifard	Kalil_2	Puskarich_2	The CORIMUNO-19 C
Arabi	El-Bendary	Kosiborod	RUXCOVID	Tomazini
Balykova_1	Fisher_1	Krolewiecki	Rahmani	Udwadia
Bauer	Furtado	Kumari	Ravikirti	Ulrich
Beigel	Gait?n-Duarte	Kyriazopoulou	Rosas_A	Vallejos
Bhushan	Galan	Lescure	Rosas_B	Veiga
Bosaeed	Geriak	Lomakin	Rutgers	Vyas
Brown	Ghanei	Lopes_1	Ruzhentsova	Wang_1
Butler	Ghati	Lopes_3	Réa?Neto	Yakoot
Cadegiani_2	Gonzalez Ochoa	Lopez-Medina	Sadeghi	Yu
Cadegiani_4	Gordon_1	Lou	Salama	Zhang_1
Cadegiani_5	Guimar?es	Lyngbakken	Salvarani	de Alencar
Cao_1	Gunst	Maghbooli	Sayad	Reis_2
Cao_2	Hamed	Mahajan	Schwartz_2	Lenze
Caricchio	Hermine	Marconi	Sekhavati	
Cavalcanti	Hermine_toci	Mobarak	Self	
Cheng	Hinks	Mohan	Shinkai	
Cohen	Horby_1	Murai	Sholzberg	
Corral-Gudino	Horby_2	Nourian	Sivapalan	

Spinner Spyropoulos Stone Strich Taher Talaschian Tang_2 Tardif The CORIMUNO-19 Collaborative group Tomazini Udwadia Ulrich

Adverse events

Darazam 3

Ader_1 EPIC-HR Mahajan Sivapalasingam_P3_C3_Critical

de Alencar

Elgohary Aman Mahmud Song Strich Ananworanich Ely Marconi Babalola Fischer Taher Mobarak Gait?n-Duarte Babalola 2 Talaschian Nourian

Balykova 2 Geriak Omrani Tang 1 Udwadia Ghati Barratt-Due Parienti Beigel Vallejos Gonzalez Ochoa Pascual-Figal Blum Gottlieb Pott-Junior Vyas Brown Guimar?es Purwati Wang 1

Buonfrate Gunst RUXCOVID Yakoot
Byakika-Kibwika Gutiérrez-Castrell?n Rastogi Zhuravel

Cadegiani 3 Hernandez-Cardenas Ravichandran Cadegiani 4 Ivashchenko Reis 1 Caricchio Johnston Rocco Castillo Kalil 2 Rosas Chahla Kasiri Rossignol Chen 3 Khodashahi Ruzhentsova Chen 4 Réa?Neto Khoo Clemency Kosiborod Salama Cohen Sayad Krishnan Criner Krolewiecki Schwartz 2 Darazam 2 Sekhavati Kumar

Davoudi-Monfare Lakkireddy Silva
Deftereos Li Sivapalan

Kyriazopoulou

Delgado-Enciso Lopes_2 Sivapalasingam_P2
Duarte Lopez-Medina Sivapalasingam P3 C1

Dubee MOVe-OUT (MK4482-002 Sivapalasingam P3 C2 Critical

Shinkai

Admission to hospital

Amaravadi STOP-COVID-2 Bikdeli

Ananworanich Schwartz_2 Connors
Cadegiani 2 Shrivastava Gonzalez Ochoa

VTE

Lawler

Lemos

Lopes 3

Marcos

Perepu Sholzberg

Spyropoulos

Cadegiani_4 Skipper
Clemency Tardif
Connors Vallejos
Delgado-Enciso Vyas

EPIC-HR Ezer Fischer

Gonzalez Ochoa

Gottlieb

Gutiérrez-Castrell?n

Hinks Johnston Kasiri

Krishnan Kumar

Lenze

Lopez-Medina

MOVe-OUT (MK4482-002)

Oldenburg Omrani

PRINCIPLE Trial Collaborative Group

Reis_1

Reis_2

Rocco

Rodrigues

Rossignol

Bleeding

Ananworanich

Bikdeli Connors

Gonzalez Ochoa

Lawler
Lemos
Lopes_3
Marcos
Oliynyk
Perepu

The REMAP-CAP, ACTIV-4a, and ATTAC(Sholzberg

Spyropoulos

The REMAP-CAP, ACTIV-4a, and ATTACC

Length of hospitalization

Davoodi 2 Abd-Elsalam 1 Rahmani Jeronimo Abd-Elsalam 3 Davoudi-Monfared Johnston Rosas Abd-Elsalam 4 Deftereos Kalil Rutgers Kalil 2 Réa?Neto Ader 1 Dorward Khodashahi Ader 2 Sadeghi Duarte Ahmed Elamir Kumari Salama Elgohary Kyriazopoulou Alamdari Salehzadeh Alavi-Moghaddam Lakkireddy Elv Salvarani Aman Furtado Lemos Sayad **Angus** Gait?n-Duarte Lescure Sekhavati Arabi Geriak Lomakin Sivapalan Bauer Ghati Lopes 1 Solaymani-Dodaran Beigel Gonzalez Lopes 2 Spinner Bhushan Gordon 1 Lopes 3 Stone Bosaeed Guimar?es Lyngbakken Taher Butler Gunst Marconi Tang 2 Cao 1 Hamed Mobarak Udwadia Cao 2 Hamidi-Alamdari Murai Ulrich Caricchio Veiga Hernandez-Cardenas Niaee Cavalcanti Hinks Nourian Wang 1 Horby 1 Pan hydroxychloroquin Wang 4 Chen 4 Pan interferon Cheng Horby 2 Yadegarinia Cohen Horby 3 Pan lopinavir Yadollahzadeh Horby 4 Pan remdesivir Corral-Gudino Zhang 1 Cremer 2 Horby 6 Zhuravel Pandit Dabbous 1 Horby 7 Pascual-Figal de Alencar Dabbous 2 Patel 2 Huang 1 Darazam 2 Jamaati Puskarich 2 Darazam 3 Jamali Moghadam Siahkal RUXCOVID

Time to symptom resolution

Duration of ventilation

Abd-Elsalam_1	Eid	Ruzhentsova ARCHITECTS_NCT04412772_A
Ader_1	Elgohary	Sadeghi Beigel

Ader_2Fisher_1SalamaCORIMUNO-SARI-ICU_NCT04324073Alavi-MoghaddamGunstSayadCORIMUNO-TOCI-ICU_NCT04331808_AAmaravadiGutiérrez-Castrell?nSchwartz 2CORIMUNO-TOCI-ICU_NCT04331808_B

Balykova_1Huang_1SelfCOV-AID_NCT04330638_ABeigelIvashchenkoSoinCOV-AID_NCT04330638_B

Bhushan Johnston Solaymani-D Davoudi-Monfared

Bosaeed Kalil Spinner Ely

Brown Kalil_2 Stone Gordon_1_A Butler Krishnan Talaschian Gordon_1_B

Byakika-Kibwika Kumar Tang_1 HMO-020-0224_NCT04377750_A

Cadegiani_3KumariTemesgenHamedCao_1LescureThomasHorby_5_ACao_2Lopez-MedinaUdwadiaHorby_5_BCaricchioLouVyasKalil

Caricchio Vyas Chahla Mahmud Wang 1 Kalil 2 Chen 1 Marconi Wang 4 Lopes 3 Chen 2 Mahajan Mohan Yakoot Chen 3 Rosas A Nourian Yethindra Chen 4 PRINCIPLE Trial Collaborative Grou Yu Rosas B Cheng Patel 2 Zhuravel Rutgers Clemency **RUXCOVID** Soin Cremer 1 Rahmani Stone

ClemencyRUXCOVIDSoinCremer_1RahmaniStoneCremer_2RamakrishnanTomaziniDarazam_2Rashad_1Veiga_ADarazam_3Rashad_3Veiga_BDavoudi-MonfaredRosasWang_1

Delgado-Enciso Rossignol

Description of studies excluded at full text stage

Description of studies excluded at full text screening stage (n=591)

This table does not list prophylaxis or antiviral antibody and cellular treatment studies, which are included in separate published network meta-analyses. References available upon request.

Study	Title	Reason for exclusion
Liu 2020	Effects of progressive muscle relaxation on anxiety and sleep quality in patients with COVID-19	Exercise/rehabilitation
Liu 2020		Exercise/renabilitation
Villar 2020	Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial	Wrong population
		01 1
	Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha and ribavirin plus lopinavir/ritonavir plus	Randomized trial with no
Zeng 2020	interferon-alphain in patients with mild to moderate novel coronavirus pneumonia	results (e.g. trial registry)
Bian 2020	Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial	Not a randomized trial
Biail 2020		Not a randomized that
Gautret 2020	Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open- label non-randomized clinical trial	Not a randomized trial
	Hydroxychloroquine and Azithromycin as a treatment of COVID-19: preliminary	
Gautret 2020	results of an open-label non-randomized clinical trial	Not a randomized trial
Cai 2020	Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study	Not a randomized trial
	Analysis of the value of traditional Chinese medicine Shufeng Jiedu Capsules	
Xiao Qi 2020	combined with Arbidol in the treatment of mild new coronavirus pneumonia	Not a randomized trial
Liu 2020	Respiratory rehabilitation in elderly patients with COVID-19: A randomized controlled study	Not a randomized trial
Liu 2020	•	
Azhar 2020	Hydroxychloroquine, Oseltamivir and Azithromycin for the Treatment of COVID-19 Infection: An RCT	Randomized trial with no results (e.g. trial registry)
Carr 2020	A new clinical trial to test high-dose vitamin C in patients with COVID-19	Not a randomized trial
	No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for	
Mahevas 2020	COVID-19 infection with oxygen requirement: results of a study using routinely collected data to emulate a target trial	Not a randomized trial
	Effect of regular intravenous immunoglobulin therapy on prognosis of severe	
Xie 2020	pneumonia in patients with COVID-19	Not a randomized trial
Zhu 2020	Arbidol Monotherapy is Superior to Lopinavir/ritonavir in Treating COVID-19	Not a randomized trial
	Guideline-based Chinese herbal medicine treatment plus standard care for severe	Traditional Chinese or
Ye 2020	coronavirus disease 2019 (G-CHAMPS): evidence from China	alternative medicine
Mong 2020	An experimental trial of recombinant human interferon alpha nasal drops to prevent	Not a randomized trial
Meng 2020	coronavirus disease 2019 in medical staff in an epidemic area	Not a randomized trial
Alabama 2020	Trial of Hydroxychloroquine In Covid-19 Kinetics	Randomized trial with no results (e.g. trial registry)
Zha 2020	Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19)	Not a randomized trial
Ye 2020	Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease 2019	Not a randomized trial
Zhou 2020	Interferon-a2b treatment for COVID-19	Not a randomized trial
		Randomized trial with no
Biosciences 2020	Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19	results (e.g. trial registry)
Branch-Elliman 2020	Sarilumab for Patients With Moderate COVID-19 Disease: A Randomized Controlled Trial With a Play-The-Winner Design	Randomized trial with no results (e.g. trial registry)
Cantini 2020	Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact	Not a randomized trial
		Randomized trial with no
Castello 2020	Pilot Study on Cytokine Filtration in COVID-19 ARDS	results (e.g. trial registry)

Center 2020	Hyperbaric Oxygen Therapy Effect in COVID-19 RCT (HBOTCOVID19)	Randomized trial with no results (e.g. trial registry)
Center 2020	Plasma Collection From Convalescent and/or Immunized Donors for the Treatment of COVID-19	Randomized trial with no results (e.g. trial registry)
Center 2020	Ruxolitinib for Treatment of Covid-19 Induced Lung Injury ARDS	Randomized trial with no results (e.g. trial registry)
Center 2020	COVID-19 Patient Positioning Pragmatic Trial	Randomized trial with no results (e.g. trial registry)
Colombia 2020	Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia	Randomized trial with no results (e.g. trial registry)
Karaahmet 2020	Potential effect of natural and anabolizan steroids in elderly patient with COVID-19	Not a randomized trial
LabibSalem 2020	The possible beneficial adjuvant effect of Influenza vaccine to minimize the severity of COVID-19	Not a randomized trial
Lenkens 2020	[Medication and comedication in COVID-19 patients]	Not a randomized trial
Diurno 2020	Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience	Not a randomized trial
Mohammadzadeh 2020	Effectiveness of electronic health care and drug monitoring program to prevent COVID-19 and adherence to therapeutic regimen in patients with ischemic heart disease - A pilot study	Others
Schumacher 2020	The impact of respiratory protective equipment on difficult airway management: a randomised, crossover, simulation study	Wrong population
Plaze 2020	Repurposing of chlorpromazine in COVID-19 treatment: the reCoVery study	Randomized trial with no results (e.g. trial registry)
Ankrum 2020	Can cell therapies halt cytokine storm in severe COVID-19 patients?	Not a randomized trial
Toniati 2020	Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy	Not a randomized trial
Havlichek 2020	A Trial of Lopinavir-Ritonavir in Covid-19	Not a randomized trial
Hong 2020	Celebrex adjuvant therapy on COVID-19: An experimental study	Not a randomized trial
Liu 2020	[Significance and operation mode of moxibustion intervention for the group under quarantine after close contact with COVID-19]	Exercise/rehabilitation
Hu 2020	Efficacy and Safety of Lianhuaqingwen Capsules, a repurposed Chinese Herb, in Patients with Coronavirus disease 2019: A multicenter, prospective, randomized controlled trial	Traditional Chinese or alternative medicine
Plaze 2020	[Repurposing chlorpromazine to treat COVID-19: the reCoVery study]	Randomized trial with no results (e.g. trial registry)
Li 2020	Application of CareDose 4D combined with Karl 3D technology in the low dose computed tomography for the follow-up of COVID-19	Diagnostic imaging
Feeney 2020	The COVIRL-001 Trial: A multicentre, prospective, randomised trial comparing standard of care (SOC) alone, SOC plus hydroxychloroquine monotherapy or SOC plus a combination of hydroxychloroquine and azithromycin in the treatment of non-critical, SARS-CoV	Randomized trial with no results (e.g. trial registry)
Feily 2020	COVID-19: Pentoxifylline as a potential adjuvant treatment	Not a randomized trial
Hu 2020	Chansu Injection Improves the Respiratory Function of Severe COVID-19 Patients	Traditional Chinese or alternative medicine
LuisCallejasRubio 2020	De Los Pulsos De Corticoides En Pacientes Con SV≠ndrome De LiberaciV≥n De Citoquinas Inducido Por InfecciV≥n Por Sars-Cov-2	Not a randomized trial
Wang 2020	Efficacy and Safety of Leflunomide for Refractory COVID-19: An Open-label Controlled Study	Not a randomized trial
Casadevall 2020	A Randomized Trial of Convalescent Plasma for COVID-19-Potentially Hopeful Signals	Not a randomized trial
Pompeii 2020	Training and Fit Testing of Health Care Personnel for Reusable Elastomeric Half-Mask Respirators Compared With Disposable N95 Respirators	Personal protective equipment

Li 2020	COVID-19: Repeatedly Video-Watching vs Combined Video-Watching and Live Demonstration as Training to Healthcare Providers for Donning and Doffing Personal Protective Equipment	Psychological and educational
Zhang 2020	A comparative study on the time to achieve negative nucleic acid testing and hospital stays between Danoprevir and Lopinavir/Ritonavir in the treatment of patients with COVID-19	Not a randomized trial
Hua 2020	Short-term skin reactions following use of N95 respirators and medical masks	Personal protective equipment
Wen 2020	[Effect of Xuebijing injection on inflammatory markers and disease outcome of coronavirus disease 2019]	Traditional Chinese or alternative medicine
CallejasRubio 2020	Eficacia de los pulsos de corticoides en pacientes con s√ndrome de liberaci√≥n de citocinas inducido por infecci√≥n por SARS-CoV-2	Not a randomized trial
Duong-Quy 2020	The use of exhaled nitric oxide and peak expiratory flow to demonstrate improved breathability and antimicrobial properties of novel face mask made with sustainable filter paper and Folium Plectranthii amboinicii oil: additional option for mask shortage d	Wrong population
Bao 2020	Successful treatment of patients severely ill with COVID-19	Not a randomized trial
Salazar 2020	Treatment of Coronavirus Disease 2019 (COVID-19) Patients with Convalescent Plasma	Not a randomized trial
Wu 2020	Identification and validation of a novel clinical signature to predict the prognosis in confirmed COVID-19 patients	Not a randomized trial
Chen 2020	Antiviral Activity and Safety of Darunavir/Cobicistat for Treatment of COVID-19	Not a randomized trial
Bretthauer 2020	Randomized Re-Opening of Training Facilities during the COVID-19 pandemic	Others
Zhao 2020	Yidu-toxicity blocking lung decoction ameliorates inflammation in severe pneumonia of SARS-COV-2 patients with Yidu-toxicity blocking lung syndrome by eliminating IL-6 and TNF-a	Traditional Chinese or alternative medicine
Guan 2020	Hydrogen/oxygen mixed gas inhalation improves disease severity and dyspnea in patients with Coronavirus disease 2019 in a recent multicenter, open-label clinical trial	Not a randomized trial
Liu 2020	Efficacy of chloroquine versus lopinavir/ritonavir in mild/general COVID-19 infection: a prospective, open-label, multicenter, randomized controlled clinical study	Randomized trial with no results (e.g. trial registry)
Boyko 2020	The first experience of using the drug Angiovit in the complex treatment of the acute stage of COVID-19 infection	Not a randomized trial
Wang 2020	Exploring an Integrative Therapy for Treating COVID-19: A Randomized Controlled Trial	Traditional Chinese or alternative medicine
Gokhale 2020	Tocilizumab improves survival in patients with persistent hypoxia in severe COVID-19 pneumonia	Not a randomized trial
Abolghasemi 2020	Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study	Not a randomized trial
Folegatti 2020	Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial	Vaccine
Govind 2020	Clozapine Treatment and Risk of COVID-19	Not a randomized trial
Shi Suofang 2020	Clinical Observation of the Rehabilitation Formula for Banking up Earth to Generate Metal in Treating COVID-19 Patients with Deficiency of Lung and Spleen Syndrome in the Recovery Stage	Traditional Chinese or alternative medicine
Ai Xiangying 2020	Effect of Integrated Traditional Chinese and Western Medicine on T Lymphocyte Subsets of Patients with Normal Type of COVID-19	Traditional Chinese or alternative medicine
Tan Shigang 2020	Effect of Intravenous Lidocaine on Central Venous Puncture Analgesia in Cases of Suspected or Confirmed COVID-19	Others
Yan 2020	Large-scale prospective clinical study on prophylactic intervention of COVID-19 in community population using Huoxiang Zhengqi Oral Liquid and Jinhao Jiere Granules. [Chinese]	Traditional Chinese or alternative medicine
Xiong 2020	Efficacy of herbal medicine (Xuanfei Baidu decoction) combined with conventional drug in treating COVID-19:A pilot randomized clinical trial	Not a randomized trial
Pang 2020	Efficacy and tolerability of bevacizumab in patients with severe Covid -19	Not a randomized trial

kamran 2020	Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial (preprint)	Not a randomized trial
Suppan 2020	Effect of an E-Learning Module on Personal Protective Equipment Proficiency by Prehospital Personnel: Web-Based, Randomized Controlled Trial	Psychological and educational
Hong 2020	Early Hydroxychloroquine Administration for Rapid Severe Acute Respiratory Syndrome Coronavirus 2 Eradication	Not a randomized trial
Keech 2020	First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine (preprint)	Vaccine
Yu 2020	Effects of Lianhua Qingwen Granules Plus Arbidol on Treatment of Mild Corona Virus Disease-19. [Chinese]	Traditional Chinese or alternative medicine
Zhang 2020	Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial (preprint)	Vaccine
Ibrahim 2020	Factors Associated with Good Patient Outcomes Following Convalescent Plasma in COVID-19: A Prospective Phase 2 Clinical Trial (preprint)	Removed from preprint server
Xiao 2020	Efficacy of Huoxiang Zhengqi dropping pills and Lianhua Qingwen granules in treatment of COVID-19: A randomized controlled trial	Traditional Chinese or alternative medicine
Mulligan 2020	Phase 1/2 study of COVID-19 RNA vaccine BNT162b1 in adults	Vaccine
Xia 2020	Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials	Vaccine
Folegatti 2020	Erratum: Department of Error (The Lancet (2020) 396(10249) (467,Äì478), (S0140673620316044), (10.1016/S0140-6736(20)31604-4))	Vaccine
Frandell 2020	The Effects of Electronic Alert Letters in the Time of COVID-19 (preprint)	Wrong population
Eslami 2020	The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19	Not a randomized trial
Qamar 2020	Protective Effects of CVD and DM Medications in SARS-CoV-2 Infection	Not a randomized trial
Sinha 2020	Interleukin-6 Receptor Inhibitor Therapy Is Associated with Improved Outcomes in Patients with Severe COVID-19 Disease (preprint)	Not a randomized trial
Walsh 2020	RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study (preprint)	Vaccine
Sheng 2020	Canakinumab to reduce deterioration of cardiac and respiratory function in SARS-CoV-2 associated myocardial injury with heightened inflammation (canakinumab in Covid-19 cardiac injury: The three C study)	Randomized trial with no results (e.g. trial registry)
Zhdanov 2020	Clinical efficacy and safety of nebulized prostacyclin in patients with sARs-CoV-2 (prospective comparative study). [Russian]	Not a randomized trial
Keech 2020	Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine	Vaccine
López Zúñiga 2020	High-Dose Corticosteroid Pulse Therapy Increases the Survival Rate in COVID-19 Patients at Risk of Cytokine Storm (preprint)	Not a randomized trial
Mohamed 2020	EARLY VIRAL CLEARANCE AMONG COVID-19 PATIENTS WHEN GARGLING WITH POVIDONE-IODINE AND ESSENTIAL OILS: A PILOT CLINICAL TRIAL (preprint)	Others
Duan Can 2020	Clinical Observation of Jinhua Qinggan Granule in Treating Pneumonia Infected by Novel Coronavirus	Traditional Chinese or alternative medicine
Hu Fen 2020	Multi-center clinical observation of honeysuckle oral liquid combined with western medicine in the treatment of common type of COVID-19	Traditional Chinese or alternative medicine
Madabhushi 2020	Time to adapt in the pandemic era: a prospective randomized non -inferiority study comparing time to intubate with and without the barrier box Erratum to hydrogen/oxygen mixed gas inhalation improves disease severity and dyspnea in patients with Coronavirus disease 2019 in a recent multicenter, open-label	Personal protective equipment
Guan 2020	clinical trial	Not a randomized trial
Rasmussen 2020	Pulmonary administration of remdesivir in the treatment of COVID-19	Not a randomized trial
Hacibekiro_lu 2020	Efficacy of convalescent plasma according to blood groups in COVID-19 patients	Not a randomized trial
Li 2020	Regarding "Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A-†multicenter, single-blind, randomized controlled trial,Äù	Not a randomized trial

Seneviratne 2020	Efficacy of commercial mouth-rinses on SARS-CoV-2 viral load in saliva: Randomized Control Trial in Singapore (preprint)	Others
Sadoff 2020	Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial (preprint)	Vaccine
Chen 2020	The efficacy and safety of traditional Chinese medicines, modified Radix Fici Simplicissimae, combined with Western medicines amongst patients infected with the 2019 novel coronavirus (SARS-CoV-2) in tropical tourist area, China	Traditional Chinese or alternative medicine
Ayerdi 2020	Preventive efficacy of tenofovir/emtricitabine against SARS-CoV-2 among PREP users	Not a randomized trial
Gergi 2020	Thrombo-inflammation response to Tocilizumab in COVID-19	Not a randomized trial
Khan 2020	Ivermectin treatment may improve the prognosis of patients with COVID-19	Not a randomized trial
Center 2020	Pilot Randomized Controlled Trial: Fluoxetine to Reduce Hospitalization From COVID-19 Infection (FloR COVID-19)	Randomized trial with no results (e.g. trial registry)
Anderson 2020	Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults	Vaccine
Myasnikov 2020	Efficacy of Interferon Gamma in the Prevention of SARS-CoV-2 Infection (COVID-19): Results of a Prospective Controlled Trial A multi-center, randomized controlled trial by the Integrative Management in Japan	Not a randomized trial
Takayama 2020	for Epidemic Disease (IMJEDI study-RCT) on the use of Kampo medicine, kakkonto with shosaikotokakikyosekko, in mild-to-moderate COVID-19 patients for symptomatic relief and	Randomized trial with no results (e.g. trial registry)
Pu 2020	An in-depth investigation of the safety and immunogenicity of an inactivated SARS-CoV-2 vaccine (preprint)	Vaccine
Fong 2020	Impact of aerosol box on intubation during COVID-19: a simulation study of normal and difficult airways	Personal protective equipment
Li 2020	Convalescent Plasma Treatment in Severe and Life-Threatening COVID-19: A Randomized Controlled Clinical Trial	Randomized trial with no results (e.g. trial registry)
Selman 2020	Results of a Chilean Nation-Wide Network of Blood Banks for Convalescent Plasma Collection for Pandemic SARS-CoV-2 Treatment	Not a randomized trial
Cabanov 2020	Treatment with tocilizumab does not inhibit induction of anti-COVID-19 antibodies in patients with severe SARS-CoV-2 infection	Not a randomized trial
Han 2020	RUXCOVID: A phase 3, randomized, placebo-controlled study evaluating the efficacy and safety of ruxolitinib in patients with COVID-19-associated cytokine storm	Randomized trial with no results (e.g. trial registry)
Marshall 2020	A phase II trial to promote recovery from COVID-19 with endocrine therapy	Randomized trial with no results (e.g. trial registry)
Strohbehn 2020	COVIDOSE: Low-dose tocilizumab in the treatment of COVID-19 pneumonitis	Randomized trial with no results (e.g. trial registry)
Villa 2020	Blood purification therapy with a hemodiafilter featuring enhanced adsorptive properties for cytokine removal in patients presenting COVID-19: a pilot study	Not a randomized trial
Wu Haiyan 2020	Effect of emotional care based on traditional Chinese medicine combining respiratory muscle training on depression and anxiety among patients with COVID-19	Traditional Chinese or alternative medicine
Zhou 2020	Clinical study on the treatment of patients with novel coronavirus pneumonia and asymptomatic infection with integrated traditional Chinese and western medicine	Traditional Chinese or alternative medicine
Zhu Xiaoqing 2020	Study on the application value of psychological nursing in pregnant women suspected of new coronavirus pneumonia	Psychological and educational
Ai 2020	Therapeutic effect of integrated traditional Chinese and western medicine on COVID-19 in Guangzhou	Traditional Chinese or alternative medicine
Xia 2020	Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial	Vaccine
Walsh 2020	Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates.	Vaccine
Fragoso-Saavedra 2020	A parallel-group, multicenter randomized, double-blinded, placebo-controlled, phase 2/3, clinical trial to test the efficacy of pyridostigmine bromide at low doses to reduce mortality or invasive mechanical ventilation in adults with severe SARS-CoV-2 inf	Randomized trial with no results (e.g. trial registry)

Wanjarkhedkar 2020	A prospective clinical study of an Ayurveda regimen in COVID 19 patients	Traditional Chinese or alternative medicine
Yang 2020	Clinical Characteristics and Outcomes of COVID-19 Patients Receiving Compassionate Use Leronlimab	Not a randomized trial
Singh 2020	In adults exposed to COVID-19, hydroxychloroquine did not reduce confirmed or probable COVID-19;trial stopped for futility	Not a randomized trial
BelenguerMuncharaz 2020	Effectiveness of non-invasive ventilation in intensive care unit admitted patients due to SARS-CoV-2 pneumonia	Not a randomized trial
Lanthier 2020	[In patients hospitalized for COVID-19, does dexamethasone reduce 28-days mortality compared to standard treatment?] Plasma Angiotensin Peptide Profiling and ACE (Angiotensin-Converting Enzyme)-2	Not a randomized trial
Kintscher 2020	Activity in COVID-19 Patients Treated With Pharmacological Blockers of the Renin- Angiotensin System	Not a randomized trial
Sivapalan 2020	Proactive prophylaxis with azithromycin and hydroxychloroquine in hospitalized patients with COVID-19 (ProPAC-COVID): a statistical analysis plan	Randomized trial with no results (e.g. trial registry)
Hashim 2020	Controlled randomized clinical trial on using Ivermectin with Doxycycline for treating COVID-19 patients in Baghdad, Iraq	Not a randomized trial
Petrak 2020	Early Tocilizumab Dosing is Associated with Improved Survival In Critically III Patients Infected With Sars-CoV-2	Not a randomized trial
Chang 2020	Safety and Efficacy of Bronchoscopy in Critically III Patients with Coronavirus Disease 2019	Not a randomized trial
Ikonomidis 2020	Tocilizumab improves oxidative stress and endothelial glycocalyx: a mechanism that may explain the effects of biological treatment on COVID-19. (Special Issue: COVID-19 and treatments: particular emphasis on potential toxic effects.)	Wrong population
Garcia-Fernandez 2020	Usefulness and safety of self-electrocardiographic monitoring during treatment with hydroxychloroquine and azithromycin in COVID-19 patients	Not a randomized trial
Wu 2020	Phase 1 trial for treatment of COVID-19 patients with pulmonary fibrosis using hESC-IMRCs	Not a randomized trial
Araimo 2020	Ozone as Adjuvant Support in the Treatment of COVID-19: A Preliminary Report of Probiozovid Trial	Oxygen delivery
Masiv° 2020	Lack of detrimental effect of corticosteroids on antibody responses to SARS-CoV-2 and viral clearance in patients hospitalized with COVID-19	Not a randomized trial
Shaw 2020	Wearing of Cloth or Disposable Surgical Face Masks has no Effect on Vigorous Exercise Performance in Healthy Individuals	Personal protective equipment
Spoorthi 2020 Ward 2020	Utility of Ivermectin and Doxycycline combination for the treatment of SARS-CoV-2 Phase 1 trial of a Candidate Recombinant Virus-Like Particle Vaccine for Covid-19 Disease Produced in Plants	Not a randomized trial Vaccine
Yan 2020	Effects and Safety of Herbal Medicines among Community-dwelling Residents during COVID-19 Pandemic: A Large Prospective, Randomized Controlled Trial (RCT)	Traditional Chinese or alternative medicine
Che 2020	Randomized, double-blinded and placebo-controlled phase II trial of an inactivated SARS-CoV-2 vaccine in healthy adults	Vaccine
Dhibar 2020	Post-exposure prophylaxis with hydroxychloroquine for the prevention of COVID-19, a myth or a reality? The PEP-CQ Study.	Not a randomized trial
Strohbehn 2020	COVIDOSE: A phase 2 clinical trial of low-dose tocilizumab in the treatment of non-critical COVID-19 pneumonia.	Not a randomized trial
Bundgaard 2020	Effectiveness of Adding a Mask Recommendation to Other Public Health Measures to Prevent SARS-CoV-2 Infection in Danish Mask Wearers : A Randomized Controlled Trial.	Personal protective equipment
Ramasamy 2020	Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime- boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial	Vaccine
Shogenova 2020	Effect of thermal helium-oxygen mixture on viral load in COVID-19	Oxygen delivery
Zhang 2020	Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.	Vaccine

NoorAzhar 2020	COVID-19 aerosol box as protection from droplet and aerosol contaminations in healthcare workers performing airway intubation: a randomised cross-over simulation study	Personal protective equipment
Bautin 2020	Inhalation surfactant therapy in the integrated treatment of severe COVID-19 pneumonia	Not a randomized trial
Younie 2020	Improving young children's handwashing behaviour and understanding of germs: The impact of A Germ's Journey educational resources in schools and public spaces.	Psychological and educational
Erdem 2020	Treatment of SARS-cov-2 pneumonia with favipiravir: Early results from the Ege University cohort, Turkey.	Not a randomized trial
Zhou 2020	Low-dose corticosteroid combined with immunoglobulin reverses deterioration in severe cases with COVID-19.	Not a randomized trial
Hong 2020	Celebrex Adjuvant Therapy on Coronavirus Disease 2019: An Experimental Study	Not a randomized trial
Piralla 2020	Residual SARS-CoV-2 RNA in nasal swabs of convalescent COVID-19 patients: Is prolonged quarantine always justified?	Not a randomized trial
Liu 2020	The dual role of anti-viral therapy in the treatment of Coronavirus disease 2019.	Not a randomized trial
Alamdari 2020	Application of methylene blue -vitamin C - N-acetyl cysteine for treatment of critically ill COVID-19 patients, report of a phase-I clinical trial. (Special Issue: Therapeutic targets and pharmacological treatment of COVID-19.)	Not a randomized trial
Potere 2020	Low-dose subcutaneous tocilizumab to prevent disease progression in patients with moderate COVID-19 pneumonia and hyperinflammation. (Special Issue: Coronavirus (COVID-19) collection.)	Not a randomized trial
Chen 2020	Clinical efficacy and safety of favipiravir in the treatment of COVID-19 patients	Not a randomized trial
Gold 2020	Efficacy of m-Health for the detection of adverse events following immunization - The stimulated telephone assisted rapid safety surveillance (STARSS) randomised control trial	Others
Luo 2020	Application of chest low-dose CT screening of Corona Virus Disease 2019 with a third-generation dual-source scanner	Diagnostic imaging
Li 2020	Evaluation of low-dose CT protocol of novel coronavirus pneumonia based on infection prevention and control	Diagnostic imaging
Rao 2020	AYUSH medicine as add-on therapy for mild category COVID-19; an open label randomised, controlled clinical trial.	Traditional Chinese or alternative medicine
De Marchi 2020	Effects of photobiomodulation therapy combined with static magnetic field (PBMT-sMF) in patients with severe COVID-19 requiring intubation: a pragmatic randomized placebo-controlled trial	Exercise/rehabilitation
Polack 2020	Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine	Vaccine
Voysey 2020	Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK	Vaccine
Devos 2020	Correction to: A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodi	Randomized trial with no results (e.g. trial registry)
RachesElla 2020	Safety and immunogenicity clinical trial of an inactivated SARS-CoV-2 vaccine, BBV152 (a phase 2, double-blind, randomised controlled trial) and the persistence of immune responses from a phase 1 follow-up report	Vaccine
ShilongYang 2020	Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD protein vaccine against COVID-19 in adults: pooled analysis of two randomized, double-blind, placebo-controlled, phase 1 and 2 trials	Vaccine
Folegatti 2020	Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.	Vaccine
Shah 2020	Safety and efficacy of ozone therapy in mild to moderate COVID-19 patients: A Phase 1/11 Randomized control Trial (SEOT study)	Oxygen delivery
Moniuszko- Malinowska 2021	Convalescent Plasma Transfusion for the Treatment of COVID-19,ÄîExperience from Poland: A Multicenter Study	Not a randomized trial
Panigada 2020	Effect of heparin on viscoelastic parameters of COVID-19 critically ill patients. A Viscoelastic Coagulation Monitor (VCM) analysis	Not a randomized trial

Alsan 2020	Comparison of Knowledge and Information-Seeking Behavior After General COVID-19 Public Health Messages and Messages Tailored for Black and Latinx Communities : A Randomized Controlled Trial.	Wrong population
Baden 2020	Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.	Vaccine
Mugheddu 2020	Safety of secukinumab treatment in COVID-19 affected psoriatic patients.	Not a randomized trial
Al-Sadawi 2020	Hydroxychloroquine and Azithromycin Usage in African American Patients With Coronavirus Disease 2019 (COVID-19) and Their Effects on QT Interval	Not a randomized trial
Feng 2020	Differentiation between COVID-19 and bacterial pneumonia using radiomics of chest computed tomography and clinical features	Not a randomized trial
Namazi 2020	Ellagic acid can possibly be an adjuvant treatment for COVID-19	Not a randomized trial
Sardari 2021	Therapeutic effect of thyme (Thymus vulgaris) essential oil on patients with covid19: A randomized clinical trial	Traditional Chinese or alternative medicine
Carbillon 2021	Hydroxychloroquine at usual doses as an option for coronavirus disease 2019 treatment.	Not a randomized trial
Janapala 2020	Novaferon, treatment in COVID-19 patients.	Not a randomized trial
Kollias 2020	Anticoagulation therapy in COVID-19: Is there a dose-dependent benefit?	Not a randomized trial
Flisiak 2020	Remdesivir-based therapy improved recovery of patients with COVID-19 in the SARSTer multicentre, real-world study.	Not a randomized trial
Gautret 2021	Safety profile of hydroxychloroquine and azithromycin combined treatment in COVID- 19 patients	Not a randomized trial
Gautret 2021	Clinical efficacy and safety profile of hydroxychloroquine and azithromycin against COVID-19	Not a randomized trial
Moisset 2021	Nasopharyngeal swab-induced pain for SARS-CoV-2 screening: a randomised controlled trial of conventional and self-swabbing.	Wrong population
Dillon 2020	A real-world data study of coronavirus-2019 disease severity in patients with multiple sclerosis treated with ocrelizumab	Not a randomized trial
Karan 2020	Clinical outcomes in patients with COVID-19 infection during phase IV studies of cladribine tablets for treatment of multiple sclerosis	Not a randomized trial
Papamanoli 2020	76. Effect of Early Administration of Systemic Corticosteroids on Outcomes in Patients with COVID-19 Pneumonia	Not a randomized trial
Reig 2020	560. Repurposing Eravacycline for the Treatment of SARS-CoV-2 Infections	Not a randomized trial
Poulakou 2021	Beneficial Effects of Intermediate Dosage of Anticoagulation Treatment on the Prognosis of Hospitalized COVID-19 Patients: The ETHRA Study.	Not a randomized trial
Raj 2020	Effect of a novel ayurvedic preparation, Raj Nirvan Bati (rnb), on symptomatic patients of covid-19	Traditional Chinese or alternative medicine
Liu 2020	[Effect of moxibustion on clinical symptoms, peripheral inflammatory indexes and T lymphocyte subsets in COVID-19 patients]	Traditional Chinese or alternative medicine
LeBon 2021	Efficacy and safety of oral corticosteroids and olfactory training in the management of COVID-19-related loss of smell.	Not a randomized trial
Folegatti 2020	Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial (vol 396, pg 467, 2020)	Vaccine
Al Shehry 2021	Safety and Efficacy of Convalescent Plasma for Severe COVID-19: Interim Report of a Multicenter Phase II Study from Saudi Arabia	Not a randomized trial
Sadoff 2021	Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine.	Vaccine
Singh 2021	The outcome of fluticasone nasal spray on anosmia and triamcinolone oral paste in taste dysgeusia in COVID-19 patients	Not a randomized trial
Vanassche 2020	A randomized, open-label, adaptive, proof-of-concept clinical trial of modulation of host thromboinflammatory response in patients with COVID-19: the DAWn-Antico study (vol 21, 1005, 2020)	Randomized trial with no results (e.g. trial registry)
Katia 2021	Efficacy of canakinumab in mild or severe COVID-19 pneumonia	Not a randomized trial

Chitra 2021	An Open Clinical Evaluation Of Selected Siddha Regimen In Expediting The Management Of Covid-19 ,ÄìA Randomized Controlled Study	Traditional Chinese or alternative medicine
JiaLiu 2021	Chinese medicine (Q-14) in the Treatment of Patients with Coronavirus Disease 2019 (COVID-19): A Single-center, Open label, Randomised Controlled Trial	Traditional Chinese or alternative medicine
Hariri 2021	Rate control in atrial fibrillation using Landiolol is safe in critically ill Covid-19 patients. THERAPEUTIC EFFECT of VITAMIN A on COVID-19 PATIENTS and ITS PROPHYLACTIC	Not a randomized trial
Embase 2021 ProQuestCentral	EFFECT on CONTACTS Self-proning in COVID-19 patients on low-flow oxygen therapy. A cluster randomised	Not a randomized trial
2021	controlled trial	Oxygen delivery
Ella 2021	Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial.	Vaccine
Dixon 2020	The Relevance of Oxytocin & Dynorphin in COVID-19: Towards a Prophylactic Treatment (preprint)	Not a randomized trial
	Effectiveness of a Mobile Phone-Based Intervention to Reduce Mental Health Problems in Healthcare Workers During the COVID-19 Pandemic: A Randomized	
Fiol-DeRoque 2021	Controlled Trial (PsyCovidApp Trial) (preprint)	Wrong population
Ball 2021	Nebulised heparin for patients on ventilation: implications for COVID-19 pneumonia.	Not a randomized trial
Chen 2020	Corticosteroid Therapy Is Associated With Improved Outcome in Critically III Coronavirus Disease 2019 Patients With Hyperinflammatory Phenotype.	Not a randomized trial
Singh 2021	The outcome of fluticasone nasal spray on anosmia and triamcinolone oral paste in dysgeusia in COVID-19 patients.	Not a randomized trial
Acosta-Ampudia 2021	COVID-19 convalescent plasma composition and immunological effects in severe patients	Not a randomized trial
Liangjianghuang 2021	Ultra-short-wave diathermy shortens the course of moderate and severe COVID-19: a randomized controlled trial	Exercise/rehabilitation
Brüggemann 2021	TChloroquine for treatment of COVID-19 results in subtherapeutic exposure and prolonged QTc intervals	Not a randomized trial
PaulRHunter 2021	Estimating the effectiveness of the Pfizer COVID-19 BNT162b2 vaccine after a single dose. A reanalysis of a study of 'real-world' vaccination outcomes from Israel.	Vaccine
Luo 2021	The preventive effect of Xuebijing injection against Cytokine Storm for severe patients with COVID-19: a prospective randomized controlled trial	Traditional Chinese or alternative medicine
Bentur 2021	Phase 1 Randomized Placebo-Controlled Study in Healthy Adult Volunteers to Evaluate the Safety, Tolerability, and Pharmacokinetics of Orally Inhaled Aerosolized Hydroxychloroquine Sulfate ,Äì A Potential Treatment for COVID-19	Wrong population
Kienbacher 2021	The use of personal protection equipment does not impair the quality of cardiopulmonary resuscitation: A prospective triple-cross over randomised controlled non-inferiority trial	Personal protective equipment
Voysey 2021	Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK	Vaccine
	Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind,	vaccine
Richmond 2021	Surgical Performance Is Not Negatively Impacted by Wearing a Commercial Full-Face	Vaccine
Felinska 2021	Mask with Ad Hoc 3D-Printed Filter Connection as a Substitute for Personal Protective Equipment during the COVID-19 Pandemic: A Randomized Controlled Cross-Over Trial	Personal protective equipment
Liu 2021	Arbidol combined with the Chinese medicine Lianhuaqingwen capsule versus arbidol alone in the treatment of COVID-19.	Not a randomized trial
Emary 2021	Efficacy of ChAdOx1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 VOC 202012/01 (B.1.1.7) (preprint)	Vaccine
Voysey 2021	Single Dose-†Administration,-†And-†The-†Influence Of-†The-†Timing Of-†The-†Booster Dose-†On Immunogenicity and Efficacy Of-†ChAdOx1 nCoV- 19-†(AZD1222)-†Vaccine (preprint)	Vaccine
Guenezan 2021	Povidone Iodine Mouthwash, Gargle, and Nasal Spray to Reduce Nasopharyngeal Viral Load in Patients With COVID-19: A Randomized Clinical Trial.	Others
	2000 ducing with covid 15. A nandomized chined that.	J. 11.11.13

J	Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in	Vassina
Logunov 2021	Russia.	Vaccine
Rais 2021	A Randomized open label parallel group pilot study to evaluate efficacy of Ayurveda interventions in the management of Asymptomatic and Mild COVID-19 patients-Experiences of a Lucknow based Level 2 hospital of Uttar Pradesh, India	Traditional Chinese or alternative medicine
Devpura 2021	Randomized Placebo-Controlled Pilot Clinical Trial on the Efficacy of Ayurvedic Treatment Regime on COVID-19 Positive Patients	Traditional Chinese or alternative medicine
Wu 2021	Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial	Vaccine
Chappell 2021	First Report of a Phase 1 Randomised Trial of Molecular Clamp-Stabilised Spike Protein-Based and MF59-Adjuvanted Vaccine for SARS-CoV-2 (preprint) Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2:	Vaccine
Voysey 2021	an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK (vol 397, pg 99, 2021)	Vaccine
Vowels 2021	Partner Support and Goal Outcomes during COVID-19: A Mixed Methods Study	Not a randomized trial
Wakita 2021	Comparison of the clinical performance and usefulness of five SARS-CoV-2 antibody tests.	Not a randomized trial
Alemanno 2021	COVID-19 cognitive deficits after respiratory assistance in the subacute phase: A COVID-rehabilitation unit experience.	Not a randomized trial
Abou-Arab 2021	Microvascular flow alterations in critically ill COVID-19 patients: A prospective study.	Not a randomized trial
Chu 2021	A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine	Vaccine
Li 2020	The Effect of Cognitive Behavioral Therapy on Depression, Anxiety, and Stress in Patients With COVID-19: A Randomized Controlled Trial	Psychological and educational
Donato 2021	Clinical and laboratory evaluation of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma.	Not a randomized trial
Mammen 2021	Assessing of the Factors Associated with Mortality Among the Patients of PLACID Trial (A Phase II, Open Label, Randomized Controlled Trial to Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated Complications in Moderate Dise A double blinded placebo controlled comparative clinical trial to evaluate the effectiveness of Siddha medicines, Kaba Sura Kudineer (KSK) & Diavembu	Not a randomized trial
Srivastava 2021	Kudineer (NVK) along with standard Allopathy treatment in the management of symptomatic COVID 19 pat	Randomized trial with no results (e.g. trial registry)
Andrani 2020	Effectiveness of helmet CPAP to reduce intubation and mortality rate in patients with COVID-19	Not a randomized trial
Aschieri 2020	Hospital mortality and safety of therapeutic vs. prophylactic doses of low molecular weight heparin in COVID-19 patients	Not a randomized trial
Ramasamy 2020	Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial (vol 396, pg 1979, 2020)	Vaccine
Voysey 2021	Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials	Vaccine
Vergori 2020	Prophylactic dose of low-molecular-weight heparin (LMWH) might not be sufficient to mitigate the clinical scenario in patients with COVID-19 and severe pneumonia	Not a randomized trial
Gupta 2020	Determining the usage and efficacy of COVID-19 convalescent plasma harvested at our blood centre	Not a randomized trial
Terpos 2020	Rapid Reduction of Anti-Sars-Cov-2 Antibodies in Convalescent Plasma Donors;Results of a Phase 2 Clinical Study	Not a randomized trial
Perez-Jacobo 2020	Phase I and Preliminary Results of a Phase II Study (TERAPLASCoV2) of Convalescent Plasma in Patients with Severe and Life-Threatening Pneumonia Caused By Sars-Cov-2	Not a randomized trial
Dummer 2020	Clinical Trial to Evaluate an Approved ITP Therapy Targeting Spleen Tyrosine Kinase (SYK) for Prevention and Treatment of COVID-19 Related Complications	Randomized trial with no results (e.g. trial registry)

Chambers 2020	COVID-19-Associated Coagulopathy: Safety and Efficacy of Prophylactic Anticoagulation Therapy in Hospitalized Adults with COVID-19	Randomized trial with no results (e.g. trial registry)
Hernandez-Cedeno 2021	CIGB-258, a peptide derived from human heat-shock protein 60, decreases hyperinflammation in COVID-19 patients.	Not a randomized trial
Chavarria 2021	Antioxidants and pentoxifylline as coadjuvant measures to standard therapy to improve prognosis of patients with pneumonia by COVID-19	Not a randomized trial
ArturoChang- Monteagudo 2021	A single dose of SARS CoV 2 FINLAY FR 1A dimeric RBD recombinant vaccine enhances neutralization response in COVID19 convalescents, with excellent safety profile. A preliminary report of an open-label phase 1 clinical trial	Vaccine
VivekShinde 2021	Preliminary Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.351 Variant	Vaccine
Ozlu 2021	The effects of progressive muscle relaxation exercises on the anxiety and sleep quality of patients with COVID-19: A randomized controlled study	Exercise/rehabilitation
Gyselinck 2021	Correction to: Direct antivirals working against the novel coronavirus: azithromycin (DAWn-AZITHRO), a randomized, multicenter, open-label, adaptive, proof-of-concept clinical trial of new antivirals working against SARS-CoV-2-azithromycin trial.	Not a randomized trial
Ella 2021	Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial	Vaccine
DiTano 2021	[The AFFIRM-AHF trial: results, impact of COVID-19 and clinical implications]. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost	Not a randomized trial
Logunov 2021	COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia (vol 397, pg 671, 2021) Hepatic manifestations of COVID-19 and effect of remdesivir on liver function in	Vaccine
Aleem 2021 Jiang 2020	patients with COVID-19 illness A combination regimen by lopinave/litonawe, emtricitabine and tenofovir alafenamide fumarate for treatment of novel coronavirus pneumonia (TARCoV)	Not a randomized trial Not a randomized trial
Stephenson 2021	Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19	Vaccine
Lin 2021	Mycobacterium vaccae Nebulization in the Treatment of COVID-19: A Randomized, Double-Blind, Placebo-Controlled Trial	Others
Li Xingang 2020	Clinical study of glucocorticoids in the treatment of severe patients with new coronavirus pneumonia	Not a randomized trial
Xue Ping 2020	Observation on the application of small and medium-dose glucocorticoids in the treatment of elderly patients with common new type coronavirus pneumonia	Not a randomized trial
Latorre 2021	4CPS-338,ÄÖUse and efficacy of tocilizumab in patients with severe COVID-19 pneumonia Self-proning in COVID-19 patients on low-flow oxygen therapy: a cluster randomised	Not a randomized trial
Kharat 2021	controlled trial	Oxygen delivery
Awasthi 2021	Plasma IL-6 levels following corticosteroid therapy as an indicator of ICU length of stay in critically ill COVID-19 patients	Not a randomized trial
Madhi 2021	Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant	Vaccine
Cantarelli 2021	5PSQ-178,ÄÖHepatotoxicity associated with acute tocilizumab treatment in patients with SARS-CoV-2 infection	Not a randomized trial
Dutt 2021	A randomized and comparative study to assess safety and efficacy of supplemental treatment of a herbal formulation - Aayudh Advance comprising essential oils in patients with corona virus 2019 (COVID-19)	Traditional Chinese or alternative medicine
Silveira 2021	Efficacy of Brazilian Green Propolis (EPP-AF®) as an adjunct treatment for hospitalized COVID-19 patients: a randomized, controlled clinical trial	Nutrition and supplements
Wei 2020	Early antiviral therapy of abidol combined with lopinavir/ritonavir and recombinant interferon α-2b for patients with COVID-19 in Zhejiang: A multicenter prospective study	Not a randomized trial
Bradley 2021	Antibody Responses after a Single Dose of SARS-CoV-2 mRNA Vaccine.	Not a randomized trial
Benenson 2021	BNT162b2 mRNA Covid-19 Vaccine Effectiveness among Health Care Workers.	Not a randomized trial

HannaHuang 2021	Use of Chlorhexidine to Eradicate Oropharyngeal SARS-CoV-2 in COVID-19 Patients.	Others
Grieco 2021	Effect of Helmet Noninvasive Ventilation vs High-Flow Nasal Oxygen on Days Free of Respiratory Support in Patients With COVID-19 and Moderate to Severe Hypoxemic Respiratory Failure: The HENIVOT Randomized Clinical Trial.	Oxygen delivery
Lin 2021	Decreased mortality in acute respiratory distress syndrome patients treated with corticosteroids: an updated meta-analysis of randomized clinical trials with trial sequential analysis	Not a randomized trial
	Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised,	
Yang 2021	double-blind, placebo-controlled, phase 1 and 2 trials	Vaccine
Meza 2021	Angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers for COVID-19: A living systematic review of randomized clinical trials	Not a randomized trial
Altuntas 2021	Convalescent plasma therapy in patients with COVID-19	Not a randomized trial
Kow 2021	The association between the use of ivermectin and mortality in patients with COVID- 19: a meta-analysis.	Not a randomized trial
Goldberg 2021	A real-life setting evaluation of the effect of remdesivir on viral load in COVID-19 patients admitted to a large tertiary centre in Israel.	Not a randomized trial
Majewski 2021	Chloroquine and hydroxychloroquine - safety profile of potential COVID-19 drugs from the rheumatologist's perspective.	Not a randomized trial
SusanMBueno 2021	Interim Report: Safety And Immunogenicity Of An Inactivated Vaccine Against Sars- Cov-2 In Healthy Chilean Adults In A Phase 3 Clinical Trial	Vaccine
Emary 2021	Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial	Vaccine
Chowdhury 2021	A Comparative Study on Ivermectin-Doxycycline and Hydroxychloroquine- Azithromycin Therapy on COVID-19 Patients	Not a randomized trial
	The effects of combination of <i>Zingiber officinale</i> and Echinacea on alleviation of clinical symptoms and hospitalization rate of suspected COVID-19	Traditional Chinese or
Mesri 2021	outpatients: a randomized controlled trial. Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine (KCONVAC) in	alternative medicine
Hong-XingPan 2021	Healthy Adults: Two Randomized, Double-blind, and Placebo-controlled Phase 1/2 Clinical Trials	Vaccine
Kadali 2021	Adverse effects of COVID-19 mRNA-1273 vaccine: A randomized, cross-sectional study on healthcare workers with detailed self-reported symptoms.	Vaccine
Caracciolo 2021	Efficacy and Effect of Inhaled Adenosine Treatment in Hospitalized COVID-19 Patients.	Not a randomized trial
Goldin 2021	Treatment-dose LMWH versus prophylactic/intermediate dose heparins in high risk COVID-19 inpatients: Rationale and design of the HEP-COVID Trial.	Randomized trial with no results (e.g. trial registry)
McEneny-King 2021	Pharmacokinetic and Pharmacodynamic Evaluation of Ravulizumab in Adults with Severe Coronavirus Disease 2019.	Randomized trial with no results (e.g. trial registry)
· ·	The effect of azoximer bromide (Polyoxidonium–Æ) in patients hospitalized with coronavirus disease (COVID-19): an open-label, multicentre, interventional clinical	
Efimov 2021	study Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled	Not a randomized trial
Voysey 2021	analysis of four randomised trials (vol 397, pg 881, 2021)	Vaccine
Pu 2021	The safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in Chinese adults aged 18-59 years: a phase I randomized, double-blinded, controlled trial	Vaccine
Agusti 2021	Early treatment with inhaled budesonide to prevent clinical deterioration in patients with COVID-19	Not a randomized trial
Backer 2021	A randomized, double-blind, placebo-controlled phase 1 trial of inhaled and intranasal niclosamide: A broad spectrum antiviral candidate for treatment of COVID-19.	Wrong population
	A SINGLE BLIND, PLACEBO-CONTROLLED RANDOMIZED STUDY OF THE SAFETY, REACTOGENICITY AND IMMUNOGENICITY OF THE "EPIVACCORONA"	
Ryzhikov 2021	VACCINE FOR THE PREVENTION OF COVID-19, IN VOLUNTEERS AGED 18-60 YEARS (PHASE I-II)	Vaccine
Diaz 2020	Geographical disparities in clinical outcomes of severe COVID-19 patients treated with remdesivir	Not a randomized trial

Castagna 2020	Baseline characteristics associated with clinical improvement and mortality in hospitalized patients with moderate COVID-19	Not a randomized trial
Arribas 2020	Impact of concomitant hydroxychloroquine use on safety and efficacy of remdesivir in moderate COVID-19 patients	Not a randomized trial
Bosaeed 2021	Multicentre randomised double-blinded placebo-controlled trial of favipiravir in adults with mild COVID-19.	Randomized trial with no results (e.g. trial registry)
Kosari 2021	The effect of propolis plus Hyoscyamus niger L. methanolic extract on clinical symptoms in patients with acute respiratory syndrome suspected to COVID-19: A clinical trial.	Others
Kamran 2021	Clearing the Fog: Is Hydroxychloroquine Effective in Reducing Coronavirus Disease- 2019 Progression? A Randomized Controlled Trial	Not a randomized trial
Gonzalez-Castro 2021	Combined therapy of tocilizumab and corticosteroids in severe SARS-CoV-2 disease.	Not a randomized trial
Lopes 2021	Randomized Clinical Trial to Evaluate a Routine Full Anticoagulation Strategy in Patients with Coronavirus Infection (SARS-CoV2) Admitted to Hospital: Rationale and Design of the ACTION (AntiCoagulaTlon cOroNavirus),ÄìCoalition IV Trial Self-proning in covid-19 patients on low-flow Oxygen therapy. A cluster randomised	Randomized trial with no results (e.g. trial registry)
Kharat 2021	Controlled trial	Oxygen delivery
Ryzhikov 2021	A single blind, placebo-controlled randomized study of the safety, reactogenicity and immunogenicity of the "EpiVacCorona" Vaccine for the prevention of COVID-19, in volunteers aged 18-60 years (phase I-II) (vol 11, pg 283, 2021)	Vaccine
Goepfert 2021	Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1-2, dose-ranging study.	Vaccine
Chappell 2021	Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial.	Vaccine
Sadoff 2021	Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19.	Vaccine
Pandit 2021	Effectiveness and safety of thymosin alpha-1 in patients with severe COVID-19: A prospective open-label study	Not a randomized trial
Li 2021	Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study.	Vaccine
Xu 2021	Efficacy and safety of Reduning injection in the treatment of COVID-19: a randomized, multicenter clinical study.	Traditional Chinese or alternative medicine
Körper 2021	Donors for SARS-CoV-2 Convalescent Plasma for a Controlled Clinical Trial: Donor Characteristics, Content and Time Course of SARS-CoV-2 Neutralizing Antibodies	Not a randomized trial
Ella 2021	Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial (Jan, 10.1016/S1473-3099(20)30942-7, 2021)	Vaccine
Wang 2021	Safety and immunogenicity of COVID-19 vaccination in patients with non-alcoholic fatty liver disease (CHESS2101): a multicenter study	Not a randomized trial
Ni 2021	Effects of Shuanghuanglian oral liquids on patients with COVID-19: a randomized, open-label, parallel-controlled, multicenter clinical trial	Traditional Chinese or alternative medicine
Gras-Valenti 2021	[Effectiveness of the first dose of BNT162b2 vaccine to preventing covid-19 in healthcare personnel.]	Vaccine
Pan 2021	Immunogenicity and safety of a SARS-CoV-2 inactivated vaccine in healthy adults: randomized, double-blind, and placebo-controlled phase 1 and phase 2 clinical trials	Vaccine
Padilla 2021	Clinical Outcomes of COVID-19 Patients Treated with Convalescent Plasma or Remdesivir Alone and in Combination at a Community Hospital in California's Central Valley.	Not a randomized trial
Pulsipher 2021	Remdesivir Use in COVID-19 Patients: Cutaneous Adverse Effect or Disease Manifestation?	Not a randomized trial
Abu-Raddad 2021	Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants.	Not a randomized trial
Shinde 2021	Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant.	Vaccine

Okumus 2021	Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID-19 patients.	Not a randomized trial
	Favipiravir and Hydroxychloroquine Combination Therapy in Patients with Moderate to Severe COVID-19 (FACCT): An Open-Label, Multicentre, Randomised, Controlled	Removed from preprint
Bosaeed 2021	Trial (preprint) Blood purification techniques, inflammatory mediators and mortality in COVID-19	server
Hashemian 2020	patients	Not a randomized trial
Dal 2021	Covid-19 Clinical Course and Blood Groups: Turkish Population-Based Study	Not a randomized trial
	Effectiveness of hydrogen peroxide as auxiliary treatment for COVID-19 hospitalized	
DiDomenico 2021	patients - preliminary results of a randomized double-blind clinical trial	Others
Bakhshaliyev 2021	The impact of hydroxychloroquine-azithromycin combination on Tpeak-to-end and Tpeak-to-end/QT ratio during a short treatment course.	Not a randomized trial
Barrett 2021	Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses	Vaccine
Arrieta 2021	Safety and Antibody Kinetics of COVID-19 Convalescent Plasma for the Treatment of Moderate to Severe Cases of SARS-CoV-2 Infection in Pediatric Patients.	Not a randomized trial
Sahin 2021	Effectiveness of ozone therapy in addition to conventional treatment on mortality in patients with COVID-19.	Oxygen delivery
	Effect of a single high dose of Vitamin D-3 on hospital length of stay in patients with	, ,
Kara 2021	moderate to severe COVID-19 A randomized clinical trial	Not a randomized trial
Stephenson 2021	Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19.	Vaccine
Wu 2021	Tolerability, Safety, Pharmacokinetics, and Immunogenicity of a Novel SARS-CoV-2 Neutralizing Antibody, Etesevimab in Chinese Healthy Adults: A Randomized, Double- Blind, Placebo-Controlled, First-In-Human Phase 1 Study.	Wrong population
Sanger 2021	A randomized controlled clinical trial to evaluate the potential of ayurvedic medicines in patients with mild symptoms of COVID-19	Traditional Chinese or alternative medicine
English 2021	Results of the cellular immuno-therapy for covid-19 related acute respiratory distress syndrome (circa-phase i trial	Not a randomized trial
PhilipeGobeil 2021	Interim Report of a Phase 2 Randomized Trial of a Plant-Produced Virus-Like Particle Vaccine for Covid-19 in Healthy Adults Aged 18-64 and Older Adults Aged 65 and Older	Vaccine
Babamahmoodi 2021	Effect of a herbal medicine containing Satureja hortensis L., Hypericum perforatum L. and foeniculum vulgare L. on patients with COVID-19 infection	Traditional Chinese or alternative medicine
Freeman 2021	Effects of different types of written vaccination information on COVID-19 vaccine hesitancy in the UK (OCEANS-III): a single-blind, parallel-group, randomised controlled trial.	Vaccine
Supady 2021	Cytokine adsorption in patients with severe COVID-19 pneumonia requiring extracorporeal membrane oxygenation (CYCOV): a single centre, open-label, randomised, controlled trial.	External organ support
Bian 2021	Safety and efficacy of meplazumab in healthy volunteers and COVID-19 patients: a randomized phase 1 and an exploratory phase 2 trial.	Not a randomized trial
Pimpinelli 2021	Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution.	Vaccine
lannone 2021	Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine during lxekizumab treatment for hidradenitis suppurativa	Vaccine
Ward 2021	Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19.	Vaccine
Keyhani 2021	A telehealth-based randomized controlled trial: A model for outpatient trials of off- label medications during the COVID-19 pandemic.	Not a randomized trial
Madhi 2021	Efficacy of the ChAdOxl nCoV-19 Covid-19 Vaccine against the B.1.351 Variant	Vaccine
Sehgal 2021	A randomised trial of Mycobacterium w in critically ill patients with COVID-19: ARMY- 1	Others
AlKaabi 2021	Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial	Vaccine

Zolotovskaia 2021	[Post-COVID-19 asthenic syndrome]	Not a randomized trial
Selvaraj 2021	Tocilizumab in Hospitalized Patients with COVID-19: A Meta Analysis of Randomized Controlled Trials	Not a randomized trial
Gagneux-Brunon 2021	Acceptability of a COVID-19 pre-exposure prophylaxis trial with hydroxychloroquine in French healthcare workers during the first wave of COVID-19 pandemic	Not a randomized trial
Tian 2021	Efficacy and safety of short-wave diathermy treatment for moderate COVID-19 patients: a prospective, double-blind, randomized controlled clinical study	Exercise/rehabilitation
Meister 2021	Virucidal Efficacy of Different Oral Rinses Against Severe Acute Respiratory Syndrome Coronavirus 2 (vol 222, pg 1289, 2020)	Not a randomized trial
Adly 2021	Telemanagement of Home-Isolated COVID-19 Patients Using Oxygen Therapy With Noninvasive Positive Pressure Ventilation and Physical Therapy Techniques: Randomized Clinical Trial.	Oxygen delivery
Feng 2021	Traditional Chinese Medicine Shenhuang Granule in Patients with Severe/Critical COVID-19: A Randomized Controlled Multicenter Trial	Traditional Chinese or alternative medicine
Takuva 2021	Thromboembolic Events in the South African Ad26.COV2.S Vaccine Study.	Vaccine
Oakes 2021	Effect of Opt-In vs Opt-Out Framing on Enrollment in a COVID-19 Surveillance Testing Program: The COVID SAFE Randomized Clinical Trial.	Wrong population
Gupta 2021	Prospective, randomized, open-label, blinded end point, two-arm, comparative clinical study to evaluate the efficacy and safety of a Fixed Ayurvedic Regimen (FAR) as add-on to conventional treatment in the management of mild and moderate COVID-19 patients	Traditional Chinese or alternative medicine
Patchen 2021	Genetically Predicted Serum Vitamin D and COVID-19: A Mendelian Randomization Study	Not a randomized trial
McQuade 2021	ChAdOx1 nCoV-19 vaccine: asymptomatic efficacy estimates	Not a randomized trial
Sarmiento 2021	Ruxolitinib for Severe COVID-19-Related Hyperinflammation in Nonresponders to Steroids	Not a randomized trial
Jaber 2021	Effect of the use of an endotracheal tube and stylet versus an endotracheal tube alone on first-attempt intubation success: a multicentre, randomised clinical trial in 999 patients.	Wrong population
Richier 2021	Efficacit√© du Tocilizumab dans la COVID-19¬†mod√©r√©e √† s√©v√®re¬†: une cohorte fran√Baise expos√©-non expos√©	Not a randomized trial
Spagnuolo 2021	Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19 (vol 10, 21291, 2020)	Not a randomized trial
Sozio 2021	CORonavirus-19 mild to moderate pneumonia Management with blood Ozonization in patients with Respiratory failure (CORMOR) multicentric prospective randomized clinical trial	Oxygen delivery
AlShehry 2021	Safety and Efficacy of Convalescent Plasma for Severe COVID-19: Interim Report of a Multicenter Phase II Study from Saudi Arabia (vol 9, pg 16, 2021)	Not a randomized trial
ArvindChopra 2021	Coadministration of AYUSH 64 as an adjunct to Standard of Care in mild and moderate COVID-19: A randomised, controlled, multicentric clinical trial	Traditional Chinese or alternative medicine
Pan 2021	Immunogenicity and safety of a severe acute respiratory syndrome coronavirus 2 inactivated vaccine in healthy adults: randomized, double-blind, and placebocontrolled phase 1 and phase 2 clinical trials.	Vaccine
Lanthier 2021	[In patients hospitalized for COVID-19 with hypoxia and systemic inflammation, does tocilizumab reduce 28-days mortality compared to standard treatment, and is it safe?]	Not a randomized trial
Nursilawatisyamsi 2021	The effectiveness of poly-herbal adjuvants for the standard treatment of COVID 19 in patients withmoderate degree	Traditional Chinese or alternative medicine
dePaulaEduardo 2021	Salivary SARS-CoV-2 load reduction with mouthwash use: a randomized pilot clinical trial	Others
Polineni 2021	A phase iia, double-blinded, randomized placebo-controlled trial of mapkapk2 inhibition by ati-450 in treatment of moderate-severe covid-19 pneumonia	Randomized trial with no results (e.g. trial registry)
Hulbert 2021	Respiratory disease, and treatment / thematic poster session a novel approach to medical monitoring during the sars-cov-2 pandemic supporting the activ 4b outpatient anticoagulation trial	Not a randomized trial
		,

Youssef 2021 comorbidities		Not a randomized trial
Administration of COVID System	D-19 convalescent plasma in a metropolitan health care	Not a randomized trial
	city of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS- a single-arm substudy of a phase 2/3 clinical trial	Vaccine
Inhaled nitric oxide for t Wolak 2021 adults	the treatment of COVID-19 and other viral pneumonias in	Randomized trial with no results (e.g. trial registry)
Mertes 2021 COVID-19-related ARDS	n of trans-crocetin enhances oxygenation in patients with receiving mechanical ventilation	Randomized trial with no results (e.g. trial registry)
•	imated, social media video intervention on COVID-19 andomized controlled trial of 15,163 adults in the USA, Mexico, n.	Wrong population
Potential effects of itolia with severe COVID-19.	zumab treatment on plasma interleukin-6 levels in patients	Not a randomized trial
Tolerability and Immuno nCoV-19 (AZD1222) (pre	ogenicity After a Late Second Dose or a Third Dose of ChAdOx1 eprint)	Vaccine
Protein Vaccine (MVCCC	city of a Recombinant Stabilized Prefusion SARS-CoV-2 Spike DV1901) Adjuvanted with CpG 1018 and Aluminum Hydroxide se 1, dose-escalation study	Vaccine
participants (CombiVacs Borobia 2021 trial	actogenicity of BNT162b2 booster in ChAdOx1-S-primed S): a multicentre, open-label, randomised, controlled, phase 2	Vaccine
	immunogenicity of an inactivated SARS-CoV-2 vaccine children and adolescents: a double-blind, randomised, inical trial	Vaccine
	VX-CoV2373 Covid-19 Vaccine	Vaccine
Rodriguez-Blanco Short-Term Effects of a	Conditioning Telerehabilitation Program in Confined Patients	
•	n the Acute Phase. A Pilot Randomized Controlled Trial prove severe COVID-19 via ameliorating endothelial injury	Exercise/rehabilitation
Kim 2021 and inflammation: A pre Randomised, controlled	eliminary pilot study. I, open label, multicentre clinical trial to explore safety and	Not a randomized trial
Kjellberg 2021 adult patients with COV		Oxygen delivery
Edara 2021 B.1.617 Variants	nduced Neutralizing-Antibody Responses to the SARS-CoV-2	Vaccine
	city of an inactivated SARS-CoV-2 vaccine in healthy adults A randomized, double-blind, placebo-controlled, phase 1/2	Vaccine
Efficacy and safety of ar interim results of a doul	n inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): ble-blind, randomised, placebo-controlled, phase 3 trial in	
Tanriover 2021 Turkey		Vaccine
	ds against covid ,Äì 19 in Kirkuk city/ Iraq	Traditional Chinese or alternative medicine
	thylene blue photochemical treatment as a reliable SARS-CoV- ion method for blood safety and convalescent plasma therapy	Not a randomized trial
Phase I/II Clinical Trial o	f Autologous Activated Platelet-Rich Plasma (aaPRP) in the ronavirus Disease 2019 (COVID-19) Patients	Not a randomized trial
The Effect of Intravenou	us Autologous Activated Platelet-Rich Plasma Therapy on ine" IL-1β Levels in Severe and Critical COVID-19	Not a randomized trial
	ntedanib for pulmonary fibrosis in severe pneumonia induced	Not a randomized trial
•	treatment of COVID-19 among hospitalized patients	Not a randomized trial

Torres 2021	Effect of Physician-Delivered COVID-19 Public Health Messages and Messages Acknowledging Racial Inequity on Black and White Adults' Knowledge, Beliefs, and Practices Related to COVID-19: A Randomized Clinical Trial	Wrong population
Liu 2021	Combination of Hua Shi Bai Du Granule (Q-14) and Standard Care in the Treatment of Patients with Coronavirus Disease 2019 (COVID-19): A Single-center, Open-label, Randomized Controlled Trial	Traditional Chinese or alternative medicine
Gonzalez-Gerez 2021	Short-Term Effects of a Respiratory Telerehabilitation Program in Confined COVID-19 Patients in the Acute Phase: A Pilot Study	Exercise/rehabilitation
Wanfangdan 2020	Influence of Baduanjin on the health effects of patients with cold-dampness- stagnation type of new coronavirus pneumonia	Exercise/rehabilitation
Hu Cong 2020	The clinical efficacy of high-dose or low-dose chloroquine diphosphate as an adjuvant treatment for hospitalized patients with novel coronavirus pneumonia Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine released the results of a multi-center clinical study of hydroxychloroquine in the treatment of	Not a randomized trial
NR 2020	novel coronavirus pneumonia %J Journal of Shanghai Jiaotong University (Medical Edition	Not a randomized trial
Wei Runan 2020	A multi-center, prospective study of early abidol + lopinavir/ritonavir + recombinant interferon α-2b combined antiviral therapy in patients with novel coronavirus pneumonia in Zhejiang Province Preliminary clinical efficacy analysis of traditional Chinese medicine taken orally plus	Not a randomized trial
Wang Yali 2020	fumigation combined with super-high dose vitamin C in the treatment of new coronavirus pneumonia	Others
Li Min 2020	Observation of the application effect of high-flow humidification oxygen therapy through the nose in the treatment of new coronavirus pneumonia complicated with acute respiratory failure	Oxygen delivery
Summer Games 2020	Comparison of the clinical effects of conventional nasal catheter oxygen inhalation and high-flow oxygen inhalation in the treatment of new coronavirus pneumonia	Oxygen delivery
Liu Huijun 2020	Clinical effect of dulaglutide injection in the treatment of new type of coronavirus pneumonia with type 2 diabetes	Randomized trial with no results (e.g. trial registry)
Yan Bohua 2020	Large-sample prospective clinical study of Huoxiangzhengqi Oral Liquid and Jinhaojiere Granules in the preventive intervention of COVID-19 in the community %J Chinese Journal of Chinese Materia Medica	Traditional Chinese or alternative medicine
Sun Huimin 2020	Clinical Observation of Lianhua Qingke Granules in Treating Mild and Common New Type Coronavirus Pneumonia	Traditional Chinese or alternative medicine
Shi Suofang 2020	Clinical Study on Treatment of 30 Cases of Qi and Yin Deficiency Syndrome in the Recovery Period of Novel Coronavirus Pneumonia by Comprehensive Therapy of Traditional Chinese Medicine	Traditional Chinese or alternative medicine
Liu Lin 2020	Effect of moxibustion on clinical symptoms, peripheral blood inflammatory indexes and T lymphocyte subsets in patients with new coronavirus pneumonia	Traditional Chinese or alternative medicine
Huffin 2020	Multicenter clinical observation of honeysuckle oral liquid combined with western medicine in the treatment of common type of new coronavirus pneumonia	Traditional Chinese or alternative medicine
Zhang Youli 2020	Analysis of Clinical Efficacy of Honeysuckle Oral Liquid in the Treatment of 80 Cases of New Coronavirus Pneumonia	Traditional Chinese or alternative medicine
Ding Xiaojuan 2020	Clinical efficacy and mechanism of Qingfei Touxie Fuzheng Recipe in the treatment of new coronavirus pneumonia	Traditional Chinese or alternative medicine
Ding Xiaojuan 2020	Study on the Clinical Efficacy and Mechanism of Qingfei Toxie Fuzheng Decoction in the Treatment of Novel Coronavirus Pneumonia	Traditional Chinese or alternative medicine
Yu Ping 2020	Efficacy of Lianhua Qingwen Granules combined with Arbidol in the treatment of mild new coronavirus pneumonia	Traditional Chinese or alternative medicine
Duan Can 2020	Clinical Observation of Jinhua Qinggan Granules in Treating New Type Coronavirus Infected Pneumonia	Traditional Chinese or alternative medicine
Zhang Chuantao 2020	Clinical study on the treatment of new type of coronavirus pneumonia (COVID-19	Traditional Chinese or alternative medicine
Fu Xiaoxia 2020	Clinical Study on 37 Cases of Novel Coronavirus Pneumonia Treated by Integrated Traditional Chinese and Western Medicine	Traditional Chinese or alternative medicine

Yan Bohua 2020	Large-sample prospective clinical study on the preventive intervention of COVID-19 in the community by the combined use of Huoxiangzhengqi oral liquid and Jinhaojiere granules	Traditional Chinese or alternative medicine
Qiu Min 2020	Observation on the Efficacy of Maxing Xuanfei Jiedu Decoction in the Treatment of New Type Coronavirus Pneumonia	Traditional Chinese or alternative medicine
Wang Yali 2020	Preliminary clinical efficacy analysis of oral Chinese medicine plus fumigation combined with super-high dose vitamin C in the treatment of new coronavirus pneumonia	Traditional Chinese or alternative medicine
Sun Huimin 2020	Study on the clinical efficacy of Lianhua Qingke Granules in the treatment of mild and common new coronavirus pneumonia	Traditional Chinese or alternative medicine
Liu Mailan 2020	Research on the Significance and Operation Mode of Moxibustion Intervention for New Coronavirus Pneumonia Close Contact and Isolated Persons	Traditional Chinese or alternative medicine
Wang 2021	Efficacy and Safety of Leflunomide for Refractory COVID-19: A Pilot Study	Not a randomized trial
Olender 2021	Remdesivir Versus Standard-of-Care for Severe Coronavirus Disease 2019 Infection: An Analysis of 28-Day Mortality	Not a randomized trial
[DataMissing] 2021	Early convalescent plasma may lower risk and progression of COVID in seniors ,Äî Argentine trial	Not a randomized trial
Plaza 2020	Use of Convalescent Plasma in COVID-19 Patients: Guayaquil, Ecuador Experience	Not a randomized trial
Premachandran 2021	AVIFAVIR in Treating Patients with Moderate COVID 19Ivashchenko AA, Kirill AD, Natalia VV, et al. AVIFAVIR for treatment of patients with moderate COVID-19: interim results of a phase II/III multicenter randomized clinical trial. Clin Infect Dis. 2021;	Not a randomized trial
Haibel 2021	Successful treatment of severe COVID-19 pneumonia and cytokine release with simultaneous tocilizumab and anakinra with one-month follow-up	Not a randomized trial
Weinbergerova 2021	Successful early treatment combining remdesivir with high-titer convalescent plasma among COVID-19-infected hematological patients	Not a randomized trial
Schernthaner 2021	Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19 (Diabetes Metab J 2021;45:251-9).	Not a randomized trial
AntoniaAnna 2021	Candesartan as a tentative treatment for COVID-19: a prospective non-randomized open-label study. (Special Issue: Coronavirus (COVID-19) collection.)	Not a randomized trial
MousaviDarzikolaee 2021	Low-dose whole-lung irradiation in severe COVID-19 pneumonia: a controlled clinical trial.	Not a randomized trial
Reactions Weekly 2021	Remdesivir vs tocilizumab in COVID-19: adverse event profiles	Not a randomized trial
Mousavi 2021	Melatonin effects on sleep quality and outcomes of COVID-19 patients: An open-label, Randomized, Controlled Trial.	Not a randomized trial
Zhang 2021	SIM01 as a novel microbiome replacement therapy for COVID-19: An open-label pilot study	Not a randomized trial
Ebrahimi 2021	Evaluating the efficacy of extracted squalene from seed oil in the form of microemulsion for the treatment of COVID-19: A clinical study	Not a randomized trial
Gupta 2021	Open-label randomized control trial of hydroxychloroquine in patients with moderate to severe coronavirus disease 2019 infection	Not a randomized trial
Khah 2021	The effect of online mindfulness program on physical pain, stress and depression in the covid-19 patients: A randomized control trail	Psychological and educational
Elzein 2021	In vivo evaluation of the virucidal efficacy of chlorhexidine and povidone-iodine mouthwashes against salivary SARS-CoV-2. A randomized-controlled clinical trial	Others
DeMarchi 2021	Effects of Photobiomodulation Therapy Combined with Static Magnetic Field in Severe COVID-19 Patients Requiring Intubation: A Pragmatic Randomized Placebo-Controlled Trial	Others
Rangon 2021	Auricular Neuromodulation for Mass Vagus Nerve Stimulation: Insights From SOS COVID-19 a Multicentric, Randomized, Controlled, Double-Blind French Pilot Study	Others
Granados-Montiel 2021	New prophylaxis regimen for SARS-CoV-2 infection in health professionals with low doses of hydroxychloroquine and bromhexine: a randomised, double-blind placebo clinical trial (ELEVATE Trial).	Randomized trial with no results (e.g. trial registry)

	SPIKE-1: A Randomised Phase II/III trial in a community setting, assessing use of camostat in reducing the clinical progression of COVID-19 by blocking SARS-CoV-2	Randomized trial with no
Halford 2021	Spike protein-initiated membrane fusion	results (e.g. trial registry)
Meng 2021	Safety, tolerability, pharmacokinetic characteristics, and immunogenicity of MW33: A Phase 1 clinical study of the SARS-CoV-2 RBD-targeting monoclonal antibody.	Wrong population
Holman 2021	Accelerated first-in-human clinical trial of EIDD-2801/MK-4482 (molnupiravir), a ribonucleoside analog with potent antiviral activity against SARS-CoV-2 Cytokine adsorption in patients with severe COVID-19 pneumonia requiring	Wrong population
Supady 2021	extracorporeal membrane oxygenation (CYCOV): a single centre, open-label, randomised, controlled trial (vol 9, pg 755, 2021)	External organ support
MohammadBargahi 2021	Effect of Balloon-Blowing on Dyspnea and Oxygenation in Noncritical Adult Covid19 Patients: A Pilot Study	Oxygen delivery
Fakhr 2021	Inhaled High Dose Nitric Oxide is a Safe and Effective Respiratory Treatment in Spontaneous Breathing Hospitalized Patients with COVID-19 pneumonia	Oxygen delivery
Ehrmann 2021	Awake prone positioning for COVID-19 acute hypoxaemic respiratory failure: a randomised, controlled, multinational, open-label meta-trial	Oxygen delivery
AlKaabi 2021	Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial.	Vaccine
AlKaabi 2021	Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in AdultsA Randomized Clinical Trial: The Journal of the American Medical Association	Vaccine
Shu 2021	Immunogenicity and safety of a recombinant fusion protein vaccine (V-01) against coronavirus disease 2019 in healthy adults: a randomized, double-blind, placebocontrolled, phase II trial.	Vaccine
Mulhern 2021	Humoral Response to mRNA versus an Adenovirus Vector-Based SARS-COV2 (Ad26.COV2.S) Vaccine in Dialysis Patients.	Vaccine
Wu 2021	Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial.	Vaccine
YongliangFeng 2021	Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccine in High-Risk Occupational Population: a randomized, parallel, controlled clinical trial	Vaccine
Segundo 2021	Immune assessment of BNT162b2 m-RNA-spike based vaccine response in adults	Vaccine
ValerieGOUNANT 2021	Efficacy of SARS-CoV-2 vaccine in thoracic cancer patients: a prospective study supporting a third dose in patients with minimal serologic response after two vaccine doses	Vaccine
Urbanowicz 2021	Two doses of the SARS-CoV-2 BNT162b2 vaccine enhances antibody responses to variants in individuals with prior SARS-CoV-2 infection.	Vaccine
Ali 2021	Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents.	Vaccine
Kremsner 2021	Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2: A phase 1 randomized clinical trial.	Vaccine
	Safety and immunogenicity of a recombinant interferon-armed RBD dimer vaccine (V-01) for COVID-19 in healthy adults: a randomized, double-blind, placebo-controlled,	
Zhang 2021	Phase I trial. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-	Vaccine
Madhi 2021	CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial. A Phase 2/3, Observer-Blind, Randomised, Controlled Study to Assess the Safety and	Vaccine
Kulkarni 2021	Immunogenicity of SII-ChAdOx1 nCOV-19 (COVID-19 Vaccine) in Adults in India (preprint) Additional heterologous versus homologous booster vaccination in	Vaccine
MichaelBonelli 2021	immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomized controlled trial	Vaccine
Meylan 2021	Safety and efficacy of the Oxford-AstraZeneca vaccine: Interim analysis of four randomized controlled trials	Vaccine
Elayman 2024	Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001	Vaccino
Flaxman 2021	and COV002)	Vaccine

	Efficacy of Huoxiang Zhengqi dropping pills and Lianhua Qingwen granules in treatment of COVID-19: a randomized controlled trial. (Special Issue:	Traditional Chinese or
Xiao 2020	Pharmacoepidemiology and pathogenetics of 2019-nCoV.)	alternative medicine
Koshak 2021	Nigella sativa for the treatment of COVID-19;an open-label randomized controlled clinical trial	Traditional Chinese or alternative medicine
Donousch 2021	A randomized, open-label, multicentre, comparative study of therapeutic efficacy, safety, and tolerability of BNO 1030 extract, containing marshmallow root, chamomile flowers, horsetail herb, walnut leaves, yarrow herb, oak bark, dandelion herb, in the	Traditional Chinese or alternative medicine
Popovych 2021	tr Efficacy of two siddha polyherbal decoctions, Nilavembu Kudineer and Kaba Sura	alternative medicine
Srivastava 2021	Kudineer, along with standard allopathy treatment in the management of mild to moderate symptomatic COVID-19 patients-a double-blind, placebo-controlled, clinical trial	Traditional Chinese or alternative medicine
Jayanthi 2021	A randomized control study to evaluate the role of herbal immunomodulators in boosting the immunity and overall health of healthcare workers in COVID-19 wards: An exploratory, feedback clinical study	Traditional Chinese or alternative medicine
50,000000000000000000000000000000000000	<u> </u>	areamative meananie
Mohamed 2021	The effect of aerobic exercise on immune biomarkers and symptoms severity and progression in patients with COVID-19: A randomized control trial	Exercise/rehabilitation
Almaghlouth 2021	THE USE OF SINGLE THERAPY WITH TOCILIZUMAB VERSUS COMBINATION THERAPY WITH REMDESIVIR IN SARS-COV-2 PATIENTS IN EL PASO TEXAS	Duplicate
Papachristofilou 2021	Low dose radiation therapy for severe COVID-19 pneumonia: a randomized double- blind study	Others
Corritori 2021	Multicenter, open-labeled efficacy study of avifavir in patients with COVID-19	Not a randomized trial
Avdeev 2021	Beneficial effects of inhaled surfactant in patients with COVID-19-associated acute respiratory distress syndrome.	Not a randomized trial
KaviSharma 2021	Prospective, Randomized, Parallel-Group, Open-Label Study to Evaluate the Efficacy and Safety of IMU-838, in Combination with Oseltamivir, in Adults with Coronavirus Disease 19 The IONIC Trial	Randomized trial with no results (e.g. trial registry)
Liu 2021	Effect of qigong exercise and acupressure rehabilitation program on pulmonary function and respiratory symptoms in patients hospitalized with severe COVID-19: a randomized controlled trial	Exercise/rehabilitation
Liu 2021	Effect of qigong exercise and acupressure rehabilitation program on pulmonary function and respiratory symptoms in patients hospitalized with severe COVID-19	Exercise/rehabilitation
McClellandlii 2021	Low-Dose Whole Thorax Radiation Therapy for COVID-19 Pneumonia: Inpatient Onboarding Process for a Randomized Controlled Trial	External organ support
Esposito 2021	Effects of different dialysis techniques on inflammation in maintenance hemodialysis patients with covid-19: A randomized study	External organ support
Dengiz 2022	Ozone gas applied through nebulization as adjuvant treatment for lung respiratory diseases due to COVID-19 infections: a prospective randomized trial	External organ support
Pablo-Marcos 2021	[YODADA Y PEROXIDO DE HIDROGENO EN PACIENTES CON COVID-19].	Not a randomized trial
Ortiz 2021	The clinical efficacy of low-dose whole-lung irradiation in moderate-to-severe COVID-19 pneumonia: RTMX-20 trial	Not a randomized trial
	Lactobacillus plantarum induces innate cytokine responses that potentially provide a protective benefit against COVID-19: A single-arm, double-blind, prospective trial	
Kageyama 2022	combined with an in vitro cytokine response assay	Not a randomized trial
Gong 2021	Efficacy and Safety of Lianhuaqingwen Capsules for the Prevention of Coronavirus Disease 2019: A Prospective Open-Label Controlled Trial	Not a randomized trial
Shindo 2021	Japanese, multicenter, phase II trial of combination therapy with favipiravir and methylprednisolone for COVID,Äê19 patients with non,Äêcritical respiratory failure: the J,Äêcritical trial	Not a randomized trial
Feng 2021	Yindan Jiedu granules exhibit anti-inflammatory effect in patients with novel Coronavirus disease (COVID-19) by suppressing the NF-kappaB signaling pathway	Not a randomized trial
Abolghasemi 2021	Impact of time and mechanical ventilation on convalescent plasma in severe/critically ill COVID-19 patients	Not a randomized trial
Campione 2021	Lactoferrin as antiviral treatment in COVID-19 management: Preliminary evidence	Not a randomized trial

wang 2021	Potent Anti-Delta Effect By a Booster Third-Dose of UB-612, a Precision-Designed SARS-CoV-2 Multitope Protein-Peptide Vaccine (preprint)	Not a randomized trial
Grbovic 2021	The effects of respiratory exercises on partial pressures of gases and anxiety in the acute phase of COVID-19 infection	Not a randomized trial
Perrone 2021	Correction to: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial	Not a randomized trial
Mahajan 2021	Role of Dexamethasone on Oxygen Requirement, Mortality, and Survival Incidence among COVID-19 Patients: Quasi-Experimental Study.	Not a randomized trial
Erelel 2021	Early Effects of Low Molecular Weight Heparin Therapy with Soft-Mist Inhaler for COVID-19-Induced Hypoxemia: A Phase IIb Trial	Not a randomized trial
Dehghan 2021	The potential anti-inflammatory effects of zerumbone in covid-19 patients	Not a randomized trial
Soliman 2021	Impact of Vitamin D Therapy on the Progress COVID-19: Six Weeks Follow-Up Study of Vitamin D Deficient Elderly Diabetes Patients	Not a randomized trial
Khamis 2021	Convalescent Plasma Therapy in Critically III COVID-19 Patients: An Open Label Trial	Not a randomized trial
Kerekes 2021	Differential Effect of Vaccine Effectiveness and Safety on COVID-19 Vaccine Acceptance across Socioeconomic Groups in an International Sample	Not a randomized trial
Alsuwaidan 2021	The utilization of hydroxychloroquine to reduce the main signs and symptoms of COVID-19 patients, a cross-sectional study	Not a randomized trial
Mateo 2020	Remdesivir Reduces Time to Recovery in Adults Hospitalized with COVID-19: A Meaningful Step in Therapeutic Discovery	Not a randomized trial
Lakkireddy 2021	Author Correction: Impact of daily high dose oral vitamin D therapy on the inflammatory markers in patients with COVID 19 disease (Scientific Reports, (2021), 11, 1, (10641), 10.1038/s41598-021-90189-4)	Not a randomized trial
Wenban 2021	Dexamethasone treatment may mitigate adverse effects of vitamin D deficiency in hospitalized Covid-19 patients.	Not a randomized trial
Kalil 2021	Baricitinib: the first immunomodulatory treatment to reduce COVID-19 mortality in a placebo-controlled trial.	Not a randomized trial
Al-Kuraishy 2021	Impact of Sitagliptin in Non-Diabetic Covid-19 Patients.	Not a randomized trial
Kravchenko 2021	Covid-19 in pregnancy: Special characteristics of the course and rational therapy with recombinant interferon alfa-2b formulations	Not a randomized trial
Vercueil 2021	Efficacy of Serotherapy on an N501Y Variant of SARS-CoV-2 in a Patient With Chronic Lymphocytic Leukemia	Not a randomized trial
Yadav 2021	Humoral Response to One and Two Doses of ChAdOx1-S Vaccine in Patients on Hemodialysis	Not a randomized trial
Pfeifer 2021	Phase I study in healthy participants to evaluate safety, tolerability, and pharmacokinetics of inhaled nezulcitinib, a potential treatment for COVID-19.	Wrong population
VanWyk 2021	Switching to dolutegravir/lamivudine (DTG/3TC) fixed-dose combination (FDC) is non-inferior to continuing a tenofovir alafenamide (TAF)-based regimen (TBR) in maintaining virological suppression through 96 weeks (TANGO study)	Wrong population
Li 2021	Safety, tolerability, pharmacokinetics and immunogenicity of a monoclonal antibody (SCTA01) targeting SARS-CoV-2 in healthy adults: A randomized, double-blind, placebo-controlled, phase I study.	Wrong population
Borujerdi 2022	Effects of Iranian Polyherbal Syrup (Zufa syrup) on oxygen saturation and clinical symptoms in suspected patients with COVID-19: a triple-blinded, randomized, placebo-controlled trial	Nutrition and supplements
PereMillat-Martinez 2021	Convalescent plasma for outpatients with early COVID-19	Others
Helsingen 2021	Covid-19 transmission in fitness centers in Norway - a randomized trial	Others
Hore 2024	Whole-Lung Low-Dose Radiation Therapy (LD-RT) for Non-Intubated Oxygen- Dependent Patients with COVID-19-Related Pneumonia Receiving Dexamethasone	Othors
Hess 2021	and/or Remdesevir	Others
Hess 2021	Reduced Intubation Rates Following Whole-Lung Low-Dose Radiation Therapy (LD-RT) in Patients With COVID-19-Related Pneumonia	Others

Dominguez-Nicolas	Low-field thoracic magnetic stimulation increases peripheral oxygen saturation levels in coronavirus disease (COVID-19) patients: A single-blind, sham-controlled, crossover	
2021	study.	Others
daSilvaSantos 2021	Beneficial effects of a mouthwash containing an antiviral phthalocyanine derivative on the length of hospital stay for COVID-19: randomised trial.	Others
	ORAL GARGLE OF ETHANOL-BASED MOUTHWASH SOLUTION AND ITS EFFECTS ON	
CyrilVitug 2021	ADULT PATIENTS WITH MILD COVID-19 INFECTION: AN OPEN LABEL-RANDOMIZED CONTROLLED TRIAL	Others
Cymvitag 2021	Effect of PEP flute self-care versus usual care in early covid-19: non-drug, open label,	Circis
Mollerup 2021	randomised controlled trial in a Danish community setting.	Oxygen delivery
	Dyspnoea and clinical outcome in critically ill patients receiving noninvasive support	
Menga 2021	for COVID-19 respiratory failure: <i>post hoc</i> analysis of a randomised clinical trial.	Oxygen delivery
MikeFralick 2021	Prone positioning of patients with moderate hypoxia due to COVID-19: A multicenter pragmatic randomized trial	Oxygen delivery
WIREFIANCE 2021		Oxygen delivery
Menga 2021	Dyspnoea and clinical outcome in critically ill patients receiving noninvasive support for COVID-19 respiratory failure: post hoc analysis of a randomised clinical trial	Oxygen delivery
	Use of Airway Pressure Release Ventilation in Patients With Acute Respiratory Failure	
Ibarra-Estrada 2021	Due to Coronavirus Disease 2019: Results of a Single-Center Randomized Controlled Trial	Oxygen delivery
	Comparison of High-Flow Nasal Cannula and Noninvasive Ventilation in Acute	
Nair 2021	Hypoxemic Respiratory Failure Due to Severe COVID-19 Pneumonia.	Oxygen delivery
	Inhaled beclomethasone in the treatment of early COVID,Äê19: A	Randomized trial with no
Ranasinha 2021	placebo,Äêcontrolled, randomized trial	results (e.g. trial registry)
	A multi-center, adaptive, randomized, platform trial to evaluate the effect of	Dandamizad trial with no
Reis 2021	repurposed medicines in outpatients with early coronavirus disease 2019 (COVID-19) and high-risk for complications: the TOGETHER master trial protocol (preprint)	Randomized trial with no results (e.g. trial registry)
	A multicenter, open-label, randomized, proof-of-concept phase ii clinical trial to	
	Assess the efficacy and safety of icatibant in patients infected with sars-cov-2 (covid-	Randomized trial with no
Gonzv°lez 2021	19) And admitted to hospital units without invasive mechanical ventilation. StudyPro	results (e.g. trial registry)
	Double-blind Placebo-controlled Randomized Clinical Trial to Assess the Efficacy of Montelukast in Mild to Moderate Respiratory Symptoms of Patients With Long COVID	Randomized trial with no
Mera-Cordero 2021	E-SPERANZA COVID PROJECT Study Protocol (preprint)	results (e.g. trial registry)
	Glenzocimab, a novel antiplatelet therapy in COVID-19 related acute respiratory	Randomized trial with no
Comenducci 2021	distress syndrome (ARDS): the garden study, a phase 2 clinical trial Efficacy and safety of Lianhua Qingwen capsules, a repurposed Chinese herb, in	results (e.g. trial registry)
	patients with Coronavirus disease 2019: A multicenter, prospective, randomized	Traditional Chinese or
Hu 2021	controlled trial [Phytomedicine 85 (2021) 153242]	alternative medicine
	Efficacy and safety of Bufei Huoxue capsules in the management of convalescent patients with COVID-19 infection: A multicentre, double-blind, and randomised	Traditional Chinese or
Chen 2021	controlled trial	alternative medicine
	Efficacy and Safety of Lianhuaqingwen Capsules, a repurposed Chinese Herb, in Patients with Coronavirus disease 2019: A multicenter, prospective, randomized	Traditional Chinese or
Hu 2021	controlled trial [Phytomedicine 85 (2021) 153242].	alternative medicine
7ang 2024	Therapeutic Effects of Traditional Chinese Medicine (Maxingshigan-Weijing	Traditional Chinese or
Zeng 2021	Decoction) on COVID-19: an open-label randomized controlled trial	alternative medicine
Zeng 2021	[Moxibustion on mental disorder in close contacts of coronavirus disease 2019: a randomized controlled trial].	Traditional Chinese or alternative medicine
	Kabasura Kudineer (KSK), a poly-herbal Siddha medicine, reduced SARS-CoV-2 viral	
	load in asymptomatic COVID-19 individuals as compared to vitamin C and zinc supplementation: findings from a prospective, exploratory, open-labeled,	Traditional Chinese or
Natarajan 2021	comparative, randomized c	alternative medicine
		Traditional Chinese or
Hu 2021	Cinobufacini Improves the Respiratory Function of Severe COVID-19 Patients	alternative medicine
An 2021	Efficacy of Jinhua Qinggan Granules Combined With Western Medicine in the Treatment of Confirmed and Suspected COVID-19: A Randomized Controlled Trial.	Traditional Chinese or alternative medicine
, 111 2021	Treatment of Committee and Suspected Covid-13. A Nationilized Controlled Hidl.	arternative medicine

Kumar 2021	Neutralization of SARS-CoV-2 Variants in Transplant Recipients After Two and Three Doses of mRNA-1273 Vaccine: Secondary Analysis of a Randomized Trial.	Vaccine
Kremsner 2021	Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial	Vaccine
Ramos-Martinez 2021	Effect of bcg revaccination on occupationally exposed medical personnel vaccinated against sars-cov-2	Vaccine
	Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co- administered with seasonal influenza vaccines: an exploratory substudy of a	
Toback 2021	randomised, observer-blinded, placebo-controlled, phase 3 trial	Vaccine
Lazarus 2021	Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial	Vaccine
Lazarus 2021		vaccine
Ella 2021	Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial BioNTech/Pfizer vaccine after Oxford/AZ vaccine increased immune response vs. no	Vaccine
Granwehr 2021	second vaccine	Vaccine
Asano 2021	Immunogenicity and safety of AZD1222 (ChAdOx1 nCoV-19) against SARS-CoV-2 in Japan: A double-blind, randomized controlled phase 1/2 trial	Vaccine
Enng 2021	Correlates of protection against symptomatic and asymptomatic SARS-CoV-2	Vassino
Feng 2021	infection. Safety and immunogenicity of a SARS-CoV-2 recombinant protein vaccine with AS03	Vaccine
Communicated and 2024	adjuvant in healthy adults: interim findings from a phase 2, randomised, dose-finding,	Vaccina
SaranyaSridhar 2021	multi-centre study	Vaccine
Wise 2021	Vaccinating against covid and flu at same time is safe, study shows COVID-19 vaccine in participants (ptcpts) with cancer: Subgroup analysis of	Vaccine
Thomas 2021	efficacy/safety from a global phase III randomized trial of the BNT162b2 (tozinameran) mRNA vaccine	Vaccine
Lisa 2021	Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico	Vaccine
KimberlyAKraynyak 2021	SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label Trial	Vaccine
Formica 2021	Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trial	Vaccine
Clemens 2021	Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil	Vaccine
	The Safety and Immunogenicity of Concomitant Administration of COVID-19 Vaccines (ChAdOx1 or BNT162b2) with Seasonal Influenza Vaccines in Adults: A Phase IV,	
Lazarus 2021	Multicentre Randomised Controlled Trial with Blinding (ComFluCOV) (preprint)	Vaccine
Falsey 2021	Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine. Safety and Immunogenicity of an Inactivated SARS-CoV-2 Vaccine in a Subgroup of	Vaccine
Bueno 2021	Healthy Adults in Chile. A Phase III, Observer-blind, Randomized, Placebo-controlled Study of the Efficacy, Safety, and Immunogenicity of SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged	Vaccine
Fadlyana 2021	18,Äì59 Years: An Interim Analysis in Indonesia	Vaccine
ElSahly 2021	Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase.	Vaccine
LindseyRBaden 2021	Covid-19 in the Phase 3 Trial of mRNA-1273 During the Delta-variant Surge	Vaccine
Xia 2021	Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial	Vaccine
Thomas 2021	Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months.	Vaccine
Richmond 2021	Persistence of the immune responses and cross-neutralizing activity with Variants of Concern following two doses of adjuvanted SCB-2019 COVID-19 vaccine.	Vaccine
	Homeopathic Medicines Used as Prophylaxis in Kolkata during the COVID-19	
Mukherjee 2021	Pandemic: A Community-Based, Cluster-Randomized Trial	Inaccessible full text

	Cytoresc, or cytosorb for COVID-19 patients with vasoplegic shock: A prospective	
Stockmann 2021	randomized pilot study	Inaccessible full text
	BLOCKADE OF INTERLEUKIN SEVENTEEN (IL-17A) IN HOSPITALIZED COVID-19	
Resende 2021	PATIENTS - THE BISHOP STUDY	Inaccessible full text
	Effect of the control	
	Efficacy of ixekizumab vs. IL-2 vs. colchicine vs. Standard of care for the treatment of	
	hospitalized patients with COVID-19: Preliminary results of a randomized clinical trial	
BonifV°cio 2021	(struck: Survival trial using cytokine inhibitors)	Inaccessible full text
Zupanets 2021	Quercetin effectiveness in patients with COVID-19 associated pneumonia	Inaccessible full text
	Efficacy and Safety of Ivermectin for Treatment and prophylaxis of COVID-19	Removed from preprint
Not reported	Pandemic	server
	Comparison of two different lung ultrasound imaging protocols in COVID-19	
Ökmen 2021	pneumonia.	Diagnostic imaging
	KalHydrogen inhalation in rehabilitation program of the medical staff recovered from	
Shogenova 2021	COVID-19.	Wrong population
	Effect of rivaroxaban (10mg) versus observation on the risk of thrombosis at discharge	
Ramos 2021	in individuals with covid-19	Wrong population
	Design and implementation of an international, multi-arm, multi-stage platform	
	master protocol for trials of novel SARS-CoV-2 antiviral agents: Therapeutics for	Randomized trial with no
Murray 2021	Inpatients with COVID-19 (TICO/ACTIV-3).	results (e.g. trial registry)
	Fidelity, tolerability and safety of acute high-intensity interval training after	·
Foged 2021	hospitalisation for COVID-19: a randomised cross-over trial	Wrong population



Study	Differences between study preprint and peer-reviewed publications
Abdelmaksoud, 2020	No substantive differences between the preprint and peer-reviewed publications.
Abdulamir_2, 2021	The peer-reviewed report includes a second trial registration. Funding is reported as none in the peer-reviewed report. Age, smoking, respiratory condition, CVD, diabetes, and hypertension are not included in the peer-reviewed report. Since patients included in the preprint and peer-reviewed paper are the same, we retained extractions from the preprint. Follow-up time for mortality is 30 days in the peer-reviewed report. Follow-up time for time to recovery (cure) is no longer reported in the peer-reviewed report. Mean and variance for time to recovery (cure) changed. We rated mortality and time-to-symptom resolution at probably high risk of bias for selective reporting. The peer-reviewed paper includes follow-up times that contradict the trial registration.
Ader_1_antiviral drugs, 2021; Discovery	No substantive differences between the preprint and peer-reviewed publications.
Ader_2_remdesi vir, 2021; Discovery	Viral clearance at day 8 is included in the supplement of the peer-reviewed report but not the preprint.
Babalola, 2021	The peer-reviewed paper reports that lopinavir-ritonavir is part of standard care. The peer-reviewed paper reports more details on randomization and allocation concealment. Risk of bias due to randomization changed from probably low to definitely low.
Barratt-Due, 2021; NOR- Solidarity	No substantive differences between the preprint and peer-reviewed publications.

Blum, 2021

Funding source was not reported in the preprint but is reported in the publication.

Median age is reported in the publication but not in the preprint.

The publication reports oxygen saturation, CRP, d-dimer, and lymphocyte count.

The results for adverse events leading to discontinuation changed from the preprint to the publication.

The publication reports additional details about the randomization process. The risk of bias for randomization changed from probably low to definitely low.

Cadegiani_1, 2021; EAT-DUTA AndroCoV

Baseline oxygen saturation is reported in the peer-reviewed publication but not the preprint.

Baseline CRP, d-Dimer, and LDH is reported in the peer-reviewed publication but not the preprint.

The peer-reviewed publication reports no events for mortality. The preprint did not explicitly report mortality.

The peer-reviewed publication reports no events for mechanical ventilation. The preprint did not explicitly report mechanical ventilation.

The peer-reviewed publication reports no events for admission to hospital. The preprint did not explicitly report admission to hospital.

The peer-reviewed publication reports no events for adverse events leading to discontinuation. The preprint did not explicitly report adverse events leading to discontinuation.

The peer-reviewed publication reports events for viral clearance at day 7. The preprint did not report this outcome.

The median time to symptom resolution changed between the preprint and peer-reviewed publications. The peer-reviewed publication only reports this outcome among those analysed, whereas the preprint reports this outcome among the ITT sample. The timepoint of this outcome changed from 60 days in the preprint to 30 days in the peer-reviewed publication.

Bias due to missing data was rated at high risk of bias since data in the peer-reviewed publication was only available for 87/130 (66.92%) of the participants.

Bias due to competing risk changed from probably low risk of bias to definitely low risk of bias. No deaths were confirmed in the peer-reviewed publication.

Chaccour, 2020; SAINT	No substantive differences between the preprint and peer-reviewed publications.
Chen_2, 2021	The peer-reviewed publication reports mean oxygen saturation levels at baseline whereas the preprint does not.
Chen_5, 2020	No substantive differences between the preprint and peer-reviewed publications.
Corral-Gudino, 2020; GLUCOCOVID	The peer-reviewed publication stratifies reporting for those who were truly randomized and those who were allocated by preference. The peer-reviewed publication mentions that the study terminated early due to decline of new cases. The number analysed in the methylprednisolone group was greater by one in the peer-reviewed publication compared to the preprint. Age, % male, % respiratory condition, % cardiovascular disease, % diabetes, % hypertension changed between the peer-reviewed and preprint publications. The peer-reviewed publication mentions that no patients took immunosuppressants prior to enrolment, whereas the preprint did not. The peer-reviewed publication reports baseline qSOFA score, whereas the preprint did not. Baseline CRP, d-Dimer, and lymphocyte count changed between the peer-reviewed and preprint publications. The peer-reviewed paper reports mortality among the randomized ITT sample. The event numbers and N analysed changed from those extracted from the preprint. The timeframe for mortality was explicitly reported as 28 days in the peer-reviewed publication. The peer-reviewed paper reports mechanical ventilation among the randomized ITT sample. The event numbers and N analysed changed from those extracted from the preprint. The peer-reviewed publication reports length of hospital stay whereas the preprint does not. The peer-reviewed publication reported more information on the method of randomization and allocation concealment compared to the preprint. Therefore, the rating for bias due to randomization changed from probably low to definitely low.

Cruz, 2020; ATENEA-Co-300	No substantive differences between the preprint and peer-reviewed publications.
Darazam_1, 2021; COVIFERON	The publication reports a name for the trial. The preprint reports no funding but the publication reports institutional funding.
Darazam_2, 2021; COVIFERON	No substantive differences between the preprint and peer-reviewed publications.
Davoudi- Monfared, 2020	No substantive differences between the preprint and peer-reviewed publications.
Delgado-Enciso, 2021; TX- COVID19	The preprint reports results on the first 84 patients recruited in the trial whereas the publication reports on 214 patients. Age, % male, smokers, respiratory condition, diabetes, hypertension, and oxygen saturation changed. The publication additionally reports the proportion of mild, moderate, and severe patients. The numbers for mortality, admission to hospital, adverse events leading to discontinuation, and time to symptom resolution changed.
Duarte, 2021	The preprint reports interim results and the publication reports final trials and so there are changes in baseline characteristics and number of participants randomized. The publication reports that the industry sponsor paid publishing fees. Age, % male, respiratory conditions, cardiovascular conditions, diabetes, and hypertension changed from the preprint to the publication. The proportion of participants receiving supplemental oxygen changed from the preprint to the publication. CRP, D-dimer, LDH, and lymphocyte count changed from the preprint to the publication. Results for mortality, ventilation, adverse events, and duration of hospitalization changed. Risk of bias for missing outcome data for mortality and mechanical ventilation changed from probably low to definitely low.

Dubee, 2021; HYCOVID	The preprint did not include information on allocation concealment but the publication reported on allocation concealment. The risk of bias due
IIICOVID	to randomization changed from probably low to definitely low.
Feld, 2020	The peer-reviewed publication reports % with diabetes and hypertension whereas the preprint does not.
Ghandehari, 2021	The peer-reviewed publication does not report the total number of patients that required ventilation at any point during the trial, however the preprint does. We retained the numbers from the preprint in our analyses. The median duration of hospitalization changed by 0.5 days in the progesterone group from the preprint.
Gonzalez-Ochoa, 2021	The publication reports baseline characteristics for the ITT population whereas the preprint reports baseline characteristics for the PP population. Age, male, respiratory condition, cardiovascular disease, diabetes, hypertension, and ACE inhibitors/ARB changed. The publication reports ITT outcome data for mortality, ventilation, hospitalization, venous thromboembolism, and duration of hospitalization whereas the preprint reports PP outcome data. Risk of bias changed from high to low for missing outcome data for mortality, ventilation, hospitalization, venous thromboembolism, and duration of hospitalization.
Gordon, 2021; REMAP-CAP	% with respiratory condition, % with cardiovascular condition, and % with diabetes changed. % with confirmed COVID19 changed. % on oxygen therapy at baseline changed. Baseline CRP, d-Dimer, and lymphocyte count changed. The peer-reviewed publication reports number of patients progressing to intubation in patients who are not mechanically vented at baseline. The preprint only reported the composite of death amd need for ECMO/ventilation. The peer-reviewed paper reports median (IQR) values for duration of hospitalization, whereas the preprint only included the Kaplan Meier curve. The peer-reviewed paper reports median (IQR) values ICU length of stay, whereas the preprint only included the Kaplan Meier curve

	The peer-reviewed paper reports ventilator free days, whereas the preprint does not.
Hernandez- Cardenas, 2021	No substantive differences between the preprint and peer-reviewed publications.
Horby_dexameth asone, 2020; RECOVERY	Number of males/females differ between the preprint and the peer-reviewed publications. Number of patients with positive PCR tests at baseline between the preprint and the peer-reviewed publications. There are more events for mortality and invasive mechanical ventilation in the peer-reviewed publication compared to the preprint. Discrepancies between the preliminary and final report: female who are pregnant changed. with confirmed COVID-19 at baseline changed. The number of events for mechanical ventilation among those who were not vented at baseline was greater in the final report compared to the preliminary report. Compared to the preliminary report, the final report includes a Kaplan Meier curve on discharge from hospital. The IQR for duration of hospital stay was extracted from the final report. Compared to the preliminary report, the final report includes a Kaplan Meier curve on successful removal from invasive mechanical ventilation. The median and IQR for duration of ventilation was extracted from the final report.
Horby_hydroxyc hloroquine, 2020; RECOVERY	There is one more male listed in the preprint report. There are more patients with laboratory-confirmed COVID19 in the trial report than in the preprint.

Horby_lopinavir- ritonavir, 2020; RECOVERY	There are more patients with baseline positive PCR results reported in the publication than in the preprint. The published report includes additional mortality events that likely accrued since the preprint was released. The published report includes additional mechanical ventilation events that likely accrued since the preprint was released. The published report includes IQR for duration of hospitalization and the preprint does not.
Horby_azithromy cin, 2021; RECOVERY	% with confirmed COVID-19 at baseline changed. The number of patients randomized to the usual care group was one less in the peer-reviewed publication compared to the preprint. There were more events for mortality at 28 days in the peer-reviewed publication compared to the preprint. The number of patients analyzed for this outcome in the usual care group is one less in the peer-reviewed publication compared to the preprint. There were more events for mechanical ventilation among those not vented at baseline in the peer-reviewed publication compared to the preprint. The number of patients analyzed for this outcome in the usual care group is one less in the peer-reviewed publication compared to the preprint.
Horby_tocilizuma b, 2021; RECOVERY	The number of pregnant patients is greater in the peer-reviewed report compared to the preprint. The number of confirmed COVID-19 cases is greater in the peer-reviewed report compared to the preprint. The number of events for mortality increased from the preprint. The number of events for need for mechanical ventilation increased from the preprint. Median duration of hospital stay in the tocilizumab group changed from 20 (preprint) to 19 days (peer-reviewed).
Horby_aspirin, 2021; RECOVERY	No substantive differences between the preprint and peer-reviewed publications.
Huang_2, 2020	Adverse events leading to discontinuation was reported in the peer- reviewed publication but not in the preprint.

Ivashchenko, 2020	Age, % male, oxygen saturation, and C-reactive protein are reported in the supplementary appendix of the preprint. The peer-reviewed publication does not include a supplementary appendix. % with pregnancy is only reported in the peer-reviewed publication. There was one more event for mortality reported in the peer-reviewed publication compared to the preprint. Adverse events leading to discontinuation was not reported in the preprint but was reported in the peer-reviewed publication.
Jagannathan, 2021	The publication reports the proportion of patients with respiratory conditions. The publication reports the proportion of patients with cardiovascular disease. The publication reports the proportion of patients with diabetes. The publication reports the proportion of patients with hypertension.
JamaliMoghada mSiahkali, 2021	The publication reports the number of patients with confirmed COVID-19.
Johnston, 2021; The COVID-19 Early Treatment Study	No substantive differences between the preprint and peer-reviewed publications.
Kirti, 2021	No substantive differences between the preprint and peer-reviewed publications.
Krolewiecki, 2021	The trial registration was incorrectly reported in the preprint. The publication additionally reports mortality. Duration of follow-up changed from 7 days to 30 days for mechanical ventilation.
Kumar, 2021	No substantive differences between the preprint and peer-reviewed publications.
Lawler, 2021; ATTACC, ACTIV- 4a, REMAP-CAP	Peer-reviewed publication reports a higher proportion of patients with severe cardiovascular disease at baseline. Peer-reviewed publication reports one less patient randomized to the usual care group.

	Peer-reviewed publication explicitly reports denominator for in-hospital mortality as 1180 (therapeutic heparin) and 1046 (usual care).
Lescure, 2021	No substantive differences between the preprint and peer-reviewed publications.
Li_1, 2020; ELACOI	No substantive differences between the preprint and peer-reviewed publications.
Li_2, 2021	The preprint reports duration of hospital stay whereas the peer-reviewed publication does not. The data was retained in our analyses.
Liesenborghs, 2021; LAWn	No substantive differences between the preprint and peer-reviewed publications.
Lopes_2, 2021	Age, % male, % smoker, % with respiratory condition, % with cardiovascular condition, % with diabetes changed between the preprint and peer-reviewed publication. Illness severity score changed. % on oxygen therapy at baseline changed. Quantity of supplemental oxygen at baseline changed. Baseline ALT, d-Dimer, LDH, and lymphocyte count changed. The number of patients randomized changed since the preprint reported interim results only. The number of events for mortality increased in the peer-reviewed publication. The number of patients analysed for this outcome also increased. The number of patients analysed for AEs leading to discontinuation increased. The number of patients analysed for duration of hospital stay increased. Median duration of hospital stay changed between the preprint and peer-reviewed publication.
Lopez-Medina, 2021; EPIC	The final report includes one more event for mortality in the placebo group. The final report includes mechanical ventilation at day 8.
Lou, 2020	No substantive differences between the preprint and peer-reviewed publications.

Lyngbakken, 2020; NO COVID	The published report includes a link to the protocol on OSF but the preprint does not. The protocol does not change the risk of bias rating of selective reporting. Deaths are reported in the published report but not the preprint. The published report includes a link to a data repository that reports data on MV and duration of hospitalization.
Marconi, 2021; COV-BARRIER	The peer-reviewed report includes 60 day mortality whereas the preprint only includes 28 day mortality. The peer-reviewed report includes more details on randomization. The risk of bias rating changed from probably low to definitely low risk of bias. The peer-reviewed report includes a protocol in the supplementary appendix. We changed selective reporting for outcomes mechanical ventilation, AEs leading to discontinuation, and time to improvement from probably low to definitely low risk of bias.
Mobarak, 2021; DISCOVER	The peer-reviewed paper reports proportion of patients on oxygen therapy at baseline. The preprint does not. The peer-reviewed paper reports more events for all-cause mortality than the preprint: 71/541 (sofosbuvir-daclatasvir) and 62/542 (placebo) vs 68/541 (sofosbuvir-daclatasvir) and 60/542 (placebo). The peer-reviewed paper reports fewer events for mechanical ventilation than the preprint: 13/541 (sofosbuvir-daclatasvir) and 10/542 (placebo) vs 18/541 (sofosbuvir-daclatasvir) and 12/542 (placebo).
Mohan, 2021; RIVET-COV	No substantive differences between the preprint and peer-reviewed publications.

Murai, 2021	Age, % male, % with COPD and asthma, % with cardiovascular disease, % with diabetes, % with hypertension changed. % with confirmed COVID-19 was not reported in the preprint but was reported in the peer-reviewed publication. % on oxygen therapy and non-invasive mechanical ventilation at baseline changed. Baseline CRP, d-Dimer, and lymphocyte count changed. The number of events for mortality in the vitamin D3 arm increased by 1 in the peer-reviewed publication. The number of patients analysed for this outcome changed between the preprint and peer-reviewed publication. The number of events for mechanical ventilation in the vitamin D3 arm increased by 1 in the peer-reviewed publication. The number of patients analysed for this outcome changed between the preprint and peer-reviewed publication. The number of patients analysed for duration of hospital stay changed between the preprint and peer-reviewed publication. The variability reported in the preprint was a 95% CI whereas the peer-reviewed publication reported an IQR. The number of patients analysed for duration of mechanical ventilation changed in the vitamin D3 arm. The peer-reviewed publication reports a mean whereas the preprint only included a Kaplan Meier curve from which we could extract a median. The variability for this outcome changed between the preprint and the peer-reviewed publication.
Nojomi, 2020	The publication describes a method for allocation concealment and the preprint does not. We revised the risk of bias from probably high to definitely low risk of bias for allocation concealment.
Pan, 2020; SOLIDARITY	Funding description mentions that drugs were donated by pharmaceutical companies in the peer-reviewed publication. Number of events for mechanical ventilation in the comparison of lopinavir-ritonavir and standard care is greater in the peer-reviewed publication compared to the preprint.
Panda, 2021; SEV COVID Trial	No substantive differences between the preprint and peer-reviewed publications.

Perepu, 2021	No substantive differences between the preprint and peer-reviewed publications.
Perlin, 2021	The peer-reviewed publication additionally reports industry funding. The peer-reviewed publication additionally reports proportion of patients receiving non-invasive ventilation at baseline. The peer-reviewed publication additionally reports AEs leading to discontinuation: 3/40 (CERC-002) and 8/42 (placebo).
Puskarich, 2021	The publication reports on mortality, ventilation, and admission to hospital that were not reported in the preprint.
Ramachandran, 2021	No substantive differences between the preprint and peer-reviewed publications.
Ramakrishnan, 2021; STOIC	The publication additionally reports patients with asthma at baseline. The publication additionally reports patients with cardiovascular disease at baseline. The publication additionally reports patients with diabetes at baseline. The publication additionally reports 95% confidence intervals for time to symptom resolution. For the preprint, interquartile ranges were extracted from the KM curve.
Reis_2, 2021; TOGETHER	N randomized changed from the preprint to the publication. % male, smokers, respiratory condition, cvd, diabetes, and hypertension changed from the preprint to the publication. The publication reports mechanical ventilation, which was not reported in the preprint. Results for mortality, hospitalization, viral clearance, duration of hospitalization, duration of ventilation, and time to viral clearance changed between the preprint and the publication.
Rocco, 2020	No substantive differences between the preprint and peer-reviewed publications.

Roostaei Firozabad, 2021	The publication reported baseline respiratory condition and cardiovascular disease, while the preprint did not. The preprint reported that there were no cases of diabetes or hypertension whereas the publication reported cases of diabetes and hypertension. The publication reported the percentage of participants with confirmed COVID-19, while the preprint did not The publication reports oxygen saturation, while the preprint does not.
Rosas, 2021; COVACTA	The peer-reviewed publication included the study protocol in the appendix. Therefore, the risk of bias rating for selective reporting changed from probably low to definitely low risk of bias for the outcomes mechanical ventilation, adverse events leading to discontinuation, and ICU length of stay.
Salama, 2020; EMPACTA	Baseline CRP and d-Dimer is different between the preprint and peer-reviewed publications. The peer-reviewed paper reports on mechanical ventilation as an outcome whereas the preprint does not.
Sigamani, 2020	No substantive differences between the preprint and peer-reviewed publications.
Silva Borba, 2020; CloroCovid-19	No substantive differences between the preprint and peer-reviewed publications.
Tang_1, 2020	Mortality was reported in the peer-reviewed publication but not in the preprint.
Tardif, 2021; COLCORONA	The publication additionally lists an institutional source of funding that was not specified in the preprint. The publication lists Greece as a country in which the trial was conducted. Age changed from the preprint to publication.
Tornling, 2021; ATTRACT	Compared to the preprint, the peer-reviewed publication reports a greater proportion of patients on supplemental oxygen at baseline (71.70% versus 57.55%). Baseline CRP levels changed. The peer-reviewed report includes further details on allocation

	concealment. We changed the risk of bias rating for allocation concealment from probably low to definitely low.
Trieu, 2021; ARTI-19	No substantive differences between the preprint and peer-reviewed publications.
Vlaar, 2020; PANAMO	The peer-reviewed publication describes concealed allocation whereas the preprint did not report this detail. Bias due to randomization changed from probably high to definitely low.
Wang_4, 2020	No substantive differences between the preprint and peer-reviewed publications.
Yu_inhaled budesonide, 2021; PRINCIPLE	Age, % male, current or unspecified smokers, former smokers, respiratory condition, cardiovascular disease, diabetes, hypertension, ACE inhibitors/ARB use, confirmed COVID-19, and N randomized changed between the peer-reviewed paper and preprint. The peer-reviewed paper reports secondary outcomes among those who were concurrently randomized, irrespective of SARS-COV-2 status (Table S2). The preprint reports secondary outcomes among those who were concurrently randomized, but SARS-COV-2 positive. The peer-reviewed paper reports mortality at 28 days. The preprint only reports events for mortality and/or hospitalization at 28 days. The peer-reviewed paper reports duration of hospital stay and admission to hospital. The preprint did not report duration of hospital stay. We changed our risk of bias rating for selective reporting for mechanical ventilation to definitely low risk of bias. Initially data was only presented among those who were SARS-COV-2 positive. The peer-reviewed paper, however, reports data for all patients, irrespective of SARS-COV-2 status.

Zhang_1, 2021	Age, % male, % respiratory condition, % cardiovascular disease, % diabetes, % hypertension, and % on oxygen therapy and mechanical ventilation at baseline changed. The number of patients analysed for the outcome mechanical ventilation between the preprint and the peer-reviewed publication. Length of hospital stay and the number of patients analysed for the outcome changed between the preprint and the peer-reviewed publication. Ventilator-free days and the number of patients analysed for the outcome changed between the preprint and the peer-reviewed publication. The number of patients analysed for the outcome duration of mechanical ventilation changed between the preprint and the peer-reviewed publication. The peer-reviewed paper explicitly mentioned allocation concealment whereas the preprint did not. The rating for bias due to randomization changed from probably low to definitely low.
Zheng, 2020	Chronic bronchitis is only reported in the peer-reviewed publication. Coronary heart disease is only reported in the peer-reviewed publication. Diabetes is only reported in the peer-reviewed publication. Hypertension is only reported in the peer-reviewed publication. Lymphopenia is only reported in the peer-reviewed publication.



Mortality

				Mortality				
Treatment 1	Treatment 2	Trial	First author	Randomization	Deviations from the intended	Missing outcome data	Measurement of outcome	Selection of the reported
(acetyl)cysteine	standard care/placebo							
		13687	de Alencar	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		48051	Taher	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
2-deoxy-D-glucose	standard care/placebo							
		66751a	Narayan Bhatt	probably high risk of bias	high risk of bias	low risk of bias	low risk of bias	low risk of bias
5-alpha reductase inhibitor	standard care/placebo						_	
	19047, 3397	8, Cadegiani, Cadegi	Cadegiani_1	probably low risk of bias	low risk of bias	high risk of bias	low risk of bias	probably low risk of bias
		35590	Zarehoseinzade	probably low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
ACEi/ARB	calcium channel blockers							
		34054	Nouri-Vaskeh	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
ACEI/ARB	standard care/placebo							
		10463, 49441	Duarte	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		26081	Cohen	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		27349	Lopes_1	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		49084, Puskarich	Puskarich	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		43232	Geriak	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		48571	Bauer	low risk of bias	high risk of bias	low risk of bias	low risk of bias	low risk of bias
		Puskarich_inpatier		low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
AFO-202 beta glucan	beta-glucans							
. 0	0	65044	Raghavan	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
			•					
AFO-202 beta glucan	standard care/placebo							
<u> </u>	.,	65044	Raghavan	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
AXL inhibitor	standard care/placebo							
		Wilkinson	Wilkinson	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably high risk of bias
BCG vaccine	standard care/placebo							
	•	16984	Padmanabhan	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
				F /				
CK-A agonist and CCK-B antagonist	standard care/placebo							
0	.,	Lattmann	Lattmann	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
				. , ,	, , ,			
CERC-002	standard care/placebo							
		38214	Perlin	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	high risk of bias
GM-CSF inhibitor	standard care/placebo							
		Patel_2	Patel_2	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		41974	Temesgen	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		47226a	Fisher_1	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		36763	Cremer_2	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
IV reverse transcriptase inhibitor	standard care/placebo							
	Startage Care, process	8469	Ren	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
			******	, , , , , , , , , , , , , , , , , , , ,	, 1227,			
IL1 inhibitors	standard care/placebo							
		25655	Cremer_1	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
			- IMUNO-19 Collaborative	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		Kyriazopoulou	Kyriazopoulou	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		54072	Caricchio	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		2.072			12.11.11.11.01.01.01			211 1121 21 0143
IL6 receptor antagonist	standard care/placebo							
	7, 5, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1,	66149	Lomakin	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
IL6 receptor antagonists	:eptor antagonists, corticosteroids (systemic)						
			TRE_EudraCT2020-00203	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
IL6 receptor antagonists	IL6 receptor antagonists, favipirav	rir						
		25294, Zhao_1	Zhao_1	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
IL6 receptor antagonists	corticosteroids (systemic)							

		41237	Rashad_2	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
L6 receptor antagonists	favipiravir							
		25294, Zhao_1	Zhao_1	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
L6 receptor antagonists	standard care/placebo							
	7,	33303_B, Rosas	Rosas_B	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		16128_B	Hermine_B	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		16127	Salvarani	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		16340, 23643_B	Salama_B	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		27470_B	Veiga_B	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		30638, 42046_B	Horby_5_B	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		RIMUNO-SARI-1_NCT041UN		low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		MUNO-SARI-ICU_NCTOUNC	OUNO-SARI-ICU_NCT04324 OUNO-TOCI-ICU_NCT04331	low risk of bias	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias
				low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		COV-AID_NCT043306:OV- OVIDOSE2-SSA_NCT0441DOS		low risk of bias	probably high risk of bias	low risk of bias low risk of bias	low risk of bias low risk of bias	low risk of bias low risk of bias
		OVIDSTORM_NCT0457/IDS		low risk of bias low risk of bias	probably high risk of bias probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		COVITOZ_NCT04377IDS			probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		MO-020-0224_NCT0437-02			low risk of bias	low risk of bias	low risk of bias	low risk of bias
		REMDACTA NCT04409:MD		low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		SARCOVID NCT043578RC		low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		ICOR_EudraCT2020-00OR_I	_		probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		RTRE_EudraCT2020-00TRE_		low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		RTRE_EudraCT2020-00FRE_			probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		COVID_EudraCT2020-0IVID			probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		Rutgers_B	Rutgers_B	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		Sivapalasingam_P2 _. Siv		probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Sivapalasingam_P3_Giva	palasingam_P3_C1_B	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
to continue to the continue to the forms.	-tdd/-lb							
ntagonists, corticosteroids (syste	standard care/placebo	33303_A, Rosas	Rosas A	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		16128 A	Hermine_A	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		16340, 23643_A	Salama_A	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		27470_A	Veiga_A	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		29298, 34438	Lescure	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		30638, 42046_A	Horby_5_A	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		34439	Soin	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
	COR	RIMUNO-SARI-1_NCT041UN	O-SARI-1_NCT043240	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
	CORIN	MUNO-SARI-ICU_NCT0UNC	-SARI-ICU_NCT04324	low risk of bias	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias
	CORIN	MUNO-TOCI-ICU_NCT0UNC	-TOCI-ICU_NCT0433	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		COV-AID_NCT0433060OV-	AID_NCT04330638_/	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		OVIDOSE2-SSA_NCT0441DOS		low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		OVIDSTORM_NCT0457/IDS	_	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		COVITOZ_NCT044357:OVI		low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		MO-020-0224_NCT0437-02			low risk of bias	low risk of bias	low risk of bias	low risk of bias
		REMDACTA_NCT04409:MD		low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		SARCOVID_NCT04357&RCC		low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		ICOR_EudraCT2020-00DR_I		low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		RTRE_EudraCT2020-00FRE_		low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
	SAI	RTRE_EudraCT2020-00FRE_			probably high risk of bias probably high risk of bias	low risk of bias low risk of bias	low risk of bias low risk of bias	low risk of bias low risk of bias
		Rutgers_A Talaschian	Rutgers_A Talaschian	probably high risk of bias probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Sivapalasingam_P2_Siv		probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Sivapalasingam P3 Giva			low risk of bias	low risk of bias	low risk of bias	low risk of bias
	Si	ivapalasingam_P3_C2_apal		the state of the s	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		iivapalasingam_P3_C3_apal			low risk of bias	low risk of bias	low risk of bias	low risk of bias
	3.	Hermine_toci	Hermine_toci	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		47857	Hamed	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
ceptor antagonists, favipiravir	favipiravir	25294, Zhao_1	Zhao_1	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		2323 1, 21100_1	20_1	p. 20001) mg// hisk of bids	p. obboty mgirrisk or bids	ion risk of blus	TOTAL TOTAL DIGG.	producty tow tisk of bias
	standard care/placebo				and the latest and the	1. (1. ***	1	1
ermediate-dose enoxaparin					probably high rick of high	low risk of bias	low risk of bias	low risk of bias
rmediate-dose enoxaparin		52393, Perepu	Perepu	probably high risk of bias	probably high risk of bias	IOM LISK OF DIGS	IOW HISK OF DIAS	IOW HISK OF DIAS
ermediate-dose enoxaparin JAK inhibitors	standard care/placebo	52393, Perepu	Perepu	probably high risk of bias	probably flight risk of bias	IOW FISK OF DIAS	low risk of bias	IOW HISK OF DIAS

		Kalil	Kalil	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
	62.	263, Marconi, Marco	Marconi	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		48879 RUXCOVID	Guimarães RUXCOVID	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias low risk of bias
	Fly WHO COV-BA	RRIER_Addendum,	Ely	low risk of bias low risk of bias	low risk of bias low risk of bias	low risk of bias low risk of bias	low risk of bias low risk of bias	low risk of bias
	Ely, WIIO_COV BA	initizit_Addendam,	Liy	low risk of blas	low risk of blus	10W H3R OF Bla3	10W HSR OF Blus	10W H3K OF Bla3
L-arginine	standard care/placebo							
		64005	Fiorentino	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
ate, N-acetylcysteine, nicotinamide rib	standard care/placebo							
rate, N-acetylcysterile, incotinamide no	standard care/placebo	14670	Altay	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		11070	711004	probably high risk of blas	producty mgm now or blus	1011 1131 01 5143	10W HSK OF Blas	producty for this or bias
NK1 antagonist	standard care/placebo							
		10086	Mehboob	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
NSAID, azithromycin	NSAID, azithromycin, corticosteroi		Charact	1. 21.002.	and the block of the con-	Leader of the control	1. 2.1	In the filter
		64198	Ghanei	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
NSAID, azithromycin	lopinavir-ritonavir							
, determination	iopinarii Ittoliarii	64198	Ghanei	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
NSAID, azithromycin, corticosteroid	lopinavir-ritonavir							
		64198	Ghanei	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
PF-07321332/ritonavir	standard care/placebo	EPIC-HR	EPIC-HR	probably low rick of him	low rick of hins	low risk of hins	low risk of hins	low risk of hins
		EFIC-FIN	EFIC-FIN	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
SGLT2 inhibitors	standard care/placebo							
	7,	54586	Kosiborod	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
TNF inhibitors	standard care/placebo							
		47226b	Fisher_2	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		52260	Fakharian	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
alpha lipoic acid	standard care/placebo							
агрпа протс асти	standard care/placebo	1284	Zhong	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		1204	Znong	low risk of bids	probably high risk of bias	low risk of blus	low risk of bids	10W TISK OF BIGS
, curcuminoids, piperine, resveratrol,	standard care/placebo							
		67818	Majeed	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
ngiotensin type 2 receptor agonist	standard care/placebo							
		28441	Tornling	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
antihepaciviral	nromycin, hydroxychloroquine, oselt	tamivir						
unanepasivii ui	, 2,, a. o.,, ci iloroquine, 03eii	44111	Elgohary	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably high risk of bias
			J,					,, g
antihepaciviral	lopinavir-ritonavir							
		Yadollahzadeh	Yadollahzadeh	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
antihepaciviral	ravidasvir, sofosbuvir	57630	Abbass	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		3/030	Annass	TOW FISK OF DIAS	probably flightrisk of bias	IOW FISH OF DIAS	TOW TISK OF DIAS	probably low risk of blas
antihepaciviral	standard care/placebo							
		11065	Sadeghi	probably high risk of bias	high risk of bias	low risk of bias	low risk of bias	probably high risk of bias
		Yakoot	Yakoot	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		29517	Nourian	low risk of bias	high risk of bias	low risk of bias	low risk of bias	low risk of bias
		Mobarak	Mobarak	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		45668	Sayad	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		51681 57630	El-Bendary Abbass	probably high risk of bias low risk of bias	probably high risk of bias probably high risk of bias	low risk of bias low risk of bias	low risk of bias low risk of bias	probably low risk of bias probably low risk of bias
		37030	Whyass	IOW HSK OF DIAS	probably night risk of bias	IOW HISK OF DIAS	10W Hisk Of Dids	Propably low risk of plas
artemisinin	standard care/placebo							
			Trieu	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
aspirin	aspirin, atorvastatin							
		Ghati	Ghati	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
	f. II. door on Proceed 1991							
aspirin	full-dose anticoagulation							

		67646	Connors	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
aspirin	standard care/placebo							
		Ghati Horby_7	Ghati Horby_7	probably high risk of bias low risk of bias	probably high risk of bias probably high risk of bias	low risk of bias low risk of bias	low risk of bias low risk of bias	low risk of bias low risk of bias
		67646	Connors	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		07040	Comiors	low risk of blus	IOW HISK OF DIGS	low risk of bids	10W 113K OT DIAS	10W H3K OF Blu3
aspirin	statins							
		Ghati	Ghati	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
aspirin, atorvastatin	standard care/placebo	A	AL					
		Ghati	Ghati	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
aspirin, atorvastatin	statins							
aspinii, atoi vastatiii	Stating	Ghati	Ghati	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
				, , ,	, , ,			
atazanavir, dolutegravir, ritonavir	lopinavir-ritonavir							
		53056	Kalantari	probably high risk of bias	high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
azithromycin	azithromycin, hydroxychloroquine	1 NCT0422555	Aufan NICTO ADDESS	anababb bid to the fit	and a block in the Color	and ablichial Charles	Januarial Chiling	Januari I., China
			Axfors_NCT04335552 Axfors_NCT04338698	probably high risk of bias probably high risk of bias	probably high risk of bias probably high risk of bias	probably high risk of bias probably high risk of bias	low risk of bias low risk of bias	low risk of bias low risk of bias
		1_140104556098	ZV1012_IAC104220038	Propably High risk of plas	Propably High risk of plas	probably high risk of bias	TOW HISK OF DIAS	IOW HISK OI DIGS
azithromycin	hromycin, hydroxychloroquine, oselta	amivir						
, .	, , , , , , , , , , , , , , , , , , , ,		Axfors_NCT04338698	probably high risk of bias	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias
azithromycin	azithromycin, oseltamivir							
		1_NCT04338698	Axfors_NCT04338698	probably high risk of bias	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias
azithromycin	clarithromycin							
azithromycin	Ciaritiii OiriyCiii	58017	Rashad_3	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		38017	Nasilau_5	IOW HISK OF DIAS	probably flight fisk of bias	IOW HISK OF DIAS	IOW HSK OF DIAS	probably low risk of bias
azithromycin	hydroxychloroquine							
		1_NCT04335552	Axfors_NCT04335552	probably high risk of bias	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias
		18375	Brown	low risk of bias	high risk of bias	low risk of bias	low risk of bias	low risk of bias
azithromycin	hydroxychloroquine, oseltamivir	4 110704220000	A 5: NCT04220500	and the back of the first	b.b. b.b. a.t. a.t.	and the last of a figure	In the other	1
		1_NC104338698	Axfors_NCT04338698	probably high risk of bias	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias
azithromycin	oseltamivir							
azianomyan	oseitav.ii	1 NCT04338698	Axfors_NCT04338698	probably high risk of bias	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias
				, , , , , , , , , , , , , , , , , , ,	, , O	,, 0		
azithromycin	standard care/placebo							
		11639, 12378	Sekhavati	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		12439	Furtado	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
			Axfors_NCT04335552	probably high risk of bias	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias
		22569, 29803 34434	Horby_4 IPLE Trial Collaborative (low risk of bias low risk of bias	probably high risk of bias probably high risk of bias	low risk of bias low risk of bias	low risk of bias low risk of bias	low risk of bias low risk of bias
		40804	Hinks	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		Oldenburg	Oldenburg	low risk of bias	low risk of bias	high risk of bias	low risk of bias	low risk of bias
		58017	Rashad_3	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
thromycin, hydroxychloroquine	hromycin, hydroxychloroquine, oselta							
		1_NCT04338698	Axfors_NCT04338698	probably high risk of bias	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias
thromusin hudrouushlars	azithromusia osoltaszinia							
thromycin, hydroxychloroquine	azithromycin, oseltamivir	1 NCT0/338609	Axfors_NCT04338698	probably high risk of bias	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias
		1_140104556098	WIND 140104220038	probably high risk of bids	Propably High risk of plas	probably high risk of bias	IOW HISK UI DIAS	IOW HISK OF DIAS
hromycin, hydroxychloroquine	hydroxychloroquine							
, , , , , , , , , , , , , , , , , , , ,	, , , , , , , , ,	22152, 9166	Cavalcanti	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		1_NCT04335552	Axfors_NCT04335552	probably high risk of bias	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias
		20005	Omrani	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		33489, Johnston	Johnston	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
aitheann ain budannahlas : 'c	budan ablancada as trust							
zithromycin, hydroxychloroquine	hydroxychloroquine, oseltamivir	1 NCT04229609	Avfors NCT04229609	probably high risk of bias	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias
		1_140104556098	WIND 140104220038	probably high risk of blas	Propably High risk of plas	probably high risk of bias	IOW HISK UI DIAS	IOW HSK OF DIAS
ithromycin, hydroxychloroquine	oseltamivir							

		1_NCT04338698 A	Axfors_NCT04338698	probably high risk of bias	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias
azithromycin, hydroxychloroquine	standard care/placebo							
		22152, 9166 1_NCT04335552 A 20005 33489, Johnston 48002 60017	Cavalcanti Axfors_NCT04335552 Omrani Johnston Sivapalan Rodrigues	low risk of bias probably high risk of bias low risk of bias probably low risk of bias low risk of bias low risk of bias	probably high risk of bias probably high risk of bias low risk of bias low risk of bias low risk of bias low risk of bias	low risk of bias probably high risk of bias low risk of bias low risk of bias low risk of bias low risk of bias	low risk of bias low risk of bias	low risk of bias low risk of bias probably low risk of bias probably low risk of bias low risk of bias probably low risk of bias
thromycin, hydroxychloroquine, oseltami	azithromycin, oseltamivir							
		1_NCT04338698 A	Axfors_NCT04338698	probably high risk of bias	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias
thromycin, hydroxychloroquine, oseltami	hydroxychloroquine, oseltamivir	1_NCT04338698 A	Axfors_NCT04338698	probably high risk of bias	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias
thromycin, hydroxychloroquine, oseltam	oseltamivir	1_NCT04338698 A	Axfors_NCT04338698	probably high risk of bias	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias
azithromycin, oseltamivir	hydroxychloroquine, oseltamivir	1_NCT04338698 A	Axfors_NCT04338698	probably high risk of bias	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias
azithromycin, oseltamivir	oseltamivir	1_NCT04338698 A	Axfors_NCT04338698	probably high risk of bias	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias
azithromycin, vitamins	favipiravir	Who I'l	Mb - 12					
		Khavkina	Khavkina	probably high risk of bias	probably high risk of bias	probably low risk of bias	low risk of bias	probably low risk of bias
azithromycin, vitamins	cychloroquine, interferon alpha, um	ifenovir Khavkina	Khavkina	probably high risk of bias	probably high risk of bias	probably low risk of bias	low risk of bias	probably low risk of bias
baloxavir marboxil	favipiravir	2637, Lou, Lou (1	Lou	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
baloxavir marboxil	standard care/placebo	2637, Lou, Lou (1)	Lou	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
beta-glucans	standard care/placebo	65044	Raghavan	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
bradykinin inhibitors	standard care/placebo	10832	Mansour	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
bromelain, quercetin, vitamin C	standard care/placebo	Onal	Onal	probably high risk of bias	high risk of bias	low risk of bias	low risk of bias	low risk of bias
bromhexine hydrochloride	standard care/placebo	12212 13888 35697	Li_3 Ansarin Tolouian	low risk of bias probably high risk of bias probably high risk of bias	probably high risk of bias probably high risk of bias probably high risk of bias	low risk of bias low risk of bias probably low risk of bias	low risk of bias low risk of bias low risk of bias	high risk of bias low risk of bias probably low risk of bias
cacifediol	standard care/placebo	68592	Maghbooli	low risk of bias	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias
lcium release-activated calcium inhibito	standard care/placebo	10964	Miller	probably high risk of bias	high risk of bias	low risk of bias	low risk of bias	low risk of bias
cannabidiol	standard care/placebo	66954	Crippa	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
cefepime	ceftazidime	70011	Eid	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
cefepime	standard care/placebo	70011	Eid	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
ceftazidime	standard care/placebo	70011	Eid	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias

chloroquine `	hydroxychloroquine							
		1129, 2118	Silva Borba	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
clarithromycin	standard care/placebo							
		58017	Rashad_3	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
colchicine	standard care/placebo							
coichichie	Standard Care/placebo	7189	Deftereos	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		11	Salehzadeh	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		28222, 45870	Tardif	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		10500, xx	Lopes_2	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		Horby_6	Horby_6	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		64351	Dorward	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		64385	Pascual-Figal	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
			•		. , ,			
chicine, emtricitabine, tenofovir, statir	emtricitabine, tenofovir							
		Gaitan-Duarte	Gaitan-Duarte	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
chicine, emtricitabine, tenofovir, statir	standard care/placebo							
		Gaitan-Duarte	Gaitan-Duarte	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
colchicine, statin olch	hicine, emtricitabine, tenofovi							
		Gaitan-Duarte	Gaitan-Duarte	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
colchicine, statin	emtricitabine, tenofovir							
		Gaitan-Duarte	Gaitan-Duarte	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
anishistan	atom dond constitutions							
colchicine, statin	standard care/placebo	Gaitan-Duarte	Gaitan-Duarte	low risk of bias	anababb biab sist of his	low risk of bias	low risk of bias	low risk of bias
		Gallali-Duarte	Gallaii-Duai le	IOW FISK OF DIAS	probably high risk of bias	low risk of bias	IOM LISK OF DIAS	IOW LISK OF DIAS
(systemic), doxycycline, intranasal corlfac	rtory training standard care/r	nlaceho						
(systemic), doxycycline, miranasar comac	ctory training, standard care, p	Husain	Husain	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
				,, 0	, ,			, , , , , , , , , , , , , , , , , , , ,
corticosteroids (systemic)	standard care/placebo							
`,	.,	29672, 6743	Corral-Gudino	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		33381, 7002, 8619	Horby_1	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		10699	Jeronimo	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		12062	Dequin	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		12141	Tomazini	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		12146	Angus	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		12076_NCT043250 S	iterne_NCT04325061	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		12076_NCT042445: 5	iterne_NCT04244591	probably low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		13208	Edalatifard	probably high risk of bias	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias
		2	Farahani	probably low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		27640	Tang_2	probably low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		31583	Jamaati	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		49210	Munch_1	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
	ata ata ata ata ata ata							
orticosteroids (systemic), tacrolimus	standard care/placebo	F4.43F	Calactit	analysis is the first of the	anababb bish til of the	lavorials affilias	Januarial - China	lanced to China
		51435	Solanich	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
	histin							
curcumin, piperine	probiotics	40000	Day	probably low side of his	low rick of him	low rick of his a	low rich of him	neohobly less siels of his
		48609	Pawar	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
curcumin, vitamin C, zinc	standard care/placebo							
curcumin, vitamiff C, ZiffC	stanuaru care/piace00	37882	Yogesh	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		3/882	rogesti	probably high risk of blas	probably flight risk of bias	TOW FISH OF DIAS	TOW TISK OF DIAS	probably low risk of blas
diammonium glycyrrhizinate	standard care/placebo							
a.a	standard care/ place00	Csun	Sun	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		Court	Juli	producty might hak of bids	producty might risk of blas	.OW HISK OF DIGS	.ow risk or bids	probably low risk of bias
doxycycline	standard care/placebo							
donycyclinic	standard care, pidecoo	55459, Butler_doxycly	Butler	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		,,,,			, , , , , , , , , , , , , , , , , , , ,			
doxycycline, ivermectin	standard care/placebo							
	.,	43517	Mahmud	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
electrolyzed saline	standard care/placebo							

		13074, 53789	Delgado-Enciso	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
and delication and for the	de de de constitue de							
emtricitabine, tenofovir	standard care/placebo	50792	Parienti	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		Gaitan-Duarte	Gaitan-Duarte	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
for a state of	de de de contra de la color							
famotidine	standard care/placebo	Samimagham	Samimagham	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
					, , , , , , , , , , , , , , , , , , , ,			, , , , , , , , , , , , , , , , , , , ,
favipiravir	xychloroquine, interferon alpha, umi		Khandilaa	and a block in the sint of him	and habit, bish side of his	and babble law sigh, of bins	lass vials of bina	and the law side of him
		Khavkina	Khavkina	probably high risk of bias	probably high risk of bias	probably low risk of bias	low risk of bias	probably low risk of bias
favipiravir	lopinavir-ritonavir							
		35903	Solaymani-Dodaran	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
favipiravir	standard care/placebo							
TO THE TOTAL PROPERTY OF THE TOTAL PROPERTY		2637, Lou, Lou (1	Lou	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		10147, 10287, 997	Ivashchenko	probably high risk of bias	high risk of bias	low risk of bias	low risk of bias	low risk of bias
		24988, Udwadia	Udwadia	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		27459 40875	Balykova_1 Zhao_2	probably high risk of bias low risk of bias	high risk of bias probably high risk of bias	low risk of bias low risk of bias	low risk of bias low risk of bias	probably low risk of bias probably low risk of bias
		32586	Balykova_2	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		60646	Shinkai	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
favipiravir	umifenovir	173	Chen_2	probably high rick of hins	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		1/3	chen_z	probably high risk of bias	probably fligh risk of blas	IOW FISK OF DIAS	IOW FISK OF DIAS	IOW FISK OF DIAS
favipiravir, hydrochloroquine	standard care/placebo							
		Bosaeed	Bosaeed	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
febuxostat	hydroxychloroquine							
Tebuxostat	nydroxychioroquine	7586, Davoodi	Davoodi	probably high risk of bias	probably high risk of bias	probably high risk of bias	low risk of bias	probably low risk of bias
				p. 0.2.0.,g 0. 0.0.	product, mgare area	processy mg. names and		process, and a second
fluvoxamine	standard care/placebo							
		18818	Lenze	low risk of bias	low risk of bias	high risk of bias	low risk of bias	low risk of bias
		70784, Reis_2	Reis_2	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
full-dose anticoagulant	intermediate-dose anticoagulation							
		Spyropoulos	Spyropoulos	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
f. H. Janes and Communication of	to the second se							
full-dose anticoagulation	intermediate-dose anticoagulation	65782	Oliynyk	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		67889	Marcos	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
					. , ,			
full-dose anticoagulation	standard care/placebo	42026		In the filter		In the Charter	L. C.L. Chi.	1
	24044 4	13836	Lemos P, ACTIV-4a, and ATTACO	low risk of bias low risk of bias	probably high risk of bias probably high risk of bias	low risk of bias low risk of bias	low risk of bias low risk of bias	low risk of bias low risk of bias
	54044, A	35895, Bikdeli	Bikdeli	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		47030	Lopes_3	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		56911, Lawler	Lawler	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		Sholzberg	Sholzberg	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		64008	Ananworanich	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		67646	Connors	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
II-dose anticoagulation, thrombolys	sis standard care/placebo							
an-uose anticoaguiation, trirombolys	ois Stanuaru Care/piacedo	65552_P1	Barrett_P1	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		65552_P2	Barrett_P2	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
hydroxychloroquine	hydroxychloroquine, lopinavir-ritonav	vir 52697	Arabi	low risk of bias	probably high risk of bias	low risk of higs	low risk of hiss	probably high risk of bias
		5209/	Arabi	IOW FISK OF DIAS	probably high risk of bias	low risk of bias	low risk of bias	probably filgh risk of bias
hydroxychloroquine	hydroxychloroquine, zinc							
		21407	Abd-Elsalam	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
hudromehloroguis -	interferon alpha							
hydroxychloroquine	interieron aipna							
		18336 Khamir	Khamis	nrohably high risk of high	high risk of hige	low risk of hige	low risk of hige	probably low risk of hine
		18336, Khamis	Khamis	probably high risk of bias	high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
hydroxychloroquine	interferon beta, lopinavir-ritonavir	18336, Khamis	Khamis	probably high risk of bias	high risk of bias	low risk of bias	low risk of bias	probably low risk of bias

		45662, Ader_1	Ader_1	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
hydroxychloroquine	ivermectin							
пушохустогодите	Weimeean	Gonzalez 34666	Gonzalez Galan	probably high risk of bias	low risk of bias low risk of bias	low risk of bias low risk of bias	low risk of bias low risk of bias	probably low risk of bias probably low risk of bias
hydroxychloroquine	lopinavir-ritonavir							
		Reis_1	Reis_1	low risk of bias	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias
		45662, Ader_1 52697	Ader_1	low risk of bias low risk of bias	probably high risk of bias	low risk of bias low risk of bias	low risk of bias low risk of bias	low risk of bias
		52097	Arabi	IOW FISK OF DIAS	probably high risk of bias	IOW FISK OF DIAS	IOW FISK OF DIAS	probably high risk of bias
hydroxychloroquine	standard care/placebo							
, , ,		3321, 776	Tang_1	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		C158	Chen_3	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		6987	Chen_4	probably high risk of bias	probably high risk of bias	high risk of bias	low risk of bias	probably low risk of bias
		8057, Chen (Cheng-I	Chen_5	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		14989, 8444, xx	Horby_2	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		8565	Skipper	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		22152, 9166	Cavalcanti	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		11299	Abd-Elsalam_1	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		13936	Ulrich	probably low risk of bias	low risk of bias	high risk of bias	low risk of bias	low risk of bias
	156		Pan_hydroxychloroquine		probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		16085, 38308	Dubée	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
			Axfors_NCT04345289	probably high risk of bias	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias
		1_NC104335552 1_NL8490	Axfors_NCT04335552 Axfors_NL8490	probably high risk of bias probably high risk of bias	probably high risk of bias probably high risk of bias	probably high risk of bias probably high risk of bias	low risk of bias low risk of bias	low risk of bias probably low risk of bias
		_	Axfors_NCT04342650	probably high risk of bias	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias
			Axfors_NCT04323527	probably high risk of bias	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias
			kfors_ChiCTR200003120	probably high risk of bias	probably high risk of bias	probably high risk of bias	low risk of bias	probably low risk of bias
			Axfors_NCT04333654	probably high risk of bias	low risk of bias	probably high risk of bias	low risk of bias	probably low risk of bias
			Axfors_NCT04345692	probably high risk of bias	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias
			Axfors_NCT04342221	probably high risk of bias	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias
			Axfors_NCT04340544	probably high risk of bias	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias
		16281	Lyngbakken	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		18245, 23358	Self	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		20005	Omrani	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		Reis_1	Reis_1	low risk of bias	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias
		33489, Johnston	Johnston	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		45662, Ader_1	Ader_1	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		29663	Hernandez-Cardenas	low risk of bias	low risk of bias	low risk of bias	low risk of bias	high risk of bias
		Gonzalez	Gonzalez	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		33028	Amaravadi	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		41434 Schwartz_2	Réa-Neto Schwartz_2	low risk of bias low risk of bias	probably high risk of bias low risk of bias	low risk of bias low risk of bias	low risk of bias low risk of bias	low risk of bias low risk of bias
		52697	Arabi	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably high risk of bias
		32037	Alabi	IOW HISK OF DIAS	probably flight fisk of bias	IOW HISK OF DIAS	IOW HISK OF DIAS	probably flight fisk of bias
hydroxychloroquine, lopinavir-ritonavir	hydroxychloroquine, umifenovii	r						
		23259, 8	Nojomi	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
hydroxychloroquine, lopinavir-ritonavir	lopinavir-ritonavir							
		52697	Arabi	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably high risk of bias
hada ahla a hada hada hada ha	ata a da ad as as Asta a d							
hydroxychloroquine, lopinavir-ritonavir	standard care/placebo	F2C07	Arab:	low risk of his a	probably high viels of his	low rick of him	low risk of him	probably bigh sigh of his
		52697	Arabi	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably high risk of bias
hydroxychloroquine, oseltamivir	oseltamivir							
, arony critor oquine, oscitariiivii	osc.turiivii	1 NCT04338698	Axfors_NCT04338698	probably high risk of bias	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias
			2.2270 .330030	, seeing man in the state of State	,,g.r risk or blus	1 222.7		is it is the or olds
hydroxychloroquine, rivabirin	lopinavir-ritonavir, ribavirin							
		46308_severe	Singh_3	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
hydroxychloroquine, rivabirin	standard care/placebo							
		46308_non severe	Singh_2	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		46308_severe	Singh_3	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
Salada da de Parada da Caracteria de Caracte	de de de de Contra							
inhaled nebulised interferon beta-1a	standard care/placebo	10057	84-1	law dal - Chin	Januaria - Chin	high risk of hias	January China	and habital to the state of the
		18657	Monk	low risk of bias	low risk of bias	nigh risk of bias	low risk of bias	probably low risk of bias

inhaled pan-JAK inhibitor	standard care/placebo	34842	Cinch 1	and habit the state of him	land sight of bins	lass siels of bine	lann sielt of bies	lass siels of bion
		34842	Singh_1	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
interferon alpha	ecombinant super combinant inte	rferon						
interieron dipila	combinant super combinant mee	32737, 7, 9574	Li_2	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
			_					
interferon alpha	standard care/placebo							
		35022	Pandit	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		59366, 60209	Bhushan	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
interferon beta	standard care/placebo	11541, 11937	Rahmani	and ballet high viels of him	and bable bish side of him	high risk of bias	low risk of bias	probably low risk of bias
		11541, 11937 15632, Pan_interfer	Pan_interferon	probably high risk of bias low risk of bias	probably high risk of bias probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		39381, Darazam (2	Darazam_2	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably high risk of bias
		Kalil 2	Kalil 2	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
			Davoudi-Monfared	low risk of bias	high risk of bias	probably high risk of bias	low risk of bias	probably low risk of bias
					<u> </u>	. , ,		
terferon beta, lopinavir-ritonavir	lopinavir-ritonavir				44			
		45662, Ader_1	Ader_1	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
terferon beta, lopinavir-ritonavir	antihepaciviral	******	Ale Charles II		and the back of a first	1. 2.1. (1)	to the char	1. 2.1
		Mostafa	Alavi-Moghaddam	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
terferon beta, lopinavir-ritonavir	standard care/placebo							
	standard care/placebo	45662, Ader_1	Ader_1	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		,			product, inguitable of class			
interferon beta, ribavirin	standard care/placebo							
		2942	Hung	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
interferon gamma	standard care/placebo							
		9880	Esquivel-Moynelo	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
terferon kappa, trefoil factor 2	standard care/placebo							
interieron kappa, treion factor 2	standard care/placebo	13797	Fu	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		13737	Tu .	probably high hisk of blas	probably riight risk of bias	low risk of blas	10W 113K OT DIU3	probably low risk of bias
intranasal corticosteroids	standard care/placebo							
		57833	Song	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		Clemency	Clemency	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Ezer	Ezer	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
itolizumab	standard care/placebo	24247 //	W 4		and the best of a constant	In the filter	to set office	In the other
		21347, Kumar	Kumar_1	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
itraconazole	standard care/placebo							
1.1 0.01.02010	standard care/placebo	36093, Liesenborgl	Liesenborghs	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
				,, ,,,	,,			
ivermectin	lopinavir-ritonavir							
		25394, Babalola	Babalola	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
ivermectin	standard care/placebo	40440 //	W. I	1, 1, 51		1	In the Con-	1
		49440, Krolewieck Niaee	Krolewiecki Niaee	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		Niaee 53436, Ravikirti	Niaee Ravikirti	low risk of bias low risk of bias	probably high risk of bias low risk of bias	low risk of bias low risk of bias	low risk of bias low risk of bias	probably low risk of bias low risk of bias
		Mohan	Mohan	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		34416, 41159, Lop	Lopez-Medina	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Gonzalez	Gonzalez	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		47181, Abd-Elsalam	Abd-Elsalam_3	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		Chahla	Chahla	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		51938	Vallejos	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
leflunomide	standard care/placebo			and the last of the first	and the base of the	1	In the Con-	and the second second
		8784	Hu	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		13540	Wang_5	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
levamisole	standard care/placebo							
ic valingoic		37198, Roostaei Firoz	Roostaei Firozabad	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		,		, , , , , , , , , , , , , , , , , , , ,				
lopinavir-ritonavir	lopinavir-ritonavir, ribavirin							

		10067, 2615	Huang_2	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
lopinavir-ritonavir	ribavirin							
·		10067, 2615	Huang_2	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
lopinavir-ritonavir	standard care/placebo							
		330	Cao_1	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		1243, 234	Li	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		14781, 14883	Horby_3	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		15632, Pan_lopinavir-rit F			probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		Reis_1	Reis_1	low risk of bias	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias
		45662, Ader_1	Ader_1	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		52697	Arabi	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably high risk of bias
lopinavir-ritonavir	umifenovir							
		1243, 234	Li	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
lopinavir-ritonavir, ribavirin	ribavirin							
		10067, 2615	Huang_2	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
lopinavir-ritonavir, ribavirin	standard care/placebo							
		46308_severe	Singh_3	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
mavrilimumab	standard care/placebo							
		36763	Cremer_2	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
melatonin	standard care/placebo							
		Farnoosh	Farnoosh	probably low risk of bias	low risk of bias	high risk of bias	low risk of bias	probably high risk of bias
		68591	Hasan	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
methylene blue	standard care/placebo							
		45012	Hamidi-Alamdari	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		Alamdari	Alamdari	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
molnupiravir	standard care/placebo							
		41971	Khoo	probably high risk of bias	high risk of bias	low risk of bias	low risk of bias	probably high risk of bias
		46473, Fischer	Fischer	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		MOVe-OUT (MK4482-/I	OVe-OUT (MK4482-002		low risk of bias	low risk of bias	low risk of bias	low risk of bias
		CR216-21	Vyas	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		CTRI/2021/06/0339	Krishnan	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		HCR/III/MOLCOV/04/20	Kumar_2	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
nanocurcumin	standard care/placebo							
		16167	Valizadeh	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		24721	Tahmasebi	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
niclosamaide	standard care/placebo							
		Abdulamir_2	Abdulamir_2	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
nitazoxanide	standard care/placebo							
		16339, 24799	Rocco	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		50790, Blum	Blum	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Silva	Silva	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		Rossignol	Rossignol	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
nitric oxide	standard care/placebo							
		Moni	Moni	low risk of bias	probably high risk of bias	probably low risk of bias	low risk of bias	probably high risk of bias
omega 3	standard care/placebo							
		37721	Doaei	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably high risk of bias
		60421	Kosmopoulos	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
opaganib	standard care/placebo							
		Winthrop	Winthrop	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
peginterferon lambda	standard care/placebo							
		18418, 28233	Feld	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias

pentoxifylline	standard care/placebo								
		21098	Malonado	probably high risk of bias	probably high risk of bias	high risk of bias	low risk of bias	probably low risk of bias	
		67125	Azizi	probably low risk of bias	low risk of bias	high risk of bias	low risk of bias	low risk of bias	
polymerized type I collagen	standard care/placebo			_					
		Méndez-Flores	Méndez-Flores	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias	
probiotics	standard care/placebo								
		44556	Gutiérrez-Castrellón	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	
		68436	Ivashkin	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	
progesterone	standard care/placebo								
		32075, Ghandehai	Ghandehari	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	
proxalutamide	standard care/placebo								
		Cadegiani (proxulatun	Cadegiani_2	probably low risk of bias		low risk of bias	low risk of bias	probably low risk of bias	
		48943	Cadegiani_5	high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	
		Cadegiani (female col	Cadegiani_4	high risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias	Terminated early for
pyridostigmine	standard care/placebo								
		Fragoso-Saavedra	Fragoso-Saavedra	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	
quercetin	standard care/placebo								
		49941	Di Pierro_1	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	
		51397	Di Pierro_2	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably high risk of bias	
ravidasvir, sofosbuvir	standard care/placebo								
		57630	Abbass	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	
					, , , ,			,,	
nt human granulocyte colony-stimulati	standard care/placebo								
, , , , , , , , , , , , , , , , , , , ,		12705	Cheng	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	
		12,03	cheng	iou risk of sids	probably ingritisk of blas	iou risk or blus	10W HSR OF BIOS	probably low risk or blus	
remdesivir	standard care/placebo								
	отольно от о, разово	2408	Wang_1	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	
		11347	Spinner	low risk of bias	high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	
		15633, 3821	Beigel	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	
		15632, Pan_remdes	Pan_remdesivir	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	
		37778	Mahajan	high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	
		39725	Criner	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably high risk of bias	
		Ader (remdesivir)	Ader_2	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	
								low risk of bias	
		68059	Abd-Elsalam_4	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias		
		Gottlieb_2, PINETR	Gottlieb_2	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	
resveratrol	standard care/placebo								
		65305	McCreary	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias	
ribavirin, sofosbuvir-daclatasvir	standard care/placebo								
		11010	Kasgari	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	
secukinumab	standard care/placebo								
		Resende	Resende	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	
serine protease inhibitors	standard care/placebo								
		40853	Gunst	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	
		70176	Zhuravel	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	
sildenafil	standard care/placebo								
		Santamarina	Santamarina	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias	probably low risk of bias	
sitagliptin	sitagliptin, spironolactone								
5.	5 , ,	Abbasi	Abbasi	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	
				, , , , , , , , , , , , , , , , , , , ,	,,			, Jacon, Islanda Biologia	
sitagliptin	spironolactone								
OP.v	-F.: 2.1010cconc	Abbasi	Abbasi	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	
		. 100001		p. 2222. jgir riok or blus	,s. e a a a a a a a a a a a a a a a a a a			process, service of pras	
sitagliptin	standard care/placebo								
Stag.iptiii	standard care, placebo	Abbasi	Abbasi	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	
		Annasi	Unnan	probably High risk of bids	producty mgm risk of blds	IOW HISK OF DIAS	10W H3K OI DIGS	probably low risk of bids	

sitagliptin, spironolactone	spironolactone							
		Abbasi	Abbasi	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
sitagliptin, spironolactone	standard care/placebo							
		Abbasi	Abbasi	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
spironolactone	standard care/placebo							
	,,	Abbasi	Abbasi	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
				process, inglition of cites	process, ingirine or ever			p. 6161, 1811, 1811, 1811, 1811, 1811, 1811, 1811, 1811, 1811, 1811, 1811, 1811, 1811, 1811, 1811, 1811, 1811,
statins	standard care/placebo							
Statins	standard care, placebo	Ghati	Ghati	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		dilati	dilati	probably flight fisk of bias	probably flight lisk of bias	IOW HISK OF DIAS	IOW HISK OF DIAS	IOW HISK OF DIAS
sulodexide	standard care/placebo							
Sulodexide	standard care/placebo	24046 24575	Consider College	and the late of the second	I. del effere	In the Color of Live	to the contraction	In the filter
		21816, 34575	Gonzalez-Ochoa	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
synthetic VIP	standard care/placebo							
		38756	Youssef	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
thalidomide	standard care/placebo							
		Amra	Amra	probably high risk of bias	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias
triazavirin	standard care/placebo							
		12679	Wu	high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
rosine kinase inhibitors	standard care/placebo							
	,	49287	Aman	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		60872	Strich	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		00072	Strict	probably low risk of blus	10 W TISK OF BIGS	1011 11510 01 5103	ion risk of bids	1011 1131 01 5103
umifenovir	standard saro/plasabo							
uninenovii	standard care/placebo	1243, 234	Li	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		12798	Yethindra	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		24810	Yadegarinia	high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably high risk of bias
		35511	Khodashahi	probably low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		52841	Darazam_3	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably high risk of bias
		Ramachandran	Ramachandran	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
vilobelimab	standard care/placebo							
		14404, 9802	Vlaar	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
								and the second s
vitamin C	standard care/placebo							
		26123, Zhang	Zhang_1	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		25793	Kumari	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
	21/0		maliMoghadamSiahka		probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
	3140	31458	Thomas	low risk of bias	probably high risk of bias	probably high risk of bias	low risk of bias	probably low risk of bias
		31436	IIIOIIIdS	IOW FISK OF DIAS	probably flight risk of blas	probably flight risk of bias	IOW HSK OF DIAS	probably low risk of bias
wita-min C	uitami C							
vitamin C	vitamin C, zinc		_					
		31458	Thomas	low risk of bias	probably high risk of bias	probably high risk of bias	low risk of bias	probably low risk of bias
vitamin C	zinc							
		31458	Thomas	low risk of bias	probably high risk of bias	probably high risk of bias	low risk of bias	probably low risk of bias
vitamin C, vitamin E	standard care/placebo							
	-	68016	Hakamifard	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
vitamin C, zinc	standard care/placebo							
	zanadra care, pracebo	31458	Thomas	low risk of bias	probably high risk of bias	probably high risk of bias	low risk of bias	probably low risk of bias
		31430	montas	IOW LISK OF DIAS	Propably High risk of plas	brongert High Hisk of pids	10W H3K OI DIG3	producty low risk of blds
vitamin C zinc	zinc							
vitamin C, zinc	zinc	24.450	T1	In the first			1. 2.1.(1)	and the land of the
		31458	Thomas	low risk of bias	probably high risk of bias	probably high risk of bias	low risk of bias	probably low risk of bias
vitamin D	standard care/placebo							
		11879	Castillo	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		18947, 31936	Murai	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		44830	Lakkireddy	high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		46627	Elamir	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		40027						
		40027						
xiyanping	standard care/placebo	40027						
xiyanping	standard care/placebo		Zhang 3		probably high risk of higs	low risk of hias	low risk of hias	probably low risk of hias
xiyanping	standard care/placebo	43229	Zhang_3	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias

zinc	standard care/placebo							
		34745	Patel_1	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		31458	Thomas	low risk of bias	probably high risk of bias	probably high risk of bias	low risk of bias	probably low risk of bias

Manhaniani	Mandilation

				Mechanical Ventilat				
Treatment 1	Treatment 2	Trial	First author	Randomization	Deviations from the intended	Missing outcome data	Measurement of outcome	Selection of the reported
(acetyl)cysteine	standard care/placebo							
		13687	de Alencar	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		48051	Taher	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
2-deoxy-D-glucose	standard care/placebo							
		66751a	Narayan Bhatt	probably high risk of bias	high risk of bias	low risk of bias	low risk of bias	low risk of bias
English and discharge to billion	standard san falsasla							
5-alpha reductase inhibitor	standard care/placebo	78, Cadegiani, Cadegi	Cadegiani 1	probably low risk of bias	low risk of bias	high risk of bias	low risk of bias	probably low risk of bias
	19047, 339	78, Cadegiani, Cadegi	Cadegiani_1	probably low risk of bias	IOW FISK OF DIAS	riigh risk of blas	IOM LISK OF DIAS	probably low risk of bias
ACEi/ARB	calcium channel blockers							
ACEI/AND	Calcium Chamilei biockers	34054	Nouri-Vaskeh	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		34034	Woull Vaskell	low risk of bias	low risk of bids	10W 113K OI DIU3	low risk of blus	probably low risk of bias
ACEi/ARB	standard care/placebo							
ACEITAND	standard care/placebo	10463, 49441	Duarte	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		26081	Cohen	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		27349	Lopes 1	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		49084, Puskarich	Puskarich	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		43232	Geriak	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		48571	Bauer	low risk of bias	high risk of bias	low risk of bias	low risk of bias	low risk of bias
		Puskarich_inpatien	Puskarich_2	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
			_					
AFO-202 beta glucan	beta-glucans							
		65044	Raghavan	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
AFO-202 beta glucan	standard care/placebo							
		65044	Raghavan	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
C-A agonist and CCK-B antagonist	standard care/placebo							
		Lattmann	Lattmann	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
GM-CSF inhibitor	standard care/placebo	47226-	Fish on 4	Investely a Children	and ablable blab with a fibra-	Laurentalis a Clates	Lancadal a Chilas	land state of lates
		47226a	Fisher_1	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
IL1 inhibitors	standard care/placebo							
ILI IIIIIbitois	standard care/placebo	28284 IN	IUNO-19 Collaborative	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		Kyriazopoulou	Kyriazopoulou	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		54072	Caricchio	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		3.072	Carreemo	iow risk of bids	ion risk of bias	TOW TISK OF BIAS	iow risk or blus	ion risk or bias
IL6 receptor antagonist	standard care/placebo							
neer coop to raining of the	отпольной польтории польто	66149	Lomakin	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
					_			<u>.</u>
IL6 receptor antagonists L	6 receptor antagonists, favipi	ravir						
		25294, Zhao_1	Zhao_1	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
IL6 receptor antagonists	favipiravir							
		25294, Zhao_1	Zhao_1	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
IL6 receptor antagonists	standard care/placebo							
		33303_B, Rosas	Rosas_B	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		16128	Hermine	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		16127	Salvarani	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		16283	Stone	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
eptor antagonists, corticosteroic	standard care/placebo							
		47857	Hamed	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
or antagonists, corticosteroids (sy	standard care/placebo	22202	D	Invested that	and the block of the	In the first	law dit 611	land to the
		33303_A, Rosas	Rosas_A	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
	224	16340, 23643	Salama Cordon 1	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
	33:	304, Gordon_v1, Gord 27470	Gordon_1	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		2/4/0 29298. 34438	Veiga Lescure	low risk of bias low risk of bias	probably high risk of bias low risk of bias	low risk of bias low risk of bias	low risk of bias low risk of bias	low risk of bias low risk of bias
		29298, 34438 34439	Soin	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		34433	30111	probably mgm risk or blas	probably high risk of bids	IOW HISK OF DIAS	IOW HISK OF DIAS	10 W 113K UI DIAS

		Rutgers	Rutgers	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		Talaschian	Talaschian	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Hermine_toci	Hermine_toci	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		30638, 42047	Horby_5	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
L6 receptor antagonists, favipiravir	favipiravir							
		25294, Zhao_1	Zhao_1	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
JAK inhibitors	standard care/placebo	41.01	Con 2	lave side of him	anabable biab viale of bias	lass vials of him	lass vials of him	manhabbulan viels of hise
		4161	Cao_2 Kalil	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
	-	Kalil		low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
	6.	2263, Marconi, Marc	Marconi	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		48879	Guimarães	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		RUXCOVID	RUXCOVID	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
NSAID, azithromycin	NSAID, azithromycin, corticoste	eroid						
	, , ,	64198	Ghanei	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
NSAID, azithromycin	lopinavir-ritonavir	54400						
		64198	Ghanei	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
NSAID, azithromycin, corticosteroid	lopinavir-ritonavir							
, , , , , , , , , , , , , , , , , , , ,		64198	Ghanei	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
SGLT2 inhibitors	standard care/placebo							
		54586	Kosiborod	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
TNF inhibitors	standard care/placebo							
THE HUMBICOIS	2.a.iaaia tare, piacebo	47226b	Fisher_2	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		52260	Fakharian	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
				, , , , , , , , , , , , , , , , , , , ,	,,			
curcuminoids, piperine, resveratro	standard care/placebo							
		67818	Majeed	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
raiotonoin tumo 3t	standard save /aleas !-							
ngiotensin type 2 receptor agonist	standard care/placebo	28441	Tornling	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Z0441	TOTTINING	probably low risk of bids	IOW HISK OI DIAS	TOW TISK UI DIAS	IOW HISK OF DIAS	IOW HISK OF DIAS
antihepaciviral	ravidasvir, sofosbuvir							
		57630	Abbass	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
antihepaciviral	standard care/placebo							
		11065	Sadeghi	probably high risk of bias	high risk of bias	low risk of bias	low risk of bias	probably high risk of bias
		Yakoot	Yakoot	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		29517	Nourian	low risk of bias	high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		Mobarak	Mobarak	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		45668	Sayad	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		51681	El-Bendary	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		57630	Abbass	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
aspirin	aspirin, atorvastatin							
	,	Ghati	Ghati	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
aspirin	standard care/placebo	_,						
		Ghati	Ghati	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		Horby_7	Horby_7	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
aspirin	statins							
изріі ІІ	Statilis	Ghati	Ghati	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
				, 2222,	,			, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
aspirin, atorvastatin	standard care/placebo							
		Ghati	Ghati	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
aspirin, atorvastatin	statins	Chart	Charl	and habitable blade and a first	and all belief also affect	lass state of the co	Leveral of his	and all the state of the
		Ghati	Ghati	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
atazanavir, dolutegravir, ritonavir	lopinavir-ritonavir							
ituzunavii, uoiutegravii, iitulidvii	iopinavii-litoliavii							

		53056	Kalantari	probably high risk of bias	high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
azithromycin	hydroxychloroquine							
aziciioniyan	nyaroxyemoroquine	18375	Brown	low risk of bias	high risk of bias	low risk of bias	low risk of bias	low risk of bias
azithromycin	standard care/placebo							
uziem omyem	Starradia care, praceso	11639, 12378	Sekhavati	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		12439	Furtado	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		22569, 29803	Horby_4	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
			PLE Trial Collaborative		probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		40804	Hinks	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
azithromycin, hydroxychloroquine	hydroxychloroquine							
	,,,	22152, 9166	Cavalcanti	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
althorough body while a solution	standard save fals sales							
azithromycin, hydroxychloroquine	standard care/placebo	22152, 9166	Cavalcanti	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		48002	Sivapalan	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
baloxavir marboxil	favipiravir	2027 Jan Jan /1	Leu	law side of bigs	and hable bigh vists of high	lavveigle of bios	lavveide of bios	lavveigle of bine
		2637, Lou, Lou (1	Lou	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
baloxavir marboxil	standard care/placebo							
		2637, Lou, Lou (1	Lou	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
beta-glucans	standard care/placebo							
Deta glacaris	Starradia care, praceso	65044	Raghavan	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
bromhexine hydrochloride	standard care/placebo	42242		lauratah afilika	and the block of the artists of block	Laurentale of little	Laurentelle affilia	lannatal affices
		12212 13888	Li_3	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias low risk of bias	low risk of bias
		35697	Ansarin Tolouian	probably high risk of bias probably high risk of bias	probably high risk of bias probably high risk of bias	low risk of bias probably low risk of bias	low risk of bias	low risk of bias probably low risk of bias
		33037	Toloulan	probably high risk of bias	probably high hisk of bias	probably low risk of blas	low risk of blus	probably low risk of bids
cacifediol	standard care/placebo							
	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	68593	Maghbooli	low risk of bias	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias
um release-activated calcium inhibi	standard care/placebo	68593	Maghbooli	low risk of bias	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias
ım release-activated calcium inhibi		68593 10964	Maghbooli Miller	low risk of bias probably high risk of bias	low risk of bias high risk of bias	probably high risk of bias	low risk of bias	low risk of bias probably high risk of bias
	standard care/placebo							
um release-activated calcium inhibi colchicine		10964	Miller	probably high risk of bias	high risk of bias	low risk of bias	low risk of bias	probably high risk of bias
	standard care/placebo	10964 7189	Miller Deftereos	probably high risk of bias	high risk of bias probably high risk of bias	low risk of bias	low risk of bias	probably high risk of bias
	standard care/placebo	10964 7189 28222, 45870	Miller Deftereos Tardif	probably high risk of bias	high risk of bias	low risk of bias	low risk of bias	probably high risk of bias
	standard care/placebo	10964 7189	Miller Deftereos	probably high risk of bias low risk of bias probably low risk of bias	high risk of bias probably high risk of bias low risk of bias probably high risk of bias	low risk of bias low risk of bias low risk of bias	low risk of bias low risk of bias low risk of bias	probably high risk of bias low risk of bias low risk of bias
	standard care/placebo	10964 7189 28222, 45870 Horby_6	Miller Deftereos Tardif Horby_6	probably high risk of bias low risk of bias probably low risk of bias low risk of bias	high risk of bias probably high risk of bias low risk of bias	low risk of bias low risk of bias low risk of bias low risk of bias	low risk of bias low risk of bias low risk of bias low risk of bias	probably high risk of bias low risk of bias low risk of bias low risk of bias
colchicine	standard care/placebo standard care/placebo	10964 7189 28222, 45870 Horby_6 64351	Miller Deftereos Tardif Horby_6 Dorward	probably high risk of bias low risk of bias probably low risk of bias low risk of bias low risk of bias	high risk of bias probably high risk of bias low risk of bias probably high risk of bias probably high risk of bias	low risk of bias	low risk of bias	probably high risk of bias low risk of bias low risk of bias low risk of bias low risk of bias
colchicine	standard care/placebo	10964 7189 28222, 45870 Horby_6 64351	Miller Deftereos Tardif Horby_6 Dorward	probably high risk of bias low risk of bias probably low risk of bias low risk of bias low risk of bias	high risk of bias probably high risk of bias low risk of bias probably high risk of bias probably high risk of bias probably high risk of bias	low risk of bias	low risk of bias	probably high risk of bias low risk of bias low risk of bias low risk of bias low risk of bias
colchicine	standard care/placebo standard care/placebo	10964 7189 28222, 45870 Horby_6 64351 64385	Miller Deftereos Tardif Horby_6 Dorward Pascual-Figal	probably high risk of bias low risk of bias probably low risk of bias low risk of bias low risk of bias low risk of bias	high risk of bias probably high risk of bias low risk of bias probably high risk of bias probably high risk of bias	low risk of bias	low risk of bias	probably high risk of bias low risk of bias
colchicine nicine, emtricitabine, tenofovir, sta	standard care/placebo standard care/placebo	7189 28222, 45870 Horby_6 64351 64385 Gaitan-Duarte	Miller Deftereos Tardif Horby_6 Dorward Pascual-Figal Gaitan-Duarte	probably high risk of bias low risk of bias probably low risk of bias low risk of bias low risk of bias low risk of bias	high risk of bias probably high risk of bias low risk of bias probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
colchicine nicine, emtricitabine, tenofovir, sta	standard care/placebo standard care/placebo emtricitabine, tenofovir	10964 7189 28222, 45870 Horby_6 64351 64385	Miller Deftereos Tardif Horby_6 Dorward Pascual-Figal	probably high risk of bias low risk of bias probably low risk of bias low risk of bias low risk of bias low risk of bias	high risk of bias probably high risk of bias low risk of bias probably high risk of bias probably high risk of bias probably high risk of bias	low risk of bias	low risk of bias	probably high risk of bias low risk of bias low risk of bias low risk of bias low risk of bias
colchicine nicine, emtricitabine, tenofovir, sta	standard care/placebo standard care/placebo emtricitabine, tenofovir standard care/placebo	7189 28222, 45870 Horby_6 64351 64385 Gaitan-Duarte	Miller Deftereos Tardif Horby_6 Dorward Pascual-Figal Gaitan-Duarte	probably high risk of bias low risk of bias probably low risk of bias low risk of bias low risk of bias low risk of bias	high risk of bias probably high risk of bias low risk of bias probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
colchicine nicine, emtricitabine, tenofovir, sta nicine, emtricitabine, tenofovir, sta	standard care/placebo standard care/placebo emtricitabine, tenofovir	7189 28222, 45870 Horby_6 64351 64385 Gaitan-Duarte	Miller Deftereos Tardif Horby_6 Dorward Pascual-Figal Gaitan-Duarte	probably high risk of bias low risk of bias probably low risk of bias low risk of bias low risk of bias low risk of bias	high risk of bias probably high risk of bias low risk of bias probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
colchicine nicine, emtricitabine, tenofovir, sta iicine, emtricitabine, tenofovir, sta colchicine, statin :	standard care/placebo standard care/placebo emtricitabine, tenofovir standard care/placebo	10964 7189 28222, 45870 Horby_6 64351 64385 Gaitan-Duarte Gaitan-Duarte	Miller Deftereos Tardif Horby_6 Dorward Pascual-Figal Gaitan-Duarte Gaitan-Duarte	probably high risk of bias low risk of bias probably low risk of bias	high risk of bias probably high risk of bias low risk of bias probably high risk of bias	low risk of bias	low risk of bias	probably high risk of bias low risk of bias low risk of bias low risk of bias low risk of bias low risk of bias low risk of bias
colchicine nicine, emtricitabine, tenofovir, sta	standard care/placebo standard care/placebo emtricitabine, tenofovir standard care/placebo	7189 28222, 45870 Horby_6 64351 64385 Gaitan-Duarte Gaitan-Duarte r, statin Gaitan-Duarte	Miller Deftereos Tardif Horby_6 Dorward Pascual-Figal Gaitan-Duarte Gaitan-Duarte Gaitan-Duarte	probably high risk of bias low risk of bias probably low risk of bias	high risk of bias probably high risk of bias low risk of bias probably high risk of bias	low risk of bias	low risk of bias	probably high risk of bias low risk of bias low risk of bias low risk of bias low risk of bias low risk of bias low risk of bias low risk of bias
colchicine nicine, emtricitabine, tenofovir, sta nicine, emtricitabine, tenofovir, sta colchicine, statin :	standard care/placebo standard care/placebo emtricitabine, tenofovir standard care/placebo	10964 7189 28222, 45870 Horby_6 64351 64385 Gaitan-Duarte Gaitan-Duarte	Miller Deftereos Tardif Horby_6 Dorward Pascual-Figal Gaitan-Duarte Gaitan-Duarte	probably high risk of bias low risk of bias probably low risk of bias	high risk of bias probably high risk of bias low risk of bias probably high risk of bias	low risk of bias	low risk of bias	probably high risk of bias low risk of bias low risk of bias low risk of bias low risk of bias low risk of bias low risk of bias
colchicine nicine, emtricitabine, tenofovir, sta nicine, emtricitabine, tenofovir, sta colchicine, statin :	standard care/placebo standard care/placebo emtricitabine, tenofovir standard care/placebo	7189 28222, 45870 Horby_6 64351 64385 Gaitan-Duarte Gaitan-Duarte r, statin Gaitan-Duarte	Miller Deftereos Tardif Horby_6 Dorward Pascual-Figal Gaitan-Duarte Gaitan-Duarte Gaitan-Duarte	probably high risk of bias low risk of bias probably low risk of bias	high risk of bias probably high risk of bias low risk of bias probably high risk of bias	low risk of bias	low risk of bias	probably high risk of bias low risk of bias low risk of bias low risk of bias low risk of bias low risk of bias low risk of bias low risk of bias low risk of bias
colchicine nicine, emtricitabine, tenofovir, sta nicine, emtricitabine, tenofovir, sta colchicine, statin :l	standard care/placebo standard care/placebo emtricitabine, tenofovir standard care/placebo nicine, emtricitabine, tenofovir emtricitabine, tenofovir	7189 28222, 45870 Horby_6 64351 64385 Gaitan-Duarte Gaitan-Duarte r, statin Gaitan-Duarte	Miller Deftereos Tardif Horby_6 Dorward Pascual-Figal Gaitan-Duarte Gaitan-Duarte Gaitan-Duarte	probably high risk of bias low risk of bias probably low risk of bias	high risk of bias probably high risk of bias low risk of bias probably high risk of bias	low risk of bias	low risk of bias	probably high risk of bias low risk of bias low risk of bias low risk of bias low risk of bias low risk of bias low risk of bias low risk of bias
colchicine hicine, emtricitabine, tenofovir, sta hicine, emtricitabine, tenofovir, sta colchicine, statin colchicine, statin colchicine, statin	standard care/placebo standard care/placebo emtricitabine, tenofovir standard care/placebo nicine, emtricitabine, tenofovir emtricitabine, tenofovir standard care/placebo	10964 7189 28222, 45870 Horby_6 64351 64385 Gaitan-Duarte Gaitan-Duarte Gaitan-Duarte Gaitan-Duarte Gaitan-Duarte	Miller Deftereos Tardif Horby_6 Dorward Pascual-Figal Gaitan-Duarte Gaitan-Duarte Gaitan-Duarte	probably high risk of bias low risk of bias probably low risk of bias	high risk of bias probably high risk of bias low risk of bias probably high risk of bias probably high risk of bias probably high risk of bias probably high risk of bias	low risk of bias	low risk of bias	probably high risk of bias low risk of bias low risk of bias low risk of bias low risk of bias low risk of bias low risk of bias low risk of bias low risk of bias
colchicine hicine, emtricitabine, tenofovir, sta hicine, emtricitabine, tenofovir, sta colchicine, statin :l	standard care/placebo standard care/placebo emtricitabine, tenofovir standard care/placebo nicine, emtricitabine, tenofovir emtricitabine, tenofovir	10964 7189 28222, 45870 Horby_6 64351 64385 Gaitan-Duarte Gaitan-Duarte Gaitan-Duarte Gaitan-Duarte Gaitan-Duarte	Miller Deftereos Tardif Horby_6 Dorward Pascual-Figal Gaitan-Duarte Gaitan-Duarte Gaitan-Duarte Gaitan-Duarte	probably high risk of bias low risk of bias probably low risk of bias	high risk of bias probably high risk of bias low risk of bias probably high risk of bias probably high risk of bias probably high risk of bias probably high risk of bias	low risk of bias	low risk of bias	probably high risk of bias low risk of bias low risk of bias low risk of bias low risk of bias low risk of bias low risk of bias low risk of bias low risk of bias
hicine, emtricitabine, tenofovir, sta hicine, emtricitabine, tenofovir, sta colchicine, statin : colchicine, statin colchicine, statin	standard care/placebo standard care/placebo emtricitabine, tenofovir standard care/placebo nicine, emtricitabine, tenofovir emtricitabine, tenofovir standard care/placebo	10964 7189 28222, 45870 Horby_6 64351 64385 Gaitan-Duarte Gaitan-Duarte Gaitan-Duarte Gaitan-Duarte Gaitan-Duarte	Miller Deftereos Tardif Horby_6 Dorward Pascual-Figal Gaitan-Duarte Gaitan-Duarte Gaitan-Duarte Gaitan-Duarte Gaitan-Duarte	probably high risk of bias low risk of bias probably low risk of bias	high risk of bias probably high risk of bias low risk of bias probably high risk of bias probably high risk of bias probably high risk of bias probably high risk of bias probably high risk of bias probably high risk of bias probably high risk of bias probably high risk of bias	low risk of bias	low risk of bias	probably high risk of bias low risk of bias low risk of bias low risk of bias low risk of bias low risk of bias low risk of bias low risk of bias low risk of bias low risk of bias
colchicine hicine, emtricitabine, tenofovir, sta hicine, emtricitabine, tenofovir, sta colchicine, statin colchicine, statin colchicine, statin	standard care/placebo standard care/placebo emtricitabine, tenofovir standard care/placebo nicine, emtricitabine, tenofovir emtricitabine, tenofovir standard care/placebo	10964 7189 28222, 45870 Horby_6 64351 64385 Gaitan-Duarte Gaitan-Duarte Gaitan-Duarte Gaitan-Duarte Gaitan-Duarte	Miller Deftereos Tardif Horby_6 Dorward Pascual-Figal Gaitan-Duarte Gaitan-Duarte Gaitan-Duarte Gaitan-Duarte Corral-Gudino	probably high risk of bias low risk of bias probably low risk of bias	high risk of bias probably high risk of bias low risk of bias probably high risk of bias probably high risk of bias probably high risk of bias probably high risk of bias probably high risk of bias probably high risk of bias	low risk of bias	low risk of bias	probably high risk of bias low risk of bias low risk of bias low risk of bias low risk of bias low risk of bias low risk of bias low risk of bias low risk of bias low risk of bias low risk of bias
colchicine nicine, emtricitabine, tenofovir, sta nicine, emtricitabine, tenofovir, sta colchicine, statin colchicine, statin colchicine, statin	standard care/placebo standard care/placebo emtricitabine, tenofovir standard care/placebo nicine, emtricitabine, tenofovir emtricitabine, tenofovir standard care/placebo	7189 28222, 45870 Horby_6 64351 64385 Gaitan-Duarte Gaitan-Duarte Gaitan-Duarte Gaitan-Duarte Gaitan-Duarte 4, statin Gaitan-Duarte Gaitan-Duarte 29672, 6743 33381, 7002, 861	Miller Deftereos Tardif Horby_6 Dorward Pascual-Figal Gaitan-Duarte Gaitan-Duarte Gaitan-Duarte Gaitan-Duarte Corral-Gudino Horby_1	probably high risk of bias low risk of bias probably low risk of bias low risk of bias low risk of bias low risk of bias low risk of bias low risk of bias low risk of bias	high risk of bias probably high risk of bias low risk of bias probably high risk of bias	low risk of bias	low risk of bias	probably high risk of bias low risk of bias low risk of bias low risk of bias low risk of bias low risk of bias low risk of bias low risk of bias low risk of bias low risk of bias low risk of bias low risk of bias

		12141	Tomazini	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		12146 13208	Angus Edalatifard	probably high risk of bias probably high risk of bias	probably high risk of bias probably high risk of bias	low risk of bias probably high risk of bias	low risk of bias low risk of bias	low risk of bias low risk of bias
		13208	Farahani	probably low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		31583	Jamaati	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		27641	Tang_2	probably low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
				p. 1000 /	process,ge. ce.			p. 2222. / 222
corticosteroids (systemic), tacrolim	us standard care/placebo							
		51435	Solanich	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
curcumin, piperine	probiotics							
curcumin, piperine	problotics	48609	Pawar	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
				product, row row or area				product, rounding and
doxycycline	standard care/placebo							
	5	55459, Butler_doxycly	Butler	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
doxycycline, ivermectin	ivermectin	Ahmed	Ahmed	anababb lass side of him	low risk of bias	low risk of bias	low risk of bias	archable law risk of hiss
		Annea	Anmed	probably low risk of bias	IOW FISK OF DIAS	IOW FISK OF DIAS	IOW FISK OF DIAS	probably low risk of bias
doxycycline, ivermectin	standard care/placebo							
zzycycinie, remeetii	standard care, placebo	Ahmed	Ahmed	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
emtricitabine, tenofovir	standard care/placebo							
		Gaitan-Duarte	Gaitan-Duarte	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
for the t	Indian to the control							
favipiravir	lopinavir-ritonavir	35903	Colarmani Dadas	low risk of hise	probably high risk of his	low rick of him	low rick of hise	probably low risk of his
		35903	Solaymani-Dodaran	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
favipiravir	standard care/placebo							
	, , , , , , , , , , , , , , , , , , ,	2637, Lou, Lou (1	Lou	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		10147, 10287, 997	Ivashchenko	probably high risk of bias	high risk of bias	low risk of bias	low risk of bias	low risk of bias
		32588	Ruzhentsova	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		24988, Udwadia	Udwadia	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		32586	Balykova_2	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		60646	Shinkai	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		27460	Balykova_1	probably high risk of bias	high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
favipiravir, hydrochloroquine	standard care/placebo	D d	D d	Learning of the co	and ball to black of the of the	lancatale afficia	lass what a fiblica	Lance of the Addition
		Bosaeed	Bosaeed	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
fluvoxamine	standard care/placebo							
патоланине	standard care, placeso	18818	Lenze	low risk of bias	low risk of bias	high risk of bias	low risk of bias	low risk of bias
		70784, Reis_2	Reis_2	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		· -						
full-dose anticoagulant	intermediate-dose anticoagula							
		Spyropoulos	Spyropoulos	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
full does outline and att	internediate description	ation .						
full-dose anticoagulation	intermediate-dose anticoagula		Oliveryle	probably high rick of high	probably high rick of hise	low rick of hine	low rick of hins	probably law rick of hise
		65782	Oliynyk	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
full-dose anticoagulation	standard care/placebo							
	atamaana dare, pideebo	47030	Lopes_3	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		Sholzberg	Sholzberg	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		64008	Ananworanich	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
hydroxychloroquine	droxychloroquine, lopinavir-rit							
		52697	Arabi	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
hydroxychloroquine	hydroxychloroquine, zinc							
riyuroxycnioroquine	nyuroxychioroquine, zinc	21407	Abd-Elsalam	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		21407	Apu-Lisdidiii	probably night risk of bids	probably high risk of bids	TOW TISK OF DIAS	10W 115K UI DIdS	probably low risk of blas
hydroxychloroquine	interferon beta, lopinavir-ritor	navir						
		45662, Ader_1	Ader_1	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
hydroxychloroquine	ivermectin							
		34666	Galan	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias

hydroxychloroquine	lopinavir-ritonavir							
		45662, Ader_1	Ader_1	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		52697	Arabi	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
hydroxychloroquine	standard care/placebo							
		14989, 8444, xx	Horby_2	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		22152, 9166	Cavalcanti	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		11299	Abd-Elsalam_1	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		13936	Ulrich	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
	1563		n_hydroxychloroquin		probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		16085, 38308	Dubée	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		16281	Lyngbakken	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		18245, 23358	Self	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		45662, Ader_1	Ader_1	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		41434 Schwartz 2	Réa-Neto	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		Schwartz_2 52697	Schwartz_2 Arabi	low risk of bias low risk of bias	low risk of bias probably high risk of bias	low risk of bias low risk of bias	low risk of bias low risk of bias	low risk of bias probably low risk of bias
		32097	Alabi	IOW LISK OF DIAS	probably flight risk of bias	IOW LISK OF DIAS	IOW HSK OF DIAS	probably low risk of bias
roxychloroquine, lopinavir-ritonav	hydroxychloroquine, umifenov	vir						
		23259, 8	Nojomi	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
droxychloroquine, lopinavir-ritonav	lopinavir-ritonavir	E2C07	Arab:	low rich of him	probably high viels of his	low rick of him	low risk of hise	probably less siels of his
		52697	Arabi	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
roxychloroquine, lopinavir-ritonav	standard care/placebo							
		52697	Arabi	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
hydroxychloroquine, rivabirin	lopinavir-ritonavir, ribavirin							
		46308_severe	Singh_3	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably high risk of bias
bundan malala sa su ta a satura latata	standard san falsasha							
hydroxychloroquine, rivabirin	standard care/placebo	46308_non severe	Singh_2	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably high risk of bias
		46308_severe		probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably high risk of bias
		40306_severe	Singh_3	probably flight risk of bias	probably high risk of bias	IOW FISK OF DIAS	IOM LISK OF DIAS	probably flight risk of bias
inhaled corticosteroids	standard care/placebo							
		57300, Yu	Yu	probably low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably high risk of bias
					, , ,			, , ,
inhaled pan-JAK inhibitor	standard care/placebo							
		34842	Singh_1	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
interferon alpha	mbinant super combinant inte		11: 2	anabable bish vist of biss	anabable bish viste of biss	lass viels of bion	lavveid, of bios	lass viels of bios
		32737, 7, 9574	Li_2	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
interferon alpha	standard care/placebo							
meneral dipila	standard care/placebo	35022	Pandit	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		59366, 60209	Bhushan	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably high risk of bias
interferon beta	standard care/placebo							
		11541, 11937	Rahmani	probably high risk of bias	probably high risk of bias	high risk of bias	low risk of bias	probably low risk of bias
		15632, Pan_interfer	Pan_interferon	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		39381, Darazam (2	Darazam_2	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		Kalil_2	Kalil_2	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		11243, 5514, 824	Davoudi-Monfared	low risk of bias	high risk of bias	probably high risk of bias	low risk of bias	probably low risk of bias
terferon beta, lopinavir-ritonavir	lopinavir-ritonavir							
		45662, Ader_1	Ader_1	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
nterferon beta, lopinavir-ritonavir	sofosbuvir							
		Mostafa	Alavi-Moghaddam	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
ntorforon hota Ioninavir ritaravia	standard care/placeho							
nterferon beta, lopinavir-ritonavir	standard care/placebo	45662, Ader_1	Ader_1	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		43002, MUEI_1	Auci_1	IOW HISK OF DIAS	Propably High FISK OF DIGS	IOW HISK OF DIAS	IOW HISK OF DIAS	IOW HSK OF DIAS
interferon beta, ribavirin	standard care/placebo							
		2942	Hung	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
			•					

itolizumab	standard care/placebo							
		21347, Kumar	Kumar_1	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
	standard san falsasha							
itraconazole	standard care/placebo		Linconhougho	anabable bish viste of biss	anahahi, hiah sist of bios	lavorials of bine	land sight of bigs	love side of bigs
		36093, Liesenborgl	Liesenborghs	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
li como o etilo	standard sars/alasaha							
ivermectin	standard care/placebo	49440, Krolewieck	Krolewiecki	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
							low risk of bias	
		Ahmed 53436, Ravikirti	Ahmed Ravikirti	probably low risk of bias low risk of bias	low risk of bias low risk of bias	low risk of bias low risk of bias	low risk of bias	probably low risk of bias low risk of bias
		Mohan	Mohan	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		34416, 41159, Lop	Lopez-Medina	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		47181, Abd-Elsalam	Abd-Elsalam_3	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		35667	Pott-Junior	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		51938	Vallejos	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
leronlimab	standard care/placebo							
		36109	Skendelas	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
Landan da albana da	standard san falasaha							
lopinavir-ritonavir	standard care/placebo		Con 1	lauratal - China	anahahir high status fists	lavoratale of the second	love sight a filtra	lanced to a filter
		330	Cao_1	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		14781, 14883	Horby_3	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
	1	L5632, Pan_lopinavir-rit Par			probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		45662, Ader_1	Ader_1	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		52697	Arabi	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
pinavir-ritonavir, ribavirin	standard care/placebo							
		46308_severe	Singh_3	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably high risk of bias
mavrilimumab	standard care/placebo							
		36763	Cremer_2	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
metisoprinol	standard care/placebo							
		Migled	Migled	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
molnupiravir	standard care/placebo							
		CR216-21	Vyas	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
nitazoxanide	standard care/placebo							
		50790, Blum	Blum	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
nitric oxide	standard care/placebo							
		Moni	Moni	low risk of bias	probably high risk of bias	probably low risk of bias	low risk of bias	probably low risk of bias
opaganib	standard care/placebo							
		Winthrop	Winthrop	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
pentoxifylline	standard care/placebo							
		21098	Malonado	probably high risk of bias	probably high risk of bias	high risk of bias	low risk of bias	probably low risk of bias
		67125	Azizi	probably low risk of bias	low risk of bias	high risk of bias	low risk of bias	probably low risk of bias
olymerized type I collagen	standard care/placebo							
		Méndez-Flores	Méndez-Flores	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
probiotics	standard care/placebo							
		68436	Ivashkin	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
progesterone	standard care/placebo							
1 .0		32075, Ghandeha	Ghandehari	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		and a second		,	, 222.,	5. 5.60		.5
proxalutamide	standard care/placebo							
p	TIT. I Care, placebo	Cadegiani (proxulatun	Cadegiani_2	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		48943	Cadegiani_5	high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		Cadegiani (female col	Cadegiani_4	high risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		Sacgiani (icinaic col	Caucgiani_4	HIGH HAK OF DIGS	TOW TISK OF DIAS	10W HISK OF DIAS	TOW TISK OF DIAS	Propably low risk of plas

pyridostigmine	standard care/placebo							
		Fragoso-Saavedra	Fragoso-Saavedra	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
quercetin	standard care/placebo							
		49941	Di Pierro_1	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
unidonia sofosbinia	standard sare/aleasha							
ravidasvir, sofosbuvir	standard care/placebo	57630	Abbass	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low rick of hige
		57030	ADDASS	IOW FISK OF DIAS	probably high risk of bias	low risk of bias	IOW FISK OF DIAS	probably low risk of bias
numan granulocyte colony-stimula	standard care/placebo							
naman granalocyte colony stimute	Staridard care, placebo	12705	Cheng	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		12,03	Circing	ion risk or blas	probably ingit tisk of blus	1011 1131 01 2103	iow risk or blus	probably low risk of blus
remdesivir	standard care/placebo							
		2408	Wang_1	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		11347	Spinner	low risk of bias	high risk of bias	probably low risk of bias	low risk of bias	low risk of bias
		15633, 3821	Beigel	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		15632, Pan_remdes	Pan_remdesivir	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		37778	Mahajan	high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		Ader (remdesivir)	Ader_2	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		68059	Abd-Elsalam_4	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
resveratrol	standard care/placebo							
		65305	McCreary	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
the data and allowed the state of	standard of the							
ribavirin, sofosbuvir-daclatasvir	standard care/placebo	11010	Vee	low sight of his a	anahahir high siste of hi	lavorials of the s	lavorials of the	anahahli lamatik aftir
		11010	Kasgari	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
secukinumab	standard sare/aleasha							
Secukinumab	standard care/placebo	Resende	Resende	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		Resenue	Resenue	probably flight risk of bias	probably flight fisk of bias	IOW FISK OF DIAS	IOW LISK OF DIAS	probably low risk of bias
serine protease inhibitors	standard care/placebo							
serine processe inilibitors	Staridard care, placebo	40853	Gunst	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		10033	Curist	ion risk or blas	1011 1131 01 5143	1011 11311 01 2113	iow risk or blus	10 W FISH OF BIAS
sildenafil	standard care/placebo							
		Santamarina	Santamarina	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias	probably low risk of bias
sitagliptin	sitagliptin, spironolactone							
sitagliptin	sitagliptin, spironolactone	Abbasi	Abbasi	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
sitagliptin	sitagliptin, spironolactone		Abbasi	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
sitagliptin sitagliptin	sitagliptin, spironolactone	Abbasi				low risk of bias		
			Abbasi Abbasi	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	
sitagliptin	spironolactone	Abbasi						
		Abbasi Abbasi	Abbasi	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
sitagliptin	spironolactone	Abbasi						probably low risk of bias
sitagliptin sitagliptin	spironolactone standard care/placebo	Abbasi Abbasi	Abbasi	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
sitagliptin	spironolactone	Abbasi Abbasi Abbasi	Abbasi Abbasi	probably high risk of bias probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
sitagliptin sitagliptin	spironolactone standard care/placebo	Abbasi Abbasi	Abbasi	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
sitagliptin sitagliptin sitagliptin, spironolactone	spironolactone standard care/placebo spironolactone	Abbasi Abbasi Abbasi	Abbasi Abbasi	probably high risk of bias probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
sitagliptin sitagliptin	spironolactone standard care/placebo	Abbasi Abbasi Abbasi	Abbasi Abbasi Abbasi	probably high risk of bias probably high risk of bias probably high risk of bias	probably high risk of bias probably high risk of bias probably high risk of bias	low risk of bias low risk of bias low risk of bias	low risk of bias low risk of bias low risk of bias	probably low risk of bias probably low risk of bias probably low risk of bias
sitagliptin sitagliptin sitagliptin, spironolactone	spironolactone standard care/placebo spironolactone	Abbasi Abbasi Abbasi	Abbasi Abbasi	probably high risk of bias probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
sitagliptin sitagliptin sitagliptin, spironolactone sitagliptin, spironolactone	spironolactone standard care/placebo spironolactone standard care/placebo	Abbasi Abbasi Abbasi	Abbasi Abbasi Abbasi	probably high risk of bias probably high risk of bias probably high risk of bias	probably high risk of bias probably high risk of bias probably high risk of bias	low risk of bias low risk of bias low risk of bias	low risk of bias low risk of bias low risk of bias	probably low risk of bias probably low risk of bias probably low risk of bias
sitagliptin sitagliptin sitagliptin, spironolactone	spironolactone standard care/placebo spironolactone	Abbasi Abbasi Abbasi Abbasi	Abbasi Abbasi Abbasi	probably high risk of bias	probably high risk of bias	low risk of bias low risk of bias low risk of bias	low risk of bias low risk of bias low risk of bias low risk of bias	probably low risk of bias
sitagliptin sitagliptin sitagliptin, spironolactone sitagliptin, spironolactone	spironolactone standard care/placebo spironolactone standard care/placebo	Abbasi Abbasi Abbasi	Abbasi Abbasi Abbasi	probably high risk of bias probably high risk of bias probably high risk of bias	probably high risk of bias probably high risk of bias probably high risk of bias	low risk of bias low risk of bias low risk of bias	low risk of bias low risk of bias low risk of bias	probably low risk of bias probably low risk of bias probably low risk of bias
sitagliptin sitagliptin sitagliptin, spironolactone sitagliptin, spironolactone spironolactone	spironolactone standard care/placebo spironolactone standard care/placebo standard care/placebo	Abbasi Abbasi Abbasi Abbasi	Abbasi Abbasi Abbasi	probably high risk of bias	probably high risk of bias	low risk of bias low risk of bias low risk of bias	low risk of bias low risk of bias low risk of bias low risk of bias	probably low risk of bias
sitagliptin sitagliptin sitagliptin, spironolactone sitagliptin, spironolactone	spironolactone standard care/placebo spironolactone standard care/placebo	Abbasi Abbasi Abbasi Abbasi	Abbasi Abbasi Abbasi Abbasi	probably high risk of bias	probably high risk of bias	low risk of bias low risk of bias low risk of bias	low risk of bias low risk of bias low risk of bias low risk of bias	probably low risk of bias
sitagliptin sitagliptin sitagliptin, spironolactone sitagliptin, spironolactone spironolactone	spironolactone standard care/placebo spironolactone standard care/placebo standard care/placebo	Abbasi Abbasi Abbasi Abbasi	Abbasi Abbasi Abbasi	probably high risk of bias	probably high risk of bias	low risk of bias low risk of bias low risk of bias low risk of bias	low risk of bias low risk of bias low risk of bias low risk of bias	probably low risk of bias
sitagliptin sitagliptin sitagliptin, spironolactone sitagliptin, spironolactone spironolactone	spironolactone standard care/placebo spironolactone standard care/placebo standard care/placebo	Abbasi Abbasi Abbasi Abbasi Abbasi Ghati	Abbasi Abbasi Abbasi Abbasi Ghati	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
sitagliptin sitagliptin sitagliptin, spironolactone sitagliptin, spironolactone spironolactone	spironolactone standard care/placebo spironolactone standard care/placebo standard care/placebo	Abbasi Abbasi Abbasi Abbasi Abbasi Ghati	Abbasi Abbasi Abbasi Abbasi Ghati	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
sitagliptin sitagliptin sitagliptin, spironolactone sitagliptin, spironolactone spironolactone statins	spironolactone standard care/placebo spironolactone standard care/placebo standard care/placebo	Abbasi Abbasi Abbasi Abbasi Abbasi Ghati	Abbasi Abbasi Abbasi Abbasi Ghati	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
sitagliptin sitagliptin sitagliptin, spironolactone sitagliptin, spironolactone spironolactone statins	spironolactone standard care/placebo spironolactone standard care/placebo standard care/placebo	Abbasi Abbasi Abbasi Abbasi Abbasi Ghati 64621	Abbasi Abbasi Abbasi Abbasi Ghati Davoodi_2	probably high risk of bias low risk of bias	probably high risk of bias low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
sitagliptin sitagliptin sitagliptin, spironolactone sitagliptin, spironolactone spironolactone statins	spironolactone standard care/placebo spironolactone standard care/placebo standard care/placebo	Abbasi Abbasi Abbasi Abbasi Abbasi Ghati 64621	Abbasi Abbasi Abbasi Abbasi Ghati Davoodi_2	probably high risk of bias low risk of bias	probably high risk of bias low risk of bias	low risk of bias	low risk of bias low risk of bias	probably low risk of bias
sitagliptin sitagliptin sitagliptin, spironolactone sitagliptin, spironolactone spironolactone statins	spironolactone standard care/placebo spironolactone standard care/placebo standard care/placebo standard care/placebo	Abbasi Abbasi Abbasi Abbasi Abbasi Ghati 64621	Abbasi Abbasi Abbasi Abbasi Ghati Davoodi_2	probably high risk of bias low risk of bias	probably high risk of bias low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
sitagliptin sitagliptin sitagliptin, spironolactone sitagliptin, spironolactone spironolactone spironolactone statins sulodexide thalidomide	spironolactone standard care/placebo spironolactone standard care/placebo standard care/placebo standard care/placebo standard care/placebo standard care/placebo	Abbasi Abbasi Abbasi Abbasi Abbasi Abbasi 21816, 34575	Abbasi Abbasi Abbasi Abbasi Abbasi Ghati Davoodi_2 Gonzalez-Ochoa	probably high risk of bias	probably high risk of bias low risk of bias low risk of bias	low risk of bias	low risk of bias low risk of bias	probably low risk of bias low risk of bias
sitagliptin sitagliptin sitagliptin, spironolactone sitagliptin, spironolactone spironolactone statins	spironolactone standard care/placebo spironolactone standard care/placebo standard care/placebo standard care/placebo	Abbasi Abbasi Abbasi Abbasi Abbasi Abbasi 21816, 34575 Amra	Abbasi Abbasi Abbasi Abbasi Abbasi Ghati Davoodi_2 Gonzalez-Ochoa	probably high risk of bias low risk of bias probably low risk of bias probably low risk of bias	probably high risk of bias low risk of bias low risk of bias	low risk of bias probably high risk of bias	low risk of bias	probably low risk of bias low risk of bias
sitagliptin sitagliptin sitagliptin, spironolactone sitagliptin, spironolactone spironolactone spironolactone statins sulodexide thalidomide	spironolactone standard care/placebo spironolactone standard care/placebo standard care/placebo standard care/placebo standard care/placebo standard care/placebo	Abbasi Abbasi Abbasi Abbasi Abbasi Abbasi 21816, 34575	Abbasi Abbasi Abbasi Abbasi Abbasi Ghati Davoodi_2 Gonzalez-Ochoa	probably high risk of bias	probably high risk of bias low risk of bias low risk of bias	low risk of bias	low risk of bias low risk of bias	probably low risk of bias probably low risk of bias

	6087	2 Strich	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
umifenovir standa	ard care/placebo						
	5284	1 Darazam_3	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
vitamin C standa	ard care/placebo						
	26123, 2	hang Zhang_1	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
	2579	3 Kumari	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
	31401, JamaliMog	hadamlamaliMoghadamSiahkal	i probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
vitamin D standa	ard care/placebo						
	18947, 3	1936 Murai	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
zinc standa	ard care/placebo						
	3474	5 Patel_1	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias

Hospital Admission Trial Deviations from the intended Treatment 1 Treatment 2 First author Randomization Missing outcome data Measurement of outcome Selection of the reported 5-alpha reductase inhibitor standard care/placebo 19047, 33978, Cadegiani, Cadegi Cadegiani_1 probably low risk of bias low risk of bias low risk of bias ACEi/ARB standard care/placebo 49084, Puskarich Puskarich low risk of bias nirmatrelvir/ritonavir standard care/placebo EPIC-HR EPIC-HR probably low risk of bias antihepaciviral standard care/placebo 24460 Roozbeh low risk of bias artemisinin standard care/placebo Trieu probably high risk of bias probably high risk of bias low risk of bias low risk of bias probably low risk of bias aspirin full-dose anticoagulation 67646 Connors low risk of bias aspirin standard care/placebo low risk of bias 67646 Connors low risk of bias low risk of bias low risk of bias low risk of bias azithromycin standard care/placebo 34434 CIPLE Trial Collaborative G low risk of bias probably high risk of bias low risk of bias low risk of bias low risk of bias 40804 Hinks low risk of bias probably high risk of bias low risk of bias low risk of bias low risk of bias Oldenburg Oldenburg low risk of bias low risk of bias low risk of bias low risk of bias azithromycin, hydroxychloroquine doxycycline Sobngwi Sobngwi low risk of bias probably high risk of bias low risk of bias low risk of bias low risk of bias azithromycin, hydroxychloroquine hydroxychloroquine 20005 Omrani low risk of bias low risk of bias low risk of bias low risk of bias probably low risk of bias 33489, Johnston Johnston probably low risk of bias low risk of bias low risk of bias low risk of bias probably low risk of bias azithromycin, hydroxychloroquine standard care/placebo 20005 Omrani low risk of bias low risk of bias low risk of bias low risk of bias probably low risk of bias 33489, Johnston probably low risk of bias low risk of bias low risk of bias probably low risk of bias Johnston low risk of bias 60017 low risk of bias low risk of bias probably low risk of bias Rodrigues low risk of bias low risk of bias cannabidiol standard care/placebo 66954 probably low risk of bias Crippa low risk of bias low risk of bias low risk of bias low risk of bias colchicine standard care/placebo 28222, 45870 Tardif probably low risk of bias electrolyzed saline standard care/placebo 13074, 53789 Delgado-Enciso probably high risk of bias probably high risk of bias low risk of bias low risk of bias low risk of bias emtricitabine, tenofovir standard care/placebo probably low risk of bias 50792 Parienti low risk of bias probably high risk of bias low risk of bias low risk of bias Arruda Arruda probably high risk of bias probably high risk of bias low risk of bias low risk of bias low risk of bias emtricitabine, tenofovir tenofovir Arruda Arruda probably high risk of bias probably high risk of bias low risk of bias low risk of bias low risk of bias favipiravir standard care/placebo 32588 Ruzhentsova probably high risk of bias probably high risk of bias low risk of bias probably low risk of bias febuxostat hydroxychloroquine 7586, Davoodi Davoodi probably high risk of bias probably high risk of bias probably high risk of bias low risk of bias probably low risk of bias fluvoxamine standard care/placebo 18818 Lenze low risk of bias 70784, Reis_2 Reis_2 low risk of bias low risk of bias low risk of bias low risk of bias STOP-COVID-2 low risk of bias low risk of bias Reiersen probably low risk of bias low risk of bias low risk of bias

full-dose anticoagulation	standard care/placebo							
		64008	Ananworanich	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		67646	Connors	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
hydroxychloroquine	lopinavir-ritonavir							
		Reis_1	Reis_1	low risk of bias	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias
hydroxychloroquine	standard care/placebo							
		8565	Skipper	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		20005	Omrani	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		Reis_1	Reis_1	low risk of bias	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias
		33489, Johnston	Johnston	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		33028	Amaravadi	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Schwartz_2	Schwartz_2	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
intranasal corticosteroids	standard care/placebo							
		Clemency	Clemency	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Ezer	Ezer	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
ranasal hypertonic polymer spra	y standard care/placebo							
,,	,	47064	Shrivastava	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		.,		,,	,,	151111111111111111111111111111111111111		p. 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
ivermectin	standard care/placebo							
Wermeetin	Standard care/placebo	34416, 41159, Lopi	Lopez-Medina	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		51938	Vallejos	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Buonfrate	Buonfrate	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		pullilare	puominate	IOW LISK OF DIGS	IOW LIPK OLDIGZ	IOM LISK OF DIAS	IOM LIPK OF DIRP	IOW HSK OF DIAS
lavanicala	stondard sons/alasaba							
levamisole	standard care/placebo	27400 0	December 1 Floresheed	and all the same of the of the a	Lance State of Little a	In the China	Territoria de China	Laure State of Billion
		37198, Roostaei Firoz	Roostaei Firozabad	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
lopinavir-ritonavir	standard care/placebo							
							low risk of bias	low risk of bias
		Reis_1	Reis_1	low risk of bias	low risk of bias	probably high risk of bias	IOW TISK OF BIGS	1011 1151 01 5105
		veiz_1	Kels_1	IOW FISK OF DIAS	IOW RISK OT DIAS	probably fligh risk of bias	IOW HISK OF BIAS	1011 1151 01 5145
metisoprinol	standard care/placebo							
metisoprinol	standard care/placebo	Migled	Migled	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
metisoprinol molnupiravir	standard care/placebo	Migled	Migled	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		Migled 46473, Fischer	Migled Fischer	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		Migled 46473, Fischer MOVe-OUT (MK4482-M	Migled Fischer OVe-OUT (MK4482-002	probably high risk of bias low risk of bias probably low risk of bias	probably high risk of bias low risk of bias low risk of bias	low risk of bias low risk of bias low risk of bias	low risk of bias low risk of bias low risk of bias	probably low risk of bias probably low risk of bias low risk of bias
		Migled 46473, Fischer MOVe-OUT (MK4482-/	Migled Fischer	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
	standard care/placebo	Migled 46473, Fischer MOVe-OUT (MK4482-/ CR216-21 CTR1/2021/06/0339	Migled Fischer OVe-OUT (MK4482-002	probably high risk of bias low risk of bias probably low risk of bias	probably high risk of bias low risk of bias low risk of bias	low risk of bias low risk of bias low risk of bias	low risk of bias low risk of bias low risk of bias	probably low risk of bias probably low risk of bias low risk of bias
·	standard care/placebo	Migled 46473, Fischer MOVe-OUT (MK4482-/	Migled Fischer OVe-OUT (MK4482-002 Vyas	probably high risk of bias low risk of bias probably low risk of bias low risk of bias	probably high risk of bias low risk of bias low risk of bias probably high risk of bias	low risk of bias low risk of bias low risk of bias low risk of bias	low risk of bias low risk of bias low risk of bias low risk of bias	probably low risk of bias probably low risk of bias low risk of bias low risk of bias
	standard care/placebo	Migled 46473, Fischer MOVe-OUT (MK4482-/ CR216-21 CTR1/2021/06/0339	Migled Fischer OVe-OUT (MK4482-002 Vyas Krishnan	probably high risk of bias low risk of bias probably low risk of bias low risk of bias low risk of bias	probably high risk of bias low risk of bias low risk of bias probably high risk of bias probably high risk of bias	low risk of bias low risk of bias low risk of bias low risk of bias probably low risk of bias	low risk of bias	probably low risk of bias probably low risk of bias low risk of bias low risk of bias low risk of bias
	standard care/placebo	Migled 46473, Fischer MOVe-OUT (MK4482-4) CR216-21 CTRI/2021/06/0339 HCR/III/MOLCOV/04/2(Migled Fischer OVe-OUT (MK4482-002 Vyas Krishnan	probably high risk of bias low risk of bias probably low risk of bias low risk of bias low risk of bias	probably high risk of bias low risk of bias low risk of bias probably high risk of bias probably high risk of bias	low risk of bias low risk of bias low risk of bias low risk of bias probably low risk of bias	low risk of bias	probably low risk of bias probably low risk of bias low risk of bias low risk of bias low risk of bias
molnupiravir	standard care/placebo	Migled 46473, Fischer MOVe-OUT (MK4482-4) CR216-21 CTRI/2021/06/0339 HCR/III/MOLCOV/04/2(Migled Fischer OVe-OUT (MK4482-002 Vyas Krishnan	probably high risk of bias low risk of bias probably low risk of bias low risk of bias low risk of bias	probably high risk of bias low risk of bias low risk of bias probably high risk of bias probably high risk of bias	low risk of bias low risk of bias low risk of bias low risk of bias probably low risk of bias	low risk of bias	probably low risk of bias probably low risk of bias low risk of bias low risk of bias low risk of bias
molnupiravir	standard care/placebo	Migled 46473, Fischer MOVe-OUT (MK4482-4 CR216-21 CTRI/2021/06/0339 HCR/III/MOLCOV/04/2(/placebo	Migled Fischer OVe-OUT (MK4482-002 Vyas Krishnan Kumar_2	probably high risk of bias low risk of bias probably low risk of bias low risk of bias probably high risk of bias	probably high risk of bias low risk of bias low risk of bias probably high risk of bias probably high risk of bias probably high risk of bias	low risk of bias low risk of bias low risk of bias low risk of bias probably low risk of bias low risk of bias	low risk of bias	probably low risk of bias probably low risk of bias low risk of bias low risk of bias low risk of bias probably low risk of bias
molnupiravir	standard care/placebo	Migled 46473, Fischer MOVe-OUT (MK4482-4 CR216-21 CTRI/2021/06/0339 HCR/III/MOLCOV/04/2(/placebo	Migled Fischer OVe-OUT (MK4482-002 Vyas Krishnan Kumar_2	probably high risk of bias low risk of bias probably low risk of bias low risk of bias probably high risk of bias	probably high risk of bias low risk of bias low risk of bias probably high risk of bias probably high risk of bias probably high risk of bias	low risk of bias low risk of bias low risk of bias low risk of bias probably low risk of bias low risk of bias	low risk of bias	probably low risk of bias probably low risk of bias low risk of bias low risk of bias low risk of bias probably low risk of bias
molnupiravir mometasone nasal spray	standard care/placebo	Migled 46473, Fischer MOVe-OUT (MK4482-4 CR216-21 CTRI/2021/06/0339 HCR/III/MOLCOV/04/2(/placebo	Migled Fischer OVe-OUT (MK4482-002 Vyas Krishnan Kumar_2	probably high risk of bias low risk of bias probably low risk of bias low risk of bias probably high risk of bias	probably high risk of bias low risk of bias low risk of bias probably high risk of bias probably high risk of bias probably high risk of bias	low risk of bias low risk of bias low risk of bias low risk of bias probably low risk of bias low risk of bias	low risk of bias	probably low risk of bias probably low risk of bias low risk of bias low risk of bias low risk of bias probably low risk of bias
molnupiravir mometasone nasal spray	standard care/placebo	Migled 46473, Fischer MOVe-OUT (MK4482-4 CR216-21 CTRI/2021/06/0339 HCR/III/MOLCOV/04/2(/placebo 48548	Migled Fischer OVe-OUT (MK4482-002 Vyas Krishnan Kumar_2 Kasiri	probably high risk of bias low risk of bias probably low risk of bias low risk of bias probably high risk of bias probably low risk of bias	probably high risk of bias low risk of bias low risk of bias probably high risk of bias probably high risk of bias probably high risk of bias	low risk of bias low risk of bias low risk of bias low risk of bias probably low risk of bias low risk of bias	low risk of bias	probably low risk of bias probably low risk of bias low risk of bias low risk of bias low risk of bias probably low risk of bias probably low risk of bias
molnupiravir mometasone nasal spray	standard care/placebo	Migled 46473, Fischer MOVe-OUT (MK4482-4 CR216-21 CTRI/2021/06/0339 HCR/III/MOLCOV/04/2(/placebo 48548	Migled Fischer OVe-OUT (MK4482-002 Vyas Krishnan Kumar_2 Kasiri	probably high risk of bias low risk of bias probably low risk of bias low risk of bias probably high risk of bias probably low risk of bias	probably high risk of bias low risk of bias low risk of bias probably high risk of bias probably high risk of bias probably high risk of bias	low risk of bias low risk of bias low risk of bias low risk of bias probably low risk of bias low risk of bias	low risk of bias	probably low risk of bias probably low risk of bias low risk of bias low risk of bias low risk of bias probably low risk of bias probably low risk of bias
molnupiravir mometasone nasal spray nanocurcimin	standard care/placebo factory training, standard care, standard care/placebo	Migled 46473, Fischer MOVe-OUT (MK4482-4 CR216-21 CTRI/2021/06/0339 HCR/III/MOLCOV/04/2(/placebo 48548	Migled Fischer OVe-OUT (MK4482-002 Vyas Krishnan Kumar_2 Kasiri Ahmadi	probably high risk of bias low risk of bias probably low risk of bias low risk of bias probably high risk of bias probably low risk of bias	probably high risk of bias low risk of bias low risk of bias probably high risk of bias probably high risk of bias probably high risk of bias	low risk of bias low risk of bias low risk of bias low risk of bias probably low risk of bias low risk of bias	low risk of bias	probably low risk of bias probably low risk of bias low risk of bias low risk of bias low risk of bias probably low risk of bias probably low risk of bias probably low risk of bias
molnupiravir mometasone nasal spray nanocurcimin	standard care/placebo factory training, standard care, standard care/placebo	Migled 46473, Fischer MOVe-OUT (MK4482-4 CR216-21 CTRI/2021/06/0339 HCR/III/MOLCOV/04/20 /placebo 48548 49064	Migled Fischer OVe-OUT (MK4482-002 Vyas Krishnan Kumar_2 Kasiri Ahmadi	probably high risk of bias low risk of bias probably low risk of bias low risk of bias probably high risk of bias probably low risk of bias low risk of bias	probably high risk of bias low risk of bias low risk of bias probably high risk of bias probably high risk of bias probably high risk of bias low risk of bias	low risk of bias low risk of bias low risk of bias low risk of bias probably low risk of bias low risk of bias low risk of bias	low risk of bias	probably low risk of bias probably low risk of bias low risk of bias low risk of bias low risk of bias probably low risk of bias probably low risk of bias probably low risk of bias
molnupiravir mometasone nasal spray nanocurcimin	standard care/placebo factory training, standard care, standard care/placebo	Migled 46473, Fischer MOVe-OUT (MK4482-4) CR216-21 CTRI/2021/06/0339 HCR/III/MOLCOV/04/2(/placebo 48548	Migled Fischer OVe-OUT (MK4482-002 Vyas Krishnan Kumar_2 Kasiri Ahmadi	probably high risk of bias low risk of bias probably low risk of bias low risk of bias low risk of bias probably high risk of bias probably low risk of bias low risk of bias	probably high risk of bias low risk of bias low risk of bias probably high risk of bias probably high risk of bias probably high risk of bias low risk of bias	low risk of bias low risk of bias low risk of bias low risk of bias probably low risk of bias low risk of bias low risk of bias	low risk of bias	probably low risk of bias probably low risk of bias low risk of bias low risk of bias low risk of bias probably low risk of bias probably low risk of bias probably low risk of bias
molnupiravir mometasone nasal spray nanocurcimin nitazoxanide	standard care/placebo factory training, standard care, standard care/placebo standard care/placebo	Migled 46473, Fischer MOVe-OUT (MK4482-4 CR216-21 CTRI/2021/06/0339 HCR/III/MOLCOV/04/20 /placebo 48548 49064	Migled Fischer OVe-OUT (MK4482-002 Vyas Krishnan Kumar_2 Kasiri Ahmadi	probably high risk of bias low risk of bias probably low risk of bias low risk of bias probably high risk of bias probably low risk of bias low risk of bias	probably high risk of bias low risk of bias low risk of bias probably high risk of bias probably high risk of bias probably high risk of bias low risk of bias	low risk of bias low risk of bias low risk of bias low risk of bias probably low risk of bias low risk of bias low risk of bias	low risk of bias	probably low risk of bias probably low risk of bias low risk of bias low risk of bias low risk of bias probably low risk of bias probably low risk of bias probably low risk of bias
molnupiravir mometasone nasal spray nanocurcimin	standard care/placebo factory training, standard care, standard care/placebo	Migled 46473, Fischer MOVe-OUT (MK4482-4 CR216-21 CTRI/2021/06/0339 HCR/III/MOLCOV/04/2(/placebo 48548 49064 16339, 24799 Rossignol	Migled Fischer OVe-OUT (MK4482-002 Vyas Krishnan Kumar_2 Kasiri Ahmadi Rocco Rossignol	probably high risk of bias low risk of bias probably low risk of bias low risk of bias probably high risk of bias probably low risk of bias low risk of bias low risk of bias	probably high risk of bias low risk of bias low risk of bias probably high risk of bias probably high risk of bias probably high risk of bias low risk of bias low risk of bias	low risk of bias low risk of bias low risk of bias low risk of bias probably low risk of bias low risk of bias low risk of bias low risk of bias	low risk of bias	probably low risk of bias probably low risk of bias low risk of bias low risk of bias low risk of bias probably low risk of bias probably low risk of bias probably low risk of bias
molnupiravir mometasone nasal spray nanocurcimin nitazoxanide	standard care/placebo factory training, standard care, standard care/placebo standard care/placebo	Migled 46473, Fischer MOVe-OUT (MK4482-4 CR216-21 CTRI/2021/06/0339 HCR/III/MOLCOV/04/20 /placebo 48548 49064	Migled Fischer OVe-OUT (MK4482-002 Vyas Krishnan Kumar_2 Kasiri Ahmadi	probably high risk of bias low risk of bias probably low risk of bias low risk of bias probably high risk of bias probably low risk of bias low risk of bias	probably high risk of bias low risk of bias low risk of bias probably high risk of bias probably high risk of bias probably high risk of bias low risk of bias	low risk of bias low risk of bias low risk of bias low risk of bias probably low risk of bias low risk of bias low risk of bias	low risk of bias	probably low risk of bias probably low risk of bias low risk of bias low risk of bias low risk of bias probably low risk of bias probably low risk of bias probably low risk of bias
molnupiravir mometasone nasal spray nanocurcimin nitazoxanide omega 3	standard care/placebo factory training, standard care, standard care/placebo standard care/placebo	Migled 46473, Fischer MOVe-OUT (MK4482-4 CR216-21 CTRI/2021/06/0339 HCR/III/MOLCOV/04/2(/placebo 48548 49064 16339, 24799 Rossignol	Migled Fischer OVe-OUT (MK4482-002 Vyas Krishnan Kumar_2 Kasiri Ahmadi Rocco Rossignol	probably high risk of bias low risk of bias probably low risk of bias low risk of bias probably high risk of bias probably low risk of bias low risk of bias low risk of bias	probably high risk of bias low risk of bias low risk of bias probably high risk of bias probably high risk of bias probably high risk of bias low risk of bias low risk of bias	low risk of bias low risk of bias low risk of bias low risk of bias probably low risk of bias low risk of bias low risk of bias low risk of bias	low risk of bias	probably low risk of bias probably low risk of bias low risk of bias low risk of bias low risk of bias probably low risk of bias probably low risk of bias probably low risk of bias
molnupiravir mometasone nasal spray nanocurcimin nitazoxanide	standard care/placebo factory training, standard care, standard care/placebo standard care/placebo	Migled 46473, Fischer MOVe-OUT (MK4482-4) CR216-21 CTRI/2021/06/0339 HCR/III/MOLCOV/04/2(/placebo 48548 49064 16339, 24799 Rossignol	Migled Fischer OVe-OUT (MK4482-002 Vyas Krishnan Kumar_2 Kasiri Ahmadi Rocco Rossignol Kosmopoulos	probably high risk of bias low risk of bias probably low risk of bias low risk of bias probably high risk of bias probably low risk of bias	probably high risk of bias low risk of bias low risk of bias probably high risk of bias probably high risk of bias probably high risk of bias low risk of bias low risk of bias low risk of bias probably high risk of bias	low risk of bias low risk of bias low risk of bias low risk of bias probably low risk of bias	low risk of bias	probably low risk of bias probably low risk of bias probably low risk of bias probably low risk of bias probably low risk of bias probably low risk of bias probably low risk of bias probably low risk of bias
mometasone nasal spray nanocurcimin nitazoxanide omega 3	standard care/placebo factory training, standard care, standard care/placebo standard care/placebo standard care/placebo	Migled 46473, Fischer MOVe-OUT (MK4482-4 CR216-21 CTRI/2021/06/0339 HCR/III/MOLCOV/04/2(/placebo 48548 49064 16339, 24799 Rossignol 60421	Migled Fischer OVe-OUT (MK4482-002 Vyas Krishnan Kumar_2 Kasiri Ahmadi Rocco Rossignol Kosmopoulos	probably high risk of bias low risk of bias probably low risk of bias low risk of bias probably high risk of bias probably low risk of bias low risk of bias low risk of bias low risk of bias low risk of bias	probably high risk of bias low risk of bias low risk of bias probably high risk of bias probably high risk of bias probably high risk of bias low risk of bias low risk of bias probably high risk of bias low risk of bias	low risk of bias low risk of bias low risk of bias low risk of bias probably low risk of bias	low risk of bias	probably low risk of bias probably low risk of bias low risk of bias low risk of bias low risk of bias probably low risk of bias
mometasone nasal spray nanocurcimin nitazoxanide omega 3	standard care/placebo factory training, standard care, standard care/placebo standard care/placebo standard care/placebo	Migled 46473, Fischer MOVe-OUT (MK4482-4) CR216-21 CTRI/2021/06/0339 HCR/III/MOLCOV/04/2(/placebo 48548 49064 16339, 24799 Rossignol	Migled Fischer OVe-OUT (MK4482-002 Vyas Krishnan Kumar_2 Kasiri Ahmadi Rocco Rossignol Kosmopoulos	probably high risk of bias low risk of bias probably low risk of bias low risk of bias probably high risk of bias probably low risk of bias	probably high risk of bias low risk of bias low risk of bias probably high risk of bias probably high risk of bias probably high risk of bias low risk of bias low risk of bias low risk of bias probably high risk of bias	low risk of bias low risk of bias low risk of bias low risk of bias probably low risk of bias	low risk of bias	probably low risk of bias probably low risk of bias probably low risk of bias probably low risk of bias probably low risk of bias probably low risk of bias probably low risk of bias probably low risk of bias
molnupiravir mometasone nasal spray nanocurcimin nitazoxanide omega 3 peginterferon lambda	standard care/placebo factory training, standard care, standard care/placebo standard care/placebo standard care/placebo standard care/placebo	Migled 46473, Fischer MOVe-OUT (MK4482-4 CR216-21 CTRI/2021/06/0339 HCR/III/MOLCOV/04/2(/placebo 48548 49064 16339, 24799 Rossignol 60421	Migled Fischer OVe-OUT (MK4482-002 Vyas Krishnan Kumar_2 Kasiri Ahmadi Rocco Rossignol Kosmopoulos	probably high risk of bias low risk of bias probably low risk of bias low risk of bias probably high risk of bias probably low risk of bias low risk of bias low risk of bias low risk of bias low risk of bias	probably high risk of bias low risk of bias low risk of bias probably high risk of bias probably high risk of bias probably high risk of bias low risk of bias low risk of bias probably high risk of bias low risk of bias	low risk of bias low risk of bias low risk of bias low risk of bias probably low risk of bias	low risk of bias	probably low risk of bias probably low risk of bias low risk of bias low risk of bias low risk of bias probably low risk of bias
molnupiravir mometasone nasal spray nanocurcimin nitazoxanide omega 3	standard care/placebo factory training, standard care, standard care/placebo standard care/placebo standard care/placebo	Migled 46473, Fischer MOVe-OUT (MK4482-/ CR216-21 CTRI/2021/06/0339 HCR/III/MOLCOV/04/2(/placebo 48548 49064 16339, 24799 Rossignol 60421 18418, 28233 agannathan, Jagannathi	Migled Fischer OVe-OUT (MK4482-002 Vyas Krishnan Kumar_2 Kasiri Ahmadi Rocco Rossignol Kosmopoulos Feld Jagannathan	probably high risk of bias low risk of bias probably low risk of bias low risk of bias probably high risk of bias probably low risk of bias	probably high risk of bias low risk of bias low risk of bias probably high risk of bias probably high risk of bias probably high risk of bias low risk of bias low risk of bias low risk of bias probably high risk of bias low risk of bias probably high risk of bias	low risk of bias low risk of bias low risk of bias low risk of bias probably low risk of bias	low risk of bias	probably low risk of bias probably low risk of bias low risk of bias low risk of bias low risk of bias probably low risk of bias
mometasone nasal spray nanocurcimin nitazoxanide omega 3 peginterferon lambda	standard care/placebo factory training, standard care, standard care/placebo standard care/placebo standard care/placebo standard care/placebo	Migled 46473, Fischer MOVe-OUT (MK4482-4 CR216-21 CTRI/2021/06/0339 HCR/III/MOLCOV/04/2(/placebo 48548 49064 16339, 24799 Rossignol 60421	Migled Fischer OVe-OUT (MK4482-002 Vyas Krishnan Kumar_2 Kasiri Ahmadi Rocco Rossignol Kosmopoulos	probably high risk of bias low risk of bias probably low risk of bias low risk of bias probably high risk of bias probably low risk of bias low risk of bias low risk of bias low risk of bias low risk of bias	probably high risk of bias low risk of bias low risk of bias probably high risk of bias probably high risk of bias probably high risk of bias low risk of bias low risk of bias probably high risk of bias low risk of bias	low risk of bias low risk of bias low risk of bias low risk of bias probably low risk of bias	low risk of bias	probably low risk of bias probably low risk of bias low risk of bias low risk of bias low risk of bias probably low risk of bias
molnupiravir mometasone nasal spray nanocurcimin nitazoxanide omega 3 peginterferon lambda polymerized type I collagen	standard care/placebo factory training, standard care, standard care/placebo standard care/placebo standard care/placebo standard care/placebo standard care/placebo standard care/placebo	Migled 46473, Fischer MOVe-OUT (MK4482-M	Migled Fischer OVe-OUT (MK4482-002 Vyas Krishnan Kumar_2 Kasiri Ahmadi Rocco Rossignol Kosmopoulos Feld Jagannathan	probably high risk of bias low risk of bias probably low risk of bias low risk of bias probably high risk of bias probably low risk of bias	probably high risk of bias low risk of bias low risk of bias probably high risk of bias probably high risk of bias probably high risk of bias low risk of bias low risk of bias low risk of bias probably high risk of bias low risk of bias probably high risk of bias	low risk of bias low risk of bias low risk of bias low risk of bias probably low risk of bias	low risk of bias	probably low risk of bias probably low risk of bias low risk of bias low risk of bias low risk of bias probably low risk of bias
molnupiravir mometasone nasal spray nanocurcimin nitazoxanide omega 3 peginterferon lambda	standard care/placebo factory training, standard care, standard care/placebo standard care/placebo standard care/placebo standard care/placebo standard care/placebo standard care/placebo	Migled 46473, Fischer MOVe-OUT (MK4482-4) CR216-21 CTRI/2021/06/0339 HCR/III/MOLCOV/04/2(/placebo 48548 49064 16339, 24799 Rossignol 60421 18418, 28233 agannathan, Jagannathi Méndez-Flores gation	Migled Fischer OVe-OUT (MK4482-002 Vyas Krishnan Kumar_2 Kasiri Ahmadi Rocco Rossignol Kosmopoulos Feld Jagannathan Méndez-Flores	probably high risk of bias low risk of bias probably low risk of bias low risk of bias probably high risk of bias probably low risk of bias low risk of bias low risk of bias low risk of bias low risk of bias low risk of bias low risk of bias probably low risk of bias probably low risk of bias	probably high risk of bias low risk of bias low risk of bias probably high risk of bias probably high risk of bias probably high risk of bias low risk of bias low risk of bias low risk of bias probably high risk of bias low risk of bias low risk of bias probably low risk of bias low risk of bias	low risk of bias low risk of bias low risk of bias low risk of bias probably low risk of bias	low risk of bias	probably low risk of bias probably low risk of bias
molnupiravir mometasone nasal spray nanocurcimin nitazoxanide omega 3 peginterferon lambda polymerized type I collagen	standard care/placebo factory training, standard care, standard care/placebo standard care/placebo standard care/placebo standard care/placebo standard care/placebo standard care/placebo	Migled 46473, Fischer MOVe-OUT (MK4482-M	Migled Fischer OVe-OUT (MK4482-002 Vyas Krishnan Kumar_2 Kasiri Ahmadi Rocco Rossignol Kosmopoulos Feld Jagannathan	probably high risk of bias low risk of bias probably low risk of bias low risk of bias probably high risk of bias probably low risk of bias	probably high risk of bias low risk of bias low risk of bias probably high risk of bias probably high risk of bias probably high risk of bias low risk of bias low risk of bias low risk of bias probably high risk of bias low risk of bias probably high risk of bias	low risk of bias low risk of bias low risk of bias low risk of bias probably low risk of bias	low risk of bias	probably low risk of bias probably low risk of bias low risk of bias low risk of bias low risk of bias probably low risk of bias
molnupiravir mometasone nasal spray nanocurcimin nitazoxanide omega 3 peginterferon lambda polymerized type I collagen	standard care/placebo factory training, standard care, standard care/placebo standard care/placebo standard care/placebo standard care/placebo standard care/placebo standard care/placebo	Migled 46473, Fischer MOVe-OUT (MK4482-4) CR216-21 CTRI/2021/06/0339 HCR/III/MOLCOV/04/2(/placebo 48548 49064 16339, 24799 Rossignol 60421 18418, 28233 agannathan, Jagannathi Méndez-Flores gation	Migled Fischer OVe-OUT (MK4482-002 Vyas Krishnan Kumar_2 Kasiri Ahmadi Rocco Rossignol Kosmopoulos Feld Jagannathan Méndez-Flores	probably high risk of bias low risk of bias probably low risk of bias low risk of bias probably high risk of bias probably low risk of bias low risk of bias low risk of bias low risk of bias low risk of bias low risk of bias low risk of bias probably low risk of bias probably low risk of bias	probably high risk of bias low risk of bias low risk of bias probably high risk of bias probably high risk of bias probably high risk of bias low risk of bias low risk of bias low risk of bias probably high risk of bias low risk of bias low risk of bias probably low risk of bias low risk of bias	low risk of bias low risk of bias low risk of bias low risk of bias probably low risk of bias	low risk of bias	probably low risk of bias probably low risk of bias
mometasone nasal spray nanocurcimin nitazoxanide omega 3 peginterferon lambda polymerized type I collagen	standard care/placebo factory training, standard care, standard care/placebo standard care/placebo standard care/placebo standard care/placebo standard care/placebo standard care/placebo	Migled 46473, Fischer MOVe-OUT (MK4482-4) CR216-21 CTRI/2021/06/0339 HCR/III/MOLCOV/04/2(/placebo 48548 49064 16339, 24799 Rossignol 60421 18418, 28233 agannathan, Jagannathi Méndez-Flores gation	Migled Fischer OVe-OUT (MK4482-002 Vyas Krishnan Kumar_2 Kasiri Ahmadi Rocco Rossignol Kosmopoulos Feld Jagannathan Méndez-Flores	probably high risk of bias low risk of bias probably low risk of bias low risk of bias probably high risk of bias probably low risk of bias low risk of bias low risk of bias low risk of bias low risk of bias low risk of bias low risk of bias probably low risk of bias probably low risk of bias	probably high risk of bias low risk of bias low risk of bias probably high risk of bias probably high risk of bias probably high risk of bias low risk of bias low risk of bias low risk of bias probably high risk of bias low risk of bias low risk of bias probably low risk of bias low risk of bias	low risk of bias low risk of bias low risk of bias low risk of bias probably low risk of bias	low risk of bias	probably low risk of bias probably low risk of bias

		44556	Gutiérrez-Castrellón	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	
proxalutamide	standard care/placebo								
		Cadegiani (proxulatun	Cadegiani_2	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	
		Cadegiani (female col	Cadegiani_4	high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	Terminated early for benef
quercetin	standard care/placebo								
		49941	Di Pierro_1	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	
		51397	Di Pierro_2	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	
remdesivir	standard care/placebo								
		Gottlieb_2, PINETR	Gottlieb_2	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	
resveratrol	standard care/placebo								
		65305	McCreary	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	
sulodexide	standard care/placebo								
		21816, 34575	Gonzalez-Ochoa	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	
tenofovir	standard care/placebo								
		Arruda	Arruda	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	
vitamin C	standard care/placebo					_			_
		31458	Thomas	low risk of bias	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	
vitamin C	vitamin C, zinc					_			
		31458	Thomas	low risk of bias	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	
vitamin C	zinc								_
		31458	Thomas	low risk of bias	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	
vitamin C, zinc	standard care/placebo								_
		31458	Thomas	low risk of bias	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	
vitamin C, zinc	zinc								
		31458	Thomas	low risk of bias	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	
zinc	standard care/placebo								
		31458	Thomas	low risk of bias	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	

low risk of bias probably low risk of bias

Adverse Events Leading to Discontinuation											
Treatment 1	Treatment 2	Trial	First author	dverse Events Leading to Disco Randomization	Deviations from the intended	Missing outcome data	Measurement of outcome	Selection of the reported			
(acetyl)cysteine	standard care/placebo	IIIai	riist autiloi	Kanuomization	Deviations from the intended	iviissiiig outcome data	ivieasurement of outcome	Selection of the reported			
(decey, jeysteme	Standard care, placeso	13687	de Alencar	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias			
		48051	Taher	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias			
5-alpha reductase inhibitor	standard care/placebo										
	19047, 339	978, Cadegiani, Cadegi	Cadegiani_1	probably low risk of bias	low risk of bias	high risk of bias	low risk of bias	probably low risk of bias			
		35590	Zarehoseinzade	probably low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably low risk of bias			
ACEi/ARB	calcium channel blockers										
ACEITAND	calcium chamici biockers	34054	Nouri-Vaskeh	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias			
								p. 100.00, 100.00			
ACEi/ARB	standard care/placebo				_						
		10463, 49441	Duarte	probably high risk of bias	probably high risk of bias	low risk of bias	high risk of bias	low risk of bias			
		26081	Cohen	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias			
		43232	Geriak	probably high risk of bias	probably high risk of bias	low risk of bias	high risk of bias	probably low risk of bias			
(-A agonist and CCV-B antagonist	standard care/placebo										
K-A agonist and CCK-B antagonist	standard care/pidce00	Lattmann	Lattmann	probably high risk of bias	probably high risk of bias	low risk of bias	high risk of bias	low risk of bias			
		Luttinuilli	Luccinaiiii	producty might have of bids	p. Codoly High Hak Or bids	1044 1131 01 0103	Tilgii Hak Ol Dida	TOW TISK OF DIGS			
CK2 inhibitor	standard care/placebo										
		13070, 26887	Cruz	probably high risk of bias	probably high risk of bias	low risk of bias	high risk of bias	low risk of bias			
V reverse transcriptase inhibitor	standard care/placebo										
		8469	Ren	probably high risk of bias	probably high risk of bias	low risk of bias	high risk of bias	probably low risk of bias			
IL1 inhibitors	standard care/placebo										
ILI IIIIIDIOIS	standard care, placebo	Kyriazopoulou	Kyriazopoulou	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias			
		54072	Caricchio	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias			
IL6 receptor antagonists	standard care/placebo										
		33303, Rosas	Rosas	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias			
or antagonists, corticosteroids (sys	standard care/placebo	45240 22542	Calana	and the later of the officer	Laure dell' a Clicture	Laurental a Chita	land delta filter	Learn State of Little			
		16340, 23643 Talaschian	Salama Talaschian	probably low risk of bias	low risk of bias	low risk of bias low risk of bias	low risk of bias low risk of bias	low risk of bias			
			Sivapalasingam_P2	probably low risk of bias probably low risk of bias	low risk of bias low risk of bias	low risk of bias	low risk of bias	probably low risk of bias low risk of bias			
			Sivapalasingam_P3_C1	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias			
	Sir		palasingam_P3_C2_Criti		low risk of bias						
			palasingam_P3_C3_Crit		low risk of bias						
JAK inhibitors	standard care/placebo										
	(62263, Marconi, Marco	Marconi	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias			
		48879	Guimarães	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias			
	El- WILO COV	RUXCOVID	RUXCOVID	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias			
	EIY, WHO_COV-	-BARRIER_Addendum,	Ely	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias			
L-arginine	standard care/placebo										
	112.12.12 3di c/ pidee500	64005	Fiorentino	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias			
NSAIDs	paracetamol										
		Ravichandran	Ravichandran	probably high risk of bias	probably high risk of bias	low risk of bias	high risk of bias	low risk of bias			
PF-07321332/ritonavir	standard care/placebo	FR.0.10	EDIO :::	and the late of th	In the first	In the Control	La contract de la	In the Control			
		EPIC-HR	EPIC-HR	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias			
SGLT2 inhibitors	standard care/placebo										
SULI Z ITITIDILOTS	stanuaru care/piacebo	54586	Kosiborod	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias			
		34300	NOSIDOI OG	104 1131 01 5103	TOW FISH OF DIGS	1044 1131 01 0103	TOW HISK OF DIGG	1044 1131 01 5103			
alpha lipoic acid	standard care/placebo										
		1284	Zhong	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias			
andrographolide	standard care/placebo							probably low risk of bias			
		W/anaratna	Wanaratna								

Wanaratna

Wanaratna

standard care/placebo

es, curcuminoids, piperine, resveratro

		67818	Majeed	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
antihepaciviral	and the second s							
anunepacivirai	romycin, hydroxychloroquine, oselta	44111	Elgohary	low risk of bias	probably high risk of bias	low risk of bias	high risk of bias	probably high risk of bias
		44111	Ligoriai y	low risk of blus	probably riight risk of bias	low risk of bids	Thigh tisk of blas	probably high risk of bias
antihepaciviral	standard care/placebo							
·		Yakoot	Yakoot	low risk of bias	probably high risk of bias	low risk of bias	high risk of bias	low risk of bias
		29517	Nourian	low risk of bias	high risk of bias	low risk of bias	high risk of bias	probably low risk of bias
		Mobarak	Mobarak	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		45668	Sayad	low risk of bias	probably high risk of bias	low risk of bias	high risk of bias	probably low risk of bias
artemisinin	standard care/placebo		T-1	and the broken detection	and the black of the Color	1	high risk of bias	Laure de la Childre
			Trieu	probably high risk of bias	probably high risk of bias	low risk of bias	nigh risk of bias	low risk of bias
aspirin	aspirin, atorvastatin							
азрин	uspiini, atorvastatiii	Ghati	Ghati	probably high risk of bias	probably high risk of bias	low risk of bias	high risk of bias	probably low risk of bias
		Citati	G.I.G.C.	producty mg. risk of sids	probably mgn risk of bids	1011 1131 01 5103	Ingil risk of bias	producty for the creat
aspirin	standard care/placebo							
		Ghati	Ghati	probably high risk of bias	probably high risk of bias	low risk of bias	high risk of bias	probably low risk of bias
aspirin	statins							
		Ghati	Ghati	probably high risk of bias	probably high risk of bias	low risk of bias	high risk of bias	probably low risk of bias
aspirin, atorvastatin	standard care/placebo	Ch. at	Ch a th	and the broken detection	and the black of the Color	1	to the trade of the co	and the first of the second
		Ghati	Ghati	probably high risk of bias	probably high risk of bias	low risk of bias	high risk of bias	probably low risk of bias
aspirin, atorvastatin	statins							
aspirin, acorvastatiii	Statills	Ghati	Ghati	probably high risk of bias	probably high risk of bias	low risk of bias	high risk of bias	probably low risk of bias
			2	present inglition of blus	,		- Mg. T. M. OT Oldo	,
azithromycin	azithromycin, hydroxychloroquine							
•	, , , , , ,	31471	Purwati	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
azithromycin	azithromycin, lopinavir-ritonavir							
		31471	Purwati	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
azithromycin	doxycycline, lopinavir-ritonavir							
		31471	Purwati	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
azithromycin	hydroxychloroquine							
azitiii oiiiyciii	nyuroxychioroquine	18375	Brown	low risk of bias	high risk of bias	low risk of bias	high risk of bias	low risk of bias
		10373	biowii	10W HSK OF Blas	mgn risk of blus	low risk of bids	THE IT TISK OF DIAS	IOW HISK OF DIAS
azithromycin	standard care/placebo							
,		11639, 12378	Sekhavati	probably high risk of bias	probably high risk of bias	low risk of bias	high risk of bias	probably low risk of bias
ithromycin, hydroxychloroquine	azithromycin, lopinavir-ritonavir							
		31471	Purwati	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
ithromycin, hydroxychloroquine	doxycycline							
		Sobngwi	Sobngwi	low risk of bias	probably high risk of bias	low risk of bias	high risk of bias	probably low risk of bias
thromusin hydroxychlorai	dowersling loninguis sites as its							
ithromycin, hydroxychloroquine	doxycycline, lopinavir-ritonavir	31471	Purwati	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		314/1	ruiWdli	probably low risk of blas	IOW HISK OF DIdS	TOW FISH OF DIAS	10W Hisk Of Dids	bionapik iow lisk of plas
hromycin, hydroxychloroquine	hydroxychloroquine							
	, a. o., jano. oqunic	20005	Omrani	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		33489, Johnston	Johnston	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
hromycin, hydroxychloroquine	standard care/placebo							
		20005	Omrani	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		33489, Johnston	Johnston	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		48002	Sivapalan	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		Babalola_2	Babalola_2	probably high risk of bias	probably high risk of bias	low risk of bias	high risk of bias	probably low risk of bias
- Marian and a final and a standard and	decreased as leaders to de-							
azithromycin, lopinavir-ritonavir	doxycycline, lopinavir-ritonavir	21.471	Dun.et:	probably law risk of his	low risk of his s	low rick of him	low risk of him	probably low siels of his
		31471	Purwati	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
berberine	standard care/placebo							
DC. DC. IIIC	startaara care/placebo							

		21845	Zhang	probably high risk of bias	probably high risk of bias	low risk of bias	high risk of bias	probably low risk of bias
haranta da hada da da da	ata a da ad as as Asta as bas							
bromhexine hydrochloride	standard care/placebo	12212	Li_3	low risk of bias	probably high risk of bias	low risk of bias	high risk of bias	probably low risk of bias
cannabidiol	standard care/placebo							
	,	66954	Crippa	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
chlorhexidine gluconate mouthwash	hydrogen peroxide mouthwash							
		Chaudhary	Chaudhary	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
chlorhexidine gluconate mouthwash	povidone-iodine mouthwash							
		Chaudhary	Chaudhary	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
chlorhexidine gluconate mouthwash	saline mouthwash							
		Chaudhary	Chaudhary	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
dila control	books and books to							
chloroquine	hydroxychloroquine	6987	Chen_4	probably high risk of bias	probably high risk of bias	high risk of bias	high risk of bias	low risk of bias
		0307	chen	probably ingirrisk or blas	producty riight risk of blus	ingii risk or sids	1116.11131.01.0103	1011 1131 01 5103
chloroquine	standard care/placebo							
		6987	Chen_4	probably high risk of bias	probably high risk of bias	high risk of bias	high risk of bias	low risk of bias
colchicine	standard care/placebo							
		7189	Deftereos	low risk of bias	probably high risk of bias	low risk of bias	high risk of bias	low risk of bias
		10500, xx 64385	Lopes_2 Pascual-Figal	probably low risk of bias low risk of bias	low risk of bias probably high risk of bias	low risk of bias low risk of bias	low risk of bias probably high risk of bias	probably low risk of bias probably low risk of bias
		04363	rascual-rigal	IOW HSK OF DIAS	probably flight risk of bias	IOW TISK OF DIAS	probably flight risk of blas	probably low risk of bias
Ichicine, emtricitabine, tenofovir, stat	emtricitabine, tenofovir							
		Gaitan-Duarte	Gaitan-Duarte	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
chicine, emtricitabine, tenofovir, stat	standard care/placebo							
emente, emercicasme, terrorovii, stat	Starradia care, placeso	Gaitan-Duarte	Gaitan-Duarte	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
colchicine, statin	chicine, emtricitabine, tenofovir, s	Gaitan-Duarte	Gaitan-Duarte	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		Guitaii Buurte	Cartair Baarte	1011 1131 01 5103	probably high risk of bias	iow risk or blus	1011 11311 01 0103	1011 1131 01 5103
colchicine, statin	emtricitabine, tenofovir							
		Gaitan-Duarte	Gaitan-Duarte	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
colchicine, statin	standard care/placebo							
		Gaitan-Duarte	Gaitan-Duarte	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
diammonium glygyrrhizinata	standard saro/placebo							
diammonium glycyrrhizinate	standard care/placebo	C195	Zhou	probably high risk of bias	probably high risk of bias	low risk of bias	high risk of bias	probably low risk of bias
doxycycline, ivermectin	standard care/placebo	43517	Mahmud	low rick of high	low rick of hine	low rick of hine	low risk of hips	probably law rick of him
		43517	Mahmud	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
electrolyzed saline	standard care/placebo							
		13074, 53789	Delgado-Enciso	probably high risk of bias	probably high risk of bias	low risk of bias	high risk of bias	low risk of bias
emtricitabine, tenofovir	standard care/placebo							
emercialities remotorii	Starradia care, praceso	50792	Parienti	low risk of bias	probably high risk of bias	low risk of bias	high risk of bias	low risk of bias
		Gaitan-Duarte	Gaitan-Duarte	low risk of bias	probably high risk of bias	low risk of bias	high risk of bias	low risk of bias
famotidine	standard care/placebo							
iumodume	Standard care/placebo	Samimagham	Samimagham	low risk of bias	probably high risk of bias	low risk of bias	high risk of bias	probably low risk of bias
favipiravir	standard care/placebo	10147, 10287, 997	Ivashchenko	probably high risk of bias	high risk of bias	low risk of bias	high risk of bias	probably low risk of bias
		32588	Ruzhentsova	probably high risk of bias	probably high risk of bias	low risk of bias	high risk of bias	low risk of bias
		24988, Udwadia	Udwadia	probably high risk of bias	probably high risk of bias	low risk of bias	high risk of bias	low risk of bias
		32586	Balykova_2	low risk of bias	probably high risk of bias	low risk of bias	high risk of bias	low risk of bias
		60646	Shinkai	low risk of bias	probably high risk of bias	low risk of bias	high risk of bias	probably low risk of bias
fluvoxamine	standard care/placebo							

		18818	Lenze	low risk of bias	low risk of bias	high risk of bias	low risk of bias	low risk of bias
full-dose anticoagulation	standard care/placebo							
		64008	Ananworanich	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
hydrogen peroxide mouthwash	povidone-iodine mouthwash							
nyarogen peroxiae moaenwasii	portaone roune mouthwash	Chaudhary	Chaudhary	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		,	,					
hydrogen peroxide mouthwash	saline mouthwash							
		Chaudhary	Chaudhary	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
hadaa ahlaa ah	the of the body back of the state of	٠.						
hydroxychloroquine	interferon beta, lopinavir-ritonavi	45662, Ader_1	Ader_1	low risk of bias	probably high risk of bias	low risk of bias	high risk of bias	low risk of bias
		45002, Adci_1	Addi_i	IOW HISK OF DIAS	probably high risk of bias	low risk of blus	High risk of bids	low risk of bids
hydroxychloroquine	lopinavir-ritonavir							
		Reis_1	Reis_1	low risk of bias	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias
		45662, Ader_1	Ader_1	low risk of bias	probably high risk of bias	low risk of bias	high risk of bias	low risk of bias
hydroxychloroquine	remdesivir	21100 52704	Darrott Dur	low rich of his a	probably high sigh of his	low rick of him	high right of him	probably low-risk of his
		31188, 52761	Barratt-Due	low risk of bias	probably high risk of bias	low risk of bias	high risk of bias	probably low risk of bias
hydroxychloroquine	standard care/placebo							
, , , , , , , , , , , , , , , , , , , ,		3321, 776	Tang_1	low risk of bias	probably high risk of bias	low risk of bias	high risk of bias	low risk of bias
		C158	Chen_3	probably high risk of bias	probably high risk of bias	low risk of bias	high risk of bias	probably low risk of bias
		6987	Chen_4	probably high risk of bias	probably high risk of bias	high risk of bias	high risk of bias	low risk of bias
		16085, 38308	Dubée	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		20005	Omrani Baia 1	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Reis_1 33489, Johnston	Reis_1 Johnston	low risk of bias probably low risk of bias	low risk of bias low risk of bias	probably high risk of bias low risk of bias	low risk of bias low risk of bias	low risk of bias low risk of bias
		45662, Ader_1	Ader_1	low risk of bias	probably high risk of bias	low risk of bias	high risk of hias	low risk of bias
		29663	Hernandez-Cardenas	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably high risk of bias
		31188, 52761	Barratt-Due	low risk of bias	probably high risk of bias	low risk of bias	high risk of bias	probably low risk of bias
		41434	Réa-Neto	low risk of bias	probably high risk of bias	low risk of bias	high risk of bias	low risk of bias
		Byakika-Kibwika	Byakika-Kibwika	low risk of bias	probably high risk of bias	low risk of bias	high risk of bias	low risk of bias
		Schwartz_2	Schwartz_2	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
hydroxychloroquine, rivabirin	lopinavir-ritonavir, ribavirin	46200	Ciaab 2	anahahir biah siak af bias	anababb, biab sist of biss	lass siels of bion	high risk of bias	low risk of bias
		46308_severe	Singh_3	probably high risk of bias	probably high risk of bias	low risk of bias	nigh risk of bias	low risk of bias
hydroxychloroquine, rivabirin	standard care/placebo							
,,	, p	46308_severe	Singh_3	probably high risk of bias	probably high risk of bias	low risk of bias	high risk of bias	low risk of bias
		-	0 =	, , ,	. , ,			
inhaled nebulised interferon beta-1a	standard care/placebo							
		18657	Monk	low risk of bias	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias
labeled and 1810 billion	stondoud acceleto							
inhaled pan-JAK inhibitor	standard care/placebo	34842	Singh_1	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		34042	2IIIRII ^T T	probably low risk of bias	IOW HSK OF DIAS	IOW FISK OF DIAS	IOW HISK OF DIAS	probably low risk of bias
interferon alpha	combinant super combinant interfe	eron						
		32737, 7, 9574	Li_2	probably high risk of bias	probably high risk of bias	low risk of bias	high risk of bias	low risk of bias
interferon beta	standard care/placebo							
		39381, Darazam (2	Darazam_2	low risk of bias low risk of bias	probably high risk of bias	low risk of bias	high risk of bias	probably low risk of bias low risk of bias
		Kalil_2	Kalil_2 Davoudi-Monfared	low risk of bias	low risk of bias high risk of bias	low risk of bias probably high risk of bias	low risk of bias high risk of bias	low risk of bias
		11243, 3314, 024:	Davouui-ivioillale0	IOW HSK OF DIAS	High HSK OF Dids	probably high risk of bias	Trigit Haw Of Dids	10 M LIPY OI DIG?
interferon beta, lopinavir-ritonavir	lopinavir-ritonavir							
		45662, Ader_1	Ader_1	low risk of bias	probably high risk of bias	low risk of bias	high risk of bias	low risk of bias
interferon beta, lopinavir-ritonavir	standard care/placebo							
		45662, Ader_1	Ader_1	low risk of bias	probably high risk of bias	low risk of bias	high risk of bias	low risk of bias
interferon beta, ribavirin	standard care/placebo							
interieron peta, ribavirin	stanuaru care/piacebo	2942	Hung	probably high risk of bias	probably high risk of bias	low risk of bias	high risk of bias	low risk of bias
		2372		producty materials of blas	Proposit Rit Lisk of pigs	1011 1131 01 0103	- THE THE PLANT DIGG	1011 1101 01 0103
interferon kappa, trefoil factor 2	standard care/placebo							
		13797	Fu	probably high risk of bias	probably high risk of bias	low risk of bias	high risk of bias	low risk of bias

intranasal corticosteroids	standard care/placebo							
		57833	Song	probably high risk of bias	probably high risk of bias	low risk of bias	high risk of bias	low risk of bias
		Clemency	Clemency	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
ntranasal hypertonic polymer spray	standard care/placebo							
		47065	Shrivastava	probably high risk of bias	probably high risk of bias	low risk of bias	high risk of bias	low risk of bias
itolizumab	standard care/placebo							
		21347, Kumar	Kumar_1	probably high risk of bias	probably high risk of bias	low risk of bias	high risk of bias	probably low risk of bias
itraconazole	standard care/placebo							
		36093, Liesenborgl	Liesenborghs	probably high risk of bias	probably high risk of bias	low risk of bias	high risk of bias	low risk of bias
ivermectin	lopinavir-ritonavir							
		25394, Babalola	Babalola	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
ivermectin	standard care/placebo							
		49440, Krolewieck	Krolewiecki	low risk of bias	probably high risk of bias	low risk of bias	high risk of bias	low risk of bias
		34416, 41159, Lopi	Lopez-Medina	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		35667	Pott-Junior	low risk of bias	probably high risk of bias	low risk of bias	high risk of bias	probably low risk of bias
		Chahla	Chahla	probably high risk of bias	probably high risk of bias	low risk of bias	high risk of bias	probably low risk of bias
		51938	Vallejos	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Buonfrate	Buonfrate	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		500	5401111410		1011 1131 01 0100	.011 1011 01 0100	1011-1011-01-0100	1011 101 01 0103
leflunomide	standard care/placebo							
ichanolinac	Landord care, pracebo	13540	Wang_5	probably high risk of bias	probably high risk of bias	low risk of bias	high risk of bias	probably low risk of bias
		133.0		p. 2 3 3 3 7 11 3 1 3 1 3 1 3 1 3 1 3 1 3 1	p. 2.20017g 1101. 01. 0103		ing. Flori of Sido	p. 23doi j ion flor of blus
leronlimab	standard care/placebo							
ic. oido	Startagra cure, pracebo	36109	Skendelas	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		30103	Skeridelas	probably low risk of bias	TOW TISK OF DIGS	JOW HISK OF DIGS	IOW HISK OF DIGS	productly low risk of bids
levamisole	standard care/placebo							
icvaniisoic		37198, Roostaei Firoz	Roostaei Firozahad	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		3, 130, NOOSIACI I II UZ	oostaci i ii ozabdu	Propubly low risk of plas	IOW HISK OF DIGS	TOW TISK OF DIAS	IOW HISK OF DIAS	TOW TISK OF DIAS
lopinavir-ritonavir	lopinavir-ritonavir, novaferor	1						
TOPITION THOUSAND	οριπανιι πτοπανιι, ποναιειοι	10121, 2338	Zheng	probably high risk of bias	probably high risk of bias	low risk of bias	high risk of bias	low risk of bias
		10121, 2330	Literig	probably flight flak of bids	probably high hisk of bids	IOW HISK OF DIAS	Aligh risk of blas	TOW TISK OF DIAS
lopinavir-ritonavir	lopinavir-ritonavir, ribavirin							
TOPHIGNI TITOHAVII	.opinavii ntonavii, nodviilii	10067, 2615	Huang 2	probably high risk of bias	probably high risk of bias	low risk of bias	high risk of bias	low risk of bias
		10007, 2013	riuarig_2	probably flight fisk of bias	probably flight risk of bias	IOW HISK OF DIAS	High risk of bias	IOW HISK OF BIRES
lopinavir-ritonavir	novaferon							
iopiliavii-litoliavii	liovaleioii	10121, 2338	Zheng	probably high rick of high	probably high risk of bias	low risk of bias	high risk of bias	low risk of bias
		10121, 2338	zneng	probably high risk of bias	probably flight fisk of bias	IOM LISK OF DIGS	HIGH HISK OF DIAS	IOM LISK OF DIGS
loninguir ritonguir	ribaviria							
lopinavir-ritonavir	ribavirin	10067 2615	Hunes 2	probably bigh sigh of his	probably high risk of his	low risk of bias	high risk of bias	low risk of bias
		10067, 2615	Huang_2	probably high risk of bias	probably high risk of bias	IOW LISK OF DISS	riigii risk ot bias	IOW FISK OT DIAS
lopinavir-ritonavir	standard care/placets							
iopinavir-ritonavir	standard care/placebo	1242 224	11	lass vials of hins	anababb bish sist of the	lacciate of bigs	and habit law side of the	and habitation state of the s
		1243, 234	Li Dain 4	low risk of bias	probably high risk of bias	low risk of bias	probably low risk of bias	probably low risk of bias
		Reis_1	Reis_1	low risk of bias	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias
		45662, Ader_1	Ader_1	low risk of bias	probably high risk of bias	low risk of bias	high risk of bias	low risk of bias
	,							
lopinavir-ritonavir	umifenovir							
		1243, 234	Li	low risk of bias	probably high risk of bias	low risk of bias	probably low risk of bias	probably low risk of bias
lopinavir-ritonavir, novaferon	novaferon							
		10121, 2338	Zheng	probably high risk of bias	probably high risk of bias	low risk of bias	high risk of bias	low risk of bias
lopinavir-ritonavir, ribavirin	ribavirin							
		10067, 2615	Huang_2	probably high risk of bias	probably high risk of bias	low risk of bias	high risk of bias	low risk of bias
lopinavir-ritonavir, ribavirin	standard care/placebo							
		46308_severe	Singh_3	probably high risk of bias	probably high risk of bias	low risk of bias	high risk of bias	low risk of bias
melatonin	standard care/placebo							
melatonin	standard care/placebo	Farnoosh	Farnoosh	probably low risk of bias	low risk of bias	high risk of bias	low risk of bias	probably low risk of bias
melatonin		Farnoosh	Farnoosh	probably low risk of bias	low risk of bias	high risk of bias	low risk of bias	probably low risk of bias
melatonin molnupiravir	standard care/placebo	Farnoosh	Farnoosh	probably low risk of bias	low risk of bias	high risk of bias	low risk of bias	probably low risk of bias

		44074	When	and the block of the board	high risk of bias	Learning of the co	high risk of bias	In control of lates
		41971 46473, Fischer	Khoo Fischer	probably high risk of bias low risk of bias	low risk of bias	low risk of bias low risk of bias	low risk of bias	low risk of bias low risk of bias
		MOVe-OUT (MK4482-/IC			low risk of bias	low risk of bias	low risk of bias	low risk of bias
		CR216-21	Vyas	low risk of bias	probably high risk of bias	low risk of bias	high risk of bias	low risk of bias
		CTRI/2021/06/0339	Krishnan	low risk of bias	probably high risk of bias	low risk of bias	high risk of bias	low risk of bias
		HCR/III/MOLCOV/04/20	Kumar_2	probably high risk of bias	probably high risk of bias	low risk of bias	high risk of bias	probably low risk of bias
			Kumar_2	probably riight has of blas	probably riight lisk of blas	low risk of blas	mgm risk or blus	probably low risk of blus
ometasone nasal spray	factory training, standard care,	/placebo 48548	Kasiri	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
				product, ich ich chick				
nitazoxanide	standard care/placebo	16339, 24799	Rocco	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		50790, Blum	Blum	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		Silva	Silva	low risk of bias	probably high risk of bias	low risk of bias	probably high risk of bias	probably low risk of bias
		Rossignol	Rossignol	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
mitaria aviida	aton doud sous /aloss bo							
nitric oxide	standard care/placebo	Moni	Moni	low risk of bias	probably high risk of bias	probably low risk of bias	high risk of bias	probably low risk of bias
					process, mg. rem or and	,		p
omega 3	standard care/placebo							
		60421	Kosmopoulos	low risk of bias	probably high risk of bias	low risk of bias	high risk of bias	probably low risk of bias
opaganib	standard care/placebo							
		Winthrop	Winthrop	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
pentoxifylline	standard care/placebo							
		21098	Malonado	probably high risk of bias	probably high risk of bias	high risk of bias	high risk of bias	probably low risk of bias
vidone-iodine mouthwash	saline mouthwash							
idone-iodine modiliwasii	Saine moutiwasii	Chaudhary	Chaudhary	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		•	·					
probiotics	standard care/placebo	44550	C. I'' C	In the state of the state of	territoria del controlo de	Learning of the co	Territoria de Carta d	Laurente La Chillana
		44556	Gutiérrez-Castrellón	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
progesterone	standard care/placebo							
		32075, Ghandehai	Ghandehari	probably high risk of bias	probably high risk of bias	low risk of bias	probably high risk of bias	probably low risk of bias
proxalutamide	standard care/placebo							
p. c		33610	Cadegiani_3	high risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		Cadegiani (female col	Cadegiani_4	high risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
and death and a	-tdd/-lb							
pyridostigmine	standard care/placebo	Fragoso-Saavedra	Fragoso-Saavedra	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		Tragoso Sauveure	Tragoso Saaveara	probably low risk of bias	low risk of bids	low risk of bias	10W HSR OF Blus	probably low risk of bias
quercetin	standard care/placebo							
		51397	Di Pierro_2	probably high risk of bias	probably high risk of bias	low risk of bias	high risk of bias	probably low risk of bias
remdesivir	standard care/placebo							
		2408	Wang_1	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		11347	Spinner	low risk of bias	high risk of bias	probably low risk of bias	probably high risk of bias	low risk of bias
		15633, 3821	Beigel	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		31188, 52761	Barratt-Due	low risk of bias	probably high risk of bias	low risk of bias	high risk of bias	probably low risk of bias
		37778	Mahajan	high risk of bias	probably high risk of bias	low risk of bias	high risk of bias	probably low risk of bias
							high risk of bias	probably high risk of bias
		39725	Criner	probably high risk of bias	probably high risk of bias	low risk of bias		
		Gottlieb_2, PINETR	Gottlieb_2	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
rin, sofosbuvir-daclatasvir	standard care/placebo							
		11010	Kasgari	low risk of bias	probably high risk of bias	low risk of bias	high risk of bias	probably low risk of bias
erine protease inhibitors	standard care/placebo							
22 proceduc illimotors	Standard care/placebo	40853	Gunst	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		70176	Zhuravel	low risk of bias	probably high risk of bias	low risk of bias	high risk of bias	probably low risk of bias
ctatics								
statins	standard care/placebo	Ghati	Ghati	probably high risk of bias	probably high risk of bias	low risk of bias	high risk of bias	probably low risk of bias
statins	standard care/placebo	Ghati	Ghati	probably high risk of bias	probably high risk of bias	low risk of bias	high risk of bias	probably low risk of bias

		21816, 34575	Gonzalez-Ochoa	probably low risk of bias	low risk of bias	high risk of bias	low risk of bias	probably low risk of bias
triazavirin	standard care/placebo							
	.,	12679	Wu	high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
tyrosine kinase inhibitors	standard care/placebo							
		49287	Aman	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		60872	Strich	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
umifenovir	standard care/placebo							
		1243, 234	Li	low risk of bias	probably high risk of bias	low risk of bias	probably low risk of bias	probably low risk of bias
		35511	Khodashahi	probably low risk of bias	probably high risk of bias	low risk of bias	high risk of bias	probably low risk of bias
		52841	Darazam_3	low risk of bias	probably high risk of bias	low risk of bias	high risk of bias	probably low risk of bias
vilobelimab	standard care/placebo							
		14404, 9802	Vlaar	probably high risk of bias	probably high risk of bias	low risk of bias	high risk of bias	probably low risk of bias
vitamin C	standard care/placebo							
		26123, Zhang	Zhang_1	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		31458	Thomas	low risk of bias	probably high risk of bias	probably high risk of bias	high risk of bias	low risk of bias
vitamin C	vitamin C, zinc							
		31458	Thomas	low risk of bias	probably high risk of bias	probably high risk of bias	high risk of bias	low risk of bias
vitamin C	zinc							
		31458	Thomas	low risk of bias	probably high risk of bias	probably high risk of bias	high risk of bias	low risk of bias
vitamin C, zinc	standard care/placebo							
		31458	Thomas	low risk of bias	probably high risk of bias	probably high risk of bias	high risk of bias	low risk of bias
vitamin C, zinc	zinc							
		31458	Thomas	low risk of bias	probably high risk of bias	probably high risk of bias	high risk of bias	low risk of bias
vitamin D	standard care/placebo							
		11879	Castillo	probably high risk of bias	probably high risk of bias	low risk of bias	high risk of bias	low risk of bias
		18926	Ratogi	probably high risk of bias	probably high risk of bias	low risk of bias	probably low risk of bias	low risk of bias
		44830	Lakkireddy	high risk of bias	probably high risk of bias	low risk of bias	high risk of bias	probably low risk of bias
xiyanping	standard care/placebo							
		43229	Zhang_3	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
zinc	standard care/placebo							
		31458	Thomas	low risk of bias	probably high risk of bias	probably high risk of bias	high risk of bias	low risk of bias

Viral Clearance

	1			Viral Clearance					
Treatment 1	Treatment 2	Trial	First author	Randomization	Deviations from the intended	Missing outcome data	Measurement of outcome	Selection of the reported	Other
2-deoxy-D-glucose	standard care/placebo								
		66751a	Narayan Bhatt	probably high risk of bias	high risk of bias	low risk of bias	low risk of bias	low risk of bias	
		66751b	Narayan Bhatt	probably high risk of bias	high risk of bias	low risk of bias	low risk of bias	low risk of bias	
5-alpha reductase inhibitor	standard care/placebo								
	19047, 33978,	, Cadegiani, Cadegi	Cadegiani_1	probably low risk of bias	low risk of bias	high risk of bias	low risk of bias	probably low risk of bias	
HIV reverse transcriptase inhibitor	standard care/placebo								
		8469	Ren	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	
NSAIDs	paracetamol								
		Ravichandran	Ravichandran	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	
andrographolide	standard care/placebo								
		Wanaratna	Wanaratna	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias	
s, curcuminoids, piperine, resveratro	standard care/placebo								
		67818	Majeed	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias	
antihepaciviral	ravidasvir, sofosbuvir								
		57630	Abbass	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	
antihepaciviral	standard care/placebo								
		51681	El-Bendary	probably high risk of bias	probably high risk of bias	high risk of bias	low risk of bias	probably low risk of bias	
		57630	Abbass	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	
azelastine	standard care/placebo								
		Klussmann	Klussmann	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias	
azithromycin	azithromycin, hydroxychloroquine								
		31471	Purwati	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias	
azithromycin	azithromycin, lopinavir-ritonavir				_				
		31471	Purwati	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias	
azithromycin	doxycycline, lopinavir-ritonavir								
		31471	Purwati	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias	
azithromycin	lincomycin								
		6669	Guvenmez	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	
azithromycin, hydroxychloroquine	azithromycin, lopinavir-ritonavir								
		31471	Purwati	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias	
azithromycin, hydroxychloroquine	doxycycline								
		Sobngwi	Sobngwi	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	
azithromycin, hydroxychloroquine	doxycycline, lopinavir-ritonavir								
		31471	Purwati	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias	
azithromycin, hydroxychloroquine	hydroxychloroquine								
		20005	Omrani	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	
		33489, Johnston	Johnston	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	
azithromycin, hydroxychloroquine	standard care/placebo								
		20005	Omrani	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	
		33489, Johnston	Johnston	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	
		60017	Rodrigues	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias	
		Babalola_2	Babalola_2	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	
azithromycin, lopinavir-ritonavir	doxycycline, lopinavir-ritonavir								
		31471	Purwati	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias	
baloxavir marboxil	favipiravir								
		2637, Lou, Lou (1	Lou	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	

baloxavir marboxil	standard care/placebo			. <u></u>				
		2637, Lou, Lou (1	Lou	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
bromhexine hydrochloride	standard care/placebo							
		35697	Tolouian	probably high risk of bias	probably high risk of bias	probably low risk of bias	low risk of bias	probably low risk of bias
corticosteroids (systemic)	standard care/placebo							
(0,000.00,000	, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	10699	Jeronimo	low risk of bias	low risk of bias	high risk of bias	low risk of bias	low risk of bias
		27641	Tang_2	probably low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		27041	idlig_2	probably low risk of bias	probably flight risk of bias	IOW HISK OF BIAS	IOW HISK OF DIAS	probably low risk of bias
decree de la Commenta								
doxycycline, ivermectin	ivermectin							
		Ahmed	Ahmed	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
doxycycline, ivermectin	standard care/placebo							
		Ahmed	Ahmed	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
favipiravir	standard care/placebo							
		2637, Lou, Lou (1	Lou	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		10147, 10287, 997	Ivashchenko	probably high risk of bias	high risk of bias	low risk of bias	low risk of bias	low risk of bias
		32588	Ruzhentsova	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		24988, Udwadia	Udwadia	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		32586	Balykova_2	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		27462	Balykova_1	probably high risk of bias	high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		404	parkrova_1	biopapià ingli lisk oi pigs	riigii riak Ur bids	IOW HISK UI DIGS	IOW HISK OF DIAS	probably low risk of blas
fordingsylle	ctandard /-l!							
favipravir	standard care/placebo	40075	76- 2	law side of his con-	anahahir historia (d. 1864)	lavo dale efficie	Januara - Chiles	lavorated of literary
		40875	Zhao_2	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
fluvoxamine	standard care/placebo							
		70784, Reis_2	Reis_2	low risk of bias	low risk of bias	high risk of bias	low risk of bias	low risk of bias
ull-dose anticoagulation	intermediate-dose anticoagulat	ion		. <u> </u>				
		67889	Marcos	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
								encentral e
hydroxychloroquine	interferon beta, lopinavir-ritona	avir						
		45662, Ader_1	Ader_1	low risk of bias	probably high risk of bias	high risk of bias	low risk of bias	low risk of bias
		, <u>-</u>			, ,			
hydroxychloroquine	lopinavir-ritonavir							
							low risk of bias	low risk of bias
nydroxyemoroqume		pilot 4	Huang 1	probably high rick of hige	probably high rick of hige			
nyaroxyemoroquine		pilot_4	Huang_1	probably high risk of bias	probably high risk of bias	low risk of bias		
пуштохустногодите		Reis_1	Reis_1	low risk of bias	low risk of bias	probably high risk of bias	low risk of bias	probably low risk of bias
nyuroxyemoroqume								
	·	Reis_1	Reis_1	low risk of bias	low risk of bias	probably high risk of bias	low risk of bias	probably low risk of bias
hydroxychloroquine	standard care/placebo	Reis_1 45662, Ader_1	Reis_1 Ader_1	low risk of bias low risk of bias	low risk of bias probably high risk of bias	probably high risk of bias high risk of bias	low risk of bias low risk of bias	probably low risk of bias low risk of bias
	·	Reis_1 45662, Ader_1 3321, 776	Reis_1 Ader_1 Tang_1	low risk of bias low risk of bias low risk of bias	low risk of bias probably high risk of bias probably high risk of bias	probably high risk of bias high risk of bias low risk of bias	low risk of bias low risk of bias low risk of bias	probably low risk of bias low risk of bias low risk of bias
	·	Reis_1 45662, Ader_1 3321, 776 C158	Reis_1 Ader_1	low risk of bias low risk of bias	low risk of bias probably high risk of bias	probably high risk of bias high risk of bias	low risk of bias low risk of bias	probably low risk of bias low risk of bias low risk of bias low risk of bias
	·	Reis_1 45662, Ader_1 3321, 776	Reis_1 Ader_1 Tang_1	low risk of bias low risk of bias low risk of bias	low risk of bias probably high risk of bias probably high risk of bias	probably high risk of bias high risk of bias low risk of bias	low risk of bias low risk of bias low risk of bias	probably low risk of bias low risk of bias low risk of bias
	·	Reis_1 45662, Ader_1 3321, 776 C158	Reis_1 Ader_1 Tang_1 Chen_3	low risk of bias low risk of bias low risk of bias probably high risk of bias	low risk of bias probably high risk of bias probably high risk of bias probably high risk of bias	probably high risk of bias high risk of bias low risk of bias low risk of bias	low risk of bias low risk of bias low risk of bias low risk of bias	probably low risk of bias low risk of bias low risk of bias low risk of bias
	·	Reis_1 45662, Ader_1 3321, 776 C158 6987 13936	Reis_1 Ader_1 Tang_1 Chen_3 Chen_4 Ulrich	low risk of bias low risk of bias low risk of bias probably high risk of bias probably high risk of bias probably low risk of bias	low risk of bias probably high risk of bias probably high risk of bias probably high risk of bias probably high risk of bias low risk of bias	probably high risk of bias high risk of bias low risk of bias low risk of bias high risk of bias	low risk of bias	probably low risk of bias low risk of bias
	·	Reis_1 45662, Ader_1 3321, 776 C158 6987 13936 16085, 38308	Reis_1 Ader_1 Tang_1 Chen_3 Chen_4 Ulrich Dubée	low risk of bias low risk of bias low risk of bias probably high risk of bias probably low risk of bias probably low risk of bias low risk of bias	low risk of bias probably high risk of bias low risk of bias low risk of bias	probably high risk of bias high risk of bias low risk of bias low risk of bias high risk of bias high risk of bias high risk of bias	low risk of bias low risk of bias	probably low risk of bias
	·	Reis_1 45662, Ader_1 3321, 776 C158 6987 13936 16085, 38308 20005	Reis_1 Ader_1 Tang_1 Chen_3 Chen_4 Ulrich Dubée Omrani	low risk of bias low risk of bias low risk of bias probably high risk of bias probably low risk of bias low risk of bias low risk of bias	low risk of bias probably high risk of bias low risk of bias low risk of bias low risk of bias	probably high risk of bias high risk of bias low risk of bias low risk of bias high risk of bias high risk of bias high risk of bias low risk of bias	low risk of bias low risk of bias	probably low risk of bias
	·	Reis_1 45662, Ader_1 3321, 776 C158 6987 13936 16085, 38308 20005 Reis_1	Reis_1 Ader_1 Tang_1 Chen_3 Chen_4 Ulrich Dubée Omrani Reis_1	low risk of bias low risk of bias low risk of bias probably high risk of bias probably low risk of bias low risk of bias low risk of bias low risk of bias	low risk of bias probably high risk of bias low risk of bias low risk of bias low risk of bias low risk of bias	probably high risk of bias high risk of bias low risk of bias low risk of bias high risk of bias high risk of bias high risk of bias low risk of bias probably high risk of bias	low risk of bias low risk of bias	probably low risk of bias probably low risk of bias
	·	Reis_1 45662, Ader_1 3321, 776 C158 6987 13936 16085, 38308 20005 Reis_1 33489, Johnston	Reis_1 Ader_1 Tang_1 Chen_3 Chen_4 Ulrich Dubée Omrani Reis_1 Johnston	low risk of bias low risk of bias low risk of bias probably high risk of bias probably low risk of bias probably low risk of bias low risk of bias low risk of bias probably low risk of bias	low risk of bias probably high risk of bias low risk of bias	probably high risk of bias high risk of bias low risk of bias low risk of bias high risk of bias high risk of bias high risk of bias low risk of bias probably high risk of bias low risk of bias	low risk of bias	probably low risk of bias probably low risk of bias low risk of bias
	·	Reis_1 45662, Ader_1 3321, 776 C158 6987 13936 16085, 38308 20005 Reis_1 33489, Johnston 45662, Ader_1	Reis_1 Ader_1 Tang_1 Chen_3 Chen_4 Ulrich Dubée Omrani Reis_1 Johnston Ader_1	low risk of bias low risk of bias low risk of bias probably high risk of bias probably low risk of bias	probably high risk of bias low risk of bias low risk of bias low risk of bias low risk of bias probably high risk of bias	probably high risk of bias high risk of bias low risk of bias low risk of bias high risk of bias high risk of bias high risk of bias low risk of bias probably high risk of bias low risk of bias high risk of bias	low risk of bias	probably low risk of bias probably low risk of bias low risk of bias
	·	Reis_1 45662, Ader_1 3321, 776 C158 6987 13936 16085, 38308 20005 Reis_1 33489, Johnston 45662, Ader_1 33028	Reis_1 Ader_1 Tang_1 Chen_3 Chen_4 Ulrich Dubée Omrani Reis_1 Johnston Ader_1 Amaravadi	low risk of bias low risk of bias probably high risk of bias probably low risk of bias probably low risk of bias probably low risk of bias low risk of bias	probably high risk of bias low risk of bias low risk of bias low risk of bias low risk of bias probably high risk of bias probably high risk of bias	probably high risk of bias high risk of bias low risk of bias low risk of bias high risk of bias high risk of bias high risk of bias low risk of bias probably high risk of bias low risk of bias low risk of bias low risk of bias	low risk of bias	probably low risk of bias probably low risk of bias low risk of bias low risk of bias probably low risk of bias low risk of bias
	·	Reis_1 45662, Ader_1 3321, 776 C158 6987 13936 16085, 38308 20005 Reis_1 33489, Johnston 45662, Ader_1	Reis_1 Ader_1 Tang_1 Chen_3 Chen_4 Ulrich Dubée Omrani Reis_1 Johnston Ader_1	low risk of bias low risk of bias low risk of bias probably high risk of bias probably low risk of bias	probably high risk of bias low risk of bias low risk of bias low risk of bias low risk of bias probably high risk of bias	probably high risk of bias high risk of bias low risk of bias low risk of bias high risk of bias high risk of bias high risk of bias low risk of bias probably high risk of bias low risk of bias high risk of bias	low risk of bias	probably low risk of bias probably low risk of bias low risk of bias probably low risk of bias low risk of bias
	·	Reis_1 45662, Ader_1 3321, 776 C158 6987 13936 16085, 38308 20005 Reis_1 33489, Johnston 45662, Ader_1 33028	Reis_1 Ader_1 Tang_1 Chen_3 Chen_4 Ulrich Dubée Omrani Reis_1 Johnston Ader_1 Amaravadi	low risk of bias low risk of bias probably high risk of bias probably low risk of bias probably low risk of bias probably low risk of bias low risk of bias	probably high risk of bias low risk of bias low risk of bias low risk of bias low risk of bias probably high risk of bias probably high risk of bias	probably high risk of bias high risk of bias low risk of bias low risk of bias high risk of bias high risk of bias high risk of bias low risk of bias probably high risk of bias low risk of bias low risk of bias low risk of bias	low risk of bias	probably low risk of bias probably low risk of bias low risk of bias low risk of bias probably low risk of bias low risk of bias
hydroxychloroquine	·	Reis_1 45662, Ader_1 3321, 776 C158 6987 13936 16085, 38308 20005 Reis_1 33489, Johnston 45662, Ader_1 33028 Byakika-Kibwika	Reis_1 Ader_1 Tang_1 Chen_3 Chen_4 Ulrich Dubée Omrani Reis_1 Johnston Ader_1 Amaravadi	low risk of bias low risk of bias probably high risk of bias probably low risk of bias probably low risk of bias probably low risk of bias low risk of bias	probably high risk of bias low risk of bias low risk of bias low risk of bias low risk of bias probably high risk of bias probably high risk of bias	probably high risk of bias high risk of bias low risk of bias low risk of bias high risk of bias high risk of bias high risk of bias low risk of bias probably high risk of bias low risk of bias low risk of bias low risk of bias	low risk of bias	probably low risk of bias probably low risk of bias low risk of bias low risk of bias probably low risk of bias low risk of bias
hydroxychloroquine	standard care/placebo	Reis_1 45662, Ader_1 3321, 776 C158 6987 13936 16085, 38308 20005 Reis_1 33489, Johnston 45662, Ader_1 33028 Byakika-Kibwika	Reis_1 Ader_1 Tang_1 Chen_3 Chen_4 Ulrich Dubée Omrani Reis_1 Johnston Ader_1 Amaravadi	low risk of bias low risk of bias probably high risk of bias probably low risk of bias probably low risk of bias probably low risk of bias low risk of bias	probably high risk of bias low risk of bias low risk of bias low risk of bias low risk of bias probably high risk of bias probably high risk of bias	probably high risk of bias high risk of bias low risk of bias low risk of bias high risk of bias high risk of bias high risk of bias low risk of bias probably high risk of bias low risk of bias low risk of bias low risk of bias	low risk of bias	probably low risk of bias probably low risk of bias low risk of bias low risk of bias probably low risk of bias low risk of bias
hydroxychloroquine	standard care/placebo	Reis_1 45662, Ader_1 3321, 776 C158 6987 13936 16085, 38308 20005 Reis_1 33489, Johnston 45662, Ader_1 33028 Byakika-Kibwika	Reis_1 Ader_1 Tang_1 Chen_3 Chen_4 Ulrich Dubée Omrani Reis_1 Johnston Ader_1 Amaravadi Byakika-Kibwika	low risk of bias low risk of bias probably high risk of bias probably low risk of bias probably low risk of bias	low risk of bias probably high risk of bias low risk of bias probably high risk of bias probably high risk of bias probably high risk of bias	probably high risk of bias high risk of bias low risk of bias low risk of bias high risk of bias high risk of bias high risk of bias low risk of bias probably high risk of bias low risk of bias high risk of bias low risk of bias high risk of bias	low risk of bias	probably low risk of bias probably low risk of bias
hydroxychloroquine interferon alpha	standard care/placebo	Reis_1 45662, Ader_1 3321, 776 C158 6987 13936 16085, 38308 20005 Reis_1 33489, Johnston 45662, Ader_1 33028 Byakika-Kibwika	Reis_1 Ader_1 Tang_1 Chen_3 Chen_4 Ulrich Dubée Omrani Reis_1 Johnston Ader_1 Amaravadi Byakika-Kibwika	low risk of bias low risk of bias probably high risk of bias probably low risk of bias probably low risk of bias	low risk of bias probably high risk of bias low risk of bias probably high risk of bias probably high risk of bias probably high risk of bias	probably high risk of bias high risk of bias low risk of bias low risk of bias high risk of bias high risk of bias high risk of bias low risk of bias probably high risk of bias low risk of bias high risk of bias low risk of bias high risk of bias	low risk of bias	probably low risk of bias probably low risk of bias
hydroxychloroquine	standard care/placebo	Reis_1 45662, Ader_1 3321, 776 C158 6987 13936 16085, 38308 20005 Reis_1 33489, Johnston 45662, Ader_1 33028 Byakika-Kibwika	Reis_1 Ader_1 Tang_1 Chen_3 Chen_4 Ulrich Dubée Omrani Reis_1 Johnston Ader_1 Amaravadi Byakika-Kibwika	low risk of bias low risk of bias probably high risk of bias probably high risk of bias probably low risk of bias low risk of bias low risk of bias low risk of bias probably low risk of bias low risk of bias probably low risk of bias low risk of bias low risk of bias low risk of bias	low risk of bias probably high risk of bias low risk of bias probably high risk of bias probably high risk of bias probably high risk of bias	probably high risk of bias high risk of bias low risk of bias low risk of bias high risk of bias high risk of bias high risk of bias low risk of bias probably high risk of bias low risk of bias low risk of bias low risk of bias low risk of bias	low risk of bias	probably low risk of bias probably low risk of bias
hydroxychloroquine interferon alpha	standard care/placebo	Reis_1 45662, Ader_1 3321, 776 C158 6987 13936 16085, 38308 20005 Reis_1 33489, Johnston 45662, Ader_1 33028 Byakika-Kibwika	Reis_1 Ader_1 Tang_1 Chen_3 Chen_4 Ulrich Dubée Omrani Reis_1 Johnston Ader_1 Amaravadi Byakika-Kibwika	low risk of bias low risk of bias probably high risk of bias probably low risk of bias probably low risk of bias probably low risk of bias low risk of bias low risk of bias probably high risk of bias probably high risk of bias	probably high risk of bias low risk of bias probably high risk of bias	probably high risk of bias high risk of bias low risk of bias low risk of bias high risk of bias high risk of bias low risk of bias probably high risk of bias low risk of bias	low risk of bias	probably low risk of bias probably low risk of bias
hydroxychloroquine interferon alpha	standard care/placebo	Reis_1 45662, Ader_1 3321, 776 C158 6987 13936 16085, 38308 20005 Reis_1 33489, Johnston 45662, Ader_1 33028 Byakika-Kibwika	Reis_1 Ader_1 Tang_1 Chen_3 Chen_4 Ulrich Dubée Omrani Reis_1 Johnston Ader_1 Amaravadi Byakika-Kibwika	low risk of bias low risk of bias probably high risk of bias probably high risk of bias probably low risk of bias low risk of bias low risk of bias low risk of bias probably low risk of bias low risk of bias probably low risk of bias low risk of bias low risk of bias low risk of bias	low risk of bias probably high risk of bias low risk of bias probably high risk of bias probably high risk of bias probably high risk of bias	probably high risk of bias high risk of bias low risk of bias low risk of bias high risk of bias high risk of bias high risk of bias low risk of bias probably high risk of bias low risk of bias low risk of bias low risk of bias low risk of bias	low risk of bias	probably low risk of bias probably low risk of bias
hydroxychloroquine interferon alpha interferon alpha	standard care/placebo combinant super combinant inte	Reis_1 45662, Ader_1 3321, 776 C158 6987 13936 16085, 38308 20005 Reis_1 33489, Johnston 45662, Ader_1 33028 Byakika-Kibwika	Reis_1 Ader_1 Tang_1 Chen_3 Chen_4 Ulrich Dubée Omrani Reis_1 Johnston Ader_1 Amaravadi Byakika-Kibwika	low risk of bias low risk of bias probably high risk of bias probably low risk of bias probably low risk of bias probably low risk of bias low risk of bias low risk of bias probably high risk of bias probably high risk of bias	probably high risk of bias low risk of bias probably high risk of bias	probably high risk of bias high risk of bias low risk of bias low risk of bias high risk of bias high risk of bias low risk of bias probably high risk of bias low risk of bias	low risk of bias	probably low risk of bias probably low risk of bias
hydroxychloroquine interferon alpha	standard care/placebo combinant super combinant inte	Reis_1 45662, Ader_1 3321, 776 C158 6987 13936 16085, 38308 20005 Reis_1 33489, Johnston 45662, Ader_1 33028 Byakika-Kibwika erferon 32737, 7, 9574 35022 59366, 60209	Reis_1 Ader_1 Tang_1 Chen_3 Chen_4 Ulrich Dubée Omrani Reis_1 Johnston Ader_1 Amaravadi Byakika-Kibwika Li_2 Pandit Bhushan	low risk of bias low risk of bias probably high risk of bias probably high risk of bias probably low risk of bias low risk of bias low risk of bias low risk of bias probably low risk of bias low risk of bias probably low risk of bias low risk of bias low risk of bias probably high risk of bias probably high risk of bias	probably high risk of bias low risk of bias low risk of bias low risk of bias low risk of bias probably high risk of bias	probably high risk of bias high risk of bias low risk of bias low risk of bias high risk of bias high risk of bias high risk of bias low risk of bias probably high risk of bias low risk of bias	low risk of bias	probably low risk of bias probably low risk of bias
hydroxychloroquine interferon alpha interferon alpha	standard care/placebo combinant super combinant inte	Reis_1 45662, Ader_1 3321, 776 C158 6987 13936 16085, 38308 20005 Reis_1 33489, Johnston 45662, Ader_1 33028 Byakika-Kibwika	Reis_1 Ader_1 Tang_1 Chen_3 Chen_4 Ulrich Dubée Omrani Reis_1 Johnston Ader_1 Amaravadi Byakika-Kibwika	low risk of bias low risk of bias probably high risk of bias probably low risk of bias probably low risk of bias probably low risk of bias low risk of bias low risk of bias probably high risk of bias probably high risk of bias	probably high risk of bias low risk of bias probably high risk of bias	probably high risk of bias high risk of bias low risk of bias low risk of bias high risk of bias high risk of bias low risk of bias probably high risk of bias low risk of bias	low risk of bias	probably low risk of bias probably low risk of bias
hydroxychloroquine interferon alpha interferon alpha	standard care/placebo combinant super combinant inte standard care/placebo lopinavir-ritonavir	Reis_1 45662, Ader_1 3321, 776 C158 6987 13936 16085, 38308 20005 Reis_1 33489, Johnston 45662, Ader_1 33028 Byakika-Kibwika erferon 32737, 7, 9574 35022 59366, 60209	Reis_1 Ader_1 Tang_1 Chen_3 Chen_4 Ulrich Dubée Omrani Reis_1 Johnston Ader_1 Amaravadi Byakika-Kibwika Li_2 Pandit Bhushan	low risk of bias low risk of bias probably high risk of bias probably high risk of bias probably low risk of bias low risk of bias low risk of bias low risk of bias probably low risk of bias low risk of bias probably low risk of bias low risk of bias low risk of bias probably high risk of bias probably high risk of bias	probably high risk of bias low risk of bias low risk of bias low risk of bias low risk of bias probably high risk of bias	probably high risk of bias high risk of bias low risk of bias low risk of bias high risk of bias high risk of bias high risk of bias low risk of bias probably high risk of bias low risk of bias	low risk of bias	probably low risk of bias probably low risk of bias probably low risk of bias low risk of bias low risk of bias
hydroxychloroquine interferon alpha interferon alpha	standard care/placebo combinant super combinant inte standard care/placebo lopinavir-ritonavir	Reis_1 45662, Ader_1 3321, 776 C158 6987 13936 16085, 38308 20005 Reis_1 33489, Johnston 45662, Ader_1 33028 Byakika-Kibwika erferon 32737, 7, 9574 35022 59366, 60209	Reis_1 Ader_1 Tang_1 Chen_3 Chen_4 Ulrich Dubée Omrani Reis_1 Johnston Ader_1 Amaravadi Byakika-Kibwika Li_2 Pandit Bhushan	low risk of bias low risk of bias probably high risk of bias probably low risk of bias probably low risk of bias low risk of bias low risk of bias low risk of bias probably low risk of bias low risk of bias low risk of bias probably low risk of bias low risk of bias probably high risk of bias low risk of bias low risk of bias	low risk of bias probably high risk of bias low risk of bias probably high risk of bias	probably high risk of bias high risk of bias low risk of bias low risk of bias high risk of bias high risk of bias high risk of bias low risk of bias probably high risk of bias low risk of bias	low risk of bias	probably low risk of bias probably low risk of bias
hydroxychloroquine interferon alpha interferon alpha	standard care/placebo combinant super combinant inte standard care/placebo lopinavir-ritonavir	Reis_1 45662, Ader_1 3321, 776 C158 6987 13936 16085, 38308 20005 Reis_1 33489, Johnston 45662, Ader_1 33028 Byakika-Kibwika erferon 32737, 7, 9574 35022 59366, 60209	Reis_1 Ader_1 Tang_1 Chen_3 Chen_4 Ulrich Dubée Omrani Reis_1 Johnston Ader_1 Amaravadi Byakika-Kibwika Li_2 Pandit Bhushan	low risk of bias low risk of bias probably high risk of bias probably high risk of bias probably low risk of bias low risk of bias low risk of bias low risk of bias probably low risk of bias low risk of bias probably low risk of bias low risk of bias low risk of bias probably high risk of bias probably high risk of bias	probably high risk of bias low risk of bias low risk of bias low risk of bias low risk of bias probably high risk of bias	probably high risk of bias high risk of bias low risk of bias low risk of bias high risk of bias high risk of bias high risk of bias low risk of bias probably high risk of bias low risk of bias	low risk of bias	probably low risk of bias probably low risk of bias

interferon gamma	standard care/placebo							
		9880	Esquivel-Moynelo	probably high risk of bias	probably high risk of bias	high risk of bias	low risk of bias	probably low risk of bias
interferon kappa, trefoil factor 2	standard care/placebo							
птенения карра, пени насти 2	Standard Care/placebo	13797	Fu	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		23/3/	. u	producty ingit tisk of bids	p. OcoolyBil Hak of bids	10 11 11 10 10 10 10 10 10 10 10 10 10 1	1011 1131 01 0103	producty tow than or bids
intranasal corticosteroids	standard care/placebo							
		57833	Song	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
ivermectin	lopinavir-ritonavir							
		25394, Babalola	Babalola	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
ivermectin	standard care/placebo							
Wermecun	standard care, placebo	Ahmed	Ahmed	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		27334, Chaccour	Chaccour	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		53436, Ravikirti	Ravikirti	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Bukhari	Bukhari	probably high risk of bias	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias
		Mohan	Mohan	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Schwartz	Schwartz	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		35667	Pott-Junior	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		Kishoria	Kishoria	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
leflunomide	standard care/placebo							
		8784	Hu	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		13540	Wang_5	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
lopinavir-ritonavir	lopinavir-ritonavir, novafero	n						
iopinavii-ritoriavii	iopinavii-ritoriavii, novalero	10121, 2338	Zheng	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		10121, 2550	Ziiciig	probably riight risk of bias	probably riight risk of bias	low risk of bias	low risk of bids	low risk of bias
lopinavir-ritonavir	lopinavir-ritonavir, ribavirir	ı						
	, , ,	10067, 2615	Huang_2	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		·	<u></u>					
lopinavir-ritonavir	novaferon							
		10121, 2338	Zheng	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
lopinavir-ritonavir								
Topinavii Titonavii	ribavirin							
iopinavii ritoriavii	ribavirin	10067, 2615	Huang_2	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
·		10067, 2615	Huang_2	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
lopinavir-ritonavir	standard care/placebo							
·		330	Cao_1	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
·		330 1243, 234	Cao_1 Li	low risk of bias low risk of bias	probably high risk of bias probably high risk of bias	low risk of bias low risk of bias	low risk of bias low risk of bias	probably low risk of bias low risk of bias
·		330 1243, 234 Reis_1	Cao_1 Li Reis_1	low risk of bias low risk of bias low risk of bias	probably high risk of bias probably high risk of bias low risk of bias	low risk of bias low risk of bias probably high risk of bias	low risk of bias low risk of bias low risk of bias	probably low risk of bias low risk of bias probably low risk of bias
		330 1243, 234	Cao_1 Li	low risk of bias low risk of bias	probably high risk of bias probably high risk of bias	low risk of bias low risk of bias	low risk of bias low risk of bias	probably low risk of bias low risk of bias
		330 1243, 234 Reis_1	Cao_1 Li Reis_1	low risk of bias low risk of bias low risk of bias	probably high risk of bias probably high risk of bias low risk of bias	low risk of bias low risk of bias probably high risk of bias	low risk of bias low risk of bias low risk of bias	probably low risk of bias low risk of bias probably low risk of bias
lopinavir-ritonavir	standard care/placebo	330 1243, 234 Reis_1	Cao_1 Li Reis_1	low risk of bias low risk of bias low risk of bias	probably high risk of bias probably high risk of bias low risk of bias	low risk of bias low risk of bias probably high risk of bias	low risk of bias low risk of bias low risk of bias	probably low risk of bias low risk of bias probably low risk of bias
lopinavir-ritonavir lopinavir-ritonavir	standard care/placebo umifenovir	330 1243, 234 Reis_1 45662, Ader_1	Cao_1 Li Reis_1 Ader_1	low risk of bias low risk of bias low risk of bias low risk of bias	probably high risk of bias probably high risk of bias low risk of bias probably high risk of bias	low risk of bias low risk of bias probably high risk of bias high risk of bias	low risk of bias low risk of bias low risk of bias low risk of bias	probably low risk of bias low risk of bias probably low risk of bias low risk of bias
lopinavir-ritonavir lopinavir-ritonavir	standard care/placebo	330 1243, 234 Reis 1 45662, Ader_1	Cao_1 Li Reis_1 Ader_1	low risk of bias low risk of bias low risk of bias low risk of bias	probably high risk of bias probably high risk of bias low risk of bias probably high risk of bias probably high risk of bias	low risk of bias low risk of bias probably high risk of bias high risk of bias low risk of bias	low risk of bias low risk of bias low risk of bias low risk of bias	probably low risk of bias low risk of bias probably low risk of bias low risk of bias
lopinavir-ritonavir lopinavir-ritonavir	standard care/placebo umifenovir	330 1243, 234 Reis_1 45662, Ader_1	Cao_1 Li Reis_1 Ader_1	low risk of bias low risk of bias low risk of bias low risk of bias	probably high risk of bias probably high risk of bias low risk of bias probably high risk of bias	low risk of bias low risk of bias probably high risk of bias high risk of bias	low risk of bias low risk of bias low risk of bias low risk of bias	probably low risk of bias low risk of bias probably low risk of bias low risk of bias
lopinavir-ritonavir lopinavir-ritonavir lopinavir-ritonavir, novaferon	standard care/placebo umifenovir novaferon	330 1243, 234 Reis 1 45662, Ader_1	Cao_1 Li Reis_1 Ader_1	low risk of bias low risk of bias low risk of bias low risk of bias	probably high risk of bias probably high risk of bias low risk of bias probably high risk of bias probably high risk of bias	low risk of bias low risk of bias probably high risk of bias high risk of bias low risk of bias	low risk of bias low risk of bias low risk of bias low risk of bias	probably low risk of bias low risk of bias probably low risk of bias low risk of bias
lopinavir-ritonavir lopinavir-ritonavir	standard care/placebo umifenovir	330 1243, 234 Reis_1 45662, Ader_1 1243, 234	Cao_1 Li Reis_1 Ader_1 Li	low risk of bias low risk of bias probably high risk of bias	probably high risk of bias probably high risk of bias low risk of bias probably high risk of bias probably high risk of bias probably high risk of bias	low risk of bias low risk of bias probably high risk of bias high risk of bias low risk of bias	low risk of bias low risk of bias low risk of bias low risk of bias low risk of bias	probably low risk of bias low risk of bias probably low risk of bias low risk of bias low risk of bias
lopinavir-ritonavir lopinavir-ritonavir	standard care/placebo umifenovir novaferon	330 1243, 234 Reis 1 45662, Ader_1	Cao_1 Li Reis_1 Ader_1	low risk of bias low risk of bias low risk of bias low risk of bias	probably high risk of bias probably high risk of bias low risk of bias probably high risk of bias probably high risk of bias	low risk of bias low risk of bias probably high risk of bias high risk of bias low risk of bias	low risk of bias low risk of bias low risk of bias low risk of bias	probably low risk of bias low risk of bias probably low risk of bias low risk of bias
lopinavir-ritonavir lopinavir-ritonavir lopinavir-ritonavir, novaferon lopinavir-ritonavir, ribavirin	standard care/placebo umifenovir novaferon ribavirin	330 1243, 234 Reis_1 45662, Ader_1 1243, 234	Cao_1 Li Reis_1 Ader_1 Li	low risk of bias low risk of bias probably high risk of bias	probably high risk of bias probably high risk of bias low risk of bias probably high risk of bias probably high risk of bias probably high risk of bias	low risk of bias low risk of bias probably high risk of bias high risk of bias low risk of bias	low risk of bias low risk of bias low risk of bias low risk of bias low risk of bias	probably low risk of bias low risk of bias probably low risk of bias low risk of bias low risk of bias
lopinavir-ritonavir lopinavir-ritonavir opinavir-ritonavir, novaferon	standard care/placebo umifenovir novaferon	330 1243, 234 Reis_1 45662, Ader_1 1243, 234 10121, 2338	Cao_1 Li Reis_1 Ader_1 Li Zheng Huang_2	low risk of bias robably high risk of bias probably high risk of bias	probably high risk of bias probably high risk of bias low risk of bias probably high risk of bias probably high risk of bias probably high risk of bias probably high risk of bias	low risk of bias low risk of bias probably high risk of bias high risk of bias low risk of bias low risk of bias	low risk of bias	probably low risk of bias low risk of bias probably low risk of bias
lopinavir-ritonavir lopinavir-ritonavir opinavir-ritonavir, novaferon lopinavir-ritonavir, ribavirin	standard care/placebo umifenovir novaferon ribavirin	330 1243, 234 Reis_1 45662, Ader_1 1243, 234	Cao_1 Li Reis_1 Ader_1 Li	low risk of bias low risk of bias probably high risk of bias	probably high risk of bias probably high risk of bias low risk of bias probably high risk of bias probably high risk of bias probably high risk of bias	low risk of bias low risk of bias probably high risk of bias high risk of bias low risk of bias	low risk of bias low risk of bias low risk of bias low risk of bias low risk of bias	probably low risk of bias low risk of bias probably low risk of bias low risk of bias low risk of bias
lopinavir-ritonavir lopinavir-ritonavir lopinavir-ritonavir, novaferon lopinavir-ritonavir, ribavirin metisoprinol	standard care/placebo umifenovir novaferon ribavirin standard care/placebo	330 1243, 234 Reis_1 45662, Ader_1 1243, 234 10121, 2338	Cao_1 Li Reis_1 Ader_1 Li Zheng Huang_2	low risk of bias robably high risk of bias probably high risk of bias	probably high risk of bias probably high risk of bias low risk of bias probably high risk of bias probably high risk of bias probably high risk of bias probably high risk of bias	low risk of bias low risk of bias probably high risk of bias high risk of bias low risk of bias low risk of bias	low risk of bias	probably low risk of bias low risk of bias probably low risk of bias
lopinavir-ritonavir lopinavir-ritonavir lopinavir-ritonavir, novaferon lopinavir-ritonavir, ribavirin	standard care/placebo umifenovir novaferon ribavirin	330 1243, 234 Reis_1 45662, Ader_1 1243, 234 10121, 2338 10067, 2615 Migled	Cao_1 Li Reis_1 Ader_1 Li Zheng Huang_2 Migled	low risk of bias robably high risk of bias probably high risk of bias	probably high risk of bias probably high risk of bias low risk of bias probably high risk of bias	low risk of bias low risk of bias probably high risk of bias high risk of bias low risk of bias low risk of bias low risk of bias	low risk of bias	probably low risk of bias low risk of bias probably low risk of bias
lopinavir-ritonavir lopinavir-ritonavir lopinavir-ritonavir, novaferon lopinavir-ritonavir, ribavirin metisoprinol	standard care/placebo umifenovir novaferon ribavirin standard care/placebo	330 1243, 234 Reis_1 45662, Ader_1 1243, 234 10121, 2338	Cao_1 Li Reis_1 Ader_1 Li Zheng Huang_2	low risk of bias fow risk of bias probably high risk of bias probably high risk of bias	probably high risk of bias probably high risk of bias low risk of bias probably high risk of bias probably high risk of bias probably high risk of bias probably high risk of bias	low risk of bias low risk of bias probably high risk of bias high risk of bias low risk of bias low risk of bias	low risk of bias	probably low risk of bias low risk of bias probably low risk of bias probably low risk of bias
lopinavir-ritonavir lopinavir-ritonavir lopinavir-ritonavir, novaferon lopinavir-ritonavir, ribavirin metisoprinol	standard care/placebo umifenovir novaferon ribavirin standard care/placebo	330 1243, 234 Reis_1 45662, Ader_1 1243, 234 10121, 2338 10067, 2615 Migled	Cao_1 Li Reis_1 Ader_1 Li Zheng Huang_2 Migled Fischer	low risk of bias low risk of bias probably high risk of bias probably high risk of bias probably high risk of bias	probably high risk of bias probably high risk of bias low risk of bias probably high risk of bias probably high risk of bias probably high risk of bias probably high risk of bias probably high risk of bias	low risk of bias low risk of bias probably high risk of bias high risk of bias low risk of bias low risk of bias low risk of bias low risk of bias	low risk of bias	probably low risk of bias low risk of bias probably low risk of bias
lopinavir-ritonavir lopinavir-ritonavir lopinavir-ritonavir, novaferon lopinavir-ritonavir, ribavirin metisoprinol	standard care/placebo umifenovir novaferon ribavirin standard care/placebo	330 1243, 234 Reis_1 45662, Ader_1 1243, 234 10121, 2338 10067, 2615 Migled	Cao_1 Li Reis_1 Ader_1 Li Zheng Huang_2 Migled Fischer Vyas	low risk of bias low risk of bias probably high risk of bias probably high risk of bias probably high risk of bias	probably high risk of bias probably high risk of bias low risk of bias probably high risk of bias	low risk of bias low risk of bias probably high risk of bias high risk of bias low risk of bias	low risk of bias	probably low risk of bias low risk of bias probably low risk of bias probably low risk of bias low risk of bias
lopinavir-ritonavir lopinavir-ritonavir lopinavir-ritonavir, novaferon lopinavir-ritonavir, ribavirin metisoprinol	standard care/placebo umifenovir novaferon ribavirin standard care/placebo	330 1243, 234 Reis_1 45662, Ader_1 1243, 234 10121, 2338 10067, 2615 Migled	Cao_1 Li Reis_1 Ader_1 Li Zheng Huang_2 Migled Fischer Vyas Krishnan	low risk of bias low risk of bias probably high risk of bias probably high risk of bias low risk of bias low risk of bias	probably high risk of bias probably high risk of bias low risk of bias probably high risk of bias probably high risk of bias probably high risk of bias probably high risk of bias probably high risk of bias probably high risk of bias low risk of bias probably high risk of bias probably high risk of bias	low risk of bias low risk of bias probably high risk of bias high risk of bias low risk of bias	low risk of bias	probably low risk of bias low risk of bias probably low risk of bias probably low risk of bias low risk of bias low risk of bias low risk of bias
lopinavir-ritonavir lopinavir-ritonavir lopinavir-ritonavir, novaferon lopinavir-ritonavir, ribavirin metisoprinol	standard care/placebo umifenovir novaferon ribavirin standard care/placebo	330 1243, 234 Reis_1 45662, Ader_1 1243, 234 10121, 2338 10067, 2615 Migled 46473, Fischer CR216-21 CTRI/2021/06/0339 ICR/III/MOLCOV/04/2(Cao_1 Li Reis_1 Ader_1 Li Zheng Huang_2 Migled Fischer Vyas Krishnan Kumar_2	low risk of bias low risk of bias low risk of bias probably high risk of bias probably high risk of bias low risk of bias low risk of bias low risk of bias probably high risk of bias	probably high risk of bias probably high risk of bias low risk of bias probably high risk of bias	low risk of bias low risk of bias probably high risk of bias high risk of bias low risk of bias	low risk of bias	probably low risk of bias low risk of bias probably low risk of bias probably low risk of bias low risk of bias low risk of bias low risk of bias probably low risk of bias
lopinavir-ritonavir lopinavir-ritonavir lopinavir-ritonavir, novaferon lopinavir-ritonavir, ribavirin metisoprinol molnupiravir	standard care/placebo umifenovir novaferon ribavirin standard care/placebo standard care/placebo	330 1243, 234 Reis_1 45662, Ader_1 1243, 234 10121, 2338 10067, 2615 Migled	Cao_1 Li Reis_1 Ader_1 Li Zheng Huang_2 Migled Fischer Vyas Krishnan	low risk of bias low risk of bias probably high risk of bias probably high risk of bias low risk of bias low risk of bias	probably high risk of bias probably high risk of bias low risk of bias probably high risk of bias probably high risk of bias probably high risk of bias probably high risk of bias probably high risk of bias probably high risk of bias low risk of bias probably high risk of bias probably high risk of bias	low risk of bias low risk of bias probably high risk of bias high risk of bias low risk of bias	low risk of bias	probably low risk of bias low risk of bias probably low risk of bias probably low risk of bias low risk of bias low risk of bias low risk of bias
lopinavir-ritonavir lopinavir-ritonavir lopinavir-ritonavir, novaferon lopinavir-ritonavir, ribavirin metisoprinol molnupiravir	standard care/placebo umifenovir novaferon ribavirin standard care/placebo standard care/placebo	330 1243, 234 Reis_1 45662, Ader_1 1243, 234 10121, 2338 10067, 2615 Migled 46473, Fischer CR216-21 CTRI/2021/06/0339 ICR/III/MOLCOV/04/2(Cao_1 Li Reis_1 Ader_1 Li Zheng Huang_2 Migled Fischer Vyas Krishnan Kumar_2	low risk of bias low risk of bias low risk of bias probably high risk of bias probably high risk of bias low risk of bias low risk of bias low risk of bias probably high risk of bias	probably high risk of bias probably high risk of bias low risk of bias probably high risk of bias	low risk of bias low risk of bias probably high risk of bias high risk of bias low risk of bias	low risk of bias	probably low risk of bias low risk of bias probably low risk of bias probably low risk of bias low risk of bias low risk of bias low risk of bias probably low risk of bias

		16339, 24799 Silva	Rocco Silva	low risk of bias low risk of bias	low risk of bias probably high risk of bias	high risk of bias low risk of bias	low risk of bias low risk of bias	probably low risk of bias low risk of bias
nitric oxide	standard care/placebo							
		Moni	Moni	low risk of bias	probably high risk of bias	high risk of bias	low risk of bias	low risk of bias
peginterferon lambda	standard care/placebo							
		18418, 28233	Feld	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
prolectin-M	standard care/placebo							
		Sigamani, Sigamani	Sigamani	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
proxalutamide	standard care/placebo							
		33610	Cadegiani_3	high risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
quercetin	standard care/placebo							
		51397	Di Pierro_2	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
ravidasvir, sofosbuvir	standard care/placebo							
		57630	Abbass	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
nt human granulocyte colony-stimula	standard care/placebo							
		12705	Cheng	low risk of bias	probably high risk of bias	high risk of bias	low risk of bias	low risk of bias
remdesivir	standard care/placebo							
		2408	Wang_1	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
serine protease inhibitors	standard care/placebo							
		70176	Zhuravel	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
triazavirin	standard care/placebo							
		12679	Wu	high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
umifenovir	standard care/placebo							
		1243, 234 Ramachandran	Li Ramachandran	low risk of bias low risk of bias	probably high risk of bias low risk of bias	low risk of bias low risk of bias	low risk of bias low risk of bias	low risk of bias high risk of bias

 T1	

				venous minomboembo	113111			
Treatment 1	Treatment 2	Trial	First author	Randomization	Deviations from the intended	Missing outcome data	Measurement of outcome	Selection of the reported
Intermediate-dose enoxaparin	standard care/placebo							
		52393, Perepu	Perepu	probably high risk of bias	probably high risk of bias	low risk of bias	high risk of bias	low risk of bias
aspirin	full-dose anticoagulation							
		67646	Connors	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
aspirin	standard care/placebo							
		67646	Connors	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
full-dose anticoagulant	intermediate-dose anticoagulation		Commenter	and the late of the second	land deline filter	Learning of the co	In the state of the state of	In the filter
		Spyropoulos	Spyropoulos	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		67889	Marcos	low risk of bias	probably high risk of bias	low risk of bias	high risk of bias	probably low risk of bias
full-dose anticoagulation	standard care/placebo							
· · · · · · · · · · · · · · · · · · ·	310.100.0000	13836	Lemos	low risk of bias	probably high risk of bias	low risk of bias	high risk of bias	probably low risk of bias
	34844,	ATTACC/ACTIV-4a/RAF	, ACTIV-4a, and ATTACC		probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		35895, Bikdeli	Bikdeli	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		56911, Lawler	Lawler	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		Sholzberg	Sholzberg	low risk of bias	probably high risk of bias	low risk of bias	high risk of bias	low risk of bias
		67646	Connors	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		47030	Lopes_3	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
serine protease inhibitors	standard care/placebo							
		70176	Zhuravel	low risk of bias	probably high risk of bias	low risk of bias	high risk of bias	probably low risk of bias
sulodexide	standard care/placebo							
		21816, 34575	Gonzalez-Ochoa	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		,						

Clinically Important Bleeding Treatment 1 Treatment 2 Trial First author Randomization Deviations from the intended Missing outcome data Measurement of outcome Selection of the reported Intermediate-dose anticoagulant standard care/placebo 52393, Perepu Perepu probably high risk of bias probably high risk of bias low risk of bias low risk of bias aspirin full-dose anticoagulation 67646 Connors low risk of bias low risk of bias low risk of bias low risk of bias aspirin standard care/placebo 67646 low risk of bias low risk of bias Connors low risk of bias low risk of bias full-dose anticoagulation intermediate-dose anticoagulation probably low risk of bias 65782 low risk of bias Oliynyk probably high risk of bias probably high risk of bias probably low risk of bias 67889 Marcos low risk of bias probably high risk of bias low risk of bias low risk of bias low risk of bias Spyropoulos low risk of bias low risk of bias low risk of bias Spyropoulos probably low risk of bias full-dose anticoagulation standard care/placebo

		13836	Lemos	low risk of bias	probably high risk of bias	low risk of bias	high risk of bias	probably low risk of bias
	34844,	ATTACC/ACTIV-4a/RAF	, ACTIV-4a, and ATTACC	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		35895, Bikdeli	Bikdeli	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		56911, Lawler	Lawler	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		Sholzberg	Sholzberg	low risk of bias	probably high risk of bias	low risk of bias	high risk of bias	low risk of bias
		64008	Ananworanich	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		67646	Connors	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		47030	Lopes_3	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
ull-dose anticoagulation, thrombolysi	standard care/placebo							
		65552_P1	Barrett_P1	low risk of bias	probably high risk of bias	low risk of bias	high risk of bias	low risk of bias
		65552_P2	Barrett_P2	low risk of bias	probably high risk of bias	low risk of bias	high risk of bias	low risk of bias
sulodexide	standard care/placebo							
		21816, 34575	Gonzalez-Ochoa	probably low risk of bias	low risk of bias	high risk of bias	low risk of bias	low risk of bias

Hospital Length of Stay

				Hospit	tal Length of Stay				
Treatment 1	Treatment 2	Trial	First author	Randomization	Deviations from the intended	Missing outcome data	Measurement of outcome	Selection of the reported	Other (Competing risks)
(acetyl)cysteine	standard care/placebo								
, ,,,	.,	13687	de Alencar	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
		48051	Taher	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
		40051	Tunci	probably low risk of bias	10 11 1131 01 5143	IOW TISK OF BIAS	10W H3K OF Blu3	probably low risk of bias	10W TISK OF BIAS
2 days Dalassa	standard san falsasha								
2-deoxy-D-glucose	standard care/placebo								
		66751a	Narayan Bhatt	probably high risk of bias	high risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		66751b	Narayan Bhatt	probably high risk of bias	high risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
5-alpha reductase inhibitor	standard care/placebo								
		35590	Zarehoseinzade	probably low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably low risk of bias	probably low risk of bias
				process, remained and	process, ion tion or one			product, in the control of	process, restricted and
ACEi/ARB	calcium channel blockers								
ACEI/AND	Calcium chamile blockers	24054	No. of Marchali	Laure dalle a Children	Lance State of Little	In the section	Lance State of Literature	Lance and Landing	In the office
		34054	Nouri-Vaskeh	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
ACEi/ARB	standard care/placebo								
		10463, 49441	Duarte	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		26081	Cohen	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		27349	Lopes_1	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		43232	Geriak	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		48571	Bauer	low risk of bias	high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
		Puskarich_inpatien	Puskarich_2	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably high risk of bias	low risk of bias
AFO-202 beta glucan	beta-glucans								
		65044	Raghavan	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
AFO-202 beta glucan	standard care/placebo								
711 O 202 Deta glacali	Staridard care, praceso	65044	Raghavan	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
		03044	Nagilavali	probably flight flak of blas	probably flight risk of bias	IOW FISK OF DIAS	IOW HISK OF DIAS	probably low risk of bias	IOW FISK OF DIAS
and a language of the									
CCK-A agonist and CCK-B antagonist	standard care/placebo								
		Lattmann	Lattmann	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
CD24Fc	standard care/placebo								
		Song_2	Song_2	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
GM-CSF inhibitor	standard care/placebo								
Civi Cor minorcor	Startaura care, praecoo	Patel 2	Patel_2	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		ratei_2	ratei_2	probably low risk of bias	IOW IISK OI DIAS	IOW TISK OF DIAS	IOW HSK OF DIAS	IOW HSK OF DIAS	IOW FISH OF DIAS
HIV reverse transcriptase inhibitor	standard care/placebo								
		8469	Ren	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
IL1 inhibitors	standard care/placebo								
		Kyriazopoulou	Kyriazopoulou	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		54072	Caricchio	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		34072	Carreemo	1044 115K 01 6183	10W 113K OT BIA3	IOW TISK OF BIAS	IOW HISK OF BIAS	10W H3K OF Bla3	10W TISK OF BIAS
IL6 receptor antagonist	standard care/placebo								
		66149	Lomakin	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
IL6 receptor antagonists	standard care/placebo								
		11850	Wang_4	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		16127	Salvarani	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
		16283	Stone	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		10203	Storic	producti, low hisk or blas	ion not of blus	IOW HISK OF DIGG	1044 1131 01 5103	1011 1152 01 5105	E. County 10 W Halk Of Dida
anton antonomisto, continuator de la	atomiloud coup /ula : : ! :								
eptor antagonists, corticosteroids (sys	standard care/placebo								
		33303, Rosas	Rosas	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		16340, 23643	Salama	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
				low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
	33	3304, Gordon_v1, Gorc	Gordon_1					IOW HSK OF DIAS	10 W TISK OF DIGS
	33		Gordon_1 Veiga	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
	33	3304, Gordon_v1, Gord 27470	Veiga	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
	33	3304, Gordon_v1, Gord 27470 29298, 34438	Veiga Lescure	low risk of bias low risk of bias	probably high risk of bias low risk of bias	low risk of bias low risk of bias	low risk of bias low risk of bias	low risk of bias low risk of bias	low risk of bias low risk of bias
	33	3304, Gordon_v1, Gord 27470 29298, 34438 Rutgers	Veiga Lescure Rutgers	low risk of bias low risk of bias probably high risk of bias	probably high risk of bias low risk of bias probably high risk of bias	low risk of bias low risk of bias low risk of bias	low risk of bias low risk of bias low risk of bias	low risk of bias low risk of bias probably low risk of bias	low risk of bias low risk of bias low risk of bias
	33	3304, Gordon_v1, Gord 27470 29298, 34438 Rutgers 30638, 42048	Veiga Lescure Rutgers Horby_5	low risk of bias low risk of bias probably high risk of bias low risk of bias	probably high risk of bias low risk of bias probably high risk of bias probably high risk of bias	low risk of bias low risk of bias low risk of bias low risk of bias	low risk of bias low risk of bias low risk of bias low risk of bias	low risk of bias low risk of bias probably low risk of bias low risk of bias	low risk of bias low risk of bias low risk of bias low risk of bias
	33	3304, Gordon_v1, Gord 27470 29298, 34438 Rutgers	Veiga Lescure Rutgers	low risk of bias low risk of bias probably high risk of bias	probably high risk of bias low risk of bias probably high risk of bias	low risk of bias low risk of bias low risk of bias	low risk of bias low risk of bias low risk of bias	low risk of bias low risk of bias probably low risk of bias	low risk of bias low risk of bias low risk of bias
		3304, Gordon_v1, Gord 27470 29298, 34438 Rutgers 30638, 42048	Veiga Lescure Rutgers Horby_5	low risk of bias low risk of bias probably high risk of bias low risk of bias	probably high risk of bias low risk of bias probably high risk of bias probably high risk of bias	low risk of bias low risk of bias low risk of bias low risk of bias	low risk of bias low risk of bias low risk of bias low risk of bias	low risk of bias low risk of bias probably low risk of bias low risk of bias	low risk of bias low risk of bias low risk of bias low risk of bias
JAK inhibitors	3: standard care/placebo	3304, Gordon_v1, Gord 27470 29298, 34438 Rutgers 30638, 42048	Veiga Lescure Rutgers Horby_5	low risk of bias low risk of bias probably high risk of bias low risk of bias	probably high risk of bias low risk of bias probably high risk of bias probably high risk of bias probably high risk of bias	low risk of bias low risk of bias low risk of bias low risk of bias	low risk of bias low risk of bias low risk of bias low risk of bias	low risk of bias low risk of bias probably low risk of bias low risk of bias	low risk of bias low risk of bias low risk of bias low risk of bias
JAK inhibitors		3304, Gordon_v1, Gord 27470 29298, 34438 Rutgers 30638, 42048	Veiga Lescure Rutgers Horby_5	low risk of bias low risk of bias probably high risk of bias low risk of bias	probably high risk of bias low risk of bias probably high risk of bias probably high risk of bias	low risk of bias low risk of bias low risk of bias low risk of bias	low risk of bias low risk of bias low risk of bias low risk of bias	low risk of bias low risk of bias probably low risk of bias low risk of bias	low risk of bias low risk of bias low risk of bias low risk of bias
JAK inhibitors		3304, Gordon_v1, Gordon_v1, Gordon_v1, Gordon_v1, Gordon 29298, 34438 Rutgers 30638, 42048 47857	Veiga Lescure Rutgers Horby_5 Hamed	low risk of bias low risk of bias probably high risk of bias low risk of bias probably high risk of bias	probably high risk of bias low risk of bias probably high risk of bias probably high risk of bias probably high risk of bias	low risk of bias low risk of bias low risk of bias low risk of bias low risk of bias	low risk of bias low risk of bias low risk of bias low risk of bias low risk of bias	low risk of bias low risk of bias probably low risk of bias low risk of bias probably low risk of bias	low risk of bias low risk of bias low risk of bias low risk of bias low risk of bias

	623	263, Marconi, Marco	Marconi	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		48879	Guimarães	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
	51, 14410, 604,04	RUXCOVID	RUXCOVID	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
	Ely, WHO_COV-BA	ARRIER_Addendum,	Ely	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
L-arginine	standard care/placebo								
z digiiiic	staridard care, praceso	64005	Fiorentino	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
				1000 1000 0000					
NSAID, azithromycin	NSAID, azithromycin, corticostero	id							
		64198	Ghanei	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
NSAID, azithromycin	lopinavir-ritonavir								
		64198	Ghanei	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
NSAID, azithromycin, corticosteroid	lopinavir-ritonavir	64400	Charact	Laure dell'afficia	and the bit of the state of the state of	1	1	Learn state of the co	Lancada La Chica
		64198	Ghanei	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
TNF inhibitors	standard care/placebo								
THE IIIIIDITOIS	standard care/placebo	52260	Fakharian	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		32200	Taknanan	probably high risk of bias	probably riight risk of bias	IOW HISK OF BIGS	IOW HISK OF BIAS	10W FISK OF Blus	10W 113K OF DIGS
es, curcuminoids, piperine, resveratro	standard care/placebo								
.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		67818	Majeed	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
			•						
antihepaciviral	romycin, hydroxychloroquine, ose	Itamivir						444	
		44111	Elgohary	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably high risk of bias	low risk of bias
antihepaciviral	lopinavir-ritonavir								
		Yadollahzadeh	Yadollahzadeh	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	probably high risk of bias
antibonosis incl	stondard sare/aleacha								
antihepaciviral	standard care/placebo	11065	Sadeghi	probably high risk of bias	high risk of bias	low risk of bias	low risk of bias	probably high risk of bias	low risk of bias
		29517	Nourian	low risk of bias	high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Mobarak	Mobarak	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		45668	Sayad	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
		51681	El-Bendary	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
aspirin	aspirin, atorvastatin								
		Ghati	Ghati	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
aspirin	standard care/placebo	AL							
		Ghati	Ghati	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Horby_7	Horby_7	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
aspirin	statins								
аэрин	Statins	Ghati	Ghati	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Gilde	O.I.G.C.	producty ingit tisk of bids	producty mgm risk of bids	1011 11511 01 5105	1011 1131 01 5103	ion risk of bias	10W HISK OF BIAS
aspirin, atorvastatin	standard care/placebo								
		Ghati	Ghati	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
aspirin, atorvastatin	statins								
		Ghati	Ghati	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
atana and a data and a second	Indian Indian								
atazanavir, dolutegravir, ritonavir	lopinavir-ritonavir	53056	Kalantari	probably high risk of bias	high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	probably low risk of bias
		33056	Kalantari	probably high risk of bias	fligh risk of bias	TOW FISK OF DIAS	IOW FISK OF DIAS	probably low risk of bias	probably low risk of bias
azithromycin	standard care/placebo								
ozicii oniyeni	Startagra care/process	11639, 12378	Sekhavati	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
		12439	Furtado	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		22569, 29803	Horby_4	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		40804	Hinks	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
azithromycin, hydroxychloroquine	hydroxychloroquine								
		22152, 9166	Cavalcanti	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		33489, Johnston	Johnston	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
- the constant backer and	standard confete d								
azithromycin, hydroxychloroquine	standard care/placebo	22152 0166	Cavalant:	low risk of his	probably high sists of hiss	low rick of him	low rich of him	low risk of hise	low rick of hine
		22152, 9166	Cavalcanti	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias

		33489, Johnston 48002	Johnston Sivapalan	probably low risk of bias low risk of bias	low risk of bias low risk of bias	low risk of bias low risk of bias	low risk of bias low risk of bias	low risk of bias low risk of bias	low risk of bias probably low risk of bias
beta-glucans	standard care/placebo	65044	Raghavan	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
		03044	Nagriavari	probably flight fisk of bias	probably flight fisk of bias	IOW HISK OF DIAS	IOW HISK OF DIAS	probably low risk of bias	IOW HISK OF DIAS
bradykinin inhibitors	standard care/placebo								
		10832	Mansour	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
bromhexine hydrochloride	standard care/placebo	42000		and the bloke of the other	and the blok of the filter	Learn State of District	Learning of the co	In the Children	and the land of the second
		13888 35697	Ansarin Tolouian	probably high risk of bias probably high risk of bias	probably high risk of bias probably high risk of bias	low risk of bias probably low risk of bias	low risk of bias low risk of bias	low risk of bias probably low risk of bias	probably low risk of bias probably low risk of bias
		33097	Toloulan	probably flight fisk of bias	brongnik tilkit tiek of pige	probably low risk of bias	IOW LISK OF DIAS	probably low risk of bias	probably low risk of bias
colchicine	standard care/placebo								
	••	7189	Deftereos	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
		11	Salehzadeh	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		10500, xx	Lopes_2	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
		Horby_6	Horby_6	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		64351	Dorward	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		64385	Pascual-Figal	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	probably high risk of bias
Ichicino omtricitabina tanafacia del	omtricitation to of								
Ichicine, emtricitabine, tenofovir, stat	emtricitabine, tenofovir	Gaitan-Duarte	Gaitan-Duarte	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	probably low risk of bias
		Gallan-Duarte	Gallan-Duarte	IOW FISK OF DIAS	probably flight risk of blas	IOW FISK OF DIAS	IOW FISK OF DIAS	probably low risk of bias	probably low risk of bias
Ichicine, emtricitabine, tenofovir, stat	standard care/placebo								
ichichic, chichetabhic, teriolovii, stat	standard care, placebo	Gaitan-Duarte	Gaitan-Duarte	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	probably low risk of bias
				1011 1011 01 0100	process, mg. men er eres	1011 11011 011 0110		process, roll roll of order	p. 0. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1.
colchicine, statin	hicine, emtricitabine, tenofov	rir, statin							
		Gaitan-Duarte	Gaitan-Duarte	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	probably low risk of bias
								ородория Становия	
colchicine, statin	emtricitabine, tenofovir								
		Gaitan-Duarte	Gaitan-Duarte	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	probably low risk of bias
colchicine, statin	standard care/placebo								
		Gaitan-Duarte	Gaitan-Duarte	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	probably low risk of bias
corticosteroids (systemic)	standard care/placebo								
corticosterolas (systemic)	standard care, placebo	29672, 6743	Corral-Gudino	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		33381, 7002, 861!	Horby_1	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		10699	Jeronimo	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
		12146	Angus	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		31583	Jamaati	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		27642	Tang_2	probably low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	probably high risk of bias
corticosteroids (systemic), tacrolimus	standard care/placebo								
		51435	Solanich	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
decrease Pro-									
doxycycline	standard care/placebo	55459, Butler_doxycly	Butler	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	probably high risk of bias
		55459, Butlet_doxycly	butter	IOW HSK OF DIAS	brongnik tilkit tiek of pige	IOW FISK OF DIAS	IOM LISK OF DIAS	IOW TISK OF DIAS	probably flight fisk of bias
doxycycline, ivermectin	ivermectin								
23. jojume, remeduli	· · · · · · · · · · · · · · · · · · ·	Ahmed	Ahmed	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias	probably low risk of bias
				product, and a second	101111111111111111111111111111111111111			process, roll roll of order	p. 0.10.1. / 10.1. 10.1. 1.1. 1.1. 1.1. 1
doxycycline, ivermectin	standard care/placebo								
		Ahmed	Ahmed	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias	probably low risk of bias
emtricitabine, tenofovir	standard care/placebo								
		Gaitan-Duarte	Gaitan-Duarte	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	probably low risk of bias
f w	ata a da ada ada ada ada ada ada ada ada								
famotidine	standard care/placebo	Cambridge	Cambridge	lauratet aftitar	anahahir high dala dala	lavorately of the co	Januarial - China	lancated of the con-	Januard of Street
		Samimagham	Samimagham	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
favipiravir	lopinavir-ritonavir								
iavipiiavii	TOPHIUVII TILOTIAVII	35903	Solaymani-Dodaran	low risk of bias	probably high risk of bias	high risk of bias	high risk of bias	low risk of bias	probably low risk of bias
			.,		,, 3				, , , , , , , , , , , , , , , , , , , ,
favipiravir	standard care/placebo								
		24988, Udwadia	Udwadia	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias

favipiravir, hydrochloroquine	standard care/placebo								
		Bosaeed	Bosaeed	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
ravir, inhaled nebulised interferon be	hydroxychloroquine								
		18336, Khamis	Khamis	probably high risk of bias	high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	probably low risk of bias
fluvoxamine	standard care/placebo								
		18818	Lenze	low risk of bias	low risk of bias	high risk of bias	low risk of bias	low risk of bias	low risk of bias
		70784, Reis_2	Reis_2	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
6.0.1									
full-dose anticoagulation	standard care/placebo								
		13836	Lemos	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	probably high risk of bias
		47030	Lopes_3	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
budaana aasa Ma	standard confetence								
hydrogen peroxide	standard care/placebo	64224	D' Daniel de	In a state of the co	Laure dell'a Chilan	Laurental a Chilana	Lance State of Man	landel affilia	and the late of the second
		64234	Di Domenico	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
buden editors a tra	and an artist and the standard for the standard								
hydroxychloroquine	ydroxychloroquine, lopinavir-ritona		A le !	In a state of the co	and the best of the state of th	Laurental a Chilana	Lance State of Billion	In a delicable	Land St. Latters
		52697	Arabi	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
buden editors a tra	budan ablanca to a star								
hydroxychloroquine	hydroxychloroquine, zinc	21407	Abd Cleeless	anabable biab side of bias	anababb bish sist of biss	lass vials of hims	lass sials of bine	anahahlu lawaish of hisa	lass siels of high
		21407	Abd-Elsalam	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
buden editors a tra	the of the ball to the test of the second								
hydroxychloroquine	interferon beta, lopinavir-ritonavir		Ada. 4	In a state of the co	and the best of the state of th	Laurental a Chilana	Lance State of Billion	In the State of State	Land St. Latters
		45662, Ader_1	Ader_1	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
h. dan ahlaran in a									
hydroxychloroquine	ivermectin	Canada	Canadan	anabable biab side of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Gonzalez	Gonzalez	probably high risk of bias	IOW FISK OF DIAS	low risk of bias	IOW FISK OF DIAS	IOW FISK OF DIAS	low risk of bias
h. dan ahlaran in a	lopinavir-ritonavir								
hydroxychloroquine	iopinavir-ritonavir	milat 4	Unana 1	anabably bish sist of biss	anababb bish sist of biss	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		pilot_4 45662, Ader_1	Huang_1 Ader_1	probably high risk of bias low risk of bias	probably high risk of bias probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		52697	Arabi	low risk of bias	1 - 1	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		32037	Aldui	IOW TISK OF DIAS	probably high risk of bias	IOW HISK OF DIAS	IOW TISK OF DIAS	IOW HISK OF DIAS	IOW HISK OF DIAS
hydroxychloroquine	standard care/placebo								
nydroxychloroquine	standard care/placebo	6987	Chen_4	probably high risk of bias	probably high risk of bias	high risk of bias	low risk of bias	low risk of bias	low risk of bias
		14989, 8444, xx	Horby_2	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		22152, 9166	Cavalcanti	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		11299	Abd-Elsalam_1	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
		13936	Ulrich	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
	15632		Pan_hydroxychloroquine		probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
	13032	16281	Lyngbakken	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
		33489, Johnston	Johnston	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		45662, Ader_1	Ader_1	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		29663	Hernandez-Cardenas	low risk of bias	low risk of bias	low risk of bias	low risk of bias	high risk of bias	low risk of bias
		Gonzalez	Gonzalez	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		41434	Réa-Neto	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		52697	Arabi	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		3203.	, , , , , , , , , , , , , , , , , , , ,	1011-11011-01-0100	p. 2 2001) Tilgit Tibit O. Dida	.011 1.01 0.1 0.10			1011-11011-01-0100-
ydroxychloroquine, lopinavir-ritonav	hvdroxychloroguine, umifenovir								
,,	,,	23259, 8	Nojomi	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		, 3	,		,				
ydroxychloroquine, lopinavir-ritonav	i lopinavir-ritonavir								
, , , , , , , , , , , , , , , , , , , ,		52697	Arabi	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
ydroxychloroquine, lopinavir-ritonav	i standard care/placebo								
		52697	Arabi	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
			• •		, , , , , , , , , , , , , , , , , , , ,				
hydroxychloroquine, rivabirin	lopinavir-ritonavir, ribavirin								
, ,		46308_severe	Singh_3	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
			- 5	, , , , , , , , , , , , , , , , , , , ,	, , , , ,			, ,	
hydroxychloroquine, rivabirin	standard care/placebo								
, . , , , , ,		46308 non severe	Singh_2	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
		46308_severe	Singh_3	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
			- 0		, , , , , , , , , , , , , , , , , , , ,				
inhaled nebulised interferon beta-1a	standard care/placebo								

		18657	Monk	low risk of bias	low risk of bias	high risk of bias	low risk of bias	probably high risk of bias	low risk of bias
inhaled pan-JAK inhibitor	standard care/placebo								
	, p	34842	Singh_1	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
interferon alpha	combinant super combinant int	terferon							
		32737, 7, 9574	Li_2	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
interferon alpha	standard care/placebo								
		35022 59366, 60209	Pandit Bhushan	probably high risk of bias probably high risk of bias	probably high risk of bias probably high risk of bias	low risk of bias low risk of bias	low risk of bias low risk of bias	probably low risk of bias probably high risk of bias	low risk of bias low risk of bias
interferon beta	standard care/placebo								
		11541, 11937	Rahmani	probably high risk of bias	probably high risk of bias	high risk of bias	low risk of bias	low risk of bias	low risk of bias
		15632, Pan_interfer	Pan_interferon	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		39381, Darazam (2	Darazam_2	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Kalil_2	Kalil_2 Davoudi-Monfared	low risk of bias low risk of bias	low risk of bias	low risk of bias probably high risk of bias	low risk of bias low risk of bias	low risk of bias low risk of bias	low risk of bias probably high risk of bias
		11243, 3314, 624.	Davodul-Iviolilared	IOW HISK OF DIAS	High risk of blas	probably flight fisk of bias	IOW HISK OF DIAS	IOW HISK OF DIAS	probably flight flak of blas
interferon beta, lopinavir-ritonavir	antihepaciviral								
		Mostafa	Alavi-Moghaddam	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
interferon beta, lopinavir-ritonavir	lopinavir-ritonavir								
		45662, Ader_1	Ader_1	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
interferon beta, lopinavir-ritonavir	standard care/placebo								
		45662, Ader_1	Ader_1	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
interferon beta, ribavirin	standard care/placebo								
meneron beta, ribariin	standard care, placese	2942	Hung	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
interferon kappa, trefoil factor 2	standard care/placebo								
		13797	Fu	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
intranasal corticosteroids	standard care/placebo								
		57833	Song	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
itraconazole	standard care/placebo								
	.,	36093, Liesenborgl	Liesenborghs	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
ivermectin	standard care/placebo								
Wermeetin	Standard care, placebo	Niaee	Niaee	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Ahmed	Ahmed	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias	probably low risk of bias
		Abdulamir_Rezai	Rezai	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias	probably low risk of bias	probably high risk of bias
		Gonzalez	Gonzalez	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		47181, Abd-Elsalam	Abd-Elsalam_3	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
leflunomide	standard care/placebo								
		13540	Wang_5	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
levamisole	standard care/placebo	37198, Roostaei Firoz	Roostaei Firozahad	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
		37130, 1100314111102	Roostaciiiozabaa	probably low risk of bias	10W H3K OF Bla3	low risk of blas	low risk of bids	probably low risk of bias	low risk of blas
lopinavir-ritonavir	lopinavir-ritonavir, ribavirir	n							
		10067, 2615	Huang_2	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
lopinavir-ritonavir	ribavirin								
		10067, 2615	Huang_2	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
lopinavir-ritonavir	standard care/placebo								
		330	Cao_1	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		14781, 14883	Horby_3	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
	1	.5632, Pan_lopinavir-rit			probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		45662, Ader_1 52697	Ader_1 Arabi	low risk of bias low risk of bias	probably high risk of bias probably high risk of bias	low risk of bias low risk of bias	low risk of bias low risk of bias	low risk of bias low risk of bias	low risk of bias low risk of bias
		3203,		1511 1151 01 0100	, attacky man risk of blus	12.11.11.11.01.01.01			1511 11517 01 0103
lopinavir-ritonavir, ribavirin	ribavirin								

		10067, 2615	Huang_2	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
lopinavir-ritonavir, ribavirin	standard care/placebo								
iopinavii-ritonavii, ribavii ii	standard care/placebo	46308_severe	Singh_3	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
mavrilimumab	standard care/placebo								
		36763	Cremer_2	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
melatonin	standard care/placebo								
		Farnoosh	Farnoosh	probably low risk of bias	low risk of bias	high risk of bias	low risk of bias	probably high risk of bias	low risk of bias
methylene blue	standard care/placebo								
		45012 Alamdari	Hamidi-Alamdari Alamdari	probably high risk of bias probably high risk of bias	probably high risk of bias probably high risk of bias	low risk of bias low risk of bias			
mupadolimab	standard care/placebo								
		Miller	Miller	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
nitazoxanide	standard care/placebo								
		50790, Blum	Blum	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
nitric oxide	standard care/placebo								
		Moni	Moni	low risk of bias	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
opaganib	standard care/placebo								
		Winthrop	Winthrop	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
pentoxifylline	standard care/placebo								
pentoxinyimie	Staridard care, pideebo	21098	Malonado	probably high risk of bias	probably high risk of bias	high risk of bias	low risk of bias	probably low risk of bias	low risk of bias
		67125	Azizi	probably low risk of bias	low risk of bias	high risk of bias	low risk of bias	low risk of bias	high risk of bias
polymerized type I collagen	standard care/placebo								
p - 7	,	Méndez-Flores	Méndez-Flores	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
probiotics	standard care/placebo								
products	staridard care, piaceso	68436	Ivashkin	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
progestorone	standard care/placebo								
progesterone	standard care/placebo	32075, Ghandehai	Ghandehari	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
proxalutamide	standard care/placebo	48943	Cadegiani_5	high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		46943	Cauegiani_5	High risk of plas	probably high risk of bias	IOW TISK OF DIAS	IOW TISK OF DIAS	IOW HSK OF DIAS	IOW TISK OF DIdS
pyridostigmine	standard care/placebo								
		Fragoso-Saavedra	Fragoso-Saavedra	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias	probably low risk of bias
quercetin	standard care/placebo								
		49941	Di Pierro_1	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
nt human granulocyte colony-stimula	standard care/placebo								
ne naman granalocyte colony stimula	standard care, placebo	12705	Cheng	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
remdesivir	standard care/placebo	2408	Wang_1	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		11347	Spinner	low risk of bias	high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
		15633, 3821	Beigel	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		15632, Pan_remdes Ader (remdesivir)	Pan_remdesivir Ader_2	low risk of bias low risk of bias	probably high risk of bias probably high risk of bias	low risk of bias low risk of bias			
		68059	Abd-Elsalam_4	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	probably high risk of bias
ribavirin, sofosbuvir-daclatasvir	standard care/placebo								
TIDAVITII, SOIOSDUVII-UACIAIASVII	stariuaru care/pidce00	11010	Kasgari	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	probably low risk of bias
secukinumab	standard care/placebo	Resende	Resende	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		nesenue	nesenue	Propably High lisk of plas	probably high risk of bids	IOW HISK OF DIdS	IOW HISK OF DIGS	IOW HISK OF DIAS	IOW HISK OF DIdS
serine protease inhibitors	standard care/placebo								

		40853 70176	Gunst Zhuravel	low risk of bias low risk of bias	low risk of bias probably high risk of bias	low risk of bias low risk of bias	low risk of bias low risk of bias	low risk of bias low risk of bias	low risk of bias probably low risk of bias
sildenafil	standard care/placebo								
		Santamarina	Santamarina	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
sitagliptin	sitagliptin, spironolactone								
		Abbasi	Abbasi	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
sitagliptin	spironolactone								
		Abbasi	Abbasi	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
sitagliptin	standard care/placebo								
		Abbasi	Abbasi	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
sitagliptin, spironolactone	spironolactone	Abbasi	Abbasi	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
		Abbasi	Abbasi	probably flight fisk of bias	probably flight fisk of blas	IOW HISK OF DIAS	IOW HISK OF DIAS	probably low risk of bias	IOW HISK OF DIAS
sitagliptin, spironolactone	standard care/placebo								
		Abbasi	Abbasi	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
spironolactone	standard care/placebo								
		Abbasi	Abbasi	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
statins	standard care/placebo								
		Ghati	Ghati	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		64621	Davoodi_2	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias	probably low risk of bias
sulodexide	standard care/placebo								
		21816, 34575	Gonzalez-Ochoa	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
tyrosine kinase inhibitors	standard care/placebo								
		49287	Aman	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias	probably high risk of bias
umifenovir	standard care/placebo								
dimenovii	standard care, placebo	24810	Yadegarinia	high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably high risk of bias	low risk of bias
		35511	Khodashahi	probably low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
		52841	Darazam_3	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
vitamin C	standard care/placebo								
		26123, Zhang	Zhang_1	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias	probably high risk of bias
		25793	Kumari	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
	3140)1, JamaliMoghadama	ımaliMoghadamSiahkal	i probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
vitamin C, vitamin E	standard care/placebo								
		68016	Hakamifard	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
vitamin D	standard care/placebo								
		18947, 31936	Murai	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		44830	Lakkireddy	high risk of bias	probably high risk of bias	high risk of bias	low risk of bias	low risk of bias	low risk of bias
		46627	Elamir	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
		68594	Maghbooli	low risk of bias	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias

ICU Length of Stay

				ICU	Length of Stay				
Treatment 1	Treatment 2	Trial	First author	Randomization	Deviations from the intended	Missing outcome data	Measurement of outcome	Selection of the reported	Other (Competing risks)
(acetyl)cysteine	standard care/placebo								
		13687	de Alencar	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
		48051	Taher	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
5-alpha reductase inhibitor	standard care/placebo								
		35590	Zarehoseinzade	probably low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
ACEi/ARB	calcium channel blockers								
		34054	Nouri-Vaskeh	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
								. ,	
GM-CSF inhibitor	standard care/placebo								
	.,	Patel_2	Patel_2	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		=	-						
IL1 inhibitors	standard care/placebo								
		Kyriazopoulou	Kyriazopoulou	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		, ,	, ,						
6 receptor antagonists, corticostero	id standard care/placebo								
	.,	47857	Hamed	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
				, , ,				. ,	
eptor antagonists, corticosteroids (s	ys standard care/placebo								
		33303, Rosas	Rosas	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
	333	04, Gordon_v1, Gord	Gordon_1	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		34439	Soin	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Rutgers	Rutgers	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
				, , 6	, , , , , , , , , , , , , , , , , , , ,			,,	
JAK inhibitors	standard care/placebo								
		2263, Marconi, Marco	Marconi	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		48879	Guimarães	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
	Flv. WHO COV-B	ARRIER Addendum,	Ely	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
	_,,,	,	/		1011 11011 011 0110				
TNF inhibitors	standard care/placebo								
	,,,	52260	Fakharian	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
				, , 6	, , , , , , , , , , , , , , , , , , , ,				
antihepaciviral	standard care/placebo								
·	.,	29517	Nourian	low risk of bias	high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
								. ,	
azithromycin	standard care/placebo								
,	.,	11639, 12378	Sekhavati	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
				, , ,				. ,	
bradykinin inhibitors	standard care/placebo								
,	.,	10832	Mansour	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	probably low risk of bias
bromhexine hydrochloride	standard care/placebo								
,	.,	35697	Tolouian	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	probably high risk of bias
				, , ,				. ,	
colchicine	standard care/placebo								
		10500, xx	Lopes_2	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias	probably low risk of bias
		64385	Pascual-Figal	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
			<u>.</u>						
corticosteroids (systemic)	standard care/placebo								
		12146	Angus	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		2	Farahani	probably low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
		31583	Jamaati	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
full-dose anticoagulation	standard care/placebo								
		35895, Bikdeli	Bikdeli	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
ull-dose anticoagulation, thromboly	si standard care/placebo								
-		65552_P1	Barrett_P1	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
		65552_P2	Barrett_P2	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	probably high risk of bias
		_	_						
hydroxychloroquine	ıydroxychloroquine, lopinavir-ritor	navir							
		52697	Arabi	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
								<u> </u>	
hydroxychloroquine	lopinavir-ritonavir								

		52697	Arabi	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
hydroxychloroquine	standard care/placebo								
nydroxychioroquine	standard care/placebo	41434	Réa-Neto	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		52697	Arabi	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
ydroxychloroquine, lopinavir-ritonavi	lopinavir-ritonavir								
		52697	Arabi	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
ydroxychloroquine, lopinavir-ritonavi	standard care/placebo								
, , , , , ,		52697	Arabi	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
interferon beta	standard care/placebo								
	, p	11541, 11937	Rahmani	probably high risk of bias	probably high risk of bias	high risk of bias	low risk of bias	probably low risk of bias	low risk of bias
		11243, 5514, 824	Davoudi-Monfared	low risk of bias	high risk of bias	probably high risk of bias	low risk of bias	probably low risk of bias	probably high risk of bias
itraconazole	standard care/placebo								
		36093, Liesenborgl	Liesenborghs	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
lopinavir-ritonavir	standard care/placebo								
		330	Cao_1	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
		52697	Arabi	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
melatonin, vitamin C, zinc sulfate	standard care/placebo								
		61784	Darban	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
nitric oxide	standard care/placebo								
		Moni	Moni	low risk of bias	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
pentoxifylline	standard care/placebo								
p		67125	Azizi	probably low risk of bias	low risk of bias	high risk of bias	low risk of bias	probably low risk of bias	low risk of bias
ribavirin, sofosbuvir-daclatasvir	standard care/placebo								
Tibavitti, solosbuvii-uaciatasvii	stanuaru care/piaceoo	11010	Kasgari	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
					product, ingion and				
secukinumab	standard care/placebo								
	standard care/placebo		Resende	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
secukinumab sildenafil	standard care/placebo	Resende	Resende	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Resende Santamarina e	Resende Santamarina	probably high risk of bias	probably high risk of bias	low risk of bias probably low risk of bias	low risk of bias	low risk of bias probably low risk of bias	low risk of bias
sildenafil	standard care/placebo	Resende Santamarina	Resende	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
sildenafil	standard care/placebo	Resende Santamarina e	Resende Santamarina	probably high risk of bias	probably high risk of bias	low risk of bias probably low risk of bias	low risk of bias	low risk of bias probably low risk of bias probably low risk of bias	low risk of bias low risk of bias probably low risk of bias
sildenafil sitagliptin	standard care/placebo	Resende Santamarina e	Resende Santamarina	probably high risk of bias	probably high risk of bias	low risk of bias probably low risk of bias	low risk of bias	low risk of bias probably low risk of bias	low risk of bias
sildenafil sitagliptin	standard care/placebo	Resende Santamarina e Abbasi	Resende Santamarina Abbasi	probably high risk of bias low risk of bias probably high risk of bias	probably high risk of bias low risk of bias probably high risk of bias	low risk of bias probably low risk of bias low risk of bias	low risk of bias low risk of bias low risk of bias	low risk of bias probably low risk of bias probably low risk of bias	low risk of bias low risk of bias probably low risk of bias
sildenafil sitagliptin sitagliptin	standard care/placebo sitagliptin, spironolacton spironolactone	Resende Santamarina e Abbasi	Resende Santamarina Abbasi	probably high risk of bias low risk of bias probably high risk of bias	probably high risk of bias low risk of bias probably high risk of bias	low risk of bias probably low risk of bias low risk of bias	low risk of bias low risk of bias low risk of bias	low risk of bias probably low risk of bias probably low risk of bias	low risk of bias low risk of bias probably low risk of bias
sildenafil sitagliptin sitagliptin sitagliptin	standard care/placebo sitagliptin, spironolacton spironolactone standard care/placebo	Resende Santamarina e Abbasi Abbasi	Resende Santamarina Abbasi Abbasi	probably high risk of bias low risk of bias probably high risk of bias probably high risk of bias	probably high risk of bias low risk of bias probably high risk of bias probably high risk of bias	low risk of bias probably low risk of bias low risk of bias low risk of bias	low risk of bias low risk of bias low risk of bias	low risk of bias probably low risk of bias probably low risk of bias probably low risk of bias	low risk of bias low risk of bias probably low risk of bias probably low risk of bias
sildenafil sitagliptin sitagliptin	standard care/placebo sitagliptin, spironolacton spironolactone	Resende Santamarina e Abbasi Abbasi	Resende Santamarina Abbasi Abbasi	probably high risk of bias low risk of bias probably high risk of bias probably high risk of bias	probably high risk of bias low risk of bias probably high risk of bias probably high risk of bias	low risk of bias probably low risk of bias low risk of bias low risk of bias	low risk of bias low risk of bias low risk of bias	low risk of bias probably low risk of bias probably low risk of bias probably low risk of bias	low risk of bias low risk of bias probably low risk of bias probably low risk of bias
sildenafil sitagliptin sitagliptin sitagliptin sitagliptin	standard care/placebo sitagliptin, spironolacton spironolactone standard care/placebo spironolactone	Resende Santamarina e Abbasi Abbasi	Resende Santamarina Abbasi Abbasi	probably high risk of bias low risk of bias probably high risk of bias probably high risk of bias probably high risk of bias	probably high risk of bias low risk of bias probably high risk of bias probably high risk of bias probably high risk of bias	low risk of bias probably low risk of bias low risk of bias low risk of bias	low risk of bias low risk of bias low risk of bias low risk of bias	probably low risk of bias	low risk of bias low risk of bias probably low risk of bias probably low risk of bias probably low risk of bias
sildenafil sitagliptin sitagliptin sitagliptin	standard care/placebo sitagliptin, spironolacton spironolactone standard care/placebo	Resende Santamarina e Abbasi Abbasi	Resende Santamarina Abbasi Abbasi	probably high risk of bias low risk of bias probably high risk of bias probably high risk of bias probably high risk of bias	probably high risk of bias low risk of bias probably high risk of bias probably high risk of bias probably high risk of bias	low risk of bias probably low risk of bias low risk of bias low risk of bias	low risk of bias low risk of bias low risk of bias low risk of bias	probably low risk of bias	low risk of bias low risk of bias probably low risk of bias probably low risk of bias probably low risk of bias
sildenafil sitagliptin sitagliptin sitagliptin sitagliptin sitagliptin, spironolactone	standard care/placebo sitagliptin, spironolacton spironolactone standard care/placebo spironolactone standard care/placebo	Resende Santamarina e Abbasi Abbasi Abbasi	Resende Santamarina Abbasi Abbasi Abbasi	probably high risk of bias low risk of bias probably high risk of bias	probably high risk of bias low risk of bias probably high risk of bias	low risk of bias probably low risk of bias low risk of bias low risk of bias low risk of bias	low risk of bias	probably low risk of bias	low risk of bias low risk of bias probably low risk of bias
sildenafil sitagliptin sitagliptin sitagliptin sitagliptin	standard care/placebo sitagliptin, spironolacton spironolactone standard care/placebo spironolactone	Resende Santamarina e Abbasi Abbasi Abbasi Abbasi	Resende Santamarina Abbasi Abbasi Abbasi Abbasi	probably high risk of bias low risk of bias probably high risk of bias	probably high risk of bias low risk of bias probably high risk of bias	low risk of bias probably low risk of bias	low risk of bias	probably low risk of bias	low risk of bias low risk of bias probably low risk of bias
sildenafil sitagliptin sitagliptin sitagliptin sitagliptin, spironolactone sitagliptin, spironolactone	standard care/placebo sitagliptin, spironolactone spironolactone standard care/placebo spironolactone standard care/placebo standard care/placebo	Resende Santamarina e Abbasi Abbasi Abbasi Abbasi Abbasi	Resende Santamarina Abbasi Abbasi Abbasi	probably high risk of bias low risk of bias probably high risk of bias	probably high risk of bias low risk of bias probably high risk of bias	low risk of bias probably low risk of bias low risk of bias low risk of bias low risk of bias	low risk of bias	probably low risk of bias	low risk of bias low risk of bias probably low risk of bias
sildenafil sitagliptin sitagliptin sitagliptin sitagliptin sitagliptin, spironolactone	standard care/placebo sitagliptin, spironolacton spironolactone standard care/placebo spironolactone standard care/placebo	Resende Santamarina e Abbasi Abbasi Abbasi Abbasi Abbasi	Resende Santamarina Abbasi Abbasi Abbasi Abbasi Abbasi	probably high risk of bias low risk of bias probably high risk of bias	probably high risk of bias low risk of bias probably high risk of bias	low risk of bias probably low risk of bias	low risk of bias	probably low risk of bias	low risk of bias low risk of bias probably low risk of bias
sildenafil sitagliptin sitagliptin sitagliptin sitagliptin, spironolactone sitagliptin, spironolactone	standard care/placebo sitagliptin, spironolactone spironolactone standard care/placebo spironolactone standard care/placebo standard care/placebo	Resende Santamarina e Abbasi Abbasi Abbasi Abbasi Abbasi	Resende Santamarina Abbasi Abbasi Abbasi Abbasi	probably high risk of bias low risk of bias probably high risk of bias	probably high risk of bias low risk of bias probably high risk of bias	low risk of bias probably low risk of bias	low risk of bias	probably low risk of bias	low risk of bias low risk of bias probably low risk of bias
sildenafil sitagliptin sitagliptin sitagliptin sitagliptin, spironolactone sitagliptin, spironolactone spironolactone tyrosine kinase inhibitors	standard care/placebo sitagliptin, spironolactone spironolactone standard care/placebo spironolactone standard care/placebo standard care/placebo standard care/placebo	Resende Santamarina e Abbasi Abbasi Abbasi Abbasi Abbasi	Resende Santamarina Abbasi Abbasi Abbasi Abbasi Abbasi Abbasi	probably high risk of bias low risk of bias probably high risk of bias	probably high risk of bias low risk of bias probably high risk of bias low risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias low risk of bias probably low risk of bias low risk of bias
sildenafil sitagliptin sitagliptin sitagliptin sitagliptin, spironolactone sitagliptin, spironolactone	standard care/placebo sitagliptin, spironolactone spironolactone standard care/placebo spironolactone standard care/placebo standard care/placebo	Resende Santamarina e Abbasi Abbasi Abbasi Abbasi Abbasi 49287 60872	Resende Santamarina Abbasi Abbasi Abbasi Abbasi Abbasi Abbasi Arman Strich	probably high risk of bias low risk of bias probably high risk of bias	probably high risk of bias low risk of bias probably high risk of bias low risk of bias low risk of bias	low risk of bias low risk of bias	low risk of bias	probably low risk of bias low risk of bias low risk of bias	low risk of bias low risk of bias probably low risk of bias low risk of bias low risk of bias
sildenafil sitagliptin sitagliptin sitagliptin sitagliptin, spironolactone sitagliptin, spironolactone stagliptin, spironolactone tyrosine kinase inhibitors	standard care/placebo sitagliptin, spironolactone spironolactone standard care/placebo spironolactone standard care/placebo standard care/placebo standard care/placebo standard care/placebo	Resende Santamarina e Abbasi Abbasi Abbasi Abbasi Abbasi 49287 60872	Resende Santamarina Abbasi Abbasi Abbasi Abbasi Abbasi Abbasi Zhang_1	probably high risk of bias low risk of bias probably high risk of bias	probably high risk of bias low risk of bias probably high risk of bias low risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias low risk of bias probably low risk of bias low risk of bias

vitamin D	standard care/placebo								
		68595	Maghbooli	low risk of bias	low risk of bias	probably high risk of bias	low risk of bias	probably low risk of bias	low risk of bias

Ventilator-Free Days

					lator-Free Days				
Treatment 1	Treatment 2	Trial	First author	Randomization	Deviations from the intended	Missing outcome data	Measurement of outcome	Selection of the reported	Other (Competing risks)
(acetyl)cysteine	standard care/placebo								
		48051	Taher	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
ACEi/ARB	standard care/placebo								
		Puskarich_inpatien	Puskarich_2	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably high risk of bias	low risk of bias
eptor antagonists, corticosteroids (sys	standard care/placebo								
		33303, Rosas	Rosas	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
	33	3304, Gordon_v1, Gorc	Gordon_1	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		27470	Veiga	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		34439	Soin	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
				,, 0	,, 6				
JAK inhibitors	standard care/placebo								
	• • • • • • • • • • • • • • • • • • • •	62263, Marconi, Marco	Marconi	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		-BARRIER Addendum,	Ely	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
	2.7, 11.10_001	b, miner_, tadendam,	,	IOW FISH OF ENDS	10 W FISK OF Elds	10 W TISK OF BIGS	ion risk of sids	1011 11311 01 2123	1011 11311 01 5165
azithromycin	hydroxychloroquine								
uzitinomyem	nyaroxyemoroquine	18375	Brown	low risk of bias	high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		10373	biowii	1044 115K 01 15la3	riigii risk or blus	IOW FISH OF BIAS	IOW FISH OF BIAS	low hisk of bias	low risk of bias
azithromycin	standard care/placebo								
azitiii olliyelli	stanuaru care/piace00	12439	Furtado	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		12433	Turtado	IOW HISK OF BIAS	probably night risk of bias	IOW FISH OF DIAS	IOW FISK OF BIAS	IOW HISK OF BIAS	IOW HISK OF BIAS
corticosteroids (systemic)	standard care/placebo								
corticosteroias (systemic)	standard care/placebo	12141	Tomazini	low risk of bias	archable high sigh of high	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		12141	TOTTIAZITII	IOW FISK OF DIAS	probably high risk of bias	IOW FISK OF DIAS	IOW FISK OF DIAS	IOW FISK OF DIAS	IOW FISK OF DIAS
full dans autieses daties	stonderd sons/aleasha								
full-dose anticoagulation	standard care/placebo	42026	1	land data of the c	and all the date of the	Lancada District	Laure state of lates	land dale of his a	and all the state of the
		13836	Lemos	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		35895, Bikdeli	Bikdeli	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Sholzberg	Sholzberg	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
ull-dose anticoagulation, thrombolysi	standard care/placebo								
		65552_P1	Barrett_P1	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		65552_P2	Barrett_P2	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
hydroxychloroquine iyo	froxychloroquine, lopinavir-rit								
		52697	Arabi	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably high risk of bias	low risk of bias
hydroxychloroquine ii	nterferon beta, lopinavir-riton								
		45662, Ader_1	Ader_1	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
hydroxychloroquine	lopinavir-ritonavir								
		45662, Ader_1	Ader_1	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		52697	Arabi	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably high risk of bias	low risk of bias
hydroxychloroquine	standard care/placebo								
		45662, Ader_1	Ader_1	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		41434	Réa-Neto	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		52697	Arabi	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably high risk of bias	low risk of bias
ydroxychloroquine, lopinavir-ritonavi	lopinavir-ritonavir								
		52697	Arabi	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably high risk of bias	low risk of bias
ydroxychloroquine, lopinavir-ritonavi	standard care/placebo								
		52697	Arabi	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably high risk of bias	low risk of bias
interferon beta, lopinavir-ritonavir	lopinavir-ritonavir								
,		45662, Ader_1	Ader_1	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		/							
interferon beta, lopinavir-ritonavir	standard care/placebo								
	TIE. T. Sur C/ Procedo	45662, Ader_1	Ader_1	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		15002,71001_1	,,,,,,,	1011 1.01 01 0.03	p. 12 do. j ing. i ibi o. bias	.011 1101 01 0103	1011 1151 01 5105	1011-101-01-0100	1011-1011-01-0100
lopinavir-ritonavir	standard care/placebo								
Topinavii ritoriavii	standard care, pideebo	45662, Ader_1	Ader_1	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		52697	Auei_1 Arabi	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably high risk of bias	low risk of bias
		32037	Alabi	IOW HSK OF DIdS	probably high risk of blas	IOW HSK OF DIAS	IOW HSK OF DIAS	probably flight fish of blas	IOW HSK OF DIAS

remdesivir	standard care/placebo								
		Ader (remdesivir)	Ader_2	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
secukinumab	standard care/placebo								
		Resende	Resende	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
tyrosine kinase inhibitors	standard care/placebo								
		49287	Aman	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably high risk of bias	low risk of bias
vitamin C	standard care/placebo								
		26123, Zhang	Zhang_1	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias

Duration of Ventilation

				Durati	on of Ventilation				
Treatment 1	Treatment 2	Trial	First author	Randomization	Deviations from the intended	Missing outcome data	Measurement of outcome	Selection of the reported	Other (Competing risks)
5-alpha reductase inhibitor	standard care/placebo								
		35590	Zarehoseinzade	probably low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
IL1 inhibitors	standard care/placebo								
		54072	Caricchio	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
IL6 receptor antagonists	siltuxumab								
120 1000 providence		OV-AID NCT0433063	OV-AID NCT04330638	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
			017.110.10.1330030_	iow risk of blus	probably ingit risk of bias	IOW FISH OF BIAS	iow risk or sids	ion risk or blus	ion risk or blus
IL6 receptor antagonists	standard care/placebo								
izo receptor antagonists	standard care, placebo	33303 B, Rosas	Rosas B	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		16283	Stone	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably high risk of bias
		27470_B	Veiga B	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		30638, 42046_B	Horby_5_B	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
	CORIA		IUNO-SARI-ICU_NCT043		probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
						low risk of bias	low risk of bias	low risk of bias	low risk of bias
			JNO-TOCI-ICU_NCT0433		probably high risk of bias				
			OV-AID_NCT04330638_		probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
	HMC	0-020-0224_NC1043.	0-020-0224_NC1043777	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably high risk of bias
6 receptor antagonists, corticosteroid	standard care/placebo								
		47857	Hamed	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
eptor antagonists, corticosteroids (sys	standard care/placebo								
		33303_A, Rosas	Rosas_A	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
	3330	04_A, Gordon_v1, Go	Gordon_1_A	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
	3330	04_B, Gordon_v1, Go	Gordon_1_B	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		27470_A	Veiga_A	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		30638, 42046_A	Horby 5 A	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		34439	Soin	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
	CORIMU	JNO-TOCI-ICU NCTO	JNO-TOCI-ICU_NCT0433		probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
			OV-AID NCT04330638		probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
			-020-0224 NCT043777		low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably high risk of bias
		Rutgers	Rutgers	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
		natgers	Matgers	probably ingliffix or bias	probably ingit risk of bias	IOW FISH OF BIAS	iow risk or sids	probably low risk or blus	ion risk or bias
JAK inhibitors	standard care/placebo								
JAK IIIIIDICOIS	standard care, placebo	4161	Cao_2	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	probably high risk of bias
		Kalil	Kalil	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		48879	Guimarães	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias	probably low risk of bias
	Flo. MUIO. COV.B								<u> </u>
	Ely, WHO_COV-B	BARRIER_Addendum,	Ely	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
antihepaciviral	standard care/placebo								
		45668	Sayad	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
corticosteroids (systemic)	standard care/placebo								
		12141	Tomazini	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
corticosteroids (systemic), tacrolimus	standard care/placebo								
		51435	Solanich	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
fluvoxamine	standard care/placebo								
		18818	Lenze	low risk of bias	low risk of bias	high risk of bias	low risk of bias	low risk of bias	low risk of bias
		70784, Reis_2	Reis_2	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
			-						
ull-dose anticoagulation, thrombolysi	standard care/placebo								
g,	.,,,	65552_P1	Barrett_P1	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
		65552_P2	Barrett_P2	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	probably high risk of bias
					,			,	,,
full-dose anticoagulation	standard care/placebo								
Tan dose and todgulation	standard care, placebo	47030	Lopes_3	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	probably high risk of bias
		- 7030	Lopes_5	IOW HISK OF DIGS	brongers might have of pigs	IOW HAR OF DIGS	IOW HISK OF DIGS	IOW HISK OF DIAS	probably high his or bids
hydroxychloroquine	standard care/placebo								
nyuroxyumoroquine	Standard care/ place00	29663	Hernandez-Cardenas	low risk of bias	low risk of bias	low risk of bias	low risk of bias	high risk of bias	low risk of bias
		23003	ricinanuez-Carueilas	IOW HISK OF DIAS	IOW HAR OF DIAS	IOW HISK UI DIAS	IOW HISK OF DIAS	riigii risk Ur bias	IOW LISK OF DIAS
interferon beta	standard care/placebo								
interieron beta	stanuaru care/piacebo	K-III a	Kelli 2	Januarial Addition	Januarial Addition	lass and the first	Januarial of the co	Januarial - Chiles	biob sist of the
		Kalil_2	Kalil_2	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	nigh risk of blas

		11243, 5514, 824	Davoudi-Monfared	low risk of bias	high risk of bias	probably high risk of bias	low risk of bias	probably low risk of bias	probably high risk of bias
itraconazole	standard care/placebo								
	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	36093, Liesenborgl	Liesenborghs	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
lopinavir-ritonavir	standard care/placebo								
		330	Cao_1	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
mavrilimumab	standard care/placebo								
		36763	Cremer_2	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
nitric oxide	standard care/placebo								
		Moni	Moni	low risk of bias	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	high risk of bias
pyridostigmine	standard care/placebo								
		Fragoso-Saavedra	Fragoso-Saavedra	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
remdesivir	standard care/placebo								
		2408	Wang_1	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		15633, 3821	Beigel	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		37778	Mahajan	high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
ribavirin, sofosbuvir-daclatasvir	standard care/placebo								
		11010	Kasgari	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
secukinumab	standard care/placebo								
		Resende	Resende	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
sildenafil	standard care/placebo								
		Santamarina	Santamarina	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
siltuxumab	standard care/placebo								
		COV-AID_NCT04330600	OV-AID_NCT04330638_I	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
tyrosine kinase inhibitors	standard care/placebo								
		49287	Aman	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably high risk of bias	low risk of bias
umifenovir	standard care/placebo								
		52841	Darazam_3	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
vitamin C	standard care/placebo								
		26123, Zhang	Zhang_1	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
vitamin D	standard care/placebo								
		18947, 31936	Murai	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias

Time to Symptom Resolution/Clinical Improvement Treatment 1 Treatment 2 Trial First author Randomization Deviations from the intended Missing outcome data Measurement of outcome Selection of the reported Other (Co.												
Treatment 1	Treatment 2	Trial	First author	Randomization	Deviations from the intended	Missing outcome data	Measurement of outcome	Selection of the reported	Other (Competing risks)			
2-deoxy-D-glucose	standard care/placebo											
		66751a 66751b	Narayan Bhatt Narayan Bhatt	probably high risk of bias probably high risk of bias	high risk of bias high risk of bias	low risk of bias low risk of bias	high risk of bias high risk of bias	low risk of bias low risk of bias	probably low risk of bias			
		007310	ivarayan bilatt	probably flight risk of bias	High risk of bias	IOW TISK OF DIAS	HIGH LISK OF DIAS	IOW HSK OF DIAS	probably low risk of bias			
5-alpha reductase inhibitor	standard care/placebo											
	19047, 33978,	Cadegiani, Cadegi	Cadegiani_1	probably low risk of bias	low risk of bias	high risk of bias	low risk of bias	probably low risk of bias	low risk of bias			
AXL inhibitor	standard care/placebo											
		Wilkinson	Wilkinson	low risk of bias	probably high risk of bias	low risk of bias	high risk of bias	low risk of bias	probably low risk of bias			
GM-CSF inhibitor	standard care/placebo											
GIVI CSI IIIIIISICOI	Standard care, placeso	Patel_2	Patel_2	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias			
		41974	Temesgen	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably high risk of bias	low risk of bias			
		47226a	Fisher_1	low risk of bias	probably high risk of bias	low risk of bias	high risk of bias	probably low risk of bias	low risk of bias			
IL1 inhibitors	standard care/placebo	25655	C	and the ball of the second of the second	Lance della of little	Lance State of Billion	Lance State of Library	and the land of the control	Laure dell' a Children			
		25655 54072	Cremer_1 Caricchio	probably low risk of bias low risk of bias	low risk of bias low risk of bias	low risk of bias low risk of bias	low risk of bias low risk of bias	probably low risk of bias low risk of bias	low risk of bias low risk of bias			
		34072	Cariccino	IOW HISK OF DIAS	IOW TISK OF DIAS	IOW HISK OF DIAS	IOW HISK OF DIAS	IOW HISK OF DIAS	IOW HISK OF DIAS			
IL6 receptor antagonists	standard care/placebo											
		11850	Wang_4	probably high risk of bias	probably high risk of bias	low risk of bias	high risk of bias	probably low risk of bias	probably low risk of bias			
		16283	Stone	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias			
		Talaschian	Talaschian	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias			
	standard seed following											
eptor antagonists, corticosteroids (sys	standard care/placebo	33303, Rosas	Rosas	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias			
		16340, 23643	Salama	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias			
		29298, 34438	Lescure	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias			
		34439	Soin	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias			
JAK inhibitors	standard care/placebo											
		4161	Cao_2	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias			
	6226	Kalil 63, Marconi, Marco	Kalil Marconi	low risk of bias low risk of bias	low risk of bias low risk of bias	low risk of bias low risk of bias	low risk of bias low risk of bias	low risk of bias low risk of bias	low risk of bias low risk of bias			
	0220	RUXCOVID	RUXCOVID	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias			
	Ely, WHO_COV-BAR		Ely	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias			
rate, N-acetylcysteine, nicotinamide r	standard care/placebo											
		14670	Altay	probably high risk of bias	probably high risk of bias	low risk of bias	high risk of bias	probably low risk of bias	low risk of bias			
NSAID, azithromycin	NSAID, azithromycin, corticosteroid											
NSAID, azitiiloiliyciii	NSAID, azitilioniyciii, corticosteroid	64198	Ghanei	low risk of bias	probably high risk of bias	low risk of bias	high risk of hias	probably low risk of bias	low risk of bias			
		0.130	Gildilei	10W HSK OF Blas	producty mgm tisk of blus	1011 1131 01 5143	mgii riok or bido	productly four risk of bids	1011 TISK OF BIGS			
NSAID, azithromycin	lopinavir-ritonavir											
		64198	Ghanei	low risk of bias	probably high risk of bias	low risk of bias	high risk of bias	probably low risk of bias	low risk of bias			
NSAID, azithromycin, corticosteroid	lopinavir-ritonavir	C4100	Chanai	law sists of hims	and habit high sigh of high	lass siels of bine	high sigh of high	and bable last side of bins	lass state of bine			
		64198	Ghanei	low risk of bias	probably high risk of bias	low risk of bias	high risk of bias	probably low risk of bias	low risk of bias			
NSAIDs	paracetamol											
		Ravichandran	Ravichandran	probably high risk of bias	probably high risk of bias	low risk of bias	high risk of bias	low risk of bias	low risk of bias			
TNF inhibitors	standard care/placebo											
		47226b	Fisher_2	low risk of bias	probably high risk of bias	high risk of bias	high risk of bias	probably low risk of bias	low risk of bias			
antihepaciviral	romycin, hydroxychloroquine, oselta	amivir										
апинерацинан	romyon, nyaroxyonioroquine, oseita	44111	Elgohary	low risk of bias	probably high risk of bias	low risk of bias	high risk of bias	probably high risk of bias	low risk of bias			
			2.50,	TOTAL TIDAL OF DIAG	p. 13001 mgm ms. C. blus	.on risk of bids	Tilgit 113k Ct Dius	p. 23001 mgi non or blus	1011 1131 01 3143			
antihepaciviral	standard care/placebo											
		11065	Sadeghi	probably high risk of bias	high risk of bias	low risk of bias	low risk of bias	probably high risk of bias	low risk of bias			
		Yakoot	Yakoot	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias			
		29517	Nourian	low risk of bias	high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias			
		45668	Sayad	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias			
artemisinin	standard care/placebo											
ai terinisiiiii	Standard care/ praceso											

			Trieu	probably high risk of bias	probably high risk of bias	low risk of bias	high risk of bias	low risk of bias	low risk of bias
azithromycin	clarithromycin								
aziem em yem	ciantin omycin	58017	Rashad_1	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably high risk of bias	low risk of bias
azithromycin	hydroxychloroquine								
22	,,	18375	Brown	low risk of bias	high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
azithromycin	standard care/placebo								
		34434 ::II 58017	PLE Trial Collaborative (Rashad_1	low risk of bias low risk of bias	probably high risk of bias probably high risk of bias	low risk of bias low risk of bias	high risk of bias low risk of bias	low risk of bias probably high risk of bias	low risk of bias low risk of bias
azithromycin, hydroxychloroquine	hydroxychloroquine								
		33489, Johnston	Johnston	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
azithromycin, hydroxychloroquine	standard care/placebo								
		33489, Johnston	Johnston	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
baloxavir marboxil	favipiravir								
		2637, Lou, Lou (1	Lou	low risk of bias	probably high risk of bias	low risk of bias	high risk of bias	probably low risk of bias	low risk of bias
baloxavir marboxil	standard care/placebo								
		2637, Lou, Lou (1	Lou	low risk of bias	probably high risk of bias	low risk of bias	high risk of bias	probably low risk of bias	low risk of bias
bromhexine hydrochloride	hydroxychloroquine								
,	, , ,	12212	Li_3	low risk of bias	probably high risk of bias	low risk of bias	high risk of bias	high risk of bias	probably low risk of bias
		12212	Li_3	low risk of bias	probably high risk of bias	low risk of bias	high risk of bias	high risk of bias	probably low risk of bias
		27338a (moderate 27338a (moderate	Li_3 Li_3	probably high risk of bias probably high risk of bias	probably high risk of bias probably high risk of bias	low risk of bias low risk of bias	low risk of bias low risk of bias	low risk of bias low risk of bias	probably low risk of bias probably low risk of bias
		27338b (severe)	Li_3	probably high risk of bias	probably high risk of bias	high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		27338b (severe)		probably high risk of bias	probably high risk of bias	high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
bromhexine hydrochloride	standard care/placebo								
	, , , , , , , , , , , , , , , , , , ,	12212	Li_3	low risk of bias	probably high risk of bias	low risk of bias	high risk of bias	high risk of bias	probably low risk of bias
		27338a (moderate	Li_3	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		27338b (severe) 35697	Li_3 Tolouian	probably high risk of bias probably high risk of bias	probably high risk of bias probably high risk of bias	high risk of bias probably low risk of bias	low risk of bias low risk of bias	low risk of bias probably low risk of bias	probably low risk of bias low risk of bias
		33037	roiodian	probably flight fisk of blas	probably high risk of bias	probably low risk of bias	IOW TISK OF DIAS	probably low risk of bias	IOW HISK OF DIAS
cium release-activated calcium inhibi	mupadolimab								
		10964 Miller	Miller Miller	probably high risk of bias probably low risk of bias	high risk of bias low risk of bias	low risk of bias low risk of bias	low risk of bias probably low risk of bias	probably high risk of bias probably low risk of bias	low risk of bias low risk of bias
		······c·	······c·	producty to the risk of bids	TOW TISK OF SIGS	10 W 115K OT DIGS	probably low risk or blus	probably low risk or blus	TOW TISK OF DIGS
cium release-activated calcium inhibi	standard care/placebo								
		10964 10964	Miller Miller	probably high risk of bias probably high risk of bias	high risk of bias high risk of bias	low risk of bias low risk of bias	low risk of bias low risk of bias	probably high risk of bias probably high risk of bias	low risk of bias low risk of bias
		Miller	Miller	probably low risk of bias	low risk of bias	low risk of bias	probably low risk of bias	probably low risk of bias	low risk of bias
		Miller	Miller	probably low risk of bias	low risk of bias	low risk of bias	probably low risk of bias	probably low risk of bias	low risk of bias
cannabidiol	standard care/placebo								
		66954	Crippa	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
cefepime	ceftazidime								
		70011	Eid	probably high risk of bias	probably high risk of bias	low risk of bias	high risk of bias	probably low risk of bias	low risk of bias
cefepime	standard care/placebo								
	, p. 10000	70011	Eid	probably high risk of bias	probably high risk of bias	low risk of bias	high risk of bias	probably low risk of bias	low risk of bias
coftonidime	standard sare (aless)								
ceftazidime	standard care/placebo	70011	Eid	probably high risk of bias	probably high risk of bias	low risk of bias	high risk of bias	probably low risk of bias	low risk of bias
clarithromycin	standard care/placebo	58017	Rashad_1	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably high risk of bias	low risk of bias
		30017	Na31144_1	TOW FISH OF DIGS	producty high has of bias	10W HSK OF Blas	1047 1131 01-11113	producty high has of blas	10W HISK OF DIAS
colchicine	standard care/placebo								
		64351 64385	Dorward Pascual-Figal	low risk of bias low risk of bias	probably high risk of bias probably high risk of bias	low risk of bias low risk of bias	high risk of bias low risk of bias	low risk of bias probably low risk of bias	low risk of bias probably high risk of bias
		04363	i ascuai-i igai	TOW TISK OF DIGS	bronanty mgm nak of pids	10W HSK OF DIAS	IOW HISK OF DIAS	Progably low risk of plas	bronanty mgm nak of plas

corticosteroids (systemic)	standard care/placebo								
		13208	Edalatifard	probably high risk of bias	probably high risk of bias	probably high risk of bias	probably low risk of bias	probably low risk of bias	low risk of bias
		27643	Tang_2	probably low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	probably high risk of bias
corticosteroids (systemic), tacrolimus	s standard care/placebo								
		51435	Solanich	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
doxycycline	standard care/placebo								
		55459, Butler_doxycly	Butler	low risk of bias	probably high risk of bias	low risk of bias	high risk of bias	low risk of bias	probably low risk of bias
doxycycline, ivermectin	standard care/placebo								
		43517	Mahmud	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
electrolyzed saline	standard care/placebo								
		13074, 53789	Delgado-Enciso	probably high risk of bias	probably high risk of bias	low risk of bias	high risk of bias	probably low risk of bias	low risk of bias
enisamium	standard care/placebo								
		26217	Holubovska	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
favipiravir	lopinavir-ritonavir								
- P - P	4	35903	Solaymani-Dodaran	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
					process, inglition of also				process, ion rion or also
favipiravir	standard care/placebo								
F		2637, Lou, Lou (1	Lou	low risk of bias	probably high risk of bias	low risk of bias	high risk of bias	probably low risk of bias	low risk of bias
		10147, 10287, 997	Ivashchenko	probably high risk of bias	high risk of bias	low risk of bias	high risk of bias	low risk of bias	low risk of bias
		32588	Ruzhentsova	probably high risk of bias	probably high risk of bias	low risk of bias	high risk of bias	low risk of bias	probably low risk of bias
		24988, Udwadia	Udwadia	probably high risk of bias	probably high risk of bias	low risk of bias	high risk of bias	low risk of bias	low risk of bias
		27459	Balykova_1	probably high risk of bias	high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
		32586	Balykova 2	low risk of bias	probably high risk of bias	low risk of bias	high risk of bias	low risk of bias	low risk of bias
			,		process, inglition of also				
favipiravir	umifenovir								
		173	Chen_2	probably high risk of bias	probably high risk of bias	low risk of bias	high risk of bias	low risk of bias	low risk of bias
			*	process, mg	process, mg. nen er ane				
favipiravir, hydrochloroquine	standard care/placebo								
		Bosaeed	Bosaeed	low risk of bias	probably high risk of bias	low risk of bias	high risk of bias	low risk of bias	low risk of bias
		Bosaeed	Bosaeed	low risk of bias	probably high risk of bias	low risk of bias	high risk of bias	low risk of bias	low risk of bias
fluvoxamine	standard care/placeho	Bosaeed	Bosaeed	low risk of bias	probably high risk of bias	low risk of bias	high risk of bias	low risk of bias	low risk of bias
fluvoxamine	standard care/placebo						o de la companya de l		
fluvoxamine	standard care/placebo	Bosaeed 70784, Reis_2	Bosaeed Reis_2	low risk of bias	probably high risk of bias	low risk of bias	high risk of bias	low risk of bias	low risk of bias probably low risk of bias
							o de la companya de l		
fluvoxamine hydrogen peroxide	standard care/placebo	70784, Reis_2	Reis_2	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
							o de la companya de l		
hydrogen peroxide	standard care/placebo	70784, Reis_2 64234	Reis_2	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		70784, Reis_2 64234 navir	Reis_2 Di Domenico	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias probably low risk of bias
hydrogen peroxide	standard care/placebo	70784, Reis_2 64234	Reis_2	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
hydrogen peroxide hydroxychloroquine	standard care/placebo	70784, Reis_2 64234 navir	Reis_2 Di Domenico	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias probably low risk of bias
hydrogen peroxide	standard care/placebo	70784, Reis_2 64234 navir 45662, Ader_1	Reis_2 Di Domenico Ader_1	low risk of bias low risk of bias low risk of bias	low risk of bias low risk of bias probably high risk of bias	low risk of bias low risk of bias low risk of bias	low risk of bias low risk of bias high risk of bias	low risk of bias low risk of bias low risk of bias	probably low risk of bias probably low risk of bias low risk of bias
hydrogen peroxide hydroxychloroquine	standard care/placebo	70784, Reis_2 64234 navir 45662, Ader_1 pilot_4	Reis_2 Di Domenico Ader_1 Huang_1	low risk of bias low risk of bias low risk of bias probably high risk of bias	low risk of bias low risk of bias probably high risk of bias probably high risk of bias	low risk of bias low risk of bias low risk of bias	low risk of bias low risk of bias high risk of bias high risk of bias	low risk of bias low risk of bias low risk of bias probably low risk of bias	probably low risk of bias probably low risk of bias low risk of bias probably low risk of bias
hydrogen peroxide hydroxychloroquine	standard care/placebo	70784, Reis_2 64234 navir 45662, Ader_1	Reis_2 Di Domenico Ader_1	low risk of bias low risk of bias low risk of bias	low risk of bias low risk of bias probably high risk of bias	low risk of bias low risk of bias low risk of bias	low risk of bias low risk of bias high risk of bias	low risk of bias low risk of bias low risk of bias	probably low risk of bias probably low risk of bias low risk of bias
hydrogen peroxide hydroxychloroquine hydroxychloroquine	standard care/placebo interferon beta, lopinavir-riton lopinavir-ritonavir	70784, Reis_2 64234 navir 45662, Ader_1 pilot_4	Reis_2 Di Domenico Ader_1 Huang_1	low risk of bias low risk of bias low risk of bias probably high risk of bias	low risk of bias low risk of bias probably high risk of bias probably high risk of bias	low risk of bias low risk of bias low risk of bias	low risk of bias low risk of bias high risk of bias high risk of bias	low risk of bias low risk of bias low risk of bias probably low risk of bias	probably low risk of bias probably low risk of bias low risk of bias probably low risk of bias
hydrogen peroxide hydroxychloroquine	standard care/placebo	70784, Reis_2 64234 navir 45662, Ader_1 pilot_4 45662, Ader_1	Reis_2 Di Domenico Ader_1 Huang_1 Ader_1	low risk of bias low risk of bias low risk of bias probably high risk of bias	low risk of bias low risk of bias probably high risk of bias probably high risk of bias	low risk of bias low risk of bias low risk of bias	low risk of bias low risk of bias high risk of bias high risk of bias high risk of bias	low risk of bias low risk of bias low risk of bias probably low risk of bias	probably low risk of bias probably low risk of bias low risk of bias probably low risk of bias
hydrogen peroxide hydroxychloroquine hydroxychloroquine	standard care/placebo interferon beta, lopinavir-riton lopinavir-ritonavir	70784, Reis_2 64234 havir 45662, Ader_1 pilot_4 45662, Ader_1	Reis_2 Di Domenico Ader_1 Huang_1 Ader_1 Chen_1	low risk of bias low risk of bias low risk of bias probably high risk of bias low risk of bias probably low risk of bias	low risk of bias low risk of bias probably high risk of bias probably high risk of bias probably high risk of bias low risk of bias	low risk of bias	low risk of bias low risk of bias high risk of bias high risk of bias high risk of bias low risk of bias	low risk of bias low risk of bias low risk of bias probably low risk of bias low risk of bias probably low risk of bias	probably low risk of bias probably low risk of bias low risk of bias probably low risk of bias low risk of bias probably low risk of bias
hydrogen peroxide hydroxychloroquine hydroxychloroquine	standard care/placebo interferon beta, lopinavir-riton lopinavir-ritonavir	70784, Reis_2 64234 navir 45662, Ader_1 pilot_4 45662, Ader_1 434 3321, 776	Reis_2 Di Domenico Ader_1 Huang_1 Ader_1 Chen_1 Tang_1	low risk of bias low risk of bias low risk of bias probably high risk of bias low risk of bias low risk of bias	low risk of bias low risk of bias probably high risk of bias	low risk of bias	low risk of bias low risk of bias high risk of bias high risk of bias high risk of bias low risk of bias high risk of bias	low risk of bias low risk of bias low risk of bias probably low risk of bias low risk of bias probably low risk of bias low risk of bias	probably low risk of bias probably low risk of bias low risk of bias probably low risk of bias low risk of bias probably low risk of bias low risk of bias low risk of bias
hydrogen peroxide hydroxychloroquine hydroxychloroquine	standard care/placebo interferon beta, lopinavir-riton lopinavir-ritonavir	70784, Reis_2 64234 navir 45662, Ader_1 pilot_4 45662, Ader_1 434 3321, 776 C158	Reis_2 Di Domenico Ader_1 Huang_1 Ader_1 Chen_1 Tang_1 Chen_3	low risk of bias low risk of bias low risk of bias probably high risk of bias low risk of bias probably low risk of bias low risk of bias probably high risk of bias	low risk of bias low risk of bias probably high risk of bias probably high risk of bias low risk of bias probably high risk of bias probably high risk of bias	low risk of bias	low risk of bias low risk of bias high risk of bias high risk of bias high risk of bias low risk of bias high risk of bias high risk of bias high risk of bias	low risk of bias low risk of bias low risk of bias probably low risk of bias low risk of bias probably low risk of bias probably low risk of bias probably low risk of bias	probably low risk of bias probably low risk of bias low risk of bias probably low risk of bias low risk of bias probably low risk of bias low risk of bias low risk of bias
hydrogen peroxide hydroxychloroquine hydroxychloroquine	standard care/placebo interferon beta, lopinavir-riton lopinavir-ritonavir	70784, Reis_2 64234 navir 45662, Ader_1 pilot_4 45662, Ader_1 434 3321, 776 C158 6987	Reis_2 Di Domenico Ader_1 Huang_1 Ader_1 Chen_1 Tang_1 Chen_3 Chen_4	low risk of bias low risk of bias low risk of bias probably high risk of bias low risk of bias probably low risk of bias low risk of bias probably high risk of bias probably high risk of bias	low risk of bias low risk of bias probably high risk of bias	low risk of bias	low risk of bias low risk of bias high risk of bias high risk of bias high risk of bias high risk of bias high risk of bias high risk of bias high risk of bias high risk of bias	low risk of bias low risk of bias low risk of bias probably low risk of bias low risk of bias probably low risk of bias	probably low risk of bias low risk of bias probably low risk of bias low risk of bias probably low risk of bias
hydrogen peroxide hydroxychloroquine hydroxychloroquine	standard care/placebo interferon beta, lopinavir-riton lopinavir-ritonavir	70784, Reis_2 64234 havir 45662, Ader_1 pilot_4 45662, Ader_1 434 3321, 776 C158 6987 11299	Reis_2 Di Domenico Ader_1 Huang_1 Ader_1 Chen_1 Tang_1 Chen_3 Chen_4 Abd-Elsalam_1	low risk of bias low risk of bias low risk of bias probably high risk of bias low risk of bias low risk of bias probably low risk of bias probably high risk of bias probably high risk of bias probably high risk of bias	low risk of bias low risk of bias probably high risk of bias	low risk of bias	low risk of bias low risk of bias high risk of bias high risk of bias high risk of bias high risk of bias high risk of bias high risk of bias high risk of bias probably high risk of bias	low risk of bias low risk of bias low risk of bias probably low risk of bias low risk of bias probably low risk of bias probably low risk of bias probably low risk of bias probably low risk of bias probably low risk of bias probably low risk of bias	probably low risk of bias low risk of bias low risk of bias probably low risk of bias
hydrogen peroxide hydroxychloroquine hydroxychloroquine	standard care/placebo interferon beta, lopinavir-riton lopinavir-ritonavir	70784, Reis_2 64234 havir 45662, Ader_1 pilot_4 45662, Ader_1 434 3321, 776 C158 6987 11299 12212	Reis_2 Di Domenico Ader_1 Huang_1 Ader_1 Chen_1 Tang_1 Chen_3 Chen_4 Abd-Elsalam_1 Li_3	low risk of bias low risk of bias low risk of bias probably high risk of bias low risk of bias low risk of bias probably low risk of bias probably high risk of bias probably high risk of bias low risk of bias	low risk of bias low risk of bias probably high risk of bias	low risk of bias	low risk of bias low risk of bias high risk of bias high risk of bias high risk of bias high risk of bias high risk of bias high risk of bias high risk of bias high risk of bias	low risk of bias low risk of bias low risk of bias probably low risk of bias low risk of bias probably low risk of bias	probably low risk of bias low risk of bias low risk of bias probably low risk of bias probably low risk of bias probably low risk of bias
hydrogen peroxide hydroxychloroquine hydroxychloroquine	standard care/placebo interferon beta, lopinavir-riton lopinavir-ritonavir	70784, Reis_2 64234 navir 45662, Ader_1 pilot_4 45662, Ader_1 434 3321, 776 C158 6987 11299 12212 12212	Reis_2 Di Domenico Ader_1 Huang_1 Ader_1 Chen_1 Tang_1 Chen_3 Chen_4 Abd-Elsalam_1 Li_3 Li_3	low risk of bias low risk of bias low risk of bias probably high risk of bias low risk of bias probably low risk of bias probably high risk of bias probably high risk of bias probably high risk of bias low risk of bias	low risk of bias low risk of bias probably high risk of bias	low risk of bias	low risk of bias low risk of bias high risk of bias probably high risk of bias high risk of bias high risk of bias high risk of bias	low risk of bias low risk of bias low risk of bias probably low risk of bias low risk of bias probably low risk of bias high risk of bias high risk of bias	probably low risk of bias low risk of bias low risk of bias probably low risk of bias probably low risk of bias
hydrogen peroxide hydroxychloroquine hydroxychloroquine	standard care/placebo interferon beta, lopinavir-riton lopinavir-ritonavir	70784, Reis_2 64234 navir 45662, Ader_1 pilot_4 45662, Ader_1 434 3321, 776 C158 6987 11299 12212 12212 18245, 23358	Reis_2 Di Domenico Ader_1 Huang_1 Ader_1 Chen_1 Tang_1 Chen_3 Chen_4 Abd-Elsalam_1 Li_3 Li_3 Self	low risk of bias low risk of bias low risk of bias probably high risk of bias low risk of bias low risk of bias probably low risk of bias probably high risk of bias probably high risk of bias low risk of bias low risk of bias low risk of bias	low risk of bias low risk of bias probably high risk of bias low risk of bias	low risk of bias	low risk of bias low risk of bias high risk of bias high risk of bias high risk of bias high risk of bias high risk of bias high risk of bias high risk of bias high risk of bias high risk of bias high risk of bias liow risk of bias low risk of bias	low risk of bias low risk of bias low risk of bias probably low risk of bias low risk of bias probably low risk of bias high risk of bias ligh risk of bias low risk of bias	probably low risk of bias low risk of bias low risk of bias probably low risk of bias probably low risk of bias probably low risk of bias
hydrogen peroxide hydroxychloroquine hydroxychloroquine	standard care/placebo interferon beta, lopinavir-riton lopinavir-ritonavir	70784, Reis_2 64234 havir 45662, Ader_1 pilot_4 45662, Ader_1 434 3321, 776 C158 6987 11299 12212 12212 12212 18245, 23358 33489, Johnston	Reis_2 Di Domenico Ader_1 Huang_1 Ader_1 Chen_1 Tang_1 Chen_3 Chen_4 Abd-Elsalam_1 Li_3 Li_3 Self Johnston	low risk of bias low risk of bias low risk of bias probably high risk of bias low risk of bias low risk of bias probably low risk of bias probably high risk of bias probably high risk of bias low risk of bias low risk of bias low risk of bias low risk of bias probably low risk of bias probably low risk of bias	low risk of bias low risk of bias probably high risk of bias low risk of bias low risk of bias	low risk of bias	low risk of bias low risk of bias high risk of bias probably high risk of bias high risk of bias high risk of bias high risk of bias	low risk of bias low risk of bias low risk of bias probably low risk of bias low risk of bias probably low risk of bias high risk of bias high risk of bias low risk of bias probably low risk of bias	probably low risk of bias low risk of bias probably low risk of bias probably low risk of bias probably low risk of bias probably low risk of bias low risk of bias low risk of bias
hydrogen peroxide hydroxychloroquine hydroxychloroquine	standard care/placebo interferon beta, lopinavir-riton lopinavir-ritonavir	70784, Reis_2 64234 havir 45662, Ader_1 pilot_4 45662, Ader_1 434 3321, 776 C158 6987 11299 12212 12212 18245, 23358 33489, Johnston 45662, Ader_1	Reis_2 Di Domenico Ader_1 Huang_1 Ader_1 Chen_1 Tang_1 Chen_3 Chen_4 Abd-Elsalam_1 Li_3 Li_3 Self Johnston Ader_1	low risk of bias low risk of bias low risk of bias probably high risk of bias low risk of bias low risk of bias probably low risk of bias probably high risk of bias probably high risk of bias low risk of bias	low risk of bias low risk of bias probably high risk of bias low risk of bias probably high risk of bias probably high risk of bias probably high risk of bias	low risk of bias	low risk of bias low risk of bias high risk of bias high risk of bias high risk of bias high risk of bias high risk of bias high risk of bias probably high risk of bias high risk of bias low risk of bias low risk of bias low risk of bias	low risk of bias low risk of bias low risk of bias probably low risk of bias low risk of bias probably low risk of bias high risk of bias low risk of bias probably low risk of bias low risk of bias probably low risk of bias probably low risk of bias probably low risk of bias low risk of bias	probably low risk of bias low risk of bias low risk of bias probably low risk of bias probably low risk of bias probably low risk of bias low risk of bias low risk of bias low risk of bias
hydrogen peroxide hydroxychloroquine hydroxychloroquine	standard care/placebo interferon beta, lopinavir-riton lopinavir-ritonavir	70784, Reis_2 64234 havir 45662, Ader_1 pilot_4 45662, Ader_1 434 3321, 776 C158 6987 11299 12212 12212 18245, 23358 33489, Johnston 45662, Ader_1 29663	Reis_2 Di Domenico Ader_1 Huang_1 Ader_1 Chen_1 Tang_1 Chen_3 Chen_4 Abd-Elsalam_1 Li_3 Self Johnston Ader_1 Hernander_Cardenas	low risk of bias low risk of bias low risk of bias probably high risk of bias low risk of bias low risk of bias probably high risk of bias probably high risk of bias probably high risk of bias low risk of bias	low risk of bias low risk of bias probably high risk of bias low risk of bias probably high risk of bias low risk of bias	low risk of bias	low risk of bias low risk of bias high risk of bias high risk of bias high risk of bias high risk of bias high risk of bias high risk of bias high risk of bias high risk of bias low risk of bias	low risk of bias low risk of bias low risk of bias probably low risk of bias low risk of bias low risk of bias probably low risk of bias low risk of bias low risk of bias probably high risk of bias probably high risk of bias	probably low risk of bias low risk of bias low risk of bias probably low risk of bias probably low risk of bias
hydrogen peroxide hydroxychloroquine hydroxychloroquine	standard care/placebo interferon beta, lopinavir-riton lopinavir-ritonavir	70784, Reis_2 64234 navir 45662, Ader_1 pilot_4 45662, Ader_1 434 3321, 776 C158 6987 11299 12212 12212 18245, 23358 33489, Johnston 45662, Ader_1 29663 27338a (moderate	Reis_2 Di Domenico Ader_1 Huang_1 Ader_1 Chen_1 Tang_1 Chen_3 Chen_4 Abd-Elsalam_1 Li_3 Li_3 Self Johnston Ader_1 Hernandez-Cardenas Li_3 Li_3	low risk of bias low risk of bias low risk of bias probably high risk of bias low risk of bias low risk of bias probably low risk of bias probably high risk of bias probably high risk of bias low risk of bias probably low risk of bias low risk of bias probably low risk of bias probably low risk of bias low risk of bias	low risk of bias low risk of bias probably high risk of bias low risk of bias low risk of bias probably high risk of bias	low risk of bias	low risk of bias low risk of bias high risk of bias high risk of bias high risk of bias high risk of bias high risk of bias high risk of bias high risk of bias high risk of bias jow risk of bias low risk of bias	low risk of bias low risk of bias low risk of bias probably low risk of bias low risk of bias low risk of bias probably low risk of bias high risk of bias low risk of bias low risk of bias probably low risk of bias probably low risk of bias low risk of bias low risk of bias probably high risk of bias low risk of bias	probably low risk of bias low risk of bias low risk of bias probably low risk of bias probably low risk of bias
hydrogen peroxide hydroxychloroquine hydroxychloroquine	standard care/placebo interferon beta, lopinavir-riton lopinavir-ritonavir	70784, Reis_2 64234 havir 45662, Ader_1 pilot_4 45662, Ader_1 434 3321, 776 C158 6987 11299 12212 12213 18245, 23358 33489, Johnston 45662, Ader_1 29663 27338a (moderate 27338a (moderate	Reis_2 Di Domenico Ader_1 Huang_1 Ader_1 Chen_1 Tang_1 Chen_3 Chen_4 Abd-Esalam_1 Li_3 Li_3 Self Johnston Ader_1 Hernandez-Cardenas Li_3 Li_3 Li_3 Li_3 Li_3	low risk of bias low risk of bias low risk of bias probably high risk of bias low risk of bias low risk of bias probably low risk of bias probably high risk of bias probably high risk of bias low risk of bias low risk of bias low risk of bias low risk of bias probably high risk of bias	low risk of bias low risk of bias probably high risk of bias low risk of bias probably high risk of bias	low risk of bias	low risk of bias low risk of bias high risk of bias high risk of bias high risk of bias high risk of bias high risk of bias high risk of bias high risk of bias probably high risk of bias probably high risk of bias low risk of bias	low risk of bias low risk of bias low risk of bias probably low risk of bias low risk of bias probably low risk of bias high risk of bias high risk of bias low risk of bias probably low risk of bias probably low risk of bias low risk of bias probably low risk of bias	probably low risk of bias low risk of bias probably low risk of bias probably low risk of bias probably low risk of bias probably low risk of bias probably low risk of bias probably low risk of bias
hydrogen peroxide hydroxychloroquine hydroxychloroquine	standard care/placebo interferon beta, lopinavir-riton lopinavir-ritonavir	70784, Reis_2 64234 navir 45662, Ader_1 pilot_4 45662, Ader_1 434 3321, 776 C158 6987 11299 12212 12212 18245, 23358 33489, Johnston 45662, Ader_1 29663 27338a (moderate 27338b (severe)	Reis_2 Di Domenico Ader_1 Huang_1 Ader_1 Chen_1 Tang_1 Chen_3 Chen_4 Abd-Elsalam_1 i_3 Self Johnston Ader_1 Hernandez-Cardenas i_3 i_3 i_3 i_3 i_3 i_3 i_3 i_3	low risk of bias low risk of bias low risk of bias probably high risk of bias low risk of bias low risk of bias probably high risk of bias probably high risk of bias probably high risk of bias low risk of bias low risk of bias low risk of bias low risk of bias probably low risk of bias probably high risk of bias low risk of bias probably high risk of bias	low risk of bias low risk of bias probably high risk of bias low risk of bias low risk of bias probably high risk of bias	low risk of bias	low risk of bias low risk of bias high risk of bias probably high risk of bias high risk of bias low risk of bias	low risk of bias low risk of bias low risk of bias probably low risk of bias low risk of bias probably low risk of bias high risk of bias low risk of bias low risk of bias probably low risk of bias	probably low risk of bias low risk of bias low risk of bias probably low risk of bias probably low risk of bias probably low risk of bias
hydrogen peroxide hydroxychloroquine hydroxychloroquine	standard care/placebo interferon beta, lopinavir-riton lopinavir-ritonavir	70784, Reis_2 64234 navir 45662, Ader_1 pilot_4 45662, Ader_1 434 3321, 776 C158 6987 11299 12212 12212 18245, 23358 33489, Johnston 45662, Ader_1 29663 27338a (moderate 27338b (severe)	Reis_2 Di Domenico Ader_1 Huang_1 Ader_1 Chen_1 Tang_1 Chen_3 Chen_4 Abd-Elsalam_1 Li_3 Li_3 Self Johnston Ader_1 Hernandez-Cardenas Li_3 Li_3 Li_3 Li_3 Li_3 Li_3 Li_3 Li_3	low risk of bias low risk of bias low risk of bias probably high risk of bias low risk of bias low risk of bias probably high risk of bias probably high risk of bias probably high risk of bias low risk of bias low risk of bias low risk of bias low risk of bias probably low risk of bias probably low risk of bias probably high risk of bias	low risk of bias low risk of bias probably high risk of bias low risk of bias low risk of bias probably high risk of bias	low risk of bias high risk of bias high risk of bias	low risk of bias low risk of bias high risk of bias high risk of bias high risk of bias high risk of bias high risk of bias high risk of bias high risk of bias high risk of bias probably high risk of bias low risk of bias	low risk of bias low risk of bias low risk of bias probably low risk of bias low risk of bias low risk of bias probably low risk of bias	probably low risk of bias low risk of bias probably low risk of bias probably low risk of bias probably low risk of bias
hydrogen peroxide hydroxychloroquine hydroxychloroquine	standard care/placebo interferon beta, lopinavir-riton lopinavir-ritonavir	70784, Reis_2 64234 navir 45662, Ader_1 pilot_4 45662, Ader_1 434 3321, 776 C158 6987 11299 12212 12212 18245, 23358 33489, Johnston 45662, Ader_1 29663 27338a (moderate 27338b (severe)	Reis_2 Di Domenico Ader_1 Huang_1 Ader_1 Chen_1 Tang_1 Chen_3 Chen_4 Abd-Elsalam_1 i_3 Self Johnston Ader_1 Hernandez-Cardenas i_3 i_3 i_3 i_3 i_3 i_3 i_3 i_3	low risk of bias low risk of bias low risk of bias probably high risk of bias low risk of bias low risk of bias probably high risk of bias probably high risk of bias probably high risk of bias low risk of bias low risk of bias low risk of bias low risk of bias probably low risk of bias probably high risk of bias low risk of bias probably high risk of bias	low risk of bias low risk of bias probably high risk of bias low risk of bias low risk of bias probably high risk of bias	low risk of bias	low risk of bias low risk of bias high risk of bias probably high risk of bias high risk of bias low risk of bias	low risk of bias low risk of bias low risk of bias probably low risk of bias low risk of bias probably low risk of bias high risk of bias low risk of bias low risk of bias probably low risk of bias	probably low risk of bias low risk of bias low risk of bias probably low risk of bias probably low risk of bias probably low risk of bias

		Schwartz_2	Schwartz_2	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
ydroxychloroquine, lopinavir-ritonavi h	vdrovychloroguine umifenovii	r							
yuroxychioroquine, iopinavii-ittoriavi	yaroxycinoroquine, arimenovii	23259, 8	Nojomi	low risk of bias	probably high risk of bias	low risk of bias	high risk of bias	probably low risk of bias	low risk of bias
						_			
inhaled corticosteroids	standard care/placebo	29771, 38831	Ramakrishnan	probably high risk of bias	probably high risk of bias	low risk of bias	high risk of bias	probably low risk of bias	probably low risk of bias
		57300, Yu	Yu	probably low risk of bias	probably high risk of bias	low risk of bias	high risk of bias	low risk of bias	probably low risk of bias
Scholad ask Prodicts from horse de	standard confelencies								
inhaled nebulised interferon beta-1a	standard care/placebo	18657	Monk	low risk of bias	low risk of bias	high risk of bias	high risk of bias	low risk of bias	low risk of bias
						, and the second	,		
interferon alpha con	nbinant super combinant interf	feron 32737, 7, 9574	Li_2	probably high risk of bias	probably high risk of bias	low risk of bias	high risk of bias	low risk of bias	low risk of bias
		32/3/, /, 93/4	LI_Z	probably flight fisk of bias	probably flight risk of bias	IOW HSK OF DIAS	HIGH HSK OF DIAS	IOW HSK OF DIAS	IOW HSK OF DIAS
interferon alpha	standard care/placebo								
		59366, 60209	Bhushan	probably high risk of bias	probably high risk of bias	low risk of bias	high risk of bias	probably high risk of bias	probably high risk of bias
interferon beta	standard care/placebo					_			
		11541, 11937	Rahmani	probably high risk of bias	probably high risk of bias	high risk of bias	low risk of bias	probably low risk of bias	low risk of bias
		39381, Darazam (2 Kalil_2	Darazam_2 Kalil_2	low risk of bias low risk of bias	probably high risk of bias low risk of bias	low risk of bias low risk of bias	low risk of bias low risk of bias	low risk of bias low risk of bias	low risk of bias low risk of bias
			Davoudi-Monfared	low risk of bias	high risk of bias	probably high risk of bias	low risk of bias	probably low risk of bias	probably high risk of bias
total from the table to the decision to	Instanta de deservito								
interferon beta, lopinavir-ritonavir	lopinavir-ritonavir	45662, Ader_1	Ader_1	low risk of bias	probably high risk of bias	low risk of bias	high risk of bias	low risk of bias	low risk of bias
		,	· · · -		, , O		•		
interferon beta, lopinavir-ritonavir	sofosbuvir	Mostafa	Alavi-Moghaddam	probably high risk of bias	arabable biab siste of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
		IVIOSIAIA	Alavi-iviogilauuaiii	probably flight fisk of bias	probably high risk of bias	IOW HSK OF DIAS	IOW TISK OF DIAS	probably low risk of bias	IOW HSK OF DIAS
interferon beta, lopinavir-ritonavir	standard care/placebo								
		45662, Ader_1	Ader_1	low risk of bias	probably high risk of bias	low risk of bias	high risk of bias	low risk of bias	low risk of bias
interferon beta, ribavirin	standard care/placebo								
		2942	Hung	probably high risk of bias	probably high risk of bias	low risk of bias	high risk of bias	low risk of bias	low risk of bias
intranasal corticosteroids	standard care/placebo								
	отельного, рассосо	Clemency	Clemency	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
itraconazole	standard care/placebo								
itraconazoie		36093, Liesenborgl	Liesenborghs	probably high risk of bias	probably high risk of bias	low risk of bias	high risk of bias	probably low risk of bias	low risk of bias
					. , ,		, and the second		
ivermectin	standard care/placebo	Abdulamir_Rezai	Rezai	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias	probably low risk of bias	probably high risk of bias
		Mohan	Mohan	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		34416, 41159, Lopi	Lopez-Medina	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Chahla Buonfrate	Chahla Buonfrate	probably high risk of bias low risk of bias	probably high risk of bias low risk of bias	low risk of bias low risk of bias	high risk of bias low risk of bias	probably low risk of bias low risk of bias	low risk of bias probably low risk of bias
		Buomate	buominate	IOW HISK OF BIAS	IOW HSK OF DIAS	IOW HISK OF DIAS	IOW HISK OF DIAS	IOW HISK OF DIAS	probably low risk of bias
ivermectin nasal spray	standard care/placebo								
		49942	Aref	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably high risk of bias	probably low risk of bias
leflunomide	standard care/placebo								
		8784	Hu	probably high risk of bias	probably high risk of bias	low risk of bias	high risk of bias	low risk of bias	low risk of bias
lopinavir-ritonavir	standard care/placebo								
		330	Cao_1	low risk of bias	probably high risk of bias	low risk of bias	high risk of bias	probably low risk of bias	low risk of bias
		45662, Ader_1	Ader_1	low risk of bias	probably high risk of bias	low risk of bias	high risk of bias	low risk of bias	low risk of bias
lopinavir-ritonavir, ribavirin	ribavirin								
		10067, 2615	Huang_2	probably high risk of bias	probably high risk of bias	low risk of bias	high risk of bias	probably low risk of bias	low risk of bias
mavrilimumab	standard care/placebo								
morning.	2.2adi a cai c, piacebo	36763	Cremer_2	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
analate ele	aton doud on a fall and a								
melatonin	standard care/placebo	Farnoosh	Farnoosh	probably low risk of bias	low risk of bias	high risk of bias	low risk of bias	probably high risk of bias	low risk of bias
				,, 				,	

CELLE 21 System (CRISTAND) So Control (CRIST										
Part	molnupiravir	standard care/placebo								
March Marc										
majoritalmen production of the control										
Lipid Miller (Miller (Miller)			HCR/III/MOLCOV/04/20	Kumar_2	probably nigh risk of bias	probably high risk of bias	IOW RISK OT DIAS	nigh risk of bias	probably low risk of bias	low risk of bias
Lipid Miller (Miller (Miller)	munadolimah	standard care/placeho								
Anterior Marie Mar	mapadomiab	standard care, placebo		Miller	nrohahly high risk of hias	high risk of hias	low risk of hias	low risk of hias	probably high risk of hias	low risk of hias
Miler Miller Miler										
Sundant conspiration of sundan										
Ramburorimin davolari caveljalosko 1965 Armad 1966 Warrad files 1967 Warrad 1968 Warrad 19										
Separation of transfer configuration of tran					p. 0.0.0.	101111111111111111111111111111111111111		p. 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	p. 2 2 2 2 1 1 1 1 2 1 2 1 2 1 2 1 2 1 2	
inclinariation shared configuration and configur	nanocurcimin	standard care/placebo								
Aboutamin(2) Aboutamin(2) Aboutamin(3) About			49064	Ahmadi	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
Aboutamin(2) Aboutamin(2) Aboutamin(3) About										
missenamide Sandord care/placedo Moni Moni Moni bow max of bias bow max of bia	niclosamaide	standard care/placebo							_	
Resigned Personal Resigned Personal Per			Abdulamir_2	Abdulamir_2	probably high risk of bias	probably high risk of bias	low risk of bias	high risk of bias	low risk of bias	probably low risk of bias
Resigned Personal Resigned Personal Per										
Intercopate standard care/placetor works of base	nitazoxanide	standard care/placebo								
opaganib standard carriplanebo with the probably low risk of bias low risk			Rossignol	Rossignol	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
opaganib standard carriplanebo with the probably low risk of bias low risk										
peginterferon lembidy standard care/placebo Winthrop Winthrop Now risk of bias Dow	nitric oxide	standard care/placebo								
peginterferon lambda standard care/placebo 19514, lagarmathum, lagarmathum lag			Moni	Moni	low risk of bias	probably high risk of bias	probably low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
peginterferon lambda standard care/placebo 19514, lagarmathum, lagarmathum lag	annanih	-todo-d -o/-lob-								
peginterferon lambda standard care/placebo 15044, Jagamnathan, Jagamnathan Jag	Ораданів	stanuaru care/piacebo		Winthron	low risk of higs	low risk of higs	low risk of higs	low risk of hips	low risk of higs	low rick of higs
19514, I.gennathan, I.gennathan			wiitiiop	wintinop	IOW FISH OF BIAS	IOW HISK OF DIAS	IOW HISK OF DIAS	IOW HISK OF DIAS	IOW HISK OF DIAS	IOW HISK OF DIAS
19514, I.gennathan, I.gennathan	neginterferon lambda	standard care/placeho								
probebitics standard care/placebo standard c	peginterior iumbuu			Jagannathan	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
progesterone standard care/placebo provalutamide standard care/placebo standard care/pla			-8	8	1011 11011 011 0110	process, remained energy	1011 1111 01 0100			process, and an extension
progesterone standard care/placebo provalutamide p	probiotics	standard care/placebo								
proxalutamide standard care/placebo proxalutamide standard care/placebo standard care/pla			44556	Gutiérrez-Castrellón	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
proxalutamide standard care/placebo proxalutamide standard care/placebo standard care/pla										
proxalutamide standard care/placebo 336.10 Cadegiani 3 high reak of bias low risk of bias low risk of bias low risk of bias low risk of bias probably low risk of bias remdesivir standard care/placebo 2408 2408 11347 Spinner 115633, 3821 1869 Ader (remdesivir) Ader 2 Ader (remdesivir) Ader 2 Ader (remdesivir) Saline irrigation Saline irrigation Saline irrigation Saline irrigation Standard care/placebo 16351, 6 Kimura 16351, 6	progesterone	standard care/placebo								
thuman granulocyte colony-stimula standard care/placebo 12705 Cheng low risk of bias probably high risk of bias low risk			32075, Ghandehai	Ghandehari	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
thuman granulocyte colony-stimula standard care/placebo 12705 Cheng low risk of bias probably high risk of bias low risk										
thuman granulocyte colony-stimula standard care/placebo 12705 Cheng low risk of bias probably high risk of bias low risk of	proxalutamide	standard care/placebo								
remdesivir standard care/placebo remdesivir standard care/placebo remdesivir standard care/placebo 2408 Wang, 1 11347 Spinner 11348 Low risk of bias 11347 Spinner 11348 Low risk of bias 11348 Low risk of bi			33610	Cadegiani_3	high risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias	probably low risk of bias
remdesivir standard care/placebo remdesivir standard care/placebo remdesivir standard care/placebo 2408 Wang, 1 11347 Spinner 11348 Low risk of bias 11347 Spinner 11348 Low risk of bias 11348 Low risk of bi										
remdesivir standard care/placebo 2408 Wang_1 11347 Spinner low risk of bias 10w risk of bi	nt human granulocyte colony-stimula	standard care/placebo		Charac	Learning of the co	and the best of the	Laure of the A Children	Leader of Day	Lancable of the co	to match of litera
Adag Wang 1 11347 Spinner 11347 Spinner 115633, 3821 Beigel low risk of bias 115633, 3821 Beigel low risk of bias 10w risk of bias low risk of			12/05	Cheng	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
Adag Wang 1 11347 Spinner 11347 Spinner 115633, 3821 Beigel low risk of bias 115633, 3821 Beigel low risk of bias 10w risk of bias low risk of	romdocivir	standard saro/placobo								
11347 Spinner 15633,3821 Beigel low risk of bias probably low risk of bias	Terridesivii	standard care, placebo		Wang 1	low risk of higs	low risk of higs	low risk of higs	low risk of higs	low risk of higs	low rick of higs
15633, 3821 Beigel Ader (remdesivir) Ader 2 low risk of bias probably high risk of bias probably high risk of bias low risk of bias low risk of bias low risk of bias probably high risk of bias low risk of bias low risk of bias probably low risk of bias low risk										
Ader (remdesivir) Ader_2 low risk of bias probably high risk of bias low risk of bias low risk of bias probably low risk of bias saline irrigation. **Saline irrigation** **Saline irrigation** **Ine irrigation, triamcinolone acetonide** **Saline irrigation** **Saline irrigation, surfactant** **Saline irrig							<u> </u>			
saline irrigation saline irrigation, surfactant 16351, 6 Kimura probably high risk of bias probably high risk of bias high risk of bias high risk of bias low risk of bias probably low risk of bias probably high risk of bias low risk of bias probably high risk of bias low risk of bias probably high risk of bias low risk of bias probably high risk of bias low risk of bias low risk of bias probably high risk of bias low risk of bias low risk of bias probably high risk of bias low risk of bias low risk of bias probably high risk of bias low risk of bias low risk of bias probably high risk of bias low risk of bias low risk of bias probably high risk of bias low risk of bias low risk of bias low risk of bias probably high risk of bias low risk of bi										
saline irrigation line irrigation, triamcinolone acetonide 52585 Yildiz probably high risk of bias probably high risk of bias probably high risk of bias low risk of bias probably high risk of bias low risk of bias low risk of bias probably low risk of bias probably low risk of bias probably low risk of bias low risk of bias low risk of bias probably low risk of bias probably low risk of bias probably low risk of bias probably low risk of bias l			rider (remdesivin)	/ tdc:	ion risk of bids	probably ingit tisk of bias	ion risk or sids	10 W TISK OF BIGS	probably ion risk of blus	ion risk or bids
saline irrigation line irrigation, triamcinolone acetonide 52585 Yildiz probably high risk of bias probably high risk of bias probably high risk of bias low risk of bias probably high risk of bias low risk of bias low risk of bias probably low risk of bias probably low risk of bias probably low risk of bias low risk of bias low risk of bias probably low risk of bias probably low risk of bias probably low risk of bias probably low risk of bias l	saline irrigation	saline irrigation, surfacta	nt							
saline irrigation line irrigation, triamcinolone acetonide 52585 Yildiz probably high risk of bias probably high risk of bias low risk of bias low risk of bias probably low risk of bias probably high risk of bias low risk of bias low risk of bias probably low risk of bias probably low risk of bias probably high risk of bias probably high risk of bias low risk of bias low risk of bias probably low risk of bias probably low risk of bias low risk of bias low risk of bias probably low risk of bias low risk of bias probably low risk of bias low risk of bias low risk of bias low risk of bias probably low risk of bias low risk of bias probably low risk of bias low ri	9			Kimura	probably high risk of bias	probably high risk of bias	high risk of bias	high risk of bias	low risk of bias	probably low risk of bias
saline irrigation standard care/placebo 16351, 6 Kimura probably high risk of bias high risk of bias high risk of bias high risk of bias probably low risk of bias low risk of bias probably low risk of bias low risk of bias probably low risk of bias low risk of bias probably low risk of bias low risk of bias low risk of bias probably low risk of bias low risk of bi										
saline irrigation standard care/placebo 16351, 6 Kimura probably high risk of bias low risk of bias probably high risk of bias probably high risk of bias low risk of bias high risk of bias probably low risk of bias probably low risk of bias low risk of bias probably low risk of bias probably low risk of bias low r	saline irrigation lin	e irrigation, triamcinolone a								
saline irrigation standard care/placebo 16351, 6 Kimura probably high risk of bias low risk of bias probably high risk of bias probably high risk of bias low risk of bias high risk of bias probably low risk of bias probably low risk of bias low risk of bias probably low risk of bias probably low risk of bias low r				Yildiz	probably high risk of bias	probably high risk of bias	low risk of bias	high risk of bias	probably low risk of bias	low risk of bias
16351, 6 Kimura probably high risk of bias low risk of bias probably high risk of bias low risk of bias probably high risk of bias low risk of bias probably low risk of bias low risk of bias low risk of bias probably low risk of bias low risk of bias low risk of bias probably low risk of bias low risk of bias low risk of bias probably low risk of bias										
saline irrigation, surfactant standard care/placebo 16351, 6 Kimura probably high risk of bias probably high risk of bias probably high risk of bias high risk of bias high risk of bias high risk of bias low risk of bias probably low risk of bias high risk of bias low risk of bias probably low risk of bias probably low risk of bias low risk of bias low risk of bias probably low risk of bias low risk of bias probably low risk of bias l	saline irrigation	standard care/placebo								
saline irrigation, surfactant standard care/placebo 16351, 6 Kimura probably high risk of bias probably high risk of bias low risk of bias probably low risk of bias probably low risk of bias probably high risk of bias low										probably low risk of bias
16351, 6 Kimura probably high risk of bias probably high risk of bias probably high risk of bias low risk of bias probably low risk of bias probably high risk of bias low risk of bias low risk of bias probably low risk of bias low risk of			52585	Yildiz	probably high risk of bias	probably high risk of bias	low risk of bias	high risk of bias	probably low risk of bias	low risk of bias
16351, 6 Kimura probably high risk of bias probably high risk of bias probably high risk of bias low risk of bias probably low risk of bias probably high risk of bias low risk of bias low risk of bias probably low risk of bias low risk of										
serine protease inhibitors standard care/placebo S2585 Yildiz probably high risk of bias probably high risk of bias probably high risk of bias low risk of bias	saline irrigation, surfactant	standard care/placebo		W	and all his to the first	and the board of the	Land out the	Link and the	In the first	and the second
serine protease inhibitors standard care/placebo 40853 Gunst low risk of bias probably high risk of bias probably high risk of bias low risk of bias low risk of bias high risk of bias probably low risk of bias			16351, 6	Kimura	probably high risk of bias	probably high risk of bias	high risk of bias	high risk of bias	low risk of bias	probably low risk of bias
serine protease inhibitors standard care/placebo 40853 Gunst low risk of bias probably high risk of bias probably high risk of bias low risk of bias low risk of bias high risk of bias probably low risk of bias	line indeeding talence to the control	stondond/.l.								
serine protease inhibitors standard care/placebo 40853 Gunst low risk of bias	ime irrigation, triamcinolone acetonic	standard care/placebo		Vild:-	probably bigh viels of his	probably high sigh of his	low risk of him	high righ of him	probably low risk of his	low rich of him
40853 Gunst low risk of bias			52585	TIIQIZ	probably fligh risk of bias	probably fligh risk of bias	IOW FISK OF DIAS	nigh risk of bias	probably low risk of bias	IOW TISK OF DIAS
40853 Gunst low risk of bias	serine protesse inhibitors	standard saro/placete								
	serine procease infinitions	Stanuaru Care/piacebo		Gunst	low risk of hias	low risk of higs	low risk of hias	low risk of hige	low risk of hias	low risk of hige
70270 Entitled 104 134 Of title 9700001 High 134 Of title 104 Of title										
			70170	Ziidiavei	IOW HISK OF DIAS	Producty mgn risk of bids	IOW HISK OF DIGS	IOW HISK OF DIGS	IOW HISK OF DIAS	1044 1134 01 0103


triazavirin	standard care/placebo								
		12679	Wu	high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
tyrosine kinase inhibitors	standard care/placebo								
cyrosine milase milaseors	Standard care, process	60872	Strich	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
umifenovir	standard care/placebo								
		12798	Yethindra	probably high risk of bias	probably high risk of bias	low risk of bias	high risk of bias	probably low risk of bias	low risk of bias
		52841	Darazam_3	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	probably low risk of bias
vitamin C	standard care/placebo								
		25793	Kumari	probably high risk of bias	probably high risk of bias	low risk of bias	high risk of bias	probably low risk of bias	low risk of bias
		31458	Thomas	low risk of bias	probably high risk of bias	probably high risk of bias	high risk of bias	probably low risk of bias	probably low risk of bias
vitamin C	vitamin C, zinc								
		31458	Thomas	low risk of bias	probably high risk of bias	probably high risk of bias	high risk of bias	probably low risk of bias	probably low risk of bias
vitamin C	zinc								
		31458	Thomas	low risk of bias	probably high risk of bias	probably high risk of bias	high risk of bias	probably low risk of bias	probably low risk of bias
vitamin C, zinc	standard care/placebo	31458	Thomas	low risk of bias	arabable biab side of bias	anababb bish sist of biss	high state of high	and ballet law viels of him	and habit the wint of him
		31458	inomas	IOW FISK OF DIAS	probably high risk of bias	probably high risk of bias	high risk of bias	probably low risk of bias	probably low risk of bias
vitamin C, zinc	zinc								
		31458	Thomas	low risk of bias	probably high risk of bias	probably high risk of bias	high risk of bias	probably low risk of bias	probably low risk of bias
xiyanping	standard care/placebo	42220	71	Land State of the second	and the best of the section of the	In control of litera	In white of the co	Learning of the	Land St. of the co
		43229	Zhang_3	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
zinc	standard care/placebo								
	.,	31458	Thomas	low risk of bias	probably high risk of bias	probably high risk of bias	high risk of bias	probably low risk of bias	probably low risk of bias

Time to Viral Clearance

				Time t	o Viral Clearance				
Treatment 1	Treatment 2	Trial	First author	Randomization	Deviations from the intended	Missing outcome data	Measurement of outcome	Selection of the reported	Other (Competing risks)
2-deoxy-D-glucose	standard care/placebo	66751a	Narayan Bhatt	probably high risk of bias	high risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
CCK-A agonist and CCK-B antagonist	standard care/placebo	Lattmann	Lattmann	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
CK2 inhibitor	standard care/placebo	13070, 26887	Cruz	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably high risk of bias	probably low risk of bias
HIV reverse transcriptase inhibitor	standard care/placebo	8469	Ren	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
IL6 receptor antagonists	standard care/placebo	11850	Wang_4	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	probably low risk of bias
JAK inhibitors	standard care/placebo	4161	Cao_2	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	probably low risk of bias
L-arginine	standard care/placebo	64005	Fiorentino	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
es, curcuminoids, piperine, resveratro	standard care/placebo	67818	Majeed	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
antihepaciviral ro	mycin, hydroxychloroquine, ose	eltamivir 44111	Elgohary	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably high risk of bias	probably low risk of bias
azithromycin	clarithromycin	58017	Rashad_1	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably high risk of bias	low risk of bias
azithromycin	standard care/placebo	58017	Rashad_1	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably high risk of bias	low risk of bias
azithromycin, hydroxychloroquine	hydroxychloroquine	33489, Johnston	Johnston	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
azithromycin, hydroxychloroquine	standard care/placebo	33489, Johnston	Johnston	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
azithromycin, vitamins	favipiravir	Khavkina	Khavkina	probably high risk of bias	probably high risk of bias	probably low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
azithromycin, vitamins cyc	chloroquine, interferon alpha, u	mifenovir Khavkina	Khavkina	probably high risk of bias	probably high risk of bias	probably low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
baloxavir marboxil	favipiravir	2637, Lou, Lou (1	Lou	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
baloxavir marboxil	standard care/placebo	2637, Lou, Lou (1	Lou	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
cannabidiol	standard care/placebo	66954	Crippa	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
clarithromycin	standard care/placebo	58017	Rashad_1	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably high risk of bias	low risk of bias
corticosteroids (systemic)	standard care/placebo	27644	Tang_2	probably low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	probably high risk of bias
doxycycline, ivermectin	ivermectin	Ahmed	Ahmed	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias	probably low risk of bias
doxycycline, ivermectin	standard care/placebo	Ahmed	Ahmed	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias	probably low risk of bias

favipiravir	cychloroquine, interferon alpha,								
		Khavkina	Khavkina	probably high risk of bias	probably high risk of bias	probably low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
favipiravir	standard care/placebo								
ιανιμιιανιι	staridard care/placebo	2637, Lou, Lou (1	Lou	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		32588	Ruzhentsova	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		24988, Udwadia	Udwadia	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		40875	Zhao 2	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
			· · · <u>-</u> ·		, , , , ,				
hydroxychloroquine	ıydroxychloroquine, lopinavir-rit	onavir							
		52697	Arabi	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
								-	
hydroxychloroquine	lopinavir-ritonavir								
		pilot_4	Huang_1	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		52697	Arabi	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
hydroxychloroquine	standard care/placebo								
		3321, 776	Tang_1	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		C158	Chen_3	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
		6987 8057, Chen (Cheng-I	Chen_4	probably high risk of bias	probably high risk of bias	high risk of bias low risk of bias	low risk of bias low risk of bias	low risk of bias	low risk of bias low risk of bias
			Chen_5	low risk of bias	probably high risk of bias			low risk of bias	
		11299 33489, Johnston	Abd-Elsalam_1 Johnston	probably high risk of bias probably low risk of bias	probably high risk of bias low risk of bias	low risk of bias low risk of bias	low risk of bias low risk of bias	probably low risk of bias low risk of bias	low risk of bias low risk of bias
		Byakika-Kibwika	Byakika-Kibwika	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	probably low risk of bias
		52697	Arabi	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
		32037	Aldbi	10W FISK OF BIAS	probably high risk of bias	10W 115K OT BIAS	IOW TISK OF DIAS	probably low risk of bias	10W FISH OF BIGS
ydroxychloroquine, lopinavir-ritonav	vi lopinavir-ritonavir								
, ,		52697	Arabi	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
					, , , ,				
ydroxychloroquine, lopinavir-ritonav	vi standard care/placebo								
		52697	Arabi	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
hydroxychloroquine, rivabirin	lopinavir-ritonavir, ribavirir	1							
		46308_severe	Singh_3	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
hydroxychloroquine, rivabirin	standard care/placebo								
		46308_non severe	Singh_2	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		46308_severe	Singh_3	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
interferen eleke		f							
interferon alpha	combinant super combinant int	32737, 7, 9574	Li_2	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		32/3/, /, 93/4	LI_Z	probably flight risk of bias	probably flight risk of bias	low risk of bias	IOW LISK OF DIAS	IOW TISK OF DIAS	IOM LISK OF DIAS
interferon beta, ribavirin	standard care/placebo								
meneron beta, ribaviini	staridara care, piacebo	2942	Hung	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		2542	riung	probably high hisk of bias	probably riight risk of bias	IOW HISK OF BIGS	IOW FISH OF BIGS	10W H3K OF Blas	10W FISK OF BIGS
interferon gamma	standard care/placebo								
ge	3.00.00 G. 3, p. 2000	9880	Esquivel-Moynelo	probably high risk of bias	probably high risk of bias	high risk of bias	low risk of bias	probably low risk of bias	low risk of bias
			.,	, , , , ,	, , , , , , , , , , , , , , , , , , , ,	3		, ,	
interferon kappa, trefoil factor 2	standard care/placebo								
		13797	Fu	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
ivermectin	lopinavir-ritonavir								
		25394, Babalola	Babalola	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
ivermectin	standard care/placebo								
		Ahmed	Ahmed	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias	probably low risk of bias
		27334, Chaccour	Chaccour	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias	probably low risk of bias
		35667	Pott-Junior	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
because able to the least	stondowl/.l								
ivermectin nasal spray	standard care/placebo	40042	Aref	probably bigh sigh of him	probably high sigh of his	low rick of him	low rich of hise	probably high sigh of his	probably low-risk of his
ivermectin nasal spray	standard care/placebo	49942	Aref	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably high risk of bias	probably low risk of bias
	**	49942	Aref	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably high risk of bias	probably low risk of bias
ivermectin nasal spray	standard care/placebo								
· ·	**	49942 8784 13540	Aref Hu Wang_5	probably high risk of bias probably high risk of bias probably high risk of bias	probably high risk of bias probably high risk of bias probably high risk of bias	low risk of bias low risk of bias low risk of bias	low risk of bias low risk of bias low risk of bias	probably high risk of bias low risk of bias low risk of bias	probably low risk of bias low risk of bias low risk of bias


lopinavir-ritonavir	lopinavir-ritonavir, novaferor	n 10121, 2338	Zheng	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
Indian de elegación	Indianal de alternación diberdale								
lopinavir-ritonavir	lopinavir-ritonavir, ribavirin	10067, 2615	Huang_2	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
lopinavir-ritonavir	novaferon				44				
		10121, 2338	Zheng	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
lopinavir-ritonavir	ribavirin								
торитами-птопами	HDAVIIII	10067, 2615	Huang_2	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		10007, 2013	riuarig_2	probably flight risk of bias	probably riight risk of bias	IOW HISK OF DIAS	IOW HISK OF DIAS	IOW FISK OF BIAS	IOW HISK OF DIAS
lopinavir-ritonavir	standard care/placebo								
Topinarii Titoriarii	Staridard care, places	1243, 234	Li	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		52697	Arabi	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
				1011 1111 01 0100	process, man man er eine			process, ican ican creati	
lopinavir-ritonavir	umifenovir								
·		1243, 234	Li	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
					, , ,				
lopinavir-ritonavir, novaferon	novaferon								
		10121, 2338	Zheng	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
					- · · · · · -				
lopinavir-ritonavir, ribavirin	ribavirin								
		10067, 2615	Huang_2	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
lopinavir-ritonavir, ribavirin	standard care/placebo								
		46308_severe	Singh_3	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
molnupiravir	standard care/placebo								
		46473, Fischer	Fischer	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
nitric oxide	standard care/placebo								
		Moni	Moni	low risk of bias	probably high risk of bias	high risk of bias	low risk of bias	low risk of bias	low risk of bias
peginterferon lambda	standard care/placebo								
		18418, 28233	Feld	low risk of bias	low risk of bias	low risk of bias	low risk of bias	high risk of bias	low risk of bias
	19514, Jag	gannathan, Jagannath	Jagannathan	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
and a contract to both the trace	ata a da ad assas fala a da a								
serine protease inhibitors	standard care/placebo	70176	76	law sists of him	arehably high sigh of high	lass siels of bion	lass side of him	anahahir larr siak of hisa	anababb law side of high
		70176	Zhuravel	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	probably low risk of bias
triazavirin	standard care/placebo								
Ulazavii iii	Standard care/ pidcebo	12679	Wu	high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	probably low risk of bias
		120/3	vv u	mgn nok or bras	producty might hisk of bias	TOW TISK OF DIAS	IOW HISK OF DIAS	Propagit IOM LISK OF DIGS	producty low risk of bids
umifenovir	standard care/placebo								
dimension.	Staridard care, pracebo	1243, 234	Li	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		,	=		1				
vitamin D	standard care/placebo								
		18926	Ratogi	probably high risk of bias	probably high risk of bias	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias
			ŭ						
xiyanping	standard care/placebo								
		43229	Zhang_3	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
zinc	standard care/placebo								
		Abdelmaksoud, Has: Ha	assan, Abdelmaksoud	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	probably low risk of bias




NETWORK PLOTS

The size of the circles is proportional to the number of patients randomised to that intervention and the size of the lines is proportional to the inverse of the standard error of the effect estimate.


Mortality




Mechanical ventilation




Adverse events leading to discontinuation




Admission to hospital




Venous thromboembolism




Clinically-important bleeding




Duration of hospital stay




Duration of mechanical ventilation



Time to symptom resolution





								Admi	ssion to hosp	pital												
Comparison		Direct es	timate						Indirect es	stimate						Network e	stimate					
		Relative e	estimate		Absolute	estimate (per 1,000)		Relative es	stimate		Absolute e	estimate (pe	r 1,000)		Relative es	stimate		Absolute e	stimate (per	1,000)	
Treatment 1	Treatment 2	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit	Final rating	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit	Final rating	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit	Final rating
aspirin	standard care/placebo	0.31	0.01	9.57	-28.94	-42.22	256.27	VERY LOW	NA	NA	NA	NA	NA	NA	NA	0.00	0.00	0.07	-42.40	-42.68	-40.61	VERY LOW
azithromycin	standard care/placebo	0.99	0.01	2.20	-0.42	-22.12	46.56	VERY LOW	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.08	0.57	2.29	5.75	-18.07	47.78	VERY LOW
azithromycin, hydroxychloroquine	standard care/placebo	1.03	0.33	3.29	1.33	-28.32	85.34	LOW	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.18	0.40	3.31	13.68	-24.82	89.14	LOW
colchicine	standard care/placebo	0.79	0.22	2.83	-8.84	-33.05	69.34	LOW	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.79	0.35	1.77	-6.43	-26.97	29.66	LOW
electrolyzed saline	standard care/placebo	0.73	0.07	1.45	-28.21	-39.35	18.04	VERY LOW	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.73	0.10	0.99	-26.35	-38.33	-1.39	VERY LOW
fluvoxamine	standard care/placebo	0.74	0.35	1.47	-10.62	-27.47	18.98	VERY LOW	NA NA	NA NA	NA NA	NA.	NA NA	NA	NA NA	0.70	0.34	1.23	-11.54	-27.37	9.00	VERY LOW
full-dose anticoagulant	standard care/placebo	0.61	0.15	2.60	-16.07	-36.12	61.12	LOW	NA NA	NA NA	NA NA	NA.	NA NA	NA	NA NA	0.60	0.17	2.10	-10.74	-34.92	45.81	LOW
(hydroxy)chloroquine	standard care/placebo	0.90	0.45	1.80	-4.08	-23.12	31.55	LOW	NA NA	NA NA	NA	NA.	NA NA	NA	NA NA	0.95	0.50	1.85	0.23	-20.83	33.21	LOW
intranasal corticosteroids	standard care/placebo	0.91	0.29	2.84	-3.81	-29.90	69.84	LOW	NA.	NA	NA	NA	NA	NA	NA NA	0.90	0.32	2.46	0.40	-28.68	56.19	LOW
intranasal hypertonic polymer spray	standard care/placebo	1.65	0.31	8.63	25.78	-28.84	235.22	VERY LOW	NA	NA	NA	NA	NA	NA	NA NA	1.69	0.43	7.29	43.42	-23.54	203.09	VERY LOW
ivermectin	standard care/placebo	0.55	0.21	1.37	-18.89	-33.35	14.92	LOW	NA.	NA	NA	NA	NA	NA	NA NA	0.54	0.23	1.19	-17.60	-32.38	7.05	LOW
lopinavir-ritonavir	standard care/placebo	0.85	0.20	3.63	-6.11	-33.85	96.54	VERY LOW	NA	NA	NA	NA	NA	NA	NA	0.71	0.26	1.94	-8.23	-31.14	36.04	VERY LOW
molnupiravir	standard care/placebo	0.55	0.31	0.95	-18.66	-29.09	-2.13	VERY LOW	NA	NA	NA	NA	NA	NA	NA	0.54	0.30	0.90	-18.69	-29.17	-4.65	MODERATE
nitazoxanide	standard care/placebo	0.63	0.15	2.47	-15.46	-35.89	56.48	LOW	NA	NA	NA	NA	NA	NA	NA	0.57	0.16	1.80	-13.69	-35.30	31.70	LOW
nirmatrelvir/ritonavir	standard care/placebo	0.14	0.03	0.61	-36.52	-41.27	-16.19	LOW	NA	NA	NA	NA	NA	NA	NA	0.13	0.04	0.40	-35.95	-40.95	-25.80	MODERATE
probiotics	standard care/placebo	1.00	0.02	60.02	0.00	-41.94	685.28	VERY LOW	NA	NA	NA	NA	NA	NA	NA	0.00	0.00	6.77E+12	709.46	-42.68	957.32	VERY LOW
proxalutamide	standard care/placebo	0.07	0.01	0.33	-39.75	-42.12	-28.25	VERY LOW	NA	NA	NA	NA	NA	NA	NA	0.03	0.00	0.12	-41.00	-42.51	-37.49	VERY LOW
remdesivir	standard care/placebo	0.27	0.06	1.28	-30.84	-40.17	11.27	LOW	NA	NA	NA	NA	NA	NA	NA	0.25	0.07	0.86	-29.31	-39.71	-6.16	LOW
sulodexide	standard care/placebo	0.55	0.14	2.11	-18.93	-36.44	43.43	VERY LOW	NA	NA	NA	NA	NA	NA	NA	0.54	0.21	1.39	-16.55	-33.27	15.14	VERY LOW
aspirin	azithromycin	NA	NA	NA	NA	NA	NA	NA	0.00	0.00	0.07	-48.14	-90.29	-23.93	VERY LOW	0.00	0.00	0.07	-48.14	-90.29	-23.93	VERY LOW
aspirin	azithromycin, hydroxychloroquine	NA	NA	NA	NA	NA	NA	NA	0.00	0.00	0.06	-56.08	-131.53	-17.40	VERY LOW	0.00	0.00	0.06	-56.08	-131.53	-17.40	VERY LOW
aspirin	colchicine	NA	NA	NA	NA	NA	NA	NA	0.00	0.00	0.09	-35.97	-72.23	-14.93	VERY LOW	0.00	0.00	0.09	-35.97	-72.23	-14.93	VERY LOW
aspirin	electrolyzed saline	NA	NA	NA	NA	NA	NA	NA	0.00	0.00	0.23	-16.05	-41.15	-3.80	VERY LOW	0.00	0.00	0.23	-16.05	-41.15	-3.80	VERY LOW
aspirin	fluvoxamine	NA	NA	NA	NA	NA	NA	NA	0.00	0.00	0.10	-30.86	-51.56	-14.58	VERY LOW	0.00	0.00	0.10	-30.86	-51.56	-14.58	VERY LOW
full-dose anticoagulant	aspirin	3.67	0.15	87.39	NA	NA	NA	VERY LOW	NA	NA	NA	NA	NA	NA	NA	7.18E+15	8.65	3.04E+46	31.65	7.33	88.07	VERY LOW
aspirin	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	0.00	0.00	0.07	-42.63	-75.68	-21.32	VERY LOW	0.00	0.00	0.07	-42.63	-75.68	-21.32	VERY LOW
aspirin	intranasal corticosteroids	NA	NA	NA	NA	NA	NA	NA	0.00	0.00	0.08	-42.79	-98.72	-13.55	VERY LOW	0.00	0.00	0.08	-42.79	-98.72	-13.55	VERY LOW
aspirin	intranasal hypertonic polymer spray	NA	NA	NA	NA	NA	NA	NA	0.00	0.00	0.04	-85.82	-245.59	-18.77	VERY LOW	0.00	0.00	0.04	-85.82	-245.59	-18.77	VERY LOW
aspirin	ivermectin	NA	NA	NA	NA	NA	NA	NA	0.00	0.00	0.13	-24.80	-49.59	-9.58	VERY LOW	0.00	0.00	0.13	-24.80	-49.59	-9.58	VERY LOW
aspirin	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.00	0.00	0.10	-34.16	-78.53	-11.06	VERY LOW	0.00	0.00	0.10	-34.16	-78.53	-11.06	VERY LOW
aspirin	molnupiravir	NA	NA	NA	NA	NA	NA	NA	0.00	0.00	0.13	-23.71	-37.89	-12.78	VERY LOW	0.00	0.00	0.13	-23.71	-37.89	-12.78	VERY LOW
aspirin	nitazoxanide	NA	NA	NA	NA	NA	NA	NA	0.00	0.00	0.13	-28.71	-74.13	-6.86	VERY LOW	0.00	0.00	0.13	-28.71	-74.13	-6.86	VERY LOW
aspirin	nirmatrelvir/ritonavir	NA	NA	NA	NA	NA	NA	NA	0.00	0.00	0.55	-6.45	-16.77	-1.23	VERY LOW	0.00	0.00	0.55	-6.45	-16.77	-1.23	VERY LOW
aspirin	probiotics	NA	NA	NA	NA	NA	NA	NA	0.00	0.00	1.18E+44	-751.85	-1000.00	0.00	VERY LOW	0.00	0.00	1.18E+44	-751.85	-1000.00	0.00	VERY LOW
aspirin	proxalutamide	NA	NA	NA	NA	NA	NA	NA	0.00	0.00	2.77	-1.39	-5.14	0.81	VERY LOW	0.00	0.00	2.77	-1.39	-5.14	0.81	VERY LOW
aspirin	remdesivir	NA	NA	NA	NA	NA	NA	NA	0.00	0.00	0.28	-13.09	-36.45	-2.44	VERY LOW	0.00	0.00	0.28	-13.09	-36.45	-2.44	VERY LOW
aspirin	sulodexide	NA	NA	NA	NA	NA	NA	NA	0.00	0.00	0.13	-25.85	-57.61	-8.76	VERY LOW	0.00	0.00	0.13	-25.85	-57.61	-8.76	VERY LOW
azithromycin	azithromycin, hydroxychloroquine	NA	NA	NA	NA	NA	NA	NA	0.92	0.27	3.44	-7.93	-87.05	49.79	VERY LOW	0.92	0.27	3.44	-7.93	-87.05	49.79	VERY LOW
azithromycin	colchicine	NA	NA	NA	NA	NA	NA	NA	1.37	0.51	4.31	12.18	-28.86	58.94	VERY LOW	1.37	0.51	4.31	12.18	-28.86	58.94	VERY LOW
azithromycin	electrolyzed saline	NA	NA	NA	NA	NA	NA	NA	3.38	0.94	13.95	32.10	-1.77	76.18	VERY LOW	3.38	0.94	13.95	32.10	-1.77	76.18	VERY LOW
azithromycin	fluvoxamine	NA	NA	NA	NA	NA	NA	NA	1.54	0.66	4.66	17.28	-13.86	63.50	VERY LOW	1.54	0.66	4.66	17.28	-13.86	63.50	VERY LOW
azithromycin	full-dose anticoagulant	NA	NA	NA	NA	NA	NA	NA	1.80	0.44	7.78	16.49	-44.51	66.55	VERY LOW	1.80	0.44	7.78	16.49	-44.51	66.55	VERY LOW
azithromycin	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	1.13	0.45	3.06	5.51	-34.87	52.08	VERY LOW	1.13	0.45	3.06	5.51	-34.87	52.08	VERY LOW
azithromycin	intranasal corticosteroids	NA	NA	NA	NA	NA	NA	NA	1.21	0.37	4.32	5.35	-55.09	57.30	VERY LOW	1.21	0.37	4.32	5.35	-55.09	57.30	VERY LOW

								Admi	ssion to hosp	oital												
Comparison		Direct es	timate						Indirect es							Network e	stimate					
		Relative e			Absolute	estimate ((per 1,000)		Relative es			Absolute e	estimate (pe	er 1.000)		Relative es			Absolute e	estimate (pe	r 1.000)	
		Point estimate	CI lower	CI upper	Point estimate	CI lower	CI upper	Final rating	Point estimate	CI lower	CI upper	Point estimate	CI lower	CI upper	Final rating	Point estimate	CI lower	CI upper	Point estimate	CI lower	CI upper	Final rating
Treatment 1	Treatment 2		limit	limit																		
azithromycin	intranasal hypertonic polymer spray	NA	NA	NA	NA	NA	NA	NA	0.64	0.13	3.11	-37.68	-198.12	43.98	VERY LOW	0.64	0.13	3.11	-37.68	-198.12	43.98	VERY LOW
azithromycin	ivermectin	NA	NA	NA	NA	NA	NA	NA	2.01	0.73	6.47	23.34	-10.35	68.40	VERY LOW	2.01	0.73	6.47	23.34	-10.35	68.40	VERY LOW
azithromycin	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	1.53	0.47	5.45	13.98	-35.70	62.62	VERY LOW	1.53	0.47	5.45	13.98	-35.70	62.62	VERY LOW
azithromycin	molnupiravir	NA	NA	NA	NA	NA	NA	NA	2.00	0.90	5.38	24.44	-3.00	68.45	VERY LOW	2.00	0.90	5.38	24.44	-3.00	68.45	VERY LOW
azithromycin	nitazoxanide	NA	NA	NA	NA	NA	NA	NA NA	1.91	0.51	8.45	19.44	-31.29	68.29	VERY LOW	1.91	0.51	8.45	19.44	-31.29	68.29	VERY LOW
azithromycin	nirmatrelvir/ritonavir	NA	NA	NA	NA	NA	NA NA	NA NA	8.21	2.32	34.72	41.70	16.21	84.01	VERY LOW	8.21	2.32	34.72	41.70	16.21	84.01	VERY LOW
azithromycin	probiotics	NA	NA	NA	NA	NA	NA NA	NA NA	2.20E+04	0.00	1.06E+53	-703.71	-973.94	66.29	VERY LOW	21979.16	0.00	1.06E+53	-703.71	-973.94	66.29	VERY LOW
azithromycin	proxalutamide	NA	NA	NA	NA	NA	NA	NA NA	36.78	8.00	305.30	46.75	22.70	88.78	VERY LOW	36.78	8.00	305.30	46.75	22.70	88.78	VERY LOW
azithromycin	remdesivir	NA	NA	NA	NA	NA	NA	NA NA	4.29	1.09	19.97	35.06	2.70	78.81	VERY LOW	4.29	1.09	19.97	35.06	2.70	78.81	VERY LOW
azithromycin	sulodexide	NA	NA	NA	NA NA	NA	NA NA	NA NA	1.99	0.65	6.87	22.30	-16.29	67.88	VERY LOW	1.99	0.65	6.87	22.30	-16.29	67.88	VERY LOW
azithromycin, hydroxychloroquine	colchicine	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.49	0.39	5.66 18.12	20.11 40.03	-31.78 -6.16	98.21 116.88	LOW	1.49 3.66	0.39	5.66 18.12	20.11 40.03	-31.78 -6.16	98.21 116.88	VERY LOW
azithromycin, hydroxychloroquine	electrolyzed saline	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	3.66 1.68	0.78	6.07	25.22	-0.16	102.18	VERY LOW VERY LOW	1.68	0.78	6.07	25.22	-0.16		VERY LOW
azithromycin, hydroxychloroquine	fluvoxamine	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.00	0.38	9.90	24.42	-45.05	102.16	LOW	1.00	0.30	9.90	24.42	-45.05	102.18 104.75	LOW
azithromycin, hydroxychloroquine	full-dose anticoagulant	1.37	0.36	5.23	NA NA	NA NA	NA NA	VERY LOW	3.04E+09	1.92	3.29E+28	NA	-45.05 NA	NA	VERY LOW	1.95	0.36	3.57	13.45	-45.05	83.19	LOW
azithromycin, hydroxychloroquine	(hydroxy)chloroquine	NA	NA	NA	NA NA	NA NA	NA NA	NA NA	1.31	0.30	5.64	13.28	-55.95	94.06	LOW	1.23	0.41	5.64	13.45	-51.13	94.06	LOW
azithromycin, hydroxychloroquine	intranasal corticosteroids	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.69	0.30	3.93	-29.74	-194.85	75.16	VERY LOW	0.69	0.30	3.93	-29.74	-194.85	75.16	VERY LOW
azithromycin, hydroxychloroquine	intranasal hypertonic polymer spray	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	2.19	0.11	8.62	31.28	-194.65	108.11	LOW	2.19	0.11	8.62	31.28	-194.05	108.11	LOW
azithromycin, hydroxychloroquine	ivermectin	NA NA	NA	NA	NA NA	NA NA	NA NA	NA NA	1.65	0.57	6.69	21.91	-34.60	98.73	VERY LOW	1.65	0.57	6.69	21.91	-34.60	98.73	VERY LOW
azithromycin, hydroxychloroquine azithromycin, hydroxychloroquine	lopinavir-ritonavir molnupiravir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	2.18	0.41	7.32	32.37	-8.77	108.54	VERY LOW	2.18	0.41	7.32	32.37	-8.77	108.54	VERY LOW
azithromycin, hydroxychloroquine	nitazoxanide	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	2.18	0.00	10.79	27.37	-32.68	108.34	LOW	2.18	0.00	10.79	27.37	-32.68	108.34	LOW
azithromycin, hydroxychloroquine	nirmatrelvir/ritonavir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	8.90	1.92	45.22	49.63	10.04	125.22	LOW	8.90	1.92	45.22	49.63	10.04	125.22	LOW
azithromycin, hydroxychloroquine	probiotics	NA NA	NA NA	NA	NA NA	NA NA	NA NA	NA NA	2.38E+04	0.00	1.28E+53	-695.78	-980.14	86.00	VERY LOW	2.38E+04	0.00	1.28E+53	-695.78	-980.14	86.00	VERY LOW
azithromycin, hydroxychloroquine	proxalutamide	NA NA	NA NA	NA	NA NA	NA NA	NA NA	NA NA	40.08	6.89	362.30	54.68	15.97	130.19	VERY LOW	40.08	6.89	362.30	54.68	15.97	130.19	VERY LOW
azithromycin, hydroxychloroquine	remdesivir	NA NA	NA NA	NA	NA NA	NA NA	NA NA	NA NA	4.64	0.09	25.62	42.99	-1.84	119.12	LOW	4.64	0.09	25.62	42.99	-1.84	119.12	LOW
azithromycin, hydroxychloroquine	sulodexide	NA NA	NA.	NA	NA NA	NA NA	NA NA	NA NA	2.16	0.52	8.97	30.23	-19.80	108.02	VERY LOW	2.16	0.52	8.97	30.23	-19.80	108.02	VERY LOW
colchicine	electrolyzed saline	NA NA	NA.	NA	NA NA	NA NA	NA NA	NA NA	2.46	0.61	10.17	19.92	-12.09	58.46	VERY LOW	2.46	0.61	10.17	19.92	-12.09	58.46	VERY LOW
colchicine	fluvoxamine	NA NA	NA NA	NA	NA NA	NA	NA NA	NA NA	1.11	0.43	3.48	5.11	-23.54	45.43	VERY LOW	1.11	0.43	3.48	5.11	-23.54	45.43	VERY LOW
colchicine	full-dose anticoagulant	NA	NA	NA	NA NA	NA	NA	NA NA	1.31	0.29	5.81	4.31	-55.79	47.87	LOW	1.31	0.29	5.81	4.31	-55.79	47.87	LOW
colchicine	(hydroxy)chloroquine	NA	NA	NA	NA	NA NA	NA NA	NA NA	0.82	0.29	2.31	-6.67	-45.80	34.23	LOW	0.82	0.29	2.31	-6.67	-45.80	34.23	LOW
colchicine	intranasal corticosteroids	NA	NA	NA	NA	NA	NA	NA NA	0.88	0.24	3.21	-6.83	-66.37	39.57	LOW	0.88	0.24	3.21	-6.83	-66.37	39.57	LOW
colchicine	intranasal hypertonic polymer spray	NA	NA	NA	NA	NA	NA	NA NA	0.46	0.09	2.29	-49.85	-211.16	27.38	VERY LOW	0.46	0.09	2.29	-49.85	-211.16	27.38	VERY LOW
colchicine	ivermectin	NA	NA	NA	NA	NA	NA	NA	1.46	0.47	4.78	11.17	-20.79	50.42	LOW	1.46	0.47	4.78	11.17	-20.79	50.42	LOW
colchicine	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	1.11	0.30	4.03	1.80	-47.15	44.70	VERY LOW	1.11	0.30	4.03	1.80	-47.15	44.70	VERY LOW
colchicine	molnupiravir	NA	NA	NA	NA	NA	NA	NA	1.45	0.57	4.07	12.26	-12.36	49.98	VERY LOW	1.45	0.57	4.07	12.26	-12.36	49.98	VERY LOW
colchicine	nitazoxanide	NA	NA	NA	NA	NA	NA	NA	1.38	0.34	6.25	7.26	-42.18	50.03	LOW	1.38	0.34	6.25	7.26	-42.18	50.03	LOW
colchicine	nirmatrelvir/ritonavir	NA	NA	NA	NA	NA	NA	NA	5.98	1.51	25.55	29.52	6.70	65.81	LOW	5.98	1.51	25.55	29.52	6.70	65.81	LOW
colchicine	probiotics	NA	NA	NA	NA	NA	NA	NA	1.50E+04	0.00	7.44E+52	-715.89	-982.58	48.80	VERY LOW	1.50E+04	0.00	7.44E+52	-715.89	-982.58	48.80	VERY LOW
colchicine	proxalutamide	NA	NA	NA	NA	NA	NA	NA	26.47	5.46	219.76	34.57	13.74	70.66	VERY LOW	26.47	5.46	219.76	34.57	13.74	70.66	VERY LOW
colchicine	remdesivir	NA	NA	NA	NA	NA	NA	NA	3.10	0.72	14.53	22.88	-7.61	60.38	LOW	3.10	0.72	14.53	22.88	-7.61	60.38	LOW
colchicine	sulodexide	NA	NA	NA	NA	NA	NA	NA	1.44	0.42	5.06	10.12	-27.37	49.72	VERY LOW	1.44	0.42	5.06	10.12	-27.37	49.72	VERY LOW
electrolyzed saline	fluvoxamine	NA	NA	NA	NA	NA	NA	NA	0.46	0.13	1.78	-14.81	-39.09	14.47	VERY LOW	0.46	0.13	1.78	-14.81	-39.09	14.47	VERY LOW
electrolyzed saline	full-dose anticoagulant	NA	NA	NA	NA	NA	NA	NA	0.53	0.09	2.82	-15.61	-73.45	20.03	VERY LOW	0.53	0.09	2.82	-15.61	-73.45	20.03	VERY LOW
electrolyzed saline	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	0.33	0.09	1.22	-26.58	-62.48	5.96	VERY LOW	0.33	0.09	1.22	-26.58	-62.48	5.96	VERY LOW

								Admi	ssion to hosp	oital												
Comparison		Direct es	timate						Indirect es	timate						Network e	stimate					
		Relative e	estimate		Absolute	estimate ((per 1,000)		Relative es	timate		Absolute e	stimate (pe	r 1,000)		Relative es	timate		Absolute e	stimate (per	1,000)	
Treatment 1	Treatment 2	Point estimate	CI lower	CI upper limit	Point estimate	CI lower limit	CI upper limit	Final rating	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit	Final rating	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit	Final rating
electrolyzed saline	intranasal corticosteroids	NA	NA	NA	NA	NA	NA	NA	0.36	0.07	1.68	-26.75	-84.77	11.79	VERY LOW	0.36	0.07	1.68	-26.75	-84.77	11.79	VERY LOW
electrolyzed saline	intranasal hypertonic polymer spray	NA NA	NA NA	NA.	NA NA	NA NA	NA NA	NA NA	0.19	0.03	1.13	-69.77	-229.85	1.73	VERY LOW	0.19	0.03	1.13	-69.77	-229.85	1.73	VERY LOW
electrolyzed saline	ivermectin	NA NA	NA NA	NA.	NA NA	NA NA	NA NA	NA NA	0.59	0.14	2.49	-8.75	-36.94	20.46	VERY LOW	0.59	0.14	2.49	-8.75	-36.94	20.46	VERY LOW
electrolyzed saline	lopinavir-ritonavir	NA	NA	NA.	NA	NA	NA.	NA NA	0.45	0.09	2.04	-18.12	-64.85	15.98	VERY LOW	0.45	0.09	2.04	-18.12	-64.85	15.98	VERY LOW
electrolyzed saline	molnupiravir	NA	NA	NA	NA	NA	NA	NA NA	0.59	0.17	2.16	-7.66	-26.94	19.41	VERY LOW	0.59	0.17	2.16	-7.66	-26.94	19.41	VERY LOW
electrolyzed saline	nitazoxanide	NA	NA	NA	NA	NA	NA	NA	0.56	0.11	3.06	-12.66	-60.36	21.40	VERY LOW	0.56	0.11	3.06	-12.66	-60.36	21.40	VERY LOW
electrolyzed saline	nirmatrelvir/ritonavir	NA	NA	NA	NA	NA	NA	NA	2.42	0.47	12.76	9.60	-6.43	35.37	VERY LOW	2.42	0.47	12.76	9.60	-6.43	35.37	VERY LOW
electrolyzed saline	probiotics	NA	NA	NA	NA	NA	NA	NA	6.31E+03	0.00	3.10E+52	-735.81	-995.08	26.29	VERY LOW	6.31E+03	0.00	3.10E+52	-735.81	-995.08	26.29	VERY LOW
electrolyzed saline	proxalutamide	NA	NA	NA	NA	NA	NA	NA	10.94	1.74	101.39	14.65	2.22	39.65	VERY LOW	10.94	1.74	101.39	14.65	2.22	39.65	VERY LOW
electrolyzed saline	remdesivir	NA	NA	NA	NA	NA	NA	NA	1.27	0.23	7.19	2.96	-23.71	30.65	VERY LOW	1.27	0.23	7.19	2.96	-23.71	30.65	VERY LOW
electrolyzed saline	sulodexide	NA	NA	NA	NA	NA	NA	NA	0.59	0.13	2.57	-9.80	-44.00	20.46	VERY LOW	0.59	0.13	2.57	-9.80	-44.00	20.46	VERY LOW
fluvoxamine	full-dose anticoagulant	NA	NA	NA	NA	NA	NA	NA	1.16	0.26	4.63	-0.79	-59.72	32.15	VERY LOW	1.16	0.26	4.63	-0.79	-59.72	32.15	VERY LOW
fluvoxamine	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	0.74	0.27	1.71	-11.77	-48.85	17.66	VERY LOW	0.74	0.27	1.71	-11.77	-48.85	17.66	VERY LOW
fluvoxamine	intranasal corticosteroids	NA	NA	NA	NA	NA	NA	NA	0.78	0.22	2.51	-11.93	-70.20	24.36	VERY LOW	0.78	0.22	2.51	-11.93	-70.20	24.36	VERY LOW
fluvoxamine	intranasal hypertonic polymer spray	NA	NA	NA	NA	NA	NA	NA	0.41	0.08	1.80	-54.96	-216.05	15.65	VERY LOW	0.41	0.08	1.80	-54.96	-216.05	15.65	VERY LOW
fluvoxamine	ivermectin	NA	NA	NA	NA	NA	NA	NA	1.30	0.44	3.55	6.06	-23.35	31.67	VERY LOW	1.30	0.44	3.55	6.06	-23.35	31.67	VERY LOW
fluvoxamine	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.99	0.28	3.08	-3.30	-50.54	27.86	VERY LOW	0.99	0.28	3.08	-3.30	-50.54	27.86	VERY LOW
fluvoxamine	molnupiravir	NA	NA	NA	NA	NA	NA	NA	1.30	0.54	2.91	7.15	-13.95	30.32	VERY LOW	1.30	0.54	2.91	7.15	-13.95	30.32	VERY LOW
fluvoxamine	nitazoxanide	NA	NA	NA	NA	NA	NA	NA	1.22	0.32	4.90	2.15	-45.53	33.11	VERY LOW	1.22	0.32	4.90	2.15	-45.53	33.11	VERY LOW
fluvoxamine	nirmatrelvir/ritonavir	NA	NA	NA	NA	NA	NA	NA	5.31	1.37	19.93	24.41	5.72	45.75	VERY LOW	5.31	1.37	19.93	24.41	5.72	45.75	VERY LOW
fluvoxamine	probiotics	NA	NA	NA	NA	NA	NA	NA	1.29E+04	0.00	6.88E+52	-720.99	-983.27	40.22	VERY LOW	1.29E+04	0.00	6.88E+52	-720.99	-983.27	40.22	VERY LOW
fluvoxamine	proxalutamide	NA	NA	NA	NA	NA	NA	NA	23.44	4.98	177.81	29.47	13.36	50.03	VERY LOW	23.44	4.98	177.81	29.47	13.36	50.03	VERY LOW
fluvoxamine	remdesivir	NA	NA	NA	NA	NA	NA	NA	2.76	0.66	11.48	17.77	-10.08	41.45	VERY LOW	2.76	0.66	11.48	17.77	-10.08	41.45	VERY LOW
fluvoxamine	sulodexide	NA	NA	NA	NA	NA	NA	NA	1.29	0.38	3.77	5.01	-31.19	31.81	VERY LOW	1.29	0.38	3.77	5.01	-31.19	31.81	VERY LOW
full-dose anticoagulant	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	0.63	0.15	2.63	-10.98	-53.99	49.13	LOW	0.63	0.15	2.63	-10.98	-53.99	49.13	LOW
full-dose anticoagulant	intranasal corticosteroids	NA	NA	NA	NA	NA	NA	NA	0.67	0.14	3.37	-11.14	-73.52	53.55	LOW	0.67	0.14	3.37	-11.14	-73.52	53.55	LOW
full-dose anticoagulant	intranasal hypertonic polymer spray	NA	NA	NA	NA	NA	NA	NA	0.35	0.05	2.37	-54.17	-216.87	35.69	VERY LOW	0.35	0.05	2.37	-54.17	-216.87	35.69	VERY LOW
full-dose anticoagulant	ivermectin	NA	NA	NA	NA	NA	NA	NA	1.12	0.25	5.18	6.85	-28.90	65.49	LOW	1.12	0.25	5.18	6.85	-28.90	65.49	LOW
full-dose anticoagulant	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.85	0.17	4.28	-2.51	-54.30	59.55	VERY LOW	0.85	0.17	4.28	-2.51	-54.30	59.55	VERY LOW
full-dose anticoagulant	molnupiravir	NA	NA	NA	NA	NA	NA	NA	1.12	0.29	4.55	7.95	-20.93	65.79	VERY LOW	1.12	0.29	4.55	7.95	-20.93	65.79	VERY LOW
full-dose anticoagulant	nitazoxanide	NA	NA	NA	NA	NA	NA	NA	1.06	0.19	6.29	2.94	-50.08	65.90	VERY LOW	1.06	0.19	6.29	2.94	-50.08	65.90	VERY LOW
full-dose anticoagulant	nirmatrelvir/ritonavir	NA	NA	NA	NA	NA	NA	NA	4.58	0.84	26.59	25.21	-1.02	82.07	VERY LOW	4.58	0.84	26.59	25.21	-1.02	82.07	VERY LOW
full-dose anticoagulant	probiotics	NA	NA	NA	NA	NA	NA	NA	1.11E+04	0.00	4.41E+52	-720.20	-991.16	54.64	VERY LOW	1.11E+04	0.00	4.41E+52	-720.20	-991.16	54.64	VERY LOW
full-dose anticoagulant	proxalutamide	NA	NA	NA	NA	NA	NA	NA	20.63	3.13	211.21	30.26	5.85	86.74	VERY LOW	20.63	3.13	211.21	30.26	5.85	86.74	VERY LOW
full-dose anticoagulant	remdesivir	NA	NA	NA	NA	NA	NA	NA	2.38	0.42	14.79	18.56	-15.42	76.59	VERY LOW	2.38	0.42	14.79	18.56	-15.42	76.59	VERY LOW
full-dose anticoagulant	sulodexide	NA	NA	NA	NA	NA	NA	NA	1.10	0.23	5.42	5.80	-34.81	64.90	VERY LOW	1.10	0.23	5.42	5.80	-34.81	64.90	VERY LOW
(hydroxy)chloroquine	intranasal corticosteroids	NA	NA	NA	NA	NA	NA	NA NA	1.07	0.32	3.63	-0.16	-59.48	44.71	LOW	1.07	0.32	3.63	-0.16	-59.48	44.71	LOW
(hydroxy)chloroquine	intranasal hypertonic polymer spray	NA	NA	NA	NA	NA	NA NA	NA NA	0.56	0.11	2.63	-43.19	-204.19	33.72	VERY LOW	0.56	0.11	2.63	-43.19	-204.19	33.72	VERY LOW
(hydroxy)chloroquine	ivermectin	NA 0.04	NA	NA 0.40	NA	NA	NA NA	NA VEDVI OM	1.78	0.64	5.25	17.83	-14.13	54.77	LOW	1.78	0.64	5.25	17.83	-14.13	54.77	LOW
lopinavir-ritonavir	(hydroxy)chloroquine	0.64	0.16	2.49	NA	NA	NA NA	VERY LOW	NA 4.77	NA 0.70	NA 1.05	NA 10.00	NA 0.40	NA 50.07	NA VEDVI OM	0.74	0.27	2.01	-8.47	-42.36	32.46	VERY LOW
(hydroxy)chloroquine	molnupiravir	NA	NA	NA	NA	NA	NA NA	NA NA	1.77	0.79	4.35	18.92	-6.43	53.87	VERY LOW	1.77	0.79	4.35	18.92	-6.43	53.87	VERY LOW
(hydroxy)chloroquine	nitazoxanide	NA	NA	NA	NA	NA	NA	NA NA	1.69	0.45	7.15	13.92	-35.80	55.00	LOW	1.69	0.45	7.15	13.92	-35.80	55.00	LOW
(hydroxy)chloroquine	nirmatrelvir/ritonavir	NA NA	NA	NA	NA NA	NA	NA NA	NA NA	7.24	2.01	29.11	36.19	12.92	69.81	LOW	7.24	2.01	29.11	36.19	12.92	69.81	LOW
(hydroxy)chloroquine	probiotics	NA	NA	NA	NA	NA	NA	NA	1.83E+04	0.00	9.92E+52	-709.22	-976.69	57.53	VERY LOW	1.83E+04	0.00	9.92E+52	-709.22	-976.69	57.53	VERY LOW

								Admi	ssion to hosp	ital												
Comparison		Direct es	timate						Indirect es	timate						Network e	stimate					
		Relative e	estimate		Absolute	estimate	(per 1,000)		Relative es	timate		Absolute e	stimate (pe	r 1,000)		Relative es	timate		Absolute e	estimate (pe	r 1,000)	
Treatment 1	Treatment 2	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit	Final rating	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit	Final rating	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit	Final rating
(hydroxy)chloroquine	proxalutamide	NA	NA	NA	NA	NA	NA	NA	32.23	7.03	254.26	41.24	20.02	74.26	VERY LOW	32.23	7.03	254.26	41.24	20.02	74.26	VERY LOW
(hydroxy)chloroquine	remdesivir	NA	NA	NA	NA	NA	NA	NA	3.77	0.94	16.84	29.54	-1.17	64.90	LOW	3.77	0.94	16.84	29.54	-1.17	64.90	LOW
(hydroxy)chloroquine	sulodexide	NA	NA	NA	NA	NA	NA	NA	1.76	0.56	5.59	16.78	-20.89	54.83	VERY LOW	1.76	0.56	5.59	16.78	-20.89	54.83	VERY LOW
intranasal corticosteroids	intranasal hypertonic polymer spray	NA	NA	NA	NA	NA	NA	NA	0.53	0.09	2.97	-43.03	-205.77	46.77	VERY LOW	0.53	0.09	2.97	-43.03	-205.77	46.77	VERY LOW
intranasal corticosteroids	ivermectin	NA	NA	NA	NA	NA	NA	NA	1.68	0.45	6.33	17.99	-20.92	76.05	LOW	1.68	0.45	6.33	17.99	-20.92	76.05	LOW
intranasal corticosteroids	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	1.27	0.30	5.34	8.63	-45.48	69.62	VERY LOW	1.27	0.30	5.34	8.63	-45.48	69.62	VERY LOW
intranasal corticosteroids	molnupiravir	NA	NA	NA	NA	NA	NA	NA	1.67	0.54	5.36	19.09	-13.46	75.60	VERY LOW	1.67	0.54	5.36	19.09	-13.46	75.60	VERY LOW
intranasal corticosteroids	nitazoxanide	NA	NA	NA	NA	NA	NA	NA	1.59	0.34	8.04	14.08	-40.36	74.53	LOW	1.59	0.34	8.04	14.08	-40.36	74.53	LOW
intranasal corticosteroids	nirmatrelvir/ritonavir	NA	NA	NA	NA	NA	NA	NA	6.88	1.48	33.16	36.35	5.64	92.29	LOW	6.88	1.48	33.16	36.35	5.64	92.29	LOW
intranasal corticosteroids	probiotics	NA	NA	NA	NA	NA	NA	NA	1.58E+04	0.00	8.79E+52	-709.06	-984.62	67.44	VERY LOW	1.58E+04	0.00	8.79E+52	-709.06	-984.62	67.44	VERY LOW
intranasal corticosteroids	proxalutamide	NA	NA	NA	NA	NA	NA	NA	30.68	5.33	270.58	41.40	12.06	97.19	VERY LOW	30.68	5.33	270.58	41.40	12.06	97.19	VERY LOW
intranasal corticosteroids	remdesivir	NA	NA	NA	NA	NA	NA	NA	3.56	0.72	18.77	29.70	-7.65	86.66	LOW	3.56	0.72	18.77	29.70	-7.65	86.66	LOW
intranasal corticosteroids	sulodexide	NA	NA	NA	NA	NA	NA	NA	1.64	0.41	6.63	16.94	-26.65	75.74	VERY LOW	1.64	0.41	6.63	16.94	-26.65	75.74	VERY LOW
intranasal hypertonic polymer spray	ivermectin	NA	NA	NA	NA	NA	NA	NA	3.16	0.64	17.20	61.02	-11.12	221.22	VERY LOW	3.16	0.64	17.20	61.02	-11.12	221.22	VERY LOW
intranasal hypertonic polymer spray	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	2.40	0.43	13.98	51.66	-30.54	212.94	VERY LOW	2.40	0.43	13.98	51.66	-30.54	212.94	VERY LOW
intranasal hypertonic polymer spray	molnupiravir	NA	NA	NA	NA	NA	NA	NA	3.16	0.72	15.27	62.11	-6.67	222.60	VERY LOW	3.16	0.72	15.27	62.11	-6.67	222.60	VERY LOW
intranasal hypertonic polymer spray	nitazoxanide	NA	NA	NA	NA	NA	NA	NA	3.01	0.50	20.38	57.11	-25.98	219.17	VERY LOW	3.01	0.50	20.38	57.11	-25.98	219.17	VERY LOW
intranasal hypertonic polymer spray	nirmatrelvir/ritonavir	NA	NA	NA	NA	NA	NA	NA	12.96	2.18	85.05	79.37	11.40	238.84	VERY LOW	12.96	2.18	85.05	79.37	11.40	238.84	VERY LOW
intranasal hypertonic polymer spray	probiotics	NA	NA	NA	NA	NA	NA	NA	3.42E+04	0.00	1.61E+53	-666.03	-978.39	151.56	VERY LOW	3.42E+04	0.00	1.61E+53	-666.03	-978.39	151.56	VERY LOW
intranasal hypertonic polymer spray	proxalutamide	NA	NA	NA	NA	NA	NA	NA	58.46	8.13	636.82	84.43	17.37	244.15	VERY LOW	58.46	8.13	636.82	84.43	17.37	244.15	VERY LOW
intranasal hypertonic polymer spray	remdesivir	NA	NA	NA	NA	NA	NA	NA	6.74	1.06	47.67	72.73	1.62	232.68	VERY LOW	6.74	1.06	47.67	72.73	1.62	232.68	VERY LOW
intranasal hypertonic polymer spray	sulodexide	NA	NA	NA	NA	NA	NA	NA	3.12	0.58	17.65	59.97	-15.06	220.68	VERY LOW	3.12	0.58	17.65	59.97	-15.06	220.68	VERY LOW
ivermectin	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.76	0.20	2.74	-9.36	-56.76	24.73	VERY LOW	0.76	0.20	2.74	-9.36	-56.76	24.73	VERY LOW
ivermectin	molnupiravir	NA	NA	NA	NA	NA	NA	NA	1.00	0.37	2.68	1.09	-19.69	28.09	VERY LOW	1.00	0.37	2.68	1.09	-19.69	28.09	VERY LOW
ivermectin	nitazoxanide	NA	NA	NA	NA	NA	NA	NA 	0.95	0.22	4.22	-3.91	-51.79	30.30	LOW	0.95	0.22	4.22	-3.91	-51.79	30.30	LOW
ivermectin	nirmatrelvir/ritonavir	NA	NA	NA	NA	NA	NA	NA 	4.07	1.00	17.61	18.36	0.45	43.71	LOW	4.07	1.00	17.61	18.36	0.45	43.71	LOW
ivermectin	probiotics	NA	NA	NA	NA	NA	NA	NA NA	1.03E+04	0.00	5.45E+52	-727.05	-988.80	36.21	VERY LOW	1.03E+04	0.00	5.45E+52	-727.05	-988.80	36.21	VERY LOW
ivermectin	proxalutamide	NA	NA	NA	NA NA	NA	NA NA	NA NA	18.12	3.59	148.16	23.41	8.17	48.18	VERY LOW	18.12	3.59	148.16	23.41	8.17	48.18	VERY LOW
ivermectin	remdesivir	NA	NA	NA	NA NA	NA	NA NA	NA NA	2.12	0.48	9.91	11.71	-15.95	39.38	LOW	2.12	0.48	9.91	11.71	-15.95	39.38	LOW
ivermectin	sulodexide	NA NA	NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.99 1.32	0.28	3.36 4.28	-1.05 10.46	-36.24 -16.83	29.34 56.25	VERY LOW VERY LOW	0.99 1.32	0.28	3.36 4.28	-1.05 10.46	-36.24 -16.83	29.34 56.25	VERY LOW VERY LOW
lopinavir-ritonavir lopinavir-ritonavir	molnupiravir nitazoxanide	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.32	0.43	6.40	5.45	-45.97	56.04	VERY LOW	1.32	0.43	6.40	5.45	-45.97	56.25	VERY LOW
lopinavir-ritonavir	nirmatrelvir/ritonavir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	5.40	1.20	25.95	27.72	2.68	72.50	VERY LOW	5.40	1.20	25.95	27.72	2.68	72.50	VERY LOW
lopinavir-ritonavir	probiotics	NA NA	NA	NA	NA NA	NA	NA NA	NA NA	1.34E+04	0.00	7.08E+52	-717.69	-987.17	52.94	VERY LOW	1.34E+04	0.00	7.08E+52	-717.69	-987.17	52.94	VERY LOW
lopinavir-ritonavir	proxalutamide	NA NA	NA	NA	NA NA	NA	NA NA	NA NA	24.14	4.30	215.91	32.77	9.61	77.14	VERY LOW	24.14	4.30	215.91	32.77	9.61	77.14	VERY LOW
lopinavir-ritonavir	remdesivir	NA NA	NA	NA	NA NA	NA NA	NA NA	NA NA	2.81	0.57	14.79	21.07	-11.67	67.18	VERY LOW	2.81	0.57	14.79	21.07	-11.67	67.18	VERY LOW
lopinavir-ritonavir	sulodexide	NA	NA	NA	NA	NA	NA	NA	1.30	0.32	5.22	8.31	-31.09	56.39	VERY LOW	1.30	0.32	5.22	8.31	-31.09	56.39	VERY LOW
molnupiravir	nitazoxanide	NA	NA	NA	NA	NA	NA NA	NA NA	0.95	0.26	3.67	-5.00	-51.64	21.53	VERY LOW	0.95	0.26	3.67	-5.00	-51.64	21.53	VERY LOW
molnupiravir	nirmatrelvir/ritonavir	NA	NA	NA	NA	NA	NA	NA NA	4.09	1.15	15.10	17.26	2.80	32.50	VERY LOW	4.09	1.15	15.10	17.26	2.80	32.50	VERY LOW
molnupiravir	probiotics	NA	NA	NA	NA	NA	NA	NA NA	1.02E+04	0.00	5.18E+52	-728.15	-985.61	30.44	VERY LOW	1.02E+04	0.00	5.18E+52	-728.15	-985.61	30.44	VERY LOW
molnupiravir	proxalutamide	NA	NA	NA	NA	NA	NA	NA NA	17.99	4.09	134.60	22.31	11.36	36.49	VERY LOW	17.99	4.09	134.60	22.31	11.36	36.49	VERY LOW
molnupiravir	remdesivir	NA	NA	NA	NA	NA	NA	NA NA	2.13	0.54	8.74	10.62	-14.80	29.05	VERY LOW	2.13	0.54	8.74	10.62	-14.80	29.05	VERY LOW
molnupiravir	sulodexide	NA	NA	NA	NA	NA	NA	NA	0.99	0.32	2.86	-2.14	-35.52	19.98	VERY LOW	0.99	0.32	2.86	-2.14	-35.52	19.98	VERY LOW
nitazoxanide	nirmatrelvir/ritonavir	NA	NA	NA	NA	NA	NA	NA	4.31	0.79	23.13	22.26	-1.63	67.94	LOW	4.31	0.79	23.13	22.26	-1.63	67.94	LOW
IIItazokariiue	IIIIIIIau Eivii/IIIoiiavii	INA	INA	11/7	INA	INA	INA	11/7	4.51	0.19	20.10	22.20	-1.00	07.34	LOVV	4.51	0.13	20.10	22.20	1 -1.00	07.34	LOW

Complete network meta-analysis results and GRADE

								Admis	ssion to hos	oital												
Comparison		Direct es	timate						Indirect es	timate						Network e	stimate					
		Relative e	stimate		Absolute	estimate	(per 1,000)		Relative es	timate		Absolute e	stimate (pe	r 1,000)		Relative es	stimate		Absolute e	estimate (pe	r 1,000)	
Treatment 1	Treatment 2	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit	Final rating	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit	Final rating	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit	Final rating
nitazoxanide	probiotics	NA	NA	NA	NA	NA	NA	NA	1.08E+04	0.00	5.20E+52	-723.15	-991.73	48.30	VERY LOW	1.08E+04	0.00	5.20E+52	-723.15	-991.73	48.30	VERY LOW
nitazoxanide	proxalutamide	NA	NA	NA	NA	NA	NA	NA	19.32	2.92	185.59	27.31	5.53	72.67	VERY LOW	19.32	2.92	185.59	27.31	5.53	72.67	VERY LOW
nitazoxanide	remdesivir	NA	NA	NA	NA	NA	NA	NA	2.24	0.38	12.95	15.62	-16.90	62.73	VERY LOW	2.24	0.38	12.95	15.62	-16.90	62.73	VERY LOW
nitazoxanide	sulodexide	NA	NA	NA	NA	NA	NA	NA	1.04	0.22	4.62	2.86	-36.71	51.67	VERY LOW	1.04	0.22	4.62	2.86	-36.71	51.67	VERY LOW
nirmatrelvir/ritonavir	probiotics	NA	NA	NA	NA	NA	NA	NA	2.55E+03	0.00	1.25E+52	-745.41	-998.00	10.70	VERY LOW	2.55E+03	0.00	1.25E+52	-745.41	-998.00	10.70	VERY LOW
nirmatrelvir/ritonavir	proxalutamide	NA	NA	NA	NA	NA	NA	NA	4.45	0.70	42.78	5.05	-1.03	15.41	VERY LOW	4.45	0.70	42.78	5.05	-1.03	15.41	VERY LOW
nirmatrelvir/ritonavir	remdesivir	NA	NA	NA	NA	NA	NA	NA	0.52	0.09	2.94	-6.64	-30.44	8.35	VERY LOW	0.52	0.09	2.94	-6.64	-30.44	8.35	VERY LOW
nirmatrelvir/ritonavir	sulodexide	NA	NA	NA	NA	NA	NA	NA	0.24	0.05	1.04	-19.40	-51.42	0.17	VERY LOW	0.24	0.05	1.04	-19.40	-51.42	0.17	VERY LOW
probiotics	proxalutamide	NA	NA	NA	NA	NA	NA	NA	0.00	0.00	2.43E+14	750.46	-2.92	999.76	VERY LOW	0.00	0.00	2.43E+14	750.46	-2.92	999.76	VERY LOW
probiotics	remdesivir	NA	NA	NA	NA	NA	NA	NA	0.00	0.00	2.93E+13	738.77	-22.04	996.56	VERY LOW	0.00	0.00	2.93E+13	738.77	-22.04	996.56	VERY LOW
probiotics	sulodexide	NA	NA	NA	NA	NA	NA	NA	0.00	0.00	1.20E+13	726.00	-38.78	989.53	VERY LOW	0.00	0.00	1.20E+13	726.00	-38.78	989.53	VERY LOW
proxalutamide	remdesivir	NA	NA	NA	NA	NA	NA	NA	0.11	0.01	0.81	-11.69	-34.94	-0.69	VERY LOW	0.11	0.01	0.81	-11.69	-34.94	-0.69	VERY LOW
proxalutamide	sulodexide	NA	NA	NA	NA	NA	NA	NA	0.05	0.01	0.29	-24.45	-55.99	-7.36	VERY LOW	0.05	0.01	0.29	-24.45	-55.99	-7.36	VERY LOW
remdesivir	sulodexide	NA	NA	NA	NA	NA	NA	NA	0.46	0.09	2.18	-12.76	-46.60	16.17	VERY LOW	0.46	0.09	2.18	-12.76	-46.60	16.17	VERY LOW

									A	dverse events											
Comparison		Direct estimate Relative estimate			Absolute estimate	(4.000)			Indirect estimat		Absolute estima	1- (1 000)			Network estima Relative estim		laborator.	estimate (per 1.000)			
Treatment 1	Treatment 2		ver limit		Point estimate	4	CI upper limit	Final rating		CI lower limit		Point estimate	CI lower limit	Final rating		CI lower limit CI upp		nate CI lower limit	CI upper limit	Final rating	Reasons for downgrading
ACE/ARB	standard care/placebo		۱A	NA	24	-251	304	VERY LOW	NA	NA NA	NA	NA	NA NA	NA	NA	NA N		-19	27	LOW	RoB, Imprecision
(acetyl)cysteine	standard care/placebo		NΑ	NA	0	-508	507	LOW	NA	NA NA	NA	NA	NA NA	NA	NA	NA N		-24	23	MODERATE	Imprecision
antihepaciviral aspirin	standard care/placebo standard care/placebo		NA NA	NA NA	-6 9	-140 -1253	126 1271	LOW VERY LOW	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA N		-9 -6	8 24	HIGH	RoB. Imprecision
aspirin aspirin, statins	standard care/placebo standard care/placebo		NA NA	NA NA	9	-1253 -1262	12/1	VERY LOW VERY LOW	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA N		-6 -9	24	MODERATE	RoB, Imprecision
azithromycin	standard care/placebo		NA	NA NA	0	-1262	1262	VERY LOW	NA NA	NA NA	-0.004	-4	-32 25	LOW	NA NA	NA N		-24	20	LOW	RoB, Imprecision
azithromycin, hydroxychloroquine	standard care/placebo		۱A	NA	31	-131	208	LOW	NA	NA NA	0.006	6	-33 46	LOW	NA	NA N		-13	23	MODERATE	Imprecision
azithromycin, hydroxychloroquine, oseltamivir	standard care/placebo	107	NΑ	NA	NA	NA	NA	NA	NA	NA NA	0.055	55	12 99	VERY LOW	NA	NA N		12	99	LOW	RoB, Imprecision
azithromycin, lopinavir-ritonavir colchicine	standard care/placebo standard care/placebo		NA NA	NA NA	NA 30	NA -228	NA 288	NA VERY LOW	NA NA	NA NA	-0.001 NA	-1 NA	-24 23 NA NA	MODERATE	NA NA	NA N		-24 -10	23 59	MODERATE LOW	Imprecision RoB, Imprecision
colchicine, emtricitabine, tenofovir, statins	standard care/placebo		NA.	NA NA	31	-1231	1293	VERY LOW	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA N		3	61	LOW	RoB, Imprecision
colchicine, statins	standard care/placebo	NA N	NA.	NA.	13	-1249	1275	VERY LOW	NA	NA NA	NA	NA	NA NA	NA NA	NA	NA N	IA 14	-8	35	LOW	RoB, Imprecision
IL6 receptor antagonists with corticosteroids (systemic)	standard care/placebo		NΑ	NA	0	-83	95	LOW	NA	NA NA	NA	NA	NA NA	NA	NA	NA N	IA -4	-13	4	HIGH	
doxycycline, ivermectin	standard care/placebo		NA NA	NA NA	10 NA	-1252 NA	1272 NA	VERY LOW NA	NA NA	NA NA	NA	NA .	NA NA -27 17	NA LOW	NA NA	NA N		-7 -27	27	MODERATE LOW	Imprecision
doxycycline, lopinavir-ritonavir	standard care/placebo standard care/placebo		NA NA	NA NA	NA 27	-1236	NA 1289	VERYLOW	NA NA	NA NA	-0.005 NA	-5 NA	-27 17 NA NA	LOW NA	NA NA	NA NA		-27	62	LOW	RoB, Imprecision
emtricitabine, tenofovir	standard care/placebo		NA	NA NA	53	-476	590	VERY LOW	NA.	NA NA	NA NA	NA.	NA NA	NA NA	NA NA	NA N		-2	46	LOW	RoB. Imprecision
favipiravir	standard care/placebo		NΑ	NA	25	-88	143	VERY LOW	NA	NA NA	NA	NA	NA NA	NA	NA	NA N	IA 5	-9	20	MODERATE	RoB
full-dose anticoagulant	standard care/placebo		۱A	NA	-3	-1266	1259	VERY LOW	NA	NA NA	NA	NA	NA NA	NA	NA	NA N		-29	22	MODERATE	Imprecision
(hydroxy)chloroquine	standard care/placebo		NA NA	NA NA	23	-7 -505	53 506	VERY LOW	NA NA	NA NA	0.025 NA	25 NA	-79 128 NA NA	VERY LOW	NA NA	NA N		-8	24	LOW	RoB, Imprecision
IL1 inhibitors IL6 receptor antagonists without corticosteroids (systemic)	standard care/placebo		NA NA	NA NA	-2	-1264	1260	VERY LOW	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA N		-13	9	HIGH	
interferon beta (subcutaneous)	standard care/placebo	NA N	NA.	NA NA	1	-250	252	LOW	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA N		-30	31	MODERATE	Imprecision
interferon beta (subcutaneous), lopinavir-ritonavir	standard care/placebo		۱A	NA	297	-967	1560	VERY LOW	NA	NA NA	NA	NA	NA NA	NA	NA	NA N		216	366	MODERATE	RoB
intranasal corticosteroids	standard care/placebo		NA.	NA	-5	-249	239	LOW	NA	NA NA	NA	NA	NA NA	NA NA	NA	NA N		-25	9	MODERATE	Imprecision
ivermectin JAK inhibitors	standard care/placebo standard care/placebo		NA NA	NA NA	39 6	-77 -183	158 182	VERY LOW LOW	NA NA	NA NA	0.041 NA	41 NA	-36 118 NA NA	VERY LOW NA	NA NA	NA N		-4 -6	9	MODERATE HIGH	RoB
lopinavir-ritonavir	standard care/placebo		NA.	NA NA	54	-103	333	VERY LOW	NA NA	NA NA	0.014	14	-60 88	VERY LOW	NA NA	NA N		27	72	MODERATE	RoB
molnupiravir	standard care/placebo		NA	NA	-1	-57	57	LOW	NA	NA NA	NA	NA	NA NA	NA	NA	NA N	IA 0	-2	2	HIGH	
nitazoxanide	standard care/placebo		NΑ	NA	25	-131	194	LOW	NA	NA NA	NA	NA	NA NA	NA	NA	NA N		-7	10	HIGH	
nirmatrelvir/ritonavir	standard care/placebo		NA NA	NA NA	-19	-1281 -1262	1243 1262	VERY LOW VERY LOW	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA N	IA -19	-38 -13	0	MODERATE	Imprecision
probiotics proxalutamide	standard care/placebo standard care/placebo		NA NA	NA NA	-1	-1202	505	VERY LOW	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA		-13	13	MODERATE	RoB
remdesivir	standard care/placebo		NA.	NA NA	15	-59	94	LOW	NA NA	NA NA	NA	NA NA	NA NA	NA NA	NA	NA N	IA 6	-6	17	HIGH	
serine protease inhibitors	standard care/placebo		NΑ	NA	-19	-549	510	LOW	NA	NA NA	NA	NA	NA NA	NA	NA	NA N		-63	33	LOW	Imprecisionx2
SGLT2 inhibitors	standard care/placebo		NA.	NA	-18	-1280	1245	VERY LOW	NA	NA NA	NA	NA	NA NA	NA	NA	NA N		-48	13	MODERATE	Imprecision
statins sulodexide	standard care/placebo standard care/placebo		NA NA	NA NA	14	-1257 -1249	1266 1277	VERY LOW	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA N		-8	73	MODERATE VERY LOW	RoB. Imprecisionx2
tyrosine kinase inhibitors	standard care/placebo		NA.	NA NA	42	-492	572	LOW	NA NA	NA NA	NA NA	NA.	NA NA	NA NA	NA NA	NA N		19	105	MODERATE	Imprecision
umifenovir	standard care/placebo		۱A	NA	2	-251	254	VERY LOW	NA	NA NA	NA	NA	NA NA	NA	NA	NA N	IA 5	-24	34	LOW	RoB, Imprecision
vitamin D	standard care/placebo		NΑ	NA	0	-252	252	VERY LOW	NA	NA NA	NA	NA	NA NA	NA	NA	NA N		-26	24	LOW	RoB, Imprecision
ACEi/ARB ACEi/ARB	(acetyl)cysteine antihepaciviral		NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.004	4	-29 37 -20 29	LOW	NA NA	NA N		-29 -20	37 29	LOW	RoB, Imprecision
ACEI/ARB ACEI/ARB	antinepacivirai		NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.005	-5	-20 29 -33 23	LOW	NA NA	NA NA		-20	29	LOW	RoB, Imprecision RoB. Imprecision
ACEi/ARB	aspirin, statins		NA.	NA.	NA NA	NA	NA	NA NA	NA.	NA NA	0.004	4	-21 29	LOW	NA	NA N		-21	29	LOW	RoB, Imprecision
ACEi/ARB	azithromycin		NΑ	NA	NA	NA	NA	NA	NA	NA NA	0.006	6	-26 38	LOW	NA	NA N		-26	38	LOW	RoB, Imprecision
ACE/ARB	azithromycin, hydroxychloroquine		NA.	NA	NA	NA	NA	NA	NA NA	NA NA	-0.001	-1 -51	-30 28 -101 -2	LOW	NA	NA N		-30	28	LOW	RoB, Imprecision
ACEi/ARB ACEi/ARB	azithromycin, hydroxychloroquine, oseltamivir azithromycin, lopinavir-ritonavir		NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.051 0.005	-51 5	-101 -2 -28 38	LOW	NA NA	NA N		-101 -28	-2 38	LOW	RoB, Imprecision RoB. Imprecision
ACE/ARB	colchicine		NA.	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.021	-21	-63 21	VERY LOW	NA NA	NA N		-63	21	VERY LOW	RoB, Imprecisionx2
ACE/ARB	colchicine, emtricitabine, tenofovir, statins	NA N	NA	NA	NA	NA	NA	NA	NA	NA NA	-0.028	-28	-65 10	VERY LOW	NA	NA N	IA -28	-65	10	LOW	RoB, Imprecision
ACEi/ARB	colchicine, statins		NA.	NA	NA	NA	NA	NA	NA	NA NA	-0.01	-10	-41 22	LOW	NA		IA -10	-41	22	LOW	RoB, Imprecision
ACEi/ARB ACEi/ARB	IL6 receptor antagonists with corticosteroids (systemic) doxycycline, ivermectin		NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.008	-6	-17 33 -35 23	LOW	NA NA	NA N	A 8	-17 -35	33 23	LOW	RoB, Imprecision RoB, Imprecision
ACE/ARB ACE/ARB	doxycycline, Ivermectin doxycycline, Iopinavir-ritonavir		NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.009	-b 9	-35 23 -23 41	LOW	NA NA	NA N		-35	41	LOW	RoB, Imprecision
ACEi/ARB	electrolyzed saline		۱A	NA NA	NA	NA	NA	NA	NA	NA NA	-0.023	-23	-65 19	VERY LOW	NA	NA N	IA -23	-65	19	LOW	RoB, Imprecision
ACE/ARB	emtricitabine, tenofovir		NΑ	NA	NA	NA	NA	NA	NA	NA NA	-0.018	-18	-51 16	VERY LOW	NA	NA N		-51	16	LOW	RoB, Imprecision
ACEI/ARB ACEI/ARB	favlpiravir		NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.001 0.007	-1 7	-29 26 -27 42	LOW	NA NA	NA N	IA -1	-29 -27	26 42	LOW	RoB, Imprecision RoB, Imprecision
ACE/ARB ACE/ARB	full-dose anticoagulant (hydroxy)chloroquine		NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.009	-9	-27 42 -35 17	LOW	NA NA	NA N		-27 -35	17	LOW	RoB, Imprecision RoB, Imprecision
ACE/ARB	IL1 inhibitors		NA.	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.002	2	-23 28	LOW	NA NA	NA N		-23	28	LOW	RoB, Imprecision
ACEi/ARB	IL6 receptor antagonists without corticosteroids (systemic)		NΑ	NA	NA	NA	NA	NA	NA	NA NA	0.006	6	-20 31	LOW	NA	NA N		-20	31	LOW	RoB, Imprecision
ACEi/ARB	interferon beta (subcutaneous)		NA.	NA	NA	NA	NA	NA	NA	NA NA	0.004	4	-35 42	LOW	NA	NA N		-35	42	LOW	RoB, Imprecision
ACEI/ARB ACEI/ARB	interferon beta (subcutaneous), lopinavir-ritonavir intranasal corticosteroids		NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.287 0.012	-287 12	-366 -209 -17 41	VERY LOW LOW	NA NA	NA N		-366 -17	-209 41	MODERATE LOW	RoB RoB, Imprecision
ACE/ARB ACE/ARB	intranasal corticosteroids ivermectin		NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.012	12	-1/ 41 -23 26	LOW	NA NA	NA N		-17	26	LOW	RoB, Imprecision
ACE/ARB	JAK inhibitors		NA.	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.001	-1	-27 25	LOW	NA NA	NA N		-27	25	LOW	RoB, Imprecision
ACEi/ARB	lopinavir-ritonavir		۱A	NA	NA	NA	NA	NA	NA	NA NA	-0.045	-45	-78 -13	VERY LOW	NA	NA N		-78	-13	LOW	RoB, Imprecision
ACEI/ARB	molnupiravir		NA.	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.004	4	-19 27	LOW	NA NA	NA NA		-19	27	LOW	RoB, Imprecision
ACEi/ARB ACEi/ARB	nitazoxanide nirmatrelvir/ritonavir		NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.002	2 23	-23 27 -7 53	LOW VERY LOW	NA NA	NA N		-23 -7	27 53	LOW	RoB, Imprecision RoB. Imprecision
ACE/ARB	probiotics		NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.023	4	-7 33	LOW	NA NA	NA N		-23	31	LOW	RoB, Imprecision
ACEi/ARB	proxalutamide	NA N	۱A	NA NA	NA	NA	NA	NA NA	NA	NA NA	0.006	6	-23 34	LOW	NA	NA N		-23	34	LOW	RoB, Imprecision
ACE/ARB	remdesivir		NΑ	NA	NA	NA	NA	NA	NA	NA NA	-0.002	-2	-28 24	LOW	NA		IA -2	-28	24	LOW	RoB, Imprecision
ACEi/ARB ACEi/ARB	serine protease inhibitors SGLT2 inhibitors		NA.	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.02	20 21	-34 73 -17 60	VERY LOW VERY LOW	NA NA	NA N		-34 -17	73	VERY LOW	RoB, Imprecisionx2 RoB. Imprecision
ACE/ARB ACE/ARB	SGL12 inhibitors statins		NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.021	0	-17 60 -27 26	LOW	NA NA		IA 21	-1/	60 26	LOW	RoB, Imprecision
ACEI/ARB ACEI/ARB	statins		NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.01	-10	-27 26 -73 53	VERY LOW	NA NA	NA N			53	VERY LOW	RoB, Imprecisionx3
	• • • • • • • • • • • • • • • • • • • •			•								-								-	

									ļ	Adverse events														
Comparison		Direct estimate							Indirect estima								Network estimate	•						
Treatment 1	Treatment 2	Relative estima		Cl upper limit	Absolute estimate Point estimate		Clumps limit	Final rating	Relative estimate		Clumper limit	Absolute estimate Point estimate	e (per 1,000) Point estimate	CI lower limit	CI upper limit	Final rating	Relative estima Point estimate	CI lower limit	CI upper limit	Absolute estimate	, , , , , , ,	CI upper limit	Final rating	December of the designment of the second sec
ACE/ARB	tyrosine kinase inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.058	-58	-107	-9	VERYLOW	NA NA	NA NA	NA NA	Point estimate	-107	-9	LOW	Reasons for downgrading RoB, Imprecision
ACEi/ARB	umifenovir	NA	NA	NA	NA NA	NA	NA	NA	NA	NA NA	NA	-0.001	-1	-38	36	LOW	NA	NA	NA NA	-1	-38	36	LOW	RoB, Imprecision
ACEi/ARB	vitamin D	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.005	5	-29	40	LOW	NA	NA	NA	5	-29	40	LOW	RoB, Imprecision
(acetyl)cysteine	antihepaciviral	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0	-25	25	MODERATE	NA	NA	NA	0	-25	25	MODERATE	Imprecision
(acetyl)cysteine (acetyl)cysteine	aspirin aspirin, statins	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.009 0	-9 0	-37 -25	19 25	LOW	NA NA	NA NA	NA NA	-9 0	-37 -25	19 25	LOW	RoB, Imprecision RoB, Imprecision
(acetyl)cysteine	azithromycin	NA NA	NA NA	NA.	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.002	2	-30	35	LOW	NA NA	NA NA	NA NA	2	-30	35	LOW	RoB, Imprecision
(acetyl)cysteine	azithromycin, hydroxychloroquine	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.005	-5	-34	24	MODERATE	NA	NA	NA NA	-5	-34	24	MODERATE	Imprecision
(acetyl)cysteine	azithromycin, hydroxychloroquine, oseltamivir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.055	-55	-105	-6	VERY LOW	NA	NA	NA	-55	-105	-6	LOW	RoB, Imprecision
(acetyl)cysteine (acetyl)cysteine	azithromycin, lopinavir-ritonavir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.001 -0.025	-25	-32 -67	34 17	MODERATE VERY LOW	NA NA	NA NA	NA NA	-25	-32 -67	34 17	MODERATE	Imprecision RoB. Imprecision
(acetyl)cysteine	colchicine, emtricitabine, tenofovir, statins	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.025	-25	-69	5	VERY LOW	NA NA	NA NA	NA NA	-25	-69	5	LOW	RoB, Imprecision
(acetyl)cysteine	colchicine, statins	NA	NA	NA	NA NA	NA	NA	NA NA	NA	NA NA	NA	-0.014	-14	-46	18	LOW	NA	NA	NA NA	-14	-46	18	LOW	RoB, Imprecision
(acetyl)cysteine	IL6 receptor antagonists with corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.004	4	-21	29	MODERATE	NA	NA	NA	4	-21	29	MODERATE	Imprecision
(acetyl)cysteine	doxycycline, ivermectin	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.01	-10	-39	19	MODERATE	NA	NA	NA	-10	-39	19	MODERATE	Imprecision
(acetyl)cysteine (acetyl)cysteine	doxycycline, lopinavir-ritonavir electrolyzed saline	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.005 -0.027	5 -27	-28 -69	37 15	MODERATE VERY LOW	NA NA	NA NA	NA NA	-27	-28 -69	37 15	MODERATE	Imprecision RoB. Imprecision
(acetyl)cysteine	emtricitabine, tenofovir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.027	-22	-55	12	VERY LOW	NA NA	NA NA	NA NA	-27	-55	12	LOW	RoB, Imprecision
(acetyl)cysteine	favipiravir	NA	NA	NA	NA	NA	NA.	NA.	NA	NA NA	NA	-0.006	-6	-33	22	LOW	NA	NA	NA NA	-6	-33	22	LOW	RoB, Imprecision
(acetyl)cysteine	full-dose anticoagulant	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.003	3	-32	38	MODERATE	NA	NA	NA	3	-32	38	MODERATE	Imprecision
(acetyl)cysteine	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.013	-13	-39	13	LOW	NA	NA	NA	-13	-39	13	LOW	RoB, Imprecision
(acetyl)cysteine	IL1 inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.002 0.002	-2 2	-27 -24	24	MODERATE MODERATE	NA NA	NA NA	NA NA	-2	-27 -24	24	MODERATE MODERATE	Imprecision
(acetyl)cysteine	IL6 receptor antagonists without corticosteroids (systemic) interferon beta (subcutaneous)	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.002	-1	-24	28	MODERATE	NA NA	NA NA	NA NA	-1	-24	28	MODERATE	Imprecision Imprecision
(acetyl)cysteine	interferon beta (subcutaneous) interferon beta (subcutaneous), lopinavir-ritonavir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.291	-291	-370	-213	VERY LOW	NA NA	NA NA	NA NA	-291	-39	-213	MODERATE	RoB
(acetyl)cysteine	intranasal corticosteroids	NA NA	NA NA	NA.	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.008	8	-21	37	MODERATE	NA NA	NA NA	NA NA	8	-21	37	MODERATE	Imprecision
(acetyl)cysteine	ivermectin	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.003	-3	-27	22	LOW	NA	NA	NA	-3	-27	22	LOW	RoB, Imprecision
(acetyl)cysteine	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.005	-5	-31	21	MODERATE	NA	NA	NA	-5	-31	21	MODERATE	Imprecision
(acetyl)cysteine	lopinavir-ritonavir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.05	-50	-82 -24	-17 24	LOW	NA NA	NA NA	NA NA	-50	-82	-17 24	LOW MODERATE	RoB, Imprecision
(acetyl)cysteine (acetyl)cysteine	molnupiravir nitazoxanide	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.002	0 -2	-24 -27	24	MODERATE	NA NA	NA NA	NA NA	-2	-24 -27	24	MODERATE	Imprecision Imprecision
(acetyl)cysteine	nirmatrelvir/ritonavir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.019	19	-11	49	MODERATE	NA NA	NA NA	NA NA	19	-11	49	MODERATE	Imprecision
(acetyl)cysteine	probiotics	NA	NA.	NA	NA NA	NA	NA.	NA NA	NA	NA NA	NA	0	0	-27	27	MODERATE	NA NA	NA	NA NA	0	-27	27	MODERATE	Imprecision
(acetyl)cysteine	proxalutamide	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.001	1	-27	30	LOW	NA	NA	NA	1	-27	30	LOW	RoB, Imprecision
(acetyl)cysteine	remdesivir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.006	-6	-32	20	MODERATE	NA	NA	NA	-6	-32	20	MODERATE	Imprecision
(acetyl)cysteine	serine protease inhibitors	NA NA	NA	NA NA	NA NA	NA	NA NA	NA NA	NA NA	NA	NA	0.015	15	-38	69	LOW	NA NA	NA	NA NA	15 17	-38	69	LOW	Imprecisionx2
(acetyl)cysteine (acetyl)cysteine	SGLT2 inhibitors statins	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.017 -0.005	17 -5	-21 -31	55 22	LOW	NA NA	NA NA	NA NA	-5	-21 -31	55 22	LOW	Imprecisionx2 RoB, Imprecision
(acetyl)cysteine	sulodexide	NA NA	NA.	NA.	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.014	-14	-77	48	VERY LOW	NA NA	NA NA	NA NA	-14	-77	48	VERY LOW	RoB. Imprecisionx2
(acetyl)cysteine	tyrosine kinase inhibitors	NA	NA	NA	NA	NA	NA.	NA.	NA	NA	NA	-0.063	-63	-112	-13	MODERATE	NA	NA	NA	-63	-112	-13	MODERATE	Imprecision
(acetyl)cysteine	umifenovir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.005	-5	-43	32	LOW	NA	NA	NA	-5	-43	32	LOW	RoB, Imprecision
(acetyl)cysteine	vitamin D	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.001	1	-34	36	LOW	NA	NA	NA	1	-34	36	LOW	RoB, Imprecision
antihepaciviral antihepaciviral	aspirin aspirin, statins	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.009 0.000	-9 0	-26 -12	8 12	LOW	NA NA	NA NA	NA NA	-9 0	-26 -12	8 12	LOW MODERATE	RoB, Imprecision RoB
antinepaciviral	aspirin, statins azithromycin	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.000	2	-12	26	LOW	NA NA	NA NA	NA NA	2	-12	26	LOW	RoB, Imprecision
antihepaciviral	azithromycin, hydroxychloroquine	NA NA	NA NA	NA.	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.005	-5	-25	14	MODERATE	NA NA	NA NA	NA NA	-5	-25	14	MODERATE	Imprecision
azithromycin, hydroxychloroquine, oseltamivir	antihepaciviral	NA	NA	NA	56	-1119	1230	VERY LOW	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	56	13	98	LOW	RoB, Imprecision
antihepaciviral	azithromycin, lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.001	1	-24	25	MODERATE	NA	NA	NA	1	-24	25	MODERATE	Imprecision
antihepaciviral	colchicine	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.025	-25	-61	11	VERY LOW	NA	NA	NA	-25	-61	11	LOW	RoB, Imprecision
antihepaciviral antihepaciviral	colchicine, emtricitabine, tenofovir, statins	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.032 -0.014	-32 -14	-63 -37	-2 9	LOW	NA NA	NA NA	NA NA	-32 -14	-63 -37	-2 9	LOW	RoB, Imprecision
antihepaciviral	IL6 receptor antagonists with corticosteroids (systemic)	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.004	4	-8	16	HIGH	NA NA	NA NA	NA NA	4	-8	16	HIGH	RoB, Imprecision
antihepaciviral	doxycycline, ivermectin	NA	NA	NA	NA NA	NA	NA.	NA.	NA	NA NA	NA	-0.010	-10	-29	8	MODERATE	NA NA	NA	NA NA	-10	-29	8	MODERATE	Imprecision
antihepaciviral	doxycycline, lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.004	4	-19	28	MODERATE	NA	NA	NA	4	-19	28	MODERATE	Imprecision
antihepaciviral	electrolyzed saline	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.027	-27	-63	9	LOW	NA	NA	NA	-27	-63	9	LOW	RoB, Imprecision
antihepaciviral	emtricitabine, tenofovir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.022 -0.006	-22	-48 -22	3 11	LOW	NA NA	NA NA	NA NA	-22 -6	-48 -22	3 11	LOW	RoB, Imprecision
antihepaciviral antihepaciviral	favipiravir full-dose anticoagulant	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.006 0.003	-6 3	-22 -24	30	LOW	NA NA	NA NA	NA NA	-6 3	-22 -24	30	MODERATE	RoB, Imprecision Imprecision
antihepaciviral	(hydroxy)chloroquine	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.013	-13	-24	1	LOW	NA NA	NA NA	NA NA	-13	-24	1	LOW	RoB, Imprecision
antihepaciviral	IL1 inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.002	-2	-15	11	HIGH	NA	NA	NA	-2	-15	11	HIGH	
antihepaciviral	IL6 receptor antagonists without corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.001	1	-12	15	HIGH	NA	NA	NA	1	-12	15	HIGH	
antihepaciviral	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.001	-1	-32	31	MODERATE	NA	NA	NA	-1	-32	31	MODERATE	Imprecision
antihepaciviral	interferon beta (subcutaneous), lopinavir-ritonavir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.292	-292	-367 -11	-216	VERY LOW	NA NA	NA NA	NA NA	-292	-367	-216	MODERATE	RoB
antihepaciviral antihepaciviral	intranasal corticosteroids ivermectin	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.008	-3	-11 -14	27 8	MODERATE MODERATE	NA NA	NA NA	NA NA	-3	-11 -14	27 8	MODERATE MODERATE	Imprecision RoB
antihepaciviral	JAK inhibitors	NA NA	NA NA	NA.	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.005	-5	-19	8	HIGH	NA NA	NA NA	NA NA	-5	-19	8	HIGH	NOD
antihepaciviral	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.050	-50	-74	-26	LOW	NA	NA.	NA NA	-50	-74	-26	LOW	RoB, Imprecision
antihepaciviral	molnupiravir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.000	0	-9	8	HIGH	NA	NA	NA	0	-9	8	HIGH	
antihepaciviral	nitazoxanide	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.002	-2	-14	10	HIGH	NA	NA	NA	-2	-14	10	HIGH	
antihepaciviral	nirmatrelvir/ritonavir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.019	19	-2	40	MODERATE	NA NA	NA NA	NA NA	19	-2	40	MODERATE	Imprecision
antihepaciviral antihepaciviral	probiotics proxalutamide	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.000	0	-16 -17	15 19	HIGH MODERATE	NA NA	NA NA	NA NA	0	-16 -17	15 19	HIGH MODERATE	RoB
antinepaciviral	proxalutamide remdesivir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.006	-6	-17	8	HIGH	NA NA	NA NA	NA NA	-6	-17	8	MODERATE	IVOD
antihepaciviral	serine protease inhibitors	NA	NA.	NA.	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.015	15	-34	64	LOW	NA NA	NA NA	NA NA	15	-34	64	LOW	Imprecisionx2
antihepaciviral	SGLT2 inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.017	17	-15	48	MODERATE	NA	NA	NA	17	-15	48	MODERATE	Imprecision
antihepaciviral	statins	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.005	-5	-20	10	MODERATE	NA	NA	NA	-5	-20	10	MODERATE	RoB
antihepaciviral	sulodexide	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.014	-14	-74	44	VERY LOW	NA NA	NA NA	NA NA	-14	-74	44	VERY LOW	RoB, Imprecisionx2
antihepaciviral	tyrosine kinase inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.063	-63	-107	-19	LOW	NA	NA	NA	-63	-107	-19	MODERATE	Imprecision

									Ac	iverse events											
Comparison		Direct estimate Relative estimate			Absolute estimate	(nos 1 000)			Indirect estimate		Absolute estimat	do (nos 1 000)			Network estimate		Absolute estima	nto (nos 4 000)			
Treatment 1	Treatment 2		CI lower limit	CI upper limit	Point estimate	41 - 7 7	CI upper limit	Final rating		CI lower limit CI upper limit			CI lower limit CI upper limit	Final rating		CI lower limit CI upper lim		CI lower limit	CI upper limit	Final rating	Reasons for downgrading
antihepaciviral	umifenovir	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	-0.006	-6	-36 25	LOW	NA	NA NA	-6	-36	25	LOW	RoB, Imprecision
antihepaciviral	vitamin D	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	0.001	1	-26 27	LOW	NA	NA NA	1	-26	27	LOW	RoB, Imprecision
aspirin, statins	aspirin azithromycin	NA NA	NA NA	NA NA	-9 NA	-1183 NA	1166 NA	VERY LOW NA	NA NA	NA NA	NA 0.011	NA 11	NA NA -15 38	NA LOW	NA NA	NA NA	-9 11	-24 -15	6 38	LOW	RoB, Imprecision RoB, Imprecision
aspirin	azithromycin, hydroxychloroquine	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.004	4	-19 27	LOW	NA NA	NA NA	4	-19	27	LOW	RoB, Imprecision
aspirin	azithromycin, hydroxychloroquine, oseltamivir	NA NA	NA	NA	NA NA	NA	NA	NA.	NA	NA NA	-0.046	-46	-92 0	LOW	NA	NA NA	-46	-92	0	LOW	RoB, Imprecision
aspirin	azithromycin, lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	0.010	10	-18 38	LOW	NA	NA NA	10	-18	38	LOW	RoB, Imprecision
aspirin	colchicine	NA NA	NA	NA	NA	NA	NA	NA	NA	NA NA	-0.016	-16 -23	-54 22	VERY LOW	NA	NA NA	-16	-54	22	VERY LOW	RoB, Imprecisionx2
aspirin aspirin	colchicine, emtricitabine, tenofovir, statins colchicine, statins	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.023 -0.005	-23 -5	-56 10 -31 21	VERY LOW LOW	NA NA	NA NA	-23	-56 -31	10 21	LOW	RoB, Imprecision RoB, Imprecision
aspirin	IL6 receptor antagonists with corticosteroids (systemic)	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.013	13	-4 31	LOW	NA NA	NA NA	13	-4	31	LOW	RoB, Imprecision
aspirin	doxycycline, ivermectin	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	-0.001	-1	-24 21	LOW	NA	NA NA	-1	-24	21	LOW	RoB, Imprecision
aspirin	doxycycline, lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	0.014	14	-13 40	LOW	NA	NA NA	14	-13	40	LOW	RoB, Imprecision
aspirin	electrolyzed saline	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.018 -0.013	-18 -13	-56 20 -41 15	VERY LOW LOW	NA NA	NA NA	-18 -13	-56 -41	20 15	VERY LOW LOW	RoB, Imprecisionx2
aspirin aspirin	emtricitabine, tenofovir favipiravir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.013	-13	-41 15 -17 24	LOW	NA NA	NA NA	-13	-41	24	LOW	RoB, Imprecision
aspirin	full-dose anticoagulant	NA.	NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.012	12	-18 42	LOW	NA NA	NA NA	12	-18	42	LOW	RoB, Imprecision
aspirin	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	-0.004	-4	-23 14	LOW	NA	NA NA	-4	-23	14	LOW	RoB, Imprecision
aspirin	IL1 inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	0.007	7	-11 25	LOW	NA	NA NA	7	-11	25	LOW	RoB, Imprecision
aspirin aspirin	IL6 receptor antagonists without corticosteroids (systemic) interferon beta (subcutaneous)	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.011	11	-8 29 -26 43	LOW	NA NA	NA NA	11	-8 -26	29 43	LOW	RoB, Imprecision
aspirin aspirin	interferon beta (subcutaneous) interferon beta (subcutaneous), lopinavir-ritonavir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.282	-282	-26 43 -359 -206	VERY LOW	NA NA	NA NA	-282	-26 -359	-206	MODERATE	RoB, Imprecision
aspirin	intranasal corticosteroids	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.017	17	-6 40	LOW	NA NA	NA NA	17	-559	40	LOW	RoB, Imprecision
aspirin	ivermectin	NA	NA	NA NA	NA	NA	NA	NA.	NA	NA NA	0.006	6	-10 23	LOW	NA	NA NA	6	-10	23	LOW	RoB, Imprecision
aspirin	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	0.004	4	-15 22	LOW	NA	NA NA	4	-15	22	LOW	RoB, Imprecision
aspirin	lopinavir-ritonavir	NA NA	NA	NA NA	NA NA	NA	NA NA	NA NA	NA NA	NA NA	-0.041	-41	-67 -14	LOW	NA NA	NA NA	-41	-67	-14	LOW	RoB, Imprecision
aspirin aspirin	molnupiravir nitazoxanide	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.009	9 7	-6 24 -10 24	LOW	NA NA	NA NA	9 7	-6 -10	24	LOW	RoB, Imprecision RoB, Imprecision
aspirin aspirin	nitazoxanide nirmatrelvir/ritonavir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.007	28	4 52	VERY LOW	NA NA	NA NA	28	-10	52	LOW	RoB, Imprecision
aspirin	probiotics	NA NA	NA	NA.	NA NA	NA	NA	NA NA	NA.	NA NA	0.009	9	-11 29	LOW	NA	NA NA	9	-11	29	LOW	RoB, Imprecision
aspirin	proxalutamide	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	0.010	10	-11 32	LOW	NA	NA NA	10	-11	32	LOW	RoB, Imprecision
aspirin	remdesivir	NA	NA	NA	NA NA	NA	NA	NA	NA	NA NA	0.003	3	-16 22	LOW	NA	NA NA	3	-16	22	LOW	RoB, Imprecision
aspirin	serine protease inhibitors SGLT2 inhibitors	NA NA	NA	NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.024	24	-26 74 -8 60	VERY LOW	NA NA	NA NA	24	-26 -8	74 60	VERY LOW	RoB, Imprecisionx2
aspirin statins	SGL12 inhibitors aspirin	NA NA	NA NA	NA NA	NA -4	-1179	1170	VERY LOW	NA NA	NA NA	0.026 NA	NA NA	-8 60 NA NA	NA NA	NA NA	NA NA	26	-8 -22	13	LOW	RoB, Imprecision
aspirin	sulodexide	NA NA	NA NA	NA.	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.005	-5	-66 55	VERY LOW	NA NA	NA NA	-5	-66	55	VERY LOW	RoB. Imprecisionx3
aspirin	tyrosine kinase inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	-0.053	-53	-99 -8	VERY LOW	NA	NA NA	-53	-99	-8	LOW	RoB, Imprecision
aspirin	umifenovir	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	0.004	4	-29 36	LOW	NA	NA NA	4	-29	36	LOW	RoB, Imprecision
aspirin	vitamin D	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	0.010	10	-19 39	LOW	NA	NA NA	10	-19	39	LOW	RoB, Imprecision
aspirin, statins	azithromycin azithromycin, hydroxychloroguine	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.002 -0.005	-5	-21 26 -25 15	LOW	NA NA	NA NA	-5	-21 -25	26 15	LOW	RoB, Imprecision
aspirin, statins	azithromycin, hydroxychloroquine, oseltamivir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.055	-55	-99 -11	VERY LOW	NA NA	NA NA	-55	-99	-11	LOW	RoB, Imprecision
aspirin, statins	azithromycin, lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	0.001	1	-24 26	LOW	NA	NA NA	1	-24	26	LOW	RoB, Imprecision
aspirin, statins	colchicine	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	-0.025	-25	-60 11	VERY LOW	NA	NA NA	-25	-60	11	LOW	RoB, Imprecision
aspirin, statins	colchicine, emtricitabine, tenofovir, statins	NA NA	NA	NA	NA	NA	NA	NA	NA	NA NA	-0.032	-32	-62 -1	LOW	NA	NA NA	-32	-62	-1	LOW	RoB, Imprecision
aspirin, statins aspirin, statins	colchicine, statins IL6 receptor antagonists with corticosteroids (systemic)	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.014 0.004	-14	-37 9 -8 17	LOW MODERATE	NA NA	NA NA	-14	-37 -8	9	MODERATE	RoB, Imprecision
aspirin, statins	doxycycline, ivermectin	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.010	-10	-8 17	LOW	NA NA	NA NA	-10	-29	9	LOW	RoB. Imprecision
aspirin, statins	doxycycline, lopinavir-ritonavir	NA	NA	NA.	NA NA	NA	NA	NA	NA	NA NA	0.005	5	-19 29	LOW	NA	NA NA	5	-19	29	LOW	RoB, Imprecision
aspirin, statins	electrolyzed saline	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	-0.027	-27	-63 9	VERY LOW	NA	NA NA	-27	-63	9	LOW	RoB, Imprecision
aspirin, statins	emtricitabine, tenofovir	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	-0.022	-22	-47 3	LOW	NA	NA NA	-22	-47	3	LOW	RoB, Imprecision
aspirin, statins aspirin, statins	favipiravir full-dose anticoagulant	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.005 0.003	-5 3	-22 11 -24 31	LOW	NA NA	NA NA	-5 3	-22 -24	11	LOW	RoB, Imprecision RoB, Imprecision
aspirin, statins aspirin, statins	(hydroxy)chloroquine	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.013	-13	-24 31 -27 1	LOW	NA NA	NA NA	-13	-24	1	LOW	RoB, Imprecision
aspirin, statins	IL1 inhibitors	NA	NA	NA NA	NA NA	NA	NA	NA NA	NA	NA NA	-0.002	-2	-15 11	MODERATE	NA	NA NA	-2	-15	11	MODERATE	RoB
aspirin, statins	IL6 receptor antagonists without corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	0.002	2	-12 16	MODERATE	NA	NA NA	2	-12	16	MODERATE	RoB
aspirin, statins	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	0.000	0	-32 31	LOW	NA	NA NA	0	-32	31	LOW	RoB, Imprecision
aspirin, statins aspirin, statins	interferon beta (subcutaneous), lopinavir-ritonavir intranasal corticosteroids	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.291 0.008	-291 8	-367 -216 -11 27	VERY LOW LOW	NA NA	NA NA	-291 8	-367 -11	-216 27	MODERATE LOW	RoB RoB, Imprecision
aspirin, statins aspirin, statins	ivermectin	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.003	-3	-14 8	MODERATE	NA NA	NA NA	-3	-14	8	MODERATE	RoB RoB
aspirin, statins	JAK inhibitors	NA NA	NA	NA NA	NA NA	NA	NA NA	NA NA	NA NA	NA NA	-0.005	-5	-19 9	MODERATE	NA NA	NA NA	-5	-19	9	MODERATE	RoB
aspirin, statins	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	-0.049	-49	-73 -25	VERY LOW	NA	NA NA	-49	-73	-25	LOW	RoB, Imprecision
aspirin, statins	molnupiravir	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	0.000	0	-9 9	MODERATE	NA	NA NA	0	-9	9	MODERATE	RoB
aspirin, statins	nitazoxanide nirmatrelvir/ritonavir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.002 0.019	-2 19	-14 10 -2 40	MODERATE LOW	NA NA	NA NA	-2 19	-14 -2	10 40	MODERATE LOW	RoB RoB, Imprecision
aspirin, statins aspirin, statins	probiotics	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.000	0	-2 40 -16 16	MODERATE	NA NA	NA NA	0	-16	16	MODERATE	RoB, imprecision
aspirin, statins	proxalutamide	NA NA	NA	NA NA	NA NA	NA	NA NA	NA NA	NA NA	NA NA	0.002	2	-17 20	MODERATE	NA NA	NA NA	2	-17	20	MODERATE	RoB
aspirin, statins	remdesivir	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	-0.006	-6	-20 9	MODERATE	NA	NA NA	-6	-20	9	LOW	RoB
aspirin, statins	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	0.016	16	-33 64	VERY LOW	NA	NA NA	16	-33	64	VERY LOW	RoB, Imprecisionx2
aspirin, statins	SGLT2 inhibitors	NA NA	NA NA	NA NA	NA A	NA 1170	NA 1170	NA VERV LOW	NA NA	NA NA	0.017	17	-14 49	LOW	NA NA	NA NA	17	-14	49	LOW	RoB, Imprecision
statins aspirin, statins	aspirin, statins sulodexide	NA NA	NA NA	NA NA	4 NA	-1170 NA	1179 NA	VERY LOW NA	NA NA	NA NA	-0.014	NA -14	NA NA -73 45	NA VERY LOW	NA NA	NA NA	-14	-8 -73	17 45	MODERATE VERY LOW	RoB RoB, Imprecisionx2
aspirin, statins aspirin, statins	tyrosine kinase inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.062	-62	-106 -18	VERY LOW	NA NA	NA NA	-62	-106	-18	LOW	RoB, Imprecision
aspirin, statins	umifenovir	NA	NA	NA NA	NA NA	NA	NA	NA.	NA	NA NA	-0.005	-5	-35 25	LOW	NA	NA NA	-5	-35	25	LOW	RoB, Imprecision
aspirin, statins	vitamin D	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	0.001	1	-26 28	LOW	NA	NA NA	1	-26	28	LOW	RoB, Imprecision
azithromycin, hydroxychloroquine	azithromycin	NA	NA	NA	8	-1167	1182	VERY LOW	NA	NA NA	0.006	6	-32 44	LOW	NA	NA NA	8	-12	27	MODERATE	Imprecision
azithromycin azithromycin, lopinavir-ritonavir	azithromycin, hydroxychloroquine, oseltamivir azithromycin	NA NA	NA NA	NA NA	NA 2	NA -1173	NA 1176	NA VERY LOW	NA NA	NA NA	-0.058 NA	-58 NA	-106 -9 NA NA	VERY LOW NA	NA NA	NA NA	-58 2	-106 -13	-9 16	LOW	RoB, Imprecision
azitnromycin, iopinavir-ritonavir	azitnromycin	NA NA	NA	NA.		-11/3	11/6	I VERY LOW	I NA	NA NA	NA.	NA NA	INA INA	I NA	I NA	NA NA		-13	10	HIGH	

									Ac	Iverse events											
Comparison		Direct estimate Relative estimate			Absolute estimate	(4.000)			Indirect estimate		Absolute estimat	- (4.000)			Network estimat		laboration of	stimate (per 1.000)			
Treatment 1	Treatment 2		CI lower limit	CI upper limit	Point estimate	4 . , ,	CI upper limit	Final rating		CI lower limit CI upper limit		u , , , , , ,	CI lower limit	Final rating		CI lower limit CI up		ate CI lower limit	Cl upper limit	Final rating	Reasons for downgrading
azithromycin	colchicine	NA	NA	NA	NA NA	NA	NA	NA	NA	NA NA	-0.027	-27	-68 14	VERY LOW	NA		NA -27	-68	14	LOW	RoB, Imprecision
azithromycin	colchicine, emtricitabine, tenofovir, statins	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	-0.034	-34	-71 2	VERY LOW	NA		NA -34	-71	2	LOW	RoB, Imprecision
azithromycin azithromycin	colchicine, statins IL6 receptor antagonists with corticosteroids (systemic)	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.016 0.002	-16 2	-47 15 -22 26	LOW	NA NA		NA -16	-47 -22	15 26	LOW	RoB, Imprecision RoB. Imprecision
azithromycin	doxycycline, ivermectin	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.012	-12	-22 26 -40 15	LOW	NA NA		VA -12	-40	15	LOW	RoB, Imprecision
doxycycline, lopinavir-ritonavir	azithromycin	NA	NA	NA	-2	-1177	1172	VERY LOW	NA	NA NA	NA	NA NA	NA NA	NA	NA		VA -2	-15	10	HIGH	
azithromycin	electrolyzed saline	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	-0.029	-29	-71 12	VERY LOW	NA		NA -29	-71	12	LOW	RoB, Imprecision
azithromycin	emtricitabine, tenofovir	NA NA	NA	NA	NA NA	NA	NA	NA	NA NA	NA NA	-0.024 -0.008	-24	-57 8	VERY LOW LOW	NA NA		NA -24	-57 -34	8	LOW	RoB, Imprecision RoB. Imprecision
azithromycin azithromycin	favipiravir full-dose anticoagulant	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.008	-8 1	-34 18 -33 35	LOW	NA NA		NA -8	-34	18 35	LOW	RoB, Imprecision
azithromycin	(hydroxy)chloroquine	NA NA	NA NA	NA NA	-25	-1202	1152	VERY LOW	NA NA	NA NA	-0.015	-15	-39 10	LOW	NA NA		VA -15	-39	8	LOW	RoB, Imprecision
azithromycin	IL1 inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	-0.004	-4	-28 20	LOW	NA	NA 1	NA -4	-28	20	LOW	RoB, Imprecision
azithromycin	IL6 receptor antagonists without corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	-0.001	-1	-25 24	LOW	NA		NA -1	-25	24	LOW	RoB, Imprecision
azithromycin	interferon beta (subcutaneous) interferon beta (subcutaneous), lopinavir-ritonavir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.003 -0.294	-3 -294	-41 35 -372 -215	VERY LOW	NA NA		VA -3	-41 -372	-215	LOW MODERATE	RoB, Imprecision RoB
azithromycin azithromycin	interreron beta (subcutaneous), iopinavir-ritonavir intranasal corticosteroids	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.006	-294 6	-3/2 -215 -22 34	LOW	NA NA		VA -294 VA 6	-372	-215	LOW	RoB. Imprecision
azithromycin	ivermectin	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.005	-5	-28 18	LOW	NA NA		VA -5	-28	18	LOW	RoB, Imprecision
azithromycin	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	-0.007	-7	-32 17	LOW	NA	NA 1	NA -7	-32	17	LOW	RoB, Imprecision
azithromycin	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	-0.052	-52	-83 -21	MODERATE	NA		NA -52	-83	-21	LOW	RoB
azithromycin	molnupiravir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.002 -0.004	-2	-25 20	LOW	NA NA		NA -2	-25 -28	20	LOW	RoB, Imprecision
azithromycin azithromycin	nitazoxanide nirmatrelyir/ritonayir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.004	-4 17	-28 19 -13 46	LOW	NA NA		VA -4	-28 -13	19 46	LOW	RoB, Imprecision RoB, Imprecision
azithromycin	probiotics	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.002	-2	-13 46	LOW	NA NA		VA 17	-13	23	LOW	RoB, Imprecision
azithromycin	proxalutamide	NA	NA	NA	NA NA	NA	NA	NA NA	NA	NA NA	-0.001	-1	-28 26	LOW	NA		NA -1	-28	26	LOW	RoB, Imprecision
azithromycin	remdesivir	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	-0.008	-8	-33 17	LOW	NA		NA -8	-33	17	LOW	RoB, Imprecision
azithromycin	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	0.013	13	-40 66	VERY LOW	NA	18.7	NA 13	-40	66	VERY LOW	RoB, Imprecisionx2
azithromycin azithromycin	SGLT2 inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.015 -0.007	15 -7	-22 52 -32 18	VERY LOW	NA NA		NA 15	-22 -32	52 18	VERY LOW	RoB, Imprecisionx2
azithromycin azithromycin	statins sulodexide	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.007	-/	-32 18 -79 46	VERY LOW	NA NA		NA -/	-32 -79	18	VERY LOW	RoB, Imprecisionx2
azithromycin	tyrosine kinase inhibitors	NA	NA	NA	NA NA	NA	NA	NA NA	NA	NA NA	-0.065	-65	-113 -16	VERY LOW	NA		VA -65	-113	-16	LOW	RoB, Imprecision
azithromycin	umifenovir	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	-0.008	-8	-44 29	LOW	NA	NA 1	-8 AV	-44	29	LOW	RoB, Imprecision
azithromycin	vitamin D	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	-0.001	-1	-35 32	LOW	NA		NA -1	-35	32	LOW	RoB, Imprecision
azithromycin, hydroxychloroquine	azithromycin, hydroxychloroquine, oseltamivir	NA NA	NA NA	NA	NA .	NA	NA	NA	NA	NA NA	-0.050	-50	-97 -3 NA NA	VERY LOW	NA NA	10.1	VA -50	-97	-3 14	LOW	RoB, Imprecision
azithromycin, lopinavir-ritonavir azithromycin, hydroxychloroquine	azithromycin, hydroxychloroquine colchicine	NA NA	NA NA	NA NA	-4 NA	-1179 NA	1170 NA	VERY LOW NA	NA NA	NA NA	-0.020	NA -20	NA NA -59 19	NA VERY LOW	NA NA	187	VA -6	-26 -59	14	MODERATE LOW	Imprecision RoB, Imprecision
azithromycin, hydroxychloroquine	colchicine, emtricitabine, tenofovir, statins	NA NA	NA NA	NA.	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.027	-27	-61 7	VERY LOW	NA NA		VA -27	-61	7	LOW	RoB. Imprecision
azithromycin, hydroxychloroquine	colchicine, statins	NA	NA	NA	NA NA	NA	NA	NA	NA	NA NA	-0.009	-9	-36 19	LOW	NA	NA I	NA -9	-36	19	LOW	RoB, Imprecision
azithromycin, hydroxychloroquine	IL6 receptor antagonists with corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	0.009	9	-10 29	MODERATE	NA		NA 9	-10	29	MODERATE	Imprecision
azithromycin, hydroxychloroquine	doxycycline, ivermectin	NA	NA	NA	NA	NA	NA 1164	NA	NA	NA NA	-0.005	-5 NA	-29 19 NA NA	MODERATE NA	NA		NA -5	-29	19	MODERATE	Imprecision
doxycycline, lopinavir-ritonavir azithromycin, hydroxychloroguine	azithromycin, hydroxychloroquine electrolyzed saline	NA NA	NA NA	NA NA	-10 NA	-1185 NA	1164 NA	VERY LOW NA	NA NA	NA NA	-0.022	-22	NA NA -61 17	VERY LOW	NA NA	101	NA -10	-28 -61	17	LOW	Imprecision RoB. Imprecision
azithromycin, hydroxychloroquine	emetricitabine, tenofovir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.022	-17	-61 17 -46 13	LOW	NA NA		VA -22	-46	13	LOW	RoB, Imprecision
azithromycin, hydroxychloroquine	favipiravir	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	0.000	0	-23 22	LOW	NA	NA I	NA 0	-23	22	LOW	RoB, Imprecision
azithromycin, hydroxychloroquine	full-dose anticoagulant	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	0.008	8	-23 40	MODERATE	NA	NA 1	NA 8	-23	40	MODERATE	Imprecision
azithromycin, hydroxychloroquine	(hydroxy)chloroquine	NA	NA	NA	-7	-463	452	LOW	NA	NA NA	-0.005	-5	-32 23	LOW	NA		-8	-27	11	MODERATE	Imprecision
azithromycin, hydroxychloroquine	IL1 inhibitors	NA NA	NA	NA	NA NA	NA NA	NA	NA NA	NA NA	NA NA	0.003	3	-17 24	MODERATE	NA NA		NA 3	-17 -14	24	MODERATE MODERATE	Imprecision
azithromycin, hydroxychloroquine	IL6 receptor antagonists without corticosteroids (systemic) interferon beta (subcutaneous)	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.007	5	-14 27 -31 40	MODERATE MODERATE	NA NA		NA 7	-14 -31	27	MODERATE	Imprecision Imprecision
azithromycin, hydroxychloroquine	interferon beta (subcutaneous), lopinavir-ritonavir	NA NA	NA NA	NA.	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.286	-286	-363 -209	VERY LOW	NA NA		VA -286	-363	-209	MODERATE	RoB
azithromycin, hydroxychloroquine	intranasal corticosteroids	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	0.013	13	-11 38	MODERATE	NA	NA 1	NA 13	-11	38	MODERATE	Imprecision
azithromycin, hydroxychloroquine	ivermectin	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	0.002	2	-16 21	LOW	NA		NA 2	-16	21	LOW	RoB, Imprecision
azithromycin, hydroxychloroquine	JAK inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.000	0	-21 21	MODERATE	NA NA		VA 0	-21	21	MODERATE	Imprecision
azithromycin, hydroxychloroquine azithromycin, hydroxychloroquine	lopinavir-ritonavir molnupiravir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.044 0.005	-44 5	-72 -16 -13 23	VERY LOW MODERATE	NA NA		VA -44 VA 5	-72 -13	-16 23	LOW MODERATE	RoB, Imprecision Imprecision
azithromycin, hydroxychloroquine	nitazoxanide	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.003	3	-16 23	MODERATE	NA NA		VA 3	-16	23	MODERATE	Imprecision
azithromycin, hydroxychloroquine	nirmatrelvir/ritonavir	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	0.024	24	-2 50	MODERATE	NA		NA 24	-2	50	MODERATE	Imprecision
azithromycin, hydroxychloroquine	probiotics	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	0.005	5	-17 27	MODERATE	NA	181	NA 5	-17	27	MODERATE	Imprecision
azithromycin, hydroxychloroquine	proxalutamide	NA NA	NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA	NA NA	0.007	7 -1	-17 30	LOW MODERATE	NA NA		NA 7	-17	30	LOW	RoB, Imprecision
azithromycin, hydroxychloroquine azithromycin, hydroxychloroquine	remdesivir serine protease inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.001 0.021	-1 21	-21 20 -31 72	LOW	NA NA		NA -1	-21 -31	20 72	MODERATE	Imprecision Imprecisionx2
azithromycin, hydroxychloroquine azithromycin, hydroxychloroquine	SGLT2 inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.021	21	-13 58	LOW	NA NA	187	VA 21	-31	58	MODERATE	Imprecision Imprecision
azithromycin, hydroxychloroquine	statins	NA	NA	NA NA	NA NA	NA	NA	NA NA	NA	NA NA	0.001	1	-21 22	LOW	NA		VA 1	-21	22	LOW	RoB, Imprecision
azithromycin, hydroxychloroquine	sulodexide	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	-0.009	-9	-70 52	VERY LOW	NA	10.1	VA -9	-70	52	VERY LOW	RoB, Imprecisionx3
azithromycin, hydroxychloroquine	tyrosine kinase inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	-0.057	-57	-104 -11	LOW	NA		NA -57	-104	-11	MODERATE	Imprecision
azithromycin, hydroxychloroquine	umifenovir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.000	0	-34 34 -25 37	LOW	NA NA		VA 0	-34	34	LOW	RoB, Imprecision
azithromycin, hydroxychloroquine azithromycin, hydroxychloroquine, oseltamivir	vitamin D azithromycin, lopinavir-ritonavir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.006	6 56	-25 37 7 105	LOW VERY LOW	NA NA		VA 6	-25 7	37 105	LOW	RoB, Imprecision RoB, Imprecision
azithromycin, hydroxychloroquine, oseitamivir	colchicine	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.030	30	-26 86	VERY LOW	NA NA	10.1	VA 30	-26	86	VERY LOW	RoB, Imprecisionx2
azithromycin, hydroxychloroquine, oseltamivir	colchicine, emtricitabine, tenofovir, statins	NA NA	NA	NA NA	NA NA	NA	NA	NA NA	NA	NA NA	0.023	23	-29 76	VERY LOW	NA NA		VA 23	-29	76	VERY LOW	RoB, Imprecisionx2
azithromycin, hydroxychloroquine, oseltamivir	colchicine, statins	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	0.041	41	-7 90	VERY LOW	NA		NA 41	-7	90	LOW	RoB, Imprecision
azithromycin, hydroxychloroquine, oseltamivir	IL6 receptor antagonists with corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	0.060	60	15 104	LOW	NA		NA 60	15	104	LOW	RoB, Imprecision
azithromycin, hydroxychloroquine, oseltamivir	doxycycline, ivermectin	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.045	45	-1 92	LOW	NA NA	101	NA 45	-1 11	92 109	LOW	RoB, Imprecision RoB. Imprecision
azithromycin, hydroxychloroquine, oseltamivir azithromycin, hydroxychloroquine, oseltamivir	doxycycline, lopinavir-ritonavir electrolyzed saline	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.060	60 28	11 109 -27 84	VERY LOW	NA NA		NA 60	-27	109	VERY LOW	RoB, Imprecision RoB, Imprecisionx2
azithromycin, hydroxychloroquine, oseltamivir	emtricitabine, tenofovir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.028	33	-16 83	VERY LOW	NA NA		VA 28	-16	83	LOW	RoB, Imprecision
azithromycin, hydroxychloroquine, oseltamivir	favipiravir	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	0.050	50	4 96	LOW	NA	NA 1	NA 50	4	96	LOW	RoB, Imprecision
azithromycin, hydroxychloroquine, oseltamivir	full-dose anticoagulant	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	0.059	59	8 109	LOW	NA		NA 59	8	109	LOW	RoB, Imprecision
azithromycin, hydroxychloroquine, oseltamivir	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	0.042	42	-3 87	LOW	NA	NA I	NA 42	-3	87	LOW	RoB, Imprecision

									Ac	lverse events											
Comparison		Direct estimate			I & b b	(4.000)			Indirect estimat			h- (4 000)			Network estimat	e •-					
Treatment 1	Treatment 2	Relative estimate Point estimate	CI lower limit	Cl upper limit	Absolute estimate Point estimate	0 - , ,	Cl upper limit	Final rating	Relative estimate	CI lower limit CI upper limit	Absolute estimate	Point estimate	CI lower limit CI upper limit	Final rating	Relative estimate	CI lower limit CI uppe		mate (per 1,000)	Cl upper limit	Final rating	Reasons for downgrading
azithromycin, hydroxychloroquine, oseltamivir	IL1 inhibitors	NA NA	NA NA	NA NA	NA NA	NA	NA NA	NA NA	NA NA	NA NA	0.053	53	9 98	LOW	NA NA	NA NA		9	98	LOW	RoB, Imprecision
azithromycin, hydroxychloroquine, oseltamivir	IL6 receptor antagonists without corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	0.057	57	12 102	LOW	NA	NA NA	-	12	102	LOW	RoB, Imprecision
azithromycin, hydroxychloroquine, oseltamivir	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	0.055	55	1 108	LOW	NA	NA NA		1	108	LOW	RoB, Imprecision
azithromycin, hydroxychloroquine, oseltamivir azithromycin, hydroxychloroquine, oseltamivir	interferon beta (subcutaneous), lopinavir-ritonavir intranasal corticosteroids	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.236 0.063	-236 63	-323 -149 16 110	LOW	NA NA	NA NA		-323 16	-149 110	LOW	RoB, Imprecision RoB, Imprecision
azithromycin, hydroxychloroquine, oseitamivir	ivermectin	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.053	53	9 97	LOW	NA NA	NA NA		9	97	LOW	RoB, Imprecision
azithromycin, hydroxychloroquine, oseltamivir	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	0.050	50	5 95	LOW	NA	NA NA	50	5	95	LOW	RoB, Imprecision
azithromycin, hydroxychloroquine, oseltamivir	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	0.006	6	-43 55	VERY LOW	NA	NA NA		-43	55	VERY LOW	RoB, Imprecisionx2
azithromycin, hydroxychloroquine, oseltamivir	molnupiravir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.055 0.053	55 53	12 99 9 98	LOW	NA NA	NA NA		12	99 98	LOW	RoB, Imprecision
azithromycin, hydroxychloroquine, oseltamivir azithromycin, hydroxychloroquine, oseltamivir	nitazoxanide nirmatrelvir/ritonavir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.053	74	27 122	MODERATE	NA NA	NA NA		27	122	MODERATE	RoB, Imprecision
azithromycin, hydroxychloroquine, oseltamivir	probiotics	NA NA	NA NA	NA.	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.055	55	10 101	LOW	NA NA	NA NA		10	101	LOW	RoB, Imprecision
azithromycin, hydroxychloroquine, oseltamivir	proxalutamide	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	0.057	57	11 103	LOW	NA	NA NA	. 57	11	103	LOW	RoB, Imprecision
azithromycin, hydroxychloroquine, oseltamivir	remdesivir	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	0.050	50	5 94	LOW	NA	NA NA		5	94	LOW	RoB, Imprecision
azithromycin, hydroxychloroquine, oseltamivir azithromycin, hydroxychloroquine, oseltamivir	serine protease inhibitors SGLT2 inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.071	71 73	6 135 19 126	LOW	NA NA	NA NA		6 19	135 126	LOW	RoB, Imprecision RoB, Imprecision
azithromycin, hydroxychloroquine, oseitamivir	statins	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.073	51	5 96	LOW	NA NA	NA NA		5	96	LOW	RoB, Imprecision
azithromycin, hydroxychloroquine, oseltamivir	sulodexide	NA	NA	NA	NA NA	NA	NA	NA.	NA	NA NA	0.041	41	-32 114	VERY LOW	NA	NA NA		-32	114	VERY LOW	RoB, Imprecisionx2
azithromycin, hydroxychloroquine, oseltamivir	tyrosine kinase inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	-0.007	-7	-68 54	VERY LOW	NA	NA NA		-68	54	VERY LOW	RoB, Imprecisionx3
azithromycin, hydroxychloroquine, oseltamivir	umifenovir	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	0.050	50	-2 102	LOW	NA	NA NA		-2	102	LOW	RoB, Imprecision
azithromycin, hydroxychloroquine, oseltamivir	vitamin D	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.056	56	6 107 -68 17	LOW	NA NA	NA NA		6	107	LOW	RoB, Imprecision
azithromycin, lopinavir-ritonavir azithromycin, lopinavir-ritonavir	colchicine colchicine, emtricitabine, tenofovir, statins	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.026 -0.033	-26 -33	-68 17 -71 5	VERY LOW LOW	NA NA	NA NA		-68 -71	17 5	LOW	RoB, Imprecision RoB, Imprecision
azithromycin, lopinavir-ritonavir	colchicine, entriciabilite, teriorovii, statins	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.033	-15	-46 17	LOW	NA NA	NA NA		-46	17	LOW	RoB, Imprecision
azithromycin, lopinavir-ritonavir	IL6 receptor antagonists with corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	0.004	4	-22 29	MODERATE	NA	NA NA	. 4	-22	29	MODERATE	Imprecision
azithromycin, lopinavir-ritonavir	doxycycline, ivermectin	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	-0.011	-11	-40 18	MODERATE	NA	NA NA		-40	18	MODERATE	Imprecision
doxycycline, lopinavir-ritonavir	azithromycin, lopinavir-ritonavir	NA NA	NA	NA	-4	-1178	1171	VERY LOW	NA	NA NA	NA	NA	NA NA	NA	NA	NA NA		-15	7	HIGH	
azithromycin, lopinavir-ritonavir azithromycin, lopinavir-ritonavir	electrolyzed saline emtricitabine, tenofovir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.028 -0.023	-28 -23	-70 14 -56 10	LOW	NA NA	NA NA		-70 -56	14 10	LOW	RoB, Imprecision RoB, Imprecision
azithromycin, lopinavir-ritonavir	favipiravir	NA NA	NA NA	NA.	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.025	-6	-34 21	LOW	NA NA	NA NA		-34	21	LOW	RoB, Imprecision
azithromycin, lopinavir-ritonavir	full-dose anticoagulant	NA	NA	NA	NA NA	NA	NA	NA.	NA	NA NA	0.002	2	-33 37	MODERATE	NA	NA NA		-33	37	MODERATE	Imprecision
azithromycin, lopinavir-ritonavir	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	-0.014	-14	-39 11	MODERATE	NA	NA NA	-14	-39	11	MODERATE	Imprecision
azithromycin, lopinavir-ritonavir	IL1 inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	-0.003	-3	-28 23	MODERATE	NA	NA NA		-28	23	MODERATE	Imprecision
azithromycin, lopinavir-ritonavir	IL6 receptor antagonists without corticosteroids (systemic)	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.001 -0.001	-1	-25 27	MODERATE	NA NA	NA NA		-25	27 37	MODERATE MODERATE	Imprecision
azithromycin, lopinavir-ritonavir azithromycin, lopinavir-ritonavir	interferon beta (subcutaneous) interferon beta (subcutaneous), lopinavir-ritonavir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.001	-1	-40 37 -371 -214	MODERATE	NA NA	NA NA		-40 -371	-214	MODERATE	Imprecision RoB
azithromycin, lopinavir-ritonavir	intranasal corticosteroids	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.007	7	-22 36	MODERATE	NA NA	NA NA		-22	36	MODERATE	Imprecision
azithromycin, lopinavir-ritonavir	ivermectin	NA	NA	NA	NA	NA	NA	NA.	NA	NA NA	-0.004	-4	-28 21	LOW	NA	NA NA	-4	-28	21	LOW	RoB, Imprecision
azithromycin, lopinavir-ritonavir	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	-0.006	-6	-32 20	MODERATE	NA	NA NA		-32	20	MODERATE	Imprecision
azithromycin, lopinavir-ritonavir	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	-0.050	-50	-82 -18	LOW	NA	NA NA	. 00	-82	-18	LOW	RoB, Imprecision
azithromycin, lopinavir-ritonavir azithromycin, lopinavir-ritonavir	molnupiravir nitazoxanide	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.001 -0.003	-1 -3	-24 23 -28 22	MODERATE MODERATE	NA NA	NA NA		-24 -28	23	MODERATE MODERATE	Imprecision Imprecision
azithromycin, lopinavir-itonavir	nirmatrelvir/ritonavir	NA NA	NA NA	NA NA	NA NA	NA NA	NA.	NA NA	NA NA	NA NA	0.003	18	-12 49	MODERATE	NA NA	NA NA		-12	49	MODERATE	Imprecision
azithromycin, lopinavir-ritonavir	probiotics	NA	NA	NA	NA NA	NA	NA	NA.	NA	NA NA	-0.001	-1	-28 26	MODERATE	NA	NA NA	-1	-28	26	MODERATE	Imprecision
azithromycin, lopinavir-ritonavir	proxalutamide	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	0.001	1	-28 29	LOW	NA	NA NA		-28	29	LOW	RoB, Imprecision
azithromycin, lopinavir-ritonavir	remdesivir	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	-0.007	-7	-33 19	MODERATE	NA	NA NA		-33	19	MODERATE	Imprecision
azithromycin, lopinavir-ritonavir	serine protease inhibitors SGLT2 inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.015	15 16	-39 68 -22 55	LOW	NA NA	NA NA		-39 -22	68 55	LOW	Imprecisionx2
azithromycin, lopinavir-itonavir	statins	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.005	-5	-32 21	LOW	NA NA	NA NA		-32	21	LOW	RoB, Imprecision
azithromycin, lopinavir-ritonavir	sulodexide	NA	NA	NA	NA NA	NA	NA	NA	NA NA	NA NA	-0.015	-15	-78 48	VERY LOW	NA	NA NA		-78	48	VERY LOW	RoB, Imprecisionx2
azithromycin, lopinavir-ritonavir	tyrosine kinase inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	-0.063	-63	-112 -14	MODERATE	NA	NA NA		-112	-14	MODERATE	Imprecision
azithromycin, lopinavir-ritonavir	umifenovir	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	-0.006	-6	-43 31	LOW	NA	NA NA		-43	31	LOW	RoB, Imprecision
azithromycin, lopinavir-ritonavir colchicine	vitamin D colchicine, emtricitabine, tenofovir, statins	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.007	-7	-34 35 -53 38	LOW VERY LOW	NA NA	NA NA		-34 -53	35 38	LOW VERY LOW	RoB, Imprecision RoB, Imprecisionx2
colchicine	colchicine, emtricitabine, tenorovir, statins	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.007	11	-30 52	VERY LOW VERY LOW	NA NA	NA NA		-30	52	VERY LOW VERY LOW	RoB, Imprecisionx2
colchicine	IL6 receptor antagonists with corticosteroids (systemic)	NA	NA	NA	NA NA	NA	NA	NA	NA	NA NA	0.029	29	-7 65	LOW	NA	NA NA	. 29	-7	65	LOW	RoB, Imprecision
colchicine	doxycycline, ivermectin	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	0.015	15	-24 53	VERY LOW	NA	NA NA		-24	53	VERY LOW	RoB, Imprecisionx2
colchicine	doxycycline, lopinavir-ritonavir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.029	29	-12 71	VERY LOW	NA NA	NA NA		-12	71 47	LOW	RoB, Imprecision
colchicine	electrolyzed saline emtricitabine, tenofovir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.002 0.003	-2 3	-52 47 -39 45	VERY LOW	NA NA	NA NA		-52 -39	47 45	VERY LOW LOW	RoB, Imprecisionx2 RoB, Imprecision
colchicine	emtricitabine, tenorovir favipiravir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.003	19	-39 45 -18 57	VERY LOW	NA NA	NA NA		-18	57	LOW	RoB, Imprecision
colchicine	full-dose anticoagulant	NA	NA	NA NA	NA NA	NA	NA NA	NA NA	NA	NA NA	0.028	28	-15 72	VERY LOW	NA NA	NA NA		-15	72	LOW	RoB, Imprecision
colchicine	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	0.012	12	-25 48	LOW	NA	NA NA		-25	48	LOW	RoB, Imprecision
colchicine	IL1 inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	0.023	23	-13 59	VERY LOW	NA	NA NA		-13	59	LOW	RoB, Imprecision
colchicine	IL6 receptor antagonists without corticosteroids (systemic)	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.027	27	-10 63 -22 70	VERY LOW	NA NA	NA NA		-10	63 70	LOW VERY LOW	RoB, Imprecision
colchicine colchicine	interferon beta (subcutaneous) interferon beta (subcutaneous), lopinavir-ritonavir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.024 -0.267	24 -267	-22 70 -349 -184	VERY LOW MODERATE	NA NA	NA NA		-22 -349	-184	LOW	RoB, Imprecisionx2 RoB
colchicine	intranasal corticosteroids	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.033	33	-6 72	LOW	NA NA	NA NA		-6	72	LOW	RoB, Imprecision
colchicine	ivermectin	NA	NA	NA.	NA NA	NA	NA	NA	NA NA	NA NA	0.022	22	-13 57	VERY LOW	NA	NA NA		-13	57	LOW	RoB, Imprecision
colchicine	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	0.020	20	-17 56	VERY LOW	NA	NA NA		-17	56	LOW	RoB, Imprecision
colchicine	lopinavir-ritonavir	NA	NA NA	NA	NA NA	NA	NA NA	NA NA	NA NA	NA NA	-0.025	-25	-66 17	VERY LOW	NA NA	NA NA		-66 -10	17 59	LOW	RoB, Imprecision
colchicine colchicine	molnupiravir nitazoxanide	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.025	25 23	-10 59 -13 59	VERY LOW VERY LOW	NA NA	NA NA	- 20	-10 -13	59 59	LOW	RoB, Imprecision RoB, Imprecision
colchicine	nitazoxanide nirmatrelvir/ritonavir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.023	23 44	-13 59 4 83	LOW	NA NA	NA NA		-13	59 83	LOW	RoB, Imprecision
colchicine	probiotics	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.025	25	-12 62	VERY LOW	NA NA	NA NA		-12	62	LOW	RoB, Imprecision
colchicine	proxalutamide	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	0.026	26	-12 65	VERY LOW	NA	NA NA		-12	65	LOW	RoB, Imprecision
colchicine	remdesivir	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	0.019	19	-18 56	VERY LOW	NA	NA NA		-18	56	LOW	RoB, Imprecision
colchicine	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	0.040	40	-20 100	VERY LOW	NA	NA NA	40	-20	100	LOW	RoB, Imprecision

									Ac	iverse events														
Comparison		Direct estimate							Indirect estimat	е							Network estimate							
		Relative estimate	9	T	Absolute estimat			Final rating	Relative estimate			Absolute estimate	0 - , ,			Final rating	Relative estimate			Absolute estima			Final rating	
Treatment 1	Treatment 2		CI lower limit		Point estimate	CI lower limit	CI upper limit		Point estimate	CI lower limit				CI lower limit	CI upper limit	-		CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit		Reasons for downgrading
colchicine colchicine	SGLT2 inhibitors statins	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.042	42 20	-4	88 57	VERY LOW	NA NA	NA NA	NA NA	42 20	-4 -17	88 57	LOW	RoB, Imprecision RoB, Imprecision
colchicine	statins	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.020	11	-17	78	VERY LOW VERY LOW	NA NA	NA NA	NA NA	11	-17	78	VERY LOW	RoB, Imprecisionx3
colchicine	tyrosine kinase inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA.	NA NA	NA NA	NA NA	NA NA	-0.038	-38	-93	18	VERY LOW	NA NA	NA NA	NA NA	-38	-93	18	LOW	RoB, Imprecision
colchicine	umifenovir	NA	NA	NA	NA	NA	NA	NA NA	NA	NA	NA	0.020	20	-26	65	VERY LOW	NA	NA	NA	20	-26	65	VERY LOW	RoB, Imprecisionx2
colchicine	vitamin D	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.026	26	-17	69	VERY LOW	NA	NA	NA	26	-17	69	LOW	RoB, Imprecision
colchicine, statins	colchicine, emtricitabine, tenofovir, statins	NA	NA	NA	-18	-1193	1156	VERY LOW	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-18	-50	14	LOW	RoB, Imprecision
colchicine, emtricitabine, tenofovir, statins	IL6 receptor antagonists with corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA NA	NA	NA	NA	0.036	36	6	67	LOW	NA	NA	NA	36	6	67	LOW	RoB, Imprecision
colchicine, emtricitabine, tenofovir, statins	doxycycline, ivermectin	NA	NA	NA	NA	NA .	NA	NA NA	NA	NA	NA	0.022	22	-12	56	VERY LOW	NA	NA	NA	22	-12	56	LOW	RoB, Imprecision
colchicine, emtricitabine, tenofovir, statins	doxycycline, lopinavir-ritonavir electrolyzed saline	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.037	37 5	-41	73 51	LOW VERY LOW	NA NA	NA NA	NA NA	37 5	-41	73 51	LOW	RoB, Imprecision RoB, Imprecisionx2
emtricitabine, tenofovir, statins	colchicine, emtricitabine, tenofovir, statins	NA NA	NA NA	NA NA	-12	-1187	1162	VERY LOW	NA NA	NA NA	NA NA	0.005 NA	NA NA	NA	NA NA	NA NA	NA NA	NA NA	NA NA	-10	-41	24	LOW	RoB, Imprecision
colchicine, emtricitabine, tenofovir, statins	favipiravir	NA NA	NA NA	NA NA	NA	NA	NA	NA NA	NA NA	NA NA	NA NA	0.026	26	-6	59	LOW	NA NA	NA NA	NA NA	26	-6	59	LOW	RoB, Imprecision
colchicine, emtricitabine, tenofovir, statins	full-dose anticoagulant	NA NA	NA NA	NA NA	NA NA	NA NA	NA.	NA NA	NA NA	NA NA	NA NA	0.025	35	-4	75	LOW	NA NA	NA NA	NA NA	35	-4	75	LOW	RoB. Imprecision
colchicine, emtricitabine, tenofovir, statins	(hydroxy)chloroquine	NA	NA	NA NA	NA.	NA.	NA.	NA.	NA	NA	NA	0.019	19	-12	50	VERY LOW	NA NA	NA	NA NA	19	-12	50	LOW	RoB, Imprecision
colchicine, emtricitabine, tenofovir, statins	IL1 inhibitors	NA	NA	NA	NA	NA	NA	NA NA	NA	NA	NA	0.030	30	-1	61	LOW	NA	NA	NA	30	-1	61	LOW	RoB, Imprecision
colchicine, emtricitabine, tenofovir, statins	IL6 receptor antagonists without corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA NA	NA	NA	NA	0.034	34	2	65	LOW	NA	NA	NA	34	2	65	LOW	RoB, Imprecision
colchicine, emtricitabine, tenofovir, statins	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA.	NA	NA	NA	0.031	31	-11	74	VERY LOW	NA	NA	NA	31	-11	74	LOW	RoB, Imprecision
colchicine, emtricitabine, tenofovir, statins	interferon beta (subcutaneous), lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA NA	NA	NA	NA	-0.260	-260	-340	-179	VERY LOW	NA	NA	NA	-260	-340	-179	LOW	RoB, Imprecision
colchicine, emtricitabine, tenofovir, statins	intranasal corticosteroids	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.040	40	6	74	LOW	NA	NA	NA	40	6	74	LOW	RoB, Imprecision
colchicine, emtricitabine, tenofovir, statins	ivermectin	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.029	29	-1	59	LOW	NA	NA	NA	29	-1	59	LOW	RoB, Imprecision
colchicine, emtricitabine, tenofovir, statins	JAK inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.027 -0.017	-17	-5 -54	58 19	LOW VERY LOW	NA NA	NA NA	NA NA	-17	-5 -54	58 19	LOW	RoB, Imprecision
colchicine, emtricitabine, tenofovir, statins colchicine, emtricitabine, tenofovir, statins	lopinavir-ritonavir molnupiravir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.017 0.032	-17 32	-54 2	19 61	LOW LOW	NA NA	NA NA	NA NA	-17 32	-54 2	19 61	LOW	RoB, Imprecision RoB, Imprecision
colchicine, emtricitabine, tenofovir, statins	moinupiravir nitazoxanide	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.032	32	-1	60	LOW	NA NA	NA NA	NA NA	32	-1	60	LOW	RoB, Imprecision
colchicine, emtricitabine, tenorovir, statins colchicine, emtricitabine, tenofovir, statins	nitazoxanide nirmatrelvir/ritonavir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.030	51	16	86	LOW	NA NA	NA NA	NA NA	51	-1 16	86	LOW	RoB, Imprecision
colchicine, emtricitabine, tenofovir, statins	probiotics	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.031	32	0	64	LOW	NA NA	NA NA	NA NA	32	0	64	LOW	RoB, Imprecision
colchicine, emtricitabine, tenofovir, statins	proxalutamide	NA.	NA.	NA.	NA.	NA.	NA.	NA.	NA NA	NA.	NA.	0.033	33	0	67	LOW	NA NA	NA	NA.	33	0	67	LOW	RoB. Imprecision
colchicine, emtricitabine, tenofovir, statins	remdesivir	NA	NA	NA	NA	NA	NA	NA NA	NA	NA	NA	0.026	26	-5	58	LOW	NA	NA	NA	26	-5	58	LOW	RoB, Imprecision
colchicine, emtricitabine, tenofovir, statins	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA NA	NA	NA	NA	0.047	47	-9	104	LOW	NA	NA	NA	47	-9	104	LOW	RoB, Imprecision
colchicine, emtricitabine, tenofovir, statins	SGLT2 inhibitors	NA	NA	NA	NA	NA	NA	NA.	NA	NA	NA	0.049	49	7	91	LOW	NA	NA	NA	49	7	91	LOW	RoB, Imprecision
colchicine, emtricitabine, tenofovir, statins	statins	NA	NA	NA	NA	NA	NA	NA NA	NA	NA	NA	0.027	27	-4	59	LOW	NA	NA	NA	27	-4	59	LOW	RoB, Imprecision
colchicine, emtricitabine, tenofovir, statins	sulodexide	NA	NA	NA	NA	NA	NA	NA.	NA	NA	NA	0.018	18	-48	83	VERY LOW	NA	NA	NA	18	-48	83	VERY LOW	RoB, Imprecisionx2
colchicine, emtricitabine, tenofovir, statins	tyrosine kinase inhibitors	NA	NA	NA	NA	NA	NA	NA NA	NA	NA	NA	-0.030	-30	-83	22	VERY LOW	NA	NA	NA	-30	-83	22	VERY LOW	RoB, Imprecisionx2
colchicine, emtricitabine, tenofovir, statins	umifenovir	NA	NA	NA	NA NA	NA NA	NA	NA NA	NA	NA	NA	0.027	27	-14	68	VERY LOW	NA	NA	NA	27	-14	68	LOW	RoB, Imprecision
colchicine, emtricitabine, tenofovir, statins	vitamin D	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.033	33	-6	72	LOW	NA	NA	NA	33	-6	72	LOW	RoB, Imprecision
colchicine, statins colchicine, statins	IL6 receptor antagonists with corticosteroids (systemic) doxycycline, ivermectin	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.018	18	-5 -24	41 31	LOW	NA NA	NA NA	NA NA	18	-5 -24	41 31	LOW	RoB, Imprecision
colchicine, statins	doxycycline, ivermectin doxycycline, lopinavir-ritonavir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.004	18	-24	49	LOW	NA NA	NA NA	NA NA	18	-24	49	LOW	RoB, Imprecision RoB, Imprecision
colchicine, statins	electrolyzed saline	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.013	-13	-13	28	VERY LOW	NA NA	NA NA	NA NA	-13	-13	28	VERY LOW	RoB. Imprecisionx2
emtricitabine, tenofovir	colchicine, statins	NA NA	NA.	NA NA	6	-1168	1180	VERY LOW	NA NA	NA NA	NA NA	NA.	NA NA	NA NA	NA NA	NA.	NA NA	NA NA	NA NA	8	-19	36	LOW	RoB, Imprecision
colchicine, statins	favipiravir	NA	NA	NA	NA.	NA	NA	NA NA	NA	NA	NA	0.008	8	-17	34	LOW	NA	NA	NA	8	-17	34	LOW	RoB, Imprecision
colchicine, statins	full-dose anticoagulant	NA	NA	NA	NA	NA.	NA	NA NA	NA	NA	NA	0.017	17	-17	51	VERY LOW	NA	NA	NA	17	-17	51	LOW	RoB, Imprecision
colchicine, statins	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA.	NA	NA	NA	0.001	1	-23	25	LOW	NA	NA	NA	1	-23	25	LOW	RoB, Imprecision
colchicine, statins	IL1 inhibitors	NA	NA	NA	NA	NA	NA	NA NA	NA	NA	NA	0.012	12	-12	36	LOW	NA	NA	NA	12	-12	36	LOW	RoB, Imprecision
colchicine, statins	IL6 receptor antagonists without corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA.	NA	NA	NA	0.016	16	-9	39	LOW	NA	NA	NA	16	-9	39	LOW	RoB, Imprecision
colchicine, statins	interferon beta (subcutaneous)	NA	NA	NA	NA	NA NA	NA	NA NA	NA	NA	NA	0.013	13	-24	50	LOW	NA	NA	NA	13	-24	50	VERY LOW	RoB, Imprecision
colchicine, statins	interferon beta (subcutaneous), lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.278	-278	-356	-199	MODERATE	NA	NA	NA	-278	-356	-199	LOW	RoB
colchicine, statins	intranasal corticosteroids	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.022	22 11	-6 -12	49 34	LOW	NA NA	NA NA	NA NA	22	-6 -12	49 34	LOW	RoB, Imprecision
colchicine, statins	ivermectin JAK inhibitors	NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.011	11 q	-12 -15	34	LOW	NA NA	NA NA	NA NA	11	-12	34	LOW	RoB, Imprecision RoB, Imprecision
colchicine, statins	JAK Innibitors Iopinavir-ritonavir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.036	-36	-15	-5	LOW	NA NA	NA NA	NA NA	-36	-15	-5	LOW	RoB, Imprecision
colchicine, statins	molnupiravir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.014	-36	-8	35	LOW	NA NA	NA NA	NA NA	-36	-8	35	LOW	RoB, Imprecision
colchicine, statins	nitazoxanide	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.012	12	-11	35	LOW	NA NA	NA	NA NA	12	-11	35	LOW	RoB, Imprecision
colchicine, statins	nirmatrelvir/ritonavir	NA	NA	NA	NA	NA NA	NA	NA.	NA	NA	NA	0.033	33	4	62	LOW	NA	NA	NA	33	4	62	LOW	RoB, Imprecision
colchicine, statins	probiotics	NA	NA	NA	NA	NA	NA	NA NA	NA	NA	NA	0.014	14	-11	39	LOW	NA	NA	NA	14	-11	39	LOW	RoB, Imprecision
colchicine, statins	proxalutamide	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.015	15	-11	42	LOW	NA	NA	NA	15	-11	42	LOW	RoB, Imprecision
colchicine, statins	remdesivir	NA	NA	NA	NA	NA	NA	NA NA	NA	NA	NA	0.008	8	-16	32	LOW	NA	NA	NA	8	-16	32	LOW	RoB, Imprecision
colchicine, statins	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.029	29	-24	82	VERY LOW	NA	NA	NA	29	-24	82	VERY LOW	RoB, Imprecisionx2
colchicine, statins	SGLT2 inhibitors	NA	NA	NA	NA	NA	NA	NA NA	NA	NA	NA	0.031	31	-6	68	LOW	NA	NA	NA	31	-6	68	LOW	RoB, Imprecision
colchicine, statins	statins	NA	NA	NA	NA	NA	NA	NA NA	NA	NA	NA	0.009	9	-16	34	LOW	NA	NA	NA	9	-16	34	LOW	RoB, Imprecision
colchicine, statins	sulodexide tyrosine kinase inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.000	-49	-63 -97	62	VERY LOW	NA NA	NA NA	NA NA	-49	-63 -97	62	VERY LOW	RoB, Imprecisionx3
	y		NA NA	NA NA		NA NA	NA NA	NA NA	NA NA		NA NA	-0.049	-49 9	-97 -27	45		NA NA	NA NA	NA NA	-49		0 45		
colchicine, statins	umifenovir vitamin D	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.009	9	-27	45	LOW	NA NA	NA NA	NA NA	9	-27 -18	45 48	LOW	RoB, Imprecision RoB, Imprecision
IL6 receptor antagonists with corticosteroids (systemic)	doxycycline, ivermectin	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.014	-14	-18	5	MODERATE	NA NA	NA NA	NA NA	-14	-18	48 5	MODERATE	Imprecision
IL6 receptor antagonists with corticosteroids (systemic)	doxycycline, refinedin doxycycline, lopinavir-ritonavir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.000	0	-24	24	MODERATE	NA NA	NA NA	NA NA	0	-24	24	MODERATE	Imprecision
IL6 receptor antagonists with corticosteroids (systemic)	electrolyzed saline	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.031	-31	-67	5	LOW	NA NA	NA	NA NA	-31	-67	5	LOW	RoB, Imprecision
IL6 receptor antagonists with corticosteroids (systemic)	emtricitabine, tenofovir	NA	NA	NA	NA.	NA.	NA	NA NA	NA	NA	NA	-0.026	-26	-52	-1	LOW	NA NA	NA	NA NA	-26	-52	-1	LOW	RoB, Imprecision
IL6 receptor antagonists with corticosteroids (systemic)	favipiravir	NA	NA	NA	NA	NA	NA	NA NA	NA	NA	NA	-0.010	-10	-27	7	LOW	NA	NA	NA	-10	-27	7	LOW	RoB, Imprecision
IL6 receptor antagonists with corticosteroids (systemic)	full-dose anticoagulant	NA	NA	NA	NA	NA	NA	NA NA	NA	NA	NA	-0.001	-1	-28	26	MODERATE	NA	NA	NA	-1	-28	26	MODERATE	Imprecision
IL6 receptor antagonists with corticosteroids (systemic)	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.017	-17	-32	-3	LOW	NA	NA	NA	-17	-32	-3	LOW	RoB, Imprecision
IL6 receptor antagonists with corticosteroids (systemic)	IL1 inhibitors	NA	NA	NA	NA	NA	NA	NA NA	NA	NA	NA	-0.006	-6	-20	7	HIGH	NA	NA	NA	-6	-20	7	HIGH	
IL6 receptor antagonists with corticosteroids (systemic)	IL6 receptor antagonists without corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.003	-3	-17	11	HIGH	NA	NA	NA	-3	-17	11	HIGH	
IL6 receptor antagonists with corticosteroids (systemic)	interferon beta (subcutaneous)	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.005	-5	-37	27	MODERATE	NA NA	NA NA	NA NA	-5	-37	27	MODERATE	Imprecision
IL6 receptor antagonists with corticosteroids (systemic)	interferon beta (subcutaneous), lopinavir-ritonavir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.296	-296 4	-371 -16	-220	MODERATE MODERATE	NA NA	NA NA	NA NA	-296 4	-371 -16	-220	MODERATE	RoB
IL6 receptor antagonists with corticosteroids (systemic) IL6 receptor antagonists with corticosteroids (systemic)	intranasal corticosteroids	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.004 -0.007	-7	-16 -18	23	MODERATE	NA NA	NA NA	NA NA	-7	-16 -18	23	MODERATE	Imprecision RoB
ico receptor antagonists with corticosteroids (systemic)	iverinectin	NA	NA	NA.	I NA	I NA	I NA	IN/A	INA	INA.	NA.	-0.007	-1	-18	4	MODERATE	INA	NA.	I NA	-/	-18	4	MODERATE	KOR

									Ac	dverse events											
Comparison		Direct estimate Relative estimate			Absolute estimate	nor 1 000)			Indirect estimate		Absolute estimat	e (per 1 000)		_	Network estimate		Absolute estima	to (por 1 000)			
Treatment 1	Treatment 2		lower limit		Point estimate		CI upper limit	Final rating		CI lower limit CI upper limit	Point estimate	, ,	CI lower limit CI upper limit	Final rating		CI lower limit CI upper limit		CI lower limit	CI upper limit	Final rating	Reasons for downgrading
IL6 receptor antagonists with corticosteroids (systemic)	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	-0.009	-9	-24 5	MODERATE	NA	NA NA	-9	-24	5	MODERATE	Imprecision
IL6 receptor antagonists with corticosteroids (systemic)	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	-0.054	-54	-78 -30	MODERATE	NA	NA NA	-54	-78	-30	LOW	RoB
IL6 receptor antagonists with corticosteroids (systemic) IL6 receptor antagonists with corticosteroids (systemic)	molnupiravir nitazoxanide	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.004 -0.006	-4 -6	-14 5 -19 6	HIGH	NA NA	NA NA	-4 -6	-14 -19	5 6	HIGH	
IL6 receptor antagonists with corticosteroids (systemic)	nirmatrelvir/ritonavir	NA NA	NA.	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.015	15	-6 36	MODERATE	NA NA	NA NA	15	-6	36	MODERATE	Imprecision
IL6 receptor antagonists with corticosteroids (systemic)	probiotics	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	-0.004	-4	-20 11	HIGH	NA	NA NA	-4	-20	11	MODERATE	
IL6 receptor antagonists with corticosteroids (systemic)	proxalutamide	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	-0.003	-3	-21 15	LOW	NA	NA NA	-3	-21	15	LOW	RoB, Imprecision
IL6 receptor antagonists with corticosteroids (systemic)	remdesivir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.010 0.011	-10 11	-25 4 -38 60	MODERATE	NA NA	NA NA	-10 11	-25 -38	60	MODERATE	Imprecision Imprecisionx2
IL6 receptor antagonists with corticosteroids (systemic) IL6 receptor antagonists with corticosteroids (systemic)	SGLT2 inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.011	13	-19 45	MODERATE	NA NA	NA NA	13	-38 -19	45	MODERATE	Imprecisionx2 Imprecision
IL6 receptor antagonists with corticosteroids (systemic)	statins	NA NA	NA	NA	NA NA	NA	NA	NA.	NA	NA NA	-0.009	-9	-24 6	LOW	NA	NA NA	-9	-24	6	LOW	RoB, Imprecision
IL6 receptor antagonists with corticosteroids (systemic)	sulodexide	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	-0.018	-18	-78 40	VERY LOW	NA	NA NA	-18	-78	40	VERY LOW	RoB, Imprecisionx2
IL6 receptor antagonists with corticosteroids (systemic)	tyrosine kinase inhibitors	NA NA	NA	NA	NA	NA	NA	NA	NA	NA NA	-0.067	-67 -10	-111 -23	HIGH	NA NA	NA NA	-67	-111 -40	-23	MODERATE LOW	
IL6 receptor antagonists with corticosteroids (systemic) IL6 receptor antagonists with corticosteroids (systemic)	umifenovir vitamin D	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.010 -0.003	-10	-40 21 -30 24	LOW	NA NA	NA NA	-10 -3	-40	21	LOW	RoB, Imprecision RoB, Imprecision
doxycycline, ivermectin	doxycycline, lopinavir-ritonavir	NA NA	NA	NA	NA NA	NA	NA	NA.	NA	NA NA	0.015	15	-13 42	#N/A	NA	NA NA	15	-13	42	#N/A	
doxycycline, ivermectin	electrolyzed saline	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	-0.017	-17	-56 22	VERY LOW	NA	NA NA	-17	-56	22	VERY LOW	RoB, Imprecisionx2
doxycycline, ivermectin	emtricitabine, tenofovir	NA NA	NA	NA	NA	NA	NA	NA	NA	NA NA	-0.012	-12	-41 17	LOW	NA	NA NA	-12	-41 -17	17	LOW	RoB, Imprecision
doxycycline, ivermectin doxycycline, ivermectin	favipiravir full-dose anticoagulant	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.005	5 13	-17 26 -17 44	LOW MODERATE	NA NA	NA NA	13	-17	26 44	LOW MODERATE	RoB, Imprecision Imprecision
doxycycline, ivermedin	(hydroxy)chloroquine	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.003	-3	-23 17	LOW	NA NA	NA NA	-3	-23	17	LOW	RoB, Imprecision
doxycycline, ivermectin	IL1 inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	0.008	8	-11 28	MODERATE	NA	NA NA	8	-11	28	MODERATE	Imprecision
doxycycline, ivermectin	IL6 receptor antagonists without corticosteroids (systemic)	NA NA	NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.012	12	-8 32	MODERATE	NA NA	NA NA	12	-8	32	MODERATE	Imprecision
doxycycline, ivermectin doxycycline, ivermectin	interferon beta (subcutaneous) interferon beta (subcutaneous), lopinavir-ritonavir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.009	9 -281	-25 44 -358 -204	MODERATE MODERATE	NA NA	NA NA	-281	-25 -358	-204	MODERATE MODERATE	Imprecision RoB
doxycycline, ivermedin	intranasal corticosteroids	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.018	18	-556 -20 4	MODERATE	NA NA	NA NA	18	-556	42	MODERATE	Imprecision
doxycycline, ivermectin	ivermectin	NA	NA	NA	NA NA	NA	NA	NA.	NA	NA NA	0.007	7	-11 25	LOW	NA	NA NA	7	-11	25	LOW	RoB, Imprecision
doxycycline, ivermectin	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	0.005	5	-15 25	MODERATE	NA	NA NA	5	-15	25	MODERATE	Imprecision
doxycycline, ivermectin	lopinavir-ritonavir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.039 0.010	-39 10	-67 -12 -7 27	LOW	NA NA	NA NA	-39 10	-67 -7	-12 27	LOW MODERATE	RoB, Imprecision
doxycycline, ivermectin doxycycline, ivermectin	molnupiravir nitazoxanide	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.010	10 8	-/ 2/ -11 27	MODERATE	NA NA	NA NA	10	-/ -11	27	MODERATE	Imprecision Imprecision
doxycycline, ivermectin	nirmatrelvir/ritonavir	NA NA	NA	NA NA	NA NA	NA NA	NA	NA NA	NA NA	NA NA	0.029	29	4 54	MODERATE	NA NA	NA NA	29	4	54	MODERATE	Imprecision
doxycycline, ivermectin	probiotics	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	0.010	10	-11 31	MODERATE	NA	NA NA	10	-11	31	MODERATE	Imprecision
doxycycline, ivermectin	proxalutamide	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	0.011	11	-11 35	LOW	NA	NA NA	11	-11	35	LOW	RoB, Imprecision
doxycycline, ivermectin doxycycline, ivermectin	remdesivir serine protease inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.004	4 25	-16 24 -26 76	MODERATE	NA NA	NA NA	25	-16 -26	24 76	MODERATE	Imprecision Imprecisionx2
doxycycline, ivermectin	SGLT2 inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.027	27	-7 62	MODERATE	NA NA	NA NA	27	-7	62	MODERATE	Imprecision
doxycycline, ivermectin	statins	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	0.006	6	-15 26	LOW	NA	NA NA	6	-15	26	LOW	RoB, Imprecision
doxycycline, ivermectin	sulodexide	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	-0.004	-4	-65 57	VERY LOW	NA	NA NA	-4	-65	57	VERY LOW	RoB, Imprecisionx3
doxycycline, ivermectin	tyrosine kinase inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.052 0.005	-52 5	-98 -6 -29 38	MODERATE	NA NA	NA NA	-52	-98 -29	-6 38	MODERATE	Imprecision RoB Imprecision
doxycycline, ivermectin	vitamin D	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.005	11	-29 36 -20 41	LOW	NA NA	NA NA	11	-29	41	LOW	RoB, Imprecision
doxycycline, lopinavir-ritonavir	electrolyzed saline	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	-0.032	-32	-73 10	VERY LOW	NA	NA NA	-32	-73	10	LOW	RoB, Imprecision
doxycycline, lopinavir-ritonavir	emtricitabine, tenofovir	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	-0.027	-27	-59 6	LOW	NA	NA NA	-27	-59	6	LOW	RoB, Imprecision
doxycycline, lopinavir-ritonavir doxycycline, lopinavir-ritonavir	favipiravir full-dose anticoagulant	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.010 -0.001	-10 -1	-37 16 -36 33	LOW	NA NA	NA NA	-10 -1	-37 -36	16 33	LOW MODERATE	RoB, Imprecision
doxycycline, lopinavir-ritonavir	(hydroxy)chloroquine	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.018	-18	-30 33 -41 6	LOW	NA NA	NA NA	-18	-41	6	LOW	RoB, Imprecision
doxycycline, lopinavir-ritonavir	IL1 inhibitors	NA NA	NA	NA	NA NA	NA	NA	NA.	NA	NA NA	-0.007	-7	-31 18	MODERATE	NA	NA NA	-7	-31	18	MODERATE	Imprecision
doxycycline, lopinavir-ritonavir	IL6 receptor antagonists without corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	-0.003	-3	-28 22	MODERATE	NA	NA NA	-3	-28	22	MODERATE	Imprecision
doxycycline, lopinavir-ritonavir	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	-0.005	-5	-43 33	MODERATE	NA	NA NA	-5	-43	33	MODERATE	Imprecision
doxycycline, lopinavir-ritonavir doxycycline, lopinavir-ritonavir	interferon beta (subcutaneous), lopinavir-ritonavir intranasal corticosteroids	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.296 0.003	-296 3	-374 -218 -25 32	VERY LOW MODERATE	NA NA	NA NA	-296	-374 -25	-218 32	MODERATE MODERATE	RoB Imprecision
doxycycline, lopinavir-ritonavir	ivermectin	NA	NA NA	NA NA	NA	NA NA	NA NA	NA NA	NA	NA NA	-0.007	-7	-31 16	LOW	NA	NA NA	-7	-31	16	LOW	RoB, Imprecision
doxycycline, lopinavir-ritonavir	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	-0.010	-10	-35 15	MODERATE	NA	NA NA	-10	-35	15	MODERATE	Imprecision
doxycycline, lopinavir-ritonavir	lopinavir-ritonavir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.054 -0.005	-54 -5	-85 -23 -27 18	MODERATE	NA NA	NA NA	-54	-85 -27	-23 18	LOW	RoB
doxycycline, lopinavir-ritonavir doxycycline, lopinavir-ritonavir	molnupiravir nitazoxanide	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.005	-5 -7	-27 18 -30 17	MODERATE	NA NA	NA NA	-5 -7	-27 -30	18	MODERATE	Imprecision Imprecision
doxycycline, lopinavii-ritonavii doxycycline, lopinavii-ritonavii	nirmatrelvir/ritonavir	NA	NA	NA NA	NA	NA	NA	NA	NA	NA NA	0.014	14	-15 44	MODERATE	NA	NA NA	14	-15	44	MODERATE	Imprecision
doxycycline, lopinavir-ritonavir	probiotics	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	-0.005	-5	-31 21	MODERATE	NA	NA NA	-5	-31	21	MODERATE	Imprecision
doxycycline, lopinavir-ritonavir	proxalutamide	NA NA	NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.003	-3	-30 24	LOW	NA NA	NA NA	-3	-30	24	LOW	RoB, Imprecision
doxycycline, lopinavir-ritonavir doxycycline, lopinavir-ritonavir	remdesivir serine protease inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.010 0.011	-10 11	-35 14 -42 64	MODERATE	NA NA	NA NA	-10 11	-35 -42	14 64	MODERATE LOW	Imprecision Imprecisionx2
doxycycline, lopinavii-ritoriavii doxycycline, lopinavir-ritonavir	SGLT2 inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.011	13	-25 50	MODERATE	NA NA	NA NA	13	-42	50	LOW	Imprecision
doxycycline, lopinavir-ritonavir	statins	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	-0.009	-9	-35 16	LOW	NA	NA NA	-9	-35	16	LOW	RoB, Imprecision
doxycycline, lopinavir-ritonavir	sulodexide	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	-0.019	-19	-82 44	VERY LOW	NA	NA NA	-19	-82	44	VERY LOW	RoB, Imprecisionx2
doxycycline, lopinavir-ritonavir doxycycline, lopinavir-ritonavir	tyrosine kinase inhibitors umifenovir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.067 -0.010	-67 -10	-116 -19 -46 26	LOW	NA NA	NA NA	-67 -10	-116 -46	-19 26	MODERATE LOW	Imprecision RoB. Imprecision
doxycycline, lopinavir-ritonavir doxycycline, lopinavir-ritonavir	vitamin D	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.010	-10	-46 26 -37 30	LOW	NA NA	NA NA	-10	-46	30	LOW	RoB, Imprecision
electrolyzed saline	emtricitabine, tenofovir	NA NA	NA	NA NA	NA NA	NA NA	NA	NA.	NA NA	NA NA	0.005	5	-37 47	LOW	NA NA	NA NA	5	-37	47	LOW	RoB, Imprecision
electrolyzed saline	favipiravir	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	0.021	21	-16 59	VERY LOW	NA	NA NA	21	-16	59	LOW	RoB, Imprecision
electrolyzed saline	full-dose anticoagulant	NA NA	NA	NA NA	NA NA	NA NA	NA	NA NA	NA NA	NA NA	0.030	30	-13 74	VERY LOW	NA NA	NA NA	30	-13	74	LOW	RoB, Imprecision
electrolyzed saline electrolyzed saline	(hydroxy)chloroquine	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.014	14 25	-23 51 -11 62	VERY LOW	NA NA	NA NA	25	-23 -11	51 62	VERY LOW	RoB, Imprecisionx2 RoB, Imprecision
electrolyzed saline electrolyzed saline	IL6 receptor antagonists without corticosteroids (systemic)	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.025	29	-8 65	LOW	NA NA	NA NA	29	-11	65	LOW	RoB, Imprecision
electrolyzed saline	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	0.026	26	-20 73	VERY LOW	NA	NA NA	26	-20	73	VERY LOW	RoB, Imprecisionx2
electrolyzed saline	interferon beta (subcutaneous), lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	-0.265	-265	-348 -182	MODERATE	NA	NA NA	-265	-348	-182	LOW	RoB
electrolyzed saline electrolyzed saline	intranasal corticosteroids	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.035	35 24	-4 74 -11 60	LOW	NA NA	NA NA	35 24	-4 -11	74 60	LOW	RoB, Imprecision
electrolyzed saline	ivermectin	NA NA	ΝA	NA NA	NA NA	NA	NA	N/A	I NA	NA NA	0.024	24	-11 60	LOW	I NA	I INA NA	24	-11	00	LUW	RoB, Imprecision

									Ac	dverse events											
Comparison		Direct estimate Relative estimate			Absolute estimate	(ner 1 000)		1	Indirect estimate		Absolute estimat	te (per 1 000)			Network estima Relative estima		Absolute estin	nate (per 1.000)			
Treatment 1	Treatment 2		lower limit		Point estimate	0 - , ,	CI upper limit	Final rating		CI lower limit CI upper limit			CI lower limit CI upper limit	Final rating		CI lower limit CI upper		CI lower limit	CI upper limit	Final rating	Reasons for downgrading
electrolyzed saline	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	0.022	22	-15 59	LOW	NA	NA NA	22	-15	59	LOW	RoB, Imprecision
electrolyzed saline	lopinavir-ritonavir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.023 0.027	-23 27	-64 19 -8 62	VERY LOW VERY LOW	NA NA	NA NA	-23 27	-64 -8	19 62	LOW	RoB, Imprecision
electrolyzed saline electrolyzed saline	molnupiravir nitazoxanide	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.027	27	-8 62 -11 61	VERY LOW VERY LOW	NA NA	NA NA	27	-8	62	LOW	RoB, Imprecision RoB, Imprecision
electrolyzed saline	nirmatrelvir/ritonavir	NA NA	NA	NA NA	NA NA	NA	NA	NA	NA	NA NA	0.046	46	6 86	LOW	NA	NA NA	46	6	86	LOW	RoB, Imprecision
electrolyzed saline	probiotics	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	0.027	27	-11 64	VERY LOW	NA	NA NA	27	-11	64	LOW	RoB, Imprecision
electrolyzed saline	proxalutamide	NA NA	NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.028	28	-10 67 -15 58	VERY LOW VERY LOW	NA NA	NA NA	28	-10 -15	67 58	LOW	RoB, Imprecision RoB, Imprecision
electrolyzed saline	remdesivir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.021	42	-15 58 -17 102	VERYLOW	NA NA	NA NA	42	-15	102	LOW	RoB Imprecision
electrolyzed saline	SGLT2 inhibitors	NA NA	NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.044	44	-2 90	LOW	NA.	NA NA	44	-2	90	LOW	RoB, Imprecision
electrolyzed saline	statins	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	0.022	22	-15 59	VERY LOW	NA	NA NA		-15	59	LOW	RoB, Imprecision
electrolyzed saline	sulodexide	NA	NA NA	NA	NA	NA	NA NA	NA	NA NA	NA NA	0.013	13	-55 81 -91 20	VERY LOW	NA NA	NA NA	-36	-55 -91	81	VERY LOW	RoB, Imprecisionx3
electrolyzed saline electrolyzed saline	tyrosine kinase inhibitors umifenovir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.036 0.022	-36 22	-91 20 -24 67	VERY LOW VERY LOW	NA NA	NA NA	-36	-91	67	VERY LOW VERY LOW	RoB, Imprecisionx2 RoB, Imprecisionx2
electrolyzed saline	vitamin D	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	0.028	28	-15 71	VERY LOW	NA	NA NA	28	-15	71	LOW	RoB, Imprecision
emtricitabine, tenofovir	favipiravir	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	0.016	16	-11 44	LOW	NA	NA NA	16	-11	44	LOW	RoB, Imprecision
emtricitabine, tenofovir emtricitabine, tenofovir	full-dose anticoagulant (hydroxy)chloroquine	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.025	25 9	-10 60 -17 35	VERY LOW LOW	NA NA	NA NA	25	-10 -17	60 35	LOW	RoB, Imprecision RoB, Imprecision
emtricitabine, tenolovir	IL1 inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.020	20	-17 35 -6 46	LOW	NA NA	NA NA	20	-6	46	LOW	RoB, Imprecision
emtricitabine, tenofovir	IL6 receptor antagonists without corticosteroids (systemic)	NA	NA	NA.	NA	NA	NA	NA	NA	NA NA	0.024	24	-2 50	LOW	NA	NA NA	24	-2	50	LOW	RoB, Imprecision
emtricitabine, tenofovir	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	0.022	22	-17 60	VERY LOW	NA	NA NA		-17	60	LOW	RoB, Imprecision
emtricitabine, tenofovir emtricitabine, tenofovir	interferon beta (subcutaneous), lopinavir-ritonavir intranasal corticosteroids	NA NA	NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.269 0.030	-269 30	-348 -191 1 59	MODERATE	NA NA	NA NA	-269 30	-348 1	-191 59	LOW	RoB RoB, Imprecision
emtricitabine, tenofovir	ivermectin	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.030	19	-5 44	LOW	NA NA	NA NA	19	-5	44	LOW	RoB, Imprecision
emtricitabine, tenofovir	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	0.017	17	-9 43	LOW	NA	NA NA	17	-9	43	LOW	RoB, Imprecision
emtricitabine, tenofovir	lopinavir-ritonavir	NA NA	NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.028	-28	-60 5	LOW	NA NA	NA NA		-60	5	LOW	RoB, Imprecision
emtricitabine, tenofovir emtricitabine, tenofovir	molnupiravir nitazoxanide	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.022	22	-2 46 -5 45	LOW	NA NA	NA NA	22	-2 -5	46 45	LOW	RoB, Imprecision RoB, Imprecision
emtricitabine, tenofovir	nirmatrelvir/ritonavir	NA NA	NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.041	41	10 71	LOW	NA NA	NA NA	41	10	71	LOW	RoB, Imprecision
emtricitabine, tenofovir	probiotics	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	0.022	22	-5 49	LOW	NA	NA NA	22	-5	49	LOW	RoB, Imprecision
emtricitabine, tenofovir	proxalutamide	NA	NA	NA	NA	NA	NA NA	NA	NA	NA NA	0.023	23	-5 52	LOW	NA	NA NA		-5	52	LOW	RoB, Imprecision
emtricitabine, tenofovir emtricitabine, tenofovir	remdesivir serine protease inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.016	16 37	-10 43 -16 91	LOW	NA NA	NA NA	16	-10 -16	43 91	LOW	RoB, Imprecision RoB, Imprecision
emtricitabine, tenofovir	SGLT2 inhibitors	NA NA	NA	NA.	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.039	39	1 78	LOW	NA NA	NA NA	39	1	78	LOW	RoB, Imprecision
emtricitabine, tenofovir	statins	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	0.017	17	-9 44	LOW	NA	NA NA	17	-9	44	LOW	RoB, Imprecision
emtricitabine, tenofovir emtricitabine, tenofovir	sulodexide tyrosine kinase inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.040	-40	-55 71 -90 9	VERY LOW LOW	NA NA	NA NA	-40	-55 -90	71	VERY LOW LOW	RoB, Imprecisionx3
emtricitabine, tenorovir emtricitabine, tenorovir	tyrosine kinase innibitors umifenovir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.040	-40 17	-90 9	VERY LOW	NA NA	NA NA	17	-90	54	VERY LOW	RoB, Imprecision RoB, Imprecisionx2
emtricitabine, tenofovir	vitamin D	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	0.023	23	-12 58	LOW	NA	NA NA	23	-12	58	LOW	RoB, Imprecision
favipiravir	full-dose anticoagulant	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	0.009	9	-21 38	LOW	NA	NA NA	9	-21	38	LOW	RoB, Imprecision
favipiravir favipiravir	(hydroxy)chloroquine IL1 inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.008 0.004	-8	-25 11 -14 21	LOW	NA NA	NA NA	-8	-25 -14	11 21	LOW	RoB, Imprecision RoB, Imprecision
favipiravir	IL6 receptor antagonists without corticosteroids (systemic)	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.004	7	-14 21	LOW	NA NA	NA NA	7	-14	25	LOW	RoB, Imprecision
favipiravir	interferon beta (subcutaneous)	NA	NA	NA.	NA	NA	NA	NA	NA	NA NA	0.005	5	-29 39	LOW	NA	NA NA	5	-29	39	LOW	RoB, Imprecision
favipiravir	interferon beta (subcutaneous), lopinavir-ritonavir	NA NA	NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.286	-286	-363 -209	MODERATE	NA NA	NA NA	-286	-363	-209	MODERATE	RoB
favipiravir favipiravir	intranasal corticosteroids ivermectin	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.014	14	-9 36 -13 19	LOW MODERATE	NA NA	NA NA	14	-9 -13	36 19	MODERATE	RoB, Imprecision RoB
favipiravir	JAK inhibitors	NA NA	NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.000	0	-18 18	MODERATE	NA.	NA NA	0	-18		MODERATE	RoB
favipiravir	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	-0.044	-44	-70 -18	LOW	NA	NA NA	-44	-70	-18	LOW	RoB, Imprecision
favipiravir	molnupiravir nitazoxanide	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.005	5	-9 20 -13 20	MODERATE	NA NA	NA NA	5	-9 -13	20	MODERATE LOW	RoB RoB
favipiravir favipiravir	nitazoxanide nirmatrelvir/ritonavir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.004	24	-13 20 1 48	LOW	NA NA	NA NA		-13	48	LOW	RoB, Imprecision
favipiravir	probiotics	NA	NA	NA.	NA	NA	NA.	NA	NA	NA NA	0.005	5	-14 25	LOW	NA	NA NA		-14	25	LOW	RoB, Imprecision
favipiravir	proxalutamide	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	0.007	7	-14 28	LOW	NA	NA NA	7	-14	28	LOW	RoB, Imprecision
favipiravir favipiravir	remdesivir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.000	0 21	-18 18 -29 71	MODERATE VERY LOW	NA NA	NA NA	21	-18 -29	18 71	MODERATE VERY LOW	RoB Imprecisionx2
favipiravir	SGLT2 inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.021	23	-11 56	VERY LOW	NA NA	NA NA	23	-29	56	LOW	RoB, Imprecision
favipiravir	statins	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	0.001	1	-18 20	MODERATE	NA	NA NA	1	-18		MODERATE	RoB
favipiravir	sulodexide	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	-0.008	-8	-69 51	VERY LOW	NA	NA NA		-69	51	VERY LOW	RoB, Imprecisionx3
favipiravir favipiravir	tyrosine kinase inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.057 0.000	-57 0	-102 -11 -32 33	LOW	NA NA	NA NA	-57 0	-102 -32	-11 33	LOW	RoB, Imprecision RoB, Imprecision
favipiravir	vitamin D	NA NA	NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.007	7	-23 35	LOW	NA NA	NA NA	7	-23	35	LOW	RoB, Imprecision
full-dose anticoagulant	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	-0.016	-16	-45 12	LOW	NA	NA NA		-45	12	LOW	RoB, Imprecision
full-dose anticoagulant	IL1 inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.005 -0.002	-5 -2	-33 22 -30 26	MODERATE MODERATE	NA NA	NA NA	-5	-33 -30	22 26	MODERATE MODERATE	Imprecision
full-dose anticoagulant full-dose anticoagulant	IL6 receptor antagonists without corticosteroids (systemic) interferon beta (subcutaneous)	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.002	-2	-30 26 -44 36	MODERATE	NA NA	NA NA	-2	-30	36	MODERATE	Imprecision Imprecision
full-dose anticoagulant	interferon beta (subcutaneous), lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	-0.295	-295	-374 -215	MODERATE	NA	NA NA	-295	-374	-215	MODERATE	RoB
full-dose anticoagulant	intranasal corticosteroids	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	0.005	5	-27 36	MODERATE	NA	NA NA	5	-27	36	MODERATE	Imprecision
full-dose anticoagulant full-dose anticoagulant	ivermectin JAK inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.006 -0.008	-6 -8	-33 21 -37 20	LOW	NA NA	NA NA	-6 -8	-33 -37	21	LOW MODERATE	RoB, Imprecision Imprecision
full-dose anticoagulant full-dose anticoagulant	JAK inhibitors lopinavir-ritonavir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.008	-8 -53	-37 20 -87 -19	LOW	NA NA	NA NA	-8 -53	-37	-19	LOW	RoB, Imprecision
full-dose anticoagulant	molnupiravir	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	-0.003	-3	-30 23	MODERATE	NA	NA NA	-3	-30	23	MODERATE	Imprecision
full-dose anticoagulant	nitazoxanide	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	-0.005	-5	-33 22	MODERATE	NA	NA NA	-5	-33		MODERATE	Imprecision
full-dose anticoagulant full-dose anticoagulant	nirmatrelvir/ritonavir probiotics	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.016 -0.003	16 -3	-17 48 -33 26	MODERATE	NA NA	NA NA	16 -3	-17 -33	48 26	MODERATE MODERATE	Imprecision Imprecision
full-dose anticoagulant	probalutamide	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.003	-2	-33 28	LOW	NA NA	NA NA	-3	-33	28	LOW	RoB, Imprecision
full-dose anticoagulant	remdesivir	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	-0.009	-9	-38 19	MODERATE	NA	NA NA		-38	19	MODERATE	Imprecision
full-dose anticoagulant	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA NA	0.012	12	-43 66	LOW	NA	NA NA	12	-43	66	LOW	Imprecisionx2

Comparison		Discout continue								dverse events							Materials and							
		Direct estimate Relative estimate			Absolute estima	te (ner 1 000)			Indirect estima Relative estima	te e		Absolute estimate	(per 1 000)				Network estimate Relative estimat	•		Absolute estimate	(ner 1 000)			4
Treatment 1	Treatment 2		CI lower limit	CI upper limit		CI lower limit	CI upper limit	Final rating		CI lower limit	CI upper limit	Point estimate	0 - , ,	CI lower limit	CI upper limit	Final rating		CI lower limit	CI upper limit	Point estimate 0		CI upper limit	Final rating	Reasons for downgrading
full-dose anticoagulant	SGLT2 inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.014	14	-26	54	LOW	NA	NA	NA.	14	-26	54	LOW	Imprecisionx2
full-dose anticoagulant	statins	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.008	-8	-37	21	LOW	NA	NA	NA	-8	-37	21	LOW	RoB, Imprecision
full-dose anticoagulant	sulodexide	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.017	-17	-82	46	VERY LOW	NA	NA	NA	-17	-82	46	VERY LOW	RoB, Imprecisionx2
full-dose anticoagulant	tyrosine kinase inhibitors umifenovir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.066 -0.009	-66 -9	-116 -48	-16 30	MODERATE	NA NA	NA NA	NA NA	-66 -9	-116 -48	-16 30	MODERATE	Imprecision RoB. Imprecision
full-dose anticoagulant full-dose anticoagulant	umitenovir vitamin D	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.009	-9 -2	-48 -39	30	LOW	NA NA	NA NA	NA NA	-9	-48 -39	30	LOW	RoB, Imprecision
(hydroxy)chloroquine	IL1 inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA.	NA.	NA NA	NA NA	NA NA	0.011	11	-4	26	LOW	NA NA	NA NA	NA NA	11	-4	26	LOW	RoB. Imprecision
	IL6 receptor antagonists without corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.015	15	-1	30	LOW	NA	NA	NA NA	15	-1	30	LOW	RoB, Imprecision
(hydroxy)chloroquine	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.012	12	-20	45	LOW	NA	NA	NA	12	-20	45	LOW	RoB, Imprecision
interferon beta (subcutaneous), lopinavir-ritonavir	(hydroxy)chloroquine	NA	NA	NA	180	-997	1357	VERY LOW	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	278	202	354	MODERATE	RoB
(hydroxy)chloroquine	intranasal corticosteroids	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.021	21	1	41	LOW	NA	NA	NA	21	1	41	LOW	RoB, Imprecision
(hydroxy)chloroquine	ivermectin JAK inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.010	10	-3	23	LOW	NA NA	NA NA	NA NA	10	-3	23	LOW	RoB, Imprecision RoB. Imprecision
(hydroxy)chloroquine lopinavir-ritonavir	(hydroxy)chloroquine	NA NA	NA NA	NA NA	18	-441	475	VERYLOW	NA NA	NA NA	NA NA	0.008	8 3	-8 -53	59	VERY LOW	NA NA	NA NA	NA NA	37	-8 14	59	LOW	RoB, Imprecision
(hydroxy)chloroquine	molnupiravir	NA NA	NA NA	NA NA	NA NA	NA.	NA.	NA NA	NA NA	NA NA	NA NA	0.013	13	2	24	LOW	NA NA	NA NA	NA NA	13	2	24	LOW	RoB. Imprecision
(hydroxy)chloroquine	nitazoxanide	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.011	11	-3	25	LOW	NA	NA	NA	11	-3	25	LOW	RoB, Imprecision
(hydroxy)chloroquine	nirmatrelvir/ritonavir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.032	32	10	54	LOW	NA	NA	NA	32	10	54	LOW	RoB, Imprecision
(hydroxy)chloroquine	probiotics	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.013	13	-4	30	LOW	NA	NA	NA	13	-4	30	LOW	RoB, Imprecision
(hydroxy)chloroquine	proxalutamide	NA	NA	NA NA	NA	NA	NA	NA	NA	NA	NA	0.014	14	-5	34	LOW	NA	NA	NA .	14	-5	34	LOW	RoB, Imprecision
remdesivir (hydroxylchloroquine	(hydroxy)chloroquine serine protease inhibitors	NA NA	NA NA	NA NA	-36 NA	-1211 NA	1140 NA	VERY LOW NA	NA NA	NA NA	NA NA	-0.005 0.028	-5 28	-22 -21	11 78	LOW VERY LOW	NA NA	NA	NA NA	-7 28	-23 -21	8 78	LOW	RoB, Imprecision RoB, Imprecisionx2
(hydroxy)chloroquine (hydroxy)chloroquine	serine protease inhibitors SGLT2 inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.028	30	-21 -2	78 63	LOW	NA NA	NA NA	NA NA	30	-21 -2	78 63	LOW	RoB, Imprecisionx2
(hydroxy)chloroquine (hydroxy)chloroquine	SGL12 Inhibitors statins	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.030	8	-2	25	LOW	NA NA	NA NA	NA NA	8	-2	25	LOW	RoB, Imprecision
(hydroxy)chloroquine	sulodexide	NA	NA	NA NA	NA NA	NA	NA.	NA.	NA	NA.	NA	-0.001	-1	-61	58	VERY LOW	NA	NA	NA NA	-1	-61	58	VERY LOW	RoB, Imprecisionx3
(hydroxy)chloroquine	tyrosine kinase inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.049	-49	-94	-5	LOW	NA	NA	NA	-49	-94	-5	LOW	RoB, Imprecision
(hydroxy)chloroquine	umifenovir	NA	NA	NA	NA	NA	NA	NA NA	NA	NA	NA	0.008	8	-23	39	LOW	NA	NA	NA	8	-23	39	LOW	RoB, Imprecision
(hydroxy)chloroquine	vitamin D	NA	NA	NA NA	NA	NA	NA	NA NA	NA	NA	NA	0.014	14	-14	42	LOW	NA	NA	NA NA	14	-14	42	LOW	RoB, Imprecision
IL1 inhibitors	IL6 receptor antagonists without corticosteroids (systemic) interferon beta (subcutaneous)	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.004	4	-11 -31	18	HIGH MODERATE	NA NA	NA NA	NA NA	4	-11 -31	18 33	HIGH MODERATE	Imprecision
IL1 inhibitors	interferor beta (subcutaneous) interferon beta (subcutaneous), lopinavir-ritonavir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.289	-289	-365	-214	MODERATE	NA NA	NA NA	NA NA	-289	-365	-214	MODERATE	RoB
IL1 inhibitors	intranasal corticosteroids	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA.	NA NA	NA NA	NA NA	0.010	10	-10	30	MODERATE	NA NA	NA NA	NA NA	10	-10	30	MODERATE	Imprecision
IL1 inhibitors	ivermectin	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.001	-1	-13	11	MODERATE	NA	NA	NA.	-1	-13	11	MODERATE	RoB
IL1 inhibitors	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.003	-3	-18	12	HIGH	NA	NA	NA	-3	-18	12	HIGH	
IL1 inhibitors	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.048	-48	-72	-23	MODERATE	NA	NA	NA	-48	-72	-23	LOW	RoB
IL1 inhibitors	molnupiravir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.002	2	-8	12	HIGH	NA	NA	NA	2	-8	12	HIGH	
IL1 inhibitors IL1 inhibitors	nitazoxanide nirmatrelvir/ritonavir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.000	21	-13	13	HIGH MODERATE	NA NA	NA NA	NA NA	21	-13	13	HIGH MODERATE	Imprecision
II 1 inhibitors	probiotics	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.021	21	-15	18	HIGH	NA NA	NA NA	NA NA	21	-15	18	HIGH	Imprecision
IL1 inhibitors	proxalutamide	NA	NA	NA	NA	NA	NA	NA.	NA	NA.	NA	0.003	3	-15	22	LOW	NA	NA	NA.	3	-15	22	LOW	RoB, Imprecision
IL1 inhibitors	remdesivir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.004	-4	-19	11	HIGH	NA	NA	NA	-4	-19	11	HIGH	
IL1 inhibitors	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.017	17	-32	66	LOW	NA	NA	NA	17	-32	66	LOW	Imprecisionx2
IL1 inhibitors	SGLT2 inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.019	19	-13	51	LOW	NA	NA	NA NA	19	-13	51	MODERATE	Imprecision
IL1 inhibitors IL1 inhibitors	statins sulodexide	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.003 -0.012	-3 -12	-18 -72	13 47	MODERATE VERY LOW	NA NA	NA NA	NA NA	-3 -12	-18 -72	13 47	MODERATE VERY LOW	RoB
IL1 inhibitors	tyrosine kinase inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.012	-12	-12	-16	MODERATE	NA NA	NA NA	NA NA	-12	-12	-16	MODERATE	RoB, Imprecisionx2 Imprecision
IL1 inhibitors	umifenovir	NA NA	NA NA	NA NA	NA NA	NA	NA NA	NA.	NA	NA.	NA	-0.003	-3	-34	27	LOW	NA NA	NA	NA.	-3	-34	27	LOW	RoB, Imprecision
IL1 inhibitors	vitamin D	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.003	3	-24	30	LOW	NA	NA	NA.	3	-24	30	LOW	RoB, Imprecision
IL6 receptor antagonists without corticosteroids (systemic)	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.002	-2	-35	30	MODERATE	NA	NA	NA	-2	-35	30	MODERATE	Imprecision
IL6 receptor antagonists without corticosteroids (systemic)	interferon beta (subcutaneous), lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.293	-293	-369	-217	MODERATE	NA	NA	NA	-293	-369	-217	MODERATE	RoB
IL6 receptor antagonists without corticosteroids (systemic)	intranasal corticosteroids	NA NA	NA	NA NA	NA NA	NA NA	NA NA	NA	NA NA	NA NA	NA	0.006	6	-14 -17	27	MODERATE	NA NA	NA NA	NA	6	-14 -17	27	MODERATE	Imprecision
IL6 receptor antagonists without corticosteroids (systemic) IL6 receptor antagonists without corticosteroids (systemic)	ivermectin JAK inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.004 -0.007	-4	-17	8 9	MODERATE MODERATE	NA NA	NA NA	NA NA	-4	-17	8 9	MODERATE MODERATE	RoB Imprecision
IL6 receptor antagonists without corticosteroids (systemic)	Iopinavir-ritonavir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.051	-51	-76	-26	MODERATE	NA NA	NA NA	NA NA	-51	-76	-26	LOW	RoB
IL6 receptor antagonists without corticosteroids (systemic)	molnupiravir	NA	NA	NA NA	NA.	NA	NA.	NA.	NA	NA	NA	-0.002	-2	-13	9	HIGH	NA	NA	NA	-2	-13	9	HIGH	
IL6 receptor antagonists without corticosteroids (systemic)	nitazoxanide	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.004	-4	-17	10	HIGH	NA	NA	NA	-4	-17	10	HIGH	
IL6 receptor antagonists without corticosteroids (systemic)	nirmatrelvir/ritonavir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.017	17	-5	39	MODERATE	NA	NA	NA	17	-5	39	MODERATE	Imprecision
IL6 receptor antagonists without corticosteroids (systemic)	probiotics	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.002	-2	-19	15	HIGH	NA NA	NA NA	NA NA	-2	-19	15	HIGH	RoB
IL6 receptor antagonists without corticosteroids (systemic) IL6 receptor antagonists without corticosteroids (systemic)	proxalutamide remdesivir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.000	-7	-19 -23	19	MODERATE MODERATE	NA NA	NA	NA NA	-7	-19 -23	19 8	MODERATE MODERATE	RoB Imprecision
IL6 receptor antagonists without corticosteroids (systemic)	serine protease inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.014	14	-23	63	LOW	NA NA	NA NA	NA NA	14	-23	63	LOW	Imprecisionx2
IL6 receptor antagonists without corticosteroids (systemic)	SGLT2 inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.014	16	-17	48	MODERATE	NA NA	NA NA	NA NA	16	-17	48	MODERATE	Imprecision
IL6 receptor antagonists without corticosteroids (systemic)	statins	NA	NA	NA NA	NA.	NA	NA.	NA.	NA	NA	NA	-0.006	-6	-22	10	LOW	NA	NA	NA	-6	-22	10	LOW	RoB, Imprecision
IL6 receptor antagonists without corticosteroids (systemic)	sulodexide	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.016	-16	-75	43	VERY LOW	NA	NA	NA	-16	-75	43	VERY LOW	RoB, Imprecisionx2
IL6 receptor antagonists without corticosteroids (systemic)	tyrosine kinase inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.064	-64	-109	-20	HIGH	NA	NA	NA	-64	-109	-20	MODERATE	
IL6 receptor antagonists without corticosteroids (systemic)	umifenovir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.007	-7	-38	24	LOW	NA NA	NA NA	NA NA	-7	-38	24	LOW	RoB, Imprecision
IL6 receptor antagonists without corticosteroids (systemic) interferon beta (subcutaneous)	vitamin D interferon beta (subcutaneous), lopinavir-ritonavir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.001 -0.291	-1 -291	-28 -372	-210	LOW MODERATE	NA NA	NA NA	NA NA	-1 -291	-28 -372	-210	LOW MODERATE	RoB, Imprecision RoB
interferon beta (subcutaneous)	interieron beta (subcutaneous), lopinavir-ritonavir intranasal corticosteroids	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.009	-291	-372	-210 44	MODERATE	NA NA	NA NA	NA NA	-291	-372	-210	MODERATE	Imprecision
interferon beta (subcutaneous)	ivermectin	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.009	-2	-33	29	LOW	NA NA	NA NA	NA NA	-2	-33	29	LOW	RoB, Imprecision
interferon beta (subcutaneous)	JAK inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA.	-0.005	-5	-37	28	MODERATE	NA NA	NA NA	NA NA	-5	-37	28	MODERATE	Imprecision
interferon beta (subcutaneous)	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.049	-49	-87	-11	LOW	NA	NA	NA	-49	-87	-11	LOW	RoB, Imprecision
interferon beta (subcutaneous)	molnupiravir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.000	0	-30	31	MODERATE	NA	NA	NA	0	-30	31	MODERATE	Imprecision
interferon beta (subcutaneous)	nitazoxanide	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.001	-1	-33	30	MODERATE	NA	NA	NA	-1	-33	30	MODERATE	Imprecision
interferon beta (subcutaneous)	nirmatrelvir/ritonavir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.019	19	-17	55	LOW	NA NA	NA NA	NA NA	19	-17	55	MODERATE	Imprecision
	probiotics	NA	NA	NA	NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.001	2	-33 -32	34 36	MODERATE	NA NA	NA NA	NA NA	1 1	-33	34	MODERATE	Imprecision RoB Imprecision
interferon beta (subcutaneous)		N/A	NA I																					
interferon beta (subcutaneous) interferon beta (subcutaneous) interferon beta (subcutaneous)	proxalutamide remdesivir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.005	-5	-32	27	MODERATE	NA NA	NA NA	NA NA	-5	-32 -38	36 27	LOW MODERATE	Imprecision

				Adverse events																				
Comparison		Direct estimate					Indirect estimate									Network estimate								
Toronto and d	Tourism 0	Relative estimate	Oldswer Freih		Absolute estimal		Ol	Final rating	Relative estima	-	01	Absolute estimate	0 - , ,	011	Ol I'm'h	Final rating	Relative estimat		L OL	Absolute estimate	. , ,	Oleman and Free It	Final rating	D
Treatment 1 interferon beta (subcutaneous)	Treatment 2 SGLT2 inhibitors	Point estimate NA	CI lower limit	CI upper limit	Point estimate	CI lower limit	Cl upper limit	NA	Point estimate	CI lower limit	CI upper limit	Point estimate	Point estimate	CI lower limit	Cl upper limit	LOW	Point estimate	CI lower limit	CI upper limit	Point estimate	-25	CI upper limit	LOW	Reasons for downgrading Imprecisionx2
interferon beta (subcutaneous)	statins	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.004	-4	-25	29	LOW	NA NA	NA NA	NA NA	-4	-25	29	LOW	RoB. Imprecision
interferon beta (subcutaneous)	sulodexide	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA	NA NA	NA NA	NA NA	-0.014	-14	-80	52	VERY LOW	NA NA	NA NA	NA NA	-14	-80	52	VERY LOW	RoB, Imprecisionx3
interferon beta (subcutaneous)	tyrosine kinase inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.062	-62	-114	-9	MODERATE	NA	NA	NA	-62	-114	-9	MODERATE	Imprecision
interferon beta (subcutaneous)	umifenovir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.005	-5	-47	37	LOW	NA	NA	NA	-5	-47	37	LOW	RoB, Imprecision
interferon beta (subcutaneous)	vitamin D	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.002	2	-38	41	VERY LOW	NA	NA	NA	2	-38	41	LOW	RoB, Imprecision
interferon beta (subcutaneous), lopinavir-ritonavir	intranasal corticosteroids	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.299	299 289	222	377 364	MODERATE MODERATE	NA NA	NA NA	NA NA	299	222	377 364	MODERATE	RoB RoB
interferon beta (subcutaneous), lopinavir-ritonavir interferon beta (subcutaneous), lopinavir-ritonavir	.IAK inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.289	289	213 210	364	MODERATE	NA NA	NA NA	NA NA	289 286	213 210	364	MODERATE	RoB
lopinavir-ritonavir	interferon beta (subcutaneous), lopinavir-ritonavir	NA NA	NA NA	NA NA	-181	-1357	996	VERY LOW	NA NA	NA NA	NA NA	0.286 NA	NA NA	NA NA	NA	NA NA	NA NA	NA NA	NA NA	-242	-320	-164	LOW	RoB, Imprecision
interferon beta (subcutaneous), lopinavir-ritonavir	molnupiravir	NA NA	NA NA	NA NA	NA.	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.291	291	216	366	MODERATE	NA NA	NA NA	NA NA	291	216	366	MODERATE	RoB
interferon beta (subcutaneous), lopinavir-ritonavir	nitazoxanide	NA NA	NA.	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA.	0.289	289	214	365	MODERATE	NA NA	NA.	NA NA	289	214	365	MODERATE	RoB
interferon beta (subcutaneous), lopinavir-ritonavir	nirmatrelvir/ritonavir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.310	310	233	388	MODERATE	NA	NA	NA	310	233	388	MODERATE	RoB
interferon beta (subcutaneous), lopinavir-ritonavir	probiotics	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.291	291	215	367	MODERATE	NA	NA	NA	291	215	367	MODERATE	RoB
interferon beta (subcutaneous), lopinavir-ritonavir	proxalutamide	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.293	293	216	370	MODERATE	NA	NA	NA	293	216	370	MODERATE	RoB
interferon beta (subcutaneous), lopinavir-ritonavir	remdesivir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.286	286	210	362	MODERATE	NA	NA	NA	286	210	362	MODERATE	RoB
interferon beta (subcutaneous), lopinavir-ritonavir	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.307	307	217	396	MODERATE	NA	NA	NA	307	217	396	MODERATE	RoB
interferon beta (subcutaneous), lopinavir-ritonavir	SGLT2 inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.309	309	227	390	MODERATE	NA	NA	NA	309	227	390	MODERATE	RoB
interferon beta (subcutaneous), lopinavir-ritonavir interferon beta (subcutaneous), lopinavir-ritonavir	statins sulodexide	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.287	287 277	210 182	363 373	MODERATE MODERATE	NA NA	NA NA	NA NA	287 277	210 182	363 373	MODERATE MODERATE	RoB RoB
interferon beta (subcutaneous), lopinavir-ntonavir interferon beta (subcutaneous), lopinavir-ritonavir	tyrosine kinase inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.277	277	142	3/3	MODERATE	NA NA	NA NA	NA NA	229	142	3/3	MODERATE	RoB
interferon beta (subcutaneous), lopinavir-ritonavir	umifenovir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.286	286	206	367	MODERATE	NA NA	NA NA	NA NA	286	206	367	MODERATE	RoB
interferon beta (subcutaneous), lopinavir-ritonavir	vitamin D	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA	NA NA	NA NA	NA NA	0.292	292	213	372	MODERATE	NA NA	NA NA	NA NA	292	213	372	MODERATE	RoB
intranasal corticosteroids	ivermectin	NA	NA	NA	NA	NA NA	NA	NA	NA	NA	NA	-0.011	-11	-29	8	LOW	NA	NA	NA	-11	-29	8	LOW	RoB, Imprecision
intranasal corticosteroids	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.013	-13	-34	7	MODERATE	NA	NA	NA	-13	-34	7	MODERATE	Imprecision
intranasal corticosteroids	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.058	-58	-86	-29	MODERATE	NA	NA	NA	-58	-86	-29	LOW	RoB
intranasal corticosteroids	molnupiravir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.008	-8	-25	9	MODERATE	NA	NA	NA	-8	-25	9	MODERATE	Imprecision
intranasal corticosteroids	nitazoxanide	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.010	-10	-29	9	MODERATE	NA	NA	NA	-10	-29	9	MODERATE	Imprecision
intranasal corticosteroids	nirmatrelvir/ritonavir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.011 -0.008	11	-15 -30	37 13	MODERATE MODERATE	NA NA	NA NA	NA NA	11	-15 -30	37 13	MODERATE MODERATE	Imprecision
intranasal corticosteroids intranasal corticosteroids	probiotics	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.008	-8 -7	-30 -30	13	MODERATE LOW	NA NA	NA NA	NA NA	-8 -7	-30 -30	13	MODERATE LOW	Imprecision
intranasal corticosteroids	proxalutamide remdesivir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.007	-14	-34	7	MODERATE	NA NA	NA NA	NA NA	-14	-34	7	MODERATE	RoB, Imprecision Imprecision
intranasal corticosteroids	serine protease inhibitors	NA NA	NA NA	NA NA	NA NA	NA.	NA NA	NA NA	NA NA	NA NA	NA.	0.007	7	-44	58	LOW	NA NA	NA NA	NA NA	7	-44	58	LOW	Imprecisionx2
intranasal corticosteroids	SGLT2 inhibitors	NA NA	NA.	NA NA	NA.	NA.	NA NA	NA NA	NA NA	NA NA	NA.	0.009	9	-26	44	MODERATE	NA NA	NA NA	NA NA	9	-26	44	MODERATE	Imprecision
intranasal corticosteroids	statins	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.013	-13	-34	9	LOW	NA	NA	NA	-13	-34	9	LOW	RoB, Imprecision
intranasal corticosteroids	sulodexide	NA	NA	NA	NA	NA	NA NA	NA	NA	NA	NA	-0.022	-22	-83	39	VERY LOW	NA	NA	NA	-22	-83	39	VERY LOW	RoB, Imprecisionx2
intranasal corticosteroids	tyrosine kinase inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.071	-71	-117	-24	HIGH	NA	NA	NA	-71	-117	-24	MODERATE	
intranasal corticosteroids	umifenovir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.013	-13	-47	20	LOW	NA	NA	NA	-13	-47	20	LOW	RoB, Imprecision
intranasal corticosteroids	vitamin D	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.007	-7	-38	24	LOW	NA	NA	NA	-7	-38	24	LOW	RoB, Imprecision
ivermectin	JAK inhibitors	NA NA	NA NA	NA NA	NA 12	NA -1164	NA 1187	NA VERY LOW	NA NA	NA NA	NA NA	-0.002 0.051	-2 51	-15 26	11 75	MODERATE MODERATE	NA NA	NA NA	NA NA	-2 47	-15 24	11 70	MODERATE	RoB
lopinavir-ritonavir ivermectin	molnupiravir	NA NA	NA NA	NA NA	NA	-1164 NA	NA	NA NA	NA NA	NA NA	NA NA	0.003	3	20 5	10	MODERATE	NA NA	NA NA	NA NA	4/	-5	10	MODERATE	RoB
ivermectin	nitazoxanide	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.003	1	-10	12	MODERATE	NA NA	NA NA	NA NA	1	-10	12	MODERATE	RoB
ivermectin	nirmatrelvir/ritonavir	NA NA	NA.	NA NA	NA.	NA.	NA NA	NA NA	NA NA	NA NA	NA.	0.022	22	1	42	LOW	NA NA	NA.	NA NA	22	1	42	LOW	RoB. Imprecision
ivermectin	probiotics	NA	NA	NA	NA	NA	NA NA	NA	NA	NA	NA	0.003	3	-12	17	MODERATE	NA	NA	NA	3	-12	17	MODERATE	RoB
ivermectin	proxalutamide	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.004	4	-13	21	LOW	NA	NA	NA	4	-13	21	LOW	RoB, Imprecision
ivermectin	remdesivir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.003	-3	-16	10	MODERATE	NA	NA	NA	-3	-16	10	MODERATE	RoB
ivermectin	serine protease inhibitors	NA	NA	NA	NA	NA	NA NA	NA	NA	NA	NA	0.018	18	-31	67	VERY LOW	NA	NA	NA	18	-31	67	VERY LOW	RoB, Imprecisionx2
ivermectin	SGLT2 inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.020	20	-11	51	VERY LOW	NA	NA	NA	20	-11	51	LOW	RoB, Imprecision
ivermectin	statins sulodexide	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.002 -0.011	-2 -11	-16 -70	12 47	MODERATE VERY LOW	NA NA	NA NA	NA NA	-2 -11	-16 -70	12 47	MODERATE VERY LOW	RoB Imprecisions2
ivermectin	sulodexide tyrosine kinase inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.011	-11	-70	-16	LOW	NA NA	NA NA	NA NA	-11 -60	-70	-16	LOW	RoB, Imprecisionx2
ivermectin	umifenovir	NA NA	NA NA	NA NA	NΑ	NA NA	NA NA	NA	NA NA	NA NA	NA NA	-0.003	-3	-103	27	LOW	NA NA	NA	NΔ	-80	-32	27	LOW	RoB, Imprecision
ivermectin	vitamin D	NA NA	NA NA	NA NA	NA NA	NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.004	4	-23	30	LOW	NA NA	NA NA	NA NA	4	-23	30	LOW	RoB, Imprecision
JAK inhibitors	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.044	-44	-69	-19	LOW	NA	NA	NA	-44	-69	-19	LOW	RoB, Imprecision
JAK inhibitors	molnupiravir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.005	5	-6	16	HIGH	NA	NA	NA	5	-6	16	HIGH	
JAK inhibitors	nitazoxanide	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.003	3	-11	17	HIGH	NA	NA	NA	3	-11	17	HIGH	
JAK inhibitors	nirmatrelvir/ritonavir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.024	24	2	46	MODERATE	NA	NA	NA	24	2	46	MODERATE	Imprecision
JAK inhibitors	probiotics	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.005	5	-12	22	MODERATE	NA	NA	NA	5	-12	22	MODERATE	Imprecision
JAK inhibitors	proxalutamide remdesivir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.007	-1	-13 -16	26 15	LOW	NA NA	NA NA	NA NA	7 -1	-13 -16	26 15	LOW	RoB, Imprecision
JAK inhibitors JAK inhibitors	remdesivir serine protease inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-0.001 0.021	-1 21	-16 -29	15 70	LOW	NA NA	NA NA	NA NA	-1 21	-16 -29	15 70	LOW	Imprecisionx2
JAK inhibitors	SGIT2 inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.021	21	-29 -10	55	LOW	NA NA	NA NA	NA NA	21	-29	70 55	MODERATE	Imprecisionx2
JAK inhibitors	statins	NA NA	NA.	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA.	0.022	1	-16	17	MODERATE	NA NA	NA.	NA NA	1	-16	17	MODERATE	RoB
JAK inhibitors	sulodexide	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA	NA.	NA.	NA NA	-0.009	-9	-69	50	VERY LOW	NA NA	NA NA	NA NA	-9	-69	50	VERY LOW	RoB, Imprecisionx3
JAK inhibitors	tyrosine kinase inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.057	-57	-102	-13	MODERATE	NA	NA	NA	-57	-102	-13	MODERATE	Imprecision
JAK inhibitors	umifenovir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.000	0	-31	31	LOW	NA	NA	NA	0	-31	31	LOW	RoB, Imprecision
JAK inhibitors	vitamin D	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.006	6	-22	34	LOW	NA	NA	NA	6	-22	34	LOW	RoB, Imprecision
lopinavir-ritonavir	molnupiravir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.049	49	27	72	MODERATE	NA	NA	NA	49	27	72	MODERATE	RoB
lopinavir-ritonavir	nitazoxanide	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.048	48	24	71	MODERATE	NA	NA	NA	48	24	71	MODERATE	RoB
lopinavir-ritonavir	nirmatrelvir/ritonavir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.068	68	39	98	MODERATE MODERATE	NA NA	NA NA	NA NA	68	39	98	MODERATE	RoB RoB
lopinavir-ritonavir lopinavir-ritonavir	probiotics proxalutamide	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.049	49 51	24	75 78	MODERATE	NA NA	NA NA	NA NA	49 51	24 23	75 78	MODERATE	RoB
lopinavir-ritonavir	proxalutamide remdesivir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.051	44	19	78 69	LOW	NA NA	NA NA	NA NA	51	19	78 69	LOW	RoB. Imprecision
lopinavir-ritonavir	serine protease inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.065	65	12	118	LOW	NA NA	NA NA	NA NA	65	12	118	LOW	RoB, Imprecision
		NA NA	NA.	NA NA	NA.	NA NA	NA NA	NA NA	NA NA	NA NA	NA.	0.067	67	29	105	MODERATE	NA NA	NA.	NA NA	67	29		MODERATE	RoB
lopinavir-ritonavir	SGLT2 inhibitors	INA								1110											29	105	MODERATE	
lopinavir-ritonavir lopinavir-ritonavir lopinavir-ritonavir	SGL12 inhibitors statins	NA NA	NA	NA	NA	NA	NA	NA	NA NA	NA NA	NA NA	0.045	45	19	70	LOW	NA NA	NA NA	NA NA	45	19	105 70	LOW	RoB, Imprecision

Column C									Ac	Iverse events												
Second	Comparison		Direct estimate		Tab	(4 000) T					Ab b - b b' b	- (1.000)					lan		- (4 000)			
Marketon	Treatment 1	Treatment 2		Cl upper limit			Cl upper limit	Final rating				, ,	CLlower limit CLupper limit	Final rating						Cl upper limit	Final rating	Reasons for downgrading
Section Column								NA NA						VERY LOW							VERY LOW	
Tend																						
Section Content									1471				11		10.					84		RoB, Imprecision
	1 11 1																			7		Impresision
Section Control Cont								-							-							Imprecision
Table March Marc	molnupiravir	proxalutamide	NA NA	NA	NA NA	NA	NA	NA	NA	NA NA	0.002	2	-15 18	MODERATE	NA	NA 1	NA AV	2	-15	18	MODERATE	RoB
State					101							_						-				
Marchel Marc																						
The state																						
	1 11 1											-										
Property	molnupiravir			NA		NA	NA	NA	NA	NA NA		-62	-106 -19	MODERATE	NA	NA 1	NA AV	-62		-19	MODERATE	
The column The												-5						-5				
March Marc				_								1						1				
Company Comp																		21		17		Imprecision
According																		3		21		RoB. Imprecision
			NA NA	NA	NA NA	NA	NA	NA	NA	NA NA	-0.004	-4	-18 10	HIGH	NA	NA 1	NA AV	-4	-18	10		
Column												.,										
Second S																						
Company Comp								-						-	-							
Company																		_				. , ,
March Marc																						
Proposed Section Proposed Se		vitamin D			10.1							_				187		3		30	LOW	
Properties Pro																				4		
Part																						. , , ,
Processor Proc																						
Properties Pro		·		_				-		-				-								
Part																		-23		-1		
## Company of Company Market Market		sulodexide											**									· · · · · · · · · · · · · · · · · · ·
Properties Column																						
Production 15														-								
Part												-18						-18				. , , ,
PRODUCT PROD				_								-6						-6				
Production Pro	probiotics	serine protease inhibitors	NA NA	NA	NA NA	NA	NA	NA	NA	NA NA	0.016	16	-35 65	LOW	NA	NA 1	NA NA	16	-35	65	LOW	Imprecisionx2
PRODUCTION PROCESSOR PRO					18.1						0.017	- "		MODEIGHT			• •				MODEIGTIE	
Processor Section MA MA MA MA MA MA MA M																						
Proceeding																						
Production					10.1											18.7		-62				
Proceedings																		1				
Procedulation Sect 2 procedulation Sect	proxalutamide	remdesivir		NA		NA	NA	NA	NA			-7	-27 12					-7		12	LOW	RoB, Imprecision
Proceedimentals No.																		1.4				
Provindementh Substance MA	p. c.				1													16				The Line of the Li
Proceduremode Prysones interactive No. N																		-16				
Proceduration		tyrosine kinase inhibitors	NA NA	NA.	NA NA	NA	NA	NA NA	NA.	NA NA	-0.064	-64	-110 -18	LOW	NA	NA I	NA.	-64	-110	-18	LOW	. , ,
Immediativi	proxalutamide	umifenovir		NA	NA	NA	NA	NA	NA	NA NA	-0.007	-7	-40 26	LOW	NA	NA 1	NA.	-7	-40	26	LOW	RoB, Imprecision
Figure SolTz inhibitors NA NA NA NA NA NA NA N																		0				. , , ,
Image: Color Imag																						
Permedicivir Sudocisacie NA												1						1				
Premission Premission Premission Premission Impression Imp												-8						-8				
Internation NA		3										-57						-57				Imprecision
Selfar probases inhibitors SGLT inhibitors												1						1				
Serine protesse inhibitors Staters					10.1							-				187		7				
Serine protease inhibitors Subdeside																		-20				
Serine professe inhibitors Synosine kinase inhibitors NA NA NA NA NA NA NA N			101	1.01	10.		140 (1471				10 00		1401		• •		, ,		VEICE CON	
Serine protease inhibitors Unifiendity NA	serine protease inhibitors	tyrosine kinase inhibitors		NA		NA	NA	NA				-78		MODERATE		NA I	NA AV	-78		-13	MODERATE	Imprecision
SGLT2 inhibitors statins NA	serine protease inhibitors	umifenovir			1																	
SGLT2 inhibitors Suldexide NA																						
SGLT2 inhibitors																10.1						. , ,
SGLT2 inhibitors															-							Nob, Imprecisionaz
Statins Sulddexide NA																						RoB, Imprecision
Statins Stat																						
statins umifenovir NA																						
statins vitamin D NA		V																-58				
sulddexide tyrosine kinase inhibitors NA								+										6				
Sulodexide uniferovir NA																		-48				. , , ,
sulodexide vitamin D NA	sulodexide	umifenovir	NA NA	NA	NA	NA	NA	NA	NA	NA NA	0.009	9	-56 74	VERY LOW	NA	NA 1	NA AV	9	-56	74	VERY LOW	RoB, Imprecisionx3
	sulodexide	vitamin D	NA NA	NA	NA	NA	NA	NA	NA	NA NA		15	-49 79	VERY LOW	NA	NA I	NA AV	15	-49	79	VERY LOW	

									A	dverse events														
Comparison		Direct estimate							Indirect estima	ite							Network estimat	e						
		Relative estimat	е		Absolute estima	te (per 1,000)		Final rating	Relative estima	te		Absolute estimat	e (per 1,000)			Final rating	Relative estima	te		Absolute estim	nate (per 1,000)		Final rating	A
Treatment 1	Treatment 2	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit	Final rating	Point estimate	CI lower limit	CI upper limit	Point estimate	Point estimate	CI lower limit	CI upper limit	Final rating	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit	Final rating	Reasons for downgrading
tyrosine kinase inhibitors	umifenovir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.057	57	5	109	LOW	NA	NA	NA	57	5	109	LOW	RoB, Imprecision
tyrosine kinase inhibitors	vitamin D	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.063	63	13	113	LOW	NA	NA	NA	63	13	113	LOW	RoB, Imprecision
umifenovir	vitamin D	NA	NA	NA.	NA	NA	NA	NA.	NA	NA	NA	0.006	6	-32	45	LOW	NA	NA	NA	6	-32	45	LOW	RoB, Imprecision

Complete network meta-analysis results and GRADE

									(Clinically imp	ortant bleedi	ng											
Comparison		Direct es	timate						Indirect es	timate						Network es	stimate						
		Relative e	estimate		Absolute e	estimate (p	er 1,000)		Relative est	timate		Absolute es	timate (per	1,000)		Relative e	stimate		Absolute	estimate (per 1,000)		
Treatment 1	Treatment 2	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit	Final rating	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit	Final rating	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit	Final rating	Reasons for downgrading
aspirin	standard care/placebo	4.79	0.18	125.90	59.10	-13.76	666.81	VERY LOW	NA	NA	NA	NA	NA	NA	NA	1.59	0.18	9.21	20.57	-13.86	121.44	LOW	Imprecisionx2
full-dose anticoagulant	standard care/placebo	2.01	1.25	3.23	16.51	4.19	35.68	LOW	4.37	0.24	102.58	52.95	-12.75	620.94	VERY LOW	2.15	1.35	3.52	19.85	6.00	40.09	LOW	RoB, Imprecision
intermediate-dose anticoagulant	standard care/placebo	0.99	0.10	10.01	-0.20	-15.21	129.77	VERY LOW	0.49	0.05	2.64	-8.49	-15.98	26.40	LOW	0.66	0.15	2.48	-3.02	-14.38	23.81	LOW	RoB, Imprecision
sulodexide	standard care/placebo	0.32	0.01	9.72	-11.46	-16.70	126.13	VERY LOW	NA	NA	NA	NA	NA	NA	NA	0.00	0.00	0.60	-14.14	-16.88	2.55	LOW	RoB, Imprecision
full-dose anticoagulant	aspirin	1.57	0.22	11.09	NA	NA	NA	VERY LOW	NA	NA	NA	NA	NA	NA	NA	1.35	0.25	11.80	-0.72	-98.51	38.49	LOW	Imprecisionx2
aspirin	intermediate-dose anticoagulant	NA	NA	NA	NA	NA	NA	NA	2.39	0.20	23.39	23.60	-21.53	124.59	VERY LOW	2.39	0.20	23.39	23.60	-21.53	124.59	VERY LOW	RoB, Imprecisionx2
aspirin	sulodexide	NA	NA	NA	NA	NA	NA	NA	1.10E+09	2.30	3.13E+23	34.72	0.35	136.97	VERY LOW	1.10E+09	2.30	3.13E+23	34.72	0.35	136.97	VERY LOW	RoB, Imprecisionx3
intermediate-dose anticoagulant	full-dose anticoagulant	0.40	0.09	1.78	NA	NA	NA	VERY LOW	0.47	0.04	5.36	NA	NA	NA	VERY LOW	0.31	0.07	1.10	-22.88	-44.97	2.90	VERY LOW	RoB, Imprecisionx2
full-dose anticoagulant	sulodexide	NA	NA	NA	NA	NA	NA	NA	1.48E+09	3.64	4.60E+23	33.99	14.62	56.61	VERY LOW	1.48E+09	3.64	4.60E+23	33.99	14.62	56.61	VERY LOW	RoB, Imprecisionx3
intermediate-dose anticoagulant	sulodexide	NA	NA	NA	NA	NA	NA	NA	4.40E+08	1.04	1.32E+23	11.12	-8.74	40.35	VERY LOW	4.40E+08	1.04	1.32E+23	11.12	-8.74	40.35	VERY LOW	RoB, Imprecisionx3

								Duration of h	nospitalizat	ion									_	_			
Comparison		Direct es	stimate						Indirect e							Network 6	estimate						
		Relative			Absolut	e estimate	(per 1,000	0)	Relative e			Absolute	estimate (p	per 1,000)		Relative e			Absolute e	estimate (pe	er 1,000)		
		Point	CI lower	CI upper	Point	CI lower	CI upper	r Final rating	Point	CI lower	CI upper	Point	CI lower	CI upper	Final rating	Point	CI lower	CI	Point	Cl lower	Cl upper	Final rating	
Treatment 1	Treatment 2	estimate	limit	limit	estimat		limit		estimate	limit	limit	estimate	limit	limit		estimate	limit	upper	estimate	limit	limit		Reasons for downgrading
ACEi/ARB	standard care/placebo	NA	NA	NA	-0.65	-2.67	1.47	VERY LOW	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.47	-3.56	2.61	VERY LOW	RoB, Inconsistency, Imprecision
(acetyl)cysteine	standard care/placebo	NA NA	NA.	NA.	0.15	-2.72	3.02	MODERATE	NA NA	NA NA	NA.	NA NA	NA NA	NA.	NA NA	NA NA	NA	NA	-0.47	-6.39	5.6	LOW	Imprecision
antihepaciviral	standard care/placebo	NA	NA	NA	-0.39	-1.99	0.69	LOW	NA	NA	NA	-0.6	-6.99	5.75	VERY LOW	NA	NA	NA	-1.18	-4.41	2.02	LOW	RoB. Imprecision
aspirin	standard care/placebo	NA	NA	NA	-0.55	-1.58	0.55	VERY LOW	NA.	NA	NA	NA.	NA.	NA.	NA NA	NA.	NA	NA	-0.7	-5.57	4.16	VERY LOW	RoB, Inconsistency, Imprecisionx2
aspirin, statins	standard care/placebo	NA	NA	NA	0.34	-0.99	1.67	LOW	NA	NA	NA	NA	NA	NA	NA NA	NA	NA	NA	-0.23	-6.59	6.17	VERY LOW	RoB. Imprecision
azithromycin	standard care/placebo	NA	NA	NA	-0.83	-1.55	0.3	LOW	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.2	-3.51	3.91	LOW	RoB, Imprecision
azithromycin, hydroxychloroquine	standard care/placebo	NA	NA	NA	0.37	-0.8	1.52	LOW	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	1.41	-2.69	5.48	VERY LOW	RoB, Imprecision
azithromycin, hydroxychloroquine, oseltamivir	standard care/placebo	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	6.81	-1.14	14.8	VERY LOW	NA	NA	NA	6.81	-1.14	14.8	VERY LOW	RoB, Imprecisionx2
colchicine	standard care/placebo	NA	NA	NA	-4.08	-9.71	1.53	VERY LOW	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.5	-3.8	2.78	VERY LOW	RoB, Inconsistency, Imprecision
colchicine, emtricitabine, tenofovir, statins	standard care/placebo	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.14	-7.1	7.35	VERY LOW	NA	NA	NA	0.14	-7.1	7.35	VERY LOW	RoB, Imprecisionx2
colchicine, statins	standard care/placebo	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.02	-7.24	7.19	VERY LOW	NA	NA	NA	-0.02	-7.24	7.19	VERY LOW	RoB, Imprecisionx2
corticosteroids (systemic)	standard care/placebo	NA	NA	NA	0.26	-1.25	2.18	LOW	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	1.03	-2.11	4.19	LOW	RoB, Imprecision
IL6 receptor antagonists with corticosteroids (systemic)	standard care/placebo	NA	NA	NA	-4.73	-8.93	-0.45	MODERATE	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-4.9	-7.85	-1.93	MODERATE	RoB
doxycycline	standard care/placebo	NA	NA	NA	-1.34	-2.64	-0.04	LOW	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-1.34	-8.47	5.77	VERY LOW	RoB, Imprecision
emtricitabine, tenofovir	standard care/placebo	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.96	-6.28	8.2	VERY LOW	NA	NA	NA	0.96	-6.28	8.2	VERY LOW	RoB, Imprecisionx2
favipiravir	standard care/placebo	NA	NA	NA	-1.24	-2.37	-0.09	LOW	NA	NA	NA	-0.02	-5.55	5.49	VERY LOW	NA	NA	NA	-0.61	-4.38	3.15	VERY LOW	RoBx2
favipiravir, hydrochloroquine	standard care/placebo	NA	NA	NA	1	-1.77	3.77	LOW	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	1	-6.57	8.57	VERY LOW	RoB, Imprecision
full-dose anticoagulant	standard care/placebo	NA	NA	NA	0.28	-1.35	1.89	LOW	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.02	-6.34	6.25	VERY LOW	RoB, Imprecision
GM-CSF inhibitor	standard care/placebo	NA	NA	NA	0.03	-1.07	1.14	MODERATE	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.09	-5.1	5.26	LOW	Imprecision
(hydroxy)chloroquine	standard care/placebo	NA	NA	NA	2.17	-1.62	5.91	VERY LOW	NA	NA	NA	0.19	-6.28	6.67	VERY LOW	NA	NA	NA	1.99	0.03	3.92	LOW	RoB, Inconsistency
IL1 inhibitors	standard care/placebo	NA	NA	NA	-1	-2.18	0.18	MODERATE	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-1.01	-6.15	4.14	LOW	Imprecision
IL6 receptor antagonists without corticosteroids (systemic)	standard care/placebo	NA	NA	NA	-0.03	-1.24	1.18	MODERATE	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.12	-3.69	3.93	MODERATE	Imprecision
interferon alfa (subcutaneous)	standard care/placebo	NA	NA	NA	0.12	-0.98	1.21	LOW	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.08	-5.21	5.36	VERY LOW	RoB, Imprecision
interferon beta (subcutaneous)	standard care/placebo	NA	NA	NA	-0.22	-1.34	0.84	LOW	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.14	-3.44	3.15	LOW	RoB, Imprecision
interferon beta (subcutaneous), lopinavir-ritonavir	standard care/placebo	NA	NA	NA	5	3.27	6.73	MODERATE	NA	NA	NA	-0.11	-8.69	8.45	VERY LOW	NA	NA	NA	2.31	-2.63	7.28	VERY LOW	RoB
ivermectin	standard care/placebo	NA	NA	NA	-0.85	-1.93	0.4	LOW	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.22	-3.77	3.35	LOW	RoB, Imprecision
JAK inhibitors	standard care/placebo	NA	NA	NA	-1.14	-1.86	-0.42	HIGH	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.96	-4	2.1	MODERATE	
lopinavir-ritonavir	standard care/placebo	NA	NA	NA	2.44	-0.56	5.44	VERY LOW	NA	NA	NA	0.35	-3.36	4.06	VERY LOW	NA	NA	NA	0.4	-2.23	3.01	VERY LOW	RoB, Inconsistency, Imprecision
methylene blue	standard care/placebo	NA	NA	NA	-4.4	-6.04	-2.76	VERY LOW	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-4.4	-9.68	0.89	VERY LOW	RoBx2, Imprecisionx2
recombinant human granulocyte colony-stimulating factor	standard care/placebo	NA	NA	NA	-0.67	-2.33	0.99	LOW	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.68	-7.9	6.54	VERY LOW	RoB, Imprecision
remdesivir	standard care/placebo	NA	NA	NA	-0.39	-2	1.09	LOW	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.54	-3.59	2.5	LOW	RoB, Imprecision
serine protease inhibitors	standard care/placebo	NA	NA	NA	-0.35	-1.71	0.98	LOW	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.45	-5.6	4.7	VERY LOW	RoB, Imprecision
statins	standard care/placebo	NA	NA	NA	-0.46	-1.96	0.63	LOW	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.97	-5.87	3.94	VERY LOW	RoB, Imprecision
tyrosine kinase inhibitors	standard care/placebo	NA	NA	NA	0.66	-0.98	2.3	LOW	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.68	-6.57	7.91	VERY LOW	RoB, Imprecision
umifenovir	standard care/placebo	NA	NA	NA	-1.25	-3.52	1.08	LOW	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-1.22	-5.54	3.12	VERY LOW	RoB, Imprecision
vitamin C	standard care/placebo	NA	NA	NA	-1.64	-3.23	0.99	LOW	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.13	-4.83	4.59	LOW	RoB, Imprecision
vitamin D	standard care/placebo	NA	NA	NA	-1.45	-2.76	-0.17	MODERATE	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-1.9	-6.27	2.48	VERY LOW	RoB
ACE//ARB	(acetyl)cysteine	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.11	-6.81	6.65	VERY LOW	NA	NA	NA	-0.11	-6.81	6.65	VERY LOW	RoB, Inconsistency, Imprecisionx2
ACEi/ARB	antihepaciviral	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.71	-3.73	5.18	VERY LOW	NA	NA	NA	0.71	-3.73	5.18	VERY LOW	RoB, Inconsistency, Imprecisionx2
ACEi/ARB	aspirin	NA	NA	NA	NA	NA	NA	NA	NA NA	NA	NA	0.22	-5.52	6.01	VERY LOW	NA	NA	NA	0.22	-5.52	6.01	VERY LOW	RoB, Inconsistency, Imprecisionx2
ACEi/ARB	aspirin, statins	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.25	-7.33	6.83	VERY LOW	NA	NA	NA	-0.25	-7.33	6.83	VERY LOW	RoB, Inconsistency, Imprecisionx2
ACE//ARB	azithromycin	NA	NA	NA	NA	NA NA	NA	NA 	NA NA	NA	NA	-0.67	-5.5	4.15	VERY LOW	NA NA	NA	NA	-0.67	-5.5	4.15	VERY LOW	RoB, Inconsistency, Imprecisionx2
ACE//ARB	azithromycin, hydroxychloroquine	NA	NA	NA	NA	NA	NA	NA NA	NA NA	NA	NA	-1.88	-6.99	3.25	VERY LOW	NA NA	NA	NA	-1.88	-6.99	3.25	VERY LOW	RoB, Inconsistency, Imprecisionx2
ACE/ARB	azithromycin, hydroxychloroquine, oseltamivir	NA NA	NA	NA	NA	NA NA	NA	NA NA	NA NA	NA NA	NA	-7.3	-15.86	1.22	VERY LOW	NA NA	NA	NA	-7.3	-15.86	1.22	VERY LOW	RoB, Inconsistency, Imprecisionx2
ACE//ARB	colchicine	NA	NA	NA	NA	NA NA	NA	NA 	NA NA	NA NA	NA	0.03	-4.46	4.54	VERY LOW	NA NA	NA	NA	0.03	-4.46	4.54	VERY LOW	RoB, Inconsistency, Imprecision
ACE/ARB	colchicine, emtricitabine, tenofovir, statins	NA	NA	NA	NA	NA NA	NA	NA NA	NA NA	NA NA	NA	-0.62	-8.45	7.24	VERY LOW	NA NA	NA	NA	-0.62	-8.45	7.24	VERY LOW	RoB, Inconsistency, Imprecisionx2
ACE/ARB	colchicine, statins	NA	NA	NA	NA	NA NA	NA	NA NA	NA NA	NA NA	NA	-0.46	-8.26	7.38	VERY LOW	NA NA	NA	NA	-0.46	-8.26	7.38	VERY LOW	RoB, Inconsistency, Imprecisionx2
ACE/ARB	corticosteroids (systemic)	NA	NA NA	NA	NA	NA NA	NA	NA NA	NA NA	NA NA	NA NA	-1.5	-5.91	2.9	VERY LOW	NA NA	NA NA	NA NA	-1.5	-5.91	2.9	VERY LOW	RoB, Inconsistency, Imprecisionx2
ACE/ARB	IL6 receptor antagonists with corticosteroids (systemic)	NA	NA	NA	NA	NA NA	NA	NA NA	NA NA	NA NA	NA NA	4.42	0.17	8.68	LOW	NA NA	NA	NA	4.42	0.17	8.68	LOW	RoB, Inconsistency
ACE/ARB	doxycycline	NA	NA	NA	NA	NA NA	NA	NA NA	NA NA	NA NA	NA NA	0.85	-6.86	8.63	VERY LOW	NA NA	NA NA	NA	0.85	-6.86	8.63	VERY LOW	RoB, Inconsistency, Imprecisionx2
ACE/ARB	emtricitabine, tenofovir	NA	NA NA	NA	NA	NA NA	NA	NA NA	NA NA	NA NA	NA NA	-1.42	-9.33	6.46	VERY LOW	NA NA	NA NA	NA NA	-1.42	-9.33	6.46	VERY LOW	RoB, Inconsistency, Imprecisionx2
ACE/ARB	favipiravir	NA NA	NA NA	NA NA	NA	NA NA	NA	NA NA	NA NA	NA NA	NA NA	0.12	-4.73	4.99	VERY LOW	NA NA	NA NA	NA NA	0.12	-4.73	4.99	VERY LOW	RoBx2, Inconsistency, Imprecision
ACE/ARB	favipiravir, hydrochloroquine	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-1.46	-9.69	6.67	VERY LOW	NA NA	NA NA	NA NA	-1.46	-9.69	6.67	VERY LOW	RoB, Inconsistency, Imprecisionx2
ACE/ARB	full-dose anticoagulant	NA NA	NA NA	NA NA	NA	NA NA	NA	NA NA	NA NA	NA NA	NA NA	-0.46	-7.43	6.57	VERY LOW	NA NA	NA NA	NA NA	-0.46	-7.43	6.57	VERY LOW	RoB, Inconsistency, Imprecisionx2
ACEi/ARB ACEi/ARB	GM-CSF inhibitor			_	NA	NA NA	NA NA	NA NA	NA NA	NA NA		-0.54	-6.57 -6.09	5.48 1.18	VERY LOW VERY LOW	NA NA		NA NA	-0.54	-6.57	5.48 1.18	VERY LOW	RoB, Inconsistency, Imprecisionx2
ACEI/AKB	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	AN	INA	INA	NA	-2.46	-0.09	1.18	VERY LOW	INA	NA	NA	-2.46	-6.09	1.18	VERY LOW	RoB, Inconsistency, Imprecisionx2

								Duration of h															
Comparison		Direct es							Indirect e						1	Network e							
		Relative	estimate		Absolute	estimate	(per 1,00	000)	Relative e	stimate		Absolute	estimate (p	er 1,000)		Relative es	stimate		Absolute e	stimate (pe	er 1,000)		
				CI upper	Point	CI lower	CI upp		Point	CI lower	CI upper	Point	CI lower	CI upper	Final rating	1 0	CI lower	CI upper	Point	CI lower	CI upper	Final rating	
Treatment 1	Treatment 2	estimate	limit	limit	estimate	limit	limit	t	estimate	limit	limit	estimate	limit	limit		estimate	limit	limit	estimate	limit	limit		Reasons for downgrading
ACEi/ARB	IL1 inhibitors	NA	NA	NA	NA	NA	NA	. NA	NA	NA	NA	0.52	-5.5	6.55	VERY LOW	NA	NA	NA	0.52	-5.5	6.55	VERY LOW	RoB, Inconsistency, Imprecisionx2
ACEi/ARB	IL6 receptor antagonists without corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	. NA	NA	NA	NA	-0.59	-5.51	4.28	VERY LOW	NA	NA	NA	-0.59	-5.51	4.28	VERY LOW	RoB, Inconsistency, Imprecisionx2
ACEi/ARB	interferon alfa (subcutaneous)	NA	NA	NA	NA	NA	NA	. NA	NA	NA	NA	-0.55	-6.67	5.52	VERY LOW	NA	NA	NA	-0.55	-6.67	5.52	VERY LOW	RoB, Inconsistency, Imprecisionx2
ACEi/ARB	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	. NA	NA	NA	NA	-0.34	-4.84	4.17	VERY LOW	NA	NA	NA	-0.34	-4.84	4.17	VERY LOW	RoB, Inconsistency, Imprecision
ACEi/ARB	interferon beta (subcutaneous), lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	. NA	NA	NA	NA	-2.79	-8.61	3.06	VERY LOW	NA	NA	NA	-2.79	-8.61	3.06	VERY LOW	RoB, Inconsistency, Imprecisionx2
ACEi/ARB	ivermectin	NA	NA	NA	NA	NA	NA	. NA	NA	NA	NA	-0.26	-4.96	4.46	VERY LOW	NA	NA	NA	-0.26	-4.96	4.46	VERY LOW	RoB, Inconsistency, Imprecision
ACEi/ARB	JAK inhibitors	NA	NA	NA	NA	NA	NA	. NA	NA	NA	NA	0.48	-3.87	4.83	VERY LOW	NA	NA	NA	0.48	-3.87	4.83	VERY LOW	RoB, Inconsistency, Imprecision
ACEi/ARB	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	. NA	NA	NA	NA	-0.88	-4.91	3.19	VERY LOW	NA	NA	NA	-0.88	-4.91	3.19	VERY LOW	RoB, Inconsistency, Imprecision
ACEi/ARB	methylene blue	NA	NA	NA	NA	NA	NA	. NA	NA	NA	NA	3.94	-2.22	10.04	VERY LOW	NA	NA	NA	3.94	-2.22	10.04	VERY LOW	RoBx2, Inconsistency, Imprecisionx2
ACEi/ARB	recombinant human granulocyte colony-stimulating factor	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.21	-7.68	8.08	VERY LOW	NA	NA	NA	0.21	-7.68	8.08	VERY LOW	RoB, Inconsistency, Imprecisionx2
ACEi/ARB	remdesivir	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.07	-4.28	4.39	VERY LOW	NA	NA	NA	0.07	-4.28	4.39	VERY LOW	RoB, Inconsistency, Imprecision
ACEi/ARB	serine protease inhibitors	NA	NA	NA	NA	NA	NA	. NA	NA	NA	NA	-0.02	-6.02	5.98	VERY LOW	NA	NA	NA	-0.02	-6.02	5.98	VERY LOW	RoB, Inconsistency, Imprecisionx2
ACEi/ARB	statins	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.5	-5.28	6.3	VERY LOW	NA	NA	NA	0.5	-5.28	6.3	VERY LOW	RoB, Inconsistency, Imprecisionx2
ACEi/ARB	tyrosine kinase inhibitors	NA	NA	NA	NA	NA	NA		NA	NA	NA	-1.15	-9.01	6.75	VERY LOW	NA	NA	NA	-1.15	-9.01	6.75	VERY LOW	RoB, Inconsistency, Imprecisionx2
ACEi/ARB	umifenovir	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.74	-4.56	6.04	VERY LOW	NA	NA	NA	0.74	-4.56	6.04	VERY LOW	RoB, Inconsistency, Imprecisionx2
ACEi/ARB	vitamin C	NA	NA	NA	NA	NA	NA		NA	NA	NA	-0.33	-5.99	5.29	VERY LOW	NA	NA	NA	-0.33	-5.99	5.29	VERY LOW	RoB, Inconsistency, Imprecisionx2
ACEi/ARB	vitamin D	NA	NA	NA	NA	NA	NA		NA	NA	NA	1.42	-3.9	6.79	VERY LOW	NA	NA	NA	1.42	-3.9	6.79	VERY LOW	RoB, Inconsistency, Imprecisionx2
(acetyl)cysteine	antihepaciviral	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.81	-5.99	7.65	VERY LOW	NA	NA	NA	0.81	-5.99	7.65	VERY LOW	RoB, Imprecisionx2
(acetyl)cysteine	aspirin	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.34	-7.4	8.04	VERY LOW	NA	NA	NA	0.34	-7.4	8.04	VERY LOW	RoB, Inconsistency, Imprecisionx2
(acetyl)cysteine	aspirin, statins	NA	NA	NA	NA	NA	NA		NA	NA	NA	-0.15	-8.93	8.59	VERY LOW	NA	NA	NA	-0.15	-8.93	8.59	VERY LOW	RoB, Imprecisionx2
(acetyl)cysteine	azithromycin	NA	NA	NA	NA	NA	NA		NA	NA	NA	-0.56	-7.63	6.46	VERY LOW	NA	NA	NA	-0.56	-7.63	6.46	VERY LOW	RoB, Imprecisionx2
(acetyl)cysteine	azithromycin, hydroxychloroquine	NA	NA	NA	NA	NA	NA		NA	NA	NA	-1.78	-9.03	5.48	VERY LOW	NA	NA	NA	-1.78	-9.03	5.48	VERY LOW	RoB, Imprecisionx2
(acetyl)cysteine	azithromycin, hydroxychloroquine, oseltamivir	NA	NA	NA	NA	NA	NA		NA	NA	NA	-7.18	-17.19	2.76	VERY LOW	NA	NA	NA	-7.18	-17.19	2.76	VERY LOW	RoB, Imprecisionx2
(acetyl)cysteine	colchicine	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.12	-6.71	6.97	VERY LOW	NA	NA	NA	0.12	-6.71	6.97	VERY LOW	RoB, Inconsistency, Imprecisionx2
(acetyl)cysteine	colchicine, emtricitabine, tenofovir, statins	NA	NA	NA	NA	NA	NA		NA	NA	NA	-0.52	-9.91	8.85	LOW	NA	NA	NA	-0.52	-9.91	8.85	LOW	Imprecisionx2
(acetyl)cysteine	colchicine, statins	NA	NA	NA	NA	NA	NA		NA	NA	NA	-0.34	-9.74	9.02	LOW	NA	NA	NA	-0.34	-9.74	9.02	LOW	Imprecisionx2
(acetyl)cysteine	corticosteroids (systemic)	NA	NA	NA	NA	NA	NA		NA	NA	NA	-1.39	-8.18	5.34	VERY LOW	NA	NA	NA	-1.39	-8.18	5.34	VERY LOW	RoB, Imprecisionx2
(acetyl)cysteine	IL6 receptor antagonists with corticosteroids (systemic)	NA	NA	NA NA	NA	NA	NA		NA	NA	NA	4.52	-2.19	11.21	VERY LOW	NA	NA	NA	4.52	-2.19	11.21	VERY LOW	RoB, Imprecisionx2
(acetyl)cysteine	doxycycline	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.95	-8.35	10.27	VERY LOW	NA NA	NA	NA	0.95	-8.35	10.27	VERY LOW	RoB, Imprecisionx2
(acetyl)cysteine	emtricitabine, tenofovir	NA	NA	NA	NA	NA	NA		NA	NA	NA	-1.32	-10.79	8.1	LOW	NA	NA	NA	-1.32	-10.79	8.1	LOW	Imprecisionx2
(acetyl)cysteine	favipiravir	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.23	-6.86	7.28	VERY LOW	NA	NA	NA	0.23	-6.86	7.28	VERY LOW	RoBx2, Imprecisionx2
(acetyl)cysteine	favipiravir, hydrochloroquine	NA	NA	NA	NA	NA	NA		NA	NA	NA	-1.39	-11.02	8.28	VERY LOW	NA NA	NA	NA	-1.39	-11.02	8.28	VERY LOW	RoB, Imprecisionx2
(acetyl)cysteine	full-dose anticoagulant	NA	NA	NA	NA	NA	NA		NA NA	NA	NA NA	-0.36	-9.05	8.36	VERY LOW	NA NA	NA	NA	-0.36	-9.05	8.36	VERY LOW	RoB, Imprecisionx2
(acetyl)cysteine	GM-CSF inhibitor	NA	NA	NA	NA	NA NA	NA		NA NA	NA NA	NA NA	-0.45	-8.39	7.45	LOW	NA NA	NA	NA	-0.45	-8.39	7.45	LOW	Imprecisionx2
(acetyl)cysteine	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA		NA NA	NA NA	NA NA	-2.36	-8.66	3.93	VERY LOW	NA NA	NA	NA	-2.36	-8.66	3.93	VERY LOW	RoB, Inconsistency, Imprecisionx2
(acetyl)cysteine	IL1 inhibitors	NA	NA	NA NA	NA	NA NA	NA		NA NA	NA NA	NA NA	-0.49	-7.26	8.54	LOW	NA NA	NA	NA	0.62	-7.26	8.54	LOW	Imprecisionx2
(acetyl)cysteine	IL6 receptor antagonists without corticosteroids (systemic)	NA NA	NA		NA	NA NA	NA		NA NA	NA NA	NA NA		-7.61	6.59	LOW	NA NA	NA	NA	-0.49	-7.61	6.59	LOW	Imprecisionx2
(acetyl)cysteine	interferon alfa (subcutaneous)	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA		NA NA	NA NA	NA NA	-0.46 -0.24	-8.45 -7.08	7.6 6.61	VERY LOW VERY LOW	NA NA	NA NA	NA NA	-0.46 -0.24	-8.45 -7.08	7.6 6.61	VERY LOW VERY LOW	RoB, Imprecisionx2
(acetyl)cysteine	interferon beta (subcutaneous) interferon beta (subcutaneous), lopinavir-ritonavir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA		NA NA	NA NA	NA NA	-0.24	-10.47	5.11	VERY LOW VERY LOW	NA NA	NA	NA	-0.24	-10.47	5.11	VERY LOW	RoB, Imprecisionx2
(acetyl)cysteine	interreron beta (subcutaneous), iopinavir-ritonavir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA		NA NA	NA NA	NA NA	-0.16	-7.13	6.81	VERY LOW	NA NA	NA	NA NA	-2.68	-7.13	6.81	VERY LOW	RoB, Imprecisionx2
(acetyl)cysteine (acetyl)cysteine	JAK inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA		NA NA	NA NA	NA NA	0.58	-7.13	7.3	LOW	NA NA	NA	NA	0.58	-7.13 -6.16	7.3	LOW	Imprecisionx2
(acetyl)cysteine	lopinavir-ritonavir	NA	NA	NA	NA NA	NA NA	NA NA		NA NA	NA	NA NA	-0.77	-7.32	5.78	VERY LOW	NA NA	NA	NA	-0.77	-7.32	5.78	VERY LOW	RoB, Inconsistency, Imprecisionx2
(acetyl)cysteine	methylene blue	NA	NA	NA	NA NA	NA NA	NA NA		NA NA	NA NA	NA NA	4.03	-7.32	11.99	VERY LOW	NA NA	NA	NA	4.03	-3.97	11.99	VERY LOW	RoBx2, Imprecisionx2
(acetyl)cysteine	recombinant human granulocyte colony-stimulating factor	NA	NA	NA NA	NA NA	NA NA	NA NA		NA NA	NA	NA NA	0.3	-9.13	9.67	VERY LOW	NA NA	NA	NA	0.3	-9.13	9.67	VERY LOW	RoB, Imprecisionx2
(acetyl)cysteine	remdesivir	NA	NA	NA	NA	NA NA	NA		NA NA	NA	NA NA	0.17	-6.57	6.88	VERY LOW	NA NA	NA	NA	0.3	-6.57	6.88	VERY LOW	RoB, Imprecisionx2
(acetyl)cysteine	serine protease inhibitors	NA	NA	NA	NA NA	NA NA	NA		NA NA	NA	NA NA	0.09	-7.85	7.96	VERY LOW	NA NA	NA	NA	0.09	-7.85	7.96	VERY LOW	RoB, Imprecisionx2
(acetyl)cysteine	statins	NA	NA NA	NA.	NA	NA	NA.		NA NA	NA	NA NA	0.6	-7.19	8.34	VERY LOW	NA NA	NA	NA	0.6	-7.03	8.34	VERY LOW	RoB, Imprecisionx2
(acety)cysteine	tyrosine kinase inhibitors	NA	NA	NA	NA NA	NA NA	NA.		NA NA	NA	NA NA	-1.06	-10.49	8.38	VERY LOW	NA NA	NA	NA	-1.06	-10.49	8.38	VERY LOW	RoB, Imprecisionx2
(acety)cysteine	umifenovir	NA	NA NA	NA	NA NA	NA NA	NA.		NA NA	NA NA	NA NA	0.85	-6.57	8.21	VERYLOW	NA NA	NA	NA	0.85	-6.57	8.21	VERY LOW	RoB, Imprecisionx2
(acetyl)cysteine	vitamin C	NA	NA	NA	NA	NA NA	NA.		NA	NA	NA	-0.23	-7.89	7.38	VERY LOW	NA NA	NA	NA	-0.23	-7.89	7.38	VERY LOW	RoB, Imprecisionx2
(acetyl)cysteine	vitamin D	NA	NA	NA	NA NA	NA NA	NA.		NA NA	NA NA	NA NA	1.51	-5.92	8.93	VERY LOW	NA NA	NA	NA	1.51	-5.92	8.93	VERY LOW	RoB. Imprecisionx2
antihepaciviral	aspirin	NA	NA	NA	NA NA	NA NA	NA.		NA NA	NA	NA NA	-0.48	-6.33	5.33	VERY LOW	NA NA	NA	NA	-0.48	-6.33	5.33	VERY LOW	RoB, Inconsistency, Imprecisionx2
antihepaciviral	aspirin, statins	NA	NA	NA	NA NA	NA NA	NA NA	101	NA NA	NA	NA NA	-0.46	-8.09	6.17	VERY LOW	NA NA	NA	NA	-0.46	-8.09	6.17	VERY LOW	RoB, Imprecisionx2
antihepaciviral	azithromycin	NA	NA	NA	NA NA	NA NA	NA.		NA	NA	NA	-1.37	-6.31	3.53	VERY LOW	NA NA	NA	NA	-1.37	-6.31	3.53	VERY LOW	RoB. Imprecisionx2
antihepaciviral	azithromycin, hydroxychloroquine	NA	NA	NA	NA	NA NA	NA.		NA NA	NA	NA NA	-2.6	-7.77	2.58	VERY LOW	NA NA	NA	NA	-2.6	-7.77	2.58	VERY LOW	RoB, Imprecisionx2
unun opasiina.	azanomyon, nyaroxyonoroquno					1													0			72 2011	ros, improductoras

			_	_	_			Duration of h	ospitali <u>za</u> t	tion		_		_									
Comparison		Direct es	stimate						Indirect							Network 6	estimate						
		Relative	estimate		Absolut	estimate	per 1,000	0)	Relative e	estimate		Absolute	estimate (p	per 1,000)		Relative e	stimate		Absolute e	estimate (pe	er 1,000)		
		Point	CI lower	CI upper	Point	CI lower	CI upper	Final rating	Point	CI lower	CI upper	Point	CI lower	CI upper	Final rating	Point	CI lower	CI	Point	CI lower	CI upper	Final rating	
Treatment 1	Treatment 2	estimate	limit	limit	estimate	limit	limit		estimate	limit	limit	estimate	limit	limit		estimate	limit	upper	estimate	limit	limit		Reasons for downgrading
azithromycin, hydroxychloroquine, oseltamivir	antihepaciviral	NA	NA	NA	8	6.08	9.92	MODERATE	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	8	0.73	15.29	MODERATE	RoB
antihepaciviral	colchicine	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.68	-5.29	3.91	VERY LOW	NA	NA	NA	-0.68	-5.29	3.91	VERY LOW	RoB, Inconsistency, Imprecisionx2
antihepaciviral	colchicine, emtricitabine, tenofovir, statins	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-1.32	-9.21	6.58	VERY LOW	NA	NA	NA	-1.32	-9.21	6.58	VERY LOW	RoB, Imprecisionx2
antihepaciviral	colchicine, statins	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-1.14	-9.06	6.72	VERY LOW	NA	NA	NA	-1.14	-9.06	6.72	VERY LOW	RoB, Imprecisionx2
antihepaciviral	corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-2.21	-6.72	2.27	VERY LOW	NA	NA	NA	-2.21	-6.72	2.27	VERY LOW	RoB, Imprecisionx2
antihepaciviral	IL6 receptor antagonists with corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	3.71	-0.68	8.04	VERY LOW	NA	NA	NA	3.71	-0.68	8.04	VERY LOW	RoB, Imprecisionx2
antihepaciviral	doxycycline	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.16	-7.65	7.97	VERY LOW	NA	NA	NA	0.16	-7.65	7.97	VERY LOW	RoB, Imprecisionx2
antihepaciviral	emtricitabine, tenofovir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-2.14	-10.08	5.75	VERY LOW	NA	NA	NA	-2.14	-10.08	5.75	VERY LOW	RoB, Imprecisionx2
antihepaciviral	favipiravir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.57	-5.45	4.27	VERY LOW	NA	NA	NA	-0.57	-5.45	4.27	VERY LOW	RoBx2, Imprecisionx2
antihepaciviral	favipiravir, hydrochloroquine	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-2.19	-10.4	6.02	VERY LOW	NA	NA	NA	-2.19	-10.4	6.02	VERY LOW	RoB, Imprecisionx2
antihepaciviral	full-dose anticoagulant	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-1.16	-8.23	5.9	VERY LOW	NA	NA	NA	-1.16	-8.23	5.9	VERY LOW	RoB, Imprecisionx2
antihepaciviral	GM-CSF inhibitor	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-1.27	-7.37	4.83	VERY LOW	NA	NA	NA	-1.27	-7.37	4.83	VERY LOW	RoB, Imprecisionx2
antihepaciviral	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-3.18	-6.82	0.49	VERY LOW	NA	NA	NA	-3.18	-6.82	0.49	VERY LOW	RoB, Inconsistency, Imprecisionx2
antihepaciviral	IL1 inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.18	-6.28	5.88	VERY LOW	NA	NA	NA	-0.18	-6.28	5.88	VERY LOW	RoB, Imprecisionx2
antihepaciviral	IL6 receptor antagonists without corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-1.3	-6.29	3.65	VERY LOW	NA	NA	NA	-1.3	-6.29	3.65	VERY LOW	RoB, Imprecisionx2
antihepaciviral	interferon alfa (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-1.27	-7.47	4.9	VERY LOW	NA	NA	NA	-1.27	-7.47	4.9	VERY LOW	RoB, Imprecisionx2
antihepaciviral	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-1.05	-5.67	3.55	VERY LOW	NA	NA	NA	-1.05	-5.67	3.55	VERY LOW	RoB, Imprecisionx2
interferon beta (subcutaneous), lopinavir-ritonavir	antihepaciviral	NA	NA	NA	1.5	-1.92	4.92	LOW	NA	NA	NA	5.04	-1.82	11.88	VERY LOW	NA	NA	NA	3.5	-1.66	8.68	VERY LOW	RoB, Imprecision
antihepaciviral	ivermectin	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.96	-5.75	3.82	VERY LOW	NA	NA	NA	-0.96	-5.75	3.82	VERY LOW	RoB, Imprecisionx2
antihepaciviral	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.23	-4.68	4.17	LOW	NA	NA	NA	-0.23	-4.68	4.17	LOW	RoB, Imprecision
lopinavir-ritonavir	antihepaciviral	NA	NA	NA	2.6	-0.04	5.24	VERY LOW	NA	NA	NA	1.25	-3.15	5.61	VERY LOW	NA	NA	NA	1.58	-2.19	5.35	VERY LOW	RoB, Imprecisionx2
antihepaciviral	methylene blue	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	3.23	-2.99	9.37	VERY LOW	NA	NA	NA	3.23	-2.99	9.37	VERY LOW	RoBx2, Imprecisionx2
antihepaciviral	recombinant human granulocyte colony-stimulating factor	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.5	-8.42	7.38	VERY LOW	NA	NA	NA	-0.5	-8.42	7.38	VERY LOW	RoB, Imprecisionx2
antihepaciviral	remdesivir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.65	-5.07	3.78	VERY LOW	NA	NA	NA	-0.65	-5.07	3.78	VERY LOW	RoB, Imprecisionx2
antihepaciviral	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.73	-6.81	5.35	VERY LOW	NA	NA	NA	-0.73	-6.81	5.35	VERY LOW	RoB, Imprecisionx2
antihepaciviral	statins	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.21	-6.08	5.63	VERY LOW	NA	NA	NA	-0.21	-6.08	5.63	VERY LOW	RoB, Imprecisionx2
antihepaciviral	tyrosine kinase inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-1.87	-9.77	6.05	VERY LOW	NA	NA	NA	-1.87	-9.77	6.05	VERY LOW	RoB, Imprecisionx2
antihepaciviral	umifenovir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.04	-5.37	5.41	VERY LOW	NA	NA	NA	0.04	-5.37	5.41	VERY LOW	RoB, Imprecisionx2
antihepaciviral	vitamin C	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-1.06	-6.77	4.67	VERY LOW	NA	NA	NA	-1.06	-6.77	4.67	VERY LOW	RoB, Imprecisionx2
antihepaciviral	vitamin D	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.71	-4.76	6.16	VERY LOW	NA	NA	NA	0.71	-4.76	6.16	VERY LOW	RoB, Imprecisionx2
aspirin, statins	aspirin	NA	NA	NA	0.34	-0.91	1.59	LOW	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.47	-6.13	7.15	VERY LOW	RoB, Imprecision
aspirin	azithromycin	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.89	-7.02	5.2	VERY LOW	NA	NA	NA	-0.89	-7.02	5.2	VERY LOW	RoB, Inconsistency, Imprecisionx2
aspirin	azithromycin, hydroxychloroquine	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-2.11	-8.45	4.28	VERY LOW	NA	NA	NA	-2.11	-8.45	4.28	VERY LOW	RoB, Inconsistency, Imprecisionx2
aspirin	azithromycin, hydroxychloroquine, oseltamivir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-7.51	-16.9	1.76	VERY LOW	NA	NA	NA	-7.51	-16.9	1.76	VERY LOW	RoB, Inconsistency, Imprecisionx2
aspirin	colchicine	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.19	-6.09	5.69	VERY LOW	NA	NA	NA	-0.19	-6.09	5.69	VERY LOW	RoB, Inconsistency, Imprecisionx2
aspirin	colchicine, emtricitabine, tenofovir, statins	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.84	-9.53	7.85	VERY LOW	NA	NA	NA	-0.84	-9.53	7.85	VERY LOW	RoB, Inconsistency, Imprecisionx2
aspirin	colchicine, statins	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.67	-9.37	8.01	VERY LOW	NA	NA	NA	-0.67	-9.37	8.01	VERY LOW	RoB, Inconsistency, Imprecisionx2
aspirin	corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-1.73	-7.55	4.05	VERY LOW	NA	NA	NA	-1.73	-7.55	4.05	VERY LOW	RoB, Inconsistency, Imprecisionx2
aspirin	IL6 receptor antagonists with corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	4.2	-1.5	9.86	VERY LOW	NA	NA	NA	4.2	-1.5	9.86	VERY LOW	RoB, Inconsistency, Imprecisionx2
aspirin	doxycycline	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.64	-7.99	9.26	VERY LOW	NA	NA	NA	0.64	-7.99	9.26	VERY LOW	RoB, Inconsistency, Imprecisionx2
aspirin	emtricitabine, tenofovir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-1.66	-10.41	7.07	VERY LOW	NA	NA	NA	-1.66	-10.41	7.07	VERY LOW	RoB, Inconsistency, Imprecisionx2
aspirin	favipiravir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.09	-6.24	6.04	VERY LOW	NA	NA	NA	-0.09	-6.24	6.04	VERY LOW	RoBx2, Inconsistency, Imprecisionx2
aspirin	favipiravir, hydrochloroquine	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-1.71	-10.7	7.28	VERY LOW	NA	NA	NA	-1.71	-10.7	7.28	VERY LOW	RoB, Inconsistency, Imprecisionx2
aspirin	full-dose anticoagulant	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.66	-8.68	7.26	VERY LOW	NA	NA	NA	-0.66	-8.68	7.26	VERY LOW	RoB, Inconsistency, Imprecisionx2
aspirin	GM-CSF inhibitor	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.77	-7.92	6.29	VERY LOW	NA	NA	NA	-0.77	-7.92	6.29	VERY LOW	RoB, Inconsistency, Imprecisionx2
aspirin	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-2.68	-7.92	2.57	VERY LOW	NA	NA	NA	-2.68	-7.92	2.57	VERY LOW	RoB, Inconsistency, Imprecisionx2
aspirin	IL1 inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.31	-6.79	7.41	VERY LOW	NA	NA	NA	0.31	-6.79	7.41	VERY LOW	RoB, Inconsistency, Imprecisionx2
aspirin	IL6 receptor antagonists without corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.81	-7.02	5.37	VERY LOW	NA	NA	NA	-0.81	-7.02	5.37	VERY LOW	RoB, Inconsistency, Imprecisionx2
aspirin	interferon alfa (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.78	-7.96	6.4	VERY LOW	NA	NA	NA	-0.78	-7.96	6.4	VERY LOW	RoB, Inconsistency, Imprecisionx2
aspirin	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.56	-6.45	5.29	VERY LOW	NA	NA	NA	-0.56	-6.45	5.29	VERY LOW	RoB, Inconsistency, Imprecisionx2
aspirin	interferon beta (subcutaneous), lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-3.03	-9.97	3.95	VERY LOW	NA	NA	NA	-3.03	-9.97	3.95	VERY LOW	RoB, Inconsistency, Imprecisionx2
aspirin	ivermectin	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.48	-6.53	5.56	VERY LOW	NA	NA	NA	-0.48	-6.53	5.56	VERY LOW	RoB, Inconsistency, Imprecisionx2
aspirin	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.26	-5.51	5.96	VERY LOW	NA	NA	NA	0.26	-5.51	5.96	VERY LOW	RoB, Inconsistency, Imprecisionx2
aspirin	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-1.09	-6.65	4.43	VERY LOW	NA	NA	NA	-1.09	-6.65	4.43	VERY LOW	RoB, Inconsistency, Imprecisionx2
aspirin	methylene blue	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	3.72	-3.47	10.85	VERY LOW	NA	NA	NA	3.72	-3.47	10.85	VERY LOW	RoBx2, Inconsistency, Imprecisionx2
aspirin	recombinant human granulocyte colony-stimulating factor	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.03	-8.75	8.7	VERYLOW	NA	NA	NA	-0.03	-8.75	8.7	VERY LOW	RoB, Inconsistency, Imprecisionx2

								Duration of h	nospitalizat	ion													
Comparison		Direct es	timate						Indirect e							Network e	stimate	_					
		Relative			Absolute	estimate	(per 1.000	D)	Relative e	stimate		Absolute	estimate (p	er 1.000)		Relative es	stimate		Absolute e	stimate (pe	r 1.000)		
		Point	CLlower	CI	Point	CLlower		Final rating	Point	Cl lower	CL	Point	Cllower	Clupper	Final rating	Point	Cllower	CI	Point	Cllower		Final rating	
		estimate	limit	CI upper limit	estimate	limit	CI upper	1 marrating	estimate	limit	CI upper limit	estimate	limit	limit	1 marrating	estimate	limit	upper	estimate	limit	CI upper limit	T indireding	
Treatment 1	Treatment 2	NA		NA						N1A								limit					Reasons for downgrading
aspirin	remdesivir		NA		NA	NA	NA	NA	NA NA	NA	NA	-0.17	-5.92	5.58	VERY LOW	NA	NA	NA	-0.17	-5.92	5.58	VERY LOW	RoB, Inconsistency, Imprecisionx2
aspirin	serine protease inhibitors	NA	NA	NA	NA	NA 1.00	NA	NA	NA NA	NA	NA	-0.26	-7.33	6.85	VERY LOW	NA	NA	NA	-0.26	-7.33	6.85	VERY LOW	RoB, Inconsistency, Imprecisionx2
statins	aspirin	NA	NA	NA	0	-1.23	1.23	LOW	NA NA	NA	NA	-0.82	-11.07	9.49	VERY LOW	NA	NA	NA	-0.28	-6.06	5.53	VERY LOW	RoB, Imprecision
aspirin	tyrosine kinase inhibitors	NA	NA NA	NA	NA	NA NA	NA	NA 	NA NA	NA	NA	-1.38	-10.1	7.33	VERY LOW	NA NA	NA	NA	-1.38	-10.1	7.33	VERY LOW	RoB, Inconsistency, Imprecisionx2
aspirin	umifenovir	NA	NA	NA	NA	NA	NA	NA 	NA NA	NA	NA	0.52	-6.03	7.04	VERY LOW	NA	NA	NA	0.52	-6.03	7.04	VERY LOW	RoB, Inconsistency, Imprecisionx2
aspirin	vitamin C	NA	NA NA	NA	NA	NA NA	NA	NA 	NA NA	NA	NA	-0.56	-7.36	6.19	VERY LOW	NA NA	NA	NA	-0.56	-7.36	6.19	VERY LOW	RoB, Inconsistency, Imprecisionx2
aspirin	vitamin D	NA	NA	NA	NA	NA	NA	NA	NA NA	NA	NA	1.19	-5.37	7.73	VERY LOW	NA	NA	NA	1.19	-5.37	7.73	VERY LOW	RoB, Inconsistency, Imprecisionx2
aspirin, statins	azithromycin	NA	NA	NA	NA	NA	NA	NA	NA NA	NA	NA	-0.42	-7.77	6.95	VERY LOW	NA NA	NA	NA	-0.42	-7.77	6.95	VERY LOW	RoB, Imprecisionx2
aspirin, statins	azithromycin, hydroxychloroquine	NA	NA	NA	NA	NA	NA	NA 	NA NA	NA	NA	-1.66	-9.16	5.96	VERY LOW	NA NA	NA	NA	-1.66	-9.16	5.96	VERY LOW	RoB, Imprecisionx2
aspirin, statins	azithromycin, hydroxychloroquine, oseltamivir	NA	NA	NA	NA	NA	NA	NA	NA NA	NA	NA	-7.03	-17.29	3.12	VERY LOW	NA NA	NA	NA	-7.03	-17.29	3.12	VERY LOW	RoB, Imprecisionx2
aspirin, statins	colchicine	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.27	-6.86	7.49	VERY LOW	NA	NA	NA	0.27	-6.86	7.49	VERY LOW	RoB, Inconsistency, Imprecisionx2
aspirin, statins	colchicine, emtricitabine, tenofovir, statins	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.36	-10	9.26	VERY LOW	NA	NA	NA	-0.36	-10	9.26	VERY LOW	RoB, Imprecisionx2
aspirin, statins	colchicine, statins	NA	NA	NA	NA	NA	NA	NA	NA NA	NA	NA	-0.22	-9.84	9.46	VERY LOW	NA	NA	NA	-0.22	-9.84	9.46	VERY LOW	RoB, Imprecisionx2
aspirin, statins	corticosteroids (systemic)	NA	NA NA	NA	NA	NA	NA	NA 	NA NA	NA	NA	-1.25	-8.4	5.87	VERY LOW	NA NA	NA	NA	-1.25	-8.4	5.87	VERY LOW	RoB, Imprecisionx2
aspirin, statins	IL6 receptor antagonists with corticosteroids (systemic)	NA	NA	NA	NA	NA NA	NA	NA NA	NA NA	NA	NA	4.68	-2.4	11.71	VERY LOW	NA NA	NA	NA	4.68	-2.4	11.71	VERY LOW	RoB, Imprecisionx2
aspirin, statins	doxycycline	NA	NA	NA	NA	NA	NA	NA 	NA NA	NA	NA	1.11	-8.39	10.71	VERY LOW	NA	NA	NA	1.11	-8.39	10.71	VERY LOW	RoB, Imprecisionx2
aspirin, statins	emtricitabine, tenofovir	NA	NA	NA	NA	NA	NA	NA	NA NA	NA	NA	-1.17	-10.79	8.49	VERY LOW	NA	NA	NA	-1.17	-10.79	8.49	VERY LOW	RoB, Imprecisionx2
aspirin, statins	favipiravir	NA	NA	NA	NA	NA	NA	NA 	NA NA	NA	NA	0.39	-7.03	7.79	VERY LOW	NA NA	NA	NA	0.39	-7.03	7.79	VERY LOW	RoBx2, Imprecisionx2
aspirin, statins	favipiravir, hydrochloroquine	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-1.24	-11.1	8.64	VERY LOW	NA	NA	NA	-1.24	-11.1	8.64	VERY LOW	RoB, Imprecisionx2
aspirin, statins	full-dose anticoagulant	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.2	-9.17	8.74	VERY LOW	NA	NA	NA	-0.2	-9.17	8.74	VERY LOW	RoB, Imprecisionx2
aspirin, statins	GM-CSF inhibitor	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.31	-8.51	7.92	VERY LOW	NA	NA	NA	-0.31	-8.51	7.92	VERY LOW	RoB, Imprecisionx2
aspirin, statins	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-2.21	-8.84	4.5	VERY LOW	NA	NA	NA	-2.21	-8.84	4.5	VERY LOW	RoB, Inconsistency, Imprecisionx2
aspirin, statins	IL1 inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.77	-7.41	9	VERY LOW	NA	NA	NA	0.77	-7.41	9	VERY LOW	RoB, Imprecisionx2
aspirin, statins	IL6 receptor antagonists without corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.35	-7.76	7.13	VERY LOW	NA	NA	NA	-0.35	-7.76	7.13	VERY LOW	RoB, Imprecisionx2
aspirin, statins	interferon alfa (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.31	-8.54	7.99	VERY LOW	NA	NA	NA	-0.31	-8.54	7.99	VERY LOW	RoB, Imprecisionx2
aspirin, statins	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.09	-7.24	7.13	VERY LOW	NA	NA	NA	-0.09	-7.24	7.13	VERY LOW	RoB, Imprecisionx2
aspirin, statins	interferon beta (subcutaneous), lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-2.54	-10.59	5.57	VERY LOW	NA	NA	NA	-2.54	-10.59	5.57	VERY LOW	RoB, Imprecisionx2
aspirin, statins	ivermectin	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.01	-7.31	7.32	VERY LOW	NA	NA	NA	-0.01	-7.31	7.32	VERY LOW	RoB, Imprecisionx2
aspirin, statins	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.73	-6.33	7.81	VERY LOW	NA	NA	NA	0.73	-6.33	7.81	VERY LOW	RoB, Imprecisionx2
aspirin, statins	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.62	-7.53	6.3	VERY LOW	NA	NA	NA	-0.62	-7.53	6.3	VERY LOW	RoB, Inconsistency, Imprecisionx2
aspirin, statins	methylene blue	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	4.18	-4.1	12.48	VERY LOW	NA	NA	NA	4.18	-4.1	12.48	VERY LOW	RoBx2, Imprecisionx2
aspirin, statins	recombinant human granulocyte colony-stimulating factor	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.43	-9.16	10.08	VERY LOW	NA	NA	NA	0.43	-9.16	10.08	VERY LOW	RoB, Imprecisionx2
aspirin, statins	remdesivir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.31	-6.77	7.41	VERY LOW	NA	NA	NA	0.31	-6.77	7.41	VERY LOW	RoB, Imprecisionx2
aspirin, statins	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.23	-7.95	8.4	VERY LOW	NA	NA	NA	0.23	-7.95	8.4	VERY LOW	RoB, Imprecisionx2
statins	aspirin, statins	NA	NA	NA	-0.34	-1.59	0.91	LOW	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.74	-7.47	5.91	VERY LOW	RoB, Imprecision
aspirin, statins	tyrosine kinase inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.9	-10.56	8.76	VERY LOW	NA	NA	NA	-0.9	-10.56	8.76	VERY LOW	RoB, Imprecisionx2
aspirin, statins	umifenovir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.99	-6.69	8.69	VERY LOW	NA	NA	NA	0.99	-6.69	8.69	VERY LOW	RoB, Imprecisionx2
aspirin, statins	vitamin C	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.09	-8.03	7.83	VERY LOW	NA	NA	NA	-0.09	-8.03	7.83	VERY LOW	RoB, Imprecisionx2
aspirin, statins	vitamin D	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	1.66	-6.09	9.44	VERY LOW	NA	NA	NA	1.66	-6.09	9.44	VERY LOW	RoB, Imprecisionx2
azithromycin	azithromycin, hydroxychloroquine	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-1.22	-6.73	4.33	VERY LOW	NA	NA	NA	-1.22	-6.73	4.33	VERY LOW	RoB, Imprecisionx2
azithromycin	azithromycin, hydroxychloroquine, oseltamivir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-6.6	-15.46	2.15	VERY LOW	NA	NA	NA	-6.6	-15.46	2.15	VERY LOW	RoB, Imprecisionx2
azithromycin	colchicine	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.7	-4.25	5.64	VERY LOW	NA	NA	NA	0.7	-4.25	5.64	VERY LOW	RoB, Inconsistency, Imprecisionx2
azithromycin	colchicine, emtricitabine, tenofovir, statins	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.05	-7.99	8.2	VERY LOW	NA	NA	NA	0.05	-7.99	8.2	VERY LOW	RoB, Imprecisionx2
azithromycin	colchicine, statins	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.23	-7.87	8.34	VERY LOW	NA	NA	NA	0.23	-7.87	8.34	VERY LOW	RoB, Imprecisionx2
azithromycin	corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.82	-5.69	4.04	VERY LOW	NA	NA	NA	-0.82	-5.69	4.04	VERY LOW	RoB, Imprecisionx2
azithromycin	IL6 receptor antagonists with corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	5.09	0.33	9.84	MODERATE	NA	NA	NA	5.09	0.33	9.84	MODERATE	RoB
azithromycin	doxycycline	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	1.52	-6.45	9.57	VERY LOW	NA	NA	NA	1.52	-6.45	9.57	VERY LOW	RoB, Imprecisionx2
azithromycin	emtricitabine, tenofovir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.77	-8.87	7.36	VERY LOW	NA	NA	NA	-0.77	-8.87	7.36	VERY LOW	RoB, Imprecisionx2
azithromycin	favipiravir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.8	-4.49	6.11	VERY LOW	NA	NA	NA	0.8	-4.49	6.11	VERY LOW	RoBx2, Imprecisionx2
azithromycin	favipiravir, hydrochloroquine	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.8	-9.22	7.6	VERY LOW	NA	NA	NA	-0.8	-9.22	7.6	VERY LOW	RoB, Imprecisionx2
azithromycin	full-dose anticoagulant	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.22	-7.09	7.56	VERY LOW	NA	NA	NA	0.22	-7.09	7.56	VERY LOW	RoB, Imprecisionx2
azithromycin	GM-CSF inhibitor	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.11	-6.28	6.49	VERY LOW	NA	NA	NA	0.11	-6.28	6.49	VERY LOW	RoB, Imprecisionx2
azithromycin	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-1.8	-5.96	2.41	VERY LOW	NA	NA	NA	-1.8	-5.96	2.41	VERY LOW	RoB, Inconsistency, Imprecisionx2
azithromycin	IL1 inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	1.19	-5.14	7.56	VERY LOW	NA	NA	NA	1.19	-5.14	7.56	VERY LOW	RoB, Imprecisionx2
azithromycin	IL6 receptor antagonists without corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.08	-5.26	5.4	VERY LOW	NA	NA	NA	0.08	-5.26	5.4	VERY LOW	RoB, Imprecisionx2
azithromycin	interferon alfa (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.1	-6.36	6.59	VERY LOW	NA	NA	NA	0.1	-6.36	6.59	VERY LOW	RoB, Imprecisionx2
	•		•		•		•	•	•	•		•	•		•						•	•	

								Duration of I	nospitalizat	ion													
Comparison		Direct es	stimate						Indirect e	stimate						Network e	estimate						
		Relative	estimate		Absolute	estimate	(per 1,000)		Relative e	stimate		Absolute	estimate (p	per 1,000)		Relative e	stimate		Absolute e	stimate (pe	r 1,000)		
		Point	CI lower	CI upper	Point	CI lower	CI upper	Final rating	Point	CI lower	CI upper	Point	CI lower	CI upper	Final rating	Point	CI lower	CI	Point	CI lower	CI upper	Final rating	
Treatment 1	Treatment 2	estimate	limit	limit	estimate	limit	limit		estimate	limit	limit	estimate	limit	limit		estimate	limit	upper limit	estimate	limit	limit		Reasons for downgrading
azithromycin	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.33	-4.62	5.3	VERY LOW	NA	NA	NA	0.33	-4.62	5.3	VERY LOW	RoB, Imprecisionx2
azithromycin	interferon beta (subcutaneous), lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-2.12	-8.31	4.09	VERY LOW	NA	NA	NA	-2.12	-8.31	4.09	VERY LOW	RoB, Imprecisionx2
azithromycin	ivermectin	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.42	-4.72	5.54	VERY LOW	NA	NA	NA	0.42	-4.72	5.54	VERY LOW	RoB, Imprecisionx2
azithromycin	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	1.15	-3.67	5.97	VERY LOW	NA	NA	NA	1.15	-3.67	5.97	VERY LOW	RoB, Imprecisionx2
azithromycin	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.21	-4.73	4.35	VERY LOW	NA	NA	NA	-0.21	-4.73	4.35	VERY LOW	RoB, Inconsistency, Imprecision
azithromycin	methylene blue	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	4.61	-1.91	11.05	VERY LOW	NA	NA	NA	4.61	-1.91	11.05	VERY LOW	RoBx2, Imprecisionx2
azithromycin	recombinant human granulocyte colony-stimulating factor	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.88	-7.26	8.95	VERY LOW	NA	NA	NA	0.88	-7.26	8.95	VERY LOW	RoB, Imprecisionx2
azithromycin	remdesivir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.73	-4.07	5.54	VERY LOW	NA	NA	NA	0.73	-4.07	5.54	VERY LOW	RoB, Imprecisionx2
azithromycin	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.64	-5.68	6.99	VERY LOW	NA	NA	NA	0.64	-5.68	6.99	VERY LOW	RoB, Imprecisionx2
azithromycin	statins	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	1.16	-4.96	7.34	VERY LOW	NA	NA	NA	1.16	-4.96	7.34	VERY LOW	RoB, Imprecisionx2
azithromycin	tyrosine kinase inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.48	-8.59	7.63	VERY LOW	NA	NA	NA	-0.48	-8.59	7.63	VERY LOW	RoB, Imprecisionx2
azithromycin	umifenovir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	1.41	-4.29	7.13	VERY LOW	NA	NA	NA	1.41	-4.29	7.13	VERY LOW	RoB, Imprecisionx2
azithromycin	vitamin C	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.33	-5.69	6.31	VERY LOW	NA	NA	NA	0.33	-5.69	6.31	VERY LOW	RoB, Imprecisionx2
azithromycin	vitamin D	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	2.09	-3.66	7.83	VERY LOW	NA	NA	NA	2.09	-3.66	7.83	VERY LOW	RoB, Imprecisionx2
azithromycin, hydroxychloroquine	azithromycin, hydroxychloroquine, oseltamivir	NA	NA	NA	NA	NA	NA	NA 	NA NA	NA	NA	-5.4	-14.32	3.47	VERY LOW	NA NA	NA	NA	-5.4	-14.32	3.47	VERY LOW	RoB, Imprecisionx2
azithromycin, hydroxychloroquine	colchicine	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	1.92	-3.36	7.16	VERY LOW	NA	NA	NA	1.92	-3.36	7.16	VERY LOW	RoB, Inconsistency, Imprecisionx2
azithromycin, hydroxychloroquine	colchicine, emtricitabine, tenofovir, statins	NA	NA	NA	NA	NA	NA	NA 	NA	NA	NA	1.28	-7.01	9.58	VERY LOW	NA	NA	NA	1.28	-7.01	9.58	VERY LOW	RoB, Imprecisionx2
azithromycin, hydroxychloroquine	colchicine, statins	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	1.44	-6.85	9.71	VERY LOW	NA	NA	NA	1.44	-6.85	9.71	VERY LOW	RoB, Imprecisionx2
azithromycin, hydroxychloroquine	corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.39	-4.78	5.52	VERY LOW	NA	NA	NA	0.39	-4.78	5.52	VERY LOW	RoB, Imprecisionx2
azithromycin, hydroxychloroquine	IL6 receptor antagonists with corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	6.3	1.25	11.35	MODERATE	NA	NA	NA	6.3	1.25	11.35	MODERATE	RoB
azithromycin, hydroxychloroquine	doxycycline	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	2.76	-5.46	10.95	VERY LOW	NA	NA	NA	2.76	-5.46	10.95	VERY LOW	RoB, Imprecisionx2
azithromycin, hydroxychloroquine	emtricitabine, tenofovir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.45	-7.85	8.72	VERY LOW	NA	NA	NA	0.45	-7.85	8.72	VERY LOW	RoB, Imprecisionx2
azithromycin, hydroxychloroquine	favipiravir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	2.03	-3.46	7.49	VERY LOW	NA	NA	NA	2.03	-3.46	7.49	VERY LOW	RoBx2, Imprecisionx2
azithromycin, hydroxychloroquine	favipiravir, hydrochloroquine	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.4	-8.2	8.96	VERY LOW	NA	NA	NA	0.4	-8.2	8.96	VERY LOW	RoB, Imprecisionx2
azithromycin, hydroxychloroquine	full-dose anticoagulant	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	1.45	-6.05	8.94	VERY LOW	NA	NA	NA	1.45	-6.05	8.94	VERY LOW	RoB, Imprecisionx2
azithromycin, hydroxychloroquine	GM-CSF inhibitor	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	1.34	-5.26	7.9	VERY LOW	NA	NA	NA	1.34	-5.26	7.9	VERY LOW	RoB, Imprecisionx2
azithromycin, hydroxychloroquine	(hydroxy)chloroquine	NA	NA	NA	0.86	-0.66	2.43	LOW	NA NA	NA	NA	-2.25	-9.76	5.3	VERY LOW	NA NA	NA	NA	-0.58	-4.74	3.6	LOW	RoB, Imprecision
azithromycin, hydroxychloroquine	IL1 inhibitors	NA	NA	NA	NA	NA	NA	NA 	NA NA	NA	NA	2.42	-4.19	8.93	VERY LOW	NA NA	NA	NA	2.42	-4.19	8.93	VERY LOW	RoB, Imprecisionx2
azithromycin, hydroxychloroquine	IL6 receptor antagonists without corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA NA	NA NA	NA NA	NA	1.29	-4.31	6.88	VERY LOW	NA NA	NA	NA	1.29	-4.31	6.88	VERY LOW	RoB, Imprecisionx2
azithromycin, hydroxychloroquine	interferon alfa (subcutaneous)	NA	NA	NA	NA	NA	NA	NA 	NA NA	NA	NA	1.33	-5.34	8	VERY LOW	NA NA	NA	NA	1.33	-5.34	8	VERY LOW	RoB, Imprecisionx2
azithromycin, hydroxychloroquine	interferon beta (subcutaneous)	NA NA	NA	NA	NA	NA NA	NA	NA NA	NA NA	NA NA	NA	1.56	-3.72	6.76	VERY LOW	NA NA	NA NA	NA	1.56	-3.72	6.76	VERY LOW	RoB, Imprecisionx2
azithromycin, hydroxychloroquine	interferon beta (subcutaneous), lopinavir-ritonavir	NA	NA	NA	NA	NA NA	NA	NA NA			NA	-0.91	-7.23	5.42	VERY LOW	NA NA		NA	-0.91	-7.23	5.42	VERY LOW	RoB, Imprecisionx2
azithromycin, hydroxychloroquine	ivermectin	NA NA	NA NA	NA NA	NA	NA NA	NA	NA NA	NA NA	NA NA	NA NA	1.64	-3.75	7.01	VERY LOW	NA NA	NA NA	NA NA	1.64	-3.75	7.01	VERY LOW	RoB, Imprecisionx2
azithromycin, hydroxychloroquine	JAK inhibitors	NA NA	_		NA	NA NA	NA NA	NA NA				2.37	-2.77	7.47	VERY LOW				2.37	-2.77	7.47	VERY LOW	RoB, Imprecisionx2
azithromycin, hydroxychloroquine	lopinavir-ritonavir	NA NA	NA NA	NA NA	NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.01	-3.77	5.75 12.44	VERY LOW	NA NA	NA NA	NA NA	1.01	-3.77	5.75 12.44	VERY LOW	RoB, Inconsistency, Imprecisionx2
azithromycin, hydroxychloroquine azithromycin, hydroxychloroquine	methylene blue	NA	NA	NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	5.83	-0.89 -6.19	10.33	VERY LOW VERY LOW	NA NA	NA	NA	5.83 2.1	-0.89 -6.19	10.33	VERY LOW	RoBx2, Imprecisionx2 RoB, Imprecisionx2
azithromycin, hydroxychloroquine	recombinant human granulocyte colony-stimulating factor	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.96	-3.17	7.03	VERY LOW	NA NA	NA	NA	1.96	-3.17	7.03	VERY LOW	RoB, Imprecisionx2
azithromycin, nydroxychioroquine azithromycin, hydroxychloroquine	remdesivir serine protease inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.96	-3.17	8.41	VERY LOW VERY LOW	NA NA	NA NA	NA NA	1.96	-3.17	8.41	VERY LOW VERY LOW	RoB, Imprecisionx2
azithromycin, hydroxychloroquine	statins	NA	NA	NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA	2.39	-4.73	8.73	VERY LOW	NA NA	NA	NA	2.39	-4.73	8.73	VERY LOW	RoB, Imprecisionx2
azithromycin, hydroxychloroquine	tyrosine kinase inhibitors	NA NA	NA NA	NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.74	-7.55	9.02	VERY LOW	NA NA	NA	NA	0.74	-7.55	9.02	VERY LOW	RoB, Imprecisionx2
azithromycin, hydroxychloroquine azithromycin, hydroxychloroquine	tyrosine kinase innibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	2.63	-7.55	8.56	VERY LOW	NA NA	NA	NA	2.63	-7.55	8.56	VERY LOW	RoB, Imprecisionx2
azithromycin, hydroxychloroquine	vitamin C	NA	NA	NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA	1.55	-4.76	7.79	VERY LOW	NA NA	NA	NA	1.55	-4.76	7.79	VERY LOW	RoB, Imprecisionx2
azithromycin, hydroxychloroquine	vitamin D	NA NA	NA	NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	3.31	-2.69	9.29	VERY LOW	NA NA	NA	NA	3.31	-2.69	9.29	VERY LOW	RoB, Imprecisionx2
azithromycin, hydroxychloroquine, oseltamivir	colchicine	NA	NA	NA	NA	NA	NA NA	NA NA	NA NA	NA NA	NA	7.33	-1.28	15.94	VERY LOW	NA NA	NA	NA	7.33	-1.28	15.94	VERY LOW	RoB, Inconsistency, Imprecisionx2
azithromycin, hydroxychloroquine, oseitamivir	colchicine, emtricitabine, tenofovir, statins	NA.	NA NA	NA NA	NA.	NA NA	NA.	NA NA	NA NA	NA NA	NA.	6.67	-4.09	17.43	VERY LOW	NA NA	NA	NA	6.67	-4.09	17.43	VERY LOW	RoB. Imprecisionx2
azithromycin, hydroxychloroquine, oseltamivir	colchicine, statins	NA.	NA.	NA.	NA.	NA.	NA.	NA NA	NA NA	NA NA	NA.	6.84	-3.94	17.46	VERY LOW	NA NA	NA	NA	6.84	-3.94	17.45	VERY LOW	RoB, Imprecisionx2
azithromycin, hydroxychloroquine, oseltamivir	corticosteroids (systemic)	NA.	NA	NA	NA	NA.	NA.	NA NA	NA.	NA	NA	5.79	-2.76	14.34	VERY LOW	NA NA	NA	NA	5.79	-2.76	14.34	VERY LOW	RoB. Imprecisionx2
azithromycin, hydroxychloroquine, oseitamivir	IL6 receptor antagonists with corticosteroids (systemic)	NA	NA	NA	NA	NA.	NA NA	NA NA	NA	NA	NA	11.71	3.24	20.22	MODERATE	NA NA	NA	NA	11.71	3.24	20.22	MODERATE	RoB
azithromycin, hydroxychloroquine, oseitamivir	doxycycline	NA.	NA	NA	NA	NA.	NA.	NA NA	NA NA	NA	NA	8.15	-2.49	18.88	VERY LOW	NA NA	NA	NA	8.15	-2.49	18.88	VERY LOW	RoB, Imprecisionx2
azithromycin, hydroxychloroquine, oseltamivir	emtricitabine, tenofovir	NA.	NA.	NA.	NA.	NA.	NA.	NA NA	NA NA	NA.	NA.	5.86	-4.95	16.67	VERY LOW	NA NA	NA.	NA.	5.86	-4.95	16.67	VERY LOW	RoB. Imprecisionx2
azithromycin, hydroxychloroquine, oseitamivir	favioiravir	NA.	NA	NA	NA	NA NA	NA NA	NA NA	NA NA	NA	NA.	7.43	-1.27	16.24	VERY LOW	NA NA	NA	NA	7.43	-1.27	16.24	VERY LOW	RoB, Imprecisionx2
azithromycin, hydroxychloroquine, oseltamivir	favipiravir, hydrochloroquine	NA.	NA	NA	NA	NA.	NA.	NA NA	NA NA	NA	NA	5.81	-5.14	16.82	VERY LOW	NA NA	NA	NA	5.81	-5.14	16.82	VERY LOW	RoB, Imprecisionx2
azithromycin, hydroxychloroquine, oseitamivir	full-dose anticoagulant	NA.	NA	NA.	NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA.	6.83	-3.25	17.03	VERY LOW	NA NA	NA	NA	6.83	-3.14	17.03	VERY LOW	RoB, Imprecisionx2
azithromycin, hydroxychloroquine, oseltamivir	GM-CSF inhibitor	NA.	NA	NA	NA NA	NA NA	NA.	NA NA	NA NA	NA NA	NA	6.73	-2.77	16.18	VERY LOW	NA NA	NA	NA	6.73	-2.77	16.18	VERY LOW	RoB, Imprecisionx2
	I OW-OO! IIIIIDIO!	1			1973	14/3	14/1	14/3				0.70	-2.17	10.10	1 VEIXI LOW	1			0.70	-2.11	10.10	7 LIXI LOW	TOD, Imprecisional

								Duration of h	nospitalizat	tion													
Comparison		Direct es	stimate						Indirect 6	estimate						Network 6	estimate						
		Relative	estimate		Absolute	estimate	(per 1,00	00)	Relative e	estimate		Absolute (estimate (p	per 1,000)		Relative e	stimate		Absolute e	estimate (pe	er 1,000)		
		Point	CI lower	CI upper	Point	CI lower	CI uppe	er Final rating	Point	CI lower	CI upper	Point	CI lower	CI upper	Final rating	Point	CI lower	CI	Point	CI lower	CI upper	Final rating	
Treatment 1	Treatment 2	estimate	limit	limit	estimate	limit	limit		estimate	limit	limit	estimate	limit	limit		estimate	limit	limit	estimate	limit	limit		Reasons for downgrading
azithromycin, hydroxychloroquine, oseltamivir	IL1 inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	7.82	-1.61	17.33	VERY LOW	NA	NA	NA	7.82	-1.61	17.33	VERY LOW	RoB, Imprecisionx2
azithromycin, hydroxychloroquine, oseltamivir	IL6 receptor antagonists without corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	6.68	-2.12	15.53	VERY LOW	NA	NA	NA	6.68	-2.12	15.53	VERY LOW	RoB, Imprecisionx2
azithromycin, hydroxychloroquine, oseltamivir	interferon alfa (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	6.74	-2.83	16.28	VERY LOW	NA	NA	NA	6.74	-2.83	16.28	VERY LOW	RoB, Imprecisionx2
azithromycin, hydroxychloroquine, oseltamivir	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	6.96	-1.61	15.59	VERY LOW	NA	NA	NA	6.96	-1.61	15.59	VERY LOW	RoB, Imprecisionx2
azithromycin, hydroxychloroquine, oseltamivir	interferon beta (subcutaneous), lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	4.51	-4.41	13.42	VERY LOW	NA	NA	NA	4.51	-4.41	13.42	VERY LOW	RoB, Imprecisionx2
azithromycin, hydroxychloroquine, oseltamivir	ivermectin	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	7.04	-1.62	15.73	VERY LOW	NA	NA	NA	7.04	-1.62	15.73	VERY LOW	RoB, Imprecisionx2
azithromycin, hydroxychloroquine, oseltamivir	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	7.77	-0.7	16.28	VERY LOW	NA	NA	NA	7.77	-0.7	16.28	VERY LOW	RoB, Imprecisionx2
azithromycin, hydroxychloroquine, oseltamivir	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	6.41	-1.75	14.62	VERY LOW	NA	NA	NA	6.41	-1.75	14.62	VERY LOW	RoB, Inconsistency, Imprecisionx2
azithromycin, hydroxychloroquine, oseltamivir	methylene blue	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	11.24	1.7	20.74	LOW	NA	NA	NA	11.24	1.7	20.74	LOW	RoBx2
azithromycin, hydroxychloroquine, oseltamivir	recombinant human granulocyte colony-stimulating factor	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	7.49	-3.21	18.2	VERY LOW	NA	NA	NA	7.49	-3.21	18.2	VERY LOW	RoB, Imprecisionx2
azithromycin, hydroxychloroquine, oseltamivir	remdesivir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	7.35	-1.14	15.86	VERY LOW	NA	NA	NA	7.35	-1.14	15.86	VERY LOW	RoB, Imprecisionx2
azithromycin, hydroxychloroquine, oseltamivir	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	7.27	-2.21	16.75	VERY LOW	NA	NA	NA	7.27	-2.21	16.75	VERY LOW	RoB, Imprecisionx2
azithromycin, hydroxychloroquine, oseltamivir	statins	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	7.8	-1.6	17.15	VERY LOW	NA	NA	NA	7.8	-1.6	17.15	VERY LOW	RoB, Imprecisionx2
azithromycin, hydroxychloroquine, oseltamivir	tyrosine kinase inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	6.15	-4.62	16.85	VERY LOW	NA	NA	NA	6.15	-4.62	16.85	VERY LOW	RoB, Imprecisionx2
azithromycin, hydroxychloroquine, oseltamivir	umifenovir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	8.03	-1.06	17.12	VERY LOW	NA	NA	NA	8.03	-1.06	17.12	VERY LOW	RoB, Imprecisionx2
azithromycin, hydroxychloroquine, oseltamivir	vitamin C	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	6.94	-2.29	16.16	VERY LOW	NA	NA	NA	6.94	-2.29	16.16	VERY LOW	RoB, Imprecisionx2
azithromycin, hydroxychloroquine, oseltamivir	vitamin D	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	8.7	-0.35	17.82	VERY LOW	NA	NA	NA	8.7	-0.35	17.82	VERY LOW	RoB, Imprecisionx2
colchicine	colchicine, emtricitabine, tenofovir, statins	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.66	-8.58	7.31	VERY LOW	NA	NA	NA	-0.66	-8.58	7.31	VERY LOW	RoB, Inconsistency, Imprecisionx2
colchicine	colchicine, statins	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.48	-8.42	7.43	VERY LOW	NA	NA	NA	-0.48	-8.42	7.43	VERY LOW	RoB, Inconsistency, Imprecisionx2
colchicine	corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-1.53	-6.07	3.01	VERY LOW	NA	NA	NA	-1.53	-6.07	3.01	VERY LOW	RoB, Inconsistency, Imprecisionx2
colchicine	IL6 receptor antagonists with corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	4.39	-0.04	8.79	VERY LOW	NA	NA	NA	4.39	-0.04	8.79	VERY LOW	RoB, Inconsistency, Imprecisionx2
colchicine	doxycycline	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.83	-7.01	8.65	VERY LOW	NA	NA	NA	0.83	-7.01	8.65	VERY LOW	RoB, Inconsistency, Imprecisionx2
colchicine	emtricitabine, tenofovir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-1.47	-9.43	6.49	VERY LOW	NA	NA	NA	-1.47	-9.43	6.49	VERY LOW	RoB, Inconsistency, Imprecisionx2
colchicine	favipiravir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.1	-4.91	5.1	VERY LOW	NA	NA	NA	0.1	-4.91	5.1	VERY LOW	RoBx2, Inconsistency, Imprecisionx2
colchicine	favipiravir, hydrochloroquine	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-1.5	-9.79	6.73	VERY LOW	NA	NA	NA	-1.5	-9.79	6.73	VERY LOW	RoB, Inconsistency, Imprecisionx2
colchicine	full-dose anticoagulant	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.48	-7.58	6.64	VERY LOW	NA	NA	NA	-0.48	-7.58	6.64	VERY LOW	RoB, Inconsistency, Imprecisionx2
colchicine	GM-CSF inhibitor	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.59	-6.7	5.56	VERY LOW	NA	NA	NA	-0.59	-6.7	5.56	VERY LOW	RoB, Inconsistency, Imprecisionx2
colchicine	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-2.48	-6.31	1.34	VERY LOW	NA	NA	NA	-2.48	-6.31	1.34	VERY LOW	RoB, Inconsistency, Imprecisionx2
colchicine	IL1 inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.5	-5.59	6.6	VERY LOW	NA	NA	NA	0.5	-5.59	6.6	VERY LOW	RoB, Inconsistency, Imprecisionx2
colchicine	IL6 receptor antagonists without corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.62	-5.64	4.4	VERY LOW	NA	NA	NA	-0.62	-5.64	4.4	VERY LOW	RoB, Inconsistency, Imprecisionx2
colchicine	interferon alfa (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.59	-6.79	5.65	VERY LOW	NA	NA	NA	-0.59	-6.79	5.65	VERY LOW	RoB, Inconsistency, Imprecisionx2
colchicine	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.37	-5.03	4.3	VERY LOW	NA	NA	NA	-0.37	-5.03	4.3	VERY LOW	RoB, Inconsistency, Imprecisionx2
colchicine	interferon beta (subcutaneous), lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-2.81	-8.79	3.14	VERY LOW	NA	NA	NA	-2.81	-8.79	3.14	VERY LOW	RoB, Inconsistency, Imprecisionx2
colchicine	ivermectin	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.29	-5.14	4.56	VERY LOW	NA	NA	NA	-0.29	-5.14	4.56	VERY LOW	RoB, Inconsistency, Imprecisionx2
colchicine	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.45	-4.02	4.92	VERY LOW	NA	NA	NA	0.45	-4.02	4.92	VERY LOW	RoB, Inconsistency, Imprecision
colchicine	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.91	-5.11	3.31	VERY LOW	NA	NA	NA	-0.91	-5.11	3.31	VERY LOW	RoB, Inconsistency, Imprecisionx2
colchicine	methylene blue	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	3.91	-2.34	10.1	VERY LOW	NA	NA	NA	3.91	-2.34	10.1	VERY LOW	RoBx2, Inconsistency, Imprecisionx2
colchicine	recombinant human granulocyte colony-stimulating factor	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.19	-7.81	8.1	VERY LOW	NA	NA	NA	0.19	-7.81	8.1	VERY LOW	RoB, Inconsistency, Imprecisionx2
colchicine	remdesivir	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.04	-4.45	4.5	VERY LOW	NA	NA	NA	0.04	-4.45	4.5	VERY LOW	RoB, Inconsistency, Imprecision
colchicine	serine protease inhibitors	NA	NA	NA	NA	NA	NA		NA	NA	NA	-0.05	-6.17	6.06	VERY LOW	NA	NA	NA	-0.05	-6.17	6.06	VERY LOW	RoB, Inconsistency, Imprecisionx2
colchicine	statins	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.47	-5.44	6.36	VERY LOW	NA	NA	NA	0.47	-5.44	6.36	VERY LOW	RoB, Inconsistency, Imprecisionx2
colchicine	tyrosine kinase inhibitors	NA	NA	NA	NA	NA	NA	_	NA	NA	NA	-1.19	-9.11	6.77	VERY LOW	NA	NA	NA	-1.19	-9.11	6.77	VERY LOW	RoB, Inconsistency, Imprecisionx2
colchicine	umifenovir	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.71	-4.73	6.14	VERY LOW	NA	NA	NA	0.71	-4.73	6.14	VERY LOW	RoB, Inconsistency, Imprecisionx2
colchicine	vitamin C	NA	NA	NA	NA	NA	NA		NA	NA	NA	-0.37	-6.12	5.34	VERY LOW	NA	NA	NA	-0.37	-6.12	5.34	VERY LOW	RoB, Inconsistency, Imprecisionx2
colchicine	vitamin D	NA	NA	NA	NA	NA	NA		NA	NA	NA	1.39	-4.08	6.84	VERY LOW	NA	NA	NA	1.39	-4.08	6.84	VERY LOW	RoB, Inconsistency, Imprecisionx2
colchicine, statins	colchicine, emtricitabine, tenofovir, statins	NA	NA	NA	-0.17	-1.69	1.35		NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.18	-7.37	7.06	VERY LOW	RoB, Imprecision
colchicine, emtricitabine, tenofovir, statins	corticosteroids (systemic)	NA	NA	NA	NA	NA	NA		NA	NA	NA	-0.88	-8.78	6.97	VERY LOW	NA	NA	NA	-0.88	-8.78	6.97	VERY LOW	RoB, Imprecisionx2
colchicine, emtricitabine, tenofovir, statins	IL6 receptor antagonists with corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	_	NA	NA	NA	5.04	-2.81	12.82	VERY LOW	NA	NA	NA	5.04	-2.81	12.82	VERY LOW	RoB, Imprecisionx2
colchicine, emtricitabine, tenofovir, statins	doxycycline	NA	NA	NA	NA	NA	NA		NA	NA	NA	1.47	-8.61	11.62	VERY LOW	NA	NA	NA	1.47	-8.61	11.62	VERY LOW	RoB, Imprecisionx2
emtricitabine, tenofovir	colchicine, emtricitabine, tenofovir, statins	NA	NA	NA	0.83	-0.69	2.35	_	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.81	-6.37	8.05	VERY LOW	RoB, Imprecision
colchicine, emtricitabine, tenofovir, statins	favipiravir	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.74	-7.43	8.88	VERY LOW	NA	NA	NA	0.74	-7.43	8.88	VERY LOW	RoBx2, Imprecisionx2
colchicine, emtricitabine, tenofovir, statins	favipiravir, hydrochloroquine	NA	NA	NA	NA	NA	NA		NA	NA	NA	-0.86	-11.29	9.58	VERY LOW	NA	NA	NA	-0.86	-11.29	9.58	VERY LOW	RoB, Imprecisionx2
colchicine, emtricitabine, tenofovir, statins	full-dose anticoagulant	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.16	-9.41	9.72	VERY LOW	NA	NA	NA	0.16	-9.41	9.72	VERY LOW	RoB, Imprecisionx2
colchicine, emtricitabine, tenofovir, statins	GM-CSF inhibitor	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.06	-8.81	8.89	LOW	NA	NA	NA	0.06	-8.81	8.89	LOW	Imprecisionx2
colchicine, emtricitabine, tenofovir, statins	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-1.85	-9.33	5.61	VERY LOW	NA	NA	NA	-1.85	-9.33	5.61	VERY LOW	RoB, Inconsistency, Imprecisionx2
colchicine, emtricitabine, tenofovir, statins	IL1 inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	1.14	-7.78	10	LOW	NA	NA	NA	1.14	-7.78	10	LOW	Imprecisionx2

								Duration of h	hospitalizat	tion													
Comparison		Direct es							Indirect 6							Network 6							
		Relative	estimate		Absolute	estimate	(per 1,00	0)	Relative e	estimate		Absolute	estimate (p	per 1,000)		Relative e	stimate		Absolute e	stimate (pe	er 1,000)		
		Point		CI upper	Point	CI lower	CI uppe	Final rating	Point	CI lower	CI upper	Point	CI lower	CI upper	Final rating		CI lower	Cl	Point	CI lower	CI upper	Final rating	
Treatment 1	Treatment 2	estimate	limit	limit	estimate	limit	limit		estimate	limit	limit	estimate	limit	limit		estimate	limit	limit	estimate	limit	limit		Reasons for downgrading
colchicine, emtricitabine, tenofovir, statins	IL6 receptor antagonists without corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.02	-8.15	8.22	LOW	NA	NA	NA	0.02	-8.15	8.22	LOW	Imprecisionx2
colchicine, emtricitabine, tenofovir, statins	interferon alfa (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.07	-8.86	8.96	VERY LOW	NA	NA	NA	0.07	-8.86	8.96	VERY LOW	RoB, Imprecisionx2
colchicine, emtricitabine, tenofovir, statins	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.27	-7.67	8.19	VERY LOW	NA	NA	NA	0.27	-7.67	8.19	VERY LOW	RoB, Imprecisionx2
colchicine, emtricitabine, tenofovir, statins	interferon beta (subcutaneous), lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-2.17	-10.95	6.53	VERY LOW	NA	NA	NA	-2.17	-10.95	6.53	VERY LOW	RoB, Imprecisionx2
colchicine, emtricitabine, tenofovir, statins	ivermectin	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.36	-7.68	8.41	VERY LOW	NA	NA	NA	0.36	-7.68	8.41	VERY LOW	RoB, Imprecisionx2
colchicine, emtricitabine, tenofovir, statins	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	1.1	-6.78	8.89	LOW	NA	NA	NA	1.1	-6.78	8.89	LOW	Imprecisionx2
colchicine, emtricitabine, tenofovir, statins	lopinavir-ritonavir	NA	NA	NA	NA	NA.	NA	NA	NA	NA	NA	-0.26	-7.98	7.45	VERY LOW	NA	NA	NA	-0.26	-7.98	7.45	VERY LOW	RoB, Inconsistency, Imprecisionx2
colchicine, emtricitabine, tenofovir, statins	methylene blue	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	4.54	-4.44	13.51	VERY LOW	NA	NA	NA	4.54	-4.44	13.51	VERY LOW	RoBx2, Imprecisionx2
colchicine, emtricitabine, tenofovir, statins	recombinant human granulocyte colony-stimulating factor	NA	NA	NA	NA	NA	NA	NA NA	NA	NA	NA	0.81	-9.41	11.04	VERY LOW	NA	NA	NA	0.81	-9.41	11.04	VERY LOW	RoB, Imprecisionx2
colchicine, emtricitabine, tenofovir, statins	remdesivir	NA	NA	NA	NA	NA	NA	NA NA	NA	NA	NA	0.68	-7.18	8.51	VERYLOW	NA	NA	NA	0.68	-7.18	8.51	VERYLOW	RoB. Imprecisionx2
colchicine, emtricitabine, tenofovir, statins	serine protease inhibitors	NA.	NA	NA	NA	NA.	NA.	NA NA	NA.	NA	NA	0.58	-8.26	9.49	VERY LOW	NA NA	NA	NA	0.58	-8.26	9.49	VERY LOW	RoB, Imprecisionx2
colchicine, emtricitabine, tenofovir, statins	statins	NA	NA	NA	NA	NA.	NA.	NA NA	NA.	NA	NA	1.12	-7.63	9.83	VERY LOW	NA	NA	NA	1.12	-7.63	9.83	VERY LOW	RoB, Imprecisionx2
colchicine, emtricitabine, tenofovir, statins	tyrosine kinase inhibitors	NA.	NA	NA.	NA	NA NA	NA.	NA NA	NA.	NA.	NA.	-0.54	-10.75	9.69	VERY LOW	NA NA	NA.	NA	-0.54	-10.75	9.69	VERY LOW	RoB, Imprecisionx2
colchicine, emtricitabine, tenofovir, statins	umifenovir	NA.	NA	NA.	NA.	NA NA	NA.	NA NA	NA.	NA	NA.	1.35	-7.04	9.75	VERY LOW	NA.	NA.	NA	1.35	-7.04	9.75	VERY LOW	RoB, Imprecisionx2
colchicine, entiricitabine, teriorovir, statins	vitamin C	NA NA	NA	NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.27	-8.38	8.84	VERY LOW	NA NA	NA	NA	0.27	-8.38	8.84	VERY LOW	RoB, Imprecisionx2
colchicine, emtricitabine, tenofovir, statins	vitamin D	NA	NA	NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA	2.04	-6.4	10.49	VERY LOW	NA NA	NA	NA	2.04	-6.4	10.49	VERY LOW VERY LOW	RoB, Imprecisionx2
colchicine, emunicitabilite, tenorovir, statins	corticosteroids (systemic)	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-1.05	-8.91	6.84	VERY LOW	NA NA	NA NA	NA NA	-1.05	-8.91	6.84	VERY LOW VERY LOW	RoB, Imprecisionx2
colchicine, statins	IL6 receptor antagonists with corticosteroids (systemic)	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	4.87	-8.91	12.65	VERY LOW	NA NA	NA NA	NA NA	4.87	-8.91	12.65	VERY LOW VERY LOW	RoB, Imprecisionx2
colchicine, statins	doxycycline	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.28	-8.77	11.42	VERY LOW	NA NA	NA NA	NA NA	1.28	-2.99	11.42	VERYLOW	RoB, Imprecisionx2
emtricitabine, tenofovir		NA NA	NA NA	NA	INA.	-0.59	2.59	LOW	NA NA	NA NA	NA NA	NA	-6.77 NA	NA	NA NA	NA NA	NA NA	NA	0.98	-6.22	8.21	VERY LOW	RoB, Imprecision
	colchicine, statins	+			T NA		-			+		_			+	_		_					,
colchicine, statins	favipiravir	NA NA	NA NA	NA NA	NA	NA NA	NA	NA NA	NA NA	NA NA	NA NA	0.57	-7.56	8.76	VERY LOW	NA NA	NA NA	NA NA	0.57	-7.56	8.76	VERY LOW	RoBx2, Imprecisionx2
colchicine, statins	favipiravir, hydrochloroquine	_	NA NA	NA NA	NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	-1.04	-11.46 -9.61	9.35	VERY LOW		NA NA	NA NA	-1.04	-11.46 -9.61	9.35	VERY LOW	RoB, Imprecisionx2
colchicine, statins	full-dose anticoagulant	NA			NA	NA NA		NA NA	1.0.	+		0.01	0.01	0.0	VERY LOW	NA NA		-	0.01	0.01	0.0	VE. 11. 2011	RoB, Imprecisionx2
colchicine, statins	GM-CSF inhibitor	NA	NA	NA	NA	NA	NA	NA NA	NA	NA	NA	-0.1	-8.99	8.77	LOW	NA NA	NA	NA	-0.1	-8.99	8.77	LOW	Imprecisionx2
colchicine, statins	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-2.02	-9.45	5.45	VERY LOW	NA	NA	NA	-2.02	-9.45	5.45	VERY LOW	RoB, Inconsistency, Imprecisionx2
colchicine, statins	IL1 inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.99	-7.93	9.87	LOW	NA	NA	NA	0.99	-7.93	9.87	LOW	Imprecisionx2
colchicine, statins	IL6 receptor antagonists without corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.14	-8.31	8.04	LOW	NA	NA	NA	-0.14	-8.31	8.04	LOW	Imprecisionx2
colchicine, statins	interferon alfa (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.1	-9.04	8.84	VERY LOW	NA	NA	NA	-0.1	-9.04	8.84	VERY LOW	RoB, Imprecisionx2
colchicine, statins	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.11	-7.83	8.03	VERY LOW	NA	NA	NA	0.11	-7.83	8.03	VERY LOW	RoB, Imprecisionx2
colchicine, statins	interferon beta (subcutaneous), lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	NA NA	NA	NA	-2.34	-11.11	6.38	VERY LOW	NA	NA	NA	-2.34	-11.11	6.38	VERY LOW	RoB, Imprecisionx2
colchicine, statins	ivermectin	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.2	-7.87	8.25	VERY LOW	NA	NA	NA	0.2	-7.87	8.25	VERY LOW	RoB, Imprecisionx2
colchicine, statins	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.93	-6.88	8.77	LOW	NA	NA	NA	0.93	-6.88	8.77	LOW	Imprecisionx2
colchicine, statins	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.44	-8.12	7.25	VERY LOW	NA	NA	NA	-0.44	-8.12	7.25	VERY LOW	RoB, Inconsistency, Imprecisionx2
colchicine, statins	methylene blue	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	4.37	-4.58	13.31	VERY LOW	NA	NA	NA	4.37	-4.58	13.31	VERY LOW	RoBx2, Imprecisionx2
colchicine, statins	recombinant human granulocyte colony-stimulating factor	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.66	-9.6	10.83	VERY LOW	NA	NA	NA	0.66	-9.6	10.83	VERY LOW	RoB, Imprecisionx2
colchicine, statins	remdesivir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.51	-7.29	8.34	VERY LOW	NA	NA	NA	0.51	-7.29	8.34	VERY LOW	RoB, Imprecisionx2
colchicine, statins	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.43	-8.45	9.29	VERY LOW	NA	NA	NA	0.43	-8.45	9.29	VERY LOW	RoB, Imprecisionx2
colchicine, statins	statins	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.95	-7.73	9.69	VERY LOW	NA	NA	NA	0.95	-7.73	9.69	VERY LOW	RoB, Imprecisionx2
colchicine, statins	tyrosine kinase inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.72	-10.9	9.55	VERY LOW	NA	NA	NA	-0.72	-10.9	9.55	VERY LOW	RoB, Imprecisionx2
colchicine, statins	umifenovir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	1.19	-7.22	9.62	VERY LOW	NA	NA	NA	1.19	-7.22	9.62	VERY LOW	RoB, Imprecisionx2
colchicine, statins	vitamin C	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.09	-8.55	8.77	VERY LOW	NA	NA	NA	0.09	-8.55	8.77	VERY LOW	RoB, Imprecisionx2
colchicine, statins	vitamin D	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	1.86	-6.57	10.34	VERY LOW	NA	NA	NA	1.86	-6.57	10.34	VERY LOW	RoB, Imprecisionx2
corticosteroids (systemic)	IL6 receptor antagonists with corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	5.92	1.58	10.22	MODERATE	NA	NA	NA	5.92	1.58	10.22	MODERATE	RoB
corticosteroids (systemic)	doxycycline	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	2.36	-5.39	10.13	VERY LOW	NA	NA	NA	2.36	-5.39	10.13	VERY LOW	RoB, Imprecisionx2
corticosteroids (systemic)	emtricitabine, tenofovir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.07	-7.83	7.93	VERY LOW	NA	NA	NA	0.07	-7.83	7.93	VERY LOW	RoB, Imprecisionx2
corticosteroids (systemic)	favipiravir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	1.63	-3.24	6.55	VERY LOW	NA	NA	NA	1.63	-3.24	6.55	VERY LOW	RoBx2, Imprecisionx2
corticosteroids (systemic)	favipiravir, hydrochloroquine	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.02	-8.14	8.19	VERY LOW	NA	NA	NA	0.02	-8.14	8.19	VERY LOW	RoB, Imprecisionx2
corticosteroids (systemic)	full-dose anticoagulant	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	1.04	-5.98	8.1	VERY LOW	NA	NA	NA	1.04	-5.98	8.1	VERY LOW	RoB, Imprecisionx2
corticosteroids (systemic)	GM-CSF inhibitor	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.93	-5.08	7	VERY LOW	NA	NA	NA	0.93	-5.08	7	VERY LOW	RoB, Imprecisionx2
corticosteroids (systemic)	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.96	-4.66	2.73	VERY LOW	NA	NA	NA	-0.96	-4.66	2.73	VERY LOW	RoB, Inconsistency, Imprecision
corticosteroids (systemic)	IL1 inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	2.01	-3.99	8.07	VERY LOW	NA	NA	NA	2.01	-3.99	8.07	VERY LOW	RoB, Imprecisionx2
corticosteroids (systemic)	IL6 receptor antagonists without corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.91	-4.02	5.87	VERY LOW	NA	NA	NA	0.91	-4.02	5.87	VERY LOW	RoB, Imprecisionx2
corticosteroids (systemic)	interferon alfa (subcutaneous)	NA	NA	NA	NA	NA NA	NA.	NA NA	NA	NA	NA	0.95	-5.21	7.09	VERY LOW	NA	NA	NA	0.95	-5.21	7.09	VERY LOW	RoB, Imprecisionx2
corticosteroids (systemic)	interferon beta (subcutaneous)	NA.	NA	NA.	NA	NA NA	NA NA	NA NA	NA.	NA.	NA.	1.17	-3.38	5.74	VERY LOW	NA NA	NA	NA	1.17	-3.38	5.74	VERY LOW	RoB, Imprecisionx2
corticosteroids (systemic)	interferon beta (subcutaneous)	NA.	NA	NA	NA	NA NA	NA NA	NA NA	NA NA	NA	NA.	-1.29	-7.16	4.57	VERY LOW	NA NA	NA	NA	-1.29	-7.16	4.57	VERY LOW	RoB, Imprecisionx2
corticosteroids (systemic)	ivermectin	NA NA	NA	NA	NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.24	-7.10	6.02	VERYLOW	NA NA	NA	NA.	1.24	-7.10	6.02	VERY LOW	RoB, Imprecisionx2
Corticosteroias (systemic)	iverniecum	INA	INA	INA	INA	INA	INA	INA	INA	INA	INA	1.24	-3.40	0.02	VERTLOW	INA	INA	INA	1.24	-3.40	0.02	VERTLOW	Rob, imprecisions2

								Duration of h	nospitalizat	tion												_	
Comparison		Direct es	stimate						Indirect 6	estimate						Network e	estimate						
		Relative	estimate		Absolute	estimate	(per 1,00	00)	Relative e	estimate		Absolute 6	estimate (p	per 1,000)		Relative e	stimate		Absolute e	stimate (pe	er 1,000)		
		Point	CI lower	CI upper	Point	CI lower	CI uppe	er Final rating	Point	CI lower	CI upper	Point	CI lower	CI upper	Final rating	Point	CI lower	CI	Point	CI lower	CI upper	Final rating	
Treatment 1	Treatment 2	estimate	limit	limit	estimate	limit	limit		estimate	limit	limit	estimate	limit	limit		estimate	limit	upper	estimate	limit	limit		Reasons for downgrading
corticosteroids (systemic)	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	1.98	-2.41	6.37	VERY LOW	NA	NA	NA	1.98	-2.41	6.37	VERY LOW	RoB, Imprecisionx2
corticosteroids (systemic)	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.62	-3.45	4.71	VERY LOW	NA	NA	NA	0.62	-3.45	4.71	VERY LOW	RoB, Inconsistency, Imprecision
corticosteroids (systemic)	methylene blue	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	5.43	-0.75	11.58	VERY LOW	NA	NA	NA	5.43	-0.75	11.58	VERY LOW	RoBx2, Imprecisionx2
corticosteroids (systemic)	recombinant human granulocyte colony-stimulating factor	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	1.7	-6.19	9.55	VERY LOW	NA	NA	NA	1.7	-6.19	9.55	VERY LOW	RoB, Imprecisionx2
corticosteroids (systemic)	remdesivir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	1.57	-2.8	5.93	VERY LOW	NA	NA	NA	1.57	-2.8	5.93	VERY LOW	RoB, Imprecisionx2
corticosteroids (systemic)	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	1.47	-4.56	7.5	VERY LOW	NA	NA	NA	1.47	-4.56	7.5	VERY LOW	RoB, Imprecisionx2
corticosteroids (systemic)	statins	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	2	-3.81	7.8	VERY LOW	NA	NA	NA	2	-3.81	7.8	VERY LOW	RoB, Imprecisionx2
corticosteroids (systemic)	tyrosine kinase inhibitors	NA	NA	NA	NA	NA	NA	_	NA	NA	NA	0.33	-7.54	8.28	VERY LOW	NA	NA	NA	0.33	-7.54	8.28	VERY LOW	RoB, Imprecisionx2
corticosteroids (systemic)	umifenovir	NA	NA	NA	NA	NA	NA	_	NA	NA	NA	2.24	-3.1	7.59	VERY LOW	NA	NA	NA	2.24	-3.1	7.59	VERY LOW	RoB, Imprecisionx2
corticosteroids (systemic)	vitamin C	NA	NA	NA	NA	NA	NA		NA	NA	NA	1.16	-4.54	6.84	VERY LOW	NA	NA	NA	1.16	-4.54	6.84	VERY LOW	RoB, Imprecisionx2
corticosteroids (systemic)	vitamin D	NA	NA	NA	NA	NA	NA	_	NA	NA	NA	2.92	-2.44	8.31	VERY LOW	NA	NA	NA	2.92	-2.44	8.31	VERY LOW	RoB, Imprecisionx2
IL6 receptor antagonists with corticosteroids (systemic)	doxycycline	NA	NA	NA	NA	NA	NA		NA	NA	NA	-3.57	-11.24	4.15	VERY LOW	NA	NA	NA	-3.57	-11.24	4.15	VERY LOW	RoB, Imprecisionx2
IL6 receptor antagonists with corticosteroids (systemic)	emtricitabine, tenofovir	NA	NA	NA	NA	NA	NA		NA	NA	NA	-5.86	-13.64	1.98	VERY LOW	NA	NA	NA	-5.86	-13.64	1.98	VERY LOW	RoB, Imprecisionx2
IL6 receptor antagonists with corticosteroids (systemic)	favipiravir	NA	NA	NA	NA	NA	NA		NA	NA	NA	-4.29	-9.06	0.49	VERY LOW	NA	NA	NA	-4.29	-9.06	0.49	VERY LOW	RoBx2, Imprecisionx2
IL6 receptor antagonists with corticosteroids (systemic)	favipiravir, hydrochloroquine	NA NA	NA	NA	NA	NA	NA		NA NA	NA	NA	-5.9	-14.01	2.24	VERY LOW	NA NA	NA	NA	-5.9	-14.01	2.24	VERY LOW	RoB, Imprecisionx2
IL6 receptor antagonists with corticosteroids (systemic)	full-dose anticoagulant	NA	NA	NA	NA	NA	NA		NA	NA	NA	-4.87	-11.83	2.1	VERY LOW	NA	NA	NA	-4.87	-11.83	2.1	VERY LOW	RoB, Imprecisionx2
IL6 receptor antagonists with corticosteroids (systemic)	GM-CSF inhibitor	NA	NA	NA	NA	NA	NA		NA	NA	NA	-4.99	-10.92	1	VERY LOW	NA	NA	NA	-4.99	-10.92	1	VERY LOW	RoB, Imprecisionx2
IL6 receptor antagonists with corticosteroids (systemic)	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA		NA	NA	NA	-6.89	-10.41	-3.32	LOW	NA	NA	NA	-6.89	-10.41	-3.32	LOW	RoB, Inconsistency
IL6 receptor antagonists with corticosteroids (systemic)	IL1 inhibitors	NA	NA	NA	NA	NA	NA		NA	NA	NA	-3.9	-9.78	2.09	VERY LOW	NA	NA	NA	-3.9	-9.78	2.09	VERY LOW	RoB, Imprecisionx2
IL6 receptor antagonists with corticosteroids (systemic)	IL6 receptor antagonists without corticosteroids (systemic)	NA	NA	NA	NA	NA	NA		NA	NA	NA	-5.01	-9.83	-0.17	MODERATE	NA	NA	NA	-5.01	-9.83	-0.17	MODERATE	RoB
IL6 receptor antagonists with corticosteroids (systemic)	interferon alfa (subcutaneous)	NA	NA	NA	NA	NA	NA		NA	NA	NA	-4.98	-11.02	1.07	VERY LOW	NA	NA	NA	-4.98	-11.02	1.07	VERY LOW	RoB, Imprecisionx2
IL6 receptor antagonists with corticosteroids (systemic)	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-4.75	-9.18	-0.33	MODERATE	NA	NA	NA	-4.75	-9.18	-0.33	MODERATE	RoB
IL6 receptor antagonists with corticosteroids (systemic)	interferon beta (subcutaneous), lopinavir-ritonavir	NA	NA	NA	NA	NA	NA		NA	NA	NA	-7.22	-12.99	-1.42	MODERATE	NA	NA	NA	-7.22	-12.99	-1.42	MODERATE	RoB
IL6 receptor antagonists with corticosteroids (systemic)	ivermectin	NA	NA	NA	NA	NA	NA		NA	NA	NA	-4.68	-9.3	-0.02	MODERATE	NA	NA	NA	-4.68	-9.3	-0.02	MODERATE	RoB
IL6 receptor antagonists with corticosteroids (systemic)	JAK inhibitors	NA	NA	NA	NA	NA	NA		NA	NA	NA	-3.94	-8.17	0.3	VERY LOW	NA	NA	NA	-3.94	-8.17	0.3	VERY LOW	RoB, Imprecisionx2
IL6 receptor antagonists with corticosteroids (systemic)	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA		NA	NA	NA	-5.3	-9.24	-1.34	LOW	NA	NA	NA	-5.3	-9.24	-1.34	LOW	RoB, Inconsistency
IL6 receptor antagonists with corticosteroids (systemic)	methylene blue	NA	NA	NA	NA	NA	NA		NA	NA	NA	-0.49	-6.54	5.58	VERY LOW	NA NA	NA	NA	-0.49	-6.54	5.58	VERY LOW	RoBx2, Imprecisionx2
IL6 receptor antagonists with corticosteroids (systemic)	recombinant human granulocyte colony-stimulating factor	NA	NA	NA	NA	NA	NA	_	NA	NA	NA	-4.21	-12.02	3.57	VERY LOW	NA NA	NA	NA	-4.21	-12.02	3.57	VERY LOW	RoB, Imprecisionx2
IL6 receptor antagonists with corticosteroids (systemic)	remdesivir	NA	NA	NA	NA	NA NA	NA		NA NA	NA NA	NA	-4.36	-8.59	-0.14	MODERATE	NA NA	NA	NA	-4.36	-8.59	-0.14	MODERATE	RoB
IL6 receptor antagonists with corticosteroids (systemic)	serine protease inhibitors	NA	NA	NA	NA	NA	NA		NA NA	NA	NA	-4.44	-10.37	1.5	VERY LOW	NA NA	NA	NA	-4.44	-10.37	1.5	VERY LOW	RoB, Imprecisionx2
IL6 receptor antagonists with corticosteroids (systemic)	statins	NA NA	NA	NA	NA	NA NA	NA		NA NA	NA NA	NA NA	-3.93	-9.61	1.82	VERY LOW	NA NA	NA NA	NA	-3.93	-9.61	1.82	VERY LOW	RoB, Imprecisionx2
IL6 receptor antagonists with corticosteroids (systemic)	tyrosine kinase inhibitors	NA	NA	NA	NA	NA NA	NA	_				-5.58	-13.39	2.26	VERY LOW	NA NA		NA	-5.58	-13.39	2.26	VERY LOW	RoB, Imprecisionx2
IL6 receptor antagonists with corticosteroids (systemic)	umifenovir	NA NA	NA	NA	NA	NA	NA		NA NA	NA	NA NA	-3.67	-8.92	1.57	VERY LOW	NA NA	NA	NA	-3.67	-8.92	1.57	VERY LOW	RoB, Imprecisionx2
IL6 receptor antagonists with corticosteroids (systemic)	vitamin C	NA	NA	NA	NA	NA NA	NA	_	NA NA	NA NA	NA	-4.76	-10.33	0.81	VERY LOW	NA NA	NA	NA	-4.76	-10.33	0.81	VERY LOW	RoB, Imprecisionx2
IL6 receptor antagonists with corticosteroids (systemic)	vitamin D	NA NA	NA NA	NA NA	NA	NA NA	NA		NA NA	NA NA	NA NA	-3	-8.28	2.26	VERY LOW	NA NA	NA NA	NA NA	-3	-8.28	2.26	VERY LOW	RoB, Imprecisionx2
doxycycline	emtricitabine, tenofovir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA		NA NA	NA NA	NA NA	-2.3 -0.73	-12.43 -8.79	7.85 7.32	VERY LOW VERY LOW	NA NA	NA NA	NA	-2.3 -0.73	-12.43 -8.79	7.85 7.32	VERY LOW VERY LOW	RoB, Imprecisionx2
doxycycline	favipiravir hydrochloroquine	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA		NA NA	NA NA	NA NA	-0.73	-0.79	7.98	VERY LOW	NA NA	NA NA	NA NA	-0.73	-6.79	7.98	VERY LOW	RoBx2, Imprecisionx2
doxycycline	full-dose anticoagulant	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA		NA NA	NA NA	NA NA	-2.33	-12.77	8.2	VERY LOW VERY LOW	NA NA	NA NA	NA NA	-2.33	-12.77	8.2	VERY LOW VERY LOW	RoB, Imprecisionx2
doxycycline	full-dose anticoagulant GM-CSF inhibitor	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	_	NA NA	NA NA	NA NA	-1.31	-10.76	7.43	VERY LOW VERY LOW	NA NA	NA NA	NA NA	-1.31	-10.76 -10.17	7.43	VERY LOW VERY LOW	RoB, Imprecisionx2 RoB, Imprecisionx2
doxycycline	(hydroxy)chloroquine	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA		NA NA	NA NA	NA NA	-3.33	-10.17	4.04	VERY LOW	NA NA	NA NA	NA NA	-3.33	-10.17	4.04	VERY LOW VERY LOW	RoB, Inconsistency, Imprecisionx2
doxycycline	(nydroxy)chloroquine	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA		NA NA	NA NA	NA NA	-0.33	-9.08	8.47	VERY LOW	NA NA	NA	NA NA	-0.33	-9.08	8.47	VERY LOW	RoB, Imprecisionx2
doxycycline doxycycline	II 6 receptor antagonists without corticosteroids (systemic)	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	_	NA NA	NA NA	NA NA	-1.45	-9.08	6.58	VERY LOW	NA NA	NA NA	NA NA	-1.45	-9.08	6.58	VERY LOW	RoB, Imprecisionx2
doxycycline	interferon alfa (subcutaneous)	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA		NA NA	NA NA	NA NA	-1.45	-10.29	7.46	VERY LOW	NA NA	NA NA	NA NA	-1.45	-9.51	7.46	VERY LOW	RoB, Imprecisionx2
doxycycline	interferon alla (subcutaneous)	NA NA	NA NA	NA	NA NA	NA NA	NA NA		NA NA	NA NA	NA	-1.41	-9.07	6.58	VERY LOW	NA NA	NA NA	NA	-1.41	-9.07	6.58	VERY LOW VERY LOW	RoB, Imprecisionx2
doxycycline	interferon beta (subcutaneous) interferon beta (subcutaneous), lopinavir-ritonavir	NA NA	NA NA	NA NA	NA	NA NA	NA NA		NA NA	NA NA	NA NA	-3.66	-12.27	5.01	VERY LOW	NA NA	NA	NA NA	-3.66	-12.27	5.01	VERY LOW	RoB, Imprecisionx2
doxycycline	ivermectin	NA.	NA NA	NA NA	NA NA	NA NA	NA NA	_	NA.	NA NA	NA NA	-1.11	-9.09	6.86	VERY LOW	NA NA	NA	NA NA	-1.11	-9.09	6.86	VERY LOW	RoB, Imprecisionx2
doxycycline	JAK inhibitors	NA NA	NA	NA	NA	NA NA	NA NA		NA NA	NA NA	NA NA	-0.38	-8.14	7.36	VERY LOW	NA NA	NA	NA	-0.38	-8.14	7.36	VERY LOW	RoB, Imprecisionx2
doxycycline	lopinavir-ritonavir	NA NA	NA	NA	NA	NA NA	NA NA		NA NA	NA NA	NA NA	-1.74	-9.32	5.83	VERY LOW	NA NA	NA	NA	-1.74	-9.32	5.83	VERY LOW	RoB, Inconsistency, Imprecisionx2
doxycycline	methylene blue	NA	NA	NA	NA	NA NA	NA.		NA	NA	NA	3.07	-5.82	11.91	VERY LOW	NA NA	NA	NA	3.07	-5.82	11.91	VERY LOW	RoBx2, Imprecisionx2
doxycycline	recombinant human granulocyte colony-stimulating factor	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	_	NA NA	NA NA	NA NA	-0.67	-10.82	9.42	VERY LOW	NA NA	NA	NA NA	-0.67	-10.82	9.42	VERY LOW	RoB, Imprecisionx2
doxycycline	recombinant numan granulocyte colony-stimulating factor	NA	NA	NA	NA	NA NA	NA NA		NA	NA NA	NA	-0.81	-8.56	6.93	VERY LOW	NA NA	NA	NA	-0.81	-8.56	6.93	VERY LOW	RoB, Imprecisionx2
doxycycline	serine protease inhibitors	NA NA	NA	NA	NA NA	NA NA	NA NA		NA NA	NA NA	NA NA	-0.88	-9.69	7.88	VERY LOW	NA NA	NA	NA	-0.88	-9.69	7.88	VERY LOW	RoB, Imprecisionx2
doxycycline	serine protease inhibitors	NA	NA	NA NA	NA NA	NA NA	NA NA		NA	NA NA	NA	-0.85	-9.69	8.24	VERY LOW	NA NA	NA	NA	-0.35	-9.09	8.24	VERY LOW	RoB, Imprecisionx2
,,,.		NA NA	NA	NA		NA NA	NA NA	NA NA	NA NA	NA NA	NA					NA NA	NA	NA				VERY LOW	- '
doxycycline	tyrosine kinase inhibitors umifenovir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA		NA NA	NA NA	NA NA	-2.01 -0.13	-12.18 -8.5	8.12 8.21	VERY LOW VERY LOW	NA NA	NA NA	NA NA	-2.01 -0.13	-12.18 -8.5	8.12	VERY LOW VERY LOW	RoB, Imprecisionx2
doxycycline	umilenovii	INA	INA	INA	INA	INA	INA	INA	INA	INA	INA	-0.13	-0.5	0.21	VERTLOW	INA	INA	INA	-0.13	-0.5	0.21	VERTLOW	Nob, imprecisionizz

Part									Duration of h	nosnitalizat	ion													
Part	Comparison		Direct es	stimate	_	_	_	_	Daration or i								Network e	stimate	_					
Proposed			Relative	estimate		Absolute	estimate	(per 1.000)					Absolute	estimate (p	er 1.000)		Relative es	stimate		Absolute e	stimate (pe	r 1.000)		
					CI		1	i i	Final rating	Deint	CLIeures	CI		1	,,,,,	Final rating			CI				Final rating	
Company Comp	To almost 4	Total Control O							r indi rating							1 marrating							1 marrating	B
Second			NIA	NIA	NIA			110		NIA	NA	NΙΔ	4.0	0.70	7.07	VEDVLOW	NIA	NIA		4.0	0.70	7.07	VEDVLOW	
Contractive restort	,,,,			_	_									****										
Miles and Control Mile	,,,.		-	+	-		1				-	-	+	-			-					+		·
Processor Control Co		1 7 1		_		_	_				-		_		-									
Part				-	-												_							
## Company (a) Programme P					_	_	_																	. , , ,
Semicolary 1 miles 1						_																		
Performance	,				_	+	_																	
### **** Professional Professional Company (1) A. M.				_	_		_						_	-									+	F
A			-	_	_	+	1				+			-			_					+	 	·
## Performance Information Monotonics 1966				_	_												_							. ,
methodoxime function Mode				+								-											-	·
## Properties of Part Services Miles Miles	,					-	_						_				_						!	·
Performance Improved Improv				_	_																			·
emriciation Interform																				-				
## Complement for the control of the management of control of the		Toping the state of the state o		_	_	_	_	_																21 1
### emorphise product					_	_								-			_	_					 	·
## centrolative tembors** ## centrolative te				_		_	_						_			1							-	
Embridative, Interform																							-	
Employed Pyrosin seale (NETHING) MA NA NA NA NA NA NA NA					_		_																	
Programme						_	_										_							
Secondary Wallerin C		****	-	_	_	+							_				_			_				. , , ,
September Value Progress Value Val		1 1 1		_			_						+	-		-				-		-		
Engineer	Omaronabino, tonorovii	THEMINIT O					+							7.01	0.72	12.11.2011	_			1.00		0.72		. , , ,
The prise of The prise of The prise of Calcular See Prise Prise Pris				_	_		_										_							. ,
Texpression GMACSF resident					_																			·
Telephone Physiosychiorogaine NA NA NA A2 26 509 0.14 LOW NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA						_	_						_										 	. , ,
Supprover B. I whiteless M. A. N.	·						_																	
Sepirativit B. En receptor antagenetiss without controlled (systemic) NA NA NA NA NA NA NA N																								
Interferon afte (publicatemence)	ienpiienii			_	_		_									-								
Interferon Dela (pubculaneous)			-	+	_	_						-	+	+			_							·
Interferon beta (subcutameous), logonari-richovair NA		` ,				_	_						_		-	1						-		
Februaries	·	` '		_																		+	-	
Engineeric Horselform Boundary Boundar	10-1-p-10-11						_														-			,
Imprise Impr				_									_				NA							. , , ,
Foreignavir			-				_						_							_			+	
February		·				NA	_	NA		NA				-2.73	10.3								VERY LOW	
Fewpleavir Femdesivir Fem		recombinant human granulocyte colony-stimulating factor					NA	NA	NA								_					+		·
Favipravir Serine protease inhibitors NA NA NA NA NA NA NA N	favipiravir			_	_		_	NA	NA												-			RoBx2. Imprecision
Favipiravir	favipiravir	serine protease inhibitors			_	NA	NA		NA								_	_						RoBx2. Imprecisionx2
Favipiravir Tyrosine kinase inhibitors NA NA NA NA NA NA NA N							_																	
Favipiravir September Se	·	tyrosine kinase inhibitors	NA	NA	NA		_	NA		NA	NA	NA		-9.43	-		NA	NA	NA			6.87	VERY LOW	
Favipiravir Signature Favipiravir Signature		umifenovir	-				NA	NA	NA	NA	NA	NA		-5.12	6.35		NA			-	-5.12	6.35		
Favipiravir, hydrochloroquine full-dose anticoagulant NA NA NA NA NA NA NA N	favipiravir						_	_					_											RoBx2, Imprecisionx2
Favipiravir, hydrochloroquine full-dose anticoagulant NA NA NA NA NA NA NA N	favipiravir	vitamin D	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	1.29	-4.5	7.03	VERY LOW	NA	NA	NA	1.29	-4.5	7.03	VERY LOW	RoBx2, Imprecisionx2
Favipiravir, hydrochloroquine GM-CSF inhibitor NA	·					+	+	+ +			-		+				_			 				·
Favipiravir, hydrochloroquine (hydroxy)chloroquine (hydroxy)ch		9			NA	NA	NA	NA	NA	NA	NA	NA	0.94	-8.23	10.11	-	NA		NA	0.94	-8.23	10.11	VERY LOW	RoB, Imprecisionx2
Favipiravir, hydrochloroquine IL1 inhibitors NA NA NA NA NA NA NA N		(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.99	-8.78	6.84	VERY LOW	NA	NA	NA	-0.99	-8.78	6.84	VERY LOW	RoB, Inconsistency, Imprecisionx2
favipiravir, hydrochloroquine interferon alfa (subcutaneous) NA	favipiravir, hydrochloroquine	IL1 inhibitors			NA		_			NA		NA	_				NA		NA					
favipiravir, hydrochloroquine interferon alfa (subcutaneous) NA	favipiravir, hydrochloroquine	IL6 receptor antagonists without corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.9	-7.58	9.36	VERY LOW	NA	NA	NA	0.9	-7.58	9.36	VERY LOW	RoB, Imprecisionx2
favipiravir, hydrochloroquine interferon beta (subcutaneous), lopinavir-ritonavir NA										NA				-8.31			_							
favipiravir, hydrochloroquine interferon beta (subcutaneous), lopinavir-ritonavir NA	favipiravir, hydrochloroquine	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	1.15	-7.12	9.38	VERY LOW	NA	NA	NA	1.15	-7.12	9.38	VERY LOW	RoB, Imprecisionx2
favipiravir, hydrochloroquine ivermectin NA		interferon beta (subcutaneous), lopinavir-ritonavir	-	_			_	_			+		_				_							RoB, Imprecisionx2
favipiravir, hydrochloroquine JAK inhibitors NA	favipiravir, hydrochloroquine		NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	1.21	-7.13	9.58	VERY LOW	NA	NA	NA	1.21	-7.13	9.58	VERY LOW	
	favipiravir, hydrochloroquine	JAK inhibitors				_	_			NA			_		10.12				NA			10.12		
	favipiravir, hydrochloroquine	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.61	-7.42	8.61	VERY LOW	NA	NA	NA	0.61	-7.42	8.61	VERY LOW	

								Duration of h	ospitaliz <u>a</u> t	tion													
Comparison		Direct es	stimate						Indirect	estimate						Network 6	estimate						
		Relative	estimate		Absolu	te estimate	(per 1,0	000)	Relative 6	estimate		Absolute	estimate (per 1,000)		Relative e	stimate		Absolute e	stimate (pe	er 1,000)		
		Point	CI lower	CI upper	r Point	CI lower	CI upp	per Final rating	Point	CI lower	CI upper	Point	CI lower	CI upper	Final rating	Point	CI lower	. CI	Point	CI lower	CI upper	Final rating	
Treatment 1	Treatment 2	estimate	limit	limit	estimat	te limit	limit	t	estimate	limit	limit	estimate	limit	limit		estimate	limit	upper	estimate	limit	limit		Reasons for downgrading
favipiravir, hydrochloroquine	methylene blue	NA	NA	NA	NA	NA	NA	. NA	NA	NA	NA	5.43	-3.81	14.62	VERY LOW	NA	NA	NA	5.43	-3.81	14.62	VERY LOW	RoBx2, Imprecisionx2
favipiravir, hydrochloroquine	recombinant human granulocyte colony-stimulating factor	NA	NA	NA	NA	NA	NA	. NA	NA	NA	NA	1.69	-8.81	12.12	VERY LOW	NA	NA	NA	1.69	-8.81	12.12	VERY LOW	RoB, Imprecisionx2
favipiravir, hydrochloroquine	remdesivir	NA	NA	NA	NA	NA	NA	. NA	NA	NA	NA	1.53	-6.58	9.68	VERY LOW	NA	NA	NA	1.53	-6.58	9.68	VERY LOW	RoB, Imprecisionx2
favipiravir, hydrochloroquine	serine protease inhibitors	NA	NA	NA	NA	NA	NA	. NA	NA	NA	NA	1.45	-7.68	10.63	VERY LOW	NA	NA	NA	1.45	-7.68	10.63	VERY LOW	RoB, Imprecisionx2
favipiravir, hydrochloroquine	statins	NA	NA	NA	NA	NA	NA	. NA	NA	NA	NA	1.98	-7.06	11	VERY LOW	NA	NA	NA	1.98	-7.06	11	VERY LOW	RoB, Imprecisionx2
favipiravir, hydrochloroquine	tyrosine kinase inhibitors	NA	NA	NA	NA	NA	NA	. NA	NA	NA	NA	0.31	-10.14	10.81	VERY LOW	NA	NA	NA	0.31	-10.14	10.81	VERY LOW	RoB, Imprecisionx2
favipiravir, hydrochloroquine	umifenovir	NA	NA	NA	NA	NA	NA	. NA	NA	NA	NA	2.21	-6.47	10.93	VERY LOW	NA	NA	NA	2.21	-6.47	10.93	VERY LOW	RoB, Imprecisionx2
favipiravir, hydrochloroquine	vitamin C	NA	NA	NA	NA	NA	NA	. NA	NA	NA	NA	1.12	-7.75	10.03	VERY LOW	NA	NA	NA	1.12	-7.75	10.03	VERY LOW	RoB, Imprecisionx2
favipiravir, hydrochloroquine	vitamin D	NA	NA	NA	NA	NA	NA	. NA	NA	NA	NA	2.9	-5.81	11.62	VERY LOW	NA	NA	NA	2.9	-5.81	11.62	VERY LOW	RoB, Imprecisionx2
full-dose anticoagulant	GM-CSF inhibitor	NA	NA	NA	NA	NA	NA	. NA	NA	NA	NA	-0.11	-8.26	8.04	VERY LOW	NA	NA	NA	-0.11	-8.26	8.04	VERY LOW	RoB, Imprecisionx2
full-dose anticoagulant	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	. NA	NA	NA	NA	-2.01	-8.6	4.57	VERY LOW	NA	NA	NA	-2.01	-8.6	4.57	VERY LOW	RoB, Inconsistency, Imprecisionx2
full-dose anticoagulant	IL1 inhibitors	NA	NA	NA	NA	NA	NA	. NA	NA	NA	NA	0.98	-7.13	9.1	VERY LOW	NA	NA	NA	0.98	-7.13	9.1	VERY LOW	RoB, Imprecisionx2
full-dose anticoagulant	IL6 receptor antagonists without corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	. NA	NA	NA	NA	-0.14	-7.5	7.19	VERY LOW	NA	NA	NA	-0.14	-7.5	7.19	VERY LOW	RoB, Imprecisionx2
full-dose anticoagulant	interferon alfa (subcutaneous)	NA	NA	NA	NA	NA	NA	. NA	NA	NA	NA	-0.11	-8.33	8.1	VERY LOW	NA	NA	NA	-0.11	-8.33	8.1	VERY LOW	RoB, Imprecisionx2
full-dose anticoagulant	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.12	-7.03	7.18	VERY LOW	NA	NA	NA	0.12	-7.03	7.18	VERY LOW	RoB, Imprecisionx2
full-dose anticoagulant	interferon beta (subcutaneous), lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	. NA	NA	NA	NA	-2.34	-10.33	5.66	VERY LOW	NA	NA	NA	-2.34	-10.33	5.66	VERY LOW	RoB, Imprecisionx2
full-dose anticoagulant	ivermectin	NA	NA	NA	NA	NA	NA	. NA	NA	NA	NA	0.21	-7.06	7.44	VERY LOW	NA	NA	NA	0.21	-7.06	7.44	VERY LOW	RoB, Imprecisionx2
full-dose anticoagulant	JAK inhibitors	NA	NA	NA	NA	NA	NA	. NA	NA	NA	NA	0.92	-6.1	7.95	VERY LOW	NA	NA	NA	0.92	-6.1	7.95	VERY LOW	RoB, Imprecisionx2
full-dose anticoagulant	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	. NA	NA	NA	NA	-0.42	-7.23	6.39	VERY LOW	NA	NA	NA	-0.42	-7.23	6.39	VERY LOW	RoB, Inconsistency, Imprecisionx2
full-dose anticoagulant	methylene blue	NA	NA	NA	NA	NA	NA	. NA	NA	NA	NA	4.38	-3.88	12.62	VERY LOW	NA	NA	NA	4.38	-3.88	12.62	VERY LOW	RoBx2, Imprecisionx2
full-dose anticoagulant	recombinant human granulocyte colony-stimulating factor	NA	NA	NA	NA	NA	NA	. NA	NA	NA	NA	0.64	-8.93	10.22	VERY LOW	NA	NA	NA	0.64	-8.93	10.22	VERY LOW	RoB, Imprecisionx2
full-dose anticoagulant	remdesivir	NA	NA	NA	NA	NA	NA	. NA	NA	NA	NA	0.51	-6.49	7.49	VERY LOW	NA	NA	NA	0.51	-6.49	7.49	VERY LOW	RoB, Imprecisionx2
full-dose anticoagulant	serine protease inhibitors	NA	NA	NA	NA	NA	NA	. NA	NA	NA	NA	0.43	-7.72	8.57	VERY LOW	NA	NA	NA	0.43	-7.72	8.57	VERY LOW	RoB, Imprecisionx2
full-dose anticoagulant	statins	NA	NA	NA	NA	NA	NA	. NA	NA	NA	NA	0.96	-7.06	8.87	VERY LOW	NA	NA	NA	0.96	-7.06	8.87	VERY LOW	RoB, Imprecisionx2
full-dose anticoagulant	tyrosine kinase inhibitors	NA	NA	NA	NA	NA	NA	. NA	NA	NA	NA	-0.7	-10.37	8.88	VERY LOW	NA	NA	NA	-0.7	-10.37	8.88	VERY LOW	RoB, Imprecisionx2
full-dose anticoagulant	umifenovir	NA	NA	NA	NA	NA	NA	. NA	NA	NA	NA	1.2	-6.47	8.82	VERY LOW	NA	NA	NA	1.2	-6.47	8.82	VERY LOW	RoB, Imprecisionx2
full-dose anticoagulant	vitamin C	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.11	-7.77	7.99	VERY LOW	NA	NA	NA	0.11	-7.77	7.99	VERY LOW	RoB, Imprecisionx2
full-dose anticoagulant	vitamin D	NA	NA	NA	NA	NA	NA	. NA	NA	NA	NA	1.87	-5.81	9.49	VERY LOW	NA	NA	NA	1.87	-5.81	9.49	VERY LOW	RoB, Imprecisionx2
GM-CSF inhibitor	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	. NA	NA	NA	NA	-1.9	-7.44	3.64	VERY LOW	NA	NA	NA	-1.9	-7.44	3.64	VERY LOW	RoB, Inconsistency, Imprecisionx2
GM-CSF inhibitor	IL1 inhibitors	NA	NA	NA	NA	NA	NA	. NA	NA	NA	NA	1.09	-6.21	8.42	LOW	NA	NA	NA	1.09	-6.21	8.42	LOW	Imprecisionx2
GM-CSF inhibitor	IL6 receptor antagonists without corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	. NA	NA	NA	NA	-0.04	-6.49	6.41	LOW	NA	NA	NA	-0.04	-6.49	6.41	LOW	Imprecisionx2
GM-CSF inhibitor	interferon alfa (subcutaneous)	NA	NA	NA	NA	NA	NA	. NA	NA	NA	NA	0	-7.4	7.41	VERY LOW	NA	NA	NA	0	-7.4	7.41	VERY LOW	RoB, Imprecisionx2
GM-CSF inhibitor	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	. NA	NA	NA	NA	0.21	-5.92	6.36	VERY LOW	NA	NA	NA	0.21	-5.92	6.36	VERY LOW	RoB, Imprecisionx2
GM-CSF inhibitor	interferon beta (subcutaneous), lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	. NA	NA	NA	NA	-2.25	-9.4	4.95	VERY LOW	NA	NA	NA	-2.25	-9.4	4.95	VERY LOW	RoB, Imprecisionx2
GM-CSF inhibitor	ivermectin	NA	NA	NA	NA	NA	NA	. NA	NA	NA	NA	0.31	-5.99	6.59	VERY LOW	NA	NA	NA	0.31	-5.99	6.59	VERY LOW	RoB, Imprecisionx2
GM-CSF inhibitor	JAK inhibitors	NA	NA	NA	NA	NA	NA		NA	NA	NA	1.04	-5	7.07	LOW	NA	NA	NA	1.04	-5	7.07	LOW	Imprecisionx2
GM-CSF inhibitor	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	. NA	NA	NA	NA	-0.31	-6.13	5.49	VERY LOW	NA	NA	NA	-0.31	-6.13	5.49	VERY LOW	RoB, Inconsistency, Imprecisionx2
GM-CSF inhibitor	methylene blue	NA	NA	NA	NA	NA	NA		NA	NA	NA	4.48	-2.95	11.89	VERY LOW	NA	NA	NA	4.48	-2.95	11.89	VERY LOW	RoBx2, Imprecisionx2
GM-CSF inhibitor	recombinant human granulocyte colony-stimulating factor	NA	NA	NA	NA	NA	NA	. NA	NA	NA	NA	0.75	-8.18	9.57	VERY LOW	NA	NA	NA	0.75	-8.18	9.57	VERY LOW	RoB, Imprecisionx2
GM-CSF inhibitor	remdesivir	NA	NA	NA	NA	NA	NA	. NA	NA	NA	NA	0.62	-5.42	6.63	VERY LOW	NA	NA	NA	0.62	-5.42	6.63	VERY LOW	RoB, Imprecisionx2
GM-CSF inhibitor	serine protease inhibitors	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.52	-6.76	7.85	VERY LOW	NA	NA	NA	0.52	-6.76	7.85	VERY LOW	RoB, Imprecisionx2
GM-CSF inhibitor	statins	NA	NA	NA	NA	NA	NA		NA	NA	NA	1.05	-6.1	8.2	VERY LOW	NA	NA	NA	1.05	-6.1	8.2	VERY LOW	RoB, Imprecisionx2
GM-CSF inhibitor	tyrosine kinase inhibitors	NA	NA	NA	NA	NA	NA	_	NA	NA	NA	-0.6	-9.49	8.28	VERY LOW	NA	NA	NA	-0.6	-9.49	8.28	VERY LOW	RoB, Imprecisionx2
GM-CSF inhibitor	umifenovir	NA	NA	NA	NA	NA	NA		NA	NA	NA	1.3	-5.46	8.05	VERY LOW	NA	NA	NA	1.3	-5.46	8.05	VERY LOW	RoB, Imprecisionx2
GM-CSF inhibitor	vitamin C	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.22	-6.82	7.23	VERY LOW	NA	NA	NA	0.22	-6.82	7.23	VERY LOW	RoB, Imprecisionx2
GM-CSF inhibitor	vitamin D	NA	NA	NA	NA	NA	NA		NA	NA	NA	1.97	-4.8	8.75	VERY LOW	NA	NA	NA	1.97	-4.8	8.75	VERY LOW	RoB, Imprecisionx2
(hydroxy)chloroquine	IL1 inhibitors	NA	NA	NA	NA	NA	NA		NA	NA	NA	2.99	-2.53	8.49	VERY LOW	NA	NA	NA	2.99	-2.53	8.49	VERY LOW	RoB, Inconsistency, Imprecisionx2
(hydroxy)chloroquine	IL6 receptor antagonists without corticosteroids (systemic)	NA	NA	NA	NA	NA	NA		NA	NA	NA	1.87	-2.43	6.13	VERY LOW	NA	NA	NA	1.87	-2.43	6.13	VERY LOW	RoB, Inconsistency, Imprecisionx2
(hydroxy)chloroquine	interferon alfa (subcutaneous)	NA	NA	NA	NA	NA	NA	_	NA	NA	NA	1.9	-3.74	7.53	VERY LOW	NA	NA	NA	1.9	-3.74	7.53	VERY LOW	RoB, Inconsistency, Imprecisionx2
(hydroxy)chloroquine	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA		NA	NA	NA	2.13	-1.71	5.95	VERY LOW	NA	NA	NA	2.13	-1.71	5.95	VERY LOW	RoB, Inconsistency, Imprecisionx2
interferon beta (subcutaneous), lopinavir-ritor		NA	NA	NA	2	0.37	3.63		NA	NA	NA	-2.19	-10.94	6.67	VERY LOW	NA	NA	NA	0.33	-4.74	5.46	VERY LOW	RoB
ivermectin	(hydroxy)chloroquine	NA	NA	NA	0.67		3.29		NA	NA	NA	-3.38	-8.13	1.34	VERY LOW	NA	NA	NA	-2.2	-6.1	1.71	VERY LOW	RoB, Imprecision
(hydroxy)chloroquine	JAK inhibitors	NA	NA	NA	NA	NA	NA		NA	NA	NA	2.94	-0.69	6.55	VERY LOW	NA	NA	NA	2.94	-0.69	6.55	VERY LOW	RoB, Inconsistency, Imprecisionx2
lopinavir-ritonavir	(hydroxy)chloroquine	NA	NA	NA	-5	-12.37	2.51	1 VERY LOW	NA	NA	NA	-0.27	-3.44	2.92	VERY LOW	NA	NA	NA	-1.58	-4.51	1.33	VERY LOW	3, Inconsistency, Imprecision, Incohere
(hydroxy)chloroquine	methylene blue	NA	NA	NA	NA	NA	NA		NA	NA	NA	6.4	0.7	12.02	LOW	NA	NA	NA	6.4	0.7	12.02	LOW	RoBx2, Inconsistency
(hydroxy)chloroquine	recombinant human granulocyte colony-stimulating factor	NA	NA	NA	NA	NA	NA	. NA	NA	NA	NA	2.67	-4.81	10.14	VERY LOW	NA	NA	NA	2.67	-4.81	10.14	VERY LOW	RoB, Inconsistency, Imprecisionx2

Polymorphismate									Duration of h	nospitaliz <u>at</u>	ion													
Product Prod	Comparison		Direct es	stimate						Indirect e	stimate						Network e	stimate						
Property Property			Relative	estimate		Absolute	estimate	(per 1,00	00)	Relative e	stimate		Absolute	estimate (p	per 1,000)		Relative es	stimate		Absolute e	stimate (pe	r 1,000)		
Second Configuration Second Configuration			Point	CI lower	CI upper	Point	CI lower	CI uppe	er Final rating	Point	CI lower	CI upper	Point	Cl lower	CI upper	Final rating	Point	CI lower		Point	CI lower	CI upper	Final rating	
Property of the property of	Treatment 1	Treatment 2	estimate	limit		estimate	limit			estimate	limit		estimate	limit			estimate	limit	upper	estimate	limit			Reasons for downgrading
Principal processes Principal processes Principal		*** * * *	NA	NA	NA	NA	NA	NA	NA NA	NA	NA	NA	2.52	-1.1	6.13	VERYLOW	NA	NA		2.52	-1.1	6.13	VERYLOW	RoB, Inconsistency, Imprecisionx2
Contemporary Cont	(33)		NA	_	NA		_		_	NA	-		_	+		-								RoB, Inconsistency, Imprecisionx2
Company programme		statins	-	+	-	NA	_	NA	NA NA	NA	-		2.96		+	-						8.23	+	RoB, Inconsistency, Imprecisionx2
Cycle progression	12 27	tyrosine kinase inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	_	+	-	VERY LOW	NA	NA	NA	1.31			VERY LOW	RoB, Inconsistency, Imprecisionx2
Cypersystemanume		umifenovir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	3.2	-1.56	7.96	VERY LOW	NA	NA	NA	3.2	-1.56	7.96	VERY LOW	RoB, Inconsistency, Imprecisionx2
Popular political programme Comment MA MA MA MA MA MA MA M		vitamin C		_	NA	NA	NA	NA	NA	NA		NA		 	7.2	VERY LOW	NA	NA	NA		-2.98	7.2	VERY LOW	RoB, Inconsistency, Imprecisionx2
Ex-l marbles		vitamin D	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	3.89	-0.91	8.66	VERY LOW	NA	NA	NA	3.89	-0.91	8.66	VERY LOW	RoB, Inconsistency, Imprecisionx2
It implies	IL1 inhibitors	IL6 receptor antagonists without corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-1.11	-7.56	5.23	LOW	NA	NA	NA	-1.11	-7.56	5.23	LOW	Imprecisionx2
In trimbles	IL1 inhibitors	interferon alfa (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-1.08	-8.47	6.3	VERY LOW	NA	NA	NA	-1.08	-8.47	6.3	VERY LOW	RoB, Imprecisionx2
11 trivibles	IL1 inhibitors	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.87	-7	5.25	VERY LOW	NA	NA	NA	-0.87	-7	5.25	VERY LOW	RoB, Imprecisionx2
1.1 Holiston 1.0	IL1 inhibitors	interferon beta (subcutaneous), lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-3.33	-10.43	3.83	VERY LOW	NA	NA	NA	-3.33	-10.43	3.83	VERY LOW	RoB, Imprecisionx2
E. 1 Frontière Copposité récourier NA NA NA NA NA NA NA N	IL1 inhibitors	ivermectin	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.78	-7.06	5.49	VERY LOW	NA	NA	NA	-0.78	-7.06	5.49	VERY LOW	RoB, Imprecisionx2
El Frieblors	IL1 inhibitors	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.05	-6.06	5.95	LOW	NA	NA	NA	-0.05	-6.06	5.95	LOW	Imprecisionx2
El sinishibos recombinant human garuscipec convert intensing participe for participe for convert intensing participe for participate participa	IL1 inhibitors	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-1.4	-7.19	4.4	VERY LOW	NA	NA	NA	-1.4	-7.19	4.4	VERY LOW	RoB, Inconsistency, Imprecisionx2
El symbles	IL1 inhibitors	methylene blue	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	3.41	-4.01	10.77	VERY LOW	NA	NA	NA	3.41	-4.01	10.77	VERY LOW	RoBx2, Imprecisionx2
It inhibitions	IL1 inhibitors	recombinant human granulocyte colony-stimulating factor	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.32	-9.19	8.54	VERY LOW	NA	NA	NA	-0.32	-9.19	8.54	VERY LOW	RoB, Imprecisionx2
I.1 s in bibbiss Staffer NA NA NA NA NA NA NA N	IL1 inhibitors	remdesivir				NA	NA	NA	NA				-0.46	-6.43	5.51	VERY LOW	NA			-0.46	-6.43	5.51		RoB, Imprecisionx2
	IL1 inhibitors	serine protease inhibitors	+		_	NA	NA	NA	NA	-			-0.54							-0.54			-	RoB, Imprecisionx2
L1 milbilitors unifferon first MA NA NA NA NA NA NA NA		statins			<u> </u>									_										RoB, Imprecisionx2
IL 1 minibliors Vatamin C	IL1 inhibitors	tyrosine kinase inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-1.68	-10.55	7.21	VERY LOW	NA	NA	NA	-1.68	-10.55	7.21	VERY LOW	RoB, Imprecisionx2
E.1 Inchibitors Summo	IL1 inhibitors	umifenovir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.21	-6.52	6.94	VERY LOW	NA	NA	NA	0.21	-6.52	6.94	VERY LOW	RoB, Imprecisionx2
El receptor antiagentis will'out confociolescode (presented) NA NA NA NA NA NA NA N	IL1 inhibitors	vitamin C			_	NA	NA	NA	NA	-			-	-7.84		-				-		-		RoB, Imprecisionx2
Expression analysis without controlleriodic systems or interferon beta (subcularrecus) Na	IL1 inhibitors	vitamin D	+		1.0.	NA	NA	NA					-				-			+		7.01	+	RoB, Imprecisionx2
I. In receptor analogonists without controllerousles (systemic) interferon betta (budoutamous), lognature/interview NA NA NA NA NA NA NA N				_	_																			RoB, Imprecisionx2
Lift receptor arriagonists without confoosteroids (systemic) Engineeric receptor arriagonists without confoosteroids (systemic) Engineeric receptor arriagonists without confoosteroids (systemic) Refl. (specific receptor arriagonists) Refl. (specific receptor arriagonists) without confoosteroids (systemic) Refl. (specific receptor arriagonists)		` '														-	-			_				RoB, Imprecisionx2
El. receptor antagonists without confociateroids (systemic) Restriction Restriction					_																			RoB, Imprecisionx2
L.G. receptor antiagonists without confoositerositis (systemic) Loginusi-intensive NA NA NA NA NA NA NA N			+	_	_			_									_							
ILG receptor antagonists without controlesteroids (systemic) ILG receptor antagonists wit	1 111/11 1 1131 111 1111 1111 1111 1111			_		-		+																
Life receptor antagonists without confloateroids (systemic) recombinant human graulocyte colony-stimulating factor NA NA NA NA NA NA NA N		TP TO THE PROPERTY OF THE PROP			_			1.0.					_			 								
ILS receptor antagonists without corticosteroids (systemic) rendesivir NA		,	+				+	+			-		_	-		-	_			_			+	
L6 receptor antiagonists without confoosteroids (systemic) Sertine professe inhibitors NA NA NA NA NA NA NA N		0 1 1	_	_	-																			· '
IL6 receptor antagonists without corticosteroids (systemic) Statins NA NA NA NA NA NA NA N			+	_			+		_				-	+									+	
IL6 receptor antagonists without corticosteroids (systemic) Uyrosine kinase inhibitors NA NA NA NA NA NA NA N			_		_	_	_	_	_				_				_							. , ,
LiG receptor antagonists without corticosteroids (systemic)		0.000.00			_		_									-						-		
L6 receptor antagonists without corticosteroids (systemic)		3		_	_		_	+								-	_							· '
LiG receptor antagonists without corticosteroids (systemic) vitamin D				_	_								_											RoB, Imprecisionx2
interferon alfa (subcutaneous)			+				+	+			-		_				-			_			+	RoB, Imprecisionx2
interferon alfa (subcutaneous) interferon beta (subcutaneous), lopinavir-ritonavir NA		***	+	+	_	_	_	+							_		_		_					RoB, Imprecisionx2
interferon alfa (subcutaneous) NA								NA	NA NA					-	5.01	-	-					5.01		RoB, Imprecisionx2
Interferon alfa (subcutaneous) JAK inhibitors NA NA NA NA NA NA NA NA NA N	interferon alfa (subcutaneous)	, , , ,			_		NA								6.64							6.64		RoB, Imprecisionx2
Interferon alfa (subcutaneous) methylene blue NA NA NA NA NA NA NA NA NA N	interferon alfa (subcutaneous)	JAK inhibitors	+	NA	NA				_	NA	NA	NA			7.1		NA	NA	NA					RoB, Imprecisionx2
Interferon alfa (subcutaneous) methylene blue NA NA NA NA NA NA NA NA NA N	interferon alfa (subcutaneous)	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.32	-6.23	5.58	VERY LOW	NA	NA	NA	-0.32	-6.23	5.58	VERY LOW	RoB, Inconsistency, Imprecisionx2
interferon alfa (subcutaneous) remdesivir NA		methylene blue						_	_						11.96							11.96		RoBx2, Imprecisionx2
interferon alfa (subcutaneous) serine protease inhibitors NA	interferon alfa (subcutaneous)	recombinant human granulocyte colony-stimulating factor	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.76	-8.2	9.67	VERY LOW	NA	NA	NA	0.76	-8.2	9.67	VERY LOW	RoB, Imprecisionx2
interferon alfa (subcutaneous) statins NA	interferon alfa (subcutaneous)	remdesivir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.61	-5.47	6.7	VERY LOW	NA	NA	NA	0.61	-5.47	6.7	VERY LOW	RoB, Imprecisionx2
interferon alfa (subcutaneous) tyrosine kinase inhibitors NA	interferon alfa (subcutaneous)	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.53	-6.87	7.91	VERY LOW	NA	NA	NA	0.53	-6.87	7.91	VERY LOW	RoB, Imprecisionx2
interferon alfa (subcutaneous) umifenovir NA	interferon alfa (subcutaneous)	statins		_	_	NA	NA	NA	NA				1.06	-6.16	8.25	VERY LOW				1.06	-6.16	8.25		RoB, Imprecisionx2
	interferon alfa (subcutaneous)	tyrosine kinase inhibitors		_	_	NA	NA	NA	NA			NA	-0.59	-9.58	8.31	VERY LOW	NA			-0.59	-9.58	8.31		RoB, Imprecisionx2
		umifenovir		_	_		_						_											RoB, Imprecisionx2
	interferon alfa (subcutaneous)	vitamin C	+			NA	NA	NA	NA	NA			-	-	7.31	VERY LOW	-			-		7.31	+	RoB, Imprecisionx2
	interferon alfa (subcutaneous)	vitamin D	+	+	_	NA	NA	NA	NA	NA			_			VERY LOW	NA			1.97	-4.89	8.84		RoB, Imprecisionx2
	interferon beta (subcutaneous)	interferon beta (subcutaneous), lopinavir-ritonavir	+	_	NA	NA	NA	NA	NA	NA	NA	NA	-2.45	-8.39	3.48	VERY LOW	NA		NA	-2.45	-8.39	3.48	VERY LOW	RoB, Imprecisionx2
	interferon beta (subcutaneous)	ivermectin	_		_	NA	NA	NA	NA				0.07	-4.77	4.95		_				-4.77	4.95		RoB, Imprecision
		0, u. m.			_				101															RoB, Imprecisionx2
interferon beta (subcutaneous) lopinavir-ritonavir NA	interferon beta (subcutaneous)	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.54	-4.74	3.68	VERY LOW	NA	NA	NA	-0.54	-4.74	3.68	VERY LOW	RoB, Inconsistency, Imprecision

								Duration of h	nospitaliz <u>a</u> t	ion													
Comparison		Direct es	stimate						Indirect e	estimate						Network e	estimate						
		Relative	estimate		Absolute	estimate	(per 1,000)		Relative e	stimate		Absolute (estimate (p	per 1,000)		Relative es	stimate	,	Absolute e	stimate (pe	er 1,000)		
				CI upper	Point	CI lower	CI upper	Final rating	Point	CI lower	CI upper	Point	CI lower	CI upper	Final rating		CI lower	CI	Point	CI lower	CI upper	Final rating	
Treatment 1	Treatment 2	estimate	limit	limit	estimate	limit	limit		estimate	limit	limit	estimate	limit	limit		estimate	limit	limit	estimate	limit	limit		Reasons for downgrading
interferon beta (subcutaneous)	methylene blue	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	4.27	-2.01	10.46	VERY LOW	NA	NA	NA	4.27	-2.01	10.46	VERY LOW	RoBx2, Imprecisionx2
interferon beta (subcutaneous)	recombinant human granulocyte colony-stimulating factor	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.53	-7.39	8.45	VERY LOW	NA	NA	NA	0.53	-7.39	8.45	VERY LOW	RoB, Imprecisionx2
interferon beta (subcutaneous)	remdesivir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.41	-4.09	4.88	LOW	NA	NA	NA	0.41	-4.09	4.88	LOW	RoB, Imprecision
interferon beta (subcutaneous)	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.31	-5.79	6.45	VERY LOW	NA	NA	NA	0.31	-5.79	6.45	VERY LOW	RoB, Imprecisionx2
interferon beta (subcutaneous)	statins	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.84	-5.07	6.74	VERY LOW	NA	NA	NA	0.84	-5.07	6.74	VERY LOW	RoB, Imprecisionx2
interferon beta (subcutaneous)	tyrosine kinase inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.83	-8.74	7.14	VERY LOW	NA	NA	NA	-0.83	-8.74	7.14	VERY LOW	RoB, Imprecisionx2
interferon beta (subcutaneous)	umifenovir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	1.08	-4.39	6.51	VERY LOW	NA	NA	NA	1.08	-4.39	6.51	VERY LOW	RoB, Imprecisionx2
interferon beta (subcutaneous)	vitamin C	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	-5.77	5.75	VERY LOW	NA	NA	NA	0	-5.77	5.75	VERY LOW	RoB, Imprecisionx2
interferon beta (subcutaneous)	vitamin D	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	1.76	-3.71	7.25	VERY LOW	NA	NA	NA	1.76	-3.71	7.25	VERY LOW	RoB, Imprecisionx2
interferon beta (subcutaneous), lopinavir-ritonavir	ivermectin	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	2.54	-3.55	8.61	VERY LOW	NA	NA	NA	2.54	-3.55	8.61	VERY LOW	RoB, Imprecisionx2
interferon beta (subcutaneous), lopinavir-ritonavir	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	3.27	-2.57	9.12	VERY LOW	NA	NA	NA	3.27	-2.57	9.12	VERY LOW	RoB, Imprecisionx2
lopinavir-ritonavir	interferon beta (subcutaneous), lopinavir-ritonavir	NA	NA	NA	-1	-2.63	0.63	LOW	NA	NA	NA	-0.01	-8.82	8.88	VERY LOW	NA	NA	NA	-1.92	-7.12	3.29	VERY LOW	RoB, Imprecision
interferon beta (subcutaneous), lopinavir-ritonavir	methylene blue	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	6.72	-0.55	13.93	VERY LOW	NA	NA	NA	6.72	-0.55	13.93	VERY LOW	RoBx2, Imprecisionx2
interferon beta (subcutaneous), lopinavir-ritonavir	recombinant human granulocyte colony-stimulating factor	NA	NA	NA	NA	NA	NA	NA NA	NA	NA	NA	2.99	-5.79	11.78	VERY LOW	NA NA	NA	NA	2.99	-5.79	11.78	VERY LOW	RoB, Imprecisionx2
interferon beta (subcutaneous), lopinavir-ritonavir	remdesivir	NA NA	NA	NA	NA	NA NA	NA	NA NA	NA NA	NA NA	NA	2.85	-2.96	8.66	VERY LOW	NA NA	NA	NA	2.85	-2.96	8.66	VERY LOW	RoB, Imprecisionx2
interferon beta (subcutaneous), lopinavir-ritonavir	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	2.77	-4.4	9.89	VERY LOW	NA	NA	NA	2.77	-4.4	9.89	VERY LOW	RoB, Imprecisionx2
interferon beta (subcutaneous), lopinavir-ritonavir	statins	NA NA	NA	NA	NA	NA NA	NA	NA NA	NA NA	NA NA	NA	3.28	-3.7	10.24	VERY LOW	NA NA	NA	NA	3.28	-3.7	10.24	VERY LOW	RoB, Imprecisionx2
interferon beta (subcutaneous), lopinavir-ritonavir	tyrosine kinase inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	1.62	-7.11	10.42	VERY LOW	NA	NA	NA	1.62	-7.11	10.42	VERY LOW	RoB, Imprecisionx2
interferon beta (subcutaneous), lopinavir-ritonavir	umifenovir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	3.53	-3.05	10.11	VERY LOW	NA NA	NA	NA	3.53	-3.05	10.11	VERY LOW	RoB, Imprecisionx2
interferon beta (subcutaneous), lopinavir-ritonavir	vitamin C	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	2.47	-4.37	9.28	VERY LOW	NA	NA	NA	2.47	-4.37	9.28	VERY LOW	RoB, Imprecisionx2
interferon beta (subcutaneous), lopinavir-ritonavir	vitamin D	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	4.21	-2.39	10.83	VERY LOW	NA	NA	NA	4.21	-2.39	10.83	VERY LOW	RoB, Imprecisionx2
ivermectin	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.74	-3.96	5.4	VERY LOW	NA	NA	NA	0.74	-3.96	5.4	VERY LOW	RoB, Imprecisionx2
ivermectin	lopinavir-ritonavir	NA	NA	NA	NA	NA NA	NA	NA NA	NA	NA	NA	-0.62	-5	3.78	VERY LOW	NA	NA	NA	-0.62	-5	3.78	VERY LOW	RoB, Inconsistency, Imprecisionx2
ivermectin	methylene blue	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	4.18	-2.24	10.57	VERY LOW	NA	NA	NA	4.18	-2.24	10.57	VERY LOW	RoBx2, Imprecisionx2
ivermectin	recombinant human granulocyte colony-stimulating factor	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.47	-7.61	8.51	VERY LOW	NA	NA	NA	0.47	-7.61	8.51	VERY LOW	RoB, Imprecisionx2
ivermectin	remdesivir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.32	-4.39	5	LOW	NA	NA	NA	0.32	-4.39	5	LOW	RoB, Imprecision
ivermectin	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.23	-6.02	6.49	VERY LOW	NA	NA	NA	0.23	-6.02	6.49	VERY LOW	RoB, Imprecisionx2
ivermectin	statins	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.74	-5.3	6.85	VERY LOW	NA	NA	NA	0.74	-5.3	6.85	VERY LOW	RoB, Imprecisionx2
ivermectin	tyrosine kinase inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.89	-8.99	7.19	VERY LOW	NA	NA	NA	-0.89	-8.99	7.19	VERY LOW	RoB, Imprecisionx2
ivermectin	umifenovir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.99	-4.59	6.62	VERY LOW	NA	NA	NA	0.99	-4.59	6.62	VERY LOW	RoB, Imprecisionx2
ivermectin	vitamin C	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.07	-6	5.8	VERY LOW	NA	NA	NA	-0.07	-6	5.8	VERY LOW	RoB, Imprecisionx2
ivermectin	vitamin D	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	1.68	-3.96	7.3	VERY LOW	NA	NA	NA	1.68	-3.96	7.3	VERY LOW	RoB, Imprecisionx2
JAK inhibitors	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-1.36	-5.38	2.67	VERY LOW	NA	NA	NA	-1.36	-5.38	2.67	VERY LOW	RoB, Inconsistency, Imprecisionx2
JAK inhibitors	methylene blue	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	3.45	-2.66	9.53	VERY LOW	NA	NA	NA	3.45	-2.66	9.53	VERY LOW	RoBx2, Imprecisionx2
JAK inhibitors	recombinant human granulocyte colony-stimulating factor	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.28	-8.15	7.53	VERY LOW	NA	NA	NA	-0.28	-8.15	7.53	VERY LOW	RoB, Imprecisionx2
JAK inhibitors	remdesivir	NA NA	NA	NA	NA	NA NA	NA	NA NA	NA NA	NA NA	NA NA	-0.42	-4.71	3.9	LOW	NA NA	NA	NA	-0.42	-4.71	3.9	LOW	RoB, Imprecision
JAK inhibitors	serine protease inhibitors	NA	NA	NA	NA	NA NA	NA	NA NA	NA	NA NA	NA	-0.51	-6.48	5.49	VERY LOW	NA NA	NA	NA	-0.51	-6.48	5.49	VERY LOW	RoB, Imprecisionx2
JAK inhibitors	statins	NA NA	NA	NA	NA	NA NA	NA	NA NA	NA NA	NA NA	NA	0.01	-5.71	5.82	VERY LOW	NA NA	NA	NA	0.01	-5.71	5.82	VERY LOW	RoB, Imprecisionx2
JAK inhibitors	tyrosine kinase inhibitors	NA	NA	NA	NA	NA NA	NA	NA NA	NA NA	NA NA	NA	-1.64	-9.48	6.25	VERY LOW	NA NA	NA	NA	-1.64	-9.48	6.25	VERY LOW	RoB, Imprecisionx2
JAK inhibitors	umifenovir	NA NA	NA	NA	NA	NA NA	NA	NA NA	NA NA	NA NA	NA NA	0.27	-5.05	5.54	VERY LOW	NA NA	NA	NA	0.27	-5.05	5.54	VERY LOW	RoB, Imprecisionx2
JAK inhibitors	vitamin C	NA NA	NA	NA	NA	NA NA	NA NA	NA NA		NA NA	NA NA	-0.83	-6.47	4.8	VERY LOW	NA NA	NA	NA	-0.83	-6.47	4.8	VERY LOW	RoB, Imprecisionx2
JAK inhibitors	vitamin D	NA NA	NA	NA	NA	NA NA	NA	NA NA	NA NA	NA NA	NA NA	0.94	-4.38	6.27	VERY LOW	NA NA	NA NA	NA	0.94	-4.38	6.27	VERY LOW	RoB, Imprecisionx2
lopinavir-ritonavir	methylene blue	NA NA	NA	NA	NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	4.8	-1.09	10.69	VERY LOW	NA NA	NA NA	NA	4.8	-1.09	10.69	VERY LOW	RoBx2, Inconsistency, Imprecisionx2
lopinavir-ritonavir	recombinant human granulocyte colony-stimulating factor	NA NA	NA	NA	NA	NA NA	NA	NA NA	NA NA	NA NA	NA	1.07	-6.6	8.76	VERY LOW	NA NA	NA	NA	1.07	-6.6	8.76	VERY LOW	RoB, Inconsistency, Imprecisionx2
lopinavir-ritonavir	remdesivir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.94	-3.07	4.97 6.65	VERY LOW	NA NA	NA NA	NA NA	0.94	-3.07	4.97 6.65	VERY LOW	RoB, Inconsistency, Imprecision
lopinavir-ritonavir	serine protease inhibitors		_			NA NA		NA NA					-4.95		VERY LOW			_	0.85	-4.95			RoB, Inconsistency, Imprecisionx2
lopinavir-ritonavir	statins	NA NA	NA NA	NA NA	NA	NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.37	-4.21	6.91	VERY LOW	NA NA	NA NA	NA NA	1.37	-4.21	6.91	VERY LOW	RoB, Inconsistency, Imprecisionx2
lopinavir-ritonavir	tyrosine kinase inhibitors		_		NA NA	NA NA		NA NA				-0.29	-8	7.42	VERY LOW		_	_	-0.29	-8	7.42	VERY LOW	RoB, Inconsistency, Imprecisionx2
lopinavir-ritonavir	umifenovir	NA NA	NA	NA	NA	NA NA	NA	NA NA	NA NA	NA NA	NA	1.62	-3.45	6.67	VERY LOW	NA NA	NA	NA	1.62	-3.45	6.67	VERY LOW	RoB, Inconsistency, Imprecisionx2
lopinavir-ritonavir	vitamin C	NA NA	NA	NA NA	NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.54	-4.89	5.9	VERY LOW	NA NA	NA	NA	0.54	-4.89	5.9	VERY LOW	RoB, Inconsistency, Imprecisionx2
lopinavir-ritonavir	vitamin D	NA NA	NA	NA	NA	NA NA	NA	NA NA	NA NA	NA NA	NA NA	2.3	-2.8	7.36	VERY LOW	NA NA	NA NA	NA	2.3	-2.8	7.36	VERY LOW	RoB, Inconsistency, Imprecisionx2
methylene blue	recombinant human granulocyte colony-stimulating factor	NA NA	NA	NA	NA	NA NA	NA	NA NA	NA NA	NA NA	NA NA	-3.73	-12.7	5.24	VERY LOW	NA NA	NA	NA	-3.73	-12.7	5.24	VERY LOW	RoBx2, Imprecisionx2
methylene blue	remdesivir	NA NA	NA	NA	NA	NA NA	NA	NA NA	NA NA	NA NA	NA NA	-3.86	-9.95	2.24	VERY LOW	NA NA	NA	NA	-3.86	-9.95	2.24	VERY LOW	RoBx2, Imprecisionx2
methylene blue	serine protease inhibitors	NA NA	NA	NA	NA	NA 	NA	NA 	NA NA	NA NA	NA	-3.95	-11.35	3.46	VERY LOW	NA NA	NA	NA	-3.95	-11.35	3.46	VERY LOW	RoBx2, Imprecisionx2
methylene blue	statins	NA	NA	NA	NA	NA NA	NA	NA NA	NA	NA	NA	-3.43	-10.66	3.78	VERY LOW	NA NA	NA	NA	-3.43	-10.66	3.78	VERY LOW	RoBx2, Imprecisionx2
methylene blue	tyrosine kinase inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-5.08	-14.04	3.84	VERY LOW	NA	NA	NA	-5.08	-14.04	3.84	VERY LOW	RoBx2, Imprecisionx2

Complete network meta-analysis results and GRADE

								Duration of I	nospitalizat	ion													
Comparison		Direct es	stimate						Indirect e	estimate						Network	estimate						
		Relative 6	estimate		Absolute	estimate ((per 1,000)		Relative e	estimate		Absolute	estimate (p	er 1,000)		Relative e	estimate		Absolute e	estimate (pe	er 1,000)		
		Point	CI lower	CI upper	Point	CI lower	CI upper	Final rating	Point	CI lower	CI upper	Point	CI lower	CI upper	Final rating	Point	CI lower	CI	Point	CI lower	CI upper	Final rating	
Treatment 1	Treatment 2	estimate	limit	limit	estimate	limit	limit	ŭ	estimate	limit	limit	estimate	limit	limit		estimate		upper	estimate	limit	limit		Reasons for downgrading
methylene blue	umifenovir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-3.19	-9.99	3.67	VERY LOW	NA	NA	NA	-3.19	-9.99	3.67	VERY LOW	RoBx2, Imprecisionx2
methylene blue	vitamin C	NA NA	NA.	NA.	NA.	NA NA	NA NA	NA NA	NA NA	NA.	NA.	-4.27	-11.38	2.82	VERY LOW	NA NA	NA NA	NA.	-4.27	-11.38	2.82	VERY LOW	RoBx2, Imprecisionx2
methylene blue	vitamin D	NA NA	NA	NA.	NA.	NA NA	NA NA	NA NA	NA NA	NA NA	NA	-2.5	-9.33	4.37	VERY LOW	NA NA	NA	NA.	-2.5	-9.33	4.37	VERY LOW	RoBx2, Imprecisionx2
recombinant human granulocyte colony-stimulating factor	remdesivir	NA NA	NA.	NA.	NA.	NA NA	NA NA	NA NA	NA.	NA.	NA.	-0.14	-7.95	7.73	VERY LOW	NA NA	NA NA	NA.	-0.14	-7.95	7.73	VERY LOW	RoB, Imprecisionx2
recombinant human granulocyte colony-stimulating factor	serine protease inhibitors	NA NA	NA.	NA.	NA.	NA NA	NA NA	NA NA	NA NA	NA.	NA.	-0.22	-9.11	8.66	VERY LOW	NA NA	NA NA	NA.	-0.22	-9.11	8.66	VERY LOW	RoB, Imprecisionx2
recombinant human granulocyte colony-stimulating factor	statins	NA NA	NA	NA.	NA.	NA.	NA NA	NA NA	NA	NA	NA	0.29	-8.47	9.05	VERY LOW	NA	NA	NA	0.29	-8.47	9.05	VERY LOW	RoB, Imprecisionx2
recombinant human granulocyte colony-stimulating factor	tyrosine kinase inhibitors	NA NA	NA	NA	NA.	NA.	NA NA	NA NA	NA	NA	NA	-1.35	-11.57	8.91	VERY LOW	NA	NA	NA	-1.35	-11.57	8.91	VERY LOW	RoB, Imprecisionx2
recombinant human granulocyte colony-stimulating factor	umifenovir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.56	-7.89	8.96	VERY LOW	NA	NA	NA	0.56	-7.89	8.96	VERY LOW	RoB, Imprecisionx2
recombinant human granulocyte colony-stimulating factor	vitamin C	NA NA	NA	NA	NA.	NA.	NA NA	NA NA	NA	NA	NA	-0.54	-9.2	8.12	VERY LOW	NA	NA	NA	-0.54	-9.2	8.12	VERY LOW	RoB, Imprecisionx2
recombinant human granulocyte colony-stimulating factor	vitamin D	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	1.21	-7.21	9.69	VERY LOW	NA	NA	NA	1.21	-7.21	9.69	VERY LOW	RoB, Imprecisionx2
remdesivir	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.09	-6.04	5.9	VERY LOW	NA	NA	NA	-0.09	-6.04	5.9	VERY LOW	RoB, Imprecisionx2
remdesivir	statins	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.44	-5.34	6.21	VERY LOW	NA	NA	NA	0.44	-5.34	6.21	VERY LOW	RoB, Imprecisionx2
remdesivir	tyrosine kinase inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-1.23	-9.05	6.64	VERY LOW	NA	NA	NA	-1.23	-9.05	6.64	VERY LOW	RoB, Imprecisionx2
remdesivir	umifenovir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.69	-4.64	5.97	VERY LOW	NA	NA	NA	0.69	-4.64	5.97	VERY LOW	RoB, Imprecisionx2
remdesivir	vitamin C	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.41	-6.06	5.19	VERY LOW	NA	NA	NA	-0.41	-6.06	5.19	VERY LOW	RoB, Imprecisionx2
remdesivir	vitamin D	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	1.36	-3.97	6.67	VERY LOW	NA	NA	NA	1.36	-3.97	6.67	VERY LOW	RoB, Imprecisionx2
serine protease inhibitors	statins	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.51	-6.58	7.63	VERY LOW	NA	NA	NA	0.51	-6.58	7.63	VERY LOW	RoB, Imprecisionx2
serine protease inhibitors	tyrosine kinase inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-1.14	-10.03	7.76	VERY LOW	NA	NA	NA	-1.14	-10.03	7.76	VERY LOW	RoB, Imprecisionx2
serine protease inhibitors	umifenovir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.77	-5.95	7.47	VERY LOW	NA	NA	NA	0.77	-5.95	7.47	VERY LOW	RoB, Imprecisionx2
serine protease inhibitors	vitamin C	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.33	-7.28	6.69	VERY LOW	NA	NA	NA	-0.33	-7.28	6.69	VERY LOW	RoB, Imprecisionx2
serine protease inhibitors	vitamin D	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	1.42	-5.33	8.2	VERY LOW	NA	NA	NA	1.42	-5.33	8.2	VERY LOW	RoB, Imprecisionx2
statins	tyrosine kinase inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-1.63	-10.4	7.12	VERY LOW	NA	NA	NA	-1.63	-10.4	7.12	VERY LOW	RoB, Imprecisionx2
statins	umifenovir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.25	-6.32	6.76	VERY LOW	NA	NA	NA	0.25	-6.32	6.76	VERY LOW	RoB, Imprecisionx2
statins	vitamin C	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.83	-7.63	5.97	VERY LOW	NA	NA	NA	-0.83	-7.63	5.97	VERY LOW	RoB, Imprecisionx2
statins	vitamin D	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.92	-5.66	7.51	VERY LOW	NA	NA	NA	0.92	-5.66	7.51	VERY LOW	RoB, Imprecisionx2
tyrosine kinase inhibitors	umifenovir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	1.89	-6.52	10.3	VERY LOW	NA	NA	NA	1.89	-6.52	10.3	VERY LOW	RoB, Imprecisionx2
tyrosine kinase inhibitors	vitamin C	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.82	-7.85	9.43	VERY LOW	NA	NA	NA	0.82	-7.85	9.43	VERY LOW	RoB, Imprecisionx2
tyrosine kinase inhibitors	vitamin D	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	2.59	-5.85	11.03	VERY LOW	NA	NA	NA	2.59	-5.85	11.03	VERY LOW	RoB, Imprecisionx2
umifenovir	vitamin C	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-1.09	-7.49	5.3	VERY LOW	NA	NA	NA	-1.09	-7.49	5.3	VERY LOW	RoB, Imprecisionx2
umifenovir	vitamin D	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.67	-5.45	6.83	VERY LOW	NA	NA	NA	0.67	-5.45	6.83	VERY LOW	RoB, Imprecisionx2
vitamin C	vitamin D	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	1.76	-4.67	8.21	VERY LOW	NA	NA	NA	1.76	-4.67	8.21	VERY LOW	RoB, Imprecisionx2

Complete network meta-analysis results and GRADE

Expectage in the production of the production									0	uration of mecha	anical ventila	tion													
Point Clawer Cl				Direct es	timate						Indirect e	stimate						Network 6	estimate						
Treatment 1 Treatment 2 estimate limit limit estima				Relative e	estimate		Absolute	e estimate (per 1,000)		Relative e	stimate		Absolute e	estimate (p	er 1,000)		Relative	estimate		Absolute	estimate (per 1,000)		
Conficionationis (systemic) Standard careplacebo NA NA NA NA NA NA NA N					CI lowe	r Cl upper				Final rating		CI lower	CI upper	Point			Final rating	Point		CI upper	Point	CI lower	CI upper	Final rating	
LB receptor antagonists with corticosteroids (systemic) standard carelpiacebo NA NA NA NA NA NA NA N	Treatment 1	Treatment 1	Treatment 2		limit	limit	estimate		_		estimate	limit	limit	estimate	limit	limit			limit	limit	estimate	limit	limit		Reasons for downgrading
Full-dose enticoagulant Standard care-placebo NA NA NA NA NA NA NA N	orticosteroids (systemic)	corticosteroids (systemic)	standard care/placebo		NA	NA	-1.4				NA	NA	NA	NA	NA	NA				NA	-1.41				RoB, Imprecision
ILG receptor antagonisis without corticosteroids (systemic) standard carelylacebo NA	agonists with corticosteroids (systemic)	tor antagonists with corticosteroids (systemic)	standard care/placebo	NA	NA	NA	-0.97	-2.24	0.29		NA	NA	NA	NA	NA	NA	NA		NA	NA	-0.97	-2.23	0.23	LOW	RoB, Imprecision
Interferon beta (subcutaneous) Standard care/placebo NA	full-dose anticoagulant	full-dose anticoagulant	standard care/placebo	NA	NA	NA	-0.3	-1.76	1.16	LOW	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.3	-1.5	0.9	LOW	RoB, Imprecision
JAK imbibitors Standard care/placebo NA NA NA NA NA NA NA N	gonists without corticosteroids (systemic)	r antagonists without corticosteroids (systemic)	standard care/placebo	NA	NA	NA	-1.63	-3.35	0.08	LOW	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-1.6	-3.33	0.11	LOW	RoB, Imprecision
remdesivir standard care/placebo NA NA NA NA NA NA NA N	rferon beta (subcutaneous)	interferon beta (subcutaneous)	standard care/placebo	NA	NA	NA	1.2	-0.43	2.86	LOW	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	1.19	-0.31	2.73	LOW	RoB, Imprecision
Corticosteroids (systemic) IL6 receptor antagonists with corticosteroids (systemic) NA	JAK inhibitors	JAK inhibitors	standard care/placebo	NA	NA	NA	-3.19	-5.9	-0.48	HIGH	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-3.24	-5.89	-0.53	HIGH	
Corticosteroids (systemic) ILG receptor antagonists with corticosteroids	remdesivir	remdesivir	standard care/placebo	NA	NA	NA	-1.25	-3.97	1.45	LOW	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-1.25	-3.89	1.43	LOW	Imprecisionx2
corticosteroids (systemic) IL6 receptor antagonists without corticosteroids (systemic) IL6 receptor antagonists with corticosteroi	orticosteroids (systemic)	corticosteroids (systemic)	IL6 receptor antagonists with corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.42	-2.75	1.95	LOW	NA	NA	NA	-0.42	-2.75	1.95	LOW	RoB, Imprecision
Corticosteroids (systemic) interferon beta (subcutaneous) NA	orticosteroids (systemic)	corticosteroids (systemic)	full-dose anticoagulant	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-1.1	-3.45	1.23	LOW	NA	NA	NA	-1.1	-3.45	1.23	LOW	RoB, Imprecision
Corticosteroids (systemic) Gradesivir NA NA NA NA NA NA NA NA NA N	orticosteroids (systemic)	corticosteroids (systemic)	IL6 receptor antagonists without corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.2	-2.44	2.86	LOW	NA	NA	NA	0.2	-2.44	2.86	LOW	RoB, Imprecision
Corticosteroids (systemic) remdesivir NA NA NA NA NA NA NA NA NA N	orticosteroids (systemic)	corticosteroids (systemic)	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-2.58	-5.14	-0.14	MODERATE	NA	NA	NA	-2.58	-5.14	-0.14	MODERATE	RoB
IL6 receptor antagonists with corticosteroids (systemic) full-dose anticoagulant NA	orticosteroids (systemic)	corticosteroids (systemic)	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	1.84	-1.52	5.13	VERY LOW	NA	NA	NA	1.84	-1.52	5.13	VERY LOW	RoB, Imprecisionx2
IL6 receptor antagonists with corticosteroids (systemic) IL6 receptor antagonists without corticosteroids (systemic) IL6 receptor antagonists without corticosteroids (systemic) IL6 receptor antagonists with corticosteroids (systemic) JAK inhibitors NA	orticosteroids (systemic)	corticosteroids (systemic)	remdesivir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.15	-3.52	3.19	LOW	NA	NA	NA	-0.15	-3.52	3.19	LOW	RoB, Imprecision
IL6 receptor antagonists with corticosteroids (systemic) Interferon beta (subcutaneous) NA	agonists with corticosteroids (systemic)	tor antagonists with corticosteroids (systemic)	full-dose anticoagulant	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.68	-2.42	1.01	LOW	NA	NA	NA	-0.68	-2.42	1.01	LOW	RoB, Imprecision
IL6 receptor antagonists with corticosteroids (systemic) JAK inhibitors NA	agonists with corticosteroids (systemic)	tor antagonists with corticosteroids (systemic)	IL6 receptor antagonists without corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.62	-1.51	2.72	LOW	NA	NA	NA	0.62	-1.51	2.72	LOW	RoB, Imprecision
IL6 receptor antagonists with corticosteroids (systemic) remdesivir NA	agonists with corticosteroids (systemic)	tor antagonists with corticosteroids (systemic)	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-2.15	-4.21	-0.28	MODERATE	NA	NA	NA	-2.15	-4.21	-0.28	MODERATE	RoB
full-dose anticoagulant IL6 receptor antagonists without corticosteroids (systemic) NA NA <td>agonists with corticosteroids (systemic)</td> <td>tor antagonists with corticosteroids (systemic)</td> <td>JAK inhibitors</td> <td>NA</td> <td>2.25</td> <td>-0.71</td> <td>5.27</td> <td>VERY LOW</td> <td>NA</td> <td>NA</td> <td>NA</td> <td>2.25</td> <td>-0.71</td> <td>5.27</td> <td>VERY LOW</td> <td>RoB, Imprecisionx2</td>	agonists with corticosteroids (systemic)	tor antagonists with corticosteroids (systemic)	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	2.25	-0.71	5.27	VERY LOW	NA	NA	NA	2.25	-0.71	5.27	VERY LOW	RoB, Imprecisionx2
full-dose anticoagulant interferon beta (subcutaneous) NA	agonists with corticosteroids (systemic)	tor antagonists with corticosteroids (systemic)	remdesivir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.27	-2.66	3.09	LOW	NA	NA	NA	0.27	-2.66	3.09	LOW	RoB, Imprecision
full-dose anticoagulant JAK inhibitors NA	full-dose anticoagulant	full-dose anticoagulant	IL6 receptor antagonists without corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	1.3	-0.81	3.43	LOW	NA	NA	NA	1.3	-0.81	3.43	LOW	RoB, Imprecision
full-dose anticoagulant remdesivir NA	full-dose anticoagulant	full-dose anticoagulant	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-1.49	-3.47	0.42	LOW	NA	NA	NA	-1.49	-3.47	0.42	LOW	RoB, Imprecision
	full-dose anticoagulant	full-dose anticoagulant	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	2.96	-0.03	5.84	VERY LOW	NA	NA	NA	2.96	-0.03	5.84	VERY LOW	RoB, Imprecisionx2
	full-dose anticoagulant	full-dose anticoagulant	remdesivir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.96	-1.99	3.84	LOW	NA	NA	NA	0.96	-1.99	3.84	LOW	RoB, Imprecision
IL6 receptor antagonists without corticosteroids (systemic) interferon beta (subcutaneous) NA	gonists without corticosteroids (systemic)	r antagonists without corticosteroids (systemic)	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-2.78	-5.13	-0.55	MODERATE	NA	NA	NA	-2.78	-5.13	-0.55	MODERATE	RoB
IL6 receptor antagonists without corticosteroids (systemic) JAK inhibitors NA NA NA NA NA NA NA NA NA N	gonists without corticosteroids (systemic)	r antagonists without corticosteroids (systemic)	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	1.64	-1.61	4.85	LOW	NA	NA	NA	1.64	-1.61	4.85	LOW	RoB, Imprecision
IL6 receptor antagonists without corticosteroids (systemic) remdesivir NA	gonists without corticosteroids (systemic)	r antagonists without corticosteroids (systemic)	remdesivir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.38	-3.53	2.86	LOW	NA	NA	NA	-0.38	-3.53	2.86	LOW	RoB, Imprecision
interferon beta (subcutaneous) JAK inhibitors NA NA NA NA NA NA NA NA NA N	rferon beta (subcutaneous)	interferon beta (subcutaneous)	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	4.42	1.39	7.48	MODERATE	NA	NA	NA	4.42	1.39	7.48	MODERATE	RoB
interferon beta (subcutaneous) remdesivir NA	rferon beta (subcutaneous)	interferon beta (subcutaneous)	remdesivir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	2.42E+00	-0.65	5.53	VERY LOW	NA	NA	NA	2.42	-0.65	5.53	VERY LOW	RoB, Imprecisionx2
JAK inhibitors remdesivir NA	JAK inhibitors	JAK inhibitors	remdesivir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-2.00E+00	-5.7	1.81	LOW	NA	NA	NA	-2	-5.7	1.81	LOW	Imprecisionx2

									Mecha	anical ventil	lation															
Comparison		Direct est	timate					Indirect es							Network es	stimate										
		Relative e			ute estimate (p	. ,,	Final collin	Relative es				stimate (per		Final Control	Relative e					per 1,000)	GRADE				Final coffee	
Treatment 1	Treatment 2	Point estimate	CI lower limit	Cl upper Poi	nt CI lower ate limit	CI upper limit	Final rating	Point estimate	CI lower limit	CI upper limit	Point	CI lower limit	CI upper limit	Final rating	Point	CI lower limit	CI upper limit	Point estimate	CI lower	CI upper limit	Starting evidence	Starting rating	Incoherence	Imprecision	Final rating	Reasons for downgrading
ACEi/ARB	standard care/placebo	1	0.63	1.59 0.1		56.69	LOW	NA	NA	NA.	NA	NA	NA	NA	1	0.67	1.5	1.33	-35.63	48.3	Direct	MODERATE	Not serious	Serious	LOW	RoB. Imprecision
(acetyl)cysteine	standard care/placebo	0.82	0.35	1.93 -19			LOW	NA	NA	NA.	NA	NA	NA	NA.	0.82	0.42	1.56	-16.09	-63.53	52.96	Direct	HIGH	Not serious	Very serious	LOW	Imprecisionx2
antihepaciviral	standard care/placebo	0.73	0.34	1.46 -28.		44.32	VERY LOW	0.43	0.05	2.44	-62.92	-109.69	126.83	VERY LOW	0.72	0.42	1.23	-27	-64.23	22.4	Direct	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
aspirin	standard care/placebo	0.89	0.34	1.92 -11.	36 -73.72	85.63	VERY LOW	NA	NA	NA	NA	NA	NA	NA	0.91	0.6	1.32	-8.42	-43.09	31.81	Direct	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
aspirin, statins	standard care/placebo	1.33	0.27	6.64 32.	91 -82.04	349.47	VERY LOW	NA	NA	NA	NA	NA	NA	NA	1.59	0.55	4.43	69.01	-49.43	250.74	Direct	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
azithromycin	standard care/placebo	0.94	0.53	1.53 -5.8	2 -50.57	51.49	LOW	0.74	0.2	2.61	-27.52	-90.3	138.8	VERY LOW	0.93	0.67	1.27	-6.01	-34.69	26.35	Direct	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
azithromycin, hydroxychloroquine	standard care/placebo	1.81	0.61	5.56 75.	93 -41.6	305.63	VERY LOW	NA	NA	NA	NA	NA	NA	NA	1.75	0.89	3.38	75.56	-9.76	191	Direct	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
azithromycin, NSAID	standard care/placebo	NA	NA	NA N		NA	NA	0.31	0.01	2.75	-55.51	-114.97	156.21	VERY LOW	0.31	0.01	2.75	-55.51	-114.97	156.21	Indirect	MODERATE	#N/A	Extremely serious	VERY LOW	RoB, Imprecisionx3
azithromycin, NSAID, corticosteroid	standard care/placebo	NA	NA	NA N		NA	NA	0.64	0.07	4.64	-8.49	-107.19	269.42	VERY LOW	0.64	0.07	4.64	-8.49	-107.19	269.42	Indirect	MODERATE	#N/A	Extremely serious	VERY LOW	RoB, Imprecisionx3
colchicine	standard care/placebo	0.75	0.37	1.26 -26.		25.69	VERY LOW	NA	NA	NA	NA	NA	NA	NA	0.8	0.53	1.1	-20.96	-50.59	10.59	Direct	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
colchicine, emtricitabine, tenofovir, statins	standard care/placebo	0.69	0.17	2.73 -32.			VERY LOW	NA	NA	NA	NA	NA	NA	NA	0.69	0.33	1.47	-28.59	-75.32	44.92	Direct	MODERATE	#N/A	Very serious		RoB, Imprecisionx2
colchicine, statins	standard care/placebo	1.04	0.27	4.04 3.7			VERY LOW	NA	NA	NA	NA	NA	NA	NA	1.04	0.51	2.13	9.69	-53.68	104.16	Direct	MODERATE	#N/A	Very serious		RoB, Imprecisionx2
corticosteroids (systemic)	standard care/placebo	0.79	0.52	1.15 -22			LOW	NA	NA	NA	NA	NA	NA	NA	0.79	0.58	1.05	-22.26	-45.13	4.3	Direct	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
IL6 receptor antagonists with corticosteroids (systemic)	standard care/placebo	0.79	0.63	0.99 -22.	01 00.00		MODERATE	NA	NA	NA	NA	NA	NA	NA	0.79	0.63	0.98	-21.95	-39.04	-2.23	Direct	MODERATE	#N/A	Not Serious	MODEIGNIE	RoB
doxycycline	standard care/placebo	0.49	0.08	3.16 -55. 3.1 -22		111.20	VERY LOW	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.47	0.08	2.18	-43.75 -17.85	-105.02 -69.46	101.96 60.87	Direct	MODERATE	#N/A #N/A	Very serious		RoB, Imprecisionx2
emtricitabine, tenofovir	standard care/placebo	0.79	0.2									NA NA	NA		0.79	0.38	1.64							Very serious		RoB, Imprecisionx2
favipiravir favipiravir, hydrochloroquine	standard care/placebo standard care/placebo	1.31	0.47	3.71 30. 4.42 10.		_	VERY LOW	1.35 NA	0.64 NA	2.83 NA	34.79 NA	-38.74 NA	154.77 NA	VERY LOW NA	1.44	0.78	2.62	47.12 16.42	-23.13 -54.28	141.72 124.45	Direct	MODERATE	Not serious #N/A	Very serious Very serious		RoB, Imprecisionx2 RoB, Imprecisionx2
favipiravir, nydrochioroquine fluvoxamine	standard care/placebo standard care/placebo	0.72	0.27	2.11 -29.			LOW	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.73	0.5	1.42	-24 81	-54.28 -68.35	38.63	Direct	HIGH	#N/A #N/A	Very serious Very serious	LOW	Imprecisionx2
full-dose anticoagulant	standard care/placebo	0.72	0.22	1.77 -36.			VERYLOW	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.73	0.33	1.26	-34.27	-74.62	24.42	Direct	MODERATE	Not serious	Very serious		RoB, Imprecisionx2
GM-CSF inhibitor	standard care/placebo	0.00	0.22	2.55 -7.0			VERY LOW	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.03	0.33	1.97	-2.57	-62.47	88.88	Direct	MODERATE	#N/A	Very serious		RoB. Imprecisionx2
(hydroxy)chloroquine	standard care/placebo	1.27	0.97	1.72 27.		67.77	LOW	1.47	0.64	3.38	45.37	-38.96	191.25	VERY LOW	1.27	1.03	1.61	28.26	3.26	57.59	Direct	MODERATE	Not serious	Not Serious	MODERATE	RoB, Imprecisioniza
IL1 inhibitors	standard care/placebo	0.79	0.36	1.71 -22.	_		LOW	NA.	NA NA	NA.	NA.	NA.	NA.	NA NA	0.8	0.44	1.44	-18.14	-61.07	41.67	Direct	HIGH	#N/A	Very serious	LOW	Imprecisionx2
IL6 receptor antagonists without corticosteroids (systemic)	standard care/placebo	0.59	0.33	1.07 -43			LOW	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.58	0.35	0.97	-43.84	-71.53	-5.49	Direct	HIGH	Not serious	Not Serious	HIGH	,
inhaled corticosteroids	standard care/placebo	1.02	0.24	4.44 2.3			VERY LOW	NA	NA	NA.	NA	NA	NA	NA.	1.03	0.4	2.67	11.33	-66.54	140.4	Direct	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
interferon alfa (subcutaneous)	standard care/placebo	1.69	0.18	15.68 65.	75 -92.68	556.9	VERY LOW	NA	NA	NA	NA	NA	NA	NA	2.71	0.2	44.83	195.32	-93.78	819.7	Direct	MODERATE	#N/A	Extremely serious	VERY LOW	RoB, Imprecisionx3
interferon beta (subcutaneous)	standard care/placebo	1.01	0.63	1.56 1.2	9 -39.74	53.9	LOW	NA	NA	NA	NA	NA	NA	NA	1.02	0.73	1.42	3.15	-28.37	40.58	Direct	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
interferon beta (subcutaneous), lopinavir-ritonavir	standard care/placebo	1.47	0.39	5.6 45.	62 -67.88	307.7	VERY LOW	2.73	0.44	25.38	148.05	-60.87	653.09	VERY LOW	1.55	0.92	2.59	56.51	-7.75	139.2	Direct	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
intermediate-dose anticoagulant	standard care/placebo	NA	NA	NA N	NA NA	NA	NA	1.11	0.44	2.71	18.86	-60.61	143.94	VERY LOW	1.11	0.44	2.71	18.86	-60.61	143.94	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
ivermectin	standard care/placebo	0.74	0.31	1.74 -27.	78 -76.89	70.06	VERY LOW	1.43	0.56	3.55	41.78	-47.65	201.75	VERY LOW	0.99	0.54	1.85	1.71	-50.4	75.36	Direct	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
JAK inhibitors	standard care/placebo	0.77	0.48	1.17 -23.	99 -56.78	17.45	MODERATE	NA	NA	NA	NA	NA	NA	NA	0.78	0.56	1.04	-23.21	-47.28	4.29	Direct	HIGH	Not serious	Serious	MODERATE	Imprecision
lopinavir-ritonavir	standard care/placebo	1.15	0.86	1.52 14.	93 -14.95	50.33	LOW	0.62	0.19	1.99	-40.39	-91.47	91.22	VERY LOW	1.11	0.87	1.4	12.04	-12.78	39.23	Direct	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
molnupiravir	standard care/placebo	1	0.02	59.74 0	110.01		VERY LOW	NA	NA	NA	NA	NA	NA	NA	0	0	4.97E+17	179.1	-116	884	Direct	MODERATE	#N/A	Extremely serious	VERY LOW	RoB, Imprecisionx3
proxalutamide	standard care/placebo	0.08	0.03	0.26 -105			VERY LOW	NA	NA	NA	NA	NA	NA	NA	0.06	0.02	0.15	-107.28	-113.38	-96.83	Direct	LOW	Not serious	Very serious		RoBx2, Imprecisionx2
recombinant human granulocyte colony-stimulating factor	standard care/placebo	0.16	0.04	0.62 -95.			VERY LOW	NA	NA	NA	NA	NA	NA	NA	0.15	0.07	0.33	-94.93	-106.91	-75.02	Direct	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
remdesivir	standard care/placebo	0.77	0.51	1.15 -23.		15.32	LOW	NA	NA	NA	NA	NA	NA	NA	0.79	0.6	1.01	-21.63	-42.36	0.87	Direct	MODERATE	Not serious	Serious		RoB, Imprecision
serine protease inhibitors	standard care/placebo	2.27	0.39	13.14 113		516.87	VERY LOW	NA	NA	NA	NA	NA	NA	NA	2.46	0.69	11.66	159.85	-33	497.49	Direct	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
SGLT2 inhibitors	standard care/placebo	0.81	0.22	2.97 -19.			LOW	NA	NA NA	NA NA	NA	NA NA	NA NA	NA NA	0.81	0.47	1.4	-17.48	-57.86	38.41	Direct	HIGH	#N/A	Serious	MODERATE	Imprecision
statins sulodexide	standard care/placebo standard care/placebo	0.96	0.23	3.85 -3.6 3.13 -54.			VERY LOW	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.26	0.43	3.51 2.03	36.08 -44.29	-64.64 -104.54	201.98 93.4	Direct	MODERATE	Not serious Not serious	Very serious Very serious	VERY LOW	RoB, Imprecisionx2 Imprecisionx2
tyrosine kinase inhibitors	standard care/placebo	0.5	0.08	1.37 -62			VERYLOW	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.47	0.09	1	-60.05	-104.54	-3.11	Direct	MODERATE	Not serious	Very serious Very serious	VFRYLOW	RoB, Imprecisionx2
tyrosine kinase minionors vitamin C	standard care/placebo	1.19	0.14	2.73 18.		147.41	VERY LOW	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.18	0.17	2.26	22.3	-94 -41.61	112.29	Direct	MODERATE	Not serious	Very serious Very serious	VERYLOW	RoB, Imprecisionx2
vitamin D	standard care/placebo	0.45	0.33	1.31 -59	-	31.09	LOW	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.45	0.01	1.02	-56.74	-91.58	0.11	Direct	HIGH	Not serious	Very serious	LOW	Imprecisionx2
ACFi/ARB	(acetyl)cysteine	NA.	NA.	NA N		NA	NA.	1.23	0.57	2.66	17.42	-60.65	85.14	VERYLOW	1.23	0.13	2.66	17.42	-60.65	85.14	Indirect	MODERATE	Not serious	Very serious		RoB, Imprecisionx2
ACFi/ARB	antihepaciviral	NA	NA	NA N		NA.	NA.	1.38	0.71	2.74	28.33	-33.09	88.71	VERY LOW	1.38	0.71	2.74	28.33	-33.09	88.71	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB. Imprecisionx2
ACE/ARB	aspirin	NA	NA NA	NA N		NA NA	NA NA	1.1	0.64	1.97	9.75	-44.51	68.22	VERY LOW	1.1	0.64	1.97	9.75	-44.51	68.22	Indirect	MODERATE	Not serious	Very serious		RoB, Imprecisionx2
ACEi/ARB	aspirin, statins	NA	NA	NA N		NA	NA	0.63	0.21	1.94	-67.68	-253.26	61.16	VERY LOW	0.63	0.21	1.94	-67.68	-253.26	61.16	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
ACEi/ARB	azithromycin	NA	NA	NA N		NA	NA	1.07	0.65	1.81	7.34	-42.29	62.38	LOW	1.07	0.65	1.81	7.34	-42.29	62.38	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
ACEi/ARB	azithromycin, hydroxychloroquine	NA	NA	NA N	NA NA	NA	NA	0.57	0.26	1.25	-74.23	-195.27	23.8	VERY LOW	0.57	0.26	1.25	-74.23	-195.27	23.8	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
ACEi/ARB	azithromycin, NSAID	NA	NA	NA N	NA NA	NA	NA	3.22	0.35	75.16	56.83	-158.69	143.52	VERY LOW	3.22	0.35	75.16	56.83	-158.69	143.52	Indirect	MODERATE	#N/A	Extremely serious	VERY LOW	RoB, Imprecisionx3
ACEi/ARB	azithromycin, NSAID, corticosteroid	NA	NA	NA N		NA	NA	1.56	0.21	15.6	9.82	-271.07	126.23	VERY LOW	1.56	0.21	15.6	9.82	-271.07	126.23	Indirect	MODERATE	#N/A	Extremely serious		RoB, Imprecisionx3
ACEi/ARB	colchicine	NA	NA	NA N		NA	NA	1.26	0.75	2.24	22.29	-27.03	77.82	VERY LOW	1.26	0.75	2.24	22.29	-27.03	77.82	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
ACEi/ARB	colchicine, emtricitabine, tenofovir, statins	NA	NA	NA N		NA	NA	1.44	0.62	3.39	29.92	-52.27	97.47	VERY LOW	1.44	0.62	3.39	29.92	-52.27	97.47	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
ACEi/ARB	colchicine, statins	NA	NA	NA N		NA	NA	0.96	0.42	2.2	-8.36	-109.84	71.94	VERY LOW	0.96	0.42	2.2	-8.36	-109.84	71.94	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
ACEi/ARB	corticosteroids (systemic)	NA	NA	NA N		NA	NA	1.27	0.78	2.12	23.59	-22.27	75.85	VERY LOW	1.27	0.78	2.12	23.59	-22.27	75.85	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
ACEi/ARB	IL6 receptor antagonists with corticosteroids (systemic)	NA	NA	NA N		NA	NA	1.27	0.8	2.01	23.28	-19.1	73.39	LOW	1.27	0.8	2.01	23.28	-19.1	73.39	Indirect	MODERATE	#N/A	Serious	LOW	RoB, Imprecision
ACE/ARB	doxycycline	NA	NA	NA N		NA	NA NA	2.12	0.44	12.72	45.08	-104.42	128.49	VERY LOW	2.12	0.44	12.72	45.08	-104.42	128.49	Indirect	MODERATE	#N/A	Very serious		RoB, Imprecisionx2
ACEI/ARB ACEI/ARB	emtricitabine, tenofovir	NA NA	NA NA	NA N		NA NA	NA NA	1.26	0.55	2.95	19.18 -45.79	-68.07 -148.34	91.31 39.78	VERY LOW VERY LOW	1.26	0.55	2.95	19.18 -45.79	-68.07 -148.34	91.31 39.78	Indirect	MODERATE MODERATE	#N/A	Very serious		RoB, Imprecisionx2
ACEi/ARB ACEi/ARB	favipiravir	NA NA	NA NA	NA N		NA NA	NA NA	0.7	0.34	1.47 2.19	-45.79 -15.09	-148.34 -128.71	39.78 70.26	VERY LOW VERY LOW	0.7	0.34	2.19	-45.79 -15.09	-148.34 -128.71	39.78 70.26	Indirect	MODERATE	Not serious #N/A	Very serious		RoB, Imprecisionx2 RoB. Imprecisionx2
	favipiravir, hydrochloroquine	NA NA	+		_	_				_		_							_		Indirect			Very serious		. , ,
ACEi/ARB ACFi/ARB	fluvoxamine	NA NA	NA NA	NA N		NA NA	NA NA	1.37	0.64	2.98 3.42	26.14 35.6	-45.9 -33.72	90.54 98.58	VERY LOW VERY LOW	1.37	0.64	2.98 3.42	26.14 35.6	-45.9 -33.72	90.54 98.58	Indirect	MODERATE	#N/A Not serious	Very serious		RoB, Imprecisionx2
ACE/ARB ACE/ARB	full-dose anticoagulant GM-CSF inhibitor	NA NA	NA NA	NA N		NA NA	NA NA	1.54	0.71	2.59	35.6	-33.72 -95.06	98.58 81.72	VERY LOW	1.54	0.71	2.59	35.6	-33.72 -95.06	98.58 81.72	Indirect	MODERATE	Not serious #N/A	Very serious Very serious		RoB, Imprecisionx2 RoB, Imprecisionx2
ACE/ARB ACFi/ARB	(hydroxy)chloroquine	NA NA	NA NA	NA N		NA NA	NA NA	0.78	0.46	1.24	-26.93	-74 84	26.21	LOW	0.78	0.46	1.24	-26.93	-74 84	26.21	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecisionx2
ACE/ARB	(hydroxy)chloroquine IL1 inhibitors	NA NA	NA NA	NA N		NA NA	NA NA	1.25	0.49	2.58	19.47	-74.04	84.38	VERYLOW	1.25	0.49	2.58	19 47	-74.04	84.38	Indirect	MODERATE	#N/A	Very serious		RoB, Imprecisionx2
ACE/ARB	IL6 receptor antagonists without corticosteroids (systemic)	NA NA	NA NA	NA N		NA NA	NA NA	1.25	0.62	3.31	45.17	-7 42	100.34	VERYLOW	1.25	0.62	3.31	45.17	-7 42	100.34	Indirect	MODERATE	Not serious	Very serious Very serious		RoB, Imprecisionx2
ACE/ARB	inhaled corticosteroids	NA NA	NA NA	NA N	101	NA NA	NA NA	0.97	0.35	2.75	-10	-143.78	82.87	VERY LOW	0.97	0.35	2.75	-10	-143.78	82.87	Indirect	MODERATE	Not serious	Very serious		RoB, Imprecisionx2
ACE/ARB	interferon alfa (subcutaneous)	NA.	NA.	NA N		NA NA	NA NA	0.37	0.02	5.1	-193.99	-819.54	100.83	VERY LOW	0.37	0.02	5.1	-193.99	-819.54	100.83	Indirect	MODERATE	#N/A	Extremely serious		RoB. Imprecisionx3
AOLIAND	interiori ana (subcutaneous)	1170	1 14/1	140	. 144	1100	1 14/5	0.07	0.02	L 5.1	-100.00	010.04	100.03	VEIXI LOW	0.07	0.02	J. I	100.00	010.04	100.03	manect	MODEIVALE	#19/1	Parionion actions	1	Trop, imprecisions

										Mech	nanical ventila	ation															
Comparison		Direct esti							Indirect es							Network e											
		Relative es	Cllower	Clusses	Absolute	Cl lower	r 1,000) Clupper	Final rating	Relative es	timate CI lower	Clusses	Absolute e	stimate (per	r 1,000) Clupper	Final rating	Relative (Cllower	Clim		CI low	e (per 1,000)	GRADE Starting				Final rating	Reasons for
Treatment 1	Treatment 2	estimate	limit	CI upper limit	estimate	limit	limit	i marrating	estimate	limit	CI upper limit	estimate	limit	limit	I marrating	estimate	limit	CI upp	er Point estimat			evidence	Starting rating	Incoherence	Imprecision	i marramy	downgrading
ACEi/ARB	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	0.98	0.58	1.66	-1.82	-54.76	55.02	LOW	0.98	0.58	1.66	-1.82	-54.7	6 55.02	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
ACEi/ARB	interferon beta (subcutaneous), lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.65	0.34	1.24	-55.19	-146.57	23.84	VERY LOW	0.65	0.34	1.24		1.10.0	20.01	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
ACEi/ARB	intermediate-dose anticoagulant	NA	NA	NA	NA	NA	NA	NA	0.91	0.34	2.46	-17.53	-148.29	76.76	VERY LOW	0.91	0.34	2.46				Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
ACEi/ARB	ivermectin JAK inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1 1 20	0.48	2.09	-0.38 24.54	-82.66 -21.69	70.68	VERY LOW VERY LOW	1 1 20	0.48	2.09	-0.38 24.54	-82.6 -21.6		Indirect	MODERATE	Not serious Not serious	Very serious	VERY LOW VERY LOW	RoB, Imprecisionx2 RoB, Imprecisionx2
ACE//ARB	lopinavir-ritonavir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.29 0.9	0.79	1.44	-10.71	-57.28	77.28 42.61	LOW	1.29 0.9	0.79	1.44	_			Indirect	MODERATE	Not serious	Very serious Serious	LOW	RoB, Imprecision
ACE/ARB	molnupiravir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	7.72E+05	0.57	2.76E+22	-177.77	-909.37	159.35	VERY LOW	772.247.2	1 0	2.76E+				Indirect	MODERATE	#N/A	Extremely serious	VERY LOW	RoB. Imprecisionx3
ACEi/ARB	proxalutamide	NA	NA	NA	NA	NA	NA	NA	16.21	6.1	52.25	108.61	70.34	156.23	VERY LOW	16.21	6.1	52.2	_			Indirect	LOW	Not serious	Very serious	VERY LOW	RoBx2, Imprecisionx2
ACEi/ARB	recombinant human granulocyte colony-stimulating factor	NA	NA	NA	NA	NA	NA	NA	6.52	2.79	15.51	96.26	54.96	145.25	VERY LOW	6.52	2.79	15.5	1 96.26	54.9	6 145.25	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
ACEi/ARB	remdesivir	NA	NA	NA	NA	NA	NA	NA	1.27	0.79	2.07	22.96	-20.21	74.61	LOW	1.27	0.79	2.07	22.96	-20.2	1 74.61	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
ACEi/ARB	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	0.41	0.08	1.53	-158.52	-496.97	39.55	VERY LOW	0.41	0.08	1.53		_		Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
ACEi/ARB	SGLT2 inhibitors	NA	NA	NA	NA	NA	NA	NA	1.24	0.62	2.44	18.81	-48.05	81.55	VERY LOW	1.24	0.62	2.44		-48.0		Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
ACEi/ARB	statins	NA	NA	NA	NA	NA	NA	NA	0.8	0.26	2.53	-34.75	-204.16	77.84	VERY LOW	0.8	0.26	2.53				Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
ACEi/ARB ACFi/ARB	sulodexide tyrosine kinase inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	2.1	0.46	12.23 6.37	45.62 61.38	-95.87 -5.76	126.5	VERY LOW VERY LOW	2.1	0.46	12.2				Indirect	MODERATE	Not serious Not serious	Very serious Very serious	VERY LOW VERY LOW	RoB, Imprecisionx2
ACEI/ARB	vitamin C	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.85	0.92	1.84	-20.97	-118.02	58.94	VERYLOW	0.85	0.92	1.84		-		Indirect	MODERATE	Not serious	Very serious Very serious	VERYLOW	RoB, Imprecisionx2
ACEI/ARB	vitamin D	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	2.24	0.39	5.83	58.07	-9.46	118.43	VERY LOW	2.24	0.88	5.83				Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
(acetyl)cysteine	antihepaciviral	NA NA	NA.	NA NA	NA.	NA NA	NA NA	NA NA	1.12	0.49	2.65	10.91	-58.77	90.49	VERY LOW	1.12	0.49	2.65		-58.7	110.10	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
(acetyl)cysteine	aspirin	NA	NA	NA	NA	NA	NA	NA	0.9	0.42	1.94	-7.67	-70.46	69.47	VERY LOW	0.9	0.42	1.94	-7.67	-70.4	6 69.47	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
(acetyl)cysteine	aspirin, statins	NA	NA	NA	NA	NA	NA	NA	0.51	0.15	1.78	-85.1	-275.26	53.2	VERY LOW	0.51	0.15	1.78		-275.2	26 53.2	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
(acetyl)cysteine	azithromycin	NA	NA	NA	NA	NA	NA	NA	0.88	0.42	1.81	-10.09	-68.33	64.24	VERY LOW	0.88	0.42	1.81				Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
(acetyl)cysteine	azithromycin, hydroxychloroquine	NA	NA	NA	NA	NA	NA	NA	0.47	0.18	1.19	-91.65	-217.47	17.75	VERY LOW	0.47	0.18	1.19		_		Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
(acetyl)cysteine	azithromycin, NSAID	NA	NA	NA	NA	NA	NA	NA	2.64	0.27	64.18	39.41	-175.03	142.46	VERY LOW	2.64	0.27	64.1		-175.0		Indirect	HIGH	#N/A	Extremely serious		Imprecisionx3
(acetyl)cysteine	azithromycin, NSAID, corticosteroid	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.28	0.16	13.5	-7.6 4.87	-284.94	122.06	VERY LOW VERY LOW	1.28	0.16	13.5		-284.9		Indirect	HIGH	#N/A	Extremely serious	VERY LOW VERY LOW	Imprecisionx3
(acetyl)cysteine	colchicine colchicine, emtricitabine, tenofovir, statins	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.03	0.49	2.23	12.5	-52.7 -74.99	80.11 97.79	VERYLOW	1.03	0.49	2.23	4.87	-52.7 -74.9		Indirect	MODERATE MODERATE	Not serious #N/A	Very serious Very serious	VERY LOW VERY LOW	RoB, Imprecisionx2 RoB, Imprecisionx2
(acety)cysteine	colchicine, etitilicitabilie, teriolovii, statiris	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.78	0.43	2.09	-25.79	-132.39	69.29	VERY LOW	0.78	0.43	2.09		_		Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
(acetyl)cysteine	corticosteroids (systemic)	NA NA	NA.	NA NA	NA.	NA.	NA.	NA NA	1.04	0.51	2.14	6.17	-48.65	78.78	VERY LOW	1.04	0.51	2.14		-48.6		Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
(acetyl)cysteine	IL6 receptor antagonists with corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	1.04	0.51	2.05	5.85	-45.88	76.9	VERY LOW	1.04	0.51	2.05	5.85	-45.8	8 76.9	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
(acetyl)cysteine	doxycycline	NA	NA	NA	NA	NA	NA	NA	1.73	0.33	10.96	27.66	-125.49	126.24	VERY LOW	1.73	0.33	10.9	27.66	-125.4	19 126.24	Indirect	MODERATE	#N/A	Extremely serious	VERY LOW	RoB, Imprecisionx3
(acetyl)cysteine	emtricitabine, tenofovir	NA	NA	NA	NA	NA	NA	NA	1.03	0.39	2.79	1.76	-91.61	89.56	VERY LOW	1.03	0.39	2.79	1.76	-91.6	1 89.56	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
(acetyl)cysteine	favipiravir	NA	NA	NA	NA	NA	NA	NA	0.57	0.23	1.4	-63.21	-170.06	35.43	VERY LOW	0.57	0.23	1.4	-63.21	-170.0		Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
(acetyl)cysteine	favipiravir, hydrochloroquine	NA	NA	NA	NA	NA	NA	NA	0.74	0.26	2.05	-32.51	-151.59	66.42	VERY LOW	0.74	0.26	2.05		-151.5		Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
(acetyl)cysteine	fluvoxamine	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.11	0.44	2.83	8.72	-70.45	91	VERY LOW	1.11	0.44	2.83		-70.4 -57.5		Indirect	HIGH MODERATE	#N/A	Very serious	VERY LOW	Imprecisionx2
(acetyl)cysteine (acetyl)cysteine	full-dose anticoagulant GM-CSF inhibitor	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.26 0.89	0.5	3.25 2.39	18.18 -13.52	-57.51 -116.89	98.81 79.94	VERY LOW	1.26 0.89	0.5	3.25				Indirect	MODERATE	Not serious #N/A	Very serious Very serious	VERY LOW	RoB, Imprecisionx2 RoB, Imprecisionx2
(acetyl)cysteine	(hydroxy)chloroquine	NA NA	NA.	NA NA	NA.	NA.	NA.	NA NA	0.64	0.32	1.27	-44.35	-101.09	29.36	VERY LOW	0.64	0.32	1.27				Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
(acetyl)cysteine	IL1 inhibitors	NA NA	NA.	NA NA	NA.	NA.	NA.	NA NA	1.02	0.42	2.48	2.05	-75.33	84.07	LOW	1.02	0.42	2.48		-75.3		Indirect	HIGH	#N/A	Very serious	LOW	Imprecisionx2
(acetyl)cysteine	IL6 receptor antagonists without corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	1.42	0.61	3.21	27.75	-33.86	103.23	LOW	1.42	0.61	3.21		-33.8	6 103.23	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
(acetyl)cysteine	inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	0.79	0.25	2.51	-27.42	-165.92	79.04	VERY LOW	0.79	0.25	2.51	-27.42	-165.9	92 79.04	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
(acetyl)cysteine	interferon alfa (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	0.3	0.02	4.5	-211.41	-829.38	93.77	VERY LOW	0.3	0.02	4.5		_		Indirect	MODERATE	#N/A	Extremely serious	VERY LOW	RoB, Imprecisionx3
(acetyl)cysteine	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	0.8	0.38	1.66	-19.24	-80.88	56.5	VERY LOW	0.8	0.38	1.66				Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
(acetyl)cysteine	interferon beta (subcutaneous), lopinavir-ritonavir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.53	0.23	1.21	-72.61 -34.95	-169.68 -170.17	21.13 71.58	VERY LOW	0.53	0.23	1.21		_		Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
(acetyl)cysteine	intermediate-dose anticoagulant		NA NA	NA NA	NA NA		NA NA	NA NA	0.74	0.24	2.27	-34.95 -17.8	-170.17	71.58	VERYLOW	0.74	0.24	1 90				Indirect	HIGH	#N/A	Very serious	VERYLOW	Imprecisionx2
(acetyl)cysteine (acetyl)cysteine	JAK inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.06	0.33	2 19	7 12	-106.43	70.22 80.48	LOW	1.06	0.33	2.19	11.0	-106.4	10 70.22	Indirect	HIGH	Not serious Not serious	Very serious Very serious	LOW	RoB, Imprecisionx2
(acetyl)cysteine	lopinavir-ritonavir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.73	0.36	1.47	-28.13	-83.58	45.44	VERY LOW	0.73	0.36	1.47		10.2	00.10	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
(acetyl)cysteine	molnupiravir	NA NA	NA.	NA NA	NA	NA NA	NA	NA NA	6.12E+05	0	2.11E+22	-195.19	-935.65	161.54	VERY LOW	6.12E+05		2.11E+				Indirect	MODERATE	#N/A	Extremely serious	VERY LOW	RoB, Imprecisionx3
(acetyl)cysteine	proxalutamide	NA	NA	NA	NA	NA	NA	NA	13.28	4.36	47.3	91.19	42.55	160.6	VERY LOW	13.28	4.36	47.3	91.19	42.5	5 160.6	Indirect	LOW	Not serious	Very serious	VERY LOW	RoBx2, Imprecisionx2
1 777	recombinant human granulocyte colony-stimulating factor	NA	NA	NA	NA	NA	NA	NA	5.32	1.95	14.66	78.84	28.08	149.66	VERY LOW	5.32	1.95	14.6				Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
(acetyl)cysteine	remdesivir	NA	NA	NA	NA	NA	NA	NA	1.03	0.51	2.11	5.54	-47.39	77.43	VERY LOW	1.03	0.51	2.11				Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
(acetyl)cysteine	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	0.33	0.06	1.37	-175.94	-517.44	29.9	VERY LOW	0.33	0.06	1.37		_		Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
(acetyl)cysteine	SGLT2 inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.01	0.42	2.35	1.39 -52.17	-72.19 -226	81.44 72.01	LOW VERY LOW	1.01	0.42	2.35		-72.1 -226		Indirect	HIGH MODERATE	#N/A	Very serious	VERYLOW	Imprecisionx2 RoB. Imprecisionx2
(acetyl)cysteine	statins sulodexide	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.72	0.19 0.35	10.81	-52.17 28.2	-226 -116.01	124.97	VERY LOW	1.72	0.19	2.32		-116.0		Indirect	HIGH	Not serious Not serious	Very serious Extremely serious		RoB, Imprecisionx2 Imprecisionx3
(acetyl)cysteine	tyrosine kinase inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.72	0.66	5.84	43.96	-29.82	122.34	VERY LOW	1.72	0.66	5.84				Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB. Imprecisionx2
(acetyl)cysteine	vitamin C	NA NA	NA NA	NA NA	NA.	NA NA	NA NA	NA NA	0.69	0.27	1.73	-38.39	-142.22	56.99	VERY LOW	0.69	0.00	1.73				Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
(acetyl)cysteine	vitamin D	NA NA	NA.	NA NA	NA	NA NA	NA	NA NA	1.83	0.63	5.38	40.64	-33.7	119.11	LOW	1.83	0.63	5.38		-33.7		Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
antihepaciviral	aspirin	NA	NA	NA	NA	NA	NA	NA	0.8	0.41	1.54	-18.58	-74.41	40.41	VERY LOW	0.8	0.41	1.54	-18.58	-74.4	1 40.41	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
antihepaciviral	aspirin, statins	NA	NA	NA	NA	NA	NA	NA	0.45	0.14	1.49	-96.01	-282.69	33.18	VERY LOW	0.45	0.14	1.49	-96.01	-282.6	33.18	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
antihepaciviral	azithromycin	NA	NA	NA	NA	NA	NA	NA	0.78	0.41	1.44	-20.99	-70.63	35.32	VERY LOW	0.78	0.41	1.44		-70.6		Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
antihepaciviral	azithromycin, hydroxychloroquine	NA	NA	NA	NA	NA	NA	NA	0.41	0.18	0.97	-102.56	-225.32	-4.75	VERY LOW	0.41	0.18	0.97				Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
antihepaciviral	azithromycin, NSAID	NA NA	NA NA	NA NA	NA	NA NA	NA	NA NA	2.34	0.25	55.63	28.51	-187.26	116.59	VERY LOW	2.34	0.25	55.6		-187.2		Indirect	MODERATE	#N/A	Extremely serious	VERY LOW	RoB, Imprecisionx3
antihepaciviral	azithromycin, NSAID, corticosteroid	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.14	0.14	11.75	-18.51	-298.01	97.97	VERY LOW	1.14	0.14	11.7		_		Indirect	MODERATE	#N/A	Extremely serious	VERY LOW	RoB, Imprecisionx3
antihepaciviral antihepaciviral	colchicine colchicine. emtricitabine. tenofovir. statins	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.92 1.04	0.48	1.75 2.61	-6.04 1.59	-54.86 -81.39	50.02 70.92	VERY LOW VERY LOW	1.04	0.48	1.75 2.61	-6.04 1.59	-54.8 -81.3		Indirect	MODERATE MODERATE	Not serious #N/A	Very serious Very serious	VERY LOW VERY LOW	RoB, Imprecisionx2 RoB, Imprecisionx2
antihepaciviral	colchicine, emiticiabine, tenolovii, statins	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.69	0.41	1.68	-36.69	-01.39	44	VERY LOW	0.69	0.41	1.68				Indirect	MODERATE	#N/A	Very serious Very serious	VERY LOW	RoB, Imprecisionx2
antihepaciviral	corticosteroids (systemic)	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.09	0.28	1.7	-4.74	-51.02	49.65	VERY LOW	0.09	0.26	1.7	_	-51.0		Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB. Imprecisionx2
antinopacivirai	conticoateroida (ayateriilo)	14/5	19/1	1100	11/5	1 14/5	13/5	111/2	0.02	0.5	1.7	-4.74	-01.02	70.00	VEIXT LOW	0.02	0.5	1.7	-7.74	1 -01.0	- 70.00	manect	MODEIVATE	.401 3611003	- cry acriods	*LINI LOW	1.100, Imprecisionaz

Part											Mech	nanical ventila	ation															
Part	Comparison		Direct estin	imate	_	_	_	_	_	Indirect es		iarrioar verrana					Network es	timate		_	_	_						
March Marc	·		Relative es	stimate		Absolute 6	stimate (per	r 1,000)		Relative est	timate		Absolute e	stimate (per	1,000)					Absolute	estimate (per 1,000)	GRADE					
Property		.				Point	CI lower	CI upper	Final rating		CI lower		Point			Final rating	Point	Cl lower	CI upper	Point			Starting	Starting rating	Incoherence	Imprecision	Final rating	Reasons for
## Property	****					estimate	_						estimate	_		VEDVLOW			_	estimate			evidence	MODERATE	///	16	VEDVLOW	downgrading
Column C	1 1 1 1 1 1			_	_			_											_							.,		RoB, Imprecisionx2 RoB, Imprecisionx3
## Section of Control														10.110														RoB, Imprecisionx2
Property																												RoB, Imprecisionx2
					-			-																		-		RoB, Imprecisionx2
## Properties Control of the contr									_																	-		RoB. Imprecisionx2
Part					_		_	_											_		_					.,		RoB. Imprecisionx2
Part	1 1 1 1 1 1				_			_	NA							VERY LOW				_						.,		RoB, Imprecisionx2
Progress of the content of the con	antihepaciviral	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	0.57	0.31	1	-55.26	-103.74	-0.43	VERY LOW	0.57	0.31	1	-55.26	-103.74	-0.43	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
## Programmer Market Anticologophis Market Anticol	antihepaciviral	IL1 inhibitors	NA	NA	NA	NA	NA	NA	NA	0.91	0.41	2.02	-8.86	-79.71	56.92	VERY LOW	0.91	0.41	2.02	-8.86	-79.71	56.92	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
## Properties of the propertie	antihepaciviral	IL6 receptor antagonists without corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	1.25	0.59	2.61	16.84	-37.38	74.13	VERY LOW	1.25	0.59	2.61	16.84	-37.38	74.13	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
Processor Proc	antihepaciviral	inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	0.7	0.23	2.08	-38.33	-173.92	54.66	VERY LOW	0.7	0.23	2.08	-38.33	-173.92	54.66	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
Production Pro	antihepaciviral	interferon alfa (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	0.26	0.02	3.83	-222.32	-846.22	75.09	VERY LOW	0.26	0.02	3.83	-222.32	-846.22	75.09	Indirect	MODERATE	#N/A	Extremely serious	VERY LOW	RoB, Imprecisionx3
## Presentation for consequent of M.	antihepaciviral	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	0.7 1	0.37	1.32	-30.15	-83.76	27.87	VERY LOW	0.71	0.37	1.32	-30.15	-83.76	27.87	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
	interferon beta (subcutaneous), lopinavir-ritonavir	antihepaciviral	3.13	0.41	23.71	NA	NA	NA	VERY LOW	1.94	0.89	4.27	NA	1471		VERY LOW	2.13	1.06	4.38	83.52	7.69	172	Direct	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
## Secretary Marchester Mar	·	•																								-		RoB, Imprecisionx2
Part					_		_													_								RoB, Imprecisionx2
## Properties of the propertie							_			0.0.														MODERNIE		-		RoB, Imprecisionx2
### Proposed				_	_	_	_	_		0.00														MODERNIE		-		RoB, Imprecisionx2
## Propositional										0.000						-		-										RoB, Imprecisionx3
## Properties Pr				_	_		_	_																_		- ,		RoBx2, Imprecisionx2
## of the processor 10								_																				RoB, Imprecisionx2
## Septiment March	1 1 1 1 1 1	1 111		_	_		_									-										, ,		RoB, Imprecisionx2 RoB, Imprecisionx2
## componential states NA				-	-																					.,		
## contragalational subsesses NA											_								_		_			_				RoB, Imprecisionx2 RoB, Imprecisionx2
### anthrepsportrial Pyrosine branch infolders								_	_										_							-		RoB, Imprecisionx2
### anthregacional visions O. NA. NA. NA. NA. NA. NA. NA. NA. NA. NA				_	_		_	+								-										-		RoB, Imprecisionx2
### arthogoloridal valures D NA		,								_																· ·		RoB. Imprecisionx2
## aspire Septim Part Septim Part Septim Part Septim Part Septim				_				_											_							,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		RoB. Imprecisionx2
## Papers Battlemanyers NA																										.,		RoB. Imprecisionx2
Septim Authorsports prigns spring Authorsports prigns Authorsports Auth					+		NA	+	NA.		0.58	1.6	-2.41	-49.76		LOW			_				Indirect			, ,		RoB, Imprecision
## agrine addressored NA	aspirin	azithromycin, hydroxychloroquine		NA	NA.		NA	NA	NA.			1.11	-83.98		10.17	VERY LOW	-		1.11	-83.98		10.17	Indirect		Not serious	Very serious	VERY LOW	RoB. Imprecisionx2
Septim Cockholine NA NA NA NA NA NA NA N	aspirin	azithromycin, NSAID	NA	NA	NA	NA	NA	NA	NA	2.9	0.32	69.01	47.09	-164.99	128.31	VERY LOW	2.9	0.32	69.01	47.09	-164.99	128.31	Indirect	MODERATE	#N/A	Extremely serious	VERY LOW	RoB, Imprecisionx3
## A PA NA	aspirin	azithromycin, NSAID, corticosteroid	NA	NA	NA	NA	NA	NA	NA	1.41	0.19	13.93	0.07	-278.68	111.28	VERY LOW	1.41	0.19	13.93	0.07	-278.68	111.28	Indirect	MODERATE	#N/A	Extremely serious	VERY LOW	RoB, Imprecisionx3
A	aspirin	colchicine	NA	NA	NA	NA	NA	NA	NA	1.14	0.69	1.98	12.54	-32.58	62.99	LOW	1.14	0.69	1.98	12.54	-32.58	62.99	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
Section Regime Confloorationis (systemic) NA NA NA NA NA NA NA N	aspirin	colchicine, emtricitabine, tenofovir, statins	NA	NA	NA	NA	NA	NA	NA	1.31	0.55	3.02	20.17	-60.57	82.57	VERY LOW	1.31	0.55	3.02	20.17	-60.57	82.57	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
## Suprim ## Lis receptor antagonists with confoosierorids (systemic)	aspirin	colchicine, statins	NA	NA	NA	NA	NA	NA	NA	0.87	0.38	1.94	-18.11	-119.06	57.5	VERY LOW	0.87	0.38	1.94	-18.11	-119.06	57.5	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
## aspirin	aspirin	corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	1.16	0.7	1.87	13.84	-29.55	60.21	LOW	1.16	0.7	1.87	13.84	-29.55	60.21	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
Second S	aspirin	IL6 receptor antagonists with corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	1.15	0.72	1.77	13.53	-26.53	57.12	LOW	1.15	0.72	1.77	13.53	-26.53	57.12	Indirect	MODERATE	#N/A	Serious	LOW	RoB, Imprecision
Septim S	-				_				-												_				_	-		RoB, Imprecisionx2
Septim S	·								_																	-		RoB, Imprecisionx2
## A NA N		·			-																							RoB, Imprecisionx2
Septim Sulf-dose anticoagulant NA NA NA NA NA NA NA N																												RoB, Imprecisionx2
## A NA N					_				-																+			RoB, Imprecisionx2
aspirin (hydroxy)chloroquine NA								_	_												_					,		RoB, Imprecisionx2
aspirin IL1 inhibitors NA NA NA NA NA NA NA N	·				+			+								-	-											RoB, Imprecisionx2 RoB, Imprecisionx2
aspirin IL6 receptor antagonists without corticosteroids (systemic) NA																										-		RoB, Imprecisionx2
aspirin inhaled corticosteroids NA					_				-							-										-		RoB, Imprecisionx2
aspirin interferon bafa (subcutaneous) NA	·							_	_					_							_					_		RoB, Imprecisionx2
aspirin interferon beta (subcutaneous) NA	·			-	-	-	-	+												_						-		RoB, Imprecisionx3
aspirin interferon beta (subcutaneous), lopinavir-ritonavir NA	·								_										_						+	<u> </u>		RoB. Imprecision
aspirin intermediate-dose anticoagulant NA		,																	_									RoB, Imprecisionx2
aspirin ivermectin NA		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,			_			_											_							.,		RoB, Imprecisionx2
aspirin lopinavir-ritonavir NA	aspirin	ivermectin		NA	NA	NA	NA	NA	NA		0.44	1.86	-10.13			VERY LOW	0.91	0.44			-90.8	56.53	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
	aspirin	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	1.17	0.71	1.93	14.79	-28.73	61.9	LOW	1.17	0.71	1.93	14.79	-28.73	61.9	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
aspirin molnupiravir NA	aspirin	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.82	0.51	1.27	-20.46	-64.26	26.62	LOW	0.82	0.51	1.27	-20.46	-64.26	26.62	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
	aspirin	molnupiravir	NA	NA	NA	NA	NA	NA	NA	6.97E+05	0	2.48E+22	-187.52	-915.41	143.06	VERY LOW	6.97E+05	0	2.48E+2	2 -187.52	-915.41	143.06	Indirect	MODERATE	#N/A	Extremely serious	VERY LOW	RoB, Imprecisionx3
aspirin proxalutamide NA	aspirin	proxalutamide	NA	NA	NA	NA	NA	NA	NA	14.66	5.55	46.56	98.86	63.11	139.59	VERY LOW	14.66	5.55	46.56	98.86	63.11	139.59	Indirect	LOW	Not serious	Very serious	VERY LOW	RoBx2, Imprecisionx2
aspirin recombinant human granulocyte colony-stimulating factor NA	aspirin	recombinant human granulocyte colony-stimulating factor	NA	NA	NA	NA	NA	NA	NA	5.9	2.51	13.85	86.51	47.24	128.83	VERY LOW	5.9	2.51	13.85	86.51	47.24	128.83	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
aspirin remdesivir NA	aspirin	remdesivir	NA	NA	NA	NA	NA	NA	NA	1.15	0.72	1.83	13.21	-27.15	58.59	LOW	1.15	0.72	1.83	13.21	-27.15	58.59	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
	aspirin	serine protease inhibitors		NA	NA	NA	NA	NA	NA	0.01	0.07	1.38	-168.27	-508.53	29.39		0.37		1.38	-168.27	-508.53	29.39	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
		*****		_													=									.,		RoB, Imprecisionx2
				****			_			-				1471		VEIXI EOII		0.11			00.02			MODERNIE		-	VEITT EOU	RoB, Imprecisionx2
				_	_		_	_	100	1.01			00.01	101.00		VEIXI EOII				00.07	101.00	112.11		MODERNIE		.,	VEITI LOW	RoB, Imprecisionx2
		V 11 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1																										RoB, Imprecisionx2
aspirin vitamin C NA	aspirin	vitamin C	NA	NA NA	NA NA	NA	NA NA	NA	NA NA	0.77	0.35	1.62	-30.72	-126.79	44.96	VERY LOW	0.77	0.35	1.62	-30.72	-126.79	44.96	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2

										Mech	anical ventil	lation														
Comparison		Direct es	timate						Indirect es							Network e	stimate									
		Relative e			_	estimate (per			Relative es	, innato			stimate (pe			Relative e				estimate (per 1,000)	GRADE					
Treatment 1	Treatment 2	Point estimate	CI lower	r CI uppe	r Point	CI lower	CI upper limit	Final rating	Point estimate	CI lower	CI upper limit	Point	CI lower	CI upper limit	Final rating	Point estimate	CI lower	CI upper	Point estimate	CI lower CI upper	Starting evidence	Starting rating	Incoherence	Imprecision	Final rating	Reasons for downgrading
aspirin	vitamin D	NA	NA	NA.	NA	NA	NA	NA.	2 02	0.81	5.16	48.32	-17.49	102.66	VERYLOW	2.02	0.81	5.16	48.32	-17 49 102 66	Indirect	MODERATE	Not serious	Very serious	VERYLOW	RoB Imprecisionx2
aspirin, statins	azithromycin	NA NA	NA.	NA.	NA.	NA.	NA.	NA.	1.71	0.57	5.01	75.01	-48.69	259.99	VERYLOW	1.71	0.57	5.01	75.01	-48.69 259.99	Indirect	MODERATE	Not serious	Very serious		RoB. Imprecisionx2
aspirin, statins	azithromycin, hydroxychloroquine	NA.	NA.	NA.	NA.	NA.	NA	NA NA	0.91	0.26	3.12	-6.56	-175.25	195.43	VERYLOW	0.91	0.26	3.12	-6.56	-175.25 195.43	Indirect	MODERATE	Not serious	Very serious		RoB. Imprecisionx2
aspirin, statins	azithromycin, NSAID	NA	NA	NA.	NA.	NA	NA	NA.	5.21	0.47	138.64	124.51	-112.17	328.09	VERY LOW	5.21	0.47	138.64	124.51	-112.17 328.09	Indirect	MODERATE	#N/A	Extremely seriou		RoB, Imprecisionx3
aspirin, statins	azithromycin, NSAID, corticosteroid	NA	NA	NA.	NA.	NA NA	NA	NA.	2.49	0.27	30.26	77.5	-217.2	299.79	VERY LOW	2.49	0.27	30.26	77.5	-217.2 299.79	Indirect	MODERATE	#N/A	Extremely seriou		RoB, Imprecisionx3
aspirin, statins	colchicine	NA	NA.	NA.	NA	NA NA	NA	NA.	2.02	0.67	6.02	89.96	-32.46	274.81	VERY LOW	2.02	0.67	6.02	89.96	-32.46 274.81	Indirect	MODERATE	Not serious	Very serious		RoB. Imprecisionx2
aspirin, statins	colchicine, emtricitabine, tenofovir, statins	NA	NA	NA	NA	NA	NA	NA	2.31	0.63	8.17	97.59	-41.36	285.35	VERY LOW	2.31	0.63	8.17	97.59	-41.36 285.35	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
aspirin, statins	colchicine, statins	NA	NA	NA	NA	NA	NA	NA	1.53	0.43	5.29	59.31	-93.97	254.35	VERY LOW	1.53	0.43	5.29	59.31	-93.97 254.35	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
aspirin, statins	corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	2.03	0.68	5.93	91.27	-30.41	274.89	VERY LOW	2.03	0.68	5.93	91.27	-30.41 274.89	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
aspirin, statins	IL6 receptor antagonists with corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	2.02	0.69	5.74	90.95	-29.6	273.47	VERY LOW	2.02	0.69	5.74	90.95	-29.6 273.47	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
aspirin, statins	doxycycline	NA	NA	NA	NA	NA	NA	NA	3.37	0.53	24.65	112.75	-78.94	314.55	VERY LOW	3.37	0.53	24.65	112.75	-78.94 314.55	Indirect	MODERATE	#N/A	Extremely seriou	VERY LOW	RoB, Imprecisionx3
aspirin, statins	emtricitabine, tenofovir	NA	NA	NA	NA	NA	NA	NA	2.01	0.55	7.07	86.85	-56.67	278.23	VERY LOW	2.01	0.55	7.07	86.85	-56.67 278.23	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
aspirin, statins	favipiravir	NA	NA	NA	NA	NA	NA	NA	1.11	0.33	3.67	21.89	-133.28	217.35	VERY LOW	1.11	0.33	3.67	21.89	-133.28 217.35	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
aspirin, statins	favipiravir, hydrochloroquine	NA	NA	NA	NA	NA	NA	NA	1.44	0.39	5.25	52.59	-110.09	251.27	VERY LOW	1.44	0.39	5.25	52.59	-110.09 251.27	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
aspirin, statins	fluvoxamine	NA	NA	NA	NA	NA	NA	NA	2.18	0.63	7.44	93.81	-39.82	281.9	VERY LOW	2.18	0.63	7.44	93.81	-39.82 281.9	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
aspirin, statins	full-dose anticoagulant	NA	NA	NA	NA	NA	NA	NA	2.46	0.71	8.29	103.28	-29.98	291.28	VERY LOW	2.46	0.71	8.29	103.28	-29.98 291.28	Indirect	MODERATE	Not serious	Very serious		RoB, Imprecisionx2
aspirin, statins	GM-CSF inhibitor	NA	NA	NA	NA	NA	NA	NA	1.73	0.47	6.25	71.58	-79	263.33	VERY LOW	1.73	0.47	6.25	71.58	-79 263.33	Indirect	MODERATE	#N/A	Very serious		RoB, Imprecisionx2
aspirin, statins	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	1.25	0.42	3.55	40.75	-82.12	223.93	VERY LOW	1.25	0.42	3.55	40.75	-82.12 223.93	Indirect	MODERATE	Not serious	Very serious		RoB, Imprecisionx2
aspirin, statins	IL1 inhibitors	NA	NA	NA	NA	NA	NA	NA	2	0.6	6.5	87.15	-45.44	274.73	VERY LOW	2	0.6	6.5	87.15	-45.44 274.73	Indirect	MODERATE	#N/A	Very serious		RoB, Imprecisionx2
aspirin, statins	IL6 receptor antagonists without corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	2.76	0.85	8.55	112.84	-11.46	297.14	VERY LOW	2.76	0.85	8.55	112.84	-11.46 297.14	Indirect	MODERATE	Not serious	Very serious		RoB, Imprecisionx2
aspirin, statins	inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	1.55	0.37	6.25	57.68	-121.53	258.57	VERY LOW	1.55	0.37	6.25	57.68	-121.53 258.57	Indirect	MODERATE	Not serious	Very serious		RoB, Imprecisionx2
aspirin, statins	interferon alfa (subcutaneous)	NA	NA	NA.	NA	NA NA	NA	NA NA	0.57	0.03	10.04	-126.31	-757.21	243.85	VERY LOW	0.57	0.03	10.04	-126.31	-757.21 243.85	Indirect	MODERATE	#N/A	Extremely seriou		RoB, Imprecisionx3
aspirin, statins	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	1.56	0.51	4.59	65.86	-58.67	250.78	VERY LOW	1.56	0.51	4.59	65.86	-58.67 250.78	Indirect	MODERATE	Not serious	Very serious		RoB, Imprecisionx2
aspirin, statins	interferon beta (subcutaneous), lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	1.03	0.32	3.22	12.49	-133.63	205.36	VERY LOW	1.03	0.32	3.22	12.49	-133.63 205.36	Indirect	MODERATE	Not serious	Very serious	-	RoB, Imprecisionx2
aspirin, statins	intermediate-dose anticoagulant	NA	NA	NA	NA	NA	NA	NA	1.44	0.36	5.65	50.15	-124.81	252.42	VERY LOW	1.44	0.36	5.65	50.15	-124.81 252.42	Indirect	MODERATE	#N/A	Very serious		RoB, Imprecisionx2
aspirin, statins	ivermectin	NA	NA NA	NA NA	NA	NA NA	NA	NA NA	1.61 2.07	0.48	5.17	67.29 92.21	-72.69 -29.81	255.84 276.43	VERY LOW VERY LOW	1.61 2.07	0.48	5.17	67.29	-72.69 255.84	Indirect	MODERATE MODERATE	Not serious	Very serious		RoB, Imprecisionx2 RoB, Imprecisionx2
aspirin, statins	JAK inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.43	0.69	4.1	56.97	-29.81 -65.42	241.12	VERY LOW	1.43	0.69	4.1	92.21 56.97	-29.81 276.43 -65.42 241.12	Indirect	MODERATE	Not serious Not serious	Very serious Very serious		RoB, Imprecisionx2
7	4	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.43 1.21F+06	0.49	4.1 4.74F+22	-110.1	-905.42	346.81	VERYLOW	1.43 1.21E+06	0.49	4.74E+22		-905.61 346.81	Indirect	MODERATE	#N/A	. ,		. , , ,
aspirin, statins aspirin, statins	molnupiravir proxalutamide	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	25.99	6.56	114 27	176.29	57.35	358.88	VERYLOW	25.99	6.56	114 27	176.29	57.35 358.88	Indirect	LOW	Not serious	Extremely serious Very serious		RoB, Imprecisionx3 RoBx2, Imprecisionx2
aspirin, statins	recombinant human granulocyte colony-stimulating factor	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	10.41	2.85	37.29	163.94	44.1	346.95	VERYLOW	10.41	2.85	37.29	163.94	44.1 346.95	Indirect	MODERATE	Not serious	Very serious		RoB, Imprecisionx2
aspirin, statins	remdesivir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	2.02	0.68	5.78	90.63	-30.12	274.01	VERYLOW	2.02	0.68	5.78	90.63	-30.12 274.01	Indirect	MODERATE	Not serious	Very serious		RoB, Imprecisionx2
aspirin, statins	serine protease inhibitors	NA NA	NA.	NA.	NA NA	NA NA	NA	NA.	0.64	0.1	3.31	-90.85	-454.05	182.1	VERY LOW	0.64	0.1	3.31	-90.85	-454.05 182.1	Indirect	MODERATE	#N/A	Extremely seriou		RoB, Imprecisionx3
aspirin, statins	SGLT2 inhibitors	NA NA	NA.	NA.	NA NA	NA NA	NA	NA.	1.97	0.6	6.26	86.49	-46.07	273.4	VERY LOW	1.97	0.6	6.26	86.49	-46.07 273.4	Indirect	MODERATE	#N/A	Very serious		RoB, Imprecisionx2
statins	aspirin, statins	0.87	0.19	3.95	NA	NA	NA	VERY LOW	NA	NA	NA	NA	NA	NA	NA.	0.79	0.25	2.44	-32.93	-196.37 121.61	Direct	MODERATE	Not serious	Very serious		RoB, Imprecisionx2
aspirin, statins	sulodexide	NA	NA	NA	NA	NA	NA	NA	3.37	0.56	25.07	113.29	-64.63	310.35	VERY LOW	3.37	0.56	25.07	113.29	-64.63 310.35	Indirect	MODERATE	Not serious	Extremely seriou		RoB, Imprecisionx3
aspirin, statins	tyrosine kinase inhibitors	NA	NA	NA	NA	NA	NA	NA	3.81	0.97	14.73	129.05	-1.52	315.68	VERY LOW	3.81	0.97	14.73	129.05	-1.52 315.68	Indirect	MODERATE	Not serious	Very serious		RoB, Imprecisionx2
aspirin, statins	vitamin C	NA	NA	NA	NA	NA	NA	NA	1.35	0.39	4.57	46.7	-104.93	240.61	VERY LOW	1.35	0.39	4.57	46.7	-104.93 240.61	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
aspirin, statins	vitamin D	NA	NA	NA	NA	NA	NA	NA	3.56	0.92	13.6	125.74	-5.34	312.6	VERY LOW	3.56	0.92	13.6	125.74	-5.34 312.6	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
azithromycin	azithromycin, hydroxychloroquine	NA	NA	NA	NA	NA	NA	NA	0.53	0.25	1.11	-81.57	-200.66	9.47	VERY LOW	0.53	0.25	1.11	-81.57	-200.66 9.47	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
azithromycin	azithromycin, NSAID	NA	NA	NA	NA	NA	NA	NA	2.99	0.33	70.22	49.5	-163.3	125.39	VERY LOW	2.99	0.33	70.22	49.5	-163.3 125.39	Indirect	MODERATE	#N/A	Extremely seriou	VERY LOW	RoB, Imprecisionx3
azithromycin	azithromycin, NSAID, corticosteroid	NA	NA	NA	NA	NA	NA	NA	1.45	0.19	14.22	2.49	-275.35	110.58	VERY LOW	1.45	0.19	14.22	2.49	-275.35 110.58	Indirect	MODERATE	#N/A	Extremely seriou	VERY LOW	RoB, Imprecisionx3
azithromycin	colchicine	NA	NA	NA	NA	NA	NA	NA	1.17	0.75	1.95	14.95	-26.94	59.49	LOW	1.17	0.75	1.95	14.95	-26.94 59.49	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
azithromycin	colchicine, emtricitabine, tenofovir, statins	NA	NA	NA	NA	NA	NA	NA	1.34	0.59	3.01	22.58	-55.5	80.59	VERY LOW	1.34	0.59	3.01	22.58	-55.5 80.59	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
azithromycin	colchicine, statins	NA	NA	NA	NA	NA	NA	NA	0.89	0.41	1.93	-15.7	-114.19	56.08	VERY LOW	0.89	0.41	1.93	-15.7	-114.19 56.08	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
azithromycin	corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	1.19	0.77	1.83	16.25	-22.68	56.17	LOW	1.19	0.77	1.83	16.25	-22.68 56.17	Indirect	MODERATE	Not serious	Serious		RoB, Imprecision
azithromycin	IL6 receptor antagonists with corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	1.18	0.8	1.72	15.94	-19.27	52.58	LOW	1.18	0.8	1.72	15.94	-19.27 52.58	Indirect	MODERATE	#N/A	Serious		RoB, Imprecision
azithromycin	doxycycline	NA	NA	NA	NA	NA	NA	NA	1.97	0.41	11.56	37.74	-109.41	110.46	VERY LOW	1.97	0.41	11.56	37.74	-109.41 110.46	Indirect	MODERATE	#N/A	Very serious		RoB, Imprecisionx2
azithromycin	emtricitabine, tenofovir	NA	NA	NA	NA	NA	NA	NA	1.18	0.53	2.61	11.84	-71.57	73.76	VERY LOW	1.18	0.53	2.61	11.84	-71.57 73.76	Indirect	MODERATE	#N/A	Very serious		RoB, Imprecisionx2
azithromycin	favipiravir	NA	NA	NA.	NA	NA NA	NA	NA NA	0.65	0.33	1.29	-53.13	-151.97	24.28	VERY LOW	0.65	0.33	1.29	-53.13	-151.97 24.28	Indirect	MODERATE	Not serious	Very serious		RoB, Imprecisionx2
azithromycin	favipiravir, hydrochloroquine	NA NA	NA NA	NA NA	NA NA	NA NA	NA	NA NA	0.84	0.36	1.96	-22.42	-133.49	56.41	VERY LOW	0.84	0.36	1.96	-22.42	-133.49 56.41	Indirect	MODERATE	#N/A	Very serious		RoB, Imprecisionx2
azithromycin	fluvoxamine	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.27	0.62	2.63	18.8 28.27	-50.39 -36.29	73.8	VERY LOW VERY LOW	1.27	0.62	2.63	18.8 28.27	-50.39 73.8 -36.29 80.99	Indirect	MODERATE MODERATE	#N/A	Very serious		RoB, Imprecisionx2
azithromycin	full-dose anticoagulant GM-CSF inhibitor	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.43	0.69	3.04	-3.43	-36.29 -98.99	65.29	VERY LOW VERY LOW	1.43	0.69	2.3		-36.29 80.99 -98.99 65.29	Indirect	MODERATE	Not serious #N/A	Very serious		RoB, Imprecisionx2
azithromycin azithromycin	GM-CSF inhibitor (hydroxy)chloroquine	0.6	0.12	2.97	NA NA	NA NA	NA NA	VERYLOW	0.75	0.44	2.3	-3.43 NA	-98.99 NA	65.29 NA	VERY LOW VERY LOW	0.73	0.44	1.05	-3.43 -34.27	-98.99 65.29 -75.38 5.46	Direct	MODERATE	#N/A Not serious	Very serious Very serious		RoB, Imprecisionx2
azithromycin azithromycin	(hydroxy)chloroquine IL1 inhibitors	0.6 NA	0.12 NA	2.97 NA	NA NA	NA NA	NA NA	NA NA	1.16	0.49	2.29	12.13	-53.65	66.62	VERY LOW VERY LOW	1.16	0.49	2.29	-34.27 12.13	-75.38 5.46 -53.65 66.62	Indirect	MODERATE	Not serious #N/A	Very serious Very serious	VERY LOW VERY LOW	RoB, Imprecisionx2 RoB, Imprecisionx2
azithromycin	IL1 Innibitors IL6 receptor antagonists without corticosteroids (systemic)	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.16	0.59	2.29	37.83	-9.61	80.9	VERYLOW	1.16	0.59	2.29	37.83	-9.61 80.9	Indirect	MODERATE	Not serious	Very serious		RoB Imprecisionx2
azithromycin	inhaled corticosteroids (systemic)	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.9	0.88	2.91	-17.33	-9.61	67.88	VERYLOW	0.9	0.88	2.91	-17.33	-9.61 80.9 -150.14 67.88	Indirect	MODERATE	Not serious Not serious	Very serious Very serious		RoB, Imprecisionx2
azithromycin	interferon alfa (subcutaneous)	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.9	0.02	4.72	-201.32	-823.37	91.8	VERYLOW	0.9	0.02	4.72	-201.32	-823.37 91.8	Indirect	MODERATE	#N/A	Extremely serious		RoB, Imprecisionx3
azithromycin	interferon beta (subcutaneous)	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.34	0.02	1 44	-9 16	-56.22	35.99	LOW	0.91	0.02	1 44	-9 16	-56.22 35.99	Indirect	MODERATE	Not serious	Serious		RoB, Imprecision
azithromycin	interferon beta (subcutaneous), lopinavir-ritonavir	NA.	NA.	NA.	NA NA	NA NA	NA.	NA NA	0.6	0.33	1.09	-62.52	-149.87	9.07	VERYLOW	0.6	0.33	1.09	-62.52	-149.87 9.07	Indirect	MODERATE	Not serious	Very serious	VERYLOW	RoB, Imprecisionx2
azithromycin	internediate-dose anticoagulant	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.84	0.32	2.2	-02.52	-153.57	61.82	VERY LOW	0.84	0.32	2.2	-02.52	-153.57 61.82	Indirect	MODERATE	#N/A	Very serious		RoB, Imprecisionx2
azithromycin	ivermectin	NA.	NA NA	NA.	NA NA	NA NA	NA.	NA NA	0.94	0.47	1.84	-7.72	-86.97	54.44	VERY LOW	0.94	0.47	1.84	-7.72	-86.97 54.44	Indirect	MODERATE	Not serious	Very serious		RoB, Imprecisionx2
azithromycin	JAK inhibitors	NA.	NA.	NA.	NA NA	NA NA	NA NA	NA NA	1.2	0.78	1.89	17.2	-22.19	57.87	LOW	1.2	0.78	1.89	17.2	-22.19 57.87	Indirect	MODERATE	Not serious	Serious	LOW	RoB. Imprecision
azithromycin	lopinavir-ritonavir	NA.	NA.	NA.	NA NA	NA NA	NA NA	NA NA	0.84	0.70	1.24	-18.04	-57.37	22.79	LOW	0.84	0.57	1.24	-18.04	-57.37 22.79	Indirect	MODERATE	Not serious	Serious	LOW	RoB. Imprecision
azithromycin	molnupiravir	NA.	NA.	NA.	NA NA	NA NA	NA	NA NA	7.02E+05	0.07	2.54E+22	-185.11	-908.98	138.77	VERY LOW	7.02E+05	0	2.54E+22	-185.11	-908.98 138.77	Indirect	MODERATE	#N/A	Extremely seriou		RoB, Imprecisionx3
azithromycin	proxalutamide	NA	NA	NA	NA	NA	NA	NA	15.02	5.85	46.68	101.27	71.15	134.39	VERY LOW	15.02	5.85	46.68	101.27	71.15 134.39	Indirect	LOW	Not serious	Very serious		RoBx2, Imprecisionx2
azithromycin	recombinant human granulocyte colony-stimulating factor	NA	NA	NA	NA	NA	NA	NA	6.05	2.67	13.9	88.93	54.78	124.3	VERY LOW		2.67	13.9	88.93	54.78 124.3	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
		1	1	1	1							1		1		1				1 1			1	1,		. ,p

										Mech	anical ventila	ition															
Comparison		Direct esti							Indirect es							Network e											
		Relative es	Cllower	Clusses	Absolute e	stimate (per	1,000) Clupper	Final rating	Relative est	CLlower	Clure	Absolute e	cl lower	r 1,000) Cl upper	Final rating	Relative e	Cllower	Cluster	Absolute	Cl lower	per 1,000)	GRADE Starting				Final rating	Reasons for
Treatment 1	Treatment 2	estimate	limit	CI upper limit	estimate	limit	limit	i marrating	estimate	limit	CI upper limit	estimate	limit	limit	1 mai raung	estimate	limit	CI upper limit	estimate	limit	limit	evidence	Starting rating	Incoherence	Imprecision	rinarrating	downgrading
azithromycin	remdesivir	NA	NA	NA	NA	NA	NA	NA	1.18	0.79	1.78	15.62	-20.19	54.67	LOW	1.18	0.79	1.78	15.62	-20.19	54.67	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
azithromycin	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	0.38	0.08	1.39	-165.86	-505.62	30.25	VERY LOW	0.38	0.08	1.39	-165.86	-505.62	30.25	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
azithromycin	SGLT2 inhibitors	NA	NA	NA	NA	NA	NA	NA	1.15	0.61	2.15	11.48	-51.36	63.45	VERY LOW	1.15	0.61	2.15	11.48	-51.36	63.45	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
azithromycin	statins sulodexide	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.74 1.96	0.25	2.27	-42.08 38.28	-209.82 -101.94	65.33 110.51	VERY LOW VERY LOW	0.74 1.96	0.25	2.27	-42.08 38.28	-209.82	65.33 110.51	Indirect Indirect	MODERATE	Not serious Not serious	Very serious	VERY LOW VERY LOW	RoB, Imprecisionx2 RoB, Imprecisionx2
azithromycin azithromycin	tyrosine kinase inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	2.22	0.88	5.74	54.04	-9.08	102.82	VERY LOW	2.22	0.88	5.74	54.04	-9.08	102.82	Indirect	MODERATE	Not serious	Very serious Very serious	VERY LOW	RoB, Imprecisionx2
azithromycin	vitamin C	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.79	0.38	1.62	-28.31	-122.89	44.08	VERY LOW	0.79	0.38	1.62	-28.31	-122.89	44.08	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
azithromycin	vitamin D	NA	NA	NA	NA	NA	NA	NA	2.08	0.86	5.16	50.73	-12.63	100.01	VERY LOW	2.08	0.86	5.16	50.73	-12.63	100.01	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
azithromycin, hydroxychloroquine	azithromycin, NSAID	NA	NA	NA	NA	NA	NA	NA	5.68	0.57	141.31	131.07	-91.28	275.04	VERY LOW	5.68	0.57	141.31	131.07	-91.28	275.04	Indirect	MODERATE	#N/A	Extremely serious	VERY LOW	RoB, Imprecisionx3
azithromycin, hydroxychloroquine	azithromycin, NSAID, corticosteroid	NA	NA	NA	NA	NA	NA	NA	2.73	0.34	29.27	84.05	-205.6	250.71	VERY LOW	2.73	0.34	29.27	84.05	-205.6	250.71	Indirect	MODERATE	#N/A	Extremely serious	VERY LOW	RoB, Imprecisionx3
azithromycin, hydroxychloroquine	colchicine	NA	NA	NA	NA	NA	NA	NA	2.21	1.05	4.85	96.52	5.37	217.14	VERY LOW	2.21	1.05	4.85	96.52	5.37	217.14	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
azithromycin, hydroxychloroquine	colchicine, emtricitabine, tenofovir, statins	NA	NA	NA	NA	NA	NA	NA	2.52	0.93	6.89	104.15	-7.16	230.12	VERY LOW	2.52	0.93	6.89	104.15	-7.16	230.12	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
azithromycin, hydroxychloroquine	colchicine, statins	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.67	0.63	4.49 4.61	65.87 97.82	-61.13 7.76	198.6 216.23	VERY LOW VERY LOW	1.67	0.63	4.49 4.61	65.87 97.82	-61.13 7.76	198.6 216.23	Indirect	MODERATE	#N/A	Very serious	VERY LOW VERY LOW	RoB, Imprecisionx2
azithromycin, hydroxychloroquine azithromycin, hydroxychloroquine	corticosteroids (systemic) IL6 receptor antagonists with corticosteroids (systemic)	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	2.23	1.08	4.61	97.82	9.87	216.23	VERYLOW	2.23	1.08	4.61	97.82	9.87	216.23	Indirect	MODERATE	Not serious #N/A	Very serious Very serious	VERY LOW	RoB, Imprecisionx2
azithromycin, hydroxychloroquine	doxycycline	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	3.72	0.7	23.72	119.31	-45.26	259.62	VERYLOW	3.72	0.7	23.72	119.31	-45.26	259.62	Indirect	MODERATE	#N/A	Extremely serious		RoB Imprecisionx3
azithromycin, hydroxychloroquine	emtricitabine, tenofovir	NA.	NA.	NA.	NA.	NA.	NA.	NA.	2.2	0.82	6.02	93.41	-21.48	222.48	VERY LOW	2.2	0.82	6.02	93.41	-21.48	222.48	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
azithromycin, hydroxychloroquine	favipiravir	NA NA	NA.	NA.	NA.	NA NA	NA	NA NA	1.22	0.5	3.03	28.44	-97.72	164.71	VERY LOW	1.22	0.5	3.03	28.44	-97.72	164.71	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
azithromycin, hydroxychloroquine	favipiravir, hydrochloroquine	NA	NA	NA	NA	NA	NA	NA	1.58	0.56	4.46	59.14	-77.66	197.57	VERY LOW	1.58	0.56	4.46	59.14	-77.66	197.57	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
azithromycin, hydroxychloroquine	fluvoxamine	NA	NA	NA	NA	NA	NA	NA	2.39	0.94	6.15	100.37	-6.24	225.18	VERY LOW	2.39	0.94	6.15	100.37	-6.24	225.18	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
azithromycin, hydroxychloroquine	full-dose anticoagulant	NA	NA	NA	NA	NA	NA	NA	2.69	1.06	7	109.83	6.5	233.6	VERY LOW	2.69	1.06	7	109.83	6.5	233.6	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
azithromycin, hydroxychloroquine	GM-CSF inhibitor	NA	NA	NA	NA	NA	NA	NA	1.91	0.7	5.17	78.14	-45.73	209.5	VERY LOW	1.91	0.7	5.17	78.14	-45.73	209.5	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
azithromycin, hydroxychloroquine azithromycin, hydroxychloroquine	(hydroxy)chloroquine IL1 inhibitors	1.3 NA	0.35 NA	4.85 NA	NA NA	NA NA	NA NA	VERY LOW NA	2.83	0.31	79 5.35	NA 93.7	-10.75	NA 218.17	VERY LOW VERY LOW	1.37 2.19	0.7	2.64 5.35	47.3 93.7	-39.13 -10.75	160.13 218.17	Direct Indirect	MODERATE MODERATE	Not serious #N/A	Very serious	VERY LOW VERY LOW	RoB, Imprecisionx2 RoB, Imprecisionx2
azitnromycin, nydroxychioroquine azithromycin, hydroxychloroquine	IL1 innibitors IL6 receptor antagonists without corticosteroids (systemic)	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	3.03	1.31	6.96	119.4	26.97	239.15	VERYLOW	3.03	1.31	6.96	119.4	26.97	239.15	Indirect	MODERATE	Not serious	Very serious Very serious	VERY LOW	RoB, Imprecisionx2
azithromycin, hydroxychloroquine	inhaled corticosteroids (systemic)	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.69	0.53	5.47	64 23	-90.28	207.02	VERYLOW	1.69	0.53	5.47	64.23	-90.28	207.02	Indirect	MODERATE	Not serious	Very serious Very serious	VERY LOW	RoB, Imprecisionx2
azithromycin, hydroxychloroquine	interferon alfa (subcutaneous)	NA.	NA.	NA NA	NA.	NA NA	NA.	NA NA	0.64	0.04	9.39	-119 75	-734.81	207.48	VERY LOW	0.64	0.04	9.39	-119.75	-734.81	207.48	Indirect	MODERATE	#N/A	Extremely serious		RoB. Imprecisionx3
azithromycin, hydroxychloroquine	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	1.71	0.82	3.59	72.41	-20.88	191.92	VERY LOW	1.71	0.82	3.59	72.41	-20.88	191.92	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
azithromycin, hydroxychloroquine	interferon beta (subcutaneous), lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	1.13	0.49	2.59	19.05	-98.73	149.48	VERY LOW	1.13	0.49	2.59	19.05	-98.73	149.48	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
azithromycin, hydroxychloroquine	intermediate-dose anticoagulant	NA	NA	NA	NA	NA	NA	NA	1.58	0.52	4.95	56.7	-95.14	199.97	VERY LOW	1.58	0.52	4.95	56.7	-95.14	199.97	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
azithromycin, hydroxychloroquine	ivermectin	NA	NA	NA	NA	NA	NA	NA	1.76	0.71	4.31	73.85	-37.21	201.34	VERY LOW	1.76	0.71	4.31	73.85	-37.21	201.34	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
azithromycin, hydroxychloroquine	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	2.27	1.08	4.75	98.77	9.08	217.58	VERY LOW	2.27	1.08	4.75	98.77	9.08	217.58	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
azithromycin, hydroxychloroquine	lopinavir-ritonavir	NA	NA	NA NA	NA	NA NA	NA	NA NA	1.57	0.78	3.17	63.52	-25.57	180.98	VERY LOW	1.57	0.78	3.17	63.52	-25.57	180.98	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
azithromycin, hydroxychloroquine azithromycin, hydroxychloroquine	molnupiravir proxalutamide	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.32E+06 28.48	9.18	4.87E+22 100.92	-103.54 182.84	-871.17 96.97	294.41 298.81	VERY LOW VERY LOW	1.32E+06 28.48	9.18	4.87E+2	2 -103.54 182.84	-871.17 96.97	294.41 298.81	Indirect Indirect	LOW	#N/A Not serious	Extremely serious Very serious	MODERATE VERY LOW	RoB, Imprecisionx3 RoBx2, Imprecisionx2
azithromycin, hydroxychloroquine	recombinant human granulocyte colony-stimulating factor	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	11.39	4.19	31.4	170.49	83.27	286.84	VERY LOW	11.39	4.19	31.4	170.49	83.27	286.84	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
azithromycin, hydroxychloroquine	remdesivir	NA.	NA.	NA.	NA.	NA.	NA.	NA.	2.22	1.08	4.55	97.19	9.25	215.04	VERY LOW	2.22	1.08	4.55	97.19	9.25	215.04	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
azithromycin, hydroxychloroquine	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	0.71	0.13	2.95	-84.29	-430.7	145.38	VERY LOW	0.71	0.13	2.95	-84.29	-430.7	145.38	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
azithromycin, hydroxychloroquine	SGLT2 inhibitors	NA	NA	NA	NA	NA	NA	NA	2.15	0.91	5.12	93.04	-8.57	216.89	VERY LOW	2.15	0.91	5.12	93.04	-8.57	216.89	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
azithromycin, hydroxychloroquine	statins	NA	NA	NA	NA	NA	NA	NA	1.39	0.4	5	39.48	-146.95	197.9	VERY LOW	1.39	0.4	5	39.48	-146.95	197.9	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
azithromycin, hydroxychloroquine	sulodexide	NA	NA	NA	NA	NA	NA	NA	3.69	0.73	23.2	119.85	-38.59	257	VERY LOW	3.69	0.73	23.2	119.85	-38.59	257	Indirect	MODERATE	Not serious	Extremely serious		RoB, Imprecisionx3
azithromycin, hydroxychloroquine	tyrosine kinase inhibitors	NA	NA	NA	NA	NA	NA	NA	4.17	1.4	12.72	135.61	34.78	257.3	VERY LOW	4.17	1.4	12.72	135.61	34.78	257.3	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
azithromycin, hydroxychloroquine	vitamin C	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.48 3.91	0.58	3.78 11.51	53.26 132.3	-71.4 31.07	186.64 254.69	VERY LOW VERY LOW	1.48 3.91	0.58	3.78	53.26 132.3	-71.4 31.07	186.64 254.69	Indirect	MODERATE MODERATE	Not serious Not serious	Very serious Very serious	VERY LOW VERY LOW	RoB, Imprecisionx2
azithromycin, NSAID, corticosteroid	azithromycin, NSAID	1 91	0.13	27.33	NA.	NA NA	NA NA	VERYLOW	NA	NA	NA NA	NA	NA	234.09 NA	NA NA	2 12	0.17	47.22	47 01	-126.4	280.85	Direct	MODERATE	#N/A	Extremely serious		RoB. Imprecisionx3
azithromycin, NSAID	colchicine	NA.	NA NA	NA NA	NA.	NA NA	NA.	NA NA	0.39	0.02	3.65	-34.55	-109.76	178 69	VERYLOW	0.39	0.17	3.65	-34.55	-109.76	178 69	Indirect	MODERATE	#N/A	Extremely serious		RoB, Imprecisionx3
azithromycin, NSAID	colchicine, emtricitabine, tenofovir, statins	NA NA	NA.	NA NA	NA.	NA NA	NA	NA	0.44	0.02	4.51	-26.92	-134.31	188.07	VERY LOW	0.44	0.02	4.51	-26.92	-134.31	188.07	Indirect	MODERATE	#N/A	Extremely serious		RoB, Imprecisionx3
azithromycin, NSAID	colchicine, statins	NA	NA	NA	NA	NA	NA	NA	0.29	0.01	2.99	-65.2	-190.84	155.23	VERY LOW	0.29	0.01	2.99	-65.2	-190.84	155.23	Indirect	MODERATE	#N/A	Extremely serious	MODERATE	RoB, Imprecisionx3
azithromycin, NSAID	corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	0.4	0.02	3.59	-33.25	-105.33	180.25	VERY LOW	0.4	0.02	3.59	-33.25	-105.33	180.25	Indirect	MODERATE	#N/A	Extremely serious		RoB, Imprecisionx3
azithromycin, NSAID	IL6 receptor antagonists with corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	0.39	0.02	3.51	-33.56	-101.54	178.24	VERY LOW	0.39	0.02	3.51	-33.56	-101.54	178.24	Indirect	MODERATE	#N/A	Extremely serious		RoB, Imprecisionx3
azithromycin, NSAID	doxycycline	NA	NA	NA NA	NA NA	NA NA	NA	NA NA	0.65	0.02	10.32	-11.76	-182.11	210.81	VERY LOW	0.65	0.02	10.32	-11.76	-182.11	210.81	Indirect	MODERATE	#N/A	Extremely serious		RoB, Imprecisionx3
azithromycin, NSAID	emtricitabine, tenofovir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.39	0.02	3.98	-37.66 -102.62	-150.35 -230.91	179.37 114.08	VERY LOW VERY LOW	0.39	0.02	3.98	-37.66 -102.62	-150.35 -230.91	179.37	Indirect	MODERATE	#N/A #N/A	Extremely serious		RoB, Imprecisionx3
azithromycin, NSAID azithromycin, NSAID	favipiravir favipiravir, hydrochloroguine	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.22	0.01	2.11	-102.62 -71.92	-230.91 -208.7	114.08	VERY LOW VERY LOW	0.22	0.01	2.11	-102.62 -71.92	-230.91 -208.7	114.08	Indirect	MODERATE	#N/A #N/A	Extremely serious Extremely serious		RoB, Imprecisionx3 RoB, Imprecisionx3
azithromycin, NSAID	fluvoxamine	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.42	0.01	4.15	-71.92	-130.09	184	VERY LOW	0.42	0.01	4.15	-71.92	-130.09	184	Indirect	MODERATE	#N/A	Extremely serious		RoB, Imprecisionx3
azithromycin, NSAID	full-dose anticoagulant	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.42	0.02	4.75	-21.23	-117.13	194.34	VERY LOW	0.47	0.02	4.75	-21.23	-117.13	194.34	Indirect	MODERATE	#N/A	Extremely serious		RoB, Imprecisionx3
azithromycin, NSAID	GM-CSF inhibitor	NA	NA	NA	NA	NA	NA	NA	0.34	0.01	3.39	-52.93	-174.93	163.77	VERY LOW	0.34	0.01	3.39	-52.93	-174.93	163.77	Indirect	MODERATE	#N/A	Extremely serious		RoB, Imprecisionx3
azithromycin, NSAID	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	0.24	0.01	2.15	-83.77	-157.64	127.34	VERY LOW	0.24	0.01	2.15	-83.77	-157.64	127.34	Indirect	MODERATE	#N/A	Extremely serious	MODERATE	RoB, Imprecisionx3
azithromycin, NSAID	IL1 inhibitors	NA	NA	NA	NA	NA	NA	NA	0.39	0.02	3.81	-37.37	-133.67	176.92	VERY LOW	0.39	0.02	3.81	-37.37	-133.67	176.92	Indirect	MODERATE		Extremely serious		RoB, Imprecisionx3
azithromycin, NSAID	IL6 receptor antagonists without corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	0.54	0.02	5.17	-11.67	-92.14	201.83	VERY LOW	0.54	0.02	5.17	-11.67	-92.14	201.83	Indirect	MODERATE	#N/A	Extremely serious		RoB, Imprecisionx3
azithromycin, NSAID	inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	0.3	0.01	3.31	-66.83	-224.22	157.58	VERY LOW	0.3	0.01	3.31	-66.83	-224.22	157.58	Indirect	MODERATE		Extremely serious	MODERATE	RoB, Imprecisionx3
azithromycin, NSAID	interferon alfa (subcutaneous) interferon beta (subcutaneous)	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.11	0.01	3.47 2.77	-250.82 -58.66	-876.82 -138.07	104.57 154.86	VERY LOW VERY LOW	0.11	0.01	3.47 2.77	-250.82 -58.66	-876.82 -138.07	104.57 154.86	Indirect	MODERATE		Extremely serious		RoB, Imprecisionx3
azithromycin, NSAID azithromycin, NSAID	interferon beta (subcutaneous) interferon beta (subcutaneous), lopinavir-ritonavir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.3	0.01	1.88	-58.66 -112.02	-138.07 -226.91	154.86	VERY LOW VERY LOW	0.3	0.01	1.88	-58.66	-138.07	154.86	Indirect Indirect	MODERATE		Extremely serious Extremely serious		RoB, Imprecisionx3 RoB, Imprecisionx3
azithromycin, NSAID	internediate-dose anticoagulant	NA NA	NA NA	NA NA	NA.	NA NA	NA NA	NA NA	0.28	0.01	3.02	-74.37	-220.91	151.41	VERY LOW	0.28	0.01	3.02	-74.37	-227.2	151.41	Indirect	MODERATE	#N/A	Extremely serious		RoB. Imprecisionx3
azithromycin, NSAID	intermediate-dose articoagularit	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.28	0.01	2.96	-57.22	-166.61	160.91	VERY LOW	0.28	0.01	2.96	-57.22	-166.61	160.91	Indirect	MODERATE	#N/A	Extremely serious	-	RoB, Imprecisionx3
	1 111		NA	NA	NA	NA.	NA	NA NA											_		180.76				,		RoB. Imprecisionx3
azithromycin, NSAID	JAK inhibitors	NA	INA	INA	14/3	I INA	14/4	INA	0.4	0.02	3.66	-32.3	-104.8	180.76	VERY LOW	0.4	0.02	3.66	-32.3	-104.8	100.70	Indirect	MODERATE	#N/A	Extremely serious	WIODERATE	TOD, IIIIpieciaiolika

										Mech	anical ventila	tion															
Comparison		Direct esti	imate						Indirect est	timate						Network e	stimate										
		Relative es	stimate	L		stimate (per 1	. ,	Final collection	Relative esti	timate			stimate (per		Final and		estimate			estimate (p	, , , ,	GRADE				Cincle of the	
Treatment 1	Treatment 2	Point estimate	CI lower	CI upper limit	Point estimate	CI lower C	Ol upper limit	Final rating	Point estimate	CI lower	CI upper limit	Point estimate	CI lower	CI upper limit	Final rating	Point estimate	CI lower	CI upper limit	Point	CI lower	CI upper limit	Starting evidence	Starting rating	Incoherence	Imprecision	Final rating	Reasons for downgrading
azithromycin NSAID	molnupiravir	NA	NA	NA.	NA	NA NA	NA	NA	2 23F+05	0	1.32F+22	-234 61	-994 47	234 89	VERYLOW	2 23F+05		1.32F+2		-994 47	234 89	Indirect	MODERATE	#N/A	Extremely serious	MODERATE	RoB Imprecisionx3
azithromycin, NSAID	proxalutamide	NA.	NA.	NA.	NA.	NA NA	NA NA	NA NA	5.05	0.18	57.38	51.77	-10.18	263.62	VERYLOW	5.05	0.18	57.38	51.77	-10.18	263.62	Indirect	LOW	#N/A	Extremely serious		RoBx2, Imprecisionx3
azithromycin, NSAID	recombinant human granulocyte colony-stimulating factor	NA.	NA.	NA.	NA.	NA NA	NA NA	NA NA	2.02	0.08	20.7	39.43	-26.93	250.62	VERYLOW	2.02	0.08	20.7	39 43	-26.93	250.43	Indirect	MODERATE	#N/A	Extremely serious		RoB. Imprecisionx3
azithromycin, NSAID	remdesivir	NA.	NA.	NA.	NA.	NA NA	NA NA	NA NA	0.4	0.02	3.57	-33.88	-103.34	178.41	VERYLOW	0.4	0.02	3.57	-33.88	-103.34	178 41	Indirect	MODERATE	#N/A	Extremely serious		RoB. Imprecisionx3
azithromycin, NSAID	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	0.12	0	1.66	-215.36	-565.06	63.8	VERY LOW	0.12	0	1.66	-215.36	-565.06	63.8	Indirect	MODERATE	#N/A	Extremely serious	MODERATE	RoB, Imprecisionx3
azithromycin, NSAID	SGLT2 inhibitors	NA	NA	NA	NA	NA	NA	NA	0.38	0.02	3.65	-38.02	-131.16	175.43	VERY LOW	0.38	0.02	3.65	-38.02	-131.16	175.43	Indirect	MODERATE	#N/A	Extremely serious	MODERATE	RoB, Imprecisionx3
azithromycin, NSAID	statins	NA	NA	NA	NA	NA	NA	NA	0.24	0.01	2.74	-91.58	-274.96	137.24	VERY LOW	0.24	0.01	2.74	-91.58	-274.96	137.24	Indirect	MODERATE	#N/A	Extremely serious	MODERATE	RoB, Imprecisionx3
azithromycin, NSAID	sulodexide	NA	NA	NA	NA	NA	NA	NA	0.64	0.02	10.57	-11.22	-172.48	212.06	VERY LOW	0.64	0.02	10.57	-11.22	-172.48	212.06	Indirect	MODERATE	#N/A	Extremely serious	MODERATE	RoB, Imprecisionx3
azithromycin, NSAID	tyrosine kinase inhibitors	NA	NA	NA	NA	NA	NA	NA	0.73	0.03	7.77	4.54	-88.74	218.59	VERY LOW	0.73	0.03	7.77	4.54	-88.74	218.59	Indirect	MODERATE	#N/A	Extremely serious	MODERATE	RoB, Imprecisionx3
azithromycin, NSAID	vitamin C	NA	NA	NA	NA	NA	NA	NA	0.26	0.01	2.51	-77.81	-199.63	141.04	VERY LOW	0.26	0.01	2.51	-77.81	-199.63	141.04	Indirect	MODERATE	#N/A	Extremely serious	MODERATE	RoB, Imprecisionx3
azithromycin, NSAID	vitamin D	NA	NA	NA	NA	NA	NA	NA	0.69	0.03	7.18	1.23	-91.6	214.21	VERY LOW	0.69	0.03	7.18	1.23	-91.6	214.21	Indirect	MODERATE	#N/A	Extremely serious		RoB, Imprecisionx3
azithromycin, NSAID, corticosteroid	colchicine	NA	NA	NA	NA	NA	NA	NA	0.81	0.08	6.14	12.47	-95.62	291.61	VERY LOW	0.81	0.08	6.14	12.47	-95.62	291.61	Indirect	MODERATE	#N/A	Extremely serious		RoB, Imprecisionx3
azithromycin, NSAID, corticosteroid	colchicine, emtricitabine, tenofovir, statins	NA	NA	NA	NA	NA	NA	NA	0.92	0.09	7.66	20.09	-111.73	301.14	VERY LOW	0.92	0.09	7.66	20.09	-111.73	301.14	Indirect	MODERATE	#N/A	Extremely serious		RoB, Imprecisionx3
azithromycin, NSAID, corticosteroid	colchicine, statins	NA	NA	NA	NA	NA	NA	NA	0.61	0.06	5.03	-18.19	-166.89	263.86	VERY LOW	0.61	0.06	5.03	-18.19	-166.89	263.86	Indirect	MODERATE	#N/A	Extremely serious		RoB, Imprecisionx3
azithromycin, NSAID, corticosteroid	corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	0.82	0.08	6.08	13.77	-91.74	292.53	VERY LOW	0.82	0.08	6.08	13.77	-91.74	292.53	Indirect	MODERATE	#N/A	Extremely serious		RoB, Imprecisionx3
azithromycin, NSAID, corticosteroid	IL6 receptor antagonists with corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	0.81	0.08	5.98	13.45	-88.83	291.79	VERY LOW	0.81	80.0	5.98	13.45	-88.83	291.79	Indirect	MODERATE	+	Extremely serious		RoB, Imprecisionx3
azithromycin, NSAID, corticosteroid	doxycycline	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.34	0.1	18.41	35.26	-151.86	321.5	VERY LOW	1.34	0.1	18.41	35.26	-151.86	321.5	Indirect	MODERATE	#N/A	Extremely serious		RoB, Imprecisionx3
azithromycin, NSAID, corticosteroid azithromycin, NSAID, corticosteroid	emtricitabine, tenofovir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.81	0.08	6.62 3.54	9.36 -55.61	-127.72 -203.7	286.37	VERY LOW VERY LOW	0.81	0.08	6.62 3.54	9.36	-127.72 -203.7	286.37 225.89	Indirect	MODERATE		Extremely serious Extremely serious		RoB, Imprecisionx3 RoB, Imprecisionx3
azithromycin, NSAID, corticosteroid azithromycin, NSAID, corticosteroid	favipiravir hvdrochloroquine	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.45	0.04	3.54 4.87	-55.61 -24.91	-203.7 -183.95	257.52	VERY LOW	0.45	0.04	3.54 4.87	-55.61 -24.91	-203.7 -183.95	257.52	Indirect	MODERATE	#N/A	Extremely serious		RoB, Imprecisionx3 RoB. Imprecisionx3
azithromycin, NSAID, corticosteroid azithromycin, NSAID, corticosteroid	fluvoxamine	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.58	0.05	7.31	16.32	-183.95 -108.56	297.26	VERY LOW VERY LOW	0.58	0.05	7.31	16.32	-183.95 -108.56	297.26	Indirect	MODERATE	#N/A	Extremely serious	MODERATE	RoB, Imprecisionx3
azithromycin, NSAID, corticosteroid azithromycin, NSAID, corticosteroid	full-dose anticoagulant	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.87	0.08	7.31	25.78	-108.56 -97.7	306.37	VERY LOW VERY LOW	0.87	0.08	7.31	25.78	-108.56	306.37	Indirect	MODERATE	#N/A	Extremely serious		RoB, Imprecisionx3
azithromycin, NSAID, contcosteroid	GM-CSF inhibitor	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.69	0.09	5.75	-5.92	-151.14	278.88	VERY LOW	0.69	0.09	5.75	-5.92	-151.14	278.88	Indirect	MODERATE		Extremely serious		RoB, Imprecisionx3
azithromycin, NSAID, corticosteroid	(hydroxy)chloroquine	NA NA	NA.	NA.	NA.	NA NA	NA NA	NA NA	0.5	0.05	3.69	-36.75	-143.03	241.32	VERY LOW	0.5	0.05	3.69	-36.75	-143.03	241.32	Indirect	MODERATE		Extremely serious		RoB, Imprecisionx3
azithromycin. NSAID. corticosteroid	IL1 inhibitors	NA	NA	NA	NA	NA	NA	NA	0.8	0.08	6.35	9.65	-115.07	292.13	VERY LOW	0.8	0.08	6.35	9.65	-115.07	292.13	Indirect	MODERATE	#N/A	Extremely serious		RoB. Imprecisionx3
azithromycin, NSAID, corticosteroid	IL6 receptor antagonists without corticosteroids (systemic)	NA.	NA.	NA.	NA.	NA NA	NA NA	NA NA	1.1	0.11	8.75	35.35	-75.48	314.59	VERY LOW	1.1	0.11	8.75	35.35	-75.48	314.59	Indirect	MODERATE	#N/A	Extremely serious		RoB. Imprecisionx3
azithromycin, NSAID, corticosteroid	inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	0.61	0.05	5.74	-19.82	-196.48	268.96	VERY LOW	0.61	0.05	5.74	-19.82	-196.48	268.96	Indirect	MODERATE	#N/A	Extremely serious		RoB. Imprecisionx3
azithromycin, NSAID, corticosteroid	interferon alfa (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	0.23	0.01	6.24	-203.81	-837.56	206.87	VERY LOW	0.23	0.01	6.24	-203.81	-837.56	206.87	Indirect	MODERATE	#N/A	Extremely serious	MODERATE	RoB, Imprecisionx3
azithromycin, NSAID, corticosteroid	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	0.63	0.06	4.74	-11.64	-122.02	267.14	VERY LOW	0.63	0.06	4.74	-11.64	-122.02	267.14	Indirect	MODERATE	#N/A	Extremely serious	MODERATE	RoB, Imprecisionx3
azithromycin, NSAID, corticosteroid	interferon beta (subcutaneous), lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.41	0.04	3.18	-65.01	-205.2	214.12	VERY LOW	0.41	0.04	3.18	-65.01	-205.2	214.12	Indirect	MODERATE	#N/A	Extremely serious	MODERATE	RoB, Imprecisionx3
azithromycin, NSAID, corticosteroid	intermediate-dose anticoagulant	NA	NA	NA	NA	NA	NA	NA	0.58	0.05	5.2	-27.35	-201.71	256.9	VERY LOW	0.58	0.05	5.2	-27.35	-201.71	256.9	Indirect	MODERATE	#N/A	Extremely serious	MODERATE	RoB, Imprecisionx3
azithromycin, NSAID, corticosteroid	ivermectin	NA	NA	NA	NA	NA	NA	NA	0.64	0.06	5.09	-10.2	-144.19	271.9	VERY LOW	0.64	0.06	5.09	-10.2	-144.19	271.9	Indirect	MODERATE	#N/A	Extremely serious	MODERATE	RoB, Imprecisionx3
azithromycin, NSAID, corticosteroid	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	0.83	0.08	6.2	14.71	-90.35	293.4	VERY LOW	0.83	0.08	6.2	14.71	-90.35	293.4	Indirect	MODERATE	#N/A	Extremely serious	MODERATE	RoB, Imprecisionx3
lopinavir-ritonavir	azithromycin, NSAID, corticosteroid	1.6	0.19	13.35	NA	NA	NA	VERY LOW	NA	NA	NA	NA	NA	NA	NA	1.73	0.24	16.49	20.53	-254.55	123.24	Direct	MODERATE	#N/A	Extremely serious		RoB, Imprecisionx3
azithromycin, NSAID, corticosteroid	molnupiravir	NA	NA	NA	NA	NA	NA	NA	4.57E+05	0	1.73E+22	-187.59	-979.2	346.77	VERY LOW	4.57E+05	0	1.73E+2		-979.2	346.77	Indirect	MODERATE	#N/A	Extremely serious		RoB, Imprecisionx3
azithromycin, NSAID, corticosteroid	proxalutamide	NA	NA	NA	NA	NA	NA	NA	10.45	0.94	98.04	98.79	-0.51	376.68	VERY LOW	10.45	0.94	98.04	98.79	-0.51	376.68	Indirect	LOW	#N/A	Extremely serious		RoBx2, Imprecisionx3
azithromycin, NSAID, corticosteroid	recombinant human granulocyte colony-stimulating factor	NA	NA	NA	NA	NA	NA	NA	4.15	0.38	35.59	86.44	-14.49	364.98	VERY LOW	4.15	0.38	35.59	86.44	-14.49	364.98	Indirect	MODERATE	#N/A	Extremely serious		RoB, Imprecisionx3
azithromycin, NSAID, corticosteroid	remdesivir	NA	NA	NA	NA	NA	NA	NA	0.81	0.08	6.04	13.14	-90.68	291.58	VERY LOW	0.81	0.08	6.04	13.14	-90.68	291.58	Indirect	MODERATE	#N/A	Extremely serious		RoB, Imprecisionx3
azithromycin, NSAID, corticosteroid	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	0.25	0.02	2.79	-168.34	-529.01	165.9	VERY LOW	0.25	0.02	2.79	-168.34	-529.01	165.9	Indirect	MODERATE	#N/A	Extremely serious		RoB, Imprecisionx3
azithromycin, NSAID, corticosteroid	SGLT2 inhibitors	NA	NA	NA	NA	NA	NA	NA	0.79	0.08	6.22	8.99	-111.36	289.28	VERY LOW	0.79	80.0	6.22	8.99	-111.36	289.28	Indirect	MODERATE	#N/A	Extremely serious		RoB, Imprecisionx3
azithromycin, NSAID, corticosteroid	statins	NA	NA NA	NA NA	NA	NA NA	NA	NA NA	0.51	0.04	4.95	-44.57 35.79	-249.57	244.37	VERY LOW VERY LOW	0.51	0.04	4.95	-44.57	-249.57	244.37	Indirect	MODERATE	#N/A #N/A	Extremely serious		RoB, Imprecisionx3
azithromycin, NSAID, corticosteroid azithromycin, NSAID, corticosteroid	sulodexide tyrosine kinase inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.34	0.09	19.12	35.79 51.56	-145 -68 66	322.14	VERY LOW	1.34 1.53	0.09	19.12 13.13	35.79 51.56	-145 -68.66	322.14	Indirect Indirect	MODERATE	#N/A	Extremely serious Extremely serious		RoB, Imprecisionx3 RoB, Imprecisionx3
azithromycin, NSAID, corticosteroid azithromycin, NSAID, corticosteroid	vitamin C	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.55	0.14	4.43	-30.79	-176.58	251.53	VERYLOW	0.55	0.14	4.43	-30.79	-176.58	251.53	Indirect	MODERATE	#N/A	Extremely serious		RoB, Imprecisionx3
azithromycin, NSAID, corticosteroid	vitamin D	NA NA	NA NA	NA NA	NA.	NA NA	NA NA	NA NA	1.42	0.03	12.8	48.24	-72.24	325.39	VERY LOW	1.42	0.03	12.8	48.24	-72.24	325.39	Indirect	MODERATE	#N/A	Extremely serious		RoB, Imprecisionx3
colchicine	colchicine, emtricitabine, tenofovir, statins	NA NA	NA NA	NA NA	NA.	NA NA	NA NA	NA NA	1.14	0.13	2.6	7.63	-71.23	65.2	VERY LOW	1.14	0.13	2.6	7.63	-71.23	65.2	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
colchicine	colchicine, entirictabilite, teriolovii, statiris	NA NA	NA NA	NA NA	NA.	NA NA	NA NA	NA NA	0.76	0.48	1.67	-30.65	-129.89	40.58	VERY LOW	0.76	0.48	1.67	-30.65	-129.89	40.58	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
colchicine	corticosteroids (systemic)	NA.	NA.	NA NA	NA.	NA NA	NA NA	NA NA	1.01	0.62	1.57	1.3	-38.46	40.29	LOW	1.01	0.62	1.57	1.3	-38.46	40.29	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
colchicine	IL6 receptor antagonists with corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	1.01	0.63	1.49	0.99	-35.27	36.67	LOW	1.01	0.63	1.49	0.99	-35.27	36.67	Indirect	MODERATE	#N/A	Serious	LOW	RoB, Imprecision
colchicine	doxycycline	NA	NA	NA	NA	NA	NA	NA	1.67	0.35	9.92	22.79	-126.59	95.28	VERY LOW	1.67	0.35	9.92	22.79	-126.59	95.28	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
colchicine	emtricitabine, tenofovir	NA	NA	NA	NA	NA	NA	NA	1	0.43	2.26	-3.11	-87.4	58.38	VERY LOW	1	0.43	2.26	-3.11	-87.4	58.38	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
colchicine	favipiravir	NA	NA	NA	NA	NA	NA	NA	0.55	0.27	1.11	-68.08	-166.74	8.48	VERY LOW	0.55	0.27	1.11	-68.08	-166.74	8.48	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
colchicine	favipiravir, hydrochloroquine	NA	NA	NA	NA	NA	NA	NA	0.72	0.3	1.67	-37.38	-148.91	40.8	VERY LOW	0.72	0.3	1.67	-37.38	-148.91	40.8	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
colchicine	fluvoxamine	NA	NA	NA	NA	NA	NA	NA	1.08	0.5	2.25	3.85	-65.92	58.28	VERY LOW	1.08	0.5	2.25	3.85	-65.92	58.28	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
colchicine	full-dose anticoagulant	NA	NA	NA	NA	NA	NA	NA	1.22	0.57	2.58	13.31	-52	65.05	VERY LOW	1.22	0.57	2.58	13.31	-52	65.05	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
colchicine	GM-CSF inhibitor	NA	NA	NA	NA	NA	NA	NA	0.86	0.36	1.98	-18.38	-114.48	50.41	VERY LOW	0.86	0.36	1.98	-18.38	-114.48	50.41	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
colchicine	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	0.63	0.38	0.92	-49.22	-92.37	-9.21	MODERATE	0.63	0.38	0.92	-49.22	-92.37	-9.21	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
colchicine	IL1 inhibitors	NA	NA	NA	NA	NA	NA	NA	0.99	0.49	1.96	-2.82	-69.71	51.14	VERY LOW	0.99	0.49	1.96	-2.82	-69.71	51.14	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
colchicine	IL6 receptor antagonists without corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	1.37	0.72	2.5	22.88	-25.75	65.44	VERY LOW	1.37	0.72	2.5	22.88	-25.75	65.44	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
colchicine	inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	0.77	0.27	2.09	-32.29	-164.56	52.53	VERY LOW	0.77	0.27	2.09	-32.29	-164.56	52.53	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
colchicine	interferon alfa (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	0.29	0.02	4.01	-216.27	-840.87	75.99	VERY LOW	0.29	0.02	4.01	-216.27	-840.87	75.99	Indirect	MODERATE	#N/A	Extremely serious	MODERATE	RoB, Imprecisionx3
colchicine	interferon beta (subcutaneous)	NA	NA	NA	NA	NA NA	NA	NA	0.78	0.46	1.24	-24.11	-72.46	19.79	LOW	0.78	0.46	1.24	-24.11	-72.46	19.79	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
colchicine	interferon beta (subcutaneous), lopinavir-ritonavir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.51	0.26	0.94	-77.47	-166.3	-6.16	VERY LOW	0.51	0.26	0.94	-77.47	-166.3	-6.16	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
colchicine	intermediate-dose anticoagulant	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.71	0.27	1.87	-39.82	-168.93	46.51	VERY LOW VERY LOW	0.71	0.27	1.87	-39.82	-168.93	46.51	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
colchicine	ivermectin	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.8	0.38	1.58	-22.67	-101.53	39.05	VERY LOW	0.8	0.38	1.58	-22.67	-101.53 -37.73	39.05 41.52	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
colchicine colchicine	JAK inhibitors	NA NA	NA NA		NA NA	NA NA	NA NA	NA NA	1.03 0.71	0.63	1.61	2.25 -33	-37.73 -73.15	41.52 6.39	LOW	1.03 0.71	0.63	1.61	2.25 -33	-37.73 -73.15	6.39	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
colchicine	lopinavir-ritonavir molnupiravir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.71 5.95F+05		1.07 2.17E+22		-73.15 -924.51	122.96	VERYLOW				2 -200.06		122.96	Indirect	MODERATE	Not serious #N/A	Serious		RoB, Imprecisionx3
Colchicine	monupiravii	INA	INA	INA	INA	INA	INA	NA	0.90E+05	U	2.1/E+22	-200.00	-924.51	122.90	VERTLOW	13.95E+05	U	Z.1/E+2	2 -200.0b	-924.51	122.90	Indirect	WODERATE	#IN/A	Extremely serious	WODERATE	Rob, ImprecisionX3

										Mech	anical ventila	ation															
Comparison		Direct esti							Indirect es							Network 6											
		Relative es	Cllower	Cl upper	Absolute e	ctimate (per	Clupper	Final rating	Relative es	Cllower	CI upper	Absolute e	stimate (pe	Cl upper	Final rating	Relative of	CLlower	CI uppe		Cl lower	(per 1,000)	GRADE Starting				Final rating	Reasons for
Treatment 1	Treatment 2	estimate	limit	limit	estimate	limit	limit	- marrating	estimate	limit	limit	estimate	limit	limit	- marrating	estimate	limit	limit	estimate	limit	limit	evidence	Starting rating	Incoherence	Imprecision	- maraang	downgrading
colchicine	proxalutamide	NA	NA	NA	NA	NA	NA	NA	12.76	4.88	40.03	86.32	55.42	118.81	VERY LOW	12.76	4.88	40.03	86.32	55.42	118.81	Indirect	LOW	Not serious	Very serious	VERY LOW	RoBx2, Imprecisionx2
colchicine	recombinant human granulocyte colony-stimulating factor	NA	NA	NA	NA	NA	NA	NA	5.15	2.19	11.88	73.97	38.97	108.21	VERY LOW	5.15	2.19	11.88		38.97	108.21	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
colchicine	remdesivir	NA	NA	NA NA	NA	NA	NA	NA NA	1.01	0.63	1.52	0.67 -180.81	-35.97	38.44	VERYLOW	1.01	0.63	1.52		-35.97 -519.55	38.44	Indirect	MODERATE	Not serious	Serious	VERYLOW	RoB, Imprecision
colchicine colchicine	serine protease inhibitors SGLT2 inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.32	0.06	1.19	-180.81	-519.55 -67.3	15.23 47.8	VERYLOW	0.32	0.06	1.19		-67.3	15.23 47.8	Indirect	MODERATE	#N/A #N/A	Very serious Very serious	VERY LOW	RoB, Imprecisionx2 RoB. Imprecisionx2
colchicine	statins	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.63	0.49	1.95	-57.04	-225.04	49.62	VERY LOW	0.63	0.49	1.95		-225.04	49.62	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB. Imprecisionx2
colchicine	sulodexide	NA	NA.	NA.	NA	NA.	NA.	NA.	1.66	0.27	9.58	23.33	-116.79	94.79	VERY LOW	1.66	0.37	9.58		-116.79	94.79	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB. Imprecisionx2
colchicine	tyrosine kinase inhibitors	NA	NA	NA	NA	NA	NA	NA	1.89	0.72	4.91	39.09	-25.01	86.98	VERY LOW	1.89	0.72	4.91	39.09	-25.01	86.98	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
colchicine	vitamin C	NA	NA	NA	NA	NA	NA	NA	0.67	0.31	1.39	-43.26	-139.03	28.81	VERY LOW	0.67	0.31	1.39	-43.26	-139.03	28.81	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
colchicine	vitamin D	NA	NA	NA	NA	NA	NA	NA	1.76	0.71	4.41	35.78	-27.07	83.88	VERY LOW	1.76	0.71	4.41		-27.07	83.88	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
colchicine, statins	colchicine, emtricitabine, tenofovir, statins	1.5	0.41	5.47	NA	NA	NA	VERY LOW	NA	NA	NA	NA	NA	NA	NA	1.5	0.71	3.2	38.28	-30.95	118.78	Direct	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
colchicine, emtricitabine, tenofovir, statins	corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	0.89	0.4	1.98	-6.33	-60.94	69.97	VERY LOW	0.89	0.4	1.98	_	-60.94	69.97	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
colchicine, emtricitabine, tenofovir, statins	IL6 receptor antagonists with corticosteroids (systemic) doxycycline	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.88	0.4	1.92 9.7	-6.64 15.16	-58.09 -136.68	68.17	VERY LOW VERY LOW	0.88	0.4	1.92 9.7	-6.64 15.16	-58.09 -136.68	68.17	Indirect	MODERATE	#N/A #N/A	Very serious Extremely serious	VERY LOW MODERATE	RoB, Imprecisionx2
emtricitabine, tenofovir	colchicine emtricitabine tenofovir statins	1.14	0.31	4 19	NA NA	NA NA	NA NA	VERYLOW	NA	NA	NA NA	NA	-130.00 NA	NA	NA NA	1.46	0.27	2.48		-55.83	79.68	Direct	MODERATE	#N/A	Very serious	VFRYLOW	RoB, Imprecisionx2
colchicine, emtricitabine, tenofovir, statins	favipiravir	NA.	NA.	NA.	NA.	NA.	NA.	NA NA	0.48	0.19	1.29	-75.71	-182.04	23.27	VERY LOW	0.48	0.19	1.29		-182.04	23.27	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB. Imprecisionx2
colchicine, emtricitabine, tenofovir, statins	favipiravir, hydrochloroquine	NA NA	NA.	NA NA	NA	NA NA	NA.	NA NA	0.63	0.21	1.86	-45.01	-164.12	57.93	VERY LOW	0.63	0.21	1.86		-164.12	57.93	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
colchicine, emtricitabine, tenofovir, statins	fluvoxamine	NA	NA	NA	NA	NA	NA	NA	0.95	0.35	2.59	-3.78	-83.66	81.99	VERY LOW	0.95	0.35	2.59	-3.78	-83.66	81.99	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
colchicine, emtricitabine, tenofovir, statins	full-dose anticoagulant	NA	NA	NA	NA	NA	NA	NA	1.07	0.39	2.95	5.68	-69.39	90.35	VERY LOW	1.07	0.39	2.95		-69.39	90.35	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
colchicine, emtricitabine, tenofovir, statins	GM-CSF inhibitor	NA	NA	NA	NA	NA	NA	NA	0.76	0.26	2.19	-26.01	-129.26	70.16	VERY LOW	0.76	0.26	2.19		-129.26	70.16	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
colchicine, emtricitabine, tenofovir, statins	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	0.54	0.25	1.18	-56.85	-113.2	19.43	VERY LOW	0.54	0.25	1.18		-113.2	19.43	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
colchicine, emtricitabine, tenofovir, statins	IL1 inhibitors	NA	NA	NA	NA	NA NA	NA	NA NA	0.87	0.33	2.27	-10.45	-87.49	74.67	VERY LOW	0.87	0.33	2.27	-10.45	-87.49	74.67	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
colchicine, emtricitabine, tenofovir, statins colchicine, emtricitabine, tenofovir, statins	IL6 receptor antagonists without corticosteroids (systemic) inhaled corticosteroids	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.2 0.67	0.49	2.93	15.25 -39.92	-45.98 -178.95	93.54 67.71	VERY LOW VERY LOW	1.2 0.67	0.49	2.93	15.25 -39.92	-45.98 -178.95	93.54 67.71	Indirect	MODERATE MODERATE	#N/A #N/A	Very serious Very serious	VERY LOW VERY LOW	RoB, Imprecisionx2 RoB. Imprecisionx2
colchicine, emtricitabine, tenofovir, statins	interferon alfa (subcutaneous)	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.67	0.2	3.76	-223.9	-845.76	78.87	VERYLOW	0.07	0.2	3.76	-223.9	-845.76	78.87	Indirect	MODERATE	#N/A	Extremely serious		RoB, Imprecisionx3
colchicine, emiricitabine, tenolovir, statins	interferon beta (subcutaneous)	NA NA	NA NA	NA NA	NA.	NA NA	NA NA	NA NA	0.68	0.01	1.56	-31.74	-92.76	47.16	VERYLOW	0.68	0.01	1.56		-92.76	47.16	Indirect	MODERATE	#N/A	Very serious	VERYLOW	RoB. Imprecisionx2
colchicine, emtricitabine, tenofovir, statins	interferon beta (subcutaneous). lopinavir-ritonavir	NA.	NA.	NA NA	NA.	NA NA	NA NA	NA NA	0.45	0.18	1.12	-85.1	-181.97	10.97	VERY LOW	0.45	0.18	1.12		-181.97	10.97	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB. Imprecisionx2
colchicine, emtricitabine, tenofovir, statins	intermediate-dose anticoagulant	NA	NA	NA	NA	NA	NA	NA	0.63	0.19	2.04	-47.45	-181.56	61.84	VERY LOW	0.63	0.19	2.04	-47.45	-181.56	61.84	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
colchicine, emtricitabine, tenofovir, statins	ivermectin	NA	NA	NA	NA	NA	NA	NA	0.69	0.27	1.86	-30.3	-119.59	61.15	VERY LOW	0.69	0.27	1.86	-30.3	-119.59	61.15	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
colchicine, emtricitabine, tenofovir, statins	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	0.9	0.4	2.03	-5.38	-60.33	71.92	VERY LOW	0.9	0.4	2.03	-5.38	-60.33	71.92	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
colchicine, emtricitabine, tenofovir, statins	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.62	0.28	1.38	-40.62	-95.63	36.07	VERY LOW	0.62	0.28	1.38	-40.62	-95.63	36.07	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
colchicine, emtricitabine, tenofovir, statins	molnupiravir	NA	NA	NA	NA	NA	NA	NA	5.62E+05	0	1.89E+22	-207.69	-947.74	152	VERY LOW	5.62E+05	0	1.89E+2		-947.74	152	Indirect	MODERATE	#N/A	Extremely serious		RoB, Imprecisionx3
colchicine, emtricitabine, tenofovir, statins	proxalutamide	NA	NA	NA	NA	NA	NA	NA	11.28	3.51	41.67	78.69	31.09	152.67	VERY LOW	11.28	3.51	41.67		31.09	152.67	Indirect	LOW	#N/A	Very serious	VERY LOW	RoBx2, Imprecisionx2
colchicine, emtricitabine, tenofovir, statins	recombinant human granulocyte colony-stimulating factor	NA	NA NA	NA NA	NA	NA NA	NA	NA NA	4.52	1.57	13.28	66.34	16.16	141.14	VERY LOW VERY LOW	4.52	1.57	13.28		16.16	141.14	Indirect	MODERATE MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
colchicine, emtricitabine, tenofovir, statins colchicine, emtricitabine, tenofovir, statins	remdesivir serine protease inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.88	0.4	1.96	-6.96 -188.44	-59.59 -531.17	69.23 18.13	VERY LOW	0.88	0.4	1.96 1.24		-59.59 -531.17	69.23 18.13	Indirect	MODERATE	#N/A #N/A	Very serious Very serious	VERY LOW VERY LOW	RoB, Imprecisionx2 RoB, Imprecisionx2
colchicine, emtricitabine, tenofovir, statins	SGLT2 inhibitors	NA.	NA NA	NA NA	NA.	NA NA	NA.	NA NA	0.85	0.34	2.16	-11.1	-85.56	73.11	VERY LOW	0.85	0.34	2.16		-85.56	73.11	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
colchicine, emtricitabine, tenofovir, statins	statins	NA.	NA.	NA.	NA.	NA.	NA.	NA.	0.56	0.15	2.04	-64.67	-239.71	61.01	VERY LOW	0.56	0.15	2.04	-64.67	-239.71	61.01	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
colchicine, emtricitabine, tenofovir, statins	sulodexide	NA	NA	NA	NA	NA	NA	NA	1.47	0.28	9.29	15.7	-129.79	116.63	VERY LOW	1.47	0.28	9.29	15.7	-129.79	116.63	Indirect	MODERATE	#N/A	Extremely serious	MODERATE	RoB, Imprecisionx3
colchicine, emtricitabine, tenofovir, statins	tyrosine kinase inhibitors	NA	NA	NA	NA	NA	NA	NA	1.66	0.53	5.23	31.46	-42.74	113.02	VERY LOW	1.66	0.53	5.23	31.46	-42.74	113.02	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
colchicine, emtricitabine, tenofovir, statins	vitamin C	NA	NA	NA	NA	NA	NA	NA	0.59	0.22	1.59	-50.89	-152.86	46.02	VERY LOW	0.59	0.22	1.59		-152.86	46.02	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
colchicine, emtricitabine, tenofovir, statins	vitamin D	NA	NA	NA	NA	NA	NA	NA	1.55	0.51	4.81	28.15	-45.65	110.86	VERY LOW	1.55	0.51	4.81	28.15	-45.65	110.86	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
colchicine, statins	corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	1.33	0.61	2.88	31.95	-37.1	128.93	VERY LOW	1.33	0.61	2.88		-37.1	128.93	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
colchicine, statins	IL6 receptor antagonists with corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	1.32	0.63	2.8	31.64	-35.06	127.61	VERY LOW	1.32	0.63	2.8	31.64	-35.06	127.61	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
colchicine, statins	doxycycline	NA 0.76	NA 0.21	NA 2.76	NA NA	NA NA	NA NA	VERYLOW	2.22 NA	0.41 NA	14.22 NA	53.44 NA	-103.77 NA	173.59 NA	VERY LOW	0.76	0.41	14.22		-103.77 -108.52	173.59 45.02	Indirect	MODERATE	#N/A #N/A	Extremely serious	MODERATE	RoB, Imprecisionx3
colchicine, statins	colchicine, statins favipiravir	NA	NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.73	0.29	1.87	-37.43	-152 69	79 94	VERYLOW	0.76	0.36	1.59		-108.52	79.94	Indirect	MODERATE	#N/A #N/A	Very serious Very serious	VERY LOW	RoB, Imprecisionx2 RoB, Imprecisionx2
colchicine, statins	favipiravir, hydrochloroquine	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.75	0.29	2.71	-6.73	-132.09	113.49	VERY LOW	0.73	0.29	2.71	-6.73	-132.09	113.49	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
colchicine, statins	fluvoxamine	NA NA	NA.	NA NA	NA	NA NA	NA.	NA NA	1.43	0.54	3.79	34.5	-55.9	138.75	VERY LOW	1.43	0.54	3.79		-55.9	138.75	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
colchicine, statins	full-dose anticoagulant	NA	NA	NA	NA	NA	NA	NA	1.6	0.61	4.34	43.97	-42.51	148.64	VERY LOW	1.6	0.61	4.34	43.97	-42.51	148.64	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
colchicine, statins	GM-CSF inhibitor	NA	NA	NA	NA	NA	NA	NA	1.14	0.4	3.22	12.27	-99.09	125.9	VERY LOW	1.14	0.4	3.22	_	-99.09	125.9	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
colchicine, statins	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	0.82	0.38	1.72	-18.57	-89.86	78.48	VERY LOW	0.82	0.38	1.72		-89.86	78.48	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
colchicine, statins	IL1 inhibitors	NA	NA	NA	NA	NA	NA	NA	1.31	0.52	3.32	27.83	-59.58	132.14	VERY LOW	1.31	0.52	3.32	27.83	-59.58	132.14	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
colchicine, statins	IL6 receptor antagonists without corticosteroids (systemic)	NA NA	NA NA	NA	NA NA	NA NA	NA NA	NA NA	1.81	0.75	4.28	53.53 -1.64	-20.94 -146.73	151.83	VERY LOW VERY LOW	1.81	0.75	4.28	53.53 -1.64	-20.94 -146.73	151.83 122.2	Indirect	MODERATE MODERATE	#N/A	Very serious	VERY LOW VERY LOW	RoB, Imprecisionx2
colchicine, statins colchicine, statins	inhaled corticosteroids interferon alfa (subcutaneous)	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.38	0.31	3.33 5.7	-1.64 -185.62	-146.73 -804.99	122.2	VERY LOW VERY LOW	0.38	0.31	3.33 5.7	-1.64 -185.62	-146.73 -804.99	122.2	Indirect	MODERATE	#N/A #N/A	Very serious Extremely serious		RoB, Imprecisionx2 RoB, Imprecisionx3
colchicine, statins	interferon arra (subcutaneous)	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.02	0.02	2.26	6.54	-67.39	105.77	VERYLOW	1.02	0.02	2.26	-185.62 6.54	-67.39	105.77	Indirect	MODERATE	#N/A	Very serious	VFRYIOW	RoB, Imprecisionx3
colchicine, statins	interferon beta (subcutaneous), lopinavir-ritonavir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.67	0.47	1.65	-46.82	-07.39	66.9	VERY LOW	0.67	0.47	1.65		-152.38	66.9	Indirect	MODERATE	#N/A	Very serious Very serious	VERY LOW	RoB, Imprecisionx2
colchicine, statins	intermediate-dose anticoagulant	NA NA	NA NA	NA NA	NA.	NA NA	NA NA	NA NA	0.94	0.20	3.01	-9.17	-150.44	117.28	VERY LOW	0.94	0.20	3.01	-9.17	-150.44	117.28	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
colchicine, statins	ivermectin	NA	NA	NA	NA	NA	NA	NA	1.05	0.41	2.71	7.98	-90.04	117.63	VERY LOW	1.05	0.41	2.71	7.98	-90.04	117.63	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
colchicine, statins	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	1.35	0.62	2.95	32.9	-36.74	131.05	VERY LOW	1.35	0.62	2.95	32.9	-36.74	131.05	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
colchicine, statins	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.94	0.44	2.01	-2.34	-71.85	94.84	VERY LOW	0.94	0.44	2.01	-2.34	-71.85	94.84	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
colchicine, statins	molnupiravir	NA	NA	NA	NA	NA	NA	NA	8.28E+05	0	2.93E+22	-169.41	-921.66	210.02	VERY LOW	8.28E+05	_	2.93E+2		-921.66	210.02	Indirect	MODERATE	#N/A	Extremely serious	MODERATE	RoB, Imprecisionx3
colchicine, statins	proxalutamide	NA	NA	NA	NA	NA	NA	NA	16.96	5.34	62.89	116.97	52.82	211.6	VERY LOW	16.96	5.34	62.89		52.82	211.6	Indirect	LOW	#N/A	Very serious	VERY LOW	RoBx2, Imprecisionx2
colchicine, statins	recombinant human granulocyte colony-stimulating factor	NA	NA	NA	NA	NA	NA	NA	6.79	2.42	19.43	104.62	38.64	200.55	VERY LOW	6.79	2.42	19.43		38.64	200.55	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
colchicine, statins	remdesivir	NA	NA	NA	NA	NA	NA	NA	1.32	0.62	2.84	31.32	-35.99	128.08	VERY LOW	1.32	0.62	2.84		-35.99	128.08	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
colchicine, statins	serine protease inhibitors	NA	NA NA	NA	NA	NA NA	NA	NA NA	0.42	0.08	1.82	-150.16	-494.62	66.13	VERY LOW	0.42	0.08	1.82		-494.62	66.13	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
colchicine, statins	SGLT2 inhibitors	NA	NA	NA	NA	NA	NA	NA	1.29	0.53	3.15	27.18	-58.35	129.87	VERY LOW	1.29	0.53	3.15	27.18	-58.35	129.87	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2

										Mech	anical ventila	ition															
Comparison		Direct esti	mate						Indirect est	timate						Network 6	estimate										
		Relative es		I a.		stimate (per	. ,	Final rating	Relative est	umato			stimate (per		Final rating		estimate	Lac		_	(1	GRADE				Final rating	_
Treatment 1	Treatment 2	Point estimate	CI lower limit	Cl upper limit	Point estimate	CI lower limit	CI upper limit	rillai rauliy	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit	Finalitating	Point estimate	CI lower limit	CI uppe limit	er Point estimate	CI lower limit	CI upper limit	Starting evidence	Starting rating	Incoherence	Imprecision	rillai raulig	Reasons for downgrading
colchicine, statins	statins	NA	NA	NA	NA	NA	NA	NA	0.84	0.24	3	-26.39	-205.69	115.53	VERY LOW	0.84	0.24	3	-26.39	-205.69	115.53	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
colchicine, statins	sulodexide	NA	NA	NA	NA	NA	NA	NA	2.2	0.43	13.85	53.98	-96.64	172.68	VERY LOW	2.2	0.43	13.85		-96.64	172.68	Indirect	MODERATE	#N/A	Extremely serious	MODERATE	RoB, Imprecisionx3
colchicine, statins	tyrosine kinase inhibitors	NA	NA	NA	NA	NA	NA	NA	2.49	0.81	7.68	69.74	-15.23	171.97	VERY LOW	2.49	0.81	7.68	69.74	-15.23	171.97	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
colchicine, statins	vitamin C	NA	NA NA	NA NA	NA	NA NA	NA	NA NA	0.89	0.34	2.32	-12.61	-123.25	102.12	VERY LOW	0.89	0.34	2.32	-12.61	-123.25 -18.59	102.12	Indirect	MODERATE	#N/A #N/A	Very serious	VERY LOW	RoB, Imprecisionx2
colchicine, statins corticosteroids (systemic)	vitamin D IL6 receptor antagonists with corticosteroids (systemic)	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	2.34	0.78	7.04 1.42	-0.31	-18.59 -30.71	168.72 31.3	LOW	2.34	0.78	7.04	66.43 -0.31	-30.71	168.72 31.3	Indirect	MODERATE	#N/A #N/A	Very serious Serious	LOW	RoB, Imprecisionx2 RoB. Imprecision
corticosteroids (systemic)	doxycycline	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.66	0.89	9.58	21.49	-125.51	91.38	VERY LOW	1.66	0.89	9.58	21.49	-125.51	91.38	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
corticosteroids (systemic)	emtricitabine, tenofovir	NA.	NA NA	NA.	NA.	NA.	NA.	NA NA	0.99	0.45	2.2	-4.41	-86.36	54.2	VERY LOW	0.99	0.45	2.2	-4.41	-86.36	54.2	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB. Imprecisionx2
corticosteroids (systemic)	favipiravir	NA	NA	NA	NA	NA	NA	NA	0.55	0.28	1.08	-69.38	-166.68	6.29	VERY LOW	0.55	0.28	1.08	-69.38	-166.68	6.29	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
corticosteroids (systemic)	favipiravir, hydrochloroquine	NA	NA	NA	NA	NA	NA	NA	0.71	0.31	1.63	-38.68	-148.45	37.64	VERY LOW	0.71	0.31	1.63	-38.68	-148.45	37.64	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
corticosteroids (systemic)	fluvoxamine	NA	NA	NA	NA	NA	NA	NA	1.07	0.52	2.22	2.55	-64.95	54.38	VERY LOW	1.07	0.52	2.22		-64.95	54.38	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
corticosteroids (systemic)	full-dose anticoagulant	NA	NA	NA	NA	NA	NA	NA	1.21	0.59	2.53	12.01	-50.41	60.78	VERY LOW	1.21	0.59	2.53		-50.41	60.78	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
corticosteroids (systemic)	GM-CSF inhibitor	NA	NA	NA	NA	NA	NA	NA	0.86	0.37	1.92	-19.69	-113.74	46.8	VERY LOW	0.86	0.37	1.92		-113.74	46.8	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
corticosteroids (systemic)	(hydroxy)chloroquine	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.61	0.42	0.88	-50.52 -4.12	-88.2 -68.46	-14.13 47.64	MODERATE VERY LOW	0.61	0.42	0.88	-50.52 -4.12	-88.2 -68.46	-14.13 47.64	Indirect	MODERATE	Not serious #N/A	Not Serious Very serious	MODERATE VFRY LOW	RoB Imprecisionx2
corticosteroids (systemic)	IL6 receptor antagonists without corticosteroids (systemic)	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.36	0.51	2.43	21.58	-23.03	60.72	VERYLOW	1.36	0.51	2.43		-23.03	60.72	Indirect	MODERATE	Not serious	Very serious	VERYLOW	RoB Imprecisionx2
corticosteroids (systemic)	inhaled corticosteroids (systemic)	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.76	0.75	2.43	-33.59	-164.76	49.06	VERY LOW	0.76	0.75	2.43	-33.59	-164.76	49.06	Indirect	MODERATE	Not serious	Very serious Very serious	VERY LOW	RoB, Imprecisionx2
corticosteroids (systemic)	interferon alfa (subcutaneous)	NA NA	NA.	NA.	NA.	NA NA	NA	NA NA	0.29	0.02	3.96	-217.58	-841.48	74.26	VERY LOW	0.29	0.02	3.96		-841.48	74.26	Indirect	MODERATE	#N/A	Extremely serious	MODERATE	RoB, Imprecisionx3
corticosteroids (systemic)	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	0.77	0.49	1.2	-25.41	-68.88	15.48	LOW	0.77	0.49	1.2	-25.41	-68.88	15.48	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
corticosteroids (systemic)	interferon beta (subcutaneous), lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.51	0.28	0.92	-78.77	-164.62	-9.84	VERY LOW	0.51	0.28	0.92	_	-164.62	-9.84	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
corticosteroids (systemic)	intermediate-dose anticoagulant	NA	NA	NA	NA	NA	NA	NA	0.71	0.28	1.85	-41.12	-167.84	43.1	VERY LOW	0.71	0.28	1.85		-167.84	43.1	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
corticosteroids (systemic)	ivermectin	NA	NA	NA	NA	NA	NA	NA	0.79	0.4	1.53	-23.97	-101.09	35.27	VERY LOW	0.79	0.4	1.53		-101.09	35.27	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
corticosteroids (systemic)	JAK inhibitors	NA	NA NA	NA	NA	NA NA	NA	NA NA	1.01	0.66	1.56	0.95	-34.65	36.77	LOW	1.01	0.66	1.56		-34.65	36.77	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
corticosteroids (systemic)	lopinavir-ritonavir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.71 6.04F+05	0.48	1.03 2.17F+22	-34.3 -201.36	-69.77 -921.84	1.77	VERYLOW	0.71 6.04F+05	0.48	1.03 2.17E+2		-69.77 -921.84	1.77	Indirect	MODERATE	Not serious #N/A	Serious	LOW	RoB, Imprecision
corticosteroids (systemic) corticosteroids (systemic)	molnupiravir proxalutamide	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	12.67	4.95	39.43	-201.36 85.02	-921.84 60.55	117.54	VERYLOW	12.67	4.95	39.43		60.55	117.54	Indirect	LOW	#N/A Not serious	Extremely serious Very serious	VFRYIOW	RoB, Imprecisionx3 RoBx2, Imprecisionx2
corticosteroids (systemic)	recombinant human granulocyte colony-stimulating factor	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	5.11	2.27	11.65	72.67	43.07	102.56	VERYLOW	5.11	2.27	11.65		43.07	102.56	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB. Imprecisionx2
corticosteroids (systemic)	remdesivir	NA	NA.	NA.	NA.	NA NA	NA	NA NA	0.99	0.68	1.47	-0.63	-32.66	33.03	LOW	0.99	0.68	1.47	-0.63	-32.66	33.03	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
corticosteroids (systemic)	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	0.32	0.06	1.17	-182.11	-520.72	12.49	VERY LOW	0.32	0.06	1.17	-182.11	-520.72	12.49	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
corticosteroids (systemic)	SGLT2 inhibitors	NA	NA	NA	NA	NA	NA	NA	0.97	0.52	1.8	-4.78	-65.22	43.46	VERY LOW	0.97	0.52	1.8	-4.78	-65.22	43.46	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
corticosteroids (systemic)	statins	NA	NA	NA	NA	NA	NA	NA	0.63	0.21	1.9	-58.34	-225.51	46.91	VERY LOW	0.63	0.21	1.9	-58.34	-225.51	46.91	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
corticosteroids (systemic)	sulodexide	NA	NA	NA	NA	NA	NA	NA	1.65	0.37	9.47	22.03	-117.17	90.4	VERY LOW	1.65	0.37	9.47	22.03	-117.17	90.4	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
corticosteroids (systemic)	tyrosine kinase inhibitors	NA	NA	NA	NA	NA	NA	NA	1.87	0.75	4.79	37.79	-23.71	82.2	VERY LOW	1.87	0.75	4.79		-23.71	82.2	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
corticosteroids (systemic)	vitamin C	NA	NA NA	NA NA	NA NA	NA NA	NA	NA NA	0.67	0.32	1.36	-44.56 34.48	-137.55	25.05	VERY LOW VERY LOW	0.67	0.32	1.36		-137.55	25.05	Indirect	MODERATE	Not serious #N/A	Very serious	VERY LOW VERY LOW	RoB, Imprecisionx2
corticosteroids (systemic) IL6 receptor antagonists with corticosteroids (systemic)	vitamin D doxycycline	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.75 1.67	0.73	4.33 9.65	21.8	-26.51 -124.81	79.75 88.04	VERY LOW	1.75	0.73	4.33 9.65		-26.51 -124.81	79.75 88.04	Indirect Indirect	MODERATE	#N/A	Very serious Very serious	VERY LOW	RoB, Imprecisionx2 RoB, Imprecisionx2
IL6 receptor antagonists with corticosteroids (systemic)	emtricitabine, tenofovir	NA NA	NA NA	NA NA	NA.	NA.	NA NA	NA NA	0.99	0.47	2.16	-4.1	-84.43	51.77	VERY LOW	0.99	0.47	2.16		-84.43	51.77	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
IL6 receptor antagonists with corticosteroids (systemic)	favipiravir	NA	NA.	NA.	NA.	NA.	NA	NA NA	0.55	0.29	1.06	-69.07	-165.18	3.79	VERY LOW	0.55	0.29	1.06	_	-165.18	3.79	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
IL6 receptor antagonists with corticosteroids (systemic)	favipiravir, hydrochloroquine	NA	NA	NA	NA	NA	NA	NA	0.71	0.32	1.61	-38.37	-147.3	35.73	VERY LOW	0.71	0.32	1.61	-38.37	-147.3	35.73	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
IL6 receptor antagonists with corticosteroids (systemic)	fluvoxamine	NA	NA	NA	NA	NA	NA	NA	1.08	0.54	2.17	2.86	-62.51	51.24	VERY LOW	1.08	0.54	2.17	2.86	-62.51	51.24	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
IL6 receptor antagonists with corticosteroids (systemic)	full-dose anticoagulant	NA	NA	NA	NA	NA	NA	NA	1.21	0.6	2.49	12.33	-48.43	57.9	VERY LOW	1.21	0.6	2.49		-48.43	57.9	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
IL6 receptor antagonists with corticosteroids (systemic)	GM-CSF inhibitor	NA	NA	NA	NA	NA	NA	NA	0.86	0.39	1.88	-19.37	-112.27	44.01	VERY LOW	0.86	0.39	1.88		-112.27	44.01	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
IL6 receptor antagonists with corticosteroids (systemic)	(hydroxy)chloroquine	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.62	0.45	0.84 1.85	-50.21 -3.81	-84.2 -66.06	-18.7 43.98	MODERATE VERY LOW	0.62	0.45	0.84 1.85		-84.2 -66.06	-18.7 43.98	Indirect	MODERATE	#N/A #N/A	Not Serious	MODERATE VFRY LOW	RoB
IL6 receptor antagonists with corticosteroids (systemic)	IL1 inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.36	0.53	1.85	-3.81	-00.00	43.98 56.28	LOW	1.36	0.53	2.35		-00.00	43.98 56.28	Indirect	MODERATE	#N/A #N/A	Very serious Serious	I OW	RoB, Imprecisionx2 RoB, Imprecision
IL6 receptor antagonists with corticosteroids (systemic) IL6 receptor antagonists with corticosteroids (systemic)	IL6 receptor antagonists without corticosteroids (systemic)	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.76	0.79	2.35	-33.28	-162 64	47.7	VERYLOW	0.76	0.79	2.35	21.00	-162 64	56.28 47.7	Indirect	MODERATE	#N/A #N/A	Very serious	VERYLOW	RoB, Imprecisionx2
IL6 receptor antagonists with corticosteroids (systemic)	interferon alfa (subcutaneous)	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.76	0.29	3.96	-33.26	-841.89	73.8	VERY LOW	0.76	0.29	3.96		-841.89	73.8	Indirect	MODERATE	#N/A	Extremely serious	MODERATE	RoB, Imprecisionx3
IL6 receptor antagonists with corticosteroids (systemic)	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	0.77	0.52	1.15	-25.1	-66.14	12.01	LOW	0.77	0.52	1.15		-66.14	12.01	Indirect	MODERATE	#N/A	Serious	LOW	RoB, Imprecision
IL6 receptor antagonists with corticosteroids (systemic)	interferon beta (subcutaneous), lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.51	0.29	0.89	-78.46	-162.57	-11	VERY LOW	0.51	0.29	0.89	-78.46	-162.57	-11	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
IL6 receptor antagonists with corticosteroids (systemic)	intermediate-dose anticoagulant	NA	NA	NA	NA	NA	NA	NA	0.71	0.28	1.83	-40.81	-167.3	41.86	VERY LOW	0.71	0.28	1.83		-167.3	41.86	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
IL6 receptor antagonists with corticosteroids (systemic)	ivermectin	NA	NA	NA	NA	NA	NA	NA	0.79	0.41	1.51	-23.66	-99.64	32.7	VERY LOW	0.79	0.41	1.51		-99.64	32.7	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
IL6 receptor antagonists with corticosteroids (systemic)	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	1.02	0.71	1.51	1.26	-30.87	32.73	LOW	1.02	0.71	1.51	1.26	-30.87	32.73	Indirect	MODERATE	#N/A	Serious	LOW	RoB, Imprecision
IL6 receptor antagonists with corticosteroids (systemic) IL6 receptor antagonists with corticosteroids (systemic)	lopinavir-ritonavir molnupiravir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.71 6.04F+05	0.52	0.98 2.15F+22	-33.98 -201.05	-66.04 -917.37	-2.29 111.67	MODERATE VERY LOW	0.71 6.04F+05	0.52	0.98 2.15F+2	-33.98 22 -201.05	-66.04 -917.37	-2.29 111 67	Indirect	MODERATE MODERATE	#N/A #N/A	Not Serious	MODERATE	RoB
IL6 receptor antagonists with corticosteroids (systemic) IL6 receptor antagonists with corticosteroids (systemic)	molnupiravir proxalutamide	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	6.04E+05	5.14	2.15E+22 39.11	-201.05 85.33	-917.37 65.55	106.36	VERY LOW	6.04E+05	5.14	2.15E+2 39.11	22 -201.05 85.33	-917.37	111.67	Indirect	LOW	#N/A #N/A	Extremely serious Very serious	VERYLOW	RoB, Imprecisionx3 RoBx2, Imprecisionx2
IL6 receptor antagonists with corticosteroids (systemic)	recombinant human granulocyte colony-stimulating factor	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	5.12	2.35	11.48	72.99	47.35	96.78	VERY LOW	5.12	2.35	11.48		47.35	96.78	Indirect	MODERATE	#N/A	Very serious Very serious	VERY LOW	Robxz, imprecisionx2
IL6 receptor antagonists with corticosteroids (systemic)	remdesivir	NA NA	NA NA	NA NA	NA.	NA NA	NA NA	NA NA	1	0.72	1.42	-0.32	-28.41	28.81	LOW	1	0.72	1.42	-0.32	-28.41	28.81	Indirect	MODERATE	#N/A	Serious	LOW	RoB, Imprecision
IL6 receptor antagonists with corticosteroids (systemic)	serine protease inhibitors	NA	NA.	NA.	NA	NA NA	NA	NA NA	0.32	0.07	1.16	-181.8	-520.51	12.23	VERY LOW	0.32	0.07	1.16		-520.51	12.23	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
IL6 receptor antagonists with corticosteroids (systemic)	SGLT2 inhibitors	NA	NA	NA	NA	NA	NA	NA	0.97	0.54	1.75	-4.46	-62.34	40.86	VERY LOW	0.97	0.54	1.75	-4.46	-62.34	40.86	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
IL6 receptor antagonists with corticosteroids (systemic)	statins	NA	NA	NA	NA	NA	NA	NA	0.63	0.22	1.89	-58.03	-224.35	45.48	VERY LOW	0.63	0.22	1.89	-58.03	-224.35	45.48	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
IL6 receptor antagonists with corticosteroids (systemic)	sulodexide	NA	NA	NA	NA	NA	NA	NA	1.66	0.38	9.4	22.34	-116.72	87.25	VERY LOW	1.66	0.38	9.4	22.34	-116.72	87.25	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
IL6 receptor antagonists with corticosteroids (systemic)	tyrosine kinase inhibitors	NA	NA	NA	NA	NA	NA	NA	1.88	0.77	4.73	38.1	-20.9	78.38	VERY LOW	1.88	0.77	4.73		-20.9	78.38	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
IL6 receptor antagonists with corticosteroids (systemic)	vitamin C	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.67	0.33	1.33	-44.25	-135.53	22.93	VERY LOW	0.67	0.33	1.33		-135.53	22.93	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
IL6 receptor antagonists with corticosteroids (systemic)	vitamin D	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.76	0.75	4.3	34.79	-24.61	75.85	VERY LOW	1.76	0.75	4.3	34.79	-24.61	75.85	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
doxycycline doxycycline	emtricitabine, tenofovir favipiravir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.59	0.09	3.26 1.72	-25.9 -90.87	-133.15 -211.52	127.45 69.62	VERY LOW VERY LOW	0.59	0.09	3.26 1.72	-25.9 -90.87	-133.15 -211.52	127.45 69.62	Indirect	MODERATE MODERATE	#N/A #N/A	Extremely serious Extremely serious	MODERATE	RoB, Imprecisionx3 RoB, Imprecisionx3
doxycycline	favipiravir. hvdrochloroquine	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.33	0.05	2.37	-60.17	-191.44	100.91	VERY LOW	0.33	0.05	2.37	-60.17	-191.44	100.91	Indirect	MODERATE	#N/A	Extremely serious		RoB, Imprecisionx3
doxycycline	fluvoxamine	NA NA	NA NA	NA NA	NA.	NA NA	NA NA	NA NA	0.42	0.07	3.43	-18.94	-112.92	133.46	VERY LOW	0.42	0.07	3.43		-112.92		Indirect	MODERATE	#N/A	Extremely serious		RoB, Imprecisionx3
/-/																	1								,		, ,

										Mech	anical ventil	ation														
Comparison		Direct est							Indirect es							Network es										
		Relative e	1	1	_	estimate (pe		Final rating	Relative es	umato	1		stimate (pe		Final rating	Relative e				estimate (per 1,000)	GRADE				Final rating	_
Treatment 1	Treatment 2	Point estimate	CI lowe	r CI upper limit	r Point estimate	CI lower limit	CI upper limit	Final rating	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit	Final rating	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower CI upper limit	Starting evidence	Starting rating	Incoherence	Imprecision	rillarraulig	Reasons for downgrading
doxycycline	full-dose anticoagulant	NA	NA	NA	NA	NA	NA	NA	0.73	0.11	3.78	-9.48	-98.64	141.04	VERY LOW	0.73	0.11	3.78	-9.48	-98.64 141.04	Indirect	MODERATE	#N/A	Extremely serious	MODERATE	RoB, Imprecisionx3
doxycycline	GM-CSF inhibitor	NA	NA	NA	NA	NA	NA	NA	0.51	0.08	2.8	-41.17	-158.56	117.53	VERY LOW	0.51	0.08	2.8	-41.17	-158.56 117.53	Indirect	MODERATE	#N/A	Extremely serious	MODERATE	RoB, Imprecisionx3
doxycycline	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	0.37	0.06	1.73	-72.01	-143.46	74.73	VERY LOW	0.37	0.06	1.73	-72.01	-143.46 74.73	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
doxycycline	IL1 inhibitors	NA	NA	NA	NA	NA	NA	NA	0.59	0.09	3.09	-25.61	-117.73	125.98	VERY LOW	0.59	0.09	3.09	-25.61	-117.73 125.98	Indirect	MODERATE	#N/A	Extremely serious		RoB, Imprecisionx3
doxycycline	IL6 receptor antagonists without corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	0.82	0.13	4.06	0.09	-76.43	146.77	VERY LOW	0.82	0.13	4.06	0.09	-76.43 146.77	Indirect	MODERATE	#N/A	Extremely serious		RoB, Imprecisionx3
doxycycline	inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	0.45	0.07	2.78	-55.08	-204.76		VERY LOW	0.45	0.07	2.78	-55.08	-204.76 109.86	Indirect	MODERATE	#N/A	Extremely serious		RoB, Imprecisionx3
doxycycline	interferon alfa (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	0.17	0.01	3.42	-239.06	-856.4		VERY LOW	0.17	0.01	3.42	-239.06	-856.4 95.49	Indirect	MODERATE	#N/A	Extremely serious		RoB, Imprecisionx3
doxycycline	interferon beta (subcutaneous) interferon beta (subcutaneous), lopinavir-ritonavir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.46	0.08	2.23	-46.9 -100.26	-122.75 -211.4	101.69 56.23	VERY LOW VERY LOW	0.46	0.08	2.23 1.54	-46.9 -100.26	-122.75 101.69 -211.4 56.23	Indirect	MODERATE MODERATE	#N/A #N/A	Very serious Extremely serious	VERY LOW MODERATE	RoB, Imprecisionx2 RoB, Imprecisionx3
doxycycline doxycycline	interreron beta (subcutaneous), lopinavir-ritonavir intermediate-dose anticoagulant	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.3	0.05	2.46	-62.61	-211.4	103.43	VERYLOW	0.43	0.05	2.46	-62.61	-211.4 56.23 -208.36 103.43	Indirect	MODERATE	#N/A #N/A	Extremely serious		RoB, Imprecisionx3
doxycycline	intermediate-dose anticoaguiant ivermectin	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.43	0.08	2.43	-45.46	-147.81	103.43	VERYLOW	0.43	0.08	2.43	-45.46	-206.36 103.43 -147.81 108.84	Indirect	MODERATE	#N/A	Extremely serious		RoB, Imprecisionx3
doxycycline	JAK inhibitors	NA.	NA.	NA NA	NA NA	NA.	NA.	NA NA	0.61	0.1	2.91	-20.54	-90.92		VERYLOW	0.61	0.1	2.91	-20.54	-90.92 127.06	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB. Imprecisionx2
doxycycline	lopinavir-ritonavir	NA	NA	NA.	NA	NA	NA	NA.	0.42	0.07	1.99	-55.79	-125.99		VERY LOW	0.42	0.07	1.99	-55.79	-125.99 92.02	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB. Imprecisionx2
doxycycline	molnupiravir	NA	NA	NA.	NA	NA	NA	NA	3.59E+05	0	1.84E+22	-222.85	-980.01	196.33	VERY LOW	3.59E+05	0	1.84E+22		-980.01 196.33	Indirect	MODERATE	#N/A	Extremely serious	MODERATE	RoB, Imprecisionx3
doxycycline	proxalutamide	NA	NA	NA	NA	NA	NA	NA	7.72	1.08	51.14	63.53	0.89	209.94	VERY LOW	7.72	1.08	51.14	63.53	0.89 209.94	Indirect	LOW	#N/A	Extremely serious	LOW	RoBx2, Imprecisionx3
doxycycline	recombinant human granulocyte colony-stimulating factor	NA	NA	NA	NA	NA	NA	NA	3.06	0.47	17.05	51.18	-13.99	197.67	VERY LOW	3.06	0.47	17.05	51.18	-13.99 197.67	Indirect	MODERATE	#N/A	Extremely serious	MODERATE	RoB, Imprecisionx3
doxycycline	remdesivir	NA	NA	NA	NA	NA	NA	NA	0.6	0.1	2.84	-22.12	-89.64	124.04	VERY LOW	0.6	0.1	2.84	-22.12	-89.64 124.04	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
doxycycline	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	0.18	0.02	1.42	-203.6	-554.58		VERY LOW	0.18	0.02	1.42	-203.6	-554.58 40.09	Indirect	MODERATE	#N/A	Extremely serious		RoB, Imprecisionx3
doxycycline	SGLT2 inhibitors	NA	NA	NA	NA	NA	NA	NA	0.58	0.09	2.96	-26.27	-114.86		VERY LOW	0.58	0.09	2.96	-26.27	-114.86 124.92	Indirect	MODERATE	#N/A	Extremely serious		RoB, Imprecisionx3
doxycycline	statins	NA	NA	NA	NA	NA	NA	NA	0.38	0.05	2.33	-79.83	-263.2	100.92	VERY LOW	0.38	0.05	2.33	-79.83	-263.2 100.92	Indirect	MODERATE	#N/A	Extremely serious		RoB, Imprecisionx3
doxycycline	sulodexide	NA	NA	NA	NA	NA	NA	NA	1	0.11	9.39	0.54	-154.49		VERY LOW	1	0.11	9.39	0.54	-154.49 162.04	Indirect	MODERATE	#N/A	Extremely serious		RoB, Imprecisionx3
doxycycline	tyrosine kinase inhibitors vitamin C	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.12 0.4	0.16	6.5 2.06	16.3 -66.05	-71.29 -182.7	166.42 91.63	VERY LOW VERY LOW	1.12 0.4	0.16	6.5 2.06	16.3 -66.05	-71.29 166.42 -182.7 91.63	Indirect	MODERATE MODERATE	#N/A #N/A	Extremely serious		RoB, Imprecisionx3 RoB, Imprecisionx3
doxycycline doxycycline	vitamin C vitamin D	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.05	0.06	6.12	12.99	-182.7 -75.12	162.24	VERY LOW	1.05	0.06	6.12	12.99	-182.7 91.63 -75.12 162.24	Indirect	MODERATE	#N/A	Extremely serious		RoB, Imprecisionx3
emtricitabine, tenofovir	favioiravir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.55	0.13	1 44	-64.97	-174.08	_	VERYLOW	0.55	0.13	1.44	-64.97	-174 08 40 16	Indirect	MODERATE	#N/A	Very serious		RoB. Imprecisionx2
emtricitabine, tenofovir	favipiravir, hydrochloroquine	NA.	NA.	NA NA	NA NA	NA NA	NA NA	NA NA	0.72	0.24	2.08	-34.27	-155.63		VERYLOW	0.72	0.24	2.08	-34 27	-155.63 73.35	Indirect	MODERATE	#N/A	Very serious		RoB, Imprecisionx2
emtricitabine, tenofovir	fluvoxamine	NA.	NA.	NA.	NA.	NA.	NA.	NA.	1.08	0.4	2.89	6.96	-75.39	97.86	VERY LOW	1.08	0.4	2.89	6.96	-75.39 97.86	Indirect	MODERATE	#N/A	Very serious	-	RoB. Imprecisionx2
emtricitabine, tenofovir	full-dose anticoagulant	NA	NA	NA	NA	NA	NA	NA	1.22	0.45	3.32	16.42	-61.79	106.66	VERY LOW	1.22	0.45	3.32	16.42	-61.79 106.66	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
emtricitabine, tenofovir	GM-CSF inhibitor	NA	NA	NA	NA	NA	NA	NA	0.86	0.3	2.46	-15.27	-121.43	84.54	VERY LOW	0.86	0.3	2.46	-15.27	-121.43 84.54	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
emtricitabine, tenofovir	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	0.62	0.28	1.32	-46.11	-106.75	36.13	VERY LOW	0.62	0.28	1.32	-46.11	-106.75 36.13	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
emtricitabine, tenofovir	IL1 inhibitors	NA	NA	NA	NA	NA	NA	NA	0.99	0.39	2.56	0.29	-78.8	90.46	VERY LOW	0.99	0.39	2.56	0.29	-78.8 90.46	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
emtricitabine, tenofovir	IL6 receptor antagonists without corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	1.37	0.56	3.3	25.99	-39.49	109.59	VERY LOW	1.37	0.56	3.3	25.99	-39.49 109.59	Indirect	MODERATE	#N/A	Very serious		RoB, Imprecisionx2
emtricitabine, tenofovir	inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	0.77	0.23	2.55	-29.18	-169.54	84.11	VERY LOW	0.77	0.23	2.55	-29.18	-169.54 84.11	Indirect	MODERATE	#N/A	Very serious		RoB, Imprecisionx2
emtricitabine, tenofovir	interferon alfa (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	0.29	0.02	4.37	-213.16	-834.42	92.15	VERY LOW	0.29	0.02	4.37	-213.16	-834.42 92.15	Indirect	MODERATE	#N/A	Extremely serious		RoB, Imprecisionx3
emtricitabine, tenofovir	interferon beta (subcutaneous)	NA NA	NA NA	NA NA	NA	NA NA	NA	NA NA	0.78	0.34	1.74	-21	-85.79		VERY LOW	0.78	0.34	1.74	-21	-85.79 63.4	Indirect	MODERATE	#N/A	Very serious		RoB, Imprecisionx2
emtricitabine, tenofovir emtricitabine, tenofovir	interferon beta (subcutaneous), lopinavir-ritonavir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.51	0.21	1.26	-74.36 -36.71	-173.36 -173.99	26.9 77.45	VERY LOW VERY LOW	0.51	0.21	1.26	-74.36 -36.71	-173.36 26.9 -173.99 77.45	Indirect	MODERATE	#N/A #N/A	Very serious		RoB, Imprecisionx2
emtricitabine, tenofovir	intermediate-dose anticoagulant ivermectin	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.72	0.22	2.07	-19.56	-110.66	75.96	VERY LOW	0.72	0.22	2.07	-19.56	-173.99 77.45 -110.66 75.96	Indirect	MODERATE	#N/A	Very serious Very serious		RoB, Imprecisionx2 RoB, Imprecisionx2
emtricitabine, tenofovir	JAK inhibitors	NA NA	NA.	NA NA	NA NA	NA NA	NA.	NA NA	1.02	0.46	2.27	5.36	-53.72	87.98	VERY LOW	1.02	0.46	2.27	5.36	-53.72 87.98	Indirect	MODERATE	#N/A	Very serious		RoB, Imprecisionx2
emtricitabine, tenofovir	lopinavir-ritonavir	NA.	NA	NA.	NA.	NA.	NA.	NA.	0.71	0.33	1.54	-29.89	-89	52.31	VERY LOW	0.71	0.33	1.54	-29.89	-89 52.31	Indirect	MODERATE	#N/A	Very serious		RoB, Imprecisionx2
emtricitabine, tenofovir	molnupiravir	NA	NA	NA	NA	NA	NA	NA	6.19E+05	0	2.08E+22	-196.95	-940.46	168.94	VERY LOW	6.19E+05	0	2.08E+22	-196.95	-940.46 168.94	Indirect	MODERATE	#N/A	Extremely serious		RoB, Imprecisionx3
emtricitabine, tenofovir	proxalutamide	NA	NA	NA	NA	NA	NA	NA	12.89	4.02	47.31	89.43	36.91	168.64	VERY LOW	12.89	4.02	47.31	89.43	36.91 168.64	Indirect	LOW	#N/A	Very serious		RoBx2, Imprecisionx2
emtricitabine, tenofovir	recombinant human granulocyte colony-stimulating factor	NA	NA	NA	NA	NA	NA	NA	5.16	1.79	14.83	77.08	21.92	157.14	VERY LOW	5.16	1.79	14.83	77.08	21.92 157.14	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
emtricitabine, tenofovir	remdesivir	NA	NA	NA	NA	NA	NA	NA	1	0.46	2.18	3.78	-52.93	85.46	VERY LOW	1	0.46	2.18	3.78	-52.93 85.46	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
emtricitabine, tenofovir	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	0.32	0.06	1.4	-177.7	-519.81	31.93	VERY LOW	0.32	0.06	1.4	-177.7	-519.81 31.93	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
emtricitabine, tenofovir	SGLT2 inhibitors	NA	NA	NA	NA	NA	NA	NA	0.97	0.39	2.42	-0.37	-77.71	88.9	VERY LOW	0.97	0.39	2.42	-0.37	-77.71 88.9	Indirect	MODERATE	#N/A	Very serious		RoB, Imprecisionx2
emtricitabine, tenofovir	statins	NA	NA	NA	NA	NA	NA	NA	0.63	0.18	2.32	-53.93	-229.38		VERY LOW	0.63	0.18	2.32	-53.93	-229.38 76.07	Indirect	MODERATE	#N/A	Very serious	-	RoB, Imprecisionx2
emtricitabine, tenofovir	sulodexide	NA	NA	NA	NA	NA	NA	NA	1.68	0.32	10.5	26.44	-120.46	100.20	VERY LOW	1.68	0.32	10.5	26.44	-120.46 130.29	Indirect	MODERATE	#N/A	Extremely serious		RoB, Imprecisionx3
emtricitabine, tenofovir emtricitabine, tenofovir	tyrosine kinase inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.89 0.67	0.61 0.25	5.96 1.78	42.2 -40.15	-35.67 -145.15	129.22 60.2	VERY LOW VERY LOW	1.89	0.61 0.25	5.96 1.78	42.2 -40.15	-35.67 129.22 -145.15 60.2	Indirect	MODERATE	#N/A #N/A	Very serious Very serious		RoB, Imprecisionx2
emtricitabine, tenofovir emtricitabine, tenofovir	vitamin C vitamin D	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.77	0.25	1.78 5.43	-40.15 38.89	-145.15	126.84	VERY LOW	1.77	0.25	1.78 5.43	-40.15 38.89	-145.15 60.2 -38.7 126.84	Indirect	MODERATE	#N/A #N/A	Very serious Very serious		RoB, Imprecisionx2 RoB, Imprecisionx2
favipiravir	favipiravir, hydrochloroquine	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.77	0.38	3.47	30.7	-97 94	149.68	VERYLOW	1.3	0.48	3.47	30.7	-97.94 149.68	Indirect	MODERATE	#N/A	Very serious		RoB, Imprecisionx2
favipiravir	fluvoxamine	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.3	0.46	4.76	71.93	-21.99	178.13	VERYLOW	1.96	0.46	4.76	71.93	-97.94 149.66 -21.99 178.13	Indirect	MODERATE	#N/A	Very serious Very serious		RoB, Imprecisionx2
favipiravir	full-dose anticoagulant	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	2.2	0.8	5.45	81.39	-9.17	185.16	VERY LOW	2.2	0.8	5.45	81.39	-9.17 185.16	Indirect	MODERATE	Not serious	Very serious		RoB, Imprecisionx2
favipiravir	GM-CSF inhibitor	NA.	NA.	NA NA	NA NA	NA.	NA.	NA NA	1.55	0.59	4.12	49.69	-65.61	163.65	VERY LOW	1.55	0.59	4.12	49.69	-65.61 163.65	Indirect	MODERATE	#N/A	Very serious		RoB, Imprecisionx2
favipiravir	(hydroxy)chloroquine	0.11	0	2.6	NA	NA	NA	VERY LOW	1.41	0.73	2.73	NA	NA	NA	VERY LOW	1.13	0.59	2.1	18.86	-56.22 114.44	Direct	MODERATE	Not serious	Very serious		RoB, Imprecisionx2
favipiravir	IL1 inhibitors	NA	NA	NA	NA	NA	NA	NA	1.79	0.77	4.17	65.26	-27.36	171.07	VERY LOW	1.79	0.77	4.17	65.26	-27.36 171.07	Indirect	MODERATE	#N/A	Very serious		RoB, Imprecisionx2
favipiravir	IL6 receptor antagonists without corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	2.47	1.12	5.45	90.96	10.93	190.56	VERY LOW	2.47	1.12	5.45	90.96	10.93 190.56	Indirect	MODERATE	Not serious	Very serious		RoB, Imprecisionx2
favipiravir	inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	1.39	0.45	4.31	35.79	-111.27	160.88	VERY LOW	1.39	0.45	4.31	35.79	-111.27 160.88	Indirect	MODERATE	Not serious	Very serious		RoB, Imprecisionx2
favipiravir	interferon alfa (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	0.53	0.03	7.7	-148.2	-773.21	164.81	VERY LOW	0.53	0.03	7.7	-148.2	-773.21 164.81	Indirect	MODERATE	#N/A	Extremely serious	-	RoB, Imprecisionx3
favipiravir	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	1.41	0.7	2.8	43.97	-35.92	144.35	VERY LOW	1.41	0.7	2.8	43.97	-35.92 144.35	Indirect	MODERATE	Not serious	Very serious		RoB, Imprecisionx2
favipiravir	interferon beta (subcutaneous), lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.93	0.42	2.01	-9.4	-116.8	102.08	VERY LOW	0.93	0.42	2.01	-9.4	-116.8 102.08	Indirect	MODERATE	Not serious	Very serious		RoB, Imprecisionx2
favipiravir	intermediate-dose anticoagulant	NA NA	NA NA	NA NA	NA NA	NA NA	NA	NA NA	1.29	0.44	3.84	28.26	-115.61	154.68	VERY LOW	1.29	0.44	3.84	28.26	-115.61 154.68	Indirect	MODERATE	#N/A	Very serious		RoB, Imprecisionx2
favipiravir	ivermectin	NA NA	NA NA	NA NA	NA NA	NA NA	NA	NA NA	1.44	0.61	3.37	45.41	-55.33	154.6	VERY LOW	1.44	0.61	3.37	45.41	-55.33 154.6	Indirect	MODERATE	Not serious	Very serious		RoB, Imprecisionx2
favipiravir	JAK inhibitors	NA 0.60	NA 0.47	NA 2.27	NA NA	NA NA	NA NA	NA VEDV LOW	1.85	0.94	3.69	70.33	-5.04	167.54	VERY LOW	1.85	0.94	3.69	70.33	-5.04 167.54	Indirect	MODERATE	Not serious	Very serious		RoB, Imprecisionx2
lopinavir-ritonavir favipiravir	favipiravir	0.62 NA	0.17 NA	2.27 NA	NA NA	NA NA	NA NA	VERY LOW NA	1.12 1.14E+06	0.43	2.8 3.90E+22	-131.98	-887.82	NA 249.51	VERY LOW VERY LOW	0.78 1.14E+06	0.43	1.42 3.90E+22	-35.08 -131.98	-126.32 34.1 -887.82 249.51	Direct	MODERATE MODERATE	Not serious #N/A	Very serious	VERY LOW MODERATE	RoB, Imprecisionx2 RoB, Imprecisionx3
tavıpıravır favipiravir	molnupiravir proxalutamide	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.14E+06 23.22	7.82	3.90E+22 80.03	-131.98 154.4	-887.82 83.6	249.51	VERY LOW VERY LOW	1.14E+06 23.22	7.82	80.03	-131.98 154.4	-887.82 249.51 83.6 249.28	Indirect	LOW	#N/A Not serious	Very serious		RoB, Imprecisionx3 RoBx2. Imprecisionx2
lavipiravii	proxautamide	INA	I NA	INA	INA	INA	INA	INA	23.22	1.02	00.03	154.4	03.0	249.28	VERTLOW	23.22	1.02	00.03	104.4	03.0 249.28	munect	LOW	NOT SELIOUS	very serious	VERTLOW	robaz, imprecisiofixz

				_						Mech	anical ventila	ation															
Comparison		Direct esti	imate						Indirect es	timate						Network es	stimate										
		Relative es	Stimate	Chie	Absolute e	CL lower	1,000) Cl upper	Final rating	Relative est	timate	Cluster	Absolute e	Cl lower	er 1,000) Cl upper	Final rating	Relative e	Cllower	CI		Cl lower	Clupper	GRADE Starting				Final rating	Reasons for
Treatment 1	Treatment 2	estimate	limit	CI upper limit	estimate	limit	limit	rinarrating	estimate	limit	CI upper limit	estimate	limit	limit	1 mai raung	estimate	limit	CI uppe limit	estimate	limit	limit	evidence	Starting rating	Incoherence	Imprecision	T marrating	downgrading
favipiravir	recombinant human granulocyte colony-stimulating factor	NA	NA	NA	NA	NA	NA	NA	9.33	3.51	24.97	142.05	69.41	237.68	VERY LOW	9.33	3.51	24.97	142.05	69.41	237.68	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
favipiravir	remdesivir	NA	NA	NA	NA	NA	NA	NA	1.82	0.94	3.49	68.75	-5.35	165.63	VERY LOW	1.82	0.94	3.49	68.75	-5.35	165.63	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
favipiravir	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	0.58	0.11	2.36	-112.73	-461.14	103.61	VERY LOW	0.58	0.11	2.36		-461.14	103.61	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
favipiravir	SGLT2 inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.77	0.77	3.95 3.95	64.6 11.04	-24.62 -168.38	168.49	VERY LOW VERY LOW	1.77	0.77	3.95	64.6 11.04	-24.62 -168.38	168.49 152.9	Indirect	MODERATE	#N/A Not serious	Very serious		RoB, Imprecisionx2
favipiravir favipiravir	sulodexide	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	3.01	0.61	18.72	91.41	-61.66	152.9 209.85	VERY LOW	3.01	0.61	3.95 18.72		-61.66	209.85	Indirect	MODERATE	Not serious	Very serious Extremely serious	S MODERATE	RoB, Imprecisionx2 RoB. Imprecisionx3
favipiravir	tyrosine kinase inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	3.42	1.18	9.95	107.17	18.38	210.94	VERY LOW	3.42	1.18	9.95		18.38	210.94	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB. Imprecisionx2
favipiravir	vitamin C	NA	NA	NA	NA	NA	NA	NA	1.22	0.49	2.95	24.82	-90.57	143.1	VERY LOW	1.22	0.49	2.95	24.82	-90.57	143.1	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
favipiravir	vitamin D	NA	NA	NA	NA	NA	NA	NA	3.19	1.15	9.26	103.86	15.03	205.64	VERY LOW	3.19	1.15	9.26	103.86	15.03	205.64	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
favipiravir, hydrochloroquine	fluvoxamine	NA	NA	NA	NA	NA	NA	NA	1.51	0.55	4.24	41.23	-54.4	158.44	VERY LOW	1.51	0.55	4.24	41.23	-54.4	158.44	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
favipiravir, hydrochloroquine	full-dose anticoagulant	NA	NA	NA	NA	NA	NA	NA	1.7	0.61	4.79	50.69	-42.69	167.29	VERY LOW	1.7	0.61	4.79		-42.69	167.29	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
favipiravir, hydrochloroquine	GM-CSF inhibitor	NA	NA	NA	NA	NA	NA	NA	1.2	0.4	3.56	18.99	-97.08	144.33	VERY LOW	1.2	0.4	3.56		-97.08	144.33	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
favipiravir, hydrochloroquine	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	0.86	0.38	1.94	-11.84	-89.57	98.12	VERY LOW	0.86	0.38	1.94		-89.57	98.12	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
favipiravir, hydrochloroquine	IL1 inhibitors L6 receptor antagonists without corticosteroids (systemic)	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.38	0.52	3.71 4.83	34.56 60.26	-60.12 -20.8	151.58	VERY LOW VERY LOW	1.38	0.52	3.71 4.83	34.56 60.26	-60.12 -20.8	151.58 171.31	Indirect	MODERATE	#N/A #N/A	Very serious	VERY LOW	RoB, Imprecisionx2 RoB Imprecisionx2
favipiravir, hydrochloroguine	inhaled corticosteroids (systemic)	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.91	0.75	3.66	5.09	-142 66	139.03	VERYLOW	1.91	0.75	3.66		-142 66	139.03	Indirect	MODERATE	#N/A	Very serious		RoB, Imprecisionx2
favipiravir, hydrochloroquine	interferon alfa (subcutaneous)	NA.	NA.	NA NA	NA.	NA.	NA.	NA NA	0.41	0.02	6.24	-178.9	-792.66	142.99	VERY LOW	0.41	0.02	6.24		-792.66	142.99	Indirect	MODERATE	#N/A	Extremely serious		RoB. Imprecisionx3
favipiravir, hydrochloroquine	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA NA	1.08	0.46	2.54	13.27	-67.79	125.53	VERY LOW	1.08	0.46	2.54		-67.79	125.53	Indirect	MODERATE	#N/A	Very serious	1	RoB, Imprecisionx2
favipiravir, hydrochloroquine	interferon beta (subcutaneous), lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.71	0.28	1.82	-40.1	-150.6	85.71	VERY LOW	0.71	0.28	1.82	-40.1	-150.6	85.71	Indirect	MODERATE	#N/A	Very serious		RoB, Imprecisionx2
favipiravir, hydrochloroquine	intermediate-dose anticoagulant	NA	NA	NA	NA	NA	NA	NA	1	0.31	3.31	-2.44	-149.86	135.5	VERY LOW	1	0.31	3.31		-149.86	135.5	Indirect	MODERATE	#N/A	Very serious		RoB, Imprecisionx2
favipiravir, hydrochloroquine	ivermectin	NA	NA	NA	NA	NA	NA	NA	1.11	0.41	2.99	14.71	-89.43	134.98	VERY LOW	1.11	0.41	2.99		-89.43	134.98	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
favipiravir, hydrochloroquine	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	1.43	0.62	3.34	39.63	-36.85	149.63	VERY LOW	1.43	0.62	3.34	39.63	-36.85	149.63	Indirect	MODERATE	#N/A	Very serious		RoB, Imprecisionx2
favipiravir, hydrochloroquine	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.99	0.44	2.25	4.38	-71.67	114.69	VERY LOW	0.99	0.44	2.25	4.38	-71.67	114.69	Indirect	MODERATE	#N/A	Very serious		RoB, Imprecisionx2
favipiravir, hydrochloroquine	molnupiravir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	8.31E+05 17.95	5.48	2.97E+22 68.61	-162.68 123.7	-921.29 52.42	228.57	VERY LOW VERY LOW	8.31E+05 17.95	0 5.48	2.97E+2 68.61	123.7	-921.29 52.42	228.57 231.9	Indirect	MODERATE	#N/A #N/A	Extremely serious	MODERATE VERY LOW	RoB, Imprecisionx3 RoBx2, Imprecisionx2
favipiravir, hydrochloroquine favipiravir, hydrochloroquine	proxalutamide recombinant human granulocyte colony-stimulating factor	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	7.18	2.44	21.48	111.35	38.15	231.9	VERYLOW	7.18	2.44	21.48		38.15	231.9	Indirect	MODERATE	#N/A	Very serious Very serious	VERY LOW VERY LOW	RoB. Imprecisionx2
favipiravir, hydrochloroquine	remdesivir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.10	0.62	3.22	38.05	-36.49	148.11	VERY LOW	1.4	0.62	3.22	38.05	-36.49	148.11	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB. Imprecisionx2
favipiravir, hydrochloroquine	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	0.44	0.08	2	-143.43	-491.54	80.23	VERY LOW	0.44	0.08	2	-143.43	-491.54	80.23	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
favipiravir, hydrochloroquine	SGLT2 inhibitors	NA	NA	NA	NA	NA	NA	NA	1.36	0.53	3.54	33.9	-56.69	149.07	VERY LOW	1.36	0.53	3.54	33.9	-56.69	149.07	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
favipiravir, hydrochloroquine	statins	NA	NA	NA	NA	NA	NA	NA	0.88	0.24	3.33	-19.66	-200.54	129.73	VERY LOW	0.88	0.24	3.33	-19.66	-200.54	129.73	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
favipiravir, hydrochloroquine	sulodexide	NA	NA	NA	NA	NA	NA	NA	2.33	0.44	14.95	60.71	-93.51	190.05	VERY LOW	2.33	0.44	14.95	60.71	-93.51	190.05	Indirect	MODERATE	#N/A	Extremely serious	s MODERATE	RoB, Imprecisionx3
favipiravir, hydrochloroquine	tyrosine kinase inhibitors	NA	NA	NA	NA	NA	NA	NA	2.64	0.82	8.54	76.47	-14.31	191.38	VERY LOW	2.64	0.82	8.54	76.47	-14.31	191.38	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
favipiravir, hydrochloroquine	vitamin C	NA	NA NA	NA NA	NA NA	NA NA	NA	NA NA	0.94	0.34	2.59	-5.88	-122.4	119.09	VERY LOW	0.94	0.34	2.59		-122.4	119.09	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
favipiravir, hydrochloroquine fluvoxamine	vitamin D full-dose anticoagulant	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	2.47 1.12	0.78 0.45	7.91 2.92	73.16 9.46	-17.02 -64.15	187.96 85.73	VERY LOW VERY LOW	2.47 1.12	0.78 0.45	7.91		-17.02 -64.15	187.96 85.73	Indirect Indirect	MODERATE MODERATE	#N/A #N/A	Very serious Very serious		RoB, Imprecisionx2 RoB, Imprecisionx2
fluvoxamine	GM-CSF inhibitor	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.8	0.49	2.16	-22.23	-124.37	66.24	VERY LOW	0.8	0.45	2.16		-124.37	66.24	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
fluvoxamine	(hydroxy)chloroquine	NA.	NA.	NA.	NA.	NA.	NA.	NA.	0.57	0.28	1.14	-53.07	-106.79	14.34	VERY LOW	0.57	0.28	1.14	-53.07	-106.79	14.34	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
fluvoxamine	IL1 inhibitors	NA	NA	NA	NA	NA	NA	NA	0.92	0.38	2.21	-6.67	-81.51	70.37	LOW	0.92	0.38	2.21	-6.67	-81.51	70.37	Indirect	HIGH	#N/A	Very serious	LOW	Imprecisionx2
fluvoxamine	L6 receptor antagonists without corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	1.27	0.55	2.87	19.03	-39.52	88.52	LOW	1.27	0.55	2.87	19.03	-39.52	88.52	Indirect	HIGH	#N/A	Very serious	LOW	Imprecisionx2
fluvoxamine	inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	0.71	0.23	2.25	-36.14	-173.19	65.55	VERY LOW	0.71	0.23	2.25		-173.19	65.55	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
fluvoxamine	interferon alfa (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	0.27	0.02	3.95	-220.12	-838.03	80.25	VERY LOW	0.27	0.02	3.95		-838.03	80.25	Indirect	MODERATE	#N/A	Extremely serious		RoB, Imprecisionx3
fluvoxamine	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	0.72	0.34	1.48	-27.96	-86.14	42.72	VERY LOW	0.72	0.34	1.48		-86.14	42.72	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
fluvoxamine fluvoxamine	interferon beta (subcutaneous), lopinavir-ritonavir intermediate-dose anticoagulant	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.47	0.2	1.08	-81.32 -43.67	-176.74 -177.86	8.55 59.48	VERY LOW	0.47	0.2	1.08		-176.74 -177.86	8.55 59.48	Indirect	MODERATE	#N/A #N/A	Very serious Very serious	VERY LOW	RoB, Imprecisionx2
fluvoxamine	ivermectin	NA NA	NA NA	NA NA	NA.	NA NA	NA.	NA NA	0.00	0.22	1.8	-26.52	-117.00	56.48	VERYLOW	0.00	0.22	1.8		-112 34	56.48	Indirect	MODERATE	#N/A	Very serious		RoB. Imprecisionx2
fluvoxamine	JAK inhibitors	NA NA	NA NA	NA NA	NA.	NA NA	NA NA	NA NA	0.74	0.25	1.96	-1.6	-53.54	65.93	LOW	0.74	0.25	1.96	20.02	-53.54	65.93	Indirect	HIGH	#N/A	Very serious	LOW	Imprecisionx2
fluvoxamine	lopinavir-ritonavir	NA	NA.	NA NA	NA.	NA	NA	NA NA	0.66	0.33	1.32	-36.85	-89.15	30.96	VERY LOW	0.66	0.33	1.32		-89.15	30.96	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
fluvoxamine	molnupiravir	NA	NA	NA	NA	NA	NA	NA	5.64E+05	0	1.98E+22	-203.91	-940.85	146.61	VERY LOW	5.64E+05	0	1.98E+2	22 -203.91	-940.85	146.61	Indirect	MODERATE	#N/A	Extremely serious	MODERATE	RoB, Imprecisionx3
fluvoxamine	proxalutamide	NA	NA	NA	NA	NA	NA	NA	11.88	3.87	42.32	82.47	37.78	146.14	VERY LOW	11.88	3.87	42.32		37.78	146.14	Indirect	LOW	#N/A	Very serious	VERY LOW	RoBx2, Imprecisionx2
	recombinant human granulocyte colony-stimulating factor	NA	NA	NA	NA	NA	NA	NA	4.77	1.74	13.15	70.12	22.29	134.86	VERY LOW	4.77	1.74	13.15		22.29	134.86	Indirect	MODERATE	#N/A	Very serious		RoB, Imprecisionx2
fluvoxamine	remdesivir	NA	NA NA	NA NA	NA NA	NA NA	NA	NA NA	0.93	0.46	1.88	-3.18	-52.44	63.42	VERY LOW	0.93	0.46	1.88		-52.44	63.42	Indirect	MODERATE	#N/A	Very serious		RoB, Imprecisionx2
fluvoxamine	serine protease inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.29	0.05	1.26	-184.66 -7.33	-526.38 -79.01	19.24 67.84	VERY LOW	0.29	0.05	1.26		-526.38 -79.01	19.24 67.84	Indirect	MODERATE	#N/A #N/A	Very serious	VERY LOW	RoB, Imprecisionx2
fluvoxamine fluvoxamine	SGL12 inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.9	0.38	2.12	-7.33 -60.89	-79.01 -232.62	59.41	VERYLOW	0.9	0.38	2.12	-7.33 -60.89	-79.01	67.84 59.41	Indirect	MODERATE	#N/A	Very serious Very serious		Imprecisionx2 RoB, Imprecisionx2
fluvoxamine	sulodexide	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.55	0.17	9.56	19.48	-124.64	112.19	VERY LOW	1.55	0.17	9.56		-124.64	112.19	Indirect	HIGH	#N/A	Extremely serious		Imprecisionx3
fluvoxamine	tyrosine kinase inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA	NA NA	1.75	0.58	5.24	35.24	-36.55	108.48	VERY LOW	1.75	0.58	5.24		-36.55	108.48	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
fluvoxamine	vitamin C	NA	NA	NA	NA	NA	NA	NA	0.62	0.25	1.56	-47.11	-146.75	41.79	VERY LOW	0.62	0.25	1.56		-146.75	41.79	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
fluvoxamine	vitamin D	NA	NA	NA	NA	NA	NA	NA	1.64	0.57	4.73	31.93	-40.8	105.46	LOW	1.64	0.57	4.73	31.93	-40.8	105.46	Indirect	HIGH	#N/A	Very serious	LOW	Imprecisionx2
full-dose anticoagulant	GM-CSF inhibitor	NA	NA	NA	NA	NA	NA	NA	0.7	0.25	1.97	-31.7	-131.84	52.71	VERY LOW	0.7	0.25	1.97	-31.7	-131.84	52.71	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
full-dose anticoagulant	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	0.51	0.25	1.02	-62.53	-113.78	0.35	VERY LOW	0.51	0.25	1.02		-113.78	0.35	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
full-dose anticoagulant	IL1 inhibitors	NA	NA	NA	NA	NA	NA	NA	0.81	0.33	1.99	-16.13	-88.69	57.48	VERY LOW	0.81	0.33	1.99	-16.13	-88.69	57.48	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
	L6 receptor antagonists without corticosteroids (systemic)	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.12 0.63	0.48	2.57	9.57 -45.6	-46.86 -181.25	74.79 52.64	VERY LOW VERY LOW	1.12 0.63	0.48	2.57		-46.86 -181.25	74.79 52.64	Indirect	MODERATE	Not serious Not serious	Very serious		RoB, Imprecisionx2
full-dose anticoagulant full-dose anticoagulant	inhaled corticosteroids interferon alfa (subcutaneous)	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.63	0.2	3.61	-45.6 -229.59	-181.25 -849.75	70.05	VERY LOW VERY LOW	0.63	0.2	3.61		-181.25	70.05	Indirect	MODERATE	Not serious #N/A	Very serious Extremely serious		RoB, Imprecisionx2 RoB, Imprecisionx3
full-dose anticoagulant	interferon beta (subcutaneous)	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.64	0.01	1.33	-37.42	-93.68	28.58	VERY LOW	0.64	0.01	1.33	-37.42	-93.68	28.58	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB. Imprecisionx2
full-dose anticoagulant	interferon beta (subcutaneous), lopinavir-ritonavir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.42	0.18	0.97	-90.79	-184.85	-4.89	VERY LOW	0.42	0.18	0.97	-90.79	-184.85	-4.89	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
intermediate-dose anticoagulant	full-dose anticoagulant	1.7	0.75	3.91	NA	NA	NA	LOW	NA	NA	NA	NA	NA	NA	NA	1.71	0.94	3.1	53.13	-4.59	146.25	Direct	HIGH	#N/A	Very serious	LOW	Imprecisionx2
full-dose anticoagulant	ivermectin	NA	NA	NA	NA	NA	NA	NA	0.65	0.26	1.61	-35.98	-120.98	42.31	VERY LOW	0.65	0.26	1.61	-35.98	-120.98	42.31	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
			-					-			-		-		-		-		-						-	-	

				_	_					Mech	anical ventil	ation															
Comparison		Direct est	timate						Indirect est	timate						Network es	stimate										
		Relative e			Absolute esti			Final rating	Relative est	umato	Lau		stimate (per		Final rating	Relative e	oumato				.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	GRADE				Final rating	
Treatment 1	Treatment 2	Point estimate	CI lower	CI upper limit	Point C		I upper limit	Final rating	Point estimate	CI lower	CI upper limit	Point estimate	CI lower	CI upper limit	Final rating	Point estimate	CI lower	CI upper limit	Point estimate	CI lower	CI upper limit	Starting evidence	Starting rating	Incoherence	Imprecision	Final rating	Reasons for downgrading
full-dose anticoagulant	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	0.84	0.4	1.74	-11.06	-60.27	51.28	VERY LOW	0.84	0.4	1.74	-11.06	-60.27	51.28	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
full-dose anticoagulant	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.58	0.28	1.17	-46.31	-95.8	16.51	VERY LOW	0.58	0.28	1.17	-46.31	-95.8	16.51	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
full-dose anticoagulant	molnupiravir	NA	NA	NA	NA	NA	NA	NA	4.98E+05	0	1.84E+22	-213.37	-947.77	133.03	VERY LOW	4.98E+05	0	1.84E+22	-213.37	-947.77	133.03	Indirect	MODERATE	#N/A	Extremely serious	MODERATE	RoB, Imprecisionx3
full-dose anticoagulant	proxalutamide	NA	NA	NA	NA	NA	NA	NA	10.57	3.38	37.5	73.01	31.54	132.03	VERY LOW	10.57	3.38	37.5	73.01	31.54	132.03	Indirect	LOW	Not serious	Very serious	VERY LOW	RoBx2, Imprecisionx2
full-dose anticoagulant	recombinant human granulocyte colony-stimulating factor	NA	NA	NA	NA	NA	NA	NA	4.23	1.54	11.71	60.66	15.41	120.84	VERY LOW	4.23	1.54	11.71	60.66	15.41	120.84	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
full-dose anticoagulant	remdesivir	NA	NA	NA	NA	NA	NA	NA	0.83	0.4	1.67	-12.64	-59.55	49.6	VERY LOW	0.83	0.4	1.67	-12.64	-59.55	49.6	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
full-dose anticoagulant	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	0.26	0.05	1.1	-194.12	-535.92	8.09	VERY LOW	0.26	0.05	1.1	-194.12	-535.92	8.09	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
full-dose anticoagulant	SGLT2 inhibitors	NA	NA	NA	NA	NA	NA	NA	0.8	0.33	1.87	-16.79	-86.67	54.1	VERY LOW	0.8	0.33	1.87	-16.79	-86.67	54.1	Indirect	MODERATE	#N/A	Very serious		RoB, Imprecisionx2
full-dose anticoagulant	statins	NA NA	NA NA	NA NA	NA NA	NA	NA NA	NA NA	0.52	0.15	1.83	-70.35	-242.74	49 99.84	VERY LOW	0.52	0.15	1.83	-70.35	-242.74 -132.7	49	Indirect	MODERATE	Not serious	Very serious	VERY LOW MODERATE	RoB, Imprecisionx2
full-dose anticoagulant full-dose anticoagulant	sulodexide tyrosine kinase inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.37	0.27	8.79 4.64	10.02 25.78	-132.7 -44.43	99.84	VERY LOW VERY LOW	1.37	0.27	8.79 4.64	10.02 25.78	-132.7 -44.43	99.84 94.71	Indirect	MODERATE	Not serious Not serious	Extremely serious Very serious	VERY LOW	RoB, Imprecisionx3 RoB, Imprecisionx2
full-dose anticoagulant	vitamin C	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.55	0.52	1.42	-56.57	-155.78	29.47	VERY LOW	0.55	0.52	1.42	-56.57	-155.78	29.47	Indirect	MODERATE	Not serious	Very serious Very serious	VERY LOW	RoB, Imprecisionx2
full-dose anticoagulant	vitamin D	NA.	NA NA	NA NA	NA NA	NA NA	NA.	NA NA	1.45	0.49	4.3	22.46	-47.16	91.46	VERY LOW	1.45	0.49	4.3	22.46	-47.16	91.46	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB. Imprecisionx2
GM-CSF inhibitor	(hydroxy)chloroquine	NA.	NA NA	NA NA	NA NA	NA	NA	NA NA	0.72	0.33	1.58	-30.83	-98 61	63.59	VERYLOW	0.72	0.33	1.58	-30.83	-98.61	63.59	Indirect	MODERATE	#N/A	Very serious		RoB Imprecisionx2
GM-CSF inhibitor	IL1 inhibitors	NA	NA	NA	NA	NA	NA	NA	1.15	0.44	3.03	15.57	-70.17	117.87	VERY LOW	1.15	0.44	3.03	15.57	-70.17	117.87	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
GM-CSF inhibitor	IL6 receptor antagonists without corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	1.59	0.65	3.92	41.26	-30.51	137.46	VERY LOW	1.59	0.65	3.92	41.26	-30.51	137.46	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
GM-CSF inhibitor	inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	0.89	0.26	3.05	-13.9	-157.67	108.37	VERY LOW	0.89	0.26	3.05	-13.9	-157.67	108.37	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
GM-CSF inhibitor	interferon alfa (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	0.34	0.02	5.1	-197.89	-812.48	114.37	VERY LOW	0.34	0.02	5.1	-197.89	-812.48	114.37	Indirect	MODERATE	#N/A	Extremely serious		RoB, Imprecisionx3
GM-CSF inhibitor	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	0.9	0.39	2.07	-5.72	-77.22	91.26	VERY LOW	0.9	0.39	2.07	-5.72	-77.22	91.26	Indirect	MODERATE	#N/A	Very serious		RoB, Imprecisionx2
GM-CSF inhibitor	interferon beta (subcutaneous), lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.59	0.24	1.49	-59.09	-163.95	52.18	VERY LOW	0.59	0.24	1.49	-59.09	-163.95	52.18	Indirect	MODERATE	#N/A	Very serious		RoB, Imprecisionx2
GM-CSF inhibitor	intermediate-dose anticoagulant	NA	NA	NA	NA	NA	NA	NA	0.83	0.25	2.73	-21.43	-161.54	101.6	VERY LOW	0.83	0.25	2.73	-21.43	-161.54	101.6	Indirect	MODERATE	#N/A	Very serious		RoB, Imprecisionx2
GM-CSF inhibitor	ivermectin	NA	NA	NA	NA	NA	NA	NA	0.92	0.35	2.45	-4.29	-101.35	102.33	VERY LOW	0.92	0.35	2.45	-4.29	-101.35	102.33	Indirect	MODERATE	#N/A	Very serious		RoB, Imprecisionx2
GM-CSF inhibitor	JAK inhibitors	NA NA	NA NA	NA NA	NA NA	NA	NA	NA NA	1.19	0.53	2.72	20.63	-45.39	115.31	VERY LOW	1.19	0.53	2.72	20.63	-45.39	115.31	Indirect	MODERATE	#N/A	Very serious		RoB, Imprecisionx2
GM-CSF inhibitor	lopinavir-ritonavir	NA NA	NA NA	NA NA	NA NA	NA	NA NA	NA NA	0.83 7.11F+05	0.37	1.84 2.53F+22	-14.61 -181.68	-81.23 -931.19	80.02 192.67	VERY LOW	0.83	0.37	1.84 2.53F+22	-14.61 -181.68	-81.23 -931.19	80.02 192.67	Indirect	MODERATE	#N/A	Very serious		RoB, Imprecisionx2
GM-CSF inhibitor GM-CSF inhibitor	molnupiravir proxalutamide	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	7.11E+05 14.99	4.59	55.75	104 71	-931.19 44.11	192.67	VERY LOW VERY LOW	7.11E+05 14.99	0 4.59	55.75	104 71	-931.19 44.11	192.67	Indirect	MODERATE	#N/A #N/A	Extremely serious Very serious	MODERATE VERY LOW	RoB, Imprecisionx3 RoBx2. Imprecisionx2
GM-CSF Inhibitor	recombinant human granulocyte colony-stimulating factor	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	5.99	2.06	17.62	92.36	29.79	184.68	VERY LOW	5.99	2.06	17.62	92.36	29.79	184.68	Indirect	MODERATE	#N/A	Very serious Very serious	VERY LOW	RoB, Imprecisionx2
GM-CSF inhibitor	remdesivir	NA.	NA NA	NA NA	NA NA	NA NA	NA	NA NA	1.17	0.52	2.6	19.05	-45.38	112.91	VERY LOW	1.17	0.52	2.6	19.05	-45.38	112.91	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB. Imprecisionx2
GM-CSF inhibitor	serine protease inhibitors	NA	NA.	NA	NA	NA	NA	NA NA	0.37	0.07	1.65	-162.43	-508.59	53.83	VERY LOW	0.37	0.07	1.65	-162.43	-508.59	53.83	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
GM-CSF inhibitor	SGLT2 inhibitors	NA	NA	NA	NA	NA	NA	NA	1.13	0.45	2.9	14.91	-68.02	116.03	VERY LOW	1.13	0.45	2.9	14.91	-68.02	116.03	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
GM-CSF inhibitor	statins	NA	NA	NA	NA	NA	NA	NA	0.73	0.2	2.76	-38.65	-213.72	99.97	VERY LOW	0.73	0.2	2.76	-38.65	-213.72	99.97	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
GM-CSF inhibitor	sulodexide	NA	NA	NA	NA	NA	NA	NA	1.95	0.37	12.59	41.71	-108.15	157.95	VERY LOW	1.95	0.37	12.59	41.71	-108.15	157.95	Indirect	MODERATE	#N/A	Extremely serious	MODERATE	RoB, Imprecisionx3
GM-CSF inhibitor	tyrosine kinase inhibitors	NA	NA	NA	NA	NA	NA	NA	2.19	0.69	7.09	57.47	-25.72	157.06	VERY LOW	2.19	0.69	7.09	57.47	-25.72	157.06	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
GM-CSF inhibitor	vitamin C	NA	NA	NA	NA	NA	NA	NA	0.78	0.29	2.16	-24.88	-132.85	86.38	VERY LOW	0.78	0.29	2.16	-24.88	-132.85	86.38	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
GM-CSF inhibitor	vitamin D	NA	NA	NA	NA	NA	NA	NA	2.05	0.66	6.54	54.16	-28.08	153.78	VERY LOW	2.05	0.66	6.54	54.16	-28.08	153.78	Indirect	MODERATE	#N/A	Very serious		RoB, Imprecisionx2
(hydroxy)chloroquine	IL1 inhibitors	NA	NA	NA	NA	NA	NA	NA	1.6	0.85	3.03	46.4	-17.8	99.35	VERY LOW	1.6	0.85	3.03	46.4	-17.8	99.35	Indirect	MODERATE	#N/A	Very serious		RoB, Imprecisionx2
(hydroxy)chloroquine	IL6 receptor antagonists without corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	2.21	1.27	3.83	72.1	26.81	113	VERY LOW	2.21	1.27	3.83	72.1	26.81	113	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
(hydroxy)chloroquine (hydroxy)chloroquine	inhaled corticosteroids interferon alfa (subcutaneous)	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.24 0.47	0.47	3.31 6.4	16.93 -167.06	-114.14 -789.23	100.96 124.92	VERY LOW VERY LOW	1.24 0.47	0.47	3.31 6.4	16.93 -167.06	-114.14 -789.23	100.96 124.92	Indirect	MODERATE MODERATE	Not serious #N/A	Very serious	VERY LOW MODERATE	RoB, Imprecisionx2 RoB, Imprecisionx3
(hydroxy)chloroquine	interferon beta (subcutaneous)	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.25	0.85	1.89	25.11	-19.78	69	LOW	1.25	0.85	1.89	25.11	-19.78	69	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
interferon beta (subcutaneous), lopinavir-ritonavir	(hydroxy)chloroquine	1.38	0.39	4.83	NA NA	NA NA	NA	VERY LOW	2.07	0.33	18.84	NA NA	NA NA	NA NA	VERY LOW	1.21	0.71	2.05	28.25	-38.9	110.28	Direct	MODERATE	Not serious	Very serious	VERY LOW	RoB. Imprecisionx2
(hydroxy)chloroquine	intermediate-dose anticoagulant	NA	NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.15	0.46	2.99	9.4	-117.9	95.62	VERY LOW	1.15	0.46	2.99	9.4	-117.9	95.62	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB. Imprecisionx2
ivermectin	(hydroxy)chloroquine	1.11	0.28	4.34	NA	NA	NA	LOW	0.55	0.22	1.32	NA	NA	NA	VERY LOW	0.78	0.42	1.46	-26.55	-83.94	47.28	Direct	HIGH	Not serious	Very serious	LOW	Imprecisionx2
(hydroxy)chloroquine	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	1.65	1.14	2.47	51.47	14.36	90.04	MODERATE	1.65	1.14	2.47	51.47	14.36	90.04	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
lopinavir-ritonavir	(hydroxy)chloroquine	0.85	0.36	1.94	NA	NA	NA	VERY LOW	0.82	0.54	1.19	NA	NA	NA	LOW	0.87	0.63	1.17	-16.22	-52.76	17.83	Direct	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
(hydroxy)chloroquine	molnupiravir	NA	NA	NA	NA	NA	NA	NA	9.70E+05	0	3.55E+22	-150.84	-872.57	170.51	VERY LOW	9.70E+05	0	3.55E+22	-150.84	-872.57	170.51	Indirect	MODERATE	#N/A	Extremely serious	MODERATE	RoB, Imprecisionx3
(hydroxy)chloroquine	proxalutamide	NA	NA	NA	NA	NA	NA	NA	20.66	8.3	63.12	135.54	108.82	165.69	VERY LOW	20.66	8.3	63.12	135.54	108.82	165.69	Indirect	LOW	Not serious	Very serious		RoBx2, Imprecisionx2
(hydroxy)chloroquine	recombinant human granulocyte colony-stimulating factor	NA	NA	NA	NA	NA	NA	NA	8.29	3.82	18.57	123.19	92.43	155.63	VERY LOW	8.29	3.82	18.57	123.19	92.43	155.63	Indirect	MODERATE	Not serious	Very serious		RoB, Imprecisionx2
(hydroxy)chloroquine	remdesivir	NA	NA	NA	NA	NA	NA	NA	1.61	1.17	2.32	49.89	16.3	86.55	MODERATE	1.61	1.17	2.32	49.89	16.3	86.55	Indirect	MODERATE	Not serious	Not Serious	MODERNIE	RoB
(hydroxy)chloroquine	serine protease inhibitors	NA	NA NA	NA NA	NA NA	NA	NA	NA	0.52	0.11	1.87	-131.59	-468.91	63.68	VERY LOW	0.52	0.11	1.87	-131.59	-468.91	63.68	Indirect	MODERATE	#N/A	Very serious		RoB, Imprecisionx2
(hydroxy)chloroquine (hydroxy)chloroquine	SGLT2 inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.57	0.88	2.86	45.74 -7.82	-14.37 -174.96	96.52 98.6	VERY LOW VERY LOW	1.57	0.88	2.86 3.08	45.74 -7.82	-14.37 -174.96	96.52 98.6	Indirect	MODERATE MODERATE	#N/A Not serious	Very serious Very serious		RoB, Imprecisionx2 RoB. Imprecisionx2
	statins sulodexide	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	2.69	0.36	15.13	72.55	-174.96	98.6	VERYLOW	2.69	0.36	15.13	-7.82 72.55	-174.96	98.6 142.89	Indirect	MODERATE	Not serious	-,		. , ,
(hydroxy)chloroquine (hydroxy)chloroquine	sulodexide tyrosine kinase inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	3.05	1.25	7 69	72.55 88.31	-67.66 26.84	134.86	VERY LOW	3.05	1.25	7.69	72.55 88.31	-67.66 26.84	142.89	Indirect	MODERATE	Not serious Not serious	Very serious Very serious		RoB, Imprecisionx2 RoB, Imprecisionx2
(nyaroxy)chloroquine (hydroxy)chloroquine	tyrosine kinase innibitors vitamin C	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.08	0.54	2.17	5.96	-87.58	76.61	VERYLOW	1.08	0.54	2.17	5.96	-87.58	76.61	Indirect	MODERATE	Not serious Not serious	Very serious Very serious		RoB, Imprecisionx2
(hydroxy)chloroquine	vitamin D	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	2.85	1.21	6.96	85	24.01	131.92	VERY LOW	2.85	1.21	6.96	85	24.01	131.92	Indirect	MODERATE	Not serious	Very serious		RoB, Imprecisionx2
IL1 inhibitors	IL6 receptor antagonists without corticosteroids (systemic)	NA	NA.	NA NA	NA NA	NA	NA	NA NA	1.38	0.63	3.02	25.7	-32.13	91.96	LOW	1.38	0.63	3.02	25.7	-32.13	91.96	Indirect	HIGH	#N/A	Very serious	LOW	Imprecisionx2
IL1 inhibitors	inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	0.78	0.25	2.37	-29.47	-165.45	70.24	VERY LOW	0.78	0.25	2.37	-29.47	-165.45	70.24	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
IL1 inhibitors	interferon alfa (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	0.29	0.02	4.22	-213.46	-833.27	86	VERY LOW	0.29	0.02	4.22	-213.46	-833.27	86	Indirect	MODERATE	#N/A	Extremely serious	MODERATE	RoB, Imprecisionx3
IL1 inhibitors	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	0.78	0.4	1.54	-21.29	-78.84	46.45	VERY LOW	0.78	0.4	1.54	-21.29	-78.84	46.45	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
IL1 inhibitors	interferon beta (subcutaneous), lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.52	0.23	1.13	-74.65	-168.64	12.78	VERY LOW	0.52	0.23	1.13	-74.65	-168.64	12.78	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
IL1 inhibitors	intermediate-dose anticoagulant	NA	NA	NA	NA	NA	NA	NA	0.72	0.25	2.13	-37	-170.12	63.81	LOW	0.72	0.25	2.13	-37	-170.12	63.81	Indirect	HIGH	#N/A	Very serious	LOW	Imprecisionx2
IL1 inhibitors	ivermectin	NA	NA	NA	NA	NA	NA	NA	0.8	0.34	1.88	-19.85	-106.49	60.65	VERY LOW	0.8	0.34	1.88	-19.85	-106.49	60.65	Indirect	MODERATE	#N/A	Very serious		RoB, Imprecisionx2
IL1 inhibitors	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	1.03	0.53	2.02	5.07	-46.72	69.5	LOW	1.03	0.53	2.02	5.07	-46.72	69.5	Indirect	HIGH	#N/A	Very serious	LOW	Imprecisionx2
IL1 inhibitors	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.72	0.38	1.35	-30.18	-81.54	34.33	VERY LOW	0.72	0.38	1.35	-30.18	-81.54	34.33	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
IL1 inhibitors	molnupiravir	NA	NA	NA	NA	NA	NA	NA	6.19E+05	0	2.12E+22	-197.24	-933.96	151.43	VERY LOW	6.19E+05	0	2.12E+22	-197.24	-933.96	151.43	Indirect	MODERATE	#N/A	Extremely serious	MODERATE	RoB, Imprecisionx3
IL1 inhibitors	proxalutamide	NA	NA NA	NA NA	NA NA	NA	NA	NA NA	12.96	4.42	44.97	89.14	45.04	149.26	VERY LOW	12.96	4.42	44.97	89.14	45.04	149.26	Indirect	LOW	#N/A	Very serious	VERY LOW	RoBx2, Imprecisionx2
IL1 inhibitors	recombinant human granulocyte colony-stimulating factor	NA	NA	NA	NA	NA	NA	NA	5.2	2	13.74	76.79	29.94	138.19	VERY LOW	5.2	2	13.74	76.79	29.94	138.19	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2

										Mech	anical ventila	ition															
Comparison		Direct esti	mate	_	_	_	_	_	Indirect es		arnoar vortala					Network es	stimate	_	_	_	_						
		Relative es	timate		Absolute	estimate (pe	er 1,000)		Relative es	timate		Absolute es	stimate (per	r 1,000)		Relative e	stimate		Absolute	estimate (p	er 1,000)	GRADE					
			Cl lower	CI upper	Point	CI lower		Final rating	Point	Cl lower	CI upper	Point	Cl lower	CI upper	Final rating	Point		CI upper		CI lower	CI upper	Starting	Starting rating	Incoherence	Imprecision	Final rating	Reasons for
Treatment 1 IL1 inhibitors	Treatment 2 remdesivir	estimate NA	limit NA	limit NA	estimate	limit NA	limit	NA.	estimate 1.01	limit 0.53	limit 1.93	3.49	limit -45.57	limit 66.55	VERY LOW	estimate 1.01	limit 0.53	limit 1.93	estimate 3.49	-45.57	limit 66.55	evidence Indirect	MODERATE	#N/A	Very serious	VERY LOW	downgrading RoB. Imprecisionx2
IL1 inhibitors	serine protease inhibitors	NA NA	0.32	0.06	1.93	-177.99	-517.28	24.8	VERYLOW	0.32	0.55	1.32	-177.99	-517.28	24.8	Indirect	MODERATE	#N/A	Very serious Very serious	VERYLOW	RoB, Imprecisionx2						
IL1 inhibitors	SGLT2 inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.98	0.44	2.2	-0.66	-71.89	71.86	LOW	0.98	0.44	2.2	-0.66	-71.89	71.86	Indirect	HIGH	#N/A	Very serious	LOW	Imprecisionx2
IL1 inhibitors	statins	NA NA	NA NA	NA.	NA.	NA NA	NA.	NA NA	0.64	0.2	2.2	-54.22	-226.08	63.72	VERYLOW	0.64	0.2	2.2	-54.22	-226.08	63.72	Indirect	MODERATE	#N/A	Very serious	VERYLOW	RoB. Imprecisionx2
IL1 inhibitors	sulodexide	NA	NA	NA	NA	NA	NA	NA.	1.69	0.34	10.24	26.15	-116.29	116.46	LOW	1.69	0.34	10.24	26.15	-116.29	116.46	Indirect	HIGH	#N/A	Very serious	LOW	Imprecisionx2
IL1 inhibitors	tyrosine kinase inhibitors	NA	NA	NA	NA	NA.	NA	NA.	1.91	0.67	5.49	41.91	-29.75	112.57	VERY LOW	1.91	0.67	5.49	41.91	-29.75	112.57	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB. Imprecisionx2
IL1 inhibitors	vitamin C	NA	0.68	0.28	1.65	-40.44	-140.07	46.16	VERY LOW	0.68	0.28	1.65	-40.44	-140.07	46.16	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2						
IL1 inhibitors	vitamin D	NA	1.78	0.64	5.11	38.6	-33.2	108.8	LOW	1.78	0.64	5.11	38.6	-33.2	108.8	Indirect	HIGH	#N/A	Very serious	LOW	Imprecisionx2						
IL6 receptor antagonists without corticosteroids (systemic)	inhaled corticosteroids	NA	0.56	0.19	1.66	-55.17	-187.25	32.29	VERY LOW	0.56	0.19	1.66	-55.17	-187.25	32.29	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2						
IL6 receptor antagonists without corticosteroids (systemic)	interferon alfa (subcutaneous)	NA	0.21	0.01	3.03	-239.15	-861.04	53.4	VERY LOW	0.21	0.01	3.03	-239.15	-861.04	53.4	Indirect	MODERATE	#N/A	Extremely serious	MODERATE	RoB, Imprecisionx3						
IL6 receptor antagonists without corticosteroids (systemic)	interferon beta (subcutaneous)	NA	0.57	0.31	1.05	-46.99	-93.94	2.59	VERY LOW	0.57	0.31	1.05	-46.99	-93.94	2.59	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2						
IL6 receptor antagonists without corticosteroids (systemic)	interferon beta (subcutaneous), lopinavir-ritonavir	NA	0.37	0.18	0.77	-100.35	-188.75	-26.04	VERY LOW	0.37	0.18	0.77	-100.35	-188.75	-26.04	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2						
IL6 receptor antagonists without corticosteroids (systemic)	intermediate-dose anticoagulant	NA	0.52	0.19	1.49	-62.7	-191.18	26.26	LOW	0.52	0.19	1.49	-62.7	-191.18	26.26	Indirect	HIGH	#N/A	Very serious	LOW	Imprecisionx2						
IL6 receptor antagonists without corticosteroids (systemic)	ivermectin	NA	0.58	0.26	1.28	-45.55	-125.04	20.15	VERY LOW	0.58	0.26	1.28	-45.55	-125.04	20.15	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2						
IL6 receptor antagonists without corticosteroids (systemic)	JAK inhibitors	NA NA	0.75	0.42	1.37	-20.63 -55.87	-60.07 -95.65	24.54 -10.62	VERYLOW	0.75	0.42	1.37	-20.63 -55.87	-60.07 -95.65	24.54 -10.62	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2						
IL6 receptor antagonists without corticosteroids (systemic)	lopinavir-ritonavir molnupiravir	NA NA	0.52 4 19F+05	0.3	0.92 1.69F+22	-55.87 -222.94	-95.65 -947.84	-10.62 106.77	VERY LOW VERY LOW	0.52 4 19F+05	0.3	0.92 1.69F+22	-55.87 -222.94	-95.65 -947.84	-10.62 106.77	Indirect	MODERATE	Not serious #N/A	Very serious Extremely serious	72.11.2011	RoB, Imprecisionx2 RoB. Imprecisionx3						
IL6 receptor antagonists without corticosteroids (systemic) IL6 receptor antagonists without corticosteroids (systemic)	moinupiravir proxalutamide	NA NA	9.37	3.36	31.24	63 44	34.2	106.77	VERYLOW	9.37	3.36	31.69E+22	63 44	-947.84 34.2	106.77	Indirect	LOW	#N/A Not serious	Very serious	VERY LOW	RoBx2. Imprecisionx3						
IL6 receptor antagonists without corticosteroids (systemic) IL6 receptor antagonists without corticosteroids (systemic)	proxalutamide recombinant human granulocyte colony-stimulating factor	NA NA	3.76	1.54	9.5	51.09	17.33	91.85	VERY LOW VERY LOW	3.76	1.54	9.5	51.09	17.33	91.85	Indirect	MODERATE	Not serious Not serious	Very serious Very serious	VERY LOW VERY LOW	RoB. Imprecisionx2						
IL6 receptor antagonists without corticosteroids (systemic)	recombinant numan granulocyte colony-stimulating factor	NA NA	0.73	0.42	1.31	-22.21	-58.41	21.42	VERY LOW	0.73	0.42	1.31	-22.21	-58.41	21.42	Indirect	MODERATE	Not serious	Very serious Very serious	VERY LOW	RoB, Imprecisionx2						
IL6 receptor antagonists without corticosteroids (systemic)	serine protease inhibitors	NA NA	NA NA	NA NA	NA.	NA NA	NA NA	NA NA	0.73	0.05	0.93	-203.69	-542.13	-6.38	VERY LOW	0.73	0.05	0.93	-203.69	-542.13	-6.38	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
IL6 receptor antagonists without corticosteroids (systemic)	SGLT2 inhibitors	NA NA	NA.	NA.	NA.	NA.	NA.	NA NA	0.71	0.34	1.5	-26.36	-88.7	29.77	LOW	0.71	0.34	1.5	-26.36	-88.7	29.77	Indirect	HIGH	#N/A	Very serious	LOW	Imprecisionx2
IL6 receptor antagonists without corticosteroids (systemic)	statins	NA	NA.	NA NA	NA.	NA.	NA.	NA NA	0.46	0.14	1.51	-79.92	-247.47	28.53	VERY LOW	0.46	0.14	1.51	-79.92	-247.47	28.53	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
IL6 receptor antagonists without corticosteroids (systemic)	sulodexide	NA	1.22	0.26	7.27	0.45	-139.7	75.23	LOW	1.22	0.26	7.27	0.45	-139.7	75.23	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2						
IL6 receptor antagonists without corticosteroids (systemic)	tyrosine kinase inhibitors	NA	1.38	0.51	3.85	16.21	-47.02	68.99	VERY LOW	1.38	0.51	3.85	16.21	-47.02	68.99	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2						
IL6 receptor antagonists without corticosteroids (systemic)	vitamin C	NA	0.49	0.21	1.14	-66.14	-161.05	7.84	VERY LOW	0.49	0.21	1.14	-66.14	-161.05	7.84	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2						
IL6 receptor antagonists without corticosteroids (systemic)	vitamin D	NA	1.29	0.49	3.5	12.9	-50.97	65.4	LOW	1.29	0.49	3.5	12.9	-50.97	65.4	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2						
inhaled corticosteroids	interferon alfa (subcutaneous)	NA	0.38	0.02	6.35	-183.99	-802.67	145.7	VERY LOW	0.38	0.02	6.35	-183.99	-802.67	145.7	Indirect	MODERATE	#N/A	Extremely serious	MODERATE	RoB, Imprecisionx3						
inhaled corticosteroids	interferon beta (subcutaneous)	NA	1.01	0.37	2.75	8.18	-79.7	140.72	VERY LOW	1.01	0.37	2.75	8.18	-79.7	140.72	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2						
inhaled corticosteroids	interferon beta (subcutaneous), lopinavir-ritonavir	NA	0.67	0.23	1.97	-45.19	-161.82	98.53	VERY LOW	0.67	0.23	1.97	-45.19	-161.82	98.53	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2						
inhaled corticosteroids	intermediate-dose anticoagulant	NA	0.93	0.25	3.46	-7.53	-157.49	145.2	VERY LOW	0.93	0.25	3.46	-7.53	-157.49	145.2	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2						
inhaled corticosteroids	ivermectin	NA	1.03	0.34	3.2	9.62	-100.3	150.98	VERY LOW	1.03	0.34	3.2	9.62	-100.3	150.98	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2						
inhaled corticosteroids	JAK inhibitors	NA	1.33	0.49	3.63	34.54	-48.98	165.98	VERY LOW	1.33	0.49	3.63	34.54	-48.98	165.98	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2						
inhaled corticosteroids	lopinavir-ritonavir	NA	0.93	0.35	2.47	-0.71	-84.22	130.62	VERY LOW	0.93	0.35	2.47	-0.71	-84.22	130.62	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2						
inhaled corticosteroids	molnupiravir proxalutamide	NA	NA NA	NA NA	NA NA	NA NA	NA	NA NA	8.30E+05	0	2.67E+22	-167.77 118.61	-932.62 40.09	240.3 248.16	VERY LOW VERY LOW	8.30E+05	0	2.67E+22	-167.77 118.61	-932.62 40.09	240.3 248.16	Indirect	MODERATE	#N/A	Extremely serious	MODERATE VERY LOW	RoB, Imprecisionx3
mindica controcatorolac		NA NA	NA		NA NA	NA NA	NA		16.83	4.52	70.51	110.01			VERY LOW VERY LOW	16.83	4.52	70.51				Indirect	MODERATE	Not serious	Very serious		RoBx2, Imprecisionx2
inhaled corticosteroids inhaled corticosteroids	recombinant human granulocyte colony-stimulating factor remdesivir	NA NA	6.73 1.31	1.98 0.49	22.75 3.53	106.26 32.96	26.01 -48.9	235.85 163.7	VERY LOW VERY LOW	6.73 1.31	1.98 0.49	22.75 3.53	106.26 32.96	26.01 -48.9	235.85 163.7	Indirect	MODERATE	Not serious Not serious	Very serious Very serious	VERY LOW VERY LOW	RoB, Imprecisionx2 RoB, Imprecisionx2						
inhaled corticosteroids	serine protease inhibitors	NA NA	0.41	0.49	2.01	-148.52	-40.9 -497.45	90.46	VERY LOW	0.41	0.49	2.01	-148.52	-40.9	90.46	Indirect	MODERATE	#N/A	Very serious Very serious	VERY LOW	RoB, Imprecisionx2						
inhaled corticosteroids	SGLT2 inhibitors	NA NA	NA NA	NA.	NA.	NA NA	NA NA	NA NA	1.27	0.43	3.8	28.81	-68.73	164.42	VERY LOW	1.27	0.43	3.8	28.81	-68.73	164.42	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
inhaled corticosteroids	statins	NA.	NA.	NA.	NA.	NA.	NA.	NA NA	0.82	0.2	3.45	-24.75	-209.55	141.84	VERY LOW	0.82	0.2	3.45	-24.75	-209.55	141.84	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
inhaled corticosteroids	sulodexide	NA.	NA.	NA.	NA.	NA.	NA.	NA NA	2.19	0.38	15.09	55.62	-103.36	203.39	VERY LOW	2.19	0.38	15.09	55.62	-103.36	203.39	Indirect	MODERATE	Not serious	Extremely serious	MODERATE	RoB, Imprecisionx3
inhaled corticosteroids	tyrosine kinase inhibitors	NA	2.47	0.66	9.1	71.38	-25.81	206.17	VERY LOW	2.47	0.66	9.1	71.38	-25.81	206.17	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2						
inhaled corticosteroids	vitamin C	NA	0.88	0.28	2.74	-10.97	-133	132.92	VERY LOW	0.88	0.28	2.74	-10.97	-133	132.92	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2						
inhaled corticosteroids	vitamin D	NA	2.32	0.65	8.27	68.07	-28.67	202.51	VERY LOW	2.32	0.65	8.27	68.07	-28.67	202.51	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2						
interferon alfa (subcutaneous)	interferon beta (subcutaneous)	NA	2.66	0.19	44.83	192.17	-101.91	814.64	VERY LOW	2.66	0.19	44.83	192.17	-101.91	814.64	Indirect	MODERATE	#N/A	Extremely serious	MODERATE	RoB, Imprecisionx3						
interferon alfa (subcutaneous)	interferon beta (subcutaneous), lopinavir-ritonavir	NA	1.75	0.12	30.95	138.8	-170.95	759.44	VERY LOW	1.75	0.12	30.95	138.8	-170.95	759.44	Indirect	MODERATE	#N/A	Extremely serious		RoB, Imprecisionx3						
interferon alfa (subcutaneous)	intermediate-dose anticoagulant	NA	2.46	0.15	46.71	176.45	-154.83	795.42	VERY LOW	2.46	0.15	46.71	176.45	-154.83	795.42	Indirect	MODERATE	#N/A	Extremely serious		RoB, Imprecisionx3						
interferon alfa (subcutaneous)	ivermectin	NA	2.72	0.19	47.71	193.6	-114.93	815.46	VERY LOW	2.72	0.19	47.71	193.6	-114.93	815.46	Indirect	MODERATE	#N/A	Extremely serious		RoB, Imprecisionx3						
interferon alfa (subcutaneous)	JAK inhibitors	NA	3.52	0.26	58.79	218.52	-73.91	842.6	VERY LOW	3.52	0.26	58.79	218.52	-73.91	842.6	Indirect	MODERATE	#N/A	Extremely serious		RoB, Imprecisionx3						
interferon alfa (subcutaneous)	lopinavir-ritonavir	NA	NA NA	NA NA	NA NA	NA NA	NA	NA NA	2.43	0.18	41.29	183.28	-108.33	806.96	VERY LOW	2.43	0.18	41.29	183.28	-108.33	806.96	Indirect	MODERATE	#N/A	Extremely serious		RoB, Imprecisionx3
interferon alfa (subcutaneous)	molnupiravir	NA NA	NA	NA NA	NA NA	NA NA	NA	NA NA	2.67E+06	0	9.14E+22	16.21	-949.86	875.64	VERY LOW	2.67E+06	0	9.14E+22	16.21	-949.86	875.64	Indirect	MODERATE	#N/A	Extremely serious		RoB, Imprecisionx3
interferon alfa (subcutaneous)	proxalutamide	NA NA	45.27 17.83	3	886.68 333.57	302.6 290.25	13.07 -0.01	926.93 913.24	VERY LOW VERY LOW	45.27 17.83	1.18	886.68 333.57	302.6	13.07 -0.01	926.93 913.24	Indirect	LOW	#N/A #N/A	Extremely serious		RoBx2, Imprecisionx3						
interferon alfa (subcutaneous)	recombinant human granulocyte colony-stimulating factor remdesivir	NA NA	17.83 3.44	1.18 0.25	57 49	290.25	-0.01 -74 45	913.24	VERY LOW VERY LOW	17.83	0.25	57 49	290.25 216.94	-0.01 -74 45	913.24 841.12	Indirect	MODERATE	#N/A #N/A	Extremely serious Extremely serious		RoB, Imprecisionx3 RoB, Imprecisionx3						
interferon alfa (subcutaneous)	serine protease inhibitors	NA NA	1.07	0.25	24.54	35.46	-/4.45 -450.12	694 69	VERYLOW	1.07	0.25	24.54	35.46	-/4.45 -450.12	694 69	Indirect	MODERATE	#N/A #N/A	Extremely serious		RoB, Imprecisionx3						
interferon alfa (subcutaneous)	SGLT2 inhibitors	NA NA	3.35	0.03	59.7	212.8	-85.37	835.18	VERYLOW	3.35	0.03	59.7	212.8	-85.37	835.18	Indirect	MODERATE	#N/A	Extremely serious		RoB, Imprecisionx3						
interferon alfa (subcutaneous)	statins	NA NA	NA NA	2.18	0.23	42.61	159.24	-195.28	786.37	VERY LOW	2.18	0.23	42.61	159.24	-195.28	786.37	Indirect	MODERATE	#N/A	Extremely serious		RoB, Imprecisionx3					
interferon alfa (subcutaneous)	sulodexide	NA NA	NA NA	NA NA	NA.	NA NA	NA NA	NA NA	5.93	0.19	154.83	239.6	-92.92	855.93	VERY LOW	5.93	0.19	154.83	239.6	-92.92	855.93	Indirect	MODERATE	#N/A	Extremely serious		RoB, Imprecisionx3
interferon alfa (subcutaneous)	tyrosine kinase inhibitors	NA	NA.	NA NA	NA.	NA.	NA.	NA NA	6.47	0.43	123.77	255.36	-41.86	873.29	VERY LOW	6.47	0.43	123.77	255.36	-41.86	873.29	Indirect	MODERATE	#N/A	Extremely serious		RoB, Imprecisionx3
	vitamin C	NA	2.31	0.16	41.03	173.01	-140.88	791.62	VERY LOW	2.31	0.16	41.03	173.01	-140.88	791.62	Indirect	MODERATE	#N/A	Extremely serious	MODERATE	RoB, Imprecisionx3						
interferon alfa (subcutaneous)	Vitaliiii C		NA	NA	NA	NA	NA	NA	6.08	0.39	116.11	252.05	-45	867.7	VERY LOW	6.08	0.39	116.11	252.05	-45	867.7	Indirect	MODERATE	#N/A	Extremely serious		RoB, Imprecisionx3
interferon alfa (subcutaneous) interferon alfa (subcutaneous)	vitamin D	NA	NA.									-53.36		21.17	VERYLOW	0.00	0.36		50.00		21.17						RoB. Imprecisionx2
	* * *	NA NA	NA NA	NA	NA	NA	NA	NA	0.66	0.36	1.22	-55.50	-142.01	21.17	VERTLOW	0.66	0.30	1.22	-53.36	-142.01	21.17	Indirect	MODERATE	Not serious	Very serious	VERY LOW	
interferon alfa (subcutaneous)	vitamin D			_	NA NA	NA NA	NA NA	NA NA	0.66	0.36	2.43	-15.71	-142.01 -145.54	73.08	VERY LOW	0.66	0.35	1.22 2.43	-15.71	-142.01 -145.54	73.08	Indirect Indirect	MODERATE	Not serious #N/A	Very serious Very serious	VERY LOW VERY LOW	RoB, Imprecisionx2
interferon alfa (subcutaneous) interferon beta (subcutaneous) interferon beta (subcutaneous) interferon beta (subcutaneous) interferon beta (subcutaneous)	vitamin D interferon beta (subcutaneous), lopinavir-ritonavir intermediate-dose anticoagulant ivermectin	NA NA NA	NA NA NA	NA NA NA	NA NA	NA NA	NA NA	NA NA	0.92 1.02	0.35 0.51	2.43 2.05	-15.71 1.44	-145.54 -78.24	73.08 66.42	VERY LOW VERY LOW	0.92 1.02	0.35 0.51	2.43 2.05	-15.71 1.44	-145.54 -78.24	73.08 66.42		MODERATE MODERATE	#N/A Not serious	Very serious Very serious	VERY LOW VERY LOW	RoB, Imprecisionx2
interferon alfa (subcutaneous) interferon beta (subcutaneous)	vitamin D interferon beta (subcutaneous), lopinavir-ritonavir intermediate-dose anticoagulant ivermectin JAK inhibitors	NA NA NA	0.92 1.02 1.32	0.35 0.51 0.85	2.43 2.05 2.09	-15.71 1.44 26.36	-145.54 -78.24 -15.43	73.08 66.42 71.22	VERY LOW VERY LOW	0.92 1.02 1.32	0.35 0.51 0.85	2.43 2.05 2.09	-15.71 1.44 26.36	-145.54 -78.24 -15.43	73.08 66.42 71.22	Indirect	MODERATE MODERATE MODERATE	#N/A	Very serious Very serious Serious	VERY LOW VERY LOW LOW	RoB, Imprecisionx2 RoB, Imprecision						
interferon alfa (subcutaneous) interferon beta (subcutaneous) interferon beta (subcutaneous) interferon beta (subcutaneous) interferon beta (subcutaneous)	vitamin D interferon beta (subcutaneous), lopinavir-ritonavir intermediate-dose anticoagulant ivermectin	NA NA NA	NA NA NA	NA NA NA	NA NA	NA NA	NA NA	NA NA	0.92 1.02	0.35 0.51	2.43 2.05	-15.71 1.44	-145.54 -78.24	73.08 66.42	VERY LOW VERY LOW	0.92 1.02	0.35 0.51 0.85 0.61	2.43 2.05	-15.71 1.44 26.36 -8.89	-145.54 -78.24	73.08 66.42	Indirect Indirect	MODERATE MODERATE	#N/A Not serious Not serious Not serious	Very serious Very serious	VERY LOW VERY LOW LOW	RoB, Imprecisionx2

										Mech	anical ventila	ation															
Comparison		Direct esti	imate	_	_	_	_	_	Indirect est		arnoar vortale	44011				Network es	timate	_	_	_	_						
		Relative es			Absolute 6	estimate (per	1,000)		Relative est	imate		Absolute e	stimate (per	1,000)		Relative es	stimate		Absolute	estimate (per 1,000)	GRADE					
			Cl lower	CI upper	Point	CI lower		Final rating	Point	Cl lower	CI upper	Point	Cl lower	CI upper	Final rating			CI upper	Point	CI lower	CI upper	Starting	Starting rating	Incoherence	Imprecision	Final rating	Reasons for
Treatment 1	Treatment 2	estimate NA	limit	limit NA	estimate NA	limit NA	limit NA	NA.	estimate 16.49	limit	51.83	estimate 110.43	77.51	limit 148.59	VERY LOW	estimate 16.49	limit	limit 51.83	estimate 110.43	77.51	limit 148.59	evidence	LOW	Marian	Maria de la constanta de la co	VERY LOW	downgrading
interferon beta (subcutaneous)	proxalutamide recombinant human granulocyte colony-stimulating factor	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	6.64	6.42 2.92	15.33	98.08	61.43	138.05	VERYLOW	6.64	6.42 2.92	15.33	98.08	61.43	138.05	Indirect	MODERATE	Not serious Not serious	Very serious Very serious	VERY LOW VERY LOW	RoBx2, Imprecisionx2 RoB. Imprecisionx2
interferon beta (subcutaneous)	recombinant numan granulocyte colony-sumulating factor	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.29	0.85	1.98	24.78	-13.69	68.07	LOW	1.29	0.85	1.98	24.78	-13.69	68.07	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
interferon beta (subcutaneous)	serine protease inhibitors	NA.	NA.	NA NA	NA.	NA NA	NA.	NA.	0.41	0.09	1.53	-156.7	-496.49	40.09	VERY LOW	0.41	0.09	1.53	-156.7	-496.49	40.09	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB. Imprecisionx2
interferon beta (subcutaneous)	SGLT2 inhibitors	NA	NA	NA	NA	NA	NA	NA.	1.26	0.66	2.38	20.63	-43.18	76.37	VERY LOW	1.26	0.66	2.38	20.63	-43.18	76.37	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB. Imprecisionx2
interferon beta (subcutaneous)	statins	NA	NA	NA	NA	NA	NA	NA	0.81	0.27	2.52	-32.93	-200.75	76.31	VERY LOW	0.81	0.27	2.52	-32.93	-200.75	76.31	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
interferon beta (subcutaneous)	sulodexide	NA	NA	NA	NA	NA	NA	NA	2.15	0.48	12.45	47.44	-92.9	122.1	VERY LOW	2.15	0.48	12.45	47.44	-92.9	122.1	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
interferon beta (subcutaneous)	tyrosine kinase inhibitors	NA	NA	NA	NA	NA	NA	NA	2.43	0.96	6.33	63.2	-1.13	114.99	VERY LOW	2.43	0.96	6.33	63.2	-1.13	114.99	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
interferon beta (subcutaneous)	vitamin C	NA	NA	NA	NA	NA	NA	NA	0.87	0.42	1.8	-19.15	-114.63	55.74	VERY LOW	0.87	0.42	1.8	-19.15	-114.63	55.74	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
interferon beta (subcutaneous)	vitamin D	NA	NA	NA	NA	NA	NA	NA	2.28	0.93	5.7	59.89	-4.77	112.79	VERY LOW	2.28	0.93	5.7	59.89	-4.77	112.79	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
interferon beta (subcutaneous), lopinavir-ritonavir	intermediate-dose anticoagulant	NA	NA	NA	NA	NA	NA	NA	1.4	0.49	4.02	37.65	-103.44	155.15	VERY LOW	1.4	0.49	4.02	37.65	-103.44	155.15	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
interferon beta (subcutaneous), lopinavir-ritonavir	ivermectin	NA	NA	NA	NA	NA	NA	NA	1.56	0.7	3.43	54.8	-41.41	154.41	VERY LOW	1.56	0.7	3.43	54.8	-41.41	154.41	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
interferon beta (subcutaneous), lopinavir-ritonavir	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	2	1.1	3.7	79.72	10.17	166.12	VERY LOW	2	1.1	3.7	79.72	10.17	166.12	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
lopinavir-ritonavir	interferon beta (subcutaneous), lopinavir-ritonavir	0.87 NA	0.25 NA	3.05 NA	NA NA	NA NA	NA NA	VERY LOW NA	0.39 1.18F+06	0.04	2.44 4.20F+22	-122 59	-873.31	NA 245.63	VERY LOW	0.72 1.18F+06	0.42	1.23 4.20F+2	-44.48 2 -122.59	-127.26 -873.31	21.51	Direct	MODERATE	Not serious #N/A	Very serious	VERY LOW MODERATE	RoB, Imprecisionx2
interferon beta (subcutaneous), lopinavir-ritonavir interferon beta (subcutaneous), lopinavir-ritonavir	molnupiravir proxalutamide	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.18E+06 25.12	8.98	82 41	163.8	-873.31 98.91	245.63	VERYLOW	25.12	8.98	82 41	163.8	98.91	245.63	Indirect	LOW	#N/A Not serious	Extremely serious Very serious	VFRYIOW	RoB, Imprecisionx3 RoBx2, Imprecisionx2
interferon beta (subcutaneous), lopinavir-ritonavir interferon beta (subcutaneous), lopinavir-ritonavir	recombinant human granulocyte colony-stimulating factor	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	10.06	4.07	25.7	151.45	84.7	235.4	VERYLOW	10.06	4.07	25.7	151.45	84.7	235.4	Indirect	MODERATE	Not serious Not serious	Very serious Very serious	VERY LOW	RoB. Imprecisionx2
interferon beta (subcutaneous), lopinavir-ntonavir	recombinant numan granulocyte colony-sumulating factor	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.96	1.11	3.53	78.14	10.24	163.89	VERYLOW	1.96	1.11	3.53	78.14	10.24	163.89	Indirect	MODERATE	Not serious	Very serious	VERYLOW	RoB Imprecisionx2
interferon beta (subcutaneous), lopinavir-ntonavir	serine protease inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.63	0.12	2.47	-103.34	-448.56	111.6	VERYLOW	0.63	0.12	2.47	-103.34	-448.56	111.6	Indirect	MODERATE	#N/A	Very serious	VERYLOW	RoB Imprecisionx2
interferon beta (subcutaneous), lopinavir-ritonavir	SGLT2 inhibitors	NA.	NA.	NA NA	NA.	NA NA	NA.	NA NA	1.9	0.12	4.04	74	-10.62	166.63	VERY LOW	1.9	0.12	4.04	74	-10.62	166.63	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
interferon beta (subcutaneous), lopinavir-ritonavir	statins	NA NA	NA.	NA NA	NA.	NA NA	NA.	NA NA	1.23	0.39	4.06	20.44	-156.86	155.34	VERY LOW	1.23	0.39	4.06	20.44	-156.86	155.34	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
interferon beta (subcutaneous), lopinavir-ritonavir	sulodexide	NA	NA.	NA.	NA.	NA NA	NA.	NA NA	3.27	0.69	19.32	100.8	-49.96	209.81	VERY LOW	3.27	0.69	19.32	100.8	-49.96	209.81	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
interferon beta (subcutaneous), lopinavir-ritonavir	tyrosine kinase inhibitors	NA	NA.	NA NA	NA	NA NA	NA	NA NA	3.69	1.34	10.34	116.56	32	208.35	VERY LOW	3.69	1.34	10.34	116.56	32	208.35	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
interferon beta (subcutaneous), lopinavir-ritonavir	vitamin C	NA	NA	NA NA	NA	NA NA	NA	NA NA	1.32	0.57	3.03	34.21	-76.81	139.65	VERY LOW	1.32	0.57	3.03	34.21	-76.81	139.65	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
interferon beta (subcutaneous), lopinavir-ritonavir	vitamin D	NA	NA	NA	NA	NA	NA	NA	3.45	1.3	9.54	113.25	28.71	204.75	VERY LOW	3.45	1.3	9.54	113.25	28.71	204.75	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
intermediate-dose anticoagulant	ivermectin	NA	NA	NA	NA	NA	NA	NA	1.11	0.37	3.34	17.15	-93.59	152.33	VERY LOW	1.11	0.37	3.34	17.15	-93.59	152.33	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
intermediate-dose anticoagulant	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	1.43	0.55	3.69	42.07	-42.33	169.07	LOW	1.43	0.55	3.69	42.07	-42.33	169.07	Indirect	HIGH	#N/A	Very serious	LOW	RoB, Imprecisionx2
intermediate-dose anticoagulant	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.99	0.39	2.52	6.82	-77.76	134.2	VERY LOW	0.99	0.39	2.52	6.82	-77.76	134.2	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
intermediate-dose anticoagulant	molnupiravir	NA	NA	NA	NA	NA	NA	NA	8.73E+05	0	3.16E+22	-160.24	-926.13	243.94	VERY LOW	8.73E+05	0	3.16E+2	2 -160.24	-926.13	243.94	Indirect	MODERATE	#N/A	Extremely serious	MODERATE	RoB, Imprecisionx3
intermediate-dose anticoagulant	proxalutamide	NA	NA	NA	NA	NA	NA	NA	18.07	4.99	73.36	126.14	46.47	251.56	VERY LOW	18.07	4.99	73.36	126.14	46.47	251.56	Indirect	LOW	#N/A	Very serious	VERY LOW	RoBx2, Imprecisionx2
intermediate-dose anticoagulant	recombinant human granulocyte colony-stimulating factor	NA	NA	NA	NA	NA	NA	NA	7.22	2.21	23.51	113.79	31.63	239.88	VERY LOW	7.22	2.21	23.51	113.79	31.63	239.88	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
intermediate-dose anticoagulant	remdesivir	NA	NA	NA	NA	NA	NA	NA	1.4	0.55	3.57	40.49	-42.62	167.01	VERY LOW	1.4	0.55	3.57	40.49	-42.62	167.01	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
intermediate-dose anticoagulant	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	0.45	0.08	2.11	-140.99	-491.87	93.2	VERY LOW	0.45	0.08	2.11	-140.99	-491.87	93.2	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
intermediate-dose anticoagulant	SGLT2 inhibitors	NA	NA	NA	NA	NA	NA	NA	1.37	0.47	3.87	36.34	-62.18	168.07	LOW	1.37	0.47	3.87	36.34	-62.18	168.07	Indirect	HIGH	#N/A	Very serious	LOW	RoB, Imprecisionx2
intermediate-dose anticoagulant	statins	NA	NA	NA	NA	NA	NA	NA	0.88	0.22	3.65	-17.22	-204.39	147.96	VERY LOW	0.88	0.22	3.65	-17.22	-204.39	147.96	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
intermediate-dose anticoagulant	sulodexide	NA	NA	NA	NA	NA	NA	NA	2.35	0.42	16.15	63.15	-94.43	207.64	VERY LOW	2.35	0.42	16.15	63.15	-94.43	207.64	Indirect	HIGH	#N/A	Extremely serious	HIGH	RoB, Imprecisionx3
intermediate-dose anticoagulant	tyrosine kinase inhibitors	NA	NA	NA	NA	NA	NA	NA	2.64	0.76	9.13	78.91	-19.65	209.82	VERY LOW	2.64	0.76	9.13	78.91	-19.65	209.82	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
intermediate-dose anticoagulant	vitamin C	NA	NA	NA	NA	NA	NA	NA	0.94	0.3	2.9	-3.44	-125.15	136.33	VERY LOW	0.94	0.3	2.9	-3.44	-125.15	136.33	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
intermediate-dose anticoagulant	vitamin D	NA	NA	NA	NA	NA	NA	NA	2.47	0.72	8.54	75.6	-21.41	206.51	LOW	2.47	0.72	8.54	75.6	-21.41	206.51	Indirect	HIGH	#N/A	Very serious	LOW	RoB, Imprecisionx2
ivermectin	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	1.29	0.66	2.6	24.92	-34.55	102	VERY LOW	1.29	0.66	2.6	24.92	-34.55	102	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
ivermectin	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.89	0.47	1.73	-10.33	-69.31	66.75	VERY LOW	0.89	0.47	1.73	-10.33	-69.31	66.75	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
ivermectin	molnupiravir	NA	NA	NA	NA	NA	NA	NA	7.69E+05	0	2.86E+22	-177.39	-920.45	183.56	VERY LOW	7.69E+05	0	2.86E+2		-920.45	183.56	Indirect	MODERATE	#N/A	Extremely serious	-	RoB, Imprecisionx3
ivermectin	proxalutamide	NA	NA	NA	NA	NA	NA	NA	16.18	5.47	56.94	108.99	55.65	183.21	VERY LOW	16.18	5.47	56.94	108.99	55.65	183.21	Indirect	LOW	Not serious	Very serious	VERY LOW	RoBx2, Imprecisionx2
ivermectin	recombinant human granulocyte colony-stimulating factor	NA	NA	NA	NA	NA	NA	NA	6.47	2.47	17.6	96.64	41.67	171.02	VERY LOW	6.47	2.47	17.6	96.64	41.67	171.02	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
ivermectin	remdesivir	NA	NA NA	NA NA	NA	NA NA	NA	NA NA	1.26	0.66	2.48	23.34	-34.01	99.47	VERY LOW	1.26	0.66	2.48	23.34	-34.01	99.47	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
ivermectin	serine protease inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA	NA NA	0.4	0.08	1.65	-158.14 19.19	-501.95	51.11	VERY LOW VERY LOW	0.4	0.08	1.65	-158.14	-501.95	51.11	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
ivermectin	SGLT2 inhibitors statins	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.23 0.8	0.54	2.8	19.19 -34.37	-58.23 -208.07	103.56 91.88	VERY LOW VERY LOW	1.23 0.8	0.54	2.8	19.19 -34.37	-58.23 -208.07	103.56 91.88	Indirect	MODERATE MODERATE	#N/A	Very serious	VERY LOW VERY LOW	RoB, Imprecisionx2 RoB. Imprecisionx2
ivermectin	statins sulodexide	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	2.11	0.24	13.02	-34.37 46	-208.07	91.88	VERYLOW	0.8	0.24	13.02	-34.37 46	-102 22	91.88	Indirect	MODERATE	Not serious Not serious	Very serious Extremely serious		RoB, Imprecisionx2 RoB, Imprecisionx3
ivermectin	sulodexide tyrosine kinase inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	2.11	0.43	7.04	61.76	-102.22	149.32	VERY LOW VERY LOW	2.11	0.43	7.04	61.76	-102.22	149.32	Indirect	MODERATE	Not serious	Lxtremely serious Very serious	VFRYIOW	RoB, Imprecisionx3 RoB, Imprecisionx2
ivermectin	tyrosine kinase innibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.85	0.82	2.07	-20.59	-15.5 -126.34	76.29	VERYLOW	0.85	0.82	2.07	-20.59	-126.34	76.29	Indirect	MODERATE	Not serious Not serious	Very serious Very serious	VERY LOW	RoB, Imprecisionx2
ivermectin	vitamin C vitamin D	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	2.23	0.34	6.4	-20.59 58.45	-126.34 -18.13	140.98	VERYLOW	2.23	0.34	6.4	-20.59 58.45	-126.34	140.98	Indirect	MODERATE	Not serious Not serious	Very serious Very serious	VERY LOW	RoB, Imprecisionx2
JAK inhibitors	lopinavir-ritonavir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.7	0.8	1.02	-35.24	-71.62	1.26	LOW	0.7	0.6	1.02	-35.24	-71.62	1.26	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
JAK inhibitors	molnupiravir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	5.78E+05	0.47	2.14E+22	-35.24	-923.22	116.9	VERY LOW	5.78F+05		2.14E+2		-923.22	116.9	Indirect	MODERATE	#N/A	Extremely serious	MODERATE	RoB, Imprecisionx3
JAK inhibitors	proxalutamide	NA NA	NA NA	NA NA	NA NA	NA NA	NA.	NA NA	12.51	4.87	38.73	84.07	58.42	112.51	VERY LOW	12.51	4.87	38.73	84.07	58.42	112.51	Indirect	LOW	Not serious	Very serious	VERY LOW	RoBx2, Imprecisionx2
JAK inhibitors	recombinant human granulocyte colony-stimulating factor	NA NA	NA.	NA NA	NA.	NA NA	NA.	NA.	5.04	2.21	11.51	71.72	41.06	102.5	VERY LOW	5.04	2.21	11.51	71.72	41.06	102.5	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
JAK inhibitors	remdesivir	NA.	NA.	NA.	NA.	NA.	NA.	NA.	0.98	0.66	1.46	-1.58	-34.02	32.71	LOW	0.98	0.66	1.46	-1.58	-34.02	32.71	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
JAK inhibitors	serine protease inhibitors	NA.	NA.	NA NA	NA.	NA NA	NA.	NA NA	0.31	0.06	1.16	-183.06	-520.3	11.19	VERY LOW	0.31	0.06	1.16	-183.06	-520.3	11.19	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
JAK inhibitors	SGLT2 inhibitors	NA	NA	NA NA	NA	NA NA	NA	NA NA	0.96	0.5	1.77	-5.73	-66.9	43.22	LOW	0.96	0.5	1.77	-5.73	-66.9	43.22	Indirect	HIGH	#N/A	Very serious	LOW	Imprecisionx2
JAK inhibitors	statins	NA	NA	NA	NA	NA	NA	NA	0.62	0.21	1.89	-59.29	-226.16	45.87	VERY LOW	0.62	0.21	1.89	-59.29	-226.16	45.87	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
JAK inhibitors	sulodexide	NA	NA	NA	NA	NA	NA	NA	1.63	0.37	9.31	21.08	-117.95	89.8	LOW	1.63	0.37	9.31	21.08	-117.95	89.8	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
JAK inhibitors	tyrosine kinase inhibitors	NA	NA	NA	NA	NA	NA	NA	1.84	0.73	4.77	36.84	-24.63	81.49	VERY LOW	1.84	0.73	4.77	36.84	-24.63	81.49	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
JAK inhibitors	vitamin C	NA	NA	NA	NA	NA	NA	NA	0.66	0.32	1.35	-45.51	-138.18	24.17	VERY LOW	0.66	0.32	1.35	-45.51	-138.18	24.17	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
JAK inhibitors	vitamin D	NA	NA	NA	NA	NA	NA	NA	1.73	0.71	4.27	33.53	-27.94	79.44	LOW	1.73	0.71	4.27	33.53	-27.94	79.44	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
lopinavir-ritonavir	molnupiravir	NA	NA	NA	NA	NA	NA	NA	851342.68	0	.05121E+2	-167.06	-888.46	152.19	VERY LOW	851342.68	0	.05121E+	2 -167.06	-888.46	152.19	Indirect	MODERATE	#N/A	Extremely serious	MODERATE	RoB, Imprecisionx3
lopinavir-ritonavir	proxalutamide	NA	NA	NA	NA	NA	NA	NA	17.98	7.21	54.99	119.32	92.95	147.36	VERY LOW	17.98	7.21	54.99	119.32	92.95	147.36	Indirect	LOW	Not serious	Very serious	VERY LOW	RoBx2, Imprecisionx2
lopinavir-ritonavir	recombinant human granulocyte colony-stimulating factor	NA	NA	NA	NA	NA	NA	NA	7.24	3.29	16.19	106.97	75.9	137.36	VERY LOW	7.24	3.29	16.19	106.97	75.9	137.36	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
lopinavir-ritonavir	remdesivir	NA	NA	NA	NA	NA	NA	NA	1.41	1	2.01	33.66	0.4	68.13	MODERATE	1.41	1	2.01	33.66	0.4	68.13	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
•		•	•	-	•	•		•			•	•			•	-		•		•	•	•	-	•			

										Mech	anical ventila	ation															
Comparison		Direct esti	imate						Indirect est	timate						Network e	estimate	_	_	_							
		Relative es	stimate		Absolute e	stimate (per	1,000)		Relative est	timate		Absolute e	stimate (per	r 1,000)		Relative e	estimate		Absolute	estimate (per 1,000)	GRADE					
			CI lower	CI upper	Point		CI upper	Final rating	Point	CI lower	CI upper	Point	CI lower	CI upper	Final rating	Point	Cl lower			CI lower	CI upper	Starting	Starting rating	Incoherence	Imprecision	Final rating	Reasons for
Treatment 1	Treatment 2	estimate	limit	limit NA	estimate	limit NA	limit	NA NA	estimate 0.45	limit	limit	estimate -147.81	limit	limit	VERYLOW	estimate	limit	limit	estimate	-486 6	1imit 47 42	evidence	MODERATE	//2.1/4	100000	VEDVLOW	downgrading
lopinavir-ritonavir	serine protease inhibitors	NA NA	NA				NA	NA NA		0.09	1.63		-486.6	47.42		0.45	0.09	1.63	_			Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
lopinavir-ritonavir	SGLT2 inhibitors statins	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.37 0.89	0.75	2.47	29.52 -24.04	-31.52 -191.73	78.53 81.55	VERY LOW VERY LOW	1.37 0.89	0.75	2.47	29.52 -24.04	-31.52 -191.73	78.53 81.55	Indirect	MODERATE	#N/A Not serious	Very serious Very serious	VERY LOW	RoB, Imprecisionx2 RoB, Imprecisionx2
lopinavir-ritonavir	sulodexide	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	2.34	0.51	13.21	56.32	-82.88	124 99	VERYLOW	2.34	0.51	13.21	_	-82.88	124 99	Indirect	MODERATE	Not serious	Very serious	VERYLOW	RoB, Imprecisionx2
lopinavir-ritonavir	tyrosine kinase inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA	NA NA	2.66	1.08	6.72	72.09	10.76	117.17	VERY LOW	2.66	1.08	6.72		10.76	117.17	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
Iopinavir-ritonavir	vitamin C	NA NA	NA NA	NA NA	NA NA	NA NA	NA.	NA NA	0.95	0.47	1.89	-10.27	-104.17	59.85	VERYLOW	0.95	0.47	1.89	-10.27	-104 17	59.85	Indirect	MODERATE	Not serious	Very serious	VERYLOW	RoB Imprecisionx2
lopinavir-ritonavir	vitamin D	NA NA	NA NA	NA.	NA.	NA NA	NA.	NA NA	2.48	1.05	6.09	68.77	7.25	114.43	VERY LOW	2.48	1.05	6.09		7.25	114.43	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
molnupiravir	proxalutamide	NA.	NA.	NA.	NA.	NA NA	NA.	NA.	0	0	7.53F+18	286.38	-17.81	995.8	VERYLOW	0	0	7.53E+		-17.81	995.8	Indirect	LOW	#N/A	Extremely serious	LOW	RoBx2, Imprecisionx3
molnupiravir	recombinant human granulocyte colony-stimulating factor	NA	NA	NA.	NA	NA NA	NA	NA.	0	0	3.36E+18	274.03	-38.24	987.86	VERY LOW	0	0	3.36E+	18 274.03	-38.24	987.86	Indirect	MODERATE	#N/A	Extremely serious	MODERATE	RoB. Imprecisionx3
molnupiravir	remdesivir	NA	NA	NA.	NA	NA	NA	NA.	0	0	6.28E+17	200.73	-114.53	919.39	VERY LOW	0	0	6.28E+	17 200.73	-114.53	919.39	Indirect	MODERATE	#N/A	Extremely serious	MODERATE	RoB. Imprecisionx3
molnupiravir	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	0	0	1.99E+17	19.25	-584.19	879.63	VERY LOW	0	0	1.99E+		-584.19	879.63	Indirect	MODERATE	#N/A	Extremely serious	MODERATE	RoB, Imprecisionx3
molnupiravir	SGLT2 inhibitors	NA	NA	NA	NA	NA	NA	NA	0	0	6.14E+17	196.58	-147.34	929.96	VERY LOW	0	0	6.14E+	17 196.58	-147.34	929.96	Indirect	MODERATE	#N/A	Extremely serious	MODERATE	RoB, Imprecisionx3
molnupiravir	statins	NA	NA	NA	NA	NA	NA	NA	0	0	4.81E+17	143.02	-294.13	927.35	VERY LOW	0	0	4.81E+	17 143.02	-294.13	927.35	Indirect	MODERATE	#N/A	Extremely serious	MODERATE	RoB, Imprecisionx3
molnupiravir	sulodexide	NA	NA	NA	NA	NA	NA	NA	0	0	1.19E+18	223.39	-188.48	979.21	VERY LOW	0	0	1.19E+	18 223.39	-188.48	979.21	Indirect	MODERATE	#N/A	Extremely serious	MODERATE	RoB, Imprecisionx3
molnupiravir	tyrosine kinase inhibitors	NA	NA	NA	NA	NA	NA	NA	0	0	1.28E+18	239.15	-105.6	970.74	VERY LOW	0	0	1.28E+	18 239.15	-105.6	970.74	Indirect	MODERATE	#N/A	Extremely serious	MODERATE	RoB, Imprecisionx3
molnupiravir	vitamin C	NA	NA	NA	NA	NA	NA	NA	0	0	4.89E+17	156.8	-218.96	909.28	VERY LOW	0	0	4.89E+	17 156.8	-218.96	909.28	Indirect	MODERATE	#N/A	Extremely serious	MODERATE	RoB, Imprecisionx3
molnupiravir	vitamin D	NA	NA	NA	NA	NA	NA	NA	0	0	1.13E+18	235.84	-109.74	967.42	VERY LOW	0	0	1.13E+	18 235.84	-109.74	967.42	Indirect	MODERATE	#N/A	Extremely serious	MODERATE	RoB, Imprecisionx3
proxalutamide	recombinant human granulocyte colony-stimulating factor	NA	NA	NA	NA	NA	NA	NA	0.4	0.11	1.31	-12.35	-33.38	3.51	VERY LOW	0.4	0.11	1.31	-12.35	-33.38	3.51	Indirect	LOW	Not serious	Very serious	VERY LOW	RoBx2, Imprecisionx2
proxalutamide	remdesivir	NA	NA	NA	NA	NA	NA	NA	0.08	0.03	0.2	-85.65	-109.36	-63.03	VERY LOW	0.08	0.03	0.2	-85.65	-109.36	-63.03	Indirect	LOW	Not serious	Very serious	VERY LOW	RoBx2, Imprecisionx2
proxalutamide	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	0.02	0	0.12	-267.13	-605.11	-74.33	VERY LOW	0.02	0	0.12		-605.11	-74.33	Indirect	LOW	#N/A	Extremely serious	LOW	RoBx2, Imprecisionx3
proxalutamide	SGLT2 inhibitors	NA	NA	NA	NA	NA	NA	NA	0.08	0.02	0.22	-89.8	-146.28	-48.47	VERY LOW	0.08	0.02	0.22	-89.8	-146.28	-48.47	Indirect	LOW	#N/A	Very serious	VERY LOW	RoBx2, Imprecisionx2
proxalutamide	statins	NA	NA	NA	NA	NA	NA	NA	0.05	0.01	0.2	-143.36	-309.01	-42.21	VERY LOW	0.05	0.01	0.2	-143.36	-309.01	-42.21	Indirect	LOW	Not serious	Very serious	VERY LOW	RoBx2, Imprecisionx2
proxalutamide	sulodexide	NA	NA	NA	NA	NA	NA	NA	0.13	0.02	0.9	-62.99	-200.88	-1.98	VERY LOW	0.13	0.02	0.9	-62.99	-200.88	-1.98	Indirect	LOW	Not serious	Extremely serious	LOW	RoBx2, Imprecisionx3
proxalutamide	tyrosine kinase inhibitors	NA	NA	NA	NA	NA	NA	NA	0.15	0.04	0.53	-47.23	-104.67	-12.06	VERY LOW	0.15	0.04	0.53	-47.23	-104.67	-12.06	Indirect	LOW	Not serious	Very serious	VERY LOW	RoBx2, Imprecisionx2
proxalutamide	vitamin C	NA	NA	NA	NA	NA	NA	NA	0.05	0.01	0.16	-129.58	-219.72	-64.95	VERY LOW	0.05	0.01	0.16	-129.58	-219.72	-64.95	Indirect	LOW	Not serious	Very serious	VERY LOW	RoBx2, Imprecisionx2
proxalutamide	vitamin D	NA	NA	NA	NA	NA	NA	NA	0.14	0.03	0.49	-50.54	-107.7	-14.38	VERY LOW	0.14	0.03	0.49	-50.54	-107.7	-14.38	Indirect	LOW	Not serious	Very serious	VERY LOW	RoBx2, Imprecisionx2
recombinant human granulocyte colony-stimulating factor	remdesivir	NA	NA	NA	NA	NA	NA	NA	0.19	0.09	0.43	-73.3	-99.47	-45.11	VERY LOW	0.19	0.09	0.43	-73.3	-99.47	-45.11	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
recombinant human granulocyte colony-stimulating factor	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	0.06	0.01	0.27	-254.78	-592.83	-61.02	VERY LOW	0.06	0.01	0.27	-254.78	-592.83	-61.02	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
recombinant human granulocyte colony-stimulating factor	SGLT2 inhibitors	NA	NA	NA	NA	NA	NA	NA	0.19	0.07	0.48	-77.45	-134.81	-33.03	VERY LOW	0.19	0.07	0.48	-77.45	-134.81	-33.03	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
recombinant human granulocyte colony-stimulating factor	statins	NA	NA	NA	NA	NA	NA	NA	0.12	0.03	0.45	-131.01	-296.5	-28.43	VERY LOW	0.12	0.03	0.45		-296.5	-28.43	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
recombinant human granulocyte colony-stimulating factor	sulodexide	NA	NA	NA NA	NA	NA NA	NA	NA NA	0.33	0.06	2.1	-50.64	-188.95	12.92	VERY LOW	0.33	0.06	2.1	-50.64	-188.95	12.92	Indirect	MODERATE	Not serious	Extremely serious		RoB, Imprecisionx3
recombinant human granulocyte colony-stimulating factor	tyrosine kinase inhibitors	NA	NA	NA	NA	NA	NA	NA	0.37	0.11	1.18	-34.88	-93.45	4.6	VERY LOW	0.37	0.11	1.18		-93.45	4.6	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
recombinant human granulocyte colony-stimulating factor	vitamin C vitamin D	NA	NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.13	0.05	0.35	-117.23 -38.2	-208.07 -96.17	-50.31 1.81	VERY LOW VERY LOW	0.13	0.05	0.35		-208.07 -96.17	-50.31 1.81	Indirect	MODERATE MODERATE	Not serious	Very serious	VERY LOW VERY LOW	RoB, Imprecisionx2
recombinant human granulocyte colony-stimulating factor	serine protease inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.34	0.11	1.08	-30.2	-519.8	13.14	VERYLOW	0.34	0.11	1.08	-30.2	-519.8	13.14	Indirect	MODERATE	Not serious #N/A	Very serious Very serious	VERYLOW	RoB, Imprecisionx2 RoB, Imprecisionx2
remdesivir	SGLT2 inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.32	0.53	1.76	-4 15	-64 07	41.8	VERYLOW	0.32	0.07	1.76	-4 15	-64.07	41.8	Indirect	MODERATE	#N/A	Very serious	VERYLOW	RoB, Imprecisionx2
remdesivir	statins	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.98	0.33	1.70	-57.71	-224.38	46.02	VERYLOW	0.63	0.33	1.70	-57.71	-224 38	46.02	Indirect	MODERATE	Not serious	Very serious	VERYLOW	RoB, Imprecisionx2
remdesivir	sulodexide	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.66	0.22	9.39	22.66	-115.97	88.8	VERYLOW	1.66	0.22	9.39	_	-115.97	88.8	Indirect	MODERATE	Not serious	Very serious	VERYLOW	RoB, Imprecisionx2
remdesivir	tyrosine kinase inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA.	NA NA	1.88	0.76	4.77	38.42	-21.91	80.23	VERY LOW	1.88	0.76	4.77	38.42	-21.91	80.23	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
remdesivir	vitamin C	NA NA	NA NA	NA NA	NA NA	NA NA	NA.	NA NA	0.67	0.33	1.35	-43.93	-136.46	24.42	VERYLOW	0.67	0.33	1.35	_	-136 46	24.42	Indirect	MODERATE	Not serious	Very serious	VERYLOW	RoB, Imprecisionx2
remdesivir	vitamin D	NA.	NA.	NA.	NA.	NA NA	NA.	NA.	1.76	0.74	4.31	35.11	-24.79	77.76	VERY LOW	1.76	0.74	4.31	35.11	-24.79	77.76	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
serine protease inhibitors	SGLT2 inhibitors	NA.	NA.	NA.	NA.	NA NA	NA	NA.	3.05	0.77	15.66	177.33	-23.63	517.35	VERYLOW	3.05	0.77	15.66		-23.63	517.35	Indirect	MODERATE	#N/A	Very serious	VERYLOW	RoB, Imprecisionx2
serine protease inhibitors	statins	NA.	NA NA	NA NA	NA.	NA NA	NA	NA NA	2	0.38	13.11	123.77	-137.57	483.83	VERY LOW	2	0.38	13.11		-137.57	483.83	Indirect	MODERATE	#N/A	Extremely serious		RoB, Imprecisionx3
serine protease inhibitors	sulodexide	NA	NA	NA	NA	NA	NA	NA.	5.4	0.74	49.04	204.14	-27.49	551.13	VERY LOW	5.4	0.74	49.04	204.14	-27.49	551.13	Indirect	MODERATE	#N/A	Extremely serious	MODERATE	RoB, Imprecisionx3
serine protease inhibitors	tyrosine kinase inhibitors	NA	NA	NA	NA	NA	NA	NA.	5.96	1.28	34.35	219.9	19.31	559.44	VERY LOW	5.96	1.28	34.35		19.31	559.44	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
serine protease inhibitors	vitamin C	NA	NA	NA	NA	NA	NA	NA	2.1	0.5	11.3	137.55	-78.23	482.73	VERY LOW	2.1	0.5	11.3	137.55	-78.23	482.73	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
serine protease inhibitors	vitamin D	NA	NA	NA	NA	NA	NA	NA	5.54	1.22	32.13	216.59	14.8	556.71	VERY LOW	5.54	1.22	32.13	216.59	14.8	556.71	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
SGLT2 inhibitors	statins	NA	NA	NA	NA	NA	NA	NA	0.65	0.2	2.15	-53.56	-224.86	62.88	VERY LOW	0.65	0.2	2.15	-53.56	-224.86	62.88	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
SGLT2 inhibitors	sulodexide	NA	NA	NA	NA	NA	NA	NA	1.71	0.36	10.27	26.81	-115.83	113.63	LOW	1.71	0.36	10.27	26.81	-115.83	113.63	Indirect	HIGH	#N/A	Very serious	LOW	Imprecisionx2
SGLT2 inhibitors	tyrosine kinase inhibitors	NA	NA	NA	NA	NA	NA	NA	1.94	0.7	5.51	42.57	-27.18	109.51	VERY LOW	1.94	0.7	5.51	42.57	-27.18	109.51	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
SGLT2 inhibitors	vitamin C	NA	NA	NA	NA	NA	NA	NA	0.69	0.29	1.61	-39.78	-139.54	44.37	VERY LOW	0.69	0.29	1.61	-39.78	-139.54	44.37	Indirect	MODERATE	#N/A	Very serious	VERY LOW	RoB, Imprecisionx2
SGLT2 inhibitors	vitamin D	NA	NA	NA	NA	NA	NA	NA	1.81	0.67	5.02	39.25	-30.06	106.15	LOW	1.81	0.67	5.02	39.25	-30.06	106.15	Indirect	HIGH	#N/A	Very serious	LOW	Imprecisionx2
statins	sulodexide	NA	NA	NA	NA	NA	NA	NA	2.62	0.44	19.63	80.37	-88.85	260.73	VERY LOW	2.62	0.44	19.63	80.37	-88.85	260.73	Indirect	MODERATE	Not serious	Extremely serious	MODERATE	RoB, Imprecisionx3
statins	tyrosine kinase inhibitors	NA	NA	NA	NA	NA	NA	NA	3	0.75	11.51	96.13	-20.59	266.33	VERY LOW	3	0.75	11.51		-20.59	266.33	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
statins	vitamin C	NA	NA	NA	NA	NA	NA	NA	1.07	0.3	3.57	13.78	-124.67	193.24	VERY LOW	1.07	0.3	3.57	13.78	-124.67	193.24	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
statins	vitamin D	NA	NA	NA	NA	NA	NA	NA	2.81	0.72	10.67	92.82	-23.99	263.39	VERY LOW	2.81	0.72	10.67		-23.99	263.39	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
sulodexide	tyrosine kinase inhibitors	NA	NA	NA	NA	NA	NA	NA	1.13	0.17	6.28	15.76	-71.98	157.34	VERY LOW	1.13	0.17	6.28	15.76	-71.98	157.34	Indirect	MODERATE	Not serious	Extremely serious	MODERATE	RoB, Imprecisionx3
sulodexide	vitamin C	NA	NA	NA	NA	NA	NA	NA	0.4	0.07	1.99	-66.59	-181.72	82.12	VERY LOW	0.4	0.07	1.99		-181.72	82.12	Indirect	MODERATE	Not serious	Extremely serious		RoB, Imprecisionx3
sulodexide	vitamin D	NA	NA	NA	NA	NA	NA	NA	1.05	0.16	5.81	12.45	-74.03	154.88	VERY LOW	1.05	0.16	5.81	12.45	-74.03	154.88	Indirect	HIGH	Not serious	Extremely serious	HIGH	Imprecisionx3
tyrosine kinase inhibitors	vitamin C	NA	NA	NA	NA	NA	NA	NA	0.36	0.12	1.06	-82.35	-181.22	1.89	VERY LOW	0.36	0.12	1.06	-82.35	-181.22	1.89	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
tyrosine kinase inhibitors	vitamin D	NA	NA	NA	NA	NA	NA	NA	0.93	0.28	3.18	-3.31	-70.68	63.86	VERY LOW	0.93	0.28	3.18		-70.68	63.86	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
vitamin C	vitamin D	NA	NA	NA	NA	NA	NA	NA	2.63	0.91	7.81	79.04	-5.88	177.09	VERY LOW	2.63	0.91	7.81	79.04	-5.88	177.09	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2

									Mortality	y													
Comparison		Direct estimate							Indirect estimat	е		1				Network estimate							4 /
Treatment 1	Treatment 2	Relative estimate	CI lower limit	Cl upper limit	Absolute estima Point estimate		Cl upper limit	Final rating	Relative estimate Point estimate	CI lower limit	CI upper limit	Absolute estima Point estimate	e (per 1,000) Cl lower limit	Cl upper limit	Final rating	Relative estimate	CI lower limit	Cl upper limit	Absolute estim Point estimate		Cl upper limit	Final rating	Reasons for
ACE//ARB	standard care/placebo	0.9	0.49	1 62	-11 07	-61.55	65.02	VERY LOW	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA	0.86	0.56	1.32	-14.59	-53.15	34.6	VERY LOW	downgrading RoB. Imprecisionx2
(acetyl)cysteine	standard care/placebo	0.82	0.33	2.09	-20.45	-83.67	107.74	LOW	NA NA	NA NA	NA	NA NA	NA NA	NA NA	NA NA	0.81	0.4	1.64	-17.49	-74.32	66.24	LOW	Imprecisionx2
antihepaciviral	standard care/placebo	0.81	0.48	1.29	-22.31	-63.6	31.63	VERY LOW	0.25	0.06	0.77	-94.54	-120.66	-27.34	VERY LOW	0.79	0.56	1.09	-22.84	-52.06	10.39	VERY LOW	RoB, Imprecisionx2
aspirin	standard care/placebo	0.87	0.34	1.78	-14.82	-81.51	80.56	VERY LOW	NA	NA	NA	NA	NA	NA	NA	0.93	0.69	1.2	-7.49	-34.86	21	LOW	RoB, Imprecision
aspirin, statins	standard care/placebo	1.14	0.23	5.51	15.28	-96.09	321.45	VERY LOW	NA	NA	NA	NA	NA	NA	NA	1.6	0.54	4.3	68.24	-52.49	254.51	VERY LOW	RoB, Imprecisionx2
azithromycin	standard care/placebo	1	0.64	1.62	0.18	-42.82	64.85	VERY LOW	0.5	0.09	2.14	-60.32	-117.11	112.25	VERY LOW	0.98	0.78	1.25	-1.67	-25.02	25.34	LOW	RoB, Imprecision
azithromycin, hydroxychloroquine azithromycin, hydroxychloroquine, oseltamiyir	standard care/placebo	0.77 NA	0.27 NA	2.22 NA	-27.12 NA	-91.31 NA	118.73 NA	LOW NA	1.63	0.05	33.8 12.98	65.45 163.86	-122.36 -53.86	704.73 517.43	VERY LOW LOW	0.69 2.22	0.28	1.62	-28.45 163.86	-88.01 -53.86	60.63 517.43	LOW	Imprecisionx2
azithromycin, nydroxychloroquine, oseitamivir azithromycin, NSAID	standard care/placebo standard care/placebo	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.07	0.53	3.75	163.86	-53.86 -84.68	224.58	VERY LOW	1.07	0.53	3.75	163.86	-53.86	517.43 224.58	VERY LOW	Imprecisionx2 RoB, Imprecisionx2
azithromycin, NSAID, corticosteroid	standard care/placebo	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.66	0.32	2.68	-27.49	-106.54	147.32	VERY LOW	0.66	0.32	2.68	-27.49	-106.54	147.32	VERY LOW	RoB, Imprecisionx2
cefepime	standard care/placebo	0.89	0.01	53.37	-12.91	-127.8	758.57	VERY LOW	NA.	NA NA	NA NA	NA.	NA.	NA.	NA NA	12.56	0	2.88E+12	372.93	-130	870	VERY LOW	RoB, Imprecisionx3
ceftazidime	standard care/placebo	0.81	0.01	48.66	-22.09	-127.99	749.09	VERY LOW	NA	NA	NA	NA	NA	NA	NA	0	0	2.93E+15	372.14	-130	870	VERY LOW	RoB, Imprecisionx3
colchicine	standard care/placebo	0.74	0.3	1.32	-30.06	-86.51	34.84	VERY LOW	NA	NA	NA	NA	NA	NA	NA	0.93	0.65	1.16	-8.43	-38.86	17.56	LOW	RoB, Imprecision
colchicine, emtricitabine, tenofovir, statins	standard care/placebo	0.57	0.14	2.26	-51.68	-109.07	122.51	VERY LOW	NA	NA	NA	NA	NA	NA	NA	0.56	0.27	1.12	-48.59	-90.43	14.79	VERY LOW	RoB, Imprecisionx2
colchicine, statins	standard care/placebo	0.8	0.2	3.13	-23.5	-100.47	188.34	VERY LOW	NA	NA	NA	NA	NA	NA	NA	0.79	0.4	1.52	-20.06	-72.43	55.52	VERY LOW	RoB, Imprecisionx2
corticosteroids (systemic)	standard care/placebo	0.84	0.64	1.07	-19.06	-42.5	7.62	LOW	0.36	0.16	0.8	-78.83	-107.11	-22.84	VERY LOW	0.8	0.65	0.94	-23.48	-40.24	-6.94	MODERATE	RoB
IL6 receptor antagonists with corticosteroids (systemic)	standard care/placebo	0.81 3.13	0.69	0.96 23.79	-22.33 188.48	-37.05 -72.13	-4.61 650.47	MODERATE VERY LOW	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.8 3.54	0.69	0.94 25.89	-22.74 243.47	-36.5 -33.11	-6.92 668.84	MODERATE VERY LOW	RoB
doxycycline doxycycline, ivermectin	standard care/placebo	0.14	0.41	3.45	-109.41	-12.13	210.11	VERYLOW	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.54	0.05	25.89	-125.16	-130	-82 81	VERYLOW	RoB, Imprecisionx3
electrolyzed saline	standard care/placebo standard care/placebo	0.14	0.01	1.39	-109.41	-129.14 -125.9	41.77	VERY LOW VERY LOW	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.18	0.02	0.77	-125.16 -99.07	-130	-82.81 -29.88	VERY LOW VERY LOW	RoB. Imprecisionx3
emercitabine, tenofovir	standard care/placebo	0.77	0.03	2.51	-26.95	-95.37	142.78	VERY LOW	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.16	0.02	1.43	-24.76	-77.26	52.82	VERY LOW	RoB, Imprecisionx2
favipiravir	standard care/placebo	0.86	0.18	3.97	-16.64	-103.16	242.05	VERY LOW	1.3	0.65	2.65	32.31	-41.09	153.63	VERY LOW	1.31	0.67	2.59	34.02	-40.89	141.41	VERY LOW	RoB, Imprecisionx2
favipiravir, hydrochloroquine	standard care/placebo	0.96	0.23	4.02	-4.71	-96.99	245.38	VERY LOW	NA	NA	NA	NA	NA	NA	NA	0.97	0.42	2.2	2.08	-71.72	116.53	VERY LOW	RoB, Imprecisionx2
fluvoxamine	standard care/placebo	0.7	0.22	2.29	-35.65	-98.67	124.72	LOW	NA	NA	NA	NA	NA	NA	NA	0.68	0.33	1.32	-33.55	-80.72	35.41	LOW	Imprecisionx2
full-dose anticoagulant	standard care/placebo	0.96	0.6	1.38	-4.47	-47.52	40.94	LOW	0.44	0.16	1.15	-68.14	-106.1	16.73	VERY LOW	0.96	0.78	1.16	-4.67	-26.18	17.73	LOW	RoB, Imprecision
GM-CSF inhibitor	standard care/placebo	0.73	0.4	1.22	-31.7	-73.96	23.87	LOW	NA	NA	NA	NA	NA	NA	NA	0.77	0.55	1.07	-26.08	-53.86	6.23	LOW	Imprecisionx2
(hydroxy)chloroquine	standard care/placebo	1.1	0.91	1.32	10.74	-10.79	34.74	MODERATE	0.78	0.3	2.05	-25.89	-86.63	104.22	VERY LOW	1.08	0.92	1.27	10.23	-8.71	30.39	MODERATE	Imprecision
IL1 inhibitors	standard care/placebo	0.74	0.41	1.32	-30.38	-71.94 -20.96	34.97	LOW MODERATE	NA 2.4	NA 1.08	NA 5.40	NA 400.00	NA 0.40	NA 320.45	NA VERY LOW	0.75	0.48	1.15	-28.53 10.57	-63.68 -10.77	17.55 34.39	LOW MODERATE	Imprecisionx2
IL6 receptor antagonists interferon alfa (subcutaneous)	standard care/placebo standard care/placebo	1.03	0.82	1.28 36.23	2.86 167.29	-20.96 -98.13	30.09 714 1	VERYLOW	2.4 NA	1.08 NA	5.49 NA	133.62 NA	8.46 NA	320.45 NA	NA NA	1.09 8.00F+05	0.91	1.31 5.51F+21	10.57 815.6	-10.77	34.39 870	VERYLOW	Imprecision RoB. Imprecisionx3
interferon beta (subcutaneous)	standard care/placebo	0.91	0.22	1.43	-10.44	-90.13	46.53	VERY LOW	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.01	0.75	1.31	2.5	-27.58	33.24	LOW	RoB, Imprecision
interferon beta (subcutaneous), lopinavir-ritonavir	standard care/placebo	1.61	0.38	6.73	63.56	-75.79	371.25	VERY LOW	9.75	2.02	67.63	462.9	102	779.96	VERY LOW	2.06	1.17	3.62	110.32	20.02	222.58	VERY LOW	RoB, Imprecisionx2
intermediate-dose anticoagulant	standard care/placebo	0.66	0.16	2.8	-39.78	-107.04	165.01	VERY LOW	1.47	0.86	2.52	49.94	-15.66	143.32	LOW	1.15	0.72	1.81	19.05	-31.05	83.26	LOW	RoB, Imprecisionx2
intranasal corticosteroids	standard care/placebo	0.9	0.09	9.41	-11.9	-117.4	454.27	VERY LOW	NA	NA	NA	NA	NA	NA	NA	0	0	36.91	-116.29	-130	-34.8	VERY LOW	Imprecisionx3
ivermectin	standard care/placebo	0.49	0.23	1.04	-61.36	-96.11	4.44	LOW	1.19	0.49	2.74	21.13	-61.59	160.67	VERY LOW	0.63	0.37	1.05	-40.92	-76.7	6.74	LOW	Imprecisionx2
JAK inhibitors	standard care/placebo	0.63	0.42	0.93	-44.4	-71.18	-7.58	HIGH	NA	NA	NA	NA	NA	NA	NA	0.63	0.47	0.83	-43.97	-64.27	-20.22	HIGH	
lopinavir-ritonavir	standard care/placebo	1.05	0.8	1.37	5.56	-22.73	39.66	LOW	0.68	0.14	2.81	-38.25	-108.9	165.91	VERY LOW	1.06	0.88	1.28	6.91	-12.85	28.93	LOW	RoB, Imprecision
melatonin methylene blue	standard care/placebo	0.11	0.01	0.88 1.27	-113.64 -59.59	-127.86 -100.8	-13.35 29.88	VERY LOW VERY LOW	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.04	0.25	0.28	-119.4 -57.48	-129.68 -93.38	-87.44 -5.02	VERY LOW VERY LOW	RoB, Imprecisionx3
metnylene blue molnupiravir	standard care/placebo standard care/placebo	0.51	0.2	1.18	-59.59 -88.04	-100.8	19.82	VERY LOW VERY LOW	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.06	0.25	0.96	-57.48	-93.38 -129.65	-5.02 -76.21	VERY LOW VERY LOW	RoB, Imprecisionx2 RoB, Imprecisionx3
nitazoxanide	standard care/placebo	0.29	0.07	2.35	-50.04	-119.13	130.23	LOW	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.54	0.14	2.07	-40 11	-111.55	110.02	LOW	Imprecisionx2
omega 3	standard care/placebo	0.18	0.03	1.11	-103.84	-125.53	11.96	VERY LOW	NA NA	NA NA	NA NA	NA.	NA NA	NA NA	NA NA	0.11	0.01	0.57	-108	-127.9	-55.07	VERY LOW	RoB. Imprecisionx3
nirmatrelvir/ritonavir	standard care/placebo	0.05	0	1.03	-122.99	-129.68	3.06	VERY LOW	NA.	NA NA	NA	NA.	NA.	NA	NA	0	0	0.01	-129.47	-130	-125.04	VERY LOW	Imprecisionx3
probiotics	standard care/placebo	1.02	0.2	5.13	2.03	-100.72	304.01	LOW	NA	NA	NA	NA	NA	NA	NA	0.96	0.21	4.55	25.31	-97.67	292.66	LOW	Imprecisionx2
proxalutamide	standard care/placebo	0.14	0.06	0.38	-109.82	-121.69	-75.8	VERY LOW	NA	NA	NA	NA	NA	NA	NA	0.12	0.08	0.2	-111.36	-118.86	-101.23	VERY LOW	RoB, Imprecisionx2
recombinant human granulocyte colony-stimulating factor	standard care/placebo	0.21	0.04	1.19	-100	-124.67	21.5	VERY LOW	NA	NA	NA	NA	NA	NA	NA	0.19	0.04	0.64	-97.71	-124.17	-43.45	VERY LOW	RoB, Imprecisionx2
remdesivir	standard care/placebo	0.9	0.68	1.18	-11.51	-37.9	20.24	LOW	NA	NA	NA	NA	NA	NA	NA	0.91	0.73	1.11	-10.47	-30.97	11.53	LOW	RoB, Imprecision
serine protease inhibitors	standard care/placebo	0.65	0.16	2.54	-41.6	-106.72	145.23	VERY LOW	NA	NA	NA	NA	NA	NA	NA	0.67	0.24	1.86	-30.8	-94.67	85.22	VERY LOW	RoB, Imprecisionx2
SGLT2 inhibitors statins	standard care/placebo	0.74	0.2	2.75 4.9	-30.15 -1.06	-100.97 -100.92	161.54 292.51	LOW VERY LOW	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.74 1.35	0.45	1.22 3.71	-28.04 44.17	-66.56 -67.31	23.1	LOW VERY LOW	Imprecisionx2
statins sulodexide	standard care/placebo standard care/placebo	0.99	0.2	2.6	-70.56	-100.92 -119.82	149.64	VERY LOW VERY LOW	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.4	0.46	1.46	-65.23	-67.31	219.4 48.3	LOW	RoB, Imprecisionx2 Imprecisionx2
suiodexide synthetic VIP	standard care/placebo standard care/placebo	1.15	0.07	4.58	16.39	-88.81	276.43	LOW	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.16	0.08	2.38	23.28	-50.26	131.75	LOW	Imprecisionx2
tyrosine kinase inhibitors	standard care/placebo	0.43	0.12	1.33	-69.42	-111.74	35.86	LOW	NA NA	NA NA	NA	NA NA	NA NA	NA NA	NA NA	0.42	0.21	0.83	-67.45	-99.76	-18.54	LOW	Imprecisionx2
umifenovir	standard care/placebo	0.74	0.31	1.76	-30.1	-86	78.56	VERY LOW	0.01	0	2.17E+16	-127.77	-130	870	VERY LOW	0.69	0.34	1.4	-30.06	-83.04	53.45	VERY LOW	RoB, Imprecisionx2
vitamin C	standard care/placebo	0.67	0.29	1.56	-39.3	-88.3	58.62	VERY LOW	NA	NA	NA	NA	NA	NA	NA	0.63	0.31	1.25	-38.42	-84.86	30.5	VERY LOW	RoB, Imprecisionx2
vitamin D	standard care/placebo	0.62	0.24	1.53	-45.33	-95.94	56.01	VERY LOW	NA	NA	NA	NA	NA	NA	NA	0.59	0.28	1.2	-41.93	-88.34	27.28	VERY LOW	RoB, Imprecisionx2
ACEI/ARB	(acetyl)cysteine	NA	NA	NA	NA	NA	NA	NA	1.05	0.46	2.45	2.9	-90.06	79.51	VERY LOW	1.05	0.46	2.45	2.9	-90.06	79.51	VERY LOW	RoB, Imprecisionx2
ACE/ARB	antihepaciviral	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.08	0.63	1.89	8.25	-43.26	64.69	VERY LOW	1.08	0.63	1.89	8.25	-43.26	64.69	VERY LOW	RoB, Imprecisionx2
ACEI/ARB ACEI/ARB	aspirin	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.92	0.55	1.55	-7.1 -82.83	-54.67 -271.52	48.29 48.85	VERY LOW VERY LOW	0.92	0.55	1.55	-7.1 -82.83	-54.67 -271.52	48.29 48.85	VERY LOW VERY LOW	RoB, Imprecisionx2 RoB, Imprecisionx2
ACE/ARB ACE/ARB	aspirin, statins azithromycin	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.54	0.18	1.68	-82.83 -12.92	-2/1.52 -60.47	48.85	VERY LOW VERY LOW	0.54	0.18	1.68	-82.83 -12.92	-2/1.52 -60.47	48.85	VERY LOW VERY LOW	RoB, Imprecisionx2 RoB. Imprecisionx2
ACE/ARB ACE/ARB	azithromycin, hydroxychloroquine	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.26	0.53	3.31	13.86	-85.85	92.12	VERY LOW VERY LOW	1.26	0.53	3.31	13.86	-85.85	92.12	VERY LOW VERY LOW	RoB, Imprecisionx2
ACEI/ARB	azithromycin, hydroxychloroquine, oseltamivir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.38	0.06	1.75	-178.45	-531.85	41.57	VERY LOW	0.38	0.06	1.75	-178.45	-531.85	41.57	VERY LOW	RoB, Imprecisionx2
ACE/ARB	azithromycin, NSAID	NA	NA	NA	NA	NA	NA	NA	0.8	0.21	2.91	-38.89	-244.37	83.44	VERY LOW	0.8	0.21	2.91	-38.89	-244.37	83.44	VERY LOW	RoB, Imprecisionx2
ACE/ARB	azithromycin, NSAID, corticosteroid	NA	NA	NA	NA	NA	NA	NA	1.29	0.29	6.19	12.9	-164.17	108.97	VERY LOW	1.29	0.29	6.19	12.9	-164.17	108.97	VERY LOW	RoB, Imprecisionx2
ACEI/ARB	cefepime	NA	NA	NA	NA	NA	NA	NA	0.06	0	1.33E+09	-387.52	-916.33	149.68	VERY LOW	0.06	0	1.33E+09	-387.52	-916.33	149.68	VERY LOW	RoB, Imprecisionx3
ACEI/ARB	ceftazidime	NA	NA	NA	NA	NA	NA	NA	8.22E+08	0	2.66E+21	-386.73	-915.69	150.03	VERY LOW	8.22E+08	0	2.66E+21	-386.73	-915.69	150.03	VERY LOW	RoB, Imprecisionx3
ACEi/ARB	colchicine	NA	NA	NA	NA	NA	NA	NA	0.93	0.57	1.62	-6.16	-53.48	50.63	VERY LOW	0.93	0.57	1.62	-6.16	-53.48	50.63	VERY LOW	RoB, Imprecisionx2
ACE/ARB	colchicine, emtricitabine, tenofovir, statins	NA	NA	NA	NA	NA	NA	NA	1.52	0.66	3.55	34	-40.43	99.21	VERY LOW	1.52	0.66	3.55	34	-40.43	99.21	VERY LOW	RoB, Imprecisionx2
ACEI/ARB ACEI/ARB	colchicine, statins	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.09	0.49	1.74	5.47 8.89	-79.37 -32.94	77.32 60.33	VERY LOW VERY LOW	1.09	0.49	2.42	5.47 8.89	-79.37 -32.94	77.32 60.33	VERY LOW VERY LOW	RoB, Imprecisionx2
ACEI/ARB ACEI/ARB	conticosteroids (systemic)	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.08	0.67	1.74	8.89 8.15	-32.94 -33.69	60.33 58.6	VERY LOW VERY LOW	1.08	0.67	1.74	8.89 8.15	-32.94 -33.69	60.33 58.6	VERY LOW VERY LOW	RoB, Imprecisionx2 RoB, Imprecisionx2
ACE/ARB ACE/ARB	IL6 receptor antagonists with corticosteroids (systemic) doxycycline	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.24	0.07	1.09	-258.06	-683.66	25.68	VERY LOW VERY LOW	0.24	0.07	1.09	-258.06	-683.66	25.68	VERY LOW VERY LOW	RoB, Imprecisionx3
ACE/ARB	doxycycline, ivermectin	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	3.60E+18	6.04E+04	3.89E+32	110.57	58.4	162.93	VERY LOW	3.60E+18	60,440.22	3.89E+32	110.57	58.4	162.93	VERY LOW	RoB, Imprecisionx3
ACE/ARB	electrolyzed saline	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	4.89	1.04	37.25	84.48	6.32	144.89	VERY LOW	4.89	1.04	37.25	84.48	6.32	144.89	VERY LOW	RoB, Imprecisionx3
L	J. Godnoryzou samio	1907							7.00	1.04	01.20	5-7.40	0.02	1-7.00	* * L LOTT	7.00	1.04	57.25	51.40	0.02	1-1-1-00	TELL LOW	

									Mortalit	у													
Comparison		Direct estimate)					_	Indirect estimat							Network estimat	te						
		Relative estimat	te		Absolute estima			Final rating	Relative estimat	e		Absolute estima			Final rating	Relative estima			Absolute estim			Final rating	Reasons for
Treatment 1	Treatment 2	+	CI lower limit				CI upper limit		Point estimate			Point estimate	CI lower limit	CI upper limit		Point estimate							downgrading
ACEI/ARB ACEI/ARB	emtricitabine, tenofovir	NA	NA	NA NA	NA	NA	NA	NA	1.14 0.65	0.51	2.53	10.17	-74.94 -162.1	82.9	VERY LOW	1.14	0.51	2.53	10.17	-74.94 -162.1	82.9	VERY LOW	RoB, Imprecisionx2
ACEI/ARB	favipiravir favipiravir, hydrochloroquine	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.65	0.3	1.46	-48.61 -16.68	-162.1	42.78 74.69	VERY LOW	0.65	0.3	1.46	-48.61 -16.68	-162.1 -138.01	42.78 74.69	VERY LOW	RoB, Imprecisionx2 RoB, Imprecisionx2
ACE/ARB ACE/ARB	fluvoxamine	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.26	0.35	2.29	18.96	-138.01	74.09 88.79	VERYLOW	1.26	0.56	2.29	18.96	-138.01	74.09 88.79	VERY LOW	RoB, Imprecisionx2
ACEI/ARB	full-dose anticoagulant	NA NA	NA.	NA NA	NA NA	NA.	NA NA	NA.	0.9	0.56	1.45	-9.93	-54.84	42.7	VERY LOW	0.9	0.56	1.45	-9.93	-54.84	42.7	VERY LOW	RoB. Imprecisionx2
ACE//ARB	GM-CSF inhibitor	NA NA	NA.	NA NA	NA NA	NA.	NA.	NA.	1.11	0.64	1.93	11.49	-39.2	67.52	VERY LOW	1.11	0.64	1.93	11.49	-39.2	67.52	VERY LOW	RoB. Imprecisionx2
ACE/ARB	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	0.79	0.49	1.26	-24.83	-68.85	27.31	VERY LOW	0.79	0.49	1.26	-24.83	-68.85	27.31	VERY LOW	RoB, Imprecisionx2
ACEi/ARB	IL1 inhibitors	NA	NA	NA	NA	NA	NA	NA	1.15	0.62	2.1	13.94	-45.65	75.15	VERY LOW	1.15	0.62	2.1	13.94	-45.65	75.15	VERY LOW	RoB, Imprecisionx2
ACE//ARB	IL6 receptor antagonists without corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	0.78	0.49	1.26	-25.16	-70.86	27.96	VERY LOW	0.78	0.49	1.26	-25.16	-70.86	27.96	VERY LOW	RoB, Imprecisionx2
ACE//ARB	interferon alfa (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	0	0	0.48	-830.19	-921.33	-232.21	VERY LOW	0	0	0.48	-830.19	-921.33	-232.21	VERY LOW	RoB, Imprecisionx3
ACE//ARB	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	0.85	0.51	1.43	-17.09	-66.82	39.5	VERY LOW	0.85	0.51	1.43	-17.09	-66.82	39.5	VERY LOW	RoB, Imprecisionx2
ACEi/ARB	interferon beta (subcutaneous), lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.42	0.2	0.85	-124.91	-242.6	-24.27	VERY LOW	0.42	0.2	0.85	-124.91	-242.6	-24.27	VERY LOW	RoB, Imprecisionx2
ACEI/ARB ACEI/ARB	intermediate-dose anticoagulant intranasal corticosteroids	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.74 2.65F+06	0.39	1.42 1.60F+13	-33.64 101.7	-109.15 26.81	37.22 163.53	VERY LOW VERY LOW	0.74 2.65F+06	0.39	1.42 1.60E+13	-33.64 101.7	-109.15 26.81	37.22 163.53	VERY LOW	RoB, Imprecisionx2 RoB, Imprecisionx3
ACE/ARB ACE/ARB	intranasai corticosteroios ivermectin	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	2.00E+00	0.02	1.60E+13	26.32	-34.21	88.8	VERYLOW	2.00E+00	0.02	1.60E+13	26.32	-34 21	88.8	VERY LOW	RoB, Imprecisionx3
ACE/ARB	JAK inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.37	0.7	2.29	29.38	-15.97	82.5	VERY LOW	1.37	0.81	2.29	29.38	-15.97	82.5	VERYLOW	RoB, Imprecisionx2
ACE//ARB	lopinavir-ritonavir	NA.	NA.	NA.	NA.	NA.	NA.	NA.	0.81	0.5	1.3	-21.5	-66.42	31.34	VERY LOW	0.81	0.5	1.3	-21.5	-66.42	31.34	VERY LOW	RoB, Imprecisionx2
ACE/ARB	melatonin	NA	NA	NA	NA	NA	NA	NA	20.2	2.84	415.93	104.81	56.64	155.89	VERY LOW	20.2	2.84	415.93	104.81	56.64	155.89	VERY LOW	RoB, Imprecisionx3
ACE//ARB	methylene blue	NA	NA	NA	NA	NA	NA	NA	1.71	0.79	3.83	42.89	-22.3	104.22	VERY LOW	1.71	0.79	3.83	42.89	-22.3	104.22	VERY LOW	RoB, Imprecisionx2
ACEi/ARB	molnupiravir	NA	NA	NA	NA	NA	NA	NA	13.67	2.05	244.83	100.93	48.73	155.13	VERY LOW	13.67	2.05	244.83	100.93	48.73	155.13	VERY LOW	RoB, Imprecisionx3
ACEI/ARB	nitazoxanide	NA	NA	NA	NA	NA	NA	NA	1.57	0.39	6.58	25.52	-129.39	117.02	VERY LOW	1.57	0.39	6.58	25.52	-129.39	117.02	VERY LOW	RoB, Imprecisionx2
ACEi/ARB	omega 3	NA	NA	NA	NA	NA	NA	NA	7.71	1.43	66.02	93.41	27.17	148.92	VERY LOW	7.71	1.43	66.02	93.41	27.17	148.92	VERY LOW	RoB, Imprecisionx3
ACE//ARB	nirmatrelvir/ritonavir	NA	NA	NA	NA	NA	NA	NA	2.43E+09	77.69	7.68E+19	114.88	75.93	164.15	VERY LOW	2.43E+09	77.69	7.68E+19	114.88	75.93	164.15	VERY LOW	RoB, Imprecisionx3
ACE/ARB	probiotics	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.89	0.17	4.4	-39.9	-310.09	94.14 146.56	VERY LOW	0.89	0.17	4.4 13.36	-39.9	-310.09	94.14	VERY LOW	RoB, Imprecisionx2
ACE/ARB	proxalutamide recombinant human granulocyte colony-stimulating factor	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	6.92	3.64 1.26	13.36	96.77 83.12	56.98 18.19	146.56	VERY LOW	6.92 4.54	3.64 1.26	13.36	96.77 83.12	56.98	146.56	VERY LOW	RoB, Imprecisionx2 RoB, Imprecisionx2
ACE/ARB ACE/ARB	recombinant numan granulocyte colony-stimulating factor	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.95	0.59	1.54	-4.13	-48.54	48.96	LOW	0.95	0.59	1.54	-4.13	-48.54	48.96	LOW	RoB, Imprecisionx2
ACE//ARB	serine protease inhibitors	NA.	NA.	NA.	NA	NA.	NA.	NA.	1.28	0.42	4.04	16.21	-105.85	101.1	VERY LOW	1.28	0.42	4.04	16.21	-105.85	101.1	VERY LOW	RoB, Imprecisionx2
ACE/ARB	SGLT2 inhibitors	NA	NA	NA	NA	NA	NA	NA	1.16	0.6	2.24	13.44	-49.86	75.83	VERY LOW	1.16	0.6	2.24	13.44	-49.86	75.83	VERY LOW	RoB, Imprecisionx2
ACE//ARB	statins	NA	NA	NA	NA	NA	NA	NA	0.64	0.21	2.06	-58.76	-237.99	63.36	VERY LOW	0.64	0.21	2.06	-58.76	-237.99	63.36	VERY LOW	RoB, Imprecisionx2
ACEi/ARB	sulodexide	NA	NA	NA	NA	NA	NA	NA	2.18	0.56	10.72	50.64	-67.51	127.8	VERY LOW	2.18	0.56	10.72	50.64	-67.51	127.8	VERY LOW	RoB, Imprecisionx2
ACEi/ARB	synthetic VIP	NA	NA	NA	NA	NA	NA	NA	0.74	0.32	1.68	-37.87	-153.54	50.97	VERY LOW	0.74	0.32	1.68	-37.87	-153.54	50.97	VERY LOW	RoB, Imprecisionx2
ACE//ARB	tyrosine kinase inhibitors	NA	NA	NA	NA	NA	NA	NA	2.03	0.89	4.67	52.86	-9.25	112.37	VERY LOW	2.03	0.89	4.67	52.86	-9.25	112.37	VERY LOW	RoB, Imprecisionx2
ACE//ARB	umifenovir	NA	NA	NA	NA	NA	NA	NA	1.23	0.55	2.9	15.47	-76.8	89.49	VERY LOW	1.23	0.55	2.9	15.47	-76.8	89.49	VERY LOW	RoB, Imprecisionx2
ACE/ARB	vitamin C	NA	NA	NA	NA	NA	NA	NA	1.35	0.61	3.12	23.83	-53.91	93.59	VERY LOW	1.35	0.61	3.12	23.83	-53.91	93.59	VERY LOW	RoB, Imprecisionx2
ACEI/ARB (acetyl)cysteine	vitamin D antihepaciviral	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.46	0.63	3.43 2.25	27.34 5.35	-53.93 -60.52	96.43 92.63	VERY LOW VERY LOW	1.46	0.63	3.43 2.25	27.34 5.35	-53.93 -60.52	96.43 92.63	VERY LOW	RoB, Imprecisionx2 RoB, Imprecisionx2
(acety)cysteine	aspirin	NA NA	NA NA	NA NA	NA NA	NA.	NA NA	NA NA	0.87	0.41	1.85	-10	-73.96	77.39	VERYLOW	0.87	0.41	1.85	-10	-73.96	77.39	VERYLOW	RoB Imprecisionx2
(acetyl)cysteine	aspirin, statins	NA NA	NA.	NA NA	NA	NA.	NA NA	NA NA	0.51	0.15	1.84	-85.73	-278.46	63.87	VERY LOW	0.51	0.15	1.84	-85.73	-278.46	63.87	VERY LOW	RoB, Imprecisionx2
(acetyl)cysteine	azithromycin	NA	NA	NA	NA	NA	NA	NA	0.83	0.39	1.73	-15.82	-79.99	70.58	VERY LOW	0.83	0.39	1.73	-15.82	-79.99	70.58	VERY LOW	RoB, Imprecisionx2
(acetyl)cysteine	azithromycin, hydroxychloroquine	NA	NA	NA	NA	NA	NA	NA	1.19	0.39	3.66	10.96	-95.94	116.62	LOW	1.19	0.39	3.66	10.96	-95.94	116.62	LOW	Imprecisionx2
(acetyl)cysteine	azithromycin, hydroxychloroquine, oseltamivir	NA	NA	NA	NA	NA	NA	NA	0.37	0.06	1.77	-181.35	-543.42	53.07	VERY LOW	0.37	0.06	1.77	-181.35	-543.42	53.07	VERY LOW	RoB, Imprecisionx3
(acetyl)cysteine	azithromycin, NSAID	NA	NA	NA	NA	NA	NA	NA	0.76	0.18	3.11	-41.79	-248.37	97.04	VERY LOW	0.76	0.18	3.11	-41.79	-248.37	97.04	VERY LOW	RoB, Imprecisionx2
(acetyl)cysteine	azithromycin, NSAID, corticosteroid	NA NA	NA	NA	NA	NA	NA	NA	1.23	0.25	6.4	10	-172.83	129.27	VERY LOW	1.23	0.25	6.4	10	-172.83	129.27 170.67	VERY LOW	RoB, Imprecisionx2
(acetyl)cysteine (acetyl)cysteine	cefepime ceftazidime	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.06 9.22E+08	0	1.33E+09 2.56E+21	-390.42 -389.63	-935.37 -934.25	170.67 174.39	VERY LOW VERY LOW	0.06 9.22E+08	0	1.33E+09 2.56E+21	-390.42 -389.63	-935.37 -934.25	170.67	VERY LOW VERY LOW	RoB, Imprecisionx3
(acetyl)cysteine	certazionne	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	9.22E+08 0.89	0.41	2.50E+21 1.93	-389.03	-934.25	78.18	VERY LOW VERY LOW	9.22E+08 0.89	0.41	2.50E+21 1.93	-389.63	-934.25	78.18	VERY LOW	RoB, Imprecisionx3 RoB, Imprecisionx2
(acetyl)cysteine	colchicine, emtricitabine, tenofovir, statins	NA NA	NA.	NA NA	NA NA	NA.	NA NA	NA NA	1.45	0.53	3.91	31.1	-54 11	126.92	VERYLOW	1.45	0.41	3.91	31.1	-54 11	126.92	VERYLOW	RoB, Imprecisionx2
(acetyl)cysteine	colchicine, statins	NA.	NA.	NA NA	NA NA	NA.	NA.	NA.	1.02	0.39	2.74	2.57	-93.61	102.43	VERY LOW	1.02	0.39	2.74	2.57	-93.61	102.43	VERY LOW	RoB. Imprecisionx2
(acetyl)cysteine	corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	1.02	0.49	2.11	5.99	-53.99	91.68	VERY LOW	1.02	0.49	2.11	5.99	-53.99	91.68	VERY LOW	RoB, Imprecisionx2
(acetyl)cysteine	IL6 receptor antagonists with corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	1.01	0.48	2.08	5.25	-54.68	90.24	VERY LOW	1.01	0.48	2.08	5.25	-54.68	90.24	VERY LOW	RoB, Imprecisionx2
(acetyl)cysteine	doxycycline	NA	NA	NA	NA	NA	NA	NA	0.23	0.03	1.41	-260.96	-699.26	25.17	VERY LOW	0.23	0.03	1.41	-260.96	-699.26	25.17	VERY LOW	RoB, Imprecisionx3
(acetyl)cysteine	doxycycline, ivermectin	NA	NA	NA	NA	NA	NA	NA	3.46E+18	57,763.36	3.53E+32	107.67	40.24	194.33	VERY LOW	3.46E+18	57,763.36	3.53E+32	107.67	40.24	194.33	VERY LOW	Imprecisionx3
(acetyl)cysteine	electrolyzed saline	NA	NA	NA	NA	NA	NA	NA	4.62	0.92	39.43	81.58	-9.68	175.32	VERY LOW	4.62	0.92	39.43	81.58	-9.68	175.32	VERY LOW	RoB, Imprecisionx3
(acetyl)cysteine	emtricitabine, tenofovir	NA	NA	NA	NA	NA	NA	NA	1.09	0.41	2.84	7.27	-90.3	106.57	VERY LOW	1.09	0.41	2.84	7.27	-90.3	106.57	VERY LOW	RoB, Imprecisionx2
(acetyl)cysteine	favipiravir	NA	NA	NA	NA	NA	NA	NA	0.62	0.23	1.6	-51.51 -19.57	-175.2 -147.5	60.94 94.16	VERY LOW VERY LOW	0.62	0.23	1.6	-51.51 -19.57	-175.2 -147.5	60.94 94.16	VERY LOW VERY LOW	RoB, Imprecisionx2
(acetyl)cysteine (acetyl)cysteine	favipiravir, hydrochloroquine fluvoxamine	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.19	0.29	2.44 3.25	-19.57 16.06	-147.5 -76.26	94.16	LOW LOW	1.19	0.29	3.25	-19.57 16.06	-147.5 -76.26	94.16	VERY LOW LOW	RoB, Imprecisionx2 Imprecisionx2
(acetyl)cysteine	full-dose anticoagulant	NA NA	NA NA	NA NA	NA NA	NΑ	NA NA	NA NA	0.85	0.44	1.78	-12.82	-76.26	73.32	VERYLOW	0.85	0.44	1.78	-12.82	-74.07	73.32	VERYLOW	RoB. Imprecisionx2
(acety)cysteine	GM-CSF inhibitor	NA NA	NA NA	NA NA	NA NA	NA.	NA NA	NA NA	1.05	0.41	2.3	8 59	-58.01	97.29	LOW	1.05	0.41	2.3	8.59	-58.01	97.29	LOW	Imprecisionx2
(acetyl)cysteine	(hydroxy)chloroquine	NA.	NA.	NA.	NA	NA.	NA.	NA.	0.75	0.36	1.55	-27.72	-88.86	58.13	LOW	0.75	0.36	1.55	-27.72	-88.86	58.13	LOW	Imprecisionx2
(acetyl)cysteine	IL1 inhibitors	NA	NA	NA	NA	NA	NA	NA	1.09	0.47	2.49	11.05	-63.51	101.88	LOW	1.09	0.47	2.49	11.05	-63.51	101.88	LOW	Imprecisionx2
(acetyl)cysteine	IL6 receptor antagonists without corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	0.74	0.35	1.55	-28.06	-89.81	57.01	LOW	0.74	0.35	1.55	-28.06	-89.81	57.01	LOW	Imprecisionx2
(acetyl)cysteine	interferon alfa (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	0	0	0.47	-833.09	-940.61	-240.98	VERY LOW	0	0	0.47	-833.09	-940.61	-240.98	VERY LOW	RoB, Imprecisionx3
(acetyl)cysteine	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	0.8	0.37	1.73	-19.98	-84.58	67.87	VERY LOW	0.8	0.37	1.73	-19.98	-84.58	67.87	VERY LOW	RoB, Imprecisionx2
(acetyl)cysteine	interferon beta (subcutaneous), lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.39	0.16	0.96	-127.81	-256.1	-4.37	VERY LOW	0.39	0.16	0.96	-127.81	-256.1	-4.37	VERY LOW	RoB, Imprecisionx2
(acetyl)cysteine	intermediate-dose anticoagulant	NA	NA	NA	NA	NA	NA	NA	0.71	0.3	1.68	-36.54	-123.17	58.82	VERY LOW	0.71	0.3	1.68	-36.54	-123.17	58.82	VERY LOW	RoB, Imprecisionx2
(acetyl)cysteine	intranasal corticosteroids	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	2.66E+06	0.02	1.38E+13	98.8	19.31	195.4	VERY LOW	2.66E+06	0.02	1.38E+13 3.12	98.8	19.31	195.4	VERY LOW	Imprecisionx3
(acetyl)cysteine (acetyl)cysteine	ivermectin JAK inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.28	0.54	3.12	23.43	-50.14 -36.08	116.84 112.64	LOW	1.28	0.54	3.12	23.43 26.48	-50.14 -36.08	116.84 112.64	LOW	Imprecisionx2 Imprecisionx2
(acety)cysteine				INA			1471	NA NA						61.72	VERYLOW	0.77	0.6	1.57	-24.4	-36.08 -85.68	61.72		RoB. Imprecisionx2
(acetyl)cysteine	1 1 1 1 1	NA NA	NA	NA	NA	NA	NA		0.77	0.37	1.57	-24 4	-85 68									VERYLOW	
(acetyl)cysteine (acetyl)cysteine	JAK inhibitors lopinavir-ritonavir melatonin		NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.77 19.32	0.37 2.51	1.57 422.67	-24.4 101.91	-85.68 39.95	187.15	VERY LOW VERY LOW	19.32	2.51	422.67	101.91	-85.68 39.95		VERY LOW VERY LOW	RoB. Imprecisionx3
	lopinavir-ritonavir	NA																			187.15 132.68		RoB, Imprecisionx3
(acetyl)cysteine	lopinavir-ritonavir melatonin	NA NA	NA	NA	NA	NA	NA	NA	19.32	2.51	422.67	101.91	39.95	187.15	VERY LOW	19.32	2.51	422.67	101.91	39.95	187.15	VERY LOW	

									Mortalit	у													
Comparison		Direct estimate)						Indirect estimat							Network estimate							
		Relative estimat	te		Absolute estim		100 000	Final rating	Relative estimate	011 "		Absolute estima			Final rating	Relative estima			Absolute estim		1 00 11 11	Final rating	Reasons for
Treatment 1 (acetyl)cysteine	Treatment 2 omega 3	Point estimate NA	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit	NA.	Point estimate 7.36	CI lower limit	Cl upper limit 69.62	Point estimate 90.51	CI lower limit	CI upper limit	VERY LOW	Point estimate 7.36	CI lower limit	CI upper limit 69.62	Point estimate 90.51	CI lower limit	CI upper limit	VERY LOW	RoB. Imprecisionx3
(acetyl)cysteine	nirmatrelvir/ritonavir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	2.23E+09	82.83	7.38E+19	111.98	54.79	195.96	VERY LOW	2.23E+09	82.83	7.38E+19	111.98	54.79	195.96	VERY LOW	Imprecisionx3
(acetyl)cysteine	probiotics	NA	NA	NA	NA	NA	NA	NA	0.85	0.15	4.56	-42.8	-316.74	107.24	LOW	0.85	0.15	4.56	-42.8	-316.74	107.24	LOW	Imprecisionx2
(acetyl)cysteine	proxalutamide	NA	NA	NA	NA	NA	NA	NA	6.57	2.78	15.35	93.88	36.27	177.94	VERY LOW	6.57	2.78	15.35	93.88	36.27	177.94	VERY LOW	RoB, Imprecisionx2
(acetyl)cysteine	recombinant human granulocyte colony-stimulating factor	NA	NA	NA	NA	NA	NA	NA	4.36	1.03	23.61	80.22	2.19	171.67	VERY LOW	4.36	1.03	23.61	80.22	2.19	171.67	VERY LOW	RoB, Imprecisionx2
(acetyl)cysteine	remdesivir	NA	NA	NA	NA	NA	NA	NA	0.9	0.43	1.87	-7.02	-68.36	78.28	VERY LOW	0.9	0.43	1.87	-7.02	-68.36	78.28	VERY LOW	RoB, Imprecisionx2
(acetyl)cysteine	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	1.22	0.34	4.35	13.31	-116.7	122.36	VERY LOW	1.22	0.34	4.35	13.31	-116.7	122.36	VERY LOW	RoB, Imprecisionx2
(acetyl)cysteine (acetyl)cysteine	SGLT2 inhibitors statins	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.1	0.46	2.59	10.55 -61.66	-66.93 -245.36	102.84 79.14	LOW VERY LOW	1.1 0.6	0.46	2.59	10.55 -61.66	-66.93 -245.36	102.84 79.14	LOW VERY LOW	Imprecisionx2 RoB, Imprecisionx2
(acetyl)cysteine	sulodexide	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	2.07	0.17	11.52	47.74	-77.33	149.73	LOW	2.07	0.17	11.52	47 74	-77.33	149.73	LOW	Imprecisionx2
(acetyl)cysteine	synthetic VIP	NA NA	NA.	NA NA	NA.	NA.	NA.	NA.	0.7	0.26	1.87	-40.77	-164.61	71.08	LOW	0.7	0.26	1.87	-40.77	-164.61	71.08	LOW	Imprecisionx2
(acetyl)cysteine	tyrosine kinase inhibitors	NA	NA	NA	NA	NA	NA	NA	1.91	0.73	5.21	49.96	-25.01	140.63	LOW	1.91	0.73	5.21	49.96	-25.01	140.63	LOW	Imprecisionx2
(acetyl)cysteine	umifenovir	NA	NA	NA	NA	NA	NA	NA	1.17	0.43	3.21	12.57	-91.78	115.94	VERY LOW	1.17	0.43	3.21	12.57	-91.78	115.94	VERY LOW	RoB, Imprecisionx2
(acetyl)cysteine	vitamin C	NA	NA	NA	NA	NA	NA	NA	1.29	0.46	3.51	20.93	-70.04	118.9	VERY LOW	1.29	0.46	3.51	20.93	-70.04	118.9	VERY LOW	RoB, Imprecisionx2
(acetyl)cysteine	vitamin D	NA NA	NA NA	NA NA	NA NA	NA	NA NA	NA NA	1.39	0.51	3.82	24.44	-64.02	120.78	VERY LOW	1.39	0.51	3.82	24.44	-64.02 -56.07	120.78 25.88	VERY LOW VERY LOW	RoB, Imprecisionx2
antihepaciviral	aspirin aspirin, statins	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.85	0.55 0.17	1.28	-15.35 -91.08	-56.07 -279.59	25.88 35.02	VERY LOW VERY LOW	0.85	0.55 0.17	1.28	-15.35 -91.08	-56.07 -279.59	25.88 35.02	VERY LOW VERY LOW	RoB, Imprecisionx2
antihepaciviral antihepaciviral	aspirin, statins azithromycin	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.5	0.17	1.51	-91.08	-62 06	19.06	VERY LOW	0.81	0.17	1.51	-91.08	-279.59 -62.06	19.06	VERY LOW VERY LOW	RoB, Imprecisionx2 RoB, Imprecisionx2
antihepaciviral	azithromycin, hydroxychloroquine	NA NA	NA NA	NA NA	NA.	NA NA	NA NA	NA NA	1.14	0.46	2.95	5.61	-85.93	75.51	VERY LOW	1.14	0.46	2.95	5.61	-85.93	75.51	VERY LOW	RoB. Imprecisionx2
azithromycin, hydroxychloroquine, oseltamivir	antihepaciviral	13.65	0.62	301.05	NA	NA	NA	VERY LOW	0	0	0.32	NA	NA	NA	VERY LOW	2.79	0.68	16.18	186.71	-29.24	538.43	VERY LOW	, Imprecisionx2, Incohere
antihepaciviral	azithromycin, NSAID	NA	NA	NA	NA	NA	NA	NA	0.74	0.2	2.55	-47.14	-248.31	67.46	VERY LOW	0.74	0.2	2.55	-47.14	-248.31	67.46	VERY LOW	RoB, Imprecisionx2
antihepaciviral	azithromycin, NSAID, corticosteroid	NA	NA	NA	NA	NA	NA	NA	1.2	0.28	5.38	4.64	-171.03	90.96	VERY LOW	1.2	0.28	5.38	4.64	-171.03	90.96	VERY LOW	RoB, Imprecisionx2
antihepaciviral	cefepime	NA	NA	NA	NA	NA	NA	NA	0.06	0	1.16E+09	-395.77	-916.43	130.02	VERY LOW	0.06	0	1.16E+09	-395.77	-916.43	130.02	VERY LOW	RoB, Imprecisionx3
antihepaciviral antihepaciviral	ceftazidime colchicine	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	7.96E+08 0.86	0 57	2.38E+21 1.34	-394.98 -14.41	-916 -52.45	130.72 27.08	VERY LOW VERY LOW	7.96E+08 0.86	0 57	2.38E+21 1.34	-394.98 -14.41	-916 -52.45	130.72 27.08	VERY LOW VERY LOW	RoB, Imprecisionx3
antinepaciviral antihepaciviral	colchicine, emtricitabine, tenofovir, statins	NA NA	NA NA	NA	NA	NΑ	NA NA	NΑ	0.86	0.57	3.09	-14.41 25.75	-52.45	27.08 80.21	VERY LOW	1.41	0.57	3.09	-14.41 25.75	-52.45	27.08 80.21	VERY LOW	RoB, Imprecisionx2 RoB, Imprecisionx2
antihepaciviral	colchicine, entiticitabilie, teribiovii, statilis	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.41	0.47	2.1	-2.78	-84.36	59.71	VERY LOW	1.41	0.47	2.1	-2.78	-84.36	59.71	VERY LOW	RoB, Imprecisionx2
antihepaciviral	corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	0.99	0.68	1.43	0.64	-32.5	36.85	LOW	0.99	0.68	1.43	0.64	-32.5	36.85	LOW	RoB, Imprecision
antihepaciviral	IL6 receptor antagonists with corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	0.99	0.66	1.41	-0.1	-34.27	36.22	LOW	0.99	0.66	1.41	-0.1	-34.27	36.22	LOW	RoB, Imprecision
antihepaciviral	doxycycline	NA	NA	NA	NA	NA	NA	NA	0.22	0.03	1.27	-266.32	-693.36	13.16	VERY LOW	0.22	0.03	1.27	-266.32	-693.36	13.16	VERY LOW	RoB, Imprecisionx3
antihepaciviral	doxycycline, ivermectin	NA	NA	NA	NA	NA	NA	NA	3.22E+18	5.05E+04	3.79E+32	102.32	54.2	139	VERY LOW	3.22E+18	50,525.33	3.79E+32	102.32	54.2	139	VERY LOW	RoB, Imprecisionx3
antihepaciviral antihepaciviral	electrolyzed saline emtricitabine, tenofovir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	4.48	0.98	33.81 2.19	76.22 1.92	2.97 -80.65	123.59 64.07	VERY LOW	4.48 1.06	0.98	33.81 2.19	76.22 1.92	2.97 -80.65	123.59 64.07	VERY LOW VERY LOW	RoB, Imprecisionx3
antinepaciviral antihepaciviral	emiricitabine, tendrovir favipiravir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.61	0.28	1.24	-56.87	-80.05	25.13	VERY LOW	0.61	0.28	1.24	-56.87	-80.05	25.13	VERY LOW VERY LOW	RoB, Imprecisionx2 RoB, Imprecisionx2
antihepaciviral	favipiravir, hydrochloroquine	NA NA	NA NA	NA NA	NA.	NA NA	NA NA	NA NA	0.82	0.34	2.02	-24.93	-143.02	56.42	VERY LOW	0.82	0.20	2.02	-24.93	-143.02	56.42	VERY LOW	RoB, Imprecisionx2
antihepaciviral	fluvoxamine	NA	NA	NA	NA	NA	NA	NA	1.16	0.54	2.55	10.71	-64.11	68.67	VERY LOW	1.16	0.54	2.55	10.71	-64.11	68.67	VERY LOW	RoB, Imprecisionx2
antihepaciviral	full-dose anticoagulant	NA	NA	NA	NA	NA	NA	NA	0.83	0.56	1.2	-18.18	-54.91	20.15	VERY LOW	0.83	0.56	1.2	-18.18	-54.91	20.15	VERY LOW	RoB, Imprecisionx2
antihepaciviral	GM-CSF inhibitor	NA	NA	NA	NA	NA	NA	NA	1.03	0.64	1.61	3.23	-40.16	45.48	LOW	1.03	0.64	1.61	3.23	-40.16	45.48	LOW	RoB, Imprecision
antihepaciviral	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	0.73	0.49	1.04	-33.08	-68.33	4.26	VERY LOW	0.73	0.49	1.04	-33.08	-68.33	4.26	VERY LOW	RoB, Imprecisionx2
antihepaciviral	IL1 inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.06 0.72	0.61	1.83	5.69 -33.41	-49.14 -71.38	54.71 5.87	VERY LOW	1.06 0.72	0.61	1.83	5.69 -33.41	-49.14 -71.38	54.71 5.87	VERY LOW VERY LOW	RoB, Imprecisionx2
antihepaciviral antihepaciviral	IL6 receptor antagonists without corticosteroids (systemic) interferon alfa (subcutaneous)	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.72	0.49	0.45	-838.44	-71.38	-244.09	VERY LOW	0.72	0.49	0.45	-33.41	-71.38	-244.09	VERY LOW VERY LOW	RoB, Imprecisionx2 RoB, Imprecisionx3
antihepaciviral	interferon beta (subcutaneous)	NA NA	NA.	NA NA	NA.	NA.	NA NA	NA NA	0.78	0.51	1.18	-25.34	-66.51	17.21	VERY LOW	0.78	0.51	1.18	-25.34	-66.51	17.21	VERY LOW	RoB, Imprecisionx2
interferon beta (subcutaneous), lopinavir-ritonavir	antihepaciviral	9.56	1.35	67.59	NA	NA	NA	VERY LOW	1.84	0.9	3.77	NA	NA	NA	VERY LOW	2.61	1.4	4.93	133.16	39.9	247.48	VERY LOW	RoB, Imprecisionx2
antihepaciviral	intermediate-dose anticoagulant	NA	NA	NA	NA	NA	NA	NA	0.69	0.39	1.21	NA	NA	NA	VERY LOW	0.69	0.39	1.21	-41.89	-111.6	16.75	VERY LOW	RoB, Imprecisionx2
antihepaciviral	intranasal corticosteroids	NA	NA	NA	NA	NA	NA	NA	2.55E+06	0.02	1.48E+13	93.44	14.44	139.99	VERY LOW	2.55E+06	0.02	1.48E+13	93.44	14.44	139.99	VERY LOW	RoB, Imprecisionx3
antihepaciviral	ivermectin	NA	NA	NA	NA NA	NA	NA NA	NA	1.25	0.68	2.28	18.07	-37.23	68.63	VERY LOW	1.25	0.68	2.28	18.07	-37.23 -16.8	68.63	VERY LOW	RoB, Imprecisionx2
antihepaciviral	JAK inhibitors	NA 0.71	NA 0.08	NA 6	NA NA	NA NA	NA NA	NA VERY LOW	1.26	0.8	2.04	21.13 NA	-16.8 NA	60.3 NA	MODERATE	1.26	0.8	1.94	21.13	-16.8 -8.67	60.3	VERY LOW VERY LOW	RoB, Imprecisionx2
antihepaciviral	melatonin	NA	NA	NA NA	NA NA	NA NA	NA NA	NA NA	18.66	2.64	374.14	96.56	56.61	133.73	VERY LOW	18.66	2.64	374.14	96.56	56.61	133.73	VERY LOW	RoB. Imprecisionx3
antihepaciviral	methylene blue	NA	NA	NA	NA	NA	NA	NA	1.58	0.76	3.31	34.63	-25	85.62	VERY LOW	1.58	0.76	3.31	34.63	-25	85.62	VERY LOW	RoB, Imprecisionx2
antihepaciviral	molnupiravir	NA	NA	NA	NA	NA	NA	NA	12.39	1.89	213.37	92.68	44.09	132	VERY LOW	12.39	1.89	213.37	92.68	44.09	132	VERY LOW	RoB, Imprecisionx3
antihepaciviral	nitazoxanide	NA	NA	NA	NA	NA	NA	NA	1.46	0.36	5.69	17.27	-135.45	99.67	VERY LOW	1.46	0.36	5.69	17.27	-135.45	99.67	VERY LOW	RoB, Imprecisionx2
antihepaciviral	omega 3	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	7.07	1.35	59.65	85.15	25.87	127.55	VERY LOW	7.07	1.35	59.65 6.85E+19	85.15	25.87	127.55	VERY LOW	RoB, Imprecisionx3
antihepaciviral antihepaciviral	nirmatrelvir/ritonavir probiotics	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	2.14E+09	73.86	6.85E+19 3.99	106.63	76.34	140.16 81.78	VERY LOW	2.14E+09 0.82	73.86	6.85E+19	106.63	76.34	140.16 81.78	VERY LOW	RoB, Imprecisionx3 RoB, Imprecisionx2
antihepaciviral	proxalutamide	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	6.41	3.56	11.36	88 52	57 49	122.8	VERYLOW	6.41	3.56	11.36	88.52	57 49	122.8	VERYLOW	RoB, Imprecisionx2
antihepaciviral	recombinant human granulocyte colony-stimulating factor	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA	4.18	1.2	21.16	74.87	14.44	119.5	VERY LOW	4.18	1.2	21.16	74.87	14.44	119.5	VERY LOW	RoB, Imprecisionx2
antihepaciviral	remdesivir	NA	NA	NA	NA	NA	NA	NA	0.88	0.58	1.27	-12.38	-49.37	25.69	LOW	0.88	0.58	1.27	-12.38	-49.37	25.69	LOW	RoB, Imprecision
antihepaciviral	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	1.18	0.41	3.49	7.96	-111.81	81.71	VERY LOW	1.18	0.41	3.49	7.96	-111.81	81.71	VERY LOW	RoB, Imprecisionx2
antihepaciviral	SGLT2 inhibitors	NA	NA	NA	NA	NA	NA	NA	1.07	0.58	1.9	5.19	-53.18	55.86	VERY LOW	1.07	0.58	1.9	5.19	-53.18	55.86	VERY LOW	RoB, Imprecisionx2
antihepaciviral	statins	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.58	0.2	1.78	-67.01	-245.96	49.52	VERY LOW	0.58	0.2	1.78	-67.01	-245.96	49.52	VERY LOW	RoB, Imprecisionx2
antihepaciviral antihepaciviral	sulodexide synthetic VIP	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.68	0.52	10.03	42.38 -46.13	-75.68 -158.59	109.42 34.6	VERY LOW VERY LOW	0.68	0.52	10.03	42.38 -46.13	-75.68 -158.59	109.42 34.6	VERY LOW VERY LOW	RoB, Imprecisionx2 RoB, Imprecisionx2
antihepaciviral	tyrosine kinase inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.86	0.88	4.04	44.61	-136.59	91.45	VERY LOW	1.86	0.88	4.04	44.61	-11.65	91.45	VERY LOW	RoB, Imprecisionx2
antihepaciviral	umifenovir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA	1.14	0.52	2.53	7.21	-82.18	73.63	VERY LOW	1.14	0.52	2.53	7.21	-82.18	73.63	VERY LOW	RoB, Imprecisionx2
antihepaciviral	vitamin C	NA	NA	NA	NA	NA	NA	NA	1.25	0.58	2.72	15.58	-60.24	73.61	VERY LOW	1.25	0.58	2.72	15.58	-60.24	73.61	VERY LOW	RoB, Imprecisionx2
antihepaciviral	vitamin D	NA	NA	NA	NA	NA	NA	NA	1.35	0.61	2.95	19.09	-55.44	77.62	VERY LOW	1.35	0.61	2.95	19.09	-55.44	77.62	VERY LOW	RoB, Imprecisionx2
aspirin, statins	aspirin	2.73	0.48	15.5	NA	NA	NA	VERY LOW	NA	NA	NA	NA	NA	NA	NA	1.71	0.59	4.62	75.73	-45.41	260.26	VERY LOW	RoB, Imprecisionx2
aspirin	azithromycin	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.95	0.64	1.34	-5.82	-45.15	30.54	LOW	0.95	0.64	1.34	-5.82	-45.15	30.54	LOW	RoB, Imprecision
aspirin aspirin	azithromycin, hydroxychloroquine azithromycin, hydroxychloroquine, oseltamiyir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.35 0.42	0.55	3.47 1.78	20.96 -171.35	-71.9 -524.61	88.22 49.1	VERY LOW VERY LOW	1.35 0.42	0.55	3.47 1.78	20.96 -171.35	-71.9 -524.61	88.22 49.1	VERY LOW VERY LOW	RoB, Imprecisionx2 RoB, Imprecisionx2
aspirin aspirin	azithromycin, nydroxychioroquine, oseitamivir azithromycin, NSAID	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.42	0.07	2.97	-1/1.35	-524.61	49.1 81.65	VERY LOW VERY LOW	0.42	0.07	2.97	-1/1.35	-524.61	49.1 81.65	VERY LOW VERY LOW	RoB, Imprecisionx2
aspirin	azithromycin, NSAID, corticosteroid	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.4	0.34	6.36	20	-156.04	105.87	VERY LOW	1.4	0.24	6.36	20	-156.04	105.87	VERY LOW	RoB, Imprecisionx2
aspirin	cefepime	NA	NA	NA	NA	NA	NA NA	NA	0.08	0	1.46E+09	-380.42	-898.04	140.99	VERY LOW	0.08	0	1.46E+09	-380.42	-898.04	140.99	VERY LOW	RoB, Imprecisionx3
· · · · · · · · · · · · · · · · · · ·		•	•	•	•	•	_		•			•					•	•	•	•			

									Mortality	у													
Comparison		Direct estimate			1				Indirect estimat	e		1				Network estimate			1				
Treatment 1	Treatment 2	Relative estimate		Cl upper limit	Absolute estimate	CI lower limit	Cl upper limit	Final rating	Relative estimate	CI lower limit	CI upper limit	Absolute estima Point estimate	CI lower limit	Cl upper limit	Final rating	Relative estimate	CI lower limit	Cl upper limit	Absolute estim Point estimate		Cl upper limit	Final rating	Reasons for downgrading
aspirin	ceftazidime	NA.	NA NA	NA NA	NA NA	NA NA	NA NA	NA	9.09E+08	0	2.93E+21	-379.63	-898.01	142.59	VERY LOW	9.09E+08	0	2.93E+21	-379.63	-898.01	142.59	VERY LOW	RoB. Imprecisionx3
aspirin	colchicine	NA	NA	NA	NA	NA	NA	NA	1.01	0.72	1.55	0.94	-35.23	43.15	LOW	1.01	0.72	1.55	0.94	-35.23	43.15	LOW	RoB, Imprecision
aspirin	colchicine, emtricitabine, tenofovir, statins	NA	NA	NA	NA	NA	NA	NA	1.66	0.77	3.55	41.1	-27.32	92.27	VERY LOW	1.66	0.77	3.55	41.1	-27.32	92.27	VERY LOW	RoB, Imprecisionx2
aspirin	colchicine, statins	NA	NA	NA	NA	NA	NA	NA	1.18	0.58	2.4	12.57	-68.2	72.77	VERY LOW	1.18	0.58	2.4	12.57	-68.2	72.77	VERY LOW	RoB, Imprecisionx2
aspirin	corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	1.17	0.85	1.63	15.99	-14.48	49.61	LOW	1.17	0.85	1.63	15.99	-14.48	49.61	LOW	RoB, Imprecision
aspirin aspirin	IL6 receptor antagonists with corticosteroids (systemic) doxycycline	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.17 0.26	0.83	1.56	15.25 -250.96	-16.84 -676.81	46.16 28.09	VERYLOW	1.17 0.26	0.83	1.56	15.25	-16.84 -676.81	46.16 28.09	VERYLOW	RoB, Imprecision RoB, Imprecisionx3
aspirin	doxycycline doxycycline, ivermectin	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	3.93E+18	5.79E+04	3.91E+32	117.67	70.77	149.69	VERY LOW	3.93E+18	5.79E+04	3.91E+32	117.67	70.77	149.69	VERY LOW VERY LOW	RoB, Imprecisionx3
aspirin	electrolyzed saline	NA	NA	NA	NA	NA	NA	NA	5.28	1.17	40.11	91.58	19.44	134.48	VERY LOW	5.28	1.17	40.11	91.58	19.44	134.48	VERY LOW	RoB, Imprecisionx3
aspirin	emtricitabine, tenofovir	NA	NA	NA	NA	NA	NA	NA	1.25	0.61	2.53	17.27	-64.22	77.14	VERY LOW	1.25	0.61	2.53	17.27	-64.22	77.14	VERY LOW	RoB, Imprecisionx2
aspirin	favipiravir	NA	NA	NA	NA	NA	NA	NA	0.71	0.34	1.44	-41.51	-152.71	38.58	VERY LOW	0.71	0.34	1.44	-41.51	-152.71	38.58	VERY LOW	RoB, Imprecisionx2
aspirin	favipiravir, hydrochloroquine	NA	NA	NA	NA	NA	NA	NA	0.96	0.4	2.3	-9.57	-126.75	70.45	VERY LOW	0.96	0.4	2.3	-9.57	-126.75	70.45	VERY LOW	RoB, Imprecisionx2
aspirin	fluvoxamine	NA 0.52	NA 0.01	NA 20.40	NA NA	NA NA	NA NA	NA VERY LOW	1.36	0.66	2.89	26.06 NA	-47.69 NA	81.78 NA	VERY LOW MODERATE	1.36	0.66	2.89	26.06	-47.69	81.78 36.91	VERY LOW MODERATE	RoB, Imprecisionx2
full-dose anticoagulant	aspirin GM-CSF inhibitor	0.52 NA	0.01 NA	30.42 NA	NA NA	NA NA	NA NA	NA NA	1.03	0.74	1.43	18.59	-22 21	58.27	VERYLOW	1.03	0.74	1.44	18.59	-32.96 -22.21	36.91 58.27	VERYLOW	Imprecision RoB Imprecisionx2
aspirin	(hydroxy)chloroquine	NA NA	NA NA	NA NA	NA NA	NA.	NA NA	NA.	0.86	0.62	1.03	-17.72	-51.05	16.57	VERY LOW	0.86	0.62	1.03	-17.72	-51.05	16.57	VERYLOW	RoB, Imprecisionx2
aspirin	IL1 inhibitors	NA.	NA NA	NA NA	NA NA	NA NA	NA NA	NA	1.25	0.74	2.08	21.04	-32.26	66.21	VERY LOW	1.25	0.74	2.08	21.04	-32.26	66.21	VERY LOW	RoB, Imprecisionx2
aspirin	IL6 receptor antagonists without corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	0.85	0.61	1.17	-18.06	-54.03	17.13	VERY LOW	0.85	0.61	1.17	-18.06	-54.03	17.13	VERY LOW	RoB, Imprecisionx2
aspirin	interferon alfa (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	0	0	0.53	-823.09	-902.59	-228.57	VERY LOW	0	0	0.53	-823.09	-902.59	-228.57	VERY LOW	RoB, Imprecisionx3
aspirin	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	0.92	0.64	1.36	-9.99	-49.02	31.68	LOW	0.92	0.64	1.36	-9.99	-49.02	31.68	LOW	RoB, Imprecision
aspirin	interferon beta (subcutaneous), lopinavir-ritonavir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.45	0.24	0.84	-117.81	-233.34	-22.97	VERY LOW	0.45	0.24	0.84	-117.81	-233.34	-22.97	VERY LOW	RoB, Imprecisionx2
aspirin aspirin	intermediate-dose anticoagulant intranasal corticosteroids	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.81 2.97E+06	0.47	1.37 1.66E+13	-26.54 108.8	-95.33 24.27	31.68 150.39	VERY LOW VERY LOW	0.81 2.97E+06	0.47	1.37 1.66E+13	-26.54 108.8	-95.33 24.27	31.68 150.39	VERY LOW VERY LOW	RoB, Imprecisionx2 RoB, Imprecisionx3
aspirin aspirin	intranasai corticosteroids ivermectin	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	2.97E+06	0.03	1.66E+13 2.64	33.43	-20.58	150.39	VERY LOW VERY LOW	2.97E+06	0.03	1.66E+13 2.64	33.43	-20.58	150.39	VERY LOW VERY LOW	RoB, Imprecisionx3
aspirin	JAK inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.49	0.99	2.19	36.48	1.05	71.23	MODERATE	1.47	0.99	2.19	36.48	1.05	71.23	MODERATE	RoB RoB
aspirin	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.88	0.62	1.2	-14.4	-49.73	20.19	LOW	0.88	0.62	1.2	-14.4	-49.73	20.19	LOW	RoB, Imprecision
aspirin	melatonin	NA	NA	NA	NA	NA	NA	NA	22	3.21	436.72	111.91	72.06	144.25	VERY LOW	22	3.21	436.72	111.91	72.06	144.25	VERY LOW	RoB, Imprecisionx3
aspirin	methylene blue	NA	NA	NA	NA	NA	NA	NA	1.86	0.91	3.82	49.99	-7.93	96.61	VERY LOW	1.86	0.91	3.82	49.99	-7.93	96.61	VERY LOW	RoB, Imprecisionx2
aspirin	molnupiravir	NA	NA	NA	NA	NA	NA	NA	14.7	2.26	261.92	108.03	61.62	142.2	VERY LOW	14.7	2.26	261.92	108.03	61.62	142.2	VERY LOW	RoB, Imprecisionx3
aspirin	nitazoxanide	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.73 8.32	0.44	6.62	32.62 100.51	-119.19	110.73	VERY LOW VERY LOW	1.73	0.44	6.62	32.62 100.51	-119.19 42.62	110.73	VERY LOW VERY LOW	RoB, Imprecisionx2 RoB, Imprecisionx3
aspirin aspirin	omega 3 nirmatrelvir/ritonavir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	8.32 2.60E+09	1.61 91.85	8.09E+19	100.51	42.62 93.23	138.2	VERY LOW VERY LOW	8.32 2.60E+09	91.85	69.53 8.09E+19	100.51	93.23	138.2	VERY LOW VERY LOW	RoB, Imprecisionx3
aspirin	probiotics	NA.	NA NA	NA NA	NA NA	NA.	NA NA	NA.	0.96	0.2	4.63	-32.8	-300.91	95.01	VERY LOW	0.96	0.2	4.63	-32.8	-300.91	95.01	VERY LOW	RoB, Imprecisionx2
aspirin	proxalutamide	NA	NA	NA	NA	NA	NA	NA	7.54	4.32	12.96	103.87	74.66	133.4	MODERATE	7.54	4.32	12.96	103.87	74.66	133.4	MODERATE	RoB
aspirin	recombinant human granulocyte colony-stimulating factor	NA	NA	NA	NA	NA	NA	NA	4.93	1.4	24.53	90.22	30.68	131.38	VERY LOW	4.93	1.4	24.53	90.22	30.68	131.38	VERY LOW	RoB, Imprecisionx2
aspirin	remdesivir	NA	NA	NA	NA	NA	NA	NA	1.03	0.72	1.43	2.98	-31.82	38.03	LOW	1.03	0.72	1.43	2.98	-31.82	38.03	LOW	RoB, Imprecision
aspirin	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	1.39	0.48	4.04	23.31	-94.46	94.78	VERY LOW	1.39	0.48	4.04	23.31	-94.46	94.78	VERY LOW	RoB, Imprecisionx2
aspirin statins	SGLT2 inhibitors aspirin	NA 2.38	NA 0.41	NA 13.77	NA NA	NA NA	NA NA	NA VERY LOW	1.26 NA	0.7 NA	2.2 NA	20.55 NA	-36.97 NA	69.21 NA	VERY LOW NA	1.26 1.45	0.7	4.02	20.55 51.66	-36.97 -60.72	69.21 224.34	VERY LOW VERY LOW	RoB, Imprecisionx2 RoB, Imprecisionx2
aspirin	sulodexide	NA	NA	NA	NA NA	NA NA	NA NA	NA NA	2.35	0.62	11 64	57.74	-57.12	120.8	VERYLOW	2.35	0.62	11.64	57.74	-57.12	120.8	VERY LOW	RoB, Imprecisionx2
aspirin	synthetic VIP	NA.	NA NA	NA NA	NA.	NA.	NA NA	NA.	0.81	0.37	1.68	-30.77	-142.8	48.15	VERY LOW	0.81	0.37	1.68	-30.77	-142.8	48.15	VERY LOW	RoB. Imprecisionx2
aspirin	tyrosine kinase inhibitors	NA	NA	NA	NA	NA	NA	NA	2.2	1.05	4.64	59.96	4.56	104.21	VERY LOW	2.2	1.05	4.64	59.96	4.56	104.21	VERY LOW	RoB, Imprecisionx2
aspirin	umifenovir	NA	NA	NA	NA	NA	NA	NA	1.34	0.63	2.92	22.57	-65.27	83.95	VERY LOW	1.34	0.63	2.92	22.57	-65.27	83.95	VERY LOW	RoB, Imprecisionx2
aspirin	vitamin C	NA	NA	NA	NA	NA	NA	NA	1.46	0.71	3.14	30.93	-42.68	85.97	VERY LOW	1.46	0.71	3.14	30.93	-42.68	85.97	VERY LOW	RoB, Imprecisionx2
aspirin	vitamin D	NA	NA	NA	NA	NA	NA	NA	1.59	0.74	3.42	34.44	-39.2	89.96	VERY LOW	1.59	0.74	3.42	34.44	-39.2	89.96	VERY LOW	RoB, Imprecisionx2
aspirin, statins	azithromycin	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.63	0.54	4.48 9.04	69.91 96.69	-54.16 -56.47	257.17 296.71	VERY LOW VERY LOW	1.63 2.31	0.54	4.48 9.04	69.91 96.69	-54.16 -56.47	257.17 296.71	VERY LOW VERY LOW	RoB, Imprecisionx2 RoB, Imprecisionx2
aspirin, statins aspirin, statins	azithromycin, hydroxychloroquine azithromycin, hydroxychloroquine, oseltamivir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.7	0.0	4 17	-95.62	-30.47	208.05	VERYLOW	0.7	0.0	4 17	-95.62	-477 12	208.05	VERY LOW	RoB, Imprecisionx3
aspirin, statins	azithromycin, NSAID	NA.	NA NA	NA NA	NA.	NA.	NA NA	NA.	1.49	0.29	7.13	43.94	-182.02	261.91	VERY LOW	1.49	0.29	7.13	43.94	-182.02	261.91	VERY LOW	RoB. Imprecisionx2
aspirin, statins	azithromycin, NSAID, corticosteroid	NA	NA	NA	NA	NA	NA	NA	2.39	0.4	15.11	95.73	-110.92	308.91	VERY LOW	2.39	0.4	15.11	95.73	-110.92	308.91	VERY LOW	RoB, Imprecisionx3
aspirin, statins	cefepime	NA	NA	NA	NA	NA	NA	NA	0.12	0	2.73E+09	-304.69	-908.33	323.22	VERY LOW	0.12	0	2.73E+09	-304.69	-908.33	323.22	VERY LOW	RoB, Imprecisionx3
aspirin, statins	ceftazidime	NA	NA	NA	NA	NA	NA	NA	1.83E+09	0	4.81E+21	-303.9	-902.88	340.67	VERY LOW	1.83E+09	0	4.81E+21	-303.9	-902.88	340.67	VERY LOW	RoB, Imprecisionx3
aspirin, statins	colchicine	NA	NA	NA	NA	NA	NA	NA	1.74	0.58	4.89	76.67	-47.56	264.28	VERY LOW	1.74	0.58	4.89	76.67	-47.56	264.28	VERY LOW	RoB, Imprecisionx2
aspirin, statins aspirin, statins	colchicine, emtricitabine, tenofovir, statins colchicine, statins	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	2.82	0.8	9.87 6.68	116.83 88.3	-20.03 -54.06	306.89 282.52	VERY LOW VERY LOW	2.82	0.8	9.87 6.68	116.83 88.3	-20.03 -54.06	306.89 282.52	VERY LOW VERY LOW	RoB, Imprecisionx2 RoB, Imprecisionx2
aspirin, statins	corticosteroids (systemic)	NA NA	NA	NΔ	NΑ	NA NA	NΑ	NΔ	2.01	0.58	5.51	91.72	-34.00	278	VERYLOW	2.01	0.58	5.51	91.72	-30.12	278	VERYLOW	RoB, Imprecisionx2
aspirin, statins	IL6 receptor antagonists with corticosteroids (systemic)	NA.	NA NA	NA NA	NA.	NA.	NA NA	NA.	1.99	0.66	5.46	90.98	-30.66	277.98	VERY LOW	1.99	0.66	5.46	90.98	-30.66	277.98	VERY LOW	RoB. Imprecisionx2
aspirin, statins	doxycycline	NA	NA	NA	NA	NA	NA	NA	0.44	0.05	3.35	-175.23	-619.65	169.19	VERY LOW	0.44	0.05	3.35	-175.23	-619.65	169.19	VERY LOW	RoB, Imprecisionx3
aspirin, statins	doxycycline, ivermectin	NA	NA	NA	NA	NA	NA	NA	6.74E+18	1.13E+05	8.79E+32	193.4	64.95	380.51	VERY LOW	6.74E+18	1.13E+05	8.79E+32	193.4	64.95	380.51	VERY LOW	RoB, Imprecisionx3
aspirin, statins	electrolyzed saline	NA	NA	NA	NA	NA	NA	NA	9.32	1.42	81.18	167.31	30.65	357.09	VERY LOW	9.32	1.42	81.18	167.31	30.65	357.09	VERY LOW	RoB, Imprecisionx3
aspirin, statins	emtricitabine, tenofovir	NA	NA	NA	NA	NA	NA	NA	2.13	0.61	7.07	93	-53.05	287.49	VERY LOW	2.13	0.61	7.07	93	-53.05	287.49	VERY LOW	RoB, Imprecisionx2
aspirin, statins	favipiravir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.21	0.36 0.42	4.07 6.07	34.21 66.15	-129.9 -100.64	238.27 269.02	VERY LOW VERY LOW	1.21	0.36	4.07 6.07	34.21 66.15	-129.9 -100.64	238.27 269.02	VERY LOW VERY LOW	RoB, Imprecisionx2 RoB, Imprecisionx2
aspirin, statins aspirin, statins	favipiravir, hydrochloroquine fluvoxamine	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	2.35	0.42	7.82	101.79	-100.64	269.02	VERY LOW VERY LOW	2.35	0.42	7.82	101.79	-100.64	269.02	VERY LOW VERY LOW	RoB, Imprecisionx2
aspirin, statins	full-dose anticoagulant	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.67	0.56	4.59	72.9	-50.12	260.22	VERY LOW	1.67	0.56	4.59	72.9	-50.12	260.22	VERY LOW	RoB, Imprecisionx2
aspirin, statins	GM-CSF inhibitor	NA	NA	NA	NA	NA	NA	NA	2.06	0.68	5.88	94.31	-31.16	282.07	VERY LOW	2.06	0.68	5.88	94.31	-31.16	282.07	VERY LOW	RoB, Imprecisionx2
aspirin, statins	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	1.47	0.5	4.04	58	-64.2	244.89	VERY LOW	1.47	0.5	4.04	58	-64.2	244.89	VERY LOW	RoB, Imprecisionx2
aspirin, statins	IL1 inhibitors	NA	NA	NA	NA	NA	NA	NA	2.14	0.68	6.31	96.77	-31.99	286.73	VERY LOW	2.14	0.68	6.31	96.77	-31.99	286.73	VERY LOW	RoB, Imprecisionx2
aspirin, statins	IL6 receptor antagonists without corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	1.46	0.49	3.98	57.67	-65.68	245.33	VERY LOW	1.46	0.49	3.98	57.67	-65.68	245.33	VERY LOW	RoB, Imprecisionx2
aspirin, statins	interferon alfa (subcutaneous)	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.58	0 53	0.86	-747.36 65.74	-918.22 -59.01	-147.91 254.23	VERY LOW VERY LOW	1.58	0 53	0.86	-747.36 65.74	-918.22 -59.01	-147.91 254.23	VERY LOW VERY LOW	RoB, Imprecisionx3 RoB, Imprecisionx2
aspirin, statins aspirin, statins	interferon beta (subcutaneous) interferon beta (subcutaneous), lopinavir-ritonavir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.77	0.53	2.39	65.74 -42.08	-59.01 -210.17	254.23 162.49	VERY LOW VERY LOW	0.77	0.53	2.39	65.74 -42.08	-59.01 -210.17	254.23 162.49	VERY LOW VERY LOW	RoB, Imprecisionx2 RoB, Imprecisionx2
aspirin, statins	intermediate-dose anticoagulant	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.38	0.43	4.13	49.19	-89.06	241.75	VERY LOW	1.38	0.43	4.13	49.19	-210.17	241.75	VERY LOW	RoB, Imprecisionx2
aspirin, statins	intranasal corticosteroids	NA NA	NA NA	NA	NA NA	NA NA	NA NA	NA	5.07E+06	0.04	2.74E+13	184.53	44.65	383.5	VERY LOW	5.07E+06	0.04	2.74E+13	184.53	44.65	383.5	VERY LOW	RoB, Imprecisionx3
aspirin, statins	ivermectin	NA	NA	NA	NA	NA	NA	NA	2.51	0.78	8.04	109.15	-21.72	301.9	VERY LOW	2.51	0.78	8.04	109.15	-21.72	301.9	VERY LOW	RoB, Imprecisionx2

									Mortalit	У													
Comparison		Direct estimate)						Indirect estimat	е						Network estimat							
- · · · ·	T	Relative estimat	te Chileman Harit	Ol Ilasit	Absolute estima	ate (per 1,000) CI lower limit	Ol	Final rating	Relative estimate	Ol Januar Harit	Ol Ilesik	Absolute estima Point estimate		Ol	Final rating	Relative estima		Ol	Absolute estim	CI lower limit	Ol survey live it	Final rating	Reasons for
Treatment 1 aspirin, statins	Treatment 2 JAK inhibitors	Point estimate NA	CI lower limit	CI upper limit	Point estimate NA	VA NA	CI upper limit	NA.	Point estimate 2.56	CI lower limit	CI upper limit	112.21	CI lower limit	CI upper limit 299.56	VERY LOW	2.56	CI lower limit	CI upper limit	112.21	-10.22	CI upper limit 299.56	VERY LOW	RoB. Imprecisionx2
aspirin, statins	lopinavir-ritonavir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.5	0.51	4.16	61.33	-62.49	247.79	VERY LOW	1.5	0.51	4.16	61.33	-62.49	247.79	VERY LOW	RoB, Imprecisionx2
aspirin, statins	melatonin	NA	NA	NA	NA	NA	NA	NA	38.1	4.02	823.77	187.64	63.1	375.33	VERY LOW	38.1	4.02	823.77	187.64	63.1	375.33	VERY LOW	RoB, Imprecisionx3
aspirin, statins	methylene blue	NA	NA	NA	NA	NA	NA	NA	3.19	0.92	10.6	125.71	-6.17	314.72	VERY LOW	3.19	0.92	10.6	125.71	-6.17	314.72	VERY LOW	RoB, Imprecisionx2
aspirin, statins	molnupiravir	NA	NA	NA	NA	NA	NA	NA	25.81	2.8	550.12	183.76	56.42	372	VERY LOW	25.81	2.8	550.12	183.76	56.42	372	VERY LOW	RoB, Imprecisionx3
aspirin, statins	nitazoxanide	NA	NA	NA	NA	NA	NA	NA	2.96	0.51	14.85	108.35	-82.73	317.82	VERY LOW	2.96	0.51	14.85	108.35	-82.73	317.82	VERY LOW	RoB, Imprecisionx2
aspirin, statins	omega 3	NA	NA	NA	NA	NA	NA	NA	14.68	2.02	139.71	176.23	46.71	365.56	VERY LOW	14.68	2.02	139.71	176.23	46.71	365.56	VERY LOW	RoB, Imprecisionx3
aspirin, statins aspirin, statins	nirmatrelvir/ritonavir probiotics	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	4.39E+09 1.65	171.72 0.27	1.49E+20 10.56	197.71 42.93	77.17 -256.8	383.48 279.48	VERY LOW VERY LOW	4.39E+09 1.65	171.72 0.27	1.49E+20 10.56	197.71 42.93	77.17 -256.8	383.48 279.48	VERY LOW VERY LOW	RoB, Imprecisionx3 RoB, Imprecisionx3
aspirin, statins	proxalutamide	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	12.9	4.06	38.93	179.6	-230.6 58.11	366.1	VERY LOW	12.9	4.06	38.93	179.6	58.11	366.1	VERY LOW	RoB, Imprecisionx2
aspirin, statins	recombinant human granulocyte colony-stimulating factor	NA.	NA.	NA.	NA.	NA.	NA NA	NA.	8.47	1.67	53.25	165.95	36.08	353.94	VERY LOW	8.47	1.67	53.25	165.95	36.08	353.94	VERY LOW	RoB, Imprecisionx3
aspirin, statins	remdesivir	NA	NA	NA	NA	NA	NA	NA	1.77	0.59	4.83	78.7	-44.04	265.68	VERY LOW	1.77	0.59	4.83	78.7	-44.04	265.68	VERY LOW	RoB, Imprecisionx2
aspirin, statins	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	2.35	0.55	10.32	99.04	-71.19	295.85	VERY LOW	2.35	0.55	10.32	99.04	-71.19	295.85	VERY LOW	RoB, Imprecisionx2
aspirin, statins	SGLT2 inhibitors	NA	NA	NA	NA	NA	NA	NA	2.16	0.66	6.54	96.27	-36.08	287.26	VERY LOW	2.16	0.66	6.54	96.27	-36.08	287.26	VERY LOW	RoB, Imprecisionx2
statins	aspirin, statins	0.87 NA	0.19 NA	3.95 NA	NA NA	NA	NA NA	VERY LOW NA	NA	NA	NA	NA	NA	NA 331 1	NA	0.84	0.29	2.59	-24.07	-187.02	139.01 331.1	VERY LOW VERY LOW	RoB, Imprecisionx2
aspirin, statins	sulodexide	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	4.09 1.37	0.75 0.38	25.32 4.72	133.47 44.96	-26.86 -117	331.1 246.03	VERY LOW VERY LOW	4.09 1.37	0.75 0.38	25.32 4.72	133.47 44.96	-26.86 -117	331.1 246.03	VERY LOW VERY LOW	RoB, Imprecisionx3
aspirin, statins aspirin, statins	synthetic VIP tyrosine kinase inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	3.77	1.08	12.52	135 69	3.48	324 34	VERY LOW	3.77	1.08	12.52	135 69	3.48	324 34	VERY LOW VERY LOW	RoB, Imprecisionx2 RoB, Imprecisionx2
aspirin, statins	umifenovir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	2.31	0.64	7.98	98.3	-45 37	295 67	VERYLOW	2.31	0.64	7.98	98.3	-45 37	295.67	VERYLOW	RoB. Imprecisionx2
aspirin, statins	vitamin C	NA NA	NA NA	NA NA	NA	NA NA	NA NA	NA	2.53	0.71	8.36	106.66	-36.3	301.12	VERY LOW	2.53	0.71	8.36	106.66	-36.3	301.12	VERY LOW	RoB, Imprecisionx2
aspirin, statins	vitamin D	NA	NA	NA	NA	NA	NA	NA	2.74	0.72	9.25	110.17	-30.47	305.59	VERY LOW	2.74	0.72	9.25	110.17	-30.47	305.59	VERY LOW	RoB, Imprecisionx2
azithromycin, hydroxychloroquine	azithromycin	0.51	0.06	4.39	NA	NA	NA	VERY LOW	0.58	0.2	1.63	NA	NA	NA	VERY LOW	0.7	0.28	1.68	-26.78	-92.25	64.29	VERY LOW	RoB, Imprecisionx2
azithromycin, hydroxychloroquine, oseltamivir	azithromycin	0.18	0.01	4.76	NA	NA	NA	VERY LOW	9.91E+07	43.67	6.19E+26	NA	NA	NA	VERY LOW	2.26	0.54	13.42	165.53	-53.73	519.56	VERY LOW	, Imprecisionx2, Incohere
azithromycin	azithromycin, NSAID	NA	NA	NA	NA	NA	NA	NA	0.92	0.26	3.12	-25.97	-227.06 -150.12	87.22 111.51	VERY LOW	0.92	0.26	3.12	-25.97	-227.06	87.22 111.51	VERY LOW	RoB, Imprecisionx2
azithromycin azithromycin	azithromycin, NSAID, corticosteroid cefepime	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.48	0.36	6.72 1.69E+09	25.82	-150.12 -889.94	111.51	VERY LOW	1.48	0.36	6.72 1.69E+09	25.82	-150.12 -889.94	111.51	VERY LOW	RoB, Imprecisionx2 RoB, Imprecisionx3
azithromycin	cerepime	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	9.69E+08	0	3.08E+21	-374.6	-889.48	146.66	VERY LOW	9.69E+08	0	3.08E+21	-373.81	-889.48	147.14	VERY LOW VERY LOW	RoB, Imprecisionx3
azithromycin	colchicine	NA	NA	NA	NA	NA	NA	NA	1.06	0.78	1.66	6.76	-27.9	48.55	LOW	1.06	0.78	1.66	6.76	-27.9	48.55	LOW	RoB, Imprecision
azithromycin	colchicine, emtricitabine, tenofovir, statins	NA	NA	NA	NA	NA	NA	NA	1.74	0.84	3.7	46.92	-19.56	96.73	VERY LOW	1.74	0.84	3.7	46.92	-19.56	96.73	VERY LOW	RoB, Imprecisionx2
azithromycin	colchicine, statins	NA	NA	NA	NA	NA	NA	NA	1.24	0.63	2.52	18.39	-60.56	77.37	VERY LOW	1.24	0.63	2.52	18.39	-60.56	77.37	VERY LOW	RoB, Imprecisionx2
azithromycin	corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	1.22	0.93	1.7	21.81	-6.13	54.5	VERY LOW	1.22	0.93	1.7	21.81	-6.13	54.5	VERY LOW	RoB, Imprecisionx2
azithromycin	IL6 receptor antagonists with corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	1.22	0.92	1.62	21.07	-7.24	51.13	VERY LOW	1.22	0.92	1.62	21.07	-7.24	51.13	VERY LOW	RoB, Imprecisionx2
azithromycin azithromycin	doxycycline doxycycline, ivermectin	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.28 4.09E+18	0.04 6.31E+04	1.5 4.32E+32	-245.14 123.49	-669.82 78.26	33.22 154.14	VERY LOW VERY LOW	0.28 4.09E+18	0.04 6.31E+04	1.5 4.32E+32	-245.14 123.49	-669.82 78.26	33.22 154.14	VERY LOW VERY LOW	RoB, Imprecisionx3 RoB, Imprecisionx3
azithromycin	electrolyzed saline	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	5.55	1.25	42.02	97.4	25.57	138.8	VERY LOW	5.55	1.25	42.02	97.4	25.57	138.8	VERY LOW	RoB, Imprecisionx3
azithromycin	emtricitabine, tenofovir	NA NA	NA.	NA	NA NA	NA NA	NA NA	NA NA	1.31	0.66	2.65	23.09	-55.83	81.58	VERY LOW	1.31	0.66	2.65	23.09	-55.83	81.58	VERY LOW	RoB, Imprecisionx2
azithromycin	favipiravir	NA	NA	NA	NA	NA	NA	NA	0.75	0.37	1.53	-35.69	-145.01	43.9	VERY LOW	0.75	0.37	1.53	-35.69	-145.01	43.9	VERY LOW	RoB, Imprecisionx2
azithromycin	favipiravir, hydrochloroquine	NA	NA	NA	NA	NA	NA	NA	1.01	0.43	2.4	-3.75	-119.36	74.79	VERY LOW	1.01	0.43	2.4	-3.75	-119.36	74.79	VERY LOW	RoB, Imprecisionx2
azithromycin	fluvoxamine	NA	NA	NA	NA	NA	NA	NA	1.43	0.71	3.07	31.88	-40.47	86.84	VERY LOW	1.43	0.71	3.07	31.88	-40.47	86.84	VERY LOW	RoB, Imprecisionx2
azithromycin	full-dose anticoagulant	NA	NA	NA	NA	NA	NA	NA	1.02	0.76	1.42	3	-28.67	38.41	LOW	1.02	0.76	1.42	3	-28.67	38.41	LOW	RoB, Imprecision
azithromycin azithromycin	GM-CSF inhibitor (hydroxy)chloroquine	NA 0.47	NA 0.06	NA 3.77	NA NA	NA NA	NA NA	NA VERY LOW	1.27 0.93	0.86	1.95	24.41 NA	-15.23 NA	64.35 NA	VERY LOW MODERATE	1.27 0.9	0.86	1.95	24.41 -11.9	-15.23 -42.3	64.35 21.43	VERY LOW LOW	RoB, Imprecisionx2 RoB
azithromycin	IL1 inhibitors	NA	NA	NA	NA NA	NA NA	NA NA	NA NA	1.31	0.71	2.17	26.87	-24.16	70.9	VERY LOW	1.31	0.8	2.17	26.87	-24.16	70.9	VERY LOW	RoB, Imprecisionx2
azithromycin	IL6 receptor antagonists without corticosteroids (systemic)	NA NA	NA.	NA	NA	NA NA	NA NA	NA	0.9	0.67	1.22	-12.24	-45.57	22.53	LOW	0.9	0.67	1.22	-12.24	-45.57	22.53	LOW	RoB, Imprecision
azithromycin	interferon alfa (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	0	0	0.57	-817.27	-893.28	-224.44	VERY LOW	0	0	0.57	-817.27	-893.28	-224.44	VERY LOW	RoB, Imprecisionx3
azithromycin	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	0.96	0.69	1.43	-4.16	-42.44	37.28	LOW	0.96	0.69	1.43	-4.16	-42.44	37.28	LOW	RoB, Imprecision
azithromycin	interferon beta (subcutaneous), lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.48	0.26	0.88	-111.99	-225.93	-17.87	VERY LOW	0.48	0.26	0.88	-111.99	-225.93	-17.87	VERY LOW	RoB, Imprecisionx2
azithromycin	intermediate-dose anticoagulant	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.85 3 19F+06	0.51	1.44 1.77F+13	-20.72 114.62	-88.46 32.67	36.36 154.77	VERY LOW VERY LOW	0.85 3.19F+06	0.51	1.44 1.77F+13	-20.72 114 62	-88.46 32.67	36.36 154.77	VERY LOW VERY LOW	RoB, Imprecisionx2
azithromycin azithromycin	intranasal corticosteroids	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	3.19E+06 1.55	0.03	1.//E+13 2.76	39.25	-13.93	154.77 84.73	VERY LOW VERY LOW	3.19E+06 1.55	0.03	1.//E+13 2.76	39.25	-13.93	154.77 84.73	VERY LOW VERY LOW	RoB, Imprecisionx3
azithromycin	JAK inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.57	1.09	2.70	42.3	9.24	76.2	MODERATE	1.57	1.09	2.70	42.3	9.24	76.2	MODERATE	RoB RoB
azithromycin	lopinavir-ritonavir	NA NA	NA NA	NA	NA	NA	NA NA	NA	0.92	0.69	1.25	-8.57	-40.76	25.06	LOW	0.92	0.69	1.25	-8.57	-40.76	25.06	LOW	RoB, Imprecision
azithromycin	melatonin	NA	NA	NA	NA	NA	NA	NA	23.18	3.4	456.56	117.73	80.22	148.79	VERY LOW	23.18	3.4	456.56	117.73	80.22	148.79	VERY LOW	RoB, Imprecisionx3
azithromycin	methylene blue	NA	NA	NA	NA	NA	NA	NA	1.96	0.99	4.01	55.81	-1.57	101.82	VERY LOW	1.96	0.99	4.01	55.81	-1.57	101.82	VERY LOW	RoB, Imprecisionx2
azithromycin	molnupiravir	NA	NA	NA	NA	NA	NA	NA	15.54	2.39	275.09	113.85	69.18	146.7	VERY LOW	15.54	2.39	275.09	113.85	69.18	146.7	VERY LOW	RoB, Imprecisionx3
azithromycin	nitazoxanide	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.81	0.47 1.68	6.96	38.44 106.33	-113.51 49.67	116.14	VERY LOW VERY LOW	1.81 8.81	0.47	6.96	38.44 106.33	-113.51 49.67	116.14	VERY LOW VERY LOW	RoB, Imprecisionx2
azithromycin azithromycin	omega 3 nirmatrelvir/ritonavir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	8.81 2.79E+09	97.31	74 8.55E+19	106.33	102.97	142.9	VERY LOW VERY LOW	8.81 2.79E+09	97.31	8.55E+19	106.33	102.97	142.9	VERY LOW VERY LOW	RoB, Imprecisionx3
azithromycin	probiotics	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.02	0.21	4.87	-26.98	-294.81	99.86	VERY LOW	1.02	0.21	4.87	-26.98	-294.81	99.86	VERY LOW	RoB, Imprecisionx2
azithromycin	proxalutamide	NA	NA	NA	NA	NA	NA	NA	7.93	4.71	13.67	109.7	84.45	138.07	MODERATE	7.93	4.71	13.67	109.7	84.45	138.07	MODERATE	RoB
azithromycin	recombinant human granulocyte colony-stimulating factor	NA	NA	NA	NA	NA	NA	NA	5.21	1.5	26.01	96.04	38.11	136.9	VERY LOW	5.21	1.5	26.01	96.04	38.11	136.9	VERY LOW	RoB, Imprecisionx2
azithromycin	remdesivir	NA	NA	NA	NA	NA	NA	NA	1.08	0.8	1.49	8.8	-23.17	43.2	LOW	1.08	0.8	1.49	8.8	-23.17	43.2	LOW	RoB, Imprecision
azithromycin	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	1.46	0.51	4.27	29.13	-88.66	100.97	VERY LOW	1.46	0.51	4.27	29.13	-88.66	100.97	VERY LOW	RoB, Imprecisionx2
azithromycin azithromycin	SGLT2 inhibitors statins	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.32 0.73	0.77	2.32	26.37 -45.84	-29.68 -221.46	73.83 68.68	VERY LOW VERY LOW	1.32 0.73	0.77	2.32	26.37 -45.84	-29.68 -221.46	73.83 68.68	VERY LOW VERY LOW	RoB, Imprecisionx2 RoB, Imprecisionx2
azithromycin	statins sulodexide	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	2.49	0.26	12.43	-45.84 63.56	-221.46 -51.49	125.69	VERY LOW VERY LOW	2.49	0.26	12.43	-45.84 63.56	-221.46 -51.49	125.69	VERY LOW VERY LOW	RoB, Imprecisionx2
azithromycin	synthetic VIP	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.85	0.05	1.78	-24.95	-135.13	54.15	VERY LOW	0.85	0.65	1.78	-24.95	-135.13	54.15	VERY LOW	RoB, Imprecisionx2
azithromycin	tyrosine kinase inhibitors	NA NA	NA NA	NA NA	NA	NA NA	NA NA	NA	2.32	1.13	4.84	65.78	11.87	108.8	VERY LOW	2.32	1.13	4.84	65.78	11.87	108.8	VERY LOW	RoB, Imprecisionx2
azithromycin	umifenovir	NA	NA	NA	NA	NA	NA	NA	1.42	0.68	3.08	28.39	-59.12	89.01	VERY LOW	1.42	0.68	3.08	28.39	-59.12	89.01	VERY LOW	RoB, Imprecisionx2
azithromycin	vitamin C	NA	NA	NA	NA	NA	NA	NA	1.54	0.75	3.34	36.75	-36.5	91.03	VERY LOW	1.54	0.75	3.34	36.75	-36.5	91.03	VERY LOW	RoB, Imprecisionx2
azithromycin	vitamin D	NA	NA	NA	NA	NA	NA	NA	1.67	0.79	3.56	40.27	-32.12	95.21	VERY LOW	1.67	0.79	3.56	40.27	-32.12	95.21	VERY LOW	RoB, Imprecisionx2
azithromycin, hydroxychloroquine, oseltamivir	azithromycin, hydroxychloroquine	0.3	0.01	9.09	NA NA	NA	NA NA	VERY LOW	3.32E+05	10.98	1.79E+13	NA 50.75	NA	NA 00.00	VERY LOW	3.25	0.65	21.17	192.32	-39.26	543.95	VERY LOW	, Imprecisionx3, Incohere
azithromycin, hydroxychloroquine azithromycin, hydroxychloroquine	azithromycin, NSAID azithromycin, NSAID, corticosteroid	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.64 1.02	0.14	2.92 5.91	-52.75 -0.97	-261.72 -185.85	90.39	VERY LOW VERY LOW	0.64 1.02	0.14	2.92 5.91	-52.75 -0.97	-261.72 -185.85	90.39	VERY LOW VERY LOW	RoB, Imprecisionx2 RoB, Imprecisionx2
azithromycin, hydroxychloroquine azithromycin, hydroxychloroquine	azitnromycin, NSAID, contcosteroid cefepime	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.05	0.2	1.39E+09	-401.38	-185.85	157.37	VERYLOW	0.05	0.2	1.39F+09	-401.38	-949 6	157.37	VERYLOW	RoB, Imprecisionx2
aziunomyon, nyuroxyonioroquine	Сегерине	1905	18/5	110	110	110	11/1	140	0.00		1.30L 108	-401.00	-540.0	101.01	VEIXI LOW	0.00		1.552.109	-401.00	-040.0	101.01	TENT LOW	TOD, Impreciaionia

Second S										Mortality	y													
Marcis Control Contr	Comparison										0		1							1				
	Treatment 1	Treatment 2		CI lower limit	Cl upper limit			Cl upper limit	Final rating		Cl lower limit	Cl upper limit			Cl upper limit	Final rating			Cl upper limit			Cl upper limit	Final rating	Reasons for
## 1995 1995						+	_		NA		0					VERY LOW		0					VERY LOW	
STATE Column Co	azithromycin, hydroxychloroquine	colchicine	NA	NA	NA	NA	NA	NA	NA	0.75	0.3	1.89	-20.02	-86.16	72.84	VERY LOW	0.75	0.3	1.89	-20.02	-86.16	72.84	VERY LOW	RoB, Imprecisionx2
Part Control	azithromycin, hydroxychloroquine	colchicine, emtricitabine, tenofovir, statins	NA	NA	NA	NA	NA	NA	NA	1.22	0.4	0.14	20.14	00.00	110.00	VEICE COTT		0.4	3.74	20.14	00.00	119.69	VERY LOW	RoB, Imprecisionx2
Section December																								
## STATE OF COLUMN 1																								. , , ,
Column C		, , , ,																						
## 18 19 19 19 19 19 19 19			NA NA	NA.	NA NA	NA	NA NA		NA					27.23						96.71				
### PARTICIPATION NO. 10	azithromycin, hydroxychloroquine	electrolyzed saline	NA	NA	NA	NA	NA	NA	NA	3.93	0.65	35.82	70.61	-17.72	165.75	VERY LOW	3.93	0.65	35.82	70.61	-17.72	165.75	VERY LOW	RoB, Imprecisionx3
## PACES SAMPLES SAMPL																						-		
Contract		·																						
Column C											_						_							
## Comment of the Comment of Comm																								
Control Cont			NA	NA	NA	NA	NA	NA	NA	0.89				-70.97	92.17	LOW			2.25	-2.38	-70.97	92.17	LOW	
Approx. Information	azithromycin, hydroxychloroquine	(hydroxy)chloroquine	0.71	0.22	2.41	NA	NA	NA	LOW	0.69	0.09	5.24	NA	NA	NA	VERY LOW	0.64	0.26	1.48	-38.69	-101.97	49.69	LOW	Imprecisionx2
## Proposed Systematics M. W.																								
Column C										0.63					01.07							01.01		
## Property Company of the Company o										0	-						-	· -						. , ,
Property				-														-						
Column				-														-						
## STATES AND PROPERTY NAME OF THE PROPERTY NAME OF																								
## Part																								
Marrier Properties Marrier M										11.1														
## Property Approximate		·	101	101	1471			147.	1471			1.01	00.00	00.41		VEITI LOW			1.04	00.00	00.41	00.00	TEITH EOTH	
### A PART OF THE		* * * * * * * * * * * * * * * * * * * *																						
## CHANGES CHA		,																						
## A M.		·																			-			
## definition frozensomen																								F
## PROSERVENCE PRO	azithromycin, hydroxychloroquine	nirmatrelvir/ritonavir	NA	NA	NA	NA	NA	NA	NA	1.86E+09	65.08	6.93E+19	101.02	40.27	190.29	VERY LOW	1.86E+09	65.08	6.93E+19	101.02	40.27	190.29		Imprecisionx3
Common C	azithromycin, hydroxychloroquine	probiotics	NA	NA	NA	NA	NA	NA	NA	0.71	0.12	4.16	-53.77	-329.09	104.08	VERY LOW	0.71	0.12	4.16	-53.77	-329.09	104.08	VERY LOW	Imprecisionx3
### A PA NA																								
### SECTION AND NO. 19. 19. 19. 19. 19. 19. 19. 19. 19. 19																								
## Millionen No.																								
March Marc			161		161		1471		1471			4.17				VEICE COTT	1101		4.17	2.00		110.02	TEITI EOTI	
September Substantial Su							1471								01.11							07.77		
## ## ## ## ## ## ## ## ## ## ## ## ##	azithromycin, hydroxychloroquine	sulodexide	NA	NA	NA	NA	NA	NA	NA	1.76	0.36	10.27	36.77	-88.99	147.97	LOW	1.76	0.36	10.27	36.77	-88.99	147.97	LOW	
### Settlement No.	azithromycin, hydroxychloroquine	synthetic VIP		NA	NA		NA	NA	NA		0.19		-51.74					0.19		-51.74				Imprecisionx2
### ATTEMPTION PROVIDED PROVID		y															_							
### ### ### ### ### ### ### ### ### ##																								
## Annual No.				-														+						
Authorspychs (Annicon Continued Co																								· · · · · · · · · · · · · · · · · · ·
## A NA N			NA	NA	NA	NA	NA	NA	NA	3.42	0.44		191.35		559.24		3.42	0.44	33	191.35	-82.94	559.24	VERY LOW	
### Confidence on Confidence o		cefepime	NA	NA	NA	NA	NA	NA	NA	0.18	0	4.87E+09	-209.07	-895.96	566.48	VERY LOW	0.18	0	4.87E+09	-209.07	-895.96	566.48	VERY LOW	RoB, Imprecisionx3
Refinement Colciones enterior Colciones Col	azithromycin, hydroxychloroquine, oseltamivir	ceftazidime	NA	NA	NA	NA	NA	NA	NA	2.73E+09	0	8.06E+21	-208.28	-899.37	572.25	VERY LOW	2.73E+09	0	8.06E+21	-208.28		572.25		RoB, Imprecisionx3
Batterwych, phrospychrograms, cestamint Cocholome, stafens NA	, , , , , ,																							
Settlemprises Monte Mont				-																+				
### September B. Respirationspace in contamination B. Respirationspace in contamination B. Respirationspace in contamination B. Respirationspace B. Respir											0.0.													
Author/Processing Configuration Mode M																								
Earthromycin hydroxychicoquies, osellamining authromycin hydroxy																								
### APPLICATION CONTINUES AND A NA N		doxycycline, ivermectin	NA	NA	NA	NA	NA	NA	NA	1.05E+19	1.11E+05	9.49E+32	289.02	68.66	645.82	VERY LOW	1.05E+19	1.11E+05	9.49E+32	289.02	68.66	645.82	VERY LOW	RoB, Imprecisionx3
### APPLICATION CONTRIBUTION CO																						0.0.00		- 10-1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Augstromycin, hydroxychirorquine, osellamivir Swiprawit, hydroxychirorquine, osellamivir Swiprawit, hydroxychirorquine, osellamivir Swiprawith, hydroxyc																								
A																								
Azilhromycin, hydroxychloroquine, oselfamivir full-dose anticoagulant NA		,,,,																						
## 22thromycin, hydroxychloroquine, oseltamivir GM-CSF inhibitor NA NA NA NA NA NA NA N											0.00													
azithromycin, hydroxychloroquine, oseltamivir azithromycin, hydroxychloroquine, oseltamivir il. Inhibitors NA NA NA NA NA NA NA NA NA N																								
azithromycin, hydroxychloroquine, oseltamivir				-		NA					0.49	12.14	153.63						12.14	153.63		505.09		
azithromycin, hydroxychloroquine, oseltamivir interferon afta (subcutaneous) NA																								
azithromycin, hydroxychioroquine, oseltamivir interferon beta (subcutaneous) NA																								
azithromycin, hydroxychloroquine, oseltamivir interferon beta (subcutaneous), lopinavir-itlonavir NA			161	101	161		1471		1471		- u	1.0		0.10.00		VEITH EON				001.74		70.12		
azithromycin, hydroxychloroquine, oseltamivir intermediate-dose anticoagulant NA			161				1471		1471															rice, impression
azithromycin, hydroxychioroquine, oseltamivir intranasal corticosteroids NA																								
azithromycin, hydroxychloroquine, oseltamivir lvermectin NA		-															1100					400.02		
azithromycin, hydroxychloroquine, oseltamivir JAK inhibitors NA											0.00													
azithromycin, hydroxychloroquine, eseltamivir lopinavir-ritonavir NA								NA	NA															
azithromycin, hydroxychloroquine, oseltamivir melatonin NA NA NA NA NA NA NA NA S7.29 4.74 1331.82 283.26 64.96 636.38 VERYLOW 57.29 4.74 1,331.82 283.26 64.96 636.38 VERYLOW RoB, Imprecisionx3	azithromycin, hydroxychloroquine, oseltamivir	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	2.1	0.49	12.33	156.96	-62.68	509.55	VERY LOW	2.1	0.49	12.33	156.96	-62.68	509.55	VERY LOW	RoB, Imprecisionx2
	azithromycin, hydroxychloroquine, oseltamivir	melatonin	NA	NA	NA	NA	NA	NA	NA	57.29	4.74	1331.82	283.26	64.96	636.38	VERY LOW	57.29	4.74	1,331.82	283.26	64.96	636.38	VERY LOW	RoB, Imprecisionx3

									Mortality	/													
Comparison		Direct estimate							Indirect estimate	9		1				Network estimat			1				
Treatment 1	Treatment 2	Relative estimate	CI lower limit	Cl upper limit	Absolute estimate	CI lower limit	CI upper limit	Final rating	Relative estimate Point estimate	CI lower limit	Cl upper limit	Absolute estima Point estimate	CI lower limit	Cl upper limit	Final rating	Relative estimate	CI lower limit	Cl upper limit	Absolute estimate	CI lower limit	CI upper limit	Final rating	Reasons for
azithromycin, hydroxychloroquine, oseltamiyir	methylene blue	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA	4 46	0.92	28 46	221.34	-2.56	574 78	VERY LOW	4 46	0.92	28 46	221.34	-2.56	574.78	VERY LOW	downgrading RoB. Imprecisionx3
azithromycin, hydroxychloroquine, oseltamivir	molnupiravir	NA.	NA NA	NA NA	NA	NA NA	NA NA	NA	38.94	3.32	913.94	279.38	58.85	635.92	VERY LOW	38.94	3.32	913.94	279.38	58.85	635.92	VERY LOW	RoB, Imprecisionx3
azithromycin, hydroxychloroquine, oseltamivir	nitazoxanide	NA	NA	NA	NA	NA	NA	NA	3.99	0.56	38.66	203.97	-58.7	570.88	VERY LOW	3.99	0.56	38.66	203.97	-58.7	570.88	VERY LOW	RoB, Imprecisionx3
azithromycin, hydroxychloroquine, oseltamivir	omega 3	NA	NA	NA	NA	NA	NA	NA	21.12	2.24	296.9	271.86	47.11	624.6	VERY LOW	21.12	2.24	296.9	271.86	47.11	624.6	VERY LOW	RoB, Imprecisionx3
azithromycin, hydroxychloroquine, oseltamivir	nirmatrelvir/ritonavir	NA	NA	NA	NA	NA	NA	NA	7.13E+09	236.19	2.36E+20	293.34	75.5	647.08	VERY LOW	7.13E+09	236.19	2.36E+20	293.34	75.5	647.08	VERY LOW	RoB, Imprecisionx3
azithromycin, hydroxychloroquine, oseltamivir	probiotics	NA	NA	NA	NA	NA	NA	NA	2.38	0.28	22.39	138.55	-219.22	519.14	VERY LOW	2.38	0.28	22.39	138.55	-219.22	519.14	VERY LOW	RoB, Imprecisionx3
azithromycin, hydroxychloroquine, oseltamivir	proxalutamide	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	18.09 12.21	4.04 1.71	111.93 116.58	275.23	57.57	629.11	VERY LOW	18.09 12.21	4.04 1.71	111.93	275.23	57.57 39.43	629.11	VERY LOW VERY LOW	RoB, Imprecisionx2
azithromycin, hydroxychloroquine, oseltamivir azithromycin, hydroxychloroquine, oseltamivir	recombinant human granulocyte colony-stimulating factor remdesivir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	2.45	0.58	116.58	261.57 174.33	39.43 -46.05	615.96 527.39	VERY LOW VERY LOW	2.45	0.58	116.58 14.67	261.57 174.33	-46.05	615.96 527.39	VERY LOW VERY LOW	RoB, Imprecisionx3 RoB, Imprecisionx2
azithromycin, hydroxychloroquine, oseltamivir	serine protease inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	3.42	0.55	25.49	194.67	-40.03	560.49	VERY LOW	3.42	0.55	25.49	194.67	-40.03	560.49	VERY LOW	RoB, Imprecisionx3
azithromycin, hydroxychloroquine, oseltamivir	SGLT2 inhibitors	NA.	NA NA	NA.	NA NA	NA.	NA NA	NA.	3.02	0.65	18.5	191.9	-33.16	545.78	VERYLOW	3.02	0.65	18.5	191.9	-33 16	545.78	VERYLOW	RoB, Imprecisionx2
azithromycin, hydroxychloroquine, oseltamivir	statins	NA	NA	NA	NA	NA	NA	NA	1.68	0.28	12.23	119.69	-174	496.33	VERY LOW	1.68	0.28	12.23	119.69	-174	496.33	VERY LOW	RoB, Imprecisionx3
azithromycin, hydroxychloroquine, oseltamivir	sulodexide	NA	NA	NA	NA	NA	NA	NA	5.81	0.76	62.5	229.09	-12.94	589.15	VERY LOW	5.81	0.76	62.5	229.09	-12.94	589.15	VERY LOW	RoB, Imprecisionx3
azithromycin, hydroxychloroquine, oseltamivir	synthetic VIP	NA	NA	NA	NA	NA	NA	NA	1.93	0.38	12.82	140.58	-110.3	503.45	VERY LOW	1.93	0.38	12.82	140.58	-110.3	503.45	VERY LOW	RoB, Imprecisionx3
azithromycin, hydroxychloroquine, oseltamivir	tyrosine kinase inhibitors	NA	NA	NA	NA	NA	NA	NA	5.3	1.05	34.5	231.32	7.03	586.78	VERY LOW	5.3	1.05	34.5	231.32	7.03	586.78	VERY LOW	RoB, Imprecisionx3
azithromycin, hydroxychloroquine, oseltamivir	umifenovir	NA	NA	NA	NA	NA	NA	NA	3.21	0.66	22.11	193.92	-49.9	550.58	VERY LOW	3.21	0.66	22.11	193.92	-49.9	550.58	VERY LOW	RoB, Imprecisionx3
azithromycin, hydroxychloroquine, oseltamivir	vitamin C	NA	NA	NA	NA	NA	NA	NA	3.52	0.7	23.5	202.28	-24.79	559.29	VERY LOW	3.52	0.7	23.5	202.28	-24.79	559.29	VERY LOW	RoB, Imprecisionx3
azithromycin, hydroxychloroquine, oseltamivir azithromycin, NSAID, corticosteroid	vitamin D azithromycin, NSAID	NA 0.62	NA 0.11	NA 3.39	NA NA	NA NA	NA NA	NA VERY LOW	3.78 NA	0.78 NA	25.37 NA	205.8 NA	-22.67 NA	560.45 NA	VERY LOW NA	3.78	0.78	25.37	205.8 -51.79	-22.67 -203.3	560.45 80.76	VERY LOW VERY LOW	RoB, Imprecisionx3 RoB, Imprecisionx2
azithromycin, NSAID, corticosteroid	azitnromycin, NSAID cefepime	NA	NA	3.39 NA	NA NA	NA NA	NA NA	NA NA	0.08	NA 0	1.38E+09	-348.63	-942.49	288.47	VERY LOW	0.02	0.15	1.38E+09	-348.63	-203.3	288.47	VERY LOW	RoB, Imprecisionx2
azithromycin, NSAID	cerepirne	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.08E+09	0	2.57E+21	-348.63	-942.49 -944.19	291.93	VERY LOW	1.08E+09	0	2.57E+21	-348.63	-942.49	291.93	VERY LOW VERY LOW	RoB, Imprecisionx3
azithromycin, NSAID	colchicine	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.17	0.34	4.24	32.73	-81.34	236.1	VERY LOW	1.17	0.34	4.24	32.73	-81.34	236.1	VERY LOW	RoB, Imprecisionx2
azithromycin, NSAID	colchicine, emtricitabine, tenofovir, statins	NA	NA	NA	NA	NA	NA	NA	1.89	0.47	8.12	72.89	-55.55	279.82	VERY LOW	1.89	0.47	8.12	72.89	-55.55	279.82	VERY LOW	RoB, Imprecisionx2
azithromycin, NSAID	colchicine, statins	NA	NA	NA	NA	NA	NA	NA	1.34	0.35	5.65	44.36	-91.26	251.06	VERY LOW	1.34	0.35	5.65	44.36	-91.26	251.06	VERY LOW	RoB, Imprecisionx2
azithromycin, NSAID	corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	1.34	0.39	4.81	47.78	-63.56	249.15	VERY LOW	1.34	0.39	4.81	47.78	-63.56	249.15	VERY LOW	RoB, Imprecisionx2
azithromycin, NSAID	IL6 receptor antagonists with corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	1.33	0.4	4.71	47.04	-63.32	247.33	VERY LOW	1.33	0.4	4.71	47.04	-63.32	247.33	VERY LOW	RoB, Imprecisionx2
azithromycin, NSAID	doxycycline	NA	NA	NA	NA	NA	NA	NA	0.3	0.03	2.38	-219.17	-676.12	122.18	VERY LOW	0.3	0.03	2.38	-219.17	-676.12	122.18	VERY LOW	RoB, Imprecisionx3
azithromycin, NSAID	doxycycline, ivermectin	NA	NA	NA	NA	NA	NA	NA	4.44E+18	8.24E+04	5.75E+32	149.46	34.61	351.05	VERY LOW	4.44E+18	8.24E+04	5.75E+32	149.46	34.61	351.05	VERY LOW	RoB, Imprecisionx3
azithromycin, NSAID	electrolyzed saline	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	6.19	0.9	64.18 5.9	123.37 49.06	-8.28 -88.46	328.36 255.74	VERY LOW VERY LOW	6.19	0.9	64.18 5.9	123.37 49.06	-8.28 -88.46	328.36 255.74	VERY LOW VERY LOW	RoB, Imprecisionx3 RoB, Imprecisionx2
azithromycin, NSAID azithromycin, NSAID	emtricitabine, tenofovir favipiravir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.82	0.37	3.21	-9.72	-88.46 -164.02	199.15	VERY LOW VERY LOW	0.82	0.37	3.21	-9.72	-88.46	199.15	VERY LOW	RoB, Imprecisionx2
azithromycin, NSAID	favipiravir, hydrochloroquine	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.11	0.26	4.92	22.21	-142.47	242.08	VERY LOW	1.11	0.26	4.92	22.21	-142.47	242.08	VERY LOW	RoB, Imprecisionx2
azithromycin, NSAID	fluvoxamine	NA.	NA NA	NA	NA	NA NA	NA NA	NA	1.56	0.4	6.68	57.85	-74.88	264.14	VERY LOW	1.56	0.4	6.68	57.85	-74.88	264.14	VERY LOW	RoB, Imprecisionx2
azithromycin, NSAID	full-dose anticoagulant	NA	NA	NA	NA	NA	NA	NA	1.12	0.33	4.02	28.97	-84.16	232.2	VERY LOW	1.12	0.33	4.02	28.97	-84.16	232.2	VERY LOW	RoB, Imprecisionx2
azithromycin, NSAID	GM-CSF inhibitor	NA	NA	NA	NA	NA	NA	NA	1.38	0.4	5.09	50.38	-66.13	254.08	VERY LOW	1.38	0.4	5.09	50.38	-66.13	254.08	VERY LOW	RoB, Imprecisionx2
azithromycin, NSAID	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	0.99	0.29	3.49	14.06	-96.73	214.96	VERY LOW	0.99	0.29	3.49	14.06	-96.73	214.96	VERY LOW	RoB, Imprecisionx2
azithromycin, NSAID	IL1 inhibitors	NA	NA	NA	NA	NA	NA	NA	1.44	0.39	5.33	52.83	-67.86	255.37	VERY LOW	1.44	0.39	5.33	52.83	-67.86	255.37	VERY LOW	RoB, Imprecisionx2
azithromycin, NSAID	IL6 receptor antagonists without corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	0.98	0.29	3.43	13.73	-97.63	216.3	VERY LOW	0.98	0.29	3.43	13.73	-97.63	216.3	VERY LOW	RoB, Imprecisionx2
azithromycin, NSAID	interferon alfa (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	0	0	0.7	-791.3	-951.02	-216.72	VERY LOW	0	0	0.7	-791.3	-951.02	-216.72	VERY LOW	RoB, Imprecisionx3
azithromycin, NSAID	interferon beta (subcutaneous) interferon beta (subcutaneous), lopinavir-ritonavir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.06	0.31	3.87 2.04	21.8	-92.07 -248.19	225.26 131.87	VERY LOW VERY LOW	1.06 0.51	0.31	3.87	21.8 -86.02	-92.07 -248 19	225.26	VERY LOW VERY LOW	RoB, Imprecisionx2 RoB, Imprecisionx2
azithromycin, NSAID azithromycin, NSAID	interreron beta (subcutaneous), iopinavir-ritonavir intermediate-dose anticoagulant	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.51	0.14	3.6	-86.02 5.25	-248.19 -126.12	212.93	VERY LOW VERY LOW	0.51	0.14	3.6	-86.02 5.25	-248.19 -126.12	212.93	VERY LOW VERY LOW	RoB, Imprecisionx2
azithromycin, NSAID	intermediate-dose articoaguiant	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	3.45E+06	0.23	1.84E+13	140.59	19.68	351.45	VERY LOW	3.45E+06	0.23	1.84E+13	140.59	19.68	351.45	VERY LOW	RoB, Imprecisionx3
azithromycin, NSAID	ivermectin	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA.	1.68	0.45	6.73	65.21	-55.86	269.59	VERY LOW	1.68	0.45	6.73	65.21	-55.86	269.59	VERY LOW	RoB, Imprecisionx2
azithromycin, NSAID	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	1.7	0.49	6.16	68.27	-43.8	269.23	VERY LOW	1.7	0.49	6.16	68.27	-43.8	269.23	VERY LOW	RoB, Imprecisionx2
lopinavir-ritonavir	azithromycin, NSAID	1	0.2	4.97	NA	NA	NA	VERY LOW	NA	NA	NA	NA	NA	NA	NA	1	0.29	3.3	-17.39	-215.45	91.04	VERY LOW	RoB, Imprecisionx2
azithromycin, NSAID	melatonin	NA	NA	NA	NA	NA	NA	NA	26.29	2.46	535.84	143.7	32.53	343.87	VERY LOW	26.29	2.46	535.84	143.7	32.53	343.87	VERY LOW	RoB, Imprecisionx3
azithromycin, NSAID	methylene blue	NA	NA	NA	NA	NA	NA	NA	2.14	0.54	8.97	81.78	-40.94	285.29	VERY LOW	2.14	0.54	8.97	81.78	-40.94	285.29	VERY LOW	RoB, Imprecisionx2
azithromycin, NSAID	molnupiravir	NA	NA	NA	NA	NA	NA	NA	17.77	1.78	440.13	139.82	27.16	340.16	VERY LOW	17.77	1.78	440.13	139.82	27.16	340.16	VERY LOW	RoB, Imprecisionx3
azithromycin, NSAID	nitazoxanide	NA	NA	NA	NA	NA	NA	NA	1.98	0.31	11.89	64.41	-121.68	279.46	VERY LOW	1.98	0.31	11.89	64.41	-121.68	279.46	VERY LOW	RoB, Imprecisionx3
azithromycin, NSAID	omega 3	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	10.08 3.10F+09	1.15	107.88 1 22F+20	132.3 153.77	14.91 44.8	332.97 354.5	VERY LOW	10.08 3.10F+09	1.15	107.88 1 22F+20	132.3	14.91 44.8	332.97 354.5	VERY LOW	RoB, Imprecisionx3 RoB, Imprecisionx3
azithromycin, NSAID	probiotics	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	3.10E+09	0.16	8.01	-1.01	-292.8	244.12	VERY LOW	3.10E+09 1.11	0.16	8.01	-1.01	-292.8	244.12	VERY LOW VERY LOW	RoB, Imprecisionx3
azithromycin, NSAID	probletics	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	8.59	2.34	33.71	135.66	-292.8 26.13	336.16	VERY LOW	8.59	2.34	33.71	135.66	26.13	336.16	VERY LOW VERY LOW	RoB, Imprecisionx2
azithromycin, NSAID	recombinant human granulocyte colony-stimulating factor	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	5.73	1.02	42.17	122.01	-0.64	328.41	VERY LOW	5.73	1.02	42.17	122.01	-0.64	328.41	VERY LOW	RoB, Imprecisionx3
azithromycin, NSAID	remdesivir	NA	NA	NA	NA	NA	NA	NA	1.18	0.35	4.22	34.76	-77.83	236.78	VERY LOW	1.18	0.35	4.22	34.76	-77.83	236.78	VERY LOW	RoB, Imprecisionx2
azithromycin, NSAID	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	1.61	0.31	8.1	55.1	-104.38	266.57	VERY LOW	1.61	0.31	8.1	55.1	-104.38	266.57	VERY LOW	RoB, Imprecisionx2
azithromycin, NSAID	SGLT2 inhibitors	NA	NA	NA	NA	NA	NA	NA	1.44	0.38	5.64	52.33	-70.04	254.6	VERY LOW	1.44	0.38	5.64	52.33	-70.04	254.6	VERY LOW	RoB, Imprecisionx2
azithromycin, NSAID	statins	NA	NA	NA	NA	NA	NA	NA	0.8	0.17	4.01	-19.87	-229.87	212.89	VERY LOW	0.8	0.17	4.01	-19.87	-229.87	212.89	VERY LOW	RoB, Imprecisionx2
azithromycin, NSAID	sulodexide	NA	NA	NA	NA	NA	NA	NA	2.74	0.45	20.52	89.53	-69.1	301.95	VERY LOW	2.74	0.45	20.52	89.53	-69.1	301.95	VERY LOW	RoB, Imprecisionx3
azithromycin, NSAID	synthetic VIP	NA	NA	NA	NA	NA	NA	NA	0.92	0.22	3.87	1.02	-157.68	215.46	VERY LOW	0.92	0.22	3.87	1.02	-157.68	215.46	VERY LOW	RoB, Imprecisionx2
azithromycin, NSAID	tyrosine kinase inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	2.53	0.61	10.49	91.75	-30.98	296.7	VERY LOW	2.53	0.61	10.49	91.75	-30.98	296.7	VERY LOW	RoB, Imprecisionx2
azithromycin, NSAID azithromycin, NSAID	umifenovir vitamin C	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.53	0.39	6.72 7.38	54.36 62.72	-84.32 -70.96	261.18 273.83	VERY LOW VERY LOW	1.53	0.39	6.72 7.38	54.36 62.72	-84.32 -70.96	261.18 273.83	VERY LOW VERY LOW	RoB, Imprecisionx2 RoB, Imprecisionx2
azithromycin, NSAID azithromycin, NSAID	vitamin C vitamin D	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.67	0.41	7.85	66.23	-70.96 -67.22	273.83	VERY LOW VERY LOW	1.67	0.41	7.38	66.23	-70.96 -67.22	273.83	VERY LOW VERY LOW	RoB, Imprecisionx2
azithromycin, NSAID, corticosteroid	cefepime	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.05	0.40	1.24E+09	-400.42	-967.44	214.65	VERY LOW	0.05	0.40	1.24E+09	-400.42	-967.44	214.65	VERY LOW	RoB, Imprecisionx3
azithromycin, NSAID, corticosteroid	ceftazidime	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	5.89E+08	0	1.70E+21	-399.63	-968.99	215.96	VERY LOW	5.89E+08	0	1.70E+21	-399.63	-968.99	215.96	VERY LOW	RoB, Imprecisionx3
azithromycin, NSAID, corticosteroid	colchicine	NA	NA	NA	NA	NA	NA	NA	0.73	0.16	3.02	-19.06	-103.93	157.05	VERY LOW	0.73	0.16	3.02	-19.06	-103.93	157.05	VERY LOW	RoB, Imprecisionx2
azithromycin, NSAID, corticosteroid	colchicine, emtricitabine, tenofovir, statins	NA	NA	NA	NA	NA	NA	NA	1.19	0.23	5.57	21.1	-86.86	201.11	VERY LOW	1.19	0.23	5.57	21.1	-86.86	201.11	VERY LOW	RoB, Imprecisionx2
azithromycin, NSAID, corticosteroid	colchicine, statins	NA	NA	NA	NA	NA	NA	NA	0.84	0.16	3.85	-7.42	-123.48	173.79	VERY LOW	0.84	0.16	3.85	-7.42	-123.48	173.79	VERY LOW	RoB, Imprecisionx2
azithromycin, NSAID, corticosteroid	corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	0.83	0.18	3.41	-4.01	-85.73	171.2	VERY LOW	0.83	0.18	3.41	-4.01	-85.73	171.2	VERY LOW	RoB, Imprecisionx2
azithromycin, NSAID, corticosteroid	IL6 receptor antagonists with corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	0.83	0.18	3.37	-4.74	-85.65	169.74	VERY LOW	0.83	0.18	3.37	-4.74	-85.65	169.74	VERY LOW	RoB, Imprecisionx2
azithromycin, NSAID, corticosteroid	doxycycline	NA	NA	NA	NA	NA	NA	NA	0.18	0.02	1.72	-270.96	-717.99	49.17	VERY LOW	0.18	0.02	1.72	-270.96	-717.99	49.17	VERY LOW	RoB, Imprecisionx3
azithromycin, NSAID, corticosteroid	doxycycline, ivermectin	NA	NA	NA	NA	NA	NA	NA	2.70E+18	4.53E+04	3.03E+32	97.67	13.31	274.51	VERY LOW	2.70E+18	4.53E+04	3.03E+32	97.67	13.31	274.51	VERY LOW	RoB, Imprecisionx3
azithromycin, NSAID, corticosteroid	electrolyzed saline	NA	NA	NA	NA	NA	NA	NA	3.84	0.47	41.4	71.58	-33.35	250.39	VERY LOW	3.84	0.47	41.4	71.58	-33.35	250.39	VERY LOW	RoB, Imprecisionx3

									Mortality	,													
Comparison		Direct estimate							Indirect estimate	9						Network estimate	9		1				
Treatment 1	Treatment 2	Relative estimate	CI lower limit	Cl upper limit	Absolute estimate	CI lower limit	Cl upper limit	Final rating	Relative estimate Point estimate	CI lower limit	CI upper limit	Absolute estimate Point estimate	CI lower limit	Cl upper limit	Final rating	Relative estimate	CI lower limit	Cl upper limit	Absolute estim	CI lower limit	Cl upper limit	Final rating	Reasons for
azithromycin, NSAID, corticosteroid	emtricitabine, tenofovir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA	0.89	0 17	4	-2.72	-119.17	177.86	VERY LOW	0.89	0 17	4	-2 72	-119.17	177.86	VERY LOW	downgrading RoB. Imprecisionx2
azithromycin, NSAID, corticosteroid	favipiravir	NA.	NA NA	NA NA	NA	NA NA	NA NA	NA	0.5	0.1	2.29	-61.51	-200.8	123.46	VERY LOW	0.5	0.1	2.29	-61.51	-200.8	123.46	VERY LOW	RoB, Imprecisionx2
azithromycin, NSAID, corticosteroid	favipiravir, hydrochloroquine	NA	NA	NA	NA	NA	NA	NA	0.7	0.12	3.4	-29.57	-176.92	161.28	VERY LOW	0.7	0.12	3.4	-29.57	-176.92	161.28	VERY LOW	RoB, Imprecisionx2
azithromycin, NSAID, corticosteroid	fluvoxamine	NA	NA	NA	NA	NA	NA	NA	0.98	0.19	4.51	6.06	-103.94	187.14	VERY LOW	0.98	0.19	4.51	6.06	-103.94	187.14	VERY LOW	RoB, Imprecisionx2
azithromycin, NSAID, corticosteroid	full-dose anticoagulant	NA	NA	NA	NA	NA	NA	NA	0.7	0.15	2.84	-22.82	-106.66	152.61	VERY LOW	0.7	0.15	2.84	-22.82	-106.66	152.61	VERY LOW	RoB, Imprecisionx2
azithromycin, NSAID, corticosteroid	GM-CSF inhibitor	NA	NA NA	NA NA	NA NA	NA NA	NA	NA NA	0.87	0.19	3.59	-1.41	-89.44	175.1	VERY LOW	0.87	0.19	3.59	-1.41 -37.72	-89.44	175.1	VERY LOW	RoB, Imprecisionx2
azithromycin, NSAID, corticosteroid azithromycin, NSAID, corticosteroid	(hydroxy)chloroquine IL1 inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.61	0.14	2.51 3.81	-37.72 1.05	-120.06 -93.84	137.83 177.5	VERY LOW VERY LOW	0.61	0.14	2.51 3.81	-37.72 1.05	-120.06 -93.84	137.83	VERY LOW VERY LOW	RoB, Imprecisionx2 RoB, Imprecisionx2
azithromycin, NSAID, corticosteroid	IL6 receptor antagonists without corticosteroids (systemic)	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.69	0.19	2.46	-38.06	-121.8	138.21	VERY LOW	0.69	0.19	2.46	-38.06	-121.8	138.21	VERY LOW	RoB, Imprecisionx2
azithromycin, NSAID, corticosteroid	interferon alfa (subcutaneous)	NA.	NA NA	NA NA	NA NA	NA NA	NA NA	NA.	0.01	0.14	0.38	-843.09	-974.33	-254.04	VERY LOW	0.01	0.14	0.38	-843.09	-974.33	-254.04	VERY LOW	RoB, Imprecisionx3
azithromycin, NSAID, corticosteroid	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	0.66	0.14	2.72	-29.98	-116.72	146.82	VERY LOW	0.66	0.14	2.72	-29.98	-116.72	146.82	VERY LOW	RoB, Imprecisionx2
azithromycin, NSAID, corticosteroid	interferon beta (subcutaneous), lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.32	0.07	1.47	-137.81	-280.31	51.49	VERY LOW	0.32	0.07	1.47	-137.81	-280.31	51.49	VERY LOW	RoB, Imprecisionx2
azithromycin, NSAID, corticosteroid	intermediate-dose anticoagulant	NA	NA	NA	NA	NA	NA	NA	0.58	0.12	2.56	-46.53	-154.31	135.56	VERY LOW	0.58	0.12	2.56	-46.53	-154.31	135.56	VERY LOW	RoB, Imprecisionx2
azithromycin, NSAID, corticosteroid	intranasal corticosteroids	NA	NA	NA	NA	NA	NA	NA	2.15E+06	0.01	1.23E+13	88.8	-2.42	274.22	VERY LOW	2.15E+06	0.01	1.23E+13	88.8	-2.42	274.22	VERY LOW	RoB, Imprecisionx3
azithromycin, NSAID, corticosteroid	ivermectin	NA NA	NA	NA NA	NA NA	NA	NA	NA NA	1.05	0.22	4.7	13.43	-83.56	189.89 191.51	VERY LOW	1.05	0.22	4.7	13.43	-83.56 -67.4	189.89 191.51	VERY LOW	RoB, Imprecisionx2
azithromycin, NSAID, corticosteroid	JAK inhibitors azithromycin, NSAID, corticosteroid	NA 1.62	NA 0.29	NA 8.85	NA NA	NA NA	NA NA	VERY LOW	1.06 NA	0.23 NA	4.36 NA	16.48 NA	-67.4 NA	191.51 NA	VERY LOW NA	1.06 1.6	0.23	4.36 7.09	16.48 34.39	-67.4	191.51	VERY LOW VERY LOW	RoB, Imprecisionx2
azithromycin, NSAID, corticosteroid	azitnromycin, NSAID, contcosteroid melatonin	NA	0.29 NA	NA	NA NA	NA NA	NA NA	NA NA	15 98	1.33	383.07	91 92	8.92	266.75	VERYLOW	15.98	1.33	383.07	91.92	8 92	266.75	VERY LOW	RoB, Imprecisionx2 RoB, Imprecisionx3
azithromycin, NSAID, corticosteroid	methylene blue	NA NA	NA.	NA.	NA NA	NA.	NA NA	NA NA	1 33	0.26	6.27	29.99	-67.92	206.78	VERYLOW	1.33	0.26	6.27	29.99	-67.92	206.78	VERYLOW	RoB, Imprecisionx2
azithromycin, NSAID, corticosteroid	molnupiravir	NA	NA	NA	NA	NA	NA	NA	10.98	1.03	284.29	88.03	-0.66	264.81	VERY LOW	10.98	1.03	284.29	88.03	-0.66	264.81	VERY LOW	RoB, Imprecisionx3
azithromycin, NSAID, corticosteroid	nitazoxanide	NA	NA	NA	NA	NA	NA	NA	1.21	0.17	8.66	12.63	-159.26	204.07	VERY LOW	1.21	0.17	8.66	12.63	-159.26	204.07	VERY LOW	RoB, Imprecisionx3
azithromycin, NSAID, corticosteroid	omega 3	NA	NA	NA	NA	NA	NA	NA	6.2	0.71	70.38	80.51	-14.17	256.64	VERY LOW	6.2	0.71	70.38	80.51	-14.17	256.64	VERY LOW	RoB, Imprecisionx3
azithromycin, NSAID, corticosteroid	nirmatrelvir/ritonavir	NA	NA	NA	NA	NA	NA	NA	1.78E+09	67.5	6.71E+19	101.99	21.95	277.02	VERY LOW	1.78E+09	67.5	6.71E+19	101.99	21.95	277.02	VERY LOW	RoB, Imprecisionx3
azithromycin, NSAID, corticosteroid	probiotics	NA	NA	NA	NA	NA	NA	NA	0.69	0.08	5.14	-52.8	-333.09	172.21	VERY LOW	0.69	0.08	5.14	-52.8	-333.09	172.21	VERY LOW	RoB, Imprecisionx3
azithromycin, NSAID, corticosteroid	proxalutamide	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	5.35	1.14	23.71	83.88	4.37	258.92	VERY LOW	5.35	1.14	23.71	83.88	4.37	258.92	VERY LOW	RoB, Imprecisionx2
azithromycin, NSAID, corticosteroid azithromycin, NSAID, corticosteroid	recombinant human granulocyte colony-stimulating factor remdesivir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	3.6 0.73	0.51	29.29 3.02	70.22 -17.02	-28.17 -100.21	248.43 158.29	VERY LOW VERY LOW	3.6 0.73	0.51	29.29 3.02	70.22 -17.02	-28.17 -100.21	248.43 158.29	VERY LOW VERY LOW	RoB, Imprecisionx3 RoB, Imprecisionx2
azithromycin, NSAID, corticosteroid	serine protease inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.73	0.10	5.59	3.32	-100.21	191.83	VERY LOW	0.73	0.10	5.59	3.32	-100.21	191.83	VERY LOW	RoB, Imprecisionx3
azithromycin, NSAID, corticosteroid	SGLT2 inhibitors	NA.	NA.	NA.	NA.	NA.	NA.	NA.	0.9	0.18	3.93	0.55	-97.42	176.9	VERY LOW	0.9	0.18	3.93	0.55	-97.42	176.9	VERY LOW	RoB, Imprecisionx2
azithromycin, NSAID, corticosteroid	statins	NA	NA	NA	NA	NA	NA NA	NA	0.49	0.08	2.81	-71.66	-269.81	135.5	VERY LOW	0.49	0.08	2.81	-71.66	-269.81	135.5	VERY LOW	RoB, Imprecisionx3
azithromycin, NSAID, corticosteroid	sulodexide	NA	NA	NA	NA	NA	NA	NA	1.7	0.24	13.85	37.74	-102.94	223.76	VERY LOW	1.7	0.24	13.85	37.74	-102.94	223.76	VERY LOW	RoB, Imprecisionx3
azithromycin, NSAID, corticosteroid	synthetic VIP	NA	NA	NA	NA	NA	NA	NA	0.57	0.11	2.72	-50.77	-192.75	138.8	VERY LOW	0.57	0.11	2.72	-50.77	-192.75	138.8	VERY LOW	RoB, Imprecisionx2
azithromycin, NSAID, corticosteroid	tyrosine kinase inhibitors	NA	NA	NA	NA	NA	NA	NA	1.56	0.31	7.5	39.97	-55.25	216.78	VERY LOW	1.56	0.31	7.5	39.97	-55.25	216.78	VERY LOW	RoB, Imprecisionx2
azithromycin, NSAID, corticosteroid	umifenovir	NA	NA	NA	NA	NA	NA	NA	0.95	0.19	4.8	2.57	-117.66	182.72	VERY LOW	0.95	0.19	4.8	2.57	-117.66	182.72	VERY LOW	RoB, Imprecisionx2
azithromycin, NSAID, corticosteroid	vitamin C	NA	NA	NA	NA	NA	NA	NA	1.06	0.2	5.18	10.93	-98.92	191.12	VERY LOW	1.06	0.2	5.18	10.93	-98.92	191.12	VERY LOW	RoB, Imprecisionx2
azithromycin, NSAID, corticosteroid	vitamin D cefepime	NA 0.91	NA 0.02	NA 53.59	NA NA	NA NA	NA NA	NA VERY LOW	1.14 NA	0.22 NA	5.58 NA	14.45 NA	-92.52 NΔ	195.46 NA	VERY LOW	1.14	0.22	5.58 2.27F+18	14.45	-92.52 -1.000.00	195.46	VERY LOW VERY LOW	RoB, Imprecisionx2 RoB, Imprecisionx3
cefepime	colchicine	NA NA	NA	55.59 NA	NA NA	NA NA	NA NA	NA NA	13.66	0	3 13F+12	381.36	-139.67	901.34	VERYLOW	13.66	0	3 13F+12	381.36	-139.67	901.34	VERYLOW	RoB Imprecisionx3
cefepime	colchicine, emtricitabine, tenofovir, statins	NA	NA	NA	NA	NA	NA	NA	23.06	0	4.49E+12	421.52	-124.28	954.74	VERY LOW	23.06	0	4.49E+12	421.52	-124.28	954.74	VERY LOW	RoB, Imprecisionx3
cefepime	colchicine, statins	NA	NA	NA	NA	NA	NA	NA	16.51	0	3.29E+12	392.99	-163.69	934.82	VERY LOW	16.51	0	3.29E+12	392.99	-163.69	934.82	VERY LOW	RoB, Imprecisionx3
cefepime	corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	15.76	0	3.60E+12	396.41	-117.52	906.23	VERY LOW	15.76	0	3.60E+12	396.41	-117.52	906.23	VERY LOW	RoB, Imprecisionx3
cefepime	IL6 receptor antagonists with corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	15.68	0	3.67E+12	395.67	-118.06	903.71	VERY LOW	15.68	0	3.67E+12	395.67	-118.06	903.71	VERY LOW	RoB, Imprecisionx3
cefepime	doxycycline	NA	NA	NA	NA	NA	NA	NA	2.95	0	7.01E+11	129.46	-685.44	868.11	VERY LOW	2.95	0	7.01E+11	129.46	-685.44	868.11	VERY LOW	RoB, Imprecisionx3
cefepime cefepime	doxycycline, ivermectin electrolyzed saline	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	5.04E+19 70.41	1.08E+05	4.62E+38 1.63E+13	498.09 472	-0.03 -66.52	1,000.00 994.24	VERY LOW	5.04E+19 70.41	1.08E+05	4.62E+38 1.63E+13	498.09 472	-0.03 -66.52	1,000.00	VERY LOW	RoB, Imprecisionx3
cefepine	emetricitabine, tenofovir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	17.82	0	3.49F+12	397 69	-155.62	939.48	VERY LOW	17.82	0	3 49F+12	397 69	-155 62	939.24	VERYLOW	RoB, Imprecisionx3
cefepime	favipiravir	NA.	NA.	NA.	NA.	NA.	NA.	NA.	10.27	0	2.70E+12	338.91	-231.88	896.76	VERY LOW	10.27	0	2.70E+12	338.91	-231.88	896.76	VERY LOW	RoB, Imprecisionx3
cefepime	favipiravir, hydrochloroquine	NA	NA	NA	NA	NA	NA	NA	13.27	0	2.82E+12	370.84	-207.97	930.54	VERY LOW	13.27	0	2.82E+12	370.84	-207.97	930.54	VERY LOW	RoB, Imprecisionx3
cefepime	fluvoxamine	NA	NA	NA	NA	NA	NA	NA	18.99	0	4.02E+12	406.48	-144.28	943.61	VERY LOW	18.99	0	4.02E+12	406.48	-144.28	943.61	VERY LOW	RoB, Imprecisionx3
cefepime	full-dose anticoagulant	NA	NA	NA	NA	NA	NA	NA	13.33	0	2.99E+12	377.59	-141.07	891.45	VERY LOW	13.33	0	2.99E+12	377.59	-141.07	891.45	VERY LOW	RoB, Imprecisionx3
cefepime	GM-CSF inhibitor	NA	NA	NA	NA	NA	NA	NA	16.39	0	3.77E+12	399	-126.4	918.77	VERY LOW	16.39	0	3.77E+12	399	-126.4	918.77	VERY LOW	RoB, Imprecisionx3
cefepime	(hydroxy)chloroquine	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	11.5	0	2.70E+12	362.69 401.46	-154.9	874.56	VERY LOW	11.5 17.17	0	2.70E+12	362.69	-154.9 -133.26	874.56	VERY LOW	RoB, Imprecisionx3
cefepime cefepime	IL1 inhibitors IL6 receptor antagonists without corticosteroids (systemic)	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	17.17	0	3.90E+12 2.58E+12	401.46 362.36	-133.26 -157.17	926.63 876.24	VERY LOW VERY LOW	17.17	0	3.90E+12 2.58E+12	401.46 362.36	-133.26 -157.17	926.63 876.24	VERY LOW VERY LOW	RoB, Imprecisionx3 RoB, Imprecisionx3
cerepime	interferon alfa (subcutaneous)	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0	0	2.21E+09	-442.67	-1000.00	599.67	VERY LOW	0	0	2.58E+12 2.21E+09	-442.67	-1,000.00	599.67	VERY LOW	RoB, Imprecisionx3
cefepime	interferon beta (subcutaneous)	NA NA	NA NA	NA NA	NA	NA NA	NA NA	NA	12.39	0	2.84E+12	370.43	-154.06	890.6	VERY LOW	12.39	0	2.84E+12	370.43	-154.06	890.6	VERY LOW	RoB, Imprecisionx3
cefepime	interferon beta (subcutaneous), lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	6.18	0	1.32E+12	262.61	-321.96	835.74	VERY LOW	6.18	0	1.32E+12	262.61	-321.96	835.74	VERY LOW	RoB, Imprecisionx3
cefepime	intermediate-dose anticoagulant	NA	NA	NA	NA	NA	NA	NA	10.77	0	2.37E+12	353.88	-194.87	892.65	VERY LOW	10.77	0	2.37E+12	353.88	-194.87	892.65	VERY LOW	RoB, Imprecisionx3
cefepime	intranasal corticosteroids	NA	NA	NA	NA	NA	NA	NA	1.86E+06	0	4.43E+21	489.22	-86.79	1,000.00	VERY LOW	1.86E+06	0	4.43E+21	489.22	-86.79	1,000.00	VERY LOW	RoB, Imprecisionx3
cefepime	ivermectin	NA	NA	NA	NA	NA	NA	NA	20.64	0	4.49E+12	413.84	-120.75	939.45	VERY LOW	20.64	0	4.49E+12	413.84	-120.75	939.45	VERY LOW	RoB, Imprecisionx3
cefepime	JAK inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	20.09	0	4.57E+12	416.9	-102.36	930.42	VERY LOW	20.09	0	4.57E+12	416.9	-102.36	930.42	VERY LOW	RoB, Imprecisionx3
cefepime cefepime	lopinavir-ritonavir melatonin	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	11.98 408.75	0	2.72E+12 5.10E+13	366.02 492.33	-151.22 -28.36	878.44 999.14	VERY LOW VERY LOW	11.98 408.75	0	2.72E+12 5.10E+13	366.02 492.33	-151.22 -28.36	878.44 999.14	VERY LOW VERY LOW	RoB, Imprecisionx3 RoB, Imprecisionx3
cetepime	melatonin methylene blue	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	408.75	0	5.10E+13 5.70E+12	492.33	-28.36 -107.05	999.14	VERY LOW VERY LOW	408.75 24.9	0	5.10E+13 5.70E+12	492.33	-28.36	999.14	VERY LOW VERY LOW	RoB, Imprecisionx3
cefepine	molnupiravir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	284.18	0	7.48E+13	488.45	-27.54	998.08	VERY LOW	284.18	0	7.48E+13	488.45	-27.54	998.08	VERY LOW	RoB, Imprecisionx3
cefepime	nitazoxanide	NA	NA	NA	NA	NA	NA	NA	22.56	0	4.23E+12	413.04	-178.15	970.71	VERY LOW	22.56	0	4.23E+12	413.04	-178.15	970.71	VERY LOW	RoB, Imprecisionx3
cefepime	omega 3	NA	NA	NA	NA	NA	NA	NA	133.56	0	2.98E+13	480.93	-53.8	995.84	VERY LOW	133.56	0	2.98E+13	480.93	-53.8	995.84	VERY LOW	RoB, Imprecisionx3
cefepime	nirmatrelvir/ritonavir	NA	NA	NA	NA	NA	NA	NA	5.61E+12	0	3.38E+23	502.4	-0.05	1,000.00	VERY LOW	5.61E+12	0	3.38E+23	502.4	-0.05	1,000.00	VERY LOW	RoB, Imprecisionx3
cefepime	probiotics	NA	NA	NA	NA	NA	NA	NA	14.38	0	2.15E+12	347.62	-348.3	955.97	VERY LOW	14.38	0	2.15E+12	347.62	-348.3	955.97	VERY LOW	RoB, Imprecisionx3
cefepime	proxalutamide	NA	NA	NA	NA	NA	NA	NA	103.07	0	2.31E+13	484.29	-25.05	987.25	VERY LOW	103.07	0	2.31E+13	484.29	-25.05	987.25	VERY LOW	RoB, Imprecisionx3
cefepime	recombinant human granulocyte colony-stimulating factor	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA	68.75	0	1.25E+13	470.64	-67.88	991.77	VERY LOW	68.75	0	1.25E+13	470.64	-67.88	991.77	VERY LOW	RoB, Imprecisionx3
cefepime	remdesivir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	13.75	0	3.12E+12 3.82E+12	383.39 403.73	-134.44 -169.75	896.75 957.12	VERY LOW VERY LOW	13.75 20.19	0	3.12E+12 3.82E+12	383.39 403.73	-134.44 -169.75	896.75 957.12	VERY LOW	RoB, Imprecisionx3 RoB, Imprecisionx3
cefepime cefepime	serine protease inhibitors SGLT2 inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	17.32	0	3.82E+12 3.81E+12	403.73	-169.75 -136.34	957.12	VERY LOW VERY LOW	17.32	0	3.82E+12 3.81E+12	403.73	-189.75	957.12	VERY LOW VERY LOW	RoB, Imprecisionx3
cefepine	statins	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	9.54	0	2.13E+12	328.76	-291.26	924.71	VERY LOW	9.54	0	2.13E+12	328.76	-291.26	924.71	VERY LOW	RoB, Imprecisionx3
Совершие	1 Stating				10	140	.40	.40	5.54	,	2.102112	525.76	201.20	UZ-4.7 1	72.1. LOW	0.04		2.102.12	020.70	201.20	SE-7.71	TELL LOW	Aco, impreciaiorixa

									Mortality	у													
Comparison		Direct estimate)						Indirect estimate	e						Network estimate							
- · · · ·		Relative estimate	O Llawar Harit	Ol and limit	Absolute estima	ate (per 1,000) CI lower limit	Cl upper limit	Final rating	Relative estimate	Ol James Harit	Cl upper limit	Absolute estimate	te (per 1,000)	Ol	Final rating	Relative estima		Cl upper limit	Absolute estim	ate (per 1,000)	Ol limit	Final rating	Reasons for
Treatment 1 cefepime	Treatment 2 sulodexide	Point estimate NA	CI lower limit	CI upper limit	Point estimate NA	VA NA	CI upper limit	NA	Point estimate	CI lower limit	7.52E+12	438.16	-138.14	Cl upper limit 984 39	VERY LOW	Point estimate	CI lower limit	7.52E+12	438.16	-138.14	CI upper limit 984.39	VERY LOW	downgrading RoB. Imprecisionx3
cefepine	synthetic VIP	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	10.91	0	2.33E+12	349.65	-226.62	908.06	VERY LOW	10.91	0	2.33E+12	349.65	-226.62	908.06	VERY LOW	RoB, Imprecisionx3
cefepime	tyrosine kinase inhibitors	NA	NA.	NA	NA	NA	NA	NA	30.94	0	6.62E+12	440.38	-94.81	964.7	VERY LOW	30.94	0	6.62E+12	440.38	-94.81	964.7	VERY LOW	RoB, Imprecisionx3
cefepime	umifenovir	NA	NA	NA	NA	NA	NA	NA	19.38	0	4.48E+12	402.99	-158.78	947.12	VERY LOW	19.38	0	4.48E+12	402.99	-158.78	947.12	VERY LOW	RoB, Imprecisionx3
cefepime	vitamin C	NA	NA	NA	NA	NA	NA	NA	20.74	0	5.09E+12	411.35	-137.26	946.82	VERY LOW	20.74	0	5.09E+12	411.35	-137.26	946.82	VERY LOW	RoB, Imprecisionx3
cefepime	vitamin D	NA	NA	NA	NA	NA	NA	NA	19.61	0	5.26E+12	414.86	-137.15	951.84	VERY LOW	19.61	0	5.26E+12	414.86	-137.15	951.84	VERY LOW	RoB, Imprecisionx3
ceftazidime	colchicine	NA	NA	NA	NA	NA	NA	NA	0	0	3.14E+15	380.57	-141.18	900.68	VERY LOW	0	0	3.14E+15	380.57	-141.18	900.68	VERY LOW	RoB, Imprecisionx3
ceftazidime	colchicine, emtricitabine, tenofovir, statins	NA	NA	NA	NA	NA	NA	NA	0	0	5.91E+15	420.73	-124.67	953.48	VERY LOW	0	0	5.91E+15	420.73	-124.67	953.48	VERY LOW	RoB, Imprecisionx3
ceftazidime ceftazidime	colchicine, statins corticosteroids (systemic)	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.00	0	3.97E+15 3.70E+15	392.2 395.62	-164.4 -118.99	933.35 906.09	VERY LOW VERY LOW	0	0	3.97E+15 3.70E+15	392.2 395.62	-164.4 -118.99	933.35 906.09	VERY LOW VERY LOW	RoB, Imprecisionx3 RoB, Imprecisionx3
cettazidine	IL6 receptor antagonists with corticosteroids (systemic)	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.00	0	3.70E+15	394.88	-118.99	903.08	VERYLOW	0	0	3.70E+15	394.88	-118.79	903.08	VERYLOW	RoB, Imprecisionx3
ceftazidime	doxycycline	NA NA	NA.	NA NA	NA.	NA.	NA NA	NA.	0	0	1.33E+15	128.67	-715.37	873.27	VERY LOW	0	0	1.33E+15	128.67	-715.37	873.27	VERY LOW	RoB. Imprecisionx3
ceftazidime	doxycycline, ivermectin	NA	NA	NA	NA	NA	NA	NA	9.40E+09	0	4.72E+40	497.3	-21.78	1,000.00	VERY LOW	9.40E+09	0	4.72E+40	497.3	-21.78	1,000.00	VERY LOW	RoB, Imprecisionx3
ceftazidime	electrolyzed saline	NA	NA	NA	NA	NA	NA	NA	0	0	2.21E+16	471.21	-72.87	994.04	VERY LOW	0	0	2.21E+16	471.21	-72.87	994.04	VERY LOW	RoB, Imprecisionx3
ceftazidime	emtricitabine, tenofovir	NA	NA	NA	NA	NA	NA	NA	0	0	4.19E+15	396.9	-158.65	938.89	VERY LOW	0	0	4.19E+15	396.9	-158.65	938.89	VERY LOW	RoB, Imprecisionx3
ceftazidime	favipiravir	NA	NA	NA	NA	NA	NA	NA	0	0	2.64E+15	338.12	-241.63	900.48	VERY LOW	0	0	2.64E+15	338.12	-241.63	900.48	VERY LOW	RoB, Imprecisionx3
ceftazidime	favipiravir, hydrochloroquine	NA	NA	NA	NA	NA	NA	NA	0	0	3.13E+15	370.06	-214.59	930.32	VERY LOW	0	0	3.13E+15	370.06	-214.59	930.32	VERY LOW	RoB, Imprecisionx3
ceftazidime ceftazidime	fluvoxamine full-dose anticoagulant	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0	0	5.01E+15 3.01E+15	405.69 376.81	-146.62 -141.68	942.65 891.07	VERY LOW VERY LOW	0	0	5.01E+15 3.01F+15	405.69 376.81	-146.62 -141.68	942.65 891.07	VERY LOW VERY LOW	RoB, Imprecisionx3 RoB, Imprecisionx3
cettazidime	GM-CSF inhibitor	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0	0	3.01E+15 3.87E+15	398.22	-141.08	917.96	VERY LOW	0	0	3.01E+15 3.87E+15	398.22	-141.08	917.96	VERY LOW VERY LOW	RoB, Imprecisionx3
ceftazidime	(hydroxy)chloroquine	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0	0	2.69E+15	361.9	-154.57	873.88	VERY LOW	0	0	2.69E+15	361.9	-154.57	873.88	VERY LOW	RoB, Imprecisionx3
ceftazidime	IL1 inhibitors	NA NA	NA NA	NA	NA	NA	NA NA	NA	0	0	3.96E+15	400.67	-136.55	927.96	VERY LOW	0	0	3.96E+15	400.67	-136.55	927.96	VERY LOW	RoB, Imprecisionx3
ceftazidime	IL6 receptor antagonists without corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	0	0	2.75E+15	361.57	-157.59	876.05	VERY LOW	0	0	2.75E+15	361.57	-157.59	876.05	VERY LOW	RoB, Imprecisionx3
ceftazidime	interferon alfa (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	0	0	4.07E+02	-443.46	-999.99	156.73	VERY LOW	0	0	4.07E+02	-443.46	-999.99	156.73	VERY LOW	RoB, Imprecisionx3
ceftazidime	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	0.00	0	2.77E+15	369.64	-155.43	890.81	VERY LOW	0	0	2.77E+15	369.64	-155.43	890.81	VERY LOW	RoB, Imprecisionx3
ceftazidime	interferon beta (subcutaneous), lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0	0	1.62E+15	261.82	-325.35	830.42	VERY LOW	0	0	1.62E+15	261.82	-325.35	830.42	VERY LOW	RoB, Imprecisionx3
ceftazidime	intermediate-dose anticoagulant	NA	NA	NA	NA	NA	NA	NA	0	0	2.53E+15	353.09	-194.72	890.42	VERY LOW	0	0	2.53E+15	353.09	-194.72	890.42	VERY LOW	RoB, Imprecisionx3
ceftazidime ceftazidime	intranasal corticosteroids	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.01	0	1.05E+25 5.01E+15	488.43	-0.94	1,000.00 940.53	VERY LOW VERY LOW	0.01	0	1.05E+25 5.01F+15	488.43 413.06	-0.94	1,000.00 940.53	VERY LOW VERY LOW	RoB, Imprecisionx3
cettazidine	JAK inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0	0	4 72F+15	413.06 416.11	-123.29 -103.59	940.53	VERYLOW	0	0	4.72F+15	416.11	-123.29 -103.59	940.53	VERYLOW	RoB, Imprecisionx3 RoB, Imprecisionx3
ceftazidime	lopinavir-ritonavir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0	0	2.74E+15	365.23	-152.59	878.17	VERY LOW	0	0	2.74E+15	365.23	-152.59	878.17	VERY LOW	RoB, Imprecisionx3
ceftazidime	melatonin	NA NA	NA.	NA NA	NA.	NA.	NA NA	NA.	0	0	1.28E+17	491.54	-31.62	998.82	VERY LOW	0	0	1.28E+17	491.54	-31.62	998.82	VERY LOW	RoB, Imprecisionx3
ceftazidime	methylene blue	NA	NA	NA	NA	NA	NA	NA	0	0	6.54E+15	429.62	-109.5	957.29	VERY LOW	0	0	6.54E+15	429.62	-109.5	957.29	VERY LOW	RoB, Imprecisionx3
ceftazidime	molnupiravir	NA	NA	NA	NA	NA	NA	NA	0.00	0	2.09E+17	487.66	-36.68	999.65	VERY LOW	0	0	2.09E+17	487.66	-36.68	999.65	VERY LOW	RoB, Imprecisionx3
ceftazidime	nitazoxanide	NA	NA	NA	NA	NA	NA	NA	0	0	6.24E+15	412.25	-203.08	978.59	VERY LOW	0	0	6.24E+15	412.25	-203.08	978.59	VERY LOW	RoB, Imprecisionx3
ceftazidime	omega 3	NA	NA	NA	NA	NA	NA	NA	0	0	4.05E+16	480.14	-57.04	995.89	VERY LOW	0	0	4.05E+16	480.14	-57.04	995.89	VERY LOW	RoB, Imprecisionx3
ceftazidime	nirmatrelvir/ritonavir	NA	NA	NA	NA	NA	NA	NA	39359.4	0	9.03E+32	501.61	-1.11	1,000.00	VERY LOW	39,359.40	0	9.03E+32	501.61	-1.11	1,000.00	VERY LOW	RoB, Imprecisionx3
ceftazidime ceftazidime	probiotics proxalutamide	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0	0	3.86E+15 2.41E+16	346.83 483.5	-334.39 -25.36	952.69 987.3	VERY LOW VERY LOW	0	0	3.86E+15 2.41E+16	346.83 483.5	-334.39 -25.36	952.69 987.3	VERY LOW VERY LOW	RoB, Imprecisionx3
cettazidime	recombinant human granulocyte colony-stimulating factor	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0	0	1.94E+16	469.85	-25.36	987.3	VERYLOW	0	0	1.94E+16	469.85	-25.30	987.3	VERY LOW	RoB, Imprecisionx3 RoB, Imprecisionx3
ceftazidine	remdesivir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0	0	3.24F+15	382.6	-135 44	895.89	VERYLOW	0	0	3.24F+15	382.6	-135 44	895.89	VERYLOW	RoB, Imprecisionx3
ceftazidime	serine protease inhibitors	NA NA	NA.	NA NA	NA.	NA.	NA NA	NA.	0	0	4.90E+15	402.94	-187.97	956.28	VERY LOW	0	0	4.90E+15	402.94	-187.97	956.28	VERY LOW	RoB, Imprecisionx3
ceftazidime	SGLT2 inhibitors	NA	NA	NA	NA	NA	NA	NA	0	0	4.04E+15	400.17	-139.04	929.36	VERY LOW	0	0	4.04E+15	400.17	-139.04	929.36	VERY LOW	RoB, Imprecisionx3
ceftazidime	statins	NA	NA	NA	NA	NA	NA	NA	0	0	2.59E+15	327.97	-311.47	918.26	VERY LOW	0	0	2.59E+15	327.97	-311.47	918.26	VERY LOW	RoB, Imprecisionx3
ceftazidime	sulodexide	NA	NA	NA	NA	NA	NA	NA	0	0	8.85E+15	437.37	-140.17	981.91	VERY LOW	0	0	8.85E+15	437.37	-140.17	981.91	VERY LOW	RoB, Imprecisionx3
ceftazidime	synthetic VIP	NA	NA	NA	NA	NA	NA	NA	0	0	2.64E+15	348.86	-232.28	908.73	VERY LOW	0	0	2.64E+15	348.86	-232.28	908.73	VERY LOW	RoB, Imprecisionx3
ceftazidime	tyrosine kinase inhibitors	NA	NA	NA	NA	NA	NA	NA	0	0	7.44E+15	439.59	-96.45	964.29	VERY LOW	0	0	7.44E+15	439.59	-96.45	964.29	VERY LOW	RoB, Imprecisionx3
ceftazidime ceftazidime	umifenovir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0	0	4.12E+15 5.18E+15	402.2 410.56	-164.15 -141.06	943.68 947.46	VERY LOW VERY LOW	0	0	4.12E+15 5.18F+15	402.2 410.56	-164.15 -141.06	943.68 947.46	VERY LOW VERY LOW	RoB, Imprecisionx3
cettazidime	vitamin C vitamin D	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0	0	5.18E+15 5.15E+15	410.56	-141.06	947.46	VERY LOW	0	0	5.18E+15 5.15E+15	414.07	-141.06	947.46	VERY LOW VERY LOW	RoB, Imprecisionx3
colchicine	colchicine, emtricitabine, tenofovir, statins	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.63	0.75	3.48	40.16	-28.76	90.73	VERY LOW	1.63	0.75	3.48	40.16	-28.76	90.73	VERY LOW	RoB, Imprecisionx2
colchicine	colchicine, statins	NA	NA	NA	NA	NA	NA	NA	1.16	0.55	2.35	11.63	-70.68	71.56	VERY LOW	1.16	0.55	2.35	11.63	-70.68	71.56	VERY LOW	RoB, Imprecisionx2
colchicine	corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	1.16	0.8	1.55	15.05	-17.29	45.18	LOW	1.16	0.8	1.55	15.05	-17.29	45.18	LOW	RoB, Imprecision
colchicine	IL6 receptor antagonists with corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	1.16	0.77	1.51	14.31	-20.67	44.05	LOW	1.16	0.77	1.51	14.31	-20.67	44.05	LOW	RoB, Imprecision
colchicine	doxycycline	NA	NA	NA	NA	NA	NA	NA	0.26	0.03	1.43	-251.9	-678.13	26.83	VERY LOW	0.26	0.03	1.43	-251.9	-678.13	26.83	VERY LOW	RoB, Imprecisionx3
colchicine	doxycycline, ivermectin	NA	NA	NA	NA	NA	NA	NA	3.89E+18	5.72E+04	3.95E+32	116.73	68.59	146.61	VERY LOW	3.89E+18	5.72E+04	3.95E+32	116.73	68.59	146.61	VERY LOW	RoB, Imprecisionx3
colchicine colchicine	electrolyzed saline emtricitabine, tenofovir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	5.17 1.22	1.14 0.59	39.36 2.45	90.64	18.35 -65.98	132.42 75.97	VERY LOW VERY LOW	5.17 1.22	1.14 0.59	39.36 2.45	90.64	18.35 -65.98	132.42 75.97	VERY LOW VERY LOW	RoB, Imprecisionx3 RoB, Imprecisionx2
colchicine	emtricitabine, tenotovir favipiravir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.7	0.59	1.39	16.33 -42.45	-65.98 -154.91	75.97 39.14	VERY LOW	0.7	0.59	1.39	-42.45	-65.98 -154.91	75.97 39.14	VERY LOW	RoB, Imprecisionx2
colchicine	favipiravir. hydrochloroguine	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.7	0.33	2.28	-42.45	-128.14	68.99	VERY LOW	0.7	0.33	2.28	-42.45	-128.14	68.99	VERY LOW VERY LOW	RoB, Imprecisionx2
colchicine	fluvoxamine	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.34	0.64	2.85	25.12	-49.93	79.83	VERY LOW	1.34	0.64	2.85	25.12	-49.93	79.83	VERY LOW	RoB, Imprecisionx2
colchicine	full-dose anticoagulant	NA NA	NA NA	NA	NA	NA	NA	NA	0.96	0.66	1.3	-3.76	-40	29.4	LOW	0.96	0.66	1.3	-3.76	-40	29.4	LOW	RoB, Imprecision
colchicine	GM-CSF inhibitor	NA	NA	NA	NA	NA	NA	NA	1.19	0.75	1.77	17.65	-24.69	55.37	VERY LOW	1.19	0.75	1.77	17.65	-24.69	55.37	VERY LOW	RoB, Imprecisionx2
colchicine	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	0.85	0.58	1.12	-18.66	-54.49	13.45	VERY LOW	0.85	0.58	1.12	-18.66	-54.49	13.45	VERY LOW	RoB, Imprecisionx2
colchicine	IL1 inhibitors	NA	NA	NA	NA	NA	NA	NA	1.23	0.71	2.03	20.1	-34.79	64.5	VERY LOW	1.23	0.71	2.03	20.1	-34.79	64.5	VERY LOW	RoB, Imprecisionx2
colchicine	IL6 receptor antagonists without corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	0.84	0.57	1.13	-19	-56.78	14.21	VERY LOW	0.84	0.57	1.13	-19	-56.78	14.21	VERY LOW	RoB, Imprecisionx2
colchicine	interferon alfa (subcutaneous)	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0 91	0	0.53	-824.03 -10.93	-906.44 -51.38	-228.39 27.27	VERY LOW VERY LOW	0 91	0 0 61	0.53	-824.03 -10.93	-906.44 -51.38	-228.39 27.27	VERY LOW VERY LOW	RoB, Imprecisionx3
colchicine colchicine	interferon beta (subcutaneous) interferon beta (subcutaneous), lopinavir-ritonavir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.91	0.61	0.82	-10.93 -118.75	-51.38 -234.92	-24	VERY LOW VERY LOW	0.91	0.61	1.29 0.82	-10.93 -118.75	-51.38 -234.92	-24	VERY LOW	RoB, Imprecisionx2 RoB, Imprecisionx2
colchicine	interreron beta (subcutaneous), lopinavir-ritonavir intermediate-dose anticoagulant	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.45	0.23	1.33	-118.75	-234.92 -97.1	28.32	VERY LOW VERY LOW	0.45	0.23	1.33	-118.75	-234.92 -97.1	28.32	VERY LOW VERY LOW	RoB, Imprecisionx2
colchicine	intranasal corticosteroids	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	2.94E+06	0.03	1.67E+13	107.86	24.46	147.05	VERY LOW	2.94E+06	0.03	1.67E+13	107.86	24.46	147.05	VERY LOW	RoB, Imprecisionx3
colchicine	ivermectin	NA NA	NA NA	NA	NA	NA	NA NA	NA	1.45	0.79	2.56	32.49	-22.36	78.11	VERY LOW	1.45	0.79	2.56	32.49	-22.36	78.11	VERY LOW	RoB, Imprecisionx2
colchicine	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	1.47	0.94	2.12	35.54	-2.22	68.8	VERY LOW	1.47	0.94	2.12	35.54	-2.22	68.8	VERY LOW	RoB, Imprecisionx2
colchicine	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.87	0.58	1.16	-15.34	-53.63	17.27	VERY LOW	0.87	0.58	1.16	-15.34	-53.63	17.27	VERY LOW	RoB, Imprecisionx2
colchicine	melatonin	NA	NA	NA	NA	NA	NA	NA	21.63	3.11	430.45	110.97	69.66	141.56	VERY LOW	21.63	3.11	430.45	110.97	69.66	141.56	VERY LOW	RoB, Imprecisionx3

Part										Mortality	/													
March Marc	Comparison)							9													
## STATE OF				te				100 000	Final rating		011 11 11			u , , , , , ,		Final rating						100 000	Final rating	Reasons for
Miles									N/A							VERVIOW							VERVIOW	
## ALTERNAL STATES 19		,																						
STATE PRINCE PR			_				_			_				+			+	+			+			
March Color Colo	colchicine	omega 3	NA	NA	NA	NA	NA	NA	NA	8.15	1.57	68.84	99.57	39.15	136.19	VERY LOW	8.15	1.57	68.84	99.57	39.15	136.19	VERY LOW	RoB, Imprecisionx3
March Trackers No 10 10 10 10 10 10 10 1	colchicine	nirmatrelvir/ritonavir	NA	NA	NA	NA	NA	NA	NA	2.51E+09	84.76	8.03E+19	121.04	89.18	147.36	VERY LOW	2.51E+09	84.76	8.03E+19	121.04	89.18	147.36	VERY LOW	RoB, Imprecisionx3
Section Property																								
March Marc			101		1471		1401		1471		4.14	.=				VEITI LOW		7.17						
## 15 PATE 15																								
March 1979 Act 1979 Act 1970 A		1 111																						
Column		·	_				_										+			-				
Column	colchicine	statins	NA	NA	NA	NA	NA	NA	NA	0.68	0.23	2.02	-52.6	-229.92	62.76	VERY LOW	0.68	0.23	2.02	-52.6	-229.92	62.76	VERY LOW	
March Marc		sulodexide																						
Column C		·			101				1401							VEITH EOW				01.71			TEITH EOTH	
		y																						
Column C																								
Control of the Cont		* * *																						
Control Cont		**	_							1.00												0.100		
Column C																								. , ,
Column C		IL6 receptor antagonists with corticosteroids (systemic)																		_				
Property and Pro		, ,									0.02											10.00		
## CHINGS EMPINE CONTROL CONTR		,.,																						
Page																								
March Marc																								
Control Cont			101	101	1471		1401		1471	0.40				100.00	10.10	VEICE COTT			1.10	02.01	100.00	10.70	TEITH EOTH	
Column C	colchicine, emtricitabine, tenofovir, statins	fluvoxamine	NA	NA	NA	NA	NA	NA	NA	0.82	0.31	2.27			65.47	VERY LOW	0.82	0.31	2.27	-15.04		65.47	VERY LOW	RoB, Imprecisionx2
Application processed by Proposed Service Application Applicatio	colchicine, emtricitabine, tenofovir, statins	full-dose anticoagulant	NA	NA	NA	NA	NA	NA	NA	0.59	0.28	1.22	-43.92	-91.55	23.01	VERY LOW	0.59	0.28	1.22	-43.92	-91.55	23.01	VERY LOW	RoB, Imprecisionx2
Section Control of the control o	colchicine, emtricitabine, tenofovir, statins	GM-CSF inhibitor									0.00													
Control of Control o		() -) /								0.02														. , ,
Control Cont																								
Control of Principles Cont																								
Control Cont										0.56														. , ,
George controllers webbox on principation which can principative whether can't control controllers whether can't control controllers whether can't control controllers whether can't control controllers whether can't controlle			NA			NA	NA	NA																
Configure membrane banders and product of the configuration would not be configurated by the configuration would not be configurated by the configuration would not be configurated by the configuration of the configuration would not be configurated by the configuration of the configuration would not be configurated by the configuration of the configuration would not be configurated by the configuration of the configuration would not be configurated by the configuration of the configuration would not be configurated by the configuration of the configuration would not be configurated by the configuration of the configuration would not be configurated by the configuration of the configuration would not be configurated by the configuration of the configuration would not be configurated by the configuration of the config	colchicine, emtricitabine, tenofovir, statins		NA	NA	NA	NA	NA	NA	NA	0.49	0.21	1.14	-67.64	-145.5	13.04	VERY LOW	0.49	0.21	1.14	-67.64	-145.5	13.04	VERY LOW	
Continue, membrass between tendres and the properties between tendres and the proper																								
Conference membrane brokene central September (1997) September (+						
Confirme membrane transfer and membrane tr																						000		
Confirme membrane based MA MA MA MA MA MA MA M		Topological Control Co																						
Sections		****																				_		
Column C		·	NA	NA	NA	NA	NA	NA	NA	9.06	1.21		66.93	11.24	134.04	VERY LOW	9.06		166.11	66.93	11.24	134.04	VERY LOW	
Column emission in the control of		nitazoxanide																						
Continue mentionales in mentionale										4												.==		
Continue mention in the information production and parameters are continued in the information parameters and in the information parameters		****																						. , ,
Continue, emricialment fundum granutory colorisms, emricialment fundum granu		·	_		-										00.11									
Controller, emfoliable, remotive, staffer MA NA		pre-training	10.0																					,
Continues, entrolations, tendering states SQLT2 inhibitors SQLT2			NA			NA	NA	NA																. , ,
Codicinier, embridables, ferefore, statistics NA	colchicine, emtricitabine, tenofovir, statins	serine protease inhibitors					NA	NA	NA	0.83	0.25	2.93	-17.79					0.25		-17.79		73.03		RoB, Imprecisionx2
Cocicitine, enthickable, tendor, staffins Sudoexide NA																								
Cochicine, emiricialishe, Immorrier, statistis Symthetic VP NA		****	_							_														
Cochicine, emtricitative, texture, without the control of the co																								
Colchicine, entricitables, tendrow; statins		·	101	101	101		100	101		0.40	0.10	1.00	11.01	100.11	20.00	VEITI LOW		0.10	1.00	71.07	100.44	20.00	VEIG LOW	
Colchicine, matricitabine, tendovir, statins Vitamin D		y																						
Cochicine, statins Cochic	colchicine, emtricitabine, tenofovir, statins	vitamin C	NA	NA			NA	NA	NA	0.88	0.33	2.48		-93.79	69.57	VERY LOW		0.33		-10.17	-93.79	69.57	VERY LOW	RoB, Imprecisionx2
colchicine, statins Il.6 receptor antagonists with corticosteroids (systemic) NA NA NA NA NA NA NA NA NA N																								. , ,
Colchicine, statins																								. , ,
Colchicine, statins doxycycline, Ivermectin NA			_																					
Colchicine, statins electrolyzed saline NA																								
emtricitabine, tenofovir colchicine, statins colchicine, sta		,.,																						
Cotchicine, statins Favipiravir NA																								
Colchicine, statins fluvoxamine NA	colchicine, statins	favipiravir		NA	NA	NA	NA	NA	NA	0.6	0.24	1.54	-54.09	-174.43	52.52	VERY LOW	0.6	0.24	1.54	-54.09	-174.43	52.52	VERY LOW	RoB, Imprecisionx2
colchicine, statins full-dose anticoagulant NA NA <td></td> <td>10.7.0.0, 1,7.0.0.0, 1,0.0.0</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>0.02</td> <td></td>		10.7.0.0, 1,7.0.0.0, 1,0.0.0								0.02														
colchicine, statins GM-CSF inhibitor NA																								
colchicine, statins (hydroxy)chloroquine NA	-																				12.00			
colichicine, statilins IL1 Inhibitors NA																								
colchicine, statins IL6 receptor antagonists without corticosteroids (systemic) NA		(7: - 27:					_																	. , ,
		****	_																					
	colchicine, statins	interferon alfa (subcutaneous)	NA		NA	NA	NA	NA	NA	0		0.46				VERY LOW	0	0	0.46	-835.66		-246.24	VERY LOW	RoB, Imprecisionx3

									Mortality														
Comparison		Direct estimate			Ab 1. 4 1/	-1- (1.000)			Indirect estimat	9		A h h - h	- (4.000)			Network estimate			Ab t	-1- (1 000)			
Treatment 1	Treatment 2	Relative estimate	CI lower limit	Cl upper limit	Absolute estimate	CI lower limit	Cl upper limit	Final rating	Relative estimate Point estimate	CI lower limit	CI upper limit	Absolute estima Point estimate	CI lower limit	Cl upper limit	Final rating	Relative estimate	CI lower limit	Cl upper limit	Absolute estimate		Cl upper limit	Final rating	Reasons for downgrading
colchicine, statins	interferon beta (subcutaneous)	NA NA	NA NA	NA NA	NA	NA NA	NA NA	NA	0.78	0.38	1.59	-22.56	-84.53	59.45	VERY LOW	0.78	0.38	1.59	-22.56	-84.53	59.45	VERY LOW	RoB, Imprecisionx2
colchicine, statins	interferon beta (subcutaneous), lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.38	0.16	0.9	-130.38	-255.55	-13.68	VERY LOW	0.38	0.16	0.9	-130.38	-255.55	-13.68	VERY LOW	RoB, Imprecisionx2
colchicine, statins	intermediate-dose anticoagulant	NA	NA	NA	NA	NA	NA	NA	0.68	0.31	1.54	-39.11	-123.25	52.16	VERY LOW	0.68	0.31	1.54	-39.11	-123.25	52.16	VERY LOW	RoB, Imprecisionx2
colchicine, statins	intranasal corticosteroids	NA	NA	NA	NA	NA	NA	NA	2.53E+06	0.02	1.48E+13	96.23	16.19	184.31	VERY LOW	2.53E+06	0.02	1.48E+13	96.23	16.19	184.31	VERY LOW	RoB, Imprecisionx3
colchicine, statins	ivermectin	NA	NA	NA	NA	NA	NA	NA	1.25	0.54	2.86	20.85	-50.9	105.57	VERY LOW	1.25	0.54	2.86	20.85	-50.9	105.57	VERY LOW	RoB, Imprecisionx2
colchicine, statins colchicine, statins	JAK inhibitors lopinavir-ritonavir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.26	0.61	2.57	23.91 -26.97	-34.06 -84.37	101.78 50.65	VERY LOW VERY LOW	1.26 0.75	0.61	2.57	23.91 -26.97	-34.06 -84.37	101.78	VERY LOW VERY LOW	RoB, Imprecisionx2
colchicine, statins	nopinavir-ritoriavir melatonin	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	18.81	2.49	403.89	99.34	40.31	177.39	VERY LOW	18.81	2.49	403.89	99.34	40.31	177.39	VERY LOW VERY LOW	RoB, Imprecisionx2 RoB, Imprecisionx3
colchicine, statins	methylene blue	NA	NA	NA	NA	NA	NA	NA	1.58	0.63	4.03	37.41	-38.47	122.3	VERY LOW	1.58	0.63	4.03	37.41	-38.47	122.3	VERY LOW	RoB, Imprecisionx2
colchicine, statins	molnupiravir	NA	NA	NA	NA	NA	NA	NA	12.59	1.71	234.73	95.46	30.16	174.5	VERY LOW	12.59	1.71	234.73	95.46	30.16	174.5	VERY LOW	RoB, Imprecisionx3
colchicine, statins	nitazoxanide	NA	NA	NA	NA	NA	NA	NA	1.47	0.32	6.31	20.05	-136.57	127.6	VERY LOW	1.47	0.32	6.31	20.05	-136.57	127.6	VERY LOW	RoB, Imprecisionx2
colchicine, statins	omega 3	NA	NA	NA	NA	NA	NA	NA	7.18	1.18	65.17	87.93	19.1	169.92	VERY LOW	7.18	1.18	65.17	87.93	19.1	169.92	VERY LOW	RoB, Imprecisionx3
colchicine, statins	nirmatrelvir/ritonavir	NA	NA NA	NA NA	NA NA	NA	NA	NA NA	2.22E+09	79.28	7.50E+19	109.41	56.89	185.15 105.8	VERY LOW	2.22E+09	79.28	7.50E+19	109.41	56.89	185.15 105.8	VERY LOW	RoB, Imprecisionx3
colchicine, statins	probiotics proxalutamide	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.82 6.41	0.15 2.81	4.35 14.36	-45.37 91.3	-316.77 38.23	105.8	VERY LOW VERY LOW	0.82 6.41	0.15 2.81	4.35 14.36	-45.37 91.3	-316.77 38.23	105.8	VERY LOW VERY LOW	RoB, Imprecisionx2
colchicine, statins	recombinant human granulocyte colony-stimulating factor	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	4 19	1.03	23.24	77.65	3.02	162.04	VERY LOW VERY LOW	4 19	1.03	23.24	77.65	38.23	167.38	VERYLOW	RoB, Imprecisionx2
colchicine, statins	remdesivir	NA NA	NA.	NA NA	NA NA	NA NA	NA NA	NA.	0.87	0.44	1.74	-9.6	-67.41	68.64	VERY LOW	0.87	0.44	1.74	-9.6	-67.41	68.64	VERY LOW	RoB, Imprecisionx2
colchicine, statins	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	1.17	0.35	4.12	10.74	-116.01	112.3	VERY LOW	1.17	0.35	4.12	10.74	-116.01	112.3	VERY LOW	RoB, Imprecisionx2
colchicine, statins	SGLT2 inhibitors	NA	NA	NA	NA	NA	NA	NA	1.07	0.47	2.41	7.97	-65.57	93.16	VERY LOW	1.07	0.47	2.41	7.97	-65.57	93.16	VERY LOW	RoB, Imprecisionx2
colchicine, statins	statins	NA	NA	NA	NA	NA	NA	NA	0.59	0.17	2.06	-64.23	-247.73	72.22	VERY LOW	0.59	0.17	2.06	-64.23	-247.73	72.22	VERY LOW	RoB, Imprecisionx2
colchicine, statins	sulodexide	NA	NA	NA	NA	NA	NA	NA	2.01	0.46	10.75	45.16	-79.72	143.18	VERY LOW	2.01	0.46	10.75	45.16	-79.72	143.18	VERY LOW	RoB, Imprecisionx2
colchicine, statins	synthetic VIP	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA	0.68	0.26	1.79	-43.34	-163.44	62.63	VERY LOW	0.68	0.26	1.79	-43.34	-163.44	62.63	VERY LOW	RoB, Imprecisionx2
colchicine, statins	tyrosine kinase inhibitors umifenovir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.87	0.71	4.9 3.08	47.39 10	-23.94 -88.77	131.55 103.89	VERY LOW VERY LOW	1.87	0.71	4.9 3.08	47.39 10	-23.94 -88.77	131.55 103.89	VERY LOW VERY LOW	RoB, Imprecisionx2
colchicine, statins colchicine, statins	vitamin C	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.13	0.44	3.08	18.36	-88.77	103.89	VERY LOW VERY LOW	1.13	0.44	3.08	18.36	-88.77	103.89	VERY LOW VERY LOW	RoB, Imprecisionx2 RoB, Imprecisionx2
colchicine, statins	vitamin D	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.36	0.46	3.54	21.87	-68.32	112.42	VERY LOW	1.36	0.46	3.54	21.87	-68.32	112.42	VERY LOW	RoB, Imprecisionx2
corticosteroids (systemic)	IL6 receptor antagonists with corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	1	0.77	1.25	-0.74	-24.33	20.9	LOW	1	0.77	1.25	-0.74	-24.33	20.9	LOW	RoB, Imprecision
corticosteroids (systemic)	doxycycline	NA	NA	NA	NA	NA	NA	NA	0.22	0.03	1.23	-266.95	-692.47	10.11	VERY LOW	0.22	0.03	1.23	-266.95	-692.47	10.11	VERY LOW	RoB, Imprecisionx3
corticosteroids (systemic)	doxycycline, ivermectin	NA	NA	NA	NA	NA	NA	NA	3.30E+18	5.00E+04	3.41E+32	101.68	57.71	122.28	VERY LOW	3.30E+18	5.00E+04	3.41E+32	101.68	57.71	122.28	VERY LOW	RoB, Imprecisionx3
corticosteroids (systemic)	electrolyzed saline	NA	NA	NA	NA	NA	NA	NA	4.53	1.01	34.3	75.59	4.92	110.23	VERY LOW	4.53	1.01	34.3	75.59	4.92	110.23	VERY LOW	RoB, Imprecisionx3
corticosteroids (systemic)	emtricitabine, tenofovir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.07 0.61	0.54	2.09	1.28 -57.5	-77.55 -167.09	56.94 19.35	VERY LOW VERY LOW	1.07 0.61	0.54	2.09	1.28 -57.5	-77.55 -167.09	56.94 19.35	VERY LOW VERY LOW	RoB, Imprecisionx2
corticosteroids (systemic) corticosteroids (systemic)	favipiravir favipiravir, hydrochloroquine	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.61	0.3	1.19	-57.5 -25.56	-167.09	19.35 50.16	VERY LOW	0.61	0.3	1.19	-57.5 -25.56	-167.09	19.35 50.16	VERY LOW	RoB, Imprecisionx2 RoB, Imprecisionx2
corticosteroids (systemic)	fluvoxamine	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA.	1.16	0.58	2.44	10.07	-61.02	60.35	VERY LOW	1.16	0.58	2.44	10.07	-61.02	60.35	VERY LOW	RoB, Imprecisionx2
corticosteroids (systemic)	full-dose anticoagulant	NA	NA	NA	NA	NA	NA	NA	0.83	0.63	1.09	-18.81	-46.33	7.86	LOW	0.83	0.63	1.09	-18.81	-46.33	7.86	LOW	RoB, Imprecision
corticosteroids (systemic)	GM-CSF inhibitor	NA	NA	NA	NA	NA	NA	NA	1.03	0.71	1.5	2.6	-33.1	34.47	LOW	1.03	0.71	1.5	2.6	-33.1	34.47	LOW	RoB, Imprecision
corticosteroids (systemic)	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	0.74	0.57	0.93	-33.71	-60.09	-8.69	MODERATE	0.74	0.57	0.93	-33.71	-60.09	-8.69	MODERATE	RoB
corticosteroids (systemic)	IL1 inhibitors	NA	NA	NA	NA	NA	NA	NA	1.07	0.66	1.71	5.06	-43.93	44.2	LOW	1.07	0.66	1.71	5.06	-43.93	44.2	LOW	RoB, Imprecision
corticosteroids (systemic)	IL6 receptor antagonists without corticosteroids (systemic)	0.35	0.09 NA	1.34 NA	NA NA	NA NA	NA NA	VERY LOW NA	0.8	0.61	1.03	-839.08	NA -909	NA -244 41	HIGH VERY LOW	0.73	0.56	0.93	-34.05 -839.08	-62.67 -909	-7.62 -244.41	MODERATE VERY LOW	RoB
corticosteroids (systemic) corticosteroids (systemic)	interferon alfa (subcutaneous)	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.79	0.58	0.46	-839.08 -25.97	-909	-244.41 7.29	VERY LOW	0.79	0.58	0.46	-839.08 -25.97	-909 -60.27	7.29	VERY LOW	RoB, Imprecisionx3 RoB, Imprecisionx2
corticosteroids (systemic)	interferon beta (subcutaneous), lopinavir-ritonavir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.79	0.36	0.7	-133.8	-247.22	-42	VERY LOW	0.79	0.36	0.7	-133.8	-247.22	-42	VERY LOW	RoB, Imprecisionx2
corticosteroids (systemic)	intermediate-dose anticoagulant	NA	NA	NA	NA	NA	NA	NA	0.69	0.42	1.13	-42.53	-108.54	10.83	VERY LOW	0.69	0.42	1.13	-42.53	-108.54	10.83	VERY LOW	RoB, Imprecisionx2
corticosteroids (systemic)	intranasal corticosteroids	NA	NA	NA	NA	NA	NA	NA	2.52E+06	0.02	1.46E+13	92.81	9.88	122.79	VERY LOW	2.52E+06	0.02	1.46E+13	92.81	9.88	122.79	VERY LOW	RoB, Imprecisionx3
corticosteroids (systemic)	ivermectin	NA	NA	NA	NA	NA	NA	NA	1.26	0.74	2.19	17.44	-33.01	57.45	VERY LOW	1.26	0.74	2.19	17.44	-33.01	57.45	VERY LOW	RoB, Imprecisionx2
corticosteroids (systemic)	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	1.27	0.9	1.77	20.49	-8.68	46.89	LOW	1.27	0.9	1.77	20.49	-8.68	46.89	LOW	RoB, Imprecision
corticosteroids (systemic)	lopinavir-ritonavir	NA	NA	NA	NA NA	NA	NA	NA	0.75 18.87	0.57	0.96	-30.39	-58.73	-4.88 117.76	MODERATE	0.75 18.87	0.57	0.96 374 68	-30.39	-58.73	-4.88 117.76	MODERATE	RoB
corticosteroids (systemic)	melatonin methylene blue	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	18.87	2.75	374.68 3.18	95.92 34	62.21 -20.91	74.2	VERY LOW VERY LOW	18.87	2.75 0.81	374.68	95.92 34	62.21 -20.91	74.2	VERY LOW VERY LOW	RoB, Imprecisionx3
corticosteroids (systemic)	molnupiravir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	12.61	1.96	220.46	92.04	51.2	116.57	VERY LOW	12.61	1.96	220.46	92.04	51.2	116.57	VERY LOW	RoB, Imprecisionx3
corticosteroids (systemic)	nitazoxanide	NA NA	NA NA	NA NA	NA.	NA NA	NA NA	NA	1.47	0.38	5.61	16.63	-133.68	91.27	VERY LOW	1.47	0.38	5.61	16.63	-133.68	91.27	VERY LOW	RoB, Imprecisionx2
corticosteroids (systemic)	omega 3	NA	NA	NA	NA	NA	NA	NA	7.12	1.4	59.23	84.52	29.58	113.15	VERY LOW	7.12	1.4	59.23	84.52	29.58	113.15	VERY LOW	RoB, Imprecisionx3
corticosteroids (systemic)	nirmatrelvir/ritonavir	NA	NA	NA	NA	NA	NA	NA	2.25E+09	75.76	6.94E+19	105.99	87.59	122.91	VERY LOW	2.25E+09	75.76	6.94E+19	105.99	87.59	122.91	VERY LOW	RoB, Imprecisionx3
corticosteroids (systemic)	probiotics	NA	NA	NA	NA	NA	NA	NA	0.82	0.17	3.89	-48.79	-316.9	76.13	VERY LOW	0.82	0.17	3.89	-48.79	-316.9	76.13	VERY LOW	RoB, Imprecisionx2
corticosteroids (systemic)	proxalutamide	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	6.45	3.85	10.71 20.9	87.89 74.23	68.3 17.9	105.98	MODERATE	6.45 4.22	3.85 1.21	10.71	87.89 74.23	68.3 17.9	105.98	MODERATE	RoB RoB Improviolanu2
corticosteroids (systemic) corticosteroids (systemic)	recombinant human granulocyte colony-stimulating factor	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.88	0.66	20.9	74.23 -13.01	17.9 -40.61	107.38	LOW LOW	4.22 0.88	0.66	20.9	74.23 -13.01	17.9 -40.61	107.38	I OW	RoB, Imprecisionx2 RoB, Imprecision
corticosteroids (systemic)	serine protease inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.19	0.42	3.43	7.32	-109.13	74.53	VERY LOW	1.19	0.00	3.43	7.32	-109.13	74.53	VERY LOW	RoB, Imprecisionx2
corticosteroids (systemic)	SGLT2 inhibitors	NA NA	NA NA	NA NA	NA	NA NA	NA NA	NA	1.08	0.63	1.81	4.56	-49.16	46.35	LOW	1.08	0.63	1.81	4.56	-49.16	46.35	LOW	RoB, Imprecision
corticosteroids (systemic)	statins	NA	NA	NA	NA	NA	NA	NA	0.59	0.21	1.74	-67.65	-243.65	44.71	VERY LOW	0.59	0.21	1.74	-67.65	-243.65	44.71	VERY LOW	RoB, Imprecisionx2
corticosteroids (systemic)	sulodexide	NA	NA	NA	NA	NA	NA	NA	2.01	0.54	9.92	41.75	-72.4	98.78	VERY LOW	2.01	0.54	9.92	41.75	-72.4	98.78	VERY LOW	RoB, Imprecisionx2
corticosteroids (systemic)	synthetic VIP	NA	NA	NA	NA	NA	NA	NA	0.69	0.32	1.42	-46.76	-156.26	28.85	VERY LOW	0.69	0.32	1.42	-46.76	-156.26	28.85	VERY LOW	RoB, Imprecisionx2
corticosteroids (systemic)	tyrosine kinase inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.88	0.93	3.87	43.97 6.58	-7.57 -77.71	80.93	VERY LOW	1.88	0.93	3.87	43.97	-7.57 77.71	80.93	VERY LOW	RoB, Imprecisionx2
corticosteroids (systemic) corticosteroids (systemic)	umifenovir vitamin C	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.15	0.55 0.62	2.4	6.58 14.94	-77.71 -55.86	62.75 64.82	VERY LOW VERY LOW	1.15 1.25	0.55 0.62	2.4	6.58 14.94	-77.71 -55.86	62.75 64.82	VERY LOW VERY LOW	RoB, Imprecisionx2 RoB, Imprecisionx2
corticosteroids (systemic)	vitamin D	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.25	0.65	2.85	18.45	-51.98	68.53	VERY LOW VERY LOW	1.25	0.65	2.85	18.45	-55.86	68.53	VERY LOW VERY LOW	RoB, Imprecisionx2
IL6 receptor antagonists with corticosteroids (systemic)	doxycycline	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.23	0.03	1.23	-266.22	-693.73	11.42	VERY LOW	0.23	0.03	1.23	-266.22	-693.73	11.42	VERY LOW	RoB, Imprecisionx3
IL6 receptor antagonists with corticosteroids (systemic)	doxycycline, ivermectin	NA NA	NA NA	NA NA	NA	NA NA	NA NA	NA	3.42E+18	5.06E+04	3.57E+32	102.42	59.04	122.41	VERY LOW	3.42E+18	5.06E+04	3.57E+32	102.42	59.04	122.41	VERY LOW	RoB, Imprecisionx3
IL6 receptor antagonists with corticosteroids (systemic)	electrolyzed saline	NA	NA	NA	NA	NA	NA	NA	4.55	1.03	34.51	76.32	6.21	110.82	VERY LOW	4.55	1.03	34.51	76.32	6.21	110.82	VERY LOW	RoB, Imprecisionx3
IL6 receptor antagonists with corticosteroids (systemic)	emtricitabine, tenofovir	NA	NA	NA	NA	NA	NA	NA	1.08	0.55	2.1	2.02	-76.19	57.09	VERY LOW	1.08	0.55	2.1	2.02	-76.19	57.09	VERY LOW	RoB, Imprecisionx2
IL6 receptor antagonists with corticosteroids (systemic)	favipiravir	NA	NA	NA	NA	NA	NA	NA	0.62	0.3	1.21	-56.77	-164.17	19.57	VERY LOW	0.62	0.3	1.21	-56.77	-164.17	19.57	VERY LOW	RoB, Imprecisionx2
IL6 receptor antagonists with corticosteroids (systemic)	favipiravir, hydrochloroquine	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.83	0.36	1.95	-24.83 10.81	-139.46 -59.48	50.75	VERY LOW VERY LOW	0.83	0.36	1.95 2.46	-24.83 10.81	-139.46 -59.48	50.75 60.58	VERY LOW VERY LOW	RoB, Imprecisionx2
IL6 receptor antagonists with corticosteroids (systemic) IL6 receptor antagonists with corticosteroids (systemic)	fluvoxamine full-dose anticoagulant	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.84	0.59	2.46	10.81 -18.08	-59.48 -44.37	60.58 9.3	LOW	1.17 0.84	0.59	2.46	10.81 -18.08	-59.48 -44.37	9.3	LOW	RoB, Imprecisionx2 RoB, Imprecision
IL6 receptor antagonists with corticosteroids (systemic) IL6 receptor antagonists with corticosteroids (systemic)	GM-CSF inhibitor	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.04	0.00	1.53	3.33	-44.37	35.88	LOW	1.04	0.05	1.53	3.33	-44.37	35.88	LOW	RoB, Imprecision
120 1000 ptor amagorists with controlleroids (systemic)	GW-GGI IIIIIbildi	180	INC	140	140	110	130	110	1.04	0.75	1.55	3.33	-01.04	33.00	LOV	1.04	0.75	1.55	3.33	-51.04	35.00	LOTT	. vob, impreciatori

Margin Program Company (New Yorks) Margin Program Company (New Yorks) No. 10. 10. 10. 10. 10. 10. 10. 10. 10. 10										Mortalit	у													
March Marc	Comparison									Indirect estimat	te						Network estimate	е						
Control of Assertion Asser				e					Final rating	Relative estimate	e			4 , , , , ,		Final rating	Relative estima	te	100 000			T av	Final rating	Reasons for
Control of the second of the									NA.			о порран поли				MODERATE							MODERATE	downgrading
Margan part		()													_									RoB, Imprecision
Control Cont			-											+	-			+				-	+	RoB
			NA	NA	NA	NA	NA	NA	NA	0	0	0.47	-838.34	-905.36	-244.53	VERY LOW	0	0	0.47	-838.34	-905.36	-244.53	VERY LOW	RoB, Imprecisionx3
Control of Control o		,																						RoB, Imprecisionx2
Contemporary Present Information No.																								RoB, Imprecisionx2
Trigger of the Authors (1996) Trigger of the Authors (1996			101		167		1451			0.7		1.17		101.11						41.70	101.11		VEITH EOTH	RoB, Imprecisionx2
The content of the		*** *** *** ***																						RoB, Imprecisionx3 RoB, Imprecisionx2
Language (Control of Section 1999) Control o		1 111																	_					RoB, Imprecision
Section of Section Sec		1 1111	1						-															RoB
Section Sect		·	NA	NA	NA	NA	NA	NA	NA	19.11	2.81	382.99	96.66	61.78	118.1	VERY LOW	19.11	2.81	382.99	96.66	61.78	118.1	VERY LOW	RoB, Imprecisionx3
Control of the cont		methylene blue																						RoB, Imprecisionx2
Control Cont			161			1471	1401																	RoB, Imprecisionx3
Control processes of the control processes o	,																							RoB, Imprecisionx2
Secretary and Company and Co	,	1 101																						RoB, Imprecisionx3
Security of the content of the con		****																						RoB, Imprecisionx3 RoB, Imprecisionx2
Control of the cont																					0.0.00			RoB RoB
Section Control of Control Control of Control of Control Control of Control of Control of Control Control of Control of Control of Control Control of Contr		F																						RoB, Imprecisionx2
A conting and processes against a conting against a contin									-			_		-										RoB, Imprecision
March Marc		Tomas protection and the second																						RoB, Imprecisionx2
Marines presented interference property Marines Ma																								RoB, Imprecision
Marrier Supplement Marrier																								RoB, Imprecisionx2 RoB, Imprecisionx2
Manager Segress and configures opposed: Segress and configures opposed																								RoB, Imprecisionx2 RoB, Imprecisionx2
March Marc			161		167	1471		1471	1401	0.1						VEICE COTT	0.1		1.40	40.00	104.00		VEITH EOTH	RoB, Imprecisionx2
March Marc		umifenovir	NA	NA	NA	NA	NA	NA	NA	1.16	0.56	2.44	7.31	-77.91	63.97	VERY LOW	1.16		2.44	7.31			VERY LOW	RoB, Imprecisionx2
Margetine Margetine currents MA	IL6 receptor antagonists with corticosteroids (systemic)	vitamin C	NA	NA	NA	NA	NA	NA	NA	1.26	0.63	2.65	15.68	-54.74	64.79	VERY LOW	1.26	0.63	2.65	15.68	-54.74	64.79	VERY LOW	RoB, Imprecisionx2
Marcy Marc	IL6 receptor antagonists with corticosteroids (systemic)	vitamin D																						RoB, Imprecisionx2
Marcellane Mar	3-3																							RoB, Imprecisionx3
Processor Proc																							· -	RoB, Imprecisionx3 RoB, Imprecisionx3
Congress																								RoB, Imprecisionx3
Source	,.,.																							RoB, Imprecisionx3
Conception Con			NA	NA	NA	NA	NA	NA																RoB, Imprecisionx3
Composition	doxycycline	full-dose anticoagulant	NA	NA	NA	NA	NA	NA	NA	3.71	0.68	27.4	248.14	-29.35	673.74	VERY LOW	3.71	0.68	27.4	248.14	-29.35	673.74	VERY LOW	RoB, Imprecisionx3
Separation St. Intelligent Mark								1471																RoB, Imprecisionx3
Selection Marked																	_							RoB, Imprecisionx3
Description Inferior and publications NA								101													1101			RoB, Imprecisionx3 RoB, Imprecisionx3
description miles from the Standardenson, Stand										+							3.25							RoB, Imprecisionx3
March Inferior on the Ignoclament composing proper of the processing of the proc	.,									_	_						3.51							RoB, Imprecisionx3
A		1	NA	NA	NA	NA	NA	NA	NA		0.29		133.15	-175.91	565.85	VERY LOW	1.73	0.29	13.7	133.15	-175.91	565.85	VERY LOW	RoB, Imprecisionx3
Compyrights	doxycycline																							RoB, Imprecisionx3
Description MA NA NA NA NA NA NA NA																								RoB, Imprecisionx3
Best																								RoB, Imprecisionx3
Secondary Seco		1 1111									-													RoB, Imprecisionx3
Compositive														1=101							12.01			RoB, Imprecisionx3
Description Consequence			NA	NA	NA	NA		NA								_			,					RoB, Imprecisionx3
May No. May	doxycycline	molnupiravir			NA		NA	NA	NA				358.99	79.19		VERY LOW	60.65		-,	358.99	79.19	785.71		RoB, Imprecisionx3
Decoupling Dec																								RoB, Imprecisionx3
Semportation		·	-						_		-													RoB, Imprecisionx3
doxycycline proxabitamide																								RoB, Imprecisionx3 RoB, Imprecisionx3
doxysycline recombinant human granulocyte colony-stimulating factor NA NA NA NA NA NA NA N		·			101	1471	100	100	10.0	0.7 1	0.01	40.00	£ 10.10	170.00	004.40	TEITH EOIT	0.7 1	0.01	40.00	210.10	170.00	004.40	VEIXI EOVI	RoB, Imprecisionx3
doxycycline																								RoB, Imprecisionx3
doxycycline SGLT2 Inhibitors NA	doxycycline		NA	NA	NA	NA	NA	NA	NA	3.92	0.72	28.94	253.94	-23.16	680.58	VERY LOW	3.92	0.72	28.94	253.94	-23.16	680.58	VERY LOW	RoB, Imprecisionx3
doxycycline	doxycycline	The second process of																						RoB, Imprecisionx3
doxycycline sulodexide NA	doxycycline	SGLT2 inhibitors																						RoB, Imprecisionx3
Mart		*****																						RoB, Imprecisionx3
doxycycline Syrosine kinase inhibitors NA NA NA NA NA NA NA N				+																				RoB, Imprecisionx3
doxycycline umiflenovir NA		7																						RoB, Imprecisionx3
doxycycline vitamin C																								RoB, Imprecisionx3
doxycycline witamin D																								RoB, Imprecisionx3
doxycycline, lvermectin emtricitabine, tendovir NA		vitamin D	NA	NA	NA	NA	NA	NA	NA		1.01	51.65		-0.37	719.78			1.01	51.65	285.41		719.78		RoB, Imprecisionx3
Description										0	0	0					0	0	0					RoB, Imprecisionx3
doxycycline, ivermet/in favipiravir, hydrochloroquine NA		1 1 1 1 1 1 1 1 1																	, ·					RoB, Imprecisionx3
doxycycline, ivermedin fluvoxamine NA NA NA NA NA NA NA NA NA O O O -91.61 -163.27 -33.45 VERY LOW O O O -91.61 -163.27 -33.45 VERY LOW I											-						0		0					RoB, Imprecisionx3
										0	0	0					0	0	0					RoB, Imprecisionx3 Imprecisionx3
110.00 TEXT OF THE PROPERTY OF										0	0	0					0	0	0				-	RoB, Imprecisionx3
doxycycline, ivermectin GM-CSF inhibitor NA											0	0					_	0	0					Imprecisionx3

									Mortality														
Comparison		Direct estimate							Indirect estimate	е		1				Network estimate			1				
Treatment 1	Treatment 2	Relative estimate	CI lower limit	Cl upper limit	Absolute estimate	CI lower limit	Cl upper limit	Final rating	Relative estimate Point estimate	CI lower limit	Cl upper limit	Absolute estimate	e (per 1,000)	Cl upper limit	Final rating	Relative estimate	CI lower limit	Cl upper limit	Absolute estim Point estimate		Cl upper limit	Final rating	Reasons for downgrading
doxycycline, ivermectin	(hydroxy)chloroquine	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA	0	0	0	-135.4	-159.64	-92.82	VERY LOW	0	0	0	-135.4	-159.64	-92.82	VERY LOW	Imprecisionx3
doxycycline, ivermectin	IL1 inhibitors	NA	NA	NA	NA	NA	NA	NA	0	0	0	-96.63	-146.11	-45.62	VERY LOW	0	0	0	-96.63	-146.11	-45.62	VERY LOW	Imprecisionx3
doxycycline, ivermectin	IL6 receptor antagonists without corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	0	0	0	-135.73	-163.44	-91.99	VERY LOW	0	0	0	-135.73	-163.44	-91.99	VERY LOW	Imprecisionx3
doxycycline, ivermectin	interferon alfa (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	0	0	0	-940.76	-1,000.00	-335.1	VERY LOW	0	0	0	-940.76	-1,000.00	-335.1	VERY LOW	RoB, Imprecisionx3
doxycycline, ivermectin	interferon beta (subcutaneous)	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0	0	0	-127.66 -235.48	-162.13 -350.8	-80.41 -135.48	VERY LOW VERY LOW	0	0	0	-127.66 -235.48	-162.13 -350.8	-80.41 -135.48	VERY LOW VERY LOW	RoB, Imprecisionx3
doxycycline, ivermectin doxycycline, ivermectin	interferon beta (subcutaneous), lopinavir-ritonavir intermediate-dose anticoagulant	NA	NA	NA	NA	NΑ	NA NA	NA	0	0	0	-235.46	-350.8 -211.48	-82.75	VERYLOW	0	0	0	-235.48 -144.21	-350.8	-135.48	VERYLOW	RoB, Imprecisionx3 RoB, Imprecisionx3
doxycycline, ivermedin	intranasal corticosteroids	NA NA	NA NA	NA NA	NA	NA NA	NA NA	NA	0	0	6.12E+05	-8.87	-95.2	47.19	VERY LOW	0	0	6.12E+05	-8.87	-95.2	47.19	VERY LOW	Imprecisionx3
doxycycline, ivermectin	ivermectin	NA	NA	NA	NA	NA	NA	NA	0	0	0	-84.25	-135.38	-33.17	VERY LOW	0	0	0	-84.25	-135.38	-33.17	VERY LOW	Imprecisionx3
doxycycline, ivermectin	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	0	0	0	-81.19	-108.44	-35.93	VERY LOW	0	0	0	-81.19	-108.44	-35.93	VERY LOW	Imprecisionx3
doxycycline, ivermectin	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0	0	0	-132.07	-157.94	-86.91	VERY LOW	0	0	0	-132.07	-157.94	-86.91	VERY LOW	RoB, Imprecisionx3
doxycycline, ivermectin	melatonin	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0	0	0	-5.76 -67.68	-39.41 -123.61	35.01 -16.82	VERY LOW	0	0	0	-5.76 -67.68	-39.41 -123.61	35.01 -16.82	VERY LOW VERY LOW	RoB, Imprecisionx3 RoB, Imprecisionx3
doxycycline, ivermectin doxycycline, ivermectin	methylene blue molnupiravir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0	0	0	-9.64	-52 68	36.34	VERYLOW	0	0	0	-9.64	-52.68	36.34	VERYLOW	RoB, Imprecisionx3
doxycycline, ivermectin	nitazoxanide	NA	NA	NA	NA	NA	NA	NA	0	0	0	-85.05	-235.95	-10.08	VERY LOW	0	0	0	-85.05	-235.95	-10.08	VERY LOW	Imprecisionx3
doxycycline, ivermectin	omega 3	NA	NA	NA	NA	NA	NA	NA	0	0	0	-17.16	-73.25	31.12	VERY LOW	0	0	0	-17.16	-73.25	31.12	VERY LOW	RoB, Imprecisionx3
doxycycline, ivermectin	nirmatrelvir/ritonavir	NA	NA	NA	NA	NA	NA	NA	0	0	4.80E+07	4.31	-4.84	47.15	VERY LOW	0	0	4.80E+07	4.31	-4.84	47.15	VERY LOW	Imprecisionx3
doxycycline, ivermectin	probiotics	NA	NA	NA	NA	NA	NA	NA	0	0	0	-150.47	-419.59	-19.71	VERY LOW	0	0	0	-150.47	-419.59	-19.71	VERY LOW	Imprecisionx3
doxycycline, ivermectin	proxalutamide	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0	0	0	-13.8	-28.19 -84.87	29.36	VERY LOW VERY LOW	0	0	0	-13.8	-28.19 -84.87	29.36	VERY LOW VERY LOW	RoB, Imprecisionx3
doxycycline, ivermectin doxycycline, ivermectin	recombinant human granulocyte colony-stimulating factor remdesivir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0	0	0	-27.45 -114.7	-84.87 -140.48	-70.13	VERY LOW VERY LOW	0	0	0	-27.45 -114.7	-84.87	-70.13	VERY LOW VERY LOW	RoB, Imprecisionx3 RoB, Imprecisionx3
doxycycline, ivermectin	serine protease inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0	0	0	-94.36	-212.54	-70.13	VERY LOW	0	0	0	-94.36	-212.54	-70.13	VERY LOW	RoB, Imprecisionx3
doxycycline, ivermectin	SGLT2 inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0	0	0	-97.13	-151.31	-44.56	VERY LOW	0	0	0	-97.13	-151.31	-44.56	VERY LOW	Imprecisionx3
doxycycline, ivermectin	statins	NA	NA	NA	NA	NA	NA	NA	0	0	0	-169.33	-346.47	-51.13	VERY LOW	0	0	0	-169.33	-346.47	-51.13	VERY LOW	RoB, Imprecisionx3
doxycycline, ivermectin	sulodexide	NA	NA	NA	NA	NA	NA	NA	0	0	0	-59.93	-175.64	8.96	VERY LOW	0	0	0	-59.93	-175.64	8.96	VERY LOW	Imprecisionx3
doxycycline, ivermectin	synthetic VIP	NA	NA	NA	NA	NA	NA	NA	0	0	0	-148.44	-259.67	-65.42	VERY LOW	0	0	0	-148.44	-259.67	-65.42	VERY LOW	Imprecisionx3
doxycycline, ivermectin	tyrosine kinase inhibitors umifenovir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0	0	0	-57.71 -95.1	-109.27 -182.35	-8.32 -30.03	VERY LOW	0	0	0	-57.71 -95.1	-109.27 -182.35	-8.32 -30.03	VERY LOW VERY LOW	Imprecisionx3 RoB. Imprecisionx3
doxycycline, ivermectin doxycycline, ivermectin	umitenovir vitamin C	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0	0	0	-95.1 -86.74	-182.35 -158.6	-30.03	VERY LOW VERY LOW	0	0	0	-95.1 -86.74	-182.35 -158.6	-30.03	VERY LOW VERY LOW	RoB, Imprecisionx3
doxycycline, ivermectin	vitamin D	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0	0	0	-83.23	-155	-28.22	VERYLOW	0	0	0	-83.23	-155	-28.22	VERYLOW	RoB, Imprecisionx3
electrolyzed saline	emtricitabine, tenofovir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA	0.23	0.03	1.21	-74.31	-158.6	11.48	VERY LOW	0.23	0.03	1.21	-74.31	-158.6	11.48	VERY LOW	RoB, Imprecisionx3
electrolyzed saline	favipiravir	NA	NA	NA	NA	NA	NA	NA	0.13	0.02	0.68	-133.09	-248.51	-31.66	VERY LOW	0.13	0.02	0.68	-133.09	-248.51	-31.66	VERY LOW	RoB, Imprecisionx3
electrolyzed saline	favipiravir, hydrochloroquine	NA	NA	NA	NA	NA	NA	NA	0.18	0.02	1.01	-101.15	-223.06	-0.6	VERY LOW	0.18	0.02	1.01	-101.15	-223.06	-0.6	VERY LOW	RoB, Imprecisionx3
electrolyzed saline	fluvoxamine	NA	NA	NA	NA	NA	NA	NA	0.26	0.03	1.33	-65.52	-144.34	17.17	VERY LOW	0.26	0.03	1.33	-65.52	-144.34	17.17	VERY LOW	RoB, Imprecisionx3
electrolyzed saline	full-dose anticoagulant	NA	NA	NA	NA	NA	NA	NA	0.18	0.02	0.83	-94.4	-133.28	-23.23	VERY LOW	0.18	0.02	0.83	-94.4	-133.28	-23.23	VERY LOW	RoB, Imprecisionx3
electrolyzed saline electrolyzed saline	GM-CSF inhibitor (hydroxy)chloroquine	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.23	0.03	1.05 0.73	-72.99 -109.3	-118.87 -146.44	-0.41 -39.31	VERY LOW VERY LOW	0.23	0.03	1.05 0.73	-72.99 -109.3	-118.87 -146.44	-0.41 -39.31	VERY LOW VERY LOW	RoB, Imprecisionx3 RoB, Imprecisionx3
electrolyzed saline	II 1 inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.16	0.02	1 11	-70.53	-128.05	5 69	VERYLOW	0.10	0.02	1 11	-70.53	-128.05	5 69	VERYLOW	RoB Imprecisionx3
electrolyzed saline	IL6 receptor antagonists without corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	0.16	0.02	0.72	-109.64	-149.69	-37.3	VERY LOW	0.16	0.02	0.72	-109.64	-149.69	-37.3	VERY LOW	RoB, Imprecisionx3
electrolyzed saline	interferon alfa (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	0	0	0.08	-914.67	-996.05	-307.23	VERY LOW	0	0	0.08	-914.67	-996.05	-307.23	VERY LOW	RoB, Imprecisionx3
electrolyzed saline	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	0.17	0.02	0.79	-101.56	-147.65	-28.31	VERY LOW	0.17	0.02	0.79	-101.56	-147.65	-28.31	VERY LOW	RoB, Imprecisionx3
electrolyzed saline	interferon beta (subcutaneous), lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.09	0.01	0.42	-209.39	-330.33	-96.06	VERY LOW	0.09	0.01	0.42	-209.39	-330.33	-96.06	VERY LOW	RoB, Imprecisionx3
electrolyzed saline electrolyzed saline	intermediate-dose anticoagulant intranasal corticosteroids	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.15 4.04E+05	0.02	0.73 3.14E+12	-118.12 17.22	-192.42 -59.87	-35.54 98.82	VERY LOW	0.15 4.04E+05	0.02	0.73 3.14E+12	-118.12 17.22	-192.42 -59.87	-35.54 98.82	VERY LOW VERY LOW	RoB, Imprecisionx3 RoB, Imprecisionx3
electrolyzed saline	intranasai corticosteroids	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	4.04E+05	0.03	3.14E+12	-58 15	-118.06	19.12	VERYLOW	4.04E+05 0.28	0.03	3.14E+12	-58 15	-118.06	19 12	VERYLOW	RoB, Imprecisionx3
electrolyzed saline	JAK inhibitors	NA NA	NA NA	NA NA	NA	NA NA	NA NA	NA	0.28	0.04	1.29	-55.1	-95.14	15.63	VERY LOW	0.28	0.04	1.29	-55.1	-95.14	15.63	VERY LOW	RoB, Imprecisionx3
electrolyzed saline	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.17	0.02	0.74	-105.97	-144.67	-33.98	VERY LOW	0.17	0.02	0.74	-105.97	-144.67	-33.98	VERY LOW	RoB, Imprecisionx3
electrolyzed saline	melatonin	NA	NA	NA	NA	NA	NA	NA	4.08	0.25	114.2	20.33	-23.18	92.14	VERY LOW	4.08	0.25	114.2	20.33	-23.18	92.14	VERY LOW	RoB, Imprecisionx3
electrolyzed saline	methylene blue	NA	NA	NA	NA	NA	NA	NA	0.35	0.04	1.82	-41.59	-105.08	35.88	VERY LOW	0.35	0.04	1.82	-41.59	-105.08	35.88	VERY LOW	RoB, Imprecisionx3
electrolyzed saline	molnupiravir	NA	NA	NA	NA	NA	NA	NA	2.9	0.18	78.98	16.45	-34.72	88.96	VERY LOW	2.9	0.18	78.98	16.45	-34.72	88.96	VERY LOW	RoB, Imprecisionx3
electrolyzed saline	nitazoxanide omega 3	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.32	0.03	2.23	-58.96 8.93	-214.44 -50.76	39.99 81.85	VERY LOW	0.32	0.03	2.23	-58.96 8.93	-214.44 -50.76	39.99 81.85	VERY LOW VERY LOW	RoB, Imprecisionx3 RoB, Imprecisionx3
electrolyzed saline electrolyzed saline	nirmatrelvir/ritonavir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	4.88E+08	13.52	1.96E+19	30.41	2.68	99.7	VERY LOW	4.88E+08	13.52	1.96E+19	30.41	2.68	99.7	VERY LOW	RoB, Imprecisionx3
electrolyzed saline	probiotics	NA	NA	NA	NA	NA	NA	NA	0.17	0.02	1.69	-124.38	-392.78	14.76	VERY LOW	0.17	0.02	1.69	-124.38	-392.78	14.76	VERY LOW	RoB, Imprecisionx3
electrolyzed saline	proxalutamide	NA	NA	NA	NA	NA	NA	NA	1.41	0.19	6.75	12.3	-18.15	81.91	VERY LOW	1.41	0.19	6.75	12.3	-18.15	81.91	VERY LOW	RoB, Imprecisionx3
electrolyzed saline	recombinant human granulocyte colony-stimulating factor	NA	NA	NA	NA	NA	NA	NA	0.94	0.09	7.76	-1.36	-64.88	74.71	VERY LOW	0.94	0.09	7.76	-1.36	-64.88	74.71	VERY LOW	RoB, Imprecisionx3
electrolyzed saline	remdesivir	NA	NA	NA	NA	NA	NA	NA	0.2	0.03	0.87	-88.6	-126.93	-17	VERY LOW	0.2	0.03	0.87	-88.6	-126.93	-17	VERY LOW	RoB, Imprecisionx3
electrolyzed saline electrolyzed saline	serine protease inhibitors SGLT2 inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.26	0.03	1.63	-68.26 -71.03	-191.79 -133.12	25.02 6.77	VERY LOW VERY LOW	0.26 0.24	0.03	1.63	-68.26 -71.03	-191.79 -133.12	25.02 6.77	VERY LOW VERY LOW	RoB, Imprecisionx3
electrolyzed saline	SGL12 inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.24	0.03	0.81	-/1.03	-133.12	-13.61	VERY LOW	0.24	0.03	0.81	-/1.03	-322.76	-13.61	VERY LOW	RoB, Imprecisionx3
electrolyzed saline electrolyzed saline	sulodexide	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.43	0.01	3.93	-33.84	-150.79	57.42	VERY LOW	0.13	0.01	3.93	-33.84	-150.79	57.42	VERY LOW	RoB, Imprecisionx3
electrolyzed saline	synthetic VIP	NA NA	NA NA	NA	NA	NA NA	NA NA	NA	0.15	0.02	0.79	-122.35	-236.66	-22.6	VERY LOW	0.15	0.02	0.79	-122.35	-236.66	-22.6	VERY LOW	RoB, Imprecisionx3
electrolyzed saline	tyrosine kinase inhibitors	NA	NA	NA	NA	NA	NA	NA	0.41	0.05	2.15	-31.61	-92.07	43.77	VERY LOW	0.41	0.05	2.15	-31.61	-92.07	43.77	VERY LOW	RoB, Imprecisionx3
electrolyzed saline	umifenovir	NA	NA	NA	NA	NA	NA	NA	0.25	0.03	1.37	-69.01	-161.2	18.06	VERY LOW	0.25	0.03	1.37	-69.01	-161.2	18.06	VERY LOW	RoB, Imprecisionx3
electrolyzed saline	vitamin C	NA	NA	NA	NA	NA	NA	NA	0.27	0.03	1.5	-60.65	-137.56	21.7	VERY LOW	0.27	0.03	1.5	-60.65	-137.56	21.7	VERY LOW	RoB, Imprecisionx3
electrolyzed saline	vitamin D	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NΑ	0.3	0.04	1.55	-57.13 -58.79	-136.16 -177.95	23.25	VERY LOW VERY LOW	0.3	0.04	1.55	-57.13 -58.79	-136.16 -177.95	23.25	VERY LOW VERY LOW	RoB, Imprecisionx3
emtricitabine, tenofovir	favipiravir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.57	0.23	1.46	-58.79 -26.85	-177.95 -152.09	49.49 79.83	VERY LOW	0.57	0.23	1.46	-58.79 -26.85	-177.95 -152.09	49.49 79.83	VERY LOW	RoB, Imprecisionx2
emtricitabine, tenofovir emtricitabine, tenofovir	favipiravir, nydrochloroquine fluvoxamine	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.1	0.27	2.25	-26.85 8.79	-152.09 -79.49	79.83 101.16	VERY LOW VERY LOW	1.1	0.27	2.25	-26.85 8.79	-152.09 -79.49	79.83 101.16	VERY LOW VERY LOW	RoB, Imprecisionx2
emtricitabine, tenofovir	full-dose anticoagulant	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.78	0.42	1.55	-20.1	-77.81	60.55	VERY LOW	0.78	0.42	1.55	-20.1	-77.81	60.55	VERY LOW	RoB, Imprecisionx2
emtricitabine, tenofovir	GM-CSF inhibitor	NA	NA	NA	NA	NA	NA	NA	0.97	0.47	2.03	1.31	-61.06	82.99	VERY LOW	0.97	0.47	2.03	1.31	-61.06	82.99	VERY LOW	RoB, Imprecisionx2
emtricitabine, tenofovir	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	0.69	0.35	1.35	-35	-91.86	43.65	VERY LOW	0.69	0.35	1.35	-35	-91.86	43.65	VERY LOW	RoB, Imprecisionx2
emtricitabine, tenofovir	IL1 inhibitors	NA	NA	NA	NA	NA	NA	NA	1.01	0.45	2.2	3.77	-65.37	89.34	VERY LOW	1.01	0.45	2.2	3.77	-65.37	89.34	VERY LOW	RoB, Imprecisionx2
emtricitabine, tenofovir	IL6 receptor antagonists without corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	0.68	0.35	1.35	-35.33	-92.62	45.09	VERY LOW	0.68	0.35	1.35	-35.33	-92.62	45.09	VERY LOW	RoB, Imprecisionx2
emtricitabine, tenofovir	interferon alfa (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	0	0	0.43	-840.36	-945.09	-253.1	VERY LOW	0	0	0.43	-840.36	-945.09	-253.1	VERY LOW	RoB, Imprecisionx3

									Mortality	/													
Comparison		Direct estimate							Indirect estimate	9						Network estimate	e		1				
Treatment 1	Treatment 2	Relative estimate	CI lower limit	Cl upper limit	Absolute estimate	CI lower limit	CI upper limit	Final rating	Relative estimate Point estimate	CI lower limit	CI upper limit	Absolute estima Point estimate	te (per 1,000)	Cl upper limit	Final rating	Relative estimate	CI lower limit	Cl upper limit	Absolute estim	CI lower limit	Cl upper limit	Final rating	Reasons for
emtricitabine, tenofovir	interferon beta (subcutaneous)	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA	0.74	0.37	1 52	-27.26	-89.43	55 85	VERY LOW	0.74	0.37	1.52	-27.26	-89.43	55.85	VERY LOW	downgrading RoB. Imprecisionx2
emtricitabine, tenofovir	interferon beta (subcutaneous), lopinavir-ritonavir	NA NA	NA NA	NA NA	NA	NA NA	NA NA	NA	0.36	0.15	0.85	-135.08	-258.34	-18.42	VERY LOW	0.36	0.15	0.85	-135.08	-258.34	-18.42	VERY LOW	RoB, Imprecisionx2
emtricitabine, tenofovir	intermediate-dose anticoagulant	NA	NA	NA	NA	NA	NA	NA	0.65	0.29	1.45	-43.81	-127.56	47.36	VERY LOW	0.65	0.29	1.45	-43.81	-127.56	47.36	VERY LOW	RoB, Imprecisionx2
emtricitabine, tenofovir	intranasal corticosteroids	NA	NA	NA	NA	NA	NA	NA	2.37E+06	0.02	1.33E+13	91.53	16.99	181.75	VERY LOW	2.37E+06	0.02	1.33E+13	91.53	16.99	181.75	VERY LOW	RoB, Imprecisionx3
emtricitabine, tenofovir	ivermectin	NA	NA	NA	NA	NA	NA	NA	1.18	0.51	2.79	16.15	-55.38	102.15	VERY LOW	1.18	0.51	2.79	16.15	-55.38	102.15	VERY LOW	RoB, Imprecisionx2
emtricitabine, tenofovir	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	1.2	0.58	2.44	19.21	-38.77	98.65	VERY LOW	1.2	0.58	2.44	19.21	-38.77	98.65	VERY LOW	RoB, Imprecisionx2
emtricitabine, tenofovir	lopinavir-ritonavir	NA NA	NA NA	NA NA	NA NA	NA NA	NA	NA	0.71 17.61	0.36	1.39 385.2	-31.67	-89.41 35.3	47.27	VERY LOW	0.71 17.61	0.36	1.39	-31.67	-89.41 35.3	47.27	VERY LOW VERY LOW	RoB, Imprecisionx2
emtricitabine, tenofovir emtricitabine, tenofovir	melatonin methylene blue	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	17.61	2.35 0.6	385.2	94.64 32.71	35.3 -41.96	174.32 119.19	VERY LOW VERY LOW	17.61	2.35 0.6	385.2 3.83	94.64	-41.96	174.32 119.19	VERY LOW VERY LOW	RoB, Imprecisionx3 RoB, Imprecisionx2
emtricitabine, tendrovir	molnupiravir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	12.01	1.59	221.03	90.76	26.83	171.63	VERY LOW	12.01	1.59	221.03	90.76	26.83	171.63	VERY LOW	RoB, Imprecisionx3
emtricitabine, tenofovir	nitazoxanide	NA NA	NA.	NA.	NA.	NA.	NA.	NA.	1.39	0.3	6	15.35	-142.05	122.61	VERY LOW	1.39	0.3	6	15.35	-142.05	122.61	VERY LOW	RoB, Imprecisionx2
emtricitabine, tenofovir	omega 3	NA	NA	NA	NA	NA	NA	NA	6.8	1.15	61.38	83.23	13.35	166.24	VERY LOW	6.8	1.15	61.38	83.23	13.35	166.24	VERY LOW	RoB, Imprecisionx3
emtricitabine, tenofovir	nirmatrelvir/ritonavir	NA	NA	NA	NA	NA	NA	NA	2.02E+09	75.6	7.25E+19	104.71	52.15	182.39	VERY LOW	2.02E+09	75.6	7.25E+19	104.71	52.15	182.39	VERY LOW	RoB, Imprecisionx3
emtricitabine, tenofovir	probiotics	NA	NA	NA	NA	NA	NA	NA	0.78	0.15	4.08	-50.07	-319.81	100.63	VERY LOW	0.78	0.15	4.08	-50.07	-319.81	100.63	VERY LOW	RoB, Imprecisionx2
emtricitabine, tenofovir	proxalutamide	NA	NA	NA	NA	NA	NA	NA	6.06	2.7	13.64	86.6	33.41	164.63	VERY LOW	6.06	2.7	13.64	86.6	33.41	164.63	VERY LOW	RoB, Imprecisionx2
emtricitabine, tenofovir	recombinant human granulocyte colony-stimulating factor	NA	NA	NA	NA	NA	NA	NA	4.02	0.97	22.27	72.95	-0.84	157.79	VERY LOW	4.02	0.97	22.27	72.95	-0.84	157.79	VERY LOW	RoB, Imprecisionx2
emtricitabine, tenofovir	remdesivir	NA	NA	NA	NA	NA	NA	NA	0.83	0.41	1.65	-14.3	-71.93 -119.81	65.91	VERY LOW	0.83	0.41	1.65	-14.3	-71.93 -119.81	65.91	VERY LOW	RoB, Imprecisionx2
emtricitabine, tenofovir	serine protease inhibitors SGLT2 inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.1	0.34	3.91	6.04 3.27	-119.81 -70.17	107.84 89.87	VERY LOW	1.1	0.34	3.91	6.04 3.27	-119.81	107.84 89.87	VERY LOW VERY LOW	RoB, Imprecisionx2 RoB, Imprecisionx2
emtricitabine, tenolovir	SGL12 Inhibitors statins	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.56	0.44	1.97	-68.93	-70.17	68.15	VERY LOW	0.56	0.44	1.97	-68.93	-70.17	68.15	VERY LOW VERY LOW	RoB, Imprecisionx2
emtricitabine, tenofovir	sulodexide	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.9	0.44	10.35	40.46	-85.91	136.43	VERY LOW	1.9	0.44	10.35	40.46	-85.91	136.43	VERY LOW	RoB, Imprecisionx2
emtricitabine, tenefovir	synthetic VIP	NA NA	NA.	NA.	NA.	NA.	NA.	NA.	0.65	0.24	1.68	-48.05	-168.28	57.95	VERY LOW	0.65	0.24	1.68	-48.05	-168.28	57.95	VERY LOW	RoB, Imprecisionx2
emtricitabine, tenofovir	tyrosine kinase inhibitors	NA	NA	NA	NA	NA	NA	NA	1.77	0.68	4.57	42.69	-28.54	128.17	VERY LOW	1.77	0.68	4.57	42.69	-28.54	128.17	VERY LOW	RoB, Imprecisionx2
emtricitabine, tenofovir	umifenovir	NA	NA	NA	NA	NA	NA	NA	1.08	0.42	2.9	5.29	-93.9	101.43	VERY LOW	1.08	0.42	2.9	5.29	-93.9	101.43	VERY LOW	RoB, Imprecisionx2
emtricitabine, tenofovir	vitamin C	NA	NA	NA	NA	NA	NA	NA	1.18	0.46	3.16	13.66	-75.46	105.72	VERY LOW	1.18	0.46	3.16	13.66	-75.46	105.72	VERY LOW	RoB, Imprecisionx2
emtricitabine, tenofovir	vitamin D	NA	NA	NA	NA	NA	NA	NA	1.28	0.48	3.34	17.17	-71.54	109.79	VERY LOW	1.28	0.48	3.34	17.17	-71.54	109.79	VERY LOW	RoB, Imprecisionx2
favipiravir	favipiravir, hydrochloroquine	NA	NA	NA	NA	NA	NA	NA	1.36	0.47	3.92	31.94	-105.12	164.02	VERY LOW	1.36	0.47	3.92	31.94	-105.12	164.02	VERY LOW	RoB, Imprecisionx2
favipiravir	fluvoxamine	NA	NA	NA	NA	NA	NA	NA	1.91	0.75	5.15	67.57	-34.3	187.18	VERY LOW	1.91	0.75	5.15	67.57	-34.3	187.18	VERY LOW	RoB, Imprecisionx2
favipiravir favipiravir	full-dose anticoagulant GM-CSF inhibitor	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.37	0.69	2.78 3.61	38.69 60.1	-40.33 -22.47	148.67 169.86	VERY LOW	1.37	0.69	2.78 3.61	38.69 60.1	-40.33 -22.47	148.67 169.86	VERY LOW VERY LOW	RoB, Imprecisionx2 RoB, Imprecisionx2
favipiravir favipiravir	(hydroxy)chloroquine	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.7	0.82	2.44	23.79	-22.47	169.86	VERY LOW VERY LOW	1.7	0.82	2.44	23.79	-22.47	169.86	VERY LOW VERY LOW	RoB, Imprecisionx2
favipiravir	IL1 inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.76	0.02	3.92	62.56	-26.04	175.69	VERY LOW	1.76	0.79	3.92	62.56	-26.04	175.69	VERY LOW	RoB, Imprecisionx2
favipiravir	IL6 receptor antagonists without corticosteroids (systemic)	NA NA	NA NA	NA NA	NA NA	NA.	NA NA	NA	1.19	0.6	2.42	23.45	-55.56	132.19	VERY LOW	1.19	0.6	2.42	23.45	-55.56	132.19	VERY LOW	RoB, Imprecisionx2
favipiravir	interferon alfa (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	0	0	0.8	-781.58	-908.14	-193.72	VERY LOW	0	0	0.8	-781.58	-908.14	-193.72	VERY LOW	RoB, Imprecisionx3
favipiravir	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	1.29	0.65	2.7	31.53	-49.9	144.33	VERY LOW	1.29	0.65	2.7	31.53	-49.9	144.33	VERY LOW	RoB, Imprecisionx2
favipiravir	interferon beta (subcutaneous), lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.64	0.27	1.49	-76.3	-213.2	62.02	VERY LOW	0.64	0.27	1.49	-76.3	-213.2	62.02	VERY LOW	RoB, Imprecisionx2
favipiravir	intermediate-dose anticoagulant	NA	NA	NA	NA	NA	NA	NA	1.14	0.51	2.54	14.98	-83.79	133.11	VERY LOW	1.14	0.51	2.54	14.98	-83.79	133.11	VERY LOW	RoB, Imprecisionx2
favipiravir	intranasal corticosteroids	NA	NA	NA	NA	NA	NA	NA	4.08E+06	0.03	2.73E+13	150.31	65.74	271	VERY LOW	4.08E+06	0.03	2.73E+13	150.31	65.74	271	VERY LOW	RoB, Imprecisionx3
favipiravir	ivermectin	NA	NA	NA	NA	NA	NA	NA	2.06	0.91	4.78	74.94	-18.15	186.01	VERY LOW	2.06	0.91	4.78	74.94	-18.15	186.01	VERY LOW	RoB, Imprecisionx2
favipiravir lopinavir-ritonavir	JAK inhibitors favipiravir	NA 0.82	NA 0.23	NA 2.96	NA NA	NA NA	NA NA	NA VERY LOW	2.09	1.02	4.35 10.49	77.99 NA	-0.3 NA	187.29 NA	VERY LOW	2.09 0.81	1.02	4.35 1.53	77.99 -27.12	-0.3 -130.88	187.29 46.3	VERY LOW VERY LOW	RoB, Imprecisionx2 RoB, Imprecisionx2
lopinavir-ritonavir favioiravir	tavipiravir melatonin	0.82 NA	0.23 NA	2.96 NA	NA NA	NA NA	NA NA	NA NA	30.89	0.01 4.1	10.49 670.97	NA 153.43	72.95	NA 263.84	VERY LOW VERY LOW	30.89	0.42 4.1	670.97	-27.12 153.43	-130.88 72.95	46.3 263.84	VERY LOW VERY LOW	RoB, Imprecisionx2 RoB, Imprecisionx3
favipiravir	methylene blue	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	2.63	1.03	6.74	91.5	-1.66	205.75	VERY LOW	2.63	1.03	6.74	91.5	-1.66	205.75	VERY LOW	RoB, Imprecisionx2
favipiravir	molnupiravir	NA NA	NA.	NA NA	NA NA	NA NA	NA NA	NA NA	21.49	2.95	379.46	149.54	66.23	260.72	VERY LOW	21.49	2.95	379.46	149.54	66.23	260.72	VERY LOW	RoB, Imprecisionx3
favipiravir	nitazoxanide	NA	NA	NA	NA	NA	NA	NA	2.41	0.53	10.62	74.14	-92.72	209.77	VERY LOW	2.41	0.53	10.62	74.14	-92.72	209.77	VERY LOW	RoB, Imprecisionx2
favipiravir	omega 3	NA	NA	NA	NA	NA	NA	NA	11.92	2.07	106.86	142.02	55.06	252.45	VERY LOW	11.92	2.07	106.86	142.02	55.06	252.45	VERY LOW	RoB, Imprecisionx3
favipiravir	nirmatrelvir/ritonavir	NA	NA	NA	NA	NA	NA	NA	3.80E+09	127.27	1.16E+20	163.5	88.45	270.36	VERY LOW	3.80E+09	127.27	1.16E+20	163.5	88.45	270.36	VERY LOW	RoB, Imprecisionx3
favipiravir	probiotics	NA	NA	NA	NA	NA	NA	NA	1.35	0.26	7.39	8.71	-272.83	180.45	VERY LOW	1.35	0.26	7.39	8.71	-272.83	180.45	VERY LOW	RoB, Imprecisionx2
favipiravir	proxalutamide	NA	NA	NA	NA	NA	NA	NA	10.66	4.69	24.29	145.39	69.49	252.61	VERY LOW	10.66	4.69	24.29	145.39	69.49	252.61	VERY LOW	RoB, Imprecisionx2
favipiravir	recombinant human granulocyte colony-stimulating factor	NA	NA	NA	NA	NA	NA	NA	7.04	1.73	37.88	131.73	40.14	243.15	VERY LOW	7.04	1.73	37.88	131.73	40.14	243.15	VERY LOW	RoB, Imprecisionx2
favipiravir	remdesivir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.45	0.73	2.93	44.49	-34.32	154.25	VERY LOW	1.45	0.73	2.93	44.49	-34.32	154.25	VERY LOW	RoB, Imprecisionx2
favipiravir favipiravir	serine protease inhibitors SGLT2 inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.96	0.58	6.67 4.08	64.83	-75.8 -29.17	194.07 175.16	VERY LOW VERY LOW	1.96	0.58	6.67 4.08	64.83	-75.8 -29.17	194.07 175.16	VERY LOW VERY LOW	RoB, Imprecisionx2 RoB, Imprecisionx2
favipiravir	statins	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.98	0.78	3.36	-10.15	-29.17	148.16	VERY LOW	0.98	0.78	3.36	-10.15	-29.17	148.16	VERY LOW	RoB, Imprecisionx2
favipiravir	sulodexide	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	3.35	0.29	17.82	99.25	-35.95	224.52	VERY LOW	3.35	0.29	17.82	99.25	-35.95	224.52	VERY LOW	RoB, Imprecisionx2
favipiravir	synthetic VIP	NA	NA	NA	NA	NA	NA	NA	1.13	0.42	2.96	10.74	-119.35	141.07	VERY LOW	1.13	0.42	2.96	10.74	-119.35	141.07	VERY LOW	RoB, Imprecisionx2
favipiravir	tyrosine kinase inhibitors	NA	NA	NA	NA	NA	NA	NA	3.1	1.21	8.15	101.48	11.53	216.33	VERY LOW	3.1	1.21	8.15	101.48	11.53	216.33	VERY LOW	RoB, Imprecisionx2
umifenovir	favipiravir	0.97	0.02	56.84	NA	NA	NA	VERY LOW	0.53	0.19	1.39	NA	NA	NA	VERY LOW	0.53	0.19	1.42	-64.08	-187.9	52.16	VERY LOW	RoB, Imprecisionx2
favipiravir	vitamin C	NA	NA	NA	NA	NA	NA	NA	2.07	0.78	5.53	72.44	-32.35	190.66	VERY LOW	2.07	0.78	5.53	72.44	-32.35	190.66	VERY LOW	RoB, Imprecisionx2
favipiravir	vitamin D	NA	NA	NA	NA	NA	NA	NA	2.24	0.84	6.05	75.96	-27.2	196.19	VERY LOW	2.24	0.84	6.05	75.96	-27.2	196.19	VERY LOW	RoB, Imprecisionx2
favipiravir, hydrochloroquine	fluvoxamine	NA	NA	NA	NA	NA	NA	NA	1.42	0.49	4.23	35.64	-66.46	159.88	VERY LOW	1.42	0.49	4.23	35.64	-66.46	159.88	VERY LOW	RoB, Imprecisionx2
favipiravir, hydrochloroquine	full-dose anticoagulant	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.01	0.43	2.37	6.75	-71.25	122.2	VERY LOW	1.01	0.43	2.37	6.75	-71.25	122.2	VERY LOW	RoB, Imprecisionx2
favipiravir, hydrochloroquine favipiravir, hydrochloroquine	GM-CSF inhibitor (hydroxy)chloroquine	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.25 0.89	0.51	3.08 2.06	28.16 -8.15	-52.61 -85.23	144.78 107.31	VERY LOW VERY LOW	1.25 0.89	0.51	3.08 2.06	28.16 -8.15	-52.61 -85.23	144.78 107.31	VERY LOW VERY LOW	RoB, Imprecisionx2 RoB, Imprecisionx2
favipiravir, hydrochloroquine favipiravir, hydrochloroquine	(nydroxy)chloroquine IL1 inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.29	0.38	3.27	-8.15 30.62	-85.23 -57.9	107.31	VERY LOW VERY LOW	1.29	0.38	3.27	-8.15 30.62	-85.23 -57.9	107.31	VERY LOW VERY LOW	RoB, Imprecisionx2
favipiravir, hydrochloroquine	IL6 receptor antagonists without corticosteroids (systemic)	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.88	0.38	2.06	-8.49	-86.69	107.3	VERY LOW	0.88	0.38	2.06	-8.49	-86.69	107.3	VERY LOW	RoB, Imprecisionx2
favipiravir, hydrochloroquine	interferon alfa (subcutaneous)	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.00	0.50	0.63	-813.52	-939.39	-219.79	VERY LOW	0.00	0.30	0.63	-813.52	-939.39	-219.79	VERY LOW	RoB, Imprecisionx3
favipiravir, hydrochloroquine	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	0.96	0.4	2.28	-0.41	-81.71	117.27	VERY LOW	0.96	0.4	2.28	-0.41	-81.71	117.27	VERY LOW	RoB, Imprecisionx2
favipiravir, hydrochloroquine	interferon beta (subcutaneous), lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.47	0.17	1.26	-108.24	-244.32	37.65	VERY LOW	0.47	0.17	1.26	-108.24	-244.32	37.65	VERY LOW	RoB, Imprecisionx2
favipiravir, hydrochloroquine	intermediate-dose anticoagulant	NA	NA	NA	NA	NA	NA	NA	0.84	0.32	2.17	-16.96	-115.57	107.1	VERY LOW	0.84	0.32	2.17	-16.96	-115.57	107.1	VERY LOW	RoB, Imprecisionx2
favipiravir, hydrochloroquine	intranasal corticosteroids	NA	NA	NA	NA	NA	NA	NA	3.01E+06	0.03	2.05E+13	118.37	23.51	245.54	VERY LOW	3.01E+06	0.03	2.05E+13	118.37	23.51	245.54	VERY LOW	RoB, Imprecisionx3
favipiravir, hydrochloroquine	ivermectin	NA	NA	NA	NA	NA	NA	NA	1.53	0.57	4.01	43	-45.22	162.82	VERY LOW	1.53	0.57	4.01	43	-45.22	162.82	VERY LOW	RoB, Imprecisionx2
favipiravir, hydrochloroquine	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	1.54	0.64	3.68	46.06	-32.55	161.92	VERY LOW	1.54	0.64	3.68	46.06	-32.55	161.92	VERY LOW	RoB, Imprecisionx2
favipiravir, hydrochloroquine	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.91	0.39	2.11	-4.82	-82.42	111.14	VERY LOW	0.91	0.39	2.11	-4.82	-82.42	111.14	VERY LOW	RoB, Imprecisionx2
favipiravir, hydrochloroquine	melatonin	NA	NA	NA	NA	NA	NA	NA	23.15	2.79	500.95	121.49	43.92	237.36	VERY LOW	23.15	2.79	500.95	121.49	43.92	237.36	VERY LOW	RoB, Imprecisionx3

									Mortalit	ty													
Comparison		Direct estimate							Indirect estima							Network estimate	•						
		Relative estimat	e		Absolute estima	te (per 1,000)		Final rating	Relative estimat	e		Absolute estima	ate (per 1,000)		Final rating	Relative estima	te		Absolute estima	ate (per 1,000)		Final rating	Reasons for
Treatment 1	Treatment 2	Point estimate	CI lower limit	t CI upper limit	Point estimate	CI lower limit	CI upper limit	rinarrating	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit	rillal fatting	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit	rillal latting	downgrading
favipiravir, hydrochloroquine	methylene blue	NA	NA	NA	NA	NA	NA	NA	1.94	0.66	5.56	59.56	-31.08	181.33	VERY LOW	1.94	0.66	5.56	59.56	-31.08	181.33	VERY LOW	RoB, Imprecisionx2
favipiravir, hydrochloroquine	molnupiravir	NA	NA	NA	NA	NA	NA	NA	15.88	2.02	309.49	117.6	36.01	233.77	VERY LOW	15.88	2.02	309.49	117.6	36.01	233.77	VERY LOW	RoB, Imprecisionx3
favipiravir, hydrochloroquine	nitazoxanide	NA	NA	NA	NA	NA	NA	NA	1.79	0.35	8.53	42.2	-127.42	182.88	VERY LOW	1.79	0.35	8.53	42.2	-127.42	182.88	VERY LOW	RoB, Imprecisionx2
favipiravir, hydrochloroquine	omega 3	NA	NA	NA	NA	NA	NA	NA	8.92	1.41	81	110.08	19.41	229.04	VERY LOW	8.92	1.41	81	110.08	19.41	229.04	VERY LOW	RoB, Imprecisionx3
favipiravir, hydrochloroquine	nirmatrelvir/ritonavir	NA	NA	NA	NA	NA	NA	NA	2.68E+09	92.33	9.31E+19	131.56	57.47	246.01	VERY LOW	2.68E+09	92.33	9.31E+19	131.56	57.47	246.01	VERY LOW	RoB, Imprecisionx3
favipiravir, hydrochloroquine	probiotics	NA	NA	NA	NA	NA	NA	NA	1	0.17	5.73	-23.23	-297.04	152.48	VERY LOW	1	0.17	5.73	-23.23	-297.04	152.48	VERY LOW	RoB, Imprecisionx3
favipiravir, hydrochloroquine	proxalutamide	NA	NA	NA	NA	NA	NA	NA	7.84	3	20.23	113.45	39.15	228.15	VERY LOW	7.84	3	20.23	113.45	39.15	228.15	VERY LOW	RoB, Imprecisionx2
favipiravir, hydrochloroquine	recombinant human granulocyte colony-stimulating factor	NA	NA	NA	NA	NA	NA	NA	5.15	1.15	30.43	99.79	7.4	218.99	VERY LOW	5.15	1.15	30.43	99.79	7.4	218.99	VERY LOW	RoB, Imprecisionx2
favipiravir, hydrochloroquine	remdesivir	NA	NA	NA	NA	NA	NA	NA	1.07	0.45	2.49	12.55	-64.93	129.25	VERY LOW	1.07	0.45	2.49	12.55	-64.93	129.25	VERY LOW	RoB, Imprecisionx2
favipiravir, hydrochloroquine	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	1.44	0.39	5.5	32.89	-107.77	167.28	VERY LOW	1.44	0.39	5.5	32.89	-107.77	167.28	VERY LOW	RoB, Imprecisionx2
favipiravir, hydrochloroquine	SGLT2 inhibitors	NA	NA	NA	NA	NA	NA	NA	1.31	0.49	3.42	30.12	-60.34	150.61	VERY LOW	1.31	0.49	3.42	30.12	-60.34	150.61	VERY LOW	RoB, Imprecisionx2
favipiravir, hydrochloroquine	statins	NA	NA	NA	NA	NA	NA	NA	0.71	0.19	2.76	-42.08	-232.53	117.25	VERY LOW	0.71	0.19	2.76	-42.08	-232.53	117.25	VERY LOW	RoB, Imprecisionx2
favipiravir, hydrochloroquine	sulodexide	NA	NA	NA	NA	NA	NA	NA	2.47	0.52	14.55	67.31	-67.4	197.72	VERY LOW	2.47	0.52	14.55	67.31	-67.4	197.72	VERY LOW	RoB, Imprecisionx2
favipiravir, hydrochloroquine	synthetic VIP	NA	NA	NA	NA	NA	NA	NA	0.83	0.28	2.48	-21.2	-153.5	117.28	VERY LOW	0.83	0.28	2.48	-21.2	-153.5	117.28	VERY LOW	RoB, Imprecisionx2
favipiravir, hydrochloroquine	tyrosine kinase inhibitors	NA	NA	NA	NA	NA	NA	NA	2.28	0.78	6.74	69.54	-19.54	187.92	VERY LOW	2.28	0.78	6.74	69.54	-19.54	187.92	VERY LOW	RoB, Imprecisionx2
favipiravir, hydrochloroquine	umifenovir	NA	NA	NA	NA	NA	NA	NA	1.4	0.47	4.15	32.14	-81.88	159.38	VERY LOW	1.4	0.47	4.15	32.14	-81.88	159.38	VERY LOW	RoB, Imprecisionx2
favipiravir, hydrochloroquine	vitamin C	NA	NA	NA	NA	NA	NA	NA	1.52	0.52	4.59	40.51	-60.46	163.16	VERY LOW	1.52	0.52	4.59	40.51	-60.46	163.16	VERY LOW	RoB. Imprecisionx2
favipiravir, hydrochloroguine	vitamin D	NA	NA	NA.	NA	NA	NA	NA	1.65	0.54	4.93	44.02	-58.4	168.41	VERY LOW	1.65	0.54	4.93	44.02	-58.4	168.41	VERY LOW	RoB. Imprecisionx2
fluvoxamine	full-dose anticoagulant	NA NA	NA.	NA.	NA NA	NA NA	NA NA	NA NA	0.72	0.34	1.45	-28.88	-81.59	43.09	VERY LOW	0.72	0.34	1.45	-28.88	-81.59	43.09	VERY LOW	RoB, Imprecisionx2
fluvoxamine	GM-CSF inhibitor	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.89	0.4	1.86	-7.47	-65.53	66.81	LOW	0.89	0.4	1.86	-7.47	-65.53	66.81	LOW	Imprecisionx2
fluvoxamine	(hydroxy)chloroquine	NA NA	NA.	NA.	NA NA	NA NA	NA.	NA.	0.63	0.3	1.25	-43.79	-95.51	27.11	LOW	0.63	0.3	1.25	-43.79	-95.51	27.11	LOW	Imprecisionx2
fluvoxamine	IL1 inhibitors	NA NA	NA.	NA.	NA NA	NA NA	NA.	NA.	0.91	0.39	2.03	-5.02	-72.21	73.02	LOW	0.91	0.39	2.03	-5.02	-72.21	73.02	LOW	Imprecisionx2
fluvoxamine	IL6 receptor antagonists without corticosteroids (systemic)	NA NA	NA.	NA NA	NA NA	NA NA	NA NA	NA NA	0.63	0.3	1.25	-44.12	-97.79	27.49	LOW	0.63	0.3	1.25	-44.12	-97.79	27.49	LOW	Imprecisionx2
fluvoxamine	interferon alfa (subcutaneous)	NA NA	NA.	NA NA	NA NA	NA NA	NA NA	NA NA	0.03	0.5	0.39	-849.15	-948 31	-255 69	VERY LOW	0.05	0.5	0.39	-849.15	-948.31	-255 69	VERY LOW	RoB, Imprecisionx3
fluvoxamine	interferon beta (subcutaneous)	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.68	0.31	1.4	-36.05	-93 39	-255.09	VERYLOW	0.68	0.31	1.4	-36.05	-93.39	38 48	VERYLOW	RoB, Imprecisionx2
fluvoxamine	interferon beta (subcutaneous) interferon beta (subcutaneous), lopinavir-ritonavir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.08	0.31	0.82	-36.05	-93.39	-31.93	VERY LOW	0.08	0.13	0.82	-36.05	-93.39	-31.93	VERY LOW	RoB, Imprecisionx2
fluvoxamine	interreron beta (subcutaneous), iopinavir-ritonavir intermediate-dose anticoagulant	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.59	0.13	1.36	-143.87	-132.62	32.27	VERY LOW	0.59	0.13	1.36	-143.87	-132.62	32.27	VERY LOW VERY LOW	RoB, Imprecisionx2
fluvoxamine	intermediate-dose arricoaguiant	NA NA	NA.	NA NA	NA NA	NΔ	NA NA	NA NA	2 11F+06	0.02	1.36E+13	82.74	4	164.7	VERYLOW	2.11E+06	0.02	1.36E+13	82.74	-132.02	164.7	VERYLOW	Imprecisionx3
fluvoxamine	ivermectin	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.08	0.02	2.52	7.36	-59.59	85.26	LOW	1.08	0.02	2.52	7.36	-59 59	85.26	LOW	Imprecisionx2
		NA NA	NA NA	NA NA	NA NA	NA NA	NA NA		1.08	0.45	2.52					1.08	0.45	2.52	10.42	-59.59	81.34		
fluvoxamine	JAK inhibitors							NA				10.42	-42.66	81.34	LOW				_			LOW	Imprecisionx2
fluvoxamine	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.64	0.31	1.28	-40.46	-92.8	30.62	VERY LOW	0.64	0.31	1.28	-40.46	-92.8	30.62	VERY LOW	RoB, Imprecisionx2
fluvoxamine	melatonin	NA	NA	NA	NA	NA	NA	NA	16.25	2.04	323.77	85.85	31.62	156.77	VERY LOW	16.25	2.04	323.77	85.85	31.62	156.77	VERY LOW	RoB, Imprecisionx3
fluvoxamine	methylene blue	NA	NA	NA	NA	NA	NA	NA	1.37	0.53	3.5	23.93	-46.15	103.13	VERY LOW	1.37	0.53	3.5	23.93	-46.15	103.13	VERY LOW	RoB, Imprecisionx2
fluvoxamine	molnupiravir	NA	NA	NA	NA	NA	NA	NA	10.93	1.47	204.67	81.97	20.32	154.87	VERY LOW	10.93	1.47	204.67	81.97	20.32	154.87	VERY LOW	RoB, Imprecisionx3
fluvoxamine	nitazoxanide	NA	NA	NA	NA	NA	NA	NA	1.25	0.27	5.7	6.56	-147.89	109.26	LOW	1.25	0.27	5.7	6.56	-147.89	109.26	LOW	Imprecisionx2
fluvoxamine	omega 3	NA	NA	NA	NA	NA	NA	NA	6.18	1.04	57.22	74.45	4.59	149.2	VERY LOW	6.18	1.04	57.22	74.45	4.59	149.2	VERY LOW	RoB, Imprecisionx3
fluvoxamine	nirmatrelvir/ritonavir	NA	NA	NA	NA	NA	NA	NA	1.91E+09	68.78	6.02E+19	95.92	48.39	164.96	VERY LOW	1.91E+09	68.78	6.02E+19	95.92	48.39	164.96	VERY LOW	Imprecisionx3
fluvoxamine	probiotics	NA	NA	NA	NA	NA	NA	NA	0.71	0.13	3.76	-58.86	-328.34	87.92	LOW	0.71	0.13	3.76	-58.86	-328.34	87.92	LOW	Imprecisionx2
fluvoxamine	proxalutamide	NA	NA	NA	NA	NA	NA	NA	5.53	2.34	12.56	77.81	29.52	147.34	VERY LOW	5.53	2.34	12.56	77.81	29.52	147.34	VERY LOW	RoB, Imprecisionx2
fluvoxamine	recombinant human granulocyte colony-stimulating factor	NA	NA	NA	NA	NA	NA	NA	3.66	0.86	19.99	64.16	-8.6	140.85	VERY LOW	3.66	0.86	19.99	64.16	-8.6	140.85	VERY LOW	RoB, Imprecisionx2
fluvoxamine	remdesivir	NA	NA	NA	NA	NA	NA	NA	0.76	0.36	1.51	-23.09	-75.54	49.1	VERY LOW	0.76	0.36	1.51	-23.09	-75.54	49.1	VERY LOW	RoB, Imprecisionx2
fluvoxamine	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	1.01	0.29	3.61	-2.75	-129.38	97.27	VERY LOW	1.01	0.29	3.61	-2.75	-129.38	97.27	VERY LOW	RoB, Imprecisionx2
fluvoxamine	SGLT2 inhibitors	NA	NA	NA	NA	NA	NA	NA	0.92	0.39	2.13	-5.52	-75.48	73.75	LOW	0.92	0.39	2.13	-5.52	-75.48	73.75	LOW	Imprecisionx2
fluvoxamine	statins	NA	NA	NA	NA	NA	NA	NA	0.5	0.15	1.77	-77.72	-260.27	53.12	VERY LOW	0.5	0.15	1.77	-77.72	-260.27	53.12	VERY LOW	RoB, Imprecisionx2
fluvoxamine	sulodexide	NA	NA	NA	NA	NA	NA	NA	1.72	0.4	9.37	31.68	-90.46	122.32	LOW	1.72	0.4	9.37	31.68	-90.46	122.32	LOW	Imprecisionx2
fluvoxamine	synthetic VIP	NA	NA	NA	NA	NA	NA	NA	0.59	0.22	1.57	-56.83	-175.9	44.04	LOW	0.59	0.22	1.57	-56.83	-175.9	44.04	LOW	Imprecisionx2
fluvoxamine	tyrosine kinase inhibitors	NA	NA	NA	NA	NA	NA	NA	1.61	0.59	4.26	33.9	-32.74	109.92	LOW	1.61	0.59	4.26	33.9	-32.74	109.92	LOW	Imprecisionx2
fluvoxamine	umifenovir	NA	NA	NA	NA	NA	NA	NA	0.99	0.36	2.61	-3.49	-100.93	85.87	VERY LOW	0.99	0.36	2.61	-3.49	-100.93	85.87	VERY LOW	RoB, Imprecisionx2
fluvoxamine	vitamin C	NA	NA	NA	NA	NA	NA	NA	1.08	0.41	2.87	4.87	-78.84	89.63	VERY LOW	1.08	0.41	2.87	4.87	-78.84	89.63	VERY LOW	RoB, Imprecisionx2
fluvoxamine	vitamin D	NA	NA	NA	NA	NA	NA	NA	1.16	0.43	3.1	8.38	-75.92	91.25	VERY LOW	1.16	0.43	3.1	8.38	-75.92	91.25	VERY LOW	RoB, Imprecisionx2
full-dose anticoagulant	GM-CSF inhibitor	NA	NA	NA	NA	NA	NA	NA	1.24	0.85	1.83	21.41	-16.77	56.83	VERY LOW	1.24	0.85	1.83	21.41	-16.77	56.83	VERY LOW	RoB, Imprecisionx2
full-dose anticoagulant	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	0.88	0.68	1.14	-14.9	-44.02	13.69	LOW	0.88	0.68	1.14	-14.9	-44.02	13.69	LOW	RoB, Imprecision
full-dose anticoagulant	IL1 inhibitors	NA	NA	NA	NA	NA	NA	NA	1.28	0.79	2.07	23.87	-26.95	66.63	VERY LOW	1.28	0.79	2.07	23.87	-26.95	66.63	VERY LOW	RoB, Imprecisionx2
full-dose anticoagulant	IL6 receptor antagonists without corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	0.88	0.66	1.14	-15.24	-47.26	15.15	LOW	0.88	0.66	1.14	-15.24	-47.26	15.15	LOW	RoB, Imprecision
full-dose anticoagulant	interferon alfa (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	0	0	0.55	-820.27	-894.44	-225.51	VERY LOW	0	0	0.55	-820.27	-894.44	-225.51	VERY LOW	RoB, Imprecisionx3
full-dose anticoagulant	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	0.95	0.69	1.33	-7.16	-43.85	29.12	LOW	0.95	0.69	1.33	-7.16	-43.85	29.12	LOW	RoB, Imprecision
full-dose anticoagulant	interferon beta (subcutaneous), lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.46	0.25	0.84	-114.99	-229.12	-21.83	VERY LOW	0.46	0.25	0.84	-114.99	-229.12	-21.83	VERY LOW	RoB, Imprecisionx2
intermediate-dose anticoagulant	full-dose anticoagulant	1.47	0.71	3	NA	NA	NA	LOW	0.67	0.28	1.57	NA	NA	NA	VERY LOW	1.2	0.78	1.86	23.71	-25.08	85.12	LOW	Imprecisionx2
full-dose anticoagulant	intranasal corticosteroids	NA	NA	NA	NA	NA	NA	NA	3.05E+06	0.03	1.76E+13	111.62	29.95	147.38	VERY LOW	3.05E+06	0.03	1.76E+13	111.62	29.95	147.38	VERY LOW	RoB, Imprecisionx3
full-dose anticoagulant	ivermectin	NA	NA	NA	NA	NA	NA	NA	1.51	0.88	2.64	36.25	-15.95	79.08	VERY LOW	1.51	0.88	2.64	36.25	-15.95	79.08	VERY LOW	RoB, Imprecisionx2
full-dose anticoagulant	JAK inhibitors	NA NA	NA.	NA.	NA NA	NA NA	NA.	NA NA	1.53	1.07	2.16	39.3	7.51	69.83	MODERATE	1.53	1.07	2.16	39.3	7.51	69.83	MODERATE	RoB
full-dose anticoagulant	lopinavir-ritonavir	NA NA	NA.	NA.	NA NA	NA NA	NA NA	NA NA	0.9	0.68	1.17	-11.57	-43.05	17.92	LOW	0.9	0.68	1.17	-11.57	-43.05	17.92	LOW	RoB. Imprecision
full-dose anticoagulant	melatonin	NA NA	NA.	NA NA	NA NA	NA NA	NA NA	NA NA	22.6	3.31	456.31	114 74	79.01	141.56	VERY LOW	22.6	3.31	456.31	114 74	79.01	141.56	VERY LOW	RoB, Imprecisionx3
full-dose anticoagulant	methylene blue	NA NA	NA.	NA NA	NA NA	NA NA	NA NA	NA NA	1.91	0.97	3.87	52.81	-3.9	96.54	VERY LOW	1.91	0.97	3.87	52.81	-3.9	96.54	VERY LOW	RoB, Imprecisionx2
full-dose anticoagulant	molnupiravir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	15.01	2.36	268.07	110.85	67.72	140.38	VERYLOW	15.01	2.36	268.07	110.85	67.72	140.38	VERYLOW	RoB, Imprecisionx3
full-dose anticoagulant	nitazoxanide	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.77	0.46	6.76	35.45	-115.52	111.66	VERY LOW	1.77	0.46	6.76	35.45	-115.52	111.66	VERY LOW	RoB, Imprecisionx2
full-dose anticoagulant		NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	8.58	1.66	71.81	103.33	46.85	136.61	VERY LOW VERY LOW	8.58	1.66	71.81	103.33	46.85	136.61	VERY LOW	RoB, Imprecisionx2
	omega 3 nirmatrelvir/ritonavir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	8.58 2.70E+09	92.07	71.81 8.22E+19	103.33	101.86	136.61	VERY LOW VERY LOW	8.58 2.70E+09	92.07	71.81 8.22E+19	103.33	46.85 101.86	136.61	VERY LOW VERY LOW	
full-dose anticoagulant		NA NA	NA NA	NA NA	NA NA	NA NA	NA	NA NA	2.70E+09	0.21	8.22E+19 4.69		-297 78		VERY LOW	2.70E+09	0.21	8.22E+19 4.69	-29.98	-297.78		VERY LOW VERY LOW	RoB, Imprecisionx3 RoB, Imprecisionx2
full-dose anticoagulant full-dose anticoagulant	probiotics proxalutamide	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	7.74	4.61	12.99	-29.98 106.7	-297.78 83.24	95.28 130.47	MODERATE	7.74	0.21 4.61	12.99	-29.98 106.7	-297.78 83.24	95.28 130.47	MODERATE	RoB, Imprecisionx2
	F 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7	NA NA	NA NA		NA NA	NA NA			5.07		12.99 25.31	93.04	83.24 35.31		VERY LOW	5.07	1.46		93.04			VERY LOW	
full-dose anticoagulant	recombinant human granulocyte colony-stimulating factor			NA NA		NA NA	NA NA	NA NA		1.46				130.39	LOW LOW			25.31		35.31 -25.01	130.39 35.92		RoB, Imprecisionx2
full-dose anticoagulant	remdesivir	NA	NA	NA	NA		101	NA	1.06	0.79	1.4	5.8	-25.01	35.92		1.06	0.79	14	5.8			LOW	RoB, Imprecision
full-dose anticoagulant	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	1.43	0.5	4.1	26.14	-91.06	94.95	VERY LOW	1.43	0.5	4.1	26.14	-91.06	94.95	VERY LOW	RoB, Imprecisionx2
full-dose anticoagulant	SGLT2 inhibitors	NA	NA	NA	NA	NA	NA	NA	1.3	0.75	2.19	23.37	-32.26	67.94	VERY LOW	1.3	0.75	2.19	23.37	-32.26	67.94	VERY LOW	RoB, Imprecisionx2
full-dose anticoagulant	statins	NA	NA	NA	NA	NA	NA	NA	0.71	0.25	2.1	-48.83	-225.2	64.68	VERY LOW	0.71	0.25	2.1	-48.83	-225.2	64.68	VERY LOW	RoB, Imprecisionx2

Part										Mortality	у													
March Marc	Comparison)							e													
Part	- · · · ·	a		le Ol Iswas lisale	Ol and limit			Ol a limit	Final rating		Ot January Herela	Ol Ilesik		u , , , , ,	Ol	Final rating			Ol was as the it			Ol sur and limit	Final rating	Reasons for
Column						+	_		N/A							VEDVLOW							VEDVLOW	
March Marc																								
Marchester Column			_	-			_					4.65			-			+	4.65					
Accordange Acc		,	NA	NA	NA	NA	NA	NA			0.66	2.95	25.39		83.87	VERY LOW		0.66	2.95	25.39	-60.54	83.87	VERY LOW	
Marchest		vitamin C	NA	NA	NA	NA	NA	NA	NA	1.5	0.74	3.17	33.76	-37.82	86.08	VERY LOW	1.5	0.74	3.17	33.76	-37.82	86.08	VERY LOW	RoB, Imprecisionx2
Column	full-dose anticoagulant	vitamin D	NA	NA	NA	NA	NA	NA	NA	1.63	0.77	3.47	37.27	-34.18	88.96	VERY LOW	1.63	0.77	3.47	37.27	-34.18	88.96	VERY LOW	RoB, Imprecisionx2
		(hydroxy)chloroquine	101	101	1471		NA	NA	NA	0.71	0.49	1.02	-36.31	70.00	0.9	LOW		0.49	1.02	-36.31	-70.98	0.9	LOW	Imprecisionx2
Column C																								
GOSTIAL SAME MARKETSON DE N. D.										0.71	0.48													
Column C				-						0	0							-						
Concessor Conc																								
Part																								.,,,
Conference																								
March Marc	GM-CSF inhibitor		NA	NA	NA	NA	NA	NA	NA	1.22	0.66	2.28			63.68	LOW	1.22		2.28	+	+	63.68	LOW	
Part	GM-CSF inhibitor	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	1.23	0.79	1.91	17.89	-19.34	55.79	LOW	1.23	0.79	1.91	17.89	-19.34	55.79	LOW	Imprecisionx2
Column C	GM-CSF inhibitor	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.73	0.49	1.05	-32.98	-68.67	4.29	VERY LOW	0.73	0.49	1.05	-32.98	-68.67	4.29	VERY LOW	RoB, Imprecisionx2
Property	GM-CSF inhibitor	melatonin	NA	NA	NA	NA	NA	NA	NA	18.17	2.62	372.53	93.33	53	129.74	VERY LOW	18.17	2.62	372.53	93.33	53	129.74	VERY LOW	RoB, Imprecisionx3
Color Colo		methylene blue																						. , ,
Control Cont		·		-																				
March Marc				-														-						-
March Property P		-																****		0.1102				
Control Cont																								
Charlest															_									
Color Colo																								
DECOLUMNIAN M. M. M. M. M. M. M. M	GM-CSF inhibitor		NA	NA	NA	NA	NA	NA	NA	0.85	0.57		-15.61	-51.11	22.18	VERY LOW	0.85	0.57	1.25	-15.61	-51.11	22.18	VERY LOW	
Second column Col	GM-CSF inhibitor	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	1.15	0.39	3.43	4.73	-114.74	78.21	VERY LOW	1.15	0.39	3.43	4.73	-114.74	78.21	VERY LOW	RoB, Imprecisionx2
March Marc	GM-CSF inhibitor	SGLT2 inhibitors	NA	NA	NA	NA	NA	NA	NA	1.04	0.57	1.88	1.96	-56.29	51.98	LOW	1.04	0.57	1.88	1.96	-56.29	51.98	LOW	Imprecisionx2
Mathematical Control of Math	GM-CSF inhibitor	statins					NA	NA	NA		0.2	1.75				VERY LOW		0.2					VERY LOW	RoB, Imprecisionx2
Concess Conc																								
Control Cont			_																					
Control Cont		7																				0.1.00		
March Marc																								
Company Comp																								
Professional Confessional Con																								
Production for the production and			NA	NA	NA	NA	NA	NA	NA	0.99	0.77	1.27	-0.34	-30.71	28.6	MODERATE	0.99	0.77	1.27	-0.34	-30.71	28.6	MODERATE	
Performance (Performance of Composition Continue) Performance of Composition Continue) Per	(hydroxy)chloroquine	interferon alfa (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	0	0	0.62	-805.36	-877.46	-209.55	VERY LOW	0	0	0.62	-805.36	-877.46	-209.55	VERY LOW	
Physiophysiological programme influence and accordance of the August 1 Au	(hydroxy)chloroquine	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	1.07	0.79	1.5	7.74	-27.58	44.01	LOW	1.07	0.79	1.5	7.74	-27.58	44.01	LOW	RoB, Imprecision
Product Prod		17 77 1								0.00														. , ,
Promocylithoroughs 1-20 0-47 3.72 MA NA NA NA NA NA NA NA																								. , , ,
Product processor April Pr																								
																								ROB
Producyphorougher Prod	(,, -,																							RoB
Physionystrocognie																								
Phylogolychocquire		* * * * * * * * * * * * * * * * * * * *																						. , ,
Company Comp		molnupiravir	NA	NA	NA	NA	NA	NA	NA	17.02	2.65	307.65	125.75	84.44	153.26	VERY LOW	17.02	2.65	307.65	125.75	84.44	153.26	VERY LOW	
Product Prod	(hydroxy)chloroquine	nitazoxanide	NA	NA	NA	NA	NA	NA	NA	2	0.51	7.76	50.35	-100.87	126.35		2	0.51	7.76	50.35	-100.87	126.35	LOW	Imprecisionx2
Production Pro	(hydroxy)chloroquine	omega 3	NA	NA	NA	NA	NA	NA	NA	9.69	1.9	80.65	118.23	63.64	149.44	VERY LOW	9.69	1.9	80.65	118.23	63.64	149.44	VERY LOW	RoB, Imprecisionx3
Physionychroscopine	()																							
Production Pro																								
Phydroxy/phrosquire																								
Englishment Series professes inhibitors NA																								
Company Comp			101	101	101		1471		101	1.2	0.02	1.00	20.7		10.20	2011	1.2	0.02	1.00	20.7	0.20	40.20	2011	
Product Prod																								
(hydroxy)chloroquine Subdeside NA		11 11 11 11																						
(hydroxy)chloroquine byrosine kinase inhibitors NA		sulodexide	NA	NA	NA	NA	NA	NA	NA	2.75	0.73	13.61	75.46		134.36	LOW	2.75		13.61	75.46	-39.79	134.36	LOW	
(hydroxy)chloroquine uniflenovir NA	(hydroxy)chloroquine																							,
(hydroxy)chloroquine vitamin C NA															_									
(hydroxy)chloroquine vitamin D vitam				+															+					
IL1 inhibitors IL6 receptor antagonists without corticosteroids (systemic) NA NA NA NA NA NA NA N		** *																						. , ,
IL1 inhibitors Interferon alfa (subcutaneous) NA																								
IL1 inhibitors Interferon beta (subcutaneous) NA																								
IL inhibitors Interferon beta (subcutaneous), lopinavir-ritinavir NA	121 1111111111		161	161	1451		1471		1401	Ü					241.00	VEITH EOW		, , , , , , , , , , , , , , , , , , ,		044.10			TEITH EOTH	
IL1 inhibitors intermediate-dose anticoagulant NA NA NA NA NA NA NA N	12.111111111		161																					
IL1 inhibitors intranasal corticosteroids NA NA NA NA NA NA NA N																								
IL1 inhibitors	1111																				+			
IL1 Inhibitors Iopinavir-itonavir NA NA NA NA NA NA NA N	IL1 inhibitors	ivermectin	NA	NA	NA	NA	NA	NA	NA	1.18	0.6	2.32	12.38	-46.72	71.02	LOW	1.18	0.6	2.32	12.38	-46.72	71.02	LOW	Imprecisionx2
IL1 inhibitors	IL1 inhibitors	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	1.19	0.71	2	15.44	-27.78	65.72	LOW	1.19	0.71	2	15.44	-27.78	65.72	LOW	Imprecisionx2
IL1 inhibitors melatonin NA	IL1 inhibitors	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.7	0.43	1.13	-35.44	-77	14.66	VERY LOW	0.7	0.43	1.13	-35.44	-77	14.66	VERY LOW	
	IL1 inhibitors	melatonin	NA	NA	NA	NA	NA	NA	NA	17.9	2.48	365.93	90.87	45.04	140.33	VERY LOW	17.9	2.48	365.93	90.87	45.04	140.33	VERY LOW	RoB, Imprecisionx3

									Mortalit														/
Comparison		Direct estimate							Indirect estimat							Network estimat							
		Relative estimate			Absolute estimat			Final rating	Relative estimat			Absolute estimat	u - , ,		Final rating	Relative estima	-		Absolute estim	, , , , , ,		Final rating	Reasons for
Treatment 1	Treatment 2			CI upper limit					Point estimate	CI lower limit	CI upper limit		CI lower limit	о. орре:	1/50// 01//	Point estimate		CI upper limit		CI lower limit		LIEBULI OILI	downgrading
IL1 inhibitors	methylene blue	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.49	0.68 1.75	3.33	28.94 86.98	-33.72	88.68 137.01	VERY LOW	1.49	0.68	3.33	28.94 86.98	-33.72	88.68 137.01	VERY LOW VERY LOW	RoB, Imprecisionx2
IL1 inhibitors IL1 inhibitors	molnupiravir nitazoxanide	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	11.76	0.33	221.38 5.55	11.58	36.69 -141.51	98.97	VERY LOW LOW	11.76	1.75 0.33	221.38 5.55	11.58	36.69 -141.51	98.97	LOW	RoB, Imprecisionx3 Imprecisionx2
IL1 inhibitors	omega 3	NA NA	NA NA	NΑ	NA	NΔ	NA NA	NΔ	6.66	1.2	58.12	79.46	17.87	132 65	VERYLOW	6.66	1.2	58 12	79.46	17.87	132 65	VERYLOW	RoB. Imprecisionx3
II 1 inhibitors	nirmatrelvir/ritonavir	NA NA	NA.	NA NA	NA.	NA NA	NA NA	NA NA	2.04F+09	72 12	6 36F+19	100 94	65.25	147.06	VERYLOW	2.04F+09	72 12	6 36F+19	100.94	65.25	147.06	VERYLOW	Imprecisionx3
IL1 inhibitors	probiotics	NA NA	NA NA	NA NA	NA.	NA NA	NA NA	NA NA	0.78	0.15	3.79	-53.85	-320.86	80.3	LOW	0.78	0.15	3.79	-53.85	-320.86	80.3	LOW	Imprecisionx2
IL1 inhibitors	proxalutamide	NA NA	NA.	NA.	NA.	NA NA	NA NA	NA NA	6.05	3.17	11.57	82.83	46.31	129.71	VERY LOW	6.05	3.17	11.57	82.83	46.31	129.71	VERY LOW	RoB, Imprecisionx2
IL1 inhibitors	recombinant human granulocyte colony-stimulating factor	NA NA	NA.	NA.	NA.	NA NA	NA NA	NA NA	3.97	1.07	20.29	69.17	5.49	126.16	VERY LOW	3.97	1.07	20.29	69.17	5.49	126.16	VERY LOW	RoB, Imprecisionx2
IL1 inhibitors	remdesivir	NA	NA	NA	NA	NA	NA	NA	0.83	0.51	1.33	-18.07	-60.23	32.62	VERY LOW	0.83	0.51	1.33	-18.07	-60.23	32.62	VERY LOW	RoB. Imprecisionx2
IL1 inhibitors	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	1.12	0.36	3.49	2.27	-119.37	85.54	VERY LOW	1.12	0.36	3.49	2.27	-119.37	85.54	VERY LOW	RoB, Imprecisionx2
IL1 inhibitors	SGLT2 inhibitors	NA	NA	NA	NA	NA	NA	NA	1.01	0.52	1.96	-0.5	-63.1	59.43	LOW	1.01	0.52	1.96	-0.5	-63.1	59.43	LOW	Imprecisionx2
IL1 inhibitors	statins	NA	NA	NA	NA	NA	NA	NA	0.55	0.19	1.71	-72.7	-250.65	46	VERY LOW	0.55	0.19	1.71	-72.7	-250.65	46	VERY LOW	RoB, Imprecisionx2
IL1 inhibitors	sulodexide	NA	NA	NA	NA	NA	NA	NA	1.9	0.48	9.47	36.69	-82	110.74	LOW	1.9	0.48	9.47	36.69	-82	110.74	LOW	Imprecisionx2
IL1 inhibitors	synthetic VIP	NA	NA	NA	NA	NA	NA	NA	0.64	0.28	1.5	-51.82	-165.27	35.46	LOW	0.64	0.28	1.5	-51.82	-165.27	35.46	LOW	Imprecisionx2
IL1 inhibitors	tyrosine kinase inhibitors	NA	NA	NA	NA	NA	NA	NA	1.76	0.79	4.06	38.92	-21.24	96.34	LOW	1.76	0.79	4.06	38.92	-21.24	96.34	LOW	Imprecisionx2
IL1 inhibitors	umifenovir	NA	NA	NA	NA	NA	NA	NA	1.07	0.48	2.5	1.52	-90.83	73.37	VERY LOW	1.07	0.48	2.5	1.52	-90.83	73.37	VERY LOW	RoB, Imprecisionx2
IL1 inhibitors	vitamin C	NA	NA	NA	NA	NA	NA	NA	1.18	0.52	2.72	9.89	-66.41	76.33	VERY LOW	1.18	0.52	2.72	9.89	-66.41	76.33	VERY LOW	RoB, Imprecisionx2
IL1 inhibitors	vitamin D	NA	NA	NA	NA	NA	NA	NA	1.27	0.55	3.01	13.4	-65.61	81.24	VERY LOW	1.27	0.55	3.01	13.4	-65.61	81.24	VERY LOW	RoB, Imprecisionx2
IL6 receptor antagonists without corticosteroids (systemic)	interferon alfa (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	0	0	0.64	-805.03	-879.44	-213.23	VERY LOW	0	0	0.64	-805.03	-879.44	-213.23	VERY LOW	RoB, Imprecisionx3
IL6 receptor antagonists without corticosteroids (systemic)	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	1.08	0.78	1.52	8.08	-29.78	46.66	LOW	1.08	0.78	1.52	8.08	-29.78	46.66	LOW	RoB, Imprecision
IL6 receptor antagonists without corticosteroids (systemic)	interferon beta (subcutaneous), lopinavir-ritonavir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.53	0.29	0.96	-99.75	-213.02	-6.67 47.04	VERY LOW	0.53	0.29	0.96	-99.75 -8.48	-213.02	-6.67	VERY LOW VERY LOW	RoB, Imprecisionx2
IL6 receptor antagonists without corticosteroids (systemic)	intermediate-dose anticoagulant	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.95 3.50E+06	0.58	1.56 1.93E+13	-8.48 126.86	-75.24 45.03	47.04 164.05	VERY LOW VERY LOW	0.95 3.50E+06	0.58	1.56 1.93E+13	-8.48 126.86	-75.24 45.03	47.04 164.05	VERY LOW VERY LOW	RoB, Imprecisionx2
IL6 receptor antagonists without corticosteroids (systemic)	intranasal corticosteroids ivermectin	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	3.50E+06	0.03	1.93E+13 3.02	126.86 51.49	45.03	164.05 94.45	VERY LOW HIGH	3.50E+06 1.73	1.01	1.93E+13 3.02	126.86 51.49	45.03 0.07	164.05 94.45	VERY LOW HIGH	Imprecisionx3
IL6 receptor antagonists without corticosteroids (systemic)	JAK inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.75	1.01	2.02	54.54	22.65	94.45 86.57	HIGH	1.73	1.01	2.02	54.54	22 65	86.57	HIGH	+
IL6 receptor antagonists without corticosteroids (systemic)	JAK inhibitors lopinavir-ritonavir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA	1.75	0.79	1.33	3.67	-27.15	34.27	LOW	1.75	0.79	1.33	3.67	-27.15	34.27	LOW	RoB. Imprecision
IL6 receptor antagonists without corticosteroids (systemic) IL6 receptor antagonists without corticosteroids (systemic)	melatonin	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	25.86	3.84	509.79	129.97	93.82	157.89	VERY LOW	25.86	3.84	509.79	129.97	93.82	157.89	VERY LOW	RoB, Imprecisionx3
IL6 receptor antagonists without corticosteroids (systemic)	methylene blue	NA NA	NA.	NA.	NA.	NA NA	NA NA	NA NA	2.18	1 12	4.42	68.05	11.53	112.16	VERY LOW	2.18	1 12	4.42	68.05	11.53	112.16	VERYLOW	RoB, Imprecisionx2
IL6 receptor antagonists without corticosteroids (systemic)	molnuniravir	NA NA	NA.	NA.	NA.	NA NA	NA NA	NA NA	17.29	2.75	308.03	126.09	81.85	156 94	VERYLOW	17.29	2.75	308.03	126.09	81.85	156.94	VERYLOW	RoB. Imprecisionx3
IL6 receptor antagonists without corticosteroids (systemic)	nitazoxanide	NA NA	NA	NA	NA	NA	NA	NA	2.02	0.52	7.66	50.68	-100.24	127.13	LOW	2.02	0.52	7.66	50.68	-100.24	127.13	LOW	Imprecisionx2
IL6 receptor antagonists without corticosteroids (systemic)	omega 3	NA	NA	NA	NA	NA	NA	NA	9.81	1.92	81.73	118.57	63.69	153.44	VERY LOW	9.81	1.92	81.73	118.57	63.69	153.44	VERY LOW	RoB, Imprecisionx3
IL6 receptor antagonists without corticosteroids (systemic)	nirmatrelvir/ritonavir	NA	NA	NA	NA	NA	NA	NA	3.07E+09	107.63	9.39E+19	140.05	117.37	164.19	VERY LOW	3.07E+09	107.63	9.39E+19	140.05	117.37	164.19	VERY LOW	Imprecisionx3
IL6 receptor antagonists without corticosteroids (systemic)	probiotics	NA	NA	NA	NA	NA	NA	NA	1.14	0.23	5.38	-14.74	-283.46	112.32	LOW	1.14	0.23	5.38	-14.74	-283.46	112.32	LOW	Imprecisionx2
IL6 receptor antagonists without corticosteroids (systemic)	proxalutamide	NA	NA	NA	NA	NA	NA	NA	8.85	5.33	14.82	121.94	98.38	147.04	MODERATE	8.85	5.33	14.82	121.94	98.38	147.04	MODERATE	RoB
IL6 receptor antagonists without corticosteroids (systemic)	recombinant human granulocyte colony-stimulating factor	NA	NA	NA	NA	NA	NA	NA	5.8	1.67	28.75	108.28	50.85	146.82	VERY LOW	5.8	1.67	28.75	108.28	50.85	146.82	VERY LOW	RoB, Imprecisionx2
IL6 receptor antagonists without corticosteroids (systemic)	remdesivir	NA	NA	NA	NA	NA	NA	NA	1.21	0.91	1.59	21.04	-9.24	52.38	VERY LOW	1.21	0.91	1.59	21.04	-9.24	52.38	VERY LOW	RoB, Imprecisionx2
IL6 receptor antagonists without corticosteroids (systemic)	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	1.63	0.58	4.68	41.38	-76.66	111.49	VERY LOW	1.63	0.58	4.68	41.38	-76.66	111.49	VERY LOW	RoB, Imprecisionx2
IL6 receptor antagonists without corticosteroids (systemic)	SGLT2 inhibitors	NA	NA	NA	NA	NA	NA	NA	1.48	0.87	2.5	38.61	-16.67	84.53	LOW	1.48	0.87	2.5	38.61	-16.67	84.53	LOW	Imprecisionx2
IL6 receptor antagonists without corticosteroids (systemic)	statins	NA	NA	NA	NA	NA	NA	NA	0.81	0.29	2.38	-33.6	-209.18	79.96	VERY LOW	0.81	0.29	2.38	-33.6	-209.18	79.96	VERY LOW	RoB, Imprecisionx2
IL6 receptor antagonists without corticosteroids (systemic)	sulodexide	NA	NA	NA	NA	NA	NA	NA	2.77	0.74	13.55	75.8	-40.09	136.23	LOW	2.77	0.74	13.55	75.8	-40.09	136.23	LOW	Imprecisionx2
IL6 receptor antagonists without corticosteroids (systemic)	synthetic VIP	NA	NA	NA	NA	NA	NA	NA	0.94	0.45	1.94	-12.71	-122.73	64.61	LOW	0.94	0.45	1.94	-12.71	-122.73	64.61	LOW	Imprecisionx2
IL6 receptor antagonists without corticosteroids (systemic)	tyrosine kinase inhibitors	NA	NA	NA	NA	NA	NA	NA	2.58	1.28	5.31	78.03	24.97	119.03	LOW	2.58	1.28	5.31	78.03	24.97	119.03	LOW	Imprecisionx2
IL6 receptor antagonists without corticosteroids (systemic)	umifenovir	NA	NA	NA	NA	NA	NA	NA	1.58	0.76	3.33	40.63	-45.45	100.01	VERY LOW	1.58	0.76	3.33	40.63	-45.45	100.01	VERY LOW	RoB, Imprecisionx2
IL6 receptor antagonists without corticosteroids (systemic)	vitamin C	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.72	0.85	3.62	48.99 52.51	-23.4 -19.67	101.47 106.54	VERY LOW VERY LOW	1.72	0.85	3.62	48.99 52.51	-23.4 -19.67	101.47 106.54	VERY LOW VERY LOW	RoB, Imprecisionx2
interferon alfa (subcutaneous)	interferon beta (subcutaneous)	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	7.80E+05	1.72	3.94 5.52E+21	52.51 813.1	-19.67 218.79	106.54 895.68	VERY LOW VERY LOW	7.80E+05	1.72	5.52E+21	52.51 813.1	-19.67 218.79	106.54 895.68	VERY LOW VERY LOW	RoB, Imprecisionx2 RoB, Imprecisionx3
interferon alfa (subcutaneous)	interferon beta (subcutaneous) interferon beta (subcutaneous), lopinavir-ritonavir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	7.80E+05 3.94E+05	0.81	2.82E+21	705.28	109.59	845.79	VERY LOW	7.80E+05 3.94E+05	0.81	2.82E+21	705.28	109.59	845.79	VERY LOW VERY LOW	RoB, Imprecisionx3
interferon alfa (subcutaneous)	internediate-dose anticoagulant	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	6.76E+05	1.6	4.97E+21	796.55	200.46	898.39	VERY LOW	6.76E+05	1.6	4.97E+21	796.55	200.46	898.39	VERY LOW	RoB, Imprecisionx3
interferon alfa (subcutaneous)	intermediate-dose anticoaguiant intranasal corticosteroids	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	2.09F+13	2.94	4.97E+21 1.63E+29	931.89	281.95	1 000 00	VERYLOW	2.09F+13	2.94	4.97E+21 1.63E+29	931.89	281.95	1 000 00	VERYLOW	RoB, Imprecisionx3
interferon alfa (subcutaneous)	ivermectin	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.31F+06	2.94	8.65F+21	856.52	261.93	945.32	VERYLOW	1.31F+06	2.94	8.65F+21	856.52	261.93	945.32	VERYLOW	RoB, Imprecisionx3
interferon alfa (subcutaneous)	JAK inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.27E+06	2.78	8.74E+21	859.57	265.41	932.97	VERY LOW	1.27E+06	2.78	8.74E+21	859.57	265.41	932.97	VERY LOW	RoB, Imprecisionx3
interferon alfa (subcutaneous)	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	7.60E+05	1.6	5.22E+21	808.69	214.22	881.7	VERY LOW	7.60E+05	1.6	5.22E+21	808.69	214.22	881.7	VERY LOW	RoB, Imprecisionx3
interferon alfa (subcutaneous)	melatonin	NA NA	NA	NA	NA	NA	NA	NA	1.65E+07	34.44	1.82E+23	935	343.06	999.44	VERY LOW	1.65E+07	34.44	1.82E+23	935	343.06	999.44	VERY LOW	RoB, Imprecisionx3
interferon alfa (subcutaneous)	methylene blue	NA	NA	NA	NA	NA	NA	NA	1.58E+06	3.55	1.20E+22	873.08	273.22	961.39	VERY LOW	1.58E+06	3.55	1.20E+22	873.08	273.22	961.39	VERY LOW	RoB, Imprecisionx3
interferon alfa (subcutaneous)	molnupiravir	NA	NA	NA	NA	NA	NA	NA	1.08E+07	24.59	1.45E+23	931.12	341.16	999.21	VERY LOW	1.08E+07	24.59	1.45E+23	931.12	341.16	999.21	VERY LOW	RoB, Imprecisionx3
interferon alfa (subcutaneous)	nitazoxanide	NA	NA	NA	NA	NA	NA	NA	1.24E+06	3.23	7.67E+21	855.71	258.9	980.41	VERY LOW	1.24E+06	3.23	7.67E+21	855.71	258.9	980.41	VERY LOW	RoB, Imprecisionx3
interferon alfa (subcutaneous)	omega 3	NA	NA	NA	NA	NA	NA	NA	7.56E+06	13.58	4.35E+22	923.6	327.81	997.68	VERY LOW	7.56E+06	13.58	4.35E+22	923.6	327.81	997.68	VERY LOW	RoB, Imprecisionx3
interferon alfa (subcutaneous)	nirmatrelvir/ritonavir	NA	NA	NA	NA	NA	NA	NA	3.17E+15	1.62E+04	1.17E+41	945.07	350.77	1,000.00	VERY LOW	3.17E+15	16,172.86	1.17E+41	945.07	350.77	1,000.00	VERY LOW	RoB, Imprecisionx3
interferon alfa (subcutaneous)	probiotics	NA	NA	NA	NA	NA	NA	NA	7.79E+05	1.9	6.40E+21	790.29	206.32	964.03	VERY LOW	7.79E+05	1.9	6.40E+21	790.29	206.32	964.03	VERY LOW	RoB, Imprecisionx3
interferon alfa (subcutaneous)	proxalutamide	NA	NA	NA	NA	NA	NA	NA	6.45E+06	14.67	4.71E+22	926.96	332.48	988.41	VERY LOW	6.45E+06	14.67	4.71E+22	926.96	332.48	988.41	VERY LOW	RoB, Imprecisionx3
interferon alfa (subcutaneous)	recombinant human granulocyte colony-stimulating factor	NA	NA	NA	NA	NA	NA	NA	5.70E+06	9.53	2.71E+22	913.31	314.65	993.71	VERY LOW	5.70E+06	9.53	2.71E+22	913.31	314.65	993.71	VERY LOW	RoB, Imprecisionx3
interferon alfa (subcutaneous)	remdesivir	NA	NA	NA	NA	NA	NA	NA	8.96E+05	1.89	6.21E+21	826.06	230.93	899.58	VERY LOW	8.96E+05	1.89	6.21E+21	826.06	230.93	899.58	VERY LOW	RoB, Imprecisionx3
interferon alfa (subcutaneous)	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	1.37E+06	2.59	8.78E+21	846.4	255.03	962.89	VERY LOW	1.37E+06	2.59	8.78E+21	846.4	255.03	962.89	VERY LOW	RoB, Imprecisionx3
interferon alfa (subcutaneous)	SGLT2 inhibitors	NA	NA	NA	NA	NA	NA	NA	1.11E+06	2.36	7.63E+21	843.63	248.99	934.17	VERY LOW	1.11E+06	2.36	7.63E+21	843.63	248.99	934.17	VERY LOW	RoB, Imprecisionx3
interferon alfa (subcutaneous)	statins	NA	NA	NA	NA	NA	NA	NA	6.06E+05	1.37	4.01E+21	771.43	176.53	934.19	VERY LOW	6.06E+05	1.37	4.01E+21	771.43	176.53	934.19	VERY LOW	RoB, Imprecisionx3
interferon alfa (subcutaneous)	sulodexide	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	2.14E+06	4.01 1.53	1.37E+22	880.83	286.59	986.96	VERY LOW	2.14E+06	4.01	1.37E+22	880.83	286.59	986.96	VERY LOW	RoB, Imprecisionx3
interferon alfa (subcutaneous)	synthetic VIP		NA NA	NA NA					6.74E+05		5.00E+21	792.32	198.95	917.26	VERY LOW	6.74E+05	1.53	5.00E+21	792.32	198.95	917.26	VERY LOW	RoB, Imprecisionx3
interferon alfa (subcutaneous)	tyrosine kinase inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.96E+06 1.06E+06	4.33	1.37E+22 7.78F+21	883.05 845.66	283.62 251.66	967.9 951.03	VERY LOW VERY LOW	1.96E+06 1.06E+06	4.33	1.37E+22 7.78E+21	883.05 845.66	283.62 251.66	967.9 951.03	VERY LOW VERY LOW	RoB, Imprecisionx3
interferon alfa (subcutaneous) interferon alfa (subcutaneous)	umifenovir vitamin C	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.06E+06 1.25E+06	2.51	7.78E+21 9.60E+21	845.66 854.02	251.66 250.51	951.03 953.4	VERY LOW VERY LOW	1.06E+06 1.25E+06	2.51	7.78E+21 9.60E+21	845.66 854.02	251.66 250.51	951.03 953.4	VERY LOW VERY LOW	RoB, Imprecisionx3 RoB, Imprecisionx3
interferon alla (subcutaneous)	vitamin C vitamin D	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.40E+06	2.81	9.00E+21 9.15E+21	857.53	254.38	956.27	VERY LOW	1.40E+06	2.81	9.60E+21 9.15E+21	857.53	254.38	956.27	VERY LOW VERY LOW	RoB, Imprecisionx3
interieron aira (subcutaneous)	interferon beta (subcutaneous), lopinavir-ritonavir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.49	0.26	9.15E+21 0.91	-107.82	-224.72	-12.01	VERY LOW	0.49	0.26	9.15E+21 0.91	-107.82	-224.72	-12.01	VERY LOW	RoB, Imprecisionx2
interferon beta (subcutaneous)	interneron beta (subcutaneous), lopinavir-ritonavir intermediate-dose anticoagulant	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NΑ	0.49	0.26	1.48	-107.82	-224.72 -86.63	-12.01 42.06	VERYLOW	0.49	0.52	1.48	-107.82	-224.72 -86.63	42.06	VERYLOW	RoB, Imprecisionx2
interferon beta (subcutaneous)	intermediate-dose articoaguiant	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	3.24F+06	0.03	1.40 1.94F+13	118 78	31.07	162.83	VERYLOW	3.24F+06	0.03	1.46 1.94F+13	118.78	31.07	162.83	VERYLOW	RoB, Imprecisionx3
interferon beta (subcutaneous)	ivermectin	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.6	0.03	2.86	43.41	-12.55	92	VERY LOW	1.6	0.03	2.86	43.41	-12.55	92	VERY LOW	RoB, Imprecisionx2
Interior Deta (Subcutarious)	Ivermocum	INC	ING	130	130	110	110	110	1.0	0.0	2.00	70.71	-12.00	OL.	VEIXI LOW	1.0	0.0	2.00	75.71	-12.00	02	VEIXT LOW	

Part										Mortality														
March Marc	Comparison										9		I					e .		I				4
Property of the color of the	Treatment 1	Treatment 2		CI lower limit	Cl upper limit			Cl upper limit	Final rating		CI lower limit	Cl upper limit		u , , , , ,	Cl upper limit	Final rating		CI lower limit	Cl upper limit			Cl upper limit	Final rating	Reasons for
No. of Control No.		***************************************					_		NA							MODERATE							MODERATE	
March Marc	interferon beta (subcutaneous)	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.96	0.67	1.3	-4.41	-42.48	31.27	LOW	0.96	0.67	1.3	-4.41	-42.48	31.27		RoB, Imprecision
Property Service Property Se	interferon beta (subcutaneous)	melatonin	NA	NA	NA	NA	NA	NA	NA	23.91	3.45	480.19	121.0	00.70	100.00	VEICE COTT	20.01	3.45	480.19	121.9	80.76	156.83	VERY LOW	RoB, Imprecisionx3
Property		methylene blue									0.00													· · · · · · · · · · · · · · · · · · ·
Section Column																								. , ,
Property																								
Property of property of the control of the contro		,	101	161	1471				1471		1.70		110.40		101.01			1.70		110.40		101.01		
Control Cont		111 111	NA		NA	NA	NA		NA															
Part Column Col	interferon beta (subcutaneous)	proxalutamide	NA	NA	NA	NA	NA	NA	NA	8.2	4.69	14	113.86	82.23	145.57	MODERATE	8.2	4.69	14	113.86	82.23	145.57	MODERATE	
Manuscript	interferon beta (subcutaneous)	recombinant human granulocyte colony-stimulating factor	NA	NA	NA	NA	NA	NA	NA	5.36	1.52	26.72	100.2	39.56	144.04	VERY LOW	5.36	1.52	26.72	100.2	39.56	144.04	VERY LOW	RoB, Imprecisionx2
Property	interferon beta (subcutaneous)	remdesivir													_									
Column																								
Part					1471		1471		101	1.01						VEICE COTT	1.01						VEITH LOW	
March Marc																								· · · · · · · · · · · · · · · · · · ·
March State March Marc																								
Section of the column Sect	interferon beta (subcutaneous)	tyrosine kinase inhibitors	NA	NA	NA	NA	NA	NA	NA	2.39	1.13	5.03	69.95	12.29	116.19	VERY LOW	2.39	1.13	5.03	69.95	12.29	116.19	VERY LOW	
Part	interferon beta (subcutaneous)	umifenovir					NA	NA																
Procession Pro																								
Professional Confessional Con																		+	-					
Part																								
March Marc																								
Processor Proc															_									
Part					2.88								NA											
Tell continue Tell continu			NA	NA	NA	NA	NA	NA	NA	48.96	6.62	1009.57	229.72	136.68	342.88	VERY LOW	48.96	6.62	1,009.57	229.72	136.68	342.88	VERY LOW	
Performance	1 2 1	methylene blue																						
## Processes Pro		molnupiravir																						
Part	and the second control of the second control																							. , ,
Perform to the possible poss																								. , , ,
Principle of the Confession Agreement Prin																								
Professional Confessional September Professional Confessional September Professional Confessional September Professional Confessional September Professional Sept		proxalutamide	NA	NA	NA	NA	NA	NA	NA	16.67	8.04	35.16	221.68	130.56	334.38	VERY LOW	16.67	8.04	35.16	221.68	130.56	334.38	VERY LOW	
Performance in continue continue without process relative as the information of the continue	interferon beta (subcutaneous), lopinavir-ritonavir	recombinant human granulocyte colony-stimulating factor	NA	NA	NA	NA	NA	NA	NA	11.01	2.83	58.42	208.03	105.32	325.3	VERY LOW	11.01	2.83	58.42	208.03	105.32	325.3	VERY LOW	RoB, Imprecisionx2
Performent in Entire Annual Programmer Part Performent in Entire Control Performent i																								
March Marc			161	101	161		1471		1471						277.12					141.12				
Performance of contract contract and contr							1471																	
### Part																								
International Engineering																								
Interior Designations of September Sep	interferon beta (subcutaneous), lopinavir-ritonavir	tyrosine kinase inhibitors	NA	NA	NA	NA	NA	NA	NA	4.85	2.02	12.13	177.77	75.59	294.34	VERY LOW	4.85	2.02	12.13	177.77	75.59	294.34	VERY LOW	
Performer fine Indicatements (a proper of from the Indicatements (a proper of from the Indicatements (b) NA NA NA NA NA NA NA N	interferon beta (subcutaneous), lopinavir-ritonavir	umifenovir	NA	NA	NA	NA	NA	NA	NA	2.99	1.23	7.55	140.38	17.75	268.63	VERY LOW	2.99	1.23	7.55	140.38	17.75	268.63	VERY LOW	RoB, Imprecisionx2
######################################				-														+	+					
Intermediade does articologistic No.	and the second s																							· · · · · · · · · · · · · · · · · · ·
Performed the Authors of the Ministry of the											0.00													
Province de de servinoquient		10.000																						
Part																		-						
Informative Code anticologuist Mode Mo	intermediate-dose anticoagulant	melatonin	NA	NA	NA	NA	NA	NA	NA	27.09	3.71	543.85	138.45	81.87	205.15	VERY LOW	27.09	3.71	543.85	138.45	81.87	205.15	VERY LOW	RoB, Imprecisionx3
Intermediate-lose antinosopulari (intermediate-lose antinosopulari (interm		·		-														+						
Informedate-doss am/locagulant omega 3 NA																								
Intermediate-doese anticoagulant productions and productions and productions and productions and productions are producted as a production of the production																								
Intermediate-lose articoagulated Probibities NA		•																-						
Intermediate-does anticoagulant proxabilization of anticoagulant process anticoagulant p																								
Intermediate-does anticoagulant recombiant furnam granulogie colory-atimulating factor NA			NA	NA	NA	NA	NA	NA NA	NA	9.3	4.82	18	130.41	79.04	194.96	VERY LOW	9.3	4.82	18	130.41	79.04	194.96	VERY LOW	
Intermediate-dose anticoagulant serine protease inhibitors NA			NA				NA	NA			1.63								31.44					RoB, Imprecisionx2
Intermediate-dose anticoagulant SGLT2 inhibitors NA																								
Intermediate-dose anticoagulant statins NA																								. , , ,
Intermediate-dose anticoagulant subdexide NA																								
Intermediate-dose anticoagulant synthetic VIP NA																								
Intermediate-dose anticoagulant by rosin's kinase inhibitors NA				+						1														
Intermediate-dose anticoagulant umifenovir NA		3								2.72							2.72			+				
Intermediate-dose anticoagulant Vitamin D NA		umifenovir			NA					1.66		3.94	49.1	-49.33		VERY LOW			3.94		-49.33	136.14	VERY LOW	
intransal corticosteroids Nermectin NA NA NA NA NA NA NA N			101	101	161		1471		1401		0.0					VEICE COTT				07.47		100.7	VEITH LOW	
Intransaci corticosteroids JAK inhibitors NA NA NA NA NA NA NA N			161				1471			1.95	0.84							0.84						
Intransal corticosteroids Iopinavir-ritionavir NA										0	0							0						
Infransasi corticosteroids Melationin NA																					100.0			
infransasi corticosteroids methylene blue NA		To produce the second s								0							-							
Intransasal corticosteroids molnupiravir NA										0	0													
Intransasal corticosteroids nitazoxanide NA			NA	NA	NA	NA	NA	NA	NA	0	0	1696.67	-0.77		85.12	VERY LOW	0	0	1,696.67	-0.77	-53.73	85.12	VERY LOW	
	intranasal corticosteroids	nitazoxanide	NA	NA	NA	NA	NA	NA	NA	0	0	104.77	-76.18	-238.69	26.97	VERY LOW	0	0	104.77	-76.18	-238.69	26.97	VERY LOW	Imprecisionx3

The column The										Mortalit	у													
Marci Marc	Comparison									Indirect estimat														
## or below for the control of the c	- · · · ·	T		e Culavia diseit	Ol and limit			Ol timit	Final rating		Ol Januar Harit	Ol Ilasia			Ol	Final rating			Ol			Ol	Final rating	Reasons for
The second sec									NA	Point estimate	CI lower limit					VERVIOW	Point estimate	CI lower limit					VERVIOW	
The column										5.52F+05	0						5.52F+05	0						
Part							_				0						+	0		+		+ + +		-
Part	intranasal corticosteroids	proxalutamide	NA	NA	NA	NA	NA	NA	NA	0	0	303.37	-4.92	-28.53	76.52	VERY LOW	0	0	303.37	-4.92	-28.53	76.52	VERY LOW	RoB, Imprecisionx3
## Control of the con	intranasal corticosteroids	recombinant human granulocyte colony-stimulating factor	NA	NA	NA	NA	NA	NA	NA	0	0	195.39	-18.58	-85.39	56.93	VERY LOW	0	0	195.39	-18.58	-85.39	56.93	VERY LOW	RoB, Imprecisionx3
March Marc	intranasal corticosteroids		NA	NA	NA	NA	NA	NA	NA	0	0	41.14	-105.82	-141.25	-22.94	VERY LOW	0	0	41.14	-105.82	-141.25	-22.94	VERY LOW	RoB, Imprecisionx3
The column The	intranasal corticosteroids			101	1471	1471			1471	0	0	00.70				VEITI LOW	0	0						RoB, Imprecisionx3
Anthon Column C		111111111111111111111111111111111111111								0	0													
Principle Prin		****								0	0													
March Company March Compan					-						ŭ													
## Company of the Com		·								0	-													
March Marc										0	0													
March Company Compan										0	0													
	intranasal corticosteroids	vitamin D	NA	NA	NA	NA	NA	NA	NA	0	0		-74.35	-156.42		VERY LOW	0	0	+	-74.35	-156.42	1.54	VERY LOW	
March Marc	ivermectin	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	1.01	0.55	1.81	3.06	-40.45	55.51	LOW	1.01	0.55	1.81	3.06	-40.45	55.51	LOW	Imprecisionx2
Margar Properties 15	lopinavir-ritonavir	ivermectin	1.98	0.03	119.26	NA	NA	NA	VERY LOW	1.66	0.96	2.93	NA	NA	NA	VERY LOW	1.68	0.98	2.93	47.82	-3.24	89.93	LOW	Imprecisionx2
Property 10	ivermectin	melatonin	NA	NA	NA	NA	NA	NA	NA	14.76	2.07	320.45		35.06	128.18		14.76	2.07	320.45	78.49	35.06	128.18	VERY LOW	RoB, Imprecisionx3
		,																						
Part											_													
										_							-	-						
		-																						
March Section Sectio															113.73									
Second	ivermectin		NA	NA	NA	NA	NA	NA	NA	0.7	0.4	1.2	-30.45	-72.7	20.75	VERY LOW	0.7	0.4	1.2	-30.45	-72.7	20.75	VERY LOW	
Personal Column	ivermectin		NA	NA	NA	NA	NA	NA	NA	0.95	0.3	2.95	-10.11	-133.6	74.27	VERY LOW	0.95	0.3	2.95	-10.11	-133.6	74.27	VERY LOW	RoB, Imprecisionx2
	ivermectin	SGLT2 inhibitors	NA	NA	NA		NA	NA	NA	0.86	0.42	1.73	-12.88	-75.93	48.02	LOW	0.86	0.42	1.73	-12.88	-75.93	48.02	LOW	Imprecisionx2
Marche M	ivermectin	statins																				51100		RoB, Imprecisionx2
Description Proport Content Professor 15																								
Married Marr											_													
March Marc											0.02													
March Marc	100																							
Max Property Max																						- 1101		
Mathematical Math M																								
March Marc	JAK inhibitors	melatonin	NA	NA	NA	NA	NA	NA	NA	14.87	2.11	301.23	75.43	39.14	103.57	VERY LOW	14.87	2.11	301.23	75.43	39.14	103.57	VERY LOW	RoB, Imprecisionx3
Marchellon Mar		methylene blue																						
April Apri	1 1111																							
All Compositions											0.00													
JAK Pubbles productions		•																						. , ,
## AN FIRMSHOPS PROMISSION PROCESSAN PROCESSAN PRO											_													
Mix milestors Mix months of the mining granularity lets Mix Mix NA NA NA NA NA NA NA N																								
All An Inhabitis		p. c.																						· · · · · · · · · · · · · · · · · · ·
Ask mileture Sector problems MA MA MA MA MA MA MA M			NA	NA	NA	NA	NA	NA	NA											-33.51				
Applications Solid Problems NA NA NA NA NA NA NA N	JAK inhibitors	serine protease inhibitors	NA	NA		NA	NA	NA	NA	0.93	0.32	2.79	-13.17	-130.76	56.13	VERY LOW	0.93	0.32	2.79	-13.17	-130.76	56.13	VERY LOW	RoB, Imprecisionx2
Michibitis Successive NA NA NA NA NA NA NA N	JAK inhibitors		NA	NA	NA	NA	NA	NA	NA	0.85	0.48	1.5	-15.94	-70.83	28.72	LOW	0.85	0.48	1.5	-15.94	-70.83	28.72	LOW	
JASK imblistics Synthesis (Profile Secretary Profile Secretary		statins					NA	NA	NA			1.4								-88.14		25.68	VERY LOW	RoB, Imprecisionx2
MAX																						+		
JAK rinkblos																								
Also		V																						
March Marc																	-							
Expression Section S											_													
Indipart-infloative		VICEITIN D	101		101	100	1471	101	1471	1.01	0.40	2.00	2.01	14.00	00.00	VEITI LOW	1.01	0.40	2.00	2.04	14.00	00.00	TEITH EOTH	
																								The Little Control of
	lopinavir-ritonavir	molnupiravir	NA	NA	NA	NA	NA	NA	NA	16.77	2.62	301.02	122.42	79.61	151.38	VERY LOW	16.77	2.62	301.02	122.42	79.61	151.38	VERY LOW	
Implication		nitazoxanide	NA	NA	NA	NA	NA	NA	NA	1.96	0.51	7.56			122.38	VERY LOW	1.96	0.51	7.56		-104.2	122.38	VERY LOW	
Independent	lopinavir-ritonavir	omega 3	NA	NA	NA	NA	NA	NA	NA	9.51	1.85	79.46	114.9	59.14	147.25	VERY LOW	9.51	1.85	79.46	114.9	59.14	147.25	VERY LOW	RoB, Imprecisionx3
Independent																								
Independent	·									- ""								+						
Image: Company Imag	The state of the s	F																						
Icpinavir-itlonavir Serine protease inhibitors NA NA NA NA NA NA NA N																								
Icpinavir-intonavir SGLT2 inhibitors NA NA NA NA NA NA NA N																								
International Communication Inte	·				1451		1471		1471							VEITH EOW				07.77				
Indipolariari Sulodexide NA																								The transfer of the transfer o
Copinavir-itlonavir Synthetic VIP NA																								RoB, Imprecisionx2
		0								2.7														
	The state of the s	7	NA	NA	NA	NA	NA	NA	NA	2.51	1.24	5.18	74.36	21.65	114.32	VERY LOW	2.51	1.24	5.18	74.36	21.65	114.32	VERY LOW	
	umifenovir	lopinavir-ritonavir	0.97	0.02	58.22	NA	NA	NA	VERY LOW	0.67	0.3	1.39	NA	NA	NA	VERY LOW	0.65	0.31	1.35	-36.96	-95.68	49.33	VERY LOW	RoB, Imprecisionx2
Iopinaviriftonavir vilamin D NA	lopinavir-ritonavir	vitamin C	NA	NA	NA	NA	NA	NA	NA	1.67	0.83	3.54	45.33	-26.23	97.19	VERY LOW	1.67	0.83	3.54	45.33	-26.23	97.19	VERY LOW	RoB, Imprecisionx2
	lopinavir-ritonavir	vitamin D	NA	NA	NA	NA	NA	NA	NA	1.81	0.87	3.82	48.84	-21.78	101.63	VERY LOW	1.81	0.87	3.82	48.84	-21.78	101.63	VERY LOW	RoB, Imprecisionx2

Second Column Second Colum										Mortality	/													
March Marc	Comparison										9		1							1				
The column Column	Transment 1	Treetment 2			Cl upper limit			Cl upper limit	Final rating		CL lower limit	Cl upper limit			Cl upper limit	Final rating			Clupper limit			Clupper limit	Final rating	
### 1941 195 195 195 195 195 195 195 195 195 19									NΔ		O O					VERYLOW		Ci lower illilit					VERYLOW	
The column The			NA	NA	NA	NA	NA	NA	NA	0.72	0.02							0.02	18.65					
Part	melatonin	nitazoxanide	NA	NA	NA	NA	NA	NA	NA	0.07	0	0.89	-79.29	-229.4	-4.93	VERY LOW	0.07	0	0.89	-79.29	-229.4	-4.93	VERY LOW	RoB, Imprecisionx3
The column Column	melatonin	omega 3																						
Second Column											4.06							4.06						. , ,
Column C											0							0						
March Marc			101	101	1471				1471															
Part											0.01													
Second Column		2 222									0													
March Marc		SGLT2 inhibitors	NA	NA	NA	NA	NA	NA	NA	0.06	0			-145.36	-44.08	VERY LOW		0	0.42	-91.37	-145.36			
Column	melatonin	statins	NA	NA	NA	NA	NA	NA	NA	0.03	0	0.29	-163.57	-340.61	-46.95	VERY LOW	0.03	0	0.29	-163.57	-340.61	-46.95	VERY LOW	RoB, Imprecisionx3
Property Property											0													
		·			101				1401		٥													
March Marc		y								***												0.01		· · · · · · · · · · · · · · · · · · ·
March Marc		1 1 1									0							0						
March Company March March Company March Marc											0							0						
Part	methylene blue	molnupiravir	NA	NA	NA	NA	NA	NA	NA	8.06	1.11	155.76	58.04	6.39	114.5	VERY LOW	8.06	1.11	155.76	58.04	6.39	114.5	VERY LOW	
Properties Pro	-																							
Part	·																	_						
Description Company	·										00.00			-						-				
Column	,	F																						
Column C																								
Market M																								
Part			NA	NA	NA	NA	NA	NA	NA	0.74	0.22	2.57	-26.67	-148.6	58.54	VERY LOW	0.74	0.22	2.57	-26.67	-148.6	58.54	VERY LOW	
March Marc	methylene blue	SGLT2 inhibitors																						RoB, Imprecisionx2
Part	·	****																-						
Part																						0.101		
Institution	,																							. , ,
Column C			_																					
Processor Proc	·	vitamin C	NA	NA	NA	NA	NA	NA	NA	0.79	0.3	2.07	-19.06	-98.57	52.5	VERY LOW	0.79	0.3	2.07	-19.06	-98.57	52.5	VERY LOW	
Part	methylene blue	vitamin D	NA	NA	NA	NA	NA	NA	NA	0.85	0.32	2.25	-15.54	-94.77	54.79	VERY LOW	0.85	0.32	2.25	-15.54	-94.77	54.79	VERY LOW	RoB, Imprecisionx2
Procession Max Max	molnupiravir	nitazoxanide									0							0						
Production			161		1451		1471		1401										0.17	7.02		07.02		
Production Pro											4.98							4.98						
Production	·	F 11 11 11									0.03							0.03						
Part	·																							
Production Pro				NA	NA	NA	NA	NA	NA	0.07	0		-105.05	-133.99	-61.81	VERY LOW		0	0.45	-105.05	-133.99	-61.81	VERY LOW	
Performent	molnupiravir	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	0.09	0	0.72	-84.71	-203.8	-10.8		0.09	0	0.72	-84.71	-203.8	-10.8	VERY LOW	RoB, Imprecisionx3
Production Bulletinose NA	molnupiravir	SGLT2 inhibitors		NA			NA	NA	NA		0	0.58			-33.72	VERY LOW	0.08	0	0.58			-33.72		RoB, Imprecisionx3
Part																		, ,						· · · · · · · · · · · · · · · · · · ·
Process part Proc											0.01													
Production of the control of the c											0.01													
Marked M	·				-												-							
Part	molnupiravir	vitamin C	NA	NA	NA	NA	NA	NA	NA	0.1	0.01	0.7	-77.1	-148.59	-18.25	VERY LOW	0.1	0.01	0.7	-77.1	-148.59	-18.25	VERY LOW	RoB, Imprecisionx3
Intervalentie memberientronowis M. M. NA			_												-					+				
Production Pro		·									0.10							0.0		51100				
Probabilistics Proceedings Process Pro	****																							
Procession Pro		,											-								-348.55			+
Interzoxanide Fernicasivi NA																					-35.6			
Part			NA NA	NA.	NA	NA	NA	NA NA	NA	0.6	0.16	2.35	-29.65	-106.36	120.06	VERY LOW		0.16	2.35	-29.65	-106.36	120.06	VERY LOW	
Principle Statins NA NA NA NA NA NA NA N																							VERY LOW	
Part	****																			-				
Initiazosanide Synthetic VIP NA		***************************************																	-					. , ,
Problem Prob																								
Intazovanide unifenovir NA																								
nitazoxanide vitamin C			_																					
nitazoxanide vitamin D	***************************************	1 1 1																						
omega 3 probiblics NA	nitazoxanide	vitamin D				NA	NA	NA	NA		0.21							0.21		1.82				
omega 3 proxalutamide NA			161		1451		1471		1471		12.10							12.10						
omega 3 recombinant human granulocyte colony-stimulating factor NA NA <td></td> <td>p.co.co.co</td> <td></td>		p.co.co.co																						
omega 3 remdesivir NA																								
omega 3 serine protease inhibitors NA																								
omega 3 SGIT2 inhibitors NA NA </td <td></td> <td>10.000000</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>0.0.</td> <td></td>		10.000000									0.0.													
omega 3 statins NA																								
	,														_									
		sulodexide		NA	NA	NA	NA	NA	NA											-42.77		34.86	VERY LOW	RoB, Imprecisionx3

									Mortality	1													
Comparison		Direct estimate							Indirect estimat	e						Network estimate	e						
		Relative estimat	e		Absolute estima	te (per 1,000)			Relative estimate	9		Absolute estimat	e (per 1,000)		Final rating	Relative estima	te		Absolute estim	ate (per 1,000)		Final rating	Reasons for
Treatment 1	Treatment 2	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit	Final rating	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit	Final rating	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit	Final rating	downgrading
omega 3	synthetic VIP	NA	NA	NA	NA	NA	NA	NA	0.1	0.01	0.59	-131.28	-244.07	-43.46	VERY LOW	0.1	0.01	0.59	-131.28	-244.07	-43.46	VERY LOW	RoB, Imprecisionx3
omega 3	tyrosine kinase inhibitors	NA	NA	NA	NA	NA	NA	NA	0.26	0.03	1.57	-40.54	-95.7	19.6	VERY LOW	0.26	0.03	1.57	-40.54	-95.7	19.6	VERY LOW	RoB, Imprecisionx3
omega 3	umifenovir	NA	NA	NA	NA	NA	NA	NA	0.16	0.02	0.94	-77.94	-166.49	-5.96	VERY LOW	0.16	0.02	0.94	-77.94	-166.49	-5.96	VERY LOW	RoB, Imprecisionx3
omega 3	vitamin C	NA	NA	NA	NA NA	NA	NA	NA	0.17	0.02	1.03	-69.58	-144.68	2.64	VERY LOW	0.17	0.02	1.03	-69.58	-144.68 -141.33	2.64	VERY LOW	RoB, Imprecisionx3
omega 3 nirmatrelvir/ritonavir	vitamin D probiotics	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.19	0.02	1.18 0.01	-66.06 -154.79	-141.33 -422.66	3.36 -31.37	VERY LOW	0.19	0.02	0.01	-66.06 -154.79	-141.33 -422.66	3.36 -31.37	VERY LOW VERY LOW	RoB, Imprecisionx3
nirmatreivir/ntonavir	probletics	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0	0	0.01	-154.79	-422.00	-9.77	VERY LOW	0	0	0.01	-154.79	-422.00	-31.37	VERY LOW VERY LOW	Imprecisionx3 RoB, Imprecisionx3
nirmatrelvir/ritonavir	recombinant human granulocyte colony-stimulating factor	NA NA	NA NA	NA.	NA NA	NA.	NA.	NA NA	0	0	0.06	-31.76	-86.14	-5.3	VERY LOW	0	0	0.06	-31.76	-86.14	-5.3	VERY LOW	RoB, Imprecisionx3
nirmatrelvir/ritonavir	remdesivir	NA	NA	NA	NA	NA	NA	NA	0	0	0.01	-119.01	-141.33	-97.05	VERY LOW	0	0	0.01	-119.01	-141.33	-97.05	VERY LOW	RoB, Imprecisionx3
nirmatrelvir/ritonavir	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	0	0	0.02	-98.67	-214.8	-34.24	VERY LOW	0	0	0.02	-98.67	-214.8	-34.24	VERY LOW	RoB, Imprecisionx3
nirmatrelvir/ritonavir	SGLT2 inhibitors	NA	NA	NA	NA	NA	NA	NA	0	0	0.01	-101.44	-152.77	-62.25	VERY LOW	0	0	0.01	-101.44	-152.77	-62.25	VERY LOW	Imprecisionx3
nirmatrelvir/ritonavir	statins	NA	NA	NA	NA	NA	NA	NA	0	0	0.01	-173.64	-348.92	-62.23	VERY LOW	0	0	0.01	-173.64	-348.92	-62.23	VERY LOW	RoB, Imprecisionx3
nirmatrelvir/ritonavir	sulodexide	NA	NA	NA	NA	NA	NA	NA	0	0	0.03	-64.25	-178.05	-10.51	VERY LOW	0	0	0.03	-64.25	-178.05	-10.51	VERY LOW	Imprecisionx3
nirmatrelvir/ritonavir	synthetic VIP	NA	NA	NA	NA	NA	NA	NA	0	0	0.01	-152.76	-261.37	-78.93	VERY LOW	0	0	0.01	-152.76	-261.37	-78.93	VERY LOW	Imprecisionx3
nirmatrelvir/ritonavir	tyrosine kinase inhibitors	NA	NA	NA	NA	NA	NA	NA	0	0	0.02	-62.02	-111.15	-29	VERY LOW	0	0	0.02	-62.02	-111.15	-29	VERY LOW	Imprecisionx3
nirmatrelvir/ritonavir	umifenovir	NA	NA	NA	NA	NA	NA	NA	0	0	0.02	-99.42	-183.11	-45.77	VERY LOW	0	0	0.02	-99.42	-183.11	-45.77	VERY LOW	RoB, Imprecisionx3
nirmatrelvir/ritonavir	vitamin C	NA	NA	NA	NA	NA	NA	NA	0	0	0.02	-91.05	-160.26	-44.18	VERY LOW	0	0	0.02	-91.05	-160.26	-44.18	VERY LOW	RoB, Imprecisionx3
nirmatrelvir/ritonavir	vitamin D	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	7 77	1.56	0.02 40.54	-87.54 136.68	-156.98 12.96	-40.55 404.15	VERY LOW VERY LOW	7 77	1.56	0.02 40.54	-87.54 136.68	-156.98 12.96	-40.55 404.15	VERY LOW VERY LOW	RoB, Imprecisionx3 RoB, Imprecisionx2
probiotics probiotics	proxalutamide recombinant human granulocyte colony-stimulating factor	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	7.77 5.25	1.56	40.54 45.2	136.68	12.96 -10.5	404.15 389	VERY LOW VERY LOW	7.77 5.25	1.56 0.68	40.54 45.2	136.68	12.96	404.15 389	VERY LOW VERY LOW	RoB, Imprecisionx2 RoB, Imprecisionx3
problotics	recombinant numan granulocyte colony-sumulating factor	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.06	0.08	5.08	35.78	-10.5	304 49	VERYLOW	1.06	0.08	5.08	35.78	-10.5	304 49	VERYLOW	RoB, Imprecisionx3
probiotics	serine protease inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.43	0.23	9.46	56.12	-121.44	327.71	VERY LOW	1.43	0.23	9.46	56.12	-121.44	327.71	VERY LOW	RoB, Imprecisionx3
problotics	SGLT2 inhibitors	NA NA	NA NA	NA.	NA NA	NA NA	NA NA	NA NA	1.31	0.26	6.58	53.35	-82.88	325.22	LOW	1.31	0.26	6.58	53.35	-82.88	325.22	LOW	Imprecisionx2
problotics	statins	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.71	0.12	4.73	-18.86	-247.7	278.5	VERY LOW	0.71	0.12	4.73	-18.86	-247.7	278.5	VERY LOW	RoB, Imprecisionx3
probiotics	sulodexide	NA.	NA NA	NA NA	NA	NA NA	NA	NA NA	2.47	0.33	21.84	90.54	-80.18	366.87	VERY LOW	2.47	0.33	21.84	90.54	-80.18	366.87	VERY LOW	Imprecisionx3
probiotics	synthetic VIP	NA	NA	NA	NA	NA	NA	NA	0.83	0.15	4.55	2.03	-169.94	284.31	LOW	0.83	0.15	4.55	2.03	-169.94	284.31	LOW	Imprecisionx2
probiotics	tyrosine kinase inhibitors	NA	NA	NA	NA	NA	NA	NA	2.28	0.42	12.33	92.77	-41.66	362.25	LOW	2.28	0.42	12.33	92.77	-41.66	362.25	LOW	Imprecisionx2
probiotics	umifenovir	NA	NA	NA	NA	NA	NA	NA	1.4	0.25	7.78	55.37	-96.34	329.49	VERY LOW	1.4	0.25	7.78	55.37	-96.34	329.49	VERY LOW	RoB, Imprecisionx3
probiotics	vitamin C	NA	NA	NA	NA	NA	NA	NA	1.51	0.29	8.29	63.73	-81.85	334.17	VERY LOW	1.51	0.29	8.29	63.73	-81.85	334.17	VERY LOW	RoB, Imprecisionx2
probiotics	vitamin D	NA	NA	NA	NA	NA	NA	NA	1.63	0.3	9.03	67.25	-79.58	347.21	VERY LOW	1.63	0.3	9.03	67.25	-79.58	347.21	VERY LOW	RoB, Imprecisionx3
proxalutamide	recombinant human granulocyte colony-stimulating factor	NA	NA	NA	NA	NA	NA	NA	0.66	0.17	3.32	-13.66	-68.37	15.07	VERY LOW	0.66	0.17	3.32	-13.66	-68.37	15.07	VERY LOW	RoB, Imprecisionx2
proxalutamide	remdesivir	NA	NA	NA	NA	NA	NA	NA	0.14	0.08	0.23	-100.9	-124.18	-78.17	MODERATE	0.14	0.08	0.23	-100.9	-124.18	-78.17	MODERATE	RoB
proxalutamide	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	0.18	0.06	0.58	-80.56	-196.21	-15.39	VERY LOW	0.18	0.06	0.58	-80.56	-196.21	-15.39	VERY LOW	RoB, Imprecisionx2
proxalutamide	SGLT2 inhibitors	NA	NA	NA	NA	NA	NA	NA	0.17	0.08	0.33	-83.33	-134.88	-43.85	VERY LOW	0.17	0.08	0.33	-83.33	-134.88	-43.85	VERY LOW	RoB, Imprecisionx2
proxalutamide	statins	NA	NA	NA	NA	NA	NA	NA	0.09	0.03	0.29	-155.53	-330.79	-43.36	VERY LOW	0.09	0.03	0.29	-155.53	-330.79	-43.36	VERY LOW	RoB, Imprecisionx2
proxalutamide	sulodexide	NA	NA	NA	NA	NA	NA	NA	0.31	0.08	1.6	-46.14 -134.65	-160.34	8.65	VERY LOW	0.31	0.08	1.6	-46.14	-160.34	8.65	VERY LOW	RoB, Imprecisionx2
proxalutamide	synthetic VIP	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.11	0.04	0.25	-134.65 -43.91	-243.66 -93.5	-60.45 -9.89	VERY LOW VERY LOW	0.11	0.04	0.25	-134.65 -43.91	-243.66 -93.5	-60.45 -9.89	VERY LOW VERY LOW	RoB, Imprecisionx2 RoB, Imprecisionx2
proxalutamide proxalutamide	tyrosine kinase inhibitors umifenovir	NA NA	NA NA	NΑ	NA NA	NΑ	NA NA	NA NA	0.29	0.13	0.67	-81.31	-93.5 -165.51	-9.89	VERYLOW	0.29	0.13	0.67	-81.31	-93.5 -165.51	-9.89	VERYLOW	RoB, Imprecisionx2
proxalutamide	vitamin C	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.10	0.08	0.42	-72 94	-142.52	-25.38	VERYLOW	0.10	0.08	0.42	-72 94	-142.52	-25.38	VERYLOW	RoB Imprecisionx2
proxalutamide	vitamin D	NA.	NA NA	NA.	NA.	NA.	NA.	NA.	0.21	0.09	0.5	-69.43	-138.5	-21.46	VERY LOW	0.21	0.09	0.5	-69.43	-138.5	-21.46	VERY LOW	RoB. Imprecisionx2
recombinant human granulocyte colony-stimulating factor	remdesivir	NA.	NA NA	NA.	NA.	NA.	NA.	NA.	0.21	0.04	0.72	-87.24	-124.1	-30.42	VERY LOW	0.21	0.04	0.72	-87.24	-124.1	-30.42	VERY LOW	RoB, Imprecisionx2
recombinant human granulocyte colony-stimulating factor	serine protease inhibitors	NA.	NA	NA.	NA	NA.	NA	NA.	0.28	0.04	1.4	-66.91	-186.27	17.6	VERY LOW	0.28	0.04	1.4	-66.91	-186.27	17.6	VERY LOW	RoB, Imprecisionx3
recombinant human granulocyte colony-stimulating factor	SGLT2 inhibitors	NA	NA	NA	NA	NA	NA	NA	0.25	0.05	0.95	-69.67	-130.49	-3.49	VERY LOW	0.25	0.05	0.95	-69.67	-130.49	-3.49	VERY LOW	RoB, Imprecisionx2
recombinant human granulocyte colony-stimulating factor	statins	NA	NA	NA	NA	NA	NA	NA	0.14	0.02	0.73	-141.88	-319.93	-20.9	VERY LOW	0.14	0.02	0.73	-141.88	-319.93	-20.9	VERY LOW	RoB, Imprecisionx3
recombinant human granulocyte colony-stimulating factor	sulodexide	NA	NA	NA	NA	NA	NA	NA	0.48	0.06	3.47	-32.48	-149.52	47.86	VERY LOW	0.48	0.06	3.47	-32.48	-149.52	47.86	VERY LOW	RoB, Imprecisionx3
recombinant human granulocyte colony-stimulating factor	synthetic VIP	NA	NA	NA	NA	NA	NA	NA	0.16	0.03	0.68	-120.99	-235.13	-29.95	VERY LOW	0.16	0.03	0.68	-120.99	-235.13	-29.95	VERY LOW	RoB, Imprecisionx2
recombinant human granulocyte colony-stimulating factor	tyrosine kinase inhibitors	NA	NA	NA	NA	NA	NA	NA	0.45	0.08	1.79	-30.26	-88.19	32.96	VERY LOW	0.45	0.08	1.79	-30.26	-88.19	32.96	VERY LOW	RoB, Imprecisionx2
recombinant human granulocyte colony-stimulating factor	umifenovir	NA	NA	NA	NA	NA	NA	NA	0.27	0.05	1.19	-67.65	-156.31	10.57	VERY LOW	0.27	0.05	1.19	-67.65	-156.31	10.57	VERY LOW	RoB, Imprecisionx2
recombinant human granulocyte colony-stimulating factor	vitamin C	NA	NA	NA	NA	NA	NA	NA	0.3	0.05	1.28	-59.29	-135.83	11.68	VERY LOW	0.3	0.05	1.28	-59.29	-135.83	11.68	VERY LOW	RoB, Imprecisionx2
recombinant human granulocyte colony-stimulating factor	vitamin D	NA	NA	NA	NA	NA	NA	NA	0.32	0.06	1.37	-55.78	-134.73	15.28	VERY LOW	0.32	0.06	1.37	-55.78	-134.73	15.28	VERY LOW	RoB, Imprecisionx2
remdesivir	serine protease inhibitors SGLT2 inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.35	0.48	3.91	20.34 17.57	-97.04 -37.12	89.47 61.88	VERY LOW VERY LOW	1.35	0.48	3.91 2.09	20.34	-97.04 -37.12	89.47 61.88	VERY LOW VERY LOW	RoB, Imprecisionx2
remdesivir remdesivir		NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.67	0.71	2.09	17.57 -54.63	-37.12 -231.09		VERY LOW VERY LOW	0.67	0.71	1.98		-37.12 -231.09	61.88 59.28	VERY LOW VERY LOW	RoB, Imprecisionx2
remdesivir	statins sulodexide	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	2.29	0.24	1.98	-54.63 54.76	-231.09 -59.83	59.28 114.36	VERY LOW	2.29	0.24	1.98	-54.63 54.76	-231.09 -59.83	59.28 114.36	VERY LOW	RoB, Imprecisionx2 RoB, Imprecisionx2
remdesivir	suiodexide synthetic VIP	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.78	0.61	11.19	-33.75	-59.83 -143.31	114.36 43.65	VERY LOW VERY LOW	0.78	0.61	11.19	-33.75	-59.83	114.36 43.65	VERY LOW VERY LOW	RoB, Imprecisionx2
remdesivir	tyrosine kinase inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	2.14	1.05	4.41	56.99	4.27	96.96	VERY LOW	2.14	1.05	4.41	-33.75	4.27	96.96	VERY LOW VERY LOW	RoB, Imprecisionx2
remdesivir	tyrosine kinase innibitors umifenovir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.31	0.63	2.78	19.59	-65.76	77.29	VERY LOW	1.31	0.63	2.78	19.59	-65.76	77.29	VERY LOW VERY LOW	RoB, Imprecisionx2
remdesivir	vitamin C	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.42	0.7	3	27.96	-43.44	79.68	VERY LOW	1.42	0.03	3	27.96	-43.44	79.68	VERY LOW	RoB, Imprecisionx2
remdesivir	vitamin D	NA.	NA NA	NA.	NA	NA NA	NA NA	NA.	1.54	0.74	3.27	31.47	-39.35	83.55	VERY LOW	1.54	0.74	3.27	31.47	-39.35	83.55	VERY LOW	RoB, Imprecisionx2
serine protease inhibitors	SGLT2 inhibitors	NA	NA	NA	NA	NA	NA	NA	0.91	0.28	2.82	-2.77	-86.92	118.96	VERY LOW	0.91	0.28	2.82	-2.77	-86.92	118.96	VERY LOW	RoB, Imprecisionx2
serine protease inhibitors	statins	NA	NA	NA	NA	NA	NA	NA	0.5	0.11	2.16	-74.97	-266.94	89.94	VERY LOW	0.5	0.11	2.16	-74.97	-266.94	89.94	VERY LOW	RoB, Imprecisionx2
serine protease inhibitors	sulodexide	NA	NA	NA	NA	NA	NA	NA	1.7	0.33	10.68	34.42	-96.04	167.41	VERY LOW	1.7	0.33	10.68	34.42	-96.04	167.41	VERY LOW	RoB, Imprecisionx3
serine protease inhibitors	synthetic VIP	NA	NA	NA	NA	NA	NA	NA	0.58	0.16	1.98	-54.09	-184.13	82.6	VERY LOW	0.58	0.16	1.98	-54.09	-184.13	82.6	VERY LOW	RoB, Imprecisionx2
serine protease inhibitors	tyrosine kinase inhibitors	NA	NA	NA	NA	NA	NA	NA	1.58	0.46	5.47	36.65	-45.93	156.95	VERY LOW	1.58	0.46	5.47	36.65	-45.93	156.95	VERY LOW	RoB, Imprecisionx2
serine protease inhibitors	umifenovir	NA	NA	NA	NA	NA	NA	NA	0.98	0.27	3.32	-0.75	-108.93	122.12	VERY LOW	0.98	0.27	3.32	-0.75	-108.93	122.12	VERY LOW	RoB, Imprecisionx2
serine protease inhibitors	vitamin C	NA	NA	NA	NA	NA	NA	NA	1.05	0.31	3.65	7.62	-88.79	133.76	VERY LOW	1.05	0.31	3.65	7.62	-88.79	133.76	VERY LOW	RoB, Imprecisionx2
serine protease inhibitors	vitamin D	NA	NA	NA	NA	NA	NA	NA	1.15	0.32	4.04	11.13	-85.19	136.2	VERY LOW	1.15	0.32	4.04	11.13	-85.19	136.2	VERY LOW	RoB, Imprecisionx2
SGLT2 inhibitors	statins	NA	NA	NA	NA	NA	NA	NA	0.55	0.18	1.79	-72.2	-251.54	50.41	VERY LOW	0.55	0.18	1.79	-72.2	-251.54	50.41	VERY LOW	RoB, Imprecisionx2
SGLT2 inhibitors	sulodexide	NA	NA	NA	NA	NA	NA	NA	1.89	0.46	9.69	37.19	-82.36	114.72	LOW	1.89	0.46	9.69	37.19	-82.36	114.72	LOW	Imprecisionx2
SGLT2 inhibitors	synthetic VIP	NA	NA	NA	NA	NA	NA	NA	0.64	0.27	1.51	-51.32	-166.48	38.91	LOW	0.64	0.27	1.51	-51.32	-166.48	38.91	LOW	Imprecisionx2
SGLT2 inhibitors	tyrosine kinase inhibitors	NA	NA	NA	NA	NA	NA	NA	1.75	0.76	4.1	39.42	-22.94	101.5	LOW	1.75	0.76	4.1	39.42	-22.94	101.5	LOW	Imprecisionx2
SGLT2 inhibitors	umifenovir	NA	NA	NA	NA	NA	NA	NA	1.07	0.45	2.6	2.02	-89.86	77.07	VERY LOW	1.07	0.45	2.6	2.02	-89.86	77.07	VERY LOW	RoB, Imprecisionx2
SGLT2 inhibitors	vitamin C	NA	NA	NA	NA	NA	NA	NA	1.17	0.5	2.82	10.39	-69.02	80.89	VERY LOW	1.17	0.5	2.82	10.39	-69.02	80.89	VERY LOW	RoB, Imprecisionx2
SGLT2 inhibitors	vitamin D	NA	NA	NA	NA	NA	NA	NA	1.26	0.53	3.04	13.9	-65.43	84.49	VERY LOW	1.26	0.53	3.04	13.9	-65.43	84.49	VERY LOW	RoB, Imprecisionx2

									Mortalit	ty													
Comparison		Direct estimate							Indirect estima	te						Network estimat	е						
		Relative estimate	e		Absolute estima	te (per 1,000)		Final rating	Relative estimat	e		Absolute estimat	e (per 1,000)		Final rating	Relative estima	te		Absolute estim	ate (per 1,000)		Final rating	Reasons for
Treatment 1	Treatment 2	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit	rillal fatting	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit	Fillal fatting	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit	rillal fatting	downgrading
statins	sulodexide	NA	NA	NA	NA	NA	NA	NA	3.46	0.62	21.94	109.4	-46.39	296.84	VERY LOW	3.46	0.62	21.94	109.4	-46.39	296.84	VERY LOW	RoB, Imprecisionx3
statins	synthetic VIP	NA	NA	NA	NA	NA	NA	NA	1.16	0.32	4.14	20.89	-137.1	212.02	VERY LOW	1.16	0.32	4.14	20.89	-137.1	212.02	VERY LOW	RoB, Imprecisionx2
statins	tyrosine kinase inhibitors	NA	NA	NA	NA	NA	NA	NA	3.19	0.88	10.96	111.62	-10.63	289.75	VERY LOW	3.19	0.88	10.96	111.62	-10.63	289.75	VERY LOW	RoB, Imprecisionx2
statins	umifenovir	NA	NA	NA	NA	NA	NA	NA	1.93	0.56	6.79	74.23	-65.73	262.33	VERY LOW	1.93	0.56	6.79	74.23	-65.73	262.33	VERY LOW	RoB, Imprecisionx2
statins	vitamin C	NA	NA	NA	NA	NA	NA	NA	2.15	0.6	7.16	82.59	-50.11	264.44	VERY LOW	2.15	0.6	7.16	82.59	-50.11	264.44	VERY LOW	RoB, Imprecisionx2
statins	vitamin D	NA	NA	NA	NA	NA	NA	NA	2.32	0.63	8.04	86.1	-44.11	270.12	VERY LOW	2.32	0.63	8.04	86.1	-44.11	270.12	VERY LOW	RoB, Imprecisionx2
sulodexide	synthetic VIP	NA	NA	NA	NA	NA	NA	NA	0.34	0.06	1.5	-88.51	-213.5	46.19	LOW	0.34	0.06	1.5	-88.51	-213.5	46.19	LOW	Imprecisionx2
sulodexide	tyrosine kinase inhibitors	NA	NA	NA	NA	NA	NA	NA	0.92	0.17	4.07	2.23	-74.18	121.03	LOW	0.92	0.17	4.07	2.23	-74.18	121.03	LOW	Imprecisionx2
sulodexide	umifenovir	NA	NA	NA	NA	NA	NA	NA	0.57	0.1	2.52	-35.17	-139.74	89.93	VERY LOW	0.57	0.1	2.52	-35.17	-139.74	89.93	VERY LOW	RoB, Imprecisionx2
sulodexide	vitamin C	NA	NA	NA	NA	NA	NA	NA	0.62	0.11	2.79	-26.81	-117.25	93.4	VERY LOW	0.62	0.11	2.79	-26.81	-117.25	93.4	VERY LOW	RoB, Imprecisionx2
sulodexide	vitamin D	NA	NA	NA	NA	NA	NA	NA	0.67	0.12	3.03	-23.29	-116.37	97.94	VERY LOW	0.67	0.12	3.03	-23.29	-116.37	97.94	VERY LOW	RoB, Imprecisionx2
synthetic VIP	tyrosine kinase inhibitors	NA	NA	NA	NA	NA	NA	NA	2.73	1.03	7.52	90.74	1.42	204.83	LOW	2.73	1.03	7.52	90.74	1.42	204.83	LOW	Imprecisionx2
synthetic VIP	umifenovir	NA	NA	NA	NA	NA	NA	NA	1.68	0.61	4.77	53.34	-59.07	175.78	VERY LOW	1.68	0.61	4.77	53.34	-59.07	175.78	VERY LOW	RoB, Imprecisionx2
synthetic VIP	vitamin C	NA	NA	NA	NA	NA	NA	NA	1.82	0.68	5.09	61.7	-40.41	178.9	VERY LOW	1.82	0.68	5.09	61.7	-40.41	178.9	VERY LOW	RoB, Imprecisionx2
synthetic VIP	vitamin D	NA	NA	NA	NA	NA	NA	NA	1.97	0.71	5.67	65.22	-37.07	183.21	VERY LOW	1.97	0.71	5.67	65.22	-37.07	183.21	VERY LOW	RoB, Imprecisionx2
tyrosine kinase inhibitors	umifenovir	NA	NA	NA	NA	NA	NA	NA	0.61	0.23	1.67	-37.4	-127.9	34.2	VERY LOW	0.61	0.23	1.67	-37.4	-127.9	34.2	VERY LOW	RoB, Imprecisionx2
tyrosine kinase inhibitors	vitamin C	NA	NA	NA	NA	NA	NA	NA	0.67	0.25	1.81	-29.03	-107.99	39.21	VERY LOW	0.67	0.25	1.81	-29.03	-107.99	39.21	VERY LOW	RoB, Imprecisionx2
tyrosine kinase inhibitors	vitamin D	NA	NA	NA	NA	NA	NA	NA	0.72	0.27	1.94	-25.52	-103.52	42.29	VERY LOW	0.72	0.27	1.94	-25.52	-103.52	42.29	VERY LOW	RoB, Imprecisionx2
umifenovir	vitamin C	NA	NA	NA	NA	NA	NA	NA	1.09	0.4	2.96	8.36	-78.68	105.09	VERY LOW	1.09	0.4	2.96	8.36	-78.68	105.09	VERY LOW	RoB, Imprecisionx2
umifenovir	vitamin D	NA	NA	NA	NA	NA	NA	NA	1.18	0.42	3.27	11.88	-74.97	111.68	VERY LOW	1.18	0.42	3.27	11.88	-74.97	111.68	VERY LOW	RoB, Imprecisionx2
vitamin C	vitamin D	NA	NA	NA	NA	NA	NA	NA	1.09	0.39	2.89	3.51	-82.95	88.14	VERY LOW	1.09	0.39	2.89	3.51	-82.95	88.14	VERY LOW	RoB, Imprecisionx2

										ptom resolution													
Comparison		Direct estimate			Absolute estimat	le (ner 1 000)			Indirect estimate			Absolute estimate	e (per 1 000)		1	Network estimate			Absolute estima	ato (por 1 000)			
Treatment 1	Treatment 2	Point estimate	-	CI upper limit	- Alexandre Alexandre	CI lower limit	CI upper limit	Final rating	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit	Final rating	Point estimate	CI lower limit	CI upper limit		CI lower limit	CI upper limit	Final rating	Reasons for downgrading
antihepaciviral	standard care/placebo	0.69	0.51	0.94	-3.03	-4.87	-0.61	LOW	0.94	0.52	1.68	-0.63	-4.73	6.76	VERY LOW	0.72	0.58	0.91	-2.68	-4.17	-0.93	LOW	RoBx2
azithromycin	standard care/placebo	0.55	0.23	1.31	-4.46	-7.6	3.06	LOW	0.72	0.4	1.26	-2.82	-5.9	2.62	VERY LOW	0.57	0.45	0.74	-4.19	-5.47	-2.62	LOW	RoB, Inconsistency
azithromycin, hydroxychloroquine, oseltamivir	standard care/placebo	NA 0.00	NA 0.40	NA 0.04	NA 0.00	NA 0.05	NA 40.05	NA VERY LOW	1.24 NA	0.79 NA	1.94 NA	2.71 NA	-2.05 NA	9.25	VERY LOW NA	1.24	0.79	1.94	2.71	-2.05	9.25	VERY LOW	RoBx2, Imprecisionx2
cefepime ceftazidime	standard care/placebo	0.66	0.19	2.34	-3.36 -2.85	-8.05 -7.91	13.25 15.04	VERY LOW	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.66	0.45	0.96	-3.23 -2.71	-5.42 -5.08	-0.33 0.42	VERYLOW	RoBx2 RoB Imprecisionx2
clarithromycin	standard care/placebo	0.38	0.11	1.34	-6.14	-8.84	3.4	VERY LOW	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA.	0.45	0.49	0.64	-5.36	-6.73	-3.55	VERY LOW	RoB, Imprecisionx2
IL6 receptor antagonists with corticosteroids (systemic)	standard care/placebo	0.85	0.63	1.17	-1.46	-3.7	1.72	MODERATE	NA	NA	NA	NA	NA	NA	NA	0.85	0.66	1.11	-1.38	-3.39	1.06	LOW	Imprecision
doxycycline	standard care/placebo	1	0.28	3.53	0	-7.1	25.08	VERY LOW	NA	NA	NA	NA	NA	NA	NA	1	0.69	1.45	0.17	-3.07	4.44	LOW	RoB, Imprecision
doxycycline, ivermectin	standard care/placebo	0.81	0.23	2.86	-1.91	-7.65 -8.33	18.45	LOW	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.81	0.54	1.19	-1.75 -4 17	-4.49	1.94	LOW	Imprecisionx2
electrolyzed saline favipiravir	standard care/placebo standard care/placebo	0.67	0.16	2.02 0.92	-4.29 -3.28	-8.33 -5.06	-0.82	LOW	0.76	0.54	1 07	-2.35	-4.51	0.7	LOW	0.57	0.37	0.87	-4.17	-6.22 -4.21	-1.35 -1.57	LOW	RoB, Imprecision
favipiravir, hydrochloroquine	standard care/placebo	1.29	0.35	4.71	2.83	-6.42	36.7	VERY LOW	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA.	1.29	0.77	2.16	3.29	-2.31	11.48	VERY LOW	RoB, Imprecisionx2
GM-CSF inhibitor	standard care/placebo	0.92	0.69	1.18	-0.82	-3.1	1.77	LOW	NA	NA	NA	NA	NA	NA	NA	0.91	0.73	1.13	-0.87	-2.72	1.28	LOW	RoB, Imprecision
(hydroxy)chloroquine	standard care/placebo	0.91	0.78	1.07	-0.87	-2.22	0.69	VERY LOW	0.72	0.47	1.11	-2.78	-5.26	1.06	VERY LOW	0.88	0.77	1	-1.19	-2.31	0.05	VERY LOW	RoBx2, Imprecision
IL1 inhibitors IL6 receptor antagonists without corticosteroids (systemic)	standard care/placebo	0.82 1.09	0.4	1.55	-1.74 0.86	-5.91 -2.92	5.4	LOW	NA NA	NA NA	NA NA	NA	NA	NA NA	NA	0.83 1.09	0.6	1.14	-1.59 0.99	-3.98	1.37	LOW	Imprecisionx2
inhaled corticosteroids (systemic)	standard care/placebo standard care/placebo	0.97	0.71	1.68	-0.26	-2.92	6.69 8.6	VERY LOW	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.98	0.8	1.48	-0.09	-1.97 -3.05	4.76 3.67	LOW	Imprecisionx2 RoB, Imprecision
interferon alfa (subcutaneous)	standard care/placebo	0.86	0.49	3.07	-1.35	-7.5	20.51	VERY LOW	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.86	0.58	1.3	-1.17	-3.05	2.89	VERY LOW	RoBx2, Imprecision
interferon beta (subcutaneous)	standard care/placebo	0.86	0.61	1.21	-1.38	-3.82	2.09	LOW	NA	NA	NA	NA	NA	NA	NA	0.86	0.7	1.06	-1.34	-2.98	0.57	LOW	RoB, Imprecision
interferon beta (subcutaneous), lopinavir-ritonavir	standard care/placebo	1.42	0.4	5.07	4.16	-5.96	40.27	VERY LOW	0.8	0.48	1.32	-2	-5.14	3.18	VERY LOW	0.99	0.74	1.32	-0.05	-2.64	3.13	VERY LOW	RoBx2, Imprecision
intranasal corticosteroids	standard care/placebo	1	0.28	3.6	0	-7.15	25.71	LOW	NA	NA	NA	NA	NA	NA	NA	1	0.63	1.57	0.28	-3.6	5.64	LOW	Imprecisionx2
ivermectin JAK inhibitors	standard care/placebo	0.82	0.49 0.74	1.35	-1.83 -0.74	-5.05 -2.57	3.47 1.64	VERY LOW MODERATE	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.82	0.64 0.75	1.03	-1.76 -0.65	-3.52 -2.48	0.32 1.49	LOW	RoB, Imprecision Imprecision
JAK innibitors lopinavir-ritonavir	standard care/placebo standard care/placebo	0.93	0.74	2.37	1.35	-2.57 -4.38	13.61	VERYLOW	0.72	0.52	NA 1 02	-2.75	-4 78	0.19	VERYLOW	0.93	0.75	1.15	-0.65	-2.48 -2.55	1.49	VERYLOW	RoB, Inconsistency, Imprecision
molnupiravir	standard care/placebo	0.67	0.46	0.92	-3.31	-5.35	-0.78	MODERATE	NA	NA	NA	-2.75 NA	-4.76 NA	NA NA	NA NA	0.92	0.74	0.83	-3.32	-4.76	-1.63	MODERATE	RoB RoB
nitazoxanide	standard care/placebo	1.08	0.3	3.8	0.75	-6.89	27.77	LOW	NA	NA	NA	NA	NA	NA	NA	1.07	0.73	1.57	0.95	-2.62	5.67	LOW	Imprecisionx2
probiotics	standard care/placebo	0.72	0.2	2.56	-2.75	-7.88	15.42	LOW	NA	NA	NA	NA	NA	NA	NA	0.72	0.49	1.06	-2.62	-5.01	0.56	LOW	Imprecisionx2
proxalutamide	standard care/placebo	0.19	0.05	0.69	-7.99	-9.37	-3.06	VERY LOW	NA	NA	NA	NA	NA	NA	NA	0.19	0.12	0.3	-7.94	-8.68	-6.93	VERY LOW	RoBx2, Imprecision
recombinant human granulocyte colony-stimulating factor remdesivir	standard care/placebo standard care/placebo	0.93	0.26	3.28 1.16	-0.72 -1.26	-7.31 -3.47	22.58 1.55	VERY LOW LOW	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.93	0.63	1.36	-0.55 -1.24	-3.64 -2.85	3.51 0.62	LOW	RoB, Imprecision RoB, Imprecision
serine protease inhibitors	standard care/placebo standard care/placebo	0.87	0.65	1.72	-0.33	-3.47	7.16	VERY LOW	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.87	0.71	1.06	-1.24	-2.85 -2.83	2.97	LOW	RoB, Imprecision
umifenovir	standard care/placebo	0.92	0.43	2	-0.84	-5.64	9.87	VERY LOW	1.19	0.77	1.85	1.9	-2.31	8.42	VERY LOW	0.99	0.77	1.26	-0.07	-2.05	2.55	LOW	RoB, Imprecision
vitamin C	standard care/placebo	0.94	0.43	2.07	-0.64	-5.6	10.54	VERY LOW	NA	NA	NA	NA NA	NA	NA	NA	0.92	0.7	1.23	-0.67	-3	2.22	VERY LOW	RoB, Inconsistency, Imprecision
antihepaciviral	azithromycin	NA	NA	NA	NA	NA	NA	NA	1.27	0.9	1.77	1.5	-0.66	3.67	VERY LOW	1.27	0.9	1.77	1.5	-0.66	3.67	VERY LOW	RoBx2, Inconsistency, Imprecision
azithromycin, hydroxychloroquine, oseltamivir	antihepaciviral	1.71	0.53	5.57	NA	NA	NA	VERY LOW	NA	NA	NA	NA	NA	NA	NA	1.71	1.17	2.51	5.39	1.16	11.23	LOW	RoBx2
antihepaciviral antihepaciviral	cefepime ceftazidime	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.1	0.7	1.71	0.55	-2.72 -3.44	3.36	VERY LOW VERY LOW	1.1	0.7 0.65	1.71	0.55	-2.72 -3.44	3.36	VERY LOW VERY LOW	RoBx2, Imprecision RoBx2, Imprecision
antinepaciviral antihepaciviral	clarithromycin	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.02	1.05	2.42	2.67	0.35	4.93	LOW	1.02	1.05	2.42	2.67	0.35	4 93	LOW	RoBx2, Imprecision RoBx2
antihepaciviral	IL6 receptor antagonists with corticosteroids (systemic)	NA NA	NA.	NA NA	NA.	NA.	NA.	NA NA	0.85	0.6	1.2	-1.3	-4.17	1.39	VERY LOW	0.85	0.6	1.2	-1.3	-4.17	1.39	VERY LOW	RoBx2. Imprecision
antihepaciviral	doxycycline	NA	NA	NA	NA	NA	NA	NA	0.73	0.47	1.13	-2.86	-7.38	0.84	VERY LOW	0.73	0.47	1.13	-2.86	-7.38	0.84	VERY LOW	RoBx2, Imprecisionx2
antihepaciviral	doxycycline, ivermectin	NA	NA	NA	NA	NA	NA	NA	0.9	0.57	1.42	-0.93	-4.9	2.36	VERY LOW	0.9	0.57	1.42	-0.93	-4.9	2.36	VERY LOW	RoBx2, Imprecision
antihepaciviral	electrolyzed saline	NA	NA	NA	NA	NA	NA	NA	1.28	0.79	2.06	1.48	-1.69	4.22	VERY LOW	1.28	0.79	2.06	1.48	-1.69	4.22	VERY LOW	RoBx2, Imprecision
antihepaciviral antihepaciviral	favipiravir favipiravir hydrochloroquine	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.04	0.78	1.4	0.29 -5.97	-1.75 -14 3	2.43	VERY LOW VERY LOW	1.04	0.78	1.4	0.29 -5.97	-1.75 -14.3	2.43	VERY LOW	RoBx2, Imprecision
antihepaciviral	GM-CSF inhibitor	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.8	0.58	1.1	-1.81	-14.3	0.74	VERY LOW	0.8	0.52	1.1	-1.81	-4.44	0.74	VERY LOW	RoBx2, Imprecision
antihepaciviral	(hydroxy)chloroquine	NA	NA NA	NA	NA NA	NA	NA	NA NA	0.83	0.64	1.07	-1.49	-3.41	0.55	VERY LOW	0.83	0.64	1.07	-1.49	-3.41	0.55	VERY LOW	RoBx2, Imprecision
antihepaciviral	IL1 inhibitors	NA	NA	NA	NA	NA	NA	NA	0.88	0.59	1.3	-1.09	-4.39	1.87	VERY LOW	0.88	0.59	1.3	-1.09	-4.39	1.87	VERY LOW	RoBx2, Imprecision
antihepaciviral	IL6 receptor antagonists without corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	0.67	0.45	0.98	-3.68	-7.73	-0.21	LOW	0.67	0.45	0.98	-3.68	-7.73	-0.21	LOW	RoBx2
antihepaciviral	inhaled corticosteroids	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.74	0.49	1.12	-2.59 -1.51	-6.63 -5.85	0.86 2.01	VERY LOW VERY LOW	0.74	0.49	1.12	-2.59 -1.51	-6.63 -5.85	0.86 2.01	VERY LOW VERY LOW	RoBx2, Imprecisionx2 RoBx2, Imprecisionx2
antihepaciviral antihepaciviral	interferon alfa (subcutaneous) interferon beta (subcutaneous)	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.84	0.53	1.33	-1.51	-5.85	1.07	VERY LOW VERY LOW	0.84	0.53	1.33	-1.51	-5.85	1.07	VERY LOW VERY LOW	RoBx2, Imprecisionx2 RoBx2. Imprecision
interferon beta (subcutaneous), lopinavir-ritonavir	antihepaciviral	1.15	0.35	3.81	NA NA	NA.	NA NA	VERY LOW	1.56	1.02	2.39	NA NA	NA	NA.	LOW	1.36	0.99	1.86	2.63	-0.08	5.75	VERY LOW	RoBx2
antihepaciviral	intranasal corticosteroids	NA	NA	NA	NA	NA	NA	NA	0.72	0.44	1.2	-2.96	-8.53	1.32	VERY LOW	0.72	0.44	1.2	-2.96	-8.53	1.32	VERY LOW	RoBx2, Imprecisionx2
antihepaciviral	ivermectin	NA	NA	NA	NA	NA	NA	NA	0.89	0.64	1.23	-0.92	-3.51	1.55	VERY LOW	0.89	0.64	1.23	-0.92	-3.51	1.55	VERY LOW	RoBx2, Imprecision
antihepaciviral	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	0.78	0.57	1.06	-2.04	-4.65	0.49	VERY LOW	0.78	0.57	1.06	-2.04	-4.65	0.49	VERY LOW	RoBx2, Imprecision
antihepaciviral	lopinavir-ritonavir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.79	0.58	1.06	-1.9 0.64	-4.39 -1.62	0.52 2.91	VERY LOW VERY LOW	0.79	0.58	1.06	-1.9 0.64	-4.39 -1.62	0.52 2.91	VERY LOW	
antihepaciviral antihepaciviral	molnupiravir nitazoxanide	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.67	0.79	1.53	-3.63	-1.62 -8.58	0.35	VERYLOW	0.67	0.79	1.53	-3.63	-1.62 -8.58	0.35	VERYLOW	RoBx2, Imprecision RoBx2, Imprecisionx2
antinepaciviral	probiotics	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1	0.43	1.56	-0.07	-3.55	2.93	VERY LOW	1	0.43	1.56	-0.07	-3.55	2.93	VERY LOW	RoBx2, Imprecision
antihepaciviral	proxalutamide	NA	NA	NA	NA	NA	NA	NA	3.76	2.29	6.19	5.26	3.47	7.19	LOW	3.76	2.29	6.19	5.26	3.47	7.19	LOW	RoBx2
antihepaciviral	recombinant human granulocyte colony-stimulating factor	NA	NA	NA	NA	NA	NA	NA	0.78	0.5	1.22	-2.14	-6.47	1.42	VERY LOW	0.78	0.5	1.22	-2.14	-6.47	1.42	VERY LOW	RoBx2, Imprecisionx2
antihepaciviral	remdesivir	NA	NA	NA	NA	NA	NA	NA	0.83	0.62	1.12	-1.44	-3.85	0.93	VERY LOW	0.83	0.62	1.12	-1.44	-3.85	0.93	VERY LOW	RoBx2, Imprecision
antihepaciviral antihepaciviral	serine protease inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.75 0.74	0.52	1.09	-2.45 -2.61	-6 -5.63	0.67	VERY LOW VERY LOW	0.75 0.74	0.52 0.53	1.09	-2.45 -2.61	-6 -5.63	0.67	VERY LOW VERY LOW	RoBx2, Imprecisionx2 RoBx2, Imprecisionx2
antinepaciviral	umitenovir vitamin C	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.74	0.53	1.03	-2.61	-5.63 -5.3	0.18	VERY LOW VERY LOW	0.74	0.53	1.03	-2.61	-5.63 -5.3	0.18	VERY LOW VERY LOW	RoBx2, Imprecisionx2 RoBx2, Inconsistency, Imprecisionx2
azithromycin	azithromycin, hydroxychloroquine, oseltamivir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.79	0.33	0.77	-6.89	-13.58	-1.87	LOW	0.79	0.33	0.77	-6.89	-13.58	-1.87	LOW	RoBx2, Inconsistency
azithromycin	cefepime	NA	NA	NA	NA	NA	NA	NA	0.87	0.55	1.37	-0.95	-4.11	1.76	VERY LOW	0.87	0.55	1.37	-0.95	-4.11	1.76	VERY LOW	RoBx2, Inconsistency, Imprecision
azithromycin	ceftazidime	NA	NA	NA	NA	NA	NA	NA	0.8	0.51	1.27	-1.48	-4.85	1.38	VERY LOW	0.8	0.51	1.27	-1.48	-4.85	1.38	VERY LOW	RoB, Inconsistency, Imprecision
clarithromycin	azithromycin	0.94	0.29	3.06	NA	NA	NA	VERY LOW	NA	NA	NA	NA	NA	NA	NA	0.79	0.55	1.12	-1.17	-2.87	0.61	LOW	RoB, Imprecision
azithromycin	IL6 receptor antagonists with corticosteroids (systemic)	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.67	0.47	0.96	-2.8 -4.36	-5.56 -8.78	-0.26	LOW	0.67 0.57	0.47	0.96	-2.8 -4.36	-5.56	-0.26 -0.73	LOW	RoB, Inconsistency
azithromycin azithromycin	doxycycline ivermectin	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.57	0.37	0.9	-4.36 -2.44	-8.78 -6.35	-0.73 0.74	VERYLOW	0.57	0.37	0.9	-4.36 -2.44	-8.78 -6.35	-0.73	VERYLOW	RoB, Inconsistency RoB Inconsistency Imprecisions/2
azithromycin	electrolyzed saline	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.01	0.45	1.13	-0.02	-0.35	2.59	VERY LOW	1.01	0.62	1.13	-0.02	-0.35	2.59	VERY LOW VERY LOW	RoB, Inconsistency, Imprecision RoB, Inconsistency, Imprecision
azithromycin	favipiravir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.82	0.6	1.13	-1.21	-3.11	0.78	VERY LOW	0.82	0.6	1.13	-1.21	-3.11	0.78	VERY LOW	RoBx2, Inconsistency, Imprecision
azithromycin	favipiravir, hydrochloroquine	NA	NA	NA	NA	NA	NA	NA	0.45	0.25	0.79	-7.48	-15.74	-1.63	VERY LOW	0.45	0.25	0.79	-7.48	-15.74	-1.63	LOW	RoB, Inconsistency
azithromycin	GM-CSF inhibitor	NA	NA	NA	NA	NA	NA	NA	0.63	0.45	0.88	-3.32	-5.84	-0.9	LOW	0.63	0.45	0.88	-3.32	-5.84	-0.9	LOW	RoB, Inconsistency
azithromycin	(hydroxy)chloroquine	0.8	0.24	2.73	NA	NA	NA	VERY LOW	0.61	0.45	0.83	NA	NA	NA	LOW	0.65	0.5	0.86	-3	-4.69	-1.18	LOW	RoBx2, Inconsistency

## STORY MARKET PRINTED PRIN										Time to sym	ptom resolution													
Second S	Comparison										ө							e						
The color of the	Treatment 1	Transment 2		CI lower limit	Clupper limit			Cl upper limit	Final rating		Cl lower limit	Cl upper limit		4 , , , , , ,	Clupper limit	Final rating		CI lower limit	Cl upper limit			Cl upper limit	Final rating	Pose one for down and in a
## STOL A PROPERTY CALLED STATE 100									NA							VERY LOW		0.46					VERY LOW	RoB, Inconsistency, Imprecisionx2
## 15 15 15 15 15 15 15 15	, .	IL6 receptor antagonists without corticosteroids (systemic)	NA	NA	NA.	NA	NA	NA	NA	0.53	0.35	0.78	-5.18	-9.15		LOW	0.53	0.35	0.78	-5.18				RoB, Inconsistency
## STATE 1.5 1		inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	0.59	0.39	0.9	-4.1	-8.07	-0.73	LOW	0.59	0.39	0.9	-4.1	-8.07	-0.73		RoB, Inconsistency
The column				1471	161		101	101	101	0.00	0.41	1.01	0.01	7.20	0.42	VEITH EOW	0.00	0.41	1.07	0.01		0.42		RoBx2, Inconsistency, Imprecisionx2
Marcel Marcel																								RoB, Inconsistency
Part																								. ,
## Annual Part No. 10. 10. 10. 10. 10. 10. 10. 10. 10. 10	-			1471				101	10.1															RoB, Inconsistency
Address	azithromycin	JAK inhibitors	NA	NA	NA		NA	NA	NA	0.62	0.44	0.86	-3.54	-6.03	-1.14	LOW	0.62	0.44	0.86	-3.54	-6.03	-1.14	LOW	RoB, Inconsistency
## STATE 1. Sept. 1	azithromycin	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.62	0.45	0.86	-3.41	-5.82	-1.07	LOW	0.62	0.45	0.86	-3.41	-5.82	-1.07	LOW	RoB, Inconsistency
Part	azithromycin	molnupiravir																						RoB, Inconsistency, Imprecision
Column	-																							
The control of the		•		10.1			101					-	1.01			TEITH EOTH				1.01				
March Marc		p. c.																				0.0		,
## STORES 1.00				NA	NA.		NA	NA	NA															RoB, Inconsistency
Secretary Secr	azithromycin	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	0.59	0.4	0.88	-3.95	-7.42	-0.92	LOW	0.59	0.4	0.88	-3.95	-7.42	-0.92	LOW	RoB, Inconsistency
Processed Supplement	· · · · · · · · · · · · · · · · · · ·																							
Section Control Cont	-																							RoB, Inconsistency
## Property (Property Control of Property (Property Control of Property Control of Pro								1.0.1																
## STATE 1.00					100																			
March Marc										-					-							_		RoBx2, Imprecisionx2
## Property (approximate and property) ## Property (approximate) ## Property (appr		doxycycline		NA		NA	NA	NA	NA		0.69	2.22		-3.87		VERY LOW			2.22				VERY LOW	RoBx2, Imprecisionx2
Property Recognishment Angelorisation Angelorisat												+							-					RoBx2, Imprecisionx2
The contract of the contract																								7.00.00
Column C						-									-									
Manual Publish State																								
## After 1 - Process of the Control		OHI OOI IIIIIDKOI	10.0	1471	101	101	101		161	1.01	0.00			1.00	10.01	VEICE COTT	1.07	0.00		0.00	1.00	10.01	VEITH EOTH	RoBx2, Imprecisionx2
### Programment of the Company of th		(2: - 2/					NA																	RoBx2, Imprecisionx2
Column C	azithromycin, hydroxychloroquine, oseltamivir	IL6 receptor antagonists without corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	1.14	0.66	1.96	1.71	-4.42	8.92	VERY LOW	1.14	0.66	1.96	1.71	-4.42	8.92	VERY LOW	RoBx2, Imprecisionx2
Property																								RoBx2, Imprecisionx2
Contract										•												_		
Accordance of the control of the c					101			1.0.1			0.00				1010			5.66				1010		
Experiment in the member MA																								RoBx2, Imprecisionx2
Act Process of the process 10,000 in the process																								RoBx2, Imprecisionx2
### A MA M	azithromycin, hydroxychloroquine, oseltamivir								10.1									0.0.						RoBx2, Imprecisionx2
Activide physiologogogogogogogogogogogogogogogogogogo																								RoBx2, Inconsistency, Imprecisionx2
Extractions (Approximate processing configuration for the processing configuration for the processing of the processin		·														_								
Self-composite physiop																								. , ,
Authorizon from the information of the informatio		·																						. , ,
### Series produces enhanced produced p																							-	RoBx2, Imprecisionx2
### Annual Configure Confi	azithromycin, hydroxychloroquine, oseltamivir	remdesivir							10.1			2.33					1.43							RoBx2, Imprecisionx2
### A PA NA		·						1.0.1																RoBx2, Imprecisionx2
Celtractrine Celt																								
Configures Configures Configures NA								1.0.1				+												. , , , ,
Confession										-		-			-									RoBx2. Imprecisionx2
Cestignme	cefepime	IL6 receptor antagonists with corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	0.78	0.49	1.22	-1.85	-5.15	1.65	VERY LOW	0.78	0.49	1.22	-1.85	-5.15	1.65	VERY LOW	RoBx2, Imprecisionx2
Codesignme																VERY LOW								RoBx2, Imprecisionx2
Cefebrium Envirorative NA		2011/2/2011/2011/2011/2011/2011/2011/20																****						RoBx2, Imprecisionx2
Cefepime Swylawik, hydrochloquine NA																								. , ,
Celegime CAL-OSF inhaltor						-													-			_		. , ,
Configure Lit inhibitors NA NA NA NA NA NA NA N		,,.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,			100																			RoBx2, Imprecisionx2
Cefepime IL6 receptor antagonists without confloosteroids (systemic) NA				NA				NA																RoBx2, Imprecision
Cefepime Inhaled corticosteroids	cefepime	IL1 inhibitors	101	NA	161	NA	NA		NA		0.49		-1.64	0.07		VERY LOW	0.8	0.40		-1.64	-5.37		VEIXI EOVI	RoBx2, Imprecisionx2
Confesione Interferon alfa (subcutaneous) NA NA NA NA NA NA NA N															-0.07							-0.07		
cefepime interferon beta (subcutaneous) NA															1 040							1 242		. , ,
cefepime interferon beta (subcutaneous), lopinavir-intonavir NA								101																
Cefepime Intransal Corticosteroids NA NA NA NA NA NA NA N	*****																							
cefepime JAK inhibitors NA NA <td></td> <td>_</td> <td>_</td> <td></td> <td>RoBx2, Imprecisionx2</td>																					_	_		RoBx2, Imprecisionx2
cefepime lopinavir-illonavir NA O.72 O.47 1.11 -2.45 -5.51 O.95 VERY LOW R0Bx2, Inconsistency, Imprecision cefepime molnupiravir NA	cefepime	ivermectin				NA			NA			1.27							1.27					RoBx2, Imprecision
celepime molinupiravir NA NA <td>-</td> <td></td> <td>RoBx2, Imprecisionx2</td>	-																							RoBx2, Imprecisionx2
celepime filazoxanide NA		·		1471	100					0.72		1.11					0.72	****						
cefepime probibitics NA									10.1	1 0.00							1 0.62	0.0.						
Cefepime proxalutamide NA NA NA NA NA NA NA N	-																							
cefepime recombinant human granulocyte colory-stimulating factor NA NA </td <td></td> <td></td> <td></td> <td></td> <td>101</td> <td></td>					101																			
cefepime remdesivir NA NA NA NA NA NA NA 0.76 0.49 1.17 -1.99 -4.89 1.33 VERYLOW 0.76 0.49 1.17 -1.99 -4.89 1.33 VERYLOW 0.76 0.49 1.17 -1.99 -4.89 1.33 VERYLOW RoBx2, Imprecision			NA	NA	NA	NA	NA	NA	NA	0.71	0.42	1.22	-2.69	-7.34	1.59	VERY LOW	0.71	0.42	1.22	-2.69	-7.34	1.59	VERY LOW	RoBx2, Imprecisionx2
cefepime serine protease inhibitors NA NA NA NA NA NA NA 0.69 0.42 1.11 -3 -6.92 0.9 VERYLOW 0.69 0.42 1.11 -3 -6.92 0.9 VERYLOW ROBX2, Imprecision.																								RoBx2, Imprecision
	cefepime	serine protease inhibitors	NA	NA	NA NA	NA	NA	NA	NA	0.69	0.42	1.11	-3	-6.92	0.9	VERY LOW	0.69	0.42	1.11	-3	-6.92	0.9	VERY LOW	RoBx2, Imprecisionx2

									Time to sym	ptom resolution													
Comparison		Direct estimate			I				Indirect estima	te		I				Network estimate							
Treatment 1	Treatment 2	Relative estimate Point estimate	CI lower limit	Cl upper limit	Absolute estimate	e (per 1,000) CI lower limit	Cl upper limit	Final rating	Relative estimate	~	Cl upper limit	Absolute estimate Point estimate	te (per 1,000)	Cl upper limit	Final rating	Relative estimate	CI lower limit	Cl upper limit	Absolute estimate	CI lower limit	Cl upper limit	Final rating	Reasons for downgrading
cefepime	umifenovir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA	0.67	0.43	1.05	-3.16	-6.64	0.47	VERY LOW	0.67	0.43	1.05	-3.16	-6.64	0.47	VERY LOW	RoBx2, Imprecisionx2
cefepime	vitamin C	NA	NA	NA	NA	NA	NA	NA	0.72	0.44	1.15	-2.57	-6.22	1.15	VERY LOW	0.72	0.44	1.15	-2.57	-6.22	1.15	VERY LOW	RoBx2, Inconsistency, Imprecisionx2
ceftazidime	clarithromycin	NA	NA	NA	NA	NA	NA	NA	1.58	0.94	2.64	2.65	-0.33	6.1	VERY LOW	1.58	0.94	2.64	2.65	-0.33	6.1	VERY LOW	RoB, Imprecisionx2
ceftazidime ceftazidime	IL6 receptor antagonists with corticosteroids (systemic) doxycycline	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.84	0.53 0.42	1.33	-1.33 -2.89	-4.77 -7.76	2.36 1.61	LOW VERY LOW	0.84	0.53 0.42	1.33	-1.33 -2.89	-4.77 -7.76	2.36 1.61	VERY LOW	RoB, Imprecision RoB, Imprecisionx2
ceftazidine	doxycycline doxycycline, ivermectin	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.88	0.51	1.52	-0.96	-5.35	3.22	VERY LOW	0.88	0.51	1.52	-0.96	-5.35	3.22	VERY LOW	RoB, Imprecisionx2
ceftazidime	electrolyzed saline	NA	NA	NA	NA	NA	NA	NA	1.26	0.71	2.21	1.45	-2.2	5.22	VERY LOW	1.26	0.71	2.21	1.45	-2.2	5.22	VERY LOW	RoB, Imprecisionx2
ceftazidime	favipiravir	NA	NA	NA	NA	NA	NA	NA	1.02	0.67	1.56	0.26	-2.5	3.63	VERY LOW	1.02	0.67	1.56	0.26	-2.5	3.63	VERY LOW	RoBx2, Imprecision
ceftazidime	favipiravir, hydrochloroquine GM-CSF inhibitor	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.55	0.29	1.05	-6 -1 84	-14.54 -5.06	0.45 1.81	VERY LOW VERY LOW	0.55	0.29	1.05	-6 -1.84	-14.54 -5.06	0.45 1.81	VERY LOW VERY LOW	RoB, Imprecisionx2
ceftazidime	(hydroxy)chloroquine	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.79	0.51	1.21	-1.52	-4.2	1.8	VERY LOW	0.79	0.54	1.21	-1.52	-4.2	1.8	VERY LOW	RoBx2. Imprecision
ceftazidime	IL1 inhibitors	NA	NA	NA	NA	NA	NA	NA	0.86	0.53	1.42	-1.12	-4.91	2.83	LOW	0.86	0.53	1.42	-1.12	-4.91	2.83	LOW	RoB, Imprecision
ceftazidime	IL6 receptor antagonists without corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	0.66	0.4	1.07	-3.71	-8.17	0.61	VERY LOW	0.66	0.4	1.07	-3.71	-8.17	0.61	VERY LOW	RoB, Imprecisionx2
ceftazidime ceftazidime	inhaled corticosteroids interferon alfa (subcutaneous)	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.73	0.44	1.22	-2.62 -1.54	-7.08 -6.25	1.71	VERY LOW VERY LOW	0.73	0.44	1.22	-2.62 -1.54	-7.08 -6.25	1.71	VERY LOW VERY LOW	RoB, Imprecisionx2
certazidime	interieron aira (subcutaneous) interferon beta (subcutaneous)	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.82	0.47	1.44	-1.54	-0.25	2.14	LOW	0.82	0.47	1.44	-1.37	-0.25	2.8	LOW	RoBx2, Imprecisionx2 RoB. Imprecision
ceftazidime	interferon beta (subcutaneous), lopinavir-ritonavir	NA	NA	NA	NA	NA	NA NA	NA	0.72	0.45	1.17	-2.66	-6.65	1.4	VERY LOW	0.72	0.45	1.17	-2.66	-6.65	1.4	VERY LOW	RoB, Imprecisionx2
ceftazidime	intranasal corticosteroids	NA	NA	NA	NA	NA	NA	NA	0.71	0.39	1.29	-2.99	-8.88	2.01	VERY LOW	0.71	0.39	1.29	-2.99	-8.88	2.01	VERY LOW	RoB, Imprecisionx2
ceftazidime	ivermectin JAK inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.87	0.56	1.36	-0.95 -2.07	-4.13 -5.27	2.63 1.55	VERYLOW	0.87	0.56	1.36	-0.95 -2.07	-4.13 -5.27	2.63	VERYLOW	RoB, Imprecision
certazidime	Iopinavir-ritonavir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.77	0.5	1.19	-2.07	-5.27 -5.1	1.65	VERY LOW	0.77	0.5	1.19	-1.93	-5.2 <i>i</i> -5.1	1.65	VERY LOW VERY LOW	RoB, Imprecisionx2 RoB, Inconsistency, Imprecisionx2
ceftazidime	molnupiravir	NA NA	NA	NA	NA	NA	NA NA	NA	1.08	0.69	1.69	0.61	-2.31	4.05	LOW	1.08	0.69	1.69	0.61	-2.31	4.05	LOW	RoB, Imprecision
ceftazidime	nitazoxanide	NA	NA	NA	NA	NA	NA	NA	0.66	0.39	1.13	-3.66	-8.96	1.11	VERY LOW	0.66	0.39	1.13	-3.66	-8.96	1.11	VERY LOW	RoB, Imprecisionx2
ceftazidime	probiotics proxalutamide	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.99	0.57 2.07	1.69 6.63	-0.1 5.23	-4.07 2.67	3.88 8.46	LOW VERY LOW	0.99	0.57 2.07	1.69 6.63	-0.1	-4.07 2.67	3.88 8.46	LOW	RoB, Imprecision RoBx2
cettazidime	recombinant human granulocyte colony-stimulating factor	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.77	0.45	1.32	-2 17	-6.89	2.24	VERY LOW	0.77	0.45	1.32	5.23 -2 17	-6.89	2 24	VERYLOW	RoB Imprecisionx2
ceftazidime	remdesivir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA.	0.82	0.53	1.26	-1.47	-4.5	2.03	LOW	0.82	0.53	1.26	-1.47	-4.5	2.03	LOW	RoB, Imprecision
ceftazidime	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	0.74	0.46	1.2	-2.48	-6.5	1.58	VERY LOW	0.74	0.46	1.2	-2.48	-6.5	1.58	VERY LOW	RoB, Imprecisionx2
ceftazidime	umifenovir	NA	NA	NA	NA	NA	NA	NA	0.72	0.46	1.14	-2.64	-6.22	1.17	VERY LOW	0.72	0.46	1.14	-2.64	-6.22	1.17	VERY LOW	RoB, Imprecisionx2
ceftazidime clarithromycin	vitamin C	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.77	0.48	1.24 0.82	-2.05 -3.97	-5.8 -6.8	1.84 -1.29	VERY LOW MODERATE	0.77	0.48	1.24 0.82	-2.05 -3.97	-5.8 -6.8	1.84 -1.29	VERY LOW MODERATE	RoB, Inconsistency, Imprecisionx2 RoB
clarithromycin	IL6 receptor antagonists with corticosteroids (systemic) doxycycline	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.55	0.27	0.76	-5.53	-10.03	-1.29	MODERATE	0.55	0.34	0.62	-5.53	-10.03	-1.29	MODERATE	RoB
clarithromycin	doxycycline, ivermectin	NA	NA	NA	NA	NA	NA NA	NA	0.56	0.33	0.95	-3.61	-7.56	-0.33	MODERATE	0.56	0.33	0.95	-3.61	-7.56	-0.33	MODERATE	RoB
clarithromycin	electrolyzed saline	NA	NA	NA	NA	NA	NA	NA	0.8	0.46	1.38	-1.19	-4.33	1.56	LOW	0.8	0.46	1.38	-1.19	-4.33	1.56	LOW	RoB, Imprecision
clarithromycin clarithromycin	favipiravir favipiravir hydrochloroquine	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.65	0.44	0.97	-2.38 -8.65	-4.37 -16.96	-0.21 -2.76	LOW VERY LOW	0.65	0.44	0.97	-2.38 -8.65	-4.37 -16.96	-0.21 -2.76	LOW	RoBx2 RoB
clarithromycin	GM-CSF inhibitor	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.5	0.19	0.00	-8.00	-7.06	-2.76	MODERATE	0.35	0.19	0.00	-8.05	-7.06	-1.92	MODERATE	RoB RoB
clarithromycin	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	0.51	0.36	0.75	-4.17	-6.01	-2.09	LOW	0.51	0.36	0.75	-4.17	-6.01	-2.09	LOW	RoBx2
clarithromycin	IL1 inhibitors	NA	NA	NA	NA	NA	NA	NA	0.55	0.34	0.88	-3.77	-7.07	-0.77	MODERATE	0.55	0.34	0.88	-3.77	-7.07	-0.77	MODERATE	RoB
clarithromycin	IL6 receptor antagonists without corticosteroids (systemic) inhaled corticosteroids	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.42	0.26	0.66 0.76	-6.35 -5.27	-10.36 -9.3	-2.9 -1.81	MODERATE MODERATE	0.42	0.26	0.66	-6.35 -5.27	-10.36 -9.3	-2.9 -1.81	MODERATE	RoB RoB
clarithromycin clarithromycin	interferon alfa (subcutaneous)	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.46	0.28	0.76	-5.27	-9.3	-0.65	LOW	0.46	0.28	0.76	-5.27 -4 18	-9.3 -8.5	-1.81	LOW	RoBx2
clarithromycin	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	0.53	0.35	0.79	-4.01	-6.39	-1.57	MODERATE	0.53	0.35	0.79	-4.01	-6.39	-1.57	MODERATE	RoB
clarithromycin	interferon beta (subcutaneous), lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.46	0.29	0.72	-5.31	-8.78	-2.2	MODERATE	0.46	0.29	0.72	-5.31	-8.78	-2.2	MODERATE	RoB
clarithromycin clarithromycin	intranasal corticosteroids	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.45	0.26	0.8	-5.63 -3.6	-11.17 -6.12	-1.34 -1.1	VERY LOW MODERATE	0.45 0.55	0.26	0.8	-5.63 -3.6	-11.17 -6.12	-1.34 -1.1	VERY LOW MODERATE	RoB, Imprecisionx2
clarithromycin	JAK inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.55	0.36	0.85	-3.6	-6.12 -7.28	-1.1 -2.15	MODERATE	0.55	0.36	0.85	-3.6 -4.71	-6.12 -7.28	-1.1 -2.15	MODERATE	RoB
clarithromycin	lopinavir-ritonavir	NA NA	NA	NA	NA	NA	NA NA	NA	0.49	0.33	0.74	-4.58	-7.07	-2.07	LOW	0.49	0.33	0.74	-4.58	-7.07	-2.07	LOW	RoB, Inconsistency
clarithromycin	molnupiravir	NA	NA	NA	NA	NA	NA	NA	0.69	0.45	1.05	-2.03	-4.23	0.28	LOW	0.69	0.45	1.05	-2.03	-4.23	0.28	LOW	RoB, Imprecision
clarithromycin	nitazoxanide	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.42	0.25	0.71 1.05	-6.31 -2.74	-11.24 -6.2	-2.3 0.26	MODERATE VERY LOW	0.42	0.25	0.71 1.05	-6.31 -2.74	-11.24 -6.2	-2.3 0.26	MODERATE VERY LOW	RoB
clarithromycin clarithromycin	probiotics proxalutamide	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	2.35	1.34	1.05 4.13	2.74	0.88	0.26 4.55	VERY LOW	2.35	1.34	1.05	2.58	-6.2	0.26 4.55	VERYLOW	RoB, Imprecisionx2 RoBx2 Imprecisionx2
clarithromycin	recombinant human granulocyte colony-stimulating factor	NA NA	NA	NA	NA	NA	NA NA	NA	0.49	0.29	0.82	-4.81	-9.1	-1.24	MODERATE	0.49	0.29	0.82	-4.81	-9.1	-1.24	MODERATE	RoB
clarithromycin	remdesivir	NA	NA	NA	NA	NA	NA	NA	0.52	0.35	0.78	-4.12	-6.45	-1.71	MODERATE	0.52	0.35	0.78	-4.12	-6.45	-1.71	MODERATE	RoB
clarithromycin clarithromycin	serine protease inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.47	0.3	0.75	-5.12 -5.29	-8.61 -8.28	-1.96 -2.47	MODERATE	0.47	0.3	0.75	-5.12 -5.29	-8.61 -8.28	-1.96 -2.47	MODERATE	RoB RoB
clarithromycin	vitamin C	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.49	0.3	0.77	-5.29	-8.28	-2.47	LOW	0.49	0.3	0.77	-5.29	-8.28	-2.47	LOW	RoB. Inconsistency
IL6 receptor antagonists with corticosteroids (systemic)	doxycycline	NA NA	NA	NA	NA	NA	NA NA	NA	0.85	0.54	1.35	-1.56	-6.27	2.54	VERY LOW	0.85	0.54	1.35	-1.56	-6.27	2.54	VERY LOW	RoB, Imprecisionx2
IL6 receptor antagonists with corticosteroids (systemic)	doxycycline, ivermectin	NA	NA	NA	NA	NA	NA	NA	1.05	0.66	1.7	0.37	-3.84	4.1	MODERATE	1.05	0.66	1.7	0.37	-3.84	4.1	MODERATE	Imprecision
IL6 receptor antagonists with corticosteroids (systemic)	electrolyzed saline	NA	NA	NA	NA	NA	NA	NA	1.5	0.91	2.47	2.78	-0.66	6.02	VERY LOW	1.5	0.91	2.47	2.78	-0.66	6.02	VERY LOW	RoB, Imprecisionx2
IL6 receptor antagonists with corticosteroids (systemic) IL6 receptor antagonists with corticosteroids (systemic)	favipiravir favipiravir, hydrochloroquine	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.22 0.66	0.89	1.69	1.59 -4.67	-0.87 -13.09	4.33 1.47	VERY LOW VERY LOW	1.22 0.66	0.89	1.69	1.59 -4.67	-0.87 -13.09	4.33 1.47	VERY LOW VERY LOW	RoBx2, Imprecision RoB. Imprecisionx2
IL6 receptor antagonists with corticosteroids (systemic)	GM-CSF inhibitor	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA.	0.94	0.67	1.32	-0.51	-3.49	2.57	LOW	0.94	0.67	1.32	-0.51	-3.49	2.57	LOW	RoB, Imprecision
IL6 receptor antagonists with corticosteroids (systemic)	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	0.97	0.72	1.3	-0.19	-2.57	2.49	VERY LOW	0.97	0.72	1.3	-0.19	-2.57	2.49	VERY LOW	RoBx2, Imprecision
IL6 receptor antagonists with corticosteroids (systemic)	IL1 inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.03	0.68	1.57	0.21	-3.36	3.64	MODERATE	1.03	0.68	1.57	0.21	-3.36	3.64	MODERATE	Imprecision
IL6 receptor antagonists with corticosteroids (systemic) IL6 receptor antagonists with corticosteroids (systemic)	IL6 receptor antagonists without corticosteroids (systemic) inhaled corticosteroids	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.78	0.52	1.18	-2.38 -1.29	-6.67 -5.53	1.5 2.56	LOW VERY LOW	0.78	0.52 0.57	1.18	-2.38 -1.29	-6.67 -5.53	1.5 2.56	LOW VERY LOW	Imprecisionx2 RoB, Imprecisionx2
IL6 receptor antagonists with corticosteroids (systemic)	interferon alfa (subcutaneous)	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.99	0.61	1.59	-0.21	-4.76	3.7	VERY LOW	0.99	0.61	1.59	-0.21	-4.76	3.7	VERY LOW	RoBx2, Imprecision
IL6 receptor antagonists with corticosteroids (systemic)	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	0.99	0.71	1.38	-0.04	-2.82	2.91	LOW	0.99	0.71	1.38	-0.04	-2.82	2.91	LOW	RoB, Imprecision
IL6 receptor antagonists with corticosteroids (systemic)	interferon beta (subcutaneous), lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.86	0.59	1.28	-1.33	-5.1	2.24	VERY LOW	0.86	0.59	1.28	-1.33	-5.1	2.24	VERY LOW	RoB, Imprecisionx2
IL6 receptor antagonists with corticosteroids (systemic) IL6 receptor antagonists with corticosteroids (systemic)	intranasal corticosteroids	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.85	0.51	1.44	-1.66 0.38	-7.37 -2.52	2.96	LOW	0.85	0.51	1.44	-1.66 0.38	-7.37 -2.52	2.96	LOW	Imprecisionx2 RoB. Imprecision
IL6 receptor antagonists with corticosteroids (systemic) IL6 receptor antagonists with corticosteroids (systemic)	JAK inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.92	0.73	1.48	-0.74	-2.52	2.35	MODERATE	0.92	0.73	1.48	-0.74	-2.52	2.35	MODERATE	Imprecision
IL6 receptor antagonists with corticosteroids (systemic)	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.93	0.66	1.3	-0.6	-3.48	2.43	VERY LOW	0.93	0.66	1.3	-0.6	-3.48	2.43	VERY LOW	RoB, Inconsistency, Imprecision
IL6 receptor antagonists with corticosteroids (systemic)	molnupiravir	NA	NA	NA	NA	NA	NA	NA	1.29	0.91	1.84	1.94	-0.68	4.79	LOW	1.29	0.91	1.84	1.94	-0.68	4.79	LOW	RoB, Imprecision
IL6 receptor antagonists with corticosteroids (systemic)	nitazoxanide	NA	NA	NA	NA	NA	NA NA	NA	0.79	0.5	1.26	-2.33	-7.46	1.99	LOW	0.79	0.5	1.26	-2.33	-7.46	1.99	LOW	Imprecisionx2

										ptom resolution													
Comparison		Direct estimate Relative estimate			Absolute estimate	e (per 1 000)		1	Indirect estimate			Absolute estimat	te (per 1 000)			Network estimate Relative estimate			Absolute estima	rto (por 1 000)			
Treatment 1	Treatment 2	Point estimate	CI lower limit	CI upper limit	Point estimate		CI upper limit	Final rating	Point estimate		CI upper limit		CI lower limit	CI upper limit	Final rating		CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit	Final rating	Reasons for downgrading
IL6 receptor antagonists with corticosteroids (systemic)	probiotics	NA	NA	NA	NA	NA	NA	NA	1.18	0.74	1.88	1.23	-2.5	4.71	MODERATE	1.18	0.74	1.88	1.23	-2.5	4.71	MODERATE	Imprecision
IL6 receptor antagonists with corticosteroids (systemic)	proxalutamide	NA	NA	NA	NA	NA	NA	NA	4.42	2.65	7.4	6.56	4.32	9.13	LOW	4.42	2.65	7.4	6.56	4.32	9.13	LOW	RoBx2
IL6 receptor antagonists with corticosteroids (systemic)	recombinant human granulocyte colony-stimulating factor	NA	NA	NA	NA	NA	NA	NA	0.92	0.58	1.46	-0.84	-5.34	3.11	VERY LOW	0.92	0.58	1.46	-0.84	-5.34	3.11	VERY LOW	RoB, Imprecisionx2
IL6 receptor antagonists with corticosteroids (systemic)	remdesivir	NA	NA	NA	NA	NA	NA	NA	0.98	0.7	1.36	-0.15	-2.9	2.79	LOW	0.98	0.7	1.36	-0.15	-2.9	2.79	LOW	RoB, Imprecision
IL6 receptor antagonists with corticosteroids (systemic)	serine protease inhibitors	NA	NA NA	NA NA	NA	NA NA	NA NA	NA NA	0.88	0.59	1.32	-1.15 -1.31	-4.94 -4.64	2.44 1.97	LOW	0.88	0.59	1.32	-1.15 -1.31	-4.94 -4.64	2.44 1.97	LOW	RoB, Imprecision
IL6 receptor antagonists with corticosteroids (systemic)	umifenovir vitamin C	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.86	0.63	1.24	-1.31	-4.64 -4.26	2.67	VERY LOW	0.86	0.63	1.24	-1.31	-4.64 -4.26	2.67	LOW VERY LOW	RoB, Imprecision
IL6 receptor antagonists with corticosteroids (systemic) doxycycline	doxycycline, ivermectin	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.24	0.63	2.13	1.92	-4.20	7.01	VERY LOW	1.24	0.63	2.13	1.92	-4.20	7.01	VERY LOW VERY LOW	RoB, Inconsistency, Imprecision RoB, Imprecisionx2
doxycycline	electrolyzed saline	NA.	NA NA	NA.	NA.	NA.	NA.	NA NA	1.76	1	3.1	4 34	0.05	9.11	VERYLOW	1.76	1	3.1	4.34	0.05	9 11	MODERATE	RoB
doxycycline	favipiravir	NA.	NA	NA	NA.	NA	NA.	NA NA	1.44	0.94	2.19	3.15	-0.4	7.6	VERY LOW	1.44	0.94	2.19	3.15	-0.4	7.6	VERY LOW	RoBx2, Imprecisionx2
doxycycline	favipiravir, hydrochloroquine	NA	NA	NA	NA	NA	NA	NA	0.78	0.41	1.47	-3.11	-11.93	3.99	VERY LOW	0.78	0.41	1.47	-3.11	-11.93	3.99	VERY LOW	RoB, Imprecisionx2
doxycycline	GM-CSF inhibitor	NA	NA	NA	NA	NA	NA	NA	1.1	0.71	1.71	1.05	-2.88	5.71	VERY LOW	1.1	0.71	1.71	1.05	-2.88	5.71	VERY LOW	RoB, Imprecisionx2
doxycycline	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	1.14	0.76	1.7	1.36	-2.13	5.78	VERY LOW	1.14	0.76	1.7	1.36	-2.13	5.78	VERY LOW	RoBx2, Imprecisionx2
doxycycline	IL1 inhibitors	NA	NA	NA	NA	NA	NA	NA	1.21	0.74	1.99	1.77	-2.64	6.68	VERY LOW	1.21	0.74	1.99	1.77	-2.64	6.68	VERY LOW	RoB, Imprecisionx2
doxycycline	IL6 receptor antagonists without corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	0.92	0.57	1.49	-0.82	-5.82	4.38	VERY LOW	0.92	0.57	1.49	-0.82	-5.82	4.38	VERY LOW	RoB, Imprecisionx2
doxycycline	inhaled corticosteroids	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.02	0.62	1.7 2.01	0.27	-4.73	5.5 6.64	VERY LOW VERY LOW	1.02	0.62	1.7 2.01	0.27	-4.73 -3.85	5.5 6.64	VERY LOW VERY LOW	RoB, Imprecisionx2
doxycycline doxycycline	interferon alfa (subcutaneous) interferon beta (subcutaneous)	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.16	0.67	1.78	1.35	-3.85 -2.27	6.11	VERY LOW VERY LOW	1.16	0.67	1.78	1.35	-3.85	6.64	VERY LOW VERY LOW	RoBx2, Imprecisionx2 RoB, Imprecisionx2
doxycycline	interferon beta (subcutaneous), lopinavir-ritonavir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.01	0.76	1.63	0.23	-2.27	5.21	VERYLOW	1.01	0.63	1.63	0.23	-4.34	5.21	VERYLOW	RoB, Imprecisionx2
doxycycline	interneron beta (subcutaneous), iopinavii-intonavii	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1	0.65	1.79	-0.1	-6.41	5.68	VERY LOW	1.01	0.56	1.79	-0.1	-6.41	5.68	VERY LOW	RoB, Imprecisionx2
doxycycline	ivermectin	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.22	0.79	1.91	1.93	-1.96	6.55	VERY LOW	1.22	0.79	1.91	1.93	-1.96	6.55	VERY LOW	RoB, Imprecisionx2
doxycycline	JAK inhibitors	NA NA	NA	NA	NA	NA	NA	NA	1.08	0.7	1.66	0.82	-3.08	5.42	VERY LOW	1.08	0.7	1.66	0.82	-3.08	5.42	VERY LOW	RoB, Imprecisionx2
doxycycline	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	1.09	0.71	1.68	0.96	-2.93	5.6	VERY LOW	1.09	0.71	1.68	0.96	-2.93	5.6	VERY LOW	RoB, Inconsistency, Imprecisionx2
doxycycline	molnupiravir	NA	NA	NA	NA	NA	NA	NA	1.51	0.98	2.37	3.5	-0.18	8.02	VERY LOW	1.51	0.98	2.37	3.5	-0.18	8.02	VERY LOW	RoB, Imprecisionx2
doxycycline	nitazoxanide	NA	NA	NA	NA	NA	NA	NA	0.93	0.54	1.59	-0.77	-6.51	4.8	VERY LOW	0.93	0.54	1.59	-0.77	-6.51	4.8	VERY LOW	RoB, Imprecisionx2
doxycycline	probiotics	NA	NA	NA	NA	NA	NA	NA	1.38	0.81	2.37	2.79	-1.75	7.74	VERY LOW	1.38	0.81	2.37	2.79	-1.75	7.74	VERY LOW	RoB, Imprecisionx2
doxycycline	proxalutamide	NA	NA	NA	NA NA	NA	NA	NA NA	5.19	2.9	9.28	8.12	4.73	12.46	VERY LOW	5.19	2.9	9.28	8.12	4.73	12.46	LOW	RoBx2
doxycycline	recombinant human granulocyte colony-stimulating factor	NA	NA NA	NA	NA	NA	NA NA	NA	1.08	0.63	1.84	0.72	-4.51	5.98	VERY LOW	1.08	0.63	1.84	0.72	-4.51	5.98	VERY LOW	RoB, Imprecisionx2
doxycycline	remdesivir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.15	0.75	1.76	0.41	-2.34	5.96 5.43	VERY LOW VERY LOW	1.15	0.75	1.76	1.41 0.41	-2.34 -4.16	5.96 5.43	VERY LOW VERY LOW	RoB, Imprecisionx2 RoB, Imprecisionx2
doxycycline doxycycline	serine protease inhibitors umifenovir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.04	0.65	1.59	0.41	-4.16 -3.96	5.03	VERY LOW VERY LOW	1.04	0.65	1.67	0.41	-4.16	5.43	VERY LOW	
doxycycline	vitamin C	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.01	0.68	1.72	0.25	-3.90	5.03	VERY LOW VERY LOW	1.01	0.68	1.72	0.25	-3.90	5.03	VERY LOW VERY LOW	RoB, Imprecisionx2 RoB, Inconsistency, Imprecisionx2
doxycycline ivermectin	electrolyzed saline	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.00	0.88	2.53	2.42	-3.54	6.66	VERYLOW	1.00	0.00	2.53	2 42	-1.52	6.66	VERYLOW	RoB Imprecisions2
doxycycline, ivermectin	favipiravir	NA.	NA NA	NA NA	NA.	NA.	NA.	NA NA	1.16	0.75	1.79	1.23	-1.88	5.14	VERY LOW	1.16	0.75	1.79	1.23	-1.88	5.14	VERY LOW	RoBx2. Imprecisionx2
doxycycline, ivermectin	favipiravir, hydrochloroquine	NA NA	NA	NA	NA.	NA	NA.	NA.	0.63	0.33	1.2	-5.04	-13.71	1.7	VERY LOW	0.63	0.33	1.2	-5.04	-13.71	1.7	VERY LOW	RoB, Imprecisionx2
doxycycline, ivermectin	GM-CSF inhibitor	NA	NA	NA	NA	NA	NA	NA	0.89	0.57	1.4	-0.88	-4.39	3.25	LOW	0.89	0.57	1.4	-0.88	-4.39	3.25	LOW	RoB, Imprecision
doxycycline, ivermectin	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	0.92	0.61	1.39	-0.56	-3.58	3.3	VERY LOW	0.92	0.61	1.39	-0.56	-3.58	3.3	VERY LOW	RoBx2, Imprecision
doxycycline, ivermectin	IL1 inhibitors	NA	NA	NA	NA	NA	NA	NA	0.97	0.59	1.63	-0.16	-4.25	4.27	MODERATE	0.97	0.59	1.63	-0.16	-4.25	4.27	MODERATE	Imprecision
doxycycline, ivermectin	IL6 receptor antagonists without corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	0.74	0.45	1.23	-2.74	-7.43	1.98	LOW	0.74	0.45	1.23	-2.74	-7.43	1.98	LOW	Imprecisionx2
doxycycline, ivermectin	inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	0.83	0.49	1.39	-1.66	-6.36	3.09	VERY LOW	0.83	0.49	1.39	-1.66	-6.36	3.09	VERY LOW	RoB, Imprecisionx2
doxycycline, ivermectin	interferon alfa (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	0.93	0.53	1.64	-0.58	-5.51	4.19	VERY LOW	0.93	0.53	1.64	-0.58	-5.51	4.19	VERY LOW	RoBx2, Imprecisionx2
doxycycline, ivermectin	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	0.94	0.6	1.46	-0.4	-3.78	3.62	LOW	0.94	0.6	1.46	-0.4	-3.78	3.62	LOW	RoB, Imprecision
doxycycline, ivermectin	interferon beta (subcutaneous), lopinavir-ritonavir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.82	0.5	1.34	-1.7 -2.03	-5.94 -8.09	2.79 3.33	VERY LOW LOW	0.82	0.5	1.34	-1.7 -2.03	-5.94 -8.09	2.79	VERY LOW LOW	RoB, Imprecisionx2
doxycycline, ivermeetin	intranasal corticosteroids ivermectin	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.81	0.44	1.47	0.01	-8.09	3.33 4.1	LOW	0.81	0.44	1.47	-2.03	-8.09	3.33 4.1	LOW	Imprecisionx2 RoB, Imprecision
doxycycline, ivermectin doxycycline, ivermectin	JAK inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.99	0.56	1.36	-1.1	-3.47	2.99	MODERATE	0.99	0.56	1.36	-1.1	-3.47	2.99	MODERATE	Imprecision
doxycycline, ivermectin	Iopinavir-ritonavir	NA NA	NA NA	NA.	NA NA	NA NA	NA NA	NA NA	0.88	0.56	1.37	-0.97	-4.43	3.1	VERY LOW	0.88	0.56	1.37	-0.97	-4.43	3.1	VERY LOW	RoB, Inconsistency, Imprecision
doxycycline, ivermectin	molnupiravir	NA.	NA NA	NA	NA.	NA	NA.	NA.	1.22	0.78	1.94	1.57	-1.65	5.54	VERY LOW	1.22	0.78	1.94	1.57	-1.65	5.54	VERY LOW	RoB. Imprecisionx2
doxycycline, ivermectin	nitazoxanide	NA	NA	NA	NA.	NA	NA	NA	0.75	0.43	1.3	-2.7	-8.22	2.46	LOW	0.75	0.43	1.3	-2.7	-8.22	2.46	LOW	Imprecisionx2
doxycycline, ivermectin	probiotics	NA	NA	NA	NA	NA	NA	NA	1.12	0.64	1.93	0.87	-3.36	5.31	LOW	1.12	0.64	1.93	0.87	-3.36	5.31	LOW	Imprecisionx2
doxycycline, ivermectin	proxalutamide	NA	NA	NA	NA	NA	NA	NA	4.19	2.32	7.58	6.19	3.28	9.96	VERY LOW	4.19	2.32	7.58	6.19	3.28	9.96	LOW	RoBx2
doxycycline, ivermectin	recombinant human granulocyte colony-stimulating factor	NA	NA	NA	NA	NA	NA	NA	0.87	0.5	1.5	-1.2	-6.15	3.6	VERY LOW	0.87	0.5	1.5	-1.2	-6.15	3.6	VERY LOW	RoB, Imprecisionx2
doxycycline, ivermectin	remdesivir	NA	NA	NA	NA	NA	NA	NA	0.93	0.6	1.44	-0.51	-3.85	3.49	LOW	0.93	0.6	1.44	-0.51	-3.85	3.49	LOW	RoB, Imprecision
doxycycline, ivermectin	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	0.84	0.51	1.37	-1.51	-5.78	3	VERY LOW	0.84	0.51	1.37	-1.51	-5.78	3	VERY LOW	RoB, Imprecisionx2
doxycycline, ivermectin	umifenovir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.82	0.51	1.3	-1.68	-5.53	2.59	VERY LOW	0.82	0.51	1.3	-1.68	-5.53	2.59	VERY LOW	RoB, Imprecisionx2
doxycycline, ivermectin	vitamin C	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.88	0.54	1.42	-1.08 -1.19	-5.12 -3.71	3.24 1.89	VERY LOW VERY LOW	0.88	0.54	1.42	-1.08 -1.19	-5.12 -3.71	3.24 1.89	VERY LOW VERY LOW	RoB, Inconsistency, Imprecisionx2 RoBx2, Imprecision
electrolyzed saline electrolyzed saline	favipiravir favipiravir, hydrochloroguine	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.81	0.51	0.86	-1.19 -7.46	-3.71 -15.94	-1.22	VERY LOW VERY LOW	0.81	0.51	0.86	-1.19 -7.46	-3./1 -15.94	1.89 -1.22	MODERATE	RoBx2, Imprecision RoB
electrolyzed saline	GM-CSF inhibitor	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.44	0.23	1.01	-7.46	-15.94	0.07	VERYLOW	0.44	0.23	1.01	-7.46 -3.29	-15.94 -6.32	0.07	VERYLOW	RoB Imprecisions2
electrolyzed saline	(hydroxy)chloroquine	NA NA	NA NA	NA NA	NA.	NA.	NA.	NA NA	0.65	0.41	1.01	-2.98	-5.41	0.04	VERY LOW	0.65	0.41	1.01	-2.98	-5.41	0.04	VERY LOW	RoBx2. Imprecisionx2
electrolyzed saline	IL1 inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.68	0.4	1.17	-2.58	-6.24	1.12	VERY LOW	0.68	0.41	1.17	-2.58	-6.24	1.12	VERY LOW	RoB, Imprecisionx2
electrolyzed saline	IL6 receptor antagonists without corticosteroids (systemic)	NA NA	NA NA	NA	NA NA	NA NA	NA NA	NA NA	0.52	0.31	0.88	-5.16	-9.47	-1.1	MODERATE	0.52	0.31	0.88	-5.16	-9.47	-1.1	MODERATE	RoB
electrolyzed saline	inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	0.58	0.34	1	-4.08	-8.41	-0.01	MODERATE	0.58	0.34	1	-4.08	-8.41	-0.01	VERY LOW	RoB
electrolyzed saline	interferon alfa (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	0.66	0.37	1.18	-2.99	-7.57	1.13	VERY LOW	0.66	0.37	1.18	-2.99	-7.57	1.13	VERY LOW	RoBx2, Imprecisionx2
electrolyzed saline	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	0.66	0.41	1.06	-2.82	-5.67	0.4	VERY LOW	0.66	0.41	1.06	-2.82	-5.67	0.4	VERY LOW	RoB, Imprecisionx2
electrolyzed saline	interferon beta (subcutaneous), lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.58	0.34	0.96	-4.11	-7.95	-0.31	MODERATE	0.58	0.34	0.96	-4.11	-7.95	-0.31	MODERATE	RoB
electrolyzed saline	intranasal corticosteroids	NA	NA	NA	NA	NA	NA	NA	0.57	0.31	1.06	-4.44	-10.23	0.33	VERY LOW	0.57	0.31	1.06	-4.44	-10.23	0.33	VERY LOW	RoB, Imprecisionx2
electrolyzed saline	ivermectin	NA	NA	NA	NA	NA	NA	NA	0.69	0.43	1.13	-2.41	-5.38	0.89	VERY LOW	0.69	0.43	1.13	-2.41	-5.38	0.89	VERY LOW	RoB, Imprecisionx2
electrolyzed saline	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	0.61	0.38	0.99	-3.52	-6.54	-0.19	MODERATE	0.61	0.38	0.99	-3.52	-6.54	-0.19	MODERATE	RoB
electrolyzed saline	lopinavir-ritonavir	NA	NA	NA	NA NA	NA	NA	NA	0.62	0.39	0.99	-3.39	-6.32	-0.1	LOW	0.62	0.39	0.99	-3.39	-6.32	-0.1	LOW	RoB, Inconsistency
electrolyzed saline	molnupiravir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.86	0.53	1.4	-0.84	-3.54	2.31	LOW	0.86	0.53	1.4	-0.84	-3.54	2.31	LOW	RoB, Imprecision
electrolyzed saline	nitazoxanide	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.53	0.3	0.93	-5.12	-10.3	-0.59	VERY LOW	0.53	0.3	0.93	-5.12	-10.3	-0.59	MODERATE VERY LOW	RoB
electrolyzed saline electrolyzed saline	probiotics proxalutamide	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	2.94	0.44 1.6	1.39 5.44	-1.55 3.77	-5.37 1.49	2.15 6.69	VERY LOW VERY LOW	0.78 2.94	1.6	1.39 5.44	-1.55 3.77	-5.37 1.49	2.15 6.69	VERY LOW LOW	RoB, Imprecisionx2 RoBx2
electrolyzed saline electrolyzed saline	recombinant human granulocyte colony-stimulating factor	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.61	0.35	1.08	-3.62	-8.18	0.55	VERY LOW VERY LOW	0.61	0.35	1.08	-3.62	-8.18	0.55	VERY LOW	RoB, Imprecisionx2
electrolyzed saline electrolyzed saline	recombinant numan granulocyte colony-stimulating factor remdesivir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.65	0.35	1.08	-3.62	-5.74	0.32	VERY LOW	0.65	0.35	1.08	-3.62	-5.74	0.32	VERY LOW VERY LOW	RoB, Imprecisionx2
					1				1 2.00	2.71		1				2.30							

										tom resolution													
Comparison		Direct estimate Relative estimate			Absolute estimate	(ner 1 000)			Indirect estimate)		Absolute estimat	e (per 1 000)			Network estimate Relative estima			Absolute estim	nate (per 1,000)			1
Treatment 1	Treatment 2		CI lower limit	CI upper limit			CI upper limit	Final rating	Point estimate	CI lower limit	CI upper limit		CI lower limit	CI upper limit	Final rating	Point estimate	CI lower limit	CI upper limit			CI upper limit	Final rating	Reasons for downgrading
electrolyzed saline	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	0.59	0.35	0.99	-3.93	-7.79	-0.12	MODERATE	0.59	0.35	0.99	-3.93	-7.79	-0.12	MODERATE	RoB
electrolyzed saline	umifenovir	NA	NA	NA	NA	NA	NA	NA	0.58	0.35	0.94	-4.1	-7.48	-0.55	MODERATE	0.58	0.35	0.94	-4.1	-7.48	-0.55	MODERATE	RoB
electrolyzed saline	vitamin C favipiravir, hydrochloroguine	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.62	0.37	1.02 0.94	-3.5 -6.26	-7.09 -14.55	0.12 -0.49	VERY LOW VERY LOW	0.62	0.37	1.02 0.94	-3.5 -6.26	-7.09 -14.55	0.12 -0.49	VERY LOW LOW	RoB, Inconsistency, Imprecisionx2 RoBx2
favipiravir favipiravir	GM-CSF inhibitor	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.54	0.31	1.03	-6.26 -2.1	-14.55 -4.58	0.24	VERY LOW VERY LOW	0.54	0.31	1.03	-6.26 -2.1	-14.55 -4.58	0.24	VERY LOW	RoBx2, Imprecision
favipiravir	(hydroxy)chloroquine	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.77	0.57	1.03	-2.1	-4.58	-0.03	LOW	0.77	0.57	1.03	-2.1	-4.58	-0.03	LOW	RoBx2, Imprecision RoBx2
favipiravir	IL1 inhibitors	NA.	NA.	NA NA	NA.	NA.	NA NA	NA.	0.84	0.58	1.23	-1.39	-4.6	1.38	VERY LOW	0.84	0.58	1.23	-1.39	-4.6	1.38	VERY LOW	RoBx2. Imprecision
favipiravir	IL6 receptor antagonists without corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	0.64	0.45	0.92	-3.97	-7.92	-0.66	LOW	0.64	0.45	0.92	-3.97	-7.92	-0.66	LOW	RoBx2
favipiravir	inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	0.71	0.48	1.06	-2.89	-6.86	0.4	VERY LOW	0.71	0.48	1.06	-2.89	-6.86	0.4	VERY LOW	RoBx2, Imprecisionx2
favipiravir	interferon alfa (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	0.81	0.51	1.26	-1.8	-6.05	1.54	VERY LOW	0.81	0.51	1.26	-1.8	-6.05	1.54	VERY LOW	RoBx2, Imprecisionx2
favipiravir	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	0.81	0.61	1.07	-1.63	-3.91	0.53	VERY LOW	0.81	0.61	1.07	-1.63	-3.91	0.53	VERY LOW	RoBx2, Imprecision
favipiravir favipiravir	interferon beta (subcutaneous), lopinavir-ritonavir intranasal corticosteroids	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.71	0.5	1 14	-2.92 -3.25	-6.28 -8.77	-0.04 0.88	VERYLOW	0.71	0.5	1 14	-2.92 -3.25	-6.28 -8.77	-0.04 0.88	LOW	RoBx2 RoBx2 Imprecisionx2
favipiravir	ivermectin	NA NA	NA NA	NA NA	NA NA	NA NA	NA.	NA NA	0.7	0.43	1.14	-1.22	-3.65	1.03	VERY LOW	0.85	0.63	1.14	-1.22	-3.65	1.03	VERY LOW	RoBx2, Imprecision
favipiravir	JAK inhibitors	NA.	NA.	NA NA	NA.	NA.	NA.	NA.	0.75	0.56	1	-2.33	-4.81	-0.02	LOW	0.75	0.56	1	-2.33	-4.81	-0.02	LOW	RoBx2
lopinavir-ritonavir	favipiravir	1	0.31	3.25	NA	NA	NA	VERY LOW	1.57	1.16	2.14	NA	NA	NA	LOW	1.32	1.03	1.69	2.2	0.21	4.33	LOW	RoBx2, Inconsistency
favipiravir	molnupiravir	NA	NA	NA	NA	NA	NA	NA	1.06	0.78	1.44	0.35	-1.75	2.36	VERY LOW	1.06	0.78	1.44	0.35	-1.75	2.36	VERY LOW	RoBx2, Imprecision
favipiravir	nitazoxanide	NA	NA	NA	NA	NA	NA	NA	0.65	0.42	0.99	-3.93	-8.81	-0.06	LOW	0.65	0.42	0.99	-3.93	-8.81	-0.06	LOW	RoBx2
favipiravir	probiotics	NA	NA	NA	NA	NA	NA	NA	0.96	0.63	1.48	-0.36	-3.75	2.44	VERY LOW	0.96	0.63	1.48	-0.36	-3.75	2.44	VERY LOW	RoBx2, Imprecision
favipiravir favipiravir	proxalutamide recombinant human granulocyte colony-stimulating factor	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	3.61 0.75	2.23 0.49	5.87 1.15	4.97 -2.43	3.38 -6.68	6.58 0.98	LOW VERY LOW	3.61 0.75	2.23 0.49	5.87 1.15	4.97 -2.43	3.38 -6.68	6.58 0.98	LOW VERY LOW	RoBx2 RoBx2, Imprecisionx2
favipiravir favipiravir	recombinant human granulocyte colony-stimulating factor remdesivir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.75	0.49	1.15	-2.43	-6.68	0.98	VERY LOW VERY LOW	0.75	0.49	1.15	-2.43	-6.68	0.98	VERY LOW VERY LOW	RoBx2, Imprecisionx2 RoBx2, Imprecision
favipiravir	serine protease inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.72	0.51	1.03	-2.74	-6.17	0.4	VERY LOW	0.72	0.51	1.03	-2.74	-6.17	0.4	VERY LOW	RoBx2, Imprecisionx2
umifenovir	favipiravir	1.64	0.5	5.32	NA NA	NA	NA	VERY LOW	1.25	0.88	1.79	NA	NA	NA	LOW	1.42	1.08	1.85	2.91	0.65	5.47	LOW	RoBx2
favipiravir	vitamin C	NA	NA	NA	NA	NA	NA	NA	0.76	0.53	1.06	-2.31	-5.44	0.42	VERY LOW	0.76	0.53	1.06	-2.31	-5.44	0.42	VERY LOW	RoBx2, Inconsistency, Imprecisionx2
favipiravir, hydrochloroquine	GM-CSF inhibitor	NA	NA	NA	NA	NA	NA	NA	1.42	0.81	2.5	4.16	-1.87	12.53	VERY LOW	1.42	0.81	2.5	4.16	-1.87	12.53	VERY LOW	RoB, Imprecisionx2
favipiravir, hydrochloroquine	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	1.46	0.86	2.5	4.48	-1.28	12.75	VERY LOW	1.46	0.86	2.5	4.48	-1.28	12.75	VERY LOW	RoBx2, Imprecisionx2
favipiravir, hydrochloroquine	IL1 inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.55	0.85	2.86	4.88 2.29	-1.48 -4.5	13.39	VERY LOW VERY LOW	1.55	0.85	2.86	4.88	-1.48 -4.5	13.39	VERY LOW VERY LOW	RoB, Imprecisionx2
favipiravir, hydrochloroquine favipiravir, hydrochloroquine	IL6 receptor antagonists without corticosteroids (systemic) inhaled corticosteroids	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.18	0.65	2.16	3.38	-4.5 -3.41	11.01	VERY LOW VERY LOW	1.18	0.65	2.16	2.29	-4.5	12.08	VERY LOW VERY LOW	RoB, Imprecisionx2 RoB, Imprecisionx2
favipiravir, hydrochloroquine	interferon alfa (subcutaneous)	NA.	NA NA	NA.	NA.	NA NA	NA NA	NA NA	1.49	0.77	2.87	4.46	-2.49	13.2	VERY LOW	1.49	0.77	2.87	4.46	-2.49	13.2	VERY LOW	RoBx2, Imprecisionx2
favipiravir, hydrochloroquine	interferon beta (subcutaneous)	NA.	NA.	NA	NA.	NA	NA	NA.	1.5	0.86	2.62	4.63	-1.31	13	VERY LOW	1.5	0.86	2.62	4.63	-1.31	13	VERY LOW	RoB, Imprecisionx2
favipiravir, hydrochloroquine	interferon beta (subcutaneous), lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	1.3	0.72	2.36	3.34	-3.16	11.94	VERY LOW	1.3	0.72	2.36	3.34	-3.16	11.94	VERY LOW	RoB, Imprecisionx2
favipiravir, hydrochloroquine	intranasal corticosteroids	NA	NA	NA	NA	NA	NA	NA	1.28	0.65	2.55	3.01	-4.8	12.14	VERY LOW	1.28	0.65	2.55	3.01	-4.8	12.14	VERY LOW	RoB, Imprecisionx2
favipiravir, hydrochloroquine	ivermectin	NA	NA	NA	NA	NA	NA	NA	1.57	0.89	2.79	5.05	-0.95	13.4	VERY LOW	1.57	0.89	2.79	5.05	-0.95	13.4	VERY LOW	RoB, Imprecisionx2
favipiravir, hydrochloroquine	JAK inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.38	0.79	2.42	3.94 4.07	-2.09 -1.92	12.34 12.47	VERY LOW VERY LOW	1.38	0.79	2.42	3.94 4.07	-2.09 -1.92	12.34	VERY LOW VERY LOW	RoB, Imprecisionx2
favipiravir, hydrochloroquine favipiravir, hydrochloroquine	lopinavir-ritonavir molnupiravir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.4	1.1	3.46	6.61	0.75	14.94	VERY LOW	1.4	1.1	3.46	6.61	0.75	14.94	MODERATE	RoB, Inconsistency, Imprecisionx2 RoB
favipiravir, hydrochloroquine	nitazoxanide	NA.	NA NA	NA.	NA.	NA NA	NA NA	NA.	1.2	0.63	2.27	2.34	-5.05	11.31	VERY LOW	1.2	0.63	2.27	2.34	-5.05	11.31	VERY LOW	RoB, Imprecisionx2
favipiravir, hydrochloroquine	probiotics	NA	NA	NA	NA	NA	NA	NA	1.78	0.93	3.38	5.91	-0.53	14.45	VERY LOW	1.78	0.93	3.38	5.91	-0.53	14.45	VERY LOW	RoB, Imprecisionx2
favipiravir, hydrochloroquine	proxalutamide	NA	NA	NA	NA	NA	NA	NA	6.67	3.37	13.23	11.23	5.54	19.46	VERY LOW	6.67	3.37	13.23	11.23	5.54	19.46	LOW	RoBx2
favipiravir, hydrochloroquine	recombinant human granulocyte colony-stimulating factor	NA	NA	NA	NA	NA	NA	NA	1.39	0.73	2.64	3.83	-3.15	12.59	VERY LOW	1.39	0.73	2.64	3.83	-3.15	12.59	VERY LOW	RoB, Imprecisionx2
favipiravir, hydrochloroquine	remdesivir	NA	NA	NA	NA	NA	NA	NA	1.47	0.85	2.57	4.53	-1.4	12.89	VERY LOW	1.47	0.85	2.57	4.53	-1.4	12.89	VERY LOW	RoB, Imprecisionx2
favipiravir, hydrochloroquine favipiravir, hydrochloroquine	serine protease inhibitors umifenovir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.33	0.73	2.43	3.52 3.36	-2.98 -2.88	12.12 11.82	VERY LOW VERY LOW	1.33	0.73	2.43	3.52 3.36	-2.98 -2.88	12.12 11.82	VERY LOW VERY LOW	RoB, Imprecisionx2 RoB, Imprecisionx2
favipiravir, hydrochloroquine	vitamin C	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.39	0.74	2.51	3.95	-2.00	12.46	VERYLOW	1.39	0.74	2.51	3.95	-2.38	12.46	VERY LOW	RoB, Inconsistency, Imprecisionx2
GM-CSF inhibitor	(hydroxy)chloroquine	NA.	NA.	NA NA	NA.	NA	NA NA	NA.	1.03	0.8	1.34	0.32	-1.92	2.75	VERY LOW	1.03	0.8	1.34	0.32	-1.92	2.75	VERY LOW	RoBx2, Imprecision
GM-CSF inhibitor	IL1 inhibitors	NA	NA	NA	NA	NA	NA	NA	1.09	0.74	1.63	0.72	-2.79	3.95	LOW	1.09	0.74	1.63	0.72	-2.79	3.95	LOW	RoB, Imprecision
GM-CSF inhibitor	IL6 receptor antagonists without corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	0.83	0.57	1.22	-1.87	-6.03	1.82	VERY LOW	0.83	0.57	1.22	-1.87	-6.03	1.82	VERY LOW	RoB, Imprecisionx2
GM-CSF inhibitor	inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	0.93	0.62	1.4	-0.78	-4.97	2.89	LOW	0.93	0.62	1.4	-0.78	-4.97	2.89	LOW	RoB, Imprecision
GM-CSF inhibitor	interferon alfa (subcutaneous)	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.05	0.66	1.66	0.3	-4.16 -2.19	4.04 3.18	VERY LOW	1.05	0.66	1.66	0.3	-4.16 -2.19	4.04 3.18	VERY LOW	RoBx2, Imprecision
GM-CSF inhibitor	interferon beta (subcutaneous)	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.92	0.78	1.43	-0.82	-2.19 -4.52	3.18 2.54	LOW	0.92	0.78	1.43	-0.82	-2.19 -4.52	2.54	LOW	RoB, Imprecision
GM-CSF inhibitor	intranasal corticosteroids	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.92	0.55	1.5	-1.15	-6.8	3.3	VERY LOW	0.92	0.55	1.55	-1.15	-6.8	3.3	VERY LOW	RoB, Imprecisionx2
GM-CSF inhibitor	ivermectin	NA NA	NA NA	NA NA	NA NA	NA	NA.	NA NA	1.11	0.8	1.53	0.89	-1.9	3.66	LOW	1.11	0.8	1.53	0.89	-1.9	3.66	LOW	RoB, Imprecision
GM-CSF inhibitor	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA NA	0.98	0.72	1.33	-0.23	-3.07	2.6	LOW	0.98	0.72	1.33	-0.23	-3.07	2.6	LOW	RoB, Imprecision
GM-CSF inhibitor	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.99	0.73	1.34	-0.09	-2.87	2.7	VERY LOW	0.99	0.73	1.34	-0.09	-2.87	2.7	VERY LOW	RoB, Inconsistency, Imprecision
GM-CSF inhibitor	molnupiravir	NA	NA	NA	NA	NA	NA	NA	1.38	0.99	1.91	2.45	-0.06	5.04	VERY LOW	1.38	0.99	1.91	2.45	-0.06	5.04	VERY LOW	RoB, Imprecisionx2
GM-CSF inhibitor	nitazoxanide	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.84	0.54	1.31	-1.82	-6.9	2.37	VERY LOW	0.84	0.54	1.31	-1.82	-6.9	2.37	VERY LOW	RoB, Imprecisionx2
GM-CSF inhibitor GM-CSF inhibitor	probiotics proxalutamide	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.26 4.71	0.8 2.87	1.95 7.75	1.75 7.07	-1.92 4.98	4.99 9.36	LOW	1.26 4.71	0.8 2.87	1.95 7.75	1.75 7.07	-1.92 4.98	4.99 9.36	LOW	RoB, Imprecision RoBx2
GM-CSF inhibitor	recombinant human granulocyte colony-stimulating factor	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.98	0.63	1.52	-0.33	4.98 -4.8	9.36	LOW	0.98	0.63	1.52	-0.33	4.98	9.36	LOW	RoBx2 RoB, Imprecision
GM-CSF inhibitor	remdesivir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.04	0.03	1.4	0.37	-2.26	3.06	LOW	1.04	0.00	1.4	0.37	-2.26	3.06	LOW	RoB, Imprecision
GM-CSF inhibitor	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	0.94	0.65	1.37	-0.64	-4.35	2.74	LOW	0.94	0.65	1.37	-0.64	-4.35	2.74	LOW	RoB, Imprecision
GM-CSF inhibitor	umifenovir	NA	NA	NA	NA	NA	NA	NA	0.92	0.66	1.28	-0.8	-4.04	2.27	LOW	0.92	0.66	1.28	-0.8	-4.04	2.27	LOW	RoB, Imprecision
GM-CSF inhibitor	vitamin C	NA	NA	NA	NA	NA	NA	NA	0.98	0.68	1.4	-0.21	-3.65	2.96	VERY LOW	0.98	0.68	1.4	-0.21	-3.65	2.96	VERY LOW	RoB, Inconsistency, Imprecision
(hydroxy)chloroquine	IL1 inhibitors	NA	NA	NA	NA	NA	NA	NA	1.06	0.75	1.51	0.4	-2.77	3.1	VERY LOW	1.06	0.75	1.51	0.4	-2.77	3.1	VERY LOW	RoBx2, Imprecision
(hydroxy)chloroquine (hydroxy)chloroquine	IL6 receptor antagonists without corticosteroids (systemic)	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.81	0.58	1.13	-2.18 -1.1	-6.09 -5.02	1.05 2.12	VERY LOW VERY LOW	0.81	0.58	1.13	-2.18 -1.1	-6.09 -5.02	1.05	VERY LOW VERY LOW	RoBx2, Imprecisionx2 RoBx2. Imprecisionx2
(nydroxy)chloroquine (hydroxy)chloroquine	innaled corticosteroids interferon alfa (subcutaneous)	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.02	0.62	1.3	-1.1	-5.02 -4.24	3.26	VERY LOW VERY LOW	1.02	0.62	1.3	-1.1	-5.02	3.26	VERY LOW VERY LOW	RoBx2, Imprecisionx2 RoBx2. Imprecision
(hydroxy)chloroquine	interferon beta (subcutaneous)	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.02	0.8	1.31	0.15	-2.08	2.21	VERY LOW	1.02	0.80	1.31	0.15	-2.08	2.21	VERY LOW	RoBx2, Imprecision
interferon beta (subcutaneous), lopinavir-ritonavir	(hydroxy)chloroquine	1.08	0.33	3.54	NA NA	NA	NA	VERY LOW	0.92	0.53	1.6	NA	NA	NA	VERY LOW	1.12	0.83	1.52	1.14	-1.57	4.36	LOW	RoB, Imprecision
(hydroxy)chloroquine	intranasal corticosteroids	NA	NA	NA	NA	NA	NA	NA	0.88	0.55	1.41	-1.47	-6.95	2.61	VERY LOW	0.88	0.55	1.41	-1.47	-6.95	2.61	VERY LOW	RoBx2, Imprecisionx2
(hydroxy)chloroquine	ivermectin	NA	NA	NA	NA	NA	NA	NA	1.08	0.82	1.41	0.57	-1.8	2.71	VERY LOW	1.08	0.82	1.41	0.57	-1.8	2.71	VERY LOW	RoBx2, Imprecision
(hydroxy)chloroquine	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA NA	0.95	0.73	1.22	-0.54	-2.96	1.66	VERY LOW	0.95	0.73	1.22	-0.54	-2.96	1.66	VERY LOW	RoBx2, Imprecision
lopinavir-ritonavir	(hydroxy)chloroquine	1.07	0.61	1.87	NA	NA	NA	VERY LOW	0.94	0.69	1.28	NA	NA	NA	VERY LOW	1.04	0.83	1.31	0.41	-1.57	2.57	LOW	RoB, Imprecision


									Time to sym	ptom resolution													
Comparison		Direct estimate							Indirect estimat	e		In				Network estimate						4	
T	Total Control O	Relative estimate	d'annual de la companya de la compa	: CI upper limit	Absolute estimate	- (pa,eas)	Cl upper limit	Final rating	Point estimate		Cl upper limit	Absolute estimate Point estimate	10 (po: 1,000)	Cl upper limit	Final rating	Point estimate	-	Cl upper limit	Absolute estimate Point estimate	те (рег туссе)	Cl upper limit	Final rating	D
Treatment 1 (hydroxy)chloroquine	Treatment 2 molnupiravir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.33	1.02	1.75	2.13	0.1	4.04	LOW	1.33	1.02	1.75	2.13	0.1	4.04	LOW	Reasons for downgrading RoBx2
(hydroxy)chloroquine (hydroxy)chloroquine	nitazoxanide	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.82	0.55	1.73	-2 14	-7.01	1.65	VERYLOW	0.82	0.55	1.73	-2 14	-7.01	1.65	VERYLOW	RoBx2, Imprecisionx2
(hydroxy)chloroquine	probiotics	NA.	NA.	NA NA	NA.	NA.	NA.	NA.	1.22	0.81	1.82	1.43	-1.93	4.14	VERY LOW	1.22	0.81	1.82	1.43	-1.93	4.14	VERY LOW	RoBx2, Imprecision
(hydroxy)chloroquine	proxalutamide	NA	NA	NA	NA	NA	NA	NA	4.56	2.87	7.26	6.75	5.26	8.22	LOW	4.56	2.87	7.26	6.75	5.26	8.22	LOW	RoBx2
(hydroxy)chloroquine	recombinant human granulocyte colony-stimulating factor	NA	NA	NA	NA	NA	NA	NA	0.95	0.63	1.42	-0.64	-4.85	2.7	VERY LOW	0.95	0.63	1.42	-0.64	-4.85	2.7	VERY LOW	RoBx2, Imprecision
(hydroxy)chloroquine	remdesivir	NA	NA	NA	NA	NA	NA	NA	1.01	0.79	1.28	0.05	-2.13	2.09	VERY LOW	1.01	0.79	1.28	0.05	-2.13	2.09	VERY LOW	RoBx2, Imprecision
(hydroxy)chloroquine	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	0.91	0.66	1.27	-0.95	-4.36	1.93	VERY LOW	0.91	0.66	1.27	-0.95	-4.36	1.93	VERY LOW	RoBx2, Imprecision
(hydroxy)chloroquine	umifenovir	NA	NA	NA	NA	NA	NA	NA	0.89	0.67	1.18	-1.12	-3.97	1.38	VERY LOW	0.89	0.67	1.18	-1.12	-3.97	1.38	VERY LOW	RoBx2, Imprecision
(hydroxy)chloroquine	vitamin C	NA NA	NA	NA NA	NA 	NA NA	NA NA	NA NA	0.95	0.69	1.3	-0.52	-3.63 -7.06	2.13	VERY LOW LOW	0.95	0.69	1.3	-0.52 -2.58	-3.63 -7.06	2.13	VERY LOW LOW	RoBx2, Inconsistency, Imprecision
IL1 inhibitors	IL6 receptor antagonists without corticosteroids (systemic) inhaled corticosteroids	NA NA	NA NA	NΑ	NA NA	NA NA	NA NA	NA NA	0.76	0.49	1.19	-2.58 -1.5	-7.06	1.6	VERYLOW	0.76	0.49	1.19	-2.58 -1.5	-7.06	2.71	VERYLOW	Imprecisionx2 RoB, Imprecisionx2
II 1 inhibitors	interferon alfa (subcutaneous)	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.05	0.57	1.50	-0.42	-5.50	3.85	VERYLOW	0.85	0.57	1.50	-0.42	-5.17	3.85	VERYLOW	RoBx2 Imprecisionx2
IL1 inhibitors	interferon beta (subcutaneous)	NA	NA	NA NA	NA	NA.	NA.	NA.	0.96	0.65	1.41	-0.25	-3.32	3.14	LOW	0.96	0.65	1.41	-0.25	-3.32	3.14	LOW	RoB, Imprecision
IL1 inhibitors	interferon beta (subcutaneous), lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.84	0.54	1.29	-1.54	-5.54	2.38	VERY LOW	0.84	0.54	1.29	-1.54	-5.54	2.38	VERY LOW	RoB, Imprecisionx2
IL1 inhibitors	intranasal corticosteroids	NA	NA	NA	NA	NA	NA	NA	0.83	0.47	1.44	-1.87	-7.77	3.05	LOW	0.83	0.47	1.44	-1.87	-7.77	3.05	LOW	Imprecisionx2
IL1 inhibitors	ivermectin	NA	NA	NA	NA	NA	NA	NA	1.01	0.68	1.51	0.17	-3.04	3.62	LOW	1.01	0.68	1.51	0.17	-3.04	3.62	LOW	RoB, Imprecision
IL1 inhibitors	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	0.89	0.6	1.31	-0.94	-4.16	2.53	MODERATE	0.89	0.6	1.31	-0.94	-4.16	2.53	MODERATE	Imprecision
IL1 inhibitors	lopinavir-ritonavir	NA	NA	NA NA	NA	NA	NA	NA	0.9	0.61	1.32	-0.81	-3.99	2.64	VERY LOW	0.9	0.61	1.32	-0.81	-3.99	2.64	VERY LOW	RoB, Inconsistency, Imprecision
IL1 inhibitors	molnupiravir	NA	NA	NA	NA	NA	NA	NA	1.26	0.84	1.87	1.73	-1.2	5.02	VERY LOW	1.26	0.84	1.87	1.73	-1.2	5.02	VERY LOW	RoB, Imprecisionx2
IL1 inhibitors	nitazoxanide probiotics	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.77	0.47	1.27	-2.54 1.03	-7.86 -2.97	2.1 4.86	LOW	0.77	0.47	1.27	-2.54 1.03	-7.86 -2.97	2.1	LOW	Imprecisionx2 Imprecision
IL1 inhibitors	problotics proxalutamide	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.15 4.3	2.48	7.4	6.35	3.78	9.41	LOW	1.15 4.3	2.48	7.4	6.35	3.78	9.41	LOW	Imprecision RoBx2
IL1 inhibitors	recombinant human granulocyte colony-stimulating factor	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.89	0.54	1.47	-1.05	-5.76	3.24	VERY LOW	0.89	0.54	1.47	-1.05	-5.76	3.24	VERY LOW	RoB, Imprecisionx2
IL1 inhibitors	remdesivir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.09	0.65	1.39	-0.35	-3.4	3.03	LOW	0.95	0.65	1.47	-0.35	-3.4	3.03	LOW	RoB, Imprecision
IL1 inhibitors	serine protease inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.86	0.55	1.33	-1.35	-5.4	2.58	VERY LOW	0.86	0.55	1.33	-1.35	-5.4	2.58	VERY LOW	RoB, Imprecisionx2
IL1 inhibitors	umifenovir	NA NA	NA	NA NA	NA	NA	NA NA	NA	0.84	0.56	1.25	-1.52	-5.09	2.16	VERY LOW	0.84	0.56	1.25	-1.52	-5.09	2.16	VERY LOW	RoB, Imprecisionx2
IL1 inhibitors	vitamin C	NA	NA	NA	NA	NA	NA	NA	0.9	0.58	1.37	-0.92	-4.7	2.84	VERY LOW	0.9	0.58	1.37	-0.92	-4.7	2.84	VERY LOW	RoB, Inconsistency, Imprecision
IL6 receptor antagonists without corticosteroids (systemic)) inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	1.11	0.7	1.77	1.08	-3.71	5.88	VERY LOW	1.11	0.7	1.77	1.08	-3.71	5.88	VERY LOW	RoB, Imprecisionx2
IL6 receptor antagonists without corticosteroids (systemic)) interferon alfa (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	1.26	0.75	2.09	2.17	-2.88	7.05	VERY LOW	1.26	0.75	2.09	2.17	-2.88	7.05	VERY LOW	RoBx2, Imprecisionx2
IL6 receptor antagonists without corticosteroids (systemic)		NA	NA	NA	NA	NA	NA	NA	1.26	0.87	1.83	2.34	-1.21	6.44	VERY LOW	1.26	0.87	1.83	2.34	-1.21	6.44	VERY LOW	RoB, Imprecisionx2
IL6 receptor antagonists without corticosteroids (systemic)) interferon beta (subcutaneous), lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	1.1	0.72	1.69	1.05	-3.32	5.62	VERY LOW	1.1	0.72	1.69	1.05	-3.32	5.62	VERY LOW	RoB, Imprecisionx2
IL6 receptor antagonists without corticosteroids (systemic)) intranasal corticosteroids	NA	NA	NA	NA	NA	NA	NA	1.09	0.63	1.88	0.72	-5.44	6.17	LOW	1.09	0.63	1.88	0.72	-5.44	6.17	LOW	Imprecisionx2
IL6 receptor antagonists without corticosteroids (systemic)		NA	NA	NA	NA	NA	NA	NA	1.33	0.9	1.96	2.75	-0.9	6.92	VERY LOW	1.33	0.9	1.96	2.75	-0.9	6.92	VERY LOW	RoB, Imprecisionx2
IL6 receptor antagonists without corticosteroids (systemic)		NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.17	0.8	1.72	1.64	-2.03 -1.86	5.83 5.9	VERY LOW	1.17	0.8	1.72	1.64	-2.03 -1.86	5.83	VERY LOW	Imprecisionx2 RoB. Inconsistency. Imprecisionx2
IL6 receptor antagonists without corticosteroids (systemic) IL6 receptor antagonists without corticosteroids (systemic)) iopinavir-ritonavir) molnupiravir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.19	1.12	2.44	4.32	0.88	8.34	MODERATE	1.19	1.12	2.44	4.32	0.88	8.34	MODERATE	RoB, inconsistency, imprecisionx2
IL6 receptor antagonists without corticosteroids (systemic)	nitazoxanide	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.01	0.62	1.65	0.04	-5.53	5.27	LOW	1.01	0.62	1.65	0.04	-5.53	5.27	LOW	Imprecisionx2
IL6 receptor antagonists without corticosteroids (systemic)		NA.	NA.	NA NA	NA.	NA NA	NA.	NA NA	1.5	0.92	2.46	3.61	-0.73	8.1	LOW	1.5	0.92	2.46	3.61	-0.73	8.1	LOW	Imprecisionx2
IL6 receptor antagonists without corticosteroids (systemic)		NA NA	NA.	NA NA	NA.	NA.	NA NA	NA NA	5.65	3.3	9.69	8.94	5.81	12.78	LOW	5.65	3.3	9.69	8.94	5.81	12.78	LOW	RoBx2
IL6 receptor antagonists without corticosteroids (systemic)		NA	NA	NA	NA	NA	NA	NA	1.17	0.72	1.92	1.54	-3.53	6.42	VERY LOW	1.17	0.72	1.92	1.54	-3.53	6.42	VERY LOW	RoB, Imprecisionx2
IL6 receptor antagonists without corticosteroids (systemic)) remdesivir	NA	NA	NA	NA	NA	NA	NA	1.25	0.87	1.8	2.23	-1.3	6.33	VERY LOW	1.25	0.87	1.8	2.23	-1.3	6.33	VERY LOW	RoB, Imprecisionx2
IL6 receptor antagonists without corticosteroids (systemic)) serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	1.13	0.73	1.74	1.23	-3.17	5.82	VERY LOW	1.13	0.73	1.74	1.23	-3.17	5.82	VERY LOW	RoB, Imprecisionx2
IL6 receptor antagonists without corticosteroids (systemic)) umifenovir	NA	NA	NA	NA	NA	NA	NA	1.1	0.74	1.63	1.06	-2.92	5.42	VERY LOW	1.1	0.74	1.63	1.06	-2.92	5.42	VERY LOW	RoB, Imprecisionx2
IL6 receptor antagonists without corticosteroids (systemic)) vitamin C	NA	NA	NA	NA	NA	NA	NA	1.18	0.77	1.78	1.66	-2.51	6.09	VERY LOW	1.18	0.77	1.78	1.66	-2.51	6.09	VERY LOW	RoB, Inconsistency, Imprecisionx2
inhaled corticosteroids	interferon alfa (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	1.13	0.66	1.91	1.08	-3.95	5.95	VERY LOW	1.13	0.66	1.91	1.08	-3.95	5.95	VERY LOW	RoBx2, Imprecisionx2
inhaled corticosteroids	interferon beta (subcutaneous)	NA NA	NA	NA NA	NA NA	NA NA	NA NA	NA	1.14	0.76	1.69	1.25	-2.28 -4.4	5.36	VERY LOW	1.14	0.76	1.69	1.25	-2.28	5.36	VERY LOW LOW	RoB, Imprecisionx2
inhaled corticosteroids	interferon beta (subcutaneous), lopinavir-ritonavir		NA NA	NA NA			NA NA	NA NA	0.99	0.63		-0.04		4.5	LOW	0.99	0.63		-0.04	-4.4			RoB, Imprecision
inhaled corticosteroids inhaled corticosteroids	intranasal corticosteroids	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.98	0.55	1.72	-0.37 1.67	-6.5 -1.98	5.06 5.84	VERY LOW VERY LOW	0.98	0.55	1.72	-0.37 1.67	-6.5 -1.98	5.06	VERY LOW VERY LOW	RoB, Imprecisionx2 RoB, Imprecisionx2
inhaled corticosteroids	JAK inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.05	0.79	1.57	0.56	-3.12	4.74	LOW	1.05	0.79	1.57	0.56	-3.12	4.74	LOW	RoB, Imprecision
inhaled corticosteroids	lopinavir-ritonavir	NA.	NA.	NA NA	NA.	NA NA	NA NA	NA NA	1.07	0.71	1.59	0.69	-2.95	4.85	VERY LOW	1.07	0.71	1.59	0.69	-2.95	4.85	VERY LOW	RoB, Inconsistency, Imprecision
inhaled corticosteroids	molnupiravir	NA.	NA.	NA NA	NA NA	NA NA	NA NA	NA NA	1.48	0.98	2.25	3.23	-0.19	7.27	VERY LOW	1.48	0.98	2.25	3.23	-0.19	7.27	VERY LOW	RoB, Imprecisionx2
inhaled corticosteroids	nitazoxanide	NA	NA	NA	NA	NA	NA	NA	0.91	0.55	1.51	-1.04	-6.63	4.18	VERY LOW	0.91	0.55	1.51	-1.04	-6.63	4.18	VERY LOW	RoB, Imprecisionx2
inhaled corticosteroids	probiotics	NA	NA	NA	NA	NA	NA	NA	1.35	0.81	2.25	2.53	-1.82	7	VERY LOW	1.35	0.81	2.25	2.53	-1.82	7	VERY LOW	RoB, Imprecisionx2
inhaled corticosteroids	proxalutamide	NA	NA	NA	NA	NA	NA	NA	5.07	2.89	8.89	7.85	4.72	11.7	VERY LOW	5.07	2.89	8.89	7.85	4.72	11.7	LOW	RoBx2
inhaled corticosteroids	recombinant human granulocyte colony-stimulating factor	NA	NA	NA	NA	NA	NA	NA	1.05	0.63	1.76	0.45	-4.6	5.32	VERY LOW	1.05	0.63	1.76	0.45	-4.6	5.32	VERY LOW	RoB, Imprecisionx2
inhaled corticosteroids	remdesivir	NA	NA	NA	NA	NA	NA	NA	1.12	0.75	1.67	1.15	-2.37	5.24	VERY LOW	1.12	0.75	1.67	1.15	-2.37	5.24	VERY LOW	RoB, Imprecisionx2
inhaled corticosteroids	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	1.01	0.64	1.59	0.15	-4.23	4.73	LOW	1.01	0.64	1.59	0.15	-4.23	4.73	LOW	RoB, Imprecision
inhaled corticosteroids	umifenovir	NA	NA	NA	NA	NA	NA	NA	0.99	0.65	1.51	-0.02	-4.01	4.33	LOW	0.99	0.65	1.51	-0.02	-4.01	4.33	LOW	RoB, Imprecision
inhaled corticosteroids	vitamin C	NA	NA	NA	NA	NA	NA	NA	1.06	0.68	1.64	0.58	-3.58	4.98	VERY LOW	1.06	0.68	1.64	0.58	-3.58	4.98	VERY LOW	RoB, Inconsistency, Imprecision
interferon alfa (subcutaneous) interferon alfa (subcutaneous)	interferon beta (subcutaneous) interferon beta (subcutaneous), lopinavir-ritonavir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.01 0.88	0.64	1.58 1.45	0.17 -1.12	-3.44 -5.56	4.56 3.7	VERY LOW VERY LOW	1.01	0.64	1.58	0.17 -1.12	-3.44 -5.56	4.56	VERY LOW VERY LOW	RoBx2, Imprecision
interferon alfa (subcutaneous)	interieron beta (subcutaneous), lopinavir-ritonavir intranasal corticosteroids	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.88	0.53	1.45	-1.12	-5.56 -7.6	4.2	VERY LOW VERY LOW	0.88	0.53	1.45	-1.12	-5.56 -7.6	4.2	VERY LOW VERY LOW	RoBx2, Imprecisionx2 RoBx2, Imprecisionx2
interferon affa (subcutaneous)	intranasal corticosteroids	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.06	0.47	1.58	-1.45	-7.6	5.02	VERY LOW	1.06	0.47	1.58	-1.45 0.59	-7.6 -3.12	5.02	VERY LOW	RoBx2, Imprecisionx2 RoBx2, Imprecisionx2
interferon alfa (subcutaneous)	JAK inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.93	0.59	1.47	-0.53	-3.12	3.9	VERY LOW	0.93	0.59	1.47	-0.53	-4.26	3.9	VERY LOW	RoBx2, Imprecision
interferon alfa (subcutaneous)	lopinavir-ritonavir	NA.	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.94	0.6	1.49	-0.39	-4.09	4.02	VERY LOW	0.94	0.6	1.49	-0.39	-4.09	4.02	VERY LOW	RoBx2, Inconsistency, Imprecision
interferon alfa (subcutaneous)	molnupiravir	NA.	NA.	NA NA	NA.	NA NA	NA NA	NA NA	1.31	0.82	2.1	2.15	-1.32	6.44	VERY LOW	1.31	0.82	2.1	2.15	-1.32	6.44	VERY LOW	RoBx2, Imprecisionx2
interferon alfa (subcutaneous)	nitazoxanide	NA.	NA	NA NA	NA	NA	NA	NA NA	0.8	0.46	1.4	-2.12	-7.76	3.3	VERY LOW	0.8	0.46	1.4	-2.12	-7.76	3.3	VERY LOW	RoBx2, Imprecisionx2
interferon alfa (subcutaneous)		NA	NA	NA NA	NA.	NA	NA NA	NA	1.2	0.69	2.09	1.44	-2.96	6.2	VERY LOW	1.2	0.69	2.09	1.44	-2.96	6.2	VERY LOW	RoBx2, Imprecisionx2
interieron alla (subcutarieous)	probiotics				NA	NA	NA	NA	4.49	2.46	8.17	6.77	3.58	10.9	VERY LOW	4.49	2.46	8 17	6.77	3.58	10.9	LOW	RoBx2
interferon alfa (subcutaneous)	probiotics proxalutamide	NA	NA	NA	1905												2.40						
		NA	NA	NA	NA	NA	NA	NA	0.93	0.53	1.63	-0.63	-5.72	4.51	VERY LOW	0.93	0.53	1.63	-0.63	-5.72	4.51	VERY LOW	RoBx2, Imprecisionx2
interferon alfa (subcutaneous)	proxalutamide	1.0.1	+	NA NA			NA NA	NA NA	0.99	0.53 0.63	1.63 1.56	0.06	-5.72 -3.51	4.51 4.45	VERY LOW			1.63	0.06	-3.51	4.45	VERY LOW VERY LOW	RoBx2, Imprecisionx2 RoBx2, Imprecision
interferon alfa (subcutaneous) interferon alfa (subcutaneous) interferon alfa (subcutaneous) interferon alfa (subcutaneous)	proxalutamide recombinant human granulocyte colony-stimulating factor	NA NA NA	NA NA NA	NA NA NA	NA NA NA	NA NA NA	NA NA	NA NA	0.99	0.63 0.54	1.56 1.48	0.06 -0.94	-3.51 -5.37	4.45 3.88	VERY LOW VERY LOW	0.93 0.99 0.9	0.53 0.63 0.54	1.56 1.48	0.06 -0.94	-3.51 -5.37	4.45 3.88	VERY LOW VERY LOW	RoBx2, Imprecision RoBx2, Imprecisionx2
interferon alfa (subculaneous)	proxalutamide recombinant human granulocyte colony-stimulating factor remdesivir serine protease inhibitors umifenovir	NA NA NA NA	NA NA NA NA	NA NA NA NA	NA NA NA NA	NA NA NA	NA NA NA	NA NA NA	0.99 0.9 0.88	0.63 0.54 0.55	1.56 1.48 1.41	0.06 -0.94 -1.1	-3.51 -5.37 -5.17	4.45 3.88 3.49	VERY LOW VERY LOW VERY LOW	0.93 0.99 0.9 0.88	0.53 0.63 0.54 0.55	1.56 1.48 1.41	0.06 -0.94 -1.1	-3.51 -5.37 -5.17	4.45 3.88 3.49	VERY LOW VERY LOW VERY LOW	RoBx2, Imprecision RoBx2, Imprecisionx2 RoBx2, Imprecisionx2
interferon alfa (subcutaneous) interferon alfa (subcutaneous) interferon alfa (subcutaneous) interferon alfa (subcutaneous)	proxalutamide recombinant human granulocyte colony-stimulating factor remdesivir serine protease inhibitors	NA NA NA	NA NA NA	NA NA NA	NA NA NA	NA NA NA	NA NA	NA NA	0.99	0.63 0.54	1.56 1.48	0.06 -0.94	-3.51 -5.37	4.45 3.88	VERY LOW VERY LOW	0.93 0.99 0.9	0.53 0.63 0.54	1.56 1.48	0.06 -0.94	-3.51 -5.37	4.45 3.88	VERY LOW VERY LOW	RoBx2, Imprecision RoBx2, Imprecisionx2

									Time to sym	ptom resolution													
Comparison		Direct estimate							Indirect estima	te		_				Network estimate							
		Relative estimate	<u> </u>		Absolute estimat		Ol	Final rating	Relative estimat	~	Ol	Absolute estima	te (per 1,000)	Ol	Final rating	Relative estimate		Ol Ilasia	Absolute estima		Ol	Final rating	
Treatment 1 interferon beta (subcutaneous)	Treatment 2 intranasal corticosteroids	Point estimate NA	CI lower limit	CI upper limit NA	Point estimate NA	CI lower limit	CI upper limit	NA NA	Point estimate 0.86	0.52	Cl upper limit	Point estimate	-7.23	Cl upper limit	VERY LOW	Point estimate 0.86	CI lower limit 0.52	CI upper limit	Point estimate -1.62	-7.23	CI upper limit	VERY LOW	Reasons for downgrading RoB, Imprecisionx2
interferon beta (subcutaneous)	ivermectin	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.05	0.52	1.44	0.41	-2.24	3.04	LOW	1.05	0.52	1.44	0.41	-7.23	3.04	LOW	RoB, Imprecision
interferon beta (subcutaneous)	JAK inhibitors	NA.	NA	NA NA	NA.	NA	NA.	NA NA	0.93	0.69	1.25	-0.7	-3.4	1.95	LOW	0.93	0.69	1.25	-0.7	-3.4	1.95	LOW	RoB, Imprecision
interferon beta (subcutaneous)	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.94	0.7	1.26	-0.56	-3.22	2.07	VERY LOW	0.94	0.7	1.26	-0.56	-3.22	2.07	VERY LOW	RoB, Inconsistency, Imprecision
interferon beta (subcutaneous)	molnupiravir	NA	NA	NA	NA	NA	NA	NA	1.3	0.95	1.79	1.98	-0.39	4.38	LOW	1.3	0.95	1.79	1.98	-0.39	4.38	LOW	RoB, Imprecision
interferon beta (subcutaneous)	nitazoxanide	NA	NA	NA	NA NA	NA	NA	NA	0.8	0.52	1.24	-2.29	-7.3	1.77	VERY LOW	0.8	0.52	1.24	-2.29	-7.3	1.77	VERY LOW	RoB, Imprecisionx2
interferon beta (subcutaneous)	probiotics	NA	NA	NA	NA	NA	NA	NA	1.19	0.77	1.84	1.27	-2.28 4.7	4.38	LOW	1.19	0.77	1.84	1.27	-2.28	4.38	LOW	RoB, Imprecision
interferon beta (subcutaneous) interferon beta (subcutaneous)	proxalutamide	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	4.46 0.93	2.74	7.31	6.6	-5.18	8.67 2.87	LOW	4.46	2.74 0.6	7.31	-0.8	4.7 -5.18	8.67 2.87	LOW	RoBx2 RoB, Imprecisionx2
interieron beta (subcutaneous)	recombinant human granulocyte colony-stimulating factor	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.93	0.6	1.43	-0.8	-2.18	2.87	LOW	0.93	0.6	1.43	-0.8	-2.18	2.87	LOW	RoB, Imprecisionx2
interferon beta (subcutaneous)	serine protease inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA.	NA NA	0.89	0.62	1.28	-1.11	-4.71	2.14	LOW	0.89	0.62	1.28	-1.11	-4.71	2.14	LOW	RoB. Imprecision
interferon beta (subcutaneous)	umifenovir	NA.	NA	NA NA	NA NA	NA	NA.	NA NA	0.87	0.63	1.2	-1.27	-4.37	1.63	LOW	0.87	0.63	1.2	-1.27	-4.37	1.63	LOW	RoB, Imprecision
interferon beta (subcutaneous)	vitamin C	NA	NA	NA	NA	NA	NA	NA	0.93	0.66	1.32	-0.68	-4.01	2.34	VERY LOW	0.93	0.66	1.32	-0.68	-4.01	2.34	VERY LOW	RoB, Inconsistency, Imprecision
interferon beta (subcutaneous), lopinavir-ritonavir	intranasal corticosteroids	NA	NA	NA	NA	NA	NA	NA	0.98	0.58	1.68	-0.33	-6.28	4.74	VERY LOW	0.98	0.58	1.68	-0.33	-6.28	4.74	VERY LOW	RoB, Imprecisionx2
interferon beta (subcutaneous), lopinavir-ritonavir	ivermectin	NA	NA	NA	NA NA	NA	NA	NA	1.21	0.83	1.76	1.71	-1.63	5.35	VERY LOW	1.21	0.83	1.76	1.71	-1.63	5.35	VERY LOW	RoB, Imprecisionx2
interferon beta (subcutaneous), lopinavir-ritonavir	JAK inhibitors	NA	NA	NA	NA NA	NA	NA	NA	1.06	0.74	1.52	0.59	-2.77	4.25	LOW	1.06	0.74	1.52	0.59	-2.77	4.25	LOW	RoB, Imprecision
lopinavir-ritonavir	interferon beta (subcutaneous), lopinavir-ritonavir	1 NA	0.31	3.27	NA NA	NA NA	NA NA	VERY LOW	1.04	0.59	1.86	NA 0.07	NA 0.40	NA 0.70	VERY LOW MODERATE	0.93	0.67	1.29	-0.73	-4.05	2.26	LOW MODERATE	RoB, Imprecision RoB
interferon beta (subcutaneous), lopinavir-ritonavir interferon beta (subcutaneous), lopinavir-ritonavir	molnupiravir nitazovanide	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.5 0.92	1.03	2.18	3.27	0.18 -6.39	6.76 3.79	VERYLOW	1.5 0.92	1.03	2.18	3.27	0.18 -6.39	6.76 3.79	VERY LOW	RoB, Imprecisionx2
interferon beta (subcutaneous), lopinavir-ritonavir	probiotics	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.36	0.84	2.21	2.56	-1.52	6.56	VERY LOW	1.36	0.84	2.21	2.56	-1.52	6.56	VERY LOW	RoB, Imprecisionx2
interferon beta (subcutaneous), lopinavii-ritonavii	proxalutamide	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	5.12	3	8.69	7.89	5.13	11.16	LOW	5.12	3	8.69	7.89	5.13	11.16	LOW	RoBx2
interferon beta (subcutaneous), lopinavir-ritonavir	recombinant human granulocyte colony-stimulating factor	NA	NA	NA.	NA.	NA	NA	NA	1.06	0.66	1.72	0.49	-4.35	4.96	LOW	1.06	0.66	1.72	0.49	-4.35	4.96	LOW	RoB, Imprecision
interferon beta (subcutaneous), lopinavir-ritonavir	remdesivir	NA	NA	NA	NA	NA	NA	NA	1.13	0.79	1.61	1.19	-2	4.74	LOW	1.13	0.79	1.61	1.19	-2	4.74	LOW	RoB, Imprecision
interferon beta (subcutaneous), lopinavir-ritonavir	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	1.02	0.67	1.55	0.18	-3.96	4.31	LOW	1.02	0.67	1.55	0.18	-3.96	4.31	LOW	RoB, Imprecision
interferon beta (subcutaneous), lopinavir-ritonavir	umifenovir	NA	NA	NA	NA	NA	NA	NA	1	0.68	1.46	0.02	-3.67	3.84	LOW	1	0.68	1.46	0.02	-3.67	3.84	LOW	RoB, Imprecision
interferon beta (subcutaneous), lopinavir-ritonavir	vitamin C	NA	NA	NA	NA NA	NA	NA	NA	1.07	0.71	1.6	0.61	-3.28	4.57	VERY LOW	1.07	0.71	1.6	0.61	-3.28	4.57	VERY LOW	RoB, Inconsistency, Imprecision
intranasal corticosteroids	ivermectin	NA NA	NA	NA	NA	NA	NA NA	NA	1.23	0.74	2.04	2.04	-2.37	7.67	VERY LOW	1.23	0.74	2.04	2.04	-2.37	7.67	VERY LOW	RoB, Imprecisionx2
intranasal corticosteroids intranasal corticosteroids	JAK inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.08	0.65 0.66	1.78	0.92 1.06	-3.54 -3.37	6.59	LOW	1.08	0.65	1.78	0.92 1.06	-3.54 -3.37	6.59	LOW VERY LOW	Imprecisionx2
intranasal corticosteroids	lopinavir-ritonavir molnupiravir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.52	0.66	2.53	3.6	-3.37	9.15	VERY LOW	1.09	0.00	2.53	3.6	-0.64	9.15	VERY LOW VERY LOW	RoB, Inconsistency, Imprecisionx2 RoB, Imprecisionx2
intranasal corticosteroids	nitazoxanide	NA.	NA.	NA NA	NA.	NA.	NA.	NA NA	0.93	0.52	1.68	-0.67	-6.81	5.78	LOW	0.93	0.52	1.68	-0.67	-6.81	5.78	LOW	Imprecisionx2
intranasal corticosteroids	probiotics	NA	NA	NA.	NA.	NA	NA	NA	1.39	0.76	2.5	2.89	-2.12	8.77	LOW	1.39	0.76	2.5	2.89	-2.12	8.77	LOW	Imprecisionx2
intranasal corticosteroids	proxalutamide	NA	NA	NA	NA	NA	NA	NA	5.2	2.74	9.79	8.22	4.22	13.66	VERY LOW	5.2	2.74	9.79	8.22	4.22	13.66	LOW	RoBx2
intranasal corticosteroids	recombinant human granulocyte colony-stimulating factor	NA	NA	NA	NA	NA	NA	NA	1.08	0.6	1.96	0.82	-4.83	7.04	VERY LOW	1.08	0.6	1.96	0.82	-4.83	7.04	VERY LOW	RoB, Imprecisionx2
intranasal corticosteroids	remdesivir	NA	NA	NA	NA	NA	NA	NA	1.15	0.7	1.88	1.52	-2.8	7.13	VERY LOW	1.15	0.7	1.88	1.52	-2.8	7.13	VERY LOW	RoB, Imprecisionx2
intranasal corticosteroids	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	1.04	0.6	1.78	0.51	-4.56	6.48	VERY LOW	1.04	0.6	1.78	0.51	-4.56	6.48	VERY LOW	RoB, Imprecisionx2
intranasal corticosteroids	umifenovir	NA	NA	NA	NA	NA	NA	NA	1.02	0.61	1.7	0.35	-4.4	6.15	VERY LOW	1.02	0.61	1.7	0.35	-4.4	6.15	VERY LOW	RoB, Imprecisionx2
intranasal corticosteroids	vitamin C JAK inhibitors	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.09	0.63	1.84	0.94	-3.94 -3.89	6.78	VERY LOW LOW	1.09 0.88	0.63	1.84	0.94	-3.94 -3.89	6.78 1.66	VERY LOW LOW	RoB, Inconsistency, Imprecisionx2 RoB, Imprecision
ivermectin	JAK Inhibitors Iopinavir-ritonavir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.89	0.65	1.21	-0.98	-3.89	1.00	VERY LOW	0.89	0.65	1.21	-0.98	-3.71	1.00	VERY LOW	RoB. Inconsistency. Imprecision
ivermectin	molnupiravir	NA.	NA.	NA NA	NA.	NA.	NA.	NA NA	1.24	0.89	1.73	1.56	-0.88	4.11	LOW	1.24	0.89	1.73	1.56	-0.88	4.11	LOW	RoB, Imprecision
ivermectin	nitazoxanide	NA NA	NA	NA NA	NA.	NA	NA NA	NA NA	0.76	0.48	1.19	-2.71	-7.77	1.43	VERY LOW	0.76	0.48	1.19	-2.71	-7.77	1.43	VERY LOW	RoB, Imprecisionx2
ivermectin	probiotics	NA	NA	NA	NA	NA	NA	NA	1.13	0.72	1.77	0.86	-2.77	4.07	LOW	1.13	0.72	1.77	0.86	-2.77	4.07	LOW	RoB, Imprecision
ivermectin	proxalutamide	NA	NA	NA	NA	NA	NA	NA	4.24	2.57	7	6.18	4.17	8.42	LOW	4.24	2.57	7	6.18	4.17	8.42	LOW	RoBx2
ivermectin	recombinant human granulocyte colony-stimulating factor	NA	NA	NA	NA	NA	NA	NA	0.88	0.56	1.38	-1.21	-5.65	2.52	VERY LOW	0.88	0.56	1.38	-1.21	-5.65	2.52	VERY LOW	RoB, Imprecisionx2
ivermectin	remdesivir	NA	NA	NA	NA NA	NA	NA NA	NA	0.94	0.69	1.28	-0.52	-3.09	2.12	LOW	0.94	0.69	1.28	-0.52	-3.09	2.12	LOW	RoB, Imprecision
ivermectin	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	0.85	0.58	1.24	-1.52	-5.18	1.83	VERY LOW	0.85	0.58	1.24	-1.52	-5.18	1.83	VERY LOW	RoB, Imprecisionx2
ivermectin	umifenovir vitamin C	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.83	0.59	1.16	-1.69 -1.09	-4.87 -4.48	1.34	LOW	0.83	0.59	1.16	-1.69 -1.09	-4.87 -4.48	1.34	VERYLOW	RoB, Imprecision RoB Inconsistency Imprecision
JAK inhibitors	lopinavir-ritonavir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.01	0.75	1.37	0.13	-2.62	2.04	VERY LOW	1.01	0.61	1.37	0.13	-2.62	2.04	VERY LOW	RoB, Inconsistency, Imprecision
JAK inhibitors	molnupiravir	NA.	NA.	NA NA	NA NA	NA.	NA.	NA NA	1.41	1.03	1.94	2.68	0.2	5.27	MODERATE	1.41	1.03	1.94	2.68	0.2	5.27	MODERATE	RoB
JAK inhibitors	nitazoxanide	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.86	0.56	1.33	-1.6	-6.64	2.57	LOW	0.86	0.56	1.33	-1.6	-6.64	2.57	LOW	Imprecisionx2
JAK inhibitors	probiotics	NA	NA	NA	NA	NA	NA	NA	1.28	0.83	1.99	1.97	-1.66	5.21	LOW	1.28	0.83	1.99	1.97	-1.66	5.21	LOW	Imprecisionx2
JAK inhibitors	proxalutamide	NA	NA	NA	NA	NA	NA	NA	4.82	2.95	7.92	7.29	5.22	9.58	LOW	4.82	2.95	7.92	7.29	5.22	9.58	LOW	RoBx2
JAK inhibitors	recombinant human granulocyte colony-stimulating factor	NA	NA	NA	NA	NA	NA	NA	1	0.65	1.55	-0.1	-4.54	3.68	LOW	1	0.65	1.55	-0.1	-4.54	3.68	LOW	RoB, Imprecision
JAK inhibitors	remdesivir	NA	NA	NA	NA	NA	NA	NA	1.07	0.8	1.43	0.59	-2	3.27	LOW	1.07	0.8	1.43	0.59	-2	3.27	LOW	RoB, Imprecision
JAK inhibitors	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	0.96	0.67	1.39	-0.41	-4.1	2.98	LOW	0.96	0.67	1.39	-0.41	-4.1	2.98	LOW	RoB, Imprecision
JAK inhibitors JAK inhibitors	umifenovir vitamin C	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.94	0.68	1.3 1.43	-0.58 0.02	-3.77 -3.4	2.49 3.2	LOW VERY LOW	0.94 1.01	0.68	1.3	-0.58 0.02	-3.77 -3.4	2.49 3.2	VERY LOW	RoB, Imprecision RoB, Inconsistency, Imprecision
JAK innibitors	vitamin C molnupiravir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.01	1.02	1.43	2.54	-3.4	5.09	LOW	1.01	1.02	1.43	2.54	-3.4	5.09	LOW	RoB, Inconsistency, Imprecision RoB, Inconsistency
lopinavir-ritonavir	nitazoxanide	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.85	0.55	1.92	-1.73	-6.79	2.4	VERY LOW	0.85	0.55	1.92	-1.73	-6.79	2.4	VERY LOW	RoB, Inconsistency, Imprecisionx2
lopinavir-ritonavir	probiotics	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	1.27	0.82	1.97	1.84	-0.79	5.03	VERY LOW	1.27	0.82	1.97	1.84	-0.79	5.03	VERY LOW	RoB, Inconsistency, Imprecisionx2
lopinavir-ritonavir	proxalutamide	NA NA	NA	NA NA	NA	NA	NA	NA	4.76	2.91	7.78	7.16	5.14	9.38	LOW	4.76	2.91	7.78	7.16	5.14	9.38	LOW	RoBx2, Inconsistency
lopinavir-ritonavir	recombinant human granulocyte colony-stimulating factor	NA	NA	NA	NA	NA	NA	NA	0.99	0.64	1.53	-0.24	-4.68	3.52	VERY LOW	0.99	0.64	1.53	-0.24	-4.68	3.52	VERY LOW	RoB, Inconsistency, Imprecision
lopinavir-ritonavir	remdesivir	NA	NA	NA	NA	NA	NA	NA	1.05	0.79	1.41	0.46	-2.12	3.09	VERY LOW	1.05	0.79	1.41	0.46	-2.12	3.09	VERY LOW	RoB, Inconsistency, Imprecision
lopinavir-ritonavir	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	0.95	0.66	1.38	-0.54	-4.2	2.8	VERY LOW	0.95	0.66	1.38	-0.54	-4.2	2.8	VERY LOW	RoB, Inconsistency, Imprecision
lopinavir-ritonavir	umifenovir	NA	NA	NA	NA	NA	NA	NA	0.93	0.68	1.27	-0.71	-3.78	2.19	VERY LOW	0.93	0.68	1.27	-0.71	-3.78	2.19	VERY LOW	RoB, Inconsistency, Imprecision
lopinavir-ritonavir	vitamin C	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.99	0.7	1.41	-0.11	-3.52	3.01	VERY LOW	0.99	0.7	1.41	-0.11	-3.52	3.01	VERY LOW	RoB, Inconsistency, Imprecision
molnupiravir	nitazoxanide	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.61	0.39	0.96 1.43	-4.27 -0.71	-9.22 -4.2	-0.33 2.24	MODERATE LOW	0.61	0.39	0.96 1.43	-4.27 -0.71	-9.22 -4.2	-0.33 2.24	MODERATE	RoB RoB. Imprecision
molnupiravir molnupiravir	probiotics proxalutamide	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	3.42	2.07	1.43 5.65	4.62	2.87	6.48	LOW	3.42	2.07	1.43 5.65	-0.71 4.62	-4.2 2.87	6.48	LOW	RoB, Imprecision RoBx2
molnupiravir	recombinant human granulocyte colony-stimulating factor	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.71	0.45	1.11	-2.78	-7.1	0.46	VERY LOW	0.71	0.45	1.11	-2.78	-7.1	0.46	VERY LOW	RoB. Imprecisionx2
molnupiravir	remdesivir	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	NA NA	0.76	0.55	1.03	-2.08	-4.44	0.73	LOW	0.76	0.45	1.03	-2.70	-4.44	0.73	LOW	RoB, Imprecision
molnupiravir	serine protease inhibitors	NA NA	NA.	NA NA	NA NA	NA NA	NA NA	NA NA	0.68	0.46	1	-3.09	-6.6	0.01	VERY LOW	0.68	0.46	1	-3.09	-6.6	0.01	VERY LOW	RoB, Imprecisionx2
molnupiravir	umifenovir	NA	NA	NA	NA	NA	NA	NA	0.67	0.48	0.94	-3.25	-6.26	-0.49	MODERATE		0.48	0.94	-3.25	-6.26	-0.49	MODERATE	RoB
molnupiravir	vitamin C	NA	NA	NA	NA	NA	NA	NA	0.71	0.49	1.03	-2.66	-5.89	0.21	VERY LOW	0.71	0.49	1.03	-2.66	-5.89	0.21	VERY LOW	RoB, Inconsistency, Imprecisionx2

									Time to sym	ptom resolution													
Comparison		Direct estimate							Indirect estimat	te						Network estimat	е						
		Relative estimate			Absolute estimat	e (per 1,000)		Final rating	Relative estimate	e		Absolute estimat	te (per 1,000)		Final rating	Relative estima	ite		Absolute estima	ate (per 1,000)		First setters	
Treatment 1	Treatment 2	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit	Final rating	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit	Final rating	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit	Final rating	Reasons for downgrading
nitazoxanide	probiotics	NA	NA	NA	NA	NA	NA	NA	1.49	0.87	2.55	3.57	-1.2	8.93	LOW	1.49	0.87	2.55	3.57	-1.2	8.93	LOW	Imprecisionx2
nitazoxanide	proxalutamide	NA	NA	NA	NA	NA	NA	NA	5.58	3.11	10.03	8.89	5.19	13.68	VERY LOW	5.58	3.11	10.03	8.89	5.19	13.68	LOW	RoBx2
nitazoxanide	recombinant human granulocyte colony-stimulating factor	NA	NA	NA	NA	NA	NA	NA	1.16	0.68	1.99	1.5	-3.94	7.17	VERY LOW	1.16	0.68	1.99	1.5	-3.94	7.17	VERY LOW	RoB, Imprecisionx2
nitazoxanide	remdesivir	NA	NA	NA	NA	NA	NA	NA	1.23	0.8	1.9	2.19	-1.85	7.2	VERY LOW	1.23	0.8	1.9	2.19	-1.85	7.2	VERY LOW	RoB, Imprecisionx2
nitazoxanide	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	1.11	0.69	1.81	1.19	-3.65	6.57	VERY LOW	1.11	0.69	1.81	1.19	-3.65	6.57	VERY LOW	RoB, Imprecisionx2
nitazoxanide	umifenovir	NA	NA	NA	NA	NA	NA	NA	1.09	0.69	1.72	1.02	-3.45	6.22	VERY LOW	1.09	0.69	1.72	1.02	-3.45	6.22	VERY LOW	RoB, Imprecisionx2
nitazoxanide	vitamin C	NA	NA	NA	NA	NA	NA	NA	1.17	0.72	1.87	1.62	-3.02	6.85	VERY LOW	1.17	0.72	1.87	1.62	-3.02	6.85	VERY LOW	RoB, Inconsistency, Imprecisionx2
probiotics	proxalutamide	NA	NA	NA	NA	NA	NA	NA	3.75	2.09	6.77	5.32	2.73	8.58	VERY LOW	3.75	2.09	6.77	5.32	2.73	8.58	LOW	RoBx2
probiotics	recombinant human granulocyte colony-stimulating factor	NA	NA	NA	NA	NA	NA	NA	0.78	0.45	1.34	-2.07	-6.8	2.36	VERY LOW	0.78	0.45	1.34	-2.07	-6.8	2.36	VERY LOW	RoB, Imprecisionx2
probiotics	remdesivir	NA	NA	NA	NA	NA	NA	NA	0.83	0.54	1.28	-1.38	-4.43	2.15	LOW	0.83	0.54	1.28	-1.38	-4.43	2.15	LOW	RoB, Imprecision
probiotics	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	0.75	0.46	1.22	-2.38	-6.41	1.72	VERY LOW	0.75	0.46	1.22	-2.38	-6.41	1.72	VERY LOW	RoB, Imprecisionx2
probiotics	umifenovir	NA	NA	NA	NA	NA	NA	NA	0.73	0.47	1.16	-2.55	-6.14	1.29	VERY LOW	0.73	0.47	1.16	-2.55	-6.14	1.29	VERY LOW	RoB, Imprecisionx2
probiotics	vitamin C	NA	NA	NA	NA	NA	NA	NA	0.78	0.49	1.26	-1.95	-5.74	1.96	VERY LOW	0.78	0.49	1.26	-1.95	-5.74	1.96	VERY LOW	RoB, Inconsistency, Imprecisionx2
proxalutamide	recombinant human granulocyte colony-stimulating factor	NA	NA	NA	NA	NA	NA	NA	0.21	0.12	0.37	-7.4	-11.53	-4.15	VERY LOW	0.21	0.12	0.37	-7.4	-11.53	-4.15	LOW	RoBx2
proxalutamide	remdesivir	NA	NA	NA	NA	NA	NA	NA	0.22	0.14	0.36	-6.7	-8.72	-4.82	LOW	0.22	0.14	0.36	-6.7	-8.72	-4.82	LOW	RoBx2
proxalutamide	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	0.2	0.12	0.34	-7.71	-11.01	-4.94	LOW	0.2	0.12	0.34	-7.71	-11.01	-4.94	LOW	RoBx2
proxalutamide	umifenovir	NA	NA	NA	NA	NA	NA	NA	0.2	0.12	0.32	-7.87	-10.62	-5.49	LOW	0.2	0.12	0.32	-7.87	-10.62	-5.49	LOW	RoBx2
proxalutamide	vitamin C	NA	NA	NA	NA	NA	NA	NA	0.21	0.12	0.35	-7.28	-10.27	-4.77	LOW	0.21	0.12	0.35	-7.28	-10.27	-4.77	LOW	RoBx2, Inconsistency
recombinant human granulocyte colony-stimulating factor	remdesivir	NA	NA	NA	NA	NA	NA	NA	1.06	0.69	1.64	0.69	-2.93	5.05	VERY LOW	1.06	0.69	1.64	0.69	-2.93	5.05	VERY LOW	RoB, Imprecisionx2
recombinant human granulocyte colony-stimulating factor	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	0.96	0.59	1.56	-0.31	-4.79	4.54	LOW	0.96	0.59	1.56	-0.31	-4.79	4.54	LOW	RoB, Imprecision
recombinant human granulocyte colony-stimulating factor	umifenovir	NA	NA	NA	NA	NA	NA	NA	0.94	0.6	1.48	-0.48	-4.57	4.12	LOW	0.94	0.6	1.48	-0.48	-4.57	4.12	LOW	RoB, Imprecision
recombinant human granulocyte colony-stimulating factor	vitamin C	NA	NA	NA	NA	NA	NA	NA	1.01	0.63	1.61	0.12	-4.13	4.8	VERY LOW	1.01	0.63	1.61	0.12	-4.13	4.8	VERY LOW	RoB, Inconsistency, Imprecision
remdesivir	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	0.9	0.63	1.29	-1	-4.6	2.18	LOW	0.9	0.63	1.29	-1	-4.6	2.18	LOW	RoB, Imprecision
remdesivir	umifenovir	NA	NA	NA	NA	NA	NA	NA	0.88	0.64	1.21	-1.17	-4.27	1.69	LOW	0.88	0.64	1.21	-1.17	-4.27	1.69	LOW	RoB, Imprecision
remdesivir	vitamin C	NA	NA	NA	NA	NA	NA	NA	0.94	0.67	1.33	-0.57	-3.87	2.4	VERY LOW	0.94	0.67	1.33	-0.57	-3.87	2.4	VERY LOW	RoB, Inconsistency, Imprecision
serine protease inhibitors	umifenovir	NA	NA	NA	NA	NA	NA	NA	0.98	0.66	1.44	-0.17	-3.9	3.7	LOW	0.98	0.66	1.44	-0.17	-3.9	3.7	LOW	RoB, Imprecision
serine protease inhibitors	vitamin C	NA	NA	NA	NA	NA	NA	NA	1.05	0.69	1.58	0.43	-3.46	4.4	VERY LOW	1.05	0.69	1.58	0.43	-3.46	4.4	VERY LOW	RoB, Inconsistency, Imprecision
umifenovir	vitamin C	NA	NA	NA	NA	NA	NA	NA	1.07	0.73	1.55	0.6	-3.04	4.1	VERY LOW	1.07	0.73	1.55	0.6	-3.04	4.1	VERY LOW	RoB, Inconsistency, Imprecision

Complete network meta-analysis results and GRADE

									Venous	thromboem	bolism												
Comparison		Direct esti	mate						Indirect es	timate						Network es	stimate						
		Relative es	timate		Absolute e	stimate (per	r 1,000)		Relative es	timate		Absolute e	stimate (pe	er 1,000)		Relative e	stimate		Absolute	estimate (per 1,000)		
Treatment 1	Treatment 2	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit	Final rating	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit	Final rating	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit	Final rating	Reasons for downgrading
aspirin	standard care/placebo	2.85	0.09	87.32	54.59	-29.15	712.00	VERY LOW	NA	NA	NA	NA	NA	NA	NA	1.19E+06	1.30	4.42E+19	837.53	12.04	967.75	VERY LOW	Imprecisionx3
full-dose anticoagulant	standard care/placebo	0.52	0.33	0.84	-15.11	-21.41	-5.10	LOW	0.35	0.06	1.80	-20.69	-30.11	24.35	VERY LOW	0.50	0.32	0.78	-15.53	-21.72	-7.23	LOW	RoB, Imprecision
intermediate-dose anticoagulant	standard care/placebo	1.17	0.23	6.04	5.17	-24.79	135.23	VERY LOW	1.72	0.63	5.32	21.99	-11.66	118.39	VERY LOW	1.49	0.69	3.41	18.54	-9.83	67.39	LOW	RoB, Imprecision
sulodexide	standard care/placebo	1.01	0.10	10.17	0.41	-28.90	220.88	VERY LOW	NA	NA	NA	NA	NA	NA	NA	1.04	0.10	11.35	25.33	-29.21	227.36	VERY LOW	Imprecisionx3
full-dose anticoagulant	aspirin	0.17	0.01	5.10	NA	NA	NA	VERY LOW	NA	NA	NA	NA	NA	NA	NA	0.00	0.00	0.38	-853.06	-988.78	-27.98	VERY LOW	Imprecisionx3
aspirin	intermediate-dose anticoagulant	NA	NA	NA	NA	NA	NA	NA	7.89E+05	0.89	2.99E+19	818.98	-4.69	975.39	VERY LOW	7.89E+05	0.89	2.99E+19	818.98	-4.69	975.39	VERY LOW	Imprecisionx3
aspirin	sulodexide	NA	NA	NA	NA	NA	NA	NA	1.31E+06	0.99	3.62E+19	812.19	-3.29	995.87	VERY LOW	1.31E+06	0.99	3.62E+19	812.19	-3.29	995.87	VERY LOW	Imprecisionx3
intermediate-dose anticoagulant	full-dose anticoagulant	3.13	1.07	9.49	NA	NA	NA	LOW	2.27	0.54	10.09	NA	NA	NA	VERY LOW	3.00	1.45	6.50	34.08	7.27	80.29	MODERATE	Imprecision
full-dose anticoagulant	sulodexide	NA	NA	NA	NA	NA	NA	NA	0.48	0.04	5.07	-40.87	-242.40	15.15	VERY LOW	0.48	0.04	5.07	-40.87	-242.40	15.15	VERY LOW	RoB, Imprecisionx3
intermediate-dose anticoagulant	sulodexide	NA	NA	NA	NA	NA	NA	NA	1.43	0.12	16.82	-6.79	-209.73	74.63	VERY LOW	1.43	0.12	16.82	-6.79	-209.73	74.63	VERY LOW	RoB, Imprecisionx3



Methods

In our living network meta-analysis of drug treatments for COVID-19,1 we combined all JAK inhibitors into a single node. To compare the safety and efficacy of specific JAK inhibitors headto-head, we performed a second Bayesian NMA. We included randomised control trials (RCTs) identified up to October 18, 2020 that reported adverse events leading to discontinuation, duration of hospitalization, duration of mechanical ventilation, ICU length of stay mechanical ventilation, mortality, time to symptom resolution, time to viral clearance, and ventilator-free days in which patients were randomised to two or more of the following interventions: any JAK inhibitor, corticosteroids + IL6 receptor antagonists, standard care/placebo. Due to low event rate, we meta-analysed adverse events using the risk difference and corresponding 95% credible interval, while all other binary outcomes were meta-analysed using the odds ratio and corresponding 95% credible interval. Because we expected variation between studies for the outcomes time to symptom resolution and time to viral clearance, we first performed the analyses using the relative effect measure ratio of means and corresponding 95% credible interval before calculating the mean difference in days. All other continuous outcomes were summarised using the mean difference and corresponding 95% credible interval. Readers can find more details about the literature search, data extraction, meta-analysis, and GRADE assessment elsewhere.1

Results

Baricitinib (3 RCTs), ruxolitinib (2 RCTs), and tofacitinib (1 RCT) were the JAK inhibitors investigated in eligible trials. <u>Table 1</u> provides an overview of all 36 RCTs included in our NMA. We encourage readers to visit our website (<u>www.covid19lnma.com</u>) to view summary of findings tables for specific comparisons of interest. Risk of bias (RoB) tables, forest plots for pairwise meta-analyses, network plots, and full results of the NMA (direct, indirect, and network estimates) can be found below for all outcomes of interest.

Outcome	Risk of bias table	Forest plots	Network plot	Full results of NMA
Adverse events	Table 2	Figures 1-2	Figure 25	Table 11
Duration of hospitalization	Table 3	Figures 3-6	Figure 26	
Duration of ventilation	Table 4	Figures 7-8	Figure 27	
ICU length of stay	Table 5	Figures 9-10	Figure 28	
Mechanical ventilation	Table 6	Figures 11-14	Figure 29	
Mortality	Table 7	Figures 15-18	Figure 30	
Time to symptom resolution	Table 8	Figures 19-21	Figure 31	
Time to viral clearance	Table 9	Figure 22		
Ventilator-free days	<u>Table 10</u>	Figures 23-24	Figure 32	

 Table 1. Characteristics of included studies.

Study	Publication status Registration	Number of participants	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
ARCHITECTS_NCT04412772, 2021 ARCHITECTS	Data from meta-analysis NCT04412772	21	United States	61.5	57.1	NR	Inpatient	Severe (100%)	NR	NR	tocilizumab (8 mg/kg (up to 800 mg) single dose) placebo	Mortality
CORIMUNO-SARI- 1_NCT04324073, 2021 CORIMUNO-SARI-1	Data from meta-analysis NCT04324073	144	France	62.3	75	NR	Inpatient	Severe (100%)	NR	NR	sarilumab (400 mg for one to two doses) standard care	Mortality
CORIMUNO-SARI- ICU_NCT04324073, 2021 CORIMUNO-SARI-ICU	Data from meta-analysis NCT04324073	81	France	61.6	76.5	NR	Inpatient Intensive care (100.0%)	Severe (100%)	NR	NR	sarilumab (400 mg one to two doses) standard care	Mortality Duration of ventilation
CORIMUNO-TOCI- ICU_NCT04331808, 2021	Published NCT04331808	92	France	64.2	71.7	NR	Inpatient Intensive care (100.0%)	Severe (100%) Severe: Critical (100.0%)	100	Iv, niv, or high flow (100.0%)	tocilizumab (8 mg/kg on day 1, and 400 mg on day 3 if oxygen requirement was not decreased by more than 50%) standard care	Mortality Duration of ventilation
COV-AID_NCT04330638, 2021 COV-AID	Data from meta-analysis NCT04330638	230	Belgium	63.6	77.4	NR	Inpatient	Severe (100%)	NR	NR	tocilizumab (8 mg/kg (up to 800 mg) single dose) siltuximab (11 mg/kg single dose) standard care	Mortality Duration of ventilation
COVIDOSE2- SSA_NCT04479358, 2021 COVIDOSE2-SSA	Data from meta-analysis NCT04479358	28	United States	65	67.9	NR	Inpatient	Severe (100%)	0	Mechanical ventilation (0.0%)	tocilizumab (40 mg single dose) tocilizumab (120 mg single dose) standard care	Mortality
COVIDSTORM_NCT04577534, 2021 COVIDSTORM	Data from meta-analysis NCT04577534	39	Finland	65.7	53.9	NR	Inpatient	Severe (100%)	NR	NR	tocilizumab (8 mg/kg (up to 800 mg) single dose) standard care	Mortality
COVITOZ_NCT04435717, 2021 COVITOZ-01	Data from meta-analysis NCT04435717	26	Spain	57.5	65.4	NR	Inpatient	Severe (100%)	NR	NR	tocilizumab (8 mg/kg (up to 800 mg) single dose) tocilizumab (8 mg/kg up to 800 mg two doses) standard care	Mortality
Cao_2, 2020	Published ChiCTR-OPN- 2000029580	43	China	63	58.5	Coronary artery heart disease (7.3%) Diabetes (19.5%) Hypertension (39.0%)	Inpatient	Severe (100%)	12.2	Supplemental oxygen (87.8%) High flow or niv (12.2%)	ruxolitinib (5 mg twice daily) placebo	Mortality Mechanical ventilation Duration of hospitalization Duration of ventilation Time to symptom/clinical improvement Time to to viral clearance

Study	Publication status Registration	Number of participants	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
Ely, 2021 COV-BARRIER addendum	Pre-print NCT04421027	101	Argentina, Brazil, Mexico, United States	58.6	54.5	Chronic respiratory disease (3.0%) Diabetes (35.6%) Hypertension (54.5%)	Inpatient	Severe (100%) Severe: Critical (100.0%)	100	Iv or ecmo (100.0%)	baricitinib (4 mg daily for 14 days or until discharge) placebo	Mortality Adverse effects leading to discontinuation Duration of hospitalization ICU length of stay Ventilator-free days Duration of ventilation Time to symptom/clinical improvement
Gordon_1, 2021 REMAP-CAP	Published NCT02735707	826	United Kingdom, Netherlands, Austrialia, New Zealand, Ireland, Saudia Arabia	61.4	72.6	Respiratory condition (23.9%) Severe cardiovascular disease (10.2%) Diabetes (35.4%)	Inpatient Intensive care (100.0%)	Severe (100%) Severe: Critical (100.0%)	99.6	High-flow (28.8%) Niv (41.5%) Iv (29.4%)	tocilizumab (8 mg/kg, for a maximum of 800 mg, in 24 hours) sarilumab (400 mg single dose) standard care	Mortality Mechanical ventilation Duration of hospitalization ICU length of stay Ventilator-free days Duration of ventilation
Guimarães, 2021 STOP-COVID	Published NCT04469114	289	Brazil	56	65	Diabetes (23.5%) Hypertension (50.2%)	Inpatient	NR	0	Supplemental oxygen (75.4%) Niv, iv, or ecmo (0.0%)	tofacitinib (10 mg twice daily for up to 14 days or until hospital discharge) placebo	Mortality Mechanical ventilation Adverse effects leading to discontinuation Duration of hospitalization ICU length of stay Duration of ventilation
HMO-020-0224_NCT04377750, 2021 HMO-020-0224	Data from meta-analysis NCT04377750	54	Israel	63.1	68.5	NR	Inpatient	Severe (100%)	NR	NR	tocilizumab (8 mg/kg (up to 800 mg) single dose) placebo	Duration of ventilation
Hermine, 2020 CORIMUNO-TOCI 1	Published NCT04331808	131	France	64	67.7	Asthma (6.2%) Chronic pulmonary disease, not asthma (4.7%) Chronic cardiac disease (31.2%) Diabetes (33.6%)	Inpatient	Severe (100%)	0	Supplemental oxygen (100.0%) Niv or iv (0.0%)	tocilizumab (8 mg/kg on day 1, and 400 mg on day 3 if oxygen requirement was not decreased by more than 50%) standard care	Mortality Mechanical ventilation

Study	Publication status Registration	Number of participants	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
Hermine_toci, 2020 CORIMUNO-TOCIDEX	Pre-print NCT04476979	453	French Guiana	63.4	67.8	Asthma (8.4%) Chronic pulmonary disease - not asthma (7.2%) Chronic cardiac disease (15.8%) Diabetes (23.8%) Hypertension (37.1%)	Inpatient	Severe (100%)	0	Supplementary oxygen (100.0%) High-flow, niv, iv (0.0%)	corticosteroids, tocilizumab (10 mg/d 5 days and tapering doses up to 10 days (5mg/d for 5 days and 2.5mg/d for 5 days; 8mg/kg intravenously at day 1 with additional doses 400 mg IV recommended if no clinical response) standard care	Mortality Mechanical ventilation
Horby_5, 2021 RECOVERY	Published NCT04381936	4116	United Kingdom	63.6	67.4	Chronic lung disease (23.2%) Tuberculosis (0.2%) Heart disease (22.6%) Diabetes (28.4%)	Inpatient	Severe (100%)	54.6	Supplemental oxygen (45.4%) High-flow or niv (41.0%) Iv (13.7%)	tocilizumab (8 mg/kg, for up to a maximum of 800 mg, once) standard care	Mortality Duration of ventilation Mechanical ventilation Duration of hospitalization
ImmCoVA_NCT04412291, 2021 ImmCoVA	Data from meta-analysis NCT04412291	49	Sweden	NR	NR	NR	Inpatient	Severe (100%)	0	Iv (0.0%)	tocilizumab (8 mg/kg single dose, up to a maximum of 800 mg; another dose of 8 mg/kg may be administered after earliest 2 days) standard care	Mortality
Kalil, 2020 ACTT-2	Published NCT04401579	1033	United States, Singapore, South Korea, Mexico, Japan, Spain, United Kingdom, Denmark	55.4	63.1	Asthma (9.4%) Chronic oxygen requirement (1.6%) Chronic respiratory disease (6.7%) Cardiac valvular disease (2.1%) Congestive heart failure (6.0%) Coronary artery disease (9.8%) T2DM (35.8%) T1DM (1.0%) Hypertension (50.5%)	Inpatient	Mild/Moderate (64.5%)	31.7	Supplemental oxygen (54.6%) High-flow or niv (20.9%) Iv or ecmo (10.8%)	baricitinib (4 mg daily for 14 days) placebo	Mortality Mechanical ventilation Duration of hospitalization Duration of ventilation Time to symptom/clinical improvement

Study	Publication status Registration	Number of participants	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
Lescure, 2021	Published NCT04327388; Eudra CT (2020- 001162-12), WHO (U1111- 1249-6021)	420	Argentina, Brazil, Canada, Chile, France, Germany, Israel, Italy, Japan, Russia, Spain	59	62.7	Copd (4.3%) Asthma (4.1%) Coronary artery disease (5.3%) Diabetes (26.4%) Hypertension (42.5%)	Inpatient Intensive care (35.6%)	Severe (100%) Severe: Critical (38.9%)	19.5	Nasal cannula (42.1%) Face mask (26.7%) Nonrebreather face mask (10.5%) High-flow (6.2%) Niv (1.7%) Iv (11.5%) Other (1.2%)	sarilumab (400 mg, single dose) sarilumab (200 mg, single dose) placebo	Mortality Mechanical ventilation Duration of hospitalization Time to symptom/clinical improvement
Marconi, 2021 COV-BARRIER	Published NCT04421027	1525	Argentina, Brazil, Germany, India, Italy, Japan, Korea, Mexico, Russia, Spain, United Kingdom, United States	57.6	63.1	Chronic respiratory disease (4.6%) T1DM (30.0%) Hypertension (47.9%)	Inpatient	Severe (100%)	24.4	Supplemental oxygen (63.4%) High-flow or niv oxygen (24.4%) Iv (0.0%)	baricitinib (4 mg daily for 14 days or until discharge (patients with eGFR≥30 to <60 mL/min/1.73 m² received 2 mg)) placebo	Mortality Mechanical ventilation Adverse effects leading to discontinuation Duration of hospitalization ICU length of stay Ventilator-free days Time to symptom/clinical improvement
REMDACTA_NCT04409262, 2021 REMDACTA	Data from meta-analysis NCT04409262	640	Spain, United States, Brazil, Russia	60.3	63.3	NR	Inpatient	Severe (100%)	NR	NR	tocilizumab (8 mg/kg (up to 800 mg) for one to two doses) placebo	Mortality
RUXCOVID, 2021 RUXCOVID	Trial registration NCT04362137	432	United States, Argentina, Brazil, Colombia, France, Germany, Mexico, Peru, Russia, Spain, Turkey, United Kingdom	56.6	54.4	NR	Inpatient	Severe (100%)	0	Iv (0.0%)	ruxolitinib (5 mg twice daily for 14 days with possible extension of treatment to 28 days) placebo	Mortality Mechanical ventilation Adverse effects leading to discontinuation Duration of hospitalization Time to symptom/clinical improvement
Rosas, 2021 COVACTA	Published NCT04320615	452	Canada, Denmark, France, Germany, Italy, Netherlands, Spain, United Kingdom, United States	60.8	69.9	Chronic lung disease (16.2%) Cardiovascular impairment (28.1%) Diabetes (38.1%) Hypertension (62.1%)	Inpatient Intensive care (56.4%)	Severe (100%)	37.7	Unspecified ventilation (37.7%)	tocilizumab (8 mg/kg, maximum 800 mg, up to two times in 24 hours) placebo	Mortality Mechanical ventilation Adverse effects leading to discontinuation Duration of hospitalization ICU length of stay Ventilator-free days

Study	Publication status Registration	Number of participants	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
												Duration of ventilation Time to symptom/clinical improvement
Rutgers, 2021 PreToVid	Pre-print NL8504	354	Netherlands	66.5	67	NR	Inpatient	Severe (100%)	NR	Supplemental oxygen (96.6%)	tocilizumab (single dose of 8 mg/kg of body weight intravenously or 800mg max, second dose permitted after 8 hours if hypoxia not resolved) standard care	Mechanical ventilation Duration of hospitalization ICU length of stay Duration of ventilation
SARCOVID_NCT04357808, 2021 SARCOVID	Data from meta-analysis NCT04357808	30	Spain	61.7	66.7	NR	Inpatient	Severe (100%)	0	Mechanical ventilation (0.0%)	sarilumab (400 mg single dose) standard care	Mortality
SARICOR_EudraCT2020- 001531-27, 2021 SARICOR	Data from meta-analysis EudraCT2020- 001531-27	80	Spain	59.4	71.2	NR	Inpatient	Severe (100%)	0	Mechanical ventilation (0.0%)	sarilumab (400 mg single dose) sarilumab (200 mg single dose) standard care	Mortality
SARTRE_EudraCT2020-002037- 15, 2021 SARTRE	Data from meta-analysis EudraCT2020- 002037-15	140	Spain	58.4	72.9	NR	Inpatient	Severe (100%)	0	Mechanical ventilation (0.0%)	sarilumab (200 mg to 400 mg single dose) standard care	Mortality
Salama, 2020 EMPACTA	Published NCT04372186	388	United States, Peru, Brazil, Kenya, South Africa, Mexico	55.9	59.1	Copd (4.5%) Asthma (11.4%) Myocardial infarction (1.9%) Atrial fibrillation (3.2%) Diabetes (40.6%) Hypertension (48.3%)	Inpatient Intensive care (15.4%)	Severe (100%)	0	Ventilation (0.0%)	tocilizumab (8 mg/kg, for up to a maximum of 800 mg, in 24 hours) placebo	Mortality Mechanical ventilation Adverse effects leading to discontinuation Duration of hospitalization Time to symptom/clinical improvement
Sivapalasingam_P2, 2021 Sarilumab-COVID-19	Pre-print NCT04315298	457	United States	58.7	72.4	Tuberculosis (0.0%) Diabetes (21.4%) Hypertension (46.4%)	Inpatient	Severe (100%) Severe: Critical (49.5%)	49.5	Low-flow supplemental oxygen (27.6%) High-flow oxygen, niv, and/or iv (49.5%)	sarilumab (200 mg, given intravenously over 1 hour; patients could be re-dosed for clinical worsening at 24 hours and weekly for up to 4 doses) sarilumab (400 mg, given	Adverse effects leading to discontinuation

Study	Publication status Registration	Number of participants	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
											intravenously over 1 hour; patients could be re-dosed for clinical worsening at 24 hours and weekly for up to 4 doses) placebo	
Sivapalasingam_P3_C1, 2021 Sarilumab-COVID-19	Pre-print NCT04315298	1365	United States	61.7	64.5	Tuberculosis (0.0%) Diabetes (19.0%) Hypertension (52.7%)	Inpatient	Severe (100%) Severe: Critical (55.0%)	21.8	Low-flow supplemental oxygen (27.0%) Iv (21.8%)	sarilumab (200 mg, given intravenously over 1 hour; patients could be re-dosed for clinical worsening at 24 hours and weekly for up to 4 doses) sarilumab (400 mg, given intravenously over 1 hour; patients could be re-dosed for clinical worsening at 24 hours and weekly for up to 4 doses) placebo	Adverse effects leading to discontinuation
Sivapalasingam_P3_C2_Critical, 2021 Sarilumab-COVID-19	Pre-print NCT04315298	31	United States	48.7	71	Tuberculosis (0.0%) Diabetes (29.0%) Hypertension (41.9%)	Inpatient	Severe (100%) Severe: Critical (100.0%)	100	Iv (100.0%)	sarilumab (800 mg, given intravenously over 1 hour; patients could be re-dosed for clinical worsening at 24 hours and weekly for up to 4 doses) placebo	Mortality Adverse effects leading to discontinuation
Sivapalasingam_P3_C3_Critical, 2021 Sarilumab-COVID-19	Pre-print NCT04315298	8	United States	60.8	62.5	Tuberculosis (0.0%) Diabetes (37.5%) Hypertension (62.5%)	Inpatient	Severe (100%) Severe: Critical (100.0%)	100	Niv or high-flow oxygen (100.0%) Iv (0.0%)	sarilumab (800 mg, given intravenously over 1 hour; patients could be re-dosed for clinical worsening at 24 hours and weekly for up to 4 doses) placebo	Mortality Adverse effects leading to discontinuation
Soin, 2021 COVINTOC	Published CTRI/2020/05/0 25369	180	India	55	84.9	Copd (2.2%) Respiratory, thoracic, and mediastinal disorders (3.9%) Cardiac disorders (15.1%) Diabetes (41.3%) Hypertension (39.1%)	Inpatient	Mild/Moderate (49.2%)	31.9	Supplemental oxygen (89.9%) Niv (26.8%) Iv (5.0%)	tocilizumab (6 mg/kg, up to a maximum dose of 480 mg, single dose; 6 mg/kg (max 480 mg/kg)) standard care	Mortality Mechanical ventilation ICU length of stay Ventilator-free days Duration of ventilation Time to symptom/clinical improvement

Study	Publication status Registration	Number of participants	Country	Mean age	% Male	Comorbidities	Type of care	Severity	% Mechanical ventilation (at baseline)	Detailed ventilation (%)	Treatments (dose and duration)	Outcomes
Stone, 2020 BACC	Published NCT04356937	243	United States	59.9	58	Copd (9.1%) Asthma (9.1%) Heart failure (9.9%) Myocardial infarction (8.6%) Diabetes (30.9%) Hypertension (48.6%)	Inpatient Intensive care (4.5%)	Severe (100%)	4.5	Supplemental oxygen (79.8%) High-flow or niv (4.1%) Iv (0.4%)	tocilizumab (8mg/kg, for up to a maximum of 800 mg, once) placebo	Mortality Mechanical ventilation Duration of hospitalization Duration of ventilation Time to symptom/clinical improvement
Talaschian, 2021	Pre-print IRCT200810270 01411N4	40	Iran	61.7	52.8	Respiratory disorder (8.3%) Cardiovascular disease (44.4%) Diabetes (36.1%) Hypertension (50.0%)	Inpatient	Severe (100%)	8.3	Nasal cannula (50.0%) Simple mask (30.6%) Reservoir mask (11.1%) Niv (8.3%) Iv (0.0%)	tocilizumab (8 mg/kg (if the patient's conditions were not stable, 2 doses by 12 hours were administrated, maximum dose: 800 mg)) standard care	Mortality Mechanical ventilation Adverse effects leading to discontinuation Time to symptom/clinical improvement
Veiga, 2021 TOCIBRAS	Published NCT04403685	129	Brazil	57.5	68.2	Asthma (3.9%) Copd (3.1%) Heart failure (5.4%) Myocardial infarction (5.4%) Diabetes (32.6%) Hypertension (49.6%)	Inpatient	Severe (100%)	48.1	Supplemental oxygen (51.9%) High-flow or niv (31.8%) Iv (16.3%)	tocilizumab (8 mg/kg, for a maximum of 800 mg, in 24 hours) standard care	Mortality Mechanical ventilation Duration of hospitalization Ventilator-free days Duration of ventilation

 Table 2. Risk of bias in RCTs reporting adverse events leading to discontinuation.

Treatment 1	Treatment 2	First author	N	Randomization	Deviations from the intended intervention	Missing outcome data	Measurement of outcome	Selection of the reported results
IL6i, corticosteroids	standard care/placebo		2677					
		Rosas	438	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		Salama	377	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Talaschian	36	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		Sivapalasingam_P2	457	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Sivapalasingam_P3_C1	1330	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Sivapalasingam_P3_C2_Critical	31	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Sivapalasingam_P3_C3_Critical	8	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
JAKi	standard care/placebo		2309					
		Marconi	1502	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Guimarães	284	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Ely	99	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		RUXCOVID	424	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias

 Table 3. Risk of bias in RCTs reporting duration of hospitalisation.

Treatment 1	Treatment 2	First author	N	Randomization	Deviations from the intended intervention	Missing outcome data	Measurement of outcome	Selection of the reported results	Other
IL6i, corticosteroids	standard care/placebo		2522						
		Rosas	438	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Salama	377	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias

Treatment 1	Treatment 2	First author	N	Randomization	Deviations from the intended intervention	Missing outcome data	Measurement of outcome	Selection of the reported results	Other
		Gordon_1	803	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Veiga	129	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Lescure	372	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Rutgers	354	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
		Hamed	49	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
barticitinib	standard care/placebo		2652						
		Kalil	1033	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Marconi	1518	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Ely	101	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
ruxolitinib	standard care/placebo		472						
		Cao_2	41	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	probably low risk of bias
		RUXCOVID	431	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
tofacitinib	standard care/placebo		289						
		Guimarães	289	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias

 Table 4. Risk of bias in RCTs reporting duration of ventilation.

Treatment 1	Treatment 2	First author	N	Randomization	Deviations from the intended intervention	Missing outcome data	Measurement of outcome	Selection of the reported results	Other
IL6i, corticosteroids	standard care/placebo		826						
		Rosas	43	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Gordon_1	239	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Veiga	11	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Horby_5	405	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Soin	9	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		ARCHITECTS_NCT044 12772	19	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		CORIMUNO-TOCI- ICU_NCT04331808	9	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		COV- AID_NCT04330638	11	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		HMO-020- 0224_NCT04377750	27	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably high risk of bias
		Rutgers	45	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
		Hamed	8	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
	.1								
barticitinib	standard care/placebo		328						
		Kalil	227	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Ely	101	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias

Treatment 1	Treatment 2	First author	N	Randomization	Deviations from the intended intervention	Missing outcome data	Measurement of outcome	Selection of the reported results	Other
ruxolitinib	standard care/placebo		3						
		Cao_2	3	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	probably high risk of bias
tofacitinib	standard care/placebo		0						
		Guimarães	0	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias	probably low risk of bias

Table 5. Risk of bias in RCTs reporting ICU length of stay.

Treatment 1	Treatment 2	First author	N	Randomization	Deviations from the intended intervention	Missing outcome data	Measurement of outcome	Selection of the reported results	Other
IL6i, corticosteroids	standard care/placebo		1309						
		Rosas	303	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Gordon_1	803	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Soin	135	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Rutgers	60	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
		Hamed	8	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
barticitinib	standard care/placebo		1626						

Т	Treatment 1	Treatment 2	First author	N	Randomization	Deviations from the intended intervention	Missing outcome data	Measurement of outcome	Selection of the reported results	Other
			Marconi	1525	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
			Ely	101	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
	tofacitinib	standard care/placebo		0						
			Guimarães	0	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias

 Table 6. Risk of bias in RCTs reporting mechanical ventilation.

Treatment 1	Treatment 2	First author	N	Randomization	Deviations from the intended intervention	Missing outcome data	Measurement of outcome	Selection of the reported results
IL6i, corticosteroids	standard care/placebo		4435					
		Salama	377	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		Gordon_1	552	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		Veiga	129	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		Lescure	306	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Soin	170	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		Rosas_A	185	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		Rutgers	354	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias

Treatment 1	Treatment 2	First author	N	Deviations from the Randomization intended intervention		Missing outcome data	Measurement of outcome	Selection of the reported results
		Hamed	49	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		Hermine_toci	445	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		Horby_5	1868	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
barticitinib	standard care/placebo		2434					
		Kalil Marconi	922 1512	low risk of bias low risk of bias	low risk of bias low risk of bias	low risk of bias low risk of bias	low risk of bias low risk of bias	low risk of bias low risk of bias
ruxolitinib	standard care/placebo		472					
		Cao_2	41	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		RUXCOVID	431	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
tofacitinib	standard care/placebo		289					
		Guimarães	289	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias

 Table 7. Risk of bias in RCTs reporting mortality.

Treatment 1	Treatment 2	First author	N	Randomization	Deviations from the intended intervention	Missing outcome data	Measurement of outcome	Selection of the reported results
IL6i, corticosteroids	standard care/placebo		7431					
		Rosas_A	97	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		Hermine_A	22	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		Salama_A	312	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		Veiga_A	65	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		Lescure	416	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		Horby_5_A	3385	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		Soin	180	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		ARCHITECTS_NCT04412 772_A	20	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		CORIMUNO-SARI- 1_NCT04324073_A	7	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		CORIMUNO-SARI- ICU_NCT04324073_A	2	low risk of bias	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias
		CORIMUNO-TOCI- ICU_NCT04331808_A	12	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		COV- AID_NCT04330638_A	90	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		COVIDOSE2- SSA_NCT04479358_A	8	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias

Treatment 1	Treatment 2	First author	N	Randomization	Deviations from the intended intervention	Missing outcome data	Measurement of outcome	Selection of the reported results
		COVIDSTORM_NCT0457 7534_A	30	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		COVITOZ_NCT04435717 _A	12	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		Gordon_1_A	431	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		Gordon_1_B	96	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		HMO-020- 0224_NCT04377750_A	46	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		ImmCoVA_NCT0440926 2_A	47	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		REMDACTA_NCT044092 62_A	539	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		SARCOVID_NCT0435780 8_A	25	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		SARICOR_EudraCT2020- 001531-27_A	100	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		SARTRE_EudraCT2020- 002037-15	140	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		Rutgers_A	326	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		Sivapalasingam_P2_A	76	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Sivapalasingam_P3_C1_ A	444	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Hamed	49	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk o bias
		Hermine_toci	450	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias

Treatment 1	Treatment 2	First author	N	Randomization	Deviations from the intended intervention	Missing outcome data	Measurement of outcome	Selection of the reported results
		Stone_A	4	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
barticitinib	standard care/placebo		2659					
		Kalil	1033	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Marconi	1525	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Ely	101	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
ruxolitinib	standard care/placebo		472					
	·	Cao_2	41	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		RUXCOVID	431	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
tofacitinib	standard care/placebo		289					
		Guimarães	289	low risk of bias	low risk	of bias low risk of b	oias low risk of bias	low risk of bias

 Table 8. Risk of bias in RCTs reporting time to symptom resolution.

Treatment 1	Treatment 2	First author	N	Randomization	Deviations from the intended intervention	Missing outcome data	Measurement of outcome	Selection of the reported results	Other
IL6i, corticosteroids	standard care/placebo		1410						
		Rosas	438	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Salama	377	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Lescure	416	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Soin	179	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
barticitinib	standard care/placebo		2558						
		Kalil	1033	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Marconi	1525	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
ruxolitinib	standard care/placebo		472						
		Cao_2	41	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
		RUXCOVID	431	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias

Table 9. Risk of bias in RCTs reporting time to viral clearance.


Treatment 1	Treatment 2	First author	N	Randomization	Deviations from the intended intervention	Missing outcome data	Measurement of outcome	Selection of the reported results	Other
ruxolitinib	standard care/placebo		17						
		Cao_2	17	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	probably low risk of bias

Table 10. Risk of bias in RCTs reporting ventilator-free days.


Treatment 1	Treatment 2	First author	N	Randomization	Deviations from the intended intervention	Missing outcome data	Measurement of outcome	Selection of the reported results	Other
IL6i, corticosteroids	standard care/placebo		1299						
		Rosas	438	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Gordon_1	553	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Veiga	129	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Soin	179	probably high risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
	ato o do od								
barticitinib	standard care/placebo		1619						
		Marconi	1518	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Ely	101	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias

Figures 1-2. Forest plots: Adverse events leading to discontinuation.

AE_jaki: JAKi vs standard care/placebo




AE_jaki: IL6i vs standard care/placebo




Figures 3-6. Forest plots: Duration of hospitalisation.


Duration_of_hospitalization_jaki: ruxolitinib vs standard care/placebo



Duration_of_hospitalization_jaki: baricitinib vs standard care/placebo



Duration_of_hospitalization_jaki: tofacitinib vs standard care/placebo



Duration_of_hospitalization_jaki: corticosteroids, IL6i vs standard care/placebo






Figure 7-8. Forest plots: Duration of ventilation.


Duration_of_ventilation_jaki: corticosteroids, IL6i vs standard care/placebo



Ely -2.60 [-6.24, 1.04] Kalil -3.80 [-7.49, -0.11] HNorm(0.5) -3.19 [-5.87, -0.52] HNorm(1.0) -3.19 [-6.10, -0.29] **Turner Prior** -3.19 [-5.90, -0.48] Frequentist.fixed -3.19 [-5.78, -0.60] Frequentist.random.DL -3.19 [-5.78, -0.60] -5.00 -2.50 0.00 2.50 5.00 Mean difference

Figure 9-10. Forest plots: ICU length of stay.





ICU_stay_jaki: corticosteroids, IL6i vs standard care/placebo








Figure 11-14. Forest plots: Mortality.







mortality_jaki: baricitinib vs standard care/placebo



mortality_jaki: tofacitinib vs standard care/placebo






Figure 15-18. Forest plots: Mechanical ventilation.


MV_jaki: ruxolitinib vs standard care/placebo




 $\mathbf{MV_jaki:}\ \mathbf{corticosteroids,}\ \mathbf{IL6i}\ \mathbf{vs}\ \mathbf{standard}\ \mathbf{care/placebo}$



MV_jaki: tofacitinib vs standard care/placebo




MV_jaki: baricitinib vs standard care/placebo




Figures 19-21. Forest plots: Time to symptom resolution.

Time_to_symptom_resolution_jaki: ruxolitinib vs standard care/placebo



Time_to_symptom_resolution_jaki: baricitinib vs standard care/placebo



Time_to_symptom_resolution_jaki: corticosteroids, IL6i vs standard care/placebo






Figure 22. Forest plot: Time to viral clearance.

Time_to_viral_clearance_jaki: JAK inhibitors vs standard care/placebo



Figures 23-24. Forest plot: Ventilator-free days.

Ventilator_free_days_jaki: baricitinib vs standard care/placebo



Ventilator_free_days_jaki: corticosteroids, IL6i vs standard care/placebo




Figure 25. Network plot for adverse events leading to discontinuation.




Figure 26. Network plot for duration of hospitalisation.




Figure 27. Network plot for duration of ventilation.




Figure 28. Network plot for ICU length of stay.




Figure 29. Network plot for mechanical ventilation.




Figure 30. Network plot for mortality.




Figure 31. Network plot for time to symptom resolution.




Figure 32. Network plot for ventilator-free days.




 Table 11. Meta-analysis results, including direct, indirect, and network estimates.

		DIRECT ESTIMATES								ESTIMATES		NETWORK ESTIMATES							
Intervention 1	Intervention 2	Rela	ative effect		Absolute	e effect pe	r 1,000	Re	lative effect		Absolut	e effect per	1,000	Re	lative effect	t	Absolut	te effect per	1,000
		Point estimate	Lower Cl	Upper Cl	Point estimate	Lower Cl	Upper Cl	Point estimate	Lower CI	Upper Cl	Point estimate	Lower CI	Upper Cl	Point estimate	Lower CI	Upper Cl	Point estimate	Lower CI	Upper Cl
				Adve	erse events le	ading to di	scontinuatio	on – Relative e	ffect estima	te: NA; Ab	solute effect e	stimate: Risk	difference						
baricitinib	standard care/placebo	NA	NA	NA	-39.16	- 599.42	503.23	NA	NA	NA	NA	NA	NA	NA	NA	NA	4.57	-18.26	27.56
corticosteroids, IL6 receptor antagonists	standard care/placebo	NA	NA	NA	-1.71	-58.29	62.04	NA	NA	NA	NA	NA	NA	NA	NA	NA	-3.37	-10.24	3.48
ruxolitinib	standard care/placebo	NA	NA	NA	1.85	- 1260.1 7	1263.90	NA	NA	NA	NA	NA	NA	NA	NA	NA	1.84	-11.00	14.61
tofacitinib	standard care/placebo	NA	NA	NA	77.46	- 1185.4 7	1340.43	NA	NA	NA	NA	NA	NA	NA	NA	NA	77.45	17.06	137.36
baricitinib	corticosteroids, IL6 receptor antagonists	NA	NA	NA	NA	NA	NA	NA	NA	NA	7.94	-15.90	31.88	NA	NA	NA	7.94	-15.90	31.88
baricitinib	ruxolitinib	NA	NA	NA	NA	NA	NA	NA	NA	NA	2.77	-23.45	29.04	NA	NA	NA	2.77	-23.45	29.04
baricitinib	tofacitinib	NA	NA	NA	NA	NA	NA	NA	NA	NA	-72.91	-136.97	-7.92	NA	NA	NA	-72.91	-136.97	-7.92
corticosteroids, IL6 receptor antagonists	ruxolitinib	NA	NA	NA	NA	NA	NA	NA	NA	NA	-5.20	-19.71	9.30	NA	NA	NA	-5.20	-19.71	9.30
corticosteroids, IL6 receptor antagonists	tofacitinib	NA	NA	NA	NA	NA	NA	NA	NA	NA	-80.75	-141.11	-19.92	NA	NA	NA	-80.75	-141.11	-19.92
ruxolitinib	tofacitinib	NA	NA	NA	NA	NA	NA	NA	NA	NA	-75.67	-136.85	-13.91	NA	NA	NA	-75.67	-136.85	-13.91
	Duration of hospitalisation – Relative effect estimate: NA; Absolute effect estimate: mean difference																		
baricitinib	standard care/placebo	NA	NA	NA	-1.39	-2.37	-0.43	NA	NA	NA	NA	NA	NA	NA	NA	NA	-1.62	-7.26	4.04
corticosteroids, IL6 receptor antagonists	standard care/placebo	NA	NA	NA	-4.70	-8.88	-0.44	NA	NA	NA	NA	NA	NA	NA	NA	NA	-4.72	-8.52	-0.78
ruxolitinib	standard care/placebo	NA	NA	NA	0.14	-2.07	2.35	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.30	-6.95	7.64

tofacitinib ca corr baricitinib IL al baricitinib r baricitinib t	standard sare/placebo orticosteroids, IL6 receptor antagonists ruxolitinib	Point estimate NA NA	Lower CI NA	Upper CI NA	Absolute Point estimate -1.09	Lower Cl	r 1,000 Upper Cl	Point estimate	lative effect		Absolute	e effect per	1,000	Re	lative effect	:	Absolut	te effect per	1.000
tofacitinib ca cori baricitinib IL al baricitinib r baricitinib t	orticosteroids, IL6 receptor antagonists ruxolitinib	estimate NA	CI	CI	estimate	CI			L avvasa CI		Absolute effect per 1,000			Relative effect			Absolute effect per 1,000		
tofacitinib ca cori baricitinib IL al baricitinib r baricitinib t	orticosteroids, IL6 receptor antagonists ruxolitinib			NA	-1.09	2.76			Lower Cl	Upper Cl	Point estimate	Lower CI	Upper Cl	Point estimate	Lower CI	Upper Cl	Point estimate	Lower Cl	Upper Cl
baricitinib IL al baricitinib r baricitinib t	IL6 receptor antagonists ruxolitinib	NA	NΔ			-2.76	0.58	NA	NA	NA	NA	NA	NA	NA	NA	NA	-1.10	-10.82	8.68
baricitinib t			IVA	NA	NA	NA	NA	NA	NA	NA	3.10	-3.80	9.86	NA	NA	NA	3.10	-3.80	9.86
	tofacitinih	NA	NA	NA	NA	NA	NA	NA	NA	NA	-1.93	-11.16	7.24	NA	NA	NA	-1.93	-11.16	7.24
	toracitiiib	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.54	-11.86	10.73	NA	NA	NA	-0.54	-11.86	10.73
corticosteroids, IL6 receptor r antagonists	ruxolitinib	NA	NA	NA	NA	NA	NA	NA	NA	NA	-5.02	-13.24	3.31	NA	NA	NA	-5.02	-13.24	3.31
corticosteroids, IL6 receptor t antagonists	tofacitinib	NA	NA	NA	NA	NA	NA	NA	NA	NA	-3.64	-14.13	6.87	NA	NA	NA	-3.64	-14.13	6.87
ruxolitinib t	tofacitinib	NA	NA	NA	NA	NA	NA	NA	NA	NA	1.37	-10.80	13.57	NA	NA	NA	1.37	-10.80	13.57
Duration of ventilation – Relati							on – Relativ	e effect estin	nate: NA; Ab	solute effe	ct estimate: m	ean differen	се						
l haricitinih l	standard are/placebo	NA	NA	NA	-3.19	-5.90	-0.48	NA	NA	NA	NA	NA	NA	NA	NA	NA	-3.18	-5.93	-0.49
II 6 recentor	standard are/placebo	NA	NA	NA	-0.94	-2.23	0.32	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.94	-2.25	0.30
baricitinib IL	orticosteroids, IL6 receptor antagonists	NA	NA	NA	NA	NA	NA	NA	NA	NA	-2.23	-5.26	0.73	NA	NA	NA	-2.23	-5.26	0.73
					ICU len	gth of stay	– Relative (effect estimat	e: NA; Absol	ute effect (estimate: mea	n difference							
haricitinih	standard are/placebo	NA	NA	NA	-0.25	-1.82	1.11	NA	NA	NA	NA	NA	NA	NA	NA	NA	-1.31	-6.69	3.86
II 6 recentor	standard are/placebo	NA	NA	NA	-5.50	-9.30	-1.51	NA	NA	NA	NA	NA	NA	NA	NA	NA	-5.48	-9.28	-1.32
baricitinib IL	orticosteroids, IL6 receptor antagonists	NA	NA	NA	NA	NA	NA	NA	NA	NA	4.17	-2.74	10.47	NA	NA	NA	4.17	-2.74	10.47

				DIRECT ES	TIMATES				ESTIMATES	NETWORK ESTIMATES									
Intervention 1	Intervention 2	Rela	ative effect		Absolute	e effect pe	r 1,000	Re	lative effect		Absolut	e effect per	1,000	Re	elative effec	t	Absolut	e effect per	1,000
		Point estimate	Lower Cl	Upper Cl	Point estimate	Lower Cl	Upper Cl	Point estimate	Lower CI	Upper Cl	Point estimate	Lower CI	Upper Cl	Point estimate	Lower CI	Upper Cl	Point estimate	Lower CI	Upper Cl
baricitinib	standard care/placebo	0.79	0.38	1.58	-21.93	-68.78	55.41	NA	NA	NA	NA	NA	NA	0.80	0.52	1.19	-19.96	-52.47	19.05
corticosteroids, IL6 receptor antagonists	standard care/placebo	0.78	0.62	0.99	-22.70	-40.21	-1.27	NA	NA	NA	NA	NA	NA	0.79	0.62	1.01	-21.58	-40.16	0.93
ruxolitinib	standard care/placebo	0.88	0.22	2.98	-12.27	-88.26	165.36	NA	NA	NA	NA	NA	NA	0.87	0.36	2.04	-7.58	-70.82	94.05
tofacitinib	standard care/placebo	0.51	0.11	2.27	-53.30	- 101.21	113.59	NA	NA	NA	NA	NA	NA	0.50	0.17	1.37	-48.37	-94.21	35.12
baricitinib	corticosteroids, IL6 receptor antagonists	NA	NA	NA	NA	NA	NA	1.01	0.61	1.60	1.62	-38.42	44.25	1.01	0.61	1.60	1.62	-38.42	44.25
baricitinib	ruxolitinib	NA	NA	NA	NA	NA	NA	0.92	0.35	2.38	-12.38	-118.16	63.07	0.92	0.35	2.38	-12.38	-118.16	63.07
baricitinib	tofacitinib	NA	NA	NA	NA	NA	NA	1.59	0.53	4.96	28.40	-60.96	90.64	1.59	0.53	4.96	28.40	-60.96	90.64
corticosteroids, IL6 receptor antagonists	ruxolitinib	NA	NA	NA	NA	NA	NA	0.91	0.38	2.25	-14.00	-116.88	54.31	0.91	0.38	2.25	-14.00	-116.88	54.31
corticosteroids, IL6 receptor antagonists	tofacitinib	NA	NA	NA	NA	NA	NA	1.57	0.56	4.69	26.79	-58.22	78.79	1.57	0.56	4.69	26.79	-58.22	78.79
ruxolitinib	tofacitinib	NA	NA	NA	NA	NA	NA	1.74	0.45	6.79	40.79	-64.54	153.26	1.74	0.45	6.79	40.79	-64.54	153.26
					Mort	ality – Rela	itive effect e	estimate: odd:	s ratio; Abso	lute effect	estimate: risk	difference							
baricitinib	standard care/placebo	0.61	0.37	0.99	-46.03	-77.06	-1.46	NA	NA	NA	NA	NA	NA	0.62	0.44	0.85	-44.76	-67.97	-17.39
corticosteroids, IL6 receptor antagonists	standard care/placebo	0.80	0.68	0.96	-22.77	-37.64	-4.86	NA	NA	NA	NA	NA	NA	0.80	0.68	0.96	-22.45	-37.16	-5.28
ruxolitinib	standard care/placebo	0.93	0.18	4.37	-7.76	- 103.20	264.99	NA	NA	NA	NA	NA	NA	0.87	0.28	2.85	1.42	-87.46	173.87
tofacitinib	standard care/placebo	0.49	0.09	2.69	-61.87	- 116.90	157.01	NA	NA	NA	NA	NA	NA	0.47	0.11	1.63	-52.36	-112.81	69.09
baricitinib	corticosteroids, IL6 receptor antagonists	NA	NA	NA	NA	NA	NA	0.77	0.53	1.10	-22.31	-51.64	8.51	0.77	0.53	1.10	-22.31	-51.64	8.51

				DIRECT ES	TIMATES					INDIRECT	ESTIMATES					NETWORK	ESTIMATES		
Intervention 1	Intervention 2	Relative effect			Absolute	e effect per	1,000	Re	lative effect	:	Absolut	e effect per	1,000	Relative effect			Absolute effect per 1,000		
		Point estimate	Lower Cl	Upper Cl	Point estimate	Lower Cl	Upper Cl	Point estimate	Lower Cl	Upper Cl	Point estimate	Lower CI	Upper Cl	Point estimate	Lower CI	Upper Cl	Point estimate	Lower Cl	Upper Cl
baricitinib	ruxolitinib	NA	NA	NA	NA	NA	NA	0.71	0.21	2.27	-46.17	-220.42	48.77	0.71	0.21	2.27	-46.17	-220.42	48.77
baricitinib	tofacitinib	NA	NA	NA	NA	NA	NA	1.32	0.36	5.92	7.60	-115.20	75.53	1.32	0.36	5.92	7.60	-115.20	75.53
corticosteroids, IL6 receptor antagonists	ruxolitinib	NA	NA	NA	NA	NA	NA	0.92	0.28	2.87	-23.86	-196.23	67.78	0.92	0.28	2.87	-23.86	-196.23	67.78
corticosteroids, IL6 receptor antagonists	tofacitinib	NA	NA	NA	NA	NA	NA	1.73	0.49	7.53	29.92	-92.18	93.44	1.73	0.49	7.53	29.92	-92.18	93.44
ruxolitinib	tofacitinib	NA	NA	NA	NA	NA	NA	1.90	0.34	12.12	53.78	-99.88	237.55	1.90	0.34	12.12	53.78	-99.88	237.55
				Time	e to symptom	resolution	– Relative e	effect estimat	e: ratio of m	eans; Abso	lute effect est	imate: mean	difference						
baricitinib	standard care/placebo	0.89	0.52	1.54	-1.07	-4.83	5.40	NA	NA	NA	NA	NA	NA	0.90	0.72	1.11	-1.00	-2.85	1.13
corticosteroids, IL6 receptor antagonists	standard care/placebo	0.85	0.63	1.17	-1.48	-3.74	1.73	NA	NA	NA	NA	NA	NA	0.85	0.68	1.06	-1.45	-3.15	0.60
ruxolitinib	standard care/placebo	0.98	0.54	1.76	-0.22	-4.57	7.60	NA	NA	NA	NA	NA	NA	0.98	0.75	1.28	-0.11	-2.50	2.82
baricitinib	corticosteroids, IL6 receptor antagonists	NA	NA	NA	NA	NA	NA	1.06	0.77	1.43	0.45	-2.32	3.17	1.06	0.77	1.43	0.45	-2.32	3.17
baricitinib	ruxolitinib	NA	NA	NA	NA	NA	NA	0.92	0.64	1.29	-0.89	-4.34	2.29	0.92	0.64	1.29	-0.89	-4.34	2.29
corticosteroids, IL6 receptor antagonists	ruxolitinib	NA	NA	NA	NA	NA	NA	0.87	0.62	1.23	-1.35	-4.73	1.82	0.87	0.62	1.23	-1.35	-4.73	1.82
					Ventilat	or-free day	s – Relative	effect estima	ate: NA; Abs	olute effec	t estimate: me	an differenc	e						
baricitinib	standard care/placebo	NA	NA	NA	1.01	-0.39	2.48	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.99	-0.28	2.42
corticosteroids, IL6 receptor antagonists	standard care/placebo	NA	NA	NA	1.46	-0.06	2.98	NA	NA	NA	NA	NA	NA	NA	NA	NA	1.50	-0.01	3.00
baricitinib	corticosteroids, IL6 receptor antagonists	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.52	-2.47	1.61	NA	NA	NA	-0.52	-2.47	1.61

1. Siemieniuk RA, Bartoszko JJ, Ge L, et al. Drug treatments for covid-19: living systematic review and network meta-analysis. *Bmj* 2020;370:m2980. doi: 10.1136/bmj.m2980 [published Online First: 2020/08/01]

Relative safety and efficacy of selected drugs for treatment of non-severe covid-19

Supplementary Materials

Relative safety and efficacy of fluvoxamine, inhaled corticosteroids, molnupiravir, nirmatrelvir/ritonavir, remdesivir, sotrovimab, and standard care/placebo

Table of Contents

Figure 1 . Network plot: Admission to hospital	2
Figure 2 . Network plot: Adverse events leading to discontinuation	2
Figure 3 . Network plot: Mechanical ventilation.	3
Figure 4 . Network plot: Mortality	3
Figure 5. Network plot: Time to symptom resolution	4
Figures 6-11. Forest plots: Admission to hospital	5
Figures 12-16. Forest plots: Adverse events leading to discontinuation	8
Figures 17-21. Forest plot: Mechanical ventilation.	11
Figures 22-27. Forest plot: Mortality	14
Figures 28-30. Forest plot: Time to symptom resolution	17
Table 1. Direct, indirect and network estimates	18

Network Plots

Figure 1 . Network plot: Admission to hospital.




Figure 2 . Network plot: Adverse events leading to discontinuation.




Figure 3 . Network plot: Mechanical ventilation.




Figure 4 . Network plot: Mortality.






Figure 5. Network plot: Time to symptom resolution.




Figures 6-11. Forest plots: Admission to hospital.


admission_to_hospital: molnupiravir vs standard care/placebo




admission_to_hospital: inhaled corticosteroids vs standard care/placebo




admission_to_hospital: nirmatrelvir, ritonavir vs standard care/placebo




admission_to_hospital: remdesivir vs standard care/placebo



admission_to_hospital: sotrovimab vs standard care/placebo




admission_to_hospital: fluvoxamine vs standard care/placebo




Figures 12-16. Forest plots: Adverse events leading to discontinuation.


AE: remdesivir vs standard care/placebo




AE: inhaled corticosteroids vs standard care/placebo



AE: nirmatrelvir, ritonavir vs standard care/placebo





AE: fluvoxamine vs standard care/placebo




Figures 17-21. Forest plot: Mechanical ventilation.


MV: remdesivir vs standard care/placebo






MV: sotrovimab vs standard care/placebo






MV: inhaled corticosteroids vs standard care/placebo




Figures 22-27. Forest plot: Mortality.


mortality: remdesivir vs standard care/placebo




mortality: inhaled corticosteroids vs standard care/placebo




mortality: nirmatrelvir, ritonavir vs standard care/placebo




mortality: sotrovimab vs standard care/placebo







Figures 28-30. Forest plot: Time to symptom resolution.

Time to symptom resolution; remdesivir vs standard care/placebo








Testiment Test	Comp	parison			Direct 6	estimate					Indirect	estimate					Network	estimate		
## Annual Company of Section 1997 Company				Relative effec	ts	Absolute effect per 1,000			F	Relative effects Absolute effect per 1,000					Relative effects			Absolute effect per 1,000		
Interference Control	Treatment 1	Treatment 2	Point	CI lower		Point			Point	CI lower		Point			Point	CI lower		Point		
Engineering Standard enrophasebox 0.44 0.35 1.47 5.39 13.87 0.78 NA NA NA NA NA NA NA N			estimate	limit	CI upper limit	estimate	CI lower limit	CI upper limit	estimate	limit	CI upper limit	estimate	CI lower limit	Cl upper limit	estimate	limit	CI upper limit	estimate	CI lower limit	CI upper limit
Inhales controllerential standard carepipeache 0.88 0.29 2.25 2.25 1.15.95 44.71 NA	Admission to hospital																			
montagnitariar standard configuration st	fluvoxamine	standard care/placebo																		
Immatriely: Internative Tathander care/placebo 0.7 0.06 0.89 0.75 1.752 1.994 -1.161 NA NA NA NA NA NA NA N	inhaled corticosteroids	standard care/placebo	0.89	0.25	3.25	-2.21	-15.95	44.71	NA	NA	NA	NA	NA	NA	0.88	0.29	2.68	0.47	-15.17	33.64
International Conference Standard carry/pince(b) 0.07 0.06 1.28 15.54 9.50 2.07 5.78 NA NA NA NA NA NA NA NA NA 0.29 0.06 0.87 14.55 19.95 2.17	molnupiravir	standard care/placebo	0.55				_	-1.28	NA	NA	NA									
Security	nirmatrelvir, ritonavir	standard care/placebo							NA	NA	NA	NA	NA	NA		0.06				
Eluvosamine Inhibito Controlerenists NA NA NA NA NA NA NA N	remdesivir	standard care/placebo							NA	NA	NA									
The processing The	sotrovimab	standard care/placebo																		
Forestand Institution Forestand Fo		inhaled corticosteroids								_						_				
Figure 2015														_						
International Control Contro		·												_						
Inhelide corticosteroids infrastretivis infrastreti																				
Inhelide corticosteroids NA													_							
Inhelide corticosteroids NA		I			+															
Inhaled cordicosteroids NA NA NA NA NA NA NA N		, , , , , , , , , , , , , , , , , , , ,								_						_				
molnupiravir monterivir, ritonavir NA NA NA NA NA NA NA N					+															
molnupiravir remdesivir NA NA NA NA NA NA NA N																				
moliupiravir sotrovimab NA NA NA NA NA NA NA N	· · · · · · · · · · · · · · · · · · ·	·																		
Internative Femdesivir Fe																				
Inimate Inim	· · · · · · · · · · · · · · · · · · ·									_										
Remdesivir Sotrovimab NA NA NA NA NA NA NA N	,													_						
Adverse effects Adverse effects Adverse effects	,													_						
Fituvoxamine Standard care/placebo NA NA NA NA 24.01 -1238.17 1286.23 NA NA NA NA NA NA NA N		sotrovimab	NA	NA	NA	NA	NA	NA	1.36	0.23	7.90	1.92	-8.24	14.94	1.36	0.23	7.90	1.92	-8.24	14.94
Inhaled corticosteroids Standard care/placebo NA NA NA NA NA NA NA N		at a mala mala a mala la la cala a	NIA	NI A	NA	24.04	1220 17	1206 22	NIA	NIA	N/A	NIA		NI A	0.03	0.03	0.07	22.02	10.22	66.10
molnupiravir standard care/placebo NA NA NA NA NA NA NA N																				
nirmatrelvir, ritonavir standard care/placebo NA NA NA NA NA NA NA N																				
remdesivir standard care/placebo NA																				
fluvoxamine inhaled corticosteroids NA NA NA NA NA NA NA N	,																			
Fluvoxamine molnupiravir NA NA NA NA NA NA NA N																				
Fluvoxamine nirmatrelvir, ritonavir NA NA NA NA NA NA NA N																			_	
Fluvoxamine remdesivir NA																				
inhaled corticosteroids molnupiravir NA NA NA NA NA NA NA N		, , , , , , , , , , , , , , , , , , , ,			+															
inhaled corticosteroids nirmatrelvir, ritonavir NA NA NA NA NA NA NA N																				
inhaled corticosteroids remdesivir NA NA NA NA NA NA NA N		·																		
molnupiravir nirmatrelvir, ritonavir NA		,																		
molnupiravir remdesivir NA NA <td></td> <td></td> <td></td> <td>ł</td> <td>+</td> <td></td>				ł	+															
nirmatrelvir, ritonavir remdesivir NA		· · · · · · · · · · · · · · · · · · ·																		
Mechanical ventilation fluvoxamine standard care/placebo 0.72 0.22 2.11 -2.91 -8.20 11.53 NA														_						_
fluvoxamine standard care/placebo 0.72 0.22 2.11 -2.91 -8.20 11.53 NA 0.70 0.17 1.96 -2.14 -8.74 9.76 inhaled corticosteroids standard care/placebo 1.02 0.24 4.44 0.24 -8.08 34.80 NA	·	Terriacorvii	1,0		10.1			1.07.1	1.0.4		10/1	12.00	02170	22.125	0.0 .	0.00	0.02	12.00	02170	22.13
inhaled corticosteroids standard care/placebo 1.02 0.24 4.44 0.24 -8.08 34.80 NA NA NA NA NA NA NA N		standard care/placebo	0.72	0.22	2.11	-2.91	-8.20	11.53	NA	NA	NA	NA	NA	NA	0.70	0.17	1.96	-2.14	-8.74	9.76
molnupiravir standard care/placebo 0.44 0.12 1.65 -5.94 -9.32 6.75 NA NA NA NA NA NA 0.39 0.09 1.55 -4.98 -9.64 6.45 remdesivir standard care/placebo 0.45 0.11 1.92 -5.82 -9.48 9.52 NA NA NA NA NA 0.42 0.08 1.87 -4.50 -9.66 9.32 sotrovimab standard care/placebo 0.03 0.00 0.72 -10.24 -10.58 -2.95 NA NA NA NA NA NA 0.00 0.00 0.01 -10.58 -10.60 -10.42																				
remdesivir standard care/placebo 0.45 0.11 1.92 -5.82 -9.48 9.52 NA NA NA NA NA 0.42 0.08 1.87 -4.50 -9.66 9.32 sotrovimab standard care/placebo 0.03 0.00 0.72 -10.24 -10.58 -2.95 NA NA NA NA NA 0.00 0.00 0.01 -10.58 -10.60 -10.42		,,																		
sotrovimab standard care/placebo 0.03 0.00 0.72 -10.24 -10.58 -2.95 NA NA NA NA NA NA NA 0.00 0.00 0.01 -10.58 -10.60 -10.42																				
		- '.															+			
	fluvoxamine	inhaled corticosteroids	NA	NA	NA	NA	NA	NA	0.68	0.09	3.67	-5.83	-34.81	11.30	0.68	0.09	3.67	-5.83	-34.81	11.30

Comp	parison			Direct 6	estimate					Indirect	estimate					Network	estimate		
		Relative effects			Abs	olute effect per	1,000	R	Relative effects			Absolute effect per 1,000			Relative effects			Absolute effect per 1,000	
Treatment 1	Treatment 2	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit
fluvoxamine	molnupiravir	NA	NA	NA	NA	NA	NA	1.78	0.24	10.26	2.84	-10.51	15.95	1.78	0.24	10.26	2.84	-10.51	15.95
fluvoxamine	remdesivir	NA	NA	NA	NA	NA	NA	1.64	0.22	11.17	2.37	-12.96	15.76	1.64	0.22	11.17	2.37	-12.96	15.76
fluvoxamine	sotrovimab	NA	NA	NA	NA	NA	NA	1.66E+15	69.49	2.41E+56	8.44	1.83	20.33	1.66E+15	69.49	2.41E+56	8.44	1.83	20.33
inhaled corticosteroids	molnupiravir	NA	NA	NA	NA	NA	NA	2.65	0.37	19.86	8.67	-8.16	36.90	2.65	0.37	19.86	8.67	-8.16	36.90
inhaled corticosteroids	remdesivir	NA	NA	NA	NA	NA	NA	2.46	0.32	21.12	8.19	-10.30	36.82	2.46	0.32	21.12	8.19	-10.30	36.82
inhaled corticosteroids	sotrovimab	NA	NA	NA	NA	NA	NA	2.66E+15	104.33	3.99E+56	14.27	2.65	42.22	2.66E+15	104.33	3.99E+56	14.27	2.65	42.22
molnupiravir	remdesivir	NA	NA	NA	NA	NA	NA	0.93	0.11	8.01	-0.48	-15.41	12.28	0.93	0.11	8.01	-0.48	-15.41	12.28
molnupiravir	sotrovimab	NA	NA	NA	NA	NA	NA	9.26E+14	37.86	1.43E+56	5.60	0.93	17.02	9.26E+14	37.86	1.43E+56	5.60	0.93	17.02
remdesivir	sotrovimab	NA	NA	NA	NA	NA	NA	1.05E+15	36.44	1.50E+56	6.07	0.91	19.90	1.05E+15	36.44	1.50E+56	6.07	0.91	19.90
Mortality																			
fluvoxamine	standard care/placebo	0.70	0.22	2.29	-0.57	-1.49	2.44	NA	NA	NA	NA	NA	NA	0.68	0.24	1.86	-0.38	-1.45	1.89
inhaled corticosteroids	standard care/placebo	0.90	0.09	9.41	-0.20	-1.74	15.69	NA	NA	NA	NA	NA	NA	0.00	0.00	440924.97	61.82	-1.90	998.10
molnupiravir	standard care/placebo	0.29	0.08	1.02	-1.35	-1.74	0.03	NA	NA	NA	NA	NA	NA	0.11	0.01	0.55	-1.62	-1.88	-0.94
nirmatrelvir, ritonavir	standard care/placebo	0.12	0.01	1.39	-1.68	-1.88	0.74	NA	NA	NA	NA	NA	NA	0.00	0.00	0.01	-1.89	-1.90	-1.84
remdesivir	standard care/placebo	0.68	0.34	1.35	-0.61	-1.26	0.66	NA	NA	NA	NA	NA	NA	0.67	0.32	1.36	-0.56	-1.32	0.69
sotrovimab	standard care/placebo	0.20	0.01	5.23	-1.52	-1.89	7.95	NA	NA	NA	NA	NA	NA	0.00	0.00	0.14	-1.86	-1.90	-1.69
fluvoxamine	inhaled corticosteroids	NA	NA	NA	NA	NA	NA	#######################################	0.00	4.40E+24	-62.20	-998.81	3.60	1.17E+06	0.00	4.40E+24	-62.20	-998.81	3.60
fluvoxamine	molnupiravir	NA	NA	NA	NA	NA	NA	6.10	0.93	64.70	1.24	-0.01	3.53	6.10	0.93	64.70	1.24	-0.01	3.53
fluvoxamine	nirmatrelvir, ritonavir	NA	NA	NA	NA	NA	NA	1.41E+18	42.40	1.03E+32	1.51	0.44	3.78	1.41E+18	42.40	1.03E+32	1.51	0.44	3.78
fluvoxamine	remdesivir	NA	NA	NA	NA	NA	NA	1.02	0.29	3.61	0.18	-1.50	2.57	1.02	0.29	3.61	0.18	-1.50	2.57
fluvoxamine	sotrovimab	NA	NA	NA	NA	NA	NA	5.78E+10	4.67	2.73E+30	1.48	0.38	3.77	5.78E+10	4.67	2.73E+30	1.48	0.38	3.77
inhaled corticosteroids	molnupiravir	NA	NA	NA	NA	NA	NA	0.00	0.00	#######################################	63.45	-0.92	999.85	0.00	0.00	4.10E+06	63.45	-0.92	999.85
inhaled corticosteroids	nirmatrelvir, ritonavir	NA	NA	NA	NA	NA	NA	1.15E+10	0.00	1.42E+29	63.72	-0.06	1000.00	1.15E+10	0.00	1.42E+29	63.72	-0.06	1000.00
inhaled corticosteroids	remdesivir	NA	NA	NA	NA	NA	NA	0.00	0.00	603016.60	62.38	-2.53	998.81	0.00	0.00	6.03E+05	62.38	-2.53	998.81
inhaled corticosteroids	sotrovimab	NA	NA	NA	NA	NA	NA	11937.74	0.00	6.44E+25	63.68	-0.21	1000.00	1.19E+04	0.00	6.44E+25	63.68	-0.21	1000.00
molnupiravir	nirmatrelvir, ritonavir	NA	NA	NA	NA	NA	NA	1.97E+17	6.86	1.48E+31	0.27	0.02	0.96	1.97E+17	6.86	1.48E+31	0.27	0.02	0.96
molnupiravir	remdesivir	NA	NA	NA	NA	NA	NA	0.17	0.02	0.95	-1.06	-2.36	-0.09	0.17	0.02	0.95	-1.06	-2.36	-0.09
molnupiravir	sotrovimab	NA	NA	NA	NA	NA	NA	9.49E+09	0.61	4.37E+29	0.24	-0.02	0.95	9.49E+09	0.61	4.37E+29	0.24	-0.02	0.95
nirmatrelvir, ritonavir	remdesivir	NA	NA	NA	NA	NA	NA	0.00	0.00	0.02	-1.33	-2.59	-0.58	0.00	0.00	0.02	-1.33	-2.59	-0.58
nirmatrelvir, ritonavir	sotrovimab	NA	NA	NA	NA	NA	NA	0.00	0.00	1.05E+19	-0.03	-0.20	0.06	0.00	0.00	1.05E+19	-0.03	-0.20	0.06
remdesivir	sotrovimab	NA	NA	NA	NA	NA	NA	5.59E+10	4.50	2.50E+30	1.30	0.52	2.58	5.59E+10	4.50	2.50E+30	1.30	0.52	2.58
Time to symptom reso	lution																		
inhaled corticosteroids	standard care/placebo	0.97	0.68	1.36	-0.35	-3.91	4.40	NA	NA	NA	NA	NA	NA	0.98	0.79	1.19	-0.24	-2.62	2.32
molnupiravir	standard care/placebo	0.67	0.46	0.92	-4.12	-6.66	-0.98	NA	NA	NA	NA	NA	NA	0.67	0.54	0.80	-4.03	-5.62	-2.48
remdesivir	standard care/placebo	0.83	0.23	3.03	-2.06	-9.51	25.01	NA	NA	NA	NA	NA	NA	0.84	0.54	1.29	-1.80	-5.63	3.40
inhaled corticosteroids	molnupiravir	NA	NA	NA	NA	NA	NA	1.45	1.10	1.95	3.79	0.99	6.84	1.45	1.10	1.95	3.79	0.99	6.84
inhaled corticosteroids	remdesivir	NA	NA	NA	NA	NA	NA	1.17	0.72	1.89	1.56	-4.18	6.18	1.17	0.72	1.89	1.56	-4.18	6.18
molnupiravir	remdesivir	NA	NA	NA	NA	NA	NA	0.81	0.49	1.28	-2.23	-7.68	1.89	0.81	0.49	1.28	-2.23	-7.68	1.89
	L		<u> </u>	1		1	1									1			



Therapies for treatment and prophylaxis of COVID-19: introduction and methods for a living systematic review and network meta-analyses

An international collaborative project

Correspondence to

Reed AC Siemieniuk reed.siemieniuk@medportal.ca

Abstract

Objectives: To compare the effects of therapies for prophylaxis and treatment of COVID-19 *Design:* Living systematic review and network meta-analysis (NMA).

Data sources: U.S. Centers for Disease Control and Prevention (CDC) COVID-19 Research Articles Downloadable Database, which includes 25 electronic databases.

Study selection: We will include randomized clinical trials (RCT) in which persons exposed to COVID-19 or with suspected, probable or confirmed COVID-19 were treated with pharmaceuticals or blood products aimed at prophylaxis or treatment. Pairs of independent reviewers will screen in duplicate title and abstract and full text of potentially eligible articles. Methods: After duplicate data abstraction, we will conduct a Bayesian-random effects network meta-analysis for each of the outcomes of interest. We will assess the risk of bias of the included studies using a modification of the Cochrane Risk of Bias 2.0 tool, and the certainty of the evidence using the GRADE approach for NMA. We will classify the interventions in groups from the most to the least effective/ harmful following GRADE guidance using a minimally contextualized approach.

Publication and Updating of Results: We will publish and update the results in *The BMJ* and magicapp.org. We will update the living NMA when the question is no longer of clinical importance, or new evidence that might impact on the conclusions is unlikely to be forthcoming.

Background

COVID-19 is a rapidly evolving global health emergency. As of 27 May 2020, over 5.6 million people have been infected and of these, 335,000 have died,¹ resulting in an enormous perceived need to implement a possibly effective intervention. Public figures,² guideline bodies,³ and government agencies ⁴ have suggested using interventions without established benefit. Clinicians have responded to these suggestions by administering such interventions to large numbers of patients.⁵

With many teams conducting randomized clinical trials (RCTs) of drug interventions—over 1,000 intervention trials registered as of 10 May 2020 ⁶—evidence on the comparative effectiveness of

drug interventions will emerge rapidly. The new environment will amplify the need for evidence based medicine: distinguishing trustworthy from untrustworthy evidence, interpreting the results, and judging net benefits of interventions against standard treatment and one another.⁷

Reliable guidance for COVID-19 will require adherence to standards of trustworthy clinical practice guidelines, including methodically rigorous and rapidly updated evidence summaries. Such summaries will identify interventions with sufficient evidence of net benefit to warrant use. Establishing absence of net benefit in previously highly touted interventions may be equally important. Further, if studies suggest that more than one intervention provides net benefit, clinicians and patients will face the challenge of deciding which intervention to use.

Our living systematic review and network meta-analysis (NMA), updated in real time, will answer this urgent demand for trustworthy evidence on the available therapeutic options. This systematic review is part of the *BMJ Rapid Recommendations* project, a collaborative effort from the MAGIC Evidence Ecosystem Foundation (www.magicproject.org) and *The BMJ*. Our living NMA will thus directly inform *BMJ Rapid Recommendations*, providing trustworthy, actionable, and living guidance to clinicians and patients soon after new and potentially practice-changing evidence is made available. The living NMA will be freely available in user-friendly formats, through *The BMJ* and MAGICapp (www.magicapp.orsg), and ready for re-use and adaptation at national and local levels.

Methods

Structure and organization

The team working in the development of this living systematic review and NMA is composed of the following groups:

- a. Oversight group composed of experts in the clinical area and systematic review methodology (RAC, TA, GHG, BR, FL, SM, PV). The role of this team is to ensure that the process follows the highest methodological standards, and that the decisions made are clinically sensible and keep consistency with the needs of the BMJ Rapid Recommendations.
- b. Core systematic review team leaders. This group is composed of methodologists leading teams in charge of study identification (JB), data abstraction (DZ), data analysis (LG), and assessment of certainty of the evidence and presentation (RBP).
- c. Reviewers. This team is composed of clinicians, graduate students, methodologists, and biostatisticians conducting or providing advice for screening, data abstraction, and assessments of certainty of the evidence.

In addition, decisions in this protocol have been made considering the requirements from the *Rapid Recommendations* guideline panel, which includes patients.

Eligibility criteria

We will include RCTs in which persons exposed to COVID-19 or with suspected, probable, or confirmed COVID-19 are treated with pharmacologic or blood products aimed at prophylaxis or

treatment. We will include trials in which researchers compare any intervention against another or against no intervention, placebo, or standard of care, and report any outcome. We will include trials that report results regardless of publication status (peer-reviewed, in press, or pre-print, but not news reports alone) or language. There will be no restrictions on acuity of disease, nor setting.

We will include trials of pharmaceuticals, blood products, vitamins, minerals and, if the drug is one specific molecule, Chinese medicines. We will exclude quasi-randomized studies and randomized trials evaluating external organ support, plasma exchange, oxygen delivery, ventilation strategies, vaccination, nutrition, traditional Chinese herbal medicines (that typically include more than one molecule or a molecule without specific molecular weighted dosing), exercise/rehabilitation, psychological and educational interventions, personal protective equipment, or any other non-drug supportive care interventions.

Data sources and searches

We will search the U.S. Centers for Disease Control and Prevention (CDC) COVID-19 Research Articles Downloadable Database for eligible studies—the most comprehensive database of COVID-19 research articles from December 2019 and which is maintained by the Stephen B. Thacker CDC library ¹⁰. We will update our search daily Monday to Friday to match the update schedule of the database. The database includes 25 bibliographic and grey literature sources: Medline (Ovid and PubMed), PubMed Central, Embase, CAB Abstracts, Global Health, PsycInfo, Cochrane Library, Scopus, Academic Search Complete, Africa Wide Information, CINAHL, ProQuest Central, SciFinder, the Virtual Health Library, LitCovid, WHO COVID-19 website, CDC COVID-19 website, Eurosurveillance, China CDC Weekly, Homeland Security Digital Library, ClinicalTrials.gov, bioRxiv (preprints), medRxiv (preprints), chemRxiv (preprints), and SSRN (preprints).

We will filter the results from the CDC's database through a validated and highly sensitive machine learning model to identify RCTs. We will track preprints of RCTs until publication and data updated to match that in the peer-reviewed publication when discrepant. In addition, we will search six Chinese databases on a biweekly basis: Wanfang, CBM, CNKI, VIP, Chinese Medical Journal Net (preprints), and ChinaXiv (preprints). The search terms for COVID-19 developed by the CDC have been adapted to the Chinese language. For the search of the Chinese literature, we will also include search terms for randomized trials. The search strategy is available in the Supplementary Material.

We will also monitor living evidence retrieval services on an ongoing basis. Two such services are the Systematic and Living Map on COVID-19 Evidence by the Norwegian Institute of Public Health, in collaboration with the Cochrane Canada Centre at McMaster University, ¹² and the Living Overview of Evidence (L·OVE) by Epistemonikos Foundation. ¹³ Our publication will be accompanied with a public call for information sharing, with hopes that investigators will initiate contact and share information when available. RCTs may also be identified organically through informal networks.

Study selection

Pairs of reviewers will independently and in duplicate screen titles and abstracts followed by full texts. A third reviewer will adjudicate conflicts.

Data extraction

For each eligible trial, two reviewers, who have undergone training and have completed calibration exercises, will extract data independently and in duplicate using a standardised, pilottested data extraction form. Discrepancies will be resolved by discussion, and when necessary adjudicated by a third person. The study characteristics and baseline participant information that will be extracted is presented in Box 1.

Box 1. Study characteristics and baseline participant information that will be extracted

- Geographic location
- Physical location (outpatient, inpatient, intensive care)
- Patient and public involvement in the study design or interpretation
- Funder (public, private)
- Number randomized
- Number randomized to each intervention
- Dose, frequency, route of administration, and duration for each intervention
- Number who received each intervention
- Mean age
- Percent male
- Severity of illness (non-severe, severe, critically ill)
- Mean oxygen saturation on room air, or mean baseline amount of supplemental oxygen
- Percent receiving mechanical ventilation at baseline
- Percent current and former smokers
- Percent with hypertension
- Percent with underlying chronic respiratory condition including chronic obstructive pulmonary disease (COPD), asthma, and others
- Percent with diabetes
- Percent taking angiotension-converting-enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs)
- Mean alanine aminotransferase (ALT)
- Mean C-reactive protein (CRP)
- Mean d-dimer
- Mean lactate dehydrogenase (LDH)
- Mean lymphocyte count, and percent with lymphopaenia

Outcomes

We will begin by focusing on the patient-important outcomes listed below, based on the WHO's candidate core outcome set.¹⁴ The list of outcomes may be modified at the discretion of the BMJ

Rapid Recommendations standing panel of experts, which includes frontline healthcare workers and patient-partners. As harms are typically specific to individual pharmacologic therapies, these outcomes will be selected at the time they are needed to support specific linked Rapid Recommendations. We will extract the outcome data closest to the prespecified outcome time point.

The initial outcomes examined for the studies of treatment will include:

- Mortality (time frame: closest to 90 days)
- Mechanical ventilation in patients not initially mechanically ventilated (time frame: closest to 90 days)
- Duration of hospitalization
- Admission to hospital (time frame: closest to 28 days)
- Adverse effects leading to discontinuation of the intervention (time frame: closest to 28 days)
- Time to symptom resolution
- Time until the amount of SARS-CoV2 viral particles is below the threshold set by the RCT authors for being likely no longer infectious (as a surrogate for transmissibility)
- Undetectable nCoV-19 by PCR (time frame: closest to 7 days and not less than 4 days or more than 10 days)

The initial outcomes examined for the studies of prophylaxis will include:

- Symptomatic SARS-CoV2 infection (time frame: closest to 28 days)
- Mortality (time frame: closest to 90 days)
- Admission to hospital (time frame: closest to 28 days)
- Adverse effects leading to discontinuation of the intervention (time frame: closest to 28 days)
- Time to symptom resolution (those not infected will be considered 0)

Other outcomes that will be extracted and reported from the trials, but not initially reviewed will include:

- Ventilator-free days (time frame: 28 days)
- Venous thromboembolism (time frame: closest to 90 days)
- Clinically important bleeding (time frame: closest to 90 days)

Risk of bias assessments

Following calibration exercises, two reviewers, working independently and in duplicate, will use the Clinical Advances Through Research and Information Translation (CLARITY) revisions of the Cochrane tool for assessing risk of bias in randomized trials (RoB 2.0) to rate trials as either 'low risk of bias', 'some concerns – probably low risk of bias', 'some concerns – probably high risk of bias' and 'high risk of bias', across the following domains: bias arising from the randomization process, bias due to departures from the intended intervention, bias due to missing outcome data, bias in measurement of the outcome, bias in selection of the reported results.¹⁵ The

response choice 'some concerns' was modified to include a judgement about whether the concerns probably do or do not result in high risk of bias. ¹⁶ We will not consider judgements about applicability when considering risk of bias because applicability is judged separately within indirectness domain of the GRADE framework. ¹⁷ In addition, the modified tool includes an additional domain to assess risk of bias related to RCTs stopping early for benefit. ¹⁸ Reviewers will resolve discrepancies by discussion, and when not possible, adjudication by a third-party research methodologist. A detailed guide for our risk of bias assessments is available in the Supplementary Material. If the body of evidence is rated as high risk of bias for missing data only (i.e., no serious concerns with any other of the risk of bias domains), we may perform sensitivity analyses with worst plausible assumptions to see if results remain robust to missing data.

Treatment nodes

We will perform three separate network meta-analyses: i) pharmacologic treatments for patients with suspected or confirmed COVID-19, ii) blood products for treatment of patients with suspected or confirmed COVID-19, and iii) pharmacologic prophylactic therapy for people exposed to COVID-19.

Treatments will be grouped into common nodes based on molecule but not dose or duration: we will include all doses and durations of the same medication in a single treatment node. When an intervention includes more than one medication, it will be included as a separate node. We will include drugs from the same class within the same node. Chloroquine and hydroxychloroquine will be included in the same node for COVID-19 specific effects and separated for disease-independent adverse effects. Prespecified nodes include angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, anti-interleukin-6 agents (i.e., tocilizumab, sarilumab), glucocorticoids, interferons, JAK inhibitors, statins, antiplatelet agents, and anticoagulants. Antibiotics will be grouped into nodes by class (e.g., macrolides, beta-lactams). The NMA oversight group and the linked Rapid Recommendation panels will make final decisions on how to group treatment nodes.

Data synthesis

We will perform random-effects pairwise meta-analysis for each comparison for each outcome using the Bayesian framework. We will use a plausible prior for variance parameter, ¹⁹ and uniform prior for the effect parameter. We will calculate Ratio of Means (RoM) and corresponding 95% credible intervals (CrIs) for continuous outcomes in which we expect variationa cross populations (time to symptoms resolution and time to viral clearance) and mean differences (MDs) and corresponding 95% credible intervals (CrIs) for other continuous outcomes. For dichotomous outcomes, we will calculate odds ratios (ORs) with corresponding CrIs. Absolute effects will be calculated based on the ORs and baseline risk of standard of care.²⁰ We will create a funnel plot to assess the publication bias when 10 or more studies are available for a specific direct comparison.²¹

We will conduct a random-effects network meta-analysis using the Bayesian framework with same priors for the variance and effect parameters.¹⁹ We will use three Markov-chains with 100,000 iterations after an initial burn-in of 10,000 and a thinning of 10. We will assess the

convergence based on trace plots and the Brooks-Gelman-Rubin statistic, with an acceptable threshold of <1.05 for all nodes. If convergence is not achieved, then we will use 500,000 iterations and a burn-in of 50,000 iterations and a thinning of 10. We will use automated generation of node-splitting models to assess local incoherence and to obtain indirect estimates.²² We will estimate ranking probabilities and calculate surface under the cumulative ranking curves (SUCRA). For all dichotomous outcomes, we will calculate the absolute treatment effects of the network estimates based-on the odds ratios and the baseline risk using the transitive risks model.²³ To obtain the baseline risk, we will use the highest quality prognostic evidence available at the time of publication, typically based on a systematic review of prognostic studies.²⁴

When networks are sparse, between-study heterogeneity variances are often imprecisely estimated. That may generate implausibly wide credible intervals from network estimates, even when the direct and indirect estimates are coherent.²⁵ When this occurs, we will conduct sensitivity analyses by using empirically informative priors,²⁶ and fixed effects models.²⁵ Another situation in which implausibly wide confidence intervals occur is with random effects when the number of studies is small and the heterogeneity is considerable, particularly when study size varies markedly. This is a second situation in which we may opt for fixed effect models.

Pairwise meta-analysis will be conducted using the bayesmeta package of R version 4.0.0 (RStudio, Boston, MA).²⁷ All network meta-analyses will be performed using the *gemtc* package of R version 4.0.0 (RStudio, Boston, MA),²⁸ absolute effects in networks will be calculated using *R2jags* package of R version 4.0.0 (RStudio, Boston, MA)²⁹. *networkplot* command of Stata version 15.1 (StataCorp, College Station, Texas, USA) will be used to draw the network plots with thickness of edges of the nodes based on inverse variance.³⁰ The foundational R code that we will use is available in the Supplementary Material.

Subgroups and sensitivity analyses

We will conduct sensitivity analyses and network meta-regression to explore factors that may modify the comparative effect estimates. Specific analyses will be guided by the linked *Rapid Recommendation* guideline panels with the directive to explore a limited number of pre-defined subgroup effects with a specified rationale and anticipated direction of the effect. When sufficient heterogeneity in risk of bias exists, we will perform subgroup analyses comparing studies at low versus high risk of bias. We will classify all studies with at least 1 domain judged at high risk of bias or probably high risk of bias as a high risk of bias study. Ultimately, we will base decisions regarding the credibility of subgroup analyses on the ICEMAN instrument,³¹ and follow GRADE guidance on how to deal with low, intermediate, and high credibility subgroup effects.³²

For all outcomes, we will first include both peer-reviewed and non-peer reviewed data, and then perform a sensitivity analysis by restricting to peer-reviewed publications. When the guideline panel makes a recommendation about a drug class with more than one drug, we will consider performing a sensitivity analysis with individual molecules rather than drug class as the nodes.

Certainty assessment

We will evaluate the certainty of evidence using the GRADE approach for network metaanalysis.³³⁻³⁵ We will rate the certainty for each comparison and outcome as high, moderate, low, or very low, based on considerations of risk of bias, inconsistency, indirectness, publication bias, intransitivity, incoherence, and imprecision. If and when sufficient effective treatments are available we will, for each outcome, use the GRADE framework to make conclusions by classifying the interventions in groups from the most to the least effective using a minimally contextualized approach.³⁶

Updating

Full results will be updated at minimum every two weeks on webpages hosted by BMJ.com and magicapp.org. A summary of the interim results, risk of bias assessments, individual study data summaries, and the date of the search will be posted in a table within the online publication. Results will be updated more frequently if the project steering committee or the linked BMJ Rapid Recommendations guidelines panel judges that there is sufficient new information to possibly change practice and requests an earlier update. Updates will be submitted to international indexes through the mechanism for corrections but labelled as updates. Old versions and details of any changes will be dated and documented in the Supplementary Material. It may be necessary to adjust some of the processes, outcomes, and analytic methods based on the data. The systematic review team will decide together whether changes to the pre-specified protocol are needed and these changes will be documented in the methods section of the updated review.

External review

A standing peer-review committee editorial staff at The BMJ, clinical experts, patients, and statistician(s) will be tasked with providing feedback on the protocol and initial publication, and a subcommittee will peer review updates. The systematic review team will respond to these comments on an urgent basis. Comments from peer reviewers and responses will be made public. The study webpage will include functionality for comments to be made by any member of the public. The systematic review team will endeavor to respond to all public comments in a timely manner.

Publication

The papers will be published in a traditional format for systematic reviews and network metaanalyses. In addition, results will be published in interactive evidence summary and decision aid formats for multiple comparisons and pairwise comparisons on MAGICapp (www.magicapp.org). The publication will include infographics that highlight the key messages from the current state of the evidence.

Determining the end of project

The project will terminate at the discretion of the project oversight group, which includes representation from the MAGIC Evidence Ecosystem Foundation, The BMJ, the WHO, and international collaborators with clinical and research expertise. We anticipate that the project will end when the question is no longer of clinical importance, or new evidence that might impact on the conclusions is unlikely to be forthcoming. If the influx of new RCT results slows, then the project oversight committee may choose to decrease the frequency of updates.

Data access

All extracted data will be made available publicly at the time of the updates to be shared and used freely.

Changes to the protocol

All changes to the protocol are reported in Table 1 and will be updated as necessary.

Discussion

Our living network meta-analysis will provide up to date information to interested users, including healthcare workers, patients, healthcare agencies, guideline bodies, and governments. It will directly inform joint clinical practice guidelines from BMJ Rapid Recommendations.

We anticipate several challenges. First, living systematic reviews require substantial dedication and human resources.³⁷ To address this, we will organize our large team into smaller groups with specific responsibilities, including i) a study identification team, ii) a data extraction and management team, iii), a data analysis team, iv) a grading and publications team, and v) an oversight team. In addition, *The BMJ* will recruit a standing external review committee that will become familiar with the research methods and respond quickly to updates.

Second, the need for recurrent updates conflicts with traditional publication formats. Frequent updates resulting in new publications can have a devastating effect on a journal's impact factor. It may also be confusing for users who want to find the most recent update. To solve this problem, we plan to i) have a reference website with the links to the latest versions, ii) use headers on previous versions stating that they are outdated with a link to the current version, iii) use PubMed's corrections mechanism so that the updated publication keeps the same digital object identifier (DOI) and PubMed identification number.

Evidence summaries will also be published online with MAGICapp (<u>www.magicapp.org</u>) developed for the purpose of dynamic updating and with electronic publication formats not subject to the limitations of traditional publishing formats thus allowing presentation of evidence summaries in multilayered user-friendly formats.³⁸

Third, the optimal methodological and statistical methods may change as the number of RCTs and participants increases. In particular, early NMAs are likely to be sparse, and we may have to use specific analytic methods to accommodate these situations.²⁵ Our oversight committee and semi-independent guideline panels will provide direction and guidance on whether and how the methods should be adopted to the current situation.

Another major concern with living systematic reviews is limitations in the evidence included, in particular bias. We will assess risk of bias of each study using a standardized tool, ¹⁵ ¹⁶ and assess risk of bias for each comparison using the GRADE framework. ³³ ³⁴ Publication bias is of particular concern with living reviews: studies with positive results are more likely to be published at all, and when published are likely to be published earlier. ³⁹ We will use the GRADE approach, which

considers publication bias, to rate certainty for the estimated effect for each comparison.²¹ Clinical practice guideline panels of whom the majority will be independent of this review, will consider this issue when making recommendations for practice, and their scrutiny may bear on certainty of evidence judgements.⁹

There are at least two other groups planning a similar living systematic review and NMA.^{40 41} More than one group performing similar analyses will allow controlled replication and the scientific community to assess reproducibility of the findings. Our review has advantages over the alternatives, including the use of and experience with GRADE for NMA, an established platform in the *BMJ Rapid Recommendations* project; an established collaboration with and early involvement of the publisher (*The BMJ*); and interpretation from a semi-independent *BMJ Rapid Recommendations* guideline panels; inclusion of a dedicated search of the Chinese literature; and co-publication in MAGICapp through its interactive multilayered evidence presentation format.

Conclusions

The COVID-19 pandemic necessitates rapid interpretation of new evidence addressing therapeutic and prophylactic options. Our living systematic review and NMA will provide a reference point for those interested in the most trustworthy evidence regarding these therapies. Our project will facilitate the movement of evidence into practice much sooner than traditional publication methods.

Table 1. Changes to the protocol

Date	Change	Rationale
15 July 2020	Network analyses will only include	Early analyses with sparse data
	treatment nodes with at least 100	resulted in implausible and
	patients or at least 20 events.	uninformative effect estimates.

References


- 1. John Hopkins University. Coronavirus Resource Center 2020 [Available from: https://coronavirus.jhu.edu/map.html accessed April 27 2020.
- 2. Wong JC. Hydroxychloroquine: how an unproven drug became Trump's coronavirus 'miracle cure'. *The Guardian* 2020 07/04/2020.
- 3. Ye Z, Rochwerg B, Wang Y, et al. Treatment of patients with nonsevere and severe coronavirus disease 2019: an evidence-based guideline. *CMAJ* 2020 doi: 10.1503/cmaj.200648 [published Online First: 2020/05/01]
- 4. U.S. Food and Drug Administration. Request for Emergency Use Authorization For Use of Chloroquine Phosphate or
- Hydroxychloroquine Sulfate Supplied From the Strategic National Stockpile for Treatment of 2019 Coronavirus Disease. In: (HHS) USDoHaHS, ed., 2020:1-8.
- Kim AHJ, Sparks JA, Liew JW, et al. A Rush to Judgment? Rapid Reporting and Dissemination of Results and Its Consequences Regarding the Use of Hydroxychloroquine for COVID-19. Ann Intern Med 2020 doi: 10.7326/m20-1223 [published Online First: 2020/04/01]
- 6. Cytel. Global Coronavirus COVID-19 Clinical Trial Tracker 2020 [Available from: https://www.covid19-trials.org/ accessed 6 MAy 2020.
- 7. World Health Organization. SUBJECT IN FOCUS: providing timely and accurate information to dispel the 'infodemic'. Coronavirus disease 2019 (COVID-19) Situation Report. Geneva, Switzerland, 2020.
- 8. Institute of Medicine. Institute of Medicine (US) Committee on Standards for Developing Trustworthy Clinical Practice Guidelines. Washington, DC: National Academy Press (US) 2011.
- 9. Siemieniuk RA, Agoritsas T, Macdonald H, et al. Introduction to BMJ Rapid Recommendations. *BMJ* 2016;354:i5191. doi: 10.1136/bmj.i5191 [published Online First: 2016/09/30]
- 10. The Stephen B. Thacker CDC Library. COVID-19 Research Articles Downloadable Database:

 U.S. Centers for Disease Control and Prevention (CDC); 2020 [Available from:

 https://www.cdc.gov/library/researchguides/2019novelcoronavirus/researcharticles.html
 accessed 6 May 2020.
- 11. Marshall IJ, Noel-Storr A, Kuiper J, et al. Machine learning for identifying Randomized Controlled Trials: An evaluation and practitioner's guide. *Res Synth Methods* 2018;9(4):602-14. doi: 10.1002/jrsm.1287 [published Online First: 2018/01/10]
- 12. Norwegian Institute of Public Health. NIPH systematic and living map on COVID-19 evidence 2020 [Available from: https://www.nornesk.no/forskningskart/NIPH mainMap.html accessed 6 May 2020.
- 13. EPISTEMONIKOS Foundation. Living Overview of Evidence (L·OVE) 2020 [Available from: https://iloveevidence.com/ accessed 6 June 2020 2020.
- 14. WHO Working Group on the clinical characterization of COVID-19 infection. A candidate core outcome measure set for clinical research during the SARS-CoV-2/COVID-19 pandemic. Geneva, Switzerland: World Health Organization, 2020:1-16.
- 15. Sterne JAC, Savovic J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. *BMJ (Clinical research ed)* 2019;366:l4898. doi: 10.1136/bmj.l4898 [published Online First: 2019/08/30]

- Busse J, Guyatt G. Modification of Cochrane tool to assess risk of bias in randomized trials.
 2013. https://distillercer.com/wp-content/uploads/2014/02/Tool-to-Assess-Risk-of-Bias-in-Randomized-Controlled-Trials.docx (accessed 6 Mar 2020).
- 17. Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines: 8. Rating the quality of evidence-indirectness. *J Clin Epidemiol* 2011;64(12):1303-10. doi: 10.1016/j.jclinepi.2011.04.014 [published Online First: 2011/08/02]
- 18. Bassler D, Briel M, Montori VM, et al. Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. *Jama* 2010;303(12):1180-7. doi: 10.1001/jama.2010.310 [published Online First: 2010/03/25]
- 19. Röver C. Bayesian random-effects meta-analysis using the bayesmeta R package. *arXiv* preprint arXiv:171108683 2017
- 20. Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. *J Clin Epidemiol* 2011;64(4):383-94. doi: 10.1016/j.jclinepi.2010.04.026 [published Online First: 2011/01/05]
- 21. Guyatt GH, Oxman AD, Montori V, et al. GRADE guidelines: 5. Rating the quality of evidence-publication bias. *Journal of clinical epidemiology* 2011;64(12):1277-82. doi: 10.1016/j.jclinepi.2011.01.011 [published Online First: 2011/08/02]
- 22. van Valkenhoef G, Dias S, Ades AE, et al. Automated generation of node-splitting models for assessment of inconsistency in network meta-analysis. *Res Synth Methods* 2016;7(1):80-93. doi: 10.1002/jrsm.1167 [published Online First: 2015/10/16]
- 23. Spineli L, Brignardello-Petersen R, Heen A, et al. Obtaining absolute effect estimates to facilitate shared decision making in the context of multiple comparisons. Global Evidence Summit. Cape Town, South Africa, 2017.
- 24. Foroutan F, Guyatt G, Zuk V, et al. GRADE Guidelines 28: Use of GRADE for the assessment of evidence about prognostic factors: rating certainty in identification of groups of patients with different absolute risks. *Journal of clinical epidemiology* 2020;121:62-70. doi: 10.1016/j.jclinepi.2019.12.023 [published Online First: 2020/01/27]
- 25. Brignardello-Petersen R, Murad MH, Walter SD, et al. GRADE approach to rate the certainty from a network meta-analysis: avoiding spurious judgments of imprecision in sparse networks. *J Clin Epidemiol* 2019;105:60-67. doi: 10.1016/j.jclinepi.2018.08.022 [published Online First: 2018/09/27]
- 26. Turner RM, Davey J, Clarke MJ, et al. Predicting the extent of heterogeneity in metaanalysis, using empirical data from the Cochrane Database of Systematic Reviews. *Int J Epidemiol* 2012;41(3):818-27. doi: 10.1093/ije/dys041 [published Online First: 2012/03/31]
- 27. Röver C. Bayesian random-effects meta-analysis using the bayesmeta R~package. *Journal of Statistical Software* 2020;93(6):1-51. doi: 10.18637/jss.v093.i06
- 28. gemtc: Network Meta-Analysis Using Bayesian Methods [program]. R package version 0.8-4 version, 2020.
- 29. R2jags: Using R to Run 'JAGS' [program]. R package version 0.6-1 version, 2020.
- 30. Chaimani A, Higgins JP, Mavridis D, et al. Graphical tools for network meta-analysis in STATA. *PLoS One* 2013;8(10):e76654. doi: 10.1371/journal.pone.0076654 [published Online First: 2013/10/08]

- 31. Schandelmaier S, Briel M, Varadhan R, et al. A new instrument to assess the credibility of effect modification analyses (ICEMAN) in randomized controlled trials and meta-analyses *CMAJ* [In Press] 2020
- 32. Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines: 7. Rating the quality of evidence-inconsistency. *J Clin Epidemiol* 2011;64(12):1294-302. doi: 10.1016/j.jclinepi.2011.03.017 [published Online First: 2011/08/02]
- 33. Brignardello-Petersen R, Bonner A, Alexander PE, et al. Advances in the GRADE approach to rate the certainty in estimates from a network meta-analysis. *J Clin Epidemiol* 2018;93:36-44. doi: 10.1016/j.jclinepi.2017.10.005 [published Online First: 2017/10/21]
- 34. Puhan MA, Schunemann HJ, Murad MH, et al. A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. *Bmj* 2014;349:g5630. doi: 10.1136/bmj.g5630 [published Online First: 2014/09/26]
- 35. Brignardello-Petersen R, Mustafa RA, Siemieniuk RAC, et al. GRADE approach to rate the certainty from a network meta-analysis: Addressing Incoherence. *J Clin Epidemiol* 2018 doi: 10.1016/j.jclinepi.2018.11.025 [published Online First: 2018/12/12]
- 36. Brignardello-Petersen R, Florez I, Izcovich A, et al. GRADE approach to drawing conclusions from a network meta-analysis using a minimally contextualized framework [Submitted for publication]. 2020
- 37. Elliott JH, Synnot A, Turner T, et al. Living systematic review: 1. Introduction-the why, what, when, and how. *Journal of clinical epidemiology* 2017;91:23-30. doi: 10.1016/j.jclinepi.2017.08.010 [published Online First: 2017/09/16]
- 38. Agoritsas T, Heen AF, Brandt L, et al. Decision aids that really promote shared decision making: the pace quickens. *BMJ (Clinical research ed)* 2015;350:g7624. doi: 10.1136/bmj.g7624 [published Online First: 2015/02/12]
- 39. Hopewell S, Loudon K, Clarke MJ, et al. Publication bias in clinical trials due to statistical significance or direction of trial results. *Cochrane Database Syst Rev* 2009(1):Mr000006. doi: 10.1002/14651858.MR000006.pub3 [published Online First: 2009/01/23]
- 40. Boutron I, Chaimani A, Devane D, et al. Interventions for preventing and treating COVID-19: protocol for a living mapping of research and a living systematic review. *Zenodo* 2020. http://doi.org/10.5281/zenodo.3744600 (accessed 10 May 2020).
- 41. Juul S, Nielsen N, Bentzer P, et al. Interventions for treatment of COVID-19: a protocol for a living systematic review with network meta-analysis including individual patient data (The LIVING Project). Syst Rev 2020;9(1):108. doi: 10.1186/s13643-020-01371-0



Version: 27-10-2020

Issues to consider:

Bias from the randomization process Issues to consider: Random sequence generation Allocation concealment **Definitely low risk of** Trials that assign participants to alternative interventions using a randomly bias generated sequence and maintain allocation concealment. Examples of methods for developing a randomly generated allocation sequence include a random number generator, random number table, coin tossing, shuffling cards or envelopes, and throwing dice. If a trial is described as 'randomized' without any additional details related to how the allocation sequence was developed, we will assume that the allocation sequence was appropriately developed. Examples of methods for maintaining allocation concealment include using central allocation via a computer or phone system, pharmacy-controlled allocation, opaque sealed envelopes, and sequentially numbered drug containers. Note that an explicit description of random sequence generation is not necessary for a rating of low risk of bias. Probably low risk of Trials in which healthcare providers were blind to the intervention but bias which provide no information on allocation concealment and in which there are no major baseline imbalances. Note that an explicit description of random sequence generation is not necessary for a rating of probably low risk of bias. Probably high risk of Trials in which healthcare providers were not blind to the intervention and which provide no information on allocation concealment. bias Trials in which there are substantial baseline differences between trial arms that suggest a problem with the randomization process but there are no other limitations related to randomization. Trials in which allocation is by judgment of the clinician, by preference of Definitely high risk of the participant, by availability of the intervention, based on the results of a bias laboratory test, or other non-random rules (e.g., birthdate, etc.). Trials in which investigators enrolling participants could possibly foresee the arm to which each subsequent patient would be randomized, such as allocation using an open allocation schedule (e.g. a list of random numbers), assignment envelopes used without appropriate safeguards (e.g. use of unsealed, non-opaque or not sequentially numbered envelopes), alternation between arms, case record number, or any other explicitly unconcealed procedure, rate as high risk. Bias due to deviations from the intended intervention

Version: 27-10-2020

administered and in which there are no significant differences in administered co-interventions. Therapy trials that are described as double or triple blind. Prophylaxis trials in which participants are blind to the intervention that they have been randomized. Probably low risk of bias Probably high risk of bias Therapy trials in which healthcare providers are not blind to the intervention administered. Therapy trials in which healthcare providers are blind to the intervention administered but there are significant differences in administered co-interventions that suggests that blinding may have been compromised. Therapy trials in which healthcare providers are described as being blind to the intervention but allocation concealment was inadequate. Prophylaxis trials in which participants are not blind to the intervention that they have been randomized. Prophylaxis trials in which participants are blind to the intervention to which they have been randomized but there are significant differences in social distancing and risk-taking behaviors that suggest that blinding may have been compromised. Prophylaxis trials in which healthcare providers are not blind to the intervention and in which healthcare providers are not blind to the intervention and in which healthcare providers are not blind to the intervention and in which healthcare providers are not blind to the intervention and in which healthcare providers are not blind to the intervention and in which healthcare providers are not blind to the intervention and in which there are significant differences in administered co-interventions. Prophylaxis trials in which participants are not blind to the intervention and in which there are significant differences in administered co-interventions.	Blinding of healthcare pr	roviders/clinicians and participants
administered and in which there are no significant differences in administered co-interventions. Therapy trials that are described as double or triple blind. Prophylaxis trials in which participants are blind to the intervention that they have been randomized. Probably low risk of bias Probably high risk of bias Therapy trials in which healthcare providers are not blind to the intervention administered. Therapy trials in which healthcare providers are blind to the intervention administered but there are significant differences in administered co-interventions that suggests that blinding may have been compromised. Therapy trials in which healthcare providers are described as being blind to the intervention but allocation concealment was inadequate. Prophylaxis trials in which participants are not blind to the intervention that they have been randomized. Prophylaxis trials in which participants are blind to the intervention to which they have been randomized but there are significant differences in social distancing and risk-taking behaviors that suggest that blinding may have been compromised. Prophylaxis trials in which healthcare providers are not blind to the intervention and in which healthcare providers are not blind to the intervention and in which healthcare providers are not blind to the intervention and in which healthcare providers are not blind to the intervention and in which healthcare providers are not blind to the intervention and in which healthcare providers are not blind to the intervention and in which there are significant differences in administered co-interventions. Prophylaxis trials in which participants are not blind to the intervention and in which there are significant differences in administered co-interventions.	Imbalances in cointerver	ntions or behaviors
Prophylaxis trials in which participants are blind to the intervention that they have been randomized. Probably low risk of bias Probably high risk of bias Therapy trials in which healthcare providers are not blind to the intervention administered. Therapy trials in which healthcare providers are blind to the intervention administered but there are significant differences in administered co-interventions that suggests that blinding may have been compromised. Therapy trials in which healthcare providers are described as being blind to the intervention but allocation concealment was inadequate. Prophylaxis trials in which participants are not blind to the intervention that they have been randomized. Prophylaxis trials in which participants are blind to the intervention to which they have been randomized but there are significant differences in social distancing and risk-taking behaviors that suggest that blinding may have been compromised. Prophylaxis trials in which healthcare providers are not blind to the intervention and in which healthcare providers were very involved and counselled patients on social distancing, risk-taking behaviors, or testing for COVID-19. Therapy trials in which healthcare providers are not blind to the intervention and in which there are significant differences in administered co-interventions. Prophylaxis trials in which participants are not blind to the intervention and in which there are significant differences in social distancing and risk-taking behaviors.	Definitely low risk of bias	administered and in which there are no significant differences in
they have been randomized. Prophylaxis trials that are described as double or triple blind. Probably low risk of bias Probably high risk of bias Therapy trials in which healthcare providers are not blind to the intervention administered. Therapy trials in which healthcare providers are blind to the intervention administered but there are significant differences in administered co-interventions that suggests that blinding may have been compromised. Therapy trials in which healthcare providers are described as being blind to the intervention but allocation concealment was inadequate. Prophylaxis trials in which participants are not blind to the intervention that they have been randomized. Prophylaxis trials in which participants are blind to the intervention to which they have been randomized but there are significant differences in social distancing and risk-taking behaviors that suggest that blinding may have been compromised. Prophylaxis trials in which healthcare providers are not blind to the intervention and in which healthcare providers were very involved and counselled patients on social distancing, risk-taking behaviors, or testing for COVID-19. Therapy trials in which healthcare providers are not blind to the intervention and in which there are significant differences in administered co-interventions. Prophylaxis trials in which participants are not blind to the intervention and in which there are significant differences in social distancing and risk-taking behaviors. Bias due to missing data		Therapy trials that are described as double or triple blind.
Probably low risk of bias Probably high risk of bias Therapy trials in which healthcare providers are not blind to the intervention administered. Therapy trials in which healthcare providers are blind to the intervention administered but there are significant differences in administered co-interventions that suggests that blinding may have been compromised. Therapy trials in which healthcare providers are described as being blind to the intervention but allocation concealment was inadequate. Prophylaxis trials in which participants are not blind to the intervention that they have been randomized. Prophylaxis trials in which participants are blind to the intervention to which they have been randomized but there are significant differences in social distancing and risk-taking behaviors that suggest that blinding may have been compromised. Prophylaxis trials in which healthcare providers are not blind to the intervention and in which healthcare providers were very involved and counselled patients on social distancing, risk-taking behaviors, or testing for COVID-19. Definitely high risk of bias Therapy trials in which healthcare providers are not blind to the intervention and in which there are significant differences in administered co-intervention and in which there are significant differences in administered and in which there are significant differences in social distancing and risk-taking behaviors. Bias due to missing data		
Probably high risk of bias Therapy trials in which healthcare providers are not blind to the intervention administered. Therapy trials in which healthcare providers are blind to the intervention administered but there are significant differences in administered co-interventions that suggests that blinding may have been compromised. Therapy trials in which healthcare providers are described as being blind to the intervention but allocation concealment was inadequate. Prophylaxis trials in which participants are not blind to the intervention that they have been randomized. Prophylaxis trials in which participants are blind to the intervention to which they have been randomized but there are significant differences in social distancing and risk-taking behaviors that suggest that blinding may have been compromised. Prophylaxis trials in which healthcare providers are not blind to the intervention and in which healthcare providers were very involved and counselled patients on social distancing, risk-taking behaviors, or testing for COVID-19. Therapy trials in which healthcare providers are not blind to the intervention and in which there are significant differences in administered co-interventions. Prophylaxis trials in which participants are not blind to the intervention and in which there are significant differences in social distancing and risk-taking behaviors.		Prophylaxis trials that are described as double or triple blind.
intervention administered. Therapy trials in which healthcare providers are blind to the intervention administered but there are significant differences in administered cointerventions that suggests that blinding may have been compromised. Therapy trials in which healthcare providers are described as being blind to the intervention but allocation concealment was inadequate. Prophylaxis trials in which participants are not blind to the intervention that they have been randomized. Prophylaxis trials in which participants are blind to the intervention to which they have been randomized but there are significant differences in social distancing and risk-taking behaviors that suggest that blinding may have been compromised. Prophylaxis trials in which healthcare providers are not blind to the intervention and in which healthcare providers were very involved and counselled patients on social distancing, risk-taking behaviors, or testing for COVID-19. Definitely high risk of bias Therapy trials in which healthcare providers are not blind to the intervention and in which there are significant differences in administered co-interventions. Prophylaxis trials in which participants are not blind to the intervention and in which there are significant differences in social distancing and risk-taking behaviors.	Probably low risk of bias	
administered but there are significant differences in administered co- interventions that suggests that blinding may have been compromised. Therapy trials in which healthcare providers are described as being blind to the intervention but allocation concealment was inadequate. Prophylaxis trials in which participants are not blind to the intervention that they have been randomized. Prophylaxis trials in which participants are blind to the intervention to which they have been randomized but there are significant differences in social distancing and risk-taking behaviors that suggest that blinding may have been compromised. Prophylaxis trials in which healthcare providers are not blind to the intervention and in which healthcare providers were very involved and counselled patients on social distancing, risk-taking behaviors, or testing for COVID-19. Therapy trials in which healthcare providers are not blind to the intervention and in which there are significant differences in administered co-interventions. Prophylaxis trials in which participants are not blind to the intervention and in which there are significant differences in social distancing and risk- taking behaviors. Bias due to missing data	Probably high risk of bias	
the intervention but allocation concealment was inadequate. Prophylaxis trials in which participants are not blind to the intervention that they have been randomized. Prophylaxis trials in which participants are blind to the intervention to which they have been randomized but there are significant differences in social distancing and risk-taking behaviors that suggest that blinding may have been compromised. Prophylaxis trials in which healthcare providers are not blind to the intervention and in which healthcare providers were very involved and counselled patients on social distancing, risk-taking behaviors, or testing for COVID-19. Definitely high risk of bias Therapy trials in which healthcare providers are not blind to the intervention and in which there are significant differences in administered co-interventions. Prophylaxis trials in which participants are not blind to the intervention and in which there are significant differences in social distancing and risk-taking behaviors. Bias due to missing data		administered but there are significant differences in administered co-
that they have been randomized. Prophylaxis trials in which participants are blind to the intervention to which they have been randomized but there are significant differences in social distancing and risk-taking behaviors that suggest that blinding may have been compromised. Prophylaxis trials in which healthcare providers are not blind to the intervention and in which healthcare providers were very involved and counselled patients on social distancing, risk-taking behaviors, or testing for COVID-19. Definitely high risk of bias Therapy trials in which healthcare providers are not blind to the intervention and in which there are significant differences in administered co-interventions. Prophylaxis trials in which participants are not blind to the intervention and in which there are significant differences in social distancing and risk-taking behaviors. Bias due to missing data		Therapy trials in which healthcare providers are described as being blind to the intervention but allocation concealment was inadequate.
which they have been randomized but there are significant differences in social distancing and risk-taking behaviors that suggest that blinding may have been compromised. Prophylaxis trials in which healthcare providers are not blind to the intervention and in which healthcare providers were very involved and counselled patients on social distancing, risk-taking behaviors, or testing for COVID-19. Definitely high risk of bias Therapy trials in which healthcare providers are not blind to the intervention and in which there are significant differences in administered co-interventions. Prophylaxis trials in which participants are not blind to the intervention and in which there are significant differences in social distancing and risk-taking behaviors. Bias due to missing data		
intervention and in which healthcare providers were very involved and counselled patients on social distancing, risk-taking behaviors, or testing for COVID-19. Definitely high risk of bias Therapy trials in which healthcare providers are not blind to the intervention and in which there are significant differences in administered co-interventions. Prophylaxis trials in which participants are not blind to the intervention and in which there are significant differences in social distancing and risk-taking behaviors. Bias due to missing data		which they have been randomized but there are significant differences in social distancing and risk-taking behaviors that suggest that blinding may
intervention and in which there are significant differences in administered co-interventions. Prophylaxis trials in which participants are not blind to the intervention and in which there are significant differences in social distancing and risk-taking behaviors. Bias due to missing data		intervention and in which healthcare providers were very involved and counselled patients on social distancing, risk-taking behaviors, or testing
and in which there are significant differences in social distancing and risk-taking behaviors. Bias due to missing data	Definitely high risk of bias	intervention and in which there are significant differences in administered
		and in which there are significant differences in social distancing and risk-
Issues to consider:	Bias due to missing data	<u> </u>
	Issues to consider:	
Missing outcome measures Loss to follow-up	_	res

Version: 27-10-2020

Definitely low risk of bias	Trials in which missing outcome data (including outcome data that has been imputed) < 10%.
	For in-patient trials, we will assume low risk of bias due to missing data unless otherwise specified.
Probably low risk of bias	Trials in which missing outcome data (including outcome data that has been imputed) is between 10% to 15% and missing outcome data is unlikely to be related to the true outcome and there is no imbalance in numbers of or reasons for missing data across intervention groups.
Probably high risk of bias	Trials in which missing outcome data (including outcome data that has been imputed) is between 10% to 15% and missing outcome data is likely to be related to the true outcome or there are imbalances in numbers of or reasons for missing data across intervention groups.
Definitely high risk of bias	Trials in which missing outcome data (including outcome data that has been imputed) > 15%.

Bias due to measurement of the outcome

Issues to consider:

Blinding of outcome adjudicators

Objectivity of outcome

Note that the judgments	may differ across outcomes.
Definitely low risk of	Trials in which patients are blind to the intervention and in which
bias	outcomes are patient-reported.
	Trials in which outcomes are measured by a third-party (investigator or
	clinician) and in which the third-party is blind to the intervention.
	Trials in which the outcomes are objective (e.g., mortality, infection with
	COVID-19 confirmed by a positive RT-PCR swab, mechanical ventilation,
	admission to hospital, duration of hospital stay, ICU length of stay,
	ventilator free days, duration of mechanical ventilation, time to clinical
	improvement if clinical improvement is measured via objective criteria,
	viral clearance, time to viral clearance).
	Trials that are described as double or triple blind.
Probably low risk of	
bias	
Probably high risk of	
bias	
Definitely high risk of	Trials in which patients are not blind and in which outcomes are patient-
bias	reported (e.g., time to symptom resolution).
	Trials in which outcome adjudicators are not blind and the outcomes are
	not objective (e.g., adverse effects leading to discontinuation, transfusion-
	related acute lung injury, transfusion-associated circulatory overload,
	allergic reactions, infection with suspected/symptomatic COVID-19, venous
	thromboembolism, time to symptom resolution including fever, time to

Version: 27-10-2020

Г	The state of the s
	clinical improvement if the criteria for clinical improvement are not
	objective).
Bias in selection of the re	ported results
Issues to consider:	
Selective reporting of tim	·
Selective reporting of out	come measures
Note that we are only inte	erested in selective reporting for the outcomes for which we are extracting
data.	
Note that the judgments i	may differ across outcomes.
Definitely low risk of	Results for outcomes that were analyzed and reported according to a pre-
bias	specified statistical analysis plan or protocol (including the timepoint for
	the measurement of the outcome).
Probably low risk of	Results for outcomes that were analyzed and reported but that were not
bias	prespecified in a statistical analysis plan or protocol but the timepoint at
	which results are reported is consistent with the timepoint for other
	outcomes in the trial report or there is little reason to believe the outcome
	was selectively reported.
	Please note that outcomes that were not prespecified in a protocol or
	statistical analysis plan and that are reported in the trial preprint or
	publication should be rated at probably low risk of bias unless there are
	other important reasons to suspect that results for those outcomes were
	selectively reported (e.g., results are presented at timepoints that don't
	match the timepoints reported for other outcomes).
Probably high risk of	Results for outcomes that were analyzed and reported but that were not
bias	prespecified in a statistical analysis plan or protocol but the timepoint at
	which results are reported is not consistent with the timepoint for other
	outcomes in the trial report or there are other reasons to believe that the
	outcome is selectively reported.
Definitely high risk of	Results for outcomes that were analyzed and reported for which there are
bias	inconsistencies with the statistical analysis plan or protocol. These
	inconsistencies may include outcome measures of interest or the
	timepoints for the measurement of outcomes.
Bias due to competing ris	·
Issues to consider:	
Competing risks due to ea	arly termination (only for continuous outcomes)
Definitely low risk of	Results are very unlikely to have been affected by competing risk due to
bias	death.
	For example, the intervention arm increased the risk of death but the
	duration of hospitalization is shorter in the control arm.
Probably low risk of	Results are unlikely to have been affected by competing risk due to death.
bias	

Version: 27-10-2020

	For example, the intervention arm increased the risk of death but the
	duration of hospitalization is slightly shorter in the control arm or there is
	no appreciable difference between arms.
Probably high risk of	Results are likely to have been affected by competing risk due to death.
bias	
	For example, the intervention arm increased the risk of death and the
	duration of hospitalization is appreciably lower in the intervention arm.
	Note that for outcomes such as ICU length of stay and duration of
	ventilation in which only patients admitted to the ICU or patients are
	ventilated may be included in analyses, even small imbalances in deaths
	across trial arms may lead to bias due to competing risks because patients
	who die are also likely the ones who were admitted to the ICU or
	ventilated. While patients who die may make up only a small proportion of
	the total patients included in the trial, they may make up an appreciable
	proportion of patients who are admitted to the ICU and who are
	ventilated.
Definitely high risk of	Results are very likely to have been affected by competing risk due to
bias	death.
	For example, the intervention arm increased the risk of death and the
	duration of hospitalization is much lower in the intervention arm.